<SEC-DOCUMENT>0001178670-21-000017.txt : 20210429
<SEC-HEADER>0001178670-21-000017.hdr.sgml : 20210429
<ACCEPTANCE-DATETIME>20210429161215
ACCESSION NUMBER:		0001178670-21-000017
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		71
CONFORMED PERIOD OF REPORT:	20210331
FILED AS OF DATE:		20210429
DATE AS OF CHANGE:		20210429

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ALNYLAM PHARMACEUTICALS, INC.
		CENTRAL INDEX KEY:			0001178670
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				770602661
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36407
		FILM NUMBER:		21870690

	BUSINESS ADDRESS:	
		STREET 1:		675 WEST KENDALL STREET
		STREET 2:		HENRI A. TERMEER SQUARE
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142
		BUSINESS PHONE:		(617) 551-8200

	MAIL ADDRESS:	
		STREET 1:		675 WEST KENDALL STREET
		STREET 2:		HENRI A. TERMEER SQUARE
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ALNYLAM PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	20020724
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>alny-20210331.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2021 Workiva--><!--r:45529fdd-2cb3-415e-a8b1-14659af4a28e,g:8b4a69cc-2403-45c9-b738-5835a1e5fb0d,d:9f86b6d3686546618ade3c76e6b23fc8--><html xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml" xmlns:alny="http://www.alnylam.com/20210331" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>alny-20210331</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80L2ZyYWc6MGRmMmRjMjc5OWUxNDBiOTlkYTI5YWM1MDE5YWM4NmEvdGFibGU6YmNkMWU1NWQxYWQ3NDQ4MDk2OTk1Njc0YzVjMmM1Y2QvdGFibGVyYW5nZTpiY2QxZTU1ZDFhZDc0NDgwOTY5OTU2NzRjNWMyYzVjZF8yLTEtMS0xLTA_08072fdd-0ca9-4a9f-8650-5e2ead148d2b">false</ix:nonNumeric><ix:nonNumeric contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80L2ZyYWc6MGRmMmRjMjc5OWUxNDBiOTlkYTI5YWM1MDE5YWM4NmEvdGFibGU6YmNkMWU1NWQxYWQ3NDQ4MDk2OTk1Njc0YzVjMmM1Y2QvdGFibGVyYW5nZTpiY2QxZTU1ZDFhZDc0NDgwOTY5OTU2NzRjNWMyYzVjZF8zLTEtMS0xLTA_133e5491-2047-422c-9ace-873b2c8ac1a9">2021</ix:nonNumeric><ix:nonNumeric contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80L2ZyYWc6MGRmMmRjMjc5OWUxNDBiOTlkYTI5YWM1MDE5YWM4NmEvdGFibGU6YmNkMWU1NWQxYWQ3NDQ4MDk2OTk1Njc0YzVjMmM1Y2QvdGFibGVyYW5nZTpiY2QxZTU1ZDFhZDc0NDgwOTY5OTU2NzRjNWMyYzVjZF8zLTEtMS0xLTgyMg_f067950e-d0d8-4229-9f05-525239840789">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80L2ZyYWc6MGRmMmRjMjc5OWUxNDBiOTlkYTI5YWM1MDE5YWM4NmEvdGFibGU6YmNkMWU1NWQxYWQ3NDQ4MDk2OTk1Njc0YzVjMmM1Y2QvdGFibGVyYW5nZTpiY2QxZTU1ZDFhZDc0NDgwOTY5OTU2NzRjNWMyYzVjZF80LTEtMS0xLTA_adefb36e-2a04-436e-8ea3-685b7cff1fc2">Q1</ix:nonNumeric><ix:nonNumeric contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80L2ZyYWc6MGRmMmRjMjc5OWUxNDBiOTlkYTI5YWM1MDE5YWM4NmEvdGFibGU6YmNkMWU1NWQxYWQ3NDQ4MDk2OTk1Njc0YzVjMmM1Y2QvdGFibGVyYW5nZTpiY2QxZTU1ZDFhZDc0NDgwOTY5OTU2NzRjNWMyYzVjZF81LTEtMS0xLTA_e9366142-384d-4d5f-a03b-e902fedcf1f5">0001178670</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="alny-20210331.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i34488122c9fd4fb68a5067e173effcb0_I20210423"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-04-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="idd7204dc87d24972a01f15b098c4f56b_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id365c5f1d37444ac9e1da5b5891cd81a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="ia489a15348ae4ae390bc47557aaca423_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iae589afb590a4f5984a5dd4001d656cb_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6912a2c4b43f46838e7d9157c5b3a723_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i738b536de6724c23b1637b0913d14f26_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide9f6e15665746279d0000be700fcc6a_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i781a6cf71b15431fb0056bd6a2d9ba9f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7c2ae885ee354f1c9e0aa3c387519965_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie217873afb06447795dc36a1e1606a74_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4ed3654498ae467fa00b86595fc2fd74_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie41b061be2004e5993962162ca83d40e_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5919ecb151d7401699f63ec0b4537716_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i41a01c886cd440cd8cf8eb694fb78c84_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c5ae4ff57e341c7951e97ef4434647e_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i898030c659864177808288abf9a59aac_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic292a95f9d27470da961a5af69a8168d_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic1a5c9f95c104828afb8e8cfafe56963_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i228f04c4c7b54cc6b36a2842a9727865_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i529e7b1cdc924faf8a02fa556a4493bc_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2e5f4eb4a821432ba3f5cd2a2ffe2754_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if6294416a69f4b6daebcdebf72f5c179_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7d5f25d01b88417aa57a44792c225b17_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iebcb948108ce4342974f490750a7c986_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id329f7a0b2394ad5a1935867e133e7f0_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib01acb7d931b4460a0e434d20db18c85_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i074c45cb3f5642eea30ad48202c86fc9_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i35858c4e152c41c983e25b7741dcfb36_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1e51c390ee2b4b95b9d11592d9610350_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4219d6246f0f4615b7f66a38c10fc9fe_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0cd32b4827314c02b0aeae69087c66b0_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1a2a3f2a9d1744519ed77d4a1400c065_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic378e7f6183c40b4b7371ed7b7370867_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="product"><xbrli:measure>alny:product</xbrli:measure></xbrli:unit><xbrli:unit id="program"><xbrli:measure>alny:program</xbrli:measure></xbrli:unit><xbrli:context id="i4a2ac71261a84e87a3d5590a679c5507_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:ONPATTROMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3093ec8b753b455ebe0533565a97caff_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:ONPATTROMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie071fd2fff7141d790e9ce1f75e3ad69_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:ONPATTROMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icf591ef643074bb59a23948ceb15ebb6_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:ONPATTROMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0e00566ee692462ca9f65f7d6faa57e9_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">alny:NonUSOrEuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:ONPATTROMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i407b32b70e73469c9bb2867c7e8c53ab_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">alny:NonUSOrEuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:ONPATTROMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i938688f7d99a4e7b97c127dc1da4aa45_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:ONPATTROMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic38400d6eea7497f8bb34244730955f4_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:ONPATTROMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i86f381c6519b4114a9f993ca05678e84_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:GIVLAARIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifa94975325ea4c21bc761e8c37cace85_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:GIVLAARIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6223cc9a7bb7452ebf43606a6436d328_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:GIVLAARIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i129948d8d7484c52bc400ee978922740_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:GIVLAARIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ied24bfeab08a4433b3f48a2b7f17c882_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">alny:NonUSOrEuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:GIVLAARIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i46dfc7f31a1c42149b4c59b183486728_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">alny:NonUSOrEuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:GIVLAARIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5cd7ede64f374cf0a1a1c96376d99ca8_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:GIVLAARIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a8146b23bc64bb0989fb48fd0ed09c9_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:GIVLAARIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c6836ed9e254b72b169ede860583569_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:OXLUMOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifbd043497e914bc1bee58c0daa2546c6_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:OXLUMOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if62b86057a964bb0a0b767d745aa53b7_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:OXLUMOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic52bf960eb1f4c9ba53b059468d7993e_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:OXLUMOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic33a14cb7a1b47898a6aa7a5a5d657a4_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:OXLUMOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i416a8546a935440ba7736b9614aa8073_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:OXLUMOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id1a37ec48832445999d722992c9485a5_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i27b6b4c7a00f4e4eb8bf4fb46f229034_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i95f1c1ed3c154524aceec386b964d3e5_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic41d4a1b34194fdb92365734e524ff34_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifafd9b348c4c4d3bb08ec5381577d767_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:NovartisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia500fa9e2b224d0ea1d970ddb3c83d05_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:NovartisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b35d0a44ca0429b8b8202051f1b3678_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:VirBiotechnologyIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab7c02eb57194c1192e785ccd3886998_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:VirBiotechnologyIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i33cced07680d487d8f3ae8596484a8ca_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:OtherCollaborationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1b9f37fb1a5c435aadb1d93990451d0a_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:OtherCollaborationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id3753a1357334f66bd9801d06cb5303b_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:ClinicalTrialAndManufacturingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2e5101b0b8bd410196b91d29fd823e81_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:ExternalServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i503bb08b80284da78e7d56a82595e959_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6f98765bfdbc4e44a1223eaa20633d22_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:ClinicalTrialAndManufacturingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i99846caa80964377a5573940a812180e_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:ExternalServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic2a36524f2b9464c9ddd8548541ad993_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b580b28bb314ef6839a51260f628026_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:VirBiotechnologyIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:ClinicalTrialAndManufacturingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i09f8081c6a5246a0a017275e36ee340d_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:VirBiotechnologyIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:ExternalServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie9502a31100149eaa773ddbb07c78892_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:VirBiotechnologyIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:OtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c2e51b9aa354777af021d48ff53f086_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:VirBiotechnologyIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:ClinicalTrialAndManufacturingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d4070f9748d4216be619760cb306306_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:VirBiotechnologyIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:ExternalServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i17406128628f47da8dc12cab978ee990_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:VirBiotechnologyIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:OtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iba8c6028e53a4d3cb52c96d04a38aa3e_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:ClinicalTrialAndManufacturingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:NovartisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i403e5c57487b45d7953d44822a0f4e08_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:ExternalServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:NovartisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i040c336d87a74305b70be62dbab90158_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:NovartisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib9fefc66152040119b7d0c2744ada9b9_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:ClinicalTrialAndManufacturingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:NovartisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5a5cdc0ffb3e42fbb82f9bf7e926e815_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:ExternalServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:NovartisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e2701f10753482bb31aaa795ebf9601_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:NovartisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7032666edaaa4e429bcb5742671daf6b_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:ClinicalTrialAndManufacturingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:SanofiGenzymeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib9d9e02e83704b5dace40b5fa634af46_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:ExternalServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:SanofiGenzymeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if7a5922b1df34274baf2cab389d93825_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:SanofiGenzymeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:OtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i089d57f59b26493db395f392a738a27c_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:ClinicalTrialAndManufacturingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:SanofiGenzymeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifcf043d12a364c6d8f621f3ce9eb05b3_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:ExternalServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:SanofiGenzymeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0a0b334cef804098995f34a0b7102f9f_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:SanofiGenzymeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:OtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic693d204e9e347ae897f48a7db4e8373_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:ClinicalTrialAndManufacturingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i11ab95266c9c458da1f4e2524c453219_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:ExternalServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87f5d930fa0e4dd885c325ce478459fc_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:OtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i864e263b7e9f4629b9b97b9cfc3bed2f_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:ClinicalTrialAndManufacturingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6496ce2c62514d00a0ced101ce91a17f_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:ExternalServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab9f59c06f804edca916d76b33ea3ca1_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:OtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia5305aa8b123480a9f5873905426845c_D20190408-20190408"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalStrategicCollaborationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-08</xbrli:startDate><xbrli:endDate>2019-04-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i73f0e7523666480d9c1deb15ed7a387e_D20190408-20190408"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalStrategicCollaborationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-08</xbrli:startDate><xbrli:endDate>2019-04-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if2bf4b0c1f3049e3958e56012db213d3_I20190408"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalStrategicCollaborationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">alny:FundingAtProgramInitiationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-04-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5e0a1eb0aca04059bb786c05e4dd32bc_I20190408"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalStrategicCollaborationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">alny:FundingAtLeadCandidateIdentificationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-04-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0fe175fb793a4f5e9a26e0bd683c3620_I20190408"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalStrategicCollaborationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">alny:FundingAnAnnualDiscoveryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-04-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i971ffad5c679466dbaa1a956091dff5b_I20190408"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalStrategicCollaborationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-04-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ice333d52f3d1470e9ef529637248a8dc_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalStrategicCollaborationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:ResearchServicesObligationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i36f4850caa714d72a30d3755dee41330_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalStrategicCollaborationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:ResearchServicesObligationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie1b05d9fbec1490d8547da979164246c_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalStrategicCollaborationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:C5LicenseObligationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9afb38e70eac4aa0940613e1656a62b6_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalStrategicCollaborationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:C5LicenseObligationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5ed9a55f1a8143bd9068e4f6bbafe8a1_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalStrategicCollaborationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:C5CoCoObligationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i034331457ce94629bdc278cc2f5e440c_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalStrategicCollaborationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:C5CoCoObligationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id46811031a3d408bac58580e626f8e3b_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalStrategicCollaborationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibb1a94652b264aa4980ac89d4f3e71e0_D20210331-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalStrategicCollaborationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-31</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if0be8a0acd8c4f4a936e1a39b3321d4e_D20210331-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalStrategicCollaborationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:ResearchServicesObligationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-31</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i15dc0fb5b4cf413aa1bddc7de9dc8427_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalStrategicCollaborationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:ResearchServicesObligationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i658edd34d7bb479582be347d92985839_D20210331-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalStrategicCollaborationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:C5LicenseObligationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-31</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i861836d62a924d62ab2e4e1d6bb80274_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalStrategicCollaborationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:C5LicenseObligationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i80b049fd41474712a64d29d35fabd92b_D20210331-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalStrategicCollaborationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:C5CoCoObligationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-31</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifccb7d9fff7c476987c83ac85c1953b1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalStrategicCollaborationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:C5CoCoObligationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8ee04dc4bddd49289fea1361ef9a5f63_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalStrategicCollaborationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i845dea082db84f4bad647918893f1a91_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalStrategicCollaborationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5fd8d80f765d41dcb65fffa60ec775cf_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalStrategicCollaborationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:ResearchServicesObligationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id8599564d7e94d6db58cf776fcdfcc51_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalStrategicCollaborationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:C5LicenseObligationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7f816a549c3b442c81980771e664236b_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalStrategicCollaborationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:C5CoCoObligationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if12146e5cbeb4f978bb78a0f76137cb2_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalStrategicCollaborationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5c760c86aa8249a6be17c482badca19e_D20130201-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="alny:ResearchCollaboratorAxis">alny:NovartisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:ProductAlliancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2013-02-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d36bc345e7f4e4197c9a712cb73b817_D20130201-20130228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="alny:ResearchCollaboratorAxis">alny:NovartisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:ProductAlliancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2013-02-01</xbrli:startDate><xbrli:endDate>2013-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id397f59fc9a04a808d2a7f2a7cabc579_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="alny:ResearchCollaboratorAxis">alny:NovartisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:ProductAlliancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifd789fbb2ade454a843734d22e2a2dee_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="alny:ResearchCollaboratorAxis">alny:NovartisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:ProductAlliancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3cbd53aa2a944f6a951e88ca5b785aad_D20171001-20171031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:VirBiotechnologyIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-10-01</xbrli:startDate><xbrli:endDate>2017-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0390c083c3b0456c88744cf92cb6d82a_I20171031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:VirBiotechnologyIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2775cf552c5d4a16bd403c04d07b23ba_D20200301-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:VirBiotechnologyIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1ddcbd1cbf9d4242a0d2e7d1fd99d35f_D20200601-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:VirBiotechnologyIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i79b6733ec63b46b0b79d00ec324efa30_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:VirBiotechnologyIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="candidate"><xbrli:measure>alny:candidate</xbrli:measure></xbrli:unit><xbrli:context id="i1cb0ba7808ab43b78c92dd6668914339_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:VirBiotechnologyIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic79f02f0d0d84870a4ef4d488e636d1b_D20210331-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:VirBiotechnologyIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-31</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i730e5e5b0bcd4d5c81f5a71c66d172a2_I20200410"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:BlackstoneGroupIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2a9037b7365649f2bb1a3ef6bcbe2849_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:BlackstoneGroupIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b7aa8adee8f42469579af529e81b38d_I20300101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:BlackstoneGroupIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2030-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i49fe9edf0f9044908d252f6eb19b5518_D20200401-20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:BlackstoneGroupIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id7b8291a96fc46dd8b540dbcc7a6d813_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:BlackstoneGroupIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i399f66dd6ce741d28d06204e9a1dddfb_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:BlackstoneGroupIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i16892019541d48c892ff9d24e698ebd5_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifa5bdd3013ac476381fc4350a3ee7cf4_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic77e6331f376437fb260dd9f97ea58e8_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie8a0bfabe2b94e05a37ef21b7586c1b8_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i14ad949ff20f4e34a5bff828ba895714_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i294e21898c6c4ba19308833eeeec70d9_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8637deaa1c634995a355fa860ea50c94_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibdb3bef5ea924074b966e38860b348a9_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ief62e6e6b5794e1e9aac7a9b35576e8e_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9b9bb880bac0407b815f6fd57e76cd83_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie3ebff18dd48442faf99a73c773d55fa_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6e887f34bbab43fa8752d3d60f8d1b10_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if05c960039774dd9b4ad2920b9816c04_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6d138b2bd73a4ef49fdec7e2d7119c17_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i00ed30d5d69b424e81f823616e722813_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if93a1d02ab2c44359e2b2873b0965791_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i65a4965cd593490dbf6466695a4a77e4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i839a27ef72924781a3487df7e5d7b395_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5590fd684f1a4aa090bf9b83c5673927_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9f72f19e489246dea7d90e3176d37999_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie1d58cc31b1e414591ea2ec01318868f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i522c65977b4e4cfaa993b2b5ff3d2f94_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i641ddedd23b34601ba66a76b01282b1b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib25e85f29b8c40708ecc002c16e6e683_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9eaaf5231e504c2f914f6c3a0ddd13ee_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3f0a2ea993f04064aadad295133972b4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia79c16400354457793c02c74c6ff001d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7bf1dac612484a0685308b19a503a754_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie44adffa3b2e429993b1d4c047f9453c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i515aff7391d84e1bae1add95d453fe61_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6c2621b1e8d440ffa4c9d403e127ab4d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4526151777954123a086b101de9b112e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i233d78b0ba3f4206a3bfc816b3ab7454_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i58cbbc0a79de4859b6344bf8949aeb85_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib30b025bf153422e892ecc638911a8fc_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iab2144e8f1994353ab908cc9c23d059a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3ed44ddacf3f45e2bc4858376f339d6b_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4ef95a791e56443b9b1182d6253d4e4c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ida1aa88277834c4aa06d4523f3777c2d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alny:AccumulatedLossOnInvestmentInJointVentureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8ed22d63570b49f888c7e1fdb4cba720_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iba4e611a80aa4214b1a15ed34d5a650a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if39d09cfa6ef470198658625bf6c69f0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i088faa415d1b4a52be51abef4f75bc5c_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alny:AccumulatedLossOnInvestmentInJointVentureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i41887b4841f2496cb04e4f1ed9bd84bf_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i700594dde5154e6abd7676e0bf8a2e3e_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e5a33a85da249f89d6d9b5939bed9ea_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6a94dbeff4054c1a9f6ebaadd2bdf963_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alny:AccumulatedLossOnInvestmentInJointVentureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i867716826176427d9f8a787730df0336_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1502b1c4289f4259906b093e10b187bc_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i67bb7cc00cd44487b367ee4e7e37c13a_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i05cc6e61b17647308bdf6e55c772bfb8_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alny:AccumulatedLossOnInvestmentInJointVentureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i44ce780df6884d729dccbf45747996b9_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3242f9b2e5e34d0cbb1a6439a9c3f8bc_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iae0f5f6b01c54e3dab00225a8834ae5d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i45667cf06d374f0f8d2c6a08350e2740_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alny:AccumulatedLossOnInvestmentInJointVentureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iace4f6c1fa9543cd8b55cb7840648649_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8748a9e750264dbeb3452686c17d0b3f_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5a4a416c9f8b4fac9455e693cd9e2710_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8fda1a7ccba9498489e7ddfe1a07281b_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alny:AccumulatedLossOnInvestmentInJointVentureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id869bd21f8364305aa97626bdb27c7db_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i11580be1480f41978578dd943839ecb5_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i01494f6ccbfc49d191f7454445e0fc32_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="tranche"><xbrli:measure>alny:tranche</xbrli:measure></xbrli:unit><xbrli:context id="i7c3cf9f64e5c4dba8a27cbdc2664e3da_I20200410"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibc345957dc834afab5787e085c2b24f5_D20201231-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-31</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifeeb0e1889fe4d049042d329b80919f6_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alny:TrancheTwoLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iead1e9b005df4a1f9a86fc4b31611ed7_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alny:TrancheThreeLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id5babbf83da24b918e081dc61eef1961_I20200410"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:ONPATTROAndGIVLAARIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alny:Tranche2LoanAndTranche3LoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i01120d900c46459e8dcddb8d56d9478b_D20200410-20200410"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLiborSwapRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-10</xbrli:startDate><xbrli:endDate>2020-04-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i16e5cf96bf70403d9deb63cea2e51969_I20200410"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLiborSwapRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i08cf9801b78c48129c565578666b38ea_D20200410-20200410"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-10</xbrli:startDate><xbrli:endDate>2020-04-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i753fbbe92da442cfb258516ac25f2d2b_I20200410"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icbb72ec509854a04bfdedc3536c9cc08_D20200410-20200410"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-10</xbrli:startDate><xbrli:endDate>2020-04-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5f0630732fe54bfca1f008c864bcaa8c_D20201201-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLiborSwapRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i93e4ff2210fb41fdaf2e202c8b0d204a_D20201201-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib9d80c24381a4a579abefd71b39a3841_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i00dcec45b31345649463ce0a808354bb_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if56939063a9e4f659db2a74fe02c611f_D20200801-20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:BlackstoneLifeSciencesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:VutrisiranAndALNAGTMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-01</xbrli:startDate><xbrli:endDate>2020-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i30025a2dd91d4350946281176f871659_D20200801-20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:BlackstoneLifeSciencesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:HELIOSBPhase3ClinicalTrialMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-01</xbrli:startDate><xbrli:endDate>2020-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4349daaa321340fbb35c0fb62328e9d0_D20200801-20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:BlackstoneLifeSciencesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:ALNAGTPhase2ClinicalTrialMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-01</xbrli:startDate><xbrli:endDate>2020-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f3237ef00524733ac2cd4cdc77591ed_D20200801-20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:BlackstoneLifeSciencesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:ALNAGTPhase3ClinicalTrialMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-01</xbrli:startDate><xbrli:endDate>2020-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2e274ae018274dad8cbd61b7b4043868_D20200801-20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:BlackstoneLifeSciencesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:VutrisiranMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-01</xbrli:startDate><xbrli:endDate>2020-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d397d1b29de44e99ebf93138e25c1bc_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">alny:BlackstoneLifeSciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i021eb4ce0e054ceabf5ba8f817404e90_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DerivativeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i097088dd315b40bbb18334f3ebd18b0e_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DerivativeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i892bbea5207d47319b4fa4f08ab306e0_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DerivativeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib854d6b980064faa8bfd9bdf17daffcb_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2660c94c8bfb4720bf4ba79623dc2385_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i29e2b4a3041244bc8330c8eb0e1998c2_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6dc64ac1298247ef958115623a6ea350_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i625afeb909e24226bf8911556e57dd36_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i113a05651fb044f49ef9180c67dcd7e3_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib6505072e0e14228bee195251af31d4a_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if503e1a8de82421e9fe69c7f00e791be_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178670</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i9f86b6d3686546618ade3c76e6b23fc8_1"></div><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center;text-indent:36pt"><span><br/></span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington, D.C.&#160;&#160;20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">____________________________________________</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xL2ZyYWc6NTg4OGE0NTFjN2U0NDdhN2FjZjdhMzhiYWE0Yzk4YzcvdGV4dHJlZ2lvbjo1ODg4YTQ1MWM3ZTQ0N2E3YWNmN2EzOGJhYTRjOThjN18xMzE_f2096da3-891a-4c25-83f6-79c162e4849c">10-Q</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">____________________________________________</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.072%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.728%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331" format="ixt-sec:boolballotbox" name="dei:DocumentQuarterlyReport" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xL2ZyYWc6NTg4OGE0NTFjN2U0NDdhN2FjZjdhMzhiYWE0Yzk4YzcvdGFibGU6MDNjZjhjYTk4MjMxNDFjOGEzOGI3YjI2NzA0OTZkNzMvdGFibGVyYW5nZTowM2NmOGNhOTgyMzE0MWM4YTM4YjdiMjY3MDQ5NmQ3M18wLTAtMS0xLTA_511c018e-1692-405d-ae73-19a8e6ccd232">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xL2ZyYWc6NTg4OGE0NTFjN2U0NDdhN2FjZjdhMzhiYWE0Yzk4YzcvdGV4dHJlZ2lvbjo1ODg4YTQ1MWM3ZTQ0N2E3YWNmN2EzOGJhYTRjOThjN18zODQ4MjkwNjk5NDAz_f61f4ded-8a5d-40f7-b310-dfbd0e0aeee8">March 31, 2021</ix:nonNumeric> </span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">OR</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.072%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.728%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331" format="ixt-sec:boolballotbox" name="dei:DocumentTransitionReport" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xL2ZyYWc6NTg4OGE0NTFjN2U0NDdhN2FjZjdhMzhiYWE0Yzk4YzcvdGFibGU6ZDQ1OWNiNTVhYjJhNGNkNmI4MWE3MjU3NjZkZTRhYTIvdGFibGVyYW5nZTpkNDU5Y2I1NWFiMmE0Y2Q2YjgxYTcyNTc2NmRlNGFhMl8wLTAtMS0xLTA_65771209-bc36-466c-95ec-0654154fcb2f">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the transition period from ___________ to ___________</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Commission File Number <ix:nonNumeric contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xL2ZyYWc6NTg4OGE0NTFjN2U0NDdhN2FjZjdhMzhiYWE0Yzk4YzcvdGV4dHJlZ2lvbjo1ODg4YTQ1MWM3ZTQ0N2E3YWNmN2EzOGJhYTRjOThjN18yMTY1_1c381fde-0795-4a67-8a76-f92d766c890b">001-36407</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">__________________________________________</span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:24pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xL2ZyYWc6NTg4OGE0NTFjN2U0NDdhN2FjZjdhMzhiYWE0Yzk4YzcvdGV4dHJlZ2lvbjo1ODg4YTQ1MWM3ZTQ0N2E3YWNmN2EzOGJhYTRjOThjN18yMTY2_364c065d-e284-493c-9dfd-69dd2b1edca6">ALNYLAM PHARMACEUTICALS, INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Exact Name of Registrant as Specified in Its Charter)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">__________________________________________</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xL2ZyYWc6NTg4OGE0NTFjN2U0NDdhN2FjZjdhMzhiYWE0Yzk4YzcvdGFibGU6NzM5MGIwMzNhZGY0NGMxMmExZGJjMzI4N2I5OGZiZjUvdGFibGVyYW5nZTo3MzkwYjAzM2FkZjQ0YzEyYTFkYmMzMjg3Yjk4ZmJmNV8wLTAtMS0xLTAvdGV4dHJlZ2lvbjowOGFhYjBiZDBlZjI0YjE1YTU3ZDFjYTgwYWFkMjEzY181_64f84b67-a7dc-4c62-8b77-af28db0f2c02">Delaware</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(State or Other Jurisdiction of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Incorporation or Organization)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xL2ZyYWc6NTg4OGE0NTFjN2U0NDdhN2FjZjdhMzhiYWE0Yzk4YzcvdGFibGU6NzM5MGIwMzNhZGY0NGMxMmExZGJjMzI4N2I5OGZiZjUvdGFibGVyYW5nZTo3MzkwYjAzM2FkZjQ0YzEyYTFkYmMzMjg3Yjk4ZmJmNV8wLTEtMS0xLTAvdGV4dHJlZ2lvbjpjYjQ2YmFlZDhmMDM0M2I3ODc5OTU4NjUyNWE4OTIxN181_9b9a038f-a269-406e-a65a-b5d7b18c5270">77-0602661</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(I.R.S. Employer</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Identification No.)</span></div></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xL2ZyYWc6NTg4OGE0NTFjN2U0NDdhN2FjZjdhMzhiYWE0Yzk4YzcvdGFibGU6ZjMzMGY3ZmUwN2EwNDE3N2EyYjY4OTc4MDhlMzQyOWMvdGFibGVyYW5nZTpmMzMwZjdmZTA3YTA0MTc3YTJiNjg5NzgwOGUzNDI5Y18wLTAtMS0xLTAvdGV4dHJlZ2lvbjo0NjE2MmNkNGEzNjU0NTNlYTMzODhmNzlmNDE5NjlhMl81_02975d2f-14dd-48b8-8b05-709d03d6ab3c">675 West Kendall Street,</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xL2ZyYWc6NTg4OGE0NTFjN2U0NDdhN2FjZjdhMzhiYWE0Yzk4YzcvdGFibGU6ZjMzMGY3ZmUwN2EwNDE3N2EyYjY4OTc4MDhlMzQyOWMvdGFibGVyYW5nZTpmMzMwZjdmZTA3YTA0MTc3YTJiNjg5NzgwOGUzNDI5Y18wLTAtMS0xLTAvdGV4dHJlZ2lvbjo0NjE2MmNkNGEzNjU0NTNlYTMzODhmNzlmNDE5NjlhMl84_0e3b2568-282c-4c31-a0dd-342c5e4178c0">Henri A. Termeer Square</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xL2ZyYWc6NTg4OGE0NTFjN2U0NDdhN2FjZjdhMzhiYWE0Yzk4YzcvdGFibGU6ZjMzMGY3ZmUwN2EwNDE3N2EyYjY4OTc4MDhlMzQyOWMvdGFibGVyYW5nZTpmMzMwZjdmZTA3YTA0MTc3YTJiNjg5NzgwOGUzNDI5Y18wLTAtMS0xLTAvdGV4dHJlZ2lvbjo0NjE2MmNkNGEzNjU0NTNlYTMzODhmNzlmNDE5NjlhMl8xMQ_cbcf1c44-622d-43c3-aea2-c999eb855db5">Cambridge</ix:nonNumeric>, <ix:nonNumeric contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xL2ZyYWc6NTg4OGE0NTFjN2U0NDdhN2FjZjdhMzhiYWE0Yzk4YzcvdGFibGU6ZjMzMGY3ZmUwN2EwNDE3N2EyYjY4OTc4MDhlMzQyOWMvdGFibGVyYW5nZTpmMzMwZjdmZTA3YTA0MTc3YTJiNjg5NzgwOGUzNDI5Y18wLTAtMS0xLTAvdGV4dHJlZ2lvbjo0NjE2MmNkNGEzNjU0NTNlYTMzODhmNzlmNDE5NjlhMl8xNQ_cbc8ffa5-b736-4ebd-aa4d-cac052fed9d1">MA</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Address of Principal Executive Offices)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xL2ZyYWc6NTg4OGE0NTFjN2U0NDdhN2FjZjdhMzhiYWE0Yzk4YzcvdGFibGU6ZjMzMGY3ZmUwN2EwNDE3N2EyYjY4OTc4MDhlMzQyOWMvdGFibGVyYW5nZTpmMzMwZjdmZTA3YTA0MTc3YTJiNjg5NzgwOGUzNDI5Y18wLTEtMS0xLTAvdGV4dHJlZ2lvbjo2OGI1NTRmYzZkMWY0YmVhOGExNDNlNTQ0MzVmNDlhN181_297f193e-7130-435e-993f-d740fba2dfed">02142</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Zip Code)</span></div></td></tr></table></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xL2ZyYWc6NTg4OGE0NTFjN2U0NDdhN2FjZjdhMzhiYWE0Yzk4YzcvdGV4dHJlZ2lvbjo1ODg4YTQ1MWM3ZTQ0N2E3YWNmN2EzOGJhYTRjOThjN180ODk_b536be89-eb55-4c2a-814b-20fc8087e395">617</ix:nonNumeric>) <ix:nonNumeric contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xL2ZyYWc6NTg4OGE0NTFjN2U0NDdhN2FjZjdhMzhiYWE0Yzk4YzcvdGV4dHJlZ2lvbjo1ODg4YTQ1MWM3ZTQ0N2E3YWNmN2EzOGJhYTRjOThjN180OTM_7d826229-1df3-441e-86fd-9b1ad3b211ce"><ix:nonNumeric contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xL2ZyYWc6NTg4OGE0NTFjN2U0NDdhN2FjZjdhMzhiYWE0Yzk4YzcvdGV4dHJlZ2lvbjo1ODg4YTQ1MWM3ZTQ0N2E3YWNmN2EzOGJhYTRjOThjN180OTM_ecee9bee-f4fe-4325-b411-7c8f578c9e2c">551-8200</ix:nonNumeric></ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Registrant&#8217;s Telephone Number, Including Area Code)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">__________________________________________</span></div><div style="margin-top:10pt;padding-left:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Securities registered pursuant to Section&#160;12(b) of the Act:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:1.093%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.060%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.365%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.060%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.365%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.060%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.097%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Title of Each Class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Name of Each Exchange on Which Registered</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xL2ZyYWc6NTg4OGE0NTFjN2U0NDdhN2FjZjdhMzhiYWE0Yzk4YzcvdGFibGU6NjQ4OWI4YjQxOTU0NDExMGFjNDE2OTY0NzQ1ODVkODAvdGFibGVyYW5nZTo2NDg5YjhiNDE5NTQ0MTEwYWM0MTY5NjQ3NDU4NWQ4MF8xLTEtMS0xLTA_1c98e579-bd15-47d5-8289-da459ee4e9c8">Common Stock, $0.01&#160;par value per share</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xL2ZyYWc6NTg4OGE0NTFjN2U0NDdhN2FjZjdhMzhiYWE0Yzk4YzcvdGFibGU6NjQ4OWI4YjQxOTU0NDExMGFjNDE2OTY0NzQ1ODVkODAvdGFibGVyYW5nZTo2NDg5YjhiNDE5NTQ0MTEwYWM0MTY5NjQ3NDU4NWQ4MF8xLTMtMS0xLTA_a93458c5-dcce-4c8d-a59b-0f729642e8cb">ALNY</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xL2ZyYWc6NTg4OGE0NTFjN2U0NDdhN2FjZjdhMzhiYWE0Yzk4YzcvdGFibGU6NjQ4OWI4YjQxOTU0NDExMGFjNDE2OTY0NzQ1ODVkODAvdGFibGVyYW5nZTo2NDg5YjhiNDE5NTQ0MTEwYWM0MTY5NjQ3NDU4NWQ4MF8xLTUtMS0xLTA_fd88246c-4107-49c9-a462-91492554a38a">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:10pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160;<ix:nonNumeric contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xL2ZyYWc6NTg4OGE0NTFjN2U0NDdhN2FjZjdhMzhiYWE0Yzk4YzcvdGV4dHJlZ2lvbjo1ODg4YTQ1MWM3ZTQ0N2E3YWNmN2EzOGJhYTRjOThjN18xMDAx_13ce99b8-ed79-4cda-8d9c-687268fecbc5">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;No&#160;&#160;&#9744;</span></div><div style="margin-top:10pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;<ix:nonNumeric contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xL2ZyYWc6NTg4OGE0NTFjN2U0NDdhN2FjZjdhMzhiYWE0Yzk4YzcvdGV4dHJlZ2lvbjo1ODg4YTQ1MWM3ZTQ0N2E3YWNmN2EzOGJhYTRjOThjN18xMzI2_4912b0a0-d718-46c7-a2d9-156fd9498994">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;No&#160;&#160;&#9744;</span></div><div style="margin-top:10pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act.</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.762%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.296%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.762%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.780%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xL2ZyYWc6NTg4OGE0NTFjN2U0NDdhN2FjZjdhMzhiYWE0Yzk4YzcvdGFibGU6NTA5NzExNzIxZDJkNDdjY2EzMGQxNmQ2NDQzOGRiNzEvdGFibGVyYW5nZTo1MDk3MTE3MjFkMmQ0N2NjYTMwZDE2ZDY0NDM4ZGI3MV8wLTAtMS0xLTA_9847ed2f-fea4-4284-a189-31139cabb0f6">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%">x</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accelerated&#160;filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Smaller&#160;reporting&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331" format="ixt-sec:boolballotbox" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xL2ZyYWc6NTg4OGE0NTFjN2U0NDdhN2FjZjdhMzhiYWE0Yzk4YzcvdGFibGU6NTA5NzExNzIxZDJkNDdjY2EzMGQxNmQ2NDQzOGRiNzEvdGFibGVyYW5nZTo1MDk3MTE3MjFkMmQ0N2NjYTMwZDE2ZDY0NDM4ZGI3MV8xLTMtMS0xLTA_51441e98-64dc-4923-9096-da9ac30de2b4">&#9744;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xL2ZyYWc6NTg4OGE0NTFjN2U0NDdhN2FjZjdhMzhiYWE0Yzk4YzcvdGFibGU6NTA5NzExNzIxZDJkNDdjY2EzMGQxNmQ2NDQzOGRiNzEvdGFibGVyYW5nZTo1MDk3MTE3MjFkMmQ0N2NjYTMwZDE2ZDY0NDM4ZGI3MV8yLTEtMS0xLTA_8e7fabe3-e0d4-4272-8125-d9cb0ca0f4da">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:10pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;&#9744;</span></div><div style="margin-top:10pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;&#160;&#160;Yes&#160;&#160;<ix:nonNumeric contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331" format="ixt-sec:boolballotbox" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xL2ZyYWc6NTg4OGE0NTFjN2U0NDdhN2FjZjdhMzhiYWE0Yzk4YzcvdGV4dHJlZ2lvbjo1ODg4YTQ1MWM3ZTQ0N2E3YWNmN2EzOGJhYTRjOThjN18yMDYw_e506bd93-bdc4-459e-a037-c24d10b7dd8d">&#9744;</ix:nonNumeric>&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">x</span></div><div style="margin-top:10pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">At April&#160;23, 2021, the registrant had <ix:nonFraction unitRef="shares" contextRef="i34488122c9fd4fb68a5067e173effcb0_I20210423" decimals="INF" format="ixt:numdotdecimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xL2ZyYWc6NTg4OGE0NTFjN2U0NDdhN2FjZjdhMzhiYWE0Yzk4YzcvdGV4dHJlZ2lvbjo1ODg4YTQ1MWM3ZTQ0N2E3YWNmN2EzOGJhYTRjOThjN18yMDk3_ff4fe431-c57a-4a93-bafb-f1b47aaf4fe4">117,545,040</ix:nonFraction> shares of Common Stock, $0.01 par value per share, outstanding.</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:9pt"><span><br/></span></div></div></div><div id="i9f86b6d3686546618ade3c76e6b23fc8_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ALNYLAM PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">QUARTERLY REPORT ON FORM&#160;10-Q</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:90.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.100%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">PAGE<br/>NUMBER</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i9f86b6d3686546618ade3c76e6b23fc8_16">PART I.&#160; FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9f86b6d3686546618ade3c76e6b23fc8_16">ITEM 1. FINANCIAL STATEMENTS (Unaudited)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9f86b6d3686546618ade3c76e6b23fc8_16">CONDENSED CONSOLIDATED BALANCE SHEETS AS OF MARCH 31, 2021 AND DECEMBER 31, 2020</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i9f86b6d3686546618ade3c76e6b23fc8_16">7</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9f86b6d3686546618ade3c76e6b23fc8_22">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS FOR THE THREE MONTHS ENDED MARCH 31, 2021 AND 2020</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i9f86b6d3686546618ade3c76e6b23fc8_22">8</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9f86b6d3686546618ade3c76e6b23fc8_25">CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY FOR THE THREE MONTHS ENDED MARCH 31, 2021 AND 2020</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i9f86b6d3686546618ade3c76e6b23fc8_25">9</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9f86b6d3686546618ade3c76e6b23fc8_28">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE THREE MONTHS ENDED MARCH 31, 2021 AND 2020</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i9f86b6d3686546618ade3c76e6b23fc8_28">10</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9f86b6d3686546618ade3c76e6b23fc8_31">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i9f86b6d3686546618ade3c76e6b23fc8_31">11</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9f86b6d3686546618ade3c76e6b23fc8_79">ITEM 2. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i9f86b6d3686546618ade3c76e6b23fc8_79">26</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9f86b6d3686546618ade3c76e6b23fc8_100">ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i9f86b6d3686546618ade3c76e6b23fc8_100">35</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9f86b6d3686546618ade3c76e6b23fc8_103">ITEM 4. CONTROLS AND PROCEDURES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i9f86b6d3686546618ade3c76e6b23fc8_103">35</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i9f86b6d3686546618ade3c76e6b23fc8_106">PART II.&#160;&#160;OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9f86b6d3686546618ade3c76e6b23fc8_109">ITEM 1.</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9f86b6d3686546618ade3c76e6b23fc8_109"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9f86b6d3686546618ade3c76e6b23fc8_109">LEGAL PROCEEDINGS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i9f86b6d3686546618ade3c76e6b23fc8_109">37</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9f86b6d3686546618ade3c76e6b23fc8_112">ITEM 1A.</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9f86b6d3686546618ade3c76e6b23fc8_112"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9f86b6d3686546618ade3c76e6b23fc8_112">RISK FACTORS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i9f86b6d3686546618ade3c76e6b23fc8_109">37</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9f86b6d3686546618ade3c76e6b23fc8_115">ITEM 5. OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i9f86b6d3686546618ade3c76e6b23fc8_115">70</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9f86b6d3686546618ade3c76e6b23fc8_118">ITEM 6. EXHIBITS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i9f86b6d3686546618ade3c76e6b23fc8_118">70</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9f86b6d3686546618ade3c76e6b23fc8_121">SIGNATURES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i9f86b6d3686546618ade3c76e6b23fc8_121">71</a></span></div></td></tr></table></div><div style="margin-top:10pt;text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8220;Alnylam,&#8221; ONPATTRO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, GIVLAARI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, OXLUMO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, Alnylam Act</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> and Alnylam Assist</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> are registered trademarks of Alnylam Pharmaceuticals, Inc. Our logo, trademarks and service marks are property of Alnylam. All other trademarks or service marks appearing in this Quarterly Report on Form 10-Q are the property of their respective holders.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i9f86b6d3686546618ade3c76e6b23fc8_918"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9f86b6d3686546618ade3c76e6b23fc8_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of the federal securities laws, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. We intend these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 and are including this statement for purposes of complying with those safe harbor provisions. All statements other than statements of historical facts contained in this Quarterly Report on Form 10-Q are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;could,&#8221; &#8220;expects,&#8221; &#8220;plans,&#8221; &#8220;intends,&#8221; &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;estimates,&#8221; &#8220;predicts,&#8221; &#8220;potential,&#8221; &#8220;continue,&#8221; or the negative of these terms or other comparable terminology. These forward-looking statements include, but are not limited to, statements about: </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">risks related to the direct or indirect impact of the COVID-19 global pandemic, emerging or future variants of COVID-19 or any future pandemic, such as the scope and duration of the pandemic, government actions and restrictive measures implemented in response, the broad availability of safe and effective vaccine(s), material delays in diagnoses of rare diseases, initiation or continuation of treatment for diseases addressed by our products, or in patient enrollment in clinical trials, potential clinical trial, regulatory review and inspection or supply chain disruptions, and other potential impacts to our business, the effectiveness or timeliness of steps taken by us to mitigate the impact of the pandemic, and our ability to execute business continuity plans to address disruptions caused by the COVID-19 or any future pandemic;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.85pt">our views with respect to the potential for RNAi therapeutics and investigational therapeutics, including ONPATTRO, GIVLAARI, OXLUMO, Leqvio</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, vutrisiran and fitusiran;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">our plans for additional global regulatory filings and the continuing product launches of ONPATTRO, GIVLAARI, OXLUMO and our partner's plans with respect to Leqvio (inclisiran);</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">our expectations regarding </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">the advancement by our partner of inclisiran through United States, or U.S., regulatory review and toward the market;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">our expectations regarding potential market size for, and the successful commercialization of, ONPATTRO, GIVLAARI, OXLUMO, Leqvio (inclisiran) or any future products, including vutrisiran;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">our ability to obtain and maintain regulatory approvals and pricing and reimbursement for ONPATTRO, GIVLAARI, OXLUMO or any future products, including vutrisiran, and our partners' ability with respect to Leqvio (inclisiran) and fitusiran;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the progress of our research and development programs;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">our current and anticipated clinical trials and expectations regarding the reporting of data from these trials;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the timing of regulatory filings and interactions with or actions or advice of regulatory authorities, which may affect the design, initiation, timing, continuation and/or progress of clinical trials or result in the need for additional pre-clinical and/or clinical testing or the timing or likelihood of regulatory approvals;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the status of our manufacturing operations and any delays, interruptions or failures in the manufacture and supply of ONPATTRO, GIVLAARI, OXLUMO, or any of our product candidates (or other product candidates being developed and commercialized by our partners) by our or their contract manufacturers or by us or our partners;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">our progress continuing to build and leverage global commercial infrastructure;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">our ability to successfully expand the indication for ONPATTRO in the future;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the possible impact of any competing products on the commercial success of ONPATTRO, GIVLAARI, OXLUMO and Leqvio, as well as our product candidates, and, our, or with respect to Leqvio (inclisiran) or fitusiran, our partners', ability to compete against such products;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">our ability to manage our growth and operating expenses;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">our views and plans with respect to our 5-year </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Alnylam P</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">x25</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> strategy and our intentions to achieve the metrics associated with this strategy, including to become a top five biotech company in market capitalization by the end of 2025;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">our belief that the funding provided by our strategic financing collaboration with The Blackstone Group Inc., or Blackstone, and certain of its affiliates should enable us to achieve a self-sustainable profile without the need for future equity financing;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">our expectations regarding the length of time our current cash, cash equivalents and marketable securities will support our operations based on our current operating plan;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9f86b6d3686546618ade3c76e6b23fc8_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">our dependence on third parties for development, manufacture and distribution of products;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">our expectations regarding our corporate collaborations, including potential future licensing fees and milestone and royalty payments under existing or future agreements;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">obtaining, maintaining and protecting our intellectual property;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">our ability to attract and retain qualified key management and scientists, development, medical and commercial staff, consultants and advisors;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the outcome of litigation or other legal proceedings or of any current or future government investigation, including any investigation related to the subpoena received on or about April 9, 2021 pertaining to our marketing and promotion of ONPATTRO (patisiran) in the U.S.; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">regulatory developments in the U.S. and foreign countries;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the impact of laws and regulations;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">developments relating to our competitors and our industry; and </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">other risks and uncertainties, including those listed under the caption Part II, Item 1A, "Risk Factors" of this Quarterly Report on Form 10-Q.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The risks set forth above are not exhaustive. Other sections of this Quarterly Report on Form 10-Q may include additional factors that could adversely affect our business and financial performance. Moreover, we operate in a very competitive and rapidly changing environment. New risk factors emerge from time to time and it is not possible for management to predict all risk factors, nor can we assess the impact of all risk factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Any forward-looking statements in this Quarterly Report on Form 10-Q reflect our current views with respect to future events and with respect to our business and future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. Factors that may cause actual results to differ materially from current expectations include, among other things, those described under Part II, Item 1A, "Risk Factors" and elsewhere in this Quarterly Report on Form 10-Q. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Except as required by law, we assume no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future. You are advised, however, to consult any further disclosure we make in our reports filed with the SEC.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">This Quarterly Report on Form 10-Q may include data that we obtained from industry publications and third-party research, surveys and studies. Industry publications and third-party research, surveys and studies generally indicate that their information has been obtained from sources believed to be reliable, although they do not guarantee the accuracy or completeness of such information. This Quarterly Report on Form 10-Q also may include data based on our own internal estimates and research, including estimates regarding the impact of the COVID-19 pandemic (or related pandemic caused by coronavirus variants) on our financial statements and business operations. Our internal estimates have not been verified by any independent source and, while we believe any data obtained from industry publications and third-party research, surveys and studies are reliable, we have not independently verified such data. Such third-party data, as well as our internal estimates and research, are subject to a high degree of uncertainty and risk due to a variety of factors, including those described in Part II, Item 1A, "Risk Factors" and elsewhere in this Quarterly Report on Form 10-Q. These and other factors could cause our results to differ materially from those expressed in this Quarterly Report on Form 10-Q.</span></div><div style="margin-top:6pt;text-align:center;text-indent:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="i9f86b6d3686546618ade3c76e6b23fc8_906"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9f86b6d3686546618ade3c76e6b23fc8_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">SUMMARY OF MATERIAL RISKS ASSOCIATED WITH OUR BUSINESS</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our business is subject to numerous risks and uncertainties that you should be aware of before making an investment decision, including those highlighted in the section entitled "Risk Factors." These risks include, but are not limited to, the following:</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Business Related Risks &#8211; Risks Related to Our Financial Results</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">The current pandemic of the novel coronavirus, or COVID-19, and the future outbreak of other highly infectious or contagious diseases, could have a material adverse impact on our business, financial condition and results of operations, including our commercial operations and sales, clinical trials and pre-clinical studies.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">We are an early-stage commercial company and the marketing and sale of ONPATTRO, GIVLAARI, OXLUMO or any future products may be unsuccessful or less successful than anticipated.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">We have a history of losses and may never become and remain consistently profitable.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">We will require substantial funds to continue our research, development and commercialization activities.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Although we sold a portion of the expected royalty stream and commercial milestones related to global sales of Leqvio by Novartis AG, or Novartis, we are entitled to retain the remaining portion of such future royalties and, if certain specified thresholds are met, to the remaining portion of commercial milestone payments, and any negative developments related to Leqvio (inclisiran), such as a delay in the expected timing of the resubmission by Novartis of the New Drug Application, or NDA, for inclisiran, could have a material adverse effect on the timing or amount of those payments.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Risks Related to Our Dependence on Third Parties</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">We may not be able to execute our business strategy if we are unable to maintain existing or enter into new alliances with other companies that can provide business and scientific capabilities and funds for the development and commercialization of certain of our product candidates.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">If any collaborator materially amends, terminates or fails to perform its obligations under agreements with us, the development and commercialization of our certain of product candidates could be delayed or terminated and we could suffer other economic harm.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">We have limited manufacturing experience and resources and we must incur significant costs to develop this expertise and/or rely on third parties to manufacture our products.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">We rely on third parties to conduct our clinical trials, and if they fail to fulfill their obligations, our development plans may be adversely affected.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Risks Related to Managing Our Operations</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">If we are unable to attract and retain qualified key management and scientists, development, medical and commercial staff, consultants and advisors, our ability to implement our business plan may be adversely affected.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">We may have difficulty expanding our operations successfully as we continue our evolution from a U.S.- and EU-based company primarily involved in discovery, pre-clinical testing and clinical development into a global company that develops and commercializes multiple drugs.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Industry Related Risks &#8211; Risks Related to Development, Clinical Testing and Regulatory Approval of Our Product Candidates and the Commercialization of Our Approved Products</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Any product candidates we or our partners develop may fail in development or be delayed to a point where they do not become commercially viable.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">We or our partners may be unable to obtain U.S. or foreign regulatory approval for our or our partnered product candidates.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Even if we or our partners obtain regulatory approvals, our marketed drugs will be subject to ongoing regulatory oversight. </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Even if we receive regulatory approval to market our product candidates, and our collaborators receive regulatory approval to market product candidates discovered by us or developed with our technology, the market may not be receptive to such product candidates upon their commercial introduction, which could prevent us from becoming profitable.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">We have limited commercial experience and newly established capabilities for marketing, sales, market access and distribution, and expect to continue to invest significant financial and management resources to continue to build these capabilities, and our commercial efforts may not be successful.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9f86b6d3686546618ade3c76e6b23fc8_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">The patient populations suffering from hereditary transthyretin-mediated amyloidosis, acute hepatic porphyria and primary hyperoxaluria type 1 are small and have not been established with precision. </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">We may incur significant liability if enforcement authorities allege or determine that we are engaging in commercial activities or promoting our commercially approved products in a way that violates applicable regulations.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Any drugs we develop may become subject to unfavorable pricing regulations, third-party reimbursement practices or healthcare reform initiatives, thereby harming our business.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Governments outside the U.S. may impose strict price controls, and the U.S. government may impose price controls or reference pricing, which may adversely affect our revenues.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Risks Related to Patents, Licenses and Trade Secrets</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">If we are not able to obtain and enforce patent protection for our discoveries, our ability to develop and commercialize our product candidates will be harmed.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">We license patent rights from third-party owners. If such owners do not properly or successfully obtain, maintain or enforce the patents underlying such licenses, our competitive position and business prospects may be harmed.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Other companies or organizations may challenge our patent rights or may assert patent rights that prevent us from developing and commercializing our products.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">If we become involved in patent litigation or other proceedings related to a determination of rights, we could incur substantial costs and expenses, substantial liability for damages or be required to stop our product development and commercialization efforts.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">If we fail to comply with our obligations under any licenses or related agreements, we may be required to pay damages and could lose license or other rights that are necessary for developing, commercializing and protecting our RNAi technology.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Risks Related to Competition</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">The pharmaceutical market is intensely competitive. If we are unable to compete effectively with existing drugs, new treatment methods and new technologies, we may be unable to commercialize successfully any drugs that we or our collaborators develop.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">We face competition from other companies that are working to develop novel drugs and technology platforms using technology similar to ours. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Risks Related to Our Common Stock</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">If our stock price fluctuates, purchasers of our common stock could incur substantial losses.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">We may incur significant costs from class action litigation.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Future sales of shares of our common stock, including by our significant stockholders, us or our directors and officers, could cause the price of our common stock to decline.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Regeneron&#8217;s ownership of our common stock could delay or prevent a change in corporate control.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The summary risk factors described above should be read together with the text of the full risk factors below, in the section entitled "Risk Factors" and the other information set forth in this annual report on Form 10-K, including our consolidated financial statements and the related notes, as well as in other documents that we file with the SEC. The risks summarized above or described in full below are not the only risks that we face. Additional risks and uncertainties not precisely known to us, or that we currently deem to be immaterial may also materially adversely affect our business, financial condition, results of operations and future growth prospects.</span></div><div id="i9f86b6d3686546618ade3c76e6b23fc8_10"></div><div style="text-align:center"><span><br/></span></div><div id="i9f86b6d3686546618ade3c76e6b23fc8_13"></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="i9f86b6d3686546618ade3c76e6b23fc8_16"></div><hr style="page-break-after:always"/><div style="min-height:108pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9f86b6d3686546618ade3c76e6b23fc8_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">PART I. FINANCIAL INFORMATION</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%;text-decoration:none" href="#i9f86b6d3686546618ade3c76e6b23fc8_16">ITEM 1. FINANCIAL STATEMENTS (Unaudited)</a></span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ALNYLAM PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except per share amounts)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><div style="text-align:center;text-indent:11.25pt"><span><br/></span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:93.274%"><tr><td style="width:1.0%"></td><td style="width:72.881%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.583%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.441%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd7204dc87d24972a01f15b098c4f56b_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xNi9mcmFnOmM4NzUzODM2OGZlMzQ5OWQ4OTA1NjI3ZTdmN2U4MWEzL3RhYmxlOjJjMmQxMWM4NDU4YzQ4ZTFiMDFkNmI5NTY3N2YzNmYwL3RhYmxlcmFuZ2U6MmMyZDExYzg0NThjNDhlMWIwMWQ2Yjk1Njc3ZjM2ZjBfMy0xLTEtMS0w_9e2242cd-ce35-430c-89a3-b13036d751b3">379,543</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id365c5f1d37444ac9e1da5b5891cd81a_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xNi9mcmFnOmM4NzUzODM2OGZlMzQ5OWQ4OTA1NjI3ZTdmN2U4MWEzL3RhYmxlOjJjMmQxMWM4NDU4YzQ4ZTFiMDFkNmI5NTY3N2YzNmYwL3RhYmxlcmFuZ2U6MmMyZDExYzg0NThjNDhlMWIwMWQ2Yjk1Njc3ZjM2ZjBfMy0zLTEtMS0w_ac798048-5cf4-4140-b7ac-81bed39aade5">496,580</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd7204dc87d24972a01f15b098c4f56b_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xNi9mcmFnOmM4NzUzODM2OGZlMzQ5OWQ4OTA1NjI3ZTdmN2U4MWEzL3RhYmxlOjJjMmQxMWM4NDU4YzQ4ZTFiMDFkNmI5NTY3N2YzNmYwL3RhYmxlcmFuZ2U6MmMyZDExYzg0NThjNDhlMWIwMWQ2Yjk1Njc3ZjM2ZjBfNC0xLTEtMS0w_521ade9a-b2a3-4a04-8c4b-f0177dd0c1c7">1,273,027</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id365c5f1d37444ac9e1da5b5891cd81a_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xNi9mcmFnOmM4NzUzODM2OGZlMzQ5OWQ4OTA1NjI3ZTdmN2U4MWEzL3RhYmxlOjJjMmQxMWM4NDU4YzQ4ZTFiMDFkNmI5NTY3N2YzNmYwL3RhYmxlcmFuZ2U6MmMyZDExYzg0NThjNDhlMWIwMWQ2Yjk1Njc3ZjM2ZjBfNC0zLTEtMS0w_e68c89ee-31b4-4b84-8768-c564322c3c1b">1,333,182</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd7204dc87d24972a01f15b098c4f56b_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNi" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xNi9mcmFnOmM4NzUzODM2OGZlMzQ5OWQ4OTA1NjI3ZTdmN2U4MWEzL3RhYmxlOjJjMmQxMWM4NDU4YzQ4ZTFiMDFkNmI5NTY3N2YzNmYwL3RhYmxlcmFuZ2U6MmMyZDExYzg0NThjNDhlMWIwMWQ2Yjk1Njc3ZjM2ZjBfNS0xLTEtMS0w_f8693738-0359-40ed-8afa-fa20c27a67f7">56,967</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id365c5f1d37444ac9e1da5b5891cd81a_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNi" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xNi9mcmFnOmM4NzUzODM2OGZlMzQ5OWQ4OTA1NjI3ZTdmN2U4MWEzL3RhYmxlOjJjMmQxMWM4NDU4YzQ4ZTFiMDFkNmI5NTY3N2YzNmYwL3RhYmxlcmFuZ2U6MmMyZDExYzg0NThjNDhlMWIwMWQ2Yjk1Njc3ZjM2ZjBfNS0zLTEtMS0w_71eaa147-cb20-48b4-ab75-8d8f7068a97f">44,633</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd7204dc87d24972a01f15b098c4f56b_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xNi9mcmFnOmM4NzUzODM2OGZlMzQ5OWQ4OTA1NjI3ZTdmN2U4MWEzL3RhYmxlOjJjMmQxMWM4NDU4YzQ4ZTFiMDFkNmI5NTY3N2YzNmYwL3RhYmxlcmFuZ2U6MmMyZDExYzg0NThjNDhlMWIwMWQ2Yjk1Njc3ZjM2ZjBfNi0xLTEtMS0w_01e663a2-28dc-4ae5-a95d-e8440aa26a45">110,626</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id365c5f1d37444ac9e1da5b5891cd81a_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xNi9mcmFnOmM4NzUzODM2OGZlMzQ5OWQ4OTA1NjI3ZTdmN2U4MWEzL3RhYmxlOjJjMmQxMWM4NDU4YzQ4ZTFiMDFkNmI5NTY3N2YzNmYwL3RhYmxlcmFuZ2U6MmMyZDExYzg0NThjNDhlMWIwMWQ2Yjk1Njc3ZjM2ZjBfNi0zLTEtMS0w_2f1e178d-1df1-4994-b3cf-fb7dd63d7fce">102,413</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd7204dc87d24972a01f15b098c4f56b_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xNi9mcmFnOmM4NzUzODM2OGZlMzQ5OWQ4OTA1NjI3ZTdmN2U4MWEzL3RhYmxlOjJjMmQxMWM4NDU4YzQ4ZTFiMDFkNmI5NTY3N2YzNmYwL3RhYmxlcmFuZ2U6MmMyZDExYzg0NThjNDhlMWIwMWQ2Yjk1Njc3ZjM2ZjBfNy0xLTEtMS0w_8c393b17-0a55-4333-9628-b74328448954">73,940</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id365c5f1d37444ac9e1da5b5891cd81a_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xNi9mcmFnOmM4NzUzODM2OGZlMzQ5OWQ4OTA1NjI3ZTdmN2U4MWEzL3RhYmxlOjJjMmQxMWM4NDU4YzQ4ZTFiMDFkNmI5NTY3N2YzNmYwL3RhYmxlcmFuZ2U6MmMyZDExYzg0NThjNDhlMWIwMWQ2Yjk1Njc3ZjM2ZjBfNy0zLTEtMS0w_4f612a02-8b5d-4abb-83b0-aa87c92f8687">75,202</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd7204dc87d24972a01f15b098c4f56b_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xNi9mcmFnOmM4NzUzODM2OGZlMzQ5OWQ4OTA1NjI3ZTdmN2U4MWEzL3RhYmxlOjJjMmQxMWM4NDU4YzQ4ZTFiMDFkNmI5NTY3N2YzNmYwL3RhYmxlcmFuZ2U6MmMyZDExYzg0NThjNDhlMWIwMWQ2Yjk1Njc3ZjM2ZjBfOC0xLTEtMS0w_5cc06d72-0153-4138-a5d9-5737517e043c">75,980</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id365c5f1d37444ac9e1da5b5891cd81a_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xNi9mcmFnOmM4NzUzODM2OGZlMzQ5OWQ4OTA1NjI3ZTdmN2U4MWEzL3RhYmxlOjJjMmQxMWM4NDU4YzQ4ZTFiMDFkNmI5NTY3N2YzNmYwL3RhYmxlcmFuZ2U6MmMyZDExYzg0NThjNDhlMWIwMWQ2Yjk1Njc3ZjM2ZjBfOC0zLTEtMS0w_3312f36c-8d6d-49b6-9487-3b06c5422fd8">62,767</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivable related to the sale of future royalties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd7204dc87d24972a01f15b098c4f56b_I20210331" decimals="-3" format="ixt:numdotdecimal" name="alny:RoyaltiesReceivableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xNi9mcmFnOmM4NzUzODM2OGZlMzQ5OWQ4OTA1NjI3ZTdmN2U4MWEzL3RhYmxlOjJjMmQxMWM4NDU4YzQ4ZTFiMDFkNmI5NTY3N2YzNmYwL3RhYmxlcmFuZ2U6MmMyZDExYzg0NThjNDhlMWIwMWQ2Yjk1Njc3ZjM2ZjBfOS0xLTEtMS0w_d17b730a-a8e1-4d9f-907f-e0de94684974">500,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id365c5f1d37444ac9e1da5b5891cd81a_I20201231" decimals="-3" format="ixt:numdotdecimal" name="alny:RoyaltiesReceivableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xNi9mcmFnOmM4NzUzODM2OGZlMzQ5OWQ4OTA1NjI3ZTdmN2U4MWEzL3RhYmxlOjJjMmQxMWM4NDU4YzQ4ZTFiMDFkNmI5NTY3N2YzNmYwL3RhYmxlcmFuZ2U6MmMyZDExYzg0NThjNDhlMWIwMWQ2Yjk1Njc3ZjM2ZjBfOS0zLTEtMS0w_bfac6252-21b8-4f51-86d6-7831687d7289">500,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd7204dc87d24972a01f15b098c4f56b_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xNi9mcmFnOmM4NzUzODM2OGZlMzQ5OWQ4OTA1NjI3ZTdmN2U4MWEzL3RhYmxlOjJjMmQxMWM4NDU4YzQ4ZTFiMDFkNmI5NTY3N2YzNmYwL3RhYmxlcmFuZ2U6MmMyZDExYzg0NThjNDhlMWIwMWQ2Yjk1Njc3ZjM2ZjBfMTAtMS0xLTEtMA_58491f29-a9de-4d9a-a9d0-de6cc819682b">2,470,083</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id365c5f1d37444ac9e1da5b5891cd81a_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xNi9mcmFnOmM4NzUzODM2OGZlMzQ5OWQ4OTA1NjI3ZTdmN2U4MWEzL3RhYmxlOjJjMmQxMWM4NDU4YzQ4ZTFiMDFkNmI5NTY3N2YzNmYwL3RhYmxlcmFuZ2U6MmMyZDExYzg0NThjNDhlMWIwMWQ2Yjk1Njc3ZjM2ZjBfMTAtMy0xLTEtMA_702bf945-7ab7-449a-aafa-ffb59217a15c">2,614,777</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd7204dc87d24972a01f15b098c4f56b_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xNi9mcmFnOmM4NzUzODM2OGZlMzQ5OWQ4OTA1NjI3ZTdmN2U4MWEzL3RhYmxlOjJjMmQxMWM4NDU4YzQ4ZTFiMDFkNmI5NTY3N2YzNmYwL3RhYmxlcmFuZ2U6MmMyZDExYzg0NThjNDhlMWIwMWQ2Yjk1Njc3ZjM2ZjBfMTEtMS0xLTEtMA_fd90f67d-623c-443a-8517-ac09f815ca79">464,572</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id365c5f1d37444ac9e1da5b5891cd81a_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xNi9mcmFnOmM4NzUzODM2OGZlMzQ5OWQ4OTA1NjI3ZTdmN2U4MWEzL3RhYmxlOjJjMmQxMWM4NDU4YzQ4ZTFiMDFkNmI5NTY3N2YzNmYwL3RhYmxlcmFuZ2U6MmMyZDExYzg0NThjNDhlMWIwMWQ2Yjk1Njc3ZjM2ZjBfMTEtMy0xLTEtMA_be8c263a-853e-43e3-b434-47febd0db778">465,029</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd7204dc87d24972a01f15b098c4f56b_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xNi9mcmFnOmM4NzUzODM2OGZlMzQ5OWQ4OTA1NjI3ZTdmN2U4MWEzL3RhYmxlOjJjMmQxMWM4NDU4YzQ4ZTFiMDFkNmI5NTY3N2YzNmYwL3RhYmxlcmFuZ2U6MmMyZDExYzg0NThjNDhlMWIwMWQ2Yjk1Njc3ZjM2ZjBfMTItMS0xLTEtMA_5bb29d4b-2032-461a-b7f0-75f8eec6ae69">237,213</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id365c5f1d37444ac9e1da5b5891cd81a_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xNi9mcmFnOmM4NzUzODM2OGZlMzQ5OWQ4OTA1NjI3ZTdmN2U4MWEzL3RhYmxlOjJjMmQxMWM4NDU4YzQ4ZTFiMDFkNmI5NTY3N2YzNmYwL3RhYmxlcmFuZ2U6MmMyZDExYzg0NThjNDhlMWIwMWQ2Yjk1Njc3ZjM2ZjBfMTItMy0xLTEtMA_5d7365f9-fd2c-4695-83c9-404ecf81923c">241,485</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd7204dc87d24972a01f15b098c4f56b_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedInvestmentsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xNi9mcmFnOmM4NzUzODM2OGZlMzQ5OWQ4OTA1NjI3ZTdmN2U4MWEzL3RhYmxlOjJjMmQxMWM4NDU4YzQ4ZTFiMDFkNmI5NTY3N2YzNmYwL3RhYmxlcmFuZ2U6MmMyZDExYzg0NThjNDhlMWIwMWQ2Yjk1Njc3ZjM2ZjBfMTMtMS0xLTEtMA_c3a23ed6-2c70-4ae0-b520-a67551c519c7">40,725</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id365c5f1d37444ac9e1da5b5891cd81a_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedInvestmentsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xNi9mcmFnOmM4NzUzODM2OGZlMzQ5OWQ4OTA1NjI3ZTdmN2U4MWEzL3RhYmxlOjJjMmQxMWM4NDU4YzQ4ZTFiMDFkNmI5NTY3N2YzNmYwL3RhYmxlcmFuZ2U6MmMyZDExYzg0NThjNDhlMWIwMWQ2Yjk1Njc3ZjM2ZjBfMTMtMy0xLTEtMA_e7a010c6-c0f9-40b9-be58-319184532567">40,725</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd7204dc87d24972a01f15b098c4f56b_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xNi9mcmFnOmM4NzUzODM2OGZlMzQ5OWQ4OTA1NjI3ZTdmN2U4MWEzL3RhYmxlOjJjMmQxMWM4NDU4YzQ4ZTFiMDFkNmI5NTY3N2YzNmYwL3RhYmxlcmFuZ2U6MmMyZDExYzg0NThjNDhlMWIwMWQ2Yjk1Njc3ZjM2ZjBfMTQtMS0xLTEtMA_b80edf0e-2efa-443a-95b5-4504218c63d7">42,676</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id365c5f1d37444ac9e1da5b5891cd81a_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xNi9mcmFnOmM4NzUzODM2OGZlMzQ5OWQ4OTA1NjI3ZTdmN2U4MWEzL3RhYmxlOjJjMmQxMWM4NDU4YzQ4ZTFiMDFkNmI5NTY3N2YzNmYwL3RhYmxlcmFuZ2U6MmMyZDExYzg0NThjNDhlMWIwMWQ2Yjk1Njc3ZjM2ZjBfMTQtMy0xLTEtMA_b79a658b-4bf8-4052-8834-59b514dc4483">45,045</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd7204dc87d24972a01f15b098c4f56b_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xNi9mcmFnOmM4NzUzODM2OGZlMzQ5OWQ4OTA1NjI3ZTdmN2U4MWEzL3RhYmxlOjJjMmQxMWM4NDU4YzQ4ZTFiMDFkNmI5NTY3N2YzNmYwL3RhYmxlcmFuZ2U6MmMyZDExYzg0NThjNDhlMWIwMWQ2Yjk1Njc3ZjM2ZjBfMTUtMS0xLTEtMA_1d7b9fa0-a459-4917-a0e9-789a33b1c7a9">3,255,269</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id365c5f1d37444ac9e1da5b5891cd81a_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xNi9mcmFnOmM4NzUzODM2OGZlMzQ5OWQ4OTA1NjI3ZTdmN2U4MWEzL3RhYmxlOjJjMmQxMWM4NDU4YzQ4ZTFiMDFkNmI5NTY3N2YzNmYwL3RhYmxlcmFuZ2U6MmMyZDExYzg0NThjNDhlMWIwMWQ2Yjk1Njc3ZjM2ZjBfMTUtMy0xLTEtMA_50cd6d7c-8f1c-4528-9405-4eda9fbce972">3,407,061</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd7204dc87d24972a01f15b098c4f56b_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xNi9mcmFnOmM4NzUzODM2OGZlMzQ5OWQ4OTA1NjI3ZTdmN2U4MWEzL3RhYmxlOjJjMmQxMWM4NDU4YzQ4ZTFiMDFkNmI5NTY3N2YzNmYwL3RhYmxlcmFuZ2U6MmMyZDExYzg0NThjNDhlMWIwMWQ2Yjk1Njc3ZjM2ZjBfMTgtMS0xLTEtMA_831ca1a5-73f4-4789-ace0-a607f2660dfe">45,381</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id365c5f1d37444ac9e1da5b5891cd81a_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xNi9mcmFnOmM4NzUzODM2OGZlMzQ5OWQ4OTA1NjI3ZTdmN2U4MWEzL3RhYmxlOjJjMmQxMWM4NDU4YzQ4ZTFiMDFkNmI5NTY3N2YzNmYwL3RhYmxlcmFuZ2U6MmMyZDExYzg0NThjNDhlMWIwMWQ2Yjk1Njc3ZjM2ZjBfMTgtMy0xLTEtMA_2e6e1ea9-2818-45aa-8fdb-4b4f3c8c20eb">51,966</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd7204dc87d24972a01f15b098c4f56b_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xNi9mcmFnOmM4NzUzODM2OGZlMzQ5OWQ4OTA1NjI3ZTdmN2U4MWEzL3RhYmxlOjJjMmQxMWM4NDU4YzQ4ZTFiMDFkNmI5NTY3N2YzNmYwL3RhYmxlcmFuZ2U6MmMyZDExYzg0NThjNDhlMWIwMWQ2Yjk1Njc3ZjM2ZjBfMTktMS0xLTEtMA_93180980-4a1c-4720-988d-e4944c03a2bf">280,527</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id365c5f1d37444ac9e1da5b5891cd81a_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xNi9mcmFnOmM4NzUzODM2OGZlMzQ5OWQ4OTA1NjI3ZTdmN2U4MWEzL3RhYmxlOjJjMmQxMWM4NDU4YzQ4ZTFiMDFkNmI5NTY3N2YzNmYwL3RhYmxlcmFuZ2U6MmMyZDExYzg0NThjNDhlMWIwMWQ2Yjk1Njc3ZjM2ZjBfMTktMy0xLTEtMA_41ace118-3b2e-4668-b019-c42ca4b47912">355,909</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd7204dc87d24972a01f15b098c4f56b_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xNi9mcmFnOmM4NzUzODM2OGZlMzQ5OWQ4OTA1NjI3ZTdmN2U4MWEzL3RhYmxlOjJjMmQxMWM4NDU4YzQ4ZTFiMDFkNmI5NTY3N2YzNmYwL3RhYmxlcmFuZ2U6MmMyZDExYzg0NThjNDhlMWIwMWQ2Yjk1Njc3ZjM2ZjBfMjAtMS0xLTEtMA_d807788e-339a-4ce5-b10d-3b843e32763e">38,917</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id365c5f1d37444ac9e1da5b5891cd81a_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xNi9mcmFnOmM4NzUzODM2OGZlMzQ5OWQ4OTA1NjI3ZTdmN2U4MWEzL3RhYmxlOjJjMmQxMWM4NDU4YzQ4ZTFiMDFkNmI5NTY3N2YzNmYwL3RhYmxlcmFuZ2U6MmMyZDExYzg0NThjNDhlMWIwMWQ2Yjk1Njc3ZjM2ZjBfMjAtMy0xLTEtMA_f957006e-584c-4a3c-9609-3265d53ad06a">36,872</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd7204dc87d24972a01f15b098c4f56b_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xNi9mcmFnOmM4NzUzODM2OGZlMzQ5OWQ4OTA1NjI3ZTdmN2U4MWEzL3RhYmxlOjJjMmQxMWM4NDU4YzQ4ZTFiMDFkNmI5NTY3N2YzNmYwL3RhYmxlcmFuZ2U6MmMyZDExYzg0NThjNDhlMWIwMWQ2Yjk1Njc3ZjM2ZjBfMjEtMS0xLTEtMA_76483954-c33f-403b-a35d-a3f5150370d5">116,340</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id365c5f1d37444ac9e1da5b5891cd81a_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xNi9mcmFnOmM4NzUzODM2OGZlMzQ5OWQ4OTA1NjI3ZTdmN2U4MWEzL3RhYmxlOjJjMmQxMWM4NDU4YzQ4ZTFiMDFkNmI5NTY3N2YzNmYwL3RhYmxlcmFuZ2U6MmMyZDExYzg0NThjNDhlMWIwMWQ2Yjk1Njc3ZjM2ZjBfMjEtMy0xLTEtMA_8c0c58ec-360f-4a14-a555-0d6b1b28516f">127,207</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability related to the sale of future royalties</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd7204dc87d24972a01f15b098c4f56b_I20210331" decimals="-3" format="ixt:numdotdecimal" name="alny:RoyaltyLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xNi9mcmFnOmM4NzUzODM2OGZlMzQ5OWQ4OTA1NjI3ZTdmN2U4MWEzL3RhYmxlOjJjMmQxMWM4NDU4YzQ4ZTFiMDFkNmI5NTY3N2YzNmYwL3RhYmxlcmFuZ2U6MmMyZDExYzg0NThjNDhlMWIwMWQ2Yjk1Njc3ZjM2ZjBfMjItMS0xLTEtMA_1a613327-a02f-470a-8e05-89c0f552f35a">13,660</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id365c5f1d37444ac9e1da5b5891cd81a_I20201231" decimals="-3" format="ixt:numdotdecimal" name="alny:RoyaltyLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xNi9mcmFnOmM4NzUzODM2OGZlMzQ5OWQ4OTA1NjI3ZTdmN2U4MWEzL3RhYmxlOjJjMmQxMWM4NDU4YzQ4ZTFiMDFkNmI5NTY3N2YzNmYwL3RhYmxlcmFuZ2U6MmMyZDExYzg0NThjNDhlMWIwMWQ2Yjk1Njc3ZjM2ZjBfMjItMy0xLTEtMA_da5696f6-7155-4fa0-9978-f21e4b67a624">13,316</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd7204dc87d24972a01f15b098c4f56b_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xNi9mcmFnOmM4NzUzODM2OGZlMzQ5OWQ4OTA1NjI3ZTdmN2U4MWEzL3RhYmxlOjJjMmQxMWM4NDU4YzQ4ZTFiMDFkNmI5NTY3N2YzNmYwL3RhYmxlcmFuZ2U6MmMyZDExYzg0NThjNDhlMWIwMWQ2Yjk1Njc3ZjM2ZjBfMjMtMS0xLTEtMA_d252b9c3-e2ff-4d32-a1b3-2319ed302065">494,825</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id365c5f1d37444ac9e1da5b5891cd81a_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xNi9mcmFnOmM4NzUzODM2OGZlMzQ5OWQ4OTA1NjI3ZTdmN2U4MWEzL3RhYmxlOjJjMmQxMWM4NDU4YzQ4ZTFiMDFkNmI5NTY3N2YzNmYwL3RhYmxlcmFuZ2U6MmMyZDExYzg0NThjNDhlMWIwMWQ2Yjk1Njc3ZjM2ZjBfMjMtMy0xLTEtMA_498b6dd1-4c35-4e74-8570-24247cd78c73">585,270</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liability, net of current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd7204dc87d24972a01f15b098c4f56b_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xNi9mcmFnOmM4NzUzODM2OGZlMzQ5OWQ4OTA1NjI3ZTdmN2U4MWEzL3RhYmxlOjJjMmQxMWM4NDU4YzQ4ZTFiMDFkNmI5NTY3N2YzNmYwL3RhYmxlcmFuZ2U6MmMyZDExYzg0NThjNDhlMWIwMWQ2Yjk1Njc3ZjM2ZjBfMjQtMS0xLTEtMA_5f0c48c0-84b1-49a5-9086-9bf949ea3d48">288,015</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id365c5f1d37444ac9e1da5b5891cd81a_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xNi9mcmFnOmM4NzUzODM2OGZlMzQ5OWQ4OTA1NjI3ZTdmN2U4MWEzL3RhYmxlOjJjMmQxMWM4NDU4YzQ4ZTFiMDFkNmI5NTY3N2YzNmYwL3RhYmxlcmFuZ2U6MmMyZDExYzg0NThjNDhlMWIwMWQ2Yjk1Njc3ZjM2ZjBfMjQtMy0xLTEtMA_531d1092-2858-4d78-a720-7aea5efd0682">293,039</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue, net of current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd7204dc87d24972a01f15b098c4f56b_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xNi9mcmFnOmM4NzUzODM2OGZlMzQ5OWQ4OTA1NjI3ZTdmN2U4MWEzL3RhYmxlOjJjMmQxMWM4NDU4YzQ4ZTFiMDFkNmI5NTY3N2YzNmYwL3RhYmxlcmFuZ2U6MmMyZDExYzg0NThjNDhlMWIwMWQ2Yjk1Njc3ZjM2ZjBfMjUtMS0xLTEtMA_cc279283-a1ba-4806-891e-11e08026589a">208,123</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id365c5f1d37444ac9e1da5b5891cd81a_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xNi9mcmFnOmM4NzUzODM2OGZlMzQ5OWQ4OTA1NjI3ZTdmN2U4MWEzL3RhYmxlOjJjMmQxMWM4NDU4YzQ4ZTFiMDFkNmI5NTY3N2YzNmYwL3RhYmxlcmFuZ2U6MmMyZDExYzg0NThjNDhlMWIwMWQ2Yjk1Njc3ZjM2ZjBfMjUtMy0xLTEtMA_ef6572be-e876-4192-bce2-530f154a69b7">225,094</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd7204dc87d24972a01f15b098c4f56b_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xNi9mcmFnOmM4NzUzODM2OGZlMzQ5OWQ4OTA1NjI3ZTdmN2U4MWEzL3RhYmxlOjJjMmQxMWM4NDU4YzQ4ZTFiMDFkNmI5NTY3N2YzNmYwL3RhYmxlcmFuZ2U6MmMyZDExYzg0NThjNDhlMWIwMWQ2Yjk1Njc3ZjM2ZjBfMjYtMS0xLTEtMTgx_842b9859-9d21-478d-9cde-11524cad204a">191,590</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id365c5f1d37444ac9e1da5b5891cd81a_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xNi9mcmFnOmM4NzUzODM2OGZlMzQ5OWQ4OTA1NjI3ZTdmN2U4MWEzL3RhYmxlOjJjMmQxMWM4NDU4YzQ4ZTFiMDFkNmI5NTY3N2YzNmYwL3RhYmxlcmFuZ2U6MmMyZDExYzg0NThjNDhlMWIwMWQ2Yjk1Njc3ZjM2ZjBfMjYtMy0xLTEtMTgx_5637ddb0-b70a-4c58-9874-267d69468d72">191,278</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability related to the sale of future royalties, net of current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd7204dc87d24972a01f15b098c4f56b_I20210331" decimals="-3" format="ixt:numdotdecimal" name="alny:RoyaltyLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xNi9mcmFnOmM4NzUzODM2OGZlMzQ5OWQ4OTA1NjI3ZTdmN2U4MWEzL3RhYmxlOjJjMmQxMWM4NDU4YzQ4ZTFiMDFkNmI5NTY3N2YzNmYwL3RhYmxlcmFuZ2U6MmMyZDExYzg0NThjNDhlMWIwMWQ2Yjk1Njc3ZjM2ZjBfMjctMS0xLTEtMA_56ea8a09-8ffb-4e3b-b824-ab9fd315c5ce">1,086,065</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id365c5f1d37444ac9e1da5b5891cd81a_I20201231" decimals="-3" format="ixt:numdotdecimal" name="alny:RoyaltyLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xNi9mcmFnOmM4NzUzODM2OGZlMzQ5OWQ4OTA1NjI3ZTdmN2U4MWEzL3RhYmxlOjJjMmQxMWM4NDU4YzQ4ZTFiMDFkNmI5NTY3N2YzNmYwL3RhYmxlcmFuZ2U6MmMyZDExYzg0NThjNDhlMWIwMWQ2Yjk1Njc3ZjM2ZjBfMjctMy0xLTEtMA_054963d4-ba18-4bb7-98ab-743438bb0635">1,058,225</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd7204dc87d24972a01f15b098c4f56b_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xNi9mcmFnOmM4NzUzODM2OGZlMzQ5OWQ4OTA1NjI3ZTdmN2U4MWEzL3RhYmxlOjJjMmQxMWM4NDU4YzQ4ZTFiMDFkNmI5NTY3N2YzNmYwL3RhYmxlcmFuZ2U6MmMyZDExYzg0NThjNDhlMWIwMWQ2Yjk1Njc3ZjM2ZjBfMjgtMS0xLTEtMA_26669a1e-5968-4723-8a74-c6242bb0811b">60,461</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id365c5f1d37444ac9e1da5b5891cd81a_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xNi9mcmFnOmM4NzUzODM2OGZlMzQ5OWQ4OTA1NjI3ZTdmN2U4MWEzL3RhYmxlOjJjMmQxMWM4NDU4YzQ4ZTFiMDFkNmI5NTY3N2YzNmYwL3RhYmxlcmFuZ2U6MmMyZDExYzg0NThjNDhlMWIwMWQ2Yjk1Njc3ZjM2ZjBfMjgtMy0xLTEtMA_23af4eb6-8031-4974-8796-8bcf9fc8954a">37,908</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd7204dc87d24972a01f15b098c4f56b_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xNi9mcmFnOmM4NzUzODM2OGZlMzQ5OWQ4OTA1NjI3ZTdmN2U4MWEzL3RhYmxlOjJjMmQxMWM4NDU4YzQ4ZTFiMDFkNmI5NTY3N2YzNmYwL3RhYmxlcmFuZ2U6MmMyZDExYzg0NThjNDhlMWIwMWQ2Yjk1Njc3ZjM2ZjBfMjktMS0xLTEtMA_a4de43d0-833c-4a51-b883-75883736059b">2,329,079</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id365c5f1d37444ac9e1da5b5891cd81a_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xNi9mcmFnOmM4NzUzODM2OGZlMzQ5OWQ4OTA1NjI3ZTdmN2U4MWEzL3RhYmxlOjJjMmQxMWM4NDU4YzQ4ZTFiMDFkNmI5NTY3N2YzNmYwL3RhYmxlcmFuZ2U6MmMyZDExYzg0NThjNDhlMWIwMWQ2Yjk1Njc3ZjM2ZjBfMjktMy0xLTEtMA_c5db52df-c9d5-4981-b45e-c48cb5a4ddc3">2,390,814</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies (Note 13)</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="idd7204dc87d24972a01f15b098c4f56b_I20210331" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xNi9mcmFnOmM4NzUzODM2OGZlMzQ5OWQ4OTA1NjI3ZTdmN2U4MWEzL3RhYmxlOjJjMmQxMWM4NDU4YzQ4ZTFiMDFkNmI5NTY3N2YzNmYwL3RhYmxlcmFuZ2U6MmMyZDExYzg0NThjNDhlMWIwMWQ2Yjk1Njc3ZjM2ZjBfMzAtMS0xLTEtMA_3e4e8d7c-e733-4a8b-a632-38d4e03a830a"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="id365c5f1d37444ac9e1da5b5891cd81a_I20201231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xNi9mcmFnOmM4NzUzODM2OGZlMzQ5OWQ4OTA1NjI3ZTdmN2U4MWEzL3RhYmxlOjJjMmQxMWM4NDU4YzQ4ZTFiMDFkNmI5NTY3N2YzNmYwL3RhYmxlcmFuZ2U6MmMyZDExYzg0NThjNDhlMWIwMWQ2Yjk1Njc3ZjM2ZjBfMzAtMy0xLTEtMA_ec38adad-7659-4f35-b137-8d20166fd471"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stockholders&#8217; equity:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="id365c5f1d37444ac9e1da5b5891cd81a_I20201231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xNi9mcmFnOmM4NzUzODM2OGZlMzQ5OWQ4OTA1NjI3ZTdmN2U4MWEzL3RhYmxlOjJjMmQxMWM4NDU4YzQ4ZTFiMDFkNmI5NTY3N2YzNmYwL3RhYmxlcmFuZ2U6MmMyZDExYzg0NThjNDhlMWIwMWQ2Yjk1Njc3ZjM2ZjBfMzItMC0xLTEtMC90ZXh0cmVnaW9uOmMzODNhOGYzNTYzYTQyZDU4ZWNkODliNTE3YTllZmM1XzIy_701b265a-c89e-4f4b-b6f7-6c8d70829183"><ix:nonFraction unitRef="usdPerShare" contextRef="idd7204dc87d24972a01f15b098c4f56b_I20210331" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xNi9mcmFnOmM4NzUzODM2OGZlMzQ5OWQ4OTA1NjI3ZTdmN2U4MWEzL3RhYmxlOjJjMmQxMWM4NDU4YzQ4ZTFiMDFkNmI5NTY3N2YzNmYwL3RhYmxlcmFuZ2U6MmMyZDExYzg0NThjNDhlMWIwMWQ2Yjk1Njc3ZjM2ZjBfMzItMC0xLTEtMC90ZXh0cmVnaW9uOmMzODNhOGYzNTYzYTQyZDU4ZWNkODliNTE3YTllZmM1XzIy_e39bd595-ad75-4702-81b4-ff0cde40e8d6">0.01</ix:nonFraction></ix:nonFraction> par value per share, <ix:nonFraction unitRef="shares" contextRef="id365c5f1d37444ac9e1da5b5891cd81a_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xNi9mcmFnOmM4NzUzODM2OGZlMzQ5OWQ4OTA1NjI3ZTdmN2U4MWEzL3RhYmxlOjJjMmQxMWM4NDU4YzQ4ZTFiMDFkNmI5NTY3N2YzNmYwL3RhYmxlcmFuZ2U6MmMyZDExYzg0NThjNDhlMWIwMWQ2Yjk1Njc3ZjM2ZjBfMzItMC0xLTEtMC90ZXh0cmVnaW9uOmMzODNhOGYzNTYzYTQyZDU4ZWNkODliNTE3YTllZmM1XzQ2_13429f06-d230-4db6-ac0a-f4021916bde0"><ix:nonFraction unitRef="shares" contextRef="idd7204dc87d24972a01f15b098c4f56b_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xNi9mcmFnOmM4NzUzODM2OGZlMzQ5OWQ4OTA1NjI3ZTdmN2U4MWEzL3RhYmxlOjJjMmQxMWM4NDU4YzQ4ZTFiMDFkNmI5NTY3N2YzNmYwL3RhYmxlcmFuZ2U6MmMyZDExYzg0NThjNDhlMWIwMWQ2Yjk1Njc3ZjM2ZjBfMzItMC0xLTEtMC90ZXh0cmVnaW9uOmMzODNhOGYzNTYzYTQyZDU4ZWNkODliNTE3YTllZmM1XzQ2_fc70e64e-5917-4be6-92ef-c8ac428cbc95">5,000</ix:nonFraction></ix:nonFraction> shares authorized and <ix:nonFraction unitRef="shares" contextRef="id365c5f1d37444ac9e1da5b5891cd81a_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xNi9mcmFnOmM4NzUzODM2OGZlMzQ5OWQ4OTA1NjI3ZTdmN2U4MWEzL3RhYmxlOjJjMmQxMWM4NDU4YzQ4ZTFiMDFkNmI5NTY3N2YzNmYwL3RhYmxlcmFuZ2U6MmMyZDExYzg0NThjNDhlMWIwMWQ2Yjk1Njc3ZjM2ZjBfMzItMC0xLTEtMC90ZXh0cmVnaW9uOmMzODNhOGYzNTYzYTQyZDU4ZWNkODliNTE3YTllZmM1Xzcx_1e9f52c3-46ad-4e5a-9192-e232adb89665"><ix:nonFraction unitRef="shares" contextRef="id365c5f1d37444ac9e1da5b5891cd81a_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xNi9mcmFnOmM4NzUzODM2OGZlMzQ5OWQ4OTA1NjI3ZTdmN2U4MWEzL3RhYmxlOjJjMmQxMWM4NDU4YzQ4ZTFiMDFkNmI5NTY3N2YzNmYwL3RhYmxlcmFuZ2U6MmMyZDExYzg0NThjNDhlMWIwMWQ2Yjk1Njc3ZjM2ZjBfMzItMC0xLTEtMC90ZXh0cmVnaW9uOmMzODNhOGYzNTYzYTQyZDU4ZWNkODliNTE3YTllZmM1Xzcx_7a0cbbf6-197b-4a2e-9c7f-21d01a61b684"><ix:nonFraction unitRef="shares" contextRef="idd7204dc87d24972a01f15b098c4f56b_I20210331" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xNi9mcmFnOmM4NzUzODM2OGZlMzQ5OWQ4OTA1NjI3ZTdmN2U4MWEzL3RhYmxlOjJjMmQxMWM4NDU4YzQ4ZTFiMDFkNmI5NTY3N2YzNmYwL3RhYmxlcmFuZ2U6MmMyZDExYzg0NThjNDhlMWIwMWQ2Yjk1Njc3ZjM2ZjBfMzItMC0xLTEtMC90ZXh0cmVnaW9uOmMzODNhOGYzNTYzYTQyZDU4ZWNkODliNTE3YTllZmM1Xzcx_b1d57adc-7668-48f1-b82c-153983bc57a9"><ix:nonFraction unitRef="shares" contextRef="idd7204dc87d24972a01f15b098c4f56b_I20210331" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xNi9mcmFnOmM4NzUzODM2OGZlMzQ5OWQ4OTA1NjI3ZTdmN2U4MWEzL3RhYmxlOjJjMmQxMWM4NDU4YzQ4ZTFiMDFkNmI5NTY3N2YzNmYwL3RhYmxlcmFuZ2U6MmMyZDExYzg0NThjNDhlMWIwMWQ2Yjk1Njc3ZjM2ZjBfMzItMC0xLTEtMC90ZXh0cmVnaW9uOmMzODNhOGYzNTYzYTQyZDU4ZWNkODliNTE3YTllZmM1Xzcx_d6210fc7-f322-4a35-9024-d1abb063bb41">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding as of March&#160;31, 2021 and December&#160;31, 2020</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd7204dc87d24972a01f15b098c4f56b_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xNi9mcmFnOmM4NzUzODM2OGZlMzQ5OWQ4OTA1NjI3ZTdmN2U4MWEzL3RhYmxlOjJjMmQxMWM4NDU4YzQ4ZTFiMDFkNmI5NTY3N2YzNmYwL3RhYmxlcmFuZ2U6MmMyZDExYzg0NThjNDhlMWIwMWQ2Yjk1Njc3ZjM2ZjBfMzItMS0xLTEtMA_51951c5e-8dc8-4ad7-b1e0-0e50af9e6ef4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id365c5f1d37444ac9e1da5b5891cd81a_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xNi9mcmFnOmM4NzUzODM2OGZlMzQ5OWQ4OTA1NjI3ZTdmN2U4MWEzL3RhYmxlOjJjMmQxMWM4NDU4YzQ4ZTFiMDFkNmI5NTY3N2YzNmYwL3RhYmxlcmFuZ2U6MmMyZDExYzg0NThjNDhlMWIwMWQ2Yjk1Njc3ZjM2ZjBfMzItMy0xLTEtMA_1ee0ac5e-fa72-4556-9c92-082e99ddb826">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="idd7204dc87d24972a01f15b098c4f56b_I20210331" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xNi9mcmFnOmM4NzUzODM2OGZlMzQ5OWQ4OTA1NjI3ZTdmN2U4MWEzL3RhYmxlOjJjMmQxMWM4NDU4YzQ4ZTFiMDFkNmI5NTY3N2YzNmYwL3RhYmxlcmFuZ2U6MmMyZDExYzg0NThjNDhlMWIwMWQ2Yjk1Njc3ZjM2ZjBfMzMtMC0xLTEtMC90ZXh0cmVnaW9uOjk4OTZkZjEzZDBkMjRkNzc4ODM4ZjljZDY3Njg1NzkxXzE4_57718799-5589-4767-888f-a9157a98b289"><ix:nonFraction unitRef="usdPerShare" contextRef="id365c5f1d37444ac9e1da5b5891cd81a_I20201231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xNi9mcmFnOmM4NzUzODM2OGZlMzQ5OWQ4OTA1NjI3ZTdmN2U4MWEzL3RhYmxlOjJjMmQxMWM4NDU4YzQ4ZTFiMDFkNmI5NTY3N2YzNmYwL3RhYmxlcmFuZ2U6MmMyZDExYzg0NThjNDhlMWIwMWQ2Yjk1Njc3ZjM2ZjBfMzMtMC0xLTEtMC90ZXh0cmVnaW9uOjk4OTZkZjEzZDBkMjRkNzc4ODM4ZjljZDY3Njg1NzkxXzE4_ed6a1954-ed41-49a7-ac69-6a6911101500">0.01</ix:nonFraction></ix:nonFraction> par value per share, <ix:nonFraction unitRef="shares" contextRef="id365c5f1d37444ac9e1da5b5891cd81a_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xNi9mcmFnOmM4NzUzODM2OGZlMzQ5OWQ4OTA1NjI3ZTdmN2U4MWEzL3RhYmxlOjJjMmQxMWM4NDU4YzQ4ZTFiMDFkNmI5NTY3N2YzNmYwL3RhYmxlcmFuZ2U6MmMyZDExYzg0NThjNDhlMWIwMWQ2Yjk1Njc3ZjM2ZjBfMzMtMC0xLTEtMC90ZXh0cmVnaW9uOjk4OTZkZjEzZDBkMjRkNzc4ODM4ZjljZDY3Njg1NzkxXzQy_e5b2d55f-9376-42be-a6ba-5e509fe3976f"><ix:nonFraction unitRef="shares" contextRef="idd7204dc87d24972a01f15b098c4f56b_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xNi9mcmFnOmM4NzUzODM2OGZlMzQ5OWQ4OTA1NjI3ZTdmN2U4MWEzL3RhYmxlOjJjMmQxMWM4NDU4YzQ4ZTFiMDFkNmI5NTY3N2YzNmYwL3RhYmxlcmFuZ2U6MmMyZDExYzg0NThjNDhlMWIwMWQ2Yjk1Njc3ZjM2ZjBfMzMtMC0xLTEtMC90ZXh0cmVnaW9uOjk4OTZkZjEzZDBkMjRkNzc4ODM4ZjljZDY3Njg1NzkxXzQy_fcaf0eab-b31d-4d97-aff7-103154cd5426">250,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="idd7204dc87d24972a01f15b098c4f56b_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xNi9mcmFnOmM4NzUzODM2OGZlMzQ5OWQ4OTA1NjI3ZTdmN2U4MWEzL3RhYmxlOjJjMmQxMWM4NDU4YzQ4ZTFiMDFkNmI5NTY3N2YzNmYwL3RhYmxlcmFuZ2U6MmMyZDExYzg0NThjNDhlMWIwMWQ2Yjk1Njc3ZjM2ZjBfMzMtMC0xLTEtMC90ZXh0cmVnaW9uOjk4OTZkZjEzZDBkMjRkNzc4ODM4ZjljZDY3Njg1NzkxXzY0_1aa1182f-dca0-4570-8ed2-a91e5e15279c"><ix:nonFraction unitRef="shares" contextRef="idd7204dc87d24972a01f15b098c4f56b_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xNi9mcmFnOmM4NzUzODM2OGZlMzQ5OWQ4OTA1NjI3ZTdmN2U4MWEzL3RhYmxlOjJjMmQxMWM4NDU4YzQ4ZTFiMDFkNmI5NTY3N2YzNmYwL3RhYmxlcmFuZ2U6MmMyZDExYzg0NThjNDhlMWIwMWQ2Yjk1Njc3ZjM2ZjBfMzMtMC0xLTEtMC90ZXh0cmVnaW9uOjk4OTZkZjEzZDBkMjRkNzc4ODM4ZjljZDY3Njg1NzkxXzY0_df6f7388-9c05-435f-8e18-7eefe14c5320">117,321</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of March&#160;31, 2021; <ix:nonFraction unitRef="shares" contextRef="id365c5f1d37444ac9e1da5b5891cd81a_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xNi9mcmFnOmM4NzUzODM2OGZlMzQ5OWQ4OTA1NjI3ZTdmN2U4MWEzL3RhYmxlOjJjMmQxMWM4NDU4YzQ4ZTFiMDFkNmI5NTY3N2YzNmYwL3RhYmxlcmFuZ2U6MmMyZDExYzg0NThjNDhlMWIwMWQ2Yjk1Njc3ZjM2ZjBfMzMtMC0xLTEtMC90ZXh0cmVnaW9uOjk4OTZkZjEzZDBkMjRkNzc4ODM4ZjljZDY3Njg1NzkxXzEwNw_12bf7017-92e0-4a8f-a2cb-30274c53f729"><ix:nonFraction unitRef="shares" contextRef="id365c5f1d37444ac9e1da5b5891cd81a_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xNi9mcmFnOmM4NzUzODM2OGZlMzQ5OWQ4OTA1NjI3ZTdmN2U4MWEzL3RhYmxlOjJjMmQxMWM4NDU4YzQ4ZTFiMDFkNmI5NTY3N2YzNmYwL3RhYmxlcmFuZ2U6MmMyZDExYzg0NThjNDhlMWIwMWQ2Yjk1Njc3ZjM2ZjBfMzMtMC0xLTEtMC90ZXh0cmVnaW9uOjk4OTZkZjEzZDBkMjRkNzc4ODM4ZjljZDY3Njg1NzkxXzEwNw_b67af575-e4db-484d-b2eb-9a47f3be15f5">116,427</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of December&#160;31, 2020</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd7204dc87d24972a01f15b098c4f56b_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xNi9mcmFnOmM4NzUzODM2OGZlMzQ5OWQ4OTA1NjI3ZTdmN2U4MWEzL3RhYmxlOjJjMmQxMWM4NDU4YzQ4ZTFiMDFkNmI5NTY3N2YzNmYwL3RhYmxlcmFuZ2U6MmMyZDExYzg0NThjNDhlMWIwMWQ2Yjk1Njc3ZjM2ZjBfMzMtMS0xLTEtMA_50b7d8f9-4529-4ac3-bf7c-ede7d1862949">1,173</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id365c5f1d37444ac9e1da5b5891cd81a_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xNi9mcmFnOmM4NzUzODM2OGZlMzQ5OWQ4OTA1NjI3ZTdmN2U4MWEzL3RhYmxlOjJjMmQxMWM4NDU4YzQ4ZTFiMDFkNmI5NTY3N2YzNmYwL3RhYmxlcmFuZ2U6MmMyZDExYzg0NThjNDhlMWIwMWQ2Yjk1Njc3ZjM2ZjBfMzMtMy0xLTEtMA_5a45f4d3-3c4e-4c33-be7d-203aa0f547b0">1,164</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd7204dc87d24972a01f15b098c4f56b_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xNi9mcmFnOmM4NzUzODM2OGZlMzQ5OWQ4OTA1NjI3ZTdmN2U4MWEzL3RhYmxlOjJjMmQxMWM4NDU4YzQ4ZTFiMDFkNmI5NTY3N2YzNmYwL3RhYmxlcmFuZ2U6MmMyZDExYzg0NThjNDhlMWIwMWQ2Yjk1Njc3ZjM2ZjBfMzQtMS0xLTEtMA_660e989f-d8b7-4c9e-95f0-670e09d20088">5,747,394</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id365c5f1d37444ac9e1da5b5891cd81a_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xNi9mcmFnOmM4NzUzODM2OGZlMzQ5OWQ4OTA1NjI3ZTdmN2U4MWEzL3RhYmxlOjJjMmQxMWM4NDU4YzQ4ZTFiMDFkNmI5NTY3N2YzNmYwL3RhYmxlcmFuZ2U6MmMyZDExYzg0NThjNDhlMWIwMWQ2Yjk1Njc3ZjM2ZjBfMzQtMy0xLTEtMA_c4970306-2902-4b37-91ef-13a6ee1f0faf">5,644,074</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idd7204dc87d24972a01f15b098c4f56b_I20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xNi9mcmFnOmM4NzUzODM2OGZlMzQ5OWQ4OTA1NjI3ZTdmN2U4MWEzL3RhYmxlOjJjMmQxMWM4NDU4YzQ4ZTFiMDFkNmI5NTY3N2YzNmYwL3RhYmxlcmFuZ2U6MmMyZDExYzg0NThjNDhlMWIwMWQ2Yjk1Njc3ZjM2ZjBfMzUtMS0xLTEtMA_59394d7e-2995-44f3-9646-9279245ef15d">36,717</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id365c5f1d37444ac9e1da5b5891cd81a_I20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xNi9mcmFnOmM4NzUzODM2OGZlMzQ5OWQ4OTA1NjI3ZTdmN2U4MWEzL3RhYmxlOjJjMmQxMWM4NDU4YzQ4ZTFiMDFkNmI5NTY3N2YzNmYwL3RhYmxlcmFuZ2U6MmMyZDExYzg0NThjNDhlMWIwMWQ2Yjk1Njc3ZjM2ZjBfMzUtMy0xLTEtMA_73147315-3a27-45cc-85da-3712aa2fbc87">43,622</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idd7204dc87d24972a01f15b098c4f56b_I20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xNi9mcmFnOmM4NzUzODM2OGZlMzQ5OWQ4OTA1NjI3ZTdmN2U4MWEzL3RhYmxlOjJjMmQxMWM4NDU4YzQ4ZTFiMDFkNmI5NTY3N2YzNmYwL3RhYmxlcmFuZ2U6MmMyZDExYzg0NThjNDhlMWIwMWQ2Yjk1Njc3ZjM2ZjBfMzYtMS0xLTEtMA_16bf590e-ac28-4fb7-add6-e86c6af567f5">4,785,660</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id365c5f1d37444ac9e1da5b5891cd81a_I20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xNi9mcmFnOmM4NzUzODM2OGZlMzQ5OWQ4OTA1NjI3ZTdmN2U4MWEzL3RhYmxlOjJjMmQxMWM4NDU4YzQ4ZTFiMDFkNmI5NTY3N2YzNmYwL3RhYmxlcmFuZ2U6MmMyZDExYzg0NThjNDhlMWIwMWQ2Yjk1Njc3ZjM2ZjBfMzYtMy0xLTEtMA_751df80d-3868-439b-bdc0-d77a5b5736cd">4,585,369</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd7204dc87d24972a01f15b098c4f56b_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xNi9mcmFnOmM4NzUzODM2OGZlMzQ5OWQ4OTA1NjI3ZTdmN2U4MWEzL3RhYmxlOjJjMmQxMWM4NDU4YzQ4ZTFiMDFkNmI5NTY3N2YzNmYwL3RhYmxlcmFuZ2U6MmMyZDExYzg0NThjNDhlMWIwMWQ2Yjk1Njc3ZjM2ZjBfMzctMS0xLTEtMA_fd9535fa-cdcc-439b-8372-35154660a80b">926,190</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id365c5f1d37444ac9e1da5b5891cd81a_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xNi9mcmFnOmM4NzUzODM2OGZlMzQ5OWQ4OTA1NjI3ZTdmN2U4MWEzL3RhYmxlOjJjMmQxMWM4NDU4YzQ4ZTFiMDFkNmI5NTY3N2YzNmYwL3RhYmxlcmFuZ2U6MmMyZDExYzg0NThjNDhlMWIwMWQ2Yjk1Njc3ZjM2ZjBfMzctMy0xLTEtMA_b3d21b2f-21ea-41f3-8f88-3084025c5a28">1,016,247</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd7204dc87d24972a01f15b098c4f56b_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xNi9mcmFnOmM4NzUzODM2OGZlMzQ5OWQ4OTA1NjI3ZTdmN2U4MWEzL3RhYmxlOjJjMmQxMWM4NDU4YzQ4ZTFiMDFkNmI5NTY3N2YzNmYwL3RhYmxlcmFuZ2U6MmMyZDExYzg0NThjNDhlMWIwMWQ2Yjk1Njc3ZjM2ZjBfMzgtMS0xLTEtMA_e219c72e-0f5b-4644-92cf-4f3f29e9c91c">3,255,269</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id365c5f1d37444ac9e1da5b5891cd81a_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xNi9mcmFnOmM4NzUzODM2OGZlMzQ5OWQ4OTA1NjI3ZTdmN2U4MWEzL3RhYmxlOjJjMmQxMWM4NDU4YzQ4ZTFiMDFkNmI5NTY3N2YzNmYwL3RhYmxlcmFuZ2U6MmMyZDExYzg0NThjNDhlMWIwMWQ2Yjk1Njc3ZjM2ZjBfMzgtMy0xLTEtMA_50f09ff1-e438-4817-8f8b-9e6b21bca7ab">3,407,061</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="height:38.25pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><div id="i9f86b6d3686546618ade3c76e6b23fc8_22"></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9f86b6d3686546618ade3c76e6b23fc8_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ALNYLAM PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except per share amounts)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:93.274%"><tr><td style="width:1.0%"></td><td style="width:73.037%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.439%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.583%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.441%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Statements of Operations</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product revenues</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia489a15348ae4ae390bc47557aaca423_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yMi9mcmFnOjBmN2NkMTY0ZGEzMjQyNmQ4NWU3OWQ5MzcxMTNmNTBkL3RhYmxlOjRmMzYzODc2YmY5NzRiODliYjcyY2Q1MjczZjU4NGFmL3RhYmxlcmFuZ2U6NGYzNjM4NzZiZjk3NGI4OWJiNzJjZDUyNzNmNTg0YWZfNC0xLTEtMS0w_63ccd53f-437b-4811-b8e4-a71b6dc0adc6">135,769</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae589afb590a4f5984a5dd4001d656cb_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yMi9mcmFnOjBmN2NkMTY0ZGEzMjQyNmQ4NWU3OWQ5MzcxMTNmNTBkL3RhYmxlOjRmMzYzODc2YmY5NzRiODliYjcyY2Q1MjczZjU4NGFmL3RhYmxlcmFuZ2U6NGYzNjM4NzZiZjk3NGI4OWJiNzJjZDUyNzNmNTg0YWZfNC0zLTEtMS0w_4f96f8b2-796b-47ca-b989-20590a7ad8fb">71,938</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net revenues from collaborations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6912a2c4b43f46838e7d9157c5b3a723_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yMi9mcmFnOjBmN2NkMTY0ZGEzMjQyNmQ4NWU3OWQ5MzcxMTNmNTBkL3RhYmxlOjRmMzYzODc2YmY5NzRiODliYjcyY2Q1MjczZjU4NGFmL3RhYmxlcmFuZ2U6NGYzNjM4NzZiZjk3NGI4OWJiNzJjZDUyNzNmNTg0YWZfNS0xLTEtMS0w_7ad4a1c1-7750-4ada-a1e1-457a8f6e9672">41,797</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i738b536de6724c23b1637b0913d14f26_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yMi9mcmFnOjBmN2NkMTY0ZGEzMjQyNmQ4NWU3OWQ5MzcxMTNmNTBkL3RhYmxlOjRmMzYzODc2YmY5NzRiODliYjcyY2Q1MjczZjU4NGFmL3RhYmxlcmFuZ2U6NGYzNjM4NzZiZjk3NGI4OWJiNzJjZDUyNzNmNTg0YWZfNS0zLTEtMS0w_af04b2c9-4398-4e0f-a905-685154b9e3df">27,538</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yMi9mcmFnOjBmN2NkMTY0ZGEzMjQyNmQ4NWU3OWQ5MzcxMTNmNTBkL3RhYmxlOjRmMzYzODc2YmY5NzRiODliYjcyY2Q1MjczZjU4NGFmL3RhYmxlcmFuZ2U6NGYzNjM4NzZiZjk3NGI4OWJiNzJjZDUyNzNmNTg0YWZfNi0xLTEtMS0w_d1d17b89-cb12-47f5-84fe-e455a87fb820">177,566</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide9f6e15665746279d0000be700fcc6a_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yMi9mcmFnOjBmN2NkMTY0ZGEzMjQyNmQ4NWU3OWQ5MzcxMTNmNTBkL3RhYmxlOjRmMzYzODc2YmY5NzRiODliYjcyY2Q1MjczZjU4NGFmL3RhYmxlcmFuZ2U6NGYzNjM4NzZiZjk3NGI4OWJiNzJjZDUyNzNmNTg0YWZfNi0zLTEtMS0w_50590d2f-0954-457c-8865-170c619c30d9">99,476</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating costs and expenses:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods sold</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yMi9mcmFnOjBmN2NkMTY0ZGEzMjQyNmQ4NWU3OWQ5MzcxMTNmNTBkL3RhYmxlOjRmMzYzODc2YmY5NzRiODliYjcyY2Q1MjczZjU4NGFmL3RhYmxlcmFuZ2U6NGYzNjM4NzZiZjk3NGI4OWJiNzJjZDUyNzNmNTg0YWZfOC0xLTEtMS0w_a2378341-9f1b-4dd0-9604-bb2557719286">23,023</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide9f6e15665746279d0000be700fcc6a_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yMi9mcmFnOjBmN2NkMTY0ZGEzMjQyNmQ4NWU3OWQ5MzcxMTNmNTBkL3RhYmxlOjRmMzYzODc2YmY5NzRiODliYjcyY2Q1MjczZjU4NGFmL3RhYmxlcmFuZ2U6NGYzNjM4NzZiZjk3NGI4OWJiNzJjZDUyNzNmNTg0YWZfOC0zLTEtMS0w_d0d1f058-924d-4119-8bda-cb184e096fc0">13,302</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of collaborations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="alny:CostOfCollaborationManufacturingAndRoyalties" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yMi9mcmFnOjBmN2NkMTY0ZGEzMjQyNmQ4NWU3OWQ5MzcxMTNmNTBkL3RhYmxlOjRmMzYzODc2YmY5NzRiODliYjcyY2Q1MjczZjU4NGFmL3RhYmxlcmFuZ2U6NGYzNjM4NzZiZjk3NGI4OWJiNzJjZDUyNzNmNTg0YWZfOS0xLTEtMS02ODU_c8cfe557-e4fb-4190-9297-8094425a06f5">8,039</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide9f6e15665746279d0000be700fcc6a_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="alny:CostOfCollaborationManufacturingAndRoyalties" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yMi9mcmFnOjBmN2NkMTY0ZGEzMjQyNmQ4NWU3OWQ5MzcxMTNmNTBkL3RhYmxlOjRmMzYzODc2YmY5NzRiODliYjcyY2Q1MjczZjU4NGFmL3RhYmxlcmFuZ2U6NGYzNjM4NzZiZjk3NGI4OWJiNzJjZDUyNzNmNTg0YWZfOS0zLTEtMS02ODU_86a8e56f-72be-411e-ab3f-d28e6a9b7068">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yMi9mcmFnOjBmN2NkMTY0ZGEzMjQyNmQ4NWU3OWQ5MzcxMTNmNTBkL3RhYmxlOjRmMzYzODc2YmY5NzRiODliYjcyY2Q1MjczZjU4NGFmL3RhYmxlcmFuZ2U6NGYzNjM4NzZiZjk3NGI4OWJiNzJjZDUyNzNmNTg0YWZfOS0xLTEtMS0w_98062a4b-d51e-411d-b683-39dc63dd8441">185,899</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide9f6e15665746279d0000be700fcc6a_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yMi9mcmFnOjBmN2NkMTY0ZGEzMjQyNmQ4NWU3OWQ5MzcxMTNmNTBkL3RhYmxlOjRmMzYzODc2YmY5NzRiODliYjcyY2Q1MjczZjU4NGFmL3RhYmxlcmFuZ2U6NGYzNjM4NzZiZjk3NGI4OWJiNzJjZDUyNzNmNTg0YWZfOS0zLTEtMS0w_6c43da1d-b1cd-4b98-b85a-d8c2a734402a">169,571</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yMi9mcmFnOjBmN2NkMTY0ZGEzMjQyNmQ4NWU3OWQ5MzcxMTNmNTBkL3RhYmxlOjRmMzYzODc2YmY5NzRiODliYjcyY2Q1MjczZjU4NGFmL3RhYmxlcmFuZ2U6NGYzNjM4NzZiZjk3NGI4OWJiNzJjZDUyNzNmNTg0YWZfMTAtMS0xLTEtMA_4c3b7db0-c126-4998-99f6-ffe29f907b6c">146,859</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide9f6e15665746279d0000be700fcc6a_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yMi9mcmFnOjBmN2NkMTY0ZGEzMjQyNmQ4NWU3OWQ5MzcxMTNmNTBkL3RhYmxlOjRmMzYzODc2YmY5NzRiODliYjcyY2Q1MjczZjU4NGFmL3RhYmxlcmFuZ2U6NGYzNjM4NzZiZjk3NGI4OWJiNzJjZDUyNzNmNTg0YWZfMTAtMy0xLTEtMA_24ff3e7c-c09d-48a4-a082-f1fc733df8ec">126,761</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating costs and expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yMi9mcmFnOjBmN2NkMTY0ZGEzMjQyNmQ4NWU3OWQ5MzcxMTNmNTBkL3RhYmxlOjRmMzYzODc2YmY5NzRiODliYjcyY2Q1MjczZjU4NGFmL3RhYmxlcmFuZ2U6NGYzNjM4NzZiZjk3NGI4OWJiNzJjZDUyNzNmNTg0YWZfMTEtMS0xLTEtMA_9dd10383-047e-4cd9-8756-ea8e2f28126e">363,820</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide9f6e15665746279d0000be700fcc6a_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yMi9mcmFnOjBmN2NkMTY0ZGEzMjQyNmQ4NWU3OWQ5MzcxMTNmNTBkL3RhYmxlOjRmMzYzODc2YmY5NzRiODliYjcyY2Q1MjczZjU4NGFmL3RhYmxlcmFuZ2U6NGYzNjM4NzZiZjk3NGI4OWJiNzJjZDUyNzNmNTg0YWZfMTEtMy0xLTEtMA_e0b95f45-417e-48a5-b4da-26413b93c7a6">309,634</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yMi9mcmFnOjBmN2NkMTY0ZGEzMjQyNmQ4NWU3OWQ5MzcxMTNmNTBkL3RhYmxlOjRmMzYzODc2YmY5NzRiODliYjcyY2Q1MjczZjU4NGFmL3RhYmxlcmFuZ2U6NGYzNjM4NzZiZjk3NGI4OWJiNzJjZDUyNzNmNTg0YWZfMTItMS0xLTEtMA_30c39a08-261d-4984-a2b7-4b22e0593cd0">186,254</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide9f6e15665746279d0000be700fcc6a_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yMi9mcmFnOjBmN2NkMTY0ZGEzMjQyNmQ4NWU3OWQ5MzcxMTNmNTBkL3RhYmxlOjRmMzYzODc2YmY5NzRiODliYjcyY2Q1MjczZjU4NGFmL3RhYmxlcmFuZ2U6NGYzNjM4NzZiZjk3NGI4OWJiNzJjZDUyNzNmNTg0YWZfMTItMy0xLTEtMA_66d11d1a-17d7-48b9-a5f5-902bf270e161">210,158</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (expense) income:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yMi9mcmFnOjBmN2NkMTY0ZGEzMjQyNmQ4NWU3OWQ5MzcxMTNmNTBkL3RhYmxlOjRmMzYzODc2YmY5NzRiODliYjcyY2Q1MjczZjU4NGFmL3RhYmxlcmFuZ2U6NGYzNjM4NzZiZjk3NGI4OWJiNzJjZDUyNzNmNTg0YWZfMTQtMS0xLTEtMA_23d4ef98-176a-4e66-b588-eb189a46ff78">32,515</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide9f6e15665746279d0000be700fcc6a_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yMi9mcmFnOjBmN2NkMTY0ZGEzMjQyNmQ4NWU3OWQ5MzcxMTNmNTBkL3RhYmxlOjRmMzYzODc2YmY5NzRiODliYjcyY2Q1MjczZjU4NGFmL3RhYmxlcmFuZ2U6NGYzNjM4NzZiZjk3NGI4OWJiNzJjZDUyNzNmNTg0YWZfMTQtMy0xLTEtMA_887ccff4-8f22-4c02-a082-e4993ed07ab4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yMi9mcmFnOjBmN2NkMTY0ZGEzMjQyNmQ4NWU3OWQ5MzcxMTNmNTBkL3RhYmxlOjRmMzYzODc2YmY5NzRiODliYjcyY2Q1MjczZjU4NGFmL3RhYmxlcmFuZ2U6NGYzNjM4NzZiZjk3NGI4OWJiNzJjZDUyNzNmNTg0YWZfMTUtMS0xLTEtMA_3a070ce2-43f3-4314-8811-dee10a14ee80">450</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide9f6e15665746279d0000be700fcc6a_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yMi9mcmFnOjBmN2NkMTY0ZGEzMjQyNmQ4NWU3OWQ5MzcxMTNmNTBkL3RhYmxlOjRmMzYzODc2YmY5NzRiODliYjcyY2Q1MjczZjU4NGFmL3RhYmxlcmFuZ2U6NGYzNjM4NzZiZjk3NGI4OWJiNzJjZDUyNzNmNTg0YWZfMTUtMy0xLTEtMA_2b5e5eba-778f-4bac-8658-bf9b038c0bc9">5,480</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yMi9mcmFnOjBmN2NkMTY0ZGEzMjQyNmQ4NWU3OWQ5MzcxMTNmNTBkL3RhYmxlOjRmMzYzODc2YmY5NzRiODliYjcyY2Q1MjczZjU4NGFmL3RhYmxlcmFuZ2U6NGYzNjM4NzZiZjk3NGI4OWJiNzJjZDUyNzNmNTg0YWZfMTYtMS0xLTEtMA_cc6a939a-ea2c-4e14-b6a3-3dbc767e902b">19,044</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide9f6e15665746279d0000be700fcc6a_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yMi9mcmFnOjBmN2NkMTY0ZGEzMjQyNmQ4NWU3OWQ5MzcxMTNmNTBkL3RhYmxlOjRmMzYzODc2YmY5NzRiODliYjcyY2Q1MjczZjU4NGFmL3RhYmxlcmFuZ2U6NGYzNjM4NzZiZjk3NGI4OWJiNzJjZDUyNzNmNTg0YWZfMTYtMy0xLTEtMA_962b0082-118b-4fa5-9f74-631d88225273">23,032</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other (expense) income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yMi9mcmFnOjBmN2NkMTY0ZGEzMjQyNmQ4NWU3OWQ5MzcxMTNmNTBkL3RhYmxlOjRmMzYzODc2YmY5NzRiODliYjcyY2Q1MjczZjU4NGFmL3RhYmxlcmFuZ2U6NGYzNjM4NzZiZjk3NGI4OWJiNzJjZDUyNzNmNTg0YWZfMTgtMS0xLTEtMA_65c1c772-62db-4763-a9e0-bbddf9cf8e4f">13,021</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide9f6e15665746279d0000be700fcc6a_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yMi9mcmFnOjBmN2NkMTY0ZGEzMjQyNmQ4NWU3OWQ5MzcxMTNmNTBkL3RhYmxlOjRmMzYzODc2YmY5NzRiODliYjcyY2Q1MjczZjU4NGFmL3RhYmxlcmFuZ2U6NGYzNjM4NzZiZjk3NGI4OWJiNzJjZDUyNzNmNTg0YWZfMTgtMy0xLTEtMA_ee3c0f07-47cc-485d-a69f-1e04c7ab4f7d">28,512</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yMi9mcmFnOjBmN2NkMTY0ZGEzMjQyNmQ4NWU3OWQ5MzcxMTNmNTBkL3RhYmxlOjRmMzYzODc2YmY5NzRiODliYjcyY2Q1MjczZjU4NGFmL3RhYmxlcmFuZ2U6NGYzNjM4NzZiZjk3NGI4OWJiNzJjZDUyNzNmNTg0YWZfMTktMS0xLTEtMA_d42b0225-eaa4-4595-bc2b-98b04aef0faa">199,275</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide9f6e15665746279d0000be700fcc6a_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yMi9mcmFnOjBmN2NkMTY0ZGEzMjQyNmQ4NWU3OWQ5MzcxMTNmNTBkL3RhYmxlOjRmMzYzODc2YmY5NzRiODliYjcyY2Q1MjczZjU4NGFmL3RhYmxlcmFuZ2U6NGYzNjM4NzZiZjk3NGI4OWJiNzJjZDUyNzNmNTg0YWZfMTktMy0xLTEtMA_ed65fe37-253b-4374-8d2d-cf9f829265f0">181,646</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yMi9mcmFnOjBmN2NkMTY0ZGEzMjQyNmQ4NWU3OWQ5MzcxMTNmNTBkL3RhYmxlOjRmMzYzODc2YmY5NzRiODliYjcyY2Q1MjczZjU4NGFmL3RhYmxlcmFuZ2U6NGYzNjM4NzZiZjk3NGI4OWJiNzJjZDUyNzNmNTg0YWZfMjAtMS0xLTEtMA_5ea94c6d-2e2d-4e75-a1dd-dfad110e1548">1,016</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide9f6e15665746279d0000be700fcc6a_D20200101-20200331" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yMi9mcmFnOjBmN2NkMTY0ZGEzMjQyNmQ4NWU3OWQ5MzcxMTNmNTBkL3RhYmxlOjRmMzYzODc2YmY5NzRiODliYjcyY2Q1MjczZjU4NGFmL3RhYmxlcmFuZ2U6NGYzNjM4NzZiZjk3NGI4OWJiNzJjZDUyNzNmNTg0YWZfMjAtMy0xLTEtMA_f9abec99-95a8-4ddd-9660-08e353e45a9b">575</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yMi9mcmFnOjBmN2NkMTY0ZGEzMjQyNmQ4NWU3OWQ5MzcxMTNmNTBkL3RhYmxlOjRmMzYzODc2YmY5NzRiODliYjcyY2Q1MjczZjU4NGFmL3RhYmxlcmFuZ2U6NGYzNjM4NzZiZjk3NGI4OWJiNzJjZDUyNzNmNTg0YWZfMjEtMS0xLTEtMA_f8e541f9-8015-40e9-ba34-7da825deefed">200,291</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide9f6e15665746279d0000be700fcc6a_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yMi9mcmFnOjBmN2NkMTY0ZGEzMjQyNmQ4NWU3OWQ5MzcxMTNmNTBkL3RhYmxlOjRmMzYzODc2YmY5NzRiODliYjcyY2Q1MjczZjU4NGFmL3RhYmxlcmFuZ2U6NGYzNjM4NzZiZjk3NGI4OWJiNzJjZDUyNzNmNTg0YWZfMjEtMy0xLTEtMA_d298190e-6dab-469f-b47c-98a472fd165f">182,221</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per common share - basic and diluted</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yMi9mcmFnOjBmN2NkMTY0ZGEzMjQyNmQ4NWU3OWQ5MzcxMTNmNTBkL3RhYmxlOjRmMzYzODc2YmY5NzRiODliYjcyY2Q1MjczZjU4NGFmL3RhYmxlcmFuZ2U6NGYzNjM4NzZiZjk3NGI4OWJiNzJjZDUyNzNmNTg0YWZfMjItMS0xLTEtMA_3ef2e0f1-f62b-44e4-a886-d7db0451a569">1.71</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ide9f6e15665746279d0000be700fcc6a_D20200101-20200331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yMi9mcmFnOjBmN2NkMTY0ZGEzMjQyNmQ4NWU3OWQ5MzcxMTNmNTBkL3RhYmxlOjRmMzYzODc2YmY5NzRiODliYjcyY2Q1MjczZjU4NGFmL3RhYmxlcmFuZ2U6NGYzNjM4NzZiZjk3NGI4OWJiNzJjZDUyNzNmNTg0YWZfMjItMy0xLTEtMA_df9f50bd-2a4b-4f2f-95a9-0490de4c5446">1.62</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares used to compute basic and diluted net loss per common share</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yMi9mcmFnOjBmN2NkMTY0ZGEzMjQyNmQ4NWU3OWQ5MzcxMTNmNTBkL3RhYmxlOjRmMzYzODc2YmY5NzRiODliYjcyY2Q1MjczZjU4NGFmL3RhYmxlcmFuZ2U6NGYzNjM4NzZiZjk3NGI4OWJiNzJjZDUyNzNmNTg0YWZfMjMtMS0xLTEtMA_0fe40dd5-05ff-4c6b-a376-40019f617ba4">117,080</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ide9f6e15665746279d0000be700fcc6a_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yMi9mcmFnOjBmN2NkMTY0ZGEzMjQyNmQ4NWU3OWQ5MzcxMTNmNTBkL3RhYmxlOjRmMzYzODc2YmY5NzRiODliYjcyY2Q1MjczZjU4NGFmL3RhYmxlcmFuZ2U6NGYzNjM4NzZiZjk3NGI4OWJiNzJjZDUyNzNmNTg0YWZfMjMtMy0xLTEtMA_eee079f0-090d-4e72-977b-60934de04fee">112,748</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Statements of Comprehensive Loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yMi9mcmFnOjBmN2NkMTY0ZGEzMjQyNmQ4NWU3OWQ5MzcxMTNmNTBkL3RhYmxlOjRmMzYzODc2YmY5NzRiODliYjcyY2Q1MjczZjU4NGFmL3RhYmxlcmFuZ2U6NGYzNjM4NzZiZjk3NGI4OWJiNzJjZDUyNzNmNTg0YWZfMjYtMS0xLTEtMA_6c5aa7ab-baa6-46f2-b114-8452003a1794">200,291</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide9f6e15665746279d0000be700fcc6a_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yMi9mcmFnOjBmN2NkMTY0ZGEzMjQyNmQ4NWU3OWQ5MzcxMTNmNTBkL3RhYmxlOjRmMzYzODc2YmY5NzRiODliYjcyY2Q1MjczZjU4NGFmL3RhYmxlcmFuZ2U6NGYzNjM4NzZiZjk3NGI4OWJiNzJjZDUyNzNmNTg0YWZfMjYtMy0xLTEtMA_72d4e83c-0e91-467e-999f-2b584dd6c8a3">182,221</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive (loss) income:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized (loss) gain on marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yMi9mcmFnOjBmN2NkMTY0ZGEzMjQyNmQ4NWU3OWQ5MzcxMTNmNTBkL3RhYmxlOjRmMzYzODc2YmY5NzRiODliYjcyY2Q1MjczZjU4NGFmL3RhYmxlcmFuZ2U6NGYzNjM4NzZiZjk3NGI4OWJiNzJjZDUyNzNmNTg0YWZfMjgtMS0xLTEtMA_735d5c55-9cf3-4583-8db3-7d300eaa7278">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide9f6e15665746279d0000be700fcc6a_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yMi9mcmFnOjBmN2NkMTY0ZGEzMjQyNmQ4NWU3OWQ5MzcxMTNmNTBkL3RhYmxlOjRmMzYzODc2YmY5NzRiODliYjcyY2Q1MjczZjU4NGFmL3RhYmxlcmFuZ2U6NGYzNjM4NzZiZjk3NGI4OWJiNzJjZDUyNzNmNTg0YWZfMjgtMy0xLTEtMA_8d490a57-5bab-4b21-a8b5-e6ba96c8d498">4,045</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation gains</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yMi9mcmFnOjBmN2NkMTY0ZGEzMjQyNmQ4NWU3OWQ5MzcxMTNmNTBkL3RhYmxlOjRmMzYzODc2YmY5NzRiODliYjcyY2Q1MjczZjU4NGFmL3RhYmxlcmFuZ2U6NGYzNjM4NzZiZjk3NGI4OWJiNzJjZDUyNzNmNTg0YWZfMjktMS0xLTEtMA_ddfe1d67-55ac-4159-aa98-8e265b63aeb9">6,848</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide9f6e15665746279d0000be700fcc6a_D20200101-20200331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yMi9mcmFnOjBmN2NkMTY0ZGEzMjQyNmQ4NWU3OWQ5MzcxMTNmNTBkL3RhYmxlOjRmMzYzODc2YmY5NzRiODliYjcyY2Q1MjczZjU4NGFmL3RhYmxlcmFuZ2U6NGYzNjM4NzZiZjk3NGI4OWJiNzJjZDUyNzNmNTg0YWZfMjktMy0xLTEtMA_f10e3ad1-0549-4d0b-9acc-2fab0c2aa0d9">340</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Defined benefit pension plans, net of tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yMi9mcmFnOjBmN2NkMTY0ZGEzMjQyNmQ4NWU3OWQ5MzcxMTNmNTBkL3RhYmxlOjRmMzYzODc2YmY5NzRiODliYjcyY2Q1MjczZjU4NGFmL3RhYmxlcmFuZ2U6NGYzNjM4NzZiZjk3NGI4OWJiNzJjZDUyNzNmNTg0YWZfMzAtMS0xLTEtMA_aafd16d4-ae06-4665-ab06-c7827cec122f">58</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide9f6e15665746279d0000be700fcc6a_D20200101-20200331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yMi9mcmFnOjBmN2NkMTY0ZGEzMjQyNmQ4NWU3OWQ5MzcxMTNmNTBkL3RhYmxlOjRmMzYzODc2YmY5NzRiODliYjcyY2Q1MjczZjU4NGFmL3RhYmxlcmFuZ2U6NGYzNjM4NzZiZjk3NGI4OWJiNzJjZDUyNzNmNTg0YWZfMzAtMy0xLTEtMA_f7612a14-b6e3-4289-9fb8-3718ab8fda81">74</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other comprehensive income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yMi9mcmFnOjBmN2NkMTY0ZGEzMjQyNmQ4NWU3OWQ5MzcxMTNmNTBkL3RhYmxlOjRmMzYzODc2YmY5NzRiODliYjcyY2Q1MjczZjU4NGFmL3RhYmxlcmFuZ2U6NGYzNjM4NzZiZjk3NGI4OWJiNzJjZDUyNzNmNTg0YWZfMzEtMS0xLTEtMA_8c87ae09-bf25-42be-8807-f8135cc42ef7">6,905</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide9f6e15665746279d0000be700fcc6a_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yMi9mcmFnOjBmN2NkMTY0ZGEzMjQyNmQ4NWU3OWQ5MzcxMTNmNTBkL3RhYmxlOjRmMzYzODc2YmY5NzRiODliYjcyY2Q1MjczZjU4NGFmL3RhYmxlcmFuZ2U6NGYzNjM4NzZiZjk3NGI4OWJiNzJjZDUyNzNmNTg0YWZfMzEtMy0xLTEtMA_fa79e7be-7ec2-422f-9029-adec164f8b71">4,459</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yMi9mcmFnOjBmN2NkMTY0ZGEzMjQyNmQ4NWU3OWQ5MzcxMTNmNTBkL3RhYmxlOjRmMzYzODc2YmY5NzRiODliYjcyY2Q1MjczZjU4NGFmL3RhYmxlcmFuZ2U6NGYzNjM4NzZiZjk3NGI4OWJiNzJjZDUyNzNmNTg0YWZfMzItMS0xLTEtMA_3a718066-c594-404a-a84f-ad36b74e8906">193,386</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide9f6e15665746279d0000be700fcc6a_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yMi9mcmFnOjBmN2NkMTY0ZGEzMjQyNmQ4NWU3OWQ5MzcxMTNmNTBkL3RhYmxlOjRmMzYzODc2YmY5NzRiODliYjcyY2Q1MjczZjU4NGFmL3RhYmxlcmFuZ2U6NGYzNjM4NzZiZjk3NGI4OWJiNzJjZDUyNzNmNTg0YWZfMzItMy0xLTEtMA_04c886bc-60e7-4f7e-bc3e-48c328339065">177,762</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:10pt;text-align:center"><span><br/></span></div><div style="margin-top:10pt;text-align:center"><span><br/></span></div><div style="margin-top:10pt;text-align:center"><span><br/></span></div><div style="margin-top:10pt;text-align:center"><span><br/></span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><div id="i9f86b6d3686546618ade3c76e6b23fc8_25"></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9f86b6d3686546618ade3c76e6b23fc8_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ALNYLAM PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.804%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.748%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.748%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.964%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.397%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.964%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.970%"></td><td style="width:0.1%"></td></tr><tr style="height:27pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total<br/>Stockholders&#8217;<br/>Equity</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance as of December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i781a6cf71b15431fb0056bd6a2d9ba9f_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yNS9mcmFnOmZhNDE3YThiNWEyYjQwYmViMzBkYjcwYzZkYzVjMTljL3RhYmxlOmM1ZTdhZmI5NmQxYzQzODA5YmExOTFiMzkxMjY0YTM0L3RhYmxlcmFuZ2U6YzVlN2FmYjk2ZDFjNDM4MDliYTE5MWIzOTEyNjRhMzRfMi0xLTEtMS0w_bb1db569-0863-4466-a6ff-dd7f155a35c8">116,427</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i781a6cf71b15431fb0056bd6a2d9ba9f_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yNS9mcmFnOmZhNDE3YThiNWEyYjQwYmViMzBkYjcwYzZkYzVjMTljL3RhYmxlOmM1ZTdhZmI5NmQxYzQzODA5YmExOTFiMzkxMjY0YTM0L3RhYmxlcmFuZ2U6YzVlN2FmYjk2ZDFjNDM4MDliYTE5MWIzOTEyNjRhMzRfMi0zLTEtMS0w_56f22f65-cb37-40b2-a7fb-d7d60f82b544">1,164</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c2ae885ee354f1c9e0aa3c387519965_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yNS9mcmFnOmZhNDE3YThiNWEyYjQwYmViMzBkYjcwYzZkYzVjMTljL3RhYmxlOmM1ZTdhZmI5NmQxYzQzODA5YmExOTFiMzkxMjY0YTM0L3RhYmxlcmFuZ2U6YzVlN2FmYjk2ZDFjNDM4MDliYTE5MWIzOTEyNjRhMzRfMi01LTEtMS0w_6dff58c9-26ad-475e-b7f3-4213b538d988">5,644,074</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie217873afb06447795dc36a1e1606a74_I20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yNS9mcmFnOmZhNDE3YThiNWEyYjQwYmViMzBkYjcwYzZkYzVjMTljL3RhYmxlOmM1ZTdhZmI5NmQxYzQzODA5YmExOTFiMzkxMjY0YTM0L3RhYmxlcmFuZ2U6YzVlN2FmYjk2ZDFjNDM4MDliYTE5MWIzOTEyNjRhMzRfMi03LTEtMS0w_78cc7e0c-46d4-4b44-b5a2-e47cd20bf691">43,622</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4ed3654498ae467fa00b86595fc2fd74_I20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yNS9mcmFnOmZhNDE3YThiNWEyYjQwYmViMzBkYjcwYzZkYzVjMTljL3RhYmxlOmM1ZTdhZmI5NmQxYzQzODA5YmExOTFiMzkxMjY0YTM0L3RhYmxlcmFuZ2U6YzVlN2FmYjk2ZDFjNDM4MDliYTE5MWIzOTEyNjRhMzRfMi05LTEtMS0w_b9194760-da1e-41d0-bc42-fadb345ba018">4,585,369</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id365c5f1d37444ac9e1da5b5891cd81a_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yNS9mcmFnOmZhNDE3YThiNWEyYjQwYmViMzBkYjcwYzZkYzVjMTljL3RhYmxlOmM1ZTdhZmI5NmQxYzQzODA5YmExOTFiMzkxMjY0YTM0L3RhYmxlcmFuZ2U6YzVlN2FmYjk2ZDFjNDM4MDliYTE5MWIzOTEyNjRhMzRfMi0xMS0xLTEtMA_4d30b6f1-cf16-458d-8924-367797fa1d0d">1,016,247</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercise of common stock options, net of tax withholdings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie41b061be2004e5993962162ca83d40e_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yNS9mcmFnOmZhNDE3YThiNWEyYjQwYmViMzBkYjcwYzZkYzVjMTljL3RhYmxlOmM1ZTdhZmI5NmQxYzQzODA5YmExOTFiMzkxMjY0YTM0L3RhYmxlcmFuZ2U6YzVlN2FmYjk2ZDFjNDM4MDliYTE5MWIzOTEyNjRhMzRfMy0xLTEtMS0w_88fdcf38-bf7b-4210-9667-aeecc99c7fb3">614</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie41b061be2004e5993962162ca83d40e_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yNS9mcmFnOmZhNDE3YThiNWEyYjQwYmViMzBkYjcwYzZkYzVjMTljL3RhYmxlOmM1ZTdhZmI5NmQxYzQzODA5YmExOTFiMzkxMjY0YTM0L3RhYmxlcmFuZ2U6YzVlN2FmYjk2ZDFjNDM4MDliYTE5MWIzOTEyNjRhMzRfMy0zLTEtMS0w_fdc4b75b-59cc-4c54-848a-ec64bddc1479">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5919ecb151d7401699f63ec0b4537716_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yNS9mcmFnOmZhNDE3YThiNWEyYjQwYmViMzBkYjcwYzZkYzVjMTljL3RhYmxlOmM1ZTdhZmI5NmQxYzQzODA5YmExOTFiMzkxMjY0YTM0L3RhYmxlcmFuZ2U6YzVlN2FmYjk2ZDFjNDM4MDliYTE5MWIzOTEyNjRhMzRfMy01LTEtMS0w_fe76ea53-e810-412b-b89f-2e24d9c30b86">47,028</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yNS9mcmFnOmZhNDE3YThiNWEyYjQwYmViMzBkYjcwYzZkYzVjMTljL3RhYmxlOmM1ZTdhZmI5NmQxYzQzODA5YmExOTFiMzkxMjY0YTM0L3RhYmxlcmFuZ2U6YzVlN2FmYjk2ZDFjNDM4MDliYTE5MWIzOTEyNjRhMzRfMy0xMS0xLTEtMA_a004a8fb-cc36-474b-a8f8-ff1d30307b21">47,034</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock under equity plans</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie41b061be2004e5993962162ca83d40e_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yNS9mcmFnOmZhNDE3YThiNWEyYjQwYmViMzBkYjcwYzZkYzVjMTljL3RhYmxlOmM1ZTdhZmI5NmQxYzQzODA5YmExOTFiMzkxMjY0YTM0L3RhYmxlcmFuZ2U6YzVlN2FmYjk2ZDFjNDM4MDliYTE5MWIzOTEyNjRhMzRfNC0xLTEtMS0w_fc207848-33e2-45bd-8f8f-3951282b8f68">280</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie41b061be2004e5993962162ca83d40e_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yNS9mcmFnOmZhNDE3YThiNWEyYjQwYmViMzBkYjcwYzZkYzVjMTljL3RhYmxlOmM1ZTdhZmI5NmQxYzQzODA5YmExOTFiMzkxMjY0YTM0L3RhYmxlcmFuZ2U6YzVlN2FmYjk2ZDFjNDM4MDliYTE5MWIzOTEyNjRhMzRfNC0zLTEtMS0w_945f9a70-1c1f-4e73-be3b-fb7f5df09bba">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5919ecb151d7401699f63ec0b4537716_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yNS9mcmFnOmZhNDE3YThiNWEyYjQwYmViMzBkYjcwYzZkYzVjMTljL3RhYmxlOmM1ZTdhZmI5NmQxYzQzODA5YmExOTFiMzkxMjY0YTM0L3RhYmxlcmFuZ2U6YzVlN2FmYjk2ZDFjNDM4MDliYTE5MWIzOTEyNjRhMzRfNC01LTEtMS0w_90d92fe2-ddba-4755-b572-250b1d8252aa">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yNS9mcmFnOmZhNDE3YThiNWEyYjQwYmViMzBkYjcwYzZkYzVjMTljL3RhYmxlOmM1ZTdhZmI5NmQxYzQzODA5YmExOTFiMzkxMjY0YTM0L3RhYmxlcmFuZ2U6YzVlN2FmYjk2ZDFjNDM4MDliYTE5MWIzOTEyNjRhMzRfNC0xMS0xLTEtMA_cb2983ab-04bc-461b-8fe7-c0bc375b9ac6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation expense related to equity-classified awards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5919ecb151d7401699f63ec0b4537716_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yNS9mcmFnOmZhNDE3YThiNWEyYjQwYmViMzBkYjcwYzZkYzVjMTljL3RhYmxlOmM1ZTdhZmI5NmQxYzQzODA5YmExOTFiMzkxMjY0YTM0L3RhYmxlcmFuZ2U6YzVlN2FmYjk2ZDFjNDM4MDliYTE5MWIzOTEyNjRhMzRfNS01LTEtMS0w_fe393b42-df8b-4cbc-98ec-5cbf9f85ef2b">56,295</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yNS9mcmFnOmZhNDE3YThiNWEyYjQwYmViMzBkYjcwYzZkYzVjMTljL3RhYmxlOmM1ZTdhZmI5NmQxYzQzODA5YmExOTFiMzkxMjY0YTM0L3RhYmxlcmFuZ2U6YzVlN2FmYjk2ZDFjNDM4MDliYTE5MWIzOTEyNjRhMzRfNS0xMS0xLTEtMA_28e0c5ab-e51d-42d6-83af-28ae43863dc4">56,295</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41a01c886cd440cd8cf8eb694fb78c84_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yNS9mcmFnOmZhNDE3YThiNWEyYjQwYmViMzBkYjcwYzZkYzVjMTljL3RhYmxlOmM1ZTdhZmI5NmQxYzQzODA5YmExOTFiMzkxMjY0YTM0L3RhYmxlcmFuZ2U6YzVlN2FmYjk2ZDFjNDM4MDliYTE5MWIzOTEyNjRhMzRfNi03LTEtMS0w_4de0b5d6-0193-4b0e-b1da-3b8eabd5903b">6,905</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yNS9mcmFnOmZhNDE3YThiNWEyYjQwYmViMzBkYjcwYzZkYzVjMTljL3RhYmxlOmM1ZTdhZmI5NmQxYzQzODA5YmExOTFiMzkxMjY0YTM0L3RhYmxlcmFuZ2U6YzVlN2FmYjk2ZDFjNDM4MDliYTE5MWIzOTEyNjRhMzRfNi0xMS0xLTEtMA_bc0cf00e-30b4-4094-9cc8-3f6bd2339f7a">6,905</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8c5ae4ff57e341c7951e97ef4434647e_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yNS9mcmFnOmZhNDE3YThiNWEyYjQwYmViMzBkYjcwYzZkYzVjMTljL3RhYmxlOmM1ZTdhZmI5NmQxYzQzODA5YmExOTFiMzkxMjY0YTM0L3RhYmxlcmFuZ2U6YzVlN2FmYjk2ZDFjNDM4MDliYTE5MWIzOTEyNjRhMzRfNy05LTEtMS0w_a9a30df6-11de-48e5-aa72-d5dd1a415f38">200,291</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yNS9mcmFnOmZhNDE3YThiNWEyYjQwYmViMzBkYjcwYzZkYzVjMTljL3RhYmxlOmM1ZTdhZmI5NmQxYzQzODA5YmExOTFiMzkxMjY0YTM0L3RhYmxlcmFuZ2U6YzVlN2FmYjk2ZDFjNDM4MDliYTE5MWIzOTEyNjRhMzRfNy0xMS0xLTEtMA_3de5233f-0b09-4b45-9d22-da0679974014">200,291</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance as of March 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i898030c659864177808288abf9a59aac_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yNS9mcmFnOmZhNDE3YThiNWEyYjQwYmViMzBkYjcwYzZkYzVjMTljL3RhYmxlOmM1ZTdhZmI5NmQxYzQzODA5YmExOTFiMzkxMjY0YTM0L3RhYmxlcmFuZ2U6YzVlN2FmYjk2ZDFjNDM4MDliYTE5MWIzOTEyNjRhMzRfOC0xLTEtMS0w_8659e44c-0b39-452c-8161-e76475f209e9">117,321</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i898030c659864177808288abf9a59aac_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yNS9mcmFnOmZhNDE3YThiNWEyYjQwYmViMzBkYjcwYzZkYzVjMTljL3RhYmxlOmM1ZTdhZmI5NmQxYzQzODA5YmExOTFiMzkxMjY0YTM0L3RhYmxlcmFuZ2U6YzVlN2FmYjk2ZDFjNDM4MDliYTE5MWIzOTEyNjRhMzRfOC0zLTEtMS0w_df51c063-6b50-46a0-8964-fb666279a0e7">1,173</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic292a95f9d27470da961a5af69a8168d_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yNS9mcmFnOmZhNDE3YThiNWEyYjQwYmViMzBkYjcwYzZkYzVjMTljL3RhYmxlOmM1ZTdhZmI5NmQxYzQzODA5YmExOTFiMzkxMjY0YTM0L3RhYmxlcmFuZ2U6YzVlN2FmYjk2ZDFjNDM4MDliYTE5MWIzOTEyNjRhMzRfOC01LTEtMS0w_f366a3ee-f644-4589-b9cf-51d46b4cd93f">5,747,394</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic1a5c9f95c104828afb8e8cfafe56963_I20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yNS9mcmFnOmZhNDE3YThiNWEyYjQwYmViMzBkYjcwYzZkYzVjMTljL3RhYmxlOmM1ZTdhZmI5NmQxYzQzODA5YmExOTFiMzkxMjY0YTM0L3RhYmxlcmFuZ2U6YzVlN2FmYjk2ZDFjNDM4MDliYTE5MWIzOTEyNjRhMzRfOC03LTEtMS0w_9dc24a9f-c6b3-462e-a99d-fc4f5ee32c70">36,717</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i228f04c4c7b54cc6b36a2842a9727865_I20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yNS9mcmFnOmZhNDE3YThiNWEyYjQwYmViMzBkYjcwYzZkYzVjMTljL3RhYmxlOmM1ZTdhZmI5NmQxYzQzODA5YmExOTFiMzkxMjY0YTM0L3RhYmxlcmFuZ2U6YzVlN2FmYjk2ZDFjNDM4MDliYTE5MWIzOTEyNjRhMzRfOC05LTEtMS0w_bb47771a-2a24-47da-ac2a-90767f730540">4,785,660</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd7204dc87d24972a01f15b098c4f56b_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yNS9mcmFnOmZhNDE3YThiNWEyYjQwYmViMzBkYjcwYzZkYzVjMTljL3RhYmxlOmM1ZTdhZmI5NmQxYzQzODA5YmExOTFiMzkxMjY0YTM0L3RhYmxlcmFuZ2U6YzVlN2FmYjk2ZDFjNDM4MDliYTE5MWIzOTEyNjRhMzRfOC0xMS0xLTEtMA_6ec85e22-c245-48f3-ac82-fb4854ff23ab">926,190</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.804%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.748%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.748%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.964%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.397%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.964%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.970%"></td><td style="width:0.1%"></td></tr><tr style="height:26pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Other</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Comprehensive</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Loss</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total<br/>Stockholders&#8217;<br/>Equity</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance as of December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i529e7b1cdc924faf8a02fa556a4493bc_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yNS9mcmFnOmZhNDE3YThiNWEyYjQwYmViMzBkYjcwYzZkYzVjMTljL3RhYmxlOjhlNjQ5MTEwZDM2ZjQ5ODc5MzRiMGY5NzIyYThiZjBkL3RhYmxlcmFuZ2U6OGU2NDkxMTBkMzZmNDk4NzkzNGIwZjk3MjJhOGJmMGRfMi0xLTEtMS0w_246d32e7-13f8-45ca-93bd-dac04f69a82c">112,188</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i529e7b1cdc924faf8a02fa556a4493bc_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yNS9mcmFnOmZhNDE3YThiNWEyYjQwYmViMzBkYjcwYzZkYzVjMTljL3RhYmxlOjhlNjQ5MTEwZDM2ZjQ5ODc5MzRiMGY5NzIyYThiZjBkL3RhYmxlcmFuZ2U6OGU2NDkxMTBkMzZmNDk4NzkzNGIwZjk3MjJhOGJmMGRfMi0zLTEtMS0w_a7148ed7-5c8c-4a82-ad64-f41cfe2c03a8">1,122</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e5f4eb4a821432ba3f5cd2a2ffe2754_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yNS9mcmFnOmZhNDE3YThiNWEyYjQwYmViMzBkYjcwYzZkYzVjMTljL3RhYmxlOjhlNjQ5MTEwZDM2ZjQ5ODc5MzRiMGY5NzIyYThiZjBkL3RhYmxlcmFuZ2U6OGU2NDkxMTBkMzZmNDk4NzkzNGIwZjk3MjJhOGJmMGRfMi01LTEtMS0w_3b66eadd-2a34-4372-a37a-6e28cf5af4d6">5,201,176</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if6294416a69f4b6daebcdebf72f5c179_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yNS9mcmFnOmZhNDE3YThiNWEyYjQwYmViMzBkYjcwYzZkYzVjMTljL3RhYmxlOjhlNjQ5MTEwZDM2ZjQ5ODc5MzRiMGY5NzIyYThiZjBkL3RhYmxlcmFuZ2U6OGU2NDkxMTBkMzZmNDk4NzkzNGIwZjk3MjJhOGJmMGRfMi03LTEtMS0w_a0ef1436-141b-4183-a0a9-9956b18047af">36,518</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7d5f25d01b88417aa57a44792c225b17_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yNS9mcmFnOmZhNDE3YThiNWEyYjQwYmViMzBkYjcwYzZkYzVjMTljL3RhYmxlOjhlNjQ5MTEwZDM2ZjQ5ODc5MzRiMGY5NzIyYThiZjBkL3RhYmxlcmFuZ2U6OGU2NDkxMTBkMzZmNDk4NzkzNGIwZjk3MjJhOGJmMGRfMi05LTEtMS0w_2677c8a9-760e-47b9-a006-1978b1ed065b">3,727,088</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebcb948108ce4342974f490750a7c986_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yNS9mcmFnOmZhNDE3YThiNWEyYjQwYmViMzBkYjcwYzZkYzVjMTljL3RhYmxlOjhlNjQ5MTEwZDM2ZjQ5ODc5MzRiMGY5NzIyYThiZjBkL3RhYmxlcmFuZ2U6OGU2NDkxMTBkMzZmNDk4NzkzNGIwZjk3MjJhOGJmMGRfMi0xMS0xLTEtMA_a7f70021-8949-46e1-be26-c01de43c6f5b">1,438,692</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercise of common stock options, net of tax withholdings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id329f7a0b2394ad5a1935867e133e7f0_D20200101-20200331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yNS9mcmFnOmZhNDE3YThiNWEyYjQwYmViMzBkYjcwYzZkYzVjMTljL3RhYmxlOjhlNjQ5MTEwZDM2ZjQ5ODc5MzRiMGY5NzIyYThiZjBkL3RhYmxlcmFuZ2U6OGU2NDkxMTBkMzZmNDk4NzkzNGIwZjk3MjJhOGJmMGRfNC0xLTEtMS0w_bc50968d-2135-40b4-9491-b8c81f8cca5e">976</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id329f7a0b2394ad5a1935867e133e7f0_D20200101-20200331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yNS9mcmFnOmZhNDE3YThiNWEyYjQwYmViMzBkYjcwYzZkYzVjMTljL3RhYmxlOjhlNjQ5MTEwZDM2ZjQ5ODc5MzRiMGY5NzIyYThiZjBkL3RhYmxlcmFuZ2U6OGU2NDkxMTBkMzZmNDk4NzkzNGIwZjk3MjJhOGJmMGRfNC0zLTEtMS0w_9ad3077c-4da1-4eca-9c88-c1f6140dd7a1">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib01acb7d931b4460a0e434d20db18c85_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yNS9mcmFnOmZhNDE3YThiNWEyYjQwYmViMzBkYjcwYzZkYzVjMTljL3RhYmxlOjhlNjQ5MTEwZDM2ZjQ5ODc5MzRiMGY5NzIyYThiZjBkL3RhYmxlcmFuZ2U6OGU2NDkxMTBkMzZmNDk4NzkzNGIwZjk3MjJhOGJmMGRfNC01LTEtMS0w_1c623fdb-9a5b-4ad9-8c55-e75fe00f8f84">54,212</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide9f6e15665746279d0000be700fcc6a_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yNS9mcmFnOmZhNDE3YThiNWEyYjQwYmViMzBkYjcwYzZkYzVjMTljL3RhYmxlOjhlNjQ5MTEwZDM2ZjQ5ODc5MzRiMGY5NzIyYThiZjBkL3RhYmxlcmFuZ2U6OGU2NDkxMTBkMzZmNDk4NzkzNGIwZjk3MjJhOGJmMGRfNC0xMS0xLTEtMA_4feeaa01-d17c-43d1-8356-6a64a1943950">54,221</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock under equity plans</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id329f7a0b2394ad5a1935867e133e7f0_D20200101-20200331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yNS9mcmFnOmZhNDE3YThiNWEyYjQwYmViMzBkYjcwYzZkYzVjMTljL3RhYmxlOjhlNjQ5MTEwZDM2ZjQ5ODc5MzRiMGY5NzIyYThiZjBkL3RhYmxlcmFuZ2U6OGU2NDkxMTBkMzZmNDk4NzkzNGIwZjk3MjJhOGJmMGRfNS0xLTEtMS0w_e689d6f5-3033-42c8-8a9f-38a59d06e4b1">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation expense related to equity-classified awards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib01acb7d931b4460a0e434d20db18c85_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yNS9mcmFnOmZhNDE3YThiNWEyYjQwYmViMzBkYjcwYzZkYzVjMTljL3RhYmxlOjhlNjQ5MTEwZDM2ZjQ5ODc5MzRiMGY5NzIyYThiZjBkL3RhYmxlcmFuZ2U6OGU2NDkxMTBkMzZmNDk4NzkzNGIwZjk3MjJhOGJmMGRfNy01LTEtMS0w_dda2e165-da24-41b0-b0dc-124269017852">34,578</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide9f6e15665746279d0000be700fcc6a_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yNS9mcmFnOmZhNDE3YThiNWEyYjQwYmViMzBkYjcwYzZkYzVjMTljL3RhYmxlOjhlNjQ5MTEwZDM2ZjQ5ODc5MzRiMGY5NzIyYThiZjBkL3RhYmxlcmFuZ2U6OGU2NDkxMTBkMzZmNDk4NzkzNGIwZjk3MjJhOGJmMGRfNy0xMS0xLTEtMA_3227b3e0-4f6d-4dfb-9b9f-7f9a709f8c2c">34,578</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i074c45cb3f5642eea30ad48202c86fc9_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yNS9mcmFnOmZhNDE3YThiNWEyYjQwYmViMzBkYjcwYzZkYzVjMTljL3RhYmxlOjhlNjQ5MTEwZDM2ZjQ5ODc5MzRiMGY5NzIyYThiZjBkL3RhYmxlcmFuZ2U6OGU2NDkxMTBkMzZmNDk4NzkzNGIwZjk3MjJhOGJmMGRfOC03LTEtMS0w_d9154be4-cceb-4879-bbd2-d0d7eb9266ac">4,459</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide9f6e15665746279d0000be700fcc6a_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yNS9mcmFnOmZhNDE3YThiNWEyYjQwYmViMzBkYjcwYzZkYzVjMTljL3RhYmxlOjhlNjQ5MTEwZDM2ZjQ5ODc5MzRiMGY5NzIyYThiZjBkL3RhYmxlcmFuZ2U6OGU2NDkxMTBkMzZmNDk4NzkzNGIwZjk3MjJhOGJmMGRfOC0xMS0xLTEtMA_d63dcccc-5d8c-4713-a5fa-e563984fd3a7">4,459</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i35858c4e152c41c983e25b7741dcfb36_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yNS9mcmFnOmZhNDE3YThiNWEyYjQwYmViMzBkYjcwYzZkYzVjMTljL3RhYmxlOjhlNjQ5MTEwZDM2ZjQ5ODc5MzRiMGY5NzIyYThiZjBkL3RhYmxlcmFuZ2U6OGU2NDkxMTBkMzZmNDk4NzkzNGIwZjk3MjJhOGJmMGRfOS05LTEtMS0w_5cf5e905-5fe2-4f41-81dc-2466e17f4f82">182,221</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide9f6e15665746279d0000be700fcc6a_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yNS9mcmFnOmZhNDE3YThiNWEyYjQwYmViMzBkYjcwYzZkYzVjMTljL3RhYmxlOjhlNjQ5MTEwZDM2ZjQ5ODc5MzRiMGY5NzIyYThiZjBkL3RhYmxlcmFuZ2U6OGU2NDkxMTBkMzZmNDk4NzkzNGIwZjk3MjJhOGJmMGRfOS0xMS0xLTEtMA_1483e831-88cb-48d5-aa73-0cd946c558cd">182,221</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance as of March 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1e51c390ee2b4b95b9d11592d9610350_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yNS9mcmFnOmZhNDE3YThiNWEyYjQwYmViMzBkYjcwYzZkYzVjMTljL3RhYmxlOjhlNjQ5MTEwZDM2ZjQ5ODc5MzRiMGY5NzIyYThiZjBkL3RhYmxlcmFuZ2U6OGU2NDkxMTBkMzZmNDk4NzkzNGIwZjk3MjJhOGJmMGRfMTAtMS0xLTEtMA_75c410a9-db8a-4516-b7dc-3d29b6bede69">113,168</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e51c390ee2b4b95b9d11592d9610350_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yNS9mcmFnOmZhNDE3YThiNWEyYjQwYmViMzBkYjcwYzZkYzVjMTljL3RhYmxlOjhlNjQ5MTEwZDM2ZjQ5ODc5MzRiMGY5NzIyYThiZjBkL3RhYmxlcmFuZ2U6OGU2NDkxMTBkMzZmNDk4NzkzNGIwZjk3MjJhOGJmMGRfMTAtMy0xLTEtMA_9e0598f6-5c3b-487b-adcb-18ba5873e0e4">1,131</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4219d6246f0f4615b7f66a38c10fc9fe_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yNS9mcmFnOmZhNDE3YThiNWEyYjQwYmViMzBkYjcwYzZkYzVjMTljL3RhYmxlOjhlNjQ5MTEwZDM2ZjQ5ODc5MzRiMGY5NzIyYThiZjBkL3RhYmxlcmFuZ2U6OGU2NDkxMTBkMzZmNDk4NzkzNGIwZjk3MjJhOGJmMGRfMTAtNS0xLTEtMA_c63d4ed3-0b3f-4c6a-9303-440e11e66431">5,289,966</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0cd32b4827314c02b0aeae69087c66b0_I20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yNS9mcmFnOmZhNDE3YThiNWEyYjQwYmViMzBkYjcwYzZkYzVjMTljL3RhYmxlOjhlNjQ5MTEwZDM2ZjQ5ODc5MzRiMGY5NzIyYThiZjBkL3RhYmxlcmFuZ2U6OGU2NDkxMTBkMzZmNDk4NzkzNGIwZjk3MjJhOGJmMGRfMTAtNy0xLTEtMA_d1aaac73-72cd-4e85-b667-b816f16b1317">32,059</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1a2a3f2a9d1744519ed77d4a1400c065_I20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yNS9mcmFnOmZhNDE3YThiNWEyYjQwYmViMzBkYjcwYzZkYzVjMTljL3RhYmxlOjhlNjQ5MTEwZDM2ZjQ5ODc5MzRiMGY5NzIyYThiZjBkL3RhYmxlcmFuZ2U6OGU2NDkxMTBkMzZmNDk4NzkzNGIwZjk3MjJhOGJmMGRfMTAtOS0xLTEtMA_56a0b9a3-c5c7-4b45-85b7-531f48eef57d">3,909,309</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic378e7f6183c40b4b7371ed7b7370867_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yNS9mcmFnOmZhNDE3YThiNWEyYjQwYmViMzBkYjcwYzZkYzVjMTljL3RhYmxlOjhlNjQ5MTEwZDM2ZjQ5ODc5MzRiMGY5NzIyYThiZjBkL3RhYmxlcmFuZ2U6OGU2NDkxMTBkMzZmNDk4NzkzNGIwZjk3MjJhOGJmMGRfMTAtMTEtMS0xLTA_02297ada-a805-4d21-937b-d82a4c7165dd">1,349,729</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><div id="i9f86b6d3686546618ade3c76e6b23fc8_28"></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9f86b6d3686546618ade3c76e6b23fc8_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ALNYLAM PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:93.567%"><tr><td style="width:1.0%"></td><td style="width:72.806%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.581%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.557%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yOC9mcmFnOmUzZDg2ZjExMWM3ODQwYTVhN2EyOGE3OWViOGIxN2QwL3RhYmxlOjJhZGY5OWY2YTA0NjRkNTBiOTkxMTZjNDc0M2M4ZTdiL3RhYmxlcmFuZ2U6MmFkZjk5ZjZhMDQ2NGQ1MGI5OTExNmM0NzQzYzhlN2JfMy0xLTEtMS0w_a1ad6034-7124-4fe4-8264-27a2aa082829">200,291</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide9f6e15665746279d0000be700fcc6a_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yOC9mcmFnOmUzZDg2ZjExMWM3ODQwYTVhN2EyOGE3OWViOGIxN2QwL3RhYmxlOjJhZGY5OWY2YTA0NjRkNTBiOTkxMTZjNDc0M2M4ZTdiL3RhYmxlcmFuZ2U6MmFkZjk5ZjZhMDQ2NGQ1MGI5OTExNmM0NzQzYzhlN2JfMy0zLTEtMS0w_c2ee1da2-515f-4860-a002-368554ebe7da">182,221</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-cash adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationAmortizationAndAccretionNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yOC9mcmFnOmUzZDg2ZjExMWM3ODQwYTVhN2EyOGE3OWViOGIxN2QwL3RhYmxlOjJhZGY5OWY2YTA0NjRkNTBiOTkxMTZjNDc0M2M4ZTdiL3RhYmxlcmFuZ2U6MmFkZjk5ZjZhMDQ2NGQ1MGI5OTExNmM0NzQzYzhlN2JfNS0xLTEtMS0w_4c645db1-1463-4c1e-9581-ef4cd8047a57">12,601</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide9f6e15665746279d0000be700fcc6a_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationAmortizationAndAccretionNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yOC9mcmFnOmUzZDg2ZjExMWM3ODQwYTVhN2EyOGE3OWViOGIxN2QwL3RhYmxlOjJhZGY5OWY2YTA0NjRkNTBiOTkxMTZjNDc0M2M4ZTdiL3RhYmxlcmFuZ2U6MmFkZjk5ZjZhMDQ2NGQ1MGI5OTExNmM0NzQzYzhlN2JfNS0zLTEtMS0w_efd7a116-6a50-4517-9502-297238c909d6">7,613</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization and interest accretion related to operating leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="alny:AmortizationAndInterestAccretionRelatedToOperatingLeases" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yOC9mcmFnOmUzZDg2ZjExMWM3ODQwYTVhN2EyOGE3OWViOGIxN2QwL3RhYmxlOjJhZGY5OWY2YTA0NjRkNTBiOTkxMTZjNDc0M2M4ZTdiL3RhYmxlcmFuZ2U6MmFkZjk5ZjZhMDQ2NGQ1MGI5OTExNmM0NzQzYzhlN2JfNi0xLTEtMS0w_0d286142-2e1c-4911-991b-5f515f2c510a">10,261</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide9f6e15665746279d0000be700fcc6a_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="alny:AmortizationAndInterestAccretionRelatedToOperatingLeases" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yOC9mcmFnOmUzZDg2ZjExMWM3ODQwYTVhN2EyOGE3OWViOGIxN2QwL3RhYmxlOjJhZGY5OWY2YTA0NjRkNTBiOTkxMTZjNDc0M2M4ZTdiL3RhYmxlcmFuZ2U6MmFkZjk5ZjZhMDQ2NGQ1MGI5OTExNmM0NzQzYzhlN2JfNi0zLTEtMS0w_86303acf-395f-46df-8493-c18b02103a7b">9,393</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-cash interest expense on liability related to the sale of future royalties</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="alny:NonCashInterestExpenseOnSaleOfFutureRoyalties" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yOC9mcmFnOmUzZDg2ZjExMWM3ODQwYTVhN2EyOGE3OWViOGIxN2QwL3RhYmxlOjJhZGY5OWY2YTA0NjRkNTBiOTkxMTZjNDc0M2M4ZTdiL3RhYmxlcmFuZ2U6MmFkZjk5ZjZhMDQ2NGQ1MGI5OTExNmM0NzQzYzhlN2JfNy0xLTEtMS0w_c66fabd5-109f-42e5-b7d8-fc7f1a309233">28,184</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide9f6e15665746279d0000be700fcc6a_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="alny:NonCashInterestExpenseOnSaleOfFutureRoyalties" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yOC9mcmFnOmUzZDg2ZjExMWM3ODQwYTVhN2EyOGE3OWViOGIxN2QwL3RhYmxlOjJhZGY5OWY2YTA0NjRkNTBiOTkxMTZjNDc0M2M4ZTdiL3RhYmxlcmFuZ2U6MmFkZjk5ZjZhMDQ2NGQ1MGI5OTExNmM0NzQzYzhlN2JfNy0zLTEtMS0w_a9ae7042-9fb5-47af-af7f-5addaa6827b9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yOC9mcmFnOmUzZDg2ZjExMWM3ODQwYTVhN2EyOGE3OWViOGIxN2QwL3RhYmxlOjJhZGY5OWY2YTA0NjRkNTBiOTkxMTZjNDc0M2M4ZTdiL3RhYmxlcmFuZ2U6MmFkZjk5ZjZhMDQ2NGQ1MGI5OTExNmM0NzQzYzhlN2JfOC0xLTEtMS0w_3fd6c478-52bf-4fdf-a314-e5d8fece757a">55,690</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide9f6e15665746279d0000be700fcc6a_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yOC9mcmFnOmUzZDg2ZjExMWM3ODQwYTVhN2EyOGE3OWViOGIxN2QwL3RhYmxlOjJhZGY5OWY2YTA0NjRkNTBiOTkxMTZjNDc0M2M4ZTdiL3RhYmxlcmFuZ2U6MmFkZjk5ZjZhMDQ2NGQ1MGI5OTExNmM0NzQzYzhlN2JfOC0zLTEtMS0w_43821925-f4c3-403a-8d19-87c0c6d812d5">34,578</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Realized and unrealized gain on marketable equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNiGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yOC9mcmFnOmUzZDg2ZjExMWM3ODQwYTVhN2EyOGE3OWViOGIxN2QwL3RhYmxlOjJhZGY5OWY2YTA0NjRkNTBiOTkxMTZjNDc0M2M4ZTdiL3RhYmxlcmFuZ2U6MmFkZjk5ZjZhMDQ2NGQ1MGI5OTExNmM0NzQzYzhlN2JfOS0xLTEtMS0w_dd16f25e-2083-423c-b929-5f11ec4b1ed1">47,016</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide9f6e15665746279d0000be700fcc6a_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNiGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yOC9mcmFnOmUzZDg2ZjExMWM3ODQwYTVhN2EyOGE3OWViOGIxN2QwL3RhYmxlOjJhZGY5OWY2YTA0NjRkNTBiOTkxMTZjNDc0M2M4ZTdiL3RhYmxlcmFuZ2U6MmFkZjk5ZjZhMDQ2NGQ1MGI5OTExNmM0NzQzYzhlN2JfOS0zLTEtMS0w_472cbb2a-e3f8-44bd-9aaa-9bf0d51e6386">24,111</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherOperatingActivitiesCashFlowStatement" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yOC9mcmFnOmUzZDg2ZjExMWM3ODQwYTVhN2EyOGE3OWViOGIxN2QwL3RhYmxlOjJhZGY5OWY2YTA0NjRkNTBiOTkxMTZjNDc0M2M4ZTdiL3RhYmxlcmFuZ2U6MmFkZjk5ZjZhMDQ2NGQ1MGI5OTExNmM0NzQzYzhlN2JfMTEtMS0xLTEtMA_44f3a47d-2ae6-4662-8b2d-404ba173612e">30,777</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide9f6e15665746279d0000be700fcc6a_D20200101-20200331" decimals="-3" name="us-gaap:OtherOperatingActivitiesCashFlowStatement" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yOC9mcmFnOmUzZDg2ZjExMWM3ODQwYTVhN2EyOGE3OWViOGIxN2QwL3RhYmxlOjJhZGY5OWY2YTA0NjRkNTBiOTkxMTZjNDc0M2M4ZTdiL3RhYmxlcmFuZ2U6MmFkZjk5ZjZhMDQ2NGQ1MGI5OTExNmM0NzQzYzhlN2JfMTEtMy0xLTEtMA_da789f00-dc84-4a94-ad6a-8f9f803fc577">660</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yOC9mcmFnOmUzZDg2ZjExMWM3ODQwYTVhN2EyOGE3OWViOGIxN2QwL3RhYmxlOjJhZGY5OWY2YTA0NjRkNTBiOTkxMTZjNDc0M2M4ZTdiL3RhYmxlcmFuZ2U6MmFkZjk5ZjZhMDQ2NGQ1MGI5OTExNmM0NzQzYzhlN2JfMTMtMS0xLTEtMA_71ea47a0-4168-41f7-8f43-36a6e49c62c5">10,709</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide9f6e15665746279d0000be700fcc6a_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yOC9mcmFnOmUzZDg2ZjExMWM3ODQwYTVhN2EyOGE3OWViOGIxN2QwL3RhYmxlOjJhZGY5OWY2YTA0NjRkNTBiOTkxMTZjNDc0M2M4ZTdiL3RhYmxlcmFuZ2U6MmFkZjk5ZjZhMDQ2NGQ1MGI5OTExNmM0NzQzYzhlN2JfMTMtMy0xLTEtMA_6c03b729-7932-47d8-bb8e-9fc49545eeac">32,882</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yOC9mcmFnOmUzZDg2ZjExMWM3ODQwYTVhN2EyOGE3OWViOGIxN2QwL3RhYmxlOjJhZGY5OWY2YTA0NjRkNTBiOTkxMTZjNDc0M2M4ZTdiL3RhYmxlcmFuZ2U6MmFkZjk5ZjZhMDQ2NGQ1MGI5OTExNmM0NzQzYzhlN2JfMTUtMS0xLTEtMA_9ed9de06-2596-4f4b-bff0-cd88ff2d0689">1,934</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide9f6e15665746279d0000be700fcc6a_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yOC9mcmFnOmUzZDg2ZjExMWM3ODQwYTVhN2EyOGE3OWViOGIxN2QwL3RhYmxlOjJhZGY5OWY2YTA0NjRkNTBiOTkxMTZjNDc0M2M4ZTdiL3RhYmxlcmFuZ2U6MmFkZjk5ZjZhMDQ2NGQ1MGI5OTExNmM0NzQzYzhlN2JfMTUtMy0xLTEtMA_7ab1a8c5-b9da-48a2-bcee-0204db7a0f92">11,952</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yOC9mcmFnOmUzZDg2ZjExMWM3ODQwYTVhN2EyOGE3OWViOGIxN2QwL3RhYmxlOjJhZGY5OWY2YTA0NjRkNTBiOTkxMTZjNDc0M2M4ZTdiL3RhYmxlcmFuZ2U6MmFkZjk5ZjZhMDQ2NGQ1MGI5OTExNmM0NzQzYzhlN2JfMTYtMS0xLTEtMA_60e3c30b-4dfa-4662-b866-829091bf1f4f">13,654</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide9f6e15665746279d0000be700fcc6a_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yOC9mcmFnOmUzZDg2ZjExMWM3ODQwYTVhN2EyOGE3OWViOGIxN2QwL3RhYmxlOjJhZGY5OWY2YTA0NjRkNTBiOTkxMTZjNDc0M2M4ZTdiL3RhYmxlcmFuZ2U6MmFkZjk5ZjZhMDQ2NGQ1MGI5OTExNmM0NzQzYzhlN2JfMTYtMy0xLTEtMA_f148d117-8ec7-420f-a92e-4a714f8583b3">19,958</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable, accrued expenses and other liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yOC9mcmFnOmUzZDg2ZjExMWM3ODQwYTVhN2EyOGE3OWViOGIxN2QwL3RhYmxlOjJhZGY5OWY2YTA0NjRkNTBiOTkxMTZjNDc0M2M4ZTdiL3RhYmxlcmFuZ2U6MmFkZjk5ZjZhMDQ2NGQ1MGI5OTExNmM0NzQzYzhlN2JfMTctMS0xLTEtMA_41f86537-e898-40d2-a623-04abfa340e64">66,573</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide9f6e15665746279d0000be700fcc6a_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yOC9mcmFnOmUzZDg2ZjExMWM3ODQwYTVhN2EyOGE3OWViOGIxN2QwL3RhYmxlOjJhZGY5OWY2YTA0NjRkNTBiOTkxMTZjNDc0M2M4ZTdiL3RhYmxlcmFuZ2U6MmFkZjk5ZjZhMDQ2NGQ1MGI5OTExNmM0NzQzYzhlN2JfMTctMy0xLTEtMA_73788935-ef5d-4894-80ba-82b2dabdb11a">14,215</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yOC9mcmFnOmUzZDg2ZjExMWM3ODQwYTVhN2EyOGE3OWViOGIxN2QwL3RhYmxlOjJhZGY5OWY2YTA0NjRkNTBiOTkxMTZjNDc0M2M4ZTdiL3RhYmxlcmFuZ2U6MmFkZjk5ZjZhMDQ2NGQ1MGI5OTExNmM0NzQzYzhlN2JfMTgtMS0xLTEtMA_f93901c6-f99c-4ccd-aa83-32286166f99e">27,804</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide9f6e15665746279d0000be700fcc6a_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yOC9mcmFnOmUzZDg2ZjExMWM3ODQwYTVhN2EyOGE3OWViOGIxN2QwL3RhYmxlOjJhZGY5OWY2YTA0NjRkNTBiOTkxMTZjNDc0M2M4ZTdiL3RhYmxlcmFuZ2U6MmFkZjk5ZjZhMDQ2NGQ1MGI5OTExNmM0NzQzYzhlN2JfMTgtMy0xLTEtMA_a0908501-ae33-4d4a-8042-f20719ac291c">4,030</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yOC9mcmFnOmUzZDg2ZjExMWM3ODQwYTVhN2EyOGE3OWViOGIxN2QwL3RhYmxlOjJhZGY5OWY2YTA0NjRkNTBiOTkxMTZjNDc0M2M4ZTdiL3RhYmxlcmFuZ2U6MmFkZjk5ZjZhMDQ2NGQ1MGI5OTExNmM0NzQzYzhlN2JfMTktMS0xLTEtMA_68b5b91d-976c-4f4b-b9d2-eecbdf265dbd">9,060</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide9f6e15665746279d0000be700fcc6a_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yOC9mcmFnOmUzZDg2ZjExMWM3ODQwYTVhN2EyOGE3OWViOGIxN2QwL3RhYmxlOjJhZGY5OWY2YTA0NjRkNTBiOTkxMTZjNDc0M2M4ZTdiL3RhYmxlcmFuZ2U6MmFkZjk5ZjZhMDQ2NGQ1MGI5OTExNmM0NzQzYzhlN2JfMTktMy0xLTEtMA_0301d1aa-29bd-489e-a9ac-e7f7f854c9e3">9,036</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yOC9mcmFnOmUzZDg2ZjExMWM3ODQwYTVhN2EyOGE3OWViOGIxN2QwL3RhYmxlOjJhZGY5OWY2YTA0NjRkNTBiOTkxMTZjNDc0M2M4ZTdiL3RhYmxlcmFuZ2U6MmFkZjk5ZjZhMDQ2NGQ1MGI5OTExNmM0NzQzYzhlN2JfMjAtMS0xLTEtMA_e6856502-eb8f-4362-b74d-8624f871ff66">235,660</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide9f6e15665746279d0000be700fcc6a_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yOC9mcmFnOmUzZDg2ZjExMWM3ODQwYTVhN2EyOGE3OWViOGIxN2QwL3RhYmxlOjJhZGY5OWY2YTA0NjRkNTBiOTkxMTZjNDc0M2M4ZTdiL3RhYmxlcmFuZ2U6MmFkZjk5ZjZhMDQ2NGQ1MGI5OTExNmM0NzQzYzhlN2JfMjAtMy0xLTEtMA_f66baa00-7d4c-47ed-bcc0-f34ef0cff8fc">246,161</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of property, plant and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yOC9mcmFnOmUzZDg2ZjExMWM3ODQwYTVhN2EyOGE3OWViOGIxN2QwL3RhYmxlOjJhZGY5OWY2YTA0NjRkNTBiOTkxMTZjNDc0M2M4ZTdiL3RhYmxlcmFuZ2U6MmFkZjk5ZjZhMDQ2NGQ1MGI5OTExNmM0NzQzYzhlN2JfMjItMS0xLTEtMA_8ad43a65-6771-4279-accb-66b3516da6a1">17,178</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide9f6e15665746279d0000be700fcc6a_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yOC9mcmFnOmUzZDg2ZjExMWM3ODQwYTVhN2EyOGE3OWViOGIxN2QwL3RhYmxlOjJhZGY5OWY2YTA0NjRkNTBiOTkxMTZjNDc0M2M4ZTdiL3RhYmxlcmFuZ2U6MmFkZjk5ZjZhMDQ2NGQ1MGI5OTExNmM0NzQzYzhlN2JfMjItMy0xLTEtMA_59909cdc-0bb5-4f2e-b872-74e0818a6fa4">19,617</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yOC9mcmFnOmUzZDg2ZjExMWM3ODQwYTVhN2EyOGE3OWViOGIxN2QwL3RhYmxlOjJhZGY5OWY2YTA0NjRkNTBiOTkxMTZjNDc0M2M4ZTdiL3RhYmxlcmFuZ2U6MmFkZjk5ZjZhMDQ2NGQ1MGI5OTExNmM0NzQzYzhlN2JfMjMtMS0xLTEtMA_19cf3db3-ca56-415d-8fbb-b5b2aee892f5">345,954</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide9f6e15665746279d0000be700fcc6a_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yOC9mcmFnOmUzZDg2ZjExMWM3ODQwYTVhN2EyOGE3OWViOGIxN2QwL3RhYmxlOjJhZGY5OWY2YTA0NjRkNTBiOTkxMTZjNDc0M2M4ZTdiL3RhYmxlcmFuZ2U6MmFkZjk5ZjZhMDQ2NGQ1MGI5OTExNmM0NzQzYzhlN2JfMjMtMy0xLTEtMA_9b80dbbe-b1d4-416e-a29e-c811a84cce09">396,409</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sales and maturities of marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yOC9mcmFnOmUzZDg2ZjExMWM3ODQwYTVhN2EyOGE3OWViOGIxN2QwL3RhYmxlOjJhZGY5OWY2YTA0NjRkNTBiOTkxMTZjNDc0M2M4ZTdiL3RhYmxlcmFuZ2U6MmFkZjk5ZjZhMDQ2NGQ1MGI5OTExNmM0NzQzYzhlN2JfMjQtMS0xLTEtODc2_f6af33d6-d380-4fae-bf85-2289ed9e6d7f">438,682</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide9f6e15665746279d0000be700fcc6a_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yOC9mcmFnOmUzZDg2ZjExMWM3ODQwYTVhN2EyOGE3OWViOGIxN2QwL3RhYmxlOjJhZGY5OWY2YTA0NjRkNTBiOTkxMTZjNDc0M2M4ZTdiL3RhYmxlcmFuZ2U6MmFkZjk5ZjZhMDQ2NGQ1MGI5OTExNmM0NzQzYzhlN2JfMjQtMy0xLTEtODc2_239b9765-3c7d-4151-a8ee-dc48493e86e2">539,614</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of restricted investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireRestrictedInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yOC9mcmFnOmUzZDg2ZjExMWM3ODQwYTVhN2EyOGE3OWViOGIxN2QwL3RhYmxlOjJhZGY5OWY2YTA0NjRkNTBiOTkxMTZjNDc0M2M4ZTdiL3RhYmxlcmFuZ2U6MmFkZjk5ZjZhMDQ2NGQ1MGI5OTExNmM0NzQzYzhlN2JfMjQtMS0xLTEtMA_f9c02699-a410-414e-bc27-16c0925c0287">10,650</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide9f6e15665746279d0000be700fcc6a_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireRestrictedInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yOC9mcmFnOmUzZDg2ZjExMWM3ODQwYTVhN2EyOGE3OWViOGIxN2QwL3RhYmxlOjJhZGY5OWY2YTA0NjRkNTBiOTkxMTZjNDc0M2M4ZTdiL3RhYmxlcmFuZ2U6MmFkZjk5ZjZhMDQ2NGQ1MGI5OTExNmM0NzQzYzhlN2JfMjQtMy0xLTEtMA_00961663-104f-4ad5-af0e-f59a7a40f991">9,900</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from maturity of restricted investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleOfRestrictedInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yOC9mcmFnOmUzZDg2ZjExMWM3ODQwYTVhN2EyOGE3OWViOGIxN2QwL3RhYmxlOjJhZGY5OWY2YTA0NjRkNTBiOTkxMTZjNDc0M2M4ZTdiL3RhYmxlcmFuZ2U6MmFkZjk5ZjZhMDQ2NGQ1MGI5OTExNmM0NzQzYzhlN2JfMjUtMS0xLTEtMA_8e5c092b-0967-4595-b312-56393214f4a9">10,650</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide9f6e15665746279d0000be700fcc6a_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromSaleOfRestrictedInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yOC9mcmFnOmUzZDg2ZjExMWM3ODQwYTVhN2EyOGE3OWViOGIxN2QwL3RhYmxlOjJhZGY5OWY2YTA0NjRkNTBiOTkxMTZjNDc0M2M4ZTdiL3RhYmxlcmFuZ2U6MmFkZjk5ZjZhMDQ2NGQ1MGI5OTExNmM0NzQzYzhlN2JfMjUtMy0xLTEtMA_85802541-0ca2-4ded-b204-ba29e659c87d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other investing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yOC9mcmFnOmUzZDg2ZjExMWM3ODQwYTVhN2EyOGE3OWViOGIxN2QwL3RhYmxlOjJhZGY5OWY2YTA0NjRkNTBiOTkxMTZjNDc0M2M4ZTdiL3RhYmxlcmFuZ2U6MmFkZjk5ZjZhMDQ2NGQ1MGI5OTExNmM0NzQzYzhlN2JfMjctMS0xLTEtMA_ebf33add-4ad1-49d2-b9da-800077fad69c">4,198</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide9f6e15665746279d0000be700fcc6a_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yOC9mcmFnOmUzZDg2ZjExMWM3ODQwYTVhN2EyOGE3OWViOGIxN2QwL3RhYmxlOjJhZGY5OWY2YTA0NjRkNTBiOTkxMTZjNDc0M2M4ZTdiL3RhYmxlcmFuZ2U6MmFkZjk5ZjZhMDQ2NGQ1MGI5OTExNmM0NzQzYzhlN2JfMjctMy0xLTEtMA_98461d66-ea44-42f2-b28b-72cdf840724c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash provided by investing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yOC9mcmFnOmUzZDg2ZjExMWM3ODQwYTVhN2EyOGE3OWViOGIxN2QwL3RhYmxlOjJhZGY5OWY2YTA0NjRkNTBiOTkxMTZjNDc0M2M4ZTdiL3RhYmxlcmFuZ2U6MmFkZjk5ZjZhMDQ2NGQ1MGI5OTExNmM0NzQzYzhlN2JfMjgtMS0xLTEtMA_31351f70-ce1c-422a-802b-37a09c4e1bd6">71,352</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide9f6e15665746279d0000be700fcc6a_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yOC9mcmFnOmUzZDg2ZjExMWM3ODQwYTVhN2EyOGE3OWViOGIxN2QwL3RhYmxlOjJhZGY5OWY2YTA0NjRkNTBiOTkxMTZjNDc0M2M4ZTdiL3RhYmxlcmFuZ2U6MmFkZjk5ZjZhMDQ2NGQ1MGI5OTExNmM0NzQzYzhlN2JfMjgtMy0xLTEtMA_82e3a27a-9da3-428b-9c2d-439c1eb9a6b5">113,688</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from exercise of stock options and other types of equity, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yOC9mcmFnOmUzZDg2ZjExMWM3ODQwYTVhN2EyOGE3OWViOGIxN2QwL3RhYmxlOjJhZGY5OWY2YTA0NjRkNTBiOTkxMTZjNDc0M2M4ZTdiL3RhYmxlcmFuZ2U6MmFkZjk5ZjZhMDQ2NGQ1MGI5OTExNmM0NzQzYzhlN2JfMzAtMS0xLTEtMA_aa172176-4f37-4a43-add3-b6a599aee176">46,977</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide9f6e15665746279d0000be700fcc6a_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yOC9mcmFnOmUzZDg2ZjExMWM3ODQwYTVhN2EyOGE3OWViOGIxN2QwL3RhYmxlOjJhZGY5OWY2YTA0NjRkNTBiOTkxMTZjNDc0M2M4ZTdiL3RhYmxlcmFuZ2U6MmFkZjk5ZjZhMDQ2NGQ1MGI5OTExNmM0NzQzYzhlN2JfMzAtMy0xLTEtMA_41cc4366-540b-4b54-8963-32d544bcf2a7">53,869</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from development derivative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromDerivativeInstrumentFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yOC9mcmFnOmUzZDg2ZjExMWM3ODQwYTVhN2EyOGE3OWViOGIxN2QwL3RhYmxlOjJhZGY5OWY2YTA0NjRkNTBiOTkxMTZjNDc0M2M4ZTdiL3RhYmxlcmFuZ2U6MmFkZjk5ZjZhMDQ2NGQ1MGI5OTExNmM0NzQzYzhlN2JfMzItMS0xLTEtMA_ca43f32d-d11a-45b3-84c3-1bb74b88949d">4,200</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide9f6e15665746279d0000be700fcc6a_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromDerivativeInstrumentFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yOC9mcmFnOmUzZDg2ZjExMWM3ODQwYTVhN2EyOGE3OWViOGIxN2QwL3RhYmxlOjJhZGY5OWY2YTA0NjRkNTBiOTkxMTZjNDc0M2M4ZTdiL3RhYmxlcmFuZ2U6MmFkZjk5ZjZhMDQ2NGQ1MGI5OTExNmM0NzQzYzhlN2JfMzItMy0xLTEtMA_446462ca-f114-4d6d-815e-c7d77f09ae55">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yOC9mcmFnOmUzZDg2ZjExMWM3ODQwYTVhN2EyOGE3OWViOGIxN2QwL3RhYmxlOjJhZGY5OWY2YTA0NjRkNTBiOTkxMTZjNDc0M2M4ZTdiL3RhYmxlcmFuZ2U6MmFkZjk5ZjZhMDQ2NGQ1MGI5OTExNmM0NzQzYzhlN2JfMzctMS0xLTEtMA_a311539d-afd8-480d-b12b-3f0ef5eacaa1">51,177</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide9f6e15665746279d0000be700fcc6a_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yOC9mcmFnOmUzZDg2ZjExMWM3ODQwYTVhN2EyOGE3OWViOGIxN2QwL3RhYmxlOjJhZGY5OWY2YTA0NjRkNTBiOTkxMTZjNDc0M2M4ZTdiL3RhYmxlcmFuZ2U6MmFkZjk5ZjZhMDQ2NGQ1MGI5OTExNmM0NzQzYzhlN2JfMzctMy0xLTEtMA_d593ab50-6880-4f68-a7cd-0066e2632eec">53,869</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash, cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yOC9mcmFnOmUzZDg2ZjExMWM3ODQwYTVhN2EyOGE3OWViOGIxN2QwL3RhYmxlOjJhZGY5OWY2YTA0NjRkNTBiOTkxMTZjNDc0M2M4ZTdiL3RhYmxlcmFuZ2U6MmFkZjk5ZjZhMDQ2NGQ1MGI5OTExNmM0NzQzYzhlN2JfMzgtMS0xLTEtMA_ba4fa6c2-7d74-4153-9b81-47f574cb12e2">3,910</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide9f6e15665746279d0000be700fcc6a_D20200101-20200331" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yOC9mcmFnOmUzZDg2ZjExMWM3ODQwYTVhN2EyOGE3OWViOGIxN2QwL3RhYmxlOjJhZGY5OWY2YTA0NjRkNTBiOTkxMTZjNDc0M2M4ZTdiL3RhYmxlcmFuZ2U6MmFkZjk5ZjZhMDQ2NGQ1MGI5OTExNmM0NzQzYzhlN2JfMzgtMy0xLTEtMA_fbb13245-57f9-4cba-a4c6-cd5e7cfa1671">631</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net decrease in cash, cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yOC9mcmFnOmUzZDg2ZjExMWM3ODQwYTVhN2EyOGE3OWViOGIxN2QwL3RhYmxlOjJhZGY5OWY2YTA0NjRkNTBiOTkxMTZjNDc0M2M4ZTdiL3RhYmxlcmFuZ2U6MmFkZjk5ZjZhMDQ2NGQ1MGI5OTExNmM0NzQzYzhlN2JfMzktMS0xLTEtMA_235dabbd-88b9-4670-a9f6-a20b7832f2af">117,041</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide9f6e15665746279d0000be700fcc6a_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yOC9mcmFnOmUzZDg2ZjExMWM3ODQwYTVhN2EyOGE3OWViOGIxN2QwL3RhYmxlOjJhZGY5OWY2YTA0NjRkNTBiOTkxMTZjNDc0M2M4ZTdiL3RhYmxlcmFuZ2U6MmFkZjk5ZjZhMDQ2NGQ1MGI5OTExNmM0NzQzYzhlN2JfMzktMy0xLTEtMA_61babc63-30c8-4c73-8e1c-8d1a18fe8bb7">79,235</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash, beginning of period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id365c5f1d37444ac9e1da5b5891cd81a_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yOC9mcmFnOmUzZDg2ZjExMWM3ODQwYTVhN2EyOGE3OWViOGIxN2QwL3RhYmxlOjJhZGY5OWY2YTA0NjRkNTBiOTkxMTZjNDc0M2M4ZTdiL3RhYmxlcmFuZ2U6MmFkZjk5ZjZhMDQ2NGQ1MGI5OTExNmM0NzQzYzhlN2JfNDAtMS0xLTEtMA_23da9bb6-6d42-43f6-abe5-23512d3f777f">499,046</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebcb948108ce4342974f490750a7c986_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yOC9mcmFnOmUzZDg2ZjExMWM3ODQwYTVhN2EyOGE3OWViOGIxN2QwL3RhYmxlOjJhZGY5OWY2YTA0NjRkNTBiOTkxMTZjNDc0M2M4ZTdiL3RhYmxlcmFuZ2U6MmFkZjk5ZjZhMDQ2NGQ1MGI5OTExNmM0NzQzYzhlN2JfNDAtMy0xLTEtMA_bc3d96d4-968b-4d5d-ba08-b5ee80bfcf0a">549,628</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash, end of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd7204dc87d24972a01f15b098c4f56b_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yOC9mcmFnOmUzZDg2ZjExMWM3ODQwYTVhN2EyOGE3OWViOGIxN2QwL3RhYmxlOjJhZGY5OWY2YTA0NjRkNTBiOTkxMTZjNDc0M2M4ZTdiL3RhYmxlcmFuZ2U6MmFkZjk5ZjZhMDQ2NGQ1MGI5OTExNmM0NzQzYzhlN2JfNDEtMS0xLTEtMA_90fd83ce-9736-4df3-b812-3a67ef9c8891">382,005</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic378e7f6183c40b4b7371ed7b7370867_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yOC9mcmFnOmUzZDg2ZjExMWM3ODQwYTVhN2EyOGE3OWViOGIxN2QwL3RhYmxlOjJhZGY5OWY2YTA0NjRkNTBiOTkxMTZjNDc0M2M4ZTdiL3RhYmxlcmFuZ2U6MmFkZjk5ZjZhMDQ2NGQ1MGI5OTExNmM0NzQzYzhlN2JfNDEtMy0xLTEtMA_913f0330-ce2e-4619-843e-8e7ed84c6205">470,393</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Supplemental disclosure of noncash investing and financing activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Capital expenditures included in accounts payable and accrued expenses</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yOC9mcmFnOmUzZDg2ZjExMWM3ODQwYTVhN2EyOGE3OWViOGIxN2QwL3RhYmxlOjJhZGY5OWY2YTA0NjRkNTBiOTkxMTZjNDc0M2M4ZTdiL3RhYmxlcmFuZ2U6MmFkZjk5ZjZhMDQ2NGQ1MGI5OTExNmM0NzQzYzhlN2JfNDMtMS0xLTEtMA_134eddfd-c926-4252-8f12-23c21a10a09a">7,289</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide9f6e15665746279d0000be700fcc6a_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yOC9mcmFnOmUzZDg2ZjExMWM3ODQwYTVhN2EyOGE3OWViOGIxN2QwL3RhYmxlOjJhZGY5OWY2YTA0NjRkNTBiOTkxMTZjNDc0M2M4ZTdiL3RhYmxlcmFuZ2U6MmFkZjk5ZjZhMDQ2NGQ1MGI5OTExNmM0NzQzYzhlN2JfNDMtMy0xLTEtMA_44a14e23-cf16-4ccf-a95c-50f87ddb3962">6,619</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:10pt;text-align:center"><span><br/></span></div><div style="margin-top:10pt;text-align:center"><span><br/></span></div><div style="margin-top:10pt;text-align:center"><span><br/></span></div><div style="margin-top:10pt;text-align:center"><span><br/></span></div><div style="margin-top:10pt;text-align:center"><span><br/></span></div><div style="margin-top:10pt;text-align:center"><span><br/></span></div><div style="margin-top:10pt;text-align:center"><span><br/></span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><div id="i9f86b6d3686546618ade3c76e6b23fc8_31"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9f86b6d3686546618ade3c76e6b23fc8_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ALNYLAM PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div id="i9f86b6d3686546618ade3c76e6b23fc8_34"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">1. <ix:nonNumeric contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331" name="us-gaap:NatureOfOperations" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8zNC9mcmFnOjc0MDI0ZTZjMDNjNjRkNTI4YzJlNzBjNWI5YTU0ZTVhL3RleHRyZWdpb246NzQwMjRlNmMwM2M2NGQ1MjhjMmU3MGM1YjlhNTRlNWFfMjc4Ng_d9f6175d-d46b-4037-b10b-78332e16485b" continuedAt="i9a7a7814a3604b819b26256c11cf7411" escape="true">NATURE OF BUSINESS</ix:nonNumeric></span></div><ix:continuation id="i9a7a7814a3604b819b26256c11cf7411"><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Alnylam Pharmaceuticals, Inc. (also referred to as Alnylam, we, our or us) commenced operations on June&#160;14, 2002 as a biopharmaceutical company seeking to develop and commercialize novel therapeutics based on RNA interference, or RNAi. We are committed to the advancement of our company strategy of building a multi-product, global, commercial biopharmaceutical company with a deep and sustainable clinical pipeline of RNAi therapeutics for future growth and a robust, organic research engine for sustainable innovation and great potential for patient impact. Since inception, we have focused on discovering, developing and commercializing RNAi therapeutics by establishing and maintaining a strong intellectual property position in the RNAi field, establishing strategic alliances with leading pharmaceutical and life sciences companies, generating revenues through licensing agreements, and ultimately developing and commercializing RNAi therapeutics globally, either independently or with our strategic partners. We have devoted substantially all of our efforts to business planning, research, development, manufacturing and early commercial efforts, acquiring, filing and expanding intellectual property rights, recruiting management and technical staff, and raising capital. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In early 2021, we launched our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Alnylam P</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">x25 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">strategy, which focuses on our planned transition to a top five biotech company, as measured by market capitalization, by the end of 2025. With </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Alnylam P</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">x25</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, we aim to deliver transformative rare and prevalent disease medicines for patients around the world through sustainable innovation, delivering exceptional financial performance and driving profitability.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of March&#160;31, 2021, we have <ix:nonFraction unitRef="product" contextRef="idd7204dc87d24972a01f15b098c4f56b_I20210331" decimals="INF" format="ixt-sec:numwordsen" name="alny:NumberOfMarketedProducts" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8zNC9mcmFnOjc0MDI0ZTZjMDNjNjRkNTI4YzJlNzBjNWI5YTU0ZTVhL3RleHRyZWdpb246NzQwMjRlNmMwM2M2NGQ1MjhjMmU3MGM1YjlhNTRlNWFfODI0NjMzNzIxNDMwOQ_890dcaf1-f039-4a43-b339-676c52a439bd">four</ix:nonFraction> products that have received marketing approval, including <ix:nonFraction unitRef="product" contextRef="idd7204dc87d24972a01f15b098c4f56b_I20210331" decimals="INF" format="ixt-sec:numwordsen" name="alny:NumberOfPartneredProducts" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8zNC9mcmFnOjc0MDI0ZTZjMDNjNjRkNTI4YzJlNzBjNWI5YTU0ZTVhL3RleHRyZWdpb246NzQwMjRlNmMwM2M2NGQ1MjhjMmU3MGM1YjlhNTRlNWFfODI0NjMzNzIxNDMxNw_426c642a-a06e-4b17-bab4-c16cf9f78474">one</ix:nonFraction> partnered product, and <ix:nonFraction unitRef="program" contextRef="idd7204dc87d24972a01f15b098c4f56b_I20210331" decimals="INF" format="ixt-sec:numwordsen" name="alny:NumberOfClinicalProgramsInLateStages" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8zNC9mcmFnOjc0MDI0ZTZjMDNjNjRkNTI4YzJlNzBjNWI5YTU0ZTVhL3RleHRyZWdpb246NzQwMjRlNmMwM2M2NGQ1MjhjMmU3MGM1YjlhNTRlNWFfODI0NjMzNzIxNDMyNQ_39f39d04-634b-464e-b037-444624a26542">six</ix:nonFraction> late-stage investigational programs advancing towards potential commercialization. We currently generate product revenues from ONPATTRO in the U.S., Europe, Japan and in several additional countries as well as from GIVLAARI and OXLUMO in the U.S. and several countries in Europe.</span></div></ix:continuation><div id="i9f86b6d3686546618ade3c76e6b23fc8_37"></div><div style="margin-top:15pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2. <ix:nonNumeric contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8zNy9mcmFnOjYwMTQxMmZlMWFjYjRkZjBhNmIwMWI1ZWY5ODM2Njg3L3RleHRyZWdpb246NjAxNDEyZmUxYWNiNGRmMGE2YjAxYjVlZjk4MzY2ODdfODA1Mw_457d56be-4ea4-419d-98c6-349d195936b9" continuedAt="i54f699c0d81b45f48e23d6f1dd92eb1b" escape="true">BASIS OF PRESENTATION AND PRINCIPLES OF CONSOLIDATION</ix:nonNumeric></span></div><ix:continuation id="i54f699c0d81b45f48e23d6f1dd92eb1b" continuedAt="i9ee9b86e51384638812824ee752f7123"><ix:nonNumeric contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8zNy9mcmFnOjYwMTQxMmZlMWFjYjRkZjBhNmIwMWI1ZWY5ODM2Njg3L3RleHRyZWdpb246NjAxNDEyZmUxYWNiNGRmMGE2YjAxYjVlZjk4MzY2ODdfODA1NA_bf3306dc-932e-4923-a7e0-90afe48df245" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The accompanying condensed consolidated financial statements of Alnylam are unaudited and have been prepared in accordance with accounting principles generally accepted in the United States of America, or GAAP, applicable to interim periods and, in the opinion of management, include all normal and recurring adjustments that are necessary to state fairly the results of operations for the reported periods. Our condensed consolidated financial statements have also been prepared on a basis substantially consistent with, and should be read in conjunction with, our audited consolidated financial statements for the year ended December&#160;31, 2020, which were included in our Annual Report on Form 10-K that was filed with the Securities and Exchange Commission on February 11, 2021. The year-end condensed consolidated balance sheet data was derived from our audited financial statements but does not include all disclosures required by GAAP. The results of our operations for any interim period are not necessarily indicative of the results of our operations for any other interim period or for a full fiscal year.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The accompanying condensed consolidated financial statements reflect the operations of Alnylam and our wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our significant accounting policies are described in Note 2 of the Notes to Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December&#160;31, 2020.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8zNy9mcmFnOjYwMTQxMmZlMWFjYjRkZjBhNmIwMWI1ZWY5ODM2Njg3L3RleHRyZWdpb246NjAxNDEyZmUxYWNiNGRmMGE2YjAxYjVlZjk4MzY2ODdfODA2MA_661ccdc2-4764-425c-b819-af8d0964d68d" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Use of Estimates</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. In our condensed consolidated financial statements, we use estimates and assumptions related to our inventory valuation and related reserves, liability related to the sale of future royalties, development derivative liability, income taxes, revenue recognition, research and development expenses, and stock-based compensation. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable. Actual results could differ from those estimates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The full extent to which the COVID-19 pandemic will directly or indirectly impact our business, results of operations and financial condition, including sales, expenses, reserves and allowances, the supply of our products and product candidates, clinical trials and research and development costs, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and variants thereof, and the actions taken to contain or treat it or vaccinate against it, as well as the economic impact on local, regional, national and international customers and markets. We have made estimates of the impact of COVID-19 within our financial statements and there may be changes to those estimates in future periods. Actual results may differ from these estimates.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9f86b6d3686546618ade3c76e6b23fc8_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ALNYLAM PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="i9ee9b86e51384638812824ee752f7123"><ix:nonNumeric contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331" name="alny:LiquidityPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8zNy9mcmFnOjYwMTQxMmZlMWFjYjRkZjBhNmIwMWI1ZWY5ODM2Njg3L3RleHRyZWdpb246NjAxNDEyZmUxYWNiNGRmMGE2YjAxYjVlZjk4MzY2ODdfODA1NQ_93135ab1-881e-4e21-80e1-7e5e1aa287ff" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Liquidity</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Based on our current operating plan, we believe that our cash, cash equivalents and marketable securities as of March&#160;31, 2021, together with the cash we expect to generate from product sales and under our current alliances, in addition to our strategic financing collaboration with The Blackstone Group Inc. and certain of its affiliates, will be sufficient to enable us to advance our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Alnylam P</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">x25 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">strategy for at least the next 12 months from the filing of this Quarterly Report on Form 10-Q.</span></div></ix:nonNumeric></ix:continuation><div id="i9f86b6d3686546618ade3c76e6b23fc8_40"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80MC9mcmFnOmViNzk5OGUzNTJhZDQ1ZTE4YTU5OTVmMWQ2YWJmNmMzL3RleHRyZWdpb246ZWI3OTk4ZTM1MmFkNDVlMThhNTk5NWYxZDZhYmY2YzNfMTc5_171ae792-438c-412c-ad63-e05f86fc45ea" continuedAt="i851929836be545aeb5053baeb69c3fdf" escape="true">NET PRODUCT REVENUES</ix:nonNumeric></span></div><ix:continuation id="i851929836be545aeb5053baeb69c3fdf"><ix:nonNumeric contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80MC9mcmFnOmViNzk5OGUzNTJhZDQ1ZTE4YTU5OTVmMWQ2YWJmNmMzL3RleHRyZWdpb246ZWI3OTk4ZTM1MmFkNDVlMThhNTk5NWYxZDZhYmY2YzNfMTgy_e04487e8-38f4-417b-97df-74eff533db57" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net product revenues consist of the following:</span></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:18pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:82.309%"><tr><td style="width:1.0%"></td><td style="width:58.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.971%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.510%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.972%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ONPATTRO</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a2ac71261a84e87a3d5590a679c5507_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80MC9mcmFnOmViNzk5OGUzNTJhZDQ1ZTE4YTU5OTVmMWQ2YWJmNmMzL3RhYmxlOmJmZWJkMzA5MmE1YTQzMjNiM2Q2NWI0YTdjMzUzNGZiL3RhYmxlcmFuZ2U6YmZlYmQzMDkyYTVhNDMyM2IzZDY1YjRhN2MzNTM0ZmJfMy0xLTEtMS0w_7e19c57e-433b-4413-aac4-7f00758eb48a">49,471</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3093ec8b753b455ebe0533565a97caff_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80MC9mcmFnOmViNzk5OGUzNTJhZDQ1ZTE4YTU5OTVmMWQ2YWJmNmMzL3RhYmxlOmJmZWJkMzA5MmE1YTQzMjNiM2Q2NWI0YTdjMzUzNGZiL3RhYmxlcmFuZ2U6YmZlYmQzMDkyYTVhNDMyM2IzZDY1YjRhN2MzNTM0ZmJfMy0zLTEtMS0w_5e79f756-d0a4-4c62-a536-d6b04e02d9e6">37,196</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie071fd2fff7141d790e9ce1f75e3ad69_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80MC9mcmFnOmViNzk5OGUzNTJhZDQ1ZTE4YTU5OTVmMWQ2YWJmNmMzL3RhYmxlOmJmZWJkMzA5MmE1YTQzMjNiM2Q2NWI0YTdjMzUzNGZiL3RhYmxlcmFuZ2U6YmZlYmQzMDkyYTVhNDMyM2IzZDY1YjRhN2MzNTM0ZmJfNC0xLTEtMS0w_3549d691-4acd-4684-b02e-4b40cb7928cd">40,653</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf591ef643074bb59a23948ceb15ebb6_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80MC9mcmFnOmViNzk5OGUzNTJhZDQ1ZTE4YTU5OTVmMWQ2YWJmNmMzL3RhYmxlOmJmZWJkMzA5MmE1YTQzMjNiM2Q2NWI0YTdjMzUzNGZiL3RhYmxlcmFuZ2U6YmZlYmQzMDkyYTVhNDMyM2IzZDY1YjRhN2MzNTM0ZmJfNC0zLTEtMS0w_b018b104-3076-4de6-b03d-dcbb1082bfc1">21,166</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rest of World (primarily Japan)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e00566ee692462ca9f65f7d6faa57e9_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80MC9mcmFnOmViNzk5OGUzNTJhZDQ1ZTE4YTU5OTVmMWQ2YWJmNmMzL3RhYmxlOmJmZWJkMzA5MmE1YTQzMjNiM2Q2NWI0YTdjMzUzNGZiL3RhYmxlcmFuZ2U6YmZlYmQzMDkyYTVhNDMyM2IzZDY1YjRhN2MzNTM0ZmJfNS0xLTEtMS0w_a0841052-9c75-4356-a562-a538d1f98f37">11,827</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i407b32b70e73469c9bb2867c7e8c53ab_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80MC9mcmFnOmViNzk5OGUzNTJhZDQ1ZTE4YTU5OTVmMWQ2YWJmNmMzL3RhYmxlOmJmZWJkMzA5MmE1YTQzMjNiM2Q2NWI0YTdjMzUzNGZiL3RhYmxlcmFuZ2U6YmZlYmQzMDkyYTVhNDMyM2IzZDY1YjRhN2MzNTM0ZmJfNS0zLTEtMS0w_1fcbafc4-2ea1-450c-88bf-17a61f07d229">8,302</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i938688f7d99a4e7b97c127dc1da4aa45_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80MC9mcmFnOmViNzk5OGUzNTJhZDQ1ZTE4YTU5OTVmMWQ2YWJmNmMzL3RhYmxlOmJmZWJkMzA5MmE1YTQzMjNiM2Q2NWI0YTdjMzUzNGZiL3RhYmxlcmFuZ2U6YmZlYmQzMDkyYTVhNDMyM2IzZDY1YjRhN2MzNTM0ZmJfNi0xLTEtMS0w_17e2f5dc-fe57-454f-827c-c46c5a70c220">101,951</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic38400d6eea7497f8bb34244730955f4_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80MC9mcmFnOmViNzk5OGUzNTJhZDQ1ZTE4YTU5OTVmMWQ2YWJmNmMzL3RhYmxlOmJmZWJkMzA5MmE1YTQzMjNiM2Q2NWI0YTdjMzUzNGZiL3RhYmxlcmFuZ2U6YmZlYmQzMDkyYTVhNDMyM2IzZDY1YjRhN2MzNTM0ZmJfNi0zLTEtMS0w_09385378-c3c0-4953-9ad3-55d797f998cb">66,664</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">GIVLAARI</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86f381c6519b4114a9f993ca05678e84_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80MC9mcmFnOmViNzk5OGUzNTJhZDQ1ZTE4YTU5OTVmMWQ2YWJmNmMzL3RhYmxlOmJmZWJkMzA5MmE1YTQzMjNiM2Q2NWI0YTdjMzUzNGZiL3RhYmxlcmFuZ2U6YmZlYmQzMDkyYTVhNDMyM2IzZDY1YjRhN2MzNTM0ZmJfOS0xLTEtMS0w_405806b8-37db-46f5-84fc-2dca7f559d49">17,762</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa94975325ea4c21bc761e8c37cace85_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80MC9mcmFnOmViNzk5OGUzNTJhZDQ1ZTE4YTU5OTVmMWQ2YWJmNmMzL3RhYmxlOmJmZWJkMzA5MmE1YTQzMjNiM2Q2NWI0YTdjMzUzNGZiL3RhYmxlcmFuZ2U6YmZlYmQzMDkyYTVhNDMyM2IzZDY1YjRhN2MzNTM0ZmJfOS0zLTEtMS0w_47d3476b-0144-4731-a17d-1670314e9489">5,274</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6223cc9a7bb7452ebf43606a6436d328_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80MC9mcmFnOmViNzk5OGUzNTJhZDQ1ZTE4YTU5OTVmMWQ2YWJmNmMzL3RhYmxlOmJmZWJkMzA5MmE1YTQzMjNiM2Q2NWI0YTdjMzUzNGZiL3RhYmxlcmFuZ2U6YmZlYmQzMDkyYTVhNDMyM2IzZDY1YjRhN2MzNTM0ZmJfMTAtMS0xLTEtMA_11415fea-6fa3-4929-8e5b-2f35924efe8f">6,873</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i129948d8d7484c52bc400ee978922740_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80MC9mcmFnOmViNzk5OGUzNTJhZDQ1ZTE4YTU5OTVmMWQ2YWJmNmMzL3RhYmxlOmJmZWJkMzA5MmE1YTQzMjNiM2Q2NWI0YTdjMzUzNGZiL3RhYmxlcmFuZ2U6YmZlYmQzMDkyYTVhNDMyM2IzZDY1YjRhN2MzNTM0ZmJfMTAtMy0xLTEtMA_05ab7a44-9356-4b98-bcbe-37db36217a12">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rest of World </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied24bfeab08a4433b3f48a2b7f17c882_D20210101-20210331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80MC9mcmFnOmViNzk5OGUzNTJhZDQ1ZTE4YTU5OTVmMWQ2YWJmNmMzL3RhYmxlOmJmZWJkMzA5MmE1YTQzMjNiM2Q2NWI0YTdjMzUzNGZiL3RhYmxlcmFuZ2U6YmZlYmQzMDkyYTVhNDMyM2IzZDY1YjRhN2MzNTM0ZmJfMTEtMS0xLTEtMA_3981a0d0-a4ad-4216-80e1-a77e27253b1c">38</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46dfc7f31a1c42149b4c59b183486728_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80MC9mcmFnOmViNzk5OGUzNTJhZDQ1ZTE4YTU5OTVmMWQ2YWJmNmMzL3RhYmxlOmJmZWJkMzA5MmE1YTQzMjNiM2Q2NWI0YTdjMzUzNGZiL3RhYmxlcmFuZ2U6YmZlYmQzMDkyYTVhNDMyM2IzZDY1YjRhN2MzNTM0ZmJfMTEtMy0xLTEtMA_90309062-e13d-414c-b318-641449cbf358">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cd7ede64f374cf0a1a1c96376d99ca8_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80MC9mcmFnOmViNzk5OGUzNTJhZDQ1ZTE4YTU5OTVmMWQ2YWJmNmMzL3RhYmxlOmJmZWJkMzA5MmE1YTQzMjNiM2Q2NWI0YTdjMzUzNGZiL3RhYmxlcmFuZ2U6YmZlYmQzMDkyYTVhNDMyM2IzZDY1YjRhN2MzNTM0ZmJfMTItMS0xLTEtMA_598777e2-b5b2-4414-a9eb-b5e486c0030c">24,673</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a8146b23bc64bb0989fb48fd0ed09c9_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80MC9mcmFnOmViNzk5OGUzNTJhZDQ1ZTE4YTU5OTVmMWQ2YWJmNmMzL3RhYmxlOmJmZWJkMzA5MmE1YTQzMjNiM2Q2NWI0YTdjMzUzNGZiL3RhYmxlcmFuZ2U6YmZlYmQzMDkyYTVhNDMyM2IzZDY1YjRhN2MzNTM0ZmJfMTItMy0xLTEtMA_079e91a0-f580-4542-b9f8-e58e572bff3a">5,274</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OXLUMO</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c6836ed9e254b72b169ede860583569_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80MC9mcmFnOmViNzk5OGUzNTJhZDQ1ZTE4YTU5OTVmMWQ2YWJmNmMzL3RhYmxlOmJmZWJkMzA5MmE1YTQzMjNiM2Q2NWI0YTdjMzUzNGZiL3RhYmxlcmFuZ2U6YmZlYmQzMDkyYTVhNDMyM2IzZDY1YjRhN2MzNTM0ZmJfMTUtMS0xLTEtMzQyOA_343c3a71-14df-4baa-a1c2-4b981b85ae70">1,408</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbd043497e914bc1bee58c0daa2546c6_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80MC9mcmFnOmViNzk5OGUzNTJhZDQ1ZTE4YTU5OTVmMWQ2YWJmNmMzL3RhYmxlOmJmZWJkMzA5MmE1YTQzMjNiM2Q2NWI0YTdjMzUzNGZiL3RhYmxlcmFuZ2U6YmZlYmQzMDkyYTVhNDMyM2IzZDY1YjRhN2MzNTM0ZmJfMTUtMy0xLTEtMzQyOA_c4027548-844e-4106-be43-e4ee7c5204e6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62b86057a964bb0a0b767d745aa53b7_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80MC9mcmFnOmViNzk5OGUzNTJhZDQ1ZTE4YTU5OTVmMWQ2YWJmNmMzL3RhYmxlOmJmZWJkMzA5MmE1YTQzMjNiM2Q2NWI0YTdjMzUzNGZiL3RhYmxlcmFuZ2U6YmZlYmQzMDkyYTVhNDMyM2IzZDY1YjRhN2MzNTM0ZmJfMTUtMS0xLTEtMjg0NQ_ef275819-44ab-46b2-8fdd-a1d97b0cf215">7,737</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic52bf960eb1f4c9ba53b059468d7993e_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80MC9mcmFnOmViNzk5OGUzNTJhZDQ1ZTE4YTU5OTVmMWQ2YWJmNmMzL3RhYmxlOmJmZWJkMzA5MmE1YTQzMjNiM2Q2NWI0YTdjMzUzNGZiL3RhYmxlcmFuZ2U6YmZlYmQzMDkyYTVhNDMyM2IzZDY1YjRhN2MzNTM0ZmJfMTUtMy0xLTEtMjg0NQ_8a54e146-5ee1-41dd-8149-e15124b5c328">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic33a14cb7a1b47898a6aa7a5a5d657a4_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80MC9mcmFnOmViNzk5OGUzNTJhZDQ1ZTE4YTU5OTVmMWQ2YWJmNmMzL3RhYmxlOmJmZWJkMzA5MmE1YTQzMjNiM2Q2NWI0YTdjMzUzNGZiL3RhYmxlcmFuZ2U6YmZlYmQzMDkyYTVhNDMyM2IzZDY1YjRhN2MzNTM0ZmJfMTctMS0xLTEtMTg2Ng_ecc0981a-3b19-4b89-b563-58e25b02578e">9,145</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i416a8546a935440ba7736b9614aa8073_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80MC9mcmFnOmViNzk5OGUzNTJhZDQ1ZTE4YTU5OTVmMWQ2YWJmNmMzL3RhYmxlOmJmZWJkMzA5MmE1YTQzMjNiM2Q2NWI0YTdjMzUzNGZiL3RhYmxlcmFuZ2U6YmZlYmQzMDkyYTVhNDMyM2IzZDY1YjRhN2MzNTM0ZmJfMTctMy0xLTEtMTg3NQ_4ca45d9d-e0f3-4cdb-bce3-24d2eadca3be">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net product revenues</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia489a15348ae4ae390bc47557aaca423_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80MC9mcmFnOmViNzk5OGUzNTJhZDQ1ZTE4YTU5OTVmMWQ2YWJmNmMzL3RhYmxlOmJmZWJkMzA5MmE1YTQzMjNiM2Q2NWI0YTdjMzUzNGZiL3RhYmxlcmFuZ2U6YmZlYmQzMDkyYTVhNDMyM2IzZDY1YjRhN2MzNTM0ZmJfMTQtMS0xLTEtMA_9afd9f11-afef-4326-8077-d0debe0c1d88">135,769</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae589afb590a4f5984a5dd4001d656cb_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80MC9mcmFnOmViNzk5OGUzNTJhZDQ1ZTE4YTU5OTVmMWQ2YWJmNmMzL3RhYmxlOmJmZWJkMzA5MmE1YTQzMjNiM2Q2NWI0YTdjMzUzNGZiL3RhYmxlcmFuZ2U6YmZlYmQzMDkyYTVhNDMyM2IzZDY1YjRhN2MzNTM0ZmJfMTQtMy0xLTEtMA_59f5c29f-e4b1-4ca8-ab9a-f7db073ec4f6">71,938</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331" name="us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80MC9mcmFnOmViNzk5OGUzNTJhZDQ1ZTE4YTU5OTVmMWQ2YWJmNmMzL3RleHRyZWdpb246ZWI3OTk4ZTM1MmFkNDVlMThhNTk5NWYxZDZhYmY2YzNfMTg0_cc79e106-c859-45da-83f5-a216adbb36b0" escape="true"><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the balance of our receivables related to our net product revenues: </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:82.456%"><tr><td style="width:1.0%"></td><td style="width:57.942%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.686%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.937%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables included in &#8220;Accounts receivable, net&#8221;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1a37ec48832445999d722992c9485a5_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80MC9mcmFnOmViNzk5OGUzNTJhZDQ1ZTE4YTU5OTVmMWQ2YWJmNmMzL3RhYmxlOjZkMzYxODQ2NjNkYjRjZWE5YjUyOTcwNWYwZTFhMTU2L3RhYmxlcmFuZ2U6NmQzNjE4NDY2M2RiNGNlYTliNTI5NzA1ZjBlMWExNTZfMS0xLTEtMS0w_da645163-2b2d-41ab-8910-57ea1e1ebfc4">91,516</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27b6b4c7a00f4e4eb8bf4fb46f229034_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80MC9mcmFnOmViNzk5OGUzNTJhZDQ1ZTE4YTU5OTVmMWQ2YWJmNmMzL3RhYmxlOjZkMzYxODQ2NjNkYjRjZWE5YjUyOTcwNWYwZTFhMTU2L3RhYmxlcmFuZ2U6NmQzNjE4NDY2M2RiNGNlYTliNTI5NzA1ZjBlMWExNTZfMS0zLTEtMS0w_4d980a8c-a61d-4d65-8c06-74ac3a88f0ea">68,871</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div id="i9f86b6d3686546618ade3c76e6b23fc8_43"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RleHRyZWdpb246MWE2ZWQwNzZlMTc2NDkyMzllYTFhMjgxNTMwYjdjYjRfMzExMDE_76c84d48-7d13-40c4-b03e-fc691b69ce31" continuedAt="i108bd5e09d1e4d369eb3b40f2da56ed1" escape="true">NET REVENUES FROM COLLABORATIONS</ix:nonNumeric></span></div><ix:continuation id="i108bd5e09d1e4d369eb3b40f2da56ed1" continuedAt="i96cbba1bde35402f91c3fc68af69a844"><ix:nonNumeric contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331" name="us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RleHRyZWdpb246MWE2ZWQwNzZlMTc2NDkyMzllYTFhMjgxNTMwYjdjYjRfMzExMjA_d211761f-df36-4afb-81e1-9fa6ba55c9f4" escape="true"><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Net revenues from collaborations consist of the following:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:84.941%"><tr><td style="width:1.0%"></td><td style="width:63.616%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.111%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.660%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.113%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron Pharmaceuticals</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95f1c1ed3c154524aceec386b964d3e5_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RhYmxlOjBmNmRhZjU0ZTkyYTQ0OTE5YjNkMzM0ZWEwZDg2YzIxL3RhYmxlcmFuZ2U6MGY2ZGFmNTRlOTJhNDQ5MTliM2QzMzRlYTBkODZjMjFfMi0xLTEtMS0w_f7ac0f78-dbd9-4661-a0d5-9f1d1915ce34">30,343</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic41d4a1b34194fdb92365734e524ff34_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RhYmxlOjBmNmRhZjU0ZTkyYTQ0OTE5YjNkMzM0ZWEwZDg2YzIxL3RhYmxlcmFuZ2U6MGY2ZGFmNTRlOTJhNDQ5MTliM2QzMzRlYTBkODZjMjFfMi0zLTEtMS0w_65949215-484a-416d-9f7f-d988f3fa6a6d">19,503</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Novartis AG</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifafd9b348c4c4d3bb08ec5381577d767_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RhYmxlOjBmNmRhZjU0ZTkyYTQ0OTE5YjNkMzM0ZWEwZDg2YzIxL3RhYmxlcmFuZ2U6MGY2ZGFmNTRlOTJhNDQ5MTliM2QzMzRlYTBkODZjMjFfMy0xLTEtMS0yNDEy_5d139707-947a-4ee5-9e4e-beca1c29bf0e">8,111</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia500fa9e2b224d0ea1d970ddb3c83d05_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RhYmxlOjBmNmRhZjU0ZTkyYTQ0OTE5YjNkMzM0ZWEwZDg2YzIxL3RhYmxlcmFuZ2U6MGY2ZGFmNTRlOTJhNDQ5MTliM2QzMzRlYTBkODZjMjFfMy0zLTEtMS0yNDEy_cc56bf44-3874-4247-a722-4c2f45a1370a">1,060</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vir Biotechnology</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b35d0a44ca0429b8b8202051f1b3678_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RhYmxlOjBmNmRhZjU0ZTkyYTQ0OTE5YjNkMzM0ZWEwZDg2YzIxL3RhYmxlcmFuZ2U6MGY2ZGFmNTRlOTJhNDQ5MTliM2QzMzRlYTBkODZjMjFfMy0xLTEtMS0w_516f3bbc-cb27-4e35-85af-cfd9a11ff814">2,822</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab7c02eb57194c1192e785ccd3886998_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RhYmxlOjBmNmRhZjU0ZTkyYTQ0OTE5YjNkMzM0ZWEwZDg2YzIxL3RhYmxlcmFuZ2U6MGY2ZGFmNTRlOTJhNDQ5MTliM2QzMzRlYTBkODZjMjFfMy0zLTEtMS0w_323bf31a-c688-4528-b7c6-4a40bee46b10">6,516</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33cced07680d487d8f3ae8596484a8ca_D20210101-20210331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RhYmxlOjBmNmRhZjU0ZTkyYTQ0OTE5YjNkMzM0ZWEwZDg2YzIxL3RhYmxlcmFuZ2U6MGY2ZGFmNTRlOTJhNDQ5MTliM2QzMzRlYTBkODZjMjFfNi0xLTEtMS0w_3d1a56b9-ba85-4a8b-abf8-5ed1db460f16">521</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b9f37fb1a5c435aadb1d93990451d0a_D20200101-20200331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RhYmxlOjBmNmRhZjU0ZTkyYTQ0OTE5YjNkMzM0ZWEwZDg2YzIxL3RhYmxlcmFuZ2U6MGY2ZGFmNTRlOTJhNDQ5MTliM2QzMzRlYTBkODZjMjFfNi0zLTEtMS0w_37bda0cf-6641-4bb1-86f0-285467141c1a">459</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6912a2c4b43f46838e7d9157c5b3a723_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RhYmxlOjBmNmRhZjU0ZTkyYTQ0OTE5YjNkMzM0ZWEwZDg2YzIxL3RhYmxlcmFuZ2U6MGY2ZGFmNTRlOTJhNDQ5MTliM2QzMzRlYTBkODZjMjFfNy0xLTEtMS0w_e31923c2-b75c-400c-8957-7583fd32eb12">41,797</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i738b536de6724c23b1637b0913d14f26_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RhYmxlOjBmNmRhZjU0ZTkyYTQ0OTE5YjNkMzM0ZWEwZDg2YzIxL3RhYmxlcmFuZ2U6MGY2ZGFmNTRlOTJhNDQ5MTliM2QzMzRlYTBkODZjMjFfNy0zLTEtMS0w_9e979a34-b800-456b-8f99-968765903f54">27,538</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9f86b6d3686546618ade3c76e6b23fc8_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ALNYLAM PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="i96cbba1bde35402f91c3fc68af69a844" continuedAt="ib849217a9a1a4d40843474fae4462d28"><ix:nonNumeric contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331" name="us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RleHRyZWdpb246MWE2ZWQwNzZlMTc2NDkyMzllYTFhMjgxNTMwYjdjYjRfMzExMjM_5ec13fd7-475f-47c5-a803-f725d87a543c" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the balance of our receivables and contract liabilities related to our collaboration agreements:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:84.795%"><tr><td style="width:1.0%"></td><td style="width:56.313%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.762%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.662%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.763%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables included in &#8220;Accounts receivable, net&#8221;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd7204dc87d24972a01f15b098c4f56b_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RhYmxlOjNjYjgxNWE0ODNkMDQwMjFhM2NiYjhmOWVjNzI5YTI2L3RhYmxlcmFuZ2U6M2NiODE1YTQ4M2QwNDAyMWEzY2JiOGY5ZWM3MjlhMjZfMS0xLTEtMS0w_0fb88fa7-abcf-4f72-af59-2febde262746">19,111</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id365c5f1d37444ac9e1da5b5891cd81a_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RhYmxlOjNjYjgxNWE0ODNkMDQwMjFhM2NiYjhmOWVjNzI5YTI2L3RhYmxlcmFuZ2U6M2NiODE1YTQ4M2QwNDAyMWEzY2JiOGY5ZWM3MjlhMjZfMS0zLTEtMS0w_c4ffe9f9-cc88-4dca-9fe7-806ea7c7249e">33,542</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liabilities included in &#8220;Deferred revenue&#8221;</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd7204dc87d24972a01f15b098c4f56b_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RhYmxlOjNjYjgxNWE0ODNkMDQwMjFhM2NiYjhmOWVjNzI5YTI2L3RhYmxlcmFuZ2U6M2NiODE1YTQ4M2QwNDAyMWEzY2JiOGY5ZWM3MjlhMjZfMi0xLTEtMS0w_53cb85e7-b4df-4a8b-84b2-d3e5c0aeb672">94,759</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id365c5f1d37444ac9e1da5b5891cd81a_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RhYmxlOjNjYjgxNWE0ODNkMDQwMjFhM2NiYjhmOWVjNzI5YTI2L3RhYmxlcmFuZ2U6M2NiODE1YTQ4M2QwNDAyMWEzY2JiOGY5ZWM3MjlhMjZfMi0zLTEtMS0w_7aca9adf-90db-4212-829d-6b0558f6126c">120,021</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RleHRyZWdpb246MWE2ZWQwNzZlMTc2NDkyMzllYTFhMjgxNTMwYjdjYjRfNDk0NzgwMjQwNTc4OQ_6172159f-302c-4d13-a0b8-80068eedfd57">25.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ide9f6e15665746279d0000be700fcc6a_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RleHRyZWdpb246MWE2ZWQwNzZlMTc2NDkyMzllYTFhMjgxNTMwYjdjYjRfNDk0NzgwMjQwNTc3MA_23a4c4ea-3659-44ed-bd9c-5b8465e8b6cc">14.7</ix:nonFraction> million in the three months ended March&#160;31, 2021 and 2020, respectively, that was included in the contract liability balance at the beginning of the respective period.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In order to determine revenue recognized in the period from contract liabilities, we first allocate revenue to the individual contract liability balance outstanding at the beginning of the period until the revenue exceeds that balance. If additional consideration is received on those contracts in subsequent periods, we assume all revenue recognized in the reporting period first applies to the beginning contract liability as opposed to a portion applying to the new consideration for the period.</span></div><ix:nonNumeric contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331" name="alny:ScheduleOfResearchAndDevelopmentExpensesIncurredForCollaborationAgreementsTableTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RleHRyZWdpb246MWE2ZWQwNzZlMTc2NDkyMzllYTFhMjgxNTMwYjdjYjRfMzExMTA_33733aa3-fc91-4806-b64a-b9912d1c5b81" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table provides research and development expenses incurred by type, for which we recognize net revenue, that are directly attributable to our collaboration agreements, by collaboration partner:</span></div><div><span><br/></span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:24.083%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.759%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.759%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.759%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.759%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.759%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.762%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Clinical Trial and Manufacturing</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">External Services</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Clinical Trial and Manufacturing</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">External Services</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron Pharmaceuticals</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3753a1357334f66bd9801d06cb5303b_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RhYmxlOmFhNTJiZTViM2I1NDQwNDI4NTZmNDY1ODFiMGZiNTA0L3RhYmxlcmFuZ2U6YWE1MmJlNWIzYjU0NDA0Mjg1NmY0NjU4MWIwZmI1MDRfMy0xLTEtMS0w_cb854651-3210-4201-9dd9-b6ea3cbc08d8">4,799</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e5101b0b8bd410196b91d29fd823e81_D20210101-20210331" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RhYmxlOmFhNTJiZTViM2I1NDQwNDI4NTZmNDY1ODFiMGZiNTA0L3RhYmxlcmFuZ2U6YWE1MmJlNWIzYjU0NDA0Mjg1NmY0NjU4MWIwZmI1MDRfMy0zLTEtMS0w_8744c439-0720-4a90-b91e-2ba923a33754">94</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i503bb08b80284da78e7d56a82595e959_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RhYmxlOmFhNTJiZTViM2I1NDQwNDI4NTZmNDY1ODFiMGZiNTA0L3RhYmxlcmFuZ2U6YWE1MmJlNWIzYjU0NDA0Mjg1NmY0NjU4MWIwZmI1MDRfMy01LTEtMS0w_c383d71f-c966-435f-9742-156de1db797f">12,235</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f98765bfdbc4e44a1223eaa20633d22_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RhYmxlOmFhNTJiZTViM2I1NDQwNDI4NTZmNDY1ODFiMGZiNTA0L3RhYmxlcmFuZ2U6YWE1MmJlNWIzYjU0NDA0Mjg1NmY0NjU4MWIwZmI1MDRfMy03LTEtMS0w_d073e073-5adc-46e0-be5a-56961794b7c3">4,612</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99846caa80964377a5573940a812180e_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RhYmxlOmFhNTJiZTViM2I1NDQwNDI4NTZmNDY1ODFiMGZiNTA0L3RhYmxlcmFuZ2U6YWE1MmJlNWIzYjU0NDA0Mjg1NmY0NjU4MWIwZmI1MDRfMy05LTEtMS0w_3018f510-4c4a-40d9-b572-01514390b938">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2a36524f2b9464c9ddd8548541ad993_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RhYmxlOmFhNTJiZTViM2I1NDQwNDI4NTZmNDY1ODFiMGZiNTA0L3RhYmxlcmFuZ2U6YWE1MmJlNWIzYjU0NDA0Mjg1NmY0NjU4MWIwZmI1MDRfMy0xMS0xLTEtMA_cb6d34de-d176-4d07-8932-da98171e66a7">11,491</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vir Biotechnology</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b580b28bb314ef6839a51260f628026_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RhYmxlOmFhNTJiZTViM2I1NDQwNDI4NTZmNDY1ODFiMGZiNTA0L3RhYmxlcmFuZ2U6YWE1MmJlNWIzYjU0NDA0Mjg1NmY0NjU4MWIwZmI1MDRfNC0xLTEtMS0w_92fd46e4-f512-4f38-ba6f-ee448967ca22">1,029</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09f8081c6a5246a0a017275e36ee340d_D20210101-20210331" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RhYmxlOmFhNTJiZTViM2I1NDQwNDI4NTZmNDY1ODFiMGZiNTA0L3RhYmxlcmFuZ2U6YWE1MmJlNWIzYjU0NDA0Mjg1NmY0NjU4MWIwZmI1MDRfNC0zLTEtMS0w_ca3ce9ac-c244-4809-9256-6dc53e870176">159</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9502a31100149eaa773ddbb07c78892_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RhYmxlOmFhNTJiZTViM2I1NDQwNDI4NTZmNDY1ODFiMGZiNTA0L3RhYmxlcmFuZ2U6YWE1MmJlNWIzYjU0NDA0Mjg1NmY0NjU4MWIwZmI1MDRfNC01LTEtMS0w_154e27cc-ebbb-4c56-bd77-28ecc86a460e">1,355</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c2e51b9aa354777af021d48ff53f086_D20200101-20200331" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RhYmxlOmFhNTJiZTViM2I1NDQwNDI4NTZmNDY1ODFiMGZiNTA0L3RhYmxlcmFuZ2U6YWE1MmJlNWIzYjU0NDA0Mjg1NmY0NjU4MWIwZmI1MDRfNC03LTEtMS0w_0ec23569-de18-4467-937e-d2c7aa8c0473">339</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d4070f9748d4216be619760cb306306_D20200101-20200331" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RhYmxlOmFhNTJiZTViM2I1NDQwNDI4NTZmNDY1ODFiMGZiNTA0L3RhYmxlcmFuZ2U6YWE1MmJlNWIzYjU0NDA0Mjg1NmY0NjU4MWIwZmI1MDRfNC05LTEtMS0w_45d3c048-3cb5-4197-bdd1-2b26e8e60c89">52</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17406128628f47da8dc12cab978ee990_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RhYmxlOmFhNTJiZTViM2I1NDQwNDI4NTZmNDY1ODFiMGZiNTA0L3RhYmxlcmFuZ2U6YWE1MmJlNWIzYjU0NDA0Mjg1NmY0NjU4MWIwZmI1MDRfNC0xMS0xLTEtMA_c09d75d5-7f75-4533-bcfe-17725dba98f6">1,693</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Novartis AG</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba8c6028e53a4d3cb52c96d04a38aa3e_D20210101-20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RhYmxlOmFhNTJiZTViM2I1NDQwNDI4NTZmNDY1ODFiMGZiNTA0L3RhYmxlcmFuZ2U6YWE1MmJlNWIzYjU0NDA0Mjg1NmY0NjU4MWIwZmI1MDRfNS0xLTEtMS0w_b0e5f66c-5c41-42b9-a343-c6136fe57d7a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i403e5c57487b45d7953d44822a0f4e08_D20210101-20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RhYmxlOmFhNTJiZTViM2I1NDQwNDI4NTZmNDY1ODFiMGZiNTA0L3RhYmxlcmFuZ2U6YWE1MmJlNWIzYjU0NDA0Mjg1NmY0NjU4MWIwZmI1MDRfNS0zLTEtMS0w_1502b466-6909-47f4-b02a-38b67e1b770b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i040c336d87a74305b70be62dbab90158_D20210101-20210331" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RhYmxlOmFhNTJiZTViM2I1NDQwNDI4NTZmNDY1ODFiMGZiNTA0L3RhYmxlcmFuZ2U6YWE1MmJlNWIzYjU0NDA0Mjg1NmY0NjU4MWIwZmI1MDRfNS01LTEtMS0w_f0bd53aa-6686-4fb4-ab4b-92698f1c8aff">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9fefc66152040119b7d0c2744ada9b9_D20200101-20200331" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RhYmxlOmFhNTJiZTViM2I1NDQwNDI4NTZmNDY1ODFiMGZiNTA0L3RhYmxlcmFuZ2U6YWE1MmJlNWIzYjU0NDA0Mjg1NmY0NjU4MWIwZmI1MDRfNS03LTEtMS0w_c2b128ce-8695-49e4-94b0-42b11870ed05">998</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a5cdc0ffb3e42fbb82f9bf7e926e815_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RhYmxlOmFhNTJiZTViM2I1NDQwNDI4NTZmNDY1ODFiMGZiNTA0L3RhYmxlcmFuZ2U6YWE1MmJlNWIzYjU0NDA0Mjg1NmY0NjU4MWIwZmI1MDRfNS05LTEtMS0w_9ffcbbfe-c9ae-42cd-a659-567c62772c86">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e2701f10753482bb31aaa795ebf9601_D20200101-20200331" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RhYmxlOmFhNTJiZTViM2I1NDQwNDI4NTZmNDY1ODFiMGZiNTA0L3RhYmxlcmFuZ2U6YWE1MmJlNWIzYjU0NDA0Mjg1NmY0NjU4MWIwZmI1MDRfNS0xMS0xLTEtMA_95fb5cbb-c103-433f-9d08-df4af7bd13a4">266</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7032666edaaa4e429bcb5742671daf6b_D20210101-20210331" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RhYmxlOmFhNTJiZTViM2I1NDQwNDI4NTZmNDY1ODFiMGZiNTA0L3RhYmxlcmFuZ2U6YWE1MmJlNWIzYjU0NDA0Mjg1NmY0NjU4MWIwZmI1MDRfNi0xLTEtMS0w_f67ff0b9-ee02-4cae-9e3c-4d5494852d81">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9d9e02e83704b5dace40b5fa634af46_D20210101-20210331" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RhYmxlOmFhNTJiZTViM2I1NDQwNDI4NTZmNDY1ODFiMGZiNTA0L3RhYmxlcmFuZ2U6YWE1MmJlNWIzYjU0NDA0Mjg1NmY0NjU4MWIwZmI1MDRfNi0zLTEtMS0w_45b691ef-4603-40b1-9245-75253049a05b">52</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7a5922b1df34274baf2cab389d93825_D20210101-20210331" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RhYmxlOmFhNTJiZTViM2I1NDQwNDI4NTZmNDY1ODFiMGZiNTA0L3RhYmxlcmFuZ2U6YWE1MmJlNWIzYjU0NDA0Mjg1NmY0NjU4MWIwZmI1MDRfNi01LTEtMS0w_dbd96554-3412-4b43-ac7d-4326d378ae07">859</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i089d57f59b26493db395f392a738a27c_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RhYmxlOmFhNTJiZTViM2I1NDQwNDI4NTZmNDY1ODFiMGZiNTA0L3RhYmxlcmFuZ2U6YWE1MmJlNWIzYjU0NDA0Mjg1NmY0NjU4MWIwZmI1MDRfNi03LTEtMS0w_d3315138-fc9e-486f-b783-ce69ce9e9374">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifcf043d12a364c6d8f621f3ce9eb05b3_D20200101-20200331" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RhYmxlOmFhNTJiZTViM2I1NDQwNDI4NTZmNDY1ODFiMGZiNTA0L3RhYmxlcmFuZ2U6YWE1MmJlNWIzYjU0NDA0Mjg1NmY0NjU4MWIwZmI1MDRfNi05LTEtMS0w_1f3220bc-60f8-492d-bf17-766f78a770ad">17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a0b334cef804098995f34a0b7102f9f_D20200101-20200331" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RhYmxlOmFhNTJiZTViM2I1NDQwNDI4NTZmNDY1ODFiMGZiNTA0L3RhYmxlcmFuZ2U6YWE1MmJlNWIzYjU0NDA0Mjg1NmY0NjU4MWIwZmI1MDRfNi0xMS0xLTEtMA_85353672-ed78-416a-90f9-b4ae2ec37f89">231</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic693d204e9e347ae897f48a7db4e8373_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RhYmxlOmFhNTJiZTViM2I1NDQwNDI4NTZmNDY1ODFiMGZiNTA0L3RhYmxlcmFuZ2U6YWE1MmJlNWIzYjU0NDA0Mjg1NmY0NjU4MWIwZmI1MDRfNy0xLTEtMS0w_84b1391b-81b4-4061-b949-782810731d4f">5,839</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11ab95266c9c458da1f4e2524c453219_D20210101-20210331" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RhYmxlOmFhNTJiZTViM2I1NDQwNDI4NTZmNDY1ODFiMGZiNTA0L3RhYmxlcmFuZ2U6YWE1MmJlNWIzYjU0NDA0Mjg1NmY0NjU4MWIwZmI1MDRfNy0zLTEtMS0w_fb31f892-39a1-4b0d-a8ee-402b0ea9c4cb">305</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87f5d930fa0e4dd885c325ce478459fc_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RhYmxlOmFhNTJiZTViM2I1NDQwNDI4NTZmNDY1ODFiMGZiNTA0L3RhYmxlcmFuZ2U6YWE1MmJlNWIzYjU0NDA0Mjg1NmY0NjU4MWIwZmI1MDRfNy01LTEtMS0w_3a4c19ef-c685-4955-990c-6c7409c719ec">14,452</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i864e263b7e9f4629b9b97b9cfc3bed2f_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RhYmxlOmFhNTJiZTViM2I1NDQwNDI4NTZmNDY1ODFiMGZiNTA0L3RhYmxlcmFuZ2U6YWE1MmJlNWIzYjU0NDA0Mjg1NmY0NjU4MWIwZmI1MDRfNy03LTEtMS0w_82c65267-a7ff-43a5-8f5f-428cca8cc82b">5,949</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6496ce2c62514d00a0ced101ce91a17f_D20200101-20200331" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RhYmxlOmFhNTJiZTViM2I1NDQwNDI4NTZmNDY1ODFiMGZiNTA0L3RhYmxlcmFuZ2U6YWE1MmJlNWIzYjU0NDA0Mjg1NmY0NjU4MWIwZmI1MDRfNy05LTEtMS0w_b9e94a07-4d36-450a-859d-e1f4baf74b88">69</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab9f59c06f804edca916d76b33ea3ca1_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RhYmxlOmFhNTJiZTViM2I1NDQwNDI4NTZmNDY1ODFiMGZiNTA0L3RhYmxlcmFuZ2U6YWE1MmJlNWIzYjU0NDA0Mjg1NmY0NjU4MWIwZmI1MDRfNy0xMS0xLTEtMA_7f22cf47-a038-4b7d-85b4-5a2718a46c5e">13,681</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The research and development expenses incurred for each agreement listed in the table above consist of costs incurred for (i) clinical expenses, including manufacturing of clinical product, (ii) external services including consulting services and lab supplies and services, and (iii) other expenses, including professional services, facilities and overhead allocations, and a reasonable estimate of compensation and related costs as billed to our counterparties, for which we recognize net revenue from collaborations. For the three months ended March&#160;31, 2021 and 2020, we did not incur material selling, general and administrative expenses related to our collaboration agreements.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Product Alliances</span></div><div style="margin-top:6pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Regeneron Pharmaceuticals, Inc.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In April&#160;2019, we entered into a global, strategic collaboration with Regeneron Pharmaceuticals, Inc., or Regeneron, to discover, develop and commercialize RNAi therapeutics for a broad range of diseases by addressing therapeutic targets expressed in the eye and central nervous system, or CNS, in addition to a select number of targets expressed in the liver, which we refer to as the Regeneron Collaboration. The Regeneron Collaboration is governed by a Master Agreement, referred to as the Regeneron Master Agreement, which became effective on May 21, 2019, or the Effective Date. In connection with the Regeneron Master Agreement, we and Regeneron entered into (i) a binding co-co collaboration term sheet covering the continued development of cemdisiran, our C5 small interfering RNA, or siRNA, currently in Phase 2 development for C5 complement-mediated diseases, as a monotherapy and (ii) a binding license term sheet to evaluate anti-C5 antibody-siRNA combinations for C5 complement-mediated diseases including evaluating the combination of Regeneron&#8217;s pozelimab (REGN3918), currently in Phase 2 development, and cemdisiran. The C5 co-co collaboration and license agreements were executed in August 2019.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Under the terms of the Regeneron Collaboration, we are working exclusively with Regeneron to discover RNAi therapeutics for eye and CNS diseases for an initial <ix:nonNumeric contextRef="ia5305aa8b123480a9f5873905426845c_D20190408-20190408" format="ixt-sec:durwordsen" name="alny:DiscoveryPeriodOfProgramsDevelopment" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RleHRyZWdpb246MWE2ZWQwNzZlMTc2NDkyMzllYTFhMjgxNTMwYjdjYjRfMzExMDY_983dcd27-6c0f-41a5-9406-8ad560051d1e">five-year</ix:nonNumeric> research period, which we refer to as the Initial Research Term. Regeneron has an option to extend the Initial Research Term (referred to as the Research Term Extension Period, and together with the Initial Research Term, the Research Term) for up to an additional <ix:nonNumeric contextRef="ia5305aa8b123480a9f5873905426845c_D20190408-20190408" format="ixt-sec:durwordsen" name="alny:ExtendedAdditionalDiscoveryPeriodOfProgramsDevelopment" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RleHRyZWdpb246MWE2ZWQwNzZlMTc2NDkyMzllYTFhMjgxNTMwYjdjYjRfMTAyMTE_87e234dc-be9d-4f7b-9cd7-7adc1e8220f6">five years</ix:nonNumeric>, for a research term extension fee of up to $<ix:nonFraction unitRef="usd" contextRef="i73f0e7523666480d9c1deb15ed7a387e_D20190408-20190408" decimals="INF" format="ixt:numdotdecimal" name="alny:ResearchTermExtensionFee" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RleHRyZWdpb246MWE2ZWQwNzZlMTc2NDkyMzllYTFhMjgxNTMwYjdjYjRfMTAyNTg_4bcfeecc-0d80-43a1-a88a-7fe4c7424cbb">400.0</ix:nonFraction> million. The Regeneron Collaboration also covers a select number of RNAi therapeutic programs designed to target genes expressed in the liver, including our previously announced collaboration with Regeneron to identify RNAi therapeutics for the chronic liver disease nonalcoholic steatohepatitis. We retain broad global rights to all of our other unpartnered liver-</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9f86b6d3686546618ade3c76e6b23fc8_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ALNYLAM PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="ib849217a9a1a4d40843474fae4462d28" continuedAt="i17c901c9d5c64408bd916e74798c17cd"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">directed clinical and pre-clinical pipeline programs. The Regeneron Collaboration is governed by a joint steering committee that is comprised of an equal number of representatives from each party.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Regeneron will lead development and commercialization for all programs targeting eye diseases (subject to limited exceptions), entitling us to certain potential milestone and royalty payments pursuant to the terms of a license agreement, the form of which has been agreed upon by the parties. We and Regeneron will alternate leadership on CNS and liver programs, with the lead party retaining global development and commercial responsibility. For CNS and liver programs, both we and Regeneron will have the option at lead candidate selection to enter into a&#160;co-co&#160;collaboration agreement, the form of which has been agreed upon by the parties, whereby both companies will share equally all costs of, and profits from, all development and commercialization activities under the program. If the&#160;non-lead&#160;party elects to not enter into a&#160;co-co&#160;collaboration agreement with respect to a given CNS or liver program, we and Regeneron will enter into a license agreement with respect to such program and the lead party will be the &#8220;Licensee&#8221; for the purposes of the license agreement. If the lead party for a CNS or liver program elects to not enter into the&#160;co-co&#160;collaboration agreement, then we and Regeneron will enter into a license agreement with respect to such program and leadership of the program will transfer to the other party and the former&#160;non-lead&#160;party will be the &#8220;Licensee&#8221; for the purposes of the license agreement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">With respect to the programs directed to C5 complement-mediated diseases, we retain control of cemdisiran monotherapy development, and Regeneron is leading combination product development. Under the C5 co-co collaboration agreement, we and Regeneron equally share costs and potential future profits on any monotherapy program. Under the C5 license agreement, for cemdisiran to be used as part of a combination product, Regeneron is solely responsible for all development and commercialization costs and we will receive low double-digit royalties and commercial milestones of up to $<ix:nonFraction unitRef="usd" contextRef="ia5305aa8b123480a9f5873905426845c_D20190408-20190408" decimals="INF" format="ixt:numdotdecimal" name="alny:MaximumRoyaltiesAndCommercialMilestonePaymentsUponPotentialProductSale" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RleHRyZWdpb246MWE2ZWQwNzZlMTc2NDkyMzllYTFhMjgxNTMwYjdjYjRfMTI4MjU_8b4921de-cdab-4df0-97eb-effdf8d92a01">325.0</ix:nonFraction> million on any potential combination product sales. The C5 co-co collaboration agreement, the C5 license agreement, and the Master Agreement have been combined for accounting purposes and treated as a single agreement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In connection with the Regeneron Master Agreement, Regeneron made an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="ia5305aa8b123480a9f5873905426845c_D20190408-20190408" decimals="INF" format="ixt:numdotdecimal" name="alny:UpfrontFeeReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RleHRyZWdpb246MWE2ZWQwNzZlMTc2NDkyMzllYTFhMjgxNTMwYjdjYjRfMTMxMjc_8f7b475a-093f-423a-b58a-059a98d3920d">400.0</ix:nonFraction> million. We are also eligible to receive up to an additional $<ix:nonFraction unitRef="usd" contextRef="ia5305aa8b123480a9f5873905426845c_D20190408-20190408" decimals="INF" format="ixt:numdotdecimal" name="alny:MaximumAdditionalMilestonePaymentsToBeReceiveUponAchievementOfCertainCriteria" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RleHRyZWdpb246MWE2ZWQwNzZlMTc2NDkyMzllYTFhMjgxNTMwYjdjYjRfMTMxODM_ce79c5a4-d242-454d-bd46-4cb1c00ec3a2">200.0</ix:nonFraction> million in milestone payments upon achievement of certain criteria during early clinical development for eye and CNS programs. We and Regeneron plan to advance programs directed to up to <ix:nonFraction unitRef="program" contextRef="ia5305aa8b123480a9f5873905426845c_D20190408-20190408" decimals="INF" name="alny:NumberOfTargetedPrograms" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RleHRyZWdpb246MWE2ZWQwNzZlMTc2NDkyMzllYTFhMjgxNTMwYjdjYjRfMTMzNjU_381da3a7-b286-4243-ad09-7999a29f5f44">30</ix:nonFraction> targets under the Regeneron Collaboration during the Initial Research Term. For each program, Regeneron will provide us with $<ix:nonFraction unitRef="usd" contextRef="if2bf4b0c1f3049e3958e56012db213d3_I20190408" decimals="-5" format="ixt:numdotdecimal" name="alny:PotentialProceedsFromCollaborationArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RleHRyZWdpb246MWE2ZWQwNzZlMTc2NDkyMzllYTFhMjgxNTMwYjdjYjRfMTM0OTM_f862afb4-b8a7-441a-aec4-390559c2076b">2.5</ix:nonFraction> million in funding at program initiation and an additional $<ix:nonFraction unitRef="usd" contextRef="i5e0a1eb0aca04059bb786c05e4dd32bc_I20190408" decimals="-5" format="ixt:numdotdecimal" name="alny:PotentialProceedsFromCollaborationArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RleHRyZWdpb246MWE2ZWQwNzZlMTc2NDkyMzllYTFhMjgxNTMwYjdjYjRfMTM1NDc_2328617a-4611-4087-b304-2133eead982a">2.5</ix:nonFraction> million at lead candidate identification, with the potential for approximately $<ix:nonFraction unitRef="usd" contextRef="i0fe175fb793a4f5e9a26e0bd683c3620_I20190408" decimals="-5" format="ixt:numdotdecimal" name="alny:PotentialProceedsFromCollaborationArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RleHRyZWdpb246MWE2ZWQwNzZlMTc2NDkyMzllYTFhMjgxNTMwYjdjYjRfMTM2MjE_c7f01ed3-975e-4d70-8cd9-490bd10ce7e8">30.0</ix:nonFraction> million in annual discovery funding to us as the Regeneron Collaboration reaches steady state.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Regeneron has the right to terminate the Regeneron Master Agreement for convenience upon <ix:nonNumeric contextRef="ia5305aa8b123480a9f5873905426845c_D20190408-20190408" format="ixt-sec:durwordsen" name="alny:CollaborativeAgreementTerminationPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RleHRyZWdpb246MWE2ZWQwNzZlMTc2NDkyMzllYTFhMjgxNTMwYjdjYjRfMTM4MDA_9c7cf93a-cb1b-4010-bf9b-1da8658dfce2">ninety days</ix:nonNumeric>&#8217; notice. The termination of the Regeneron Master Agreement does not affect the term of any license agreement or&#160;co-co&#160;collaboration agreement then in effect. In addition, either party may terminate the Regeneron Master Agreement for a material breach by, or insolvency of, the other party. Unless earlier terminated pursuant to its terms, the Regeneron Master Agreement will remain in effect with respect to each program until (a)&#160;such program becomes a terminated program or (b)&#160;the parties enter into a license agreement or&#160;co-co&#160;collaboration agreement with respect to such program.&#160;The Regeneron Master Agreement includes various representations, warranties, covenants, dispute escalation and resolution mechanisms, indemnities and other provisions customary for transactions of this nature.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For any license agreement subsequently entered into, the licensee will generally be responsible for its own costs and expenses incurred in connection with the development and commercialization of the collaboration products. The licensee will pay to the licensor certain development and/or commercialization milestone payments totaling up to $<ix:nonFraction unitRef="usd" contextRef="i73f0e7523666480d9c1deb15ed7a387e_D20190408-20190408" decimals="-5" format="ixt:numdotdecimal" name="alny:CollaborativeArrangementMilestonePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RleHRyZWdpb246MWE2ZWQwNzZlMTc2NDkyMzllYTFhMjgxNTMwYjdjYjRfMTQ5NDA_c6b65793-d0cd-4010-a6c5-f4052c43550d">150.0</ix:nonFraction> million for each collaboration product. In addition, following the first commercial sale of the applicable collaboration product under a license agreement, the licensee is required to make certain tiered royalty payments, ranging from low double-digits up to <ix:nonFraction unitRef="number" contextRef="i971ffad5c679466dbaa1a956091dff5b_I20190408" decimals="INF" name="alny:RoyaltyRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RleHRyZWdpb246MWE2ZWQwNzZlMTc2NDkyMzllYTFhMjgxNTMwYjdjYjRfMTUxOTQ_29ab8926-de65-41c1-b12e-1116de1676a0">20</ix:nonFraction>%, to the licensor based on the aggregate annual net sales of the collaboration product, subject to customary reductions.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For any co-co&#160;collaboration agreement subsequently entered into, we and Regeneron will share equally all costs of, and profits from, development and commercialization activities. Reimbursement of our share of costs will be recognized as a reduction to research and development expense in the condensed consolidated statements of operations and comprehensive loss. In the event that a party exercises its&#160;opt-out&#160;right, the lead party will be responsible for all costs and expenses incurred in connection with the development and commercialization of the collaboration products under the applicable&#160;co-co&#160;collaboration agreement, subject to continued sharing of costs through defined points. If a party exercises its&#160;opt-out&#160;right, following the first commercial sale of the applicable collaboration product under a&#160;co-co&#160;collaboration agreement, the lead party is required to make certain tiered royalty payments, ranging from low double-digits up to <ix:nonFraction unitRef="number" contextRef="ia5305aa8b123480a9f5873905426845c_D20190408-20190408" decimals="INF" name="alny:PercentageOfMaximumRoyaltyPayments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RleHRyZWdpb246MWE2ZWQwNzZlMTc2NDkyMzllYTFhMjgxNTMwYjdjYjRfMTYyNzA_d330a9ce-f11d-4e3f-adf7-8bd0017d001c">20</ix:nonFraction>%, to the other party based on the aggregate annual net sales of the collaboration product and the timing of the exercise of the&#160;opt-out&#160;right, subject to customary reductions and a reduction for&#160;opt-out&#160;transition costs.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Due to the uncertainty of pharmaceutical development and the high historical failure rates generally associated with drug development, we may not receive any milestone or royalty payments from Regeneron under the Regeneron Master Agreement, the C5 license agreement, or any future license agreement, or under any co-co collaboration agreement in the event we exercise our opt-out right.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9f86b6d3686546618ade3c76e6b23fc8_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ALNYLAM PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="i17c901c9d5c64408bd916e74798c17cd" continuedAt="ib8dadfffdefb4efa99fe12888caa2817"><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our obligations under the Regeneron Collaboration include: (i) a research license and research services, collectively referred to as the Research Services Obligation; (ii) a worldwide license to cemdisiran for combination therapies, and manufacturing and supply, and development service obligations, collectively referred to as the C5 License Obligation; and (iii) development, manufacturing and commercialization activities for cemdisiran monotherapies, referred to as the C5 Co-Co Obligation.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The research license is not distinct from the research services primarily as a result of Regeneron being unable to benefit on its own or with other resources reasonably available, as the license is providing access to specialized expertise, particularly as it relates to RNAi technology that is not available in the marketplace.&#160;Similarly, the worldwide license to cemdisiran for combination therapies is not distinct from the manufacturing and supply, and development service obligations, as Regeneron cannot benefit on its own from the value of the license without receipt of supply.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Separately, the cemdisiran monotherapy co-co collaboration agreement is under the scope of ASC 808 as we and Regeneron are both active participants in the development and manufacturing activities and are exposed to significant risks and rewards that are dependent on commercial success of the activities of the arrangement. The development and manufacturing activities are a combined unit of account under the scope of ASC 808 and are not deliverables under ASC 606.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The total transaction price is comprised of the&#160;$<ix:nonFraction unitRef="usd" contextRef="ia5305aa8b123480a9f5873905426845c_D20190408-20190408" decimals="INF" format="ixt:numdotdecimal" name="alny:UpfrontFeeReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RleHRyZWdpb246MWE2ZWQwNzZlMTc2NDkyMzllYTFhMjgxNTMwYjdjYjRfMTg0Nzg_f5465d88-31b0-4169-b7a6-265fdf379dcb">400.0</ix:nonFraction> million&#160;upfront payment and&#160;additional variable consideration related to research, development, manufacturing and supply activities related to the Research Services Obligation and the C5 License Obligation. We utilized the expected value method to determine the amount of reimbursement for these activities. We determined that any variable consideration related to sales-based royalties and milestones related to the worldwide license to cemdisiran for combination therapies is deemed to be constrained and therefore has been excluded from the transaction price. In addition, we are eligible to receive future milestones upon the achievement of certain criteria during early clinical development for the eye and CNS programs.&#160;We are also eligible to receive royalties on future commercial sales for certain eye, CNS or liver targets, if any; however, these amounts are excluded from variable consideration under the Regeneron Collaboration as we are only eligible to receive such amounts if, after a drug candidate is identified, the form of license agreement is subsequently executed resulting in a license that is granted to Regeneron. Any such subsequently granted license would represent a separate transaction under ASC 606. </span></div><ix:nonNumeric contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331" name="alny:ScheduleOfAllocatedTransactionPriceTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RleHRyZWdpb246MWE2ZWQwNzZlMTc2NDkyMzllYTFhMjgxNTMwYjdjYjRfMzExMDA_0bb18214-28f2-440d-a3db-944a4c0b5203" continuedAt="ie14553890d884072b2429c1a2226e10b" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We allocated the initial transaction price to each unit of account based on the applicable accounting guidance as follows, in thousands: </span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.467%"><tr><td style="width:1.0%"></td><td style="width:35.806%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.412%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.736%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.412%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.736%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.331%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.567%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:83%">Performance Obligations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:83%">Standalone Selling Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:83%">Transaction Price Allocated</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:83%">Accounting Guidance</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">Research Services Obligation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%"><ix:nonFraction unitRef="usd" contextRef="ice333d52f3d1470e9ef529637248a8dc_I20210331" decimals="-3" format="ixt:numdotdecimal" name="alny:StandaloneSellingPrice" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RhYmxlOmU4YTUzOTQzNzI3MjRkZGU4ZDZjNmZjNTlhYTVhMzY1L3RhYmxlcmFuZ2U6ZThhNTM5NDM3MjcyNGRkZThkNmM2ZmM1OWFhNWEzNjVfMS0yLTEtMS0w_fa403f3a-64b7-474d-807b-da1893746044">130,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%"><ix:nonFraction unitRef="usd" contextRef="i36f4850caa714d72a30d3755dee41330_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="alny:TransactionPrice" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RhYmxlOmU4YTUzOTQzNzI3MjRkZGU4ZDZjNmZjNTlhYTVhMzY1L3RhYmxlcmFuZ2U6ZThhNTM5NDM3MjcyNGRkZThkNmM2ZmM1OWFhNWEzNjVfMS00LTEtMS0w_82a0577e-5497-4d39-ab73-17217e3566ea">183,100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">ASC 606</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">C5 License Obligation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%"><ix:nonFraction unitRef="usd" contextRef="ie1b05d9fbec1490d8547da979164246c_I20210331" decimals="-3" format="ixt:numdotdecimal" name="alny:StandaloneSellingPrice" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RhYmxlOmU4YTUzOTQzNzI3MjRkZGU4ZDZjNmZjNTlhYTVhMzY1L3RhYmxlcmFuZ2U6ZThhNTM5NDM3MjcyNGRkZThkNmM2ZmM1OWFhNWEzNjVfMi0yLTEtMS0w_8ed98849-98b9-4885-8bcc-dd164fdf1f23">97,600</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%"><ix:nonFraction unitRef="usd" contextRef="i9afb38e70eac4aa0940613e1656a62b6_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="alny:TransactionPrice" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RhYmxlOmU4YTUzOTQzNzI3MjRkZGU4ZDZjNmZjNTlhYTVhMzY1L3RhYmxlcmFuZ2U6ZThhNTM5NDM3MjcyNGRkZThkNmM2ZmM1OWFhNWEzNjVfMi00LTEtMS0w_9a730ded-ab17-4c52-9fa0-36e7a39e0d8b">92,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:95%">ASC 606</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">C5 Co-Co Obligation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%"><ix:nonFraction unitRef="usd" contextRef="i5ed9a55f1a8143bd9068e4f6bbafe8a1_I20210331" decimals="-3" format="ixt:numdotdecimal" name="alny:StandaloneSellingPrice" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RhYmxlOmU4YTUzOTQzNzI3MjRkZGU4ZDZjNmZjNTlhYTVhMzY1L3RhYmxlcmFuZ2U6ZThhNTM5NDM3MjcyNGRkZThkNmM2ZmM1OWFhNWEzNjVfMy0yLTEtMS0w_fa87105d-e8d2-4406-b96d-edf9b4ac8cbd">364,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%"><ix:nonFraction unitRef="usd" contextRef="i034331457ce94629bdc278cc2f5e440c_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="alny:TransactionPrice" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RhYmxlOmU4YTUzOTQzNzI3MjRkZGU4ZDZjNmZjNTlhYTVhMzY1L3RhYmxlcmFuZ2U6ZThhNTM5NDM3MjcyNGRkZThkNmM2ZmM1OWFhNWEzNjVfMy00LTEtMS0w_83c25a8d-afd0-4728-b8de-c15352af9ea7">246,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">ASC 808</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%"><ix:nonFraction unitRef="usd" contextRef="id46811031a3d408bac58580e626f8e3b_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="alny:TransactionPrice" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RhYmxlOmU4YTUzOTQzNzI3MjRkZGU4ZDZjNmZjNTlhYTVhMzY1L3RhYmxlcmFuZ2U6ZThhNTM5NDM3MjcyNGRkZThkNmM2ZmM1OWFhNWEzNjVfNC00LTEtMS0w_ad6758c1-a45e-4743-a09a-a31f3bc5f63a">521,600</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The transaction price was allocated to the obligations based on the relative estimated standalone selling prices of each obligation, over which management has applied significant judgment. We developed the estimated standalone selling price for the licenses included in the Research Services Obligation and the C5 License Obligation primarily based on the probability-weighted present value of expected future cash flows associated with each license related to each specific program. In developing such estimate, we applied judgment in the determination of the forecasted revenues, taking into consideration the applicable market conditions and relevant entity-specific factors, the expected number of targets or indications expected to be pursued under each license, the probability of success, the time needed to develop a product candidate pursuant to the associated license and the discount rate. We developed the estimated standalone selling price for the services and/or manufacturing and supply included in each of the obligations, as applicable, primarily based on the nature of the services to be performed and/or goods to be manufactured and estimates of the associated costs. The estimated standalone selling price of the C5 Co-Co Obligation was developed by estimating the present value of expected future cash flows that Regeneron is entitled to receive. In developing such estimate, we applied judgment in determining the indications that will be pursued, the forecasted revenues for such indications, the probability of success and the discount rate.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For the Research Services Obligation and the C5 License Obligation accounted for under ASC 606, we measure proportional performance over time using an input method based on cost incurred relative to the total estimated costs for each of the identified obligations, on a quarterly basis, by determining the proportion of effort incurred as a percentage of total effort we expect to expend.&#160;This ratio is applied to the transaction price allocated to each obligation. Management has applied significant judgment in the process of developing our estimates. Any changes to these estimates will be recognized in the period in which they change as a cumulative catch up. We re-evaluate the transaction price as of the end of each reporting period, as of March&#160;31, 2021, the total transaction price was $<ix:nonFraction unitRef="usd" contextRef="ibb1a94652b264aa4980ac89d4f3e71e0_D20210331-20210331" decimals="-5" format="ixt:numdotdecimal" name="alny:TransactionPrice" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RleHRyZWdpb246MWE2ZWQwNzZlMTc2NDkyMzllYTFhMjgxNTMwYjdjYjRfODI0NjMzNzMwMjIzNQ_97d14e5a-6a37-43dc-b8be-6bb8a0fcfea3">530.5</ix:nonFraction>&#160;million. As of March&#160;31, 2021, the transaction price is comprised of the </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9f86b6d3686546618ade3c76e6b23fc8_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ALNYLAM PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="ib8dadfffdefb4efa99fe12888caa2817" continuedAt="i9f43f80b7f714a41ba2dbcfaafded942"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">upfront payment and variable consideration related to development, manufacture and supply activities. For the C5 Co-Co Obligation accounted for under ASC 808, the transaction price allocated to this obligation is recognized using a proportional performance method. Revenue recognized under this agreement, inclusive of the amount allocated to the C5 Co-Co Obligation, is accounted for as collaboration revenue.</span></div><ix:continuation id="ie14553890d884072b2429c1a2226e10b"><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following tables provide a summary of the transaction price allocated to each unit of account based on the applicable accounting guidance, in addition to revenue activity during the period, in thousands:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:91.374%"><tr><td style="width:1.0%"></td><td style="width:25.300%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.440%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.660%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.440%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.660%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.440%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.660%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.440%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.660%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Transaction Price Allocated</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Deferred Revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Performance Obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31,<br/>2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31,<br/>2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,<br/>2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Accounting Guidance</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Research Services Obligation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="if0be8a0acd8c4f4a936e1a39b3321d4e_D20210331-20210331" decimals="-3" format="ixt:numdotdecimal" name="alny:TransactionPrice" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RhYmxlOjZjZTM1MWQ4ZDFkNjQ5MGRhZWUyYmNkYTMwODI0NDhhL3RhYmxlcmFuZ2U6NmNlMzUxZDhkMWQ2NDkwZGFlZTJiY2RhMzA4MjQ0OGFfMi0yLTEtMS0w_16061644-b459-415b-8c38-4b92926455c2">200,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="ice333d52f3d1470e9ef529637248a8dc_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RhYmxlOjZjZTM1MWQ4ZDFkNjQ5MGRhZWUyYmNkYTMwODI0NDhhL3RhYmxlcmFuZ2U6NmNlMzUxZDhkMWQ2NDkwZGFlZTJiY2RhMzA4MjQ0OGFfMi00LTEtMS0w_59d4a0d6-c8d7-4e49-be82-d04e9b2744ec">45,100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i15dc0fb5b4cf413aa1bddc7de9dc8427_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RhYmxlOjZjZTM1MWQ4ZDFkNjQ5MGRhZWUyYmNkYTMwODI0NDhhL3RhYmxlcmFuZ2U6NmNlMzUxZDhkMWQ2NDkwZGFlZTJiY2RhMzA4MjQ0OGFfMi02LTEtMS0w_4fa15f42-c396-4d73-8b15-2285f3d09c7a">54,900</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ASC 606</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">C5 License Obligation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i658edd34d7bb479582be347d92985839_D20210331-20210331" decimals="-3" format="ixt:numdotdecimal" name="alny:TransactionPrice" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RhYmxlOjZjZTM1MWQ4ZDFkNjQ5MGRhZWUyYmNkYTMwODI0NDhhL3RhYmxlcmFuZ2U6NmNlMzUxZDhkMWQ2NDkwZGFlZTJiY2RhMzA4MjQ0OGFfMy0yLTEtMS0w_fb52b0a4-7eaf-4f94-ac53-3fc6e89ba690">83,900</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="ie1b05d9fbec1490d8547da979164246c_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RhYmxlOjZjZTM1MWQ4ZDFkNjQ5MGRhZWUyYmNkYTMwODI0NDhhL3RhYmxlcmFuZ2U6NmNlMzUxZDhkMWQ2NDkwZGFlZTJiY2RhMzA4MjQ0OGFfMy00LTEtMS0w_5f8b26f9-e150-498e-96c6-183c20739541">45,200</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i861836d62a924d62ab2e4e1d6bb80274_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RhYmxlOjZjZTM1MWQ4ZDFkNjQ5MGRhZWUyYmNkYTMwODI0NDhhL3RhYmxlcmFuZ2U6NmNlMzUxZDhkMWQ2NDkwZGFlZTJiY2RhMzA4MjQ0OGFfMy02LTEtMS0w_ffa4de3e-0613-4bf1-a1ca-db180ac0dd56">58,700</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ASC 606</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">C5 Co-Co Obligation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i80b049fd41474712a64d29d35fabd92b_D20210331-20210331" decimals="-3" format="ixt:numdotdecimal" name="alny:TransactionPrice" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RhYmxlOjZjZTM1MWQ4ZDFkNjQ5MGRhZWUyYmNkYTMwODI0NDhhL3RhYmxlcmFuZ2U6NmNlMzUxZDhkMWQ2NDkwZGFlZTJiY2RhMzA4MjQ0OGFfNC0yLTEtMS0w_d88d5d67-b12b-4203-89a5-7cb37191515c">246,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i5ed9a55f1a8143bd9068e4f6bbafe8a1_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RhYmxlOjZjZTM1MWQ4ZDFkNjQ5MGRhZWUyYmNkYTMwODI0NDhhL3RhYmxlcmFuZ2U6NmNlMzUxZDhkMWQ2NDkwZGFlZTJiY2RhMzA4MjQ0OGFfNC00LTEtMS0w_8fe5dcb9-4317-4d83-9fd2-7d73d36dddee">228,900</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="ifccb7d9fff7c476987c83ac85c1953b1_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RhYmxlOjZjZTM1MWQ4ZDFkNjQ5MGRhZWUyYmNkYTMwODI0NDhhL3RhYmxlcmFuZ2U6NmNlMzUxZDhkMWQ2NDkwZGFlZTJiY2RhMzA4MjQ0OGFfNC02LTEtMS0w_92832837-fe98-4975-89c5-2c4015945db9">231,400</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ASC 808</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="ibb1a94652b264aa4980ac89d4f3e71e0_D20210331-20210331" decimals="-3" format="ixt:numdotdecimal" name="alny:TransactionPrice" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RhYmxlOjZjZTM1MWQ4ZDFkNjQ5MGRhZWUyYmNkYTMwODI0NDhhL3RhYmxlcmFuZ2U6NmNlMzUxZDhkMWQ2NDkwZGFlZTJiY2RhMzA4MjQ0OGFfNS0yLTEtMS0w_81d473f3-fd4c-4442-85ea-5c91a637c7a9">530,500</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i8ee04dc4bddd49289fea1361ef9a5f63_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RhYmxlOjZjZTM1MWQ4ZDFkNjQ5MGRhZWUyYmNkYTMwODI0NDhhL3RhYmxlcmFuZ2U6NmNlMzUxZDhkMWQ2NDkwZGFlZTJiY2RhMzA4MjQ0OGFfNS00LTEtMS0w_d90903b5-d3e4-4c1e-a420-af308379466b">319,200</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i845dea082db84f4bad647918893f1a91_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RhYmxlOjZjZTM1MWQ4ZDFkNjQ5MGRhZWUyYmNkYTMwODI0NDhhL3RhYmxlcmFuZ2U6NmNlMzUxZDhkMWQ2NDkwZGFlZTJiY2RhMzA4MjQ0OGFfNS02LTEtMS0w_81b5740a-5714-45ac-9fad-9883e1e3e76e">345,000</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></ix:continuation><div style="margin-bottom:6pt;margin-top:12pt;text-align:center"><ix:nonNumeric contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331" name="alny:ScheduleOfRevenueRecognizedBasedOnAccountingGuidanceTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RleHRyZWdpb246MWE2ZWQwNzZlMTc2NDkyMzllYTFhMjgxNTMwYjdjYjRfMzExMTI_9f94e98e-2429-4cf7-8f9c-17cb286368d4" escape="true"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:66.959%"><tr><td style="width:1.0%"></td><td style="width:34.926%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.673%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.699%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.673%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.699%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.673%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.657%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Revenue Recognized During</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Performance Obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31, 2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31, 2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Accounting Guidance</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Research Services Obligation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i36f4850caa714d72a30d3755dee41330_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RhYmxlOmFlMzZmMTBhNDIyZTQ3N2ZhOWVlOWI4MzQ2MDA0OTdjL3RhYmxlcmFuZ2U6YWUzNmYxMGE0MjJlNDc3ZmE5ZWU5YjgzNDYwMDQ5N2NfMy0yLTEtMS0w_59b0aaea-2dbd-4f94-a3b6-00a9adec882e">9,800</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i5fd8d80f765d41dcb65fffa60ec775cf_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RhYmxlOmFlMzZmMTBhNDIyZTQ3N2ZhOWVlOWI4MzQ2MDA0OTdjL3RhYmxlcmFuZ2U6YWUzNmYxMGE0MjJlNDc3ZmE5ZWU5YjgzNDYwMDQ5N2NfMy00LTEtMS0w_80b8e1df-a516-4f79-af38-5b99b5066fd2">12,300</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ASC 606</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">C5 License Obligation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i9afb38e70eac4aa0940613e1656a62b6_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RhYmxlOmFlMzZmMTBhNDIyZTQ3N2ZhOWVlOWI4MzQ2MDA0OTdjL3RhYmxlcmFuZ2U6YWUzNmYxMGE0MjJlNDc3ZmE5ZWU5YjgzNDYwMDQ5N2NfNC0yLTEtMS0w_e463d4c4-86f9-487a-a4f0-3425be430ab4">13,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="id8599564d7e94d6db58cf776fcdfcc51_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RhYmxlOmFlMzZmMTBhNDIyZTQ3N2ZhOWVlOWI4MzQ2MDA0OTdjL3RhYmxlcmFuZ2U6YWUzNmYxMGE0MjJlNDc3ZmE5ZWU5YjgzNDYwMDQ5N2NfNC00LTEtMS0w_bb6b760b-20b5-4502-98ee-0cc5dd283195">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ASC 606</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">C5 Co-Co Obligation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i034331457ce94629bdc278cc2f5e440c_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RhYmxlOmFlMzZmMTBhNDIyZTQ3N2ZhOWVlOWI4MzQ2MDA0OTdjL3RhYmxlcmFuZ2U6YWUzNmYxMGE0MjJlNDc3ZmE5ZWU5YjgzNDYwMDQ5N2NfNS0yLTEtMS0w_d2f720f4-9f7f-4857-8de2-8bba85ea25f4">2,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i7f816a549c3b442c81980771e664236b_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RhYmxlOmFlMzZmMTBhNDIyZTQ3N2ZhOWVlOWI4MzQ2MDA0OTdjL3RhYmxlcmFuZ2U6YWUzNmYxMGE0MjJlNDc3ZmE5ZWU5YjgzNDYwMDQ5N2NfNS00LTEtMS0w_7c46a92b-67a1-4fb1-9fe8-16410e5d3f60">4,200</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ASC 808</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="id46811031a3d408bac58580e626f8e3b_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RhYmxlOmFlMzZmMTBhNDIyZTQ3N2ZhOWVlOWI4MzQ2MDA0OTdjL3RhYmxlcmFuZ2U6YWUzNmYxMGE0MjJlNDc3ZmE5ZWU5YjgzNDYwMDQ5N2NfNi0yLTEtMS0w_0a161872-6e02-4d0c-a025-393e307dcfa6">25,800</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="if12146e5cbeb4f978bb78a0f76137cb2_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RhYmxlOmFlMzZmMTBhNDIyZTQ3N2ZhOWVlOWI4MzQ2MDA0OTdjL3RhYmxlcmFuZ2U6YWUzNmYxMGE0MjJlNDc3ZmE5ZWU5YjgzNDYwMDQ5N2NfNi00LTEtMS0w_453c8b9e-c12c-475c-839c-d5a53e4b278a">16,500</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></ix:nonNumeric></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of&#160;March&#160;31, 2021, the aggregate amount of the transaction price allocated to the remaining Research Services Obligation and C5 License Obligation that was unsatisfied was&#160;$<ix:nonFraction unitRef="usd" contextRef="i8ee04dc4bddd49289fea1361ef9a5f63_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueRemainingPerformanceObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RleHRyZWdpb246MWE2ZWQwNzZlMTc2NDkyMzllYTFhMjgxNTMwYjdjYjRfMjI5NjM_f910b87e-0f6c-4659-a852-9a1eaec6bc49">188.3</ix:nonFraction> million, which&#160;is expected to be recognized through the term of the Regeneron Collaboration as the services are performed. This amount excludes the transaction price allocated to the C5 Co-Co Obligation accounted for under ASC 808. Deferred revenue related to the Regeneron Collaboration is classified as either current or non-current in the condensed consolidated balance sheets based on the period the revenue is expected to be recognized.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Novartis AG</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In February 2013, we and The Medicines Company, or MDCO, entered into a license and collaboration agreement pursuant to which we granted to MDCO an exclusive, worldwide license to develop, manufacture and commercialize RNAi therapeutics targeting proprotein convertase subtilisin/kexin type 9, or PCSK9, for the treatment of hypercholesterolemia and other human diseases, including inclisiran. We refer to this agreement, as amended through the date hereof, as the MDCO License Agreement. On January 6, 2020, Novartis completed its acquisition of MDCO, and assumed all rights and obligations under the MDCO License Agreement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of March&#160;31, 2021, we have earned $<ix:nonFraction unitRef="usd" contextRef="i5c760c86aa8249a6be17c482badca19e_D20130201-20210331" decimals="-5" format="ixt:numdotdecimal" name="alny:MilestonePaymentEarned" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RleHRyZWdpb246MWE2ZWQwNzZlMTc2NDkyMzllYTFhMjgxNTMwYjdjYjRfNDk0NzgwMjQwNjUzNg_8ea2aeca-8973-4c0e-b246-8056dc5832b3">45.0</ix:nonFraction>&#160;million of milestones and upon achievement of certain events, we will be entitled to receive additional milestones, up to an aggregate of $<ix:nonFraction unitRef="usd" contextRef="i7d36bc345e7f4e4197c9a712cb73b817_D20130201-20130228" decimals="-5" format="ixt:numdotdecimal" name="alny:MaximumNumberOfPotentialFutureMilestones" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RleHRyZWdpb246MWE2ZWQwNzZlMTc2NDkyMzllYTFhMjgxNTMwYjdjYjRfNDk0NzgwMjQwNjU1NA_1b18e5e8-35c1-4b6c-980a-07e20da3935a">135.0</ix:nonFraction>&#160;million, including $<ix:nonFraction unitRef="usd" contextRef="i7d36bc345e7f4e4197c9a712cb73b817_D20130201-20130228" decimals="-5" format="ixt:numdotdecimal" name="alny:FuturePaymentsOnAchievementOfSpecifiedRegulatoryMilestones" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RleHRyZWdpb246MWE2ZWQwNzZlMTc2NDkyMzllYTFhMjgxNTMwYjdjYjRfNDk0NzgwMjQwNjU3Ng_e1321de9-c7ee-4577-acae-19a665850c96">25.0</ix:nonFraction>&#160;million associated with the U.S. regulatory approval milestone, $<ix:nonFraction unitRef="usd" contextRef="i7d36bc345e7f4e4197c9a712cb73b817_D20130201-20130228" decimals="-5" format="ixt:numdotdecimal" name="alny:FuturePaymentsOnAchievementOfOtherSpecifiedRegulatoryMilestones" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RleHRyZWdpb246MWE2ZWQwNzZlMTc2NDkyMzllYTFhMjgxNTMwYjdjYjRfNDk0NzgwMjQwNjc0MQ_747b4bf5-09c3-4338-aad5-3d1dc7f1fd88">10.0</ix:nonFraction>&#160;million in other specified regulatory milestones and $<ix:nonFraction unitRef="usd" contextRef="i7d36bc345e7f4e4197c9a712cb73b817_D20130201-20130228" decimals="-5" format="ixt:numdotdecimal" name="alny:FuturePaymentsOnAchievementOfSpecifiedCommercializationMilestones" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RleHRyZWdpb246MWE2ZWQwNzZlMTc2NDkyMzllYTFhMjgxNTMwYjdjYjRfNDk0NzgwMjQwNjc0Nw_ef54bdc8-ea79-44d7-9317-1d86794b504b">100.0</ix:nonFraction>&#160;million in specified commercialization milestones. In addition, we will be entitled to royalties ranging from <ix:nonFraction unitRef="number" contextRef="id397f59fc9a04a808d2a7f2a7cabc579_I20210331" decimals="INF" name="alny:RoyaltyRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RleHRyZWdpb246MWE2ZWQwNzZlMTc2NDkyMzllYTFhMjgxNTMwYjdjYjRfMjQzMTk_b156a4bf-82ce-40d0-8aa7-fa9e583a37bc">10</ix:nonFraction>% up to <ix:nonFraction unitRef="number" contextRef="ifd789fbb2ade454a843734d22e2a2dee_I20210331" decimals="INF" name="alny:RoyaltyRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RleHRyZWdpb246MWE2ZWQwNzZlMTc2NDkyMzllYTFhMjgxNTMwYjdjYjRfMjQzMjg_e6f8b86f-cfc0-4284-adda-f49a78bca200">20</ix:nonFraction>% based on annual worldwide net sales of licensed products by Novartis, its affiliates and sublicensees, subject to reduction under specified circumstances. Due to the uncertainty of pharmaceutical development and the high historical failure rates generally associated with drug development, we may not receive any additional milestone payments under the MDCO License Agreement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Unless terminated earlier in accordance with the terms of the agreement, the MDCO License Agreement expires on a licensed product-by-licensed product and country-by-country basis upon expiration of the last royalty term for any licensed product in any country, where a royalty term is defined as the latest to occur of (1) the expiration of the last valid claim of patent rights covering a licensed product, (2) the expiration of the Regulatory Exclusivity, as defined in the MDCO License Agreement, and (3) the twelfth anniversary of the first commercial sale of the licensed product in such country. We estimate that our fundamental RNAi patents covering licensed products under the MDCO License Agreement will expire both in and outside of the U.S. generally between 2016 and 2028. We also estimate that our inclisiran product-specific patents covering licensed products under the MDCO License Agreement will expire in the U.S., Europe, China and Japan in 2036 and elsewhere at the end of 2033. These patent rights are subject to potential patent term extensions and/or supplemental protection certificates </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9f86b6d3686546618ade3c76e6b23fc8_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ALNYLAM PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="i9f43f80b7f714a41ba2dbcfaafded942" continuedAt="i4747985b54244f7984f389996d4f9e83"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">extending such terms in countries where such extensions may become available due to regulatory delay. In addition, more patent filings relating to the collaboration may be made in the future.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Either party may terminate the MDCO License Agreement in the event the other party fails to cure a material breach or upon patent-related challenges by the other party. In addition, Novartis has the right to terminate the agreement without cause at any time upon four months&#8217; prior written notice.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the term of the MDCO License Agreement, neither party will, alone or with an affiliate or third party, research, develop or commercialize, or grant a license to any third party to research, develop or commercialize, in any country, any siRNA product directed to the PCSK9 gene, other than a licensed product, without the prior written agreement of the other party, subject to the terms of the MDCO License Agreement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We evaluated the MDCO License Agreement and concluded that Novartis meets the definition of a customer and that the MDCO License Agreement is a contract. During 2018, we completed the performance obligations identified in the MDCO License Agreement. However, we continue to receive additional orders for supply of certain material. Given Novartis now has the ability to manufacture on its own through its own vendors, such orders will be treated as separate agreements and any associated revenue will be recognized upon transfer of control.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Vir Biotechnology, Inc. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In October 2017, we and Vir Biotechnology, Inc., or Vir, entered into a collaboration and license agreement, or the Vir Agreement, for the development and commercialization of RNAi therapeutics for infectious diseases, including chronic hepatitis B virus, or HBV, infection. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Pursuant to the Vir Agreement, we granted to Vir an exclusive license to develop, manufacture and commercialize ALN-HBV02 (VIR-2218), for all uses and purposes other than certain excluded fields, as set forth in the Vir Agreement. In addition, we granted Vir an exclusive option for up to four additional RNAi therapeutic programs for the treatment of infectious diseases. Under the terms of the Vir Agreement, for each product arising from the HBV program, including ALN-HBV02, we retained the right to opt into a profit-sharing arrangement prior to the start of a Phase 3 clinical trial. In addition, we have the right on a product-by-product basis with respect to each additional infectious disease program that Vir elects to pursue, to opt into a profit-sharing arrangement for each such product at any time during a specified period prior to the initiation of a Phase 3 clinical trial for each such product. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Pursuant to the Vir Agreement, Vir paid us an upfront fee of $<ix:nonFraction unitRef="usd" contextRef="i3cbd53aa2a944f6a951e88ca5b785aad_D20171001-20171031" decimals="-5" format="ixt:numdotdecimal" name="alny:UpfrontFeeReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RleHRyZWdpb246MWE2ZWQwNzZlMTc2NDkyMzllYTFhMjgxNTMwYjdjYjRfMTA5OTUxMTY5OTk3Ng_280ca69e-db70-422c-985c-210e47bbda8a">10.0</ix:nonFraction> million and issued to us <ix:nonFraction unitRef="shares" contextRef="i0390c083c3b0456c88744cf92cb6d82a_I20171031" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:InvestmentOwnedBalanceShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RleHRyZWdpb246MWE2ZWQwNzZlMTc2NDkyMzllYTFhMjgxNTMwYjdjYjRfMTA5OTUxMTY5OTk5Nw_f88b27da-de3a-4389-b7fe-d6cb184888c2">1,111,111</ix:nonFraction> shares of its common stock. Under the Vir Agreement, we may also receive milestone payments upon the achievement of certain development, regulatory and commercial milestones, as well as royalties on the net sales of licensed products ranging from high-single-digit to sub-teen double-digit percentages. In March 2020, we achieved a development milestone relating to ALN-HBV02 and earned a $<ix:nonFraction unitRef="usd" contextRef="i2775cf552c5d4a16bd403c04d07b23ba_D20200301-20200331" decimals="-5" format="ixt:numdotdecimal" name="alny:MilestonePaymentEarned" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RleHRyZWdpb246MWE2ZWQwNzZlMTc2NDkyMzllYTFhMjgxNTMwYjdjYjRfMTA5OTUxMTcwMDM5OQ_6d487f26-5c57-4fe9-a19e-f92b1e42d4f4">15.0</ix:nonFraction> million cash milestone and <ix:nonFraction unitRef="shares" contextRef="i2775cf552c5d4a16bd403c04d07b23ba_D20200301-20200331" decimals="INF" format="ixt:numdotdecimal" name="alny:MilestonePaymentEarnedShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RleHRyZWdpb246MWE2ZWQwNzZlMTc2NDkyMzllYTFhMjgxNTMwYjdjYjRfMTA5OTUxMTcwMDQyMg_e91c5676-b105-41c0-8eb8-def3e05f4865">1,111,111</ix:nonFraction> shares of Vir's common stock, which were received in the second quarter of 2020. In June 2020, we earned and received a $<ix:nonFraction unitRef="usd" contextRef="i1ddcbd1cbf9d4242a0d2e7d1fd99d35f_D20200601-20200630" decimals="-5" format="ixt:numdotdecimal" name="alny:MilestonePaymentEarned" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RleHRyZWdpb246MWE2ZWQwNzZlMTc2NDkyMzllYTFhMjgxNTMwYjdjYjRfMTA5OTUxMTcwMDU0Ng_ca2c7d71-643c-4dfd-8aa6-ef2b889af6eb">10.0</ix:nonFraction>&#160;million payment from Vir related to Vir's sublicense for ALN-HBV02 in China. Due to the uncertainty of pharmaceutical development and the high historical failure rates generally associated with drug development, we may not receive any additional milestone payments or any royalty payments under the Vir Agreement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In March and April 2020, we entered into amendments to the Vir Agreement to expand our collaboration to include the development and commercialization of RNAi therapeutics targeting SARS-CoV-2, the virus that causes the disease COVID-19, along with three additional targets focused on human host factors for SARS-CoV-2, including angiotensin converting enzyme-2 and transmembrane protease, serine 2 and potentially a third mutually selected host factor target. Under the Vir amendments, we and Vir were each responsible for our own pre-clinical development costs incurred in performing our allocated responsibilities under an agreed-upon initial pre-clinical development plan. Under the original agreements, we and Vir agreed to equally share certain costs incurred in connection with the manufacture of non-GMP drug product required for pre-clinical development prior to filing an IND for the first product in the coronavirus program. We also agreed that Vir would lead all development and commercialization of any selected development candidates. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In December 2020, we signed a letter agreement to amend the Vir Agreement such that we are solely responsible for conducting pre-clinical research activities under the pre-clinical development plan, related to the COVID-19 activities in the March and April 2020 amendments, at our discretion and sole expense, and effective as of July 1, 2020, we are responsible for all pre-clinical development costs incurred under such plan for such COVID-19 related activities.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Unless terminated earlier in accordance with the terms of the agreement, the Vir Agreement expires on a licensed product-by-product and country-by-country basis upon expiration of all royalty payment obligations under the agreement. If Vir does not exercise its option for an infectious disease program, the Vir Agreement will expire upon the expiration of the applicable option period with respect to such program. However, if we exercise our profit-sharing option for any product, the term of the agreement will continue until the expiration of the profit-sharing arrangement for such product. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9f86b6d3686546618ade3c76e6b23fc8_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ALNYLAM PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="i4747985b54244f7984f389996d4f9e83"><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Either party may terminate the agreement in the event the other party fails to cure a material breach, or upon patent-related challenges by the other party. In addition, Vir has the right to terminate the agreement on a program-by-program basis or in its entirety for any reason on <ix:nonNumeric contextRef="i79b6733ec63b46b0b79d00ec324efa30_D20210101-20210331" format="ixt-sec:durday" name="alny:CollaborativeAgreementTerminationPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RleHRyZWdpb246MWE2ZWQwNzZlMTc2NDkyMzllYTFhMjgxNTMwYjdjYjRfMTA5OTUxMTcwMzE0NQ_3bec4715-0674-477c-a9f2-926e7c66a30d">90</ix:nonNumeric> days&#8217; written notice.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We identified one performance obligation under the Vir Agreement, as amended, comprised of: i) the exclusive license to develop, manufacture and commercialize RNAi therapeutics (including ALN-HBV02); ii) the obligation to deliver <ix:nonFraction unitRef="candidate" contextRef="i1cb0ba7808ab43b78c92dd6668914339_I20210331" decimals="INF" format="ixt-sec:numwordsen" name="alny:CollaborativeArrangementAdditionalDevelopmentCandidatesToBeDelivered" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RleHRyZWdpb246MWE2ZWQwNzZlMTc2NDkyMzllYTFhMjgxNTMwYjdjYjRfMTA5OTUxMTcwMzQyNg_fbb449aa-a8f1-4173-af6b-de78d3445b35">four</ix:nonFraction> additional development candidates and supply product for each such RNAi therapeutic program; and iii) the obligation to deliver up to <ix:nonFraction unitRef="candidate" contextRef="i1cb0ba7808ab43b78c92dd6668914339_I20210331" decimals="INF" format="ixt-sec:numwordsen" name="alny:CollaborativeArrangementAdditionalDevelopmentCandidatesToBeDelivered" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RleHRyZWdpb246MWE2ZWQwNzZlMTc2NDkyMzllYTFhMjgxNTMwYjdjYjRfMTA5OTUxMTcwMzYwOA_f68de996-6d77-48c1-beae-5570d9fe1320">four</ix:nonFraction> development candidates and supply product for RNAi therapeutic programs targeting SARS-CoV-2. The license is not distinct from the services, including the obligation to deliver development candidates and supply product, as Vir cannot benefit on its own from the value of the license without receipt of such services and supply.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We measure proportional performance over time using an input method based on cost incurred relative to the total estimated costs for the identified performance obligation, on a quarterly basis, by determining the proportion of effort incurred as a percentage of total effort we expect to expend. This ratio is applied to the total transaction price. Management has applied significant judgment in the process of developing our estimates. Any changes to these estimates will be recognized in the period in which they change as a cumulative catch up. As of March&#160;31, 2021, the total transaction price was determined to be $<ix:nonFraction unitRef="usd" contextRef="ic79f02f0d0d84870a4ef4d488e636d1b_D20210331-20210331" decimals="-5" format="ixt:numdotdecimal" name="alny:TransactionPrice" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RleHRyZWdpb246MWE2ZWQwNzZlMTc2NDkyMzllYTFhMjgxNTMwYjdjYjRfMTA5OTUxMTcwNDYyOQ_fdde66d8-94a0-4c29-ace1-3e726e34b36c">110.1</ix:nonFraction>&#160;million, and is comprised of the upfront payment, fair value of non-cash equity consideration at contract inception, milestones achieved and variable consideration related to development, manufacture and supply activities. We utilized the expected value method to determine the amount of reimbursement for these activities. The total transaction price is allocated entirely to the single performance obligation. We determined any variable consideration related to sales-based royalties and milestones related to the exclusive license to be constrained and therefore excluded such consideration from the transaction price.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of March&#160;31, 2021, the aggregate amount of the transaction price allocated to the performance obligation that was unsatisfied was $<ix:nonFraction unitRef="usd" contextRef="i1cb0ba7808ab43b78c92dd6668914339_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueRemainingPerformanceObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RleHRyZWdpb246MWE2ZWQwNzZlMTc2NDkyMzllYTFhMjgxNTMwYjdjYjRfMTA5OTUxMTcwNTQzNw_07f4d24c-47ca-47db-ac0d-43b2664dad05">48.8</ix:nonFraction>&#160;million, which is expected to be recognized through the term of the Vir Agreement as the services are performed.</span></div></ix:continuation><div id="i9f86b6d3686546618ade3c76e6b23fc8_46"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331" name="alny:LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80Ni9mcmFnOjJkMDZmOTdlYzQxMzQ2MjE4NzVjYjg2OGU3YjIyZGY4L3RleHRyZWdpb246MmQwNmY5N2VjNDEzNDYyMTg3NWNiODY4ZTdiMjJkZjhfMzgxNQ_e276b195-7711-468b-964e-ebef4aafae74" continuedAt="id88e002142af4b8e9cbd9068d1f2c029" escape="true">LIABILITY RELATED TO THE SALE OF FUTURE ROYALTIES</ix:nonNumeric></span></div><ix:continuation id="id88e002142af4b8e9cbd9068d1f2c029" continuedAt="ifcb30e0a41894ad2a4d3021d4d03b5f1"><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In April 2020, we entered into a purchase and sale agreement, or Purchase Agreement, with BX Bodyguard Royalties L.P. (an affiliate of The Blackstone Group Inc.), or Blackstone Royalties, under which Blackstone Royalties acquired <ix:nonFraction unitRef="number" contextRef="i730e5e5b0bcd4d5c81f5a71c66d172a2_I20200410" decimals="INF" name="alny:CollaborativeArrangementRoyaltiesAndCommercialMilestonesAcquiredByCollaboratorPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80Ni9mcmFnOjJkMDZmOTdlYzQxMzQ2MjE4NzVjYjg2OGU3YjIyZGY4L3RleHRyZWdpb246MmQwNmY5N2VjNDEzNDYyMTg3NWNiODY4ZTdiMjJkZjhfMjkz_cd9189d0-8142-4ddd-95da-a8991f0c2b9a">50</ix:nonFraction>% of royalties payable, or Royalty Interest, with respect to net sales by MDCO, its affiliates or sublicensees of inclisiran and any other licensed products under the MDCO License Agreement, and <ix:nonFraction unitRef="number" contextRef="i730e5e5b0bcd4d5c81f5a71c66d172a2_I20200410" decimals="INF" name="alny:CollaborativeArrangementCommercialMilestonesAcquiredByCollaboratorPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80Ni9mcmFnOjJkMDZmOTdlYzQxMzQ2MjE4NzVjYjg2OGU3YjIyZGY4L3RleHRyZWdpb246MmQwNmY5N2VjNDEzNDYyMTg3NWNiODY4ZTdiMjJkZjhfNDg5_c5af23e2-cbe8-4200-a77c-c34a1e19ebac">75</ix:nonFraction>% of the commercial milestone payments payable under the MDCO License Agreement, together with the Royalty Interest, the Purchased Interest. If Blackstone Royalties does not receive payments in respect of the Royalty Interest by December 31, 2029, equaling at least $<ix:nonFraction unitRef="usd" contextRef="i2a9037b7365649f2bb1a3ef6bcbe2849_D20210101-20210331" decimals="INF" format="ixt:numdotdecimal" name="alny:ExpectedRoyaltyInterestPayments" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80Ni9mcmFnOjJkMDZmOTdlYzQxMzQ2MjE4NzVjYjg2OGU3YjIyZGY4L3RleHRyZWdpb246MmQwNmY5N2VjNDEzNDYyMTg3NWNiODY4ZTdiMjJkZjhfNzU2_00e161cc-478a-4ee1-a696-b21980cdd29d">1.00</ix:nonFraction>&#160;billion, Blackstone Royalties will receive <ix:nonFraction unitRef="number" contextRef="i4b7aa8adee8f42469579af529e81b38d_I20300101" decimals="INF" name="alny:CollaborativeArrangementRoyaltiesAndCommercialMilestonesAcquiredByCollaboratorPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80Ni9mcmFnOjJkMDZmOTdlYzQxMzQ2MjE4NzVjYjg2OGU3YjIyZGY4L3RleHRyZWdpb246MmQwNmY5N2VjNDEzNDYyMTg3NWNiODY4ZTdiMjJkZjhfNzk0_8e564a2b-4391-4136-a3b1-0770be926ea2">55</ix:nonFraction>% of the Royalty Interest beginning on January 1, 2030. In consideration for the sale of the Purchased Interest, Blackstone Royalties paid us $<ix:nonFraction unitRef="usd" contextRef="i49fe9edf0f9044908d252f6eb19b5518_D20200401-20200430" decimals="-5" format="ixt:numdotdecimal" name="alny:CollaborativeArrangementConsiderationReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80Ni9mcmFnOjJkMDZmOTdlYzQxMzQ2MjE4NzVjYjg2OGU3YjIyZGY4L3RleHRyZWdpb246MmQwNmY5N2VjNDEzNDYyMTg3NWNiODY4ZTdiMjJkZjhfOTM3_b1dbf7a6-65b0-45e2-b95e-f400f3009b59">500.0</ix:nonFraction>&#160;million in April 2020 and has an unconditional obligation to pay us an additional $<ix:nonFraction unitRef="usd" contextRef="id7b8291a96fc46dd8b540dbcc7a6d813_I20210331" decimals="-5" format="ixt:numdotdecimal" name="alny:RoyaltiesReceivableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80Ni9mcmFnOjJkMDZmOTdlYzQxMzQ2MjE4NzVjYjg2OGU3YjIyZGY4L3RleHRyZWdpb246MmQwNmY5N2VjNDEzNDYyMTg3NWNiODY4ZTdiMjJkZjhfMTAxNA_362f0f22-21fd-43e5-af01-b42290af1f08">500.0</ix:nonFraction>&#160;million on September 30, 2021, which was recorded as a receivable upon execution of the Purchase Agreement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We continue to own or control all inclisiran intellectual property rights and are responsible for certain ongoing manufacturing and supply obligations related to the generation of the Purchased Interest. Due to our continuing involvement, we will continue to account for any royalties and commercial milestones due to us under the MDCO License Agreement as revenue on our condensed consolidated statement of operations and comprehensive loss and record the proceeds from this transaction as a liability, net of closing costs, on our condensed consolidated balance sheet. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In order to determine the amortization of the liability related to the sale of future royalties, we are required to estimate the total amount of future payments to Blackstone Royalties over the life of the Purchase Agreement. The $<ix:nonFraction unitRef="usd" contextRef="i730e5e5b0bcd4d5c81f5a71c66d172a2_I20200410" decimals="-7" format="ixt:numdotdecimal" name="alny:RoyaltyLiabilityNoncurrent" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80Ni9mcmFnOjJkMDZmOTdlYzQxMzQ2MjE4NzVjYjg2OGU3YjIyZGY4L3RleHRyZWdpb246MmQwNmY5N2VjNDEzNDYyMTg3NWNiODY4ZTdiMjJkZjhfMTkxOQ_cf6f5482-0f4c-44b6-ad64-fd3323c4feb6">1.00</ix:nonFraction>&#160;billion liability, recorded at execution of the agreement, will be accreted to the total of these royalty and commercial milestone payments as interest expense over the life of the Purchase Agreement. At execution, our estimate of this total interest expense resulted in an effective annual interest rate of <ix:nonFraction unitRef="number" contextRef="i730e5e5b0bcd4d5c81f5a71c66d172a2_I20200410" decimals="2" name="alny:RoyaltyLiabilityInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80Ni9mcmFnOjJkMDZmOTdlYzQxMzQ2MjE4NzVjYjg2OGU3YjIyZGY4L3RleHRyZWdpb246MmQwNmY5N2VjNDEzNDYyMTg3NWNiODY4ZTdiMjJkZjhfMjIyMg_3b557da4-d843-483d-a2c3-07cb31940937">11</ix:nonFraction>%. This estimate contains assumptions that impact both the amount recorded at execution and the interest expense that will be recognized in future periods. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As payments are made to Blackstone Royalties, the balance of the liability will be effectively repaid over the life of the Purchase Agreement. The exact timing and amount of repayment is likely to change each reporting period. A significant increase or decrease in net sales of inclisiran will materially impact the liability related to the sale of future royalties, interest expense and the time period for repayment. We will periodically assess the expected payments to Blackstone Royalties and to the extent the amount or timing of such payments is materially different than our initial estimates, we will prospectively adjust the amortization of the liability related to the sale of future royalties and the related interest expense.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of March&#160;31, 2021, the carrying value of the liability related to the sale of future royalties was $<ix:nonFraction unitRef="usd" contextRef="id7b8291a96fc46dd8b540dbcc7a6d813_I20210331" decimals="-7" format="ixt:numdotdecimal" name="alny:RoyaltyLiabilityNoncurrent" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80Ni9mcmFnOjJkMDZmOTdlYzQxMzQ2MjE4NzVjYjg2OGU3YjIyZGY4L3RleHRyZWdpb246MmQwNmY5N2VjNDEzNDYyMTg3NWNiODY4ZTdiMjJkZjhfMTA5OTUxMTYzMTk1OQ_f9a10ec7-a0b1-4ccd-a5c0-dad728149e5d">1.10</ix:nonFraction>&#160;billion, net of closing costs of $<ix:nonFraction unitRef="usd" contextRef="id7b8291a96fc46dd8b540dbcc7a6d813_I20210331" decimals="-5" format="ixt:numdotdecimal" name="alny:RoyaltyLiabilityClosingCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80Ni9mcmFnOjJkMDZmOTdlYzQxMzQ2MjE4NzVjYjg2OGU3YjIyZGY4L3RleHRyZWdpb246MmQwNmY5N2VjNDEzNDYyMTg3NWNiODY4ZTdiMjJkZjhfMzI4MA_292a82d4-8771-4552-ab75-9f1e03c046e3">13.0</ix:nonFraction>&#160;million. The carrying value of the liability related to the sale of future royalties approximates fair value as </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9f86b6d3686546618ade3c76e6b23fc8_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ALNYLAM PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="ifcb30e0a41894ad2a4d3021d4d03b5f1"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">of March&#160;31, 2021 and is based on our current estimates of future royalties and commercial milestones expected to be paid to Blackstone Royalties over the life of the arrangement, which are considered Level 3 inputs.</span></div><ix:nonNumeric contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331" name="alny:ScheduleOfRoyaltyLiabilityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80Ni9mcmFnOjJkMDZmOTdlYzQxMzQ2MjE4NzVjYjg2OGU3YjIyZGY4L3RleHRyZWdpb246MmQwNmY5N2VjNDEzNDYyMTg3NWNiODY4ZTdiMjJkZjhfMzgxNg_6bb24457-360a-4f1a-abda-e171b14e4bee" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table shows the activity with respect to the liability related to the sale of future royalties, in thousands:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:87.134%"><tr><td style="width:1.0%"></td><td style="width:81.282%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.638%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.680%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying value of liability related to sale of future royalties as of December&#160;31, 2020</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i399f66dd6ce741d28d06204e9a1dddfb_I20201231" decimals="-3" format="ixt:numdotdecimal" name="alny:RoyaltyLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80Ni9mcmFnOjJkMDZmOTdlYzQxMzQ2MjE4NzVjYjg2OGU3YjIyZGY4L3RhYmxlOmY4NDg3ZjI5MmVhZDQ1ZWJhMTdiOGJiYTI5NTY2YTJlL3RhYmxlcmFuZ2U6Zjg0ODdmMjkyZWFkNDVlYmExN2I4YmJhMjk1NjZhMmVfMy0yLTEtMS0w_7f71cde7-97ab-4d31-b73f-a75ce5780e22">1,071,541</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense recognized</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a9037b7365649f2bb1a3ef6bcbe2849_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="alny:RoyaltyLiabilityInterestExpenseIncludingAmortizationOfClosingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80Ni9mcmFnOjJkMDZmOTdlYzQxMzQ2MjE4NzVjYjg2OGU3YjIyZGY4L3RhYmxlOmY4NDg3ZjI5MmVhZDQ1ZWJhMTdiOGJiYTI5NTY2YTJlL3RhYmxlcmFuZ2U6Zjg0ODdmMjkyZWFkNDVlYmExN2I4YmJhMjk1NjZhMmVfNC0yLTEtMS0yNzQ_86c64d4c-8a8d-4f32-a2de-71e232e46a44">28,184</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying value of liability related to sale of future royalties as of March&#160;31, 2021</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7b8291a96fc46dd8b540dbcc7a6d813_I20210331" decimals="-3" format="ixt:numdotdecimal" name="alny:RoyaltyLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80Ni9mcmFnOjJkMDZmOTdlYzQxMzQ2MjE4NzVjYjg2OGU3YjIyZGY4L3RhYmxlOmY4NDg3ZjI5MmVhZDQ1ZWJhMTdiOGJiYTI5NTY2YTJlL3RhYmxlcmFuZ2U6Zjg0ODdmMjkyZWFkNDVlYmExN2I4YmJhMjk1NjZhMmVfNS0yLTEtMS0yNzQ_98f505fb-3158-4e95-8ff5-49b7c3bf1d2b">1,099,725</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div id="i9f86b6d3686546618ade3c76e6b23fc8_49"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80OS9mcmFnOmYxYWI0YTVmNjYzMjQzM2FiMTJiYzczOTBlM2VkOWFlL3RleHRyZWdpb246ZjFhYjRhNWY2NjMyNDMzYWIxMmJjNzM5MGUzZWQ5YWVfMTY0OQ_5969be45-5e5b-4f7d-94d3-d226d5ddf79b" continuedAt="id33887a870cd4318b4dca44848e19fe8" escape="true">FAIR VALUE MEASUREMENTS</ix:nonNumeric></span></div><ix:continuation id="id33887a870cd4318b4dca44848e19fe8" continuedAt="iae7ad72fb6414459932612f53f712fd1"><ix:nonNumeric contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80OS9mcmFnOmYxYWI0YTVmNjYzMjQzM2FiMTJiYzczOTBlM2VkOWFlL3RleHRyZWdpb246ZjFhYjRhNWY2NjMyNDMzYWIxMmJjNzM5MGUzZWQ5YWVfMTY0NA_655376d3-475b-4898-b85f-99a48a6050bc" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following tables present information about our financial assets and liabilities that are measured at fair value on a recurring basis and indicate the fair value hierarchy of the valuation techniques we utilized to determine such fair value:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:48.973%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.650%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted<br/>Prices in<br/>Active<br/>Markets<br/>(Level 1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Observable<br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16892019541d48c892ff9d24e698ebd5_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80OS9mcmFnOmYxYWI0YTVmNjYzMjQzM2FiMTJiYzczOTBlM2VkOWFlL3RhYmxlOjdhYWQ0NzdkZjhhZDQ1OTZiM2ZmNTBiZGI0N2YxNGE2L3RhYmxlcmFuZ2U6N2FhZDQ3N2RmOGFkNDU5NmIzZmY1MGJkYjQ3ZjE0YTZfNC0yLTEtMS0w_a9ce0fc7-08d1-42bc-81e9-d5e697250ce7">177,470</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa5bdd3013ac476381fc4350a3ee7cf4_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80OS9mcmFnOmYxYWI0YTVmNjYzMjQzM2FiMTJiYzczOTBlM2VkOWFlL3RhYmxlOjdhYWQ0NzdkZjhhZDQ1OTZiM2ZmNTBiZGI0N2YxNGE2L3RhYmxlcmFuZ2U6N2FhZDQ3N2RmOGFkNDU5NmIzZmY1MGJkYjQ3ZjE0YTZfNC00LTEtMS0w_7c43dc0d-87f2-4423-8a41-917d9401270b">177,470</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic77e6331f376437fb260dd9f97ea58e8_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80OS9mcmFnOmYxYWI0YTVmNjYzMjQzM2FiMTJiYzczOTBlM2VkOWFlL3RhYmxlOjdhYWQ0NzdkZjhhZDQ1OTZiM2ZmNTBiZGI0N2YxNGE2L3RhYmxlcmFuZ2U6N2FhZDQ3N2RmOGFkNDU5NmIzZmY1MGJkYjQ3ZjE0YTZfNC02LTEtMS0w_817ac897-7870-4308-896f-774478a3f85e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8a0bfabe2b94e05a37ef21b7586c1b8_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80OS9mcmFnOmYxYWI0YTVmNjYzMjQzM2FiMTJiYzczOTBlM2VkOWFlL3RhYmxlOjdhYWQ0NzdkZjhhZDQ1OTZiM2ZmNTBiZGI0N2YxNGE2L3RhYmxlcmFuZ2U6N2FhZDQ3N2RmOGFkNDU5NmIzZmY1MGJkYjQ3ZjE0YTZfNC04LTEtMS0w_3153f079-eccf-48d8-86e1-15663b79cece">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable debt securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government-sponsored enterprise securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14ad949ff20f4e34a5bff828ba895714_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80OS9mcmFnOmYxYWI0YTVmNjYzMjQzM2FiMTJiYzczOTBlM2VkOWFlL3RhYmxlOjdhYWQ0NzdkZjhhZDQ1OTZiM2ZmNTBiZGI0N2YxNGE2L3RhYmxlcmFuZ2U6N2FhZDQ3N2RmOGFkNDU5NmIzZmY1MGJkYjQ3ZjE0YTZfNy0yLTEtMS0w_1ae3cfa9-692a-45de-ba6a-95681e3d9e18">215,200</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i294e21898c6c4ba19308833eeeec70d9_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80OS9mcmFnOmYxYWI0YTVmNjYzMjQzM2FiMTJiYzczOTBlM2VkOWFlL3RhYmxlOjdhYWQ0NzdkZjhhZDQ1OTZiM2ZmNTBiZGI0N2YxNGE2L3RhYmxlcmFuZ2U6N2FhZDQ3N2RmOGFkNDU5NmIzZmY1MGJkYjQ3ZjE0YTZfNy00LTEtMS0w_9871668d-639f-4ff0-8db0-b95800137b4b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8637deaa1c634995a355fa860ea50c94_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80OS9mcmFnOmYxYWI0YTVmNjYzMjQzM2FiMTJiYzczOTBlM2VkOWFlL3RhYmxlOjdhYWQ0NzdkZjhhZDQ1OTZiM2ZmNTBiZGI0N2YxNGE2L3RhYmxlcmFuZ2U6N2FhZDQ3N2RmOGFkNDU5NmIzZmY1MGJkYjQ3ZjE0YTZfNy02LTEtMS0w_b04474c4-a85c-4fe6-99d4-316f6b6d0289">215,200</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdb3bef5ea924074b966e38860b348a9_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80OS9mcmFnOmYxYWI0YTVmNjYzMjQzM2FiMTJiYzczOTBlM2VkOWFlL3RhYmxlOjdhYWQ0NzdkZjhhZDQ1OTZiM2ZmNTBiZGI0N2YxNGE2L3RhYmxlcmFuZ2U6N2FhZDQ3N2RmOGFkNDU5NmIzZmY1MGJkYjQ3ZjE0YTZfNy04LTEtMS0w_99e54b5e-9728-4517-9ef8-b3adeba0fb96">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief62e6e6b5794e1e9aac7a9b35576e8e_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80OS9mcmFnOmYxYWI0YTVmNjYzMjQzM2FiMTJiYzczOTBlM2VkOWFlL3RhYmxlOjdhYWQ0NzdkZjhhZDQ1OTZiM2ZmNTBiZGI0N2YxNGE2L3RhYmxlcmFuZ2U6N2FhZDQ3N2RmOGFkNDU5NmIzZmY1MGJkYjQ3ZjE0YTZfOC0yLTEtMS0w_734a7b0c-ffdf-4aa4-bc03-e7cca136bec1">1,057,827</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b9bb880bac0407b815f6fd57e76cd83_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80OS9mcmFnOmYxYWI0YTVmNjYzMjQzM2FiMTJiYzczOTBlM2VkOWFlL3RhYmxlOjdhYWQ0NzdkZjhhZDQ1OTZiM2ZmNTBiZGI0N2YxNGE2L3RhYmxlcmFuZ2U6N2FhZDQ3N2RmOGFkNDU5NmIzZmY1MGJkYjQ3ZjE0YTZfOC00LTEtMS0w_40b4bc33-156c-42fb-a436-df021b489db2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3ebff18dd48442faf99a73c773d55fa_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80OS9mcmFnOmYxYWI0YTVmNjYzMjQzM2FiMTJiYzczOTBlM2VkOWFlL3RhYmxlOjdhYWQ0NzdkZjhhZDQ1OTZiM2ZmNTBiZGI0N2YxNGE2L3RhYmxlcmFuZ2U6N2FhZDQ3N2RmOGFkNDU5NmIzZmY1MGJkYjQ3ZjE0YTZfOC02LTEtMS0w_35354bd9-1c2e-4816-879a-472164572cd8">1,057,827</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e887f34bbab43fa8752d3d60f8d1b10_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80OS9mcmFnOmYxYWI0YTVmNjYzMjQzM2FiMTJiYzczOTBlM2VkOWFlL3RhYmxlOjdhYWQ0NzdkZjhhZDQ1OTZiM2ZmNTBiZGI0N2YxNGE2L3RhYmxlcmFuZ2U6N2FhZDQ3N2RmOGFkNDU5NmIzZmY1MGJkYjQ3ZjE0YTZfOC04LTEtMS0w_0f2ffe07-ab92-416d-a380-f1b3effdfab6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable equity securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if05c960039774dd9b4ad2920b9816c04_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNi" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80OS9mcmFnOmYxYWI0YTVmNjYzMjQzM2FiMTJiYzczOTBlM2VkOWFlL3RhYmxlOjdhYWQ0NzdkZjhhZDQ1OTZiM2ZmNTBiZGI0N2YxNGE2L3RhYmxlcmFuZ2U6N2FhZDQ3N2RmOGFkNDU5NmIzZmY1MGJkYjQ3ZjE0YTZfOS0yLTEtMS0w_87e2f7ec-6ee9-4963-a8f7-616ca1a58d47">56,967</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d138b2bd73a4ef49fdec7e2d7119c17_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNi" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80OS9mcmFnOmYxYWI0YTVmNjYzMjQzM2FiMTJiYzczOTBlM2VkOWFlL3RhYmxlOjdhYWQ0NzdkZjhhZDQ1OTZiM2ZmNTBiZGI0N2YxNGE2L3RhYmxlcmFuZ2U6N2FhZDQ3N2RmOGFkNDU5NmIzZmY1MGJkYjQ3ZjE0YTZfOS00LTEtMS0w_96e32d38-d222-40a1-ad91-4aa4b6b2494f">56,967</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00ed30d5d69b424e81f823616e722813_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:EquitySecuritiesFvNi" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80OS9mcmFnOmYxYWI0YTVmNjYzMjQzM2FiMTJiYzczOTBlM2VkOWFlL3RhYmxlOjdhYWQ0NzdkZjhhZDQ1OTZiM2ZmNTBiZGI0N2YxNGE2L3RhYmxlcmFuZ2U6N2FhZDQ3N2RmOGFkNDU5NmIzZmY1MGJkYjQ3ZjE0YTZfOS02LTEtMS0w_0b5777ca-f323-4a65-89a8-5f1003619ab3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if93a1d02ab2c44359e2b2873b0965791_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:EquitySecuritiesFvNi" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80OS9mcmFnOmYxYWI0YTVmNjYzMjQzM2FiMTJiYzczOTBlM2VkOWFlL3RhYmxlOjdhYWQ0NzdkZjhhZDQ1OTZiM2ZmNTBiZGI0N2YxNGE2L3RhYmxlcmFuZ2U6N2FhZDQ3N2RmOGFkNDU5NmIzZmY1MGJkYjQ3ZjE0YTZfOS04LTEtMS0w_cbba9ce8-ecf3-4f2f-9bcd-c085900a5548">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash (money market funds)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16892019541d48c892ff9d24e698ebd5_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashAndCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80OS9mcmFnOmYxYWI0YTVmNjYzMjQzM2FiMTJiYzczOTBlM2VkOWFlL3RhYmxlOjdhYWQ0NzdkZjhhZDQ1OTZiM2ZmNTBiZGI0N2YxNGE2L3RhYmxlcmFuZ2U6N2FhZDQ3N2RmOGFkNDU5NmIzZmY1MGJkYjQ3ZjE0YTZfMTAtMi0xLTEtMA_8b306038-00a7-4328-864c-8270cadbdeb6">1,483</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa5bdd3013ac476381fc4350a3ee7cf4_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashAndCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80OS9mcmFnOmYxYWI0YTVmNjYzMjQzM2FiMTJiYzczOTBlM2VkOWFlL3RhYmxlOjdhYWQ0NzdkZjhhZDQ1OTZiM2ZmNTBiZGI0N2YxNGE2L3RhYmxlcmFuZ2U6N2FhZDQ3N2RmOGFkNDU5NmIzZmY1MGJkYjQ3ZjE0YTZfMTAtNC0xLTEtMA_7aeeeb2f-c60b-4cac-974e-d81990c60784">1,483</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic77e6331f376437fb260dd9f97ea58e8_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:RestrictedCashAndCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80OS9mcmFnOmYxYWI0YTVmNjYzMjQzM2FiMTJiYzczOTBlM2VkOWFlL3RhYmxlOjdhYWQ0NzdkZjhhZDQ1OTZiM2ZmNTBiZGI0N2YxNGE2L3RhYmxlcmFuZ2U6N2FhZDQ3N2RmOGFkNDU5NmIzZmY1MGJkYjQ3ZjE0YTZfMTAtNi0xLTEtMA_2d2251a0-7ddf-47fa-9f3a-c2dfc91cc080">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8a0bfabe2b94e05a37ef21b7586c1b8_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:RestrictedCashAndCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80OS9mcmFnOmYxYWI0YTVmNjYzMjQzM2FiMTJiYzczOTBlM2VkOWFlL3RhYmxlOjdhYWQ0NzdkZjhhZDQ1OTZiM2ZmNTBiZGI0N2YxNGE2L3RhYmxlcmFuZ2U6N2FhZDQ3N2RmOGFkNDU5NmIzZmY1MGJkYjQ3ZjE0YTZfMTAtOC0xLTEtMA_659607bb-2ce9-467f-95af-c9bbaa10212d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total financial assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if05c960039774dd9b4ad2920b9816c04_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80OS9mcmFnOmYxYWI0YTVmNjYzMjQzM2FiMTJiYzczOTBlM2VkOWFlL3RhYmxlOjdhYWQ0NzdkZjhhZDQ1OTZiM2ZmNTBiZGI0N2YxNGE2L3RhYmxlcmFuZ2U6N2FhZDQ3N2RmOGFkNDU5NmIzZmY1MGJkYjQ3ZjE0YTZfMTEtMi0xLTEtMA_36523f44-b931-4e48-99a8-86c4025826df">1,508,947</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d138b2bd73a4ef49fdec7e2d7119c17_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80OS9mcmFnOmYxYWI0YTVmNjYzMjQzM2FiMTJiYzczOTBlM2VkOWFlL3RhYmxlOjdhYWQ0NzdkZjhhZDQ1OTZiM2ZmNTBiZGI0N2YxNGE2L3RhYmxlcmFuZ2U6N2FhZDQ3N2RmOGFkNDU5NmIzZmY1MGJkYjQ3ZjE0YTZfMTEtNC0xLTEtMA_4fe8980e-7614-48bb-b972-e5fec9b5a338">235,920</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00ed30d5d69b424e81f823616e722813_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80OS9mcmFnOmYxYWI0YTVmNjYzMjQzM2FiMTJiYzczOTBlM2VkOWFlL3RhYmxlOjdhYWQ0NzdkZjhhZDQ1OTZiM2ZmNTBiZGI0N2YxNGE2L3RhYmxlcmFuZ2U6N2FhZDQ3N2RmOGFkNDU5NmIzZmY1MGJkYjQ3ZjE0YTZfMTEtNi0xLTEtMA_300023ed-26cb-49d6-806b-8f07f961d113">1,273,027</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if93a1d02ab2c44359e2b2873b0965791_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80OS9mcmFnOmYxYWI0YTVmNjYzMjQzM2FiMTJiYzczOTBlM2VkOWFlL3RhYmxlOjdhYWQ0NzdkZjhhZDQ1OTZiM2ZmNTBiZGI0N2YxNGE2L3RhYmxlcmFuZ2U6N2FhZDQ3N2RmOGFkNDU5NmIzZmY1MGJkYjQ3ZjE0YTZfMTEtOC0xLTEtMA_79eab5fa-db28-4c9b-b8d8-58d9e82a208a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Development derivative liability (Note 10)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if05c960039774dd9b4ad2920b9816c04_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80OS9mcmFnOmYxYWI0YTVmNjYzMjQzM2FiMTJiYzczOTBlM2VkOWFlL3RhYmxlOjdhYWQ0NzdkZjhhZDQ1OTZiM2ZmNTBiZGI0N2YxNGE2L3RhYmxlcmFuZ2U6N2FhZDQ3N2RmOGFkNDU5NmIzZmY1MGJkYjQ3ZjE0YTZfMTMtMi0xLTEtMA_723cc2c6-a216-45b1-8abe-d7b05903fc8d">48,038</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d138b2bd73a4ef49fdec7e2d7119c17_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:DerivativeLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80OS9mcmFnOmYxYWI0YTVmNjYzMjQzM2FiMTJiYzczOTBlM2VkOWFlL3RhYmxlOjdhYWQ0NzdkZjhhZDQ1OTZiM2ZmNTBiZGI0N2YxNGE2L3RhYmxlcmFuZ2U6N2FhZDQ3N2RmOGFkNDU5NmIzZmY1MGJkYjQ3ZjE0YTZfMTMtNC0xLTEtMA_b387e85c-5ff3-4a48-942a-a84bc7ab2e95">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00ed30d5d69b424e81f823616e722813_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:DerivativeLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80OS9mcmFnOmYxYWI0YTVmNjYzMjQzM2FiMTJiYzczOTBlM2VkOWFlL3RhYmxlOjdhYWQ0NzdkZjhhZDQ1OTZiM2ZmNTBiZGI0N2YxNGE2L3RhYmxlcmFuZ2U6N2FhZDQ3N2RmOGFkNDU5NmIzZmY1MGJkYjQ3ZjE0YTZfMTMtNi0xLTEtMA_b26ada18-5d81-4ade-845c-721d3c4e6af3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if93a1d02ab2c44359e2b2873b0965791_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80OS9mcmFnOmYxYWI0YTVmNjYzMjQzM2FiMTJiYzczOTBlM2VkOWFlL3RhYmxlOjdhYWQ0NzdkZjhhZDQ1OTZiM2ZmNTBiZGI0N2YxNGE2L3RhYmxlcmFuZ2U6N2FhZDQ3N2RmOGFkNDU5NmIzZmY1MGJkYjQ3ZjE0YTZfMTMtOC0xLTEtMA_347efdad-4e81-4152-8aad-2735c62b61a8">48,038</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:48.973%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.650%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted<br/>Prices in<br/>Active<br/>Markets<br/>(Level 1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Observable<br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65a4965cd593490dbf6466695a4a77e4_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80OS9mcmFnOmYxYWI0YTVmNjYzMjQzM2FiMTJiYzczOTBlM2VkOWFlL3RhYmxlOmQ3YTdlNjQzZTUwMDQ1YWY4NTVkZmE2NGI5ZjM2YTk3L3RhYmxlcmFuZ2U6ZDdhN2U2NDNlNTAwNDVhZjg1NWRmYTY0YjlmMzZhOTdfNC0yLTEtMS0w_d296c9c3-e311-4167-b5d9-5eb8988c7f29">20,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i839a27ef72924781a3487df7e5d7b395_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80OS9mcmFnOmYxYWI0YTVmNjYzMjQzM2FiMTJiYzczOTBlM2VkOWFlL3RhYmxlOmQ3YTdlNjQzZTUwMDQ1YWY4NTVkZmE2NGI5ZjM2YTk3L3RhYmxlcmFuZ2U6ZDdhN2U2NDNlNTAwNDVhZjg1NWRmYTY0YjlmMzZhOTdfNC00LTEtMS0w_36b20c96-3007-4ce0-826a-782ac946e466">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5590fd684f1a4aa090bf9b83c5673927_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80OS9mcmFnOmYxYWI0YTVmNjYzMjQzM2FiMTJiYzczOTBlM2VkOWFlL3RhYmxlOmQ3YTdlNjQzZTUwMDQ1YWY4NTVkZmE2NGI5ZjM2YTk3L3RhYmxlcmFuZ2U6ZDdhN2U2NDNlNTAwNDVhZjg1NWRmYTY0YjlmMzZhOTdfNC02LTEtMS0w_a2e1371c-7c3a-46e4-8e60-f9a4177b11f0">20,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f72f19e489246dea7d90e3176d37999_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80OS9mcmFnOmYxYWI0YTVmNjYzMjQzM2FiMTJiYzczOTBlM2VkOWFlL3RhYmxlOmQ3YTdlNjQzZTUwMDQ1YWY4NTVkZmE2NGI5ZjM2YTk3L3RhYmxlcmFuZ2U6ZDdhN2U2NDNlNTAwNDVhZjg1NWRmYTY0YjlmMzZhOTdfNC04LTEtMS0w_f16a241e-83ba-4159-8811-31aa7cfffe85">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1d58cc31b1e414591ea2ec01318868f_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80OS9mcmFnOmYxYWI0YTVmNjYzMjQzM2FiMTJiYzczOTBlM2VkOWFlL3RhYmxlOmQ3YTdlNjQzZTUwMDQ1YWY4NTVkZmE2NGI5ZjM2YTk3L3RhYmxlcmFuZ2U6ZDdhN2U2NDNlNTAwNDVhZjg1NWRmYTY0YjlmMzZhOTdfNS0yLTEtMS0w_90ec336b-bd79-45ed-a5fd-bbfae0f7a86f">75,726</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i522c65977b4e4cfaa993b2b5ff3d2f94_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80OS9mcmFnOmYxYWI0YTVmNjYzMjQzM2FiMTJiYzczOTBlM2VkOWFlL3RhYmxlOmQ3YTdlNjQzZTUwMDQ1YWY4NTVkZmE2NGI5ZjM2YTk3L3RhYmxlcmFuZ2U6ZDdhN2U2NDNlNTAwNDVhZjg1NWRmYTY0YjlmMzZhOTdfNS00LTEtMS0w_f85fb4a5-fe3e-4af2-9ea5-493b22a49430">75,726</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i641ddedd23b34601ba66a76b01282b1b_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80OS9mcmFnOmYxYWI0YTVmNjYzMjQzM2FiMTJiYzczOTBlM2VkOWFlL3RhYmxlOmQ3YTdlNjQzZTUwMDQ1YWY4NTVkZmE2NGI5ZjM2YTk3L3RhYmxlcmFuZ2U6ZDdhN2U2NDNlNTAwNDVhZjg1NWRmYTY0YjlmMzZhOTdfNS02LTEtMS0w_69aa462a-469f-44b5-a5d8-518d2fa70711">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib25e85f29b8c40708ecc002c16e6e683_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80OS9mcmFnOmYxYWI0YTVmNjYzMjQzM2FiMTJiYzczOTBlM2VkOWFlL3RhYmxlOmQ3YTdlNjQzZTUwMDQ1YWY4NTVkZmE2NGI5ZjM2YTk3L3RhYmxlcmFuZ2U6ZDdhN2U2NDNlNTAwNDVhZjg1NWRmYTY0YjlmMzZhOTdfNS04LTEtMS0w_ac6f4760-77be-467b-a159-beb610cc1238">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable debt securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government-sponsored enterprise securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9eaaf5231e504c2f914f6c3a0ddd13ee_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80OS9mcmFnOmYxYWI0YTVmNjYzMjQzM2FiMTJiYzczOTBlM2VkOWFlL3RhYmxlOmQ3YTdlNjQzZTUwMDQ1YWY4NTVkZmE2NGI5ZjM2YTk3L3RhYmxlcmFuZ2U6ZDdhN2U2NDNlNTAwNDVhZjg1NWRmYTY0YjlmMzZhOTdfMTAtMi0xLTEtMA_c0cbefdb-dccd-4ebe-a622-071555183cc4">245,214</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f0a2ea993f04064aadad295133972b4_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80OS9mcmFnOmYxYWI0YTVmNjYzMjQzM2FiMTJiYzczOTBlM2VkOWFlL3RhYmxlOmQ3YTdlNjQzZTUwMDQ1YWY4NTVkZmE2NGI5ZjM2YTk3L3RhYmxlcmFuZ2U6ZDdhN2U2NDNlNTAwNDVhZjg1NWRmYTY0YjlmMzZhOTdfMTAtNC0xLTEtMA_47d2567c-9fef-4f9b-9e3b-1e22b4828d8e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia79c16400354457793c02c74c6ff001d_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80OS9mcmFnOmYxYWI0YTVmNjYzMjQzM2FiMTJiYzczOTBlM2VkOWFlL3RhYmxlOmQ3YTdlNjQzZTUwMDQ1YWY4NTVkZmE2NGI5ZjM2YTk3L3RhYmxlcmFuZ2U6ZDdhN2U2NDNlNTAwNDVhZjg1NWRmYTY0YjlmMzZhOTdfMTAtNi0xLTEtMA_83e625a1-1055-4c3b-9982-b175358050bf">245,214</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7bf1dac612484a0685308b19a503a754_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80OS9mcmFnOmYxYWI0YTVmNjYzMjQzM2FiMTJiYzczOTBlM2VkOWFlL3RhYmxlOmQ3YTdlNjQzZTUwMDQ1YWY4NTVkZmE2NGI5ZjM2YTk3L3RhYmxlcmFuZ2U6ZDdhN2U2NDNlNTAwNDVhZjg1NWRmYTY0YjlmMzZhOTdfMTAtOC0xLTEtMA_1300f962-19a0-4453-8756-e496dbb503a1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65a4965cd593490dbf6466695a4a77e4_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80OS9mcmFnOmYxYWI0YTVmNjYzMjQzM2FiMTJiYzczOTBlM2VkOWFlL3RhYmxlOmQ3YTdlNjQzZTUwMDQ1YWY4NTVkZmE2NGI5ZjM2YTk3L3RhYmxlcmFuZ2U6ZDdhN2U2NDNlNTAwNDVhZjg1NWRmYTY0YjlmMzZhOTdfMTEtMi0xLTEtMA_77e52fd4-1a18-498f-80e8-5168f3120fd5">1,087,968</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i839a27ef72924781a3487df7e5d7b395_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80OS9mcmFnOmYxYWI0YTVmNjYzMjQzM2FiMTJiYzczOTBlM2VkOWFlL3RhYmxlOmQ3YTdlNjQzZTUwMDQ1YWY4NTVkZmE2NGI5ZjM2YTk3L3RhYmxlcmFuZ2U6ZDdhN2U2NDNlNTAwNDVhZjg1NWRmYTY0YjlmMzZhOTdfMTEtNC0xLTEtMA_dae1f24e-4206-414b-99b2-955e3cfa57de">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5590fd684f1a4aa090bf9b83c5673927_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80OS9mcmFnOmYxYWI0YTVmNjYzMjQzM2FiMTJiYzczOTBlM2VkOWFlL3RhYmxlOmQ3YTdlNjQzZTUwMDQ1YWY4NTVkZmE2NGI5ZjM2YTk3L3RhYmxlcmFuZ2U6ZDdhN2U2NDNlNTAwNDVhZjg1NWRmYTY0YjlmMzZhOTdfMTEtNi0xLTEtMA_c533ebb1-c169-4843-ba6f-fbff1d10192f">1,087,968</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f72f19e489246dea7d90e3176d37999_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80OS9mcmFnOmYxYWI0YTVmNjYzMjQzM2FiMTJiYzczOTBlM2VkOWFlL3RhYmxlOmQ3YTdlNjQzZTUwMDQ1YWY4NTVkZmE2NGI5ZjM2YTk3L3RhYmxlcmFuZ2U6ZDdhN2U2NDNlNTAwNDVhZjg1NWRmYTY0YjlmMzZhOTdfMTEtOC0xLTEtMA_b34b00bb-cf6e-44d8-b1eb-f90b918bb5b5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable equity securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie44adffa3b2e429993b1d4c047f9453c_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNi" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80OS9mcmFnOmYxYWI0YTVmNjYzMjQzM2FiMTJiYzczOTBlM2VkOWFlL3RhYmxlOmQ3YTdlNjQzZTUwMDQ1YWY4NTVkZmE2NGI5ZjM2YTk3L3RhYmxlcmFuZ2U6ZDdhN2U2NDNlNTAwNDVhZjg1NWRmYTY0YjlmMzZhOTdfMTItMi0xLTEtMA_cb33a238-594c-4584-854d-6852b10ebe96">44,633</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i515aff7391d84e1bae1add95d453fe61_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNi" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80OS9mcmFnOmYxYWI0YTVmNjYzMjQzM2FiMTJiYzczOTBlM2VkOWFlL3RhYmxlOmQ3YTdlNjQzZTUwMDQ1YWY4NTVkZmE2NGI5ZjM2YTk3L3RhYmxlcmFuZ2U6ZDdhN2U2NDNlNTAwNDVhZjg1NWRmYTY0YjlmMzZhOTdfMTItNC0xLTEtMA_b61fa129-5633-4a99-a3cf-1955fd900bfb">44,633</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c2621b1e8d440ffa4c9d403e127ab4d_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:EquitySecuritiesFvNi" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80OS9mcmFnOmYxYWI0YTVmNjYzMjQzM2FiMTJiYzczOTBlM2VkOWFlL3RhYmxlOmQ3YTdlNjQzZTUwMDQ1YWY4NTVkZmE2NGI5ZjM2YTk3L3RhYmxlcmFuZ2U6ZDdhN2U2NDNlNTAwNDVhZjg1NWRmYTY0YjlmMzZhOTdfMTItNi0xLTEtMA_1e8597d5-98ec-40ee-a6e4-87ca81445949">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4526151777954123a086b101de9b112e_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:EquitySecuritiesFvNi" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80OS9mcmFnOmYxYWI0YTVmNjYzMjQzM2FiMTJiYzczOTBlM2VkOWFlL3RhYmxlOmQ3YTdlNjQzZTUwMDQ1YWY4NTVkZmE2NGI5ZjM2YTk3L3RhYmxlcmFuZ2U6ZDdhN2U2NDNlNTAwNDVhZjg1NWRmYTY0YjlmMzZhOTdfMTItOC0xLTEtMA_3c5f3134-ac64-4ded-b47c-1ea01f4ab1ce">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash (money market funds)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1d58cc31b1e414591ea2ec01318868f_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashAndCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80OS9mcmFnOmYxYWI0YTVmNjYzMjQzM2FiMTJiYzczOTBlM2VkOWFlL3RhYmxlOmQ3YTdlNjQzZTUwMDQ1YWY4NTVkZmE2NGI5ZjM2YTk3L3RhYmxlcmFuZ2U6ZDdhN2U2NDNlNTAwNDVhZjg1NWRmYTY0YjlmMzZhOTdfMTMtMi0xLTEtMA_db0783ec-b0bb-49cf-92a2-073021bf4f69">1,483</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i522c65977b4e4cfaa993b2b5ff3d2f94_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashAndCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80OS9mcmFnOmYxYWI0YTVmNjYzMjQzM2FiMTJiYzczOTBlM2VkOWFlL3RhYmxlOmQ3YTdlNjQzZTUwMDQ1YWY4NTVkZmE2NGI5ZjM2YTk3L3RhYmxlcmFuZ2U6ZDdhN2U2NDNlNTAwNDVhZjg1NWRmYTY0YjlmMzZhOTdfMTMtNC0xLTEtMA_6e141b96-d4aa-4dd5-8a07-7ac0f0cee6cb">1,483</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i641ddedd23b34601ba66a76b01282b1b_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:RestrictedCashAndCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80OS9mcmFnOmYxYWI0YTVmNjYzMjQzM2FiMTJiYzczOTBlM2VkOWFlL3RhYmxlOmQ3YTdlNjQzZTUwMDQ1YWY4NTVkZmE2NGI5ZjM2YTk3L3RhYmxlcmFuZ2U6ZDdhN2U2NDNlNTAwNDVhZjg1NWRmYTY0YjlmMzZhOTdfMTMtNi0xLTEtMA_5a07769a-483e-4c4c-a0c9-90595c038d36">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib25e85f29b8c40708ecc002c16e6e683_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:RestrictedCashAndCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80OS9mcmFnOmYxYWI0YTVmNjYzMjQzM2FiMTJiYzczOTBlM2VkOWFlL3RhYmxlOmQ3YTdlNjQzZTUwMDQ1YWY4NTVkZmE2NGI5ZjM2YTk3L3RhYmxlcmFuZ2U6ZDdhN2U2NDNlNTAwNDVhZjg1NWRmYTY0YjlmMzZhOTdfMTMtOC0xLTEtMA_c6d8cb55-0496-49be-9fdb-62aa078dfff1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total financial assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie44adffa3b2e429993b1d4c047f9453c_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80OS9mcmFnOmYxYWI0YTVmNjYzMjQzM2FiMTJiYzczOTBlM2VkOWFlL3RhYmxlOmQ3YTdlNjQzZTUwMDQ1YWY4NTVkZmE2NGI5ZjM2YTk3L3RhYmxlcmFuZ2U6ZDdhN2U2NDNlNTAwNDVhZjg1NWRmYTY0YjlmMzZhOTdfMTQtMi0xLTEtMA_d41915b2-6959-4a95-a995-5fa1ef68fd45">1,475,024</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i515aff7391d84e1bae1add95d453fe61_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80OS9mcmFnOmYxYWI0YTVmNjYzMjQzM2FiMTJiYzczOTBlM2VkOWFlL3RhYmxlOmQ3YTdlNjQzZTUwMDQ1YWY4NTVkZmE2NGI5ZjM2YTk3L3RhYmxlcmFuZ2U6ZDdhN2U2NDNlNTAwNDVhZjg1NWRmYTY0YjlmMzZhOTdfMTQtNC0xLTEtMA_45c1575a-1cd0-4dca-a263-63391a58c52f">121,842</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c2621b1e8d440ffa4c9d403e127ab4d_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80OS9mcmFnOmYxYWI0YTVmNjYzMjQzM2FiMTJiYzczOTBlM2VkOWFlL3RhYmxlOmQ3YTdlNjQzZTUwMDQ1YWY4NTVkZmE2NGI5ZjM2YTk3L3RhYmxlcmFuZ2U6ZDdhN2U2NDNlNTAwNDVhZjg1NWRmYTY0YjlmMzZhOTdfMTQtNi0xLTEtMA_2b009db5-1bf5-4556-872f-47db6b7d1e70">1,353,182</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4526151777954123a086b101de9b112e_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80OS9mcmFnOmYxYWI0YTVmNjYzMjQzM2FiMTJiYzczOTBlM2VkOWFlL3RhYmxlOmQ3YTdlNjQzZTUwMDQ1YWY4NTVkZmE2NGI5ZjM2YTk3L3RhYmxlcmFuZ2U6ZDdhN2U2NDNlNTAwNDVhZjg1NWRmYTY0YjlmMzZhOTdfMTQtOC0xLTEtMA_aa1c26ed-48da-4d9d-80a2-11ea665e4eae">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Development derivative liability (Note 10)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie44adffa3b2e429993b1d4c047f9453c_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80OS9mcmFnOmYxYWI0YTVmNjYzMjQzM2FiMTJiYzczOTBlM2VkOWFlL3RhYmxlOmQ3YTdlNjQzZTUwMDQ1YWY4NTVkZmE2NGI5ZjM2YTk3L3RhYmxlcmFuZ2U6ZDdhN2U2NDNlNTAwNDVhZjg1NWRmYTY0YjlmMzZhOTdfMTYtMi0xLTEtNDEy_828d0ae7-f278-4251-ae11-fc1bed7b30bc">25,585</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i515aff7391d84e1bae1add95d453fe61_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:DerivativeLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80OS9mcmFnOmYxYWI0YTVmNjYzMjQzM2FiMTJiYzczOTBlM2VkOWFlL3RhYmxlOmQ3YTdlNjQzZTUwMDQ1YWY4NTVkZmE2NGI5ZjM2YTk3L3RhYmxlcmFuZ2U6ZDdhN2U2NDNlNTAwNDVhZjg1NWRmYTY0YjlmMzZhOTdfMTYtNC0xLTEtNDEy_47d546fd-6425-478f-8017-586d519ce623">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c2621b1e8d440ffa4c9d403e127ab4d_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:DerivativeLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80OS9mcmFnOmYxYWI0YTVmNjYzMjQzM2FiMTJiYzczOTBlM2VkOWFlL3RhYmxlOmQ3YTdlNjQzZTUwMDQ1YWY4NTVkZmE2NGI5ZjM2YTk3L3RhYmxlcmFuZ2U6ZDdhN2U2NDNlNTAwNDVhZjg1NWRmYTY0YjlmMzZhOTdfMTYtNi0xLTEtNDEy_e3329d48-2616-4fd0-b9e7-07b3bedcef1e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4526151777954123a086b101de9b112e_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80OS9mcmFnOmYxYWI0YTVmNjYzMjQzM2FiMTJiYzczOTBlM2VkOWFlL3RhYmxlOmQ3YTdlNjQzZTUwMDQ1YWY4NTVkZmE2NGI5ZjM2YTk3L3RhYmxlcmFuZ2U6ZDdhN2U2NDNlNTAwNDVhZjg1NWRmYTY0YjlmMzZhOTdfMTYtOC0xLTEtNDEy_5b9c2755-7351-4b0b-b8ce-3c3061765a24">25,585</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The carrying amounts reflected on our condensed consolidated balance sheets for cash, accounts receivable, net, other current assets, accounts payable and accrued expenses approximate fair value due to their short-term maturities. The carrying </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9f86b6d3686546618ade3c76e6b23fc8_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ALNYLAM PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="iae7ad72fb6414459932612f53f712fd1">amount of our debt as of March&#160;31, 2021 approximates fair value as the debt was drawn on December 31, 2020 and has variable interest.</ix:continuation> </span></div><div id="i9f86b6d3686546618ade3c76e6b23fc8_52"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331" name="alny:InvestmentsInMarketableDebtSecuritiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81Mi9mcmFnOmI5NWYyNjQxYWE2ZTQwMTU5MzFjODRlY2VmNTYxYWM4L3RleHRyZWdpb246Yjk1ZjI2NDFhYTZlNDAxNTkzMWM4NGVjZWY1NjFhYzhfNjM3_039d38b4-2419-4258-a6bd-12000fb06dc7" continuedAt="ie4a7c0258956491d9438199d87ae3190" escape="true">MARKETABLE DEBT SECURITIES</ix:nonNumeric></span></div><ix:continuation id="ie4a7c0258956491d9438199d87ae3190"><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We invest our excess cash balances in marketable debt securities and at each balance sheet date presented, we classify all of our investments in debt securities as available-for-sale and as current assets as they represent the investment of funds available for current operations. We did <ix:nonFraction unitRef="usd" contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331" decimals="INF" format="ixt-sec:numwordsen" name="alny:ImpairmentOfMarketableDebtSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81Mi9mcmFnOmI5NWYyNjQxYWE2ZTQwMTU5MzFjODRlY2VmNTYxYWM4L3RleHRyZWdpb246Yjk1ZjI2NDFhYTZlNDAxNTkzMWM4NGVjZWY1NjFhYzhfMzI0_3c32bd4a-5982-44de-9ba1-e1f22ad56e99"><ix:nonFraction unitRef="usd" contextRef="ide9f6e15665746279d0000be700fcc6a_D20200101-20200331" decimals="INF" format="ixt-sec:numwordsen" name="alny:ImpairmentOfMarketableDebtSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81Mi9mcmFnOmI5NWYyNjQxYWE2ZTQwMTU5MzFjODRlY2VmNTYxYWM4L3RleHRyZWdpb246Yjk1ZjI2NDFhYTZlNDAxNTkzMWM4NGVjZWY1NjFhYzhfMzI0_7f4e9928-64ec-451f-ba76-8f42a8854e60"><ix:nonFraction unitRef="usd" contextRef="ide9f6e15665746279d0000be700fcc6a_D20200101-20200331" decimals="INF" format="ixt-sec:numwordsen" name="alny:ImpairmentOfMarketableDebtSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81Mi9mcmFnOmI5NWYyNjQxYWE2ZTQwMTU5MzFjODRlY2VmNTYxYWM4L3RleHRyZWdpb246Yjk1ZjI2NDFhYTZlNDAxNTkzMWM4NGVjZWY1NjFhYzhfMzI0_adb73d4a-c146-483e-ade8-45173e82ac97"><ix:nonFraction unitRef="usd" contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331" decimals="INF" format="ixt-sec:numwordsen" name="alny:ImpairmentOfMarketableDebtSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81Mi9mcmFnOmI5NWYyNjQxYWE2ZTQwMTU5MzFjODRlY2VmNTYxYWM4L3RleHRyZWdpb246Yjk1ZjI2NDFhYTZlNDAxNTkzMWM4NGVjZWY1NjFhYzhfMzI0_b141ae81-8ee7-4093-be47-ded5abd9c181">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction>t record any impairment charges related to our marketable debt securities during the three months ended March&#160;31, 2021 or 2020.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span><br/></span></div><ix:nonNumeric contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331" name="us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81Mi9mcmFnOmI5NWYyNjQxYWE2ZTQwMTU5MzFjODRlY2VmNTYxYWM4L3RleHRyZWdpb246Yjk1ZjI2NDFhYTZlNDAxNTkzMWM4NGVjZWY1NjFhYzhfNjM4_944cf832-00ad-420b-b160-d2eb8bfce08d" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following tables summarize our marketable debt securities:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:49.779%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.632%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government-sponsored enterprise securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i233d78b0ba3f4206a3bfc816b3ab7454_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81Mi9mcmFnOmI5NWYyNjQxYWE2ZTQwMTU5MzFjODRlY2VmNTYxYWM4L3RhYmxlOjJlNzliODk4OWMxMzRmZGI5YWZiYmUwNDdkMTk3OTEyL3RhYmxlcmFuZ2U6MmU3OWI4OTg5YzEzNGZkYjlhZmJiZTA0N2QxOTc5MTJfMy0xLTEtMS0w_7feb310f-0aba-4075-bea8-53f11a1899ad">215,171</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i233d78b0ba3f4206a3bfc816b3ab7454_I20210331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81Mi9mcmFnOmI5NWYyNjQxYWE2ZTQwMTU5MzFjODRlY2VmNTYxYWM4L3RhYmxlOjJlNzliODk4OWMxMzRmZGI5YWZiYmUwNDdkMTk3OTEyL3RhYmxlcmFuZ2U6MmU3OWI4OTg5YzEzNGZkYjlhZmJiZTA0N2QxOTc5MTJfMy0zLTEtMS0w_68350d5e-c6d5-424e-b75c-f64102c783c0">87</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i233d78b0ba3f4206a3bfc816b3ab7454_I20210331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81Mi9mcmFnOmI5NWYyNjQxYWE2ZTQwMTU5MzFjODRlY2VmNTYxYWM4L3RhYmxlOjJlNzliODk4OWMxMzRmZGI5YWZiYmUwNDdkMTk3OTEyL3RhYmxlcmFuZ2U6MmU3OWI4OTg5YzEzNGZkYjlhZmJiZTA0N2QxOTc5MTJfMy01LTEtMS0w_0f0c6082-e3a9-498b-ac37-f5e04fda8a0b">58</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i233d78b0ba3f4206a3bfc816b3ab7454_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81Mi9mcmFnOmI5NWYyNjQxYWE2ZTQwMTU5MzFjODRlY2VmNTYxYWM4L3RhYmxlOjJlNzliODk4OWMxMzRmZGI5YWZiYmUwNDdkMTk3OTEyL3RhYmxlcmFuZ2U6MmU3OWI4OTg5YzEzNGZkYjlhZmJiZTA0N2QxOTc5MTJfMy03LTEtMS0w_ba7930b2-16a2-4a80-a426-3f2dd3511731">215,200</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58cbbc0a79de4859b6344bf8949aeb85_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81Mi9mcmFnOmI5NWYyNjQxYWE2ZTQwMTU5MzFjODRlY2VmNTYxYWM4L3RhYmxlOjJlNzliODk4OWMxMzRmZGI5YWZiYmUwNDdkMTk3OTEyL3RhYmxlcmFuZ2U6MmU3OWI4OTg5YzEzNGZkYjlhZmJiZTA0N2QxOTc5MTJfNC0xLTEtMS0w_629a7a37-a300-4cf1-81e3-e539a3107d0c">1,057,509</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58cbbc0a79de4859b6344bf8949aeb85_I20210331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81Mi9mcmFnOmI5NWYyNjQxYWE2ZTQwMTU5MzFjODRlY2VmNTYxYWM4L3RhYmxlOjJlNzliODk4OWMxMzRmZGI5YWZiYmUwNDdkMTk3OTEyL3RhYmxlcmFuZ2U6MmU3OWI4OTg5YzEzNGZkYjlhZmJiZTA0N2QxOTc5MTJfNC0zLTEtMS0w_8662c04d-b68b-4350-ba22-4f69d57394d1">335</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i58cbbc0a79de4859b6344bf8949aeb85_I20210331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81Mi9mcmFnOmI5NWYyNjQxYWE2ZTQwMTU5MzFjODRlY2VmNTYxYWM4L3RhYmxlOjJlNzliODk4OWMxMzRmZGI5YWZiYmUwNDdkMTk3OTEyL3RhYmxlcmFuZ2U6MmU3OWI4OTg5YzEzNGZkYjlhZmJiZTA0N2QxOTc5MTJfNC01LTEtMS0w_95dae7c1-9b37-4035-934a-4366c8c953aa">17</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58cbbc0a79de4859b6344bf8949aeb85_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81Mi9mcmFnOmI5NWYyNjQxYWE2ZTQwMTU5MzFjODRlY2VmNTYxYWM4L3RhYmxlOjJlNzliODk4OWMxMzRmZGI5YWZiYmUwNDdkMTk3OTEyL3RhYmxlcmFuZ2U6MmU3OWI4OTg5YzEzNGZkYjlhZmJiZTA0N2QxOTc5MTJfNC03LTEtMS0w_3f3a79ee-5367-41ac-a8ab-c4889a6c26b4">1,057,827</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd7204dc87d24972a01f15b098c4f56b_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81Mi9mcmFnOmI5NWYyNjQxYWE2ZTQwMTU5MzFjODRlY2VmNTYxYWM4L3RhYmxlOjJlNzliODk4OWMxMzRmZGI5YWZiYmUwNDdkMTk3OTEyL3RhYmxlcmFuZ2U6MmU3OWI4OTg5YzEzNGZkYjlhZmJiZTA0N2QxOTc5MTJfNS0xLTEtMS0w_fb1069f0-4d18-48d0-8e8f-2e3ec7ffd1aa">1,272,680</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd7204dc87d24972a01f15b098c4f56b_I20210331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81Mi9mcmFnOmI5NWYyNjQxYWE2ZTQwMTU5MzFjODRlY2VmNTYxYWM4L3RhYmxlOjJlNzliODk4OWMxMzRmZGI5YWZiYmUwNDdkMTk3OTEyL3RhYmxlcmFuZ2U6MmU3OWI4OTg5YzEzNGZkYjlhZmJiZTA0N2QxOTc5MTJfNS0zLTEtMS0w_0e5ad25b-d391-46e4-94db-b318ae6283d7">422</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idd7204dc87d24972a01f15b098c4f56b_I20210331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81Mi9mcmFnOmI5NWYyNjQxYWE2ZTQwMTU5MzFjODRlY2VmNTYxYWM4L3RhYmxlOjJlNzliODk4OWMxMzRmZGI5YWZiYmUwNDdkMTk3OTEyL3RhYmxlcmFuZ2U6MmU3OWI4OTg5YzEzNGZkYjlhZmJiZTA0N2QxOTc5MTJfNS01LTEtMS0w_afdc5694-0736-4703-979c-ac720ef89b09">75</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd7204dc87d24972a01f15b098c4f56b_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81Mi9mcmFnOmI5NWYyNjQxYWE2ZTQwMTU5MzFjODRlY2VmNTYxYWM4L3RhYmxlOjJlNzliODk4OWMxMzRmZGI5YWZiYmUwNDdkMTk3OTEyL3RhYmxlcmFuZ2U6MmU3OWI4OTg5YzEzNGZkYjlhZmJiZTA0N2QxOTc5MTJfNS03LTEtMS0w_99ac8b54-7093-46c9-9daa-6f97ea8c822e">1,273,027</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:49.779%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.632%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government-sponsored enterprise securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib30b025bf153422e892ecc638911a8fc_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81Mi9mcmFnOmI5NWYyNjQxYWE2ZTQwMTU5MzFjODRlY2VmNTYxYWM4L3RhYmxlOjBlOGYyZjg0YmE4ODQzNjc4NWY1NjM0YzkzZDAxODlkL3RhYmxlcmFuZ2U6MGU4ZjJmODRiYTg4NDM2Nzg1ZjU2MzRjOTNkMDE4OWRfNS0xLTEtMS0w_6de9bf83-462b-4f2a-af5e-afc13d7cc1ab">245,113</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib30b025bf153422e892ecc638911a8fc_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81Mi9mcmFnOmI5NWYyNjQxYWE2ZTQwMTU5MzFjODRlY2VmNTYxYWM4L3RhYmxlOjBlOGYyZjg0YmE4ODQzNjc4NWY1NjM0YzkzZDAxODlkL3RhYmxlcmFuZ2U6MGU4ZjJmODRiYTg4NDM2Nzg1ZjU2MzRjOTNkMDE4OWRfNS0zLTEtMS0w_e901387d-8679-4d61-b159-8929a8be28d1">135</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib30b025bf153422e892ecc638911a8fc_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81Mi9mcmFnOmI5NWYyNjQxYWE2ZTQwMTU5MzFjODRlY2VmNTYxYWM4L3RhYmxlOjBlOGYyZjg0YmE4ODQzNjc4NWY1NjM0YzkzZDAxODlkL3RhYmxlcmFuZ2U6MGU4ZjJmODRiYTg4NDM2Nzg1ZjU2MzRjOTNkMDE4OWRfNS01LTEtMS0w_e716df80-b1ca-4358-8242-1cb91800fbc3">34</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib30b025bf153422e892ecc638911a8fc_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81Mi9mcmFnOmI5NWYyNjQxYWE2ZTQwMTU5MzFjODRlY2VmNTYxYWM4L3RhYmxlOjBlOGYyZjg0YmE4ODQzNjc4NWY1NjM0YzkzZDAxODlkL3RhYmxlcmFuZ2U6MGU4ZjJmODRiYTg4NDM2Nzg1ZjU2MzRjOTNkMDE4OWRfNS03LTEtMS0w_c77d8dee-081c-4e96-a3fe-c0ac073817d8">245,214</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab2144e8f1994353ab908cc9c23d059a_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81Mi9mcmFnOmI5NWYyNjQxYWE2ZTQwMTU5MzFjODRlY2VmNTYxYWM4L3RhYmxlOjBlOGYyZjg0YmE4ODQzNjc4NWY1NjM0YzkzZDAxODlkL3RhYmxlcmFuZ2U6MGU4ZjJmODRiYTg4NDM2Nzg1ZjU2MzRjOTNkMDE4OWRfNi0xLTEtMS0w_3c25c536-d87e-4682-966a-a5e9ad7ae4a7">1,107,721</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab2144e8f1994353ab908cc9c23d059a_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81Mi9mcmFnOmI5NWYyNjQxYWE2ZTQwMTU5MzFjODRlY2VmNTYxYWM4L3RhYmxlOjBlOGYyZjg0YmE4ODQzNjc4NWY1NjM0YzkzZDAxODlkL3RhYmxlcmFuZ2U6MGU4ZjJmODRiYTg4NDM2Nzg1ZjU2MzRjOTNkMDE4OWRfNi0zLTEtMS0w_7367407d-3a17-416e-8e08-1129b69d1c3e">328</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iab2144e8f1994353ab908cc9c23d059a_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81Mi9mcmFnOmI5NWYyNjQxYWE2ZTQwMTU5MzFjODRlY2VmNTYxYWM4L3RhYmxlOjBlOGYyZjg0YmE4ODQzNjc4NWY1NjM0YzkzZDAxODlkL3RhYmxlcmFuZ2U6MGU4ZjJmODRiYTg4NDM2Nzg1ZjU2MzRjOTNkMDE4OWRfNi01LTEtMS0w_db5c4b23-154e-4e6e-b715-9245349d391b">81</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab2144e8f1994353ab908cc9c23d059a_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81Mi9mcmFnOmI5NWYyNjQxYWE2ZTQwMTU5MzFjODRlY2VmNTYxYWM4L3RhYmxlOjBlOGYyZjg0YmE4ODQzNjc4NWY1NjM0YzkzZDAxODlkL3RhYmxlcmFuZ2U6MGU4ZjJmODRiYTg4NDM2Nzg1ZjU2MzRjOTNkMDE4OWRfNi03LTEtMS0w_eeb124dc-9e0b-4171-a4f0-5e61cf6bb790">1,107,968</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id365c5f1d37444ac9e1da5b5891cd81a_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81Mi9mcmFnOmI5NWYyNjQxYWE2ZTQwMTU5MzFjODRlY2VmNTYxYWM4L3RhYmxlOjBlOGYyZjg0YmE4ODQzNjc4NWY1NjM0YzkzZDAxODlkL3RhYmxlcmFuZ2U6MGU4ZjJmODRiYTg4NDM2Nzg1ZjU2MzRjOTNkMDE4OWRfNy0xLTEtMS0w_c1913f0e-6025-4bd4-ac4c-8653bd278888">1,352,834</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id365c5f1d37444ac9e1da5b5891cd81a_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81Mi9mcmFnOmI5NWYyNjQxYWE2ZTQwMTU5MzFjODRlY2VmNTYxYWM4L3RhYmxlOjBlOGYyZjg0YmE4ODQzNjc4NWY1NjM0YzkzZDAxODlkL3RhYmxlcmFuZ2U6MGU4ZjJmODRiYTg4NDM2Nzg1ZjU2MzRjOTNkMDE4OWRfNy0zLTEtMS0w_c2ea4b2c-9978-4799-95f6-932a6dbc1599">463</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id365c5f1d37444ac9e1da5b5891cd81a_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81Mi9mcmFnOmI5NWYyNjQxYWE2ZTQwMTU5MzFjODRlY2VmNTYxYWM4L3RhYmxlOjBlOGYyZjg0YmE4ODQzNjc4NWY1NjM0YzkzZDAxODlkL3RhYmxlcmFuZ2U6MGU4ZjJmODRiYTg4NDM2Nzg1ZjU2MzRjOTNkMDE4OWRfNy01LTEtMS0w_8d1278f7-dee2-4dfd-9beb-081b08c2fd74">115</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id365c5f1d37444ac9e1da5b5891cd81a_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81Mi9mcmFnOmI5NWYyNjQxYWE2ZTQwMTU5MzFjODRlY2VmNTYxYWM4L3RhYmxlOjBlOGYyZjg0YmE4ODQzNjc4NWY1NjM0YzkzZDAxODlkL3RhYmxlcmFuZ2U6MGU4ZjJmODRiYTg4NDM2Nzg1ZjU2MzRjOTNkMDE4OWRfNy03LTEtMS0w_3105bd47-4e87-4f8a-9d76-ccd43679e27e">1,353,182</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331" name="us-gaap:FairValueByBalanceSheetGroupingTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81Mi9mcmFnOmI5NWYyNjQxYWE2ZTQwMTU5MzFjODRlY2VmNTYxYWM4L3RleHRyZWdpb246Yjk1ZjI2NDFhYTZlNDAxNTkzMWM4NGVjZWY1NjFhYzhfNjQw_42722d7a-4e51-4518-bcdd-a6a5e019c918" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The fair values of our marketable debt securities by classification in the condensed consolidated balance sheets were as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.128%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.422%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd7204dc87d24972a01f15b098c4f56b_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81Mi9mcmFnOmI5NWYyNjQxYWE2ZTQwMTU5MzFjODRlY2VmNTYxYWM4L3RhYmxlOmQ2OWQ0ZWE1ZWMwMjQzNjA5ODg5NTFjZjk4OGU3ODY3L3RhYmxlcmFuZ2U6ZDY5ZDRlYTVlYzAyNDM2MDk4ODk1MWNmOTg4ZTc4NjdfMS0xLTEtMS0w_6dd88d5b-1a04-4937-a821-44b1c8529699">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id365c5f1d37444ac9e1da5b5891cd81a_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81Mi9mcmFnOmI5NWYyNjQxYWE2ZTQwMTU5MzFjODRlY2VmNTYxYWM4L3RhYmxlOmQ2OWQ0ZWE1ZWMwMjQzNjA5ODg5NTFjZjk4OGU3ODY3L3RhYmxlcmFuZ2U6ZDY5ZDRlYTVlYzAyNDM2MDk4ODk1MWNmOTg4ZTc4NjdfMS0zLTEtMS0w_2503c607-8fcf-4660-8ea3-8a5c192c6f50">20,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable debt securities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd7204dc87d24972a01f15b098c4f56b_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81Mi9mcmFnOmI5NWYyNjQxYWE2ZTQwMTU5MzFjODRlY2VmNTYxYWM4L3RhYmxlOmQ2OWQ0ZWE1ZWMwMjQzNjA5ODg5NTFjZjk4OGU3ODY3L3RhYmxlcmFuZ2U6ZDY5ZDRlYTVlYzAyNDM2MDk4ODk1MWNmOTg4ZTc4NjdfMi0xLTEtMS0w_694da0b8-8f41-451e-9b49-39fec6d524c9">1,273,027</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id365c5f1d37444ac9e1da5b5891cd81a_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81Mi9mcmFnOmI5NWYyNjQxYWE2ZTQwMTU5MzFjODRlY2VmNTYxYWM4L3RhYmxlOmQ2OWQ0ZWE1ZWMwMjQzNjA5ODg5NTFjZjk4OGU3ODY3L3RhYmxlcmFuZ2U6ZDY5ZDRlYTVlYzAyNDM2MDk4ODk1MWNmOTg4ZTc4NjdfMi0zLTEtMS0w_7440f729-87e5-4e28-911f-9df9884a5076">1,333,182</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd7204dc87d24972a01f15b098c4f56b_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81Mi9mcmFnOmI5NWYyNjQxYWE2ZTQwMTU5MzFjODRlY2VmNTYxYWM4L3RhYmxlOmQ2OWQ0ZWE1ZWMwMjQzNjA5ODg5NTFjZjk4OGU3ODY3L3RhYmxlcmFuZ2U6ZDY5ZDRlYTVlYzAyNDM2MDk4ODk1MWNmOTg4ZTc4NjdfMy0xLTEtMS0w_e7795ae2-af0c-4b4d-8237-68b6cf1b2faf">1,273,027</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id365c5f1d37444ac9e1da5b5891cd81a_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81Mi9mcmFnOmI5NWYyNjQxYWE2ZTQwMTU5MzFjODRlY2VmNTYxYWM4L3RhYmxlOmQ2OWQ0ZWE1ZWMwMjQzNjA5ODg5NTFjZjk4OGU3ODY3L3RhYmxlcmFuZ2U6ZDY5ZDRlYTVlYzAyNDM2MDk4ODk1MWNmOTg4ZTc4NjdfMy0zLTEtMS0w_886c84b4-957b-4a20-8fa2-89302ac71871">1,353,182</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div id="i9f86b6d3686546618ade3c76e6b23fc8_55"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331" name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81NS9mcmFnOmJmMzFlNjM2ZGVmMTQxNGFhNDUwZmFiOTM5YWM3MDIwL3RleHRyZWdpb246YmYzMWU2MzZkZWYxNDE0YWE0NTBmYWI5MzlhYzcwMjBfMTE2Mg_e3ef3b47-ab4d-46e8-90c3-7136e5e057d7" continuedAt="i6b52e27006a14b83a4966c9dccf1a180" escape="true">OTHER BALANCE SHEET DETAILS</ix:nonNumeric></span></div><ix:continuation id="i6b52e27006a14b83a4966c9dccf1a180" continuedAt="i3f005a51ddea42429f4f818b9338a9aa"><div style="margin-top:6pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Inventory</span></div><ix:nonNumeric contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81NS9mcmFnOmJmMzFlNjM2ZGVmMTQxNGFhNDUwZmFiOTM5YWM3MDIwL3RleHRyZWdpb246YmYzMWU2MzZkZWYxNDE0YWE0NTBmYWI5MzlhYzcwMjBfMTE2Mw_4fe346ce-5d9b-4323-b3e9-2941fed6fa76" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The components of inventory are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.128%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.422%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd7204dc87d24972a01f15b098c4f56b_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryRawMaterials" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81NS9mcmFnOmJmMzFlNjM2ZGVmMTQxNGFhNDUwZmFiOTM5YWM3MDIwL3RhYmxlOmU2NGE3MmFmZjdkMzRiNjRhYTkwZTQxOGFjM2Y1NzFmL3RhYmxlcmFuZ2U6ZTY0YTcyYWZmN2QzNGI2NGFhOTBlNDE4YWMzZjU3MWZfMS0xLTEtMS0w_baa57563-4e69-44af-b441-f06674694803">53,694</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id365c5f1d37444ac9e1da5b5891cd81a_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryRawMaterials" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81NS9mcmFnOmJmMzFlNjM2ZGVmMTQxNGFhNDUwZmFiOTM5YWM3MDIwL3RhYmxlOmU2NGE3MmFmZjdkMzRiNjRhYTkwZTQxOGFjM2Y1NzFmL3RhYmxlcmFuZ2U6ZTY0YTcyYWZmN2QzNGI2NGFhOTBlNDE4YWMzZjU3MWZfMS0zLTEtMS0w_1016f75a-227f-49e4-9d61-5a85c5c91d2b">63,460</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in progress</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd7204dc87d24972a01f15b098c4f56b_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryWorkInProcess" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81NS9mcmFnOmJmMzFlNjM2ZGVmMTQxNGFhNDUwZmFiOTM5YWM3MDIwL3RhYmxlOmU2NGE3MmFmZjdkMzRiNjRhYTkwZTQxOGFjM2Y1NzFmL3RhYmxlcmFuZ2U6ZTY0YTcyYWZmN2QzNGI2NGFhOTBlNDE4YWMzZjU3MWZfMi0xLTEtMS0w_b1a7cd8f-41d9-4783-ad4c-95d75c92519e">23,593</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id365c5f1d37444ac9e1da5b5891cd81a_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryWorkInProcess" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81NS9mcmFnOmJmMzFlNjM2ZGVmMTQxNGFhNDUwZmFiOTM5YWM3MDIwL3RhYmxlOmU2NGE3MmFmZjdkMzRiNjRhYTkwZTQxOGFjM2Y1NzFmL3RhYmxlcmFuZ2U6ZTY0YTcyYWZmN2QzNGI2NGFhOTBlNDE4YWMzZjU3MWZfMi0zLTEtMS0w_562e294c-99e7-4e1b-91fd-86913dcca4d8">16,149</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd7204dc87d24972a01f15b098c4f56b_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryFinishedGoods" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81NS9mcmFnOmJmMzFlNjM2ZGVmMTQxNGFhNDUwZmFiOTM5YWM3MDIwL3RhYmxlOmU2NGE3MmFmZjdkMzRiNjRhYTkwZTQxOGFjM2Y1NzFmL3RhYmxlcmFuZ2U6ZTY0YTcyYWZmN2QzNGI2NGFhOTBlNDE4YWMzZjU3MWZfMy0xLTEtMS0w_6a89cac5-0798-4207-b80e-a30f154c308f">13,753</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id365c5f1d37444ac9e1da5b5891cd81a_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryFinishedGoods" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81NS9mcmFnOmJmMzFlNjM2ZGVmMTQxNGFhNDUwZmFiOTM5YWM3MDIwL3RhYmxlOmU2NGE3MmFmZjdkMzRiNjRhYTkwZTQxOGFjM2Y1NzFmL3RhYmxlcmFuZ2U6ZTY0YTcyYWZmN2QzNGI2NGFhOTBlNDE4YWMzZjU3MWZfMy0zLTEtMS0w_48e61539-9dc6-4e87-a827-729656d71101">12,693</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd7204dc87d24972a01f15b098c4f56b_I20210331" decimals="-3" format="ixt:numdotdecimal" name="alny:InventoryCurrentAndNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81NS9mcmFnOmJmMzFlNjM2ZGVmMTQxNGFhNDUwZmFiOTM5YWM3MDIwL3RhYmxlOmU2NGE3MmFmZjdkMzRiNjRhYTkwZTQxOGFjM2Y1NzFmL3RhYmxlcmFuZ2U6ZTY0YTcyYWZmN2QzNGI2NGFhOTBlNDE4YWMzZjU3MWZfNC0xLTEtMS0w_7c8c6e70-df39-4809-9171-c10c82d1e36b">91,040</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id365c5f1d37444ac9e1da5b5891cd81a_I20201231" decimals="-3" format="ixt:numdotdecimal" name="alny:InventoryCurrentAndNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81NS9mcmFnOmJmMzFlNjM2ZGVmMTQxNGFhNDUwZmFiOTM5YWM3MDIwL3RhYmxlOmU2NGE3MmFmZjdkMzRiNjRhYTkwZTQxOGFjM2Y1NzFmL3RhYmxlcmFuZ2U6ZTY0YTcyYWZmN2QzNGI2NGFhOTBlNDE4YWMzZjU3MWZfNC0zLTEtMS0w_cd0fcbaa-1563-46d0-b550-8ea93e5b88c8">92,302</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-indent:18pt"><span><br/></span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of March&#160;31, 2021 and December&#160;31, 2020, we held $<ix:nonFraction unitRef="usd" contextRef="i3ed44ddacf3f45e2bc4858376f339d6b_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InventoryNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81NS9mcmFnOmJmMzFlNjM2ZGVmMTQxNGFhNDUwZmFiOTM5YWM3MDIwL3RleHRyZWdpb246YmYzMWU2MzZkZWYxNDE0YWE0NTBmYWI5MzlhYzcwMjBfMTA5OTUxMTYyOTg4Mg_ddeaf93c-29fb-4933-8e87-157d82d5b909"><ix:nonFraction unitRef="usd" contextRef="i4ef95a791e56443b9b1182d6253d4e4c_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InventoryNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81NS9mcmFnOmJmMzFlNjM2ZGVmMTQxNGFhNDUwZmFiOTM5YWM3MDIwL3RleHRyZWdpb246YmYzMWU2MzZkZWYxNDE0YWE0NTBmYWI5MzlhYzcwMjBfMTA5OTUxMTYyOTg4Mg_ef1c4727-a30f-457e-9f3c-242509f999be">17.1</ix:nonFraction></ix:nonFraction> million of long- term inventory included within other assets in our condensed consolidated balance sheet as we anticipate it being consumed beyond our normal operating cycle.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9f86b6d3686546618ade3c76e6b23fc8_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ALNYLAM PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="i3f005a51ddea42429f4f818b9338a9aa"><div style="margin-top:6pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Cash, Cash Equivalents and Restricted Cash</span></div><ix:nonNumeric contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331" name="alny:ScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81NS9mcmFnOmJmMzFlNjM2ZGVmMTQxNGFhNDUwZmFiOTM5YWM3MDIwL3RleHRyZWdpb246YmYzMWU2MzZkZWYxNDE0YWE0NTBmYWI5MzlhYzcwMjBfMTE2NA_4b3d37b6-6b46-4583-98a7-6d6f9bab7ee3" escape="true"><ix:nonNumeric contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331" name="alny:ScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81NS9mcmFnOmJmMzFlNjM2ZGVmMTQxNGFhNDUwZmFiOTM5YWM3MDIwL3RleHRyZWdpb246YmYzMWU2MzZkZWYxNDE0YWE0NTBmYWI5MzlhYzcwMjBfMTE2NQ_16d41105-867e-40c8-8faf-074f80526c3a" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within our condensed consolidated balance sheets that sum to the total of these amounts shown in the condensed consolidated statements of cash flows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.128%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.422%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd7204dc87d24972a01f15b098c4f56b_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81NS9mcmFnOmJmMzFlNjM2ZGVmMTQxNGFhNDUwZmFiOTM5YWM3MDIwL3RhYmxlOjJiZjEzYzA5OTAzODQzMjBhNTlkY2ExNDUwYWY5Njk3L3RhYmxlcmFuZ2U6MmJmMTNjMDk5MDM4NDMyMGE1OWRjYTE0NTBhZjk2OTdfMi0xLTEtMS0w_48c5533c-26d1-4b30-a094-046b917cff87">379,543</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic378e7f6183c40b4b7371ed7b7370867_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81NS9mcmFnOmJmMzFlNjM2ZGVmMTQxNGFhNDUwZmFiOTM5YWM3MDIwL3RhYmxlOjJiZjEzYzA5OTAzODQzMjBhNTlkY2ExNDUwYWY5Njk3L3RhYmxlcmFuZ2U6MmJmMTNjMDk5MDM4NDMyMGE1OWRjYTE0NTBhZjk2OTdfMi0zLTEtMS0w_8a23d715-fd56-424b-b436-a9f09d12f887">467,779</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total restricted cash included in prepaid expenses, other current assets and long-term other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd7204dc87d24972a01f15b098c4f56b_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCash" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81NS9mcmFnOmJmMzFlNjM2ZGVmMTQxNGFhNDUwZmFiOTM5YWM3MDIwL3RhYmxlOjJiZjEzYzA5OTAzODQzMjBhNTlkY2ExNDUwYWY5Njk3L3RhYmxlcmFuZ2U6MmJmMTNjMDk5MDM4NDMyMGE1OWRjYTE0NTBhZjk2OTdfMy0xLTEtMS0w_14624978-c0e6-4c1b-b23f-f6d034bb1bde">2,462</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic378e7f6183c40b4b7371ed7b7370867_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCash" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81NS9mcmFnOmJmMzFlNjM2ZGVmMTQxNGFhNDUwZmFiOTM5YWM3MDIwL3RhYmxlOjJiZjEzYzA5OTAzODQzMjBhNTlkY2ExNDUwYWY5Njk3L3RhYmxlcmFuZ2U6MmJmMTNjMDk5MDM4NDMyMGE1OWRjYTE0NTBhZjk2OTdfMy0zLTEtMS0w_200374a6-8e0d-415b-aaa5-d4cf7a815cfb">2,614</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents, and restricted cash shown in the condensed consolidated statements of cash flows</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd7204dc87d24972a01f15b098c4f56b_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81NS9mcmFnOmJmMzFlNjM2ZGVmMTQxNGFhNDUwZmFiOTM5YWM3MDIwL3RhYmxlOjJiZjEzYzA5OTAzODQzMjBhNTlkY2ExNDUwYWY5Njk3L3RhYmxlcmFuZ2U6MmJmMTNjMDk5MDM4NDMyMGE1OWRjYTE0NTBhZjk2OTdfNS0xLTEtMS0w_b931ce9e-9fc3-4c78-be1a-c51c57fd0671">382,005</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic378e7f6183c40b4b7371ed7b7370867_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81NS9mcmFnOmJmMzFlNjM2ZGVmMTQxNGFhNDUwZmFiOTM5YWM3MDIwL3RhYmxlOjJiZjEzYzA5OTAzODQzMjBhNTlkY2ExNDUwYWY5Njk3L3RhYmxlcmFuZ2U6MmJmMTNjMDk5MDM4NDMyMGE1OWRjYTE0NTBhZjk2OTdfNS0zLTEtMS0w_7709aa08-61bc-4780-afe0-4cf716c109ee">470,393</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:nonNumeric><div style="margin-top:12pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Accumulated Other Comprehensive (Loss) Income</span></div><ix:nonNumeric contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331" name="us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81NS9mcmFnOmJmMzFlNjM2ZGVmMTQxNGFhNDUwZmFiOTM5YWM3MDIwL3RleHRyZWdpb246YmYzMWU2MzZkZWYxNDE0YWE0NTBmYWI5MzlhYzcwMjBfMTE2Ng_1ab168e9-2b3c-4f91-9622-c45fd5597e27" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following tables summarize the changes in accumulated other comprehensive loss, by component:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.256%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.157%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Loss on Investment in Joint Venture</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Defined Benefit Pension<br/>Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) from Debt</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Securities</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Foreign Currency Translation<br/>Adjustment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Accumulated Other</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Comprehensive Loss</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ida1aa88277834c4aa06d4523f3777c2d_I20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81NS9mcmFnOmJmMzFlNjM2ZGVmMTQxNGFhNDUwZmFiOTM5YWM3MDIwL3RhYmxlOjBmYTZiZWYxMWQ3NDQ1MWVhZDQ5ZGUyZWM1ZWIyMWY2L3RhYmxlcmFuZ2U6MGZhNmJlZjExZDc0NDUxZWFkNDlkZTJlYzVlYjIxZjZfMS0xLTEtMS0w_66f8181a-a4aa-4e45-bc46-a527a3818107">32,792</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8ed22d63570b49f888c7e1fdb4cba720_I20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81NS9mcmFnOmJmMzFlNjM2ZGVmMTQxNGFhNDUwZmFiOTM5YWM3MDIwL3RhYmxlOjBmYTZiZWYxMWQ3NDQ1MWVhZDQ5ZGUyZWM1ZWIyMWY2L3RhYmxlcmFuZ2U6MGZhNmJlZjExZDc0NDUxZWFkNDlkZTJlYzVlYjIxZjZfMS0zLTEtMS0w_acbcffae-51bc-429a-bec5-19ef7bb66932">3,754</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba4e611a80aa4214b1a15ed34d5a650a_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81NS9mcmFnOmJmMzFlNjM2ZGVmMTQxNGFhNDUwZmFiOTM5YWM3MDIwL3RhYmxlOjBmYTZiZWYxMWQ3NDQ1MWVhZDQ5ZGUyZWM1ZWIyMWY2L3RhYmxlcmFuZ2U6MGZhNmJlZjExZDc0NDUxZWFkNDlkZTJlYzVlYjIxZjZfMS01LTEtMS0w_33ded154-bbf2-4c07-87a7-71a8afbf8c93">348</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if39d09cfa6ef470198658625bf6c69f0_I20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81NS9mcmFnOmJmMzFlNjM2ZGVmMTQxNGFhNDUwZmFiOTM5YWM3MDIwL3RhYmxlOjBmYTZiZWYxMWQ3NDQ1MWVhZDQ5ZGUyZWM1ZWIyMWY2L3RhYmxlcmFuZ2U6MGZhNmJlZjExZDc0NDUxZWFkNDlkZTJlYzVlYjIxZjZfMS03LTEtMS0w_bb6adb0a-ffe5-4126-a715-1bb28423ac5f">7,424</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie217873afb06447795dc36a1e1606a74_I20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81NS9mcmFnOmJmMzFlNjM2ZGVmMTQxNGFhNDUwZmFiOTM5YWM3MDIwL3RhYmxlOjBmYTZiZWYxMWQ3NDQ1MWVhZDQ5ZGUyZWM1ZWIyMWY2L3RhYmxlcmFuZ2U6MGZhNmJlZjExZDc0NDUxZWFkNDlkZTJlYzVlYjIxZjZfMS05LTEtMS0w_265bbf0d-ebe2-4d8f-bb1c-67e1d65ec441">43,622</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive (loss) income before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i088faa415d1b4a52be51abef4f75bc5c_D20210101-20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81NS9mcmFnOmJmMzFlNjM2ZGVmMTQxNGFhNDUwZmFiOTM5YWM3MDIwL3RhYmxlOjBmYTZiZWYxMWQ3NDQ1MWVhZDQ5ZGUyZWM1ZWIyMWY2L3RhYmxlcmFuZ2U6MGZhNmJlZjExZDc0NDUxZWFkNDlkZTJlYzVlYjIxZjZfMi0xLTEtMS0w_3a8b2439-45c4-48ac-aa46-ee75c24fd557">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41887b4841f2496cb04e4f1ed9bd84bf_D20210101-20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81NS9mcmFnOmJmMzFlNjM2ZGVmMTQxNGFhNDUwZmFiOTM5YWM3MDIwL3RhYmxlOjBmYTZiZWYxMWQ3NDQ1MWVhZDQ5ZGUyZWM1ZWIyMWY2L3RhYmxlcmFuZ2U6MGZhNmJlZjExZDc0NDUxZWFkNDlkZTJlYzVlYjIxZjZfMi0zLTEtMS0w_b83b5546-9bce-4069-a34c-44a3b7d8afbe">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i700594dde5154e6abd7676e0bf8a2e3e_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81NS9mcmFnOmJmMzFlNjM2ZGVmMTQxNGFhNDUwZmFiOTM5YWM3MDIwL3RhYmxlOjBmYTZiZWYxMWQ3NDQ1MWVhZDQ5ZGUyZWM1ZWIyMWY2L3RhYmxlcmFuZ2U6MGZhNmJlZjExZDc0NDUxZWFkNDlkZTJlYzVlYjIxZjZfMi01LTEtMS0w_e2fa8c4c-dd90-43e7-b316-7d6e5d8c1223">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e5a33a85da249f89d6d9b5939bed9ea_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81NS9mcmFnOmJmMzFlNjM2ZGVmMTQxNGFhNDUwZmFiOTM5YWM3MDIwL3RhYmxlOjBmYTZiZWYxMWQ3NDQ1MWVhZDQ5ZGUyZWM1ZWIyMWY2L3RhYmxlcmFuZ2U6MGZhNmJlZjExZDc0NDUxZWFkNDlkZTJlYzVlYjIxZjZfMi03LTEtMS0w_17c323fe-2a44-4dd5-b5da-a2f01650196b">6,848</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81NS9mcmFnOmJmMzFlNjM2ZGVmMTQxNGFhNDUwZmFiOTM5YWM3MDIwL3RhYmxlOjBmYTZiZWYxMWQ3NDQ1MWVhZDQ5ZGUyZWM1ZWIyMWY2L3RhYmxlcmFuZ2U6MGZhNmJlZjExZDc0NDUxZWFkNDlkZTJlYzVlYjIxZjZfMi05LTEtMS0w_917f39ee-569e-487a-a13b-3c2a92d879a3">6,847</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from other comprehensive income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i088faa415d1b4a52be51abef4f75bc5c_D20210101-20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81NS9mcmFnOmJmMzFlNjM2ZGVmMTQxNGFhNDUwZmFiOTM5YWM3MDIwL3RhYmxlOjBmYTZiZWYxMWQ3NDQ1MWVhZDQ5ZGUyZWM1ZWIyMWY2L3RhYmxlcmFuZ2U6MGZhNmJlZjExZDc0NDUxZWFkNDlkZTJlYzVlYjIxZjZfMy0xLTEtMS0w_a54bbe9f-7f5e-4877-9c28-e00cc680c7be">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41887b4841f2496cb04e4f1ed9bd84bf_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81NS9mcmFnOmJmMzFlNjM2ZGVmMTQxNGFhNDUwZmFiOTM5YWM3MDIwL3RhYmxlOjBmYTZiZWYxMWQ3NDQ1MWVhZDQ5ZGUyZWM1ZWIyMWY2L3RhYmxlcmFuZ2U6MGZhNmJlZjExZDc0NDUxZWFkNDlkZTJlYzVlYjIxZjZfMy0zLTEtMS0w_b7c79310-3d2d-47d6-a8c7-48f50b9c627f">58</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i700594dde5154e6abd7676e0bf8a2e3e_D20210101-20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81NS9mcmFnOmJmMzFlNjM2ZGVmMTQxNGFhNDUwZmFiOTM5YWM3MDIwL3RhYmxlOjBmYTZiZWYxMWQ3NDQ1MWVhZDQ5ZGUyZWM1ZWIyMWY2L3RhYmxlcmFuZ2U6MGZhNmJlZjExZDc0NDUxZWFkNDlkZTJlYzVlYjIxZjZfMy01LTEtMS0w_6ab9349e-5818-475a-9a87-a160557d5d97">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e5a33a85da249f89d6d9b5939bed9ea_D20210101-20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81NS9mcmFnOmJmMzFlNjM2ZGVmMTQxNGFhNDUwZmFiOTM5YWM3MDIwL3RhYmxlOjBmYTZiZWYxMWQ3NDQ1MWVhZDQ5ZGUyZWM1ZWIyMWY2L3RhYmxlcmFuZ2U6MGZhNmJlZjExZDc0NDUxZWFkNDlkZTJlYzVlYjIxZjZfMy03LTEtMS0w_ae60c6d8-ea00-40f6-9633-e31d173d6682">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81NS9mcmFnOmJmMzFlNjM2ZGVmMTQxNGFhNDUwZmFiOTM5YWM3MDIwL3RhYmxlOjBmYTZiZWYxMWQ3NDQ1MWVhZDQ5ZGUyZWM1ZWIyMWY2L3RhYmxlcmFuZ2U6MGZhNmJlZjExZDc0NDUxZWFkNDlkZTJlYzVlYjIxZjZfMy05LTEtMS0w_64276716-d48c-47b7-89d5-6eaef41aa890">58</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i088faa415d1b4a52be51abef4f75bc5c_D20210101-20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81NS9mcmFnOmJmMzFlNjM2ZGVmMTQxNGFhNDUwZmFiOTM5YWM3MDIwL3RhYmxlOjBmYTZiZWYxMWQ3NDQ1MWVhZDQ5ZGUyZWM1ZWIyMWY2L3RhYmxlcmFuZ2U6MGZhNmJlZjExZDc0NDUxZWFkNDlkZTJlYzVlYjIxZjZfNC0xLTEtMS0w_013dd7f2-9947-486d-9be1-9d4ea7c933ca">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41887b4841f2496cb04e4f1ed9bd84bf_D20210101-20210331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81NS9mcmFnOmJmMzFlNjM2ZGVmMTQxNGFhNDUwZmFiOTM5YWM3MDIwL3RhYmxlOjBmYTZiZWYxMWQ3NDQ1MWVhZDQ5ZGUyZWM1ZWIyMWY2L3RhYmxlcmFuZ2U6MGZhNmJlZjExZDc0NDUxZWFkNDlkZTJlYzVlYjIxZjZfNC0zLTEtMS0w_aafe4a54-c5bf-44bd-a665-cf3c3ee9f67f">58</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i700594dde5154e6abd7676e0bf8a2e3e_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81NS9mcmFnOmJmMzFlNjM2ZGVmMTQxNGFhNDUwZmFiOTM5YWM3MDIwL3RhYmxlOjBmYTZiZWYxMWQ3NDQ1MWVhZDQ5ZGUyZWM1ZWIyMWY2L3RhYmxlcmFuZ2U6MGZhNmJlZjExZDc0NDUxZWFkNDlkZTJlYzVlYjIxZjZfNC01LTEtMS0w_6d7d72cd-d7fa-401f-8a27-6da2d99d6e9e">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e5a33a85da249f89d6d9b5939bed9ea_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81NS9mcmFnOmJmMzFlNjM2ZGVmMTQxNGFhNDUwZmFiOTM5YWM3MDIwL3RhYmxlOjBmYTZiZWYxMWQ3NDQ1MWVhZDQ5ZGUyZWM1ZWIyMWY2L3RhYmxlcmFuZ2U6MGZhNmJlZjExZDc0NDUxZWFkNDlkZTJlYzVlYjIxZjZfNC03LTEtMS0w_6cbdc3ca-9eca-405a-b91c-f8a0ffb23f49">6,848</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81NS9mcmFnOmJmMzFlNjM2ZGVmMTQxNGFhNDUwZmFiOTM5YWM3MDIwL3RhYmxlOjBmYTZiZWYxMWQ3NDQ1MWVhZDQ5ZGUyZWM1ZWIyMWY2L3RhYmxlcmFuZ2U6MGZhNmJlZjExZDc0NDUxZWFkNDlkZTJlYzVlYjIxZjZfNC05LTEtMS0w_9ec8dd97-5103-4985-a3a5-274ffdc0962a">6,905</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of March 31, 2021</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6a94dbeff4054c1a9f6ebaadd2bdf963_I20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81NS9mcmFnOmJmMzFlNjM2ZGVmMTQxNGFhNDUwZmFiOTM5YWM3MDIwL3RhYmxlOjBmYTZiZWYxMWQ3NDQ1MWVhZDQ5ZGUyZWM1ZWIyMWY2L3RhYmxlcmFuZ2U6MGZhNmJlZjExZDc0NDUxZWFkNDlkZTJlYzVlYjIxZjZfNS0xLTEtMS0w_68029368-11cc-4943-83a7-c65c4b4c6db2">32,792</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i867716826176427d9f8a787730df0336_I20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81NS9mcmFnOmJmMzFlNjM2ZGVmMTQxNGFhNDUwZmFiOTM5YWM3MDIwL3RhYmxlOjBmYTZiZWYxMWQ3NDQ1MWVhZDQ5ZGUyZWM1ZWIyMWY2L3RhYmxlcmFuZ2U6MGZhNmJlZjExZDc0NDUxZWFkNDlkZTJlYzVlYjIxZjZfNS0zLTEtMS0w_7e9e9ee8-7618-45b4-9993-5e7a53e4c9c4">3,696</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1502b1c4289f4259906b093e10b187bc_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81NS9mcmFnOmJmMzFlNjM2ZGVmMTQxNGFhNDUwZmFiOTM5YWM3MDIwL3RhYmxlOjBmYTZiZWYxMWQ3NDQ1MWVhZDQ5ZGUyZWM1ZWIyMWY2L3RhYmxlcmFuZ2U6MGZhNmJlZjExZDc0NDUxZWFkNDlkZTJlYzVlYjIxZjZfNS01LTEtMS0w_ffa082d8-0dd4-4ea1-870a-4b050ae82870">347</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i67bb7cc00cd44487b367ee4e7e37c13a_I20210331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81NS9mcmFnOmJmMzFlNjM2ZGVmMTQxNGFhNDUwZmFiOTM5YWM3MDIwL3RhYmxlOjBmYTZiZWYxMWQ3NDQ1MWVhZDQ5ZGUyZWM1ZWIyMWY2L3RhYmxlcmFuZ2U6MGZhNmJlZjExZDc0NDUxZWFkNDlkZTJlYzVlYjIxZjZfNS03LTEtMS0w_5cd061f3-1d1c-46f4-87a1-1cb167c50529">576</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic1a5c9f95c104828afb8e8cfafe56963_I20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81NS9mcmFnOmJmMzFlNjM2ZGVmMTQxNGFhNDUwZmFiOTM5YWM3MDIwL3RhYmxlOjBmYTZiZWYxMWQ3NDQ1MWVhZDQ5ZGUyZWM1ZWIyMWY2L3RhYmxlcmFuZ2U6MGZhNmJlZjExZDc0NDUxZWFkNDlkZTJlYzVlYjIxZjZfNS05LTEtMS0w_796264bd-2bc8-44b8-8446-34130538ec4f">36,717</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.256%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.157%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Loss on Investment in Joint Venture</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Defined Benefit Pension<br/>Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains from Debt<br/>Securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Foreign Currency Translation<br/>Adjustment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Accumulated Other<br/>Comprehensive Loss</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2019</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i05cc6e61b17647308bdf6e55c772bfb8_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81NS9mcmFnOmJmMzFlNjM2ZGVmMTQxNGFhNDUwZmFiOTM5YWM3MDIwL3RhYmxlOmUxMmEzOTY2NWMwYzQzNTU4OWIxODkxNmZiZTk2ZTkyL3RhYmxlcmFuZ2U6ZTEyYTM5NjY1YzBjNDM1NTg5YjE4OTE2ZmJlOTZlOTJfMS0xLTEtMS0w_d8b8df21-92e7-46d9-a1bb-72a3db02c50d">32,792</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i44ce780df6884d729dccbf45747996b9_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81NS9mcmFnOmJmMzFlNjM2ZGVmMTQxNGFhNDUwZmFiOTM5YWM3MDIwL3RhYmxlOmUxMmEzOTY2NWMwYzQzNTU4OWIxODkxNmZiZTk2ZTkyL3RhYmxlcmFuZ2U6ZTEyYTM5NjY1YzBjNDM1NTg5YjE4OTE2ZmJlOTZlOTJfMS0zLTEtMS0w_0fb4b2dd-e0f0-4a3c-9eee-e2a794511b7a">3,520</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3242f9b2e5e34d0cbb1a6439a9c3f8bc_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81NS9mcmFnOmJmMzFlNjM2ZGVmMTQxNGFhNDUwZmFiOTM5YWM3MDIwL3RhYmxlOmUxMmEzOTY2NWMwYzQzNTU4OWIxODkxNmZiZTk2ZTkyL3RhYmxlcmFuZ2U6ZTEyYTM5NjY1YzBjNDM1NTg5YjE4OTE2ZmJlOTZlOTJfMS01LTEtMS0w_e57c6fb9-201e-4bc8-a772-91d7937a61c2">137</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iae0f5f6b01c54e3dab00225a8834ae5d_I20191231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81NS9mcmFnOmJmMzFlNjM2ZGVmMTQxNGFhNDUwZmFiOTM5YWM3MDIwL3RhYmxlOmUxMmEzOTY2NWMwYzQzNTU4OWIxODkxNmZiZTk2ZTkyL3RhYmxlcmFuZ2U6ZTEyYTM5NjY1YzBjNDM1NTg5YjE4OTE2ZmJlOTZlOTJfMS03LTEtMS0w_069a1a4a-df9c-46d7-b8a2-f2f693856b37">343</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if6294416a69f4b6daebcdebf72f5c179_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81NS9mcmFnOmJmMzFlNjM2ZGVmMTQxNGFhNDUwZmFiOTM5YWM3MDIwL3RhYmxlOmUxMmEzOTY2NWMwYzQzNTU4OWIxODkxNmZiZTk2ZTkyL3RhYmxlcmFuZ2U6ZTEyYTM5NjY1YzBjNDM1NTg5YjE4OTE2ZmJlOTZlOTJfMS05LTEtMS0w_78188b93-2c31-4140-9d46-2fa7d85b2cf9">36,518</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45667cf06d374f0f8d2c6a08350e2740_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81NS9mcmFnOmJmMzFlNjM2ZGVmMTQxNGFhNDUwZmFiOTM5YWM3MDIwL3RhYmxlOmUxMmEzOTY2NWMwYzQzNTU4OWIxODkxNmZiZTk2ZTkyL3RhYmxlcmFuZ2U6ZTEyYTM5NjY1YzBjNDM1NTg5YjE4OTE2ZmJlOTZlOTJfMi0xLTEtMS0w_f8a20f55-c5fd-4682-95a7-0f1f6afe80c4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iace4f6c1fa9543cd8b55cb7840648649_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81NS9mcmFnOmJmMzFlNjM2ZGVmMTQxNGFhNDUwZmFiOTM5YWM3MDIwL3RhYmxlOmUxMmEzOTY2NWMwYzQzNTU4OWIxODkxNmZiZTk2ZTkyL3RhYmxlcmFuZ2U6ZTEyYTM5NjY1YzBjNDM1NTg5YjE4OTE2ZmJlOTZlOTJfMi0zLTEtMS0w_f7ac69ba-82fc-4d18-98cf-6286b57781d8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8748a9e750264dbeb3452686c17d0b3f_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81NS9mcmFnOmJmMzFlNjM2ZGVmMTQxNGFhNDUwZmFiOTM5YWM3MDIwL3RhYmxlOmUxMmEzOTY2NWMwYzQzNTU4OWIxODkxNmZiZTk2ZTkyL3RhYmxlcmFuZ2U6ZTEyYTM5NjY1YzBjNDM1NTg5YjE4OTE2ZmJlOTZlOTJfMi01LTEtMS0w_8667ac4d-8821-43b3-a1ae-5122ecdb98f2">1,317</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a4a416c9f8b4fac9455e693cd9e2710_D20200101-20200331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81NS9mcmFnOmJmMzFlNjM2ZGVmMTQxNGFhNDUwZmFiOTM5YWM3MDIwL3RhYmxlOmUxMmEzOTY2NWMwYzQzNTU4OWIxODkxNmZiZTk2ZTkyL3RhYmxlcmFuZ2U6ZTEyYTM5NjY1YzBjNDM1NTg5YjE4OTE2ZmJlOTZlOTJfMi03LTEtMS0w_33bd18b4-b184-4079-af79-b3388b567fa2">340</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide9f6e15665746279d0000be700fcc6a_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81NS9mcmFnOmJmMzFlNjM2ZGVmMTQxNGFhNDUwZmFiOTM5YWM3MDIwL3RhYmxlOmUxMmEzOTY2NWMwYzQzNTU4OWIxODkxNmZiZTk2ZTkyL3RhYmxlcmFuZ2U6ZTEyYTM5NjY1YzBjNDM1NTg5YjE4OTE2ZmJlOTZlOTJfMi05LTEtMS0w_0653d85b-3815-44ad-957d-e8d30cea38f7">1,657</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from other comprehensive income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45667cf06d374f0f8d2c6a08350e2740_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81NS9mcmFnOmJmMzFlNjM2ZGVmMTQxNGFhNDUwZmFiOTM5YWM3MDIwL3RhYmxlOmUxMmEzOTY2NWMwYzQzNTU4OWIxODkxNmZiZTk2ZTkyL3RhYmxlcmFuZ2U6ZTEyYTM5NjY1YzBjNDM1NTg5YjE4OTE2ZmJlOTZlOTJfMy0xLTEtMS0w_13fba60a-edf0-48ff-9417-f483e90a1c27">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iace4f6c1fa9543cd8b55cb7840648649_D20200101-20200331" decimals="-3" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81NS9mcmFnOmJmMzFlNjM2ZGVmMTQxNGFhNDUwZmFiOTM5YWM3MDIwL3RhYmxlOmUxMmEzOTY2NWMwYzQzNTU4OWIxODkxNmZiZTk2ZTkyL3RhYmxlcmFuZ2U6ZTEyYTM5NjY1YzBjNDM1NTg5YjE4OTE2ZmJlOTZlOTJfMy0zLTEtMS0w_853911ed-a7e6-4f64-9c09-212765e0a3c1">74</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8748a9e750264dbeb3452686c17d0b3f_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81NS9mcmFnOmJmMzFlNjM2ZGVmMTQxNGFhNDUwZmFiOTM5YWM3MDIwL3RhYmxlOmUxMmEzOTY2NWMwYzQzNTU4OWIxODkxNmZiZTk2ZTkyL3RhYmxlcmFuZ2U6ZTEyYTM5NjY1YzBjNDM1NTg5YjE4OTE2ZmJlOTZlOTJfMy01LTEtMS0w_016e6ebd-95e6-41af-99b5-a7bc98ec3c41">2,728</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a4a416c9f8b4fac9455e693cd9e2710_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81NS9mcmFnOmJmMzFlNjM2ZGVmMTQxNGFhNDUwZmFiOTM5YWM3MDIwL3RhYmxlOmUxMmEzOTY2NWMwYzQzNTU4OWIxODkxNmZiZTk2ZTkyL3RhYmxlcmFuZ2U6ZTEyYTM5NjY1YzBjNDM1NTg5YjE4OTE2ZmJlOTZlOTJfMy03LTEtMS0w_75996db9-aff1-4da6-a464-3386feb64318">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide9f6e15665746279d0000be700fcc6a_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81NS9mcmFnOmJmMzFlNjM2ZGVmMTQxNGFhNDUwZmFiOTM5YWM3MDIwL3RhYmxlOmUxMmEzOTY2NWMwYzQzNTU4OWIxODkxNmZiZTk2ZTkyL3RhYmxlcmFuZ2U6ZTEyYTM5NjY1YzBjNDM1NTg5YjE4OTE2ZmJlOTZlOTJfMy05LTEtMS0w_f7ff9d67-fe9b-4f7e-ae25-b5b915c9fa83">2,802</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net other comprehensive income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45667cf06d374f0f8d2c6a08350e2740_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81NS9mcmFnOmJmMzFlNjM2ZGVmMTQxNGFhNDUwZmFiOTM5YWM3MDIwL3RhYmxlOmUxMmEzOTY2NWMwYzQzNTU4OWIxODkxNmZiZTk2ZTkyL3RhYmxlcmFuZ2U6ZTEyYTM5NjY1YzBjNDM1NTg5YjE4OTE2ZmJlOTZlOTJfNC0xLTEtMS0w_7be5a85d-fd03-4314-8902-ebbad0d59a3c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iace4f6c1fa9543cd8b55cb7840648649_D20200101-20200331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81NS9mcmFnOmJmMzFlNjM2ZGVmMTQxNGFhNDUwZmFiOTM5YWM3MDIwL3RhYmxlOmUxMmEzOTY2NWMwYzQzNTU4OWIxODkxNmZiZTk2ZTkyL3RhYmxlcmFuZ2U6ZTEyYTM5NjY1YzBjNDM1NTg5YjE4OTE2ZmJlOTZlOTJfNC0zLTEtMS0w_fa8b9cfc-ff7e-451a-8f4d-1040837f16a2">74</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8748a9e750264dbeb3452686c17d0b3f_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81NS9mcmFnOmJmMzFlNjM2ZGVmMTQxNGFhNDUwZmFiOTM5YWM3MDIwL3RhYmxlOmUxMmEzOTY2NWMwYzQzNTU4OWIxODkxNmZiZTk2ZTkyL3RhYmxlcmFuZ2U6ZTEyYTM5NjY1YzBjNDM1NTg5YjE4OTE2ZmJlOTZlOTJfNC01LTEtMS0w_478da387-8433-4471-a0c0-f0c319947642">4,045</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a4a416c9f8b4fac9455e693cd9e2710_D20200101-20200331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81NS9mcmFnOmJmMzFlNjM2ZGVmMTQxNGFhNDUwZmFiOTM5YWM3MDIwL3RhYmxlOmUxMmEzOTY2NWMwYzQzNTU4OWIxODkxNmZiZTk2ZTkyL3RhYmxlcmFuZ2U6ZTEyYTM5NjY1YzBjNDM1NTg5YjE4OTE2ZmJlOTZlOTJfNC03LTEtMS0w_a82c244a-eaf8-4eab-b9c7-3876713b0d65">340</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide9f6e15665746279d0000be700fcc6a_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81NS9mcmFnOmJmMzFlNjM2ZGVmMTQxNGFhNDUwZmFiOTM5YWM3MDIwL3RhYmxlOmUxMmEzOTY2NWMwYzQzNTU4OWIxODkxNmZiZTk2ZTkyL3RhYmxlcmFuZ2U6ZTEyYTM5NjY1YzBjNDM1NTg5YjE4OTE2ZmJlOTZlOTJfNC05LTEtMS0w_47964abc-a326-4ab1-85d1-056f7722a0aa">4,459</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of March 31, 2020</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8fda1a7ccba9498489e7ddfe1a07281b_I20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81NS9mcmFnOmJmMzFlNjM2ZGVmMTQxNGFhNDUwZmFiOTM5YWM3MDIwL3RhYmxlOmUxMmEzOTY2NWMwYzQzNTU4OWIxODkxNmZiZTk2ZTkyL3RhYmxlcmFuZ2U6ZTEyYTM5NjY1YzBjNDM1NTg5YjE4OTE2ZmJlOTZlOTJfNS0xLTEtMS0w_dcb5f4b1-be1c-444b-8f0a-742122d56366">32,792</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id869bd21f8364305aa97626bdb27c7db_I20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81NS9mcmFnOmJmMzFlNjM2ZGVmMTQxNGFhNDUwZmFiOTM5YWM3MDIwL3RhYmxlOmUxMmEzOTY2NWMwYzQzNTU4OWIxODkxNmZiZTk2ZTkyL3RhYmxlcmFuZ2U6ZTEyYTM5NjY1YzBjNDM1NTg5YjE4OTE2ZmJlOTZlOTJfNS0zLTEtMS0w_83c13c54-e22d-4f8a-86be-8effe01bfc51">3,446</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11580be1480f41978578dd943839ecb5_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81NS9mcmFnOmJmMzFlNjM2ZGVmMTQxNGFhNDUwZmFiOTM5YWM3MDIwL3RhYmxlOmUxMmEzOTY2NWMwYzQzNTU4OWIxODkxNmZiZTk2ZTkyL3RhYmxlcmFuZ2U6ZTEyYTM5NjY1YzBjNDM1NTg5YjE4OTE2ZmJlOTZlOTJfNS01LTEtMS0w_91d126f8-b3d0-4b55-bd4e-04c210dbb989">4,182</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i01494f6ccbfc49d191f7454445e0fc32_I20200331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81NS9mcmFnOmJmMzFlNjM2ZGVmMTQxNGFhNDUwZmFiOTM5YWM3MDIwL3RhYmxlOmUxMmEzOTY2NWMwYzQzNTU4OWIxODkxNmZiZTk2ZTkyL3RhYmxlcmFuZ2U6ZTEyYTM5NjY1YzBjNDM1NTg5YjE4OTE2ZmJlOTZlOTJfNS03LTEtMS0w_b5df8368-2b27-4049-85e0-194bdb6c7f88">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0cd32b4827314c02b0aeae69087c66b0_I20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81NS9mcmFnOmJmMzFlNjM2ZGVmMTQxNGFhNDUwZmFiOTM5YWM3MDIwL3RhYmxlOmUxMmEzOTY2NWMwYzQzNTU4OWIxODkxNmZiZTk2ZTkyL3RhYmxlcmFuZ2U6ZTEyYTM5NjY1YzBjNDM1NTg5YjE4OTE2ZmJlOTZlOTJfNS05LTEtMS0w_4393cbd6-5345-469b-b0d8-0bb4c3e5c51c">32,059</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts reclassified out of accumulated other comprehensive loss relate to settlements of marketable debt securities and amortization of our pension obligation which are recorded as interest income and other income, respectively, in the condensed consolidated statements of operations and comprehensive loss.</span></div></ix:continuation><div id="i9f86b6d3686546618ade3c76e6b23fc8_58"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9. <ix:nonNumeric contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81OC9mcmFnOjk4M2Q1YzdiZDBlYjQ2YWE4M2JjM2RlNDJmMGM0ZTUyL3RleHRyZWdpb246OTgzZDVjN2JkMGViNDZhYTgzYmMzZGU0MmYwYzRlNTJfNTQ3OA_a78c976c-2316-4b16-a479-287b5201cdd1" continuedAt="i9e551ce221124e0cb4ab89c54f6f44f7" escape="true">CREDIT AGREEMENT</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><ix:continuation id="i9e551ce221124e0cb4ab89c54f6f44f7" continuedAt="i8aa5a0746b25469f8bb48bec9b4ccdfd"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In April 2020, we entered into a credit agreement, or Credit Agreement, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">among us, certain of our subsidiaries (such subsidiaries, together with us, the Loan Parties), funds or accounts managed or advised by GSO Capital Partners LP (now Blackstone Alternative Credit Advisors LP) and certain other affiliates of T</span><span style="background-color:#ffffff;color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">he Blackstone Group Inc.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, and the other lenders from time to time parties thereto, collectively, the Lenders, and Wilmington Trust, National Association, as the administrative agent for the Lenders. The Credit Agreement provides for a senior secured delayed draw term loan facility, referred to as the Term Loans, which consists of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="tranche" contextRef="i7c3cf9f64e5c4dba8a27cbdc2664e3da_I20200410" decimals="INF" format="ixt-sec:numwordsen" name="alny:DebtInstrumentNumberOfTranches" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81OC9mcmFnOjk4M2Q1YzdiZDBlYjQ2YWE4M2JjM2RlNDJmMGM0ZTUyL3RleHRyZWdpb246OTgzZDVjN2JkMGViNDZhYTgzYmMzZGU0MmYwYzRlNTJfMTA5OTUxMTYzNDk5Ng_7f70bb35-693f-4c9a-94b2-6557c997e076">three</ix:nonFraction></span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> tranches providing funding up to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$<ix:nonFraction unitRef="usd" contextRef="i7c3cf9f64e5c4dba8a27cbdc2664e3da_I20200410" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81OC9mcmFnOjk4M2Q1YzdiZDBlYjQ2YWE4M2JjM2RlNDJmMGM0ZTUyL3RleHRyZWdpb246OTgzZDVjN2JkMGViNDZhYTgzYmMzZGU0MmYwYzRlNTJfMTA5OTUxMTYzNDk4Nw_55ea7a98-1811-4f68-b38c-1df2c28801e0">700.0</ix:nonFraction>&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. The Tranche 1 Loan of $<ix:nonFraction unitRef="usd" contextRef="ibc345957dc834afab5787e085c2b24f5_D20201231-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromLinesOfCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81OC9mcmFnOjk4M2Q1YzdiZDBlYjQ2YWE4M2JjM2RlNDJmMGM0ZTUyL3RleHRyZWdpb246OTgzZDVjN2JkMGViNDZhYTgzYmMzZGU0MmYwYzRlNTJfODI0NjMzNzIxNjQxMA_93b44941-b9f9-4863-985a-ece3a0b23d3d">200.0</ix:nonFraction>&#160;million </span></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9f86b6d3686546618ade3c76e6b23fc8_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ALNYLAM PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="i8aa5a0746b25469f8bb48bec9b4ccdfd"><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">was drawn as of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">December&#160;31, 2020</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> and is included in long-term debt in the condensed consolidated balance sheets. The remaining two tranches will provide funds as follows:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><ix:nonNumeric contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331" name="us-gaap:ScheduleOfDebtInstrumentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81OC9mcmFnOjk4M2Q1YzdiZDBlYjQ2YWE4M2JjM2RlNDJmMGM0ZTUyL3RleHRyZWdpb246OTgzZDVjN2JkMGViNDZhYTgzYmMzZGU0MmYwYzRlNTJfNTQ3Nw_67d743b1-f4d5-4f3e-ada4-1789f59362d1" escape="true"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:61.111%"><tr><td style="width:1.0%"></td><td style="width:31.435%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.996%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.435%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.996%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.438%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Tranche</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Requested No Later Than</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate Principal Amount, up to (in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tranche 2 Loan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifeeb0e1889fe4d049042d329b80919f6_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81OC9mcmFnOjk4M2Q1YzdiZDBlYjQ2YWE4M2JjM2RlNDJmMGM0ZTUyL3RhYmxlOmFhYjcyNTE4NmZiZDQ5ZDFiZTdmMjZmZjEyODNmOTUxL3RhYmxlcmFuZ2U6YWFiNzI1MTg2ZmJkNDlkMWJlN2YyNmZmMTI4M2Y5NTFfMi00LTEtMS0w_066b0ae5-9821-457f-a6f9-4be34577a702">250,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tranche 3 Loan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iead1e9b005df4a1f9a86fc4b31611ed7_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81OC9mcmFnOjk4M2Q1YzdiZDBlYjQ2YWE4M2JjM2RlNDJmMGM0ZTUyL3RhYmxlOmFhYjcyNTE4NmZiZDQ5ZDFiZTdmMjZmZjEyODNmOTUxL3RhYmxlcmFuZ2U6YWFiNzI1MTg2ZmJkNDlkMWJlN2YyNmZmMTI4M2Y5NTFfMy00LTEtMS0w_e0df19ba-f8a5-44b2-b1a0-3387e04f8822">250,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, we may request an increase in respect of the unfunded commitments in an amount not to exceed $<ix:nonFraction unitRef="usd" contextRef="i7c3cf9f64e5c4dba8a27cbdc2664e3da_I20200410" decimals="INF" format="ixt:numdotdecimal" name="alny:LineOfCreditFacilityMaximumBorrowingCapacityAccordionFeature" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81OC9mcmFnOjk4M2Q1YzdiZDBlYjQ2YWE4M2JjM2RlNDJmMGM0ZTUyL3RleHRyZWdpb246OTgzZDVjN2JkMGViNDZhYTgzYmMzZGU0MmYwYzRlNTJfODI1_df52a532-e3e5-43dc-9681-907b9828efac">50.0</ix:nonFraction>&#160;million on terms to be agreed and subject to the consent of the Lenders providing such increase. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Tranche 2 Loan will be requested no later than June 30, 2021 and the Tranche 3 Loan will be requested no later than December 31, 2021, in each case, subject to customary terms and conditions, including, in the case of the Tranche 2 Loan and Tranche 3 Loan, either (a) the first sale of inclisiran in the U.S. for end use or consumption after FDA regulatory approval thereof or (b) revenue attributable to ONPATTRO and GIVLAARI equal to or greater than $<ix:nonFraction unitRef="usd" contextRef="id5babbf83da24b918e081dc61eef1961_I20200410" decimals="-5" format="ixt:numdotdecimal" name="alny:DebtInstrumentCovenantTermsMinimumProductRevenue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81OC9mcmFnOjk4M2Q1YzdiZDBlYjQ2YWE4M2JjM2RlNDJmMGM0ZTUyL3RleHRyZWdpb246OTgzZDVjN2JkMGViNDZhYTgzYmMzZGU0MmYwYzRlNTJfMTc1Mw_19779b44-c5fe-4e3d-91fd-8c876a66a5d1">300.0</ix:nonFraction>&#160;million as of the last day of the most recently ended twelve month period, referred to as the Subsequent Borrowing Conditions. </span><span style="background-color:#ffffff;color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the event the Subsequent Borrowing Conditions are not satisfied as of the dates set forth in the table above, the Tranche 2 Loan and Tranche 3 Loan will be funded if such Subsequent Borrowing Conditions are satisfied on or prior to December 31, 2022. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Term Loans mature in December 2027. We can elect an interest rate of either LIBOR plus <ix:nonFraction unitRef="number" contextRef="i01120d900c46459e8dcddb8d56d9478b_D20200410-20200410" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81OC9mcmFnOjk4M2Q1YzdiZDBlYjQ2YWE4M2JjM2RlNDJmMGM0ZTUyL3RleHRyZWdpb246OTgzZDVjN2JkMGViNDZhYTgzYmMzZGU0MmYwYzRlNTJfNDk0NzgwMjMzMTc0NA_a9cdb0db-170a-47bd-a597-ff65bd3af524">7</ix:nonFraction>% subject to a floor of <ix:nonFraction unitRef="number" contextRef="i16e5cf96bf70403d9deb63cea2e51969_I20200410" decimals="INF" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81OC9mcmFnOjk4M2Q1YzdiZDBlYjQ2YWE4M2JjM2RlNDJmMGM0ZTUyL3RleHRyZWdpb246OTgzZDVjN2JkMGViNDZhYTgzYmMzZGU0MmYwYzRlNTJfNDk0NzgwMjMzMTc0Nw_c3898421-4e78-44af-a3cd-690b1de151e5">1</ix:nonFraction>%, referred to as the LIBOR Rate, or a base rate plus <ix:nonFraction unitRef="number" contextRef="i08cf9801b78c48129c565578666b38ea_D20200410-20200410" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81OC9mcmFnOjk4M2Q1YzdiZDBlYjQ2YWE4M2JjM2RlNDJmMGM0ZTUyL3RleHRyZWdpb246OTgzZDVjN2JkMGViNDZhYTgzYmMzZGU0MmYwYzRlNTJfMjM0Mg_e3ebb39d-335c-400f-ad31-7a0e1fdb99bc">6</ix:nonFraction>%, subject to a floor of <ix:nonFraction unitRef="number" contextRef="i753fbbe92da442cfb258516ac25f2d2b_I20200410" decimals="INF" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81OC9mcmFnOjk4M2Q1YzdiZDBlYjQ2YWE4M2JjM2RlNDJmMGM0ZTUyL3RleHRyZWdpb246OTgzZDVjN2JkMGViNDZhYTgzYmMzZGU0MmYwYzRlNTJfMjM2OA_3753f450-1b1f-4ad5-9280-79e864a4e7aa">2</ix:nonFraction>%. We may, at our option, pay interest in kind on interest due through 2023 at </span><span style="background-color:#ffffff;color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">a rate that is <ix:nonFraction unitRef="number" contextRef="icbb72ec509854a04bfdedc3536c9cc08_D20200410-20200410" decimals="INF" name="alny:DebtInstrumentInterestInKindInterestRateIncrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81OC9mcmFnOjk4M2Q1YzdiZDBlYjQ2YWE4M2JjM2RlNDJmMGM0ZTUyL3RleHRyZWdpb246OTgzZDVjN2JkMGViNDZhYTgzYmMzZGU0MmYwYzRlNTJfMjUxNA_ec8e1791-1550-4e93-8933-a3f10acae2f4">1</ix:nonFraction>% higher than the interest rate otherwise applicable to such Term Loan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. In December 2020, we drew the Tranche 1 Loan, elected a LIBOR Rate plus <ix:nonFraction unitRef="number" contextRef="i5f0630732fe54bfca1f008c864bcaa8c_D20201201-20201231" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81OC9mcmFnOjk4M2Q1YzdiZDBlYjQ2YWE4M2JjM2RlNDJmMGM0ZTUyL3RleHRyZWdpb246OTgzZDVjN2JkMGViNDZhYTgzYmMzZGU0MmYwYzRlNTJfODI0NjMzNzIxNjQ0Mw_fccfc963-1bbe-420f-b310-3822cef09a02">7</ix:nonFraction>%, and paid a $<ix:nonFraction unitRef="usd" contextRef="i93e4ff2210fb41fdaf2e202c8b0d204a_D20201201-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityCommitmentFeeAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81OC9mcmFnOjk4M2Q1YzdiZDBlYjQ2YWE4M2JjM2RlNDJmMGM0ZTUyL3RleHRyZWdpb246OTgzZDVjN2JkMGViNDZhYTgzYmMzZGU0MmYwYzRlNTJfODI0NjMzNzIxNjQyNg_fb27a09f-b57a-4156-91f7-eaf0e7559f7a">5.0</ix:nonFraction>&#160;million funding fee. On the date the Tranche 2 Loan or Tranche 3 Loan is funded, we will pay a funding fee equal to <ix:nonFraction unitRef="number" contextRef="icbb72ec509854a04bfdedc3536c9cc08_D20200410-20200410" decimals="INF" name="us-gaap:LineOfCreditFacilityCommitmentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81OC9mcmFnOjk4M2Q1YzdiZDBlYjQ2YWE4M2JjM2RlNDJmMGM0ZTUyL3RleHRyZWdpb246OTgzZDVjN2JkMGViNDZhYTgzYmMzZGU0MmYwYzRlNTJfMjY5OA_4e299346-fa5c-4473-8400-c19c75ec9cdf">2.5</ix:nonFraction>% of the principal amount of the Term Loans funded on such date. In addition, we will pay an exit fee equal to <ix:nonFraction unitRef="number" contextRef="icbb72ec509854a04bfdedc3536c9cc08_D20200410-20200410" decimals="INF" name="alny:DebtInstrumentExitFeePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81OC9mcmFnOjk4M2Q1YzdiZDBlYjQ2YWE4M2JjM2RlNDJmMGM0ZTUyL3RleHRyZWdpb246OTgzZDVjN2JkMGViNDZhYTgzYmMzZGU0MmYwYzRlNTJfMjgxMA_fec3a5a2-8b57-48fc-a405-1ca3f4eca878">1</ix:nonFraction>% of the commitments in respect of the Term Loans, payable upon any repayment of the Term Loans or termination of the unfunded Term Loan commitments. Our interest rate was <ix:nonFraction unitRef="number" contextRef="ib9d80c24381a4a579abefd71b39a3841_I20210331" decimals="2" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81OC9mcmFnOjk4M2Q1YzdiZDBlYjQ2YWE4M2JjM2RlNDJmMGM0ZTUyL3RleHRyZWdpb246OTgzZDVjN2JkMGViNDZhYTgzYmMzZGU0MmYwYzRlNTJfMTA5OTUxMTYzNTc5Ng_4f363871-d383-4c45-a49e-204348c30b8a"><ix:nonFraction unitRef="number" contextRef="i00dcec45b31345649463ce0a808354bb_I20201231" decimals="2" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81OC9mcmFnOjk4M2Q1YzdiZDBlYjQ2YWE4M2JjM2RlNDJmMGM0ZTUyL3RleHRyZWdpb246OTgzZDVjN2JkMGViNDZhYTgzYmMzZGU0MmYwYzRlNTJfMTA5OTUxMTYzNTc5Ng_e0e6c73e-1ebb-43ad-b0b6-3475b579f581">8</ix:nonFraction></ix:nonFraction>% as of March 31, 2021 and December 31, 2020.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are obligated to pay interest due on the Term Loans from 2021 through 2022 which will be calculated without regard to the Term Loans being prepaid or an unfunded tranche being terminated during this period (in whole or in part). Any prepayments of Term Loans or terminations of unfunded tranches that occur between 2023 and 2025 are subject to a fee of up to <ix:nonFraction unitRef="number" contextRef="icbb72ec509854a04bfdedc3536c9cc08_D20200410-20200410" decimals="INF" name="alny:LineOfCreditFacilityPrepaymentAndTerminationFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81OC9mcmFnOjk4M2Q1YzdiZDBlYjQ2YWE4M2JjM2RlNDJmMGM0ZTUyL3RleHRyZWdpb246OTgzZDVjN2JkMGViNDZhYTgzYmMzZGU0MmYwYzRlNTJfMzM4OA_c5cd9559-33d4-4270-9d9f-89269dadf2e6">5</ix:nonFraction>% of the loan principal that is prepaid or the amount of the unfunded tranche that is terminated.  </span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">All obligations under the Credit Agreement are secured, subject to certain exceptions, by security interests in the following assets: (i) intellectual property owned by us relating to ONPATTRO, GIVLAARI and vutrisiran, (ii) the equity interests held by the Loan Parties in their subsidiaries, (iii) all of our ownership of the inclisiran royalty remaining after the royalty purchase under the Purchase Agreement, and (iv) material real property, and certain personal property, including, without limitation, cash held in certain deposit accounts of the Loan Parties and equipment. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Credit Agreement contains negative covenants that, among other things and subject to certain exceptions, could restrict our ability to, incur additional liens, incur additional indebtedness, make investments, including acquisitions, engage in fundamental changes, sell or dispose of assets that constitute collateral, including certain intellectual property, pay dividends or make any distribution or payment on or redeem, retire or purchase any equity interests, amend, modify or waive certain material agreements or organizational documents and make payments of certain subordinated indebtedness. </span><span style="background-color:#ffffff;color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Additionally, the Credit Agreement contains certain customary representations and warranties, affirmative covenants and provisions relating to events of default, including nonpayment of principal, interest and other amounts; failure to comply with covenants; the rendering of judgments or orders or default by us in respect of other material indebtedness; and certain insolvency and ERISA events.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> The Credit Agreement also requires us to have consolidated liquidity of at least $<ix:nonFraction unitRef="usd" contextRef="icbb72ec509854a04bfdedc3536c9cc08_D20200410-20200410" decimals="-5" format="ixt:numdotdecimal" name="alny:DebtInstrumentCovenantTermsMinimumConsolidatedLiquidity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81OC9mcmFnOjk4M2Q1YzdiZDBlYjQ2YWE4M2JjM2RlNDJmMGM0ZTUyL3RleHRyZWdpb246OTgzZDVjN2JkMGViNDZhYTgzYmMzZGU0MmYwYzRlNTJfNTE0OA_25a5f7ed-8047-4081-a893-97d58e9e2d04">100.0</ix:nonFraction>&#160;million as of the last day of each fiscal quarter. As of March&#160;31, 2021, we were in compliance with the applicable terms and conditions of the covenants under the Credit Agreement.</span></div></ix:continuation><div id="i9f86b6d3686546618ade3c76e6b23fc8_61"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10. <ix:nonNumeric contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331" name="us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF82MS9mcmFnOjI4OGMwZmM3OWViYTRlNTc5NzY5NmVlYzhlYmQ3OTk3L3RleHRyZWdpb246Mjg4YzBmYzc5ZWJhNGU1Nzk3Njk2ZWVjOGViZDc5OTdfNTc3Mg_c4990ff9-73b8-460d-bcc6-6f60b6c475e0" continuedAt="i01241b810f7c4e4b869e51abf6597130" escape="true">DEVELOPMENT DERIVATIVE LIABILITY</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="i01241b810f7c4e4b869e51abf6597130" continuedAt="ibacfed1e243d4c5ca358a5986d0d1ce9">In August 2020, we entered into a co-development agreement, referred to as the Funding Agreement, with BXLS V Bodyguard &#8211; PCP L.P. and BXLS Family Investment Partnership V &#8211; ESC L.P., collectively referred to as Blackstone Life Sciences, pursuant to which Blackstone Life Sciences will provide up to $<ix:nonFraction unitRef="usd" contextRef="if56939063a9e4f659db2a74fe02c611f_D20200801-20200831" decimals="INF" format="ixt:numdotdecimal" name="alny:CollaborativeArrangementMaximumFunding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF82MS9mcmFnOjI4OGMwZmM3OWViYTRlNTc5NzY5NmVlYzhlYmQ3OTk3L3RleHRyZWdpb246Mjg4YzBmYzc5ZWJhNGU1Nzk3Njk2ZWVjOGViZDc5OTdfMzQy_1f6935fb-5f8f-4056-a355-66875a637f72">150.0</ix:nonFraction>&#160;million in funding for the clinical development of vutrisiran and ALN-AGT, two of our cardiometabolic programs. With respect to vutrisiran, Blackstone Life Sciences has committed to provide up to $<ix:nonFraction unitRef="usd" contextRef="i30025a2dd91d4350946281176f871659_D20200801-20200831" decimals="INF" format="ixt:numdotdecimal" name="alny:CollaborativeArrangementMaximumFunding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF82MS9mcmFnOjI4OGMwZmM3OWViYTRlNTc5NzY5NmVlYzhlYmQ3OTk3L3RleHRyZWdpb246Mjg4YzBmYzc5ZWJhNGU1Nzk3Njk2ZWVjOGViZDc5OTdfNTMz_030fad78-117b-42e3-b78b-30448666a610">70.0</ix:nonFraction>&#160;million to fund development costs related to the HELIOS-B Phase 3 clinical trial. In addition, Blackstone Life Sciences has the right, but is not obligated, to fund up to $<ix:nonFraction unitRef="usd" contextRef="i4349daaa321340fbb35c0fb62328e9d0_D20200801-20200831" decimals="INF" format="ixt:numdotdecimal" name="alny:CollaborativeArrangementMaximumFunding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF82MS9mcmFnOjI4OGMwZmM3OWViYTRlNTc5NzY5NmVlYzhlYmQ3OTk3L3RleHRyZWdpb246Mjg4YzBmYzc5ZWJhNGU1Nzk3Njk2ZWVjOGViZDc5OTdfNjk5_fabb4451-62fb-4556-b3d8-f35da1019317">26.0</ix:nonFraction>&#160;million for development costs related to a Phase 2 clinical trial of ALN-AGT and up to $<ix:nonFraction unitRef="usd" contextRef="i9f3237ef00524733ac2cd4cdc77591ed_D20200801-20200831" decimals="INF" format="ixt:numdotdecimal" name="alny:CollaborativeArrangementMaximumFunding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF82MS9mcmFnOjI4OGMwZmM3OWViYTRlNTc5NzY5NmVlYzhlYmQ3OTk3L3RleHRyZWdpb246Mjg4YzBmYzc5ZWJhNGU1Nzk3Njk2ZWVjOGViZDc5OTdfNzgx_31c562d8-2e9e-41e3-a62d-78a736abdae5">54.0</ix:nonFraction>&#160;million for development costs related to a Phase 3 clinical trial of ALN-AGT. The amount of funding ultimately provided by Blackstone Life Sciences is dependent on us achieving specified development </ix:continuation></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9f86b6d3686546618ade3c76e6b23fc8_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ALNYLAM PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="ibacfed1e243d4c5ca358a5986d0d1ce9"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">milestones with respect to each clinical trial. We retain sole responsibility for the development and commercialization of both vutrisiran and ALN-AGT.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As consideration for Blackstone Life Sciences&#8217; funding for vutrisiran clinical development costs, we have agreed to pay Blackstone Life Sciences a <ix:nonFraction unitRef="number" contextRef="i2e274ae018274dad8cbd61b7b4043868_D20200801-20200831" decimals="2" name="alny:CollaborativeArrangementRoyaltiesPayablePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF82MS9mcmFnOjI4OGMwZmM3OWViYTRlNTc5NzY5NmVlYzhlYmQ3OTk3L3RleHRyZWdpb246Mjg4YzBmYzc5ZWJhNGU1Nzk3Njk2ZWVjOGViZDc5OTdfMTI3NQ_f18aedae-9d3f-466a-9a26-a4cba678ec9d">1</ix:nonFraction>% royalty on net sales of vutrisiran for a <ix:nonNumeric contextRef="i2e274ae018274dad8cbd61b7b4043868_D20200801-20200831" format="ixt-sec:duryear" name="alny:CollaborativeArrangementRoyaltiesPayableTerm" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF82MS9mcmFnOjI4OGMwZmM3OWViYTRlNTc5NzY5NmVlYzhlYmQ3OTk3L3RleHRyZWdpb246Mjg4YzBmYzc5ZWJhNGU1Nzk3Njk2ZWVjOGViZDc5OTdfMTMxOQ_96e32437-f74e-4214-a5e8-57d65e3f8659">10</ix:nonNumeric>-year term beginning upon the first commercial sale following regulatory approval of vutrisiran for ATTR-cardiomyopathy, as well as fixed payments of up to <ix:nonFraction unitRef="number" contextRef="i2e274ae018274dad8cbd61b7b4043868_D20200801-20200831" decimals="1" name="alny:CollaborativeArrangementFixedPaymentMultiplier" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF82MS9mcmFnOjI4OGMwZmM3OWViYTRlNTc5NzY5NmVlYzhlYmQ3OTk3L3RleHRyZWdpb246Mjg4YzBmYzc5ZWJhNGU1Nzk3Njk2ZWVjOGViZDc5OTdfMTQ3Nw_0d5e9e3f-6680-4e12-90a1-cb40f91205b5">2.5</ix:nonFraction> times their investment over a <ix:nonNumeric contextRef="i2e274ae018274dad8cbd61b7b4043868_D20200801-20200831" format="ixt-sec:durwordsen" name="alny:CollaborativeArrangementFixedPaymentTerm" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF82MS9mcmFnOjI4OGMwZmM3OWViYTRlNTc5NzY5NmVlYzhlYmQ3OTk3L3RleHRyZWdpb246Mjg4YzBmYzc5ZWJhNGU1Nzk3Njk2ZWVjOGViZDc5OTdfNTc3Mw_a6859f2d-7310-4da6-a727-226b5cbaa8fa">two-year</ix:nonNumeric> period upon regulatory approval of vutrisiran for ATTR-cardiomyopathy in specified countries, unless it is later withdrawn from the market following a mandatory recall. As consideration for Blackstone Life Sciences&#8217; funding for Phase 2 clinical development costs of ALN-AGT, we have agreed to pay Blackstone Life Sciences fixed payments of up to <ix:nonFraction unitRef="number" contextRef="i4349daaa321340fbb35c0fb62328e9d0_D20200801-20200831" decimals="2" name="alny:CollaborativeArrangementFixedPaymentMultiplier" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF82MS9mcmFnOjI4OGMwZmM3OWViYTRlNTc5NzY5NmVlYzhlYmQ3OTk3L3RleHRyZWdpb246Mjg4YzBmYzc5ZWJhNGU1Nzk3Njk2ZWVjOGViZDc5OTdfMTg2NQ_f8130a22-aeec-4b49-9e61-e3e976128b8a">3.25</ix:nonFraction> times their Phase 2 investment over a <ix:nonNumeric contextRef="i4349daaa321340fbb35c0fb62328e9d0_D20200801-20200831" format="ixt-sec:durwordsen" name="alny:CollaborativeArrangementFixedPaymentTerm" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF82MS9mcmFnOjI4OGMwZmM3OWViYTRlNTc5NzY5NmVlYzhlYmQ3OTk3L3RleHRyZWdpb246Mjg4YzBmYzc5ZWJhNGU1Nzk3Njk2ZWVjOGViZDc5OTdfNTc3NA_e2e03d21-a7ad-4ae3-aac7-f6995216e806">four-year</ix:nonNumeric> period upon the successful completion of the ALN-AGT Phase 2 clinical trial, unless certain regulatory events affecting the continued development of ALN-AGT occur. As consideration for Blackstone Life Sciences&#8217; funding for Phase 3 clinical development costs of ALN-AGT, we have agreed to pay Blackstone Life Sciences fixed payments of up to <ix:nonFraction unitRef="number" contextRef="i9f3237ef00524733ac2cd4cdc77591ed_D20200801-20200831" decimals="1" name="alny:CollaborativeArrangementFixedPaymentMultiplier" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF82MS9mcmFnOjI4OGMwZmM3OWViYTRlNTc5NzY5NmVlYzhlYmQ3OTk3L3RleHRyZWdpb246Mjg4YzBmYzc5ZWJhNGU1Nzk3Njk2ZWVjOGViZDc5OTdfMjI1Ng_faac4bca-2bc7-4f3d-8f41-e3f26eaf8d74">4.5</ix:nonFraction> times their Phase 3 investment over a <ix:nonNumeric contextRef="i9f3237ef00524733ac2cd4cdc77591ed_D20200801-20200831" format="ixt-sec:durwordsen" name="alny:CollaborativeArrangementFixedPaymentTerm" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF82MS9mcmFnOjI4OGMwZmM3OWViYTRlNTc5NzY5NmVlYzhlYmQ3OTk3L3RleHRyZWdpb246Mjg4YzBmYzc5ZWJhNGU1Nzk3Njk2ZWVjOGViZDc5OTdfNTc3NQ_906f5cf1-ddbf-45b8-a2ce-1e06c1a3de8a">four-year</ix:nonNumeric> period upon regulatory approval of ALN-AGT in specified countries, unless it is later withdrawn from the market following a mandatory recall.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our payment obligations under the Funding Agreement will be secured, subject to certain exceptions, by security interests in intellectual property owned by us relating to vutrisiran and ALN-AGT, as well as in our bank account in which the funding deposits will be made.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We and Blackstone Life Sciences each have the right to terminate the Funding Agreement in its entirety in the event of the other party&#8217;s bankruptcy or similar proceedings. We and Blackstone Life Sciences may each terminate the Funding Agreement in its entirety or with respect to either product in the event of an uncured material breach by the other party, or with respect to a product for certain patient health and safety reasons, or if regulatory approval in specified major market countries is not obtained for the product following the completion of clinical trials for the product. In addition, Blackstone Life Sciences has the right to terminate the Funding Agreement in its entirety upon the occurrence of certain events affecting our ability to make payments under the agreement or to develop or commercialize the products, or upon a change of control of us. Blackstone Life Sciences may also terminate the Funding Agreement with respect to a product if the joint steering committee elects to terminate the development program for that product in its entirety, if certain clinical endpoints are not achieved for that product or, with respect to vutrisiran only, if our right to develop or commercialize vutrisiran is enjoined in a specified major market as a result of an alleged patent infringement. In certain termination circumstances, we will be obligated to pay Blackstone Life Sciences an amount that is equal to, or a multiplier of, the development funding received from Blackstone Life Sciences, and we may remain obligated under certain circumstances to make the payments to Blackstone Life Sciences described above, or the royalty described above in the case of vutrisiran, should we obtain regulatory approval for vutrisiran or ALN-AGT following termination.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We account for the Funding Agreement under ASC 815 as a derivative liability, measured at fair value, within other liabilities on our condensed consolidated balance sheets. The change in fair value due to the remeasurement of the development derivative liability is recorded as other expense on our condensed consolidated statements of operations and comprehensive loss.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of March&#160;31, 2021, the derivative liability is classified as a Level 3 financial liability in the fair value hierarchy. The valuation method incorporates certain unobservable Level 3 key inputs including (i) the probability and timing of achieving stated development milestones to receive payments from Blackstone Life Sciences, (ii) the probability and timing of achieving regulatory approval and payments to Blackstone Life Sciences, (iii) an estimate of the amount and timing of the royalty payable on net sales of vutrisiran, assuming regulatory approval, (iv) our cost of borrowing (<ix:nonFraction unitRef="number" contextRef="idd7204dc87d24972a01f15b098c4f56b_I20210331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF82MS9mcmFnOjI4OGMwZmM3OWViYTRlNTc5NzY5NmVlYzhlYmQ3OTk3L3RleHRyZWdpb246Mjg4YzBmYzc5ZWJhNGU1Nzk3Njk2ZWVjOGViZDc5OTdfNTU5Ng_ec1ab204-ffa1-46ef-88f0-4da3a0b3c96c">15</ix:nonFraction>%), and (v) Blackstone Life Sciences' cost of borrowing (<ix:nonFraction unitRef="number" contextRef="i5d397d1b29de44e99ebf93138e25c1bc_I20210331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF82MS9mcmFnOjI4OGMwZmM3OWViYTRlNTc5NzY5NmVlYzhlYmQ3OTk3L3RleHRyZWdpb246Mjg4YzBmYzc5ZWJhNGU1Nzk3Njk2ZWVjOGViZDc5OTdfNTY1NQ_c6f9d38b-ec61-488d-ba77-ee965e4e2946">4</ix:nonFraction>%).</span></div><ix:nonNumeric contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331" name="us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF82MS9mcmFnOjI4OGMwZmM3OWViYTRlNTc5NzY5NmVlYzhlYmQ3OTk3L3RleHRyZWdpb246Mjg4YzBmYzc5ZWJhNGU1Nzk3Njk2ZWVjOGViZDc5OTdfNTc3Ng_d8211fa8-5017-444a-9e86-baf9643ded50" escape="true"><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table presents the activity with respect to the development derivative liability, in thousands:</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:86.549%"><tr><td style="width:1.0%"></td><td style="width:81.163%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.644%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.793%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Development derivative liability as of December&#160;31, 2020</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i021eb4ce0e054ceabf5ba8f817404e90_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF82MS9mcmFnOjI4OGMwZmM3OWViYTRlNTc5NzY5NmVlYzhlYmQ3OTk3L3RhYmxlOjQ5ODQ4MmRmNTFlZTQzOTc5MTc3ODgxMWZjYjFhMmE1L3RhYmxlcmFuZ2U6NDk4NDgyZGY1MWVlNDM5NzkxNzc4ODExZmNiMWEyYTVfMy0yLTEtMS0w_96d8b175-1fbf-4777-ba3b-0857b16fab8e">25,585</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amount received under the Funding Agreement</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i097088dd315b40bbb18334f3ebd18b0e_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF82MS9mcmFnOjI4OGMwZmM3OWViYTRlNTc5NzY5NmVlYzhlYmQ3OTk3L3RhYmxlOjQ5ODQ4MmRmNTFlZTQzOTc5MTc3ODgxMWZjYjFhMmE1L3RhYmxlcmFuZ2U6NDk4NDgyZGY1MWVlNDM5NzkxNzc4ODExZmNiMWEyYTVfNC0yLTEtMS00MDI_1052ba37-3375-477d-a4ec-5daa855aa69e">4,200</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss recorded from remeasurement of development derivative liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i097088dd315b40bbb18334f3ebd18b0e_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF82MS9mcmFnOjI4OGMwZmM3OWViYTRlNTc5NzY5NmVlYzhlYmQ3OTk3L3RhYmxlOjQ5ODQ4MmRmNTFlZTQzOTc5MTc3ODgxMWZjYjFhMmE1L3RhYmxlcmFuZ2U6NDk4NDgyZGY1MWVlNDM5NzkxNzc4ODExZmNiMWEyYTVfNC0yLTEtMS0zNDI_975ecb33-7c09-48bd-9ced-56b5ba0a8ecd">18,253</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Development derivative liability as of March&#160;31, 2021</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i892bbea5207d47319b4fa4f08ab306e0_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF82MS9mcmFnOjI4OGMwZmM3OWViYTRlNTc5NzY5NmVlYzhlYmQ3OTk3L3RhYmxlOjQ5ODQ4MmRmNTFlZTQzOTc5MTc3ODgxMWZjYjFhMmE1L3RhYmxlcmFuZ2U6NDk4NDgyZGY1MWVlNDM5NzkxNzc4ODExZmNiMWEyYTVfNS0yLTEtMS0zNDI_cbd74fc6-a938-4642-8370-cbbe39333aec">48,038</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-indent:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><div id="i9f86b6d3686546618ade3c76e6b23fc8_67"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9f86b6d3686546618ade3c76e6b23fc8_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ALNYLAM PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11. <ix:nonNumeric contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF82Ny9mcmFnOjY2OTNmOTgzOGJhNDQxODZhZWViMjE4NjljNTgzODk0L3RleHRyZWdpb246NjY5M2Y5ODM4YmE0NDE4NmFlZWIyMTg2OWM1ODM4OTRfMTQz_89fad183-235a-4635-b30c-b7c56869d899" continuedAt="i4607537d26ad4a85ad3d2444856e92df" escape="true">STOCK-BASED COMPENSATION</ix:nonNumeric></span></div><ix:continuation id="i4607537d26ad4a85ad3d2444856e92df"><ix:nonNumeric contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331" name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF82Ny9mcmFnOjY2OTNmOTgzOGJhNDQxODZhZWViMjE4NjljNTgzODk0L3RleHRyZWdpb246NjY5M2Y5ODM4YmE0NDE4NmFlZWIyMTg2OWM1ODM4OTRfMTQ0_ed7ea93f-520b-4ca9-9f48-4bd69b9c01d2" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table summarizes stock-based compensation expenses included in operating costs and expenses:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:71.929%"><tr><td style="width:1.0%"></td><td style="width:60.891%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.395%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.816%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.398%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib854d6b980064faa8bfd9bdf17daffcb_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF82Ny9mcmFnOjY2OTNmOTgzOGJhNDQxODZhZWViMjE4NjljNTgzODk0L3RhYmxlOmNmYjk4Yzk0MTdjNjQ4YmQ4YTk5NzJiN2U0M2VlMTFjL3RhYmxlcmFuZ2U6Y2ZiOThjOTQxN2M2NDhiZDhhOTk3MmI3ZTQzZWUxMWNfMi0xLTEtMS0w_b05644e7-2a64-4b09-bb63-50382566bcc2">24,375</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2660c94c8bfb4720bf4ba79623dc2385_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF82Ny9mcmFnOjY2OTNmOTgzOGJhNDQxODZhZWViMjE4NjljNTgzODk0L3RhYmxlOmNmYjk4Yzk0MTdjNjQ4YmQ4YTk5NzJiN2U0M2VlMTFjL3RhYmxlcmFuZ2U6Y2ZiOThjOTQxN2M2NDhiZDhhOTk3MmI3ZTQzZWUxMWNfMi0zLTEtMS0w_e7a42730-8de0-4590-9fd2-573c723474a4">16,049</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29e2b4a3041244bc8330c8eb0e1998c2_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF82Ny9mcmFnOjY2OTNmOTgzOGJhNDQxODZhZWViMjE4NjljNTgzODk0L3RhYmxlOmNmYjk4Yzk0MTdjNjQ4YmQ4YTk5NzJiN2U0M2VlMTFjL3RhYmxlcmFuZ2U6Y2ZiOThjOTQxN2M2NDhiZDhhOTk3MmI3ZTQzZWUxMWNfMy0xLTEtMS0w_b00d8985-6e3e-48a9-8421-42c51b1a5770">31,315</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6dc64ac1298247ef958115623a6ea350_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF82Ny9mcmFnOjY2OTNmOTgzOGJhNDQxODZhZWViMjE4NjljNTgzODk0L3RhYmxlOmNmYjk4Yzk0MTdjNjQ4YmQ4YTk5NzJiN2U0M2VlMTFjL3RhYmxlcmFuZ2U6Y2ZiOThjOTQxN2M2NDhiZDhhOTk3MmI3ZTQzZWUxMWNfMy0zLTEtMS0w_adc82e7a-f093-4a99-a356-09e30c33ae24">18,529</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF82Ny9mcmFnOjY2OTNmOTgzOGJhNDQxODZhZWViMjE4NjljNTgzODk0L3RhYmxlOmNmYjk4Yzk0MTdjNjQ4YmQ4YTk5NzJiN2U0M2VlMTFjL3RhYmxlcmFuZ2U6Y2ZiOThjOTQxN2M2NDhiZDhhOTk3MmI3ZTQzZWUxMWNfNC0xLTEtMS0w_45cdcee9-29b7-479c-86bd-49446033726b">55,690</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide9f6e15665746279d0000be700fcc6a_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF82Ny9mcmFnOjY2OTNmOTgzOGJhNDQxODZhZWViMjE4NjljNTgzODk0L3RhYmxlOmNmYjk4Yzk0MTdjNjQ4YmQ4YTk5NzJiN2U0M2VlMTFjL3RhYmxlcmFuZ2U6Y2ZiOThjOTQxN2M2NDhiZDhhOTk3MmI3ZTQzZWUxMWNfNC0zLTEtMS0w_7bd0185d-2ce9-4e93-8ba8-11adfb90edd8">34,578</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="i9f86b6d3686546618ade3c76e6b23fc8_70"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12. <ix:nonNumeric contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF83MC9mcmFnOjdiN2UzMzI4MDBmNzQ3Zjc4Y2I5NWZlZWY1MTYzOGM0L3RleHRyZWdpb246N2I3ZTMzMjgwMGY3NDdmNzhjYjk1ZmVlZjUxNjM4YzRfOTE2_fd9a4302-a1b8-4893-9a79-fc1fef95957d" continuedAt="ibdfea5e840d0463eb3347f8a003e94c7" escape="true">NET LOSS PER COMMON SHARE</ix:nonNumeric></span></div><ix:continuation id="ibdfea5e840d0463eb3347f8a003e94c7"><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We compute basic net loss per common share by dividing net loss by the weighted-average number of common shares outstanding during the period. We compute diluted net loss per common share by dividing net loss by the weighted-average number of common shares and dilutive potential common share equivalents outstanding during the period. Potential common shares consist of shares issuable upon the exercise of stock options (the proceeds of which are then assumed to have been used to repurchase outstanding shares using the treasury stock method). Because the inclusion of potential common shares would be anti-dilutive for all periods presented, diluted net loss per common share is the same as basic net loss per common share.</span></div><ix:nonNumeric contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF83MC9mcmFnOjdiN2UzMzI4MDBmNzQ3Zjc4Y2I5NWZlZWY1MTYzOGM0L3RleHRyZWdpb246N2I3ZTMzMjgwMGY3NDdmNzhjYjk1ZmVlZjUxNjM4YzRfOTE3_5d5b20d6-f46b-4756-b6d9-844f38d452f5" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following common share equivalents were excluded from the calculation of net loss per common share because their inclusion would be anti-dilutive:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.128%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.422%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i625afeb909e24226bf8911556e57dd36_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF83MC9mcmFnOjdiN2UzMzI4MDBmNzQ3Zjc4Y2I5NWZlZWY1MTYzOGM0L3RhYmxlOmIzMjZiNzAwMWUxNTQxYzliOWQ3NmJhYTVjNjZiNGMyL3RhYmxlcmFuZ2U6YjMyNmI3MDAxZTE1NDFjOWI5ZDc2YmFhNWM2NmI0YzJfMi0xLTEtMS0w_b1017301-1ef3-46a1-8915-f41072e1c60a">13,859</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i113a05651fb044f49ef9180c67dcd7e3_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF83MC9mcmFnOjdiN2UzMzI4MDBmNzQ3Zjc4Y2I5NWZlZWY1MTYzOGM0L3RhYmxlOmIzMjZiNzAwMWUxNTQxYzliOWQ3NmJhYTVjNjZiNGMyL3RhYmxlcmFuZ2U6YjMyNmI3MDAxZTE1NDFjOWI5ZDc2YmFhNWM2NmI0YzJfMi0zLTEtMS0w_cc5223a5-698b-4e00-a82a-77cf35702eab">13,609</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested restricted common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib6505072e0e14228bee195251af31d4a_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF83MC9mcmFnOjdiN2UzMzI4MDBmNzQ3Zjc4Y2I5NWZlZWY1MTYzOGM0L3RhYmxlOmIzMjZiNzAwMWUxNTQxYzliOWQ3NmJhYTVjNjZiNGMyL3RhYmxlcmFuZ2U6YjMyNmI3MDAxZTE1NDFjOWI5ZDc2YmFhNWM2NmI0YzJfMy0xLTEtMS0w_8a6939a8-a3d4-40fa-893a-a3fa58e3087a">1,538</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if503e1a8de82421e9fe69c7f00e791be_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF83MC9mcmFnOjdiN2UzMzI4MDBmNzQ3Zjc4Y2I5NWZlZWY1MTYzOGM0L3RhYmxlOmIzMjZiNzAwMWUxNTQxYzliOWQ3NmJhYTVjNjZiNGMyL3RhYmxlcmFuZ2U6YjMyNmI3MDAxZTE1NDFjOWI5ZDc2YmFhNWM2NmI0YzJfMy0zLTEtMS0w_2a7f2411-bdb3-498f-9e7c-2c2c04c6af35">1,411</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF83MC9mcmFnOjdiN2UzMzI4MDBmNzQ3Zjc4Y2I5NWZlZWY1MTYzOGM0L3RhYmxlOmIzMjZiNzAwMWUxNTQxYzliOWQ3NmJhYTVjNjZiNGMyL3RhYmxlcmFuZ2U6YjMyNmI3MDAxZTE1NDFjOWI5ZDc2YmFhNWM2NmI0YzJfNC0xLTEtMS0w_966a5335-ef35-430d-985c-37979a730495">15,397</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ide9f6e15665746279d0000be700fcc6a_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF83MC9mcmFnOjdiN2UzMzI4MDBmNzQ3Zjc4Y2I5NWZlZWY1MTYzOGM0L3RhYmxlOmIzMjZiNzAwMWUxNTQxYzliOWQ3NmJhYTVjNjZiNGMyL3RhYmxlcmFuZ2U6YjMyNmI3MDAxZTE1NDFjOWI5ZDc2YmFhNWM2NmI0YzJfNC0zLTEtMS0w_d39f9549-ec8d-4ee0-8d44-cd4afa7c6abf">15,020</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="i9f86b6d3686546618ade3c76e6b23fc8_73"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">13. <ix:nonNumeric contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF83My9mcmFnOjY2NGIzYjBhMjgyZjRjYTI4NWZjYTQxY2NmZjI1OTJlL3RleHRyZWdpb246NjY0YjNiMGEyODJmNGNhMjg1ZmNhNDFjY2ZmMjU5MmVfNjI1Mw_a39e46f1-3316-4df5-8fbc-be0b06b5aebf" continuedAt="i5534fed0602a4202b43ef78f2fd5fd47" escape="true">COMMITMENTS AND CONTINGENCIES</ix:nonNumeric></span></div><ix:continuation id="i5534fed0602a4202b43ef78f2fd5fd47" continuedAt="i8a14f033e93242509127c51f266100e0"><div style="margin-top:6pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Legal Matters</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">From time to time, we may be a party to litigation, arbitration or other legal proceedings in the course of our business, including the matters described below. The claims and legal proceedings in which we could be involved include challenges to the scope, validity or enforceability of patents relating to our products or product candidates, and challenges by us to the scope, validity or enforceability of the patents held by others. These include claims by third parties that we infringe their patents or breach our license or other agreements with such third parties. The outcome of any such legal proceedings, regardless of the merits, is inherently uncertain. In addition, litigation and related matters are costly and may divert the attention of our management and other resources that would otherwise be engaged in other activities. If we were unable to prevail in any such legal proceedings, our business, results of operations, liquidity and financial condition could be adversely affected. Our accounting policy for accrual of legal costs is to recognize such expenses as incurred.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Securities Litigation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On September 26, 2018, Caryl Hull Leavitt, individually and on behalf of all others similarly situated, filed a class action complaint for violation of federal securities laws against us, our Chief Executive Officer and our former Chief Financial Officer in the United States District Court for the Southern District of New York. By stipulation of the parties and Order of the Court dated November 20, 2018, the action was transferred to the United States District Court for the District of Massachusetts. On May 8, 2019, the Court entered an order appointing a lead plaintiff, and on July 3, 2019, lead plaintiff filed a consolidated class action complaint, or the Complaint. In addition to the originally named defendants, the Complaint also named as defendants certain of our other executive officers, and purported to be brought on behalf of a class of persons who acquired our securities between September 20, 2017 and September 12, 2018 and sought to recover damages caused by defendants&#8217; alleged violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended, and Rule 10b-5 promulgated thereunder. The Complaint alleged, among other things, that the defendants made materially false and misleading statements related to the efficacy and safety of our product, ONPATTRO. The plaintiff sought, among other things, the designation of this action as a class action, an award of unspecified compensatory damages, interest, costs and expenses, including counsel fees and expert fees, and other relief as the court deems appropriate. All defendants filed </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9f86b6d3686546618ade3c76e6b23fc8_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ALNYLAM PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="i8a14f033e93242509127c51f266100e0"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">a motion to dismiss the Complaint in its entirety on July 31, 2019. On March 23, 2020, the Court granted our motion and dismissed the Complaint without prejudice. Pursuant to a prior Order of the Court, on June 1, 2020, plaintiff filed a motion seeking leave to file a further amended complaint. That motion was fully briefed on June 22, 2020. By Memorandum &amp; Order dated March 12, 2021, the Court denied plaintiffs&#8217; motion.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On September 12, 2019, the Chester County Employees Retirement Fund, individually and on behalf of all others similarly situated, filed a purported securities class action complaint for violation of federal securities laws against us, certain of our current and former directors and officers, and the underwriters of our November 14, 2017 public stock offering, in the Supreme Court of the State of New York, New York County. On November 7, 2019, plaintiff filed an amended complaint, or the New York Complaint. The New York Complaint is brought on behalf of an alleged class of those who purchased our securities pursuant and/or traceable to our November 14, 2017 public stock offering. The New York Complaint purports to allege claims arising under Sections 11, 12(a)(2) and 15 of the Securities Act of 1933, as amended, and generally alleges that the defendants violated the federal securities laws by, among other things, making material misstatements or omissions concerning the results of our APOLLO Phase 3 clinical trial of patisiran. The plaintiff seeks, among other things, the designation of the action as a class action, an award of unspecified compensatory damages, rescissory damages, interest, costs and expenses, including counsel fees and expert fees, and other relief as the court deems appropriate. All defendants filed a joint motion to dismiss the New York Complaint in its entirety on December 20, 2019. On November 2, 2020, the Court entered a Decision and Order denying defendants&#8217; motion to dismiss. In November 2020, defendants filed a notice of appeal of the Court&#8217;s decision to the Appellate Division of the Supreme Court of the State of New York for the First Department. Defendants&#8217; appeal was fully briefed in March 2021, and the Appellate Division heard oral argument on April 7, 2021. Defendants&#8217; appeal remains pending. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We believe that the allegations contained in the New York Complaint are without merit and intend to defend the case vigorously. We cannot predict at this point the length of time that this action will be ongoing or the liabilities, if any, which may arise therefrom.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Government Investigation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On or about April 9, 2021, we received a subpoena from the U.S. Department of Justice, U.S. Attorney&#8217;s Office for the District of Massachusetts, requiring production of documents pertaining to our marketing and promotion of ONPATTRO (patisiran) in the United States. We are preparing a response to the subpoena and cooperating with the government. Experienced outside legal counsel has been retained to assist with this matter.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Since learning of this federal government investigation, and consistent with its charter, our nominating and corporate governance committee is directing our review of and response to the matter. Given the early stage and ongoing nature of the investigation, no determination has been made that a loss, if any, arising from this matter is probable or that the amount of any such loss, or range of loss, is reasonably estimable.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><div id="i9f86b6d3686546618ade3c76e6b23fc8_79"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9f86b6d3686546618ade3c76e6b23fc8_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div id="i9f86b6d3686546618ade3c76e6b23fc8_82"></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are a global commercial-stage biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. By harnessing the RNAi pathway, we have developed a new class of innovative medicines, known as RNAi therapeutics. RNAi therapeutics are comprised of small interfering RNA, or siRNA, and function upstream of conventional medicines by potently silencing messenger RNA, or mRNA, that encode for disease-causing proteins, thus preventing them from being made. We believe this is a revolutionary approach with the potential to transform the care of patients with genetic and other diseases. To date, our efforts to advance this revolutionary approach have yielded the approval of four first-in-class RNAi-based medicines, ONPATTRO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (patisiran), GIVLAARI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (givosiran), OXLUMO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (lumasiran) and Leqvio</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (inclisiran).</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our research and development strategy is to target genetically validated genes that have been implicated in the cause or pathway of human disease. We utilize a N-acetylgalactosamine (GalNAc) conjugate or lipid nanoparticle (LNP) approach to enable hepatic delivery of siRNAs. For delivery to the central nervous system, or CNS, and the eye (ocular delivery), we are utilizing an alternative conjugate approach. We are also advancing approaches for lung delivery of siRNAs. Our focus is on clinical indications where there is a high unmet need, early biomarkers for the assessment of clinical activity in Phase 1 clinical studies, and a definable path for drug development, regulatory approval, patient access and commercialization.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In early 2021, we launched our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Alnylam P</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">x25</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> strategy, which focuses on our planned transition to a top five biotech company, as measured by market capitalization, by the end of 2025. With </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Alnylam P</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">x25</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, we aim to deliver transformative rare and prevalent disease medicines for patients around the world through sustainable innovation, delivering exceptional financial performance and driving profitability. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have four marketed products and 12 clinical programs, including six in late-stage development, across four Strategic Therapeutic Areas, or &#8220;STArs:&#8221; Genetic Medicines; Cardio-Metabolic Diseases; Hepatic Infectious Diseases; and CNS/Ocular Diseases.&#160;Three of our marketed products are within the Genetic Medicines STAr, ONPATTRO, GIVLAARI and OXLUMO. ONPATTRO is approved by the United States Food and Drug Administration, or FDA, for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis, or hATTR amyloidosis, in adults and has also been approved in the European Union, or EU, for the treatment of hATTR amyloidosis in adult patients with stage 1 or stage 2 polyneuropathy, in Japan for the treatment of transthyretin, or TTR, type familial amyloidosis with polyneuropathy, and in several additional countries, including Brazil. Regulatory filings in other territories are pending and additional filings are planned for 2021 and beyond. GIVLAARI is approved in the United States, or U.S., for the treatment of adults with acute hepatic porphyria, or AHP, in the EU for the treatment of AHP in adults and adolescents aged 12 years and older, and in Brazil and Canada for the treatment of AHP in adults. We have also filed for regulatory approval for givosiran (the non-branded drug name for GIVLAARI) in Switzerland and Japan and additional regulatory filings are pending or planned for 2021 and beyond. In November 2020, we received regulatory approval for OXLUMO in the U.S. and EU for the treatment of primary hyperoxaluria type 1, or PH1, in all age groups. Regulatory filings in other territories are pending and additional filings are planned for 2021 and beyond.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our fourth product, Leqvio (inclisiran), is being developed and commercialized by our partner Novartis AG, or Novartis, and in December 2020 received marketing authorization from the European Commission, or EC, for the treatment of adults with hypercholesterolemia or mixed dyslipidemia and is in the Cardio-Metabolic Diseases STAr. With respect to regulatory review by the FDA of the New Drug Application, or NDA, filed with the FDA for inclisiran, the FDA issued a complete response letter on December 18, 2020, due to unresolved facility inspection-related conditions at a third-party manufacturing facility in Europe. Novartis is working closely with the third-party manufacturer and the FDA to obtain approval as soon as possible, and has guided for a resubmission of its NDA for inclisiran in Q2-Q3 2021.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition to our marketed products, we have six late-stage investigational programs, advancing toward potential commercialization. These programs include our wholly owned programs: givosiran (the non-branded name for GIVLAARI) for the treatment of adolescent patients with AHP; lumasiran for the treatment of PH1 and recurrent renal stones; patisiran (the non-branded drug name for ONPATTRO) for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; vutrisiran for the treatment of ATTR amyloidosis; inclisiran (the non-branded name for Leqvio) for the treatment of hypercholesterolemia and atherosclerotic cardiovascular disease, or ASCVD, is being advanced by our partner Novartis; as well as fitusiran for the treatment of hemophilia, which is being advanced by our partner Sanofi Genzyme, the specialty care global business unit of Sanofi.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In January 2021, we reported positive topline results from our HELIOS-A Phase 3 study of vutrisiran in patients with hATTR amyloidosis with polyneuropathy, and in April 2021, based on the positive HELIOS-A data, we submitted an NDA for vutrisiran. Upon obtaining results from the 18-month analysis of HELIOS-A, expected in late 2021, we plan to submit a marketing authorisation application, or MAA, in the EU as previously aligned with the European Medicines Agency, or EMA.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9f86b6d3686546618ade3c76e6b23fc8_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Based on our expertise in RNAi therapeutics and broad intellectual property estate, we have formed alliances with leading pharmaceutical and life sciences companies to support our development and commercialization efforts, including Regeneron Pharmaceuticals, Inc., or Regeneron, Novartis (which acquired our partner The Medicines Company, or MDCO, in 2020), Sanofi Genzyme, Vir Biotechnology, Inc., or Vir, and Dicerna Pharmaceuticals, Inc., or Dicerna.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have incurred significant losses since we commenced operations in 2002 and expect such losses to continue for the foreseeable future. As of March&#160;31, 2021, we had an accumulated deficit of $4.79&#160;billion. Historically, we have generated losses principally from costs associated with the establishment of late-stage clinical and commercial capabilities, including global commercial operations, research and development activities, acquiring, filing and expanding intellectual property rights, and selling, general and administrative costs. While we believe 2019 was our peak net loss year, and believe the funding provided by our strategic financing collaboration with The Blackstone Group Inc., or Blackstone, should enable us to achieve a self-sustainable financial profile without the need for future equity financing, we expect to continue to incur annual net operating losses for the foreseeable future as we expand our efforts to discover, develop and commercialize RNAi therapeutics. We also anticipate that our operating results will fluctuate for the foreseeable future. Therefore, period-to-period comparisons should not be relied upon as predictive of the results in future periods.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We currently have programs focused on a number of therapeutic areas and as of March&#160;31, 2021, we are generating net revenue from product sales for three marketed products, ONPATTRO, GIVLAARI and OXLUMO. However, our ongoing development efforts may not be successful and we may not be able to commence sales of any other products and/or successfully market and sell ONPATTRO, GIVLAARI, OXLUMO or any other approved products in the future. A substantial portion of our total revenues in recent years has been derived from collaboration revenues from strategic alliances with Regeneron, Novartis and Vir. In addition to revenues from the commercial sales of ONPATTRO, GIVLAARI, OXLUMO and potentially from sales of future products, we expect our sources of potential funding for the next several years to continue to be derived in part from existing and new strategic alliances, which may include license and other fees, funded research and development, milestone payments and royalties on product sales by our licensees, as well as funding due or available to us under our strategic financing collaboration with Blackstone.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">The COVID-19 Pandemic </span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In March 2020, the World Health Organization declared the outbreak of a novel strain of coronavirus, or COVID-19, as a pandemic, which continues to spread or resurge throughout the U.S. and worldwide. We could be materially and adversely affected by the risks, or the public perception of the risks, related to an epidemic, pandemic, outbreak, or other public health crisis, such as the current COVID-19 pandemic. We are continuing to monitor the global pandemic and spread of COVID-19 and plan to continue taking steps to identify and mitigate the adverse impacts on, and risks to, our business posed by its spread and actions taken by governmental and health authorities to address the COVID-19 pandemic. The spread of COVID-19 has caused us to modify our business practices, including implementing a global work from home policy for all employees who are able to perform their duties remotely and restricting all nonessential business travel, and we expect to continue to take actions as may be required or recommended by government authorities or as we determine are in the best interests of our employees, the patients we serve and other business partners in light of COVID-19 and variants thereof. Where and to the extent permitted to be open under local regulations, our office sites are operational with physical distancing, temperature screening, contact tracing and cleaning measures in place, as well as voluntary testing protocols in our Massachusetts facilities. At this time, we cannot predict when certain restrictions that are in place to protect our employees can be safely reduced or will no longer be needed, and such restrictions are likely to remain in place until there is widespread immunization against COVID-19. Due to the speed and fluidity with which the COVID-19 pandemic continues to evolve, and the emergence of highly contagious variants, we do not yet know the full extent of the impact of COVID-19 on our business operations. The ultimate extent of the impact of any epidemic, pandemic, outbreak, or other public health crisis on our business, financial condition and results of operations will depend on future developments, which are highly uncertain and cannot be predicted, including new information that may emerge concerning the severity of such epidemic, pandemic, outbreak, or other public health crisis and actions taken to contain or prevent the further spread, including the availability and efficacy of vaccines, among others. Accordingly, we cannot predict the extent to which our business, financial condition and results of operations will be affected. We remain focused on maintaining a strong balance sheet, liquidity and financial flexibility and continue to monitor developments as we deal with the disruptions and uncertainties from a business and financial perspective relating to COVID-19 and variants thereof. We will continue to work diligently with our partners and stakeholders to support patient access to our approved medicines, advance our product candidates under regulatory review as well as in our clinical studies to the extent safe to do so for patients, caregivers and healthcare practitioners, and ensure the continuity of our manufacturing and supply chain. For additional information related to the actual or potential impacts of COVID-19 on our business, please read Part II, Item 1A, &#8220;Risk Factors&#8221; of this Quarterly Report on Form 10-Q.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Research and Development</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Since our inception, we have focused on drug discovery and development programs. Research and development expenses represent a substantial percentage of our total operating expenses, as reflected by our broad pipeline of clinical development programs, which includes multiple programs in late-stage development.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9f86b6d3686546618ade3c76e6b23fc8_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Our Product Pipeline</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our broad pipeline, including four approved products and multiple late and early-stage investigational RNAi therapeutics, is focused in four STArs: Genetic Medicines; Cardio-Metabolic Diseases; Hepatic Infectious Diseases; and CNS/Ocular Diseases. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The chart below is a summary of our commercial products and late- and early-stage development programs as of April 29, 2021. It identifies those programs for which we have received marketing approval, the stage of our programs and our commercial rights to such programs:</span></div><div style="margin-top:6pt;text-align:center;text-indent:18pt"><img src="alny-20210331_g1.jpg" alt="alny-20210331_g1.jpg" style="height:407px;margin-bottom:5pt;vertical-align:text-bottom;width:725px"/></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the first quarter of 2021 and recent period, we reported the following updates from our commercially approved products and our late-stage clinical programs:</span></div><div style="margin-top:6pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Commercial</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">ONPATTRO</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:32.5pt">We achieved ONPATTRO global net product revenues for the first quarter of 2021 of $102.0&#160;million, and secured additional market access with over 30 countries now selling ONPATTRO through direct reimbursement, named patient sales, or reimbursed expanded access.</span></div><div style="margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">GIVLAARI</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:32.5pt">We achieved GIVLAARI global net product revenues for the first quarter of 2021 of $24.7&#160;million, received marketing authorization approval for GIVLAARI in Switzerland for the treatment of AHP in adults and adolescents, and maintained steady progress with market access efforts across the CEMEA region, with recent launch in Italy, ongoing launch in Germany, and Temporary Authorization for Use, or ATU, supply in France.</span></div><div style="margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">OXLUMO</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:32.5pt">We achieved OXLUMO global net product revenues for the first quarter of 2021 of $9.1&#160;million, and continued progress with market access efforts across the CEMEA region, with recent launch in Germany and ATU supply in France.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Late-Stage Clinical Development</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:32.5pt">We continued to advance patisiran, in development for the treatment of the cardiomyopathy of both hereditary and wild-type ATTR amyloidosis:</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9f86b6d3686546618ade3c76e6b23fc8_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:90pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:32.46pt">Continued enrollment in the APOLLO-B Phase 3 study in ATTR amyloidosis patients with cardiomyopathy and remain on track to complete enrollment in early 2021.</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:32.5pt">We continued to advance vutrisiran, a subcutaneously administered investigational RNAi therapeutic in development for the treatment of ATTR amyloidosis:</span></div><div style="margin-top:6pt;padding-left:90pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:32.46pt">Filed an NDA with the FDA;</span></div><div style="margin-top:6pt;padding-left:90pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:32.46pt">Presented positive 9-month results from the HELIOS-A Phase 3 study; and</span></div><div style="margin-top:6pt;padding-left:90pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:32.46pt">Announced that due to strong pace of enrollment in the HELIOS-B Phase 3 study, we now expect to complete study enrollment in late 2021, earlier than previously anticipated. </span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:32.5pt">We continued to advance lumasiran for the treatment of PH:</span></div><div style="margin-top:6pt;padding-left:90pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:32.46pt">Continued dosing PH1 patients with advanced renal disease in the ILLUMINATE-C Phase 3 study, and remain on track to report topline results in mid-2021.</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:32.5pt">Our partner, Novartis, continued to advance inclisiran (the non-proprietary name for Leqvio) for the treatment of hypercholesterolemia or mixed dyslipidemia: </span></div><div style="margin-top:6pt;padding-left:90pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:32.46pt">Response to U.S. Complete Response Letter to be submitted Q2-Q3 2021.</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:32.5pt">Our partner, Sanofi Genzyme, continued advancement of the ATLAS Phase 3 program for fitusiran in patients with hemophilia A or B with and without inhibitors:</span></div><div style="margin-top:6pt;padding-left:90pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:32.46pt">The amended protocol for all ongoing adult and adolescent fitusiran clinical studies, aimed at further enhancing the benefit-risk profile, was presented at the 14th Annual Congress of the European Association for Haemophilia and Allied Disorders.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">There is a risk that any drug discovery or development program may not produce revenue for a variety of reasons, including the possibility that we will not be able to adequately demonstrate the safety and effectiveness of the product candidate. Moreover, there are uncertainties specific to any new field of drug discovery, including RNAi. The success of ONPATTRO, GIVLAARI, OXLUMO or any other product candidate we develop is highly uncertain. Due to the numerous risks associated with developing drugs, including those risks associated with the COVID-19 pandemic, we cannot reasonably estimate or know the nature, timing and estimated costs of the efforts necessary to complete the development of any potential product candidate or indication, or the period, if any, in which material net cash inflows will commence from any approved product or indication. Any failure to complete any stage of the development of any potential products or any approved product for an expanded indication in a timely manner or successfully launch, market and sell any of our commercially approved products, could have a material adverse effect on our operations, financial position and liquidity. A discussion of some of the risks and uncertainties associated with completing our research and development programs within the planned timeline, or at all, and the potential consequences of failing to do so, are set forth in Part&#160;II, Item&#160;1A below under the heading &#8220;Risk Factors.&#8221;</span></div><div style="margin-top:6pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Strategic Alliances</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our business strategy is to develop and commercialize a broad pipeline of RNAi therapeutic products directed towards our four STArs. As part of this strategy, we have entered into, and expect to enter into additional, collaboration and licensing agreements as a means of obtaining resources, capabilities and funding to advance our investigational RNAi therapeutic programs.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our collaboration strategy is to form alliances that create significant value for ourselves and our collaborators in the advancement of RNAi therapeutics as a new class of innovative medicines. Specifically, with respect to our CNS/Ocular Disease pipeline, in April 2019, we entered into a global, strategic collaboration with Regeneron to discover, develop and commercialize RNAi therapeutics for a broad range of diseases by addressing disease targets expressed in the eye and CNS, in addition to a select number of targets expressed in the liver.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">With respect to our Cardio-Metabolic pipeline, in March 2013, we entered into an exclusive, worldwide license with MDCO (acquired by Novartis AG in January 2020) pursuant to which MDCO was granted the right to develop, manufacture and commercialize RNAi therapeutics targeting proprotein convertase subtilisin/kexin type 9, or PCSK9, for the treatment of hypercholesterolemia and other human diseases, including inclisiran. In March 2018, we entered into a discovery collaboration with Regeneron to identify RNAi therapeutics for nonalcoholic steatohepatitis, or NASH, and potentially other related diseases, and in November 2018, we and Regeneron entered into a separate, fifty-fifty collaboration to further research, co-develop and commercialize any therapeutic product candidates that emerge from these discovery efforts. In April 2020, we entered into a development and commercialization collaboration with Dicerna to advance investigational RNAi therapeutics for the treatment of alpha-1 antitrypsin deficiency-associated liver disease, or alpha-1 liver disease.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">With respect to our Hepatic Infectious Disease pipeline, in October 2017, we announced an exclusive licensing agreement with Vir for the development and commercialization of RNAi therapeutics for infectious diseases, including chronic hepatitis B virus, or HBV, infection. In March 2020, we announced an expansion of our exclusive licensing agreement with Vir to include </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9f86b6d3686546618ade3c76e6b23fc8_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">the development and commercialization of RNAi therapeutics targeting SARS-CoV-2, the virus that causes the disease COVID-19. In April 2020, we further expanded our broad multi-target existing collaboration for the development and commercialization of RNAi therapeutics for infectious diseases to include up to three additional targets focused on host factors for SARS-CoV-2, including angiotensin converting enzyme-2, or ACE2, and transmembrane protease, serine 2, or TMPRSS2.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">With respect to our Genetic Medicine pipeline, we formed a broad strategic alliance with Sanofi Genzyme in 2014. In January 2018, we and Sanofi Genzyme amended our 2014 collaboration and entered into the Exclusive License Agreement, referred to as the Exclusive TTR License, under which we have the exclusive right to pursue the further global development and commercialization of all TTR products, including ONPATTRO, vutrisiran and any back-up products, and the ALN-AT3 Global License Terms, referred to as the AT3 License Terms, under which Sanofi Genzyme has the exclusive right to pursue the further global development and commercialization of fitusiran and any back-up products. In April 2019, we and Sanofi Genzyme agreed to further amend the 2014 Sanofi Genzyme collaboration to conclude the research and option phase and to amend and restate the AT3 License Terms to modify certain of the business terms.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We also have entered into license agreements to obtain rights to intellectual property in the field of RNAi. In addition, because delivery of RNAi therapeutics has historically been an important objective of our research activities, we have entered into various collaboration and licensing arrangements with other companies and academic institutions to gain access to delivery technologies, including various LNP delivery technologies, and we may enter into such agreements in the future to gain access to products or technologies.</span></div><div id="i9f86b6d3686546618ade3c76e6b23fc8_85"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Estimates</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our critical accounting policies are described in the &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; section of our Annual Report on Form 10-K for the year ended December&#160;31, 2020, which we filed with the SEC on February 11, 2021.&#160;There have been no significant changes to our critical accounting policies since the beginning of this fiscal year.</span></div><div id="i9f86b6d3686546618ade3c76e6b23fc8_88"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following data summarizes the results of our operations:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.321%"><tr><td style="width:1.0%"></td><td style="width:40.771%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.857%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.857%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.857%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.860%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands, except percentages)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Dollar Change</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% of Change</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177,566&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,476&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,090&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating costs and expenses</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">363,820&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">309,634&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,186&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(186,254)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(210,158)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,904&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other (expense) income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,021)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,512&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41,533)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(146)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(200,291)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(182,221)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,070)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Discussion of Results of Operations</span></div><div style="margin-top:6pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenues</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenues consist of the following:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.660%"><tr><td style="width:1.0%"></td><td style="width:39.768%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.121%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.121%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.121%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.125%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands, except percentages)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Dollar Change</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% of Change</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135,769&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,938&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,831&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net revenues from collaborations</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,797&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,538&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,259&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177,566&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,476&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,090&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9f86b6d3686546618ade3c76e6b23fc8_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net product revenues</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Net product revenues consist of the following, by product and region:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:94.883%"><tr><td style="width:1.0%"></td><td style="width:40.964%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.921%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.416%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.921%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.416%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.921%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.416%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.925%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands, except percentages)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Dollar Change</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% of Change</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ONPATTRO</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,471&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,196&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,275&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,653&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,166&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,487&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rest of World (primarily Japan)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,827&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,302&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,525&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,951&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,664&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,287&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">GIVLAARI</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,762&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,274&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,488&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">237&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,873&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,873&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rest of World </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,673&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,274&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,399&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">368&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OXLUMO</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,408&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,408&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,737&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,737&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,145&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,145&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net product revenues</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135,769&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,938&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,831&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Net product revenues increased during the three months ended March&#160;31, 2021, as compared to the same period in the prior year, as a result of the continued, global expansion of ONPATTRO and GIVLAARI into additional major markets and increased patients on therapy, in addition to sales generated from our third commercial product, OXLUMO, following regulatory approvals in the fourth quarter of 2020.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We expect net product revenues to increase for the twelve-month period ending December&#160;31, 2021, as compared to the same period in 2020, as we continue to add new patients onto our approved, commercial products, as well as launch our approved products into additional markets, assuming regulatory approvals.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Net revenues from collaborations</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Net revenues from collaborations consist of the following:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.783%"><tr><td style="width:1.0%"></td><td style="width:44.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.041%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.555%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.041%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.555%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.041%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.555%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.046%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands, except percentages)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Dollar Change</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% of Change</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron Pharmaceuticals</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,343&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,503&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,840&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Novartis AG</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,111&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,060&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,051&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">665&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vir Biotechnology</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,822&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,516&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,694)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(57)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">521&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">459&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,797&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,538&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,259&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Net revenues from collaborations increased during the three months ended March&#160;31, 2021, as compared to the same period in the prior year, primarily due to an increase in revenue recognized in connection with our collaboration agreements with Regeneron, as a result of increased activities, and Novartis, as a result of increased shipments of material to Novartis to support the manufacture of Leqvio as Novartis executes on the product launch in Europe and prepares for other potential market approvals.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We expect net revenues from collaborations to increase for the twelve-month period ending December&#160;31, 2021, as compared to the same period in 2020, primarily due to increased activities and anticipated achievement of milestones under our collaborations with Regeneron and Novartis.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9f86b6d3686546618ade3c76e6b23fc8_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Operating Costs and Expenses</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Operating costs and expenses consist of the following:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.321%"><tr><td style="width:1.0%"></td><td style="width:40.771%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.857%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.857%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.857%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.860%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands, except percentages)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Dollar Change</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% of Change</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods sold</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,023&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,302&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,721&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of collaborations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,039&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,039&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185,899&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169,571&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,328&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146,859&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126,761&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,098&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">363,820&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">309,634&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,186&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Cost of goods sold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cost of goods sold increased during the three months ended March&#160;31, 2021, as compared to the same periods in the prior year, due to the increase in third-party royalties and sales of capitalized inventory. During the three months ended March&#160;31, 2021, product sold and recognized as revenue was substantially from capitalized inventory, whereas during the three months ended March&#160;31, 2020, a portion of the units of product sold and recognized as revenue were zero-cost inventory. We will continue to sell our zero-cost inventory of GIVLAARI and OXLUMO throughout the remainder of 2021.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We anticipate variability in our cost of goods sold as a percentage of net product revenues due to the timing of manufacturing runs and utilization and the depletion of zero-cost inventories, as well as future product launches. We expect cost of goods sold will increase for the twelve-month period ending December&#160;31, 2021, as compared to the same period in 2020, primarily as a result of an expected increase in net product sales as well as the sale of capitalized inventory.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Cost of collaborations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cost of collaborations includes costs we incur in connection with producing commercial drug supplies, such as GalNAc, for collaborators.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We expect cost of collaborations will increase for the twelve-month period ending December&#160;31, 2021, as compared to the same period in 2020, as we continue to supply material to Novartis to support the manufacturing of Leqvio as Novartis executes on the product launch in Europe and prepares for other potential market approvals.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">.&#160;</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Research and development expenses consist of the following:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.321%"><tr><td style="width:1.0%"></td><td style="width:40.771%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.857%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.857%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.857%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.860%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands, except percentages)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Dollar Change</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% of Change</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical trial and manufacturing</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,686&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,525&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,161&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation and related</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,372&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,163&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,375&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,049&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,326&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Facilities-related</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,276&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,701&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,575&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">External services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,093&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,661&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,568)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab supplies, materials and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,125&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,059&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,934)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License Fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">972&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,413&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,441)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185,899&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169,571&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,328&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For the three months ended March&#160;31, 2021, the increase in research and development expenses, as compared to the same period in the prior year, was primarily related to the following: </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Increased clinical trial and manufacturing as a result of site openings and increased enrollment in our HELIOS B and APOLLO B Phase 3 clinical trials; and </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Increased stock-based compensation primarily due to the accounting for certain performance-based stock awards.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the three months ended March&#160;31, 2021 and 2020, in connection with advancing activities under our collaboration agreements, we incurred research and development expenses, primarily related to external development and clinical expenses, including manufacturing of clinical product. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9f86b6d3686546618ade3c76e6b23fc8_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table summarizes research and development expenses incurred, for which we recognize net revenue, that are directly attributable to our collaboration agreements, by collaboration partner:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:84.502%"><tr><td style="width:1.0%"></td><td style="width:56.858%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.488%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.665%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.489%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron Pharmaceuticals</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,128&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,103&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vir Biotechnology</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,543&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,084&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Novartis AG</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,264&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">922&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,596&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,699&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Selling, general and administrative</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Selling, general and administrative expenses consist of the following:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.321%"><tr><td style="width:1.0%"></td><td style="width:40.771%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.857%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.857%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.857%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.860%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands, except percentages)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Dollar Change</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% of Change</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation and related</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,072&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,829&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,243&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consulting and professional services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,706&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,992&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,286)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,315&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,529&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,786&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Facilities-related</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,504&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,741&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,763&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,262&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,670&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,408)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146,859&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126,761&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,098&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For the three months ended March&#160;31, 2021, the increase in selling, general and administrative expenses, as compared to the same periods in the prior year, was primarily related to the following:  </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Increased stock-based compensation primarily due to the accounting for certain performance-based stock awards; and </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Increased compensation and related expenses as a result of increased headcount to support our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Alnylam P</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">x25 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">strategy.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Offset by:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Decreased other expenses as a result of a decrease in travel due to COVID-19 restrictions.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We expect that research and development expenses combined with selling, general and administrative expenses will increase for the twelve-month period ending December&#160;31, 2021, as compared to the same period in 2020, as we continue to develop our pipeline, advance our product candidates, including partnered programs, into later-stage development, prepare regulatory submissions and build-out of our global commercial infrastructure and field team to support ONPATTRO, GIVLAARI, OXLUMO and potentially additional product launches. However, we expect that certain expenses will be variable depending on the timing of manufacturing batches, clinical trial enrollment and results, regulatory review of our product candidates and programs, and stock-based compensation expenses due to our determination regarding the probability of vesting for performance-based awards.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9f86b6d3686546618ade3c76e6b23fc8_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Total Other (Expense) Income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></div><div style="margin-top:12pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total other (expense) income consists of the following:</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.321%"><tr><td style="width:1.0%"></td><td style="width:40.771%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.857%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.857%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.857%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.860%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands, except percentages)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Dollar Change</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% of Change</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32,515)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32,515)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">450&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,480&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,030)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(92)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Realized and unrealized gains on marketable equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,016&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,111&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,905&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of development derivative liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,253)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,253)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,719)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,079)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,640)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">801&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,021)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,512&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41,533)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(146)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For the three months ended March&#160;31, 2021, total other expense increased, as compared to the same period in the prior year, primarily due to the following: </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">$28.2 million of interest expense associated with the sale of future royalties; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">$4.3 million of interest expense associated with the initial draw down under our credit agreement in December 2020; and </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">$18.3 million loss as a result of a mark-to-market adjustment related to the development derivative liability.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Offset by:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Increased realized and unrealized gains in marketable equity securities.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We expect total other expense will increase for the twelve-month period ending December&#160;31, 2021, as compared to the same period in 2020, as we continue to incur interest expense on our long-term debt and sale of future royalties. </span></div><div id="i9f86b6d3686546618ade3c76e6b23fc8_91"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our cash flow activities:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.128%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.422%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(200,291)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(182,221)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,497&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,133&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(125,866)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(92,073)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(235,660)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(246,161)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by investing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,352&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113,688&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,177&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,869&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash, cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,910)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(631)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net decrease in cash, cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(117,041)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(79,235)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash, beginning of period</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">499,046&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">549,628&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash, end of period</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">382,005&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">470,393&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Since we commenced operations in 2002, we have generated significant losses. As of March&#160;31, 2021, we had an accumulated deficit of $4.79 billion. As of March&#160;31, 2021, we had cash, cash equivalents and marketable securities of $1.71 billion, compared to $1.87 billion as of December&#160;31, 2020.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Operating activities</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Net cash used in operating activities decreased during the three months ended March&#160;31, 2021, compared to the same period in 2020, primarily due to a decrease in loss from operations offset by increases in cash used in working capital related activities.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9f86b6d3686546618ade3c76e6b23fc8_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Investing activities</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Net cash provided by investing activities decreased during the three months ended March&#160;31, 2021, compared to the same period in the prior year, primarily due to a net decrease in the purchases, sales and maturities of marketable securities.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Financing activities</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Net cash provided by financing activities decreased during the three months ended March&#160;31, 2021, compared to the same period in the prior year, primarily due to decreased net proceeds of $6.9 million from the issuance of common stock in connection with stock option exercises and other types of equity, offset by proceeds of $4.2 million received in connection with the execution of the funding agreement for the clinical development of vutrisiran and ALN-AGT.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Operating Capital Requirements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We currently have programs focused on a number of therapeutic areas and, as of March&#160;31, 2021, have received regulatory approval and commercially launched three products: ONPATTRO, GIVLAARI and OXLUMO. In early 2021, we announced our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Alnylam P</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">x25 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">strategy, which is aimed at our planned transition to a top 5 biotech in market capitalization. However, our ongoing development efforts may not be successful and we may not be able to commence sales of any other products in the future. In addition, we anticipate that we will continue to generate losses as a result of planned expenditures for research and development activities relating to our research platform, our drug development programs, including clinical trial and manufacturing costs, the establishment of late-stage clinical, manufacturing and commercial capabilities, including global operations, continued management and growth of our intellectual property including our patent portfolio, collaborations and general corporate activities.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Based on our current operating plan, we believe that our cash, cash equivalents and marketable securities as of March&#160;31, 2021, together with the cash we expect to generate from product sales and under our current alliances, in addition to our strategic financing collaboration with The Blackstone Group Inc. and certain of its affiliates, will be sufficient to enable us to advance our long-term strategic goals for at least the next 12 months from the filing of this quarterly report on Form 10-Q. However, due to numerous factors described in more detail under the caption Part II, Item 1A, "Risk Factors" of this quarterly report on Form 10-Q, we may require significant additional funds earlier than we currently expect in order to continue to commercialize ONPATTRO, GIVLAARI and OXLUMO, and to develop, conduct clinical trials for, manufacture and, if approved, commercialize additional product candidates.</span></div><div id="i9f86b6d3686546618ade3c76e6b23fc8_94"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual Obligations and Commitments</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The disclosure of our contractual obligations and commitments is set forth under the heading &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8212;Contractual Obligations&#8221; in our Annual Report on Form 10-K for the year ended December&#160;31, 2020. There have been no material changes in our contractual obligations and commitments since December&#160;31, 2020. </span></div><div id="i9f86b6d3686546618ade3c76e6b23fc8_100"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Financial market risks related to interest rates are described in our Annual Report on Form 10-K for the year ended December&#160;31, 2020. As of March&#160;31, 2021, there have been no significant changes to the financial market risks described as of December&#160;31, 2020. We do not currently anticipate any other near-term changes in the nature of our financial market risk exposures or in management&#8217;s objectives and strategies with respect to managing such exposures.</span></div><div id="i9f86b6d3686546618ade3c76e6b23fc8_103"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4. CONTROLS AND PROCEDURES</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Disclosure Controls and Procedures</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our management, with the participation of our Chief Executive Officer (principal executive officer) and executive vice president, Chief Financial Officer (principal financial officer), evaluated the effectiveness of our disclosure controls and procedures as of March&#160;31, 2021. The term &#8220;disclosure controls and procedures,&#8221; as defined in Rules&#160;13a-15(e) and 15d-15(e) under the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC&#8217;s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company&#8217;s management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9f86b6d3686546618ade3c76e6b23fc8_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">March&#160;31, 2021, our Chief Executive Officer and executive vice president, Chief Financial Officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Changes in Internal Control</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">There were no changes in our internal control over financial reporting during the quarter ended March&#160;31, 2021 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><div id="i9f86b6d3686546618ade3c76e6b23fc8_106"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9f86b6d3686546618ade3c76e6b23fc8_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II. OTHER INFORMATION</span></div><div id="i9f86b6d3686546618ade3c76e6b23fc8_109"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;1. LEGAL PROCEEDINGS</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For a discussion of material pending legal proceedings, please read Note 13, Commitments and Contingencies &#8211; Legal Matters, to our condensed consolidated financial statements included in Part I, Item I, &#8220;Financial Statements (Unaudited),&#8221; of this Quarterly Report on Form 10-Q, which is incorporated into this item by reference.</span></div><div id="i9f86b6d3686546618ade3c76e6b23fc8_112"></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;1A. RISK FACTORS</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Risks Related to Our Business</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Risks Related to Our Financial Results </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">The current pandemic of COVID-19 and the future outbreak of other highly infectious or contagious diseases, could have a material adverse impact on our business, financial condition and results of operations, including our commercial operations and sales, clinical trials and pre-clinical studies.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In December 2019, a novel strain of coronavirus, or COVID-19, was reported to have surfaced and it has since reached multiple regions, countries and cities, including Cambridge, Massachusetts where our primary office and laboratory space is located, and all countries in which we have offices. The COVID-19 pandemic continues to evolve and the ultimate impact of this pandemic is highly uncertain and subject to change. To date, the pandemic has led to the implementation of various responses, including government-imposed quarantines, travel restrictions and other public health safety measures. COVID-19 has and will likely continue to impact our operations and those of our third-party partners and the ultimate impact on our business and financial results remains uncertain and cannot be predicted with confidence, and will depend on many factors, including the scope, severity, duration and any recurrence of the COVID-19 pandemic, including through any new variant strains of the underlying virus, the actions taken to contain the pandemic or mitigate its impact, the direct and indirect economic effects of the pandemic and containment measures, and the availability and efficacy of vaccines and treatments for COVID-19, among others. The continued development and fluidity of the COVID-19 pandemic precludes any prediction as to its full impact on our business. Nevertheless, the COVID-19 pandemic may adversely affect our business, financial condition and results of operations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In response to the spread of COVID-19, we took, and have continued to take, temporary precautionary measures intended to help minimize the risk of the virus to our employees and their families, including implementing a global work from home policy for nearly all employees who are able to perform their duties remotely, and have generally restricted on-site staff to only those personnel and contractors who perform activities that need to be completed on-site, limited the number of staff in any given laboratory, manufacturing facility or other facility and implemented safety practices and procedures for those individuals who are required to work in our facilities, including but not limited to mandatory health screening, the use of face coverings, physical distancing requirements and increased cleaning protocols, as well as voluntary onsite testing. We also suspended non-essential business travel for our employees and may take further measures as the pandemic continues. In addition, our customer-facing employees in most markets moved and could again need to move to virtual interactions with healthcare providers, administrators, patients, payers, regulators and other government employees. We expect to adopt and implement additional precautions commensurate with any expansion of employees returning to physical locations, and at this time, we cannot predict when certain restrictions that are in place to protect our employees can be further reduced or will no longer be needed. The effects of government-imposed quarantines and our work-from-home policies may negatively impact productivity, or disrupt, delay, or otherwise adversely impact our business. Compliance with governmental measures imposed in response to COVID-19 has caused and will continue to cause us to incur additional costs, and any inability to comply with such measures can subject us to restrictions on our business activities, fines, and other penalties, any of which can adversely affect our business. In addition, the increase in certain of our employees working remotely has amplified certain risks to our business, including increased demand on our information technology resources and systems, increased phishing and other cybersecurity attacks, and any failure to effectively manage these risks, including to timely identify and appropriately respond to any cyberattacks, could adversely impact our business operations. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As a result of the COVID-19 pandemic, we may experience disruptions that could severely impact our business and operations, including our ability to successfully commercialize our approved products, ONPATTRO, GIVLAARI and OXLUMO, and due to the current pandemic, we may not be able to meet expectations with respect to commercial sales. For example, due to the impact of the COVID-19 pandemic, product revenues in the second quarter of 2020 for ONPATTRO were less than originally forecast. In addition, we may also experience decreased patient demand for our approved products if current or potential patients decide to delay treatment as a result of the COVID-19 or a future pandemic. For example, in the second quarter of 2020, we experienced a decrease in patient demand in the U.S. due to reduced adherence as some patients skipped doses or experienced dose delays while moving to new sites of care, and additionally experienced reduced requests for genetic testing through our third party genetic testing program resulting in delays in diagnoses of the rare diseases our medicines are approved to treat. In addition, business interruptions from the current or future pandemics, including staffing shortages, production slowdowns and disruptions in delivery systems, may also adversely impact the third parties we or our partners rely </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9f86b6d3686546618ade3c76e6b23fc8_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">on in the U.S. and abroad to sufficiently manufacture our approved products and to produce product candidates in quantities we require, which may impair our commercialization efforts, our research and development activities and the potential commercialization of our product candidates. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Additionally, timely completion of pre-clinical activities and initiation of planned clinical trials is dependent upon the availability of, for example, pre-clinical and clinical trial sites, researchers and investigators, patients or healthy volunteer subjects available for recruitment and enrollment, and regulatory agency personnel, which may be adversely affected by global health matters, such as the COVID-19 pandemic. We are conducting and plan to continue to conduct pre-clinical activities and clinical trials for our drug product candidates in geographies which have been and continue to be affected by COVID-19, and believe that the COVID-19 pandemic will have an impact on various aspects of our ongoing clinical trials and on the clinical trials and pre-clinical studies we expect to initiate in 2021. For example, certain trial sites in some of our ongoing clinical trials were restricted temporarily by the institutions where they are located from scheduling patient visits or permitting onsite monitoring due to the COVID-19 pandemic, and in some of our ongoing trials, delayed or missed doses of study drug have been reported. In addition, due to the impact of the COVID-19 pandemic, enrollment delays in our APOLLO-B Phase 3 study of patisiran for the treatment of ATTR amyloidosis with cardiomyopathy resulted in a shift in the enrollment completion date from late 2020 into early 2021. Any business interruptions caused by the COVID-19 pandemic could also delay necessary interactions with local regulators, ethics committees, manufacturing sites, research or clinical trial sites and other important agencies and contractors, which could adversely impact the clinical trials of our product candidates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Health regulatory agencies globally may also experience disruptions in their operations as a result of the COVID-19 pandemic, which may impact review, inspection and approval timelines. Since March 2020, when foreign and domestic inspections of facilities were largely placed on hold, the FDA has been working to resume routine surveillance, bioresearch monitoring and pre-approval inspections on a prioritized basis. The FDA has developed a rating system to assist in determining when and where it is safest to conduct prioritized domestic inspections and resumed inspections in certain countries in early 2021. In April 2021, the FDA issued guidance for industry formally announcing plans to employ remote interactive evaluations, using risk management methods, to meet user fee commitments and goal dates. Should the FDA determine that an inspection is necessary for approval of a marketing application and an inspection cannot be completed during the review cycle due to restrictions on travel, the FDA has stated that it generally intends to issue a complete response letter. Further, if there is inadequate information to make a determination on the acceptability of a facility, the FDA may defer action on the application until an inspection can be completed. For example, in December 2020, the FDA issued a complete response letter regarding Novartis' NDA for inclisiran, stating that the agency could not approve the NDA by the Prescription Drug User Fee Act, or PDUFA, action date due to unresolved facility inspection-related conditions. Regulatory authorities outside the U.S. may adopt similar restrictions or other policy measures in response to the COVID-19 pandemic and may experience delays in their regulatory activities.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Some factors from the COVID-19 pandemic that may delay or otherwise adversely affect enrollment in and the conduct of the clinical trials of our product candidates, as well as adversely impact our business generally, include: </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the diversion of healthcare resources away from the conduct of clinical trials to focus on pandemic concerns, including the availability of materials necessary to conduct of our clinical trials;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">limitations on travel that could interrupt key trial activities, such as clinical trial site initiations and monitoring, domestic and international travel by employees, contractors or patients to clinical trial sites, including any government-imposed travel restrictions or quarantines that will impact the ability or willingness of patients, employees or contractors to travel to our research, manufacturing and clinical trial sites or secure visas or entry permissions, any of which could delay or adversely impact the conduct or progress of our clinical trials; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">interruption of, or delays in receiving, supplies of our product candidates from our contract manufacturing organizations due to staffing shortages, production slowdowns or stoppages and disruptions in delivery systems.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">These and other factors arising from the COVID-19 pandemic could worsen in countries that are already afflicted with COVID-19 or could return to countries where the pandemic has been partially contained, each of which could further adversely impact our ability to conduct clinical trials and our business generally, and could have a material adverse impact on our operations and financial condition and results. In addition, a recession, depression or other sustained adverse market event resulting from the COVID-19 pandemic could materially and adversely affect our business and the value of our common stock.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The ultimate impact of the COVID-19 pandemic remains uncertain and subject to change. We do not yet know the full extent of potential delays or impacts on our business, our commercial results, clinical trials, healthcare systems or the global economy as a whole. These effects could have a material impact on our operations, and we will continue to monitor the COVID-19 situation closely.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We are an early-stage commercial company and the marketing and sale of ONPATTRO, GIVLAARI, OXLUMO or any future products may be unsuccessful or less successful than anticipated.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In 2018, our first commercial product, ONPATTRO, was approved by the FDA and EMA, and we have since received approval and launched ONPATTRO in several additional territories. In 2019, the FDA approved our second product, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9f86b6d3686546618ade3c76e6b23fc8_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">GIVLAARI, which was also approved by the EMA and several other regulatory authorities, and in November 2020, the FDA and EMA approved our third product, OXLUMO. While we have commercially launched ONPATTRO, GIVLAARI and OXLUMO, we are an early-stage commercial company and there is limited information about our ability to successfully overcome many of the risks and uncertainties encountered by companies commercializing products in the biopharmaceutical industry. We also have several product candidates in late-stage clinical development. To execute our business plan of building a profitable, top 5 biotech company, as measured by market capitalization, over the next 5 years and achieving our P</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">x25 strategy and the metrics associated with such strategy, in addition to successfully marketing and selling our approved products we will need to successfully:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">execute product development activities and continue to leverage new technologies related to both RNAi and to the delivery of siRNAs to the relevant tissues and cells, including the CNS, eye and lung;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">build and maintain a strong intellectual property portfolio;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">gain regulatory acceptance for the development and commercialization of our product candidates and market success for our approved products, as well as any other products we commercialize;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">attract and retain customers for our products;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">develop and maintain successful strategic alliances; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">manage our spending as costs and expenses increase due to clinical trials, regulatory approvals and commercialization.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If we are unsuccessful in accomplishing these objectives, we may not be able to develop product candidates, successfully commercialize our approved products or any future products, raise capital, if needed, repay the debt we incurred in 2020 and plan to incur in 2021, expand our business, achieve financial self-sustainability or continue our operations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We have a history of losses and may never become and remain consistently profitable.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have experienced significant operating losses since our inception. As of March&#160;31, 2021, we had an accumulated deficit of $4.79 billion. Although to date we have launched three products in the U.S., EU and various other countries globally, and expect to launch our commercially approved products in additional countries during 2021 and beyond, we may never attain profitability or positive cash flow from operations. For the three months ended March&#160;31, 2021, we recognized $135.8&#160;million in net product revenues from sales of ONPATTRO, GIVLAARI and OXLUMO. While our full year 2020 operating loss improved relative to the prior year, marking 2019 as our peak operating loss year, we expect to continue to incur annual net operating losses, and will require substantial resources over the next several years as we expand our efforts to discover, develop and commercialize RNAi therapeutics, and aim to achieve self sustainability by the end of 2025. While we believe the funding provided by our strategic financing collaboration with Blackstone should enable us to achieve a self-sustainable profile without the need for future equity financing, we will depend on our ability to generate revenues to achieve this goal. In addition to revenues derived from sales of our current and future, if any, commercially approved products, we anticipate that a portion of any revenues we generate over the next several years will continue to be from alliances with pharmaceutical and biotechnology companies. We cannot be certain that we will be able to maintain our existing alliances or secure and maintain new alliances, or meet the obligations or achieve any milestones that we may be required to meet or achieve to receive payments under our existing or new alliances. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We believe that to become and remain consistently profitable, we must succeed in discovering, developing and commercializing novel drugs with significant market potential. This will require us to build upon the success we have had in a range of challenging activities, including pre-clinical testing and clinical trial stages of development, obtaining regulatory approval and reimbursement for these novel drugs and manufacturing, marketing and selling them. We may never succeed as a commercial company, and may never generate revenues that are significant enough to achieve profitability. Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. If we cannot become and remain consistently profitable, the market price of our common stock could decline. In addition, we may be unable to raise capital, expand our business, develop additional product candidates or continue our operations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We will require substantial funds to continue our research, development and commercialization activities and if the funds we require are greater than what we have estimated, we may need to critically limit or significantly scale back or cease our operations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have used substantial funds to develop our RNAi technologies and will require substantial funds to conduct further research and development, including pre-clinical testing and clinical trials of our product candidates, and to manufacture, market and sell our three approved products and any other products that are approved for commercial sale. Because the length of time or activities associated with successful development of our product candidates, including vutrisiran, may be greater than we anticipate, we are unable to estimate the actual funds we will require to develop and commercialize them.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We believe 2019 was our peak operating loss year, and believe that our strategic financing collaboration with Blackstone will enable us to achieve a self-sustainable financial profile without need for future equity financing. However, our future capital requirements and the period for which we expect our existing resources to support our operations may vary from what </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9f86b6d3686546618ade3c76e6b23fc8_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">we expect. We have based our expectations on a number of factors, many of which are difficult to predict or are outside of our control, including:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">progress in our research and development programs, as well as what may be required by regulatory bodies to advance these programs;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the timing, receipt and amount of milestone and other payments, if any, from present and future collaborators, if any, including milestone payments related to Leqvio, which is being developed and commercialized by our partner, Novartis;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">our ability to maintain and establish additional collaborative arrangements and/or new business initiatives;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the resources, time and costs required to successfully initiate and complete our pre-clinical and clinical studies, obtain regulatory approvals, prepare for global commercialization of our product candidates and obtain and maintain licenses to third-party intellectual property;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">our ability to establish, maintain and operate our own manufacturing facilities in a timely and cost-effective manner;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">our ability to manufacture, or contract with third parties for the manufacture of, our product candidates for clinical testing and commercial sale;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the impact of COVID-19 on the initiation or completion of pre-clinical studies or clinical trials and the supply of our products or product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the resources, time and cost required for the preparation, filing, prosecution, maintenance and enforcement of patent claims;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the costs associated with legal activities, including litigation and government investigations, arising in the course of our business activities and our ability to prevail or reach a satisfactory result in any such legal disputes and investigations; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the timing, receipt and amount of sales and royalties, if any, from our approved products and our potential products, if and when approved; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the outcome of the regulatory review process and commercial success of drug products for which we are entitled to receive royalties, including Leqvio.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If our estimates, predictions and financial guidance relating to these factors are incorrect, we may need to modify our operating plan and may be required to seek additional funding in the future. We may do so through either collaborative arrangements, public or private equity offerings or debt financings, royalty or other monetization transactions or a combination of one or more of these funding sources. Additional funds may not be available to us on acceptable terms or at all.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In April 2020, we entered into a credit agreement, or Credit Agreement, for up to $750.0 million among us, certain of our subsidiaries (together with us, the Loan Parties), funds or accounts managed or advised by GSO Capital Partners LP (now Blackstone Alternative Credit Advisors LP) and certain other affiliates of Blackstone, and the other lenders from time to time party thereto and Wilmington Trust, National Association, as the administrative agent for the lenders. The Credit Agreement provides for a senior secured delayed draw term loan facility to be funded in three tranches, or Term Loans, each tranche to be requested by certain dates specified in the Credit Agreement, and subject to customary terms and conditions in the case of each tranche. The Term Loans mature seven years from the date of the first draw, and bear interest at a variable rate. All obligations under the Credit Agreement are secured, subject to certain exceptions, by security interests in certain assets, including the intellectual property owned by us relating to ONPATTRO, GIVLAARI and vutrisiran, the equity interests held by the Loan Parties in their subsidiaries, all of our ownership of the inclisiran royalty remaining after the royalty purchase and material real property, and certain personal property, including, without limitation, cash held in certain deposit accounts of the Loan Parties and equipment. The Credit Agreement contains negative covenants that, among other things and subject to certain exceptions, could restrict our ability to, incur additional liens, incur additional indebtedness, make investments, including acquisitions, engage in fundamental changes, sell or dispose of assets that constitute collateral, including certain intellectual property, pay dividends or make any distribution or payment on or redeem, retire or purchase any equity interests, amend, modify or waive certain material agreements or organizational documents and make payments of certain subordinated indebtedness. The Credit Agreement also requires us to have consolidated liquidity of at least $100.0 million as of the last day of each fiscal quarter. Additionally, the Credit Agreement contains certain customary representations and warranties, affirmative covenants and provisions relating to events of default. In August 2020, in connection with execution of the funding agreement for the clinical development of vutrisiran and ALN-AGT, or Funding Agreement, we entered into the First Amendment to the Credit Agreement. The First Amendment added certain intellectual property owned by us relating to ALN-AGT as collateral under the Credit Agreement, as amended, and made certain other amendments related thereto and the Funding Agreement. In December 2020, we drew down the first tranche of $200.0 million under the Credit Agreement, as amended. Our ability to satisfy our obligations under the Credit Agreement, as amended, and meet our debt service obligations will depend upon our future performance, which will be subject to financial, business and other factors affecting our operations, many of which are beyond </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9f86b6d3686546618ade3c76e6b23fc8_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">our control. If we are unable to secure future borrowings under the term loan facility, we may not be able to replace the financing commitment on favorable terms, or at all.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The terms of any financing we may be required to pursue in the future notwithstanding the funds due or available to us from Blackstone may adversely affect the holdings or the rights of our stockholders. If we raise additional funds by issuing equity securities, further dilution to our existing stockholders will result. In addition, as a condition to providing additional funding to us, future investors may demand, and may be granted, rights superior to those of existing stockholders. For example, pursuant to our stock purchase agreement with Blackstone, we agreed to register the resale of the shares purchased on a registration statement within 60 days of April 10, 2020, and on June 5, 2020, such registration statement was filed with the SEC. In addition, subject to certain conditions, Blackstone will be entitled to participate in registered underwritten public offerings by us if other selling stockholders are included in the registration.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If we are unable to obtain additional funding on a timely basis, we may be required to significantly delay or curtail one or more of our research or development programs, or delay or curtail the further development of our global commercial infrastructure, and our ability to achieve our long-term strategic goals may be delayed or diminished. We also could be required to seek funds through arrangements with collaborators or others that may require us to relinquish rights to some of our technologies, product candidates or products that we would otherwise pursue on our own.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Although we sold a portion of the expected royalty stream and commercial milestones from the global sales of Leqvio by our collaborator, Novartis, we are entitled to retain the remaining portion of future royalties from the global sales of Leqvio and, if certain specified thresholds are met, to the remaining portion of commercial milestone payments, and any negative developments related to Leqvio could have a material adverse effect on our receipt of those payments.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In April 2020, we </span><span style="background-color:#ffffff;color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">sold to Blackstone 50% of the royalties payable to us with respect to net sales by Novartis, its affiliates or sublicensees of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Leqvio</span><span style="background-color:#ffffff;color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> and 75% of the commercial milestone payments payable to us under the MDCO agreement. If Blackstone does not receive royalty payments in respect of global sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Leqvio</span><span style="background-color:#ffffff;color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> equaling at least </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$1.00&#160;billion</span><span style="background-color:#ffffff;color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> by December 31, 2029, Blackstone&#8217;s royalty interest will increase to 55% effective January 1, 2030.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Our receipt of future royalty payments and a portion of commercial milestone payments may be negatively impacted if the Leqvio royalty stream and commercial milestones payments are insufficient to meet the specified thresholds. For example, in December 2020, the FDA issued a complete response letter regarding Novartis' NDA for inclisiran, stating that the agency could not approve the NDA by the PDUFA action date due to unresolved facility inspection-related conditions. While Leqvio was granted marketing authorization by the EC in Europe in December 2020, any negative impact to future royalty payments and commercial milestone payments that results from a delayed approval in the U.S. could affect our ability to meet the specified repayment thresholds. Additional factors that may have an adverse effect on the Leqvio royalty stream and commercial milestones include:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">companies working to develop new therapies or alternative formulations of products for ASCVD;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">foreign currency movement, which could have a negative impact on Novartis&#8217; sales of Leqvio, thereby reducing the royalties; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">any negative developments relating to Leqvio, such as safety, efficacy, or reimbursement issues, could reduce demand for Leqvio;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">any disputes concerning patents, proprietary rights, or license and collaboration agreements could negatively impact our receipt of commercial milestone payments or royalties; and </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">adverse regulatory or legislative developments could limit or prohibit the sale of Leqvio, such as restrictions on the use of Leqvio or safety-related label changes, including enhanced risk management programs, which may significantly reduce expected royalty revenue and commercial milestone payments and could require significant expense to address the associated legal and regulatory issues.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If the revenues generated by sales of Leqvio are lower than expected, our business could be materially adversely affected.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We expect our operating results to fluctuate in future periods, which may adversely affect our stock price.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our quarterly operating results have fluctuated in the past, and we believe they will continue to do so in the future. Our operating results may fluctuate due to the impact of the COVID-19 or a future pandemic, the level of success of our commercial efforts and resulting revenues, as well as the variable nature of our operating expenses as a result of the timing and magnitude of expenditures. For example, due to the impact of the COVID-19 pandemic, product revenues in the second quarter of 2020 for ONPATTRO were less than originally forecast. In addition, in one or more future periods, our results of operations may fall below the expectations of securities analysts and investors. In that event, the market price of our common stock could substantially decline. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9f86b6d3686546618ade3c76e6b23fc8_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">If the estimates we make, or the assumptions on which we rely, in preparing our condensed consolidated financial statements and/or our projected guidance prove inaccurate, our actual results may vary from those reflected in our projections and accruals.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America, or GAAP. The preparation of these condensed consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of our assets, liabilities, revenues and expenses, the amounts of charges accrued by us and related disclosure of contingent assets and liabilities. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances. We cannot assure you, however, that our estimates, or the assumptions underlying them, will be correct.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Further, from time to time we issue financial guidance relating to our expectations regarding our non-GAAP research and development and selling, general and administrative expenses, and expectations for our cash, cash equivalents and marketable securities available for operations, which guidance is based on estimates and the judgment of management. If, for any reason, our expenses differ materially from our guidance or we utilize our cash more quickly than anticipated, we may have to adjust our publicly announced financial guidance. If we fail to meet, or if we are required to change or update any element of, our publicly disclosed financial guidance or other expectations about our business, our stock price could decline.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">The investment of our cash, cash equivalents and marketable securities is subject to risks which may cause losses and affect the liquidity of these investments.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of March&#160;31, 2021, we had $1.71 billion in cash, cash equivalents and marketable securities. We historically have invested these amounts in high&#8211;grade corporate notes, commercial paper, securities issued or sponsored by the U.S. government, certificates of deposit and money market funds meeting the criteria of our investment policy, which is focused on the preservation of our capital. Corporate notes may also include foreign bonds denominated in U.S. dollars. These investments are subject to general credit, liquidity, market and interest rate risks. We may realize losses in the fair value of these investments or a complete loss of these investments, which would have a negative effect on our consolidated financial statements. In addition, should our investments cease paying or reduce the amount of interest paid to us, our interest income would suffer. The market risks associated with our investment portfolio may have an adverse effect on our results of operations, liquidity and financial condition.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Changes in tax law could adversely affect our business and financial condition. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our business is subject to numerous international, federal, state, and other governmental laws, rules, and regulations that may adversely affect our operating results, including, taxation and tax policy changes, tax rate changes, new tax laws, or revised tax law interpretations, which individually or in combination may cause our effective tax rate to increase. In the U.S., the rules dealing with federal, state, and local income taxation are constantly under review by persons involved in the legislative process and by the Internal Revenue Service and the U.S. Treasury Department. Changes to tax laws (which changes may have retroactive application) could adversely affect us or holders of our common stock. In recent years, many such changes have been made and changes are likely to continue to occur in the future. For example, the Coronavirus Aid, Relief, and Economic Security Act, or CARES Act, enacted in March 2020, which included certain changes in tax law intended to stimulate the U.S. economy in light of the COVID-19 pandemic, including temporary changes to the treatment of net operating losses, interest deductibility limitations and payroll tax matters. Future changes in tax laws could have a material adverse effect on our business, cash flow, financial condition or results of operations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Additionally, the Organization for Economic Co-operation and Development, or OECD, the EC, and individual taxing jurisdictions where we and our affiliates do business have recently focused on issues related to the taxation of multinational corporations. The OECD has released its comprehensive plan to create an agreed set of international rules for fighting base erosion and profit shifting. In addition, the OECD, the EC and individual counties are examining changes to how taxing rights should be allocated among countries considering the digital economy. As a result, the tax laws in the U.S. and other countries in which we and our affiliates do business could change on a prospective or retroactive basis and any such changes could materially adversely affect our business.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Risks Related to Our Dependence on Third Parties</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We may not be able to execute our business strategy if we are unable to maintain existing or enter into new alliances with other companies that can provide business and scientific capabilities and funds for the development and commercialization of our product candidates. If we are unsuccessful in forming or maintaining these alliances on terms favorable to us, our business may not succeed.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are continuing to advance our commercial capabilities, including in marketing, sales, market access and distribution, to support our wholly-owned products. We also continue to advance our growing pipeline of RNAi therapeutic opportunities. However, we may not have adequate capacity or capabilities to advance all of our therapeutic opportunities. Accordingly, we have entered into alliances with other companies and collaborators that we believe can provide such capabilities in certain territories and/or for certain product candidates, and we intend to enter into additional such alliances in the future. Our collaboration strategy is to form alliances that create significant value for us and our collaborators in the advancement of RNAi </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9f86b6d3686546618ade3c76e6b23fc8_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">therapeutics as a new class of innovative medicines. Specifically, with respect to our Genetic Medicine pipeline, as a result of our broad strategic alliance with Sanofi Genzyme formed in 2014, Sanofi Genzyme has the right to develop and commercialize fitusiran globally. In addition, we formed a collaboration with MDCO (which was acquired by Novartis in January 2020) to advance inclisiran. In March 2018, we entered into a discovery collaboration with Regeneron to identify RNAi therapeutics for NASH and potentially other related diseases, and in November 2018, we and Regeneron entered into a separate, fifty-fifty collaboration to further research, co-develop and commercialize any therapeutic product candidates that emerge from these discovery efforts. In October 2017, we announced an exclusive licensing agreement with Vir for the development and commercialization of RNAi therapeutics for infectious diseases, including chronic HBV infection, and in early 2020, we expanded our exclusive licensing agreement to include the development and commercialization of RNAi therapeutics targeting SARS-CoV-2, the virus that causes the disease COVID-19, as well as up to three human host factor targets relating to susceptibility to coronaviruses, for use in connection with the treatment, palliation, diagnosis or prevention of SARS-CoV-2 and other diseases caused by coronaviruses. In April 2020, we entered into a development and commercialization collaboration with Dicerna to advance investigational RNAi therapeutics for the treatment of alpha-1 liver disease. With respect to our CNS/Ocular Disease pipeline, in April 2019, we announced a global, strategic collaboration with Regeneron to discover, develop and commercialize RNAi therapeutics for a broad range of diseases by addressing therapeutic targets expressed in the eye and CNS, in addition to a select number of targets expressed in the liver. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In such alliances, we expect our current, and may expect our future, collaborators to provide substantial capabilities in clinical development, regulatory affairs, and/or marketing, sales and distribution. Under certain of our alliances, we also may expect our collaborators to develop, market and/or sell certain of our product candidates. We may have limited or no control over the development, sales, marketing and distribution activities of these third parties. Our future revenues may depend heavily on the success of the efforts of these third parties. For example, we will rely entirely on (i) Regeneron for the development and commercialization of all programs targeting eye diseases (subject to limited exceptions), and potentially other CNS and liver programs, (ii) Novartis for all future development and commercialization of Leqvio worldwide, and (iii) Sanofi Genzyme for the development and commercialization of fitusiran worldwide. In the case of each such collaboration referenced in clauses (i)-(iii) above, we are entitled to royalties on the sales of each of these products. If our collaborators are not successful in their development and/or commercialization efforts, our future revenues from RNAi therapeutics for these indications may be adversely affected. For example, while Leqvio was granted marketing authorization by the EC in Europe, in December 2020, Novartis received a complete response letter from the FDA stating that the agency could not approve the NDA by the PDUFA action date due to unresolved facility inspection-related conditions, which will likely delay the launch of Leqvio in the U.S. If the revenues generated by the royalties received by Blackstone from us with respect to Leqvio sales do not reach a certain level by the end of 2029, Blackstone will be entitled to a higher royalty percentage beginning in 2030, which would have an adverse impact on our revenues beginning in 2030.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We may not be successful in entering into future alliances on terms favorable to us due to various factors, including our ability to successfully demonstrate POC for our technology in humans in certain tissues or disease areas, including our alternative conjugate approach for delivering CNS or ocular product candidates, our ability to demonstrate the safety and efficacy of our specific drug candidates, our ability to manufacture or have third parties manufacture RNAi therapeutics, the strength of our intellectual property and/or concerns around challenges to our intellectual property. For example, our decision in October 2016 to discontinue development of revusiran could give rise to concerns around the safety and/or efficacy of our technology platform or product candidates. In addition, the occurrence of a fatal thrombotic SAE in our fitusiran study in 2017 and a subsequent pause in dosing and enrollment in fitusiran clinical studies in 2020 could contribute to further concerns about the safety of specific therapeutic candidates or therapeutic candidates for specific diseases. Even when we succeed in securing such alliances, we may not be able to maintain them if, for example, development or approval of a product candidate is delayed, challenges are raised as to the validity or scope of our intellectual property, we are unable to secure adequate reimbursement from payors or sales of an approved drug are lower than we expected.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Furthermore, any delay in entering into collaboration agreements would likely either delay the development and commercialization of certain of our product candidates and reduce their competitiveness even if they reach the market, or prevent the development of certain product candidates. Any such delay related to our collaborations could adversely affect our business.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For certain product candidates, we have formed collaborations to fund all or part of the costs of drug development and commercialization, such as our collaborations with Regeneron, Novartis, Vir, Dicerna and Sanofi Genzyme. We may not, however, be able to enter into additional collaborations for certain other programs, and the terms of any collaboration agreement we do secure may not be favorable to us. If we are not successful in our efforts to enter into future collaboration arrangements with respect to one or more of our product candidates, we may not have sufficient funds to develop these product candidates or other product candidates internally, or to bring our product candidates to market. If we do not have sufficient funds to develop and bring our product candidates to market, we will not be able to generate revenues from these product candidates, and this will substantially harm our business.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9f86b6d3686546618ade3c76e6b23fc8_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">If any collaborator materially amends, terminates or fails to perform its obligations under agreements with us, the development and commercialization of our product candidates could be delayed or terminated.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our dependence on collaborators for capabilities and funding means that our business could be adversely affected if any collaborator materially amends or terminates its collaboration agreement with us or fails to perform its obligations under that agreement. Our current or future collaborations, if any, may not be scientifically or commercially successful. Disputes may arise in the future with respect to the ownership of rights to technology or products developed with collaborators, which could have an adverse effect on our ability to develop and commercialize any affected product candidate. Our current collaborations allow, and we expect that any future collaborations will allow, either party to terminate the collaboration for a material breach by the other party. In addition, our collaborators may have additional termination rights for convenience with respect to the collaboration or a particular program under the collaboration, under certain circumstances. For example, our agreement with MDCO, which was acquired by Novartis in January 2020, relating to the development and commercialization of inclisiran worldwide may be terminated by MDCO at any time upon four months&#8217; prior written notice, provided if the agreement is terminated by MDCO for convenience, MDCO has agreed to grant a license to us under certain of our technology developed in the course of MDCO's activities under the agreement, subject to a royalty to be negotiated between the parties. Moreover, any adverse actions by Novartis with respect to the MDCO agreement could adversely impact our ability to comply with our obligations under our agreements with Blackstone. If we were to lose a commercialization collaborator, we would have to attract a new collaborator or develop expanded sales, distribution and marketing capabilities internally, which would require us to invest significant amounts of financial and management resources.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, if we have a dispute with a collaborator over the ownership of technology or other matters, or if a collaborator terminates its collaboration with us, for breach or otherwise, or determines not to pursue the research, development and/or commercialization of RNAi therapeutics, it could delay our development of product candidates, result in the need for additional company resources to develop product candidates, require us to expend time and resources to develop expanded sales and marketing capabilities on a more expedited timeline, make it more difficult for us to attract new collaborators and could adversely affect how we are perceived in the business and financial communities.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Moreover, a collaborator, or in the event of a change in control of a collaborator or the assignment of a collaboration agreement to a third party, the successor entity or assignee, as in the case of MDCO and Novartis, could determine that it is in its interests to:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">pursue alternative technologies or develop alternative products, either on its own or jointly with others, that may be competitive with the products on which it is collaborating with us or which could affect its commitment to the collaboration with us;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">pursue higher-priority programs or change the focus of its development programs, which could affect the collaborator&#8217;s commitment to us; or</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">if it has marketing rights, choose to devote fewer resources to the marketing of our product candidates, if any are approved for marketing, than it does for product candidates developed without us.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If any of these occur, the development and commercialization of one or more products or product candidates could be delayed, curtailed or terminated because we may not have sufficient financial resources or capabilities to continue such development and commercialization on our own.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We have limited manufacturing experience and resources and we must incur significant costs to develop this expertise and/or rely on third parties to manufacture our products.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have limited manufacturing experience. In order to continue to commercialize our approved products, continue to develop our current product candidates, including vutrisiran, apply for regulatory approvals and, if approved, commercialize future products, we will need to develop, contract for, or otherwise arrange for the necessary manufacturing capabilities. Historically, our internal manufacturing capabilities were limited to small-scale production of material for use in in vitro and in vivo experiments that is not required to be produced under cGMP standards. During 2012, we developed cGMP capabilities and processes for the manufacture of patisiran formulated bulk drug product for late stage clinical trial use and commercial supply. In addition, during 2020, we completed construction and qualification of our cGMP manufacturing facility in Norton, Massachusetts where we will manufacture drug substance for clinical and, eventually, commercial use. In December 2020, we began cGMP operations, and we believe this facility will enable us to initiate manufacturing for multiple new early-stage programs over the next few years, as well as provide us the manufacturing capabilities to support our late-stage and commercial programs in the future.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">At the present time, we may manufacture limited quantities of clinical trial materials ourselves, but otherwise we continue to rely on third parties to manufacture the drug substance and finished product we will require for any clinical trials that we initiate and to support the commercial supply of our approved products and any of our other product candidates. There are a limited number of manufacturers that supply synthetic siRNAs. We currently rely on a limited number of CMOs for our supply of synthetic siRNAs. There are risks inherent in pharmaceutical manufacturing that could affect the ability of our contract manufacturing organizations, or CMOs, to meet our delivery time requirements or provide adequate amounts of material to </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9f86b6d3686546618ade3c76e6b23fc8_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">meet our needs, and ultimately delay our clinical trials and potentially put at risk commercial supply, as well as result in additional expense to us. To fulfill our siRNA requirements, we will likely need to secure alternative suppliers of synthetic siRNAs and such alternative suppliers are limited and may not be readily available, or we may be unable to enter into agreements with them on reasonable terms and in a timely manner. As noted above, in order to ensure long-term supply capabilities for our RNAi therapeutics, we are developing our own capabilities to manufacture drug substance for clinical and commercial use.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition to the manufacture of the synthetic siRNAs, we may have additional manufacturing requirements related to the technology required to deliver the siRNA to the relevant cell or tissue type, such as LNPs or conjugates. In some cases, the delivery technology we utilize is highly specialized or proprietary, and for technical and/or legal reasons, we may have access to only one or a limited number of potential manufacturers for such delivery technology. In addition, the scale-up of our delivery technologies could be very difficult and/or take significant time. We also have very limited experience in such scale-up and manufacturing, requiring us to depend on a limited number of third parties, who might not be able to deliver in a timely manner, or at all. Failure by manufacturers to properly manufacture our delivery technology and/or formulate our siRNAs for delivery could result in unusable product, supply delays and shortages. Furthermore, competition for supply from our manufacturers from other companies, a breach by such manufacturers of their contractual obligations or a dispute with such manufacturers would cause delays in our discovery and development efforts, as well as additional expense to us. The CARES Act was enacted in March 2020 in response to the COVID-19 pandemic. Under the CARES Act, manufacturers must have in place a risk management plan that identifies and evaluates the risks to the supply of approved drugs for certain serious diseases or conditions for each establishment where the drug or active pharmaceutical ingredient is manufactured. The risk management plan will be subject to FDA review during an inspection. If we experience shortages in the supply of our marketed products, our results could be materially impacted. To date, several vaccines for COVID-19 have been granted Emergency Use Authorization by the FDA, and the resultant demand for vaccines and potential for manufacturing facilities and materials to be commandeered under the Defense Production Act of 1950, or equivalent foreign legislation, may make it more difficult to obtain materials or manufacturing slots for the products needed for our clinical trials or commercial products, which could lead to delays in these trials or issues with our commercial supply.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">In developing manufacturing capabilities by building our own manufacturing facilities, we have incurred substantial expenditures, and expect to incur significant additional expenditures in the future. Also, we have had to, and will likely need to continue to, hire and train qualified employees to staff our facilities. If we are unable to manufacture sufficient quantities of material or if we encounter problems with our facilities in the future, we may also need to secure alternative suppliers, and such alternative suppliers may not be available, or we may be unable to enter into agreements with them on reasonable terms and in a timely manner. Given our dependence on a limited number of CMOs to supply our commercial products and clinical candidates, and our dependence on our own facility, any delay in supply caused by the COVID-19 pandemic could impact our ability to procure sufficient supplies for our approved products, and the development of our product candidates could also be delayed. Any delay or setback in the manufacture of our approved products could impede ongoing commercial supply, which could significantly impact our revenues and operating results. In addition, to the extent we or our partners rely on CMOs outside of the U.S. to supply drug substance for our product candidates, any delays or disruptions in supply caused by the COVID-19 pandemic could have a material adverse impact on the research and development activities and potential commercialization of our or our partners' product candidates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The manufacturing process for our approved products and any other products that we may develop, is subject to the FDA and foreign regulatory authority approval process and we will need to meet, and will need to contract with CMOs who can meet, all applicable FDA and foreign regulatory authority requirements on an ongoing basis. In addition, if we receive the necessary regulatory approval for any product candidate, we also expect to rely on third parties, including potentially our commercial collaborators, to produce materials required for commercial supply. We may experience difficulty in obtaining adequate manufacturing capacity for our needs and the needs of our collaborators, who we have, in some instances, the obligation to supply. If we are unable to obtain or maintain CMOs for our product candidates and/or our marketed products, or to do so on commercially reasonable terms, we may not be able to successfully develop and commercialize our products.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">To the extent that we have existing, or enter into future, manufacturing arrangements with third parties, we depend, and will depend in the future, on these third parties, to perform their obligations in a timely manner and consistent with contractual and regulatory requirements, including those related to quality control and quality assurance. The failure of any CMO to perform its obligations as expected, or, to the extent we manufacture all or a portion of our product candidates ourselves, our failure to execute on our manufacturing requirements, could adversely affect our business in a number of ways, including:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">we or our current or future collaborators may not be able to initiate or continue clinical trials of product candidates that are under development;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">we or our current or future collaborators may be delayed in submitting regulatory applications, or receiving regulatory approvals, for our product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">we may lose the cooperation of our collaborators;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">our facilities and those of our CMOs, and our products could be the subject of inspections by regulatory authorities that could have a negative outcome and result in delays in supply;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9f86b6d3686546618ade3c76e6b23fc8_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">we may be required to cease distribution or recall some or all batches of our products or take action to recover clinical trial material from clinical trial sites; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">ultimately, we may not be able to meet commercial demands for our products.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We rely on third parties to conduct our clinical trials, and if they fail to fulfill their obligations, our development plans may be adversely affected.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We rely on independent clinical investigators, contract research organizations, or CROs, and other third-party service providers to assist us in managing, monitoring and otherwise carrying out our clinical trials. We have contracted, and we plan to continue to contract with, certain third parties to provide certain services, including site selection, enrollment, monitoring, auditing and data management services. These investigators and CROs are not our employees and we have limited control over the amount of time and resources they dedicate to our programs. These third parties may have contractual relationships with other entities, some of which may be our competitors, which may draw their time and resources away from our programs. Although we depend heavily on these parties, we control only certain aspects of their activity and therefore, we cannot be assured that these third parties will adequately perform all of their contractual obligations to us in compliance with regulatory and other legal requirements and our internal policies and procedures. Nevertheless, we are responsible for ensuring that each of our studies is conducted in accordance with the applicable protocol, legal, regulatory and scientific standards, and our reliance on third parties does not relieve us of our regulatory responsibilities. We and our CROs are required to comply with applicable GCP requirements, which are regulations and guidelines enforced by the FDA and comparable foreign regulatory authorities for all of our product candidates in clinical development, and to implement timely corrective action to any non-compliance. Regulatory authorities enforce these GCP requirements through periodic inspections of trial sponsors, principal investigators and trial sites, including in connection with the review of marketing applications. If we or any of our CROs fail to comply with applicable GCP requirements, or fail to take any such corrective action, the clinical data generated in our clinical trials may be deemed unreliable and the FDA, the EMA, the Pharmaceuticals and Medical Devices Agency in Japan or comparable foreign regulatory authorities may require us to take additional action or perform additional clinical trials before approving our marketing applications. We cannot assure you that upon inspection by a given regulatory authority in the future, such regulatory authority will determine that any of our clinical trials comply with GCP regulations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If our third-party service providers cannot adequately and timely fulfill their obligations to us for any reason, including due to disruptions caused by the COVID-19 pandemic on their operations or at the sites they are overseeing, or if the quality and accuracy of our clinical trial data is compromised due to failure by such third party to adhere to our protocols or regulatory requirements or if such third parties otherwise fail to meet deadlines, our development plans and/or regulatory reviews for marketing approvals may be delayed or terminated. As a result, our stock price would likely be negatively impacted, and our results of operations and the commercial prospects for our product candidates would be harmed, our costs could increase and our ability to generate additional revenues could be delayed.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Risks Related to Managing Our Operations</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">If we are unable to attract and retain qualified key management and scientists, development, medical and commercial staff, consultants and advisors, our ability to implement our business plan may be adversely affected.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are highly dependent upon our senior management and our scientific, clinical, sales and medical staff. The loss of the service of any of the members of our senior management, including Dr. John Maraganore, our Chief Executive Officer, may significantly delay or prevent the achievement of product development and commercialization, and other business objectives. Our employment arrangements with our key personnel are terminable without notice. We do not carry key person life insurance on any of our employees.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have grown our workforce significantly over the past several years and anticipate continuing to add additional employees as we focus on achieving our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Alnylam P</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">x25 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">strategy. We face intense competition for qualified individuals from numerous pharmaceutical and biotechnology companies, universities, governmental entities and other research institutions, many of which have substantially greater resources with which to attract and reward qualified individuals than we do. In addition, due to the risks associated with developing a new class of medicine, we may face additional challenges in attracting and retaining employees. If we are not successful commercializing our approved products, we may be unable to attract and retain highly qualified sales and marketing professionals to support our approved products and our future products, if approved, including vutrisiran. Accordingly, we may be unable to attract and retain suitably qualified individuals in order to support our growing research, development and global commercialization efforts and initiatives, and our failure to do so could have an adverse effect on our ability to implement our future business plans.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We may have difficulty expanding our operations successfully as we continue our evolution from a U.S.- and EU-based company primarily involved in discovery, pre-clinical testing and clinical development into a global company that develops and commercializes multiple drugs.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As we continue the commercial launches of our approved products, and increase the number of product candidates we are developing, we will need to continue to expand our operations in the U.S. and further develop operations in the EU and other geographies, including Asia and Latin America. To date, we have received regulatory approval for ONPATTRO in the U.S., </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9f86b6d3686546618ade3c76e6b23fc8_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">EU, Japan and other countries globally, and as a result of the January 2018 amendment to our Sanofi Genzyme collaboration, we have global development and commercialization rights for ONPATTRO. In addition, we have received regulatory approval for our second RNAi therapeutic, GIVLAARI in the U.S., EU</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, Brazil, Canada and have also filed for marketing approval in Switzerland and Japan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. In November 2020, we received regulatory approval for our third RNAi therapeutic, OXLUMO in the U.S. and EU. We plan to file for additional regulatory approvals for each of our commercially approved products in additional countries during 2021 and beyond.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">From 2016 through 2020, we grew our workforce significantly and anticipate continuing to hire additional employees globally in the future as we focus on the commercialization of ONPATTRO, GIVLAARI and OXLUMO and achieving our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Alnylam P</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">x25 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">strategy. This growth has placed a strain on our administrative and operational infrastructure and, as a result, we will need to continue to develop additional and/or new infrastructure and capabilities to support our growth and obtain additional space to conduct our global operations in the U.S., the EU, Japan, Latin America and other geographies. If we are unable to develop such additional infrastructure or obtain sufficient space to accommodate our growth in a timely manner and on commercially reasonable terms, our business could be negatively impacted. As we continue the commercialization of our approved products, and as the product candidates we develop enter and advance through clinical trials, we will need to continue to expand our global development, regulatory, manufacturing, quality, compliance, and marketing and sales capabilities, or contract with other organizations to provide these capabilities for us. In addition, as our operations continue to expand, we will need to successfully manage additional relationships with various collaborators, suppliers, distributors and other organizations. Our ability to manage our operations and future growth will require us to continue to enhance our operational, financial and management controls and systems, reporting systems and infrastructure, and policies and procedures. We may not be able to implement enhancements to our management information and control systems in an efficient or timely manner and may discover deficiencies in existing systems and controls.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">The increasing use of social media could give rise to liability.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Social media is increasingly being used to communicate about our clinical development programs and the diseases our investigational RNAi therapeutics are being developed to treat, and we are utilizing what we believe is appropriate social media in connection with our commercialization efforts for our approved products, and we intend to do the same for our future products, if approved, including vutrisiran. Social media practices in the biopharmaceutical industry continue to evolve and regulations and regulatory guidance relating to such use are evolving and not always clear. This evolution creates uncertainty and risk of noncompliance with regulations applicable to our business, resulting in potential regulatory actions against us, along with the potential for litigation related to off-label marketing or other prohibited activities. For example, for our clinical-stage candidates, patients may use social media channels to comment on their experience in an ongoing blinded clinical study or to report an alleged AE. When such disclosures occur, there is a risk that study enrollment may be adversely impacted, we fail to monitor and comply with applicable AE reporting obligations or that we may not be able to defend our business or the public&#8217;s legitimate interests in the face of the political and market pressures generated by social media due to restrictions on what we may say about our investigational products. There is also a risk of inappropriate disclosure of sensitive information or negative or inaccurate posts or comments about us on any online platform, including a blog on the internet, or a post on a website, that can be distributed rapidly and could negatively harm our reputation. If any of these events were to occur or we otherwise fail to comply with applicable regulations, we could incur liability, face regulatory actions or incur other harm to our business.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our business and operations could suffer in the event of system failures or unauthorized or inappropriate use of or access to our systems.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are increasingly dependent on our information technology systems and infrastructure for our business. We collect, store and transmit sensitive information including intellectual property, proprietary business information and personal information in connection with business operations. The secure maintenance of this information is critical to our operations and business strategy. Some of this information could be an attractive target of criminal attack or unauthorized access and use by third parties with a wide range of motives and expertise, including organized criminal groups, &#8220;hacktivists,&#8221; patient groups, disgruntled current or former employees and others. Cyber-attacks are of ever-increasing levels of sophistication, and despite our security measures, our information technology and infrastructure may be vulnerable to such attacks or may be breached, including due to employee error or malfeasance.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Despite the implementation of security measures, our internal computer systems and those of our contractors and consultants are vulnerable to damage or interruption from computer viruses, unauthorized or inappropriate access or use, natural disasters, pandemics (including COVID-19), terrorism, war, and telecommunication and electrical failures. Such events could cause interruption of our operations. For example, the loss of pre-clinical trial data or data from completed or ongoing clinical trials for our product candidates could result in delays in our regulatory filings and development efforts, as well as delays in the commercialization of our products, and significantly increase our costs. To the extent that any disruption, security breach or unauthorized or inappropriate use or access to our systems were to result in a loss of or damage to our data, or inappropriate disclosure of confidential or proprietary information, including but not limited to patient, employee or vendor information, we could incur notification obligations to affected individuals and government agencies, liability, including potential lawsuits from patients, collaborators, employees, stockholders or other third parties and liability under foreign, federal and state laws that </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9f86b6d3686546618ade3c76e6b23fc8_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">protect the privacy and security of personal information, and the development and potential commercialization of our product candidates could be delayed.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">The results of the United Kingdom&#8217;s referendum on withdrawal from the EU may have a negative effect on global economic conditions, financial markets and our business.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Following the results of a referendum in 2016, the United Kingdom, or UK, left the EU on January 31, 2020, commonly referred to as &#8220;Brexit.&#8221; Pursuant to the formal withdrawal arrangements agreed between the UK and the EU, the UK was subject to a transition period until December 31, 2020, or the Transition Period, during which EU rules continued to apply, while the future relationship between the UK and EU was formally negotiated. The UK and the EU have signed a EU-UK Trade and Cooperation Agreement, which became provisionally applicable on January 1, 2021 and will become formally applicable once ratified by both the UK and the EU. This agreement provides details on how some aspects of the UK and EU&#8217;s relationship will operate going forwards, however there are still many uncertainties. The long-term effects of Brexit will depend in part on how the EU-UK Trade and Cooperation Agreement, and any future agreements signed by the UK and the EU, take effect in practice. Such a withdrawal from the EU is unprecedented, and it is unclear how the restrictions on the UK&#8217;s access to the European single market for goods, capital, services and labor within the EU and the wider commercial, legal and regulatory environment, could impact our current and future operations and clinical activities in the UK.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For example, Brexit could result in the UK significantly altering its regulations affecting the clearance or approval of our product candidates that are developed in the UK, now that UK legislation has the potential to diverge from EU legislation. Any new regulations could add time and expense to the conduct of our business, as well as the process by which our products receive regulatory approval in the UK, the EU and elsewhere. The uncertainty concerning the UK&#8217;s legal, political and economic relationship with the EU following Brexit may also be a source of instability in the international markets, create significant currency fluctuations, and/or otherwise adversely affect trading agreements or similar cross-border co-operation arrangements (whether economic, tax, fiscal, legal, regulatory or otherwise). Any of these effects of Brexit, among others, could adversely affect our business, our results of operations, liquidity and financial condition.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Risks Related to Our Industry</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Risks Related to Development, Clinical Testing and Regulatory Approval of Our Product Candidates and the Commercialization of Our Approved Products</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Any product candidates we or our partners develop may fail in development or be delayed to a point where they do not become commercially viable.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Before obtaining regulatory approval for the commercial distribution of our product candidates, we must conduct, at our own expense, extensive nonclinical tests and clinical trials to demonstrate the safety and/or efficacy in humans of our product candidates. Nonclinical and clinical testing is expensive, difficult to design and implement, can take many years to complete and is uncertain as to outcome, and the historical failure rate for product candidates is high. We currently have multiple programs in clinical development, including internal and partnered programs in Phase 3 development, as well as several earlier-stage clinical programs. In January 2021, we announced positive topline results from the HELIOS-A Phase 3 study of vutrisiran, an investigational RNAi therapeutic in development for the treatment of ATTR amyloidosis. Based on these positive results, we submitted an NDA for vutrisiran with the FDA in April 2021. We also expect to submit an MAA in the EU upon obtaining the topline results from the 18-month analysis, which are expected in late 2021. However, we may not be able to further advance this or any other product candidate through clinical trials and regulatory approval.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Additionally, several of our planned and ongoing clinical trials, such as our HELIOS-A study, utilize an &#8220;open-label&#8221; trial design. An &#8220;open-label&#8221; clinical trial is one where both the patient and investigator know whether the patient is receiving the investigational product candidate or either an existing approved drug or placebo. Most typically, open-label clinical trials test only the investigational product candidate and sometimes may do so at different dose levels. Open-label clinical trials are subject to various limitations that may exaggerate any therapeutic effect as patients in open-label clinical trials are aware when they are receiving treatment. Open-label clinical trials may be subject to a &#8220;patient bias&#8221; where patients perceive their symptoms to have improved merely due to their awareness of receiving an experimental treatment. In addition, open-label clinical trials may be subject to an &#8220;investigator bias&#8221; where those assessing and reviewing the physiological outcomes of the clinical trials are aware of which patients have received treatment and may interpret the information of the treated group more favorably given this knowledge. The results from an open-label trial may not be predictive of future clinical trial results with any of our product candidates for which we include an open-label clinical trial when studied in a controlled environment with a placebo or active control.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If we enter into clinical trials, the results from nonclinical testing or early clinical trials of a product candidate may not predict the results that will be obtained in subsequent subjects or in subsequent human clinical trials of that product candidate or any other product candidate. There is a high failure rate for drugs proceeding through clinical studies. A number of companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in clinical development even after achieving promising results in earlier studies, and any such setbacks in our clinical development could have a material adverse effect on our business and operating results. Moreover, our approved products and our current product candidates, employ </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9f86b6d3686546618ade3c76e6b23fc8_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">novel delivery technologies that, with the exception of inclisiran, have yet to be extensively evaluated in human clinical trials and proven safe and effective.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, we, the FDA or other applicable regulatory authorities, or an IRB or similar foreign review board or committee, may delay initiation of or suspend clinical trials of a product candidate at any time for various reasons, including if we or they believe the healthy volunteer subjects or patients participating in such trials are being exposed to unacceptable health risks. Among other reasons, adverse side effects of a product candidate or related product on healthy volunteer subjects or patients in a clinical trial could result in our decision, or a decision by the FDA or foreign regulatory authorities, to suspend or terminate the trial, or, in the case of regulatory agencies, a refusal to approve a particular product candidate for any or all indications of use. For example, in October 2016, we announced our decision to discontinue development of revusiran, an investigational RNAi therapeutic that was being developed for the treatment of patients with cardiomyopathy due to hATTR amyloidosis. Our decision followed the recommendation of the revusiran ENDEAVOUR Phase 3 study Data Monitoring Committee to suspend dosing and the observation of an imbalance in mortality in revusiran-treated patients as compared to those on placebo. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Clinical trials of a new product candidate require the enrollment of a sufficient number of patients, including patients who are suffering from the disease the product candidate is intended to treat and who meet other eligibility criteria. Rates of patient enrollment are affected by many factors, including the size of the patient population, the age and condition of the patients, the stage and severity of disease, the availability of clinical trials for other investigational drugs for the same disease or condition, the nature of the protocol, the proximity of patients to clinical sites, the availability of effective treatments for the relevant disease, and the eligibility criteria for the clinical trial. For example, we or our partners may experience difficulty enrolling our clinical trials, including, but not limited to, the ongoing clinical trials for fitusiran, due to the availability of existing approved treatments, as well as other investigational treatments in development. In addition, in November 2018 we announced that due to recruitment challenges, we had discontinued a Phase 2 study of cemdisiran in atypical hemolytic uremic syndrome and are focusing our cemdisiran clinical development efforts in a different indication. Delays or difficulties in patient enrollment or difficulties retaining trial participants, including as a result of the availability of existing or other investigational treatments or safety concerns, including the impact of public health emergencies such as the COVID-19 pandemic, can result in increased costs, longer development times or termination of a clinical trial.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Although our investigational RNAi therapeutics have been generally well-tolerated in our clinical trials to date, new safety findings may emerge. For example, in September 2017, we announced that we had temporarily suspended dosing in all ongoing fitusiran studies pending further review of a fatal thrombotic SAE that occurred in a patient with hemophilia A without inhibitors who was receiving fitusiran in our Phase 2 OLE study. More recently, in October 2020, Sanofi Genzyme announced that it voluntarily paused dosing in all ongoing fitusiran clinical studies to assess reports of non-fatal thrombotic events in patients participating in the ATLAS Phase 3 program. Following an assessment of available data and alignment with the FDA in December 2020, Sanofi Genzyme announced in February 2021 that patients had been restarted on fitusiran under amended protocols in ongoing adolescent and adult clinical studies, resulting in an estimated 18-month delay in the timing of Sanofi Genzyme's planned filing for regulatory approval of fitusiran, subject to positive Phase 3 results.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As demonstrated by the discontinuation of our revusiran program in October 2016, the temporary suspension of dosing in September 2017 in our fitusiran studies, as well as Sanofi Genzyme's voluntary pause of fitusiran studies in October 2020, the occurrence of SAEs and/or adverse events, or AEs, can result in the suspension or termination of clinical trials of a product candidate by us, our partners, or the FDA or a foreign regulatory authority. The occurrence of SAEs and/or AEs could also result in refusal by the FDA or a foreign regulatory authority to approve a particular product candidate for any or all indications of use.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Clinical trials also require the review, oversight and approval of institutional review boards, or IRBs, or, outside of the U.S., an independent ethics committee, which continually review clinical investigations and protect the rights and welfare of human subjects. Inability to obtain or delay in obtaining IRB or ethics committee approval can prevent or delay the initiation and completion of clinical trials, and the FDA or foreign regulatory authorities may decide not to consider any data or information derived from a clinical investigation not subject to initial and continuing IRB or ethics committee review and approval, as the case may be, in support of a marketing application.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our product candidates that we develop may encounter problems during clinical trials that will cause us, an IRB, ethics committee or regulatory authorities to delay, suspend or terminate these trials, or that will delay or confound the analysis of data from these trials. If we experience any such problems, we may not have the financial resources to continue development of the product candidate that is affected, or development of any of our other product candidates. We may also lose, or be unable to enter into, collaborative arrangements for the affected product candidate and for other product candidates we are developing.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9f86b6d3686546618ade3c76e6b23fc8_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A failure of one or more of our clinical trials can occur at any stage of testing. We may experience numerous unforeseen events during, or as a result of, nonclinical testing and the clinical trial process that could delay or prevent regulatory approval or our ability to commercialize our product candidates, including:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">our nonclinical tests or clinical trials may produce negative or inconclusive results, and we may decide, or regulators may require us, to conduct additional nonclinical testing or clinical trials, or we may abandon projects that we expect to be promising;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">delays in filing IND applications or comparable foreign applications or delays or failure in obtaining the necessary approvals from regulators or IRBs/ethics committees in order to commence a clinical trial at a prospective trial site, or their suspension or termination of a clinical trial once commenced;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">conditions imposed on us by an IRB or ethics committee, or the FDA or comparable foreign authorities regarding the scope or design of our clinical trials;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">problems in engaging IRBs or ethics committees to oversee clinical trials or problems in obtaining or maintaining IRB or ethics committee approval of trials;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">delays in enrolling patients and volunteers into clinical trials, and variability in the number and types of patients and volunteers available for clinical trials, including as a result of the COVID-19 pandemic;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">disruptions caused by man-made or natural disasters or public health pandemics or epidemics or other business interruptions, including the current COVID-19 pandemic;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">high drop-out rates for patients and volunteers in clinical trials;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">negative or inconclusive results from our clinical trials or the clinical trials of others for product candidates similar to ours;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">inadequate supply or quality of product candidate materials or other materials necessary for the conduct of our clinical trials or disruption or delays in the clinical supply due to the COVID-19 or a future pandemic;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">greater than anticipated clinical trial costs;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">serious and unexpected drug-related side effects experienced by participants in our clinical trials or by individuals using drugs similar to our product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">poor or disappointing effectiveness of our product candidates during clinical trials;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">unfavorable FDA or other regulatory agency inspection and review of a clinical trial site or records of any clinical or nonclinical investigation;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">failure of our third-party contractors or investigators to comply with regulatory requirements, including GCP and cGMP, or otherwise meet their contractual obligations in a timely manner, or at all;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">governmental or regulatory delays and changes in regulatory requirements, policy and guidelines, including the imposition of additional regulatory oversight around clinical testing generally or with respect to our technology in particular; or</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">interpretations of data by the FDA and similar foreign regulatory agencies that differ from ours.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Even if we successfully complete clinical trials of our product candidates, any given product candidate may not prove to be a safe and effective treatment for the disease for which it was being tested.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We or our partners may be unable to obtain U.S. or foreign regulatory approval for our or our partnered product candidates and, as a result, we or our partners may be unable to commercialize such product candidates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our and our partnered product candidates are subject to extensive governmental regulations relating to, among other things, research, testing, development, manufacturing, safety, efficacy, approval, recordkeeping, reporting, labeling, storage, pricing, marketing and distribution of drugs. Rigorous nonclinical testing and clinical trials and an extensive regulatory approval process are required to be successfully completed in the U.S. and in many foreign jurisdictions before a new drug can be marketed. Satisfaction of these and other regulatory requirements is costly, time consuming, uncertain and subject to unanticipated delays. It is possible that the product candidates we and our partners are developing will not obtain the regulatory approvals necessary for us or our collaborators to begin selling them.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The time required to obtain FDA and other regulatory approvals is unpredictable but typically takes many years following the commencement of clinical trials, depending upon the type, complexity and novelty of the product candidate. The standards that the FDA and its foreign counterparts use when regulating us are not always applied predictably or uniformly and can change. Any analysis we perform of data from nonclinical and clinical activities is subject to confirmation and interpretation by regulatory authorities, which could delay, limit or prevent regulatory approval. We or our partners may also encounter unexpected delays or increased costs due to new government regulations, for example, from future legislation or administrative </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9f86b6d3686546618ade3c76e6b23fc8_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">action, or from changes in FDA policy during the period of product development, clinical trials and FDA regulatory review. It is impossible to predict whether legislative changes will be enacted, or whether FDA or foreign regulations, guidance or interpretations will be changed, or what the impact of such changes, if any, may be.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Because the drugs we or our partners are developing represent a new class of drug, the FDA and its foreign counterparts have not yet established any definitive policies, practices or guidelines in relation to these drugs. The lack of policies, practices or guidelines may hinder or slow review by the FDA of any regulatory filings that we or our partners may submit. Moreover, the FDA may respond to these submissions by defining requirements we or our partners may not have anticipated. Such responses could lead to significant delays in the development of our or our partnered product candidates. In addition, because there may be approved treatments for some of the diseases for which we or our partners may seek approval, or treatments in development which are approved by the time we or they apply for approval, in order to receive regulatory approval, we or they may need to demonstrate through clinical trials that the product candidates we develop to treat these diseases, if any, are not only safe and effective, but safer or more effective than existing products. Interruption or delays in the operations of the FDA, EMA and comparable foreign regulatory agencies due to the COVID-19 pandemic, may impact the review, inspection and approval timelines for our or our partnered product candidates. For example, as of March 18, 2021, the FDA noted it is continuing to ensure timely reviews of applications for medical products during the COVID-19 pandemic in line with its user fee performance goals and conducting mission critical domestic and foreign inspections to ensure compliance of manufacturing facilities with FDA quality standards. However, the FDA may not be able to continue its current pace and approval timelines could be extended, including where a pre-approval inspection or an inspection of clinical sites is required and due to the COVID-19 pandemic and travel restrictions the FDA is unable to complete such required inspections during the review period. In 2020, several companies announced receipt of complete response letters due to the FDA's inability to complete required inspections for their applications. In December 2020, the FDA issued a complete response letter regarding Novartis' NDA for inclisiran, stating that the agency could not approve the NDA by the PDUFA action date due to unresolved facility inspection-related conditions. Any such interruption or delay by the FDA, EMA or comparable foreign regulatory agency in light of COVID-19 pandemic could have a material adverse effect on our efforts to obtain regulatory approval for our product candidates, or our collaborator Novartis' efforts to obtain FDA approval for inclisiran, which could have a material adverse effect on our financial results.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Any delay or failure in obtaining required approvals for our product candidates or our partnered product candidates could have a material adverse effect on our ability to generate revenues from any product candidate for which we or our partners may seek approval in the future. Furthermore, any regulatory approval to market any product may be subject to limitations on the approved uses for which we or our partners may market the product or the labeling or other restrictions, which could limit each such product&#8217;s market opportunity and have a negative impact on our results of operations and our stock price. In addition, the FDA has the authority to require a Risk Evaluation and Mitigations Strategy, or REMS, plan as part of an NDA, or after approval, which may impose further requirements or restrictions on the distribution or use of an approved drug, such as limiting prescribing to certain physicians or medical centers that have undergone specialized training, limiting treatment to patients who meet certain safe-use criteria and requiring treated patients to enroll in a registry. In the EU, we or our partners could be required to adopt a similar plan, known as a risk management plan, and our products could be subject to specific risk minimization measures, such as restrictions on prescription and supply, the conduct of post-marketing safety or efficacy studies, or the distribution of patient and/or prescriber educational materials. In either instance, these limitations and restrictions may limit the size of the market for the product and affect reimbursement by third-party payors.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are also subject to numerous foreign regulatory requirements governing, among other things, the conduct of clinical trials, manufacturing and marketing authorization, pricing and third-party reimbursement. The foreign regulatory approval process varies among countries and includes all of the risks associated with FDA approval described above as well as risks attributable to the satisfaction of local regulations in foreign jurisdictions. Approval by the FDA does not ensure approval by regulatory authorities outside the U.S. and vice versa.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Even if we or our partners obtain regulatory approvals, our marketed drugs will be subject to ongoing regulatory oversight. If we or our partners fail to comply with continuing U.S. and foreign requirements, our approvals could be limited or withdrawn, we could be subject to other penalties, and our business would be seriously harmed.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Following any initial regulatory approval of drugs we or our partners may develop, including our three approved drugs, we will also be subject to continuing regulatory oversight, including the review of adverse drug experiences and clinical results that are reported after our drug products are made commercially available. This would include results from any post-marketing tests or surveillance to monitor the safety and efficacy of our approved drugs or other drug products required as a condition of approval or agreed to by us. The regulatory approvals that we receive for ONPATTRO, GIVLAARI and OXLUMO, as well as any regulatory approvals we receive for any other product candidates, including vutrisiran, may also be subject to limitations on the approved uses for which the product may be marketed. Other ongoing regulatory requirements include, among other things, submissions of safety and other post-marketing information and reports, registration and listing, as well as continued compliance with good practice quality guidelines and regulations, including current good manufacturing practice, or cGMP, requirements and good clinical practice, or GCP, requirements for any clinical trials that we conduct post-approval. In addition, we are conducting, and intend to continue to conduct, clinical trials for our product candidates, and we intend to seek approval </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9f86b6d3686546618ade3c76e6b23fc8_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">to market our product candidates, in jurisdictions outside of the U.S., and therefore will be subject to, and must comply with, regulatory requirements in those jurisdictions.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The FDA has significant post-market authority, including, for example, the authority to require labeling changes based on new safety information and to require post-market studies or clinical trials to evaluate serious safety risks related to the use of a drug and to require withdrawal of the product from the market. The FDA also has the authority to require a REMS plan after approval, which may impose further requirements or restrictions on the distribution or use of an approved drug. As our approved products are used commercially, we or others could identify previously unknown side effects or known side effects could be observed as being more frequent or severe than in clinical studies or earlier post-marketing periods, in which case:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">sales of our approved products may be more modest than originally anticipated;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">regulatory approvals for our approved products may be restricted or withdrawn;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">we may decide, or be required, to send product warning letters or field alerts to physicians, pharmacists and hospitals;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">additional nonclinical or clinical studies, changes in labeling, adoption of a REMS plan, or changes to manufacturing processes, specifications and/or facilities may be required; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">government investigations or lawsuits, including class action suits, may be brought against us.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Any of the above occurrences could reduce or prevent sales of our approved products, increase our expenses and impair our ability to successfully commercialize one or more of these products.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The CMO and manufacturing facilities we use to make our approved products and certain of our current product candidates, including our Cambridge facility, our Norton facility, and Agilent and other CMOs, will also be subject to periodic review and inspection by the FDA and other regulatory agencies. For example, Agilent and our Cambridge-based facility were subject to regulatory inspection by the FDA and the EMA in connection with the review of our applications for regulatory approval for ONPATTRO and GIVLAARI, and may be subject to similar inspection in connection with any subsequent applications for regulatory approval of one or more of our products filed in other territories. The discovery of any new or previously unknown problems with our facilities or our CMOs, or our or their manufacturing processes or facilities, may result in restrictions on the drug or CMO or facility, including delay in approval or, in the future, withdrawal of the drug from the market. We have developed cGMP capabilities and processes for the manufacture of patisiran formulated bulk drug product for commercial use. In addition, in 2020, we completed construction of a cGMP manufacturing facility for drug substance for clinical and, eventually, commercial use. We may not have the ability or capacity to manufacture material at a broader commercial scale in the future. We may manufacture clinical trial materials or we may contract a third party to manufacture these materials for us. Reliance on CMOs entails risks to which we would not be subject if we manufactured products ourselves, including reliance on the CMO for regulatory compliance.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If we or our collaborators, CMOs or service providers fail to comply with applicable continuing regulatory requirements in the U.S. or foreign jurisdictions in which we may seek to market our products, we or they may be subject to, among other things, fines, warning letters, holds on clinical trials, refusal by the FDA or foreign regulatory authorities to approve pending applications or supplements to approved applications, suspension or withdrawal of regulatory approval, product recalls and seizures, refusal to permit the import or export of products, operating restrictions, injunction, civil penalties and criminal prosecution.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Even if we receive regulatory approval to market our product candidates, the market may not be receptive to our product candidates upon their commercial introduction, which could prevent us from becoming profitable.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The product candidates that we are developing are based upon new technologies or therapeutic approaches. Key participants in pharmaceutical marketplaces, such as physicians, third-party payors and consumers, may not accept a product intended to improve therapeutic results based on RNAi technology. As a result, it may be more difficult for us to convince the medical community and third-party payors to accept and use our product, or to provide favorable reimbursement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other factors that we believe will materially affect market acceptance of our product candidates include:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the timing of our receipt of any marketing approvals, the terms of any approvals and the countries in which approvals are obtained;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the safety and efficacy of our product candidates, as demonstrated in clinical trials and as compared with alternative treatments, if any;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">relative convenience and ease of administration of our product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the willingness of patients to accept potentially new routes of administration or new or different therapeutic approaches and mechanisms of action;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the success of our physician education programs;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the availability of adequate government and third-party payor reimbursement;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9f86b6d3686546618ade3c76e6b23fc8_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the pricing of our products, particularly as compared to alternative treatments, and the market perception of such prices and any price increase that we may implement in the future; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">availability of alternative effective treatments for the diseases that product candidates we develop are intended to treat and the relative risks, benefits and costs of those treatments.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For example, ONPATTRO utilizes an intravenous mode of administration with pre-medication that physicians and/or patients may not readily adopt, or which may not compete favorably with other available options, including inotersen, marketed by Akcea in several countries, which is administered subcutaneously, or tafamidis, marketed by Pfizer in several countries, which is in pill form. In addition, fitusiran represents a new approach to treating hemophilia which may not be readily accepted by patients and their caregivers.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We are an early-stage commercial company with recently established capabilities for marketing, sales, market access and distribution, and expect to continue to invest significant financial and management resources to continue to build these capabilities and to further establish our global commercial infrastructure. Even if we successfully scale our commercial capabilities, the market may not be receptive to our commercial products.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are an early-stage commercial company, having received our first product approval only three years ago, and have established our capabilities for marketing, sales, market access and distribution over the last several years. We currently expect to rely on third parties to launch and market certain of our product candidates in certain geographies, if approved. However, we intend to commercialize ONPATTRO, GIVLAARI and OXLUMO, as well as several of our late-stage product candidates if approved, including vutrisiran, on our own globally. Accordingly, we have developed internal marketing, sales, market access and distribution capabilities as part of our core product strategy initially in the U.S. and the EU, with expansion ongoing globally, which has, and will continue to, require significant financial and management resources. For those products for which we will perform marketing, sales, market access and distribution functions ourselves, including ONPATTRO, GIVLAARI, OXLUMO and, if approved, vutrisiran, and for future products we successfully develop where we may retain certain product development and commercialization rights, we could face a number of additional risks, including:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">developing and retaining our global sales, marketing and administrative infrastructure and capabilities;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">hiring, training, managing and supervising our personnel worldwide;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the cost of establishing, or leveraging an established, marketing or sales force, which may not be justifiable in light of the revenues generated by any particular product and/or in any specific geographic region; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">our direct sales and marketing efforts may not be successful.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If we are unable to continue to develop and scale our own global marketing, sales, market access and distribution capabilities for ONPATTRO, GIVLAARI, OXLUMO and any future products, we will not be able to successfully commercialize our products without reliance on third parties.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">The patient populations suffering from hATTR amyloidosis, AHP and PH1 are small and have not been established with precision. If the actual number of patients is smaller than we estimate, or if we cannot raise awareness of these diseases and diagnosis is not improved, our revenue and ability to achieve profitability from these products may be adversely affected.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our estimates regarding the potential market size for ONPATTRO, GIVLAARI, OXLUMO or any future products, including vutrisiran, at the time we commence commercialization, may be materially different from the actual market size, including as a result of the indication approved by regulatory authorities, which could result in significant changes in our business plan and may have a material adverse effect on our results of operations and financial condition. For example, the indication approved by the FDA for ONPATTRO is for the treatment of the polyneuropathy of hATTR amyloidosis and not for the treatment of cardiomyopathy or other manifestations of the disease. In addition, the U.S. label does not include data from the exploratory cardiac endpoints included in our APOLLO Phase 3 study. This could have an adverse impact on the market opportunity for ONPATTRO in the U.S. In addition, our efforts to raise disease awareness and improve diagnosis of hATTR amyloidosis have been and may continue to be impacted by the COVID-19 pandemic. For example, Alnylam Act</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, our third-party genetic screening initiative in the U.S., Canada and Brazil, experienced a decrease in submitted samples in the second quarter of 2020 as a result of the COVID-19 pandemic. As is the case with most orphan diseases, if we cannot successfully raise awareness of these diseases and improve diagnosis, it will be more difficult or impossible to achieve profitability. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We may incur significant liability if enforcement authorities allege or determine that we are engaging in commercial activities or promoting our commercially approved products in a way that violates applicable regulations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Physicians have the discretion to prescribe approved drug products for uses that are not described in the product&#8217;s labeling and that differ from those approved by the FDA or other applicable regulatory agencies. Off-label uses are common across medical specialties. Although the FDA and other regulatory agencies that approve drug products do not regulate a physician&#8217;s practice of medicine or choice of treatments, the FDA and other regulatory agencies regulate a manufacturer&#8217;s communications regarding off-label use and prohibit off-label promotion, as well as the dissemination of false or misleading labeling or promotional materials, including by their agents. Manufacturers and their agents may not promote drugs for off-label uses or </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9f86b6d3686546618ade3c76e6b23fc8_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">provide off-label information in the promotion of drug products that is not consistent with the approved labeling for those products. For example, we may not promote ONPATTRO in the U.S. for use in any indications other than the treatment of the polyneuropathy of hATTR amyloidosis in adults. The FDA and other regulatory and enforcement authorities actively enforce laws and regulations prohibiting promotion of off-label uses and the promotion of products for which marketing approval has not been obtained. For example, in April 2021, we received a subpoena from the U.S. Department of Justice, U.S. Attorney&#8217;s Office for the District of Massachusetts, requiring production of documents pertaining to our marketing and promotion of ONPATTRO (patisiran) in the U.S. We are preparing a response to the subpoena and are cooperating with the government. If we are found to have improperly marketed or promoted ONPATTRO in connection with such subpoena, we may be subject to a broad range of civil, administrative and criminal penalties, including injunctive relief related to ONPATTRO promotional activities, substantial fines or penalties, and other legal or equitable sanctions. Any adverse decision, finding, allegation, or exercise of enforcement or regulatory discretion could harm our business, prospects, operating results, and financial condition. Other internal or government investigations or legal or regulatory proceedings, including lawsuits brought by private litigants, may also follow as a consequence.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Notwithstanding regulations related to product promotion, the FDA and other regulatory authorities allow companies to engage in truthful, non-misleading and non-promotional scientific exchange concerning their products, and we intend to engage in medical education activities and communicate with healthcare providers in compliance with all applicable laws and regulatory guidance. Nonetheless, the FDA, other applicable regulatory authorities, competitors, and other third parties may take the position that we are not in compliance with such regulations, and if such non-compliance is proven, it could harm our reputation, financial condition or divert financial and management resources from our core business, and would have a material adverse effect on our business, financial condition and results of operations. Moreover, any threatened or actual government enforcement actions or lawsuits by third parties could also generate adverse publicity, which could decrease demand for our products and require that we devote substantial resources that could be used productively on other aspects of our business.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition to our medical education efforts, we also offer patient support services to assist patients receiving treatment with our commercially approved products. Manufacturers have increasingly become the focus of government investigation of patient support programs based on allegations that through such services illegal inducements are provided to physicians and/or patients, leading to improper utilization of government resources through Medicare, Medicaid and other government programs. Companies that are found to have violated laws such as the federal Anti-Kickback Statute and/or False Claims Act, or FCA, face significant liability, including civil and administrative penalties, criminal sanctions, and potential exclusion from participation in government programs. We have designed our programs in a manner that we believe complies with all applicable laws and regulations and have implemented a robust compliance program to support a compliant corporate culture and compliance with such laws.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Any drugs we develop may become subject to unfavorable pricing regulations, third-party reimbursement practices or healthcare reform initiatives, thereby harming our business.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The regulations that govern marketing approvals, pricing and reimbursement for new drugs vary widely from country to country. Some countries require approval of the sale price of a drug before it can be marketed. In many countries, the pricing review period begins after marketing or product licensing approval is granted. In some foreign markets, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. We are actively monitoring these regulations as we market and sell ONPATTRO, GIVLAARI and OXLUMO, and as several of our other programs move through late stages of development. However, a number of our programs are currently in the earlier stages of development and we will not be able to assess the impact of price regulations for such programs for a number of years. We might obtain regulatory approval for a product, including one or more of our approved products, in a particular country, but then be subject to price regulations that delay our commercial launch of the product and negatively impact the revenues we are able to generate from the sale of the product in that country and potentially in other countries due to reference pricing.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our ability to commercialize our approved products or any future products, including vutrisiran, successfully also will depend in part on the extent to which reimbursement for these products and related treatments will be available from government health administration authorities, private health insurers and other organizations. One or more of our approved products and other products for which we are able to obtain marketing approval, including vutrisiran, may not be considered cost-effective, and the amount reimbursed may be insufficient to allow us to sell such product(s) or any future products, including vutrisiran on a competitive basis. Increasingly, the third-party payors who reimburse patients or healthcare providers, such as government and private insurance plans, are requiring that drug companies provide them with predetermined discounts from list prices, and are seeking to reduce the prices charged or the amounts reimbursed for drug products. In the U.S., we have entered into at least 30 value-based agreements, or VBAs, and are negotiating additional VBAs with commercial health insurers. The goal of these agreements is to ensure that we are paid based on the ability of our commercially approved products to deliver results in the real world setting comparable to those demonstrated in clinical trials, and the agreements are structured to link our approved products&#8217; performance in real-world use to financial terms. Partnering with payers on these agreements is intended to provide more certainty to them for their investment and help accelerate coverage decisions for patients. If the prices we are able to charge for our products, or the reimbursement provided for such products, is inadequate in light of our development and other costs, or if reimbursement is denied, our return on investment could be adversely affected. In addition, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9f86b6d3686546618ade3c76e6b23fc8_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">we have stated publicly that we intend to grow through continued scientific innovation rather than arbitrary price increases. Specifically, we have stated that we will not raise the price of any product for which we receive marketing approval over the rate of inflation, as determined by the consumer price index for urban consumers (approximately 2.2% currently) absent a significant value driver. Our patient access philosophy could also negatively impact the revenues we are able to generate from the sale of one or more of our products in the future.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Some of the drugs we market need to be administered under the supervision of a physician or other healthcare professional on an outpatient basis, including ONPATTRO, GIVLAARI and OXLUMO. Under currently applicable U.S. law, certain drugs that are not usually self-administered (including injectable drugs) may be eligible for coverage under the Medicare Part B program if:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">they are incident to a physician&#8217;s services;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">they are reasonable and necessary for the diagnosis or treatment of the illness or injury for which they are administered according to accepted standards of medical practice; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">they have been approved by the FDA and meet other requirements of the statute.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">There may be significant delays in obtaining coverage for newly approved drugs, and coverage may be more limited than the purposes for which the drug is approved by the FDA or foreign regulatory authorities. Moreover, eligibility for coverage does not imply that any drug will be reimbursed in all cases or at a rate that covers our costs, including research, development, manufacture, sale and distribution or that covers a particular provider&#8217;s cost of acquiring the drug. Interim payments for new drugs, if applicable, may also not be sufficient to cover our costs and may not be made permanent. Reimbursement may be based on payments allowed for lower-cost drugs that are already reimbursed, may be incorporated into existing payments for other services and may reflect budgetary constraints or imperfections in Medicare data. Net prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the U.S. On July 24, 2020, President Trump signed four Executive Orders aimed at lowering drug prices. The Executive Orders direct the Secretary of Health and Human Services to: eliminate protection under an Anti-Kickback Statute safe harbor for certain retrospective price reductions provided by drug manufacturers to sponsors of Medicare Part D plans or pharmacy benefit managers that are not applied at the point-of-sale; allow the importation of certain drugs from other countries through individual waivers, permitting the re-importation of insulin products, and prioritizing finalization of the proposed rule to permit the importation of drugs from Canada; depending on whether pharmaceutical manufacturers agree to other measures, ensure that payment by the Medicare program for certain Medicare Part B drugs is not higher than the payment by other designated countries; and allow certain low-income individuals receiving insulin and epinephrine purchased by a Federally Qualified Health Center, or FQHC, as part of the 340B drug program to purchase those drugs at the discounted price paid by the FQHC. Pursuant to an order entered by the U.S. District Court for the District of Columbia, the portion of the rule eliminating safe harbor protection for certain rebates related to the sale or purchase of a pharmaceutical product from a manufacturer to a plan sponsor under Medicare Part D has been delayed to January 1, 2023. Further, implementation of this change and new safe harbors for point-of-sale reductions in price for prescription pharmaceutical products and pharmacy benefit manager service fees are currently under review by the Biden administration and may be amended or repealed.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On September 13, 2020, President Trump signed an Executive Order that directs the Secretary of Health and Human Services to immediately &#8220;take appropriate steps to implement rulemaking&#8221; to test a demonstration project through the CMS Innovation Center whereby Medicare Part B reimbursement for &#8220;certain high-cost prescriptions drugs&#8221; would be no more than most-favored-nation price (i.e., the lowest price) after adjustments, for a pharmaceutical product that the drug manufacturer sells in a member country of the Organization for Economic Cooperation and Development that has a comparable per-capita gross domestic product. On November 20, 2020, CMS issued an</span><span style="color:#0f4859;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> interim final</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> rule implementing President Trump&#8217;s most favored nation executive order, effective January 1, 2021. On December 28, 2020, the United States District Court in Northern California issued a nationwide preliminary injunction against implementation of the interim final rule. The Medicare Prescription Drug, Improvement, and Modernization Act of 2003, or the Medicare Modernization Act, or MMA, contains provisions that call for the promulgation of regulations that expand pharmacists&#8217; and wholesalers&#8217; ability to import cheaper versions of an approved drug and competing products from Canada, where there are government price controls. Further, the MMA provides that these provisions, as codified under section 804 of the Federal Food, Drug, and Cosmetic Act, will not take effect, unless and until the Secretary of the HHS certifies that the implementation of the provisions will pose no additional risk to the public&#8217;s health and safety and will result in a significant reduction in the cost of products to American consumers. On September 23, 2020, the Secretary of the HHS made such certification to Congress, and on October 1, 2020, the FDA published a final rule that allows for the importation of certain prescription drugs from Canada. However, certain categories of drug products are excluded from the definition of &#8220;prescription drug&#8221; that can potentially be imported from Canada, including intravenously injected drugs, such as ONPATTRO. Under the final rule, States and Indian tribes, and in certain future circumstances pharmacists and wholesalers, may submit importation program proposals to the FDA for review and authorization. Several States, such as Florida, have taken steps to draft and submit importation program proposals to FDA for review and approval. On September 25, 2020, CMS stated drugs imported by States under this rule will not be eligible for federal rebates under Section 1927 of the Social Security Act and manufacturers would not report these drugs for &#8220;best price&#8221; or </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9f86b6d3686546618ade3c76e6b23fc8_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Average Manufacturer Price purposes. Since these drugs are not considered covered outpatient drugs, CMS further stated it will not publish a National Average Drug Acquisition Cost for these drugs. Separately, the FDA also issued a final guidance document outlining a pathway for manufacturers to obtain an additional National Drug Code for an FDA-approved drug that was originally intended to be marketed in a foreign country and that was authorized for sale in that foreign country. The market implications of the notice of Executive Orders and the final rule and guidance are unknown at this time, and a lawsuit has been filed in a federal court to challenge the final rule, but legislation, regulations or policies allowing the importation or reimportation of drugs, if enacted and implemented, could decrease the price we receive for our products and adversely affect our future revenues and prospects for profitability. Third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own reimbursement rates. Our inability to promptly obtain coverage or adequate reimbursement rates from both government-funded and private payors for our approved products, or other new drugs that we develop and for which we obtain regulatory approval could have a material adverse effect on our operating results, our ability to raise capital needed to commercialize products, and our overall financial condition.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We believe that the efforts of governments and third-party payors to contain or reduce the cost of healthcare and legislative and regulatory proposals to broaden the availability of healthcare will continue to affect the business and financial condition of pharmaceutical and biopharmaceutical companies. Specifically, there have been several recent U.S. Congressional inquiries and proposed federal and state legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drugs.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A number of other legislative and regulatory changes in the healthcare system in the U.S. and other major healthcare markets have been proposed or enacted in recent months and years, and such efforts have expanded substantially in recent years. These developments could, directly or indirectly, affect our ability to sell ONPATTRO, GIVLAARI, OXLUMO or future products, if approved, including vutrisiran, at a favorable price.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In particular, in March 2010, the Patient Protection and Affordable Care Act, also referred to as the Affordable Care Act, or the ACA, was signed into law. This legislation changed the system of healthcare insurance and benefits intended to broaden coverage and control costs. The law also contains provisions that affect companies in the pharmaceutical industry and other healthcare related industries by imposing additional costs and changes to business practices. Among the provisions affecting pharmaceutical companies are the following:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Mandatory rebates for drugs sold into the Medicaid program were increased, and the rebate requirement was extended to drugs used in risk-based Medicaid managed care plans.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">The 340B Drug Pricing Program under the Public Health Service Act was extended to require mandatory discounts for drug products sold to certain critical access hospitals, cancer hospitals and other covered entities.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Pharmaceutical companies are required to offer discounts on brand-name drugs to patients who fall within the Medicare Part D coverage gap, commonly referred to as the &#8220;donut hole.&#8221;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Pharmaceutical companies are required to pay an annual non-tax deductible fee to the federal government based on each company&#8217;s market share of prior year total sales of branded products to certain federal healthcare programs, such as Medicare, Medicaid, Department of Veterans Affairs and Department of Defense. Since we expect our branded pharmaceutical sales to constitute a small portion of the total federal healthcare program pharmaceutical market, we do not expect this annual assessment to have a material impact on our financial condition.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">The law provides that approval of an application for a follow-on biologic product may not become effective until 12 years after the date on which the reference innovator biologic product was first licensed by the FDA, with a possible six-month extension for pediatric products. After this exclusivity ends, it will be easier for generic manufacturers to enter the market, which is likely to reduce the pricing for such products and could affect our profitability.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">The law creates a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">The law expands eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to certain individuals with income at or below 133% of the federal poverty level, thereby potentially increasing a manufacturer&#8217;s Medicaid rebate liability.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">The law expands the entities eligible for discounts under the Public Health Service Act pharmaceutical pricing program.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">The law expands healthcare fraud and abuse laws, including the civil FCA and the federal Anti-Kickback Statute, new government investigative powers, and enhanced penalties for noncompliance.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">The law establishes new requirements to report financial arrangements with physicians and teaching hospitals and to annually report drug samples that manufacturers and distributors provide to physicians.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9f86b6d3686546618ade3c76e6b23fc8_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">The law establishes a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">The law established the Center for Medicare and Medicaid Innovation within the Centers for Medicare and Medicaid Services, or CMS, to test innovative payment and service delivery methods.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, other legislative changes have been proposed and adopted since the ACA was enacted. In August 2011, the Budget Control Act of 2011, among other things, created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021, was unable to reach required goals, thereby triggering the legislation&#8217;s automatic reduction to several government programs. These changes included aggregate reductions to Medicare payments to providers of 2% per fiscal year, which went into effect in April 2013 and will remain in effect through 2030; however, pursuant to the CARES Act, and subsequent legislation, these Medicare sequester reductions have been suspended from May 1, 2020 through December 31, 2021 due to the COVID-19 pandemic. The American Taxpayer Relief Act of 2012, among other things, reduced Medicare payments to several providers and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. These new laws may result in additional reductions in Medicare and other healthcare funding and otherwise affect the prices we may obtain for our approved products or any of our product candidates for which we may obtain regulatory approval, including vutrisiran, or the frequency with which our products or any future product, including vutrisiran, is prescribed or used.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The full effects of the U.S. healthcare reform legislation cannot be known until the law is fully implemented through regulations or guidance issued by the Centers for Medicare and Medicaid Services, or CMS, and other federal and state healthcare agencies. The financial impact of the U.S. healthcare reform legislation over the next few years will depend on a number of factors, including, but not limited, to the policies reflected in implementing regulations and guidance, and changes in sales volumes for products affected by the new system of rebates, discounts and fees. This legislation may also have a positive impact on our future net sales, if any, by increasing the aggregate number of persons with healthcare coverage in the U.S.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Since its enactment, there have been numerous judicial, administrative, executive, and legislative challenges to certain aspects of the ACA, and we expect there will be additional challenges and amendments to the ACA in the future. For example, the U.S. Supreme Court is currently reviewing the constitutionality of the ACA, but it is unknown when a decision will be reached. Although the Supreme Court has not yet ruled on the constitutionality of the ACA, on January 28, 2021, President Biden issued an executive order to initiate a special enrollment period from February 15, 2021 through May 15, 2021 for purposes of obtaining health insurance coverage through the ACA marketplace. The executive order also instructs certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the ACA. It is unclear how the Supreme Court ruling, other such litigation, and the healthcare reform measures of the Biden administration will impact the ACA. The costs of prescription pharmaceuticals in the U.S. have also been the subject of considerable discussion in the U.S., and members of Congress have stated that they will address such costs through new legislative measures. To date, there have been several U.S. Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs, reduce the costs of drugs under Medicare and reform government program reimbursement methodologies for drug products. The former Trump administration released a &#8220;Blueprint,&#8221; or plan, to reduce the cost of drugs, increase drug manufacturer competition, increase the negotiating power of certain federal healthcare programs, incentivize manufacturers to lower the list price of their products, and reduce the out of pocket costs of drug products paid by consumers. The former Trump administration&#8217;s Blueprint contains certain measures that the U.S. Department of Health and Human Services is already working to implement. Although some proposals related to the administration&#8217;s Blueprint may require additional authorization to become effective, may ultimately be withdrawn, or may face challenges in the courts, the Congress and the Trump administration indicated that they will continue to seek new legislative and administrative measures to control drug costs. For example, at the federal level, the U.S. government&#8217;s budget proposal for fiscal year 2021 includes a $135 billion allowance to support legislative proposals seeking to reduce drug prices, increase competition, lower out-of-pocket drug costs for patients, and increase patient access to lower-cost generic and biosimilar drugs. On March 10, 2020, the U.S. government sent &#8220;principles&#8221; for drug pricing to Congress, calling for legislation that would, among other things, cap Medicare Part D beneficiary out-of-pocket pharmacy expenses, provide an option to cap Medicare Part D beneficiary monthly out-of-pocket expenses, and place limits on pharmaceutical price increases. Likewise, the Biden administration has indicated that lowering prescription drug prices is a priority, but we do not yet know what steps the administration will take or whether such steps will be successful.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">At the state level, legislatures have become increasingly aggressive in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing. Some of these measures include price or patient reimbursement constraints, discounts, restrictions on certain product access, marketing cost disclosure and transparency measures, and, in some cases, measures designed to encourage importation from other countries and bulk purchasing. In addition, regional health care authorities and individual hospitals are increasingly using bidding procedures to determine what </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9f86b6d3686546618ade3c76e6b23fc8_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">pharmaceutical products and which suppliers will be included in their prescription drug and other health care programs. These measures could reduce the ultimate demand for our products, once approved, or put pressure on our product pricing.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We cannot predict what healthcare reform initiatives may be adopted in the future. Further federal and state legislative and regulatory developments are likely, and we expect ongoing initiatives in the U.S. to increase pressure on drug pricing. Such reforms could have an adverse effect on anticipated revenues from one or more of our approved products or other product candidates that we may successfully develop and for which we may obtain regulatory approval and may affect our overall financial condition and ability to develop drug candidates.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We are subject to U.S. and certain foreign export and import controls, sanctions, embargoes, anti-corruption laws, and anti-money laundering laws and regulations. Failure to comply with these legal standards could impair our ability to compete in domestic and international markets. We can face criminal liability and other serious consequences for violations, which can harm our business.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are subject to export control and import laws and regulations, including the U.S. Export Administration Regulations, U.S. Customs regulations, various economic and trade sanctions regulations administered by the U.S. Treasury Department&#8217;s Office of Foreign Assets Controls, the Foreign Corrupt Practices Act of 1977, as amended, the U.S. domestic bribery statute contained in 18 U.S.C. &#167; 201, the U.S. Travel Act, the USA PATRIOT Act, and other state and national anti-bribery and anti-money laundering laws in the countries in which we conduct activities. Anti-corruption laws are interpreted broadly and prohibit companies and their employees, agents, contractors, and other collaborators from authorizing, promising, offering, or providing, directly or indirectly, improper payments or anything else of value to recipients in the public or private sector. From time to time, we may engage third parties to conduct clinical trials outside of the U.S., to sell our products abroad, and/or to obtain necessary permits, licenses, patent registrations, and other regulatory approvals. We have direct or indirect interactions with officials and employees of government agencies or government-affiliated hospitals, universities, and other organizations. We can be held liable for the corrupt or other illegal activities of our employees, agents, contractors, and other collaborators, even if we do not explicitly authorize or have actual knowledge of such activities. Any violations of the laws and regulations described above may result in substantial civil and criminal fines and penalties, imprisonment, the loss of export or import privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm, and other consequences.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Governments outside the U.S. may impose strict price controls, which may adversely affect our revenues.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The pricing of prescription pharmaceuticals is also subject to governmental control outside the U.S. In these countries, pricing negotiations with governmental authorities can take considerable time after the receipt of regulatory approval for a product. To obtain reimbursement or pricing approval in some countries, we may be required to conduct a clinical trial that compares the cost-effectiveness of our product candidates to other available therapies. If reimbursement of our products is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, our ability to generate revenues and become profitable could be impaired.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In some countries, including Member States of the EU, or Japan, the pricing of prescription drugs is subject to governmental control. Additional countries may adopt similar approaches to the pricing of prescription drugs. In such countries, pricing negotiations with governmental authorities can take considerable time after receipt of regulatory approval for a product. In addition, there can be considerable pressure by governments and other stakeholders on prices and reimbursement levels, including as part of cost containment measures. Moreover, political, economic and regulatory developments may further complicate pricing negotiations, and pricing negotiations may continue after coverage and reimbursement have been obtained. Reference pricing used by various countries and parallel distribution, or arbitrage between low-priced and high-priced countries, can further reduce prices. In some countries, we may be required to conduct a clinical study or other studies that compare the cost-effectiveness of a product candidate to other available therapies in order to obtain or maintain reimbursement or pricing approval, which is time-consuming and costly. We cannot be sure that such prices and reimbursement will be acceptable to us or our strategic partners. Publication of discounts by third-party payors or authorities may lead to further pressure on the prices or reimbursement levels within the country of publication and other countries. If pricing is set at unsatisfactory levels or if reimbursement of our products is unavailable or limited in scope or amount, our revenues from sales by us or our strategic partners and the potential profitability of our approved products or any future products, including vutrisiran, in those countries would be negatively affected. Another impact from the tightening pricing control could be felt from greater competition from less expensive generic or biosimilar products once the exclusivity expires; the governments have adopted policies to switch prescribed products to generic versions in order to cut the medical cost.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9f86b6d3686546618ade3c76e6b23fc8_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">If we or our collaborators, CMOs or service providers fail to comply with healthcare laws and regulations, or legal obligations related to privacy, data protection and information security, we or they could be subject to enforcement actions, which could affect our ability to develop, market and sell our products and may harm our reputation.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As a manufacturer of pharmaceuticals, we are subject to federal, state, and comparable foreign healthcare laws and regulations pertaining to fraud and abuse and patients&#8217; rights, in addition to legal obligations related to privacy, data protection and information security. These laws and regulations include:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">The U.S. federal Anti-Kickback Statute, which prohibits, among other things, persons from knowingly and willfully soliciting, receiving, offering or paying remuneration, directly or indirectly, to induce either the referral of an individual for a healthcare item or service, or the purchasing or ordering of an item or service, for which payment may be made under a federal healthcare program such as Medicare or Medicaid.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">The U.S. federal false claims laws, including the FCA, which prohibit, among other things, individuals or entities from knowingly presenting or causing to be presented, claims for payment by government-funded programs such as Medicare or Medicaid that are false or fraudulent, making, using or causing to be made or used a false record or statement material to a false or fraudulent claim to the federal government, or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government. Manufacturers can be held liable under the FCA even when they do not submit claims directly to government payors if they are deemed to &#8220;cause&#8221; the submission of false or fraudulent claims. The FCA also permits a private individual acting as a &#8220;whistleblower&#8221; to bring actions on behalf of the federal government alleging violations of the FCA and to share in any monetary recovery.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">The federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which created federal criminal statutes that prohibit knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program or obtain, by means of false or fraudulent pretenses, representations, or promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit program, regardless of the payor (e.g., public or private) and knowingly and willfully falsifying, concealing or covering up by any trick or device a material fact or making any materially false statements in connection with the delivery of, or payment for, healthcare benefits, items or services relating to healthcare matters. Similar to the federal Anti-Kickback Statute, a person or entity can be found guilty of violating HIPAA without actual knowledge of the statute or specific intent to violate it.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, which imposes requirements relating to the privacy, security, and transmission of individually identifiable health information; and requires notification to affected individuals and regulatory authorities of certain breaches of security of individually identifiable health information.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">The U.S. federal Open Payments requirements, which were implemented by the CMS pursuant to the Physician Payments Sunshine Act as part of the ACA. Under the Open Payments Program, manufacturers of medical devices, medical supplies, biological products and drugs covered by Medicare, Medicaid and the Children&#8217;s Health Insurance Programs must report transfers of value, including consulting fees, travel reimbursements, research grants, and other payments made to physicians (currently defined to include doctors, dentists, optometrists, podiatrists and chiropractors) and teaching hospitals as well as ownership and investment interests held by physicians and their immediate family members. Legislation passed in 2018 expands the scope of covered recipients to non-physician providers such as physician assistants and advanced practice nurses, effective in 2022.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Federal statutory and regulatory requirements applicable to pricing and sales of product to Federal Government Agencies.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">State and foreign laws comparable to each of the above federal laws, including in the EU laws prohibiting giving healthcare professionals any gift or benefit in kind as an inducement to prescribe our products, national transparency laws requiring the public disclosure of payments made to healthcare professionals and institutions, and data privacy laws, in addition to anti-kickback and false claims laws applicable to commercial insurers and other non-federal payors, requirements for mandatory corporate regulatory compliance programs, and laws relating to government reimbursement programs, patient data privacy and security.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">European Privacy Laws including Regulation 2016/679, known as the General Data Protection Regulation, or the GDPR, and the e-Privacy Directive (202/58/EC), and the national laws implementing each of them, as well as the privacy laws of Japan and other territories. Failure to comply with our obligations under the privacy regime could expose us to significant fines and/or adverse publicity, which could have material adverse effects on our reputation and business.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">The California Consumer Privacy Act of 2018, or CCPA, effective as of January 1, 2020, that gives California residents expanded rights to access and require deletion of their personal information, opt out of certain personal </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9f86b6d3686546618ade3c76e6b23fc8_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">information sharing, and receive detailed information about how their personal information is used. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On November 30, 2020, the OIG published a final rule effective January 1, 2022 amending the existing safe harbor protecting certain discounts to eliminate safe harbor protection for certain rebates provided by a manufacturer of prescription pharmaceutical products to a plan sponsors under Part D or pharmacy benefit managers under contract with them. The final rule also creates new safe harbors effective January 29, 2021 for point-of-sale reductions in price on prescription pharmaceutical products and certain pharmacy benefit manager service fees. Pursuant to an order entered by the U.S. District Court for the District of Columbia, the portion of the rule eliminating safe harbor protection for certain rebates related to the sale or purchase of a pharmaceutical product from a manufacturer to a plan sponsor under Medicare Part D has been delayed to January 1, 2023. Implementation of the this change and new safe harbors for point-of-sale reductions in price for prescription pharmaceutical products and pharmacy benefit manager service fees are currently under review by the Biden administration and may be amended or repealed. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Some state laws also require pharmaceutical manufacturers to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, in addition to requiring manufacturers to report information related to payments to physicians and other healthcare provides or marketing expenditures and pricing information. State and foreign laws also govern the privacy and security of health information, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the EU, the GDPR replaced the EU Data Protection Directive on May 25, 2018. The GDPR introduced new data protection requirements in the EU, as well as potential fines for noncompliance of up to the greater of &#8364;20,000,000 or 4% of total annual global revenue. The regulation imposes numerous new requirements for the collection, use and disclosure of personal information, including: more stringent requirements relating to data subject consent; what information must be shared with data subjects regarding how their personal information is used; the obligation to notify regulators and affected individuals of personal data breaches; extensive new internal privacy governance obligations; and obligations to honor expanded rights of individuals in relation to their personal information (e.g., the right to access, correct and delete their data). In addition, the GDPR maintains the EU Data Protection Directive&#8217;s restrictions on cross-border data transfer. The GDPR increases the responsibility and liability of pharmaceutical companies in relation to processing personal data, and companies may be required to put in place additional mechanisms to ensure compliance with the new EU data protection rules. Further, Brexit has created uncertainty with regard to the status of the UK as an &#8220;adequate country&#8221; for the purposes of data transfers outside the European Economic Area, or EEA. In particular, it is unclear how data transfers to and from the UK will be regulated. These changes may require us to find alternative bases for the compliant transfer of personal data from the UK to the U.S., and we are monitoring developments in this area.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If our operations are found to be in violation of any of the aforementioned requirements, we may be subject to penalties, including civil or criminal penalties (including individual imprisonment), criminal prosecution, monetary damages, the curtailment or restructuring of our operations, loss of eligibility to obtain approvals from the FDA, or exclusion from participation in government contracting, healthcare reimbursement or other government programs, including Medicare and Medicaid, or the imposition of a corporate integrity agreement with the OIG, any of which could adversely affect our financial results. We are continuing to establish our global compliance infrastructure following the commercial launch of our three products over the last three years in the U.S., EU and multiple other geographies, and as we prepare for the launch of our products in additional countries, assuming regulatory approvals. Although effective compliance programs can mitigate the risk of investigation and prosecution for violations of these laws, these risks cannot be entirely eliminated. Any action against us for an alleged or suspected violation could cause us to incur significant legal expenses and could divert our management&#8217;s attention from the operation of our business, even if our defense is successful. In addition, achieving and sustaining compliance with applicable laws and regulations may be costly to us in terms of money, time and resources.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If we or our collaborators, CMOs or service providers fail to comply with applicable federal, state or foreign laws or regulations, we could be subject to enforcement actions, which could affect our ability to develop, market and sell our approved products, or any other future products, successfully and could harm our reputation and lead to reduced acceptance of our products by the market. These enforcement actions include, among others:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">adverse regulatory inspection findings;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">untitled letters or warning letters;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">voluntary or mandatory product recalls or public notification or medical product safety alerts to healthcare professionals;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">restrictions on, or prohibitions against, marketing our products;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">restrictions on, or prohibitions against, importation or exportation of our products;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">suspension of review or refusal to approve pending applications or supplements to approved applications;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9f86b6d3686546618ade3c76e6b23fc8_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">exclusion from participation in government-funded healthcare programs;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">exclusion from eligibility for the award of government contracts for our products;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">suspension or withdrawal of product approvals;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">product seizures;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">injunctions; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">civil and criminal penalties, up to and including criminal prosecution resulting in fines, exclusion from healthcare reimbursement programs and imprisonment.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Moreover, federal, state or foreign laws or regulations are subject to change, and while we, our collaborators, CMOs and/or service providers currently may be compliant, that could change due to changes in interpretation, prevailing industry standards or the legal structure.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We are subject to governmental regulation and other legal obligations, particularly related to privacy, data protection and information security, and we are subject to consumer protection laws that regulate our marketing practices and prohibit unfair or deceptive acts or practices. Our actual or perceived failure to comply with such obligations could harm our business.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The GDPR imposes strict requirements on controllers and processors of personal data, including special protections for &#8220;special category data,&#8221; which includes health, biometric and genetic information of data subjects located in the EU. Further, GDPR provides a broad right for EU Member States to create supplemental national laws, such as laws relating to the processing of health, genetic and biometric data, which could further limit our ability to use and share such data or could cause our costs to increase, and harm our business and financial condition. GDPR grants individuals the opportunity to object to the processing of their personal information, allows them to request deletion of personal information in certain circumstances, and provides the individual with an express right to seek legal remedy in the event the individual believes his or her rights have been violated. Further, the GDPR imposes strict rules on the transfer of personal data out of the EU to the U.S. or other regions that have not been deemed to offer &#8220;adequate&#8221; privacy protections.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Failure to comply with the requirements of the GDPR and the related national data protection laws of the EU Member States, which may deviate slightly from the GDPR, may result in fines of up to 4% of total global annual revenue, or &#8364;20,000,000, whichever is greater, and in addition to such fines, we may be the subject of litigation and/or adverse publicity, which could have material adverse effect on our reputation and business. As a result of the implementation of the GDPR, we are required to put in place additional mechanisms to ensure compliance with the new data protection rules. For example, the GDPR requires us to make more detailed disclosures to data subjects, requires disclosure of the legal basis on which we can process personal data, may make it harder for us to obtain valid consent for processing, will require the appointment of a data protection officer where sensitive personal data (i.e., health data) is processed on a large scale, introduces mandatory data breach notification requirements throughout the EU, imposes additional obligations on us when we are contracting with service providers and requires us to adopt appropriate privacy governance including policies, procedures, training and data audit.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are subject to the supervision of local data protection authorities in those jurisdictions where we are monitoring the behavior of individuals in the EU (i.e., undertaking clinical trials). We depend on a number of third parties in relation to the provision of our services, a number of which process personal data of EU individuals on our behalf. With each such provider we enter or intend to enter into contractual arrangements under which they are contractually obligated to only process personal data according to our instructions, and conduct or intend to conduct diligence to ensure that they have sufficient technical and organizational security measures in place.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are also subject to evolving European privacy laws on electronic marketing and cookies. The EU is in the process of replacing the e-Privacy Directive (2002/58/EC) with a new set of rules taking the form of a regulation, which will be directly implemented in the laws of each European member state, without the need for further enactment. While the e-Privacy Regulation was originally intended to be adopted on May 25, 2018 (alongside the GDPR), it is still going through the European legislative process. Draft regulations were rejected by the Permanent Representatives Committee of the Council of EU on November 22, 2019; it is not clear when new regulations will be adopted.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">There is significant uncertainty related to the manner in which data protection authorities will seek to enforce compliance with GDPR. Further, Brexit has created uncertainty with regard to the status of the UK as an &#8216;adequate country&#8217; for the purposes of data transfers outside the EEA. In particular, it is unclear how data transfers to and from the UK will be regulated. Enforcement uncertainty and the costs associated with ensuring GDPR and e-Privacy compliance may be onerous and may adversely affect our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Compliance with U.S. and international data protection laws and regulations could require us to take on more onerous obligations in our contracts, restrict our ability to collect, use and disclose data, or in some cases, impact our ability to operate in certain jurisdictions. Failure to comply with these laws and regulations could result in government enforcement actions (which could include civil, criminal and administrative penalties), private litigation, and/or adverse publicity and could </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9f86b6d3686546618ade3c76e6b23fc8_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">negatively affect our operating results and business. Moreover, clinical trial subjects, employees and other individuals about whom we or our potential collaborators obtain personal information, as well as the providers who share this information with us, may limit our ability to collect, use and disclose the information. Claims that we have violated individuals&#8217; privacy rights, failed to comply with data protection laws, or breached our contractual obligations, even if we are not found liable, could be expensive and time-consuming to defend and could result in adverse publicity that could harm our business.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our ability to obtain services, reimbursement or funding from the federal government may be impacted by possible reductions in federal spending and services, and any inability on our part to effectively adapt to such changes could substantially affect our financial position, results of operations and cash flows.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Under the Budget Control Act of 2011, the failure of Congress to enact deficit reduction measures of at least $1.2 trillion for the years 2013 through 2021 triggered automatic cuts to most federal programs. These cuts included aggregate reductions to Medicare payments to providers of up to 2% per fiscal year, starting in 2013. Certain of these automatic cuts have been implemented resulting in reductions in Medicare payments to physicians, hospitals, and other healthcare providers, among other things. Due to legislation amending the statute, including the Bipartisan Budget Act of 2018, these reductions will stay in effect through 2030 unless additional Congressional action is taken. Pursuant to the CARES Act, as well as subsequent legislation, these reductions have been suspended from May 1, 2020 through December 31, 2021 due to the COVID-19 pandemic. The full impact on our business of these automatic cuts is uncertain.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If other federal spending is reduced, any budgetary shortfalls may also impact the ability of relevant agencies, such as the FDA or the National Institutes of Health to continue to function. Amounts allocated to federal grants and contracts may be reduced or eliminated. These reductions may also impact the ability of relevant agencies to timely review and approve drug research and development, manufacturing, and marketing activities, which may delay our ability to develop, market and sell our approved products and any other products we may develop, including vutrisiran.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">There is a substantial risk of product liability claims in our business. If we are unable to obtain sufficient insurance, a product liability claim against us could adversely affect our business.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our business exposes us to significant potential product liability risks that are inherent in the development, testing, manufacturing and marketing of human therapeutic products. Product liability claims could delay or prevent completion of our clinical development programs. Following the decision to discontinue clinical development of revusiran, we conducted a comprehensive evaluation of available revusiran data. We reported the results of this evaluation in August 2017, however, our investigation did not result in a conclusive explanation regarding the cause of the mortality imbalance observed in the ENDEAVOUR Phase 3 study. In addition, in September 2017, we announced that we had temporarily suspended dosing in all ongoing fitusiran studies pending further review of a fatal thrombotic serious adverse event, or SAE, and agreement with regulatory authorities on a risk mitigation strategy. Notwithstanding the risks undertaken by all persons who participate in clinical trials, and the information on risks provided to study investigators and patients participating in our clinical trials, including the revusiran and fitusiran studies, it is possible that product liability claims will be asserted against us relating to the worsening of a patient&#8217;s condition, injury or death alleged to have been caused by one of our product candidates, including revusiran or fitusiran. Such claims might not be fully covered by product liability insurance. In addition, product liability claims could result in an FDA investigation of the safety and effectiveness of our approved products, our manufacturing processes and facilities or our marketing programs, and potentially a recall of our products or more serious enforcement action, limitations on the approved indications for which they may be used, or suspension or withdrawal of approvals. Regardless of the merits or eventual outcome, liability claims may also result in decreased demand for our products, injury to our reputation, costs to defend the related litigation, a diversion of management&#8217;s time and our resources, substantial monetary awards to trial participants or patients and a decline in our stock price. We currently have product liability insurance that we believe is appropriate for our stage of development, including the marketing and sale of our approved products. Any insurance we have or may obtain may not provide sufficient coverage against potential liabilities. Furthermore, clinical trial and product liability insurance is becoming increasingly expensive. As a result, we may be unable to obtain sufficient insurance at a reasonable cost to protect us against losses caused by product liability claims that could have a material adverse effect on our business.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our employees may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements or insider trading violations, which could significantly harm our business.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are exposed to the risk of employee fraud or other misconduct. Misconduct by employees could include intentional failures to comply with governmental regulations, comply with healthcare fraud and abuse and anti-kickback laws and regulations in the U.S. and abroad, or failure to report financial information or data accurately or disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Employee misconduct could also involve the improper use of, including improper trading based upon, information obtained in the course of clinical studies, which could result in regulatory sanctions and serious harm to our reputation. We have adopted a code of business conduct and ethics and a robust compliance program, but it is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9f86b6d3686546618ade3c76e6b23fc8_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business and results of operations, including the imposition of significant fines or other sanctions.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">If we do not comply with laws regulating the protection of the environment and health and human safety, our business could be adversely affected.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our research, development and manufacturing involve the use of hazardous materials, chemicals and various radioactive compounds. We maintain quantities of various flammable and toxic chemicals in our facilities in Cambridge and Norton that are required for our research, development and manufacturing activities. We are subject to federal, state and local laws and regulations governing the use, manufacture, storage, handling and disposal of these hazardous materials. We believe our procedures for storing, handling and disposing these materials in our Cambridge and Norton facilities comply with the relevant guidelines of the City of Cambridge, the town of Norton, the Commonwealth of Massachusetts and the Occupational Safety and Health Administration of the U.S. Department of Labor. Although we believe that our safety procedures for handling and disposing of these materials comply with the standards mandated by applicable regulations, the risk of accidental contamination or injury from these materials cannot be eliminated. If an accident occurs, we could be held liable for resulting damages, which could be substantial. We are also subject to numerous environmental, health and workplace safety laws and regulations, including those governing laboratory procedures, exposure to blood-borne pathogens and the handling of biohazardous materials.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Although we maintain workers&#8217; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of these materials, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our storage or disposal of biological, hazardous or radioactive materials. Additional federal, state and local laws and regulations affecting our operations may be adopted in the future. We may incur substantial costs to comply with, and substantial fines or penalties if we violate, any of these laws or regulations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Risks Related to Patents, Licenses and Trade Secrets</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">If we are not able to obtain and enforce patent protection for our discoveries, our ability to develop and commercialize our product candidates will be harmed.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our success depends, in part, on our ability to protect proprietary compositions, methods and technologies that we develop under the patent and other intellectual property laws of the U.S. and other countries, so that we can prevent others from unlawfully using our inventions and proprietary information. However, we may not hold proprietary rights to some patents required for us to manufacture and commercialize our proposed products. Because certain U.S. patent applications are confidential until the patents issue, such as applications filed prior to November 29, 2000, or applications filed after such date which will not be filed in foreign countries, third parties may have filed patent applications for subject matter covered by our pending patent applications without our being aware of those applications, and our patent applications may not have priority over those applications. For this and other reasons, we may be unable to secure desired patent rights, thereby losing desired exclusivity. Further, we or our licensees may be required to obtain licenses under third-party patents to market one or more of our or our partner's approved products, or further develop and commercialize future products, or continue to develop candidates in our pipeline being developed by us or our licensees. If licenses are not available to us or not available on reasonable terms, we or our licensees may not be able to market the affected products or conduct the desired activities.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our strategy depends on our ability to rapidly identify and seek patent protection for our discoveries. In addition, we may rely on third-party collaborators to file patent applications relating to proprietary technology that we develop jointly during certain collaborations. The process of obtaining patent protection is expensive and time-consuming. If our present or future collaborators fail to file and prosecute all necessary and desirable patent applications at a reasonable cost and in a timely manner, our business may be adversely affected. Despite our efforts and the efforts of our collaborators to protect our proprietary rights, unauthorized parties may be able to obtain and use information that we regard as proprietary. While issued patents are presumed valid, this does not guarantee that the patent will survive a validity challenge or be held enforceable. Any patents we have obtained, or obtain in the future, may be challenged, invalidated, adjudged unenforceable or circumvented by parties attempting to design around our intellectual property. Moreover, third parties or the United States Patent and Trademark Office, or USPTO, may commence interference proceedings involving our patents or patent applications. Any challenge to, finding of unenforceability or invalidation or circumvention of, our patents or patent applications, would be costly, would require significant time and attention of our management, could reduce or eliminate royalty payments to us from third party licensors and could have a material adverse effect on our business.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our pending patent applications may not result in issued patents. The patent position of pharmaceutical or biotechnology companies, including ours, is generally uncertain and involves complex legal and factual considerations. The standards that the USPTO and its foreign counterparts use to grant patents are not always applied predictably or uniformly and can change. Similarly, the ultimate degree of protection that will be afforded to biotechnology inventions, including ours, in the U.S. and foreign countries, remains uncertain and is dependent upon the scope of the protection decided upon by patent offices, courts </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9f86b6d3686546618ade3c76e6b23fc8_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">and lawmakers. Moreover, there are periodic discussions in the Congress of the United States and in international jurisdictions about modifying various aspects of patent law. For example, the America Invents Act, or AIA, included a number of changes to the patent laws of the U.S. If any of the enacted changes do not provide adequate protection for discoveries, including our ability to pursue infringers of our patents for substantial damages, our business could be adversely affected. One major provision of the AIA, which took effect in March 2013, changed U.S. patent practice from a first-to-invent to a first-to-file system. If we fail to file an invention before a competitor files on the same invention, we no longer have the ability to provide proof that we were in possession of the invention prior to the competitor&#8217;s filing date, and thus would not be able to obtain patent protection for our invention. There is also no uniform, worldwide policy regarding the subject matter and scope of claims granted or allowable in pharmaceutical or biotechnology patents.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Accordingly, we do not know the degree of future protection for our proprietary rights or the breadth of claims that will be allowed in any patents issued to us or to others. We also rely to a certain extent on trade secrets, know-how and technology, which are not protected by patents, to maintain our competitive position. If any trade secret, know-how or other technology not protected by a patent were to be disclosed to or independently developed by a competitor, our business and financial condition could be materially adversely affected.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Failure to obtain and maintain all available regulatory exclusivities, broad patent scope and to maximize patent term restoration or extension on patents covering our products may lead to loss of exclusivity and early generic entry resulting in a loss of market share and/or revenue.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We license patent rights from third-party owners. If such owners do not properly or successfully obtain, maintain or enforce the patents underlying such licenses, our competitive position and business prospects may be harmed.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are a party to a number of licenses that give us rights to third-party intellectual property that is necessary or useful for our business. In particular, we have obtained licenses from, among others, Stanford University, Ionis, the Massachusetts Institute of Technology, or MIT, Whitehead Institute for Biomedical Research, or Whitehead, Max Planck Innovation GmbH (formerly known as Garching Innovation GmbH), or Max Planck, Arbutus Biopharma Corp., or Arbutus, and Dicerna. We also intend to enter into additional licenses to third-party intellectual property in the future.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our success will depend in part on the ability of our licensors to obtain, maintain and enforce patent protection for our licensed intellectual property, in particular, those patents to which we have secured exclusive rights. Our licensors may not successfully prosecute the patent applications to which we are licensed. Even if patents issue in respect of these patent applications, our licensors may fail to maintain these patents, may determine not to pursue litigation against other companies that are infringing these patents, or may pursue such litigation less aggressively than we would. Without protection for the intellectual property we license, other companies might be able to offer substantially identical products for sale, which could adversely affect our competitive business position and harm our business prospects. In addition, we sublicense our rights under various third-party licenses to our collaborators. Any impairment of these sublicensed rights could result in reduced revenues under our collaboration agreements or result in termination of an agreement by one or more of our collaborators.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Other companies or organizations may challenge our patent rights or may assert patent rights that prevent us from developing and commercializing our products.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">RNAi is a relatively new scientific field, the commercial exploitation of which has resulted in many different patents and patent applications from organizations and individuals seeking to obtain patent protection in the field. We have obtained grants and issuances of RNAi patents and have licensed many of these patents from third parties on an exclusive basis. The issued patents and pending patent applications in the U.S. and in key markets around the world that we own or license claim many different methods, compositions and processes relating to the discovery, development, manufacture and commercialization of RNAi therapeutics.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Specifically, we have a portfolio of patents, patent applications and other intellectual property covering: fundamental aspects of the structure and uses of siRNAs, including their use as therapeutics, and RNAi-related mechanisms; chemical modifications to siRNAs that improve their suitability for therapeutic and other uses; siRNAs directed to specific targets as treatments for particular diseases; delivery technologies, such as in the fields of carbohydrate conjugates and cationic liposomes; and all aspects of our specific development candidates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As the field of RNAi therapeutics is maturing, patent applications are being fully processed by national patent offices around the world. There is uncertainty about which patents will issue, and, if they do, as to when, to whom, and with what claims. It is likely that there will be significant litigation and other proceedings, such as interference, re-examination and opposition proceedings, as well as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">inter partes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> and post-grant review proceedings introduced by provisions of the AIA, which became available to third party challengers on September 16, 2012, in various patent offices relating to patent rights in the RNAi field. In addition, third parties may challenge the validity of our patents. For example, a third party has filed an opposition in the European Patent Office, or EPO, against our owned patent EP 2723758, with claims directed to compositions and methods of ANGPTL3, arguing that the granted claims are invalid. We expect that additional oppositions will be filed in the EPO and elsewhere, and other challenges will be raised relating to other patents and patent applications in our portfolio. In many cases, the possibility of appeal exists for either us or our opponents, and it may be years before final, unappealable rulings </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9f86b6d3686546618ade3c76e6b23fc8_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">are made with respect to these patents in certain jurisdictions. The timing and outcome of these and other proceedings is uncertain and may adversely affect our business if we are not successful in defending the patentability and scope of our pending and issued patent claims. Even if our rights are not directly challenged, disputes could lead to the weakening of our intellectual property rights. Our defense against any attempt by third parties to circumvent or invalidate our intellectual property rights could be costly to us, could require significant time and attention of our management and could have a material adverse effect on our business and our ability to successfully compete in the field of RNAi.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">There are many issued and pending patents that claim aspects of oligonucleotide chemistry and modifications that we may need for our siRNA marketed products, our late-stage therapeutic candidates being developed by us or our licensees, including vutrisiran, inclisiran and fitusiran, as well as our other pipeline products. There are also many issued patents that claim targeting genes or portions of genes that may be relevant for siRNA drugs we wish to develop. In addition, there may be issued and pending patent applications that may be asserted against us in a court proceeding or otherwise based upon the asserting party&#8217;s belief that we may need such patents for our siRNA therapeutic candidates or marketed products, or further develop and commercialize future products such as inclisiran, currently under review with the FDA, or continuing to develop candidates in our pipeline being developed by us or our licensees. Thus, it is possible that one or more organizations will hold patent rights to which we may need a license, or hold patent rights which could be asserted against us. If those organizations refuse to grant us a license to such patent rights on reasonable terms and/or a court rules that we need such patent rights that have been asserted against us and we are not able to obtain a license on reasonable terms, we may be unable to market products, including ONPATTRO, GIVLAARI or OXLUMO, or perform research and development or other activities covered by such patents. For example, during 2017 and 2018, Silence filed claims in several jurisdictions, including the High Court of England and Wales, and named us and our wholly owned subsidiary Alnylam UK Ltd. as co-defendants. Silence alleged various claims, including that ONPATTRO infringed one or more Silence patents. There were also a number of related actions brought by us or Silence in connection with this intellectual property dispute. In December 2018, we entered into a Settlement and License Agreement with Silence, resolving all ongoing claims, administrative proceedings, and regulatory proceedings worldwide between us regarding, among other issues, patent infringement, patent invalidity and breach of contract.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">If we become involved in patent litigation or other proceedings related to a determination of rights, we could incur substantial costs and expenses, substantial liability for damages or be required to stop our product development and commercialization efforts.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Third parties may sue us for infringing their patent rights. For example, in October 2017 Silence sued us in the UK alleging that ONPATTRO and other investigational RNAi therapeutics we or MDCO are developing infringed one or more Silence patents. Likewise, we may need to resort to litigation to enforce a patent issued or licensed to us or to determine the scope and validity of proprietary rights of others or protect our proprietary information and trade secrets. For example, during the second quarter of 2015, we filed a trade secret misappropriation lawsuit against Dicerna to protect our rights in the RNAi assets we purchased from Merck Sharp &amp; Dohme Corp., or Merck. We and Dicerna settled the ongoing litigation between us in April 2018 and in December 2018 we and Silence settled all ongoing litigation between us. A third party may also claim that we have improperly obtained or used its confidential or proprietary information. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In protecting our intellectual patent rights through litigation or other means, a third party may claim that we have improperly asserted our rights against them. For example, in August 2017, Dicerna successfully added counterclaims against us in the above-referenced trade secret lawsuit alleging that our lawsuit represented abuse of process and claiming tortious interference with its business. In addition, in August 2017, Dicerna filed a lawsuit against us in the United States District Court of Massachusetts alleging attempted monopolization by us under the Sherman Antitrust Act. As noted above, in April 2018, we and Dicerna settled the ongoing litigation between us.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Furthermore, third parties may challenge the inventorship of our patents or licensed patents. For example, in March 2011, The University of Utah, or Utah, filed a complaint against us, Max Planck Gesellschaft Zur Foerderung Der Wissenschaften e.V. and Max Planck Innovation, together, Max Planck, Whitehead, MIT and the University of Massachusetts, claiming that a professor of Utah was the sole inventor, or in the alternative, a joint inventor of certain of our in-licensed patents. Utah was seeking correction of inventorship of the Tuschl patents, unspecified damages and other relief. After several years of court proceedings and discovery, the court granted our motions for summary judgment, and dismissed Utah&#8217;s state law damages claims as well. During the pendency of this litigation, as well as the Arbutus and Dicerna litigation described above, we incurred significant costs, and in each case, the litigation diverted the attention of our management and other resources that would otherwise have been engaged in other activities.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, in connection with certain license and collaboration agreements, we have agreed to indemnify certain third parties for certain costs incurred in connection with litigation relating to intellectual property rights or the subject matter of the agreements. The cost to us of any litigation or other proceeding relating to intellectual property rights, even if resolved in our favor, could be substantial, and litigation would divert our management&#8217;s efforts. Some of our competitors may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources. Uncertainties resulting from the initiation and continuation of any litigation or legal proceeding could delay our research, development and commercialization efforts and limit our ability to continue our operations.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9f86b6d3686546618ade3c76e6b23fc8_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If any parties successfully claim that our creation or use of proprietary technologies infringes upon or otherwise violates their intellectual property rights, we might be forced to pay damages, potentially including treble damages, if we are found to have willfully infringed on such parties&#8217; patent rights. In addition to any damages we might have to pay, a court could issue an injunction requiring us to stop the infringing activity or obtain a license. Any license required under any patent may not be made available on commercially reasonable terms, if at all. In addition, such licenses are likely to be non-exclusive and, therefore, our competitors may have access to the same technology licensed to us. If we fail to obtain a required license and are unable to design around a patent, we may be unable to effectively market some of our technology and products, which could limit our ability to generate revenues or achieve profitability and possibly prevent us from generating revenue sufficient to sustain our operations. Moreover, we expect that a number of our collaborations will provide that royalties payable to us for licenses to our intellectual property may be offset by amounts paid by our collaborators to third parties who have competing or superior intellectual property positions in the relevant fields, which could result in significant reductions in our revenues from products developed through collaborations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">If we fail to comply with our obligations under any licenses or related agreements, we may be required to pay damages and could lose license or other rights that are necessary for developing, commercializing and protecting our RNAi technology, as well as our approved products and any other product candidates that we develop, or we could lose certain rights to grant sublicenses.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our current licenses impose, and any future licenses we enter into are likely to impose, various development, commercialization, funding, milestone, royalty, diligence, sublicensing, insurance, patent prosecution and enforcement, and other obligations on us. If we breach any of these obligations, or use the intellectual property licensed to us in an unauthorized manner, we may be required to pay damages and the licensor may have the right to terminate the license or render the license non-exclusive, which could result in us being unable to develop, manufacture, market and sell products that are covered by the licensed technology or enable a competitor to gain access to the licensed technology. Moreover, we could incur significant costs and/or disruption to our business and distraction of our management defending against any breach of such licenses alleged by the licensor. For example, in June 2018, Ionis Pharmaceuticals, Inc., or Ionis, sent us a notice claiming that it was owed payments under our second amended and restated strategic collaboration and license agreement as a result of the January 2018 amendment of our collaboration agreement with Sanofi Genzyme and the related Exclusive TTR License and AT3 License Terms. Ionis claimed it was owed technology access fees, or TAF's, based on rights granted and amounts paid to us in connection with the Sanofi Genzyme restructuring. In November 2018, we received notice that Ionis had filed a Demand for Arbitration with the Boston office of the American Arbitration Association against us, asserting, among other things, breach of contract. The hearing portion of the arbitration process was completed in June 2020, and post-hearing briefing was completed in the third quarter of 2020. In October 2020, a partial award was issued by the arbitration panel seeking additional information from us. The arbitration panel issued its final award in December 2020, which ruled in favor of Ionis&#8217;s request for a TAF on certain rights the panel determined we received in the Sanofi restructuring (but rejecting the TAF amount sought by Ionis), and in favor of us in denying Ionis&#8217;s request for a TAF on a milestone payment received by us in the same restructuring. The panel&#8217;s final award also denied Ionis&#8217;s request for pre-judgement interest and attorney&#8217;s fees. Pursuant to the panel's final award, we paid $41.2 million to Ionis in January 2021. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Moreover, our licensors may own or control intellectual property that has not been licensed to us and, as a result, we may be subject to claims, regardless of their merit, that we are infringing or otherwise violating the licensor&#8217;s rights. In addition, while we cannot currently determine the amount of the royalty obligations we will be required to pay on sales of each of our approved products or future products, if any, the amounts may be significant. The amount of our future royalty obligations will depend on the technology and intellectual property we use in such products. Therefore, even if we successfully develop and commercialize products, we may be unable to achieve or maintain profitability.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Confidentiality agreements with employees and others may not adequately prevent disclosure of trade secrets and other proprietary information.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In order to protect our proprietary technology and processes, we rely in part on confidentiality agreements with our collaborators, employees, consultants, outside scientific collaborators and sponsored researchers, and other advisors. These agreements may not effectively prevent disclosure of confidential information and may not provide an adequate remedy in the event of unauthorized disclosure of confidential information. In addition, others may independently discover trade secrets and proprietary information, and in such cases we could not assert any trade secret rights against such party. Costly and time-consuming litigation could be necessary to enforce and determine the scope of our proprietary rights, and failure to obtain or maintain trade secret protection could adversely affect our competitive business position.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9f86b6d3686546618ade3c76e6b23fc8_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Risks Related to Competition</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">The pharmaceutical market is intensely competitive. If we are unable to compete effectively with existing drugs, new treatment methods and new technologies, we may be unable to commercialize successfully any drugs that we develop.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The pharmaceutical market is intensely competitive and rapidly changing. Many large pharmaceutical and biotechnology companies, academic institutions, governmental agencies and other public and private research organizations are pursuing the development of novel drugs for the same diseases that we are targeting or expect to target. Many of our competitors have:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">much greater financial, technical and human resources than we have at every stage of the discovery, development, manufacture and commercialization of products;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">more extensive experience in pre-clinical testing, conducting clinical trials, obtaining regulatory approvals, and in manufacturing, marketing and selling drug products;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">product candidates that are based on previously tested or accepted technologies;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">products that have been approved or are in late stages of development; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">collaborative arrangements in our target markets with leading companies and research institutions.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We will face intense competition from drugs that have already been approved and accepted by the medical community for the treatment of the conditions for which we may develop drugs. We also expect to face competition from new drugs that enter the market. There are a number of drugs currently under development, which may become commercially available in the future, for the treatment of conditions for which we may try to develop drugs. These drugs may be more effective, safer, less expensive, or marketed and sold more effectively, than any products we develop and commercialize. For example, we developed ONPATTRO for the treatment of hATTR amyloidosis. In August 2018, the FDA approved ONPATTRO lipid complex injection for the treatment of the polyneuropathy of hATTR amyloidosis in adults, and the EC granted marketing authorization for ONPATTRO for the treatment of hATTR amyloidosis in adults with stage 1 or stage 2 polyneuropathy. We are aware of other approved products used to treat this disease, including tafamidis, marketed by Pfizer, which is approved in a number of jurisdictions, and inotersen, developed and marketed by Ionis, as well as product candidates in various stages of clinical development, including an additional investigational drug. Finally, we are aware that BridgeBio Pharma, Inc. (formerly Eidos Therapeutics, Inc.), or BridgeBio, initiated a Phase 3 clinical trial of acoramidis, a TTR stabilizer, in ATTR-CM in February 2019, and completed enrollment of the Phase 3 clinical trial in ATTR-CM in late 2020. BridgeBio anticipates topline results from the ATTR-CM trial in late 2021 or early 2022. BridgeBio also initiated enrollment in a Phase 3 clinical trial of acoramidis in ATTR-PN patients in the fourth quarter of 2020. While we believe that ONPATTRO has and will continue to have a competitive product profile, and if approved, that vutrisiran will have a competitive product profile, it is possible that ONPATTRO and/or vutrisiran may not compete favorably with these products and product candidates, or others, and, as a result, may not achieve commercial success. Moreover, positive data and/or the commercial success of competitive products could negatively impact our stock price.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If we continue to successfully develop product candidates, and obtain approval for them, we will face competition based on many different factors, including:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the safety and effectiveness of our products relative to alternative therapies, if any;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the ease with which our products can be administered and the extent to which patients accept relatively new routes of administration;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the timing and scope of regulatory approvals for these products;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the availability and cost of manufacturing, marketing and sales capabilities;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the price of our products relative to alternative approved therapies;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">reimbursement coverage; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">patent position.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are aware of product candidates in various stages of clinical development for the treatment of PH1 which would compete with OXLUMO, our RNAi therapeutic approved in the U.S. and EU for the treatment of this disease, including Oxabact&#174;, a bacteria-based investigational therapy in Phase 3 development by OxThera AB, reloxaliase an investigational enzyme therapy in Phase 3 development for primary or severe secondary hyperoxaluria by Allena Pharmaceuticals, Inc., and nedosiran, an investigational RNAi therapeutic in development by Dicerna for the treatment of primary hyperoxaluria. In July 2019, the FDA granted a Breakthrough Therapy Designation to nedosiran for the treatment of patients with primary hyperoxaluria, and in January 2021, Dicerna announced that it completed enrollment in its PHYOX2 pivotal clinical trial of nedosiran with topline results expected in mid-2021. In April 2020, we and Dicerna granted each other a non-exclusive cross-license to our respective intellectual property related to lumasiran, and Dicerna&#8217;s nedosiran product candidate. Our competitors may develop or commercialize products with significant advantages over any products we develop based on any of the factors </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9f86b6d3686546618ade3c76e6b23fc8_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">listed above or on other factors. In addition, our competitors may develop strategic alliances with or receive funding from larger pharmaceutical or biotechnology companies, providing them with an advantage over us. Our competitors may therefore be more successful in commercializing their products than we are, which could adversely affect our competitive position and business. Competitive products may make any products we develop obsolete or noncompetitive before we can recover the expenses of developing and commercializing our product candidates. Such competitors could also recruit our employees, which could negatively impact our level of expertise and the ability to execute on our business plan. Furthermore, we also face competition from existing and new treatment methods that reduce or eliminate the need for drugs, such as the use of advanced medical devices. The development of new medical devices or other treatment methods for the diseases we are targeting could make our product candidates noncompetitive, obsolete or uneconomical.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We face competition from other companies that are working to develop novel drugs and technology platforms using technology similar to ours. If these companies develop drugs more rapidly than we do or their technologies, including delivery technologies, are more effective, our ability to successfully commercialize drugs may be adversely affected.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition to the competition we face from competing drugs in general, we also face competition from other companies working to develop novel drugs using technology that competes more directly with our own. We are aware of several other companies that are working to develop RNAi therapeutic products. Some of these companies are seeking, as we are, to develop chemically synthesized siRNAs as drugs. Others are following a gene therapy approach, with the goal of treating patients not with synthetic siRNAs but with synthetic, exogenously-introduced genes designed to produce siRNA-like molecules within cells. Companies working on chemically synthesized siRNAs include, but are not limited to, Takeda Pharmaceutical Company Ltd., or Takeda, Marina Biotech, Inc., or Marina, Arrowhead Pharmaceuticals, Inc., or Arrowhead, and its subsidiary, Calando Pharmaceuticals, Inc., or Calando, Quark Pharmaceuticals, Inc., or Quark, Silence Therapeutics plc, or Silence, Arbutus, Sylentis, S.A.U., or Sylentis, Dicerna and its collaborators, WAVE Life Sciences Ltd., or WAVE, Arcturus Therapeutics, Inc., and Genevant Sciences, launched by Arbutus and Roivant Sciences. In addition, we granted licenses or options for licenses to Ionis, Benitec Biopharma Ltd., Arrowhead, and its subsidiary, Calando, Arbutus, Quark, Sylentis and others under which these companies may independently develop RNAi therapeutics against a limited number of targets. Any one of these companies may develop its RNAi technology more rapidly and more effectively than us.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, as a result of agreements that we have entered into, Takeda has obtained a non-exclusive license, and Arrowhead, as the assignee of Novartis, has obtained specific exclusive licenses for 30 gene targets, that include access to certain aspects of our technology. We also compete with companies working to develop antisense-based drugs. Like RNAi therapeutics, antisense drugs target mRNAs in order to suppress the activity of specific genes. Akcea Therapeutics, Inc. (acquired by Ionis in October 2020) or Akcea, has received marketing approval for an antisense drug, inotersen that was developed by Ionis, for the treatment of stage 1 or stage 2 polyneuropathy in adult patients with hATTR amyloidosis. Several antisense drugs developed by Ionis have been approved and are currently marketed, and Ionis has multiple antisense product candidates in clinical trials. Ionis is also developing antisense drugs using ligand-conjugated GalNAc technology licensed from us, and these drugs have been shown to have increased potency at lower doses in clinical and pre-clinical studies, compared with antisense drugs that do not use such licensed GalNAc technology. The development of antisense drugs is more advanced than that of RNAi therapeutics, and antisense technology may become the preferred technology for drugs that target mRNAs to silence specific genes.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition to competition with respect to RNAi and with respect to specific products, we face substantial competition to discover and develop safe and effective means to deliver siRNAs to the relevant cell and tissue types. Safe and effective means to deliver siRNAs to the relevant cell and tissue types may be developed by our competitors, and our ability to successfully commercialize a competitive product would be adversely affected. In addition, substantial resources are being expended by third parties in the effort to discover and develop a safe and effective means of delivering siRNAs into the relevant cell and tissue types, both in academic laboratories and in the corporate sector. Some of our competitors have substantially greater resources than we do, and if our competitors are able to negotiate exclusive access to those delivery solutions developed by third parties, we may be unable to successfully commercialize our product candidates.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Risks Related to Our Common Stock</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">If our stock price fluctuates, purchasers of our common stock could incur substantial losses.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The market price of our common stock has fluctuated significantly and may continue to fluctuate significantly in response to factors that are beyond our control. The stock market in general has from time to time experienced extreme price and volume fluctuations, and the biotechnology sector in particular has experienced extreme price and volume fluctuations. The market prices of securities of pharmaceutical and biotechnology companies have been extremely volatile, and have experienced fluctuations that often have been unrelated or disproportionate to the clinical development progress or operating performance of these companies, including as a result of adverse development events. For example, the trading price for our common stock and the common stock of other biopharmaceutical companies was highly volatile during the initial stages of the COVID-19 pandemic. The COVID-19 pandemic has continued to evolve, and the extent to which the pandemic may impact our business will depend on future developments, which are highly uncertain and cannot be predicted with confidence. These broad market </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9f86b6d3686546618ade3c76e6b23fc8_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">and sector fluctuations have resulted and could in the future result in extreme fluctuations in the price of our common stock, which could cause purchasers of our common stock to incur substantial losses.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We may incur significant costs from class action litigation.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our stock price may fluctuate for many reasons, including as a result of public announcements regarding the progress of our development and commercialization efforts or the development and commercialization efforts of our collaborators and/or competitors, the addition or departure of our key personnel, variations in our quarterly operating results and changes in market valuations of pharmaceutical and biotechnology companies. For example, in October 2016, we announced that we were discontinuing the development of revusiran and our stock price declined significantly as a result. When the market price of a stock has been volatile as our stock price has been, holders of that stock have occasionally brought securities class action litigation against the company that issued the stock.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For example, a class action complaint was filed on September 26, 2018 in the United States District Court for the Southern District of New York (and transferred to the United States District Court for the District of Massachusetts by stipulation of the parties and Order of the Court dated November 20, 2018). The complaint, as amended, or the Complaint, alleged that we and our Chief Executive Officer, former Chief Financial Officer and certain of our other executive officers violated certain federal securities laws, specifically under Sections 10(b) and 20(a) of the Exchange Act, and Rule 10b-5 promulgated thereunder. The plaintiff sought unspecified damages on behalf of a purported class of purchasers of our common stock between September 20, 2017 and September 12, 2018. On March 23, 2020, the Court granted our motion to dismiss and dismissed the Complaint without prejudice. Pursuant to a prior Order of the Court, on June 1, 2020, plaintiff filed a motion seeking leave to file a further amended complaint, which the Court denied by Memorandum &amp; Order dated March 12, 2021. This type of litigation is often expensive and diverts management&#8217;s attention and resources, which could adversely affect the operation of our business. If we are ultimately required to pay significant defense costs, damages or settlement amounts, in excess of our insurance coverage, such payments could adversely affect our operations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We may be the target of similar litigation in the future. For example, on September 12, 2019, the Chester County Employees Retirement Fund, individually and on behalf of all others similarly situated, filed a purported securities class action complaint alleging violation of federal securities laws against us, certain of our current and former directors and officers, and the underwriters of our November 14, 2017 public stock offering, in the Supreme Court of the State of New York, New York County, or the New York State Securities Litigation. We believe the allegations in the New York State Securities Litigation are without merit and we intend to defend the case vigorously. This litigation and future litigation could result in substantial costs and divert our management&#8217;s attention and resources, which could cause serious harm to our business, operating results and financial condition. We maintain liability insurance; however, if any costs or expenses associated with this or any other litigation exceed our insurance coverage, we may be forced to bear some or all of these costs and expenses directly, which could be substantial.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Future sales of shares of our common stock, including by our significant stockholders, us or our directors and officers, could cause the price of our common stock to decline.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A small number of our stockholders beneficially own a substantial amount of our common stock. As of March 31, 2021, our seven largest stockholders beneficially owned in excess of 50% of our outstanding shares of common stock. If our significant stockholders, or we or our officers and directors, sell substantial amounts of our common stock in the public market, or there is a perception that such sales may occur, the market price of our common stock could be adversely affected. Sales of common stock by our significant stockholders might make it more difficult for us to raise funds by selling equity or equity-related securities in the future at a time and price that we deem appropriate.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Regeneron&#8217;s ownership of our common stock could delay or prevent a change in corporate control.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of May 21, 2019, the closing date of the stock purchase in connection with the 2019 Regeneron collaboration, Regeneron held approximately 4% of our outstanding common stock and has the right to increase its ownership up to 30%. This concentration of ownership could harm the market price of our common stock in the future by:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">delaying, deferring or preventing a change in control of our company;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">impeding a merger, consolidation, takeover or other business combination involving our company; or</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">discouraging a potential acquirer from making a tender offer or otherwise attempting to obtain control of our company.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Anti-takeover provisions in our charter documents and under Delaware law could make an acquisition of us, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Provisions in our certificate of incorporation and our bylaws may delay or prevent an acquisition of us or a change in our management. In addition, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors. Because our </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9f86b6d3686546618ade3c76e6b23fc8_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">board of directors is responsible for appointing the members of our management team, these provisions could in turn affect any attempt by our stockholders to replace current members of our management team. These provisions include:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">a classified board of directors;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">a prohibition on actions by our stockholders by written consent;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">limitations on the removal of directors; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">advance notice requirements for election to our board of directors and for proposing matters that can be acted upon at stockholder meetings.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law, which prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner. These provisions would apply even if the proposed merger or acquisition could be considered beneficial by some stockholders.</span></div><div id="i9f86b6d3686546618ade3c76e6b23fc8_115"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 5. OTHER INFORMATION </span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On April 27, 2021, we entered into a second amendment to our non-cancelable real property lease agreement with BMR-Fresh Pond Research Park LLC, as amended, or the BMR-665 Concord Avenue Lease, for our manufacturing facility for patisiran formulated bulk drug product for late-stage clinical trial use and commercial supply. Under the BMR-665 Concord Avenue Lease, we lease approximately 15,000 square feet of office and laboratory space located at 665 Concord Avenue, Cambridge, Massachusetts. Pursuant to the second amendment, we extended the term, which was set to expire in August 2022, for an additional five years, through September 30, 2027. We have the option to extend the BMR-665 Concord Avenue Lease for one additional five-year period.</span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div id="i9f86b6d3686546618ade3c76e6b23fc8_118"></div><div style="-sec-extract:summary;margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 6. EXHIBITS</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:6.562%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:78.465%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.673%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="alny2021q110-qex311.htm">Certification of principal executive officer pursuant to Rule&#160;13a-14(a) promulgated under the Securities Exchange Act of 1934, as amended</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="alny2021q110-qex312.htm">Certification of principal financial officer pursuant to Rule&#160;13a-14(a) promulgated under the Securities Exchange Act of 1934, as amended</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="alny2021q110-qex321.htm">Certification of principal executive officer pursuant to Rule&#160;13a-14(b) promulgated under the Securities Exchange Act of 1934, as amended, and Section&#160;1350 of Chapter&#160;63 of Title 18 of the United States Code</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="alny2021q110-qex322.htm">Certification of principal financial officer pursuant to Rule&#160;13a-14(b) promulgated under the Securities Exchange Act of 1934, as amended, and Section&#160;1350 of Chapter&#160;63 of Title 18 of the United States Code</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema Document</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Label Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as inline XBRL with applicable taxonomy extension information contained in Exhibits 101.*)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><div id="i9f86b6d3686546618ade3c76e6b23fc8_121"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9f86b6d3686546618ade3c76e6b23fc8_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:43.474%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:53.593%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ALNYLAM PHARMACEUTICALS, INC.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: April 29, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ John M. Maraganore</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">John M. Maraganore, Ph.D.<br/>Chief Executive Officer<br/>(Principal Executive Officer)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: April 29, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Jeffrey V. Poulton</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jeffrey V. Poulton<br/>Executive Vice President, Chief Financial Officer<br/>(Principal Financial and Accounting Officer)</span></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>alny2021q110-qex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="idfda35c0e9d8479ab9ceb8952fec7af8_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:10pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 31.1</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, John M. Maraganore, Ph.D., certify that&#58;</font></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">I have reviewed this Quarterly Report on Form 10-Q of Alnylam Pharmaceuticals, Inc.&#59;</font></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&#160;13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:6pt;padding-left:126pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:37.24pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:6pt;padding-left:126pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:36.67pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:6pt;padding-left:126pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:37.24pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:6pt;padding-left:126pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:36.67pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:6pt;padding-left:126pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:37.24pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:6pt;padding-left:126pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:36.67pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated&#58; April&#160;29, 2021</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; John M. Maraganore</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">John M. Maraganore, Ph.D.&#160;<br>Chief Executive Officer&#160;</font></td></tr></table></div><div style="margin-top:6pt"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>alny2021q110-qex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i4948e25c1ac44c9ea1db0610b9c7def8_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:10pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 31.2</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I,&#160;Jeffrey V. Poulton, certify that&#58;</font></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">I have reviewed this Quarterly Report on Form 10-Q of Alnylam Pharmaceuticals, Inc.&#59;</font></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&#160;13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:6pt;padding-left:126pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:37.24pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:6pt;padding-left:126pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:36.67pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:6pt;padding-left:126pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:37.24pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:6pt;padding-left:126pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:36.67pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:6pt;padding-left:126pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:37.24pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:6pt;padding-left:126pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:36.67pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated&#58; April&#160;29, 2021</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Jeffrey V. Poulton</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jeffrey V. Poulton<br>Executive Vice President, Chief Financial Officer</font></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>alny2021q110-qex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i3ff221c3a48f484e87279ae5866d0e5c_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">EXHIBIT 32.1</font></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT</font></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In connection with the Quarterly Report on Form 10-Q of Alnylam Pharmaceuticals, Inc. (the &#8220;Company&#8221;) for the quarter ended March&#160;31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), the undersigned, John M. Maraganore, Ph.D., Chief Executive Officer of the Company, hereby certifies, pursuant to Section&#160;1350 of Chapter 63 of Title 18, United States Code, that to his knowledge&#58;</font></div><div style="margin-top:6pt;padding-left:76.5pt;text-indent:-40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(1)&#160;&#160;&#160;&#160;the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-top:6pt;padding-left:76.5pt;text-indent:-40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(2)&#160;&#160;&#160;&#160;the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated&#58; April&#160;29, 2021</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; John M. Maraganore</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">John M. Maraganore, Ph.D.&#160;<br>Chief Executive Officer&#160;</font></td></tr></table></div><div style="margin-top:6pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A signed original of this written statement required by Section&#160;906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>alny2021q110-qex322.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i417c8bc7084042059b8ea1f24739af38_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">EXHIBIT 32.2</font></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT</font></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In connection with the Quarterly Report on Form 10-Q of Alnylam Pharmaceuticals, Inc. (the &#8220;Company&#8221;) for the quarter ended March&#160;31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), the undersigned,&#160;Jeffrey V. Poulton, Executive Vice President, Chief Financial Officer, hereby certifies, pursuant to Section&#160;1350 of Chapter&#160;63 of Title 18, United States Code, that to his knowledge&#58;</font></div><div style="margin-top:6pt;padding-left:76.5pt;text-indent:-40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(1)&#160;&#160;&#160;&#160;the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-top:6pt;padding-left:76.5pt;text-indent:-40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(2)&#160;&#160;&#160;&#160;the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated&#58; April&#160;29, 2021</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Jeffrey V. Poulton</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jeffrey V. Poulton<br>Executive Vice President, Chief Financial Officer</font></td></tr></table></div><div style="margin-top:6pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A signed original of this written statement required by Section&#160;906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>alny-20210331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:45529fdd-2cb3-415e-a8b1-14659af4a28e,g:8b4a69cc-2403-45c9-b738-5835a1e5fb0d-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:alny="http://www.alnylam.com/20210331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.alnylam.com/20210331">
  <xs:import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2020-01-31" schemaLocation="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="alny-20210331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="alny-20210331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="alny-20210331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="alny-20210331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.alnylam.com/role/CoverPage">
        <link:definition>0001001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDBALANCESHEETS" roleURI="http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS">
        <link:definition>1001002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" roleURI="http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical">
        <link:definition>1002003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" roleURI="http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS">
        <link:definition>1003004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" roleURI="http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY">
        <link:definition>1004005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>1005006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NATUREOFBUSINESS" roleURI="http://www.alnylam.com/role/NATUREOFBUSINESS">
        <link:definition>2101101 - Disclosure - NATURE OF BUSINESS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NATUREOFBUSINESSDetails" roleURI="http://www.alnylam.com/role/NATUREOFBUSINESSDetails">
        <link:definition>2402401 - Disclosure - NATURE OF BUSINESS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BASISOFPRESENTATIONANDPRINCIPLESOFCONSOLIDATION" roleURI="http://www.alnylam.com/role/BASISOFPRESENTATIONANDPRINCIPLESOFCONSOLIDATION">
        <link:definition>2103102 - Disclosure - BASIS OF PRESENTATION AND PRINCIPLES OF CONSOLIDATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BASISOFPRESENTATIONANDPRINCIPLESOFCONSOLIDATIONPolicies" roleURI="http://www.alnylam.com/role/BASISOFPRESENTATIONANDPRINCIPLESOFCONSOLIDATIONPolicies">
        <link:definition>2204201 - Disclosure - BASIS OF PRESENTATION AND PRINCIPLES OF CONSOLIDATION (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NETPRODUCTREVENUES" roleURI="http://www.alnylam.com/role/NETPRODUCTREVENUES">
        <link:definition>2105103 - Disclosure - NET PRODUCT REVENUES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NETPRODUCTREVENUESTables" roleURI="http://www.alnylam.com/role/NETPRODUCTREVENUESTables">
        <link:definition>2306301 - Disclosure - NET PRODUCT REVENUES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NETPRODUCTREVENUESSummaryofNetProductRevenuesDetail" roleURI="http://www.alnylam.com/role/NETPRODUCTREVENUESSummaryofNetProductRevenuesDetail">
        <link:definition>2407402 - Disclosure - NET PRODUCT REVENUES - Summary of Net Product Revenues (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NETPRODUCTREVENUESReceivablesDetail" roleURI="http://www.alnylam.com/role/NETPRODUCTREVENUESReceivablesDetail">
        <link:definition>2408403 - Disclosure - NET PRODUCT REVENUES - Receivables (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NETREVENUESFROMCOLLABORATIONS" roleURI="http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONS">
        <link:definition>2109104 - Disclosure - NET REVENUES FROM COLLABORATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NETREVENUESFROMCOLLABORATIONSTables" roleURI="http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSTables">
        <link:definition>2310302 - Disclosure - NET REVENUES FROM COLLABORATIONS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NETREVENUESFROMCOLLABORATIONSRevenuefromCollaboratorsDetail" roleURI="http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSRevenuefromCollaboratorsDetail">
        <link:definition>2411404 - Disclosure - NET REVENUES FROM COLLABORATIONS - Revenue from Collaborators (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NETREVENUESFROMCOLLABORATIONSBalanceofReceivablesandContractLiabilitiesRelatedtoCollaborationAgreementsDetail" roleURI="http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSBalanceofReceivablesandContractLiabilitiesRelatedtoCollaborationAgreementsDetail">
        <link:definition>2412405 - Disclosure - NET REVENUES FROM COLLABORATIONS - Balance of Receivables and Contract Liabilities Related to Collaboration Agreements (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NETREVENUESFROMCOLLABORATIONSAdditionalInformationDetail" roleURI="http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSAdditionalInformationDetail">
        <link:definition>2413406 - Disclosure - NET REVENUES FROM COLLABORATIONS - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NETREVENUESFROMCOLLABORATIONSScheduleofResearchandDevelopmentExpensesIncurredbyTypethatareDirectlyAttributabletoCollaborationAgreementsDetail" roleURI="http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofResearchandDevelopmentExpensesIncurredbyTypethatareDirectlyAttributabletoCollaborationAgreementsDetail">
        <link:definition>2414407 - Disclosure - NET REVENUES FROM COLLABORATIONS - Schedule of Research and Development Expenses Incurred by Type that are Directly Attributable to Collaboration Agreements (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NETREVENUESFROMCOLLABORATIONSScheduleofTransactionPriceAllocatedDetails" roleURI="http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofTransactionPriceAllocatedDetails">
        <link:definition>2415408 - Disclosure - NET REVENUES FROM COLLABORATIONS - Schedule of Transaction Price Allocated (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NETREVENUESFROMCOLLABORATIONSScheduleofDeferredRevenueDetails" roleURI="http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofDeferredRevenueDetails">
        <link:definition>2416409 - Disclosure - NET REVENUES FROM COLLABORATIONS - Schedule of Deferred Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NETREVENUESFROMCOLLABORATIONSScheduleofRevenueRecognizedbyAccountingGuidanceDetails" roleURI="http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofRevenueRecognizedbyAccountingGuidanceDetails">
        <link:definition>2417410 - Disclosure - NET REVENUES FROM COLLABORATIONS - Schedule of Revenue Recognized by Accounting Guidance (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LIABILITYRELATEDTOTHESALEOFFUTUREROYALTIES" roleURI="http://www.alnylam.com/role/LIABILITYRELATEDTOTHESALEOFFUTUREROYALTIES">
        <link:definition>2118105 - Disclosure - LIABILITY RELATED TO THE SALE OF FUTURE ROYALTIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LIABILITYRELATEDTOTHESALEOFFUTUREROYALTIESTables" roleURI="http://www.alnylam.com/role/LIABILITYRELATEDTOTHESALEOFFUTUREROYALTIESTables">
        <link:definition>2319303 - Disclosure - LIABILITY RELATED TO THE SALE OF FUTURE ROYALTIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LIABILITYRELATEDTOTHESALEOFFUTUREROYALTIESDetails" roleURI="http://www.alnylam.com/role/LIABILITYRELATEDTOTHESALEOFFUTUREROYALTIESDetails">
        <link:definition>2420411 - Disclosure - LIABILITY RELATED TO THE SALE OF FUTURE ROYALTIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTS" roleURI="http://www.alnylam.com/role/FAIRVALUEMEASUREMENTS">
        <link:definition>2121106 - Disclosure - FAIR VALUE MEASUREMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSTables" roleURI="http://www.alnylam.com/role/FAIRVALUEMEASUREMENTSTables">
        <link:definition>2322304 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSFairValueofAssetsMeasuredonaRecurringBasisDetail" roleURI="http://www.alnylam.com/role/FAIRVALUEMEASUREMENTSFairValueofAssetsMeasuredonaRecurringBasisDetail">
        <link:definition>2423412 - Disclosure - FAIR VALUE MEASUREMENTS - Fair Value of Assets Measured on a Recurring Basis (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MARKETABLEDEBTSECURITIES" roleURI="http://www.alnylam.com/role/MARKETABLEDEBTSECURITIES">
        <link:definition>2124107 - Disclosure - MARKETABLE DEBT SECURITIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MARKETABLEDEBTSECURITIESTables" roleURI="http://www.alnylam.com/role/MARKETABLEDEBTSECURITIESTables">
        <link:definition>2325305 - Disclosure - MARKETABLE DEBT SECURITIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MARKETABLEDEBTSECURITIESAdditionalInformationDetail" roleURI="http://www.alnylam.com/role/MARKETABLEDEBTSECURITIESAdditionalInformationDetail">
        <link:definition>2426413 - Disclosure - MARKETABLE DEBT SECURITIES - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MARKETABLEDEBTSECURITIESSummaryofMarketableDebtSecuritiesDetail" roleURI="http://www.alnylam.com/role/MARKETABLEDEBTSECURITIESSummaryofMarketableDebtSecuritiesDetail">
        <link:definition>2427414 - Disclosure - MARKETABLE DEBT SECURITIES - Summary of Marketable Debt Securities (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MARKETABLEDEBTSECURITIESSummaryofFairValueofMarketableDebtSecuritiesDetail" roleURI="http://www.alnylam.com/role/MARKETABLEDEBTSECURITIESSummaryofFairValueofMarketableDebtSecuritiesDetail">
        <link:definition>2428415 - Disclosure - MARKETABLE DEBT SECURITIES - Summary of Fair Value of Marketable Debt Securities (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OTHERBALANCESHEETDETAILS" roleURI="http://www.alnylam.com/role/OTHERBALANCESHEETDETAILS">
        <link:definition>2129108 - Disclosure - OTHER BALANCE SHEET DETAILS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OTHERBALANCESHEETDETAILSTables" roleURI="http://www.alnylam.com/role/OTHERBALANCESHEETDETAILSTables">
        <link:definition>2330306 - Disclosure - OTHER BALANCE SHEET DETAILS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OTHERBALANCESHEETDETAILSScheduleofInventoryDetail" roleURI="http://www.alnylam.com/role/OTHERBALANCESHEETDETAILSScheduleofInventoryDetail">
        <link:definition>2431416 - Disclosure - OTHER BALANCE SHEET DETAILS - Schedule of Inventory (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OTHERBALANCESHEETDETAILSScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetail" roleURI="http://www.alnylam.com/role/OTHERBALANCESHEETDETAILSScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetail">
        <link:definition>2432417 - Disclosure - OTHER BALANCE SHEET DETAILS - Schedule of Reconciliation of Cash, Cash Equivalents and Restricted Cash (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OTHERBALANCESHEETDETAILSSummaryofChangesinAccumulatedOtherComprehensiveIncomeLossDetails" roleURI="http://www.alnylam.com/role/OTHERBALANCESHEETDETAILSSummaryofChangesinAccumulatedOtherComprehensiveIncomeLossDetails">
        <link:definition>2433418 - Disclosure - OTHER BALANCE SHEET DETAILS - Summary of Changes in Accumulated Other Comprehensive Income (Loss) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CREDITAGREEMENT" roleURI="http://www.alnylam.com/role/CREDITAGREEMENT">
        <link:definition>2134109 - Disclosure - CREDIT AGREEMENT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CREDITAGREEMENTTables" roleURI="http://www.alnylam.com/role/CREDITAGREEMENTTables">
        <link:definition>2335307 - Disclosure - CREDIT AGREEMENT (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CREDITAGREEMENTAdditionalInformationDetails" roleURI="http://www.alnylam.com/role/CREDITAGREEMENTAdditionalInformationDetails">
        <link:definition>2436419 - Disclosure - CREDIT AGREEMENT - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DEVELOPMENTDERIVATIVELIABILITY" roleURI="http://www.alnylam.com/role/DEVELOPMENTDERIVATIVELIABILITY">
        <link:definition>2137110 - Disclosure - DEVELOPMENT DERIVATIVE LIABILITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DEVELOPMENTDERIVATIVELIABILITYTables" roleURI="http://www.alnylam.com/role/DEVELOPMENTDERIVATIVELIABILITYTables">
        <link:definition>2338308 - Disclosure - DEVELOPMENT DERIVATIVE LIABILITY (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DEVELOPMENTDERIVATIVELIABILITYNarrativeDetails" roleURI="http://www.alnylam.com/role/DEVELOPMENTDERIVATIVELIABILITYNarrativeDetails">
        <link:definition>2439420 - Disclosure - DEVELOPMENT DERIVATIVE LIABILITY - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DEVELOPMENTDERIVATIVELIABILITYDevelopmentDerivativeLiabilityActivityDetails" roleURI="http://www.alnylam.com/role/DEVELOPMENTDERIVATIVELIABILITYDevelopmentDerivativeLiabilityActivityDetails">
        <link:definition>2440421 - Disclosure - DEVELOPMENT DERIVATIVE LIABILITY - Development Derivative Liability Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDCOMPENSATION" roleURI="http://www.alnylam.com/role/STOCKBASEDCOMPENSATION">
        <link:definition>2141111 - Disclosure - STOCK-BASED COMPENSATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDCOMPENSATIONTables" roleURI="http://www.alnylam.com/role/STOCKBASEDCOMPENSATIONTables">
        <link:definition>2342309 - Disclosure - STOCK-BASED COMPENSATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDCOMPENSATIONSummaryofShareBasedCompensationExpensesIncludedOperatingCostsandExpenseDetail" roleURI="http://www.alnylam.com/role/STOCKBASEDCOMPENSATIONSummaryofShareBasedCompensationExpensesIncludedOperatingCostsandExpenseDetail">
        <link:definition>2443422 - Disclosure - STOCK-BASED COMPENSATION - Summary of Share-Based Compensation Expenses Included Operating Costs and Expense (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NETLOSSPERCOMMONSHARE" roleURI="http://www.alnylam.com/role/NETLOSSPERCOMMONSHARE">
        <link:definition>2144112 - Disclosure - NET LOSS PER COMMON SHARE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NETLOSSPERCOMMONSHARETables" roleURI="http://www.alnylam.com/role/NETLOSSPERCOMMONSHARETables">
        <link:definition>2345310 - Disclosure - NET LOSS PER COMMON SHARE (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NETLOSSPERCOMMONSHARECommonShareEquivalentsExcludedfromCalculationofNetLossPerCommonShareDetail" roleURI="http://www.alnylam.com/role/NETLOSSPERCOMMONSHARECommonShareEquivalentsExcludedfromCalculationofNetLossPerCommonShareDetail">
        <link:definition>2446423 - Disclosure - NET LOSS PER COMMON SHARE - Common Share Equivalents Excluded from Calculation of Net Loss Per Common Share (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIES" roleURI="http://www.alnylam.com/role/COMMITMENTSANDCONTINGENCIES">
        <link:definition>2147113 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="alny_C5LicenseObligationMember" abstract="true" name="C5LicenseObligationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="alny_HELIOSBPhase3ClinicalTrialMember" abstract="true" name="HELIOSBPhase3ClinicalTrialMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="alny_FuturePaymentsOnAchievementOfSpecifiedCommercializationMilestones" abstract="false" name="FuturePaymentsOnAchievementOfSpecifiedCommercializationMilestones" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alny_FundingAnAnnualDiscoveryMember" abstract="true" name="FundingAnAnnualDiscoveryMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="alny_RegeneronPharmaceuticalsIncorporationMember" abstract="true" name="RegeneronPharmaceuticalsIncorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="alny_RoyaltyLiabilityCurrent" abstract="false" name="RoyaltyLiabilityCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesLineItemsLineItems" abstract="true" name="LiabilityRelatedToTheSaleOfFutureRoyaltiesLineItemsLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="alny_ProductAlliancesMember" abstract="true" name="ProductAlliancesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="alny_ScheduleOfRoyaltyLiabilityTableTextBlock" abstract="false" name="ScheduleOfRoyaltyLiabilityTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="alny_RoyaltyLiabilityInterestExpenseIncludingAmortizationOfClosingCosts" abstract="false" name="RoyaltyLiabilityInterestExpenseIncludingAmortizationOfClosingCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alny_VutrisiranMember" abstract="true" name="VutrisiranMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="alny_ResearchServicesObligationMember" abstract="true" name="ResearchServicesObligationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="alny_ResearchTermExtensionFee" abstract="false" name="ResearchTermExtensionFee" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alny_BlackstoneLifeSciencesMember" abstract="true" name="BlackstoneLifeSciencesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="alny_ScheduleOfRevenueRecognizedBasedOnAccountingGuidanceTableTextBlock" abstract="false" name="ScheduleOfRevenueRecognizedBasedOnAccountingGuidanceTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="alny_MilestonePaymentEarnedShares" abstract="false" name="MilestonePaymentEarnedShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="alny_InvestmentsInMarketableDebtSecuritiesDisclosureTextBlock" abstract="false" name="InvestmentsInMarketableDebtSecuritiesDisclosureTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="alny_LiquidityPolicyPolicyTextBlock" abstract="false" name="LiquidityPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="alny_ScheduleOfResearchAndDevelopmentExpensesIncurredForCollaborationAgreementsTableTableTextBlock" abstract="false" name="ScheduleOfResearchAndDevelopmentExpensesIncurredForCollaborationAgreementsTableTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="alny_CollaborativeArrangementRoyaltiesPayableTerm" abstract="false" name="CollaborativeArrangementRoyaltiesPayableTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="alny_AmortizationAndInterestAccretionRelatedToOperatingLeases" abstract="false" name="AmortizationAndInterestAccretionRelatedToOperatingLeases" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alny_ExternalServicesMember" abstract="true" name="ExternalServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="alny_UpfrontFeeReceived" abstract="false" name="UpfrontFeeReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alny_ScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTableTextBlock" abstract="false" name="ScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="alny_RoyaltyLiabilityInterestRate" abstract="false" name="RoyaltyLiabilityInterestRate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="alny_FuturePaymentsOnAchievementOfSpecifiedRegulatoryMilestones" abstract="false" name="FuturePaymentsOnAchievementOfSpecifiedRegulatoryMilestones" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alny_DebtInstrumentExitFeePercent" abstract="false" name="DebtInstrumentExitFeePercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="alny_DebtInstrumentCovenantTermsMinimumConsolidatedLiquidity" abstract="false" name="DebtInstrumentCovenantTermsMinimumConsolidatedLiquidity" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alny_FundingAtLeadCandidateIdentificationMember" abstract="true" name="FundingAtLeadCandidateIdentificationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="alny_StandaloneSellingPrice" abstract="false" name="StandaloneSellingPrice" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alny_NonUSOrEuropeMember" abstract="true" name="NonUSOrEuropeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="alny_RoyaltiesReceivableCurrent" abstract="false" name="RoyaltiesReceivableCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alny_DebtInstrumentCovenantTermsMinimumProductRevenue" abstract="false" name="DebtInstrumentCovenantTermsMinimumProductRevenue" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alny_FundingAtProgramInitiationMember" abstract="true" name="FundingAtProgramInitiationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="alny_ONPATTROAndGIVLAARIMember" abstract="true" name="ONPATTROAndGIVLAARIMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="alny_RoyaltyLiabilityNoncurrent" abstract="false" name="RoyaltyLiabilityNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alny_TrancheThreeLoanMember" abstract="true" name="TrancheThreeLoanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="alny_NumberOfTargetedPrograms" abstract="false" name="NumberOfTargetedPrograms" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="alny_CollaborativeArrangementCommercialMilestonesAcquiredByCollaboratorPercent" abstract="false" name="CollaborativeArrangementCommercialMilestonesAcquiredByCollaboratorPercent" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="alny_DiscoveryPeriodOfProgramsDevelopment" abstract="false" name="DiscoveryPeriodOfProgramsDevelopment" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="alny_ALNAGTPhase3ClinicalTrialMember" abstract="true" name="ALNAGTPhase3ClinicalTrialMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="alny_LineOfCreditFacilityMaximumBorrowingCapacityAccordionFeature" abstract="false" name="LineOfCreditFacilityMaximumBorrowingCapacityAccordionFeature" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alny_CollaborativeArrangementRoyaltiesPayablePercent" abstract="false" name="CollaborativeArrangementRoyaltiesPayablePercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="alny_BlackstoneGroupIncMember" abstract="true" name="BlackstoneGroupIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="alny_NumberOfPartneredProducts" abstract="false" name="NumberOfPartneredProducts" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="alny_GIVLAARIMember" abstract="true" name="GIVLAARIMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="alny_DebtInstrumentInterestInKindInterestRateIncrease" abstract="false" name="DebtInstrumentInterestInKindInterestRateIncrease" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="alny_MaximumAdditionalMilestonePaymentsToBeReceiveUponAchievementOfCertainCriteria" abstract="false" name="MaximumAdditionalMilestonePaymentsToBeReceiveUponAchievementOfCertainCriteria" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alny_MaximumNumberOfPotentialFutureMilestones" abstract="false" name="MaximumNumberOfPotentialFutureMilestones" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alny_TrancheTwoLoanMember" abstract="true" name="TrancheTwoLoanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="alny_ONPATTROMember" abstract="true" name="ONPATTROMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="alny_PotentialProceedsFromCollaborationArrangement" abstract="false" name="PotentialProceedsFromCollaborationArrangement" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alny_MilestonePaymentEarned" abstract="false" name="MilestonePaymentEarned" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alny_ClinicalTrialAndManufacturingMember" abstract="true" name="ClinicalTrialAndManufacturingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="alny_RoyaltyRate" abstract="false" name="RoyaltyRate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="alny_CollaborativeAgreementTerminationPeriod" abstract="false" name="CollaborativeAgreementTerminationPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="alny_DebtInstrumentNumberOfTranches" abstract="false" name="DebtInstrumentNumberOfTranches" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="alny_ExtendedAdditionalDiscoveryPeriodOfProgramsDevelopment" abstract="false" name="ExtendedAdditionalDiscoveryPeriodOfProgramsDevelopment" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="alny_ALNAGTPhase2ClinicalTrialMember" abstract="true" name="ALNAGTPhase2ClinicalTrialMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="alny_ImpairmentOfMarketableDebtSecurities" abstract="false" name="ImpairmentOfMarketableDebtSecurities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alny_NonCashInterestExpenseOnSaleOfFutureRoyalties" abstract="false" name="NonCashInterestExpenseOnSaleOfFutureRoyalties" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alny_TransactionPrice" abstract="false" name="TransactionPrice" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alny_Tranche2LoanAndTranche3LoanMember" abstract="true" name="Tranche2LoanAndTranche3LoanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="alny_NumberOfClinicalProgramsInLateStages" abstract="false" name="NumberOfClinicalProgramsInLateStages" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="alny_CollaborativeArrangementFixedPaymentTerm" abstract="false" name="CollaborativeArrangementFixedPaymentTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="alny_ResearchCollaboratorDomain" abstract="true" name="ResearchCollaboratorDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="alny_GlobalStrategicCollaborationMember" abstract="true" name="GlobalStrategicCollaborationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="alny_InventoryCurrentAndNoncurrent" abstract="false" name="InventoryCurrentAndNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alny_FuturePaymentsOnAchievementOfOtherSpecifiedRegulatoryMilestones" abstract="false" name="FuturePaymentsOnAchievementOfOtherSpecifiedRegulatoryMilestones" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alny_LineOfCreditFacilityPrepaymentAndTerminationFeePercentage" abstract="false" name="LineOfCreditFacilityPrepaymentAndTerminationFeePercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="alny_OtherMember" abstract="true" name="OtherMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="alny_ExpectedRoyaltyInterestPayments" abstract="false" name="ExpectedRoyaltyInterestPayments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alny_NovartisMember" abstract="true" name="NovartisMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="alny_CollaborativeArrangementMaximumFunding" abstract="false" name="CollaborativeArrangementMaximumFunding" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alny_CollaborativeArrangementMilestonePayments" abstract="false" name="CollaborativeArrangementMilestonePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alny_NumberOfMarketedProducts" abstract="false" name="NumberOfMarketedProducts" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="alny_CollaborativeArrangementRoyaltiesAndCommercialMilestonesAcquiredByCollaboratorPercent" abstract="false" name="CollaborativeArrangementRoyaltiesAndCommercialMilestonesAcquiredByCollaboratorPercent" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="alny_C5CoCoObligationMember" abstract="true" name="C5CoCoObligationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="alny_RoyaltyLiabilityClosingCosts" abstract="false" name="RoyaltyLiabilityClosingCosts" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alny_CollaborativeArrangementConsiderationReceived" abstract="false" name="CollaborativeArrangementConsiderationReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alny_CollaborativeArrangementAdditionalDevelopmentCandidatesToBeDelivered" abstract="false" name="CollaborativeArrangementAdditionalDevelopmentCandidatesToBeDelivered" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="alny_OXLUMOMember" abstract="true" name="OXLUMOMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="alny_CostOfCollaborationManufacturingAndRoyalties" abstract="false" name="CostOfCollaborationManufacturingAndRoyalties" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock" abstract="false" name="LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="alny_OtherCollaborationsMember" abstract="true" name="OtherCollaborationsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="alny_CollaborativeArrangementFixedPaymentMultiplier" abstract="false" name="CollaborativeArrangementFixedPaymentMultiplier" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="alny_PercentageOfMaximumRoyaltyPayments" abstract="false" name="PercentageOfMaximumRoyaltyPayments" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="alny_ResearchCollaboratorAxis" abstract="true" name="ResearchCollaboratorAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="alny_MaximumRoyaltiesAndCommercialMilestonePaymentsUponPotentialProductSale" abstract="false" name="MaximumRoyaltiesAndCommercialMilestonePaymentsUponPotentialProductSale" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="alny_SanofiGenzymeMember" abstract="true" name="SanofiGenzymeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="alny_ScheduleOfAllocatedTransactionPriceTableTextBlock" abstract="false" name="ScheduleOfAllocatedTransactionPriceTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="alny_AccumulatedLossOnInvestmentInJointVentureMember" abstract="true" name="AccumulatedLossOnInvestmentInJointVentureMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesTable" abstract="true" name="LiabilityRelatedToTheSaleOfFutureRoyaltiesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="alny_VirBiotechnologyIncMember" abstract="true" name="VirBiotechnologyIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="alny_VutrisiranAndALNAGTMember" abstract="true" name="VutrisiranAndALNAGTMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>alny-20210331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:45529fdd-2cb3-415e-a8b1-14659af4a28e,g:8b4a69cc-2403-45c9-b738-5835a1e5fb0d-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.alnylam.com/role/CoverPage" xlink:type="simple" xlink:href="alny-20210331.xsd#CoverPage"/>
  <link:calculationLink xlink:role="http://www.alnylam.com/role/CoverPage" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="alny-20210331.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_145c318d-649b-4a04-acde-f0257a6487e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_d1ccd1dd-1431-4ee9-991f-7af07cd1ba91" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_145c318d-649b-4a04-acde-f0257a6487e3" xlink:to="loc_us-gaap_Liabilities_d1ccd1dd-1431-4ee9-991f-7af07cd1ba91" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_566ff37b-de52-4f6d-bb8e-574d482dd705" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_145c318d-649b-4a04-acde-f0257a6487e3" xlink:to="loc_us-gaap_CommitmentsAndContingencies_566ff37b-de52-4f6d-bb8e-574d482dd705" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_ab81a997-562c-470d-9f08-eb76cb79ed38" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_145c318d-649b-4a04-acde-f0257a6487e3" xlink:to="loc_us-gaap_StockholdersEquity_ab81a997-562c-470d-9f08-eb76cb79ed38" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_e5a1d194-c8e6-4cbc-a3b2-3c391e772cd1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_dd81bcb3-2959-4b16-93c0-310b19c68c14" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_e5a1d194-c8e6-4cbc-a3b2-3c391e772cd1" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_dd81bcb3-2959-4b16-93c0-310b19c68c14" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_7218aa30-ebf1-4c6a-a88f-dc6b966afac5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_e5a1d194-c8e6-4cbc-a3b2-3c391e772cd1" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_7218aa30-ebf1-4c6a-a88f-dc6b966afac5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_5814af74-4807-4ead-9598-9f08b6441d69" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_e5a1d194-c8e6-4cbc-a3b2-3c391e772cd1" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_5814af74-4807-4ead-9598-9f08b6441d69" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_1bc9c540-5c71-446e-a16e-6f4ce105093b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_e5a1d194-c8e6-4cbc-a3b2-3c391e772cd1" xlink:to="loc_us-gaap_InventoryNet_1bc9c540-5c71-446e-a16e-6f4ce105093b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_e1769a19-9d5c-4365-801e-3c0d46a5bd11" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_e5a1d194-c8e6-4cbc-a3b2-3c391e772cd1" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_e1769a19-9d5c-4365-801e-3c0d46a5bd11" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_3a5e5e2b-079b-472d-8bf8-045da78a6b28" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_e5a1d194-c8e6-4cbc-a3b2-3c391e772cd1" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_3a5e5e2b-079b-472d-8bf8-045da78a6b28" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_RoyaltiesReceivableCurrent_9012c296-c8e0-48d9-929d-d6a7799c4b2e" xlink:href="alny-20210331.xsd#alny_RoyaltiesReceivableCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_e5a1d194-c8e6-4cbc-a3b2-3c391e772cd1" xlink:to="loc_alny_RoyaltiesReceivableCurrent_9012c296-c8e0-48d9-929d-d6a7799c4b2e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_7cc9cee4-f00e-47fa-ae78-7190f4c170db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_f7ac3040-5677-4058-9fe4-2402897c7f1e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_7cc9cee4-f00e-47fa-ae78-7190f4c170db" xlink:to="loc_us-gaap_AssetsCurrent_f7ac3040-5677-4058-9fe4-2402897c7f1e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_3fce35dc-8c68-45bd-8e00-aa2c90c999c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_7cc9cee4-f00e-47fa-ae78-7190f4c170db" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_3fce35dc-8c68-45bd-8e00-aa2c90c999c6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_6e7f1a87-ee27-4a66-91ad-e375952474dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_7cc9cee4-f00e-47fa-ae78-7190f4c170db" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_6e7f1a87-ee27-4a66-91ad-e375952474dd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedInvestmentsNoncurrent_cd65c9b7-9cb2-4af1-a71f-e36da1471337" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedInvestmentsNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_7cc9cee4-f00e-47fa-ae78-7190f4c170db" xlink:to="loc_us-gaap_RestrictedInvestmentsNoncurrent_cd65c9b7-9cb2-4af1-a71f-e36da1471337" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_00cdfffa-066a-43d9-ac31-d9b9a39ef865" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_7cc9cee4-f00e-47fa-ae78-7190f4c170db" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_00cdfffa-066a-43d9-ac31-d9b9a39ef865" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_96c427fd-86d1-4b2a-b5c3-063aff8dff9f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_e2f4123a-34c3-4dd5-afba-c53dd8b92856" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_96c427fd-86d1-4b2a-b5c3-063aff8dff9f" xlink:to="loc_us-gaap_PreferredStockValue_e2f4123a-34c3-4dd5-afba-c53dd8b92856" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_7a9aedf1-1a64-4502-8d01-652cb1a12176" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_96c427fd-86d1-4b2a-b5c3-063aff8dff9f" xlink:to="loc_us-gaap_CommonStockValue_7a9aedf1-1a64-4502-8d01-652cb1a12176" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_2ba0506e-3369-4368-bee7-0fe9c36ff3d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_96c427fd-86d1-4b2a-b5c3-063aff8dff9f" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_2ba0506e-3369-4368-bee7-0fe9c36ff3d1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_2e26c5e6-5efe-4468-87a7-a13f56ad3568" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_96c427fd-86d1-4b2a-b5c3-063aff8dff9f" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_2e26c5e6-5efe-4468-87a7-a13f56ad3568" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_9c804102-30c5-4e2f-8d21-0f3d443a401c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_96c427fd-86d1-4b2a-b5c3-063aff8dff9f" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_9c804102-30c5-4e2f-8d21-0f3d443a401c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_3ea27480-2d95-4a33-9057-3da4f13ee335" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_3c42f4d7-6d8f-4611-913e-16035a0b6836" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_3ea27480-2d95-4a33-9057-3da4f13ee335" xlink:to="loc_us-gaap_LongTermDebt_3c42f4d7-6d8f-4611-913e-16035a0b6836" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_60bdecfc-7b81-4311-9b36-86049007f6fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_3ea27480-2d95-4a33-9057-3da4f13ee335" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_60bdecfc-7b81-4311-9b36-86049007f6fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_01aaa24f-5a37-4a05-9719-bbca84c6c75d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_3ea27480-2d95-4a33-9057-3da4f13ee335" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_01aaa24f-5a37-4a05-9719-bbca84c6c75d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_8f7f3a4e-3c1c-499c-abbc-016149f35dd2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_3ea27480-2d95-4a33-9057-3da4f13ee335" xlink:to="loc_us-gaap_LiabilitiesCurrent_8f7f3a4e-3c1c-499c-abbc-016149f35dd2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_6e3ace2e-6c59-4090-b5b8-b4c9669ff92a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_3ea27480-2d95-4a33-9057-3da4f13ee335" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_6e3ace2e-6c59-4090-b5b8-b4c9669ff92a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_RoyaltyLiabilityNoncurrent_fbca6818-391b-4306-b064-e994d4fc9ffd" xlink:href="alny-20210331.xsd#alny_RoyaltyLiabilityNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_3ea27480-2d95-4a33-9057-3da4f13ee335" xlink:to="loc_alny_RoyaltyLiabilityNoncurrent_fbca6818-391b-4306-b064-e994d4fc9ffd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_487d7509-7574-4a66-b151-70174975e902" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_b0b11d56-cdbf-425b-8bf8-03661d58fee0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_487d7509-7574-4a66-b151-70174975e902" xlink:to="loc_us-gaap_AccountsPayableCurrent_b0b11d56-cdbf-425b-8bf8-03661d58fee0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_516530b7-d9a5-4bc6-8515-d079483057e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_487d7509-7574-4a66-b151-70174975e902" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_516530b7-d9a5-4bc6-8515-d079483057e9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_383d2e55-32f2-42d7-8917-752442a53739" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_487d7509-7574-4a66-b151-70174975e902" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_383d2e55-32f2-42d7-8917-752442a53739" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_fb3ad35a-2fb5-4957-b5f8-30ba7cd23878" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_487d7509-7574-4a66-b151-70174975e902" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_fb3ad35a-2fb5-4957-b5f8-30ba7cd23878" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_RoyaltyLiabilityCurrent_d64f21d1-bdc7-42d9-a77c-5bf529a79e1a" xlink:href="alny-20210331.xsd#alny_RoyaltyLiabilityCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_487d7509-7574-4a66-b151-70174975e902" xlink:to="loc_alny_RoyaltyLiabilityCurrent_d64f21d1-bdc7-42d9-a77c-5bf529a79e1a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="alny-20210331.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:calculationLink xlink:role="http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="alny-20210331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"/>
  <link:calculationLink xlink:role="http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_25f23288-401f-454d-8c84-0ae8ac13c2cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ca2f9448-6f8a-4cf4-92ec-759127ef4002" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_25f23288-401f-454d-8c84-0ae8ac13c2cd" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ca2f9448-6f8a-4cf4-92ec-759127ef4002" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_7ce48386-967b-4ebe-94d5-e018bbdfa3e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_25f23288-401f-454d-8c84-0ae8ac13c2cd" xlink:to="loc_us-gaap_CostsAndExpenses_7ce48386-967b-4ebe-94d5-e018bbdfa3e8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_77ddb127-56db-4bf5-ab4d-523bfac2fe91" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_b7f11ef6-2095-4745-99d0-075e7321ab27" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_77ddb127-56db-4bf5-ab4d-523bfac2fe91" xlink:to="loc_us-gaap_NetIncomeLoss_b7f11ef6-2095-4745-99d0-075e7321ab27" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_5e52aaf1-ed75-49f4-992c-2572facf32a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_77ddb127-56db-4bf5-ab4d-523bfac2fe91" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_5e52aaf1-ed75-49f4-992c-2572facf32a1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_2baccdb8-365f-47f5-bdf2-6dc7e89f4035" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_43e0a36e-cd62-48b9-9698-d8457c84793e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_2baccdb8-365f-47f5-bdf2-6dc7e89f4035" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_43e0a36e-cd62-48b9-9698-d8457c84793e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_1251fde3-5ff4-4e51-afd0-044c49874b1f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_2baccdb8-365f-47f5-bdf2-6dc7e89f4035" xlink:to="loc_us-gaap_InterestExpense_1251fde3-5ff4-4e51-afd0-044c49874b1f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_fe82c6ce-6e25-4903-b135-345c8d5e85ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_2baccdb8-365f-47f5-bdf2-6dc7e89f4035" xlink:to="loc_us-gaap_InvestmentIncomeInterest_fe82c6ce-6e25-4903-b135-345c8d5e85ab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_2d091827-75d2-4757-8ee6-c0f38c3a6b17" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_CostOfCollaborationManufacturingAndRoyalties_d56b54a7-42b3-4081-bf11-2eb0f55c696c" xlink:href="alny-20210331.xsd#alny_CostOfCollaborationManufacturingAndRoyalties"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_2d091827-75d2-4757-8ee6-c0f38c3a6b17" xlink:to="loc_alny_CostOfCollaborationManufacturingAndRoyalties_d56b54a7-42b3-4081-bf11-2eb0f55c696c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_4f6b7858-57e7-4b93-ac24-4a417522005d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_2d091827-75d2-4757-8ee6-c0f38c3a6b17" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_4f6b7858-57e7-4b93-ac24-4a417522005d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_baff215e-e147-4bc0-a85a-0151a39c8d75" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_2d091827-75d2-4757-8ee6-c0f38c3a6b17" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_baff215e-e147-4bc0-a85a-0151a39c8d75" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_3fa5aa3f-ae77-4cce-9733-b2635b6c9c44" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_2d091827-75d2-4757-8ee6-c0f38c3a6b17" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_3fa5aa3f-ae77-4cce-9733-b2635b6c9c44" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_1fcf759a-14b4-4380-8613-2923a9f13529" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_105a4f4c-7e9c-4c4a-a589-21ad4266cb2d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_1fcf759a-14b4-4380-8613-2923a9f13529" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_105a4f4c-7e9c-4c4a-a589-21ad4266cb2d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax_95d3a467-a19a-4218-b972-d96c466ae540" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_1fcf759a-14b4-4380-8613-2923a9f13529" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax_95d3a467-a19a-4218-b972-d96c466ae540" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_f88458f3-afd8-4fa8-9c2f-3321383c0af1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_1fcf759a-14b4-4380-8613-2923a9f13529" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_f88458f3-afd8-4fa8-9c2f-3321383c0af1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c31dc648-6a8f-4b49-804f-e487161c8b16" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_e4b3ad91-346e-4748-ace2-55e2120715c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c31dc648-6a8f-4b49-804f-e487161c8b16" xlink:to="loc_us-gaap_OperatingIncomeLoss_e4b3ad91-346e-4748-ace2-55e2120715c3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_34808880-919e-46e1-aa08-cd3bc4376b1e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c31dc648-6a8f-4b49-804f-e487161c8b16" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_34808880-919e-46e1-aa08-cd3bc4376b1e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_3836e69a-ac5d-44ff-af4b-03c58b152332" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_b7d4c48c-f8af-4c06-811f-bf302ba61b3c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_3836e69a-ac5d-44ff-af4b-03c58b152332" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_b7d4c48c-f8af-4c06-811f-bf302ba61b3c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_802f7170-942f-4fe7-a65d-24b1440a9947" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_3836e69a-ac5d-44ff-af4b-03c58b152332" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_802f7170-942f-4fe7-a65d-24b1440a9947" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="alny-20210331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
  <link:calculationLink xlink:role="http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="alny-20210331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_3e867373-146d-4b82-a050-99584b664a6c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_45283092-4770-4d47-95ec-66819957d318" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_3e867373-146d-4b82-a050-99584b664a6c" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_45283092-4770-4d47-95ec-66819957d318" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_affc9245-ea1d-449e-a75e-805bb4d7a80e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_3e867373-146d-4b82-a050-99584b664a6c" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_affc9245-ea1d-449e-a75e-805bb4d7a80e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_7013b8d5-2538-4556-bce2-a78ef7c9f666" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_3e867373-146d-4b82-a050-99584b664a6c" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_7013b8d5-2538-4556-bce2-a78ef7c9f666" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfRestrictedInvestments_3f250506-d38d-418d-9cc4-2171895cbe22" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfRestrictedInvestments"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_3e867373-146d-4b82-a050-99584b664a6c" xlink:to="loc_us-gaap_ProceedsFromSaleOfRestrictedInvestments_3f250506-d38d-418d-9cc4-2171895cbe22" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireRestrictedInvestments_9b0713cc-be20-4d13-bb68-a6412154bf9b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireRestrictedInvestments"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_3e867373-146d-4b82-a050-99584b664a6c" xlink:to="loc_us-gaap_PaymentsToAcquireRestrictedInvestments_9b0713cc-be20-4d13-bb68-a6412154bf9b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_84665e06-15c5-45e8-8bf7-ddf3383f361f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_3e867373-146d-4b82-a050-99584b664a6c" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_84665e06-15c5-45e8-8bf7-ddf3383f361f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0d0425ec-3aa7-483e-87c8-cab6dd3606b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_4da9d1bc-d100-4649-a492-939f148cdf7f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0d0425ec-3aa7-483e-87c8-cab6dd3606b3" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_4da9d1bc-d100-4649-a492-939f148cdf7f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities_85588c44-448f-4604-a92b-88b83bbc30b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0d0425ec-3aa7-483e-87c8-cab6dd3606b3" xlink:to="loc_us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities_85588c44-448f-4604-a92b-88b83bbc30b1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f3aa48a0-e645-4075-8273-53ce1b3a1fbd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_20f74571-17b1-4047-bd86-e22cb4811c19" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f3aa48a0-e645-4075-8273-53ce1b3a1fbd" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLoss_20f74571-17b1-4047-bd86-e22cb4811c19" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_AmortizationAndInterestAccretionRelatedToOperatingLeases_f8c1ef47-77aa-45a0-a62f-090372603db2" xlink:href="alny-20210331.xsd#alny_AmortizationAndInterestAccretionRelatedToOperatingLeases"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f3aa48a0-e645-4075-8273-53ce1b3a1fbd" xlink:to="loc_alny_AmortizationAndInterestAccretionRelatedToOperatingLeases_f8c1ef47-77aa-45a0-a62f-090372603db2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_3f90e1d2-6e47-4c23-9f65-23c845e70710" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f3aa48a0-e645-4075-8273-53ce1b3a1fbd" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_3f90e1d2-6e47-4c23-9f65-23c845e70710" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_5c8b8648-406d-4ab6-b85a-396be0f625e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f3aa48a0-e645-4075-8273-53ce1b3a1fbd" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_5c8b8648-406d-4ab6-b85a-396be0f625e6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_4aa16c08-36c7-47da-93ad-795cb8ee26d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f3aa48a0-e645-4075-8273-53ce1b3a1fbd" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_4aa16c08-36c7-47da-93ad-795cb8ee26d0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_360bc6b0-1ed7-4bf6-be6d-f6c2098f5c6a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f3aa48a0-e645-4075-8273-53ce1b3a1fbd" xlink:to="loc_us-gaap_OperatingLeasePayments_360bc6b0-1ed7-4bf6-be6d-f6c2098f5c6a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_27ea22bd-e9e1-4227-af30-d5c21d09f3c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f3aa48a0-e645-4075-8273-53ce1b3a1fbd" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_27ea22bd-e9e1-4227-af30-d5c21d09f3c4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_42db4949-9122-43e9-8ca6-f9a3c9397684" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f3aa48a0-e645-4075-8273-53ce1b3a1fbd" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_42db4949-9122-43e9-8ca6-f9a3c9397684" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_f52c711d-6d8d-4076-a8a3-e3a3c4adacbe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f3aa48a0-e645-4075-8273-53ce1b3a1fbd" xlink:to="loc_us-gaap_NetIncomeLoss_f52c711d-6d8d-4076-a8a3-e3a3c4adacbe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_2205a1ba-e449-4c97-90fe-e254ce857e38" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f3aa48a0-e645-4075-8273-53ce1b3a1fbd" xlink:to="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_2205a1ba-e449-4c97-90fe-e254ce857e38" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAmortizationAndAccretionNet_06875267-b7d6-4937-bae1-dff85214df28" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationAmortizationAndAccretionNet"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f3aa48a0-e645-4075-8273-53ce1b3a1fbd" xlink:to="loc_us-gaap_DepreciationAmortizationAndAccretionNet_06875267-b7d6-4937-bae1-dff85214df28" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_35c6dba3-8a26-4282-8f4c-4d0f6e4fbac0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f3aa48a0-e645-4075-8273-53ce1b3a1fbd" xlink:to="loc_us-gaap_ShareBasedCompensation_35c6dba3-8a26-4282-8f4c-4d0f6e4fbac0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_NonCashInterestExpenseOnSaleOfFutureRoyalties_121b68e1-b512-4a5d-9d7b-a00c46d41ece" xlink:href="alny-20210331.xsd#alny_NonCashInterestExpenseOnSaleOfFutureRoyalties"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f3aa48a0-e645-4075-8273-53ce1b3a1fbd" xlink:to="loc_alny_NonCashInterestExpenseOnSaleOfFutureRoyalties_121b68e1-b512-4a5d-9d7b-a00c46d41ece" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_c4680f5d-49a1-4830-98f3-5556ad51c8af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_85903207-bbd3-47c1-8445-ef2089cd7d72" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_c4680f5d-49a1-4830-98f3-5556ad51c8af" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_85903207-bbd3-47c1-8445-ef2089cd7d72" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_743bdaef-fd2d-4d47-a768-75efa99a53c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_c4680f5d-49a1-4830-98f3-5556ad51c8af" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_743bdaef-fd2d-4d47-a768-75efa99a53c1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7f209b6f-8fb7-4c16-a90d-f24e166ff401" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_c4680f5d-49a1-4830-98f3-5556ad51c8af" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7f209b6f-8fb7-4c16-a90d-f24e166ff401" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_fd6ebe0e-1e5a-476e-b1e3-cb622afc48d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_c4680f5d-49a1-4830-98f3-5556ad51c8af" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_fd6ebe0e-1e5a-476e-b1e3-cb622afc48d7" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/NATUREOFBUSINESS" xlink:type="simple" xlink:href="alny-20210331.xsd#NATUREOFBUSINESS"/>
  <link:calculationLink xlink:role="http://www.alnylam.com/role/NATUREOFBUSINESS" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.alnylam.com/role/NATUREOFBUSINESSDetails" xlink:type="simple" xlink:href="alny-20210331.xsd#NATUREOFBUSINESSDetails"/>
  <link:calculationLink xlink:role="http://www.alnylam.com/role/NATUREOFBUSINESSDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.alnylam.com/role/BASISOFPRESENTATIONANDPRINCIPLESOFCONSOLIDATION" xlink:type="simple" xlink:href="alny-20210331.xsd#BASISOFPRESENTATIONANDPRINCIPLESOFCONSOLIDATION"/>
  <link:calculationLink xlink:role="http://www.alnylam.com/role/BASISOFPRESENTATIONANDPRINCIPLESOFCONSOLIDATION" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.alnylam.com/role/BASISOFPRESENTATIONANDPRINCIPLESOFCONSOLIDATIONPolicies" xlink:type="simple" xlink:href="alny-20210331.xsd#BASISOFPRESENTATIONANDPRINCIPLESOFCONSOLIDATIONPolicies"/>
  <link:calculationLink xlink:role="http://www.alnylam.com/role/BASISOFPRESENTATIONANDPRINCIPLESOFCONSOLIDATIONPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.alnylam.com/role/NETPRODUCTREVENUES" xlink:type="simple" xlink:href="alny-20210331.xsd#NETPRODUCTREVENUES"/>
  <link:calculationLink xlink:role="http://www.alnylam.com/role/NETPRODUCTREVENUES" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.alnylam.com/role/NETPRODUCTREVENUESTables" xlink:type="simple" xlink:href="alny-20210331.xsd#NETPRODUCTREVENUESTables"/>
  <link:calculationLink xlink:role="http://www.alnylam.com/role/NETPRODUCTREVENUESTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.alnylam.com/role/NETPRODUCTREVENUESSummaryofNetProductRevenuesDetail" xlink:type="simple" xlink:href="alny-20210331.xsd#NETPRODUCTREVENUESSummaryofNetProductRevenuesDetail"/>
  <link:calculationLink xlink:role="http://www.alnylam.com/role/NETPRODUCTREVENUESSummaryofNetProductRevenuesDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.alnylam.com/role/NETPRODUCTREVENUESReceivablesDetail" xlink:type="simple" xlink:href="alny-20210331.xsd#NETPRODUCTREVENUESReceivablesDetail"/>
  <link:calculationLink xlink:role="http://www.alnylam.com/role/NETPRODUCTREVENUESReceivablesDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONS" xlink:type="simple" xlink:href="alny-20210331.xsd#NETREVENUESFROMCOLLABORATIONS"/>
  <link:calculationLink xlink:role="http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONS" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSTables" xlink:type="simple" xlink:href="alny-20210331.xsd#NETREVENUESFROMCOLLABORATIONSTables"/>
  <link:calculationLink xlink:role="http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSRevenuefromCollaboratorsDetail" xlink:type="simple" xlink:href="alny-20210331.xsd#NETREVENUESFROMCOLLABORATIONSRevenuefromCollaboratorsDetail"/>
  <link:calculationLink xlink:role="http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSRevenuefromCollaboratorsDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSBalanceofReceivablesandContractLiabilitiesRelatedtoCollaborationAgreementsDetail" xlink:type="simple" xlink:href="alny-20210331.xsd#NETREVENUESFROMCOLLABORATIONSBalanceofReceivablesandContractLiabilitiesRelatedtoCollaborationAgreementsDetail"/>
  <link:calculationLink xlink:role="http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSBalanceofReceivablesandContractLiabilitiesRelatedtoCollaborationAgreementsDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSAdditionalInformationDetail" xlink:type="simple" xlink:href="alny-20210331.xsd#NETREVENUESFROMCOLLABORATIONSAdditionalInformationDetail"/>
  <link:calculationLink xlink:role="http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSAdditionalInformationDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofResearchandDevelopmentExpensesIncurredbyTypethatareDirectlyAttributabletoCollaborationAgreementsDetail" xlink:type="simple" xlink:href="alny-20210331.xsd#NETREVENUESFROMCOLLABORATIONSScheduleofResearchandDevelopmentExpensesIncurredbyTypethatareDirectlyAttributabletoCollaborationAgreementsDetail"/>
  <link:calculationLink xlink:role="http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofResearchandDevelopmentExpensesIncurredbyTypethatareDirectlyAttributabletoCollaborationAgreementsDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofTransactionPriceAllocatedDetails" xlink:type="simple" xlink:href="alny-20210331.xsd#NETREVENUESFROMCOLLABORATIONSScheduleofTransactionPriceAllocatedDetails"/>
  <link:calculationLink xlink:role="http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofTransactionPriceAllocatedDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofDeferredRevenueDetails" xlink:type="simple" xlink:href="alny-20210331.xsd#NETREVENUESFROMCOLLABORATIONSScheduleofDeferredRevenueDetails"/>
  <link:calculationLink xlink:role="http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofDeferredRevenueDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofRevenueRecognizedbyAccountingGuidanceDetails" xlink:type="simple" xlink:href="alny-20210331.xsd#NETREVENUESFROMCOLLABORATIONSScheduleofRevenueRecognizedbyAccountingGuidanceDetails"/>
  <link:calculationLink xlink:role="http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofRevenueRecognizedbyAccountingGuidanceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_bf7667b4-7143-4f59-abb6-a2b519f63578" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_36e90e7f-73fa-46f6-a668-5bbc9ac8e819" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_bf7667b4-7143-4f59-abb6-a2b519f63578" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_36e90e7f-73fa-46f6-a668-5bbc9ac8e819" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_2f086b48-26b3-437c-852c-0d1dfebc771d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_bf7667b4-7143-4f59-abb6-a2b519f63578" xlink:to="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_2f086b48-26b3-437c-852c-0d1dfebc771d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/LIABILITYRELATEDTOTHESALEOFFUTUREROYALTIES" xlink:type="simple" xlink:href="alny-20210331.xsd#LIABILITYRELATEDTOTHESALEOFFUTUREROYALTIES"/>
  <link:calculationLink xlink:role="http://www.alnylam.com/role/LIABILITYRELATEDTOTHESALEOFFUTUREROYALTIES" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.alnylam.com/role/LIABILITYRELATEDTOTHESALEOFFUTUREROYALTIESTables" xlink:type="simple" xlink:href="alny-20210331.xsd#LIABILITYRELATEDTOTHESALEOFFUTUREROYALTIESTables"/>
  <link:calculationLink xlink:role="http://www.alnylam.com/role/LIABILITYRELATEDTOTHESALEOFFUTUREROYALTIESTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.alnylam.com/role/LIABILITYRELATEDTOTHESALEOFFUTUREROYALTIESDetails" xlink:type="simple" xlink:href="alny-20210331.xsd#LIABILITYRELATEDTOTHESALEOFFUTUREROYALTIESDetails"/>
  <link:calculationLink xlink:role="http://www.alnylam.com/role/LIABILITYRELATEDTOTHESALEOFFUTUREROYALTIESDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.alnylam.com/role/FAIRVALUEMEASUREMENTS" xlink:type="simple" xlink:href="alny-20210331.xsd#FAIRVALUEMEASUREMENTS"/>
  <link:calculationLink xlink:role="http://www.alnylam.com/role/FAIRVALUEMEASUREMENTS" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.alnylam.com/role/FAIRVALUEMEASUREMENTSTables" xlink:type="simple" xlink:href="alny-20210331.xsd#FAIRVALUEMEASUREMENTSTables"/>
  <link:calculationLink xlink:role="http://www.alnylam.com/role/FAIRVALUEMEASUREMENTSTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.alnylam.com/role/FAIRVALUEMEASUREMENTSFairValueofAssetsMeasuredonaRecurringBasisDetail" xlink:type="simple" xlink:href="alny-20210331.xsd#FAIRVALUEMEASUREMENTSFairValueofAssetsMeasuredonaRecurringBasisDetail"/>
  <link:calculationLink xlink:role="http://www.alnylam.com/role/FAIRVALUEMEASUREMENTSFairValueofAssetsMeasuredonaRecurringBasisDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_be155c53-3529-4eeb-9480-89d5f74d7142" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_3856478e-c2d8-4c8c-9a83-395db9a61d9c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_be155c53-3529-4eeb-9480-89d5f74d7142" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_3856478e-c2d8-4c8c-9a83-395db9a61d9c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1c101e6d-6ef6-4600-bf53-04608de45340" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_be155c53-3529-4eeb-9480-89d5f74d7142" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1c101e6d-6ef6-4600-bf53-04608de45340" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_b846b389-eba7-4c90-938d-6dac3e5797a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_be155c53-3529-4eeb-9480-89d5f74d7142" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_b846b389-eba7-4c90-938d-6dac3e5797a7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_24e47433-4fbe-4b55-8dc6-5976ea7001f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_be155c53-3529-4eeb-9480-89d5f74d7142" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_24e47433-4fbe-4b55-8dc6-5976ea7001f0" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/MARKETABLEDEBTSECURITIES" xlink:type="simple" xlink:href="alny-20210331.xsd#MARKETABLEDEBTSECURITIES"/>
  <link:calculationLink xlink:role="http://www.alnylam.com/role/MARKETABLEDEBTSECURITIES" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.alnylam.com/role/MARKETABLEDEBTSECURITIESTables" xlink:type="simple" xlink:href="alny-20210331.xsd#MARKETABLEDEBTSECURITIESTables"/>
  <link:calculationLink xlink:role="http://www.alnylam.com/role/MARKETABLEDEBTSECURITIESTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.alnylam.com/role/MARKETABLEDEBTSECURITIESAdditionalInformationDetail" xlink:type="simple" xlink:href="alny-20210331.xsd#MARKETABLEDEBTSECURITIESAdditionalInformationDetail"/>
  <link:calculationLink xlink:role="http://www.alnylam.com/role/MARKETABLEDEBTSECURITIESAdditionalInformationDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.alnylam.com/role/MARKETABLEDEBTSECURITIESSummaryofMarketableDebtSecuritiesDetail" xlink:type="simple" xlink:href="alny-20210331.xsd#MARKETABLEDEBTSECURITIESSummaryofMarketableDebtSecuritiesDetail"/>
  <link:calculationLink xlink:role="http://www.alnylam.com/role/MARKETABLEDEBTSECURITIESSummaryofMarketableDebtSecuritiesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_581e1498-fb0d-4823-9d57-3377467e97c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_9438d3f5-e1c1-4128-899d-1e890a2ff789" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_581e1498-fb0d-4823-9d57-3377467e97c0" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_9438d3f5-e1c1-4128-899d-1e890a2ff789" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_4dac339b-58ac-4b44-9459-30d5fd278f38" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_581e1498-fb0d-4823-9d57-3377467e97c0" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_4dac339b-58ac-4b44-9459-30d5fd278f38" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_a77c74f1-1e73-421b-809b-6baa5493b81b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_581e1498-fb0d-4823-9d57-3377467e97c0" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_a77c74f1-1e73-421b-809b-6baa5493b81b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/MARKETABLEDEBTSECURITIESSummaryofFairValueofMarketableDebtSecuritiesDetail" xlink:type="simple" xlink:href="alny-20210331.xsd#MARKETABLEDEBTSECURITIESSummaryofFairValueofMarketableDebtSecuritiesDetail"/>
  <link:calculationLink xlink:role="http://www.alnylam.com/role/MARKETABLEDEBTSECURITIESSummaryofFairValueofMarketableDebtSecuritiesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b28990bb-8291-4b92-bbc3-a0dfdb256b5f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_e17d295f-7c32-4ac3-994b-7dda3855d6e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b28990bb-8291-4b92-bbc3-a0dfdb256b5f" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_e17d295f-7c32-4ac3-994b-7dda3855d6e7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_0e3fcb39-acbb-432d-847b-eef0d84c13a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b28990bb-8291-4b92-bbc3-a0dfdb256b5f" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_0e3fcb39-acbb-432d-847b-eef0d84c13a7" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/OTHERBALANCESHEETDETAILS" xlink:type="simple" xlink:href="alny-20210331.xsd#OTHERBALANCESHEETDETAILS"/>
  <link:calculationLink xlink:role="http://www.alnylam.com/role/OTHERBALANCESHEETDETAILS" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.alnylam.com/role/OTHERBALANCESHEETDETAILSTables" xlink:type="simple" xlink:href="alny-20210331.xsd#OTHERBALANCESHEETDETAILSTables"/>
  <link:calculationLink xlink:role="http://www.alnylam.com/role/OTHERBALANCESHEETDETAILSTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.alnylam.com/role/OTHERBALANCESHEETDETAILSScheduleofInventoryDetail" xlink:type="simple" xlink:href="alny-20210331.xsd#OTHERBALANCESHEETDETAILSScheduleofInventoryDetail"/>
  <link:calculationLink xlink:role="http://www.alnylam.com/role/OTHERBALANCESHEETDETAILSScheduleofInventoryDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_alny_InventoryCurrentAndNoncurrent_43327493-170f-4088-ab0a-5e31d253c6a3" xlink:href="alny-20210331.xsd#alny_InventoryCurrentAndNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials_d960aff1-e216-440a-bca5-7f32ebee413a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterials"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_alny_InventoryCurrentAndNoncurrent_43327493-170f-4088-ab0a-5e31d253c6a3" xlink:to="loc_us-gaap_InventoryRawMaterials_d960aff1-e216-440a-bca5-7f32ebee413a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess_e5e99f63-3d76-46e1-a569-c7931ad99123" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_alny_InventoryCurrentAndNoncurrent_43327493-170f-4088-ab0a-5e31d253c6a3" xlink:to="loc_us-gaap_InventoryWorkInProcess_e5e99f63-3d76-46e1-a569-c7931ad99123" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_13e34678-b82f-45d7-8238-230dfbd3fa2e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_alny_InventoryCurrentAndNoncurrent_43327493-170f-4088-ab0a-5e31d253c6a3" xlink:to="loc_us-gaap_InventoryFinishedGoods_13e34678-b82f-45d7-8238-230dfbd3fa2e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/OTHERBALANCESHEETDETAILSScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetail" xlink:type="simple" xlink:href="alny-20210331.xsd#OTHERBALANCESHEETDETAILSScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetail"/>
  <link:calculationLink xlink:role="http://www.alnylam.com/role/OTHERBALANCESHEETDETAILSScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_205da4f6-edb0-44c9-b5fc-d9eba37ce70f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_2860ac6e-3761-4754-bd2d-368d7a597176" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCash"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_205da4f6-edb0-44c9-b5fc-d9eba37ce70f" xlink:to="loc_us-gaap_RestrictedCash_2860ac6e-3761-4754-bd2d-368d7a597176" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f98a833c-01ca-497b-86aa-af97bad91eb3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_205da4f6-edb0-44c9-b5fc-d9eba37ce70f" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f98a833c-01ca-497b-86aa-af97bad91eb3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/OTHERBALANCESHEETDETAILSSummaryofChangesinAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" xlink:href="alny-20210331.xsd#OTHERBALANCESHEETDETAILSSummaryofChangesinAccumulatedOtherComprehensiveIncomeLossDetails"/>
  <link:calculationLink xlink:role="http://www.alnylam.com/role/OTHERBALANCESHEETDETAILSSummaryofChangesinAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_ba479b2a-d732-4a21-a9d7-e59a02917506" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_cacd30b9-0c1c-4d19-99d0-71dac3bfbbad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_ba479b2a-d732-4a21-a9d7-e59a02917506" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_cacd30b9-0c1c-4d19-99d0-71dac3bfbbad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_ddc864b1-6350-45ad-a0f7-4f55fea93980" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_ba479b2a-d732-4a21-a9d7-e59a02917506" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_ddc864b1-6350-45ad-a0f7-4f55fea93980" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/CREDITAGREEMENT" xlink:type="simple" xlink:href="alny-20210331.xsd#CREDITAGREEMENT"/>
  <link:calculationLink xlink:role="http://www.alnylam.com/role/CREDITAGREEMENT" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.alnylam.com/role/CREDITAGREEMENTTables" xlink:type="simple" xlink:href="alny-20210331.xsd#CREDITAGREEMENTTables"/>
  <link:calculationLink xlink:role="http://www.alnylam.com/role/CREDITAGREEMENTTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.alnylam.com/role/CREDITAGREEMENTAdditionalInformationDetails" xlink:type="simple" xlink:href="alny-20210331.xsd#CREDITAGREEMENTAdditionalInformationDetails"/>
  <link:calculationLink xlink:role="http://www.alnylam.com/role/CREDITAGREEMENTAdditionalInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.alnylam.com/role/DEVELOPMENTDERIVATIVELIABILITY" xlink:type="simple" xlink:href="alny-20210331.xsd#DEVELOPMENTDERIVATIVELIABILITY"/>
  <link:calculationLink xlink:role="http://www.alnylam.com/role/DEVELOPMENTDERIVATIVELIABILITY" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.alnylam.com/role/DEVELOPMENTDERIVATIVELIABILITYTables" xlink:type="simple" xlink:href="alny-20210331.xsd#DEVELOPMENTDERIVATIVELIABILITYTables"/>
  <link:calculationLink xlink:role="http://www.alnylam.com/role/DEVELOPMENTDERIVATIVELIABILITYTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.alnylam.com/role/DEVELOPMENTDERIVATIVELIABILITYNarrativeDetails" xlink:type="simple" xlink:href="alny-20210331.xsd#DEVELOPMENTDERIVATIVELIABILITYNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.alnylam.com/role/DEVELOPMENTDERIVATIVELIABILITYNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.alnylam.com/role/DEVELOPMENTDERIVATIVELIABILITYDevelopmentDerivativeLiabilityActivityDetails" xlink:type="simple" xlink:href="alny-20210331.xsd#DEVELOPMENTDERIVATIVELIABILITYDevelopmentDerivativeLiabilityActivityDetails"/>
  <link:calculationLink xlink:role="http://www.alnylam.com/role/DEVELOPMENTDERIVATIVELIABILITYDevelopmentDerivativeLiabilityActivityDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.alnylam.com/role/STOCKBASEDCOMPENSATION" xlink:type="simple" xlink:href="alny-20210331.xsd#STOCKBASEDCOMPENSATION"/>
  <link:calculationLink xlink:role="http://www.alnylam.com/role/STOCKBASEDCOMPENSATION" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.alnylam.com/role/STOCKBASEDCOMPENSATIONTables" xlink:type="simple" xlink:href="alny-20210331.xsd#STOCKBASEDCOMPENSATIONTables"/>
  <link:calculationLink xlink:role="http://www.alnylam.com/role/STOCKBASEDCOMPENSATIONTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.alnylam.com/role/STOCKBASEDCOMPENSATIONSummaryofShareBasedCompensationExpensesIncludedOperatingCostsandExpenseDetail" xlink:type="simple" xlink:href="alny-20210331.xsd#STOCKBASEDCOMPENSATIONSummaryofShareBasedCompensationExpensesIncludedOperatingCostsandExpenseDetail"/>
  <link:calculationLink xlink:role="http://www.alnylam.com/role/STOCKBASEDCOMPENSATIONSummaryofShareBasedCompensationExpensesIncludedOperatingCostsandExpenseDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.alnylam.com/role/NETLOSSPERCOMMONSHARE" xlink:type="simple" xlink:href="alny-20210331.xsd#NETLOSSPERCOMMONSHARE"/>
  <link:calculationLink xlink:role="http://www.alnylam.com/role/NETLOSSPERCOMMONSHARE" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.alnylam.com/role/NETLOSSPERCOMMONSHARETables" xlink:type="simple" xlink:href="alny-20210331.xsd#NETLOSSPERCOMMONSHARETables"/>
  <link:calculationLink xlink:role="http://www.alnylam.com/role/NETLOSSPERCOMMONSHARETables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.alnylam.com/role/NETLOSSPERCOMMONSHARECommonShareEquivalentsExcludedfromCalculationofNetLossPerCommonShareDetail" xlink:type="simple" xlink:href="alny-20210331.xsd#NETLOSSPERCOMMONSHARECommonShareEquivalentsExcludedfromCalculationofNetLossPerCommonShareDetail"/>
  <link:calculationLink xlink:role="http://www.alnylam.com/role/NETLOSSPERCOMMONSHARECommonShareEquivalentsExcludedfromCalculationofNetLossPerCommonShareDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.alnylam.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="simple" xlink:href="alny-20210331.xsd#COMMITMENTSANDCONTINGENCIES"/>
  <link:calculationLink xlink:role="http://www.alnylam.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="extended"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>alny-20210331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:45529fdd-2cb3-415e-a8b1-14659af4a28e,g:8b4a69cc-2403-45c9-b738-5835a1e5fb0d-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.alnylam.com/role/CoverPage" xlink:type="simple" xlink:href="alny-20210331.xsd#CoverPage"/>
  <link:definitionLink xlink:role="http://www.alnylam.com/role/CoverPage" xlink:type="extended" id="i873cce3da56d4e6a8f1b6cd9d16e7325_CoverPage"/>
  <link:roleRef roleURI="http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="alny-20210331.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:definitionLink xlink:role="http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="extended" id="i61431207881c4aa7a3673481f6e50dc7_CONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:roleRef roleURI="http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="alny-20210331.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:definitionLink xlink:role="http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended" id="i1c7a8ffa15d644848dbccfa2f2ec2229_CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:roleRef roleURI="http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="alny-20210331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"/>
  <link:definitionLink xlink:role="http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="extended" id="id569aca40e4e47e0bfcc19910480fc5e_CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_94347044-5d7b-4f32-aafe-cc8e91e9ce9f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_9e8fc736-6f2a-4bcb-a464-8e72b6a1bd53" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_94347044-5d7b-4f32-aafe-cc8e91e9ce9f" xlink:to="loc_us-gaap_RevenuesAbstract_9e8fc736-6f2a-4bcb-a464-8e72b6a1bd53" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9622e429-619b-474d-9943-e4d252c7e6d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_9e8fc736-6f2a-4bcb-a464-8e72b6a1bd53" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9622e429-619b-474d-9943-e4d252c7e6d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_fc26e793-b093-4bce-88b6-ef03175d4cd4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_94347044-5d7b-4f32-aafe-cc8e91e9ce9f" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_fc26e793-b093-4bce-88b6-ef03175d4cd4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_87727662-9097-4fd5-ae0a-2b92aa5531e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_fc26e793-b093-4bce-88b6-ef03175d4cd4" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_87727662-9097-4fd5-ae0a-2b92aa5531e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_CostOfCollaborationManufacturingAndRoyalties_55d1afde-2c91-4f6b-96ab-174972231926" xlink:href="alny-20210331.xsd#alny_CostOfCollaborationManufacturingAndRoyalties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_fc26e793-b093-4bce-88b6-ef03175d4cd4" xlink:to="loc_alny_CostOfCollaborationManufacturingAndRoyalties_55d1afde-2c91-4f6b-96ab-174972231926" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_9351dfda-8ab9-4ae0-ac93-5b3ddcb14ddb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_fc26e793-b093-4bce-88b6-ef03175d4cd4" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_9351dfda-8ab9-4ae0-ac93-5b3ddcb14ddb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_8a8ce690-a395-463b-af55-a9ebc9c5d82d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_fc26e793-b093-4bce-88b6-ef03175d4cd4" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_8a8ce690-a395-463b-af55-a9ebc9c5d82d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_82fa010f-d84e-4478-822c-9f6913115492" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_fc26e793-b093-4bce-88b6-ef03175d4cd4" xlink:to="loc_us-gaap_CostsAndExpenses_82fa010f-d84e-4478-822c-9f6913115492" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_6ea56993-d8d4-4acc-82f8-9892acd37738" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_94347044-5d7b-4f32-aafe-cc8e91e9ce9f" xlink:to="loc_us-gaap_OperatingIncomeLoss_6ea56993-d8d4-4acc-82f8-9892acd37738" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_ee8cf7ad-b493-4ade-9c94-cd14852e5f4f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_94347044-5d7b-4f32-aafe-cc8e91e9ce9f" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_ee8cf7ad-b493-4ade-9c94-cd14852e5f4f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_d74eb795-6ba4-44db-85b2-2177a98ac60d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_ee8cf7ad-b493-4ade-9c94-cd14852e5f4f" xlink:to="loc_us-gaap_InterestExpense_d74eb795-6ba4-44db-85b2-2177a98ac60d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_09b93983-da42-4e35-954b-817b9065190a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_ee8cf7ad-b493-4ade-9c94-cd14852e5f4f" xlink:to="loc_us-gaap_InvestmentIncomeInterest_09b93983-da42-4e35-954b-817b9065190a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_f48ffde5-77ac-4aaf-9aeb-033032a85c37" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_ee8cf7ad-b493-4ade-9c94-cd14852e5f4f" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_f48ffde5-77ac-4aaf-9aeb-033032a85c37" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_973c3f3b-8a65-4953-bb71-56f73a956932" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_ee8cf7ad-b493-4ade-9c94-cd14852e5f4f" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_973c3f3b-8a65-4953-bb71-56f73a956932" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_9c13beb6-591e-48e4-9320-821c5b475724" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_94347044-5d7b-4f32-aafe-cc8e91e9ce9f" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_9c13beb6-591e-48e4-9320-821c5b475724" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_54614ced-ee2b-4aea-903c-27dff3d6eecf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_94347044-5d7b-4f32-aafe-cc8e91e9ce9f" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_54614ced-ee2b-4aea-903c-27dff3d6eecf" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_71247ab6-bc0d-4ff4-bb42-7a6e086f4ad5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_94347044-5d7b-4f32-aafe-cc8e91e9ce9f" xlink:to="loc_us-gaap_NetIncomeLoss_71247ab6-bc0d-4ff4-bb42-7a6e086f4ad5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_a9deed92-8e25-49a5-9407-603db881845f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_94347044-5d7b-4f32-aafe-cc8e91e9ce9f" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_a9deed92-8e25-49a5-9407-603db881845f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_ce6607c7-4dbf-41c6-ab55-7752de63107b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_94347044-5d7b-4f32-aafe-cc8e91e9ce9f" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_ce6607c7-4dbf-41c6-ab55-7752de63107b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_83e63880-c7a2-4707-b975-78ffcc048ab7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_94347044-5d7b-4f32-aafe-cc8e91e9ce9f" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_83e63880-c7a2-4707-b975-78ffcc048ab7" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_ba8f4b78-4494-4c0d-916c-2a466e9a29c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_28ad1828-1a0d-4a2b-97b4-2306226b9823" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_83e63880-c7a2-4707-b975-78ffcc048ab7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_28ad1828-1a0d-4a2b-97b4-2306226b9823" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_1eeab120-c96e-4c9c-9ebf-ad464153a9d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_28ad1828-1a0d-4a2b-97b4-2306226b9823" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_1eeab120-c96e-4c9c-9ebf-ad464153a9d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_f14f6ad7-639a-495a-93cf-6cf0916f0436" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_28ad1828-1a0d-4a2b-97b4-2306226b9823" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_f14f6ad7-639a-495a-93cf-6cf0916f0436" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax_45394c75-4f07-4381-a2ae-f521742205b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_28ad1828-1a0d-4a2b-97b4-2306226b9823" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax_45394c75-4f07-4381-a2ae-f521742205b2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_ed20a202-55cf-4f44-9847-cf378ca5dd46" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_28ad1828-1a0d-4a2b-97b4-2306226b9823" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_ed20a202-55cf-4f44-9847-cf378ca5dd46" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_f51b7e7b-81fe-4cfa-bae9-1c138305c0cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_83e63880-c7a2-4707-b975-78ffcc048ab7" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_f51b7e7b-81fe-4cfa-bae9-1c138305c0cb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_4c65e3a1-0408-4a45-827a-fd6ca0fd30e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_94347044-5d7b-4f32-aafe-cc8e91e9ce9f" xlink:to="loc_us-gaap_StatementTable_4c65e3a1-0408-4a45-827a-fd6ca0fd30e8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_60358dff-4d63-4bbb-832c-e204b1067f26" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_4c65e3a1-0408-4a45-827a-fd6ca0fd30e8" xlink:to="loc_srt_ProductOrServiceAxis_60358dff-4d63-4bbb-832c-e204b1067f26" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_60358dff-4d63-4bbb-832c-e204b1067f26_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_60358dff-4d63-4bbb-832c-e204b1067f26" xlink:to="loc_srt_ProductsAndServicesDomain_60358dff-4d63-4bbb-832c-e204b1067f26_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_bf5352b2-955b-41c8-8fc4-418c995d68e7" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_60358dff-4d63-4bbb-832c-e204b1067f26" xlink:to="loc_srt_ProductsAndServicesDomain_bf5352b2-955b-41c8-8fc4-418c995d68e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_2e767576-73a0-409d-8b04-ce5299e3ee21" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_bf5352b2-955b-41c8-8fc4-418c995d68e7" xlink:to="loc_us-gaap_ProductMember_2e767576-73a0-409d-8b04-ce5299e3ee21" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_af32f604-842c-4627-88ec-f4c1f0cb992f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_4c65e3a1-0408-4a45-827a-fd6ca0fd30e8" xlink:to="loc_us-gaap_TypeOfArrangementAxis_af32f604-842c-4627-88ec-f4c1f0cb992f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_af32f604-842c-4627-88ec-f4c1f0cb992f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_af32f604-842c-4627-88ec-f4c1f0cb992f" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_af32f604-842c-4627-88ec-f4c1f0cb992f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f5479c24-0cae-4248-b919-c1dcda8ffee9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_af32f604-842c-4627-88ec-f4c1f0cb992f" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f5479c24-0cae-4248-b919-c1dcda8ffee9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_2d943a2f-2346-477a-abf6-5901378f694a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f5479c24-0cae-4248-b919-c1dcda8ffee9" xlink:to="loc_us-gaap_CollaborativeArrangementMember_2d943a2f-2346-477a-abf6-5901378f694a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="alny-20210331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
  <link:definitionLink xlink:role="http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="extended" id="i3b727cc1a8f44cdaa65be192cc1c08c7_CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_0c1fcf53-087b-4a6b-8339-416c6b88567f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c5149f2a-936f-44ed-8d7a-5ce0cea466cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0c1fcf53-087b-4a6b-8339-416c6b88567f" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c5149f2a-936f-44ed-8d7a-5ce0cea466cc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_e593ca16-8358-4528-92f4-45a6590ced5e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c5149f2a-936f-44ed-8d7a-5ce0cea466cc" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_e593ca16-8358-4528-92f4-45a6590ced5e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_1694080f-547b-421f-b8fe-e15221cc7d7a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c5149f2a-936f-44ed-8d7a-5ce0cea466cc" xlink:to="loc_us-gaap_StockholdersEquity_1694080f-547b-421f-b8fe-e15221cc7d7a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3fb06e8b-653b-4eb4-971e-37d749e2bb52" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c5149f2a-936f-44ed-8d7a-5ce0cea466cc" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3fb06e8b-653b-4eb4-971e-37d749e2bb52" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_b1447eab-921c-419d-be8f-5729d093f6ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c5149f2a-936f-44ed-8d7a-5ce0cea466cc" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_b1447eab-921c-419d-be8f-5729d093f6ce" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross_c12d547f-13fd-4d41-9118-360dd6a457c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c5149f2a-936f-44ed-8d7a-5ce0cea466cc" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross_c12d547f-13fd-4d41-9118-360dd6a457c1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross_41c49284-70b5-422f-a310-8efcc17091c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c5149f2a-936f-44ed-8d7a-5ce0cea466cc" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross_41c49284-70b5-422f-a310-8efcc17091c7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_5944136f-59e6-489c-b53a-e906259b20c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c5149f2a-936f-44ed-8d7a-5ce0cea466cc" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_5944136f-59e6-489c-b53a-e906259b20c1" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_298b4ce4-df91-4e59-9c87-da7a2c9f87bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c5149f2a-936f-44ed-8d7a-5ce0cea466cc" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_298b4ce4-df91-4e59-9c87-da7a2c9f87bb" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_9e16ad0a-8be5-4b40-ae9e-36dc36ce9646" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c5149f2a-936f-44ed-8d7a-5ce0cea466cc" xlink:to="loc_us-gaap_NetIncomeLoss_9e16ad0a-8be5-4b40-ae9e-36dc36ce9646" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_186e4a2d-41d8-4869-bf35-e077be8756d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_19023f4c-48d0-44d7-8eb0-d79ebfb5c03a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_7f86e23c-0d10-4386-9f22-6181dfa7488d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0c1fcf53-087b-4a6b-8339-416c6b88567f" xlink:to="loc_us-gaap_StatementTable_7f86e23c-0d10-4386-9f22-6181dfa7488d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_73fdbb89-d5f6-4bbc-8031-ed6c3a209556" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_7f86e23c-0d10-4386-9f22-6181dfa7488d" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_73fdbb89-d5f6-4bbc-8031-ed6c3a209556" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_73fdbb89-d5f6-4bbc-8031-ed6c3a209556_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_73fdbb89-d5f6-4bbc-8031-ed6c3a209556" xlink:to="loc_us-gaap_EquityComponentDomain_73fdbb89-d5f6-4bbc-8031-ed6c3a209556_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_a6e6865d-ad26-4a10-b9c2-5b32f56e57db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_73fdbb89-d5f6-4bbc-8031-ed6c3a209556" xlink:to="loc_us-gaap_EquityComponentDomain_a6e6865d-ad26-4a10-b9c2-5b32f56e57db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_332ce1b4-b323-4025-ad0f-fa49955d251b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_a6e6865d-ad26-4a10-b9c2-5b32f56e57db" xlink:to="loc_us-gaap_CommonStockMember_332ce1b4-b323-4025-ad0f-fa49955d251b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_f559a356-5fed-45fc-bc83-033db4f5dbbd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_a6e6865d-ad26-4a10-b9c2-5b32f56e57db" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_f559a356-5fed-45fc-bc83-033db4f5dbbd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_490d7e12-8464-4e57-ac51-69c17eb4e527" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_a6e6865d-ad26-4a10-b9c2-5b32f56e57db" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_490d7e12-8464-4e57-ac51-69c17eb4e527" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_611d2846-e4ba-4f97-8359-f6d02147c4bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_a6e6865d-ad26-4a10-b9c2-5b32f56e57db" xlink:to="loc_us-gaap_RetainedEarningsMember_611d2846-e4ba-4f97-8359-f6d02147c4bd" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="alny-20210331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:definitionLink xlink:role="http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended" id="i4569ae0c81b34ee1b8ba733c13b21f22_CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:roleRef roleURI="http://www.alnylam.com/role/NATUREOFBUSINESS" xlink:type="simple" xlink:href="alny-20210331.xsd#NATUREOFBUSINESS"/>
  <link:definitionLink xlink:role="http://www.alnylam.com/role/NATUREOFBUSINESS" xlink:type="extended" id="ib4f766f8698d4a16ac9591908a24ed1d_NATUREOFBUSINESS"/>
  <link:roleRef roleURI="http://www.alnylam.com/role/NATUREOFBUSINESSDetails" xlink:type="simple" xlink:href="alny-20210331.xsd#NATUREOFBUSINESSDetails"/>
  <link:definitionLink xlink:role="http://www.alnylam.com/role/NATUREOFBUSINESSDetails" xlink:type="extended" id="i18676e3f32de4261b39849370f179b6a_NATUREOFBUSINESSDetails"/>
  <link:roleRef roleURI="http://www.alnylam.com/role/BASISOFPRESENTATIONANDPRINCIPLESOFCONSOLIDATION" xlink:type="simple" xlink:href="alny-20210331.xsd#BASISOFPRESENTATIONANDPRINCIPLESOFCONSOLIDATION"/>
  <link:definitionLink xlink:role="http://www.alnylam.com/role/BASISOFPRESENTATIONANDPRINCIPLESOFCONSOLIDATION" xlink:type="extended" id="i9c96d575816f4efbb1da739960e1c893_BASISOFPRESENTATIONANDPRINCIPLESOFCONSOLIDATION"/>
  <link:roleRef roleURI="http://www.alnylam.com/role/BASISOFPRESENTATIONANDPRINCIPLESOFCONSOLIDATIONPolicies" xlink:type="simple" xlink:href="alny-20210331.xsd#BASISOFPRESENTATIONANDPRINCIPLESOFCONSOLIDATIONPolicies"/>
  <link:definitionLink xlink:role="http://www.alnylam.com/role/BASISOFPRESENTATIONANDPRINCIPLESOFCONSOLIDATIONPolicies" xlink:type="extended" id="ie8d68c9e80764970a1197b91342ab77c_BASISOFPRESENTATIONANDPRINCIPLESOFCONSOLIDATIONPolicies"/>
  <link:roleRef roleURI="http://www.alnylam.com/role/NETPRODUCTREVENUES" xlink:type="simple" xlink:href="alny-20210331.xsd#NETPRODUCTREVENUES"/>
  <link:definitionLink xlink:role="http://www.alnylam.com/role/NETPRODUCTREVENUES" xlink:type="extended" id="i4b9a29baefeb44c19c36a6c24c1d92ce_NETPRODUCTREVENUES"/>
  <link:roleRef roleURI="http://www.alnylam.com/role/NETPRODUCTREVENUESTables" xlink:type="simple" xlink:href="alny-20210331.xsd#NETPRODUCTREVENUESTables"/>
  <link:definitionLink xlink:role="http://www.alnylam.com/role/NETPRODUCTREVENUESTables" xlink:type="extended" id="id6c7a01d11b74834a6a4f8c15cd037cd_NETPRODUCTREVENUESTables"/>
  <link:roleRef roleURI="http://www.alnylam.com/role/NETPRODUCTREVENUESSummaryofNetProductRevenuesDetail" xlink:type="simple" xlink:href="alny-20210331.xsd#NETPRODUCTREVENUESSummaryofNetProductRevenuesDetail"/>
  <link:definitionLink xlink:role="http://www.alnylam.com/role/NETPRODUCTREVENUESSummaryofNetProductRevenuesDetail" xlink:type="extended" id="ia89884a7db324588a55f57e1994eb4aa_NETPRODUCTREVENUESSummaryofNetProductRevenuesDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_e99ece99-62a1-4556-ab1c-48cc0af6672f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_11918797-9e45-4eca-9519-063810258e3e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_e99ece99-62a1-4556-ab1c-48cc0af6672f" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_11918797-9e45-4eca-9519-063810258e3e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_2005e44b-3ffe-499e-8333-e3f5e6c127a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_e99ece99-62a1-4556-ab1c-48cc0af6672f" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_2005e44b-3ffe-499e-8333-e3f5e6c127a9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_4db6e1ce-4693-449e-8e14-0236ae98ecb2" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_2005e44b-3ffe-499e-8333-e3f5e6c127a9" xlink:to="loc_srt_StatementGeographicalAxis_4db6e1ce-4693-449e-8e14-0236ae98ecb2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_4db6e1ce-4693-449e-8e14-0236ae98ecb2_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_4db6e1ce-4693-449e-8e14-0236ae98ecb2" xlink:to="loc_srt_SegmentGeographicalDomain_4db6e1ce-4693-449e-8e14-0236ae98ecb2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_297bdef5-77be-4e27-8b3e-2d8db51ea7a0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_4db6e1ce-4693-449e-8e14-0236ae98ecb2" xlink:to="loc_srt_SegmentGeographicalDomain_297bdef5-77be-4e27-8b3e-2d8db51ea7a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_f5d93604-5dde-43d8-bac1-4ce72c331dd4" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_297bdef5-77be-4e27-8b3e-2d8db51ea7a0" xlink:to="loc_country_US_f5d93604-5dde-43d8-bac1-4ce72c331dd4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_3bbb9d1e-f2f0-4913-8894-87e4a5927fe0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EuropeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_297bdef5-77be-4e27-8b3e-2d8db51ea7a0" xlink:to="loc_srt_EuropeMember_3bbb9d1e-f2f0-4913-8894-87e4a5927fe0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_NonUSOrEuropeMember_9597241d-56ea-4014-82c5-0741ba270271" xlink:href="alny-20210331.xsd#alny_NonUSOrEuropeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_297bdef5-77be-4e27-8b3e-2d8db51ea7a0" xlink:to="loc_alny_NonUSOrEuropeMember_9597241d-56ea-4014-82c5-0741ba270271" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_4d3263b8-2167-4808-807e-132710713a3f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_2005e44b-3ffe-499e-8333-e3f5e6c127a9" xlink:to="loc_srt_ProductOrServiceAxis_4d3263b8-2167-4808-807e-132710713a3f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_4d3263b8-2167-4808-807e-132710713a3f_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_4d3263b8-2167-4808-807e-132710713a3f" xlink:to="loc_srt_ProductsAndServicesDomain_4d3263b8-2167-4808-807e-132710713a3f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_43ca69da-b250-4953-b98f-bfb6d0cd47fb" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_4d3263b8-2167-4808-807e-132710713a3f" xlink:to="loc_srt_ProductsAndServicesDomain_43ca69da-b250-4953-b98f-bfb6d0cd47fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_ecc6e9a2-2c0b-4488-a86b-4b949ddf3c67" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_43ca69da-b250-4953-b98f-bfb6d0cd47fb" xlink:to="loc_us-gaap_ProductMember_ecc6e9a2-2c0b-4488-a86b-4b949ddf3c67" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_ONPATTROMember_4af147b3-293e-4371-a01b-54ba4bb18f11" xlink:href="alny-20210331.xsd#alny_ONPATTROMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_ecc6e9a2-2c0b-4488-a86b-4b949ddf3c67" xlink:to="loc_alny_ONPATTROMember_4af147b3-293e-4371-a01b-54ba4bb18f11" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_GIVLAARIMember_58abbb06-2a97-4d0d-98f0-f6d260f1836c" xlink:href="alny-20210331.xsd#alny_GIVLAARIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_ecc6e9a2-2c0b-4488-a86b-4b949ddf3c67" xlink:to="loc_alny_GIVLAARIMember_58abbb06-2a97-4d0d-98f0-f6d260f1836c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_OXLUMOMember_3704bab0-ceb5-4381-a313-5c10f2bd3719" xlink:href="alny-20210331.xsd#alny_OXLUMOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_ecc6e9a2-2c0b-4488-a86b-4b949ddf3c67" xlink:to="loc_alny_OXLUMOMember_3704bab0-ceb5-4381-a313-5c10f2bd3719" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/NETPRODUCTREVENUESReceivablesDetail" xlink:type="simple" xlink:href="alny-20210331.xsd#NETPRODUCTREVENUESReceivablesDetail"/>
  <link:definitionLink xlink:role="http://www.alnylam.com/role/NETPRODUCTREVENUESReceivablesDetail" xlink:type="extended" id="ia8869c720e534ff58b3b157bbcc33429_NETPRODUCTREVENUESReceivablesDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_73bfb0a0-ba1b-4657-bd63-f9ddfe8d23b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_4bc3549a-4438-41b8-ad43-c12452cb62fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_73bfb0a0-ba1b-4657-bd63-f9ddfe8d23b3" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_4bc3549a-4438-41b8-ad43-c12452cb62fc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_3a701e07-d79c-4820-97b4-3309034d5951" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_73bfb0a0-ba1b-4657-bd63-f9ddfe8d23b3" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_3a701e07-d79c-4820-97b4-3309034d5951" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_f3d9cdc4-547f-4bf2-a829-bc01848f9525" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_3a701e07-d79c-4820-97b4-3309034d5951" xlink:to="loc_srt_ProductOrServiceAxis_f3d9cdc4-547f-4bf2-a829-bc01848f9525" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_f3d9cdc4-547f-4bf2-a829-bc01848f9525_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_f3d9cdc4-547f-4bf2-a829-bc01848f9525" xlink:to="loc_srt_ProductsAndServicesDomain_f3d9cdc4-547f-4bf2-a829-bc01848f9525_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_5ec5fd10-58a4-4842-af4a-a920ecc99b43" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_f3d9cdc4-547f-4bf2-a829-bc01848f9525" xlink:to="loc_srt_ProductsAndServicesDomain_5ec5fd10-58a4-4842-af4a-a920ecc99b43" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_f484b496-416d-4c38-a2c2-f9d94da953af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5ec5fd10-58a4-4842-af4a-a920ecc99b43" xlink:to="loc_us-gaap_ProductMember_f484b496-416d-4c38-a2c2-f9d94da953af" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONS" xlink:type="simple" xlink:href="alny-20210331.xsd#NETREVENUESFROMCOLLABORATIONS"/>
  <link:definitionLink xlink:role="http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONS" xlink:type="extended" id="i8739688ef52d46eb928e31a083208d54_NETREVENUESFROMCOLLABORATIONS"/>
  <link:roleRef roleURI="http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSTables" xlink:type="simple" xlink:href="alny-20210331.xsd#NETREVENUESFROMCOLLABORATIONSTables"/>
  <link:definitionLink xlink:role="http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSTables" xlink:type="extended" id="ida52b465d27a470792c9992aaee92eb0_NETREVENUESFROMCOLLABORATIONSTables"/>
  <link:roleRef roleURI="http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSRevenuefromCollaboratorsDetail" xlink:type="simple" xlink:href="alny-20210331.xsd#NETREVENUESFROMCOLLABORATIONSRevenuefromCollaboratorsDetail"/>
  <link:definitionLink xlink:role="http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSRevenuefromCollaboratorsDetail" xlink:type="extended" id="i36dfc64602ff4f259620330b456cdcc4_NETREVENUESFROMCOLLABORATIONSRevenuefromCollaboratorsDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7ca27bae-3a13-4be3-8d26-a575f863cb25" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2138d4f8-81e9-4910-9417-cc5ded69d51e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7ca27bae-3a13-4be3-8d26-a575f863cb25" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2138d4f8-81e9-4910-9417-cc5ded69d51e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_adc4fe25-b46e-4610-a28f-057cda504df4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7ca27bae-3a13-4be3-8d26-a575f863cb25" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_adc4fe25-b46e-4610-a28f-057cda504df4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_6a0dc35d-b22e-4c97-8d81-4ee429bbb760" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_adc4fe25-b46e-4610-a28f-057cda504df4" xlink:to="loc_us-gaap_TypeOfArrangementAxis_6a0dc35d-b22e-4c97-8d81-4ee429bbb760" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6a0dc35d-b22e-4c97-8d81-4ee429bbb760_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_6a0dc35d-b22e-4c97-8d81-4ee429bbb760" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6a0dc35d-b22e-4c97-8d81-4ee429bbb760_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ed64d072-cebe-4fc5-95e6-10842906a997" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_6a0dc35d-b22e-4c97-8d81-4ee429bbb760" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ed64d072-cebe-4fc5-95e6-10842906a997" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_f5f984ae-5d39-43ff-a96e-564905b46331" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ed64d072-cebe-4fc5-95e6-10842906a997" xlink:to="loc_us-gaap_CollaborativeArrangementMember_f5f984ae-5d39-43ff-a96e-564905b46331" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_90f2ed39-0b0e-49bc-8b27-dcfc83b9790f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_adc4fe25-b46e-4610-a28f-057cda504df4" xlink:to="loc_srt_CounterpartyNameAxis_90f2ed39-0b0e-49bc-8b27-dcfc83b9790f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_90f2ed39-0b0e-49bc-8b27-dcfc83b9790f_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_90f2ed39-0b0e-49bc-8b27-dcfc83b9790f" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_90f2ed39-0b0e-49bc-8b27-dcfc83b9790f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_08d71dfa-d8a2-4f76-bbd6-d9ae969f9b35" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_90f2ed39-0b0e-49bc-8b27-dcfc83b9790f" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_08d71dfa-d8a2-4f76-bbd6-d9ae969f9b35" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_RegeneronPharmaceuticalsIncorporationMember_0c3ab737-8f7d-4fed-862b-328ebbf08d42" xlink:href="alny-20210331.xsd#alny_RegeneronPharmaceuticalsIncorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_08d71dfa-d8a2-4f76-bbd6-d9ae969f9b35" xlink:to="loc_alny_RegeneronPharmaceuticalsIncorporationMember_0c3ab737-8f7d-4fed-862b-328ebbf08d42" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_NovartisMember_9a436ae0-2183-4ec7-9de0-200cac826d6f" xlink:href="alny-20210331.xsd#alny_NovartisMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_08d71dfa-d8a2-4f76-bbd6-d9ae969f9b35" xlink:to="loc_alny_NovartisMember_9a436ae0-2183-4ec7-9de0-200cac826d6f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_VirBiotechnologyIncMember_c07c34c1-0dc2-4ba6-b856-3d90823a5de7" xlink:href="alny-20210331.xsd#alny_VirBiotechnologyIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_08d71dfa-d8a2-4f76-bbd6-d9ae969f9b35" xlink:to="loc_alny_VirBiotechnologyIncMember_c07c34c1-0dc2-4ba6-b856-3d90823a5de7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_OtherCollaborationsMember_e9d9297f-bb5a-4fea-a420-586756f0fb81" xlink:href="alny-20210331.xsd#alny_OtherCollaborationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_08d71dfa-d8a2-4f76-bbd6-d9ae969f9b35" xlink:to="loc_alny_OtherCollaborationsMember_e9d9297f-bb5a-4fea-a420-586756f0fb81" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSBalanceofReceivablesandContractLiabilitiesRelatedtoCollaborationAgreementsDetail" xlink:type="simple" xlink:href="alny-20210331.xsd#NETREVENUESFROMCOLLABORATIONSBalanceofReceivablesandContractLiabilitiesRelatedtoCollaborationAgreementsDetail"/>
  <link:definitionLink xlink:role="http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSBalanceofReceivablesandContractLiabilitiesRelatedtoCollaborationAgreementsDetail" xlink:type="extended" id="ic606e65e21f040dfb20acf49a68be9a5_NETREVENUESFROMCOLLABORATIONSBalanceofReceivablesandContractLiabilitiesRelatedtoCollaborationAgreementsDetail"/>
  <link:roleRef roleURI="http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSAdditionalInformationDetail" xlink:type="simple" xlink:href="alny-20210331.xsd#NETREVENUESFROMCOLLABORATIONSAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSAdditionalInformationDetail" xlink:type="extended" id="i031af3cbd564457c833126f07f51d5e8_NETREVENUESFROMCOLLABORATIONSAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2493336a-5014-4ac0-a321-32bad4392538" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_4add214b-49bc-45d3-92a1-7d039943ffec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2493336a-5014-4ac0-a321-32bad4392538" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_4add214b-49bc-45d3-92a1-7d039943ffec" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_DiscoveryPeriodOfProgramsDevelopment_2eb16cbc-969f-4200-9b7c-d66fef7ab910" xlink:href="alny-20210331.xsd#alny_DiscoveryPeriodOfProgramsDevelopment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2493336a-5014-4ac0-a321-32bad4392538" xlink:to="loc_alny_DiscoveryPeriodOfProgramsDevelopment_2eb16cbc-969f-4200-9b7c-d66fef7ab910" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_ExtendedAdditionalDiscoveryPeriodOfProgramsDevelopment_498c92de-67e8-4beb-87b5-ea666d833c6e" xlink:href="alny-20210331.xsd#alny_ExtendedAdditionalDiscoveryPeriodOfProgramsDevelopment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2493336a-5014-4ac0-a321-32bad4392538" xlink:to="loc_alny_ExtendedAdditionalDiscoveryPeriodOfProgramsDevelopment_498c92de-67e8-4beb-87b5-ea666d833c6e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_ResearchTermExtensionFee_2e152418-bfa8-401b-9097-0f6ebb99a1de" xlink:href="alny-20210331.xsd#alny_ResearchTermExtensionFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2493336a-5014-4ac0-a321-32bad4392538" xlink:to="loc_alny_ResearchTermExtensionFee_2e152418-bfa8-401b-9097-0f6ebb99a1de" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_MaximumRoyaltiesAndCommercialMilestonePaymentsUponPotentialProductSale_830c87e1-8e1f-4746-9bc5-331b4e49b7d5" xlink:href="alny-20210331.xsd#alny_MaximumRoyaltiesAndCommercialMilestonePaymentsUponPotentialProductSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2493336a-5014-4ac0-a321-32bad4392538" xlink:to="loc_alny_MaximumRoyaltiesAndCommercialMilestonePaymentsUponPotentialProductSale_830c87e1-8e1f-4746-9bc5-331b4e49b7d5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_UpfrontFeeReceived_fd853c5e-4192-434e-ba8a-8b1469d09db8" xlink:href="alny-20210331.xsd#alny_UpfrontFeeReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2493336a-5014-4ac0-a321-32bad4392538" xlink:to="loc_alny_UpfrontFeeReceived_fd853c5e-4192-434e-ba8a-8b1469d09db8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_MaximumAdditionalMilestonePaymentsToBeReceiveUponAchievementOfCertainCriteria_0bac42f7-0475-425c-a144-e0baabc24dc4" xlink:href="alny-20210331.xsd#alny_MaximumAdditionalMilestonePaymentsToBeReceiveUponAchievementOfCertainCriteria"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2493336a-5014-4ac0-a321-32bad4392538" xlink:to="loc_alny_MaximumAdditionalMilestonePaymentsToBeReceiveUponAchievementOfCertainCriteria_0bac42f7-0475-425c-a144-e0baabc24dc4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_NumberOfTargetedPrograms_e81733f7-1e88-4339-992e-f4d7d306b36c" xlink:href="alny-20210331.xsd#alny_NumberOfTargetedPrograms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2493336a-5014-4ac0-a321-32bad4392538" xlink:to="loc_alny_NumberOfTargetedPrograms_e81733f7-1e88-4339-992e-f4d7d306b36c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_PotentialProceedsFromCollaborationArrangement_21cc6ede-d416-4909-9578-9d38e5f7d602" xlink:href="alny-20210331.xsd#alny_PotentialProceedsFromCollaborationArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2493336a-5014-4ac0-a321-32bad4392538" xlink:to="loc_alny_PotentialProceedsFromCollaborationArrangement_21cc6ede-d416-4909-9578-9d38e5f7d602" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_CollaborativeAgreementTerminationPeriod_1bacb337-5a99-454a-9874-ca6e1e8297dc" xlink:href="alny-20210331.xsd#alny_CollaborativeAgreementTerminationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2493336a-5014-4ac0-a321-32bad4392538" xlink:to="loc_alny_CollaborativeAgreementTerminationPeriod_1bacb337-5a99-454a-9874-ca6e1e8297dc" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_CollaborativeArrangementMilestonePayments_93136f46-999f-45db-92a7-f2fd503979d4" xlink:href="alny-20210331.xsd#alny_CollaborativeArrangementMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2493336a-5014-4ac0-a321-32bad4392538" xlink:to="loc_alny_CollaborativeArrangementMilestonePayments_93136f46-999f-45db-92a7-f2fd503979d4" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_RoyaltyRate_baf5b2aa-9f8e-469d-b61e-3e9e98464f6b" xlink:href="alny-20210331.xsd#alny_RoyaltyRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2493336a-5014-4ac0-a321-32bad4392538" xlink:to="loc_alny_RoyaltyRate_baf5b2aa-9f8e-469d-b61e-3e9e98464f6b" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_PercentageOfMaximumRoyaltyPayments_42a95e4d-4269-4fff-9524-73e609676cfc" xlink:href="alny-20210331.xsd#alny_PercentageOfMaximumRoyaltyPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2493336a-5014-4ac0-a321-32bad4392538" xlink:to="loc_alny_PercentageOfMaximumRoyaltyPayments_42a95e4d-4269-4fff-9524-73e609676cfc" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_TransactionPrice_166c5bae-c4d9-4ad5-a899-bed436d07ae5" xlink:href="alny-20210331.xsd#alny_TransactionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2493336a-5014-4ac0-a321-32bad4392538" xlink:to="loc_alny_TransactionPrice_166c5bae-c4d9-4ad5-a899-bed436d07ae5" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_98fa76d1-bfbf-47a9-99b0-661bdb239f8f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2493336a-5014-4ac0-a321-32bad4392538" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_98fa76d1-bfbf-47a9-99b0-661bdb239f8f" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_MilestonePaymentEarned_0bec5a96-66b3-4f81-b994-cb1dcbef98f4" xlink:href="alny-20210331.xsd#alny_MilestonePaymentEarned"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2493336a-5014-4ac0-a321-32bad4392538" xlink:to="loc_alny_MilestonePaymentEarned_0bec5a96-66b3-4f81-b994-cb1dcbef98f4" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_MaximumNumberOfPotentialFutureMilestones_2315f615-5144-406f-970f-a8801c374fcb" xlink:href="alny-20210331.xsd#alny_MaximumNumberOfPotentialFutureMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2493336a-5014-4ac0-a321-32bad4392538" xlink:to="loc_alny_MaximumNumberOfPotentialFutureMilestones_2315f615-5144-406f-970f-a8801c374fcb" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_FuturePaymentsOnAchievementOfSpecifiedRegulatoryMilestones_87674758-5eb2-4517-814a-b8a6850eccd2" xlink:href="alny-20210331.xsd#alny_FuturePaymentsOnAchievementOfSpecifiedRegulatoryMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2493336a-5014-4ac0-a321-32bad4392538" xlink:to="loc_alny_FuturePaymentsOnAchievementOfSpecifiedRegulatoryMilestones_87674758-5eb2-4517-814a-b8a6850eccd2" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_FuturePaymentsOnAchievementOfOtherSpecifiedRegulatoryMilestones_a5336fee-a78b-4858-a801-99a707a21b5f" xlink:href="alny-20210331.xsd#alny_FuturePaymentsOnAchievementOfOtherSpecifiedRegulatoryMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2493336a-5014-4ac0-a321-32bad4392538" xlink:to="loc_alny_FuturePaymentsOnAchievementOfOtherSpecifiedRegulatoryMilestones_a5336fee-a78b-4858-a801-99a707a21b5f" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_FuturePaymentsOnAchievementOfSpecifiedCommercializationMilestones_bdc3c5fb-4e57-42ce-955e-513f7b28ec7c" xlink:href="alny-20210331.xsd#alny_FuturePaymentsOnAchievementOfSpecifiedCommercializationMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2493336a-5014-4ac0-a321-32bad4392538" xlink:to="loc_alny_FuturePaymentsOnAchievementOfSpecifiedCommercializationMilestones_bdc3c5fb-4e57-42ce-955e-513f7b28ec7c" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedBalanceShares_19313369-5391-4888-9b67-860d7bd1f6b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentOwnedBalanceShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2493336a-5014-4ac0-a321-32bad4392538" xlink:to="loc_us-gaap_InvestmentOwnedBalanceShares_19313369-5391-4888-9b67-860d7bd1f6b7" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_MilestonePaymentEarnedShares_8beae3cc-5b64-4729-8464-4a55481967c2" xlink:href="alny-20210331.xsd#alny_MilestonePaymentEarnedShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2493336a-5014-4ac0-a321-32bad4392538" xlink:to="loc_alny_MilestonePaymentEarnedShares_8beae3cc-5b64-4729-8464-4a55481967c2" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_CollaborativeArrangementAdditionalDevelopmentCandidatesToBeDelivered_fdc1d09d-c5e3-439a-8e3f-3f65562aaae6" xlink:href="alny-20210331.xsd#alny_CollaborativeArrangementAdditionalDevelopmentCandidatesToBeDelivered"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2493336a-5014-4ac0-a321-32bad4392538" xlink:to="loc_alny_CollaborativeArrangementAdditionalDevelopmentCandidatesToBeDelivered_fdc1d09d-c5e3-439a-8e3f-3f65562aaae6" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3f5e925c-de67-40df-bc0f-f51863aa2a9a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2493336a-5014-4ac0-a321-32bad4392538" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3f5e925c-de67-40df-bc0f-f51863aa2a9a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_7e78c9dd-2606-4a5d-866c-f154c8b5ab76" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3f5e925c-de67-40df-bc0f-f51863aa2a9a" xlink:to="loc_us-gaap_TypeOfArrangementAxis_7e78c9dd-2606-4a5d-866c-f154c8b5ab76" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7e78c9dd-2606-4a5d-866c-f154c8b5ab76_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_7e78c9dd-2606-4a5d-866c-f154c8b5ab76" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7e78c9dd-2606-4a5d-866c-f154c8b5ab76_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_22d7d464-3347-4f3c-8db8-98e32c5901e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_7e78c9dd-2606-4a5d-866c-f154c8b5ab76" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_22d7d464-3347-4f3c-8db8-98e32c5901e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_GlobalStrategicCollaborationMember_ff5d5fe2-a201-4deb-a281-a8db900e4506" xlink:href="alny-20210331.xsd#alny_GlobalStrategicCollaborationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_22d7d464-3347-4f3c-8db8-98e32c5901e5" xlink:to="loc_alny_GlobalStrategicCollaborationMember_ff5d5fe2-a201-4deb-a281-a8db900e4506" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_ProductAlliancesMember_d19b14f2-5b3c-4be3-b31b-619aff655490" xlink:href="alny-20210331.xsd#alny_ProductAlliancesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_22d7d464-3347-4f3c-8db8-98e32c5901e5" xlink:to="loc_alny_ProductAlliancesMember_d19b14f2-5b3c-4be3-b31b-619aff655490" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_deb5748b-f6a3-4cd0-b9cb-aec2c8626e4f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3f5e925c-de67-40df-bc0f-f51863aa2a9a" xlink:to="loc_srt_RangeAxis_deb5748b-f6a3-4cd0-b9cb-aec2c8626e4f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_deb5748b-f6a3-4cd0-b9cb-aec2c8626e4f_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_deb5748b-f6a3-4cd0-b9cb-aec2c8626e4f" xlink:to="loc_srt_RangeMember_deb5748b-f6a3-4cd0-b9cb-aec2c8626e4f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0346bd0a-6946-4245-bf18-a4f374940c50" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_deb5748b-f6a3-4cd0-b9cb-aec2c8626e4f" xlink:to="loc_srt_RangeMember_0346bd0a-6946-4245-bf18-a4f374940c50" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_5c263f42-b711-4a62-b9fe-0754d6010cb7" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_0346bd0a-6946-4245-bf18-a4f374940c50" xlink:to="loc_srt_MinimumMember_5c263f42-b711-4a62-b9fe-0754d6010cb7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_1a74f6ac-d8b1-4838-a58a-12c822b0e35b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_0346bd0a-6946-4245-bf18-a4f374940c50" xlink:to="loc_srt_MaximumMember_1a74f6ac-d8b1-4838-a58a-12c822b0e35b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_a2b6c5a7-9b86-4de5-9696-ed9741e37507" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3f5e925c-de67-40df-bc0f-f51863aa2a9a" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_a2b6c5a7-9b86-4de5-9696-ed9741e37507" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_a2b6c5a7-9b86-4de5-9696-ed9741e37507_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_a2b6c5a7-9b86-4de5-9696-ed9741e37507" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_a2b6c5a7-9b86-4de5-9696-ed9741e37507_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_7814660a-b3b9-4307-a698-b406ffd21371" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_a2b6c5a7-9b86-4de5-9696-ed9741e37507" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_7814660a-b3b9-4307-a698-b406ffd21371" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_FundingAtProgramInitiationMember_2dc8ed6c-00ce-4165-b5ce-d9475d8a6412" xlink:href="alny-20210331.xsd#alny_FundingAtProgramInitiationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_7814660a-b3b9-4307-a698-b406ffd21371" xlink:to="loc_alny_FundingAtProgramInitiationMember_2dc8ed6c-00ce-4165-b5ce-d9475d8a6412" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_FundingAtLeadCandidateIdentificationMember_bc26ac54-dcdc-4e6d-98cc-4fb99c72c950" xlink:href="alny-20210331.xsd#alny_FundingAtLeadCandidateIdentificationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_7814660a-b3b9-4307-a698-b406ffd21371" xlink:to="loc_alny_FundingAtLeadCandidateIdentificationMember_bc26ac54-dcdc-4e6d-98cc-4fb99c72c950" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_FundingAnAnnualDiscoveryMember_401e883c-dba2-48fb-ab92-7808bbff2461" xlink:href="alny-20210331.xsd#alny_FundingAnAnnualDiscoveryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_7814660a-b3b9-4307-a698-b406ffd21371" xlink:to="loc_alny_FundingAnAnnualDiscoveryMember_401e883c-dba2-48fb-ab92-7808bbff2461" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_ResearchCollaboratorAxis_de2debd0-4973-4a8a-b6d8-3a29d486d7c5" xlink:href="alny-20210331.xsd#alny_ResearchCollaboratorAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3f5e925c-de67-40df-bc0f-f51863aa2a9a" xlink:to="loc_alny_ResearchCollaboratorAxis_de2debd0-4973-4a8a-b6d8-3a29d486d7c5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_ResearchCollaboratorDomain_de2debd0-4973-4a8a-b6d8-3a29d486d7c5_default" xlink:href="alny-20210331.xsd#alny_ResearchCollaboratorDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_alny_ResearchCollaboratorAxis_de2debd0-4973-4a8a-b6d8-3a29d486d7c5" xlink:to="loc_alny_ResearchCollaboratorDomain_de2debd0-4973-4a8a-b6d8-3a29d486d7c5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_ResearchCollaboratorDomain_7e22b74e-2f01-4f27-ab23-43685a91c1f4" xlink:href="alny-20210331.xsd#alny_ResearchCollaboratorDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_alny_ResearchCollaboratorAxis_de2debd0-4973-4a8a-b6d8-3a29d486d7c5" xlink:to="loc_alny_ResearchCollaboratorDomain_7e22b74e-2f01-4f27-ab23-43685a91c1f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_NovartisMember_e839d4e5-63a8-4769-992d-1e21f7c00dc2" xlink:href="alny-20210331.xsd#alny_NovartisMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alny_ResearchCollaboratorDomain_7e22b74e-2f01-4f27-ab23-43685a91c1f4" xlink:to="loc_alny_NovartisMember_e839d4e5-63a8-4769-992d-1e21f7c00dc2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_24d97e8d-d549-4185-a060-5c05aedb25e8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3f5e925c-de67-40df-bc0f-f51863aa2a9a" xlink:to="loc_srt_CounterpartyNameAxis_24d97e8d-d549-4185-a060-5c05aedb25e8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_24d97e8d-d549-4185-a060-5c05aedb25e8_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_24d97e8d-d549-4185-a060-5c05aedb25e8" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_24d97e8d-d549-4185-a060-5c05aedb25e8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7a9d543f-4f6a-4c51-9716-0baa662277a2" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_24d97e8d-d549-4185-a060-5c05aedb25e8" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7a9d543f-4f6a-4c51-9716-0baa662277a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_VirBiotechnologyIncMember_c1acf2bc-c867-450d-bba2-672d487a0b40" xlink:href="alny-20210331.xsd#alny_VirBiotechnologyIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7a9d543f-4f6a-4c51-9716-0baa662277a2" xlink:to="loc_alny_VirBiotechnologyIncMember_c1acf2bc-c867-450d-bba2-672d487a0b40" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_RegeneronPharmaceuticalsIncorporationMember_82b9d0f9-f505-4cbd-8763-fd97bd15ac1c" xlink:href="alny-20210331.xsd#alny_RegeneronPharmaceuticalsIncorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7a9d543f-4f6a-4c51-9716-0baa662277a2" xlink:to="loc_alny_RegeneronPharmaceuticalsIncorporationMember_82b9d0f9-f505-4cbd-8763-fd97bd15ac1c" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofResearchandDevelopmentExpensesIncurredbyTypethatareDirectlyAttributabletoCollaborationAgreementsDetail" xlink:type="simple" xlink:href="alny-20210331.xsd#NETREVENUESFROMCOLLABORATIONSScheduleofResearchandDevelopmentExpensesIncurredbyTypethatareDirectlyAttributabletoCollaborationAgreementsDetail"/>
  <link:definitionLink xlink:role="http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofResearchandDevelopmentExpensesIncurredbyTypethatareDirectlyAttributabletoCollaborationAgreementsDetail" xlink:type="extended" id="i8e9c6b4013944d03b7b0923506efc42b_NETREVENUESFROMCOLLABORATIONSScheduleofResearchandDevelopmentExpensesIncurredbyTypethatareDirectlyAttributabletoCollaborationAgreementsDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7bc79223-fe1a-40a2-b03c-c944a8d30968" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_b2138bae-c8e6-476f-90be-e029b6ee6ca2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7bc79223-fe1a-40a2-b03c-c944a8d30968" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_b2138bae-c8e6-476f-90be-e029b6ee6ca2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_36288480-3455-422c-862a-fc536afd98f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7bc79223-fe1a-40a2-b03c-c944a8d30968" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_36288480-3455-422c-862a-fc536afd98f0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_a2c89823-93ec-4562-bf2e-9380e62a4fec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_36288480-3455-422c-862a-fc536afd98f0" xlink:to="loc_us-gaap_TypeOfArrangementAxis_a2c89823-93ec-4562-bf2e-9380e62a4fec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a2c89823-93ec-4562-bf2e-9380e62a4fec_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_a2c89823-93ec-4562-bf2e-9380e62a4fec" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a2c89823-93ec-4562-bf2e-9380e62a4fec_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_18be133d-ca3b-4f4d-8ef9-441a53a4be5f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_a2c89823-93ec-4562-bf2e-9380e62a4fec" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_18be133d-ca3b-4f4d-8ef9-441a53a4be5f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_ClinicalTrialAndManufacturingMember_1cb8e5c8-a80b-4e3f-8799-45e9b7339277" xlink:href="alny-20210331.xsd#alny_ClinicalTrialAndManufacturingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_18be133d-ca3b-4f4d-8ef9-441a53a4be5f" xlink:to="loc_alny_ClinicalTrialAndManufacturingMember_1cb8e5c8-a80b-4e3f-8799-45e9b7339277" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_ExternalServicesMember_043dcd1c-313e-47f6-b202-ecb609439833" xlink:href="alny-20210331.xsd#alny_ExternalServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_18be133d-ca3b-4f4d-8ef9-441a53a4be5f" xlink:to="loc_alny_ExternalServicesMember_043dcd1c-313e-47f6-b202-ecb609439833" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_OtherMember_4f1f5a63-f758-45a7-b71b-052fa16ab612" xlink:href="alny-20210331.xsd#alny_OtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_18be133d-ca3b-4f4d-8ef9-441a53a4be5f" xlink:to="loc_alny_OtherMember_4f1f5a63-f758-45a7-b71b-052fa16ab612" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_f7497f56-3f40-4127-8209-9c2289b34bd2" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_36288480-3455-422c-862a-fc536afd98f0" xlink:to="loc_srt_CounterpartyNameAxis_f7497f56-3f40-4127-8209-9c2289b34bd2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f7497f56-3f40-4127-8209-9c2289b34bd2_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_f7497f56-3f40-4127-8209-9c2289b34bd2" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f7497f56-3f40-4127-8209-9c2289b34bd2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6196d434-9ab9-4a79-8916-0380601f9cfd" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_f7497f56-3f40-4127-8209-9c2289b34bd2" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6196d434-9ab9-4a79-8916-0380601f9cfd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_RegeneronPharmaceuticalsIncorporationMember_bd38fb23-04a8-45db-a5ad-6e59afb57d2c" xlink:href="alny-20210331.xsd#alny_RegeneronPharmaceuticalsIncorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6196d434-9ab9-4a79-8916-0380601f9cfd" xlink:to="loc_alny_RegeneronPharmaceuticalsIncorporationMember_bd38fb23-04a8-45db-a5ad-6e59afb57d2c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_VirBiotechnologyIncMember_18a3dd45-b3af-4e23-af8d-e413fc27f203" xlink:href="alny-20210331.xsd#alny_VirBiotechnologyIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6196d434-9ab9-4a79-8916-0380601f9cfd" xlink:to="loc_alny_VirBiotechnologyIncMember_18a3dd45-b3af-4e23-af8d-e413fc27f203" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_NovartisMember_1789f5c8-09e2-4e06-9163-fd972e6c5f5a" xlink:href="alny-20210331.xsd#alny_NovartisMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6196d434-9ab9-4a79-8916-0380601f9cfd" xlink:to="loc_alny_NovartisMember_1789f5c8-09e2-4e06-9163-fd972e6c5f5a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_SanofiGenzymeMember_05b4f4b6-ebfd-4a0d-9320-0f9e9cb1a2ba" xlink:href="alny-20210331.xsd#alny_SanofiGenzymeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6196d434-9ab9-4a79-8916-0380601f9cfd" xlink:to="loc_alny_SanofiGenzymeMember_05b4f4b6-ebfd-4a0d-9320-0f9e9cb1a2ba" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofTransactionPriceAllocatedDetails" xlink:type="simple" xlink:href="alny-20210331.xsd#NETREVENUESFROMCOLLABORATIONSScheduleofTransactionPriceAllocatedDetails"/>
  <link:definitionLink xlink:role="http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofTransactionPriceAllocatedDetails" xlink:type="extended" id="i2e85ef5c0d1749f68b4f6d3336320499_NETREVENUESFROMCOLLABORATIONSScheduleofTransactionPriceAllocatedDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_26c37c2c-c429-488c-beb0-7668cb64bb2f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_StandaloneSellingPrice_c6815397-4013-4da1-a9ba-7a3a85c0bfff" xlink:href="alny-20210331.xsd#alny_StandaloneSellingPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_26c37c2c-c429-488c-beb0-7668cb64bb2f" xlink:to="loc_alny_StandaloneSellingPrice_c6815397-4013-4da1-a9ba-7a3a85c0bfff" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_TransactionPrice_aea8fbc0-4bb5-4101-88a0-642b515ae0d5" xlink:href="alny-20210331.xsd#alny_TransactionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_26c37c2c-c429-488c-beb0-7668cb64bb2f" xlink:to="loc_alny_TransactionPrice_aea8fbc0-4bb5-4101-88a0-642b515ae0d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_70943086-255b-451f-9735-d2e86fa797fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_26c37c2c-c429-488c-beb0-7668cb64bb2f" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_70943086-255b-451f-9735-d2e86fa797fb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_7874f9fc-0c2f-4d2b-8562-b07bbcff8e9b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_70943086-255b-451f-9735-d2e86fa797fb" xlink:to="loc_srt_ProductOrServiceAxis_7874f9fc-0c2f-4d2b-8562-b07bbcff8e9b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_7874f9fc-0c2f-4d2b-8562-b07bbcff8e9b_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_7874f9fc-0c2f-4d2b-8562-b07bbcff8e9b" xlink:to="loc_srt_ProductsAndServicesDomain_7874f9fc-0c2f-4d2b-8562-b07bbcff8e9b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_9925488c-fc86-44af-afea-23d42727e69e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_7874f9fc-0c2f-4d2b-8562-b07bbcff8e9b" xlink:to="loc_srt_ProductsAndServicesDomain_9925488c-fc86-44af-afea-23d42727e69e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_ResearchServicesObligationMember_8ba85646-3445-4cbc-86d9-d6819c521b7a" xlink:href="alny-20210331.xsd#alny_ResearchServicesObligationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_9925488c-fc86-44af-afea-23d42727e69e" xlink:to="loc_alny_ResearchServicesObligationMember_8ba85646-3445-4cbc-86d9-d6819c521b7a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_C5LicenseObligationMember_6af82406-4c6f-44a7-82b2-29ae8f1dcfa9" xlink:href="alny-20210331.xsd#alny_C5LicenseObligationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_9925488c-fc86-44af-afea-23d42727e69e" xlink:to="loc_alny_C5LicenseObligationMember_6af82406-4c6f-44a7-82b2-29ae8f1dcfa9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_C5CoCoObligationMember_93f715f4-dcf7-4cba-95c5-3db678354b66" xlink:href="alny-20210331.xsd#alny_C5CoCoObligationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_9925488c-fc86-44af-afea-23d42727e69e" xlink:to="loc_alny_C5CoCoObligationMember_93f715f4-dcf7-4cba-95c5-3db678354b66" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_4cc29350-561f-4b51-8a54-a1e0e408641f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_70943086-255b-451f-9735-d2e86fa797fb" xlink:to="loc_us-gaap_TypeOfArrangementAxis_4cc29350-561f-4b51-8a54-a1e0e408641f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4cc29350-561f-4b51-8a54-a1e0e408641f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_4cc29350-561f-4b51-8a54-a1e0e408641f" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4cc29350-561f-4b51-8a54-a1e0e408641f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8e562226-98e7-4eb2-af71-f51875d95b36" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_4cc29350-561f-4b51-8a54-a1e0e408641f" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8e562226-98e7-4eb2-af71-f51875d95b36" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_GlobalStrategicCollaborationMember_115759dc-3c9e-4703-bb8d-fc219f4540dd" xlink:href="alny-20210331.xsd#alny_GlobalStrategicCollaborationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8e562226-98e7-4eb2-af71-f51875d95b36" xlink:to="loc_alny_GlobalStrategicCollaborationMember_115759dc-3c9e-4703-bb8d-fc219f4540dd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_5473ef83-d602-4c04-bbbe-0ac91abdf0fd" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_70943086-255b-451f-9735-d2e86fa797fb" xlink:to="loc_srt_CounterpartyNameAxis_5473ef83-d602-4c04-bbbe-0ac91abdf0fd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5473ef83-d602-4c04-bbbe-0ac91abdf0fd_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_5473ef83-d602-4c04-bbbe-0ac91abdf0fd" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5473ef83-d602-4c04-bbbe-0ac91abdf0fd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d4e5da26-94ce-4342-ba31-5847ed951325" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_5473ef83-d602-4c04-bbbe-0ac91abdf0fd" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d4e5da26-94ce-4342-ba31-5847ed951325" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_RegeneronPharmaceuticalsIncorporationMember_f7f8b332-82d9-4968-8431-546ed12bc774" xlink:href="alny-20210331.xsd#alny_RegeneronPharmaceuticalsIncorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d4e5da26-94ce-4342-ba31-5847ed951325" xlink:to="loc_alny_RegeneronPharmaceuticalsIncorporationMember_f7f8b332-82d9-4968-8431-546ed12bc774" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofDeferredRevenueDetails" xlink:type="simple" xlink:href="alny-20210331.xsd#NETREVENUESFROMCOLLABORATIONSScheduleofDeferredRevenueDetails"/>
  <link:definitionLink xlink:role="http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofDeferredRevenueDetails" xlink:type="extended" id="iea6d7bd4544f42f495cab147322dc839_NETREVENUESFROMCOLLABORATIONSScheduleofDeferredRevenueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7048eedc-d1c7-4f8c-bbd3-d358fe651ad1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_TransactionPrice_3ffb8f55-a0ee-4662-b6e5-f60131180ca7" xlink:href="alny-20210331.xsd#alny_TransactionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7048eedc-d1c7-4f8c-bbd3-d358fe651ad1" xlink:to="loc_alny_TransactionPrice_3ffb8f55-a0ee-4662-b6e5-f60131180ca7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_f626abf5-dd44-4a36-b9f1-805d0fec8b6c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7048eedc-d1c7-4f8c-bbd3-d358fe651ad1" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_f626abf5-dd44-4a36-b9f1-805d0fec8b6c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_80569428-80e3-485c-b5e1-07457a8cdee4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7048eedc-d1c7-4f8c-bbd3-d358fe651ad1" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_80569428-80e3-485c-b5e1-07457a8cdee4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_1d83b2ff-ffaf-4519-ad44-84a590fe8496" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_80569428-80e3-485c-b5e1-07457a8cdee4" xlink:to="loc_srt_ProductOrServiceAxis_1d83b2ff-ffaf-4519-ad44-84a590fe8496" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_1d83b2ff-ffaf-4519-ad44-84a590fe8496_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_1d83b2ff-ffaf-4519-ad44-84a590fe8496" xlink:to="loc_srt_ProductsAndServicesDomain_1d83b2ff-ffaf-4519-ad44-84a590fe8496_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_96cbab5b-a80c-4d6c-836c-99020f014bd0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_1d83b2ff-ffaf-4519-ad44-84a590fe8496" xlink:to="loc_srt_ProductsAndServicesDomain_96cbab5b-a80c-4d6c-836c-99020f014bd0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_ResearchServicesObligationMember_01645191-41b5-435d-b816-6bbdfc5fd42f" xlink:href="alny-20210331.xsd#alny_ResearchServicesObligationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_96cbab5b-a80c-4d6c-836c-99020f014bd0" xlink:to="loc_alny_ResearchServicesObligationMember_01645191-41b5-435d-b816-6bbdfc5fd42f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_C5LicenseObligationMember_21b51b2c-329a-4310-8d58-dbc906b6d262" xlink:href="alny-20210331.xsd#alny_C5LicenseObligationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_96cbab5b-a80c-4d6c-836c-99020f014bd0" xlink:to="loc_alny_C5LicenseObligationMember_21b51b2c-329a-4310-8d58-dbc906b6d262" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_C5CoCoObligationMember_528b667f-f98e-4e60-a24e-ee1f231fcaac" xlink:href="alny-20210331.xsd#alny_C5CoCoObligationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_96cbab5b-a80c-4d6c-836c-99020f014bd0" xlink:to="loc_alny_C5CoCoObligationMember_528b667f-f98e-4e60-a24e-ee1f231fcaac" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_9f862c90-c977-46c0-9b25-47ef6a56b08d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_80569428-80e3-485c-b5e1-07457a8cdee4" xlink:to="loc_us-gaap_TypeOfArrangementAxis_9f862c90-c977-46c0-9b25-47ef6a56b08d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9f862c90-c977-46c0-9b25-47ef6a56b08d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_9f862c90-c977-46c0-9b25-47ef6a56b08d" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9f862c90-c977-46c0-9b25-47ef6a56b08d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c9e4b349-0c70-4e0b-8b26-f53168e2c616" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_9f862c90-c977-46c0-9b25-47ef6a56b08d" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c9e4b349-0c70-4e0b-8b26-f53168e2c616" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_GlobalStrategicCollaborationMember_2806c656-b68f-45a2-bee4-50719fc899fe" xlink:href="alny-20210331.xsd#alny_GlobalStrategicCollaborationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c9e4b349-0c70-4e0b-8b26-f53168e2c616" xlink:to="loc_alny_GlobalStrategicCollaborationMember_2806c656-b68f-45a2-bee4-50719fc899fe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_0e2e567d-b757-498e-92e0-2e439a9e7e9b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_80569428-80e3-485c-b5e1-07457a8cdee4" xlink:to="loc_srt_CounterpartyNameAxis_0e2e567d-b757-498e-92e0-2e439a9e7e9b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0e2e567d-b757-498e-92e0-2e439a9e7e9b_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_0e2e567d-b757-498e-92e0-2e439a9e7e9b" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0e2e567d-b757-498e-92e0-2e439a9e7e9b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_93b11caf-e8fc-469a-b963-9b3114f33114" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_0e2e567d-b757-498e-92e0-2e439a9e7e9b" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_93b11caf-e8fc-469a-b963-9b3114f33114" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_RegeneronPharmaceuticalsIncorporationMember_1e316100-541a-45ae-9efa-1da07aa00848" xlink:href="alny-20210331.xsd#alny_RegeneronPharmaceuticalsIncorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_93b11caf-e8fc-469a-b963-9b3114f33114" xlink:to="loc_alny_RegeneronPharmaceuticalsIncorporationMember_1e316100-541a-45ae-9efa-1da07aa00848" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofRevenueRecognizedbyAccountingGuidanceDetails" xlink:type="simple" xlink:href="alny-20210331.xsd#NETREVENUESFROMCOLLABORATIONSScheduleofRevenueRecognizedbyAccountingGuidanceDetails"/>
  <link:definitionLink xlink:role="http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofRevenueRecognizedbyAccountingGuidanceDetails" xlink:type="extended" id="i16282b0207144f2a8330290800b7e916_NETREVENUESFROMCOLLABORATIONSScheduleofRevenueRecognizedbyAccountingGuidanceDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cdf662e5-129b-4c6c-be5d-d88cb5fd6863" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_56df583b-a08e-4453-b5f3-4e5dbe379774" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cdf662e5-129b-4c6c-be5d-d88cb5fd6863" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_56df583b-a08e-4453-b5f3-4e5dbe379774" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_a80f15bc-f9e5-4aab-aa5b-1c894f3ed656" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cdf662e5-129b-4c6c-be5d-d88cb5fd6863" xlink:to="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_a80f15bc-f9e5-4aab-aa5b-1c894f3ed656" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_435db2a7-3280-439e-9bc1-abf8fa5b1185" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cdf662e5-129b-4c6c-be5d-d88cb5fd6863" xlink:to="loc_us-gaap_Revenues_435db2a7-3280-439e-9bc1-abf8fa5b1185" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e3991b38-b31d-47ee-81ed-8f461b24fbe0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cdf662e5-129b-4c6c-be5d-d88cb5fd6863" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e3991b38-b31d-47ee-81ed-8f461b24fbe0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_4674162f-f822-43eb-92a9-a00b79601c7c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e3991b38-b31d-47ee-81ed-8f461b24fbe0" xlink:to="loc_srt_CounterpartyNameAxis_4674162f-f822-43eb-92a9-a00b79601c7c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4674162f-f822-43eb-92a9-a00b79601c7c_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_4674162f-f822-43eb-92a9-a00b79601c7c" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4674162f-f822-43eb-92a9-a00b79601c7c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8e9fb0f1-51d8-4b52-a0a7-c82192870323" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_4674162f-f822-43eb-92a9-a00b79601c7c" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8e9fb0f1-51d8-4b52-a0a7-c82192870323" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_RegeneronPharmaceuticalsIncorporationMember_c019f6d6-45d8-46f8-8f73-7646e6ea6921" xlink:href="alny-20210331.xsd#alny_RegeneronPharmaceuticalsIncorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8e9fb0f1-51d8-4b52-a0a7-c82192870323" xlink:to="loc_alny_RegeneronPharmaceuticalsIncorporationMember_c019f6d6-45d8-46f8-8f73-7646e6ea6921" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_81edf8e9-9da7-48ff-895c-938d1182f83b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e3991b38-b31d-47ee-81ed-8f461b24fbe0" xlink:to="loc_srt_ProductOrServiceAxis_81edf8e9-9da7-48ff-895c-938d1182f83b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_81edf8e9-9da7-48ff-895c-938d1182f83b_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_81edf8e9-9da7-48ff-895c-938d1182f83b" xlink:to="loc_srt_ProductsAndServicesDomain_81edf8e9-9da7-48ff-895c-938d1182f83b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_def557d1-963e-4e6c-a8a6-d34abfa4fe3a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_81edf8e9-9da7-48ff-895c-938d1182f83b" xlink:to="loc_srt_ProductsAndServicesDomain_def557d1-963e-4e6c-a8a6-d34abfa4fe3a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_ResearchServicesObligationMember_4350c062-9482-4cd1-ad19-a0fdd5e83dfd" xlink:href="alny-20210331.xsd#alny_ResearchServicesObligationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_def557d1-963e-4e6c-a8a6-d34abfa4fe3a" xlink:to="loc_alny_ResearchServicesObligationMember_4350c062-9482-4cd1-ad19-a0fdd5e83dfd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_C5LicenseObligationMember_3a2c9001-6948-4f3b-b53e-f804c0ea215e" xlink:href="alny-20210331.xsd#alny_C5LicenseObligationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_def557d1-963e-4e6c-a8a6-d34abfa4fe3a" xlink:to="loc_alny_C5LicenseObligationMember_3a2c9001-6948-4f3b-b53e-f804c0ea215e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_C5CoCoObligationMember_44eaeae0-d7d4-4171-87d6-6baf5fd2686b" xlink:href="alny-20210331.xsd#alny_C5CoCoObligationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_def557d1-963e-4e6c-a8a6-d34abfa4fe3a" xlink:to="loc_alny_C5CoCoObligationMember_44eaeae0-d7d4-4171-87d6-6baf5fd2686b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_be3bcc08-e671-4884-bbf8-83ef7177754a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e3991b38-b31d-47ee-81ed-8f461b24fbe0" xlink:to="loc_us-gaap_TypeOfArrangementAxis_be3bcc08-e671-4884-bbf8-83ef7177754a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_be3bcc08-e671-4884-bbf8-83ef7177754a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_be3bcc08-e671-4884-bbf8-83ef7177754a" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_be3bcc08-e671-4884-bbf8-83ef7177754a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_54f45078-5785-490c-959e-997ae42e4aac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_be3bcc08-e671-4884-bbf8-83ef7177754a" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_54f45078-5785-490c-959e-997ae42e4aac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_GlobalStrategicCollaborationMember_18bc879a-1aab-45a8-aac6-e38b3740ed12" xlink:href="alny-20210331.xsd#alny_GlobalStrategicCollaborationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_54f45078-5785-490c-959e-997ae42e4aac" xlink:to="loc_alny_GlobalStrategicCollaborationMember_18bc879a-1aab-45a8-aac6-e38b3740ed12" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/LIABILITYRELATEDTOTHESALEOFFUTUREROYALTIES" xlink:type="simple" xlink:href="alny-20210331.xsd#LIABILITYRELATEDTOTHESALEOFFUTUREROYALTIES"/>
  <link:definitionLink xlink:role="http://www.alnylam.com/role/LIABILITYRELATEDTOTHESALEOFFUTUREROYALTIES" xlink:type="extended" id="ia9bf8f1b16b343efa5adbe36ab90dcfa_LIABILITYRELATEDTOTHESALEOFFUTUREROYALTIES"/>
  <link:roleRef roleURI="http://www.alnylam.com/role/LIABILITYRELATEDTOTHESALEOFFUTUREROYALTIESTables" xlink:type="simple" xlink:href="alny-20210331.xsd#LIABILITYRELATEDTOTHESALEOFFUTUREROYALTIESTables"/>
  <link:definitionLink xlink:role="http://www.alnylam.com/role/LIABILITYRELATEDTOTHESALEOFFUTUREROYALTIESTables" xlink:type="extended" id="i87774a1c25a84039a35b238866d6143e_LIABILITYRELATEDTOTHESALEOFFUTUREROYALTIESTables"/>
  <link:roleRef roleURI="http://www.alnylam.com/role/LIABILITYRELATEDTOTHESALEOFFUTUREROYALTIESDetails" xlink:type="simple" xlink:href="alny-20210331.xsd#LIABILITYRELATEDTOTHESALEOFFUTUREROYALTIESDetails"/>
  <link:definitionLink xlink:role="http://www.alnylam.com/role/LIABILITYRELATEDTOTHESALEOFFUTUREROYALTIESDetails" xlink:type="extended" id="i65bc6e719f1d42908a88d881445d31c4_LIABILITYRELATEDTOTHESALEOFFUTUREROYALTIESDetails">
    <link:loc xlink:type="locator" xlink:label="loc_alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesLineItemsLineItems_7c1200b1-8945-4f2d-bb3c-5c770fb941ef" xlink:href="alny-20210331.xsd#alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesLineItemsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_CollaborativeArrangementRoyaltiesAndCommercialMilestonesAcquiredByCollaboratorPercent_35234c28-5ee8-4e59-b66c-b0b87c3712ed" xlink:href="alny-20210331.xsd#alny_CollaborativeArrangementRoyaltiesAndCommercialMilestonesAcquiredByCollaboratorPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesLineItemsLineItems_7c1200b1-8945-4f2d-bb3c-5c770fb941ef" xlink:to="loc_alny_CollaborativeArrangementRoyaltiesAndCommercialMilestonesAcquiredByCollaboratorPercent_35234c28-5ee8-4e59-b66c-b0b87c3712ed" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_CollaborativeArrangementCommercialMilestonesAcquiredByCollaboratorPercent_a4de1835-6a4e-4331-98f4-5a5f4ec324b4" xlink:href="alny-20210331.xsd#alny_CollaborativeArrangementCommercialMilestonesAcquiredByCollaboratorPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesLineItemsLineItems_7c1200b1-8945-4f2d-bb3c-5c770fb941ef" xlink:to="loc_alny_CollaborativeArrangementCommercialMilestonesAcquiredByCollaboratorPercent_a4de1835-6a4e-4331-98f4-5a5f4ec324b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_ExpectedRoyaltyInterestPayments_89ee46c9-2572-4038-861f-c68d0a3db641" xlink:href="alny-20210331.xsd#alny_ExpectedRoyaltyInterestPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesLineItemsLineItems_7c1200b1-8945-4f2d-bb3c-5c770fb941ef" xlink:to="loc_alny_ExpectedRoyaltyInterestPayments_89ee46c9-2572-4038-861f-c68d0a3db641" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_CollaborativeArrangementConsiderationReceived_a067c4d7-4d4e-4c32-a3e9-ae8616d79540" xlink:href="alny-20210331.xsd#alny_CollaborativeArrangementConsiderationReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesLineItemsLineItems_7c1200b1-8945-4f2d-bb3c-5c770fb941ef" xlink:to="loc_alny_CollaborativeArrangementConsiderationReceived_a067c4d7-4d4e-4c32-a3e9-ae8616d79540" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_RoyaltiesReceivableCurrent_8265a8de-386f-4d72-8866-6e70b14c10a2" xlink:href="alny-20210331.xsd#alny_RoyaltiesReceivableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesLineItemsLineItems_7c1200b1-8945-4f2d-bb3c-5c770fb941ef" xlink:to="loc_alny_RoyaltiesReceivableCurrent_8265a8de-386f-4d72-8866-6e70b14c10a2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_RoyaltyLiabilityNoncurrent_ca0c6ef2-0208-4aa8-9608-7579560df349" xlink:href="alny-20210331.xsd#alny_RoyaltyLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesLineItemsLineItems_7c1200b1-8945-4f2d-bb3c-5c770fb941ef" xlink:to="loc_alny_RoyaltyLiabilityNoncurrent_ca0c6ef2-0208-4aa8-9608-7579560df349" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_RoyaltyLiabilityInterestRate_2097e384-7508-4afd-a665-53d5e0c01ecd" xlink:href="alny-20210331.xsd#alny_RoyaltyLiabilityInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesLineItemsLineItems_7c1200b1-8945-4f2d-bb3c-5c770fb941ef" xlink:to="loc_alny_RoyaltyLiabilityInterestRate_2097e384-7508-4afd-a665-53d5e0c01ecd" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_RoyaltyLiabilityClosingCosts_82f2af17-671e-40fa-95ef-94b432031bcf" xlink:href="alny-20210331.xsd#alny_RoyaltyLiabilityClosingCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesLineItemsLineItems_7c1200b1-8945-4f2d-bb3c-5c770fb941ef" xlink:to="loc_alny_RoyaltyLiabilityClosingCosts_82f2af17-671e-40fa-95ef-94b432031bcf" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_RoyaltyLiabilityInterestExpenseIncludingAmortizationOfClosingCosts_1e4eaba4-19ab-4db7-9583-526289c67153" xlink:href="alny-20210331.xsd#alny_RoyaltyLiabilityInterestExpenseIncludingAmortizationOfClosingCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesLineItemsLineItems_7c1200b1-8945-4f2d-bb3c-5c770fb941ef" xlink:to="loc_alny_RoyaltyLiabilityInterestExpenseIncludingAmortizationOfClosingCosts_1e4eaba4-19ab-4db7-9583-526289c67153" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesTable_a9b4b40e-4344-497e-abf8-b1738668c038" xlink:href="alny-20210331.xsd#alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesLineItemsLineItems_7c1200b1-8945-4f2d-bb3c-5c770fb941ef" xlink:to="loc_alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesTable_a9b4b40e-4344-497e-abf8-b1738668c038" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_11ceadd1-157d-44e5-912f-8e1e6877db30" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesTable_a9b4b40e-4344-497e-abf8-b1738668c038" xlink:to="loc_srt_StatementScenarioAxis_11ceadd1-157d-44e5-912f-8e1e6877db30" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_11ceadd1-157d-44e5-912f-8e1e6877db30_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_11ceadd1-157d-44e5-912f-8e1e6877db30" xlink:to="loc_srt_ScenarioUnspecifiedDomain_11ceadd1-157d-44e5-912f-8e1e6877db30_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_8dd7e7fd-56ab-43f5-b9d5-fbc468a87ccf" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_11ceadd1-157d-44e5-912f-8e1e6877db30" xlink:to="loc_srt_ScenarioUnspecifiedDomain_8dd7e7fd-56ab-43f5-b9d5-fbc468a87ccf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_4b9f0b97-ce65-403f-bdda-65b7cd9e9c80" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_8dd7e7fd-56ab-43f5-b9d5-fbc468a87ccf" xlink:to="loc_srt_ScenarioForecastMember_4b9f0b97-ce65-403f-bdda-65b7cd9e9c80" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_f4cdb6fe-40d1-47e4-9ea4-ec3a2f92231c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesTable_a9b4b40e-4344-497e-abf8-b1738668c038" xlink:to="loc_srt_CounterpartyNameAxis_f4cdb6fe-40d1-47e4-9ea4-ec3a2f92231c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f4cdb6fe-40d1-47e4-9ea4-ec3a2f92231c_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_f4cdb6fe-40d1-47e4-9ea4-ec3a2f92231c" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f4cdb6fe-40d1-47e4-9ea4-ec3a2f92231c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5a0552fa-8180-45dd-80b4-6a0802bd99af" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_f4cdb6fe-40d1-47e4-9ea4-ec3a2f92231c" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5a0552fa-8180-45dd-80b4-6a0802bd99af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_BlackstoneGroupIncMember_19ac8574-a172-42f1-b260-e291b23c8dca" xlink:href="alny-20210331.xsd#alny_BlackstoneGroupIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5a0552fa-8180-45dd-80b4-6a0802bd99af" xlink:to="loc_alny_BlackstoneGroupIncMember_19ac8574-a172-42f1-b260-e291b23c8dca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_a4ba3c41-52e4-4f34-806c-b625d6b5f79b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesTable_a9b4b40e-4344-497e-abf8-b1738668c038" xlink:to="loc_us-gaap_TypeOfArrangementAxis_a4ba3c41-52e4-4f34-806c-b625d6b5f79b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a4ba3c41-52e4-4f34-806c-b625d6b5f79b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_a4ba3c41-52e4-4f34-806c-b625d6b5f79b" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a4ba3c41-52e4-4f34-806c-b625d6b5f79b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5b9f9693-dd72-4143-ae47-8ffda80c8e65" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_a4ba3c41-52e4-4f34-806c-b625d6b5f79b" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5b9f9693-dd72-4143-ae47-8ffda80c8e65" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_f27aa328-62f9-4b52-b0cc-d5d7777865e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5b9f9693-dd72-4143-ae47-8ffda80c8e65" xlink:to="loc_us-gaap_CollaborativeArrangementMember_f27aa328-62f9-4b52-b0cc-d5d7777865e9" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/FAIRVALUEMEASUREMENTS" xlink:type="simple" xlink:href="alny-20210331.xsd#FAIRVALUEMEASUREMENTS"/>
  <link:definitionLink xlink:role="http://www.alnylam.com/role/FAIRVALUEMEASUREMENTS" xlink:type="extended" id="i29f6048268474aa2ad18f0a0853772a6_FAIRVALUEMEASUREMENTS"/>
  <link:roleRef roleURI="http://www.alnylam.com/role/FAIRVALUEMEASUREMENTSTables" xlink:type="simple" xlink:href="alny-20210331.xsd#FAIRVALUEMEASUREMENTSTables"/>
  <link:definitionLink xlink:role="http://www.alnylam.com/role/FAIRVALUEMEASUREMENTSTables" xlink:type="extended" id="ia770f536853744ddaf892401efcd4850_FAIRVALUEMEASUREMENTSTables"/>
  <link:roleRef roleURI="http://www.alnylam.com/role/FAIRVALUEMEASUREMENTSFairValueofAssetsMeasuredonaRecurringBasisDetail" xlink:type="simple" xlink:href="alny-20210331.xsd#FAIRVALUEMEASUREMENTSFairValueofAssetsMeasuredonaRecurringBasisDetail"/>
  <link:definitionLink xlink:role="http://www.alnylam.com/role/FAIRVALUEMEASUREMENTSFairValueofAssetsMeasuredonaRecurringBasisDetail" xlink:type="extended" id="iaaa2e299b8524cf09db42d6cbf11e4d6_FAIRVALUEMEASUREMENTSFairValueofAssetsMeasuredonaRecurringBasisDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0adcf9be-ea4f-4d67-8d48-176d03ba04d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_7496231d-bf9d-48f5-a3e2-2762306a2e19" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0adcf9be-ea4f-4d67-8d48-176d03ba04d7" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_7496231d-bf9d-48f5-a3e2-2762306a2e19" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_301e60f3-fd83-4e31-9514-f2800d9ec788" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_7496231d-bf9d-48f5-a3e2-2762306a2e19" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_301e60f3-fd83-4e31-9514-f2800d9ec788" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_95778560-7b65-46bf-86bb-8a53e37aa6e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_7496231d-bf9d-48f5-a3e2-2762306a2e19" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_95778560-7b65-46bf-86bb-8a53e37aa6e0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_75c8170f-9d87-425f-a17d-7a5ed1c62852" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_7496231d-bf9d-48f5-a3e2-2762306a2e19" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_75c8170f-9d87-425f-a17d-7a5ed1c62852" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_34fd3579-47f1-4e18-8a8e-e9b948f80e92" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_7496231d-bf9d-48f5-a3e2-2762306a2e19" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_34fd3579-47f1-4e18-8a8e-e9b948f80e92" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_2af920d6-60f4-4952-91c7-92a11827b1a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_7496231d-bf9d-48f5-a3e2-2762306a2e19" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_2af920d6-60f4-4952-91c7-92a11827b1a2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_b4c6157a-7b3d-4059-9b21-cc563ef96ef6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0adcf9be-ea4f-4d67-8d48-176d03ba04d7" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_b4c6157a-7b3d-4059-9b21-cc563ef96ef6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_6f8a2499-714e-42e3-ab70-557d6717f181" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_b4c6157a-7b3d-4059-9b21-cc563ef96ef6" xlink:to="loc_us-gaap_DerivativeLiabilities_6f8a2499-714e-42e3-ab70-557d6717f181" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7b319b21-0520-4149-b865-19a9a7775397" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0adcf9be-ea4f-4d67-8d48-176d03ba04d7" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7b319b21-0520-4149-b865-19a9a7775397" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_00a1dabc-4a52-49f7-97dc-31b76db5d91f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7b319b21-0520-4149-b865-19a9a7775397" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_00a1dabc-4a52-49f7-97dc-31b76db5d91f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_00a1dabc-4a52-49f7-97dc-31b76db5d91f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_00a1dabc-4a52-49f7-97dc-31b76db5d91f" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_00a1dabc-4a52-49f7-97dc-31b76db5d91f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_1ca68652-a470-486f-bc39-5157612c4ba6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_00a1dabc-4a52-49f7-97dc-31b76db5d91f" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_1ca68652-a470-486f-bc39-5157612c4ba6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_a7e640c9-4473-4af5-99cc-2162ee5d4954" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_1ca68652-a470-486f-bc39-5157612c4ba6" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_a7e640c9-4473-4af5-99cc-2162ee5d4954" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_86650bd2-52d2-4f0c-92ae-902832d8aea9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7b319b21-0520-4149-b865-19a9a7775397" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_86650bd2-52d2-4f0c-92ae-902832d8aea9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_86650bd2-52d2-4f0c-92ae-902832d8aea9_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_86650bd2-52d2-4f0c-92ae-902832d8aea9" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_86650bd2-52d2-4f0c-92ae-902832d8aea9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_b5a398c5-0fe2-4673-b928-499f393eb8fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_86650bd2-52d2-4f0c-92ae-902832d8aea9" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_b5a398c5-0fe2-4673-b928-499f393eb8fd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_c9a22073-9ddf-478d-939c-53d30a7b7225" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_b5a398c5-0fe2-4673-b928-499f393eb8fd" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_c9a22073-9ddf-478d-939c-53d30a7b7225" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_934fcd6b-8139-49e0-8c6f-891d74566812" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_b5a398c5-0fe2-4673-b928-499f393eb8fd" xlink:to="loc_us-gaap_MoneyMarketFundsMember_934fcd6b-8139-49e0-8c6f-891d74566812" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_638b80db-9c8b-4b6b-8939-279f86ea0a13" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_b5a398c5-0fe2-4673-b928-499f393eb8fd" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_638b80db-9c8b-4b6b-8939-279f86ea0a13" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6bc75c70-c8da-4494-874b-b690a2b9640c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7b319b21-0520-4149-b865-19a9a7775397" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6bc75c70-c8da-4494-874b-b690a2b9640c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6bc75c70-c8da-4494-874b-b690a2b9640c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6bc75c70-c8da-4494-874b-b690a2b9640c" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6bc75c70-c8da-4494-874b-b690a2b9640c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_182311d8-1320-472b-9cf8-8a2b70aee0b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6bc75c70-c8da-4494-874b-b690a2b9640c" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_182311d8-1320-472b-9cf8-8a2b70aee0b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_fa21ed84-ad9a-4c2f-b8da-0fe5be1ffcd3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_182311d8-1320-472b-9cf8-8a2b70aee0b0" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_fa21ed84-ad9a-4c2f-b8da-0fe5be1ffcd3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_c673b796-b552-4666-b201-bb04ccfb5329" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_182311d8-1320-472b-9cf8-8a2b70aee0b0" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_c673b796-b552-4666-b201-bb04ccfb5329" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_cc936e9d-cc27-4f07-8cef-1a206e7fe7ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_182311d8-1320-472b-9cf8-8a2b70aee0b0" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_cc936e9d-cc27-4f07-8cef-1a206e7fe7ea" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/MARKETABLEDEBTSECURITIES" xlink:type="simple" xlink:href="alny-20210331.xsd#MARKETABLEDEBTSECURITIES"/>
  <link:definitionLink xlink:role="http://www.alnylam.com/role/MARKETABLEDEBTSECURITIES" xlink:type="extended" id="i67b160685c5a44708e24ed56536dcc19_MARKETABLEDEBTSECURITIES"/>
  <link:roleRef roleURI="http://www.alnylam.com/role/MARKETABLEDEBTSECURITIESTables" xlink:type="simple" xlink:href="alny-20210331.xsd#MARKETABLEDEBTSECURITIESTables"/>
  <link:definitionLink xlink:role="http://www.alnylam.com/role/MARKETABLEDEBTSECURITIESTables" xlink:type="extended" id="i5a2cc87f3ff54d67b0baecb82f6fefdd_MARKETABLEDEBTSECURITIESTables"/>
  <link:roleRef roleURI="http://www.alnylam.com/role/MARKETABLEDEBTSECURITIESAdditionalInformationDetail" xlink:type="simple" xlink:href="alny-20210331.xsd#MARKETABLEDEBTSECURITIESAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.alnylam.com/role/MARKETABLEDEBTSECURITIESAdditionalInformationDetail" xlink:type="extended" id="ib1bc34b7fc04459dbaec56c8745f9197_MARKETABLEDEBTSECURITIESAdditionalInformationDetail"/>
  <link:roleRef roleURI="http://www.alnylam.com/role/MARKETABLEDEBTSECURITIESSummaryofMarketableDebtSecuritiesDetail" xlink:type="simple" xlink:href="alny-20210331.xsd#MARKETABLEDEBTSECURITIESSummaryofMarketableDebtSecuritiesDetail"/>
  <link:definitionLink xlink:role="http://www.alnylam.com/role/MARKETABLEDEBTSECURITIESSummaryofMarketableDebtSecuritiesDetail" xlink:type="extended" id="if8fd6d01b8c8465b8a166252a5d82a28_MARKETABLEDEBTSECURITIESSummaryofMarketableDebtSecuritiesDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e5419dba-1919-4642-8338-60060d3732ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_2a2eec87-c91e-4eee-b934-ab8a6cd1c0a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e5419dba-1919-4642-8338-60060d3732ac" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_2a2eec87-c91e-4eee-b934-ab8a6cd1c0a1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_071d6819-c15e-46b8-ac0d-8e18242f639b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e5419dba-1919-4642-8338-60060d3732ac" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_071d6819-c15e-46b8-ac0d-8e18242f639b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_be2ebfd3-daa8-41c3-90ec-818130c16c72" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e5419dba-1919-4642-8338-60060d3732ac" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_be2ebfd3-daa8-41c3-90ec-818130c16c72" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c1a09ed8-b893-46d9-a361-f4e0e612489c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e5419dba-1919-4642-8338-60060d3732ac" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c1a09ed8-b893-46d9-a361-f4e0e612489c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_b723177e-526f-41e2-a4be-7d275156db05" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e5419dba-1919-4642-8338-60060d3732ac" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_b723177e-526f-41e2-a4be-7d275156db05" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_7ed263fc-36b4-4949-b415-29db32535b37" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_b723177e-526f-41e2-a4be-7d275156db05" xlink:to="loc_us-gaap_FinancialInstrumentAxis_7ed263fc-36b4-4949-b415-29db32535b37" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7ed263fc-36b4-4949-b415-29db32535b37_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_7ed263fc-36b4-4949-b415-29db32535b37" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7ed263fc-36b4-4949-b415-29db32535b37_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_aa78d52c-27b0-4c9e-a5d0-23f657522d8a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_7ed263fc-36b4-4949-b415-29db32535b37" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_aa78d52c-27b0-4c9e-a5d0-23f657522d8a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_14fdeb3a-d802-4b9a-b471-c3b101467ba2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_aa78d52c-27b0-4c9e-a5d0-23f657522d8a" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_14fdeb3a-d802-4b9a-b471-c3b101467ba2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_035b6dee-d146-4bd3-b1e0-583208de2856" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_aa78d52c-27b0-4c9e-a5d0-23f657522d8a" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_035b6dee-d146-4bd3-b1e0-583208de2856" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/MARKETABLEDEBTSECURITIESSummaryofFairValueofMarketableDebtSecuritiesDetail" xlink:type="simple" xlink:href="alny-20210331.xsd#MARKETABLEDEBTSECURITIESSummaryofFairValueofMarketableDebtSecuritiesDetail"/>
  <link:definitionLink xlink:role="http://www.alnylam.com/role/MARKETABLEDEBTSECURITIESSummaryofFairValueofMarketableDebtSecuritiesDetail" xlink:type="extended" id="ibd6d8291cc1d427c945f86843947aa3f_MARKETABLEDEBTSECURITIESSummaryofFairValueofMarketableDebtSecuritiesDetail"/>
  <link:roleRef roleURI="http://www.alnylam.com/role/OTHERBALANCESHEETDETAILS" xlink:type="simple" xlink:href="alny-20210331.xsd#OTHERBALANCESHEETDETAILS"/>
  <link:definitionLink xlink:role="http://www.alnylam.com/role/OTHERBALANCESHEETDETAILS" xlink:type="extended" id="i21507fb1358345949585dbe6c9874722_OTHERBALANCESHEETDETAILS"/>
  <link:roleRef roleURI="http://www.alnylam.com/role/OTHERBALANCESHEETDETAILSTables" xlink:type="simple" xlink:href="alny-20210331.xsd#OTHERBALANCESHEETDETAILSTables"/>
  <link:definitionLink xlink:role="http://www.alnylam.com/role/OTHERBALANCESHEETDETAILSTables" xlink:type="extended" id="icecaa627c5fc43ec907aa56eed05e3c1_OTHERBALANCESHEETDETAILSTables"/>
  <link:roleRef roleURI="http://www.alnylam.com/role/OTHERBALANCESHEETDETAILSScheduleofInventoryDetail" xlink:type="simple" xlink:href="alny-20210331.xsd#OTHERBALANCESHEETDETAILSScheduleofInventoryDetail"/>
  <link:definitionLink xlink:role="http://www.alnylam.com/role/OTHERBALANCESHEETDETAILSScheduleofInventoryDetail" xlink:type="extended" id="id61b201874a44035b43bdab473f6d572_OTHERBALANCESHEETDETAILSScheduleofInventoryDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems_fb2c0596-6b75-433e-a4b2-c4d0ee60343c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials_42f009e1-aecc-4500-9ee8-494c8f654dec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterials"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_fb2c0596-6b75-433e-a4b2-c4d0ee60343c" xlink:to="loc_us-gaap_InventoryRawMaterials_42f009e1-aecc-4500-9ee8-494c8f654dec" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess_a139f555-1458-4320-87e7-0fbb3b71174e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_fb2c0596-6b75-433e-a4b2-c4d0ee60343c" xlink:to="loc_us-gaap_InventoryWorkInProcess_a139f555-1458-4320-87e7-0fbb3b71174e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_f321b663-d4e7-4aa9-af91-b5db1de9cdb8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_fb2c0596-6b75-433e-a4b2-c4d0ee60343c" xlink:to="loc_us-gaap_InventoryFinishedGoods_f321b663-d4e7-4aa9-af91-b5db1de9cdb8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_InventoryCurrentAndNoncurrent_ce1ae97b-68a0-4ad2-a3ea-27fd0640e53c" xlink:href="alny-20210331.xsd#alny_InventoryCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_fb2c0596-6b75-433e-a4b2-c4d0ee60343c" xlink:to="loc_alny_InventoryCurrentAndNoncurrent_ce1ae97b-68a0-4ad2-a3ea-27fd0640e53c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_5b82bee6-cdc2-4701-884c-cb86961cbb23" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_fb2c0596-6b75-433e-a4b2-c4d0ee60343c" xlink:to="loc_us-gaap_InventoryNoncurrent_5b82bee6-cdc2-4701-884c-cb86961cbb23" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCurrentTable_5c45a65f-767a-4914-a2ea-58e04498f08c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryCurrentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_InventoryLineItems_fb2c0596-6b75-433e-a4b2-c4d0ee60343c" xlink:to="loc_us-gaap_InventoryCurrentTable_5c45a65f-767a-4914-a2ea-58e04498f08c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_f55e8d84-adbb-4bb8-bf60-afcdeef7a2e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_InventoryCurrentTable_5c45a65f-767a-4914-a2ea-58e04498f08c" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_f55e8d84-adbb-4bb8-bf60-afcdeef7a2e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_f55e8d84-adbb-4bb8-bf60-afcdeef7a2e7_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_f55e8d84-adbb-4bb8-bf60-afcdeef7a2e7" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_f55e8d84-adbb-4bb8-bf60-afcdeef7a2e7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_2aa43839-58bb-4697-9526-d105fae1f5c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_f55e8d84-adbb-4bb8-bf60-afcdeef7a2e7" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_2aa43839-58bb-4697-9526-d105fae1f5c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsMember_b3978047-6b78-421c-a74f-7a38ffeae804" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_2aa43839-58bb-4697-9526-d105fae1f5c1" xlink:to="loc_us-gaap_OtherAssetsMember_b3978047-6b78-421c-a74f-7a38ffeae804" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/OTHERBALANCESHEETDETAILSScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetail" xlink:type="simple" xlink:href="alny-20210331.xsd#OTHERBALANCESHEETDETAILSScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetail"/>
  <link:definitionLink xlink:role="http://www.alnylam.com/role/OTHERBALANCESHEETDETAILSScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetail" xlink:type="extended" id="iba321a6bd4bd47a194c1ab570ead62c8_OTHERBALANCESHEETDETAILSScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetail"/>
  <link:roleRef roleURI="http://www.alnylam.com/role/OTHERBALANCESHEETDETAILSSummaryofChangesinAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" xlink:href="alny-20210331.xsd#OTHERBALANCESHEETDETAILSSummaryofChangesinAccumulatedOtherComprehensiveIncomeLossDetails"/>
  <link:definitionLink xlink:role="http://www.alnylam.com/role/OTHERBALANCESHEETDETAILSSummaryofChangesinAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended" id="i83ef95ade1064de5bbc77f4f9cd20390_OTHERBALANCESHEETDETAILSSummaryofChangesinAccumulatedOtherComprehensiveIncomeLossDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_829131ff-8ba3-4f16-b910-f1f4df3f5334" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_71f20d54-e929-4e17-91c4-dc9a505b2217" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AOCIAttributableToParentNetOfTaxRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_829131ff-8ba3-4f16-b910-f1f4df3f5334" xlink:to="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_71f20d54-e929-4e17-91c4-dc9a505b2217" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_0c3c0b21-bd9a-42a0-97ae-f5705de6c3fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_71f20d54-e929-4e17-91c4-dc9a505b2217" xlink:to="loc_us-gaap_StockholdersEquity_0c3c0b21-bd9a-42a0-97ae-f5705de6c3fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_174263b5-d518-4095-97e1-585ffabf2d03" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_71f20d54-e929-4e17-91c4-dc9a505b2217" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_174263b5-d518-4095-97e1-585ffabf2d03" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_7c83541b-25a3-4f30-b547-3f6d435228b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_71f20d54-e929-4e17-91c4-dc9a505b2217" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_7c83541b-25a3-4f30-b547-3f6d435228b2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_bb005a54-c31f-4cc5-aa31-c5f1ebdbda17" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_71f20d54-e929-4e17-91c4-dc9a505b2217" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_bb005a54-c31f-4cc5-aa31-c5f1ebdbda17" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_4824d276-2ffe-41de-853c-18176fcfb255" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_de157ae7-f6a2-4907-8634-03a798d39e58" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_829131ff-8ba3-4f16-b910-f1f4df3f5334" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_de157ae7-f6a2-4907-8634-03a798d39e58" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_bb8cd6db-8bf7-47c6-b3a8-5eeb37862d84" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_de157ae7-f6a2-4907-8634-03a798d39e58" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_bb8cd6db-8bf7-47c6-b3a8-5eeb37862d84" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_bb8cd6db-8bf7-47c6-b3a8-5eeb37862d84_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_bb8cd6db-8bf7-47c6-b3a8-5eeb37862d84" xlink:to="loc_us-gaap_EquityComponentDomain_bb8cd6db-8bf7-47c6-b3a8-5eeb37862d84_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_dbb7b27a-3043-4f25-84ee-c2245060fe8c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_bb8cd6db-8bf7-47c6-b3a8-5eeb37862d84" xlink:to="loc_us-gaap_EquityComponentDomain_dbb7b27a-3043-4f25-84ee-c2245060fe8c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_AccumulatedLossOnInvestmentInJointVentureMember_14349ec9-ea5c-4156-b4a6-ae143b2ba997" xlink:href="alny-20210331.xsd#alny_AccumulatedLossOnInvestmentInJointVentureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_dbb7b27a-3043-4f25-84ee-c2245060fe8c" xlink:to="loc_alny_AccumulatedLossOnInvestmentInJointVentureMember_14349ec9-ea5c-4156-b4a6-ae143b2ba997" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_6d771043-0329-465d-af5e-6f1ad6d74167" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_dbb7b27a-3043-4f25-84ee-c2245060fe8c" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_6d771043-0329-465d-af5e-6f1ad6d74167" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_fcd76f17-38b7-4e59-892c-ea1890ce83b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_dbb7b27a-3043-4f25-84ee-c2245060fe8c" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_fcd76f17-38b7-4e59-892c-ea1890ce83b2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_4798e607-6c8c-40d2-a243-068c8af1329c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_dbb7b27a-3043-4f25-84ee-c2245060fe8c" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_4798e607-6c8c-40d2-a243-068c8af1329c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_5303469b-d001-4fcf-9181-3ac43e65d1e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_dbb7b27a-3043-4f25-84ee-c2245060fe8c" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_5303469b-d001-4fcf-9181-3ac43e65d1e7" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/CREDITAGREEMENT" xlink:type="simple" xlink:href="alny-20210331.xsd#CREDITAGREEMENT"/>
  <link:definitionLink xlink:role="http://www.alnylam.com/role/CREDITAGREEMENT" xlink:type="extended" id="i8253ebcd49a845dc8d655af2b3e49740_CREDITAGREEMENT"/>
  <link:roleRef roleURI="http://www.alnylam.com/role/CREDITAGREEMENTTables" xlink:type="simple" xlink:href="alny-20210331.xsd#CREDITAGREEMENTTables"/>
  <link:definitionLink xlink:role="http://www.alnylam.com/role/CREDITAGREEMENTTables" xlink:type="extended" id="i05cc7f6361c24fa8b41160b939da271d_CREDITAGREEMENTTables"/>
  <link:roleRef roleURI="http://www.alnylam.com/role/CREDITAGREEMENTAdditionalInformationDetails" xlink:type="simple" xlink:href="alny-20210331.xsd#CREDITAGREEMENTAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.alnylam.com/role/CREDITAGREEMENTAdditionalInformationDetails" xlink:type="extended" id="i0e94d148f8294f2fbedfcc3e89553139_CREDITAGREEMENTAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivableImpairedLineItems_298895ab-6979-4527-8208-a2e5629f5eeb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancingReceivableImpairedLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_DebtInstrumentNumberOfTranches_a205bb5e-7ced-4683-af13-a741c0af075a" xlink:href="alny-20210331.xsd#alny_DebtInstrumentNumberOfTranches"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancingReceivableImpairedLineItems_298895ab-6979-4527-8208-a2e5629f5eeb" xlink:to="loc_alny_DebtInstrumentNumberOfTranches_a205bb5e-7ced-4683-af13-a741c0af075a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_d5f69945-b1d2-4393-a1af-86bfb6643357" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancingReceivableImpairedLineItems_298895ab-6979-4527-8208-a2e5629f5eeb" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_d5f69945-b1d2-4393-a1af-86bfb6643357" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLinesOfCredit_87cd29e7-b58b-40c6-91c8-0340fd615054" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancingReceivableImpairedLineItems_298895ab-6979-4527-8208-a2e5629f5eeb" xlink:to="loc_us-gaap_ProceedsFromLinesOfCredit_87cd29e7-b58b-40c6-91c8-0340fd615054" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_b4956814-aff4-4f79-9c5d-ffcfa1229a9f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancingReceivableImpairedLineItems_298895ab-6979-4527-8208-a2e5629f5eeb" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_b4956814-aff4-4f79-9c5d-ffcfa1229a9f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_LineOfCreditFacilityMaximumBorrowingCapacityAccordionFeature_4eeb51dc-dcc4-472e-aad1-4f75d268ccb6" xlink:href="alny-20210331.xsd#alny_LineOfCreditFacilityMaximumBorrowingCapacityAccordionFeature"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancingReceivableImpairedLineItems_298895ab-6979-4527-8208-a2e5629f5eeb" xlink:to="loc_alny_LineOfCreditFacilityMaximumBorrowingCapacityAccordionFeature_4eeb51dc-dcc4-472e-aad1-4f75d268ccb6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_DebtInstrumentCovenantTermsMinimumProductRevenue_f0bf2074-67e5-4839-a4f2-b9aa6f13676c" xlink:href="alny-20210331.xsd#alny_DebtInstrumentCovenantTermsMinimumProductRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancingReceivableImpairedLineItems_298895ab-6979-4527-8208-a2e5629f5eeb" xlink:to="loc_alny_DebtInstrumentCovenantTermsMinimumProductRevenue_f0bf2074-67e5-4839-a4f2-b9aa6f13676c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_b7c5bcfa-3c1b-42eb-a237-4e36b78bd1b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancingReceivableImpairedLineItems_298895ab-6979-4527-8208-a2e5629f5eeb" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_b7c5bcfa-3c1b-42eb-a237-4e36b78bd1b3" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_228485be-ed49-47a5-9b38-35e16596ba5b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancingReceivableImpairedLineItems_298895ab-6979-4527-8208-a2e5629f5eeb" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_228485be-ed49-47a5-9b38-35e16596ba5b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_DebtInstrumentInterestInKindInterestRateIncrease_f51ef462-f3d8-4c45-8f19-abfd9e560787" xlink:href="alny-20210331.xsd#alny_DebtInstrumentInterestInKindInterestRateIncrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancingReceivableImpairedLineItems_298895ab-6979-4527-8208-a2e5629f5eeb" xlink:to="loc_alny_DebtInstrumentInterestInKindInterestRateIncrease_f51ef462-f3d8-4c45-8f19-abfd9e560787" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeeAmount_f699a8bb-b0fc-448d-9316-54a1f9da03be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityCommitmentFeeAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancingReceivableImpairedLineItems_298895ab-6979-4527-8208-a2e5629f5eeb" xlink:to="loc_us-gaap_LineOfCreditFacilityCommitmentFeeAmount_f699a8bb-b0fc-448d-9316-54a1f9da03be" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_bf25cf66-0f11-427e-a266-61ea9ff93442" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancingReceivableImpairedLineItems_298895ab-6979-4527-8208-a2e5629f5eeb" xlink:to="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_bf25cf66-0f11-427e-a266-61ea9ff93442" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_DebtInstrumentExitFeePercent_1bdd1699-9630-4dce-b82b-32e83456ca03" xlink:href="alny-20210331.xsd#alny_DebtInstrumentExitFeePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancingReceivableImpairedLineItems_298895ab-6979-4527-8208-a2e5629f5eeb" xlink:to="loc_alny_DebtInstrumentExitFeePercent_1bdd1699-9630-4dce-b82b-32e83456ca03" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_LineOfCreditFacilityPrepaymentAndTerminationFeePercentage_58daee22-33a3-43ec-b279-2b7fe44929df" xlink:href="alny-20210331.xsd#alny_LineOfCreditFacilityPrepaymentAndTerminationFeePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancingReceivableImpairedLineItems_298895ab-6979-4527-8208-a2e5629f5eeb" xlink:to="loc_alny_LineOfCreditFacilityPrepaymentAndTerminationFeePercentage_58daee22-33a3-43ec-b279-2b7fe44929df" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_DebtInstrumentCovenantTermsMinimumConsolidatedLiquidity_db382871-29b2-4e6d-aa1d-93bf247e3007" xlink:href="alny-20210331.xsd#alny_DebtInstrumentCovenantTermsMinimumConsolidatedLiquidity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancingReceivableImpairedLineItems_298895ab-6979-4527-8208-a2e5629f5eeb" xlink:to="loc_alny_DebtInstrumentCovenantTermsMinimumConsolidatedLiquidity_db382871-29b2-4e6d-aa1d-93bf247e3007" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfImpairedFinancingReceivableTable_4d8b5a36-27c7-4bd1-bfda-eada4c9df8f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfImpairedFinancingReceivableTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FinancingReceivableImpairedLineItems_298895ab-6979-4527-8208-a2e5629f5eeb" xlink:to="loc_us-gaap_ScheduleOfImpairedFinancingReceivableTable_4d8b5a36-27c7-4bd1-bfda-eada4c9df8f1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_26793578-68fc-41b6-b3cc-887e8be1f8db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfImpairedFinancingReceivableTable_4d8b5a36-27c7-4bd1-bfda-eada4c9df8f1" xlink:to="loc_us-gaap_CreditFacilityAxis_26793578-68fc-41b6-b3cc-887e8be1f8db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_26793578-68fc-41b6-b3cc-887e8be1f8db_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_26793578-68fc-41b6-b3cc-887e8be1f8db" xlink:to="loc_us-gaap_CreditFacilityDomain_26793578-68fc-41b6-b3cc-887e8be1f8db_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_debeb6ac-e925-492f-92ef-45755b34be97" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_26793578-68fc-41b6-b3cc-887e8be1f8db" xlink:to="loc_us-gaap_CreditFacilityDomain_debeb6ac-e925-492f-92ef-45755b34be97" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_5d8571d2-237d-4499-8990-de41ac12abec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_debeb6ac-e925-492f-92ef-45755b34be97" xlink:to="loc_us-gaap_LineOfCreditMember_5d8571d2-237d-4499-8990-de41ac12abec" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_94174b8d-002f-45f0-8e0c-9bd5c48fc9a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfImpairedFinancingReceivableTable_4d8b5a36-27c7-4bd1-bfda-eada4c9df8f1" xlink:to="loc_us-gaap_DebtInstrumentAxis_94174b8d-002f-45f0-8e0c-9bd5c48fc9a1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_94174b8d-002f-45f0-8e0c-9bd5c48fc9a1_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_94174b8d-002f-45f0-8e0c-9bd5c48fc9a1" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_94174b8d-002f-45f0-8e0c-9bd5c48fc9a1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_ec3da683-686a-4bf4-84d9-487b88643e37" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_94174b8d-002f-45f0-8e0c-9bd5c48fc9a1" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_ec3da683-686a-4bf4-84d9-487b88643e37" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_TrancheTwoLoanMember_a767e3d4-b346-4f36-a9c2-221053ba3d5a" xlink:href="alny-20210331.xsd#alny_TrancheTwoLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_ec3da683-686a-4bf4-84d9-487b88643e37" xlink:to="loc_alny_TrancheTwoLoanMember_a767e3d4-b346-4f36-a9c2-221053ba3d5a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_TrancheThreeLoanMember_6b081467-4421-40c9-9d68-4ad3c1c87c89" xlink:href="alny-20210331.xsd#alny_TrancheThreeLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_ec3da683-686a-4bf4-84d9-487b88643e37" xlink:to="loc_alny_TrancheThreeLoanMember_6b081467-4421-40c9-9d68-4ad3c1c87c89" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_Tranche2LoanAndTranche3LoanMember_a3ab2281-9138-4238-97c7-f3a53273c5f6" xlink:href="alny-20210331.xsd#alny_Tranche2LoanAndTranche3LoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_ec3da683-686a-4bf4-84d9-487b88643e37" xlink:to="loc_alny_Tranche2LoanAndTranche3LoanMember_a3ab2281-9138-4238-97c7-f3a53273c5f6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_3c184ebf-90bc-43f0-8624-5a6621ac968d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfImpairedFinancingReceivableTable_4d8b5a36-27c7-4bd1-bfda-eada4c9df8f1" xlink:to="loc_srt_ProductOrServiceAxis_3c184ebf-90bc-43f0-8624-5a6621ac968d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_3c184ebf-90bc-43f0-8624-5a6621ac968d_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_3c184ebf-90bc-43f0-8624-5a6621ac968d" xlink:to="loc_srt_ProductsAndServicesDomain_3c184ebf-90bc-43f0-8624-5a6621ac968d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_eedc375e-8cf8-415b-8279-826aa87042c8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_3c184ebf-90bc-43f0-8624-5a6621ac968d" xlink:to="loc_srt_ProductsAndServicesDomain_eedc375e-8cf8-415b-8279-826aa87042c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_ONPATTROAndGIVLAARIMember_395205a3-2370-4e7e-8316-7559b932048a" xlink:href="alny-20210331.xsd#alny_ONPATTROAndGIVLAARIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_eedc375e-8cf8-415b-8279-826aa87042c8" xlink:to="loc_alny_ONPATTROAndGIVLAARIMember_395205a3-2370-4e7e-8316-7559b932048a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_98b32d9f-0357-48ce-aff7-b24f83309eb0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfImpairedFinancingReceivableTable_4d8b5a36-27c7-4bd1-bfda-eada4c9df8f1" xlink:to="loc_us-gaap_VariableRateAxis_98b32d9f-0357-48ce-aff7-b24f83309eb0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_98b32d9f-0357-48ce-aff7-b24f83309eb0_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_98b32d9f-0357-48ce-aff7-b24f83309eb0" xlink:to="loc_us-gaap_VariableRateDomain_98b32d9f-0357-48ce-aff7-b24f83309eb0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_677848ab-ad69-4665-b7c0-06ad6d7193eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_98b32d9f-0357-48ce-aff7-b24f83309eb0" xlink:to="loc_us-gaap_VariableRateDomain_677848ab-ad69-4665-b7c0-06ad6d7193eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLiborSwapRateMember_319fe997-e7da-43d5-bc75-3570a27ae8f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LondonInterbankOfferedRateLiborSwapRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_677848ab-ad69-4665-b7c0-06ad6d7193eb" xlink:to="loc_us-gaap_LondonInterbankOfferedRateLiborSwapRateMember_319fe997-e7da-43d5-bc75-3570a27ae8f6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember_57ac6df9-d4ee-457a-8d2c-ba926cf331e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BaseRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_677848ab-ad69-4665-b7c0-06ad6d7193eb" xlink:to="loc_us-gaap_BaseRateMember_57ac6df9-d4ee-457a-8d2c-ba926cf331e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_bd6520bd-c992-42d8-a0ac-ff221762a7ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfImpairedFinancingReceivableTable_4d8b5a36-27c7-4bd1-bfda-eada4c9df8f1" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_bd6520bd-c992-42d8-a0ac-ff221762a7ec" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_bd6520bd-c992-42d8-a0ac-ff221762a7ec_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_bd6520bd-c992-42d8-a0ac-ff221762a7ec" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_bd6520bd-c992-42d8-a0ac-ff221762a7ec_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_d89343cc-1536-466f-b246-68c3e6236eea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_bd6520bd-c992-42d8-a0ac-ff221762a7ec" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_d89343cc-1536-466f-b246-68c3e6236eea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_a1fcb2d5-e78e-4f79-bcb5-2e66462eb8eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_d89343cc-1536-466f-b246-68c3e6236eea" xlink:to="loc_us-gaap_SecuredDebtMember_a1fcb2d5-e78e-4f79-bcb5-2e66462eb8eb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_1ddd73ef-2fb9-48c2-a80f-900d252957c7" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfImpairedFinancingReceivableTable_4d8b5a36-27c7-4bd1-bfda-eada4c9df8f1" xlink:to="loc_srt_RangeAxis_1ddd73ef-2fb9-48c2-a80f-900d252957c7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1ddd73ef-2fb9-48c2-a80f-900d252957c7_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_1ddd73ef-2fb9-48c2-a80f-900d252957c7" xlink:to="loc_srt_RangeMember_1ddd73ef-2fb9-48c2-a80f-900d252957c7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6f41a552-d6ef-4144-bfd2-3fd26534775e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_1ddd73ef-2fb9-48c2-a80f-900d252957c7" xlink:to="loc_srt_RangeMember_6f41a552-d6ef-4144-bfd2-3fd26534775e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_de4023e9-9cf2-49d0-b743-50c0d75adaf9" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_6f41a552-d6ef-4144-bfd2-3fd26534775e" xlink:to="loc_srt_MinimumMember_de4023e9-9cf2-49d0-b743-50c0d75adaf9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_1a14bf96-aa21-4803-8af7-3d2da216ee34" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_6f41a552-d6ef-4144-bfd2-3fd26534775e" xlink:to="loc_srt_MaximumMember_1a14bf96-aa21-4803-8af7-3d2da216ee34" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/DEVELOPMENTDERIVATIVELIABILITY" xlink:type="simple" xlink:href="alny-20210331.xsd#DEVELOPMENTDERIVATIVELIABILITY"/>
  <link:definitionLink xlink:role="http://www.alnylam.com/role/DEVELOPMENTDERIVATIVELIABILITY" xlink:type="extended" id="ia3e8773a500b44188385e9b1c1f8274d_DEVELOPMENTDERIVATIVELIABILITY"/>
  <link:roleRef roleURI="http://www.alnylam.com/role/DEVELOPMENTDERIVATIVELIABILITYTables" xlink:type="simple" xlink:href="alny-20210331.xsd#DEVELOPMENTDERIVATIVELIABILITYTables"/>
  <link:definitionLink xlink:role="http://www.alnylam.com/role/DEVELOPMENTDERIVATIVELIABILITYTables" xlink:type="extended" id="i5b8116d1427149ad87f20472490cb4da_DEVELOPMENTDERIVATIVELIABILITYTables"/>
  <link:roleRef roleURI="http://www.alnylam.com/role/DEVELOPMENTDERIVATIVELIABILITYNarrativeDetails" xlink:type="simple" xlink:href="alny-20210331.xsd#DEVELOPMENTDERIVATIVELIABILITYNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.alnylam.com/role/DEVELOPMENTDERIVATIVELIABILITYNarrativeDetails" xlink:type="extended" id="ie9e4016bd6594484b4b5a4c8ed6ba819_DEVELOPMENTDERIVATIVELIABILITYNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_643ace9b-4762-4dcf-b104-bfcda8a75489" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_CollaborativeArrangementMaximumFunding_752ed2a1-24de-4eb8-9397-fe7152d36da0" xlink:href="alny-20210331.xsd#alny_CollaborativeArrangementMaximumFunding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_643ace9b-4762-4dcf-b104-bfcda8a75489" xlink:to="loc_alny_CollaborativeArrangementMaximumFunding_752ed2a1-24de-4eb8-9397-fe7152d36da0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_CollaborativeArrangementRoyaltiesPayablePercent_c4975e7d-a681-4537-bef0-0dc3afc9d179" xlink:href="alny-20210331.xsd#alny_CollaborativeArrangementRoyaltiesPayablePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_643ace9b-4762-4dcf-b104-bfcda8a75489" xlink:to="loc_alny_CollaborativeArrangementRoyaltiesPayablePercent_c4975e7d-a681-4537-bef0-0dc3afc9d179" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_CollaborativeArrangementRoyaltiesPayableTerm_3d9d5ffb-96ba-46ef-922b-3872fc5fa037" xlink:href="alny-20210331.xsd#alny_CollaborativeArrangementRoyaltiesPayableTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_643ace9b-4762-4dcf-b104-bfcda8a75489" xlink:to="loc_alny_CollaborativeArrangementRoyaltiesPayableTerm_3d9d5ffb-96ba-46ef-922b-3872fc5fa037" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_CollaborativeArrangementFixedPaymentMultiplier_9b7f27c3-e40b-4a29-a448-b07fc2ffa8da" xlink:href="alny-20210331.xsd#alny_CollaborativeArrangementFixedPaymentMultiplier"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_643ace9b-4762-4dcf-b104-bfcda8a75489" xlink:to="loc_alny_CollaborativeArrangementFixedPaymentMultiplier_9b7f27c3-e40b-4a29-a448-b07fc2ffa8da" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_CollaborativeArrangementFixedPaymentTerm_b84885e6-c57c-4ce6-a50f-4d07959a886f" xlink:href="alny-20210331.xsd#alny_CollaborativeArrangementFixedPaymentTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_643ace9b-4762-4dcf-b104-bfcda8a75489" xlink:to="loc_alny_CollaborativeArrangementFixedPaymentTerm_b84885e6-c57c-4ce6-a50f-4d07959a886f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_9e7c282a-e479-41d1-a354-bf61336a3bc0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_643ace9b-4762-4dcf-b104-bfcda8a75489" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_9e7c282a-e479-41d1-a354-bf61336a3bc0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_e5b13714-f5ef-4d0d-8646-c5e8e97b754c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_643ace9b-4762-4dcf-b104-bfcda8a75489" xlink:to="loc_us-gaap_DerivativeTable_e5b13714-f5ef-4d0d-8646-c5e8e97b754c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_8df535c8-0520-429c-afdc-59699f8e15ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_e5b13714-f5ef-4d0d-8646-c5e8e97b754c" xlink:to="loc_us-gaap_TypeOfArrangementAxis_8df535c8-0520-429c-afdc-59699f8e15ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8df535c8-0520-429c-afdc-59699f8e15ec_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_8df535c8-0520-429c-afdc-59699f8e15ec" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8df535c8-0520-429c-afdc-59699f8e15ec_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9080b4f0-8b77-47db-a78e-6d6aa946f47d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_8df535c8-0520-429c-afdc-59699f8e15ec" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9080b4f0-8b77-47db-a78e-6d6aa946f47d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_b4162d4c-5cbe-4a36-8aeb-2bd1f15f906d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9080b4f0-8b77-47db-a78e-6d6aa946f47d" xlink:to="loc_us-gaap_CollaborativeArrangementMember_b4162d4c-5cbe-4a36-8aeb-2bd1f15f906d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_8469f2e3-4a84-4953-9eb8-3bf2801f4bfd" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_e5b13714-f5ef-4d0d-8646-c5e8e97b754c" xlink:to="loc_srt_CounterpartyNameAxis_8469f2e3-4a84-4953-9eb8-3bf2801f4bfd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8469f2e3-4a84-4953-9eb8-3bf2801f4bfd_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_8469f2e3-4a84-4953-9eb8-3bf2801f4bfd" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8469f2e3-4a84-4953-9eb8-3bf2801f4bfd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e22a3056-d48e-4abb-9f77-70fd2c5a8beb" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_8469f2e3-4a84-4953-9eb8-3bf2801f4bfd" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e22a3056-d48e-4abb-9f77-70fd2c5a8beb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_BlackstoneLifeSciencesMember_685a9297-0331-4398-9102-c4b871d0f2fe" xlink:href="alny-20210331.xsd#alny_BlackstoneLifeSciencesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e22a3056-d48e-4abb-9f77-70fd2c5a8beb" xlink:to="loc_alny_BlackstoneLifeSciencesMember_685a9297-0331-4398-9102-c4b871d0f2fe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_34d474bb-2557-49c6-b786-57792d6c25e7" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_e5b13714-f5ef-4d0d-8646-c5e8e97b754c" xlink:to="loc_srt_ProductOrServiceAxis_34d474bb-2557-49c6-b786-57792d6c25e7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_34d474bb-2557-49c6-b786-57792d6c25e7_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_34d474bb-2557-49c6-b786-57792d6c25e7" xlink:to="loc_srt_ProductsAndServicesDomain_34d474bb-2557-49c6-b786-57792d6c25e7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a583b926-53bd-4dc9-9c29-69018fe9fae8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_34d474bb-2557-49c6-b786-57792d6c25e7" xlink:to="loc_srt_ProductsAndServicesDomain_a583b926-53bd-4dc9-9c29-69018fe9fae8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_VutrisiranAndALNAGTMember_4d6ebbbd-4644-49e1-b026-6edf4cbe8c4d" xlink:href="alny-20210331.xsd#alny_VutrisiranAndALNAGTMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_a583b926-53bd-4dc9-9c29-69018fe9fae8" xlink:to="loc_alny_VutrisiranAndALNAGTMember_4d6ebbbd-4644-49e1-b026-6edf4cbe8c4d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_HELIOSBPhase3ClinicalTrialMember_6eb46dfa-ba57-4d42-9b25-4b1bdc4a43f5" xlink:href="alny-20210331.xsd#alny_HELIOSBPhase3ClinicalTrialMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_a583b926-53bd-4dc9-9c29-69018fe9fae8" xlink:to="loc_alny_HELIOSBPhase3ClinicalTrialMember_6eb46dfa-ba57-4d42-9b25-4b1bdc4a43f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_ALNAGTPhase2ClinicalTrialMember_c0edcd12-9f9f-49f7-9763-723d1e89a155" xlink:href="alny-20210331.xsd#alny_ALNAGTPhase2ClinicalTrialMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_a583b926-53bd-4dc9-9c29-69018fe9fae8" xlink:to="loc_alny_ALNAGTPhase2ClinicalTrialMember_c0edcd12-9f9f-49f7-9763-723d1e89a155" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_ALNAGTPhase3ClinicalTrialMember_e82deb45-0bbb-4adc-ab07-2ab31ee8f7e9" xlink:href="alny-20210331.xsd#alny_ALNAGTPhase3ClinicalTrialMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_a583b926-53bd-4dc9-9c29-69018fe9fae8" xlink:to="loc_alny_ALNAGTPhase3ClinicalTrialMember_e82deb45-0bbb-4adc-ab07-2ab31ee8f7e9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_VutrisiranMember_04a7dffd-3326-4802-b655-5b466ae3018e" xlink:href="alny-20210331.xsd#alny_VutrisiranMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_a583b926-53bd-4dc9-9c29-69018fe9fae8" xlink:to="loc_alny_VutrisiranMember_04a7dffd-3326-4802-b655-5b466ae3018e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_fcd37371-96d1-476f-825b-02dc53122052" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_e5b13714-f5ef-4d0d-8646-c5e8e97b754c" xlink:to="loc_dei_LegalEntityAxis_fcd37371-96d1-476f-825b-02dc53122052" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_fcd37371-96d1-476f-825b-02dc53122052_default" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_fcd37371-96d1-476f-825b-02dc53122052" xlink:to="loc_dei_EntityDomain_fcd37371-96d1-476f-825b-02dc53122052_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_4a700cd3-f5c4-4066-b528-28012e960b72" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_fcd37371-96d1-476f-825b-02dc53122052" xlink:to="loc_dei_EntityDomain_4a700cd3-f5c4-4066-b528-28012e960b72" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_BlackstoneLifeSciencesMember_7c2f3fc0-ed22-462b-8e29-6ab82b2c11e4" xlink:href="alny-20210331.xsd#alny_BlackstoneLifeSciencesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_4a700cd3-f5c4-4066-b528-28012e960b72" xlink:to="loc_alny_BlackstoneLifeSciencesMember_7c2f3fc0-ed22-462b-8e29-6ab82b2c11e4" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/DEVELOPMENTDERIVATIVELIABILITYDevelopmentDerivativeLiabilityActivityDetails" xlink:type="simple" xlink:href="alny-20210331.xsd#DEVELOPMENTDERIVATIVELIABILITYDevelopmentDerivativeLiabilityActivityDetails"/>
  <link:definitionLink xlink:role="http://www.alnylam.com/role/DEVELOPMENTDERIVATIVELIABILITYDevelopmentDerivativeLiabilityActivityDetails" xlink:type="extended" id="ia31af538dfa84c93bbd711b01cff693b_DEVELOPMENTDERIVATIVELIABILITYDevelopmentDerivativeLiabilityActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_977ab1b3-dcfe-40c2-83f9-25ab5b010299" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_7eedee15-6442-4cc5-be0f-75a374e4d06f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_977ab1b3-dcfe-40c2-83f9-25ab5b010299" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_7eedee15-6442-4cc5-be0f-75a374e4d06f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_451f951d-3e8b-49fd-b24e-9b6abc68f1b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_7eedee15-6442-4cc5-be0f-75a374e4d06f" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_451f951d-3e8b-49fd-b24e-9b6abc68f1b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_7021a0af-33d8-4536-9dc1-5f206f5b0934" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_7eedee15-6442-4cc5-be0f-75a374e4d06f" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_7021a0af-33d8-4536-9dc1-5f206f5b0934" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_b9911140-2454-480a-ab66-780c358e1675" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_7eedee15-6442-4cc5-be0f-75a374e4d06f" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_b9911140-2454-480a-ab66-780c358e1675" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_3973badd-5e94-4586-b068-fb5d5df3af0a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_73616a11-8437-49fd-9530-883ef30b6f50" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_977ab1b3-dcfe-40c2-83f9-25ab5b010299" xlink:to="loc_us-gaap_DerivativeTable_73616a11-8437-49fd-9530-883ef30b6f50" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_3f6f997b-0662-4184-b838-622cc0018271" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_73616a11-8437-49fd-9530-883ef30b6f50" xlink:to="loc_us-gaap_FinancialInstrumentAxis_3f6f997b-0662-4184-b838-622cc0018271" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3f6f997b-0662-4184-b838-622cc0018271_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_3f6f997b-0662-4184-b838-622cc0018271" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3f6f997b-0662-4184-b838-622cc0018271_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1c836635-23d7-4dc5-9430-066714694ea2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_3f6f997b-0662-4184-b838-622cc0018271" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1c836635-23d7-4dc5-9430-066714694ea2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeMember_d9403e34-d617-451d-b856-1d6915d38089" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1c836635-23d7-4dc5-9430-066714694ea2" xlink:to="loc_us-gaap_DerivativeMember_d9403e34-d617-451d-b856-1d6915d38089" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/STOCKBASEDCOMPENSATION" xlink:type="simple" xlink:href="alny-20210331.xsd#STOCKBASEDCOMPENSATION"/>
  <link:definitionLink xlink:role="http://www.alnylam.com/role/STOCKBASEDCOMPENSATION" xlink:type="extended" id="i51477bff648040f9984b4b0eadedcd0a_STOCKBASEDCOMPENSATION"/>
  <link:roleRef roleURI="http://www.alnylam.com/role/STOCKBASEDCOMPENSATIONTables" xlink:type="simple" xlink:href="alny-20210331.xsd#STOCKBASEDCOMPENSATIONTables"/>
  <link:definitionLink xlink:role="http://www.alnylam.com/role/STOCKBASEDCOMPENSATIONTables" xlink:type="extended" id="i7da62c5f8ff140e083c80254a3748e0d_STOCKBASEDCOMPENSATIONTables"/>
  <link:roleRef roleURI="http://www.alnylam.com/role/STOCKBASEDCOMPENSATIONSummaryofShareBasedCompensationExpensesIncludedOperatingCostsandExpenseDetail" xlink:type="simple" xlink:href="alny-20210331.xsd#STOCKBASEDCOMPENSATIONSummaryofShareBasedCompensationExpensesIncludedOperatingCostsandExpenseDetail"/>
  <link:definitionLink xlink:role="http://www.alnylam.com/role/STOCKBASEDCOMPENSATIONSummaryofShareBasedCompensationExpensesIncludedOperatingCostsandExpenseDetail" xlink:type="extended" id="iff1a349cdf104dbe92ba99eac582e9d1_STOCKBASEDCOMPENSATIONSummaryofShareBasedCompensationExpensesIncludedOperatingCostsandExpenseDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2658b752-e11b-47b8-8f60-4e0bb3e9bad7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_2b25605c-43a1-4fe8-aabe-cb30887a14c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2658b752-e11b-47b8-8f60-4e0bb3e9bad7" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_2b25605c-43a1-4fe8-aabe-cb30887a14c8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_68ec98ad-e01f-4206-96ff-3323fa4253f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2658b752-e11b-47b8-8f60-4e0bb3e9bad7" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_68ec98ad-e01f-4206-96ff-3323fa4253f7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_fe507e7d-43a7-44d7-8374-c64b2757a49b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_68ec98ad-e01f-4206-96ff-3323fa4253f7" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_fe507e7d-43a7-44d7-8374-c64b2757a49b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_fe507e7d-43a7-44d7-8374-c64b2757a49b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_fe507e7d-43a7-44d7-8374-c64b2757a49b" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_fe507e7d-43a7-44d7-8374-c64b2757a49b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_fe46ffb4-ae26-4ff6-91c7-cdb46747168a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_fe507e7d-43a7-44d7-8374-c64b2757a49b" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_fe46ffb4-ae26-4ff6-91c7-cdb46747168a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_304ceda5-476d-43cf-8429-a27734bfaf5b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_fe46ffb4-ae26-4ff6-91c7-cdb46747168a" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_304ceda5-476d-43cf-8429-a27734bfaf5b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_6d39f54d-6655-4651-b1dd-3f98ae6c9d4d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_fe46ffb4-ae26-4ff6-91c7-cdb46747168a" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_6d39f54d-6655-4651-b1dd-3f98ae6c9d4d" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/NETLOSSPERCOMMONSHARE" xlink:type="simple" xlink:href="alny-20210331.xsd#NETLOSSPERCOMMONSHARE"/>
  <link:definitionLink xlink:role="http://www.alnylam.com/role/NETLOSSPERCOMMONSHARE" xlink:type="extended" id="i14a2d9182e734f9c9a3d18be4d8445b4_NETLOSSPERCOMMONSHARE"/>
  <link:roleRef roleURI="http://www.alnylam.com/role/NETLOSSPERCOMMONSHARETables" xlink:type="simple" xlink:href="alny-20210331.xsd#NETLOSSPERCOMMONSHARETables"/>
  <link:definitionLink xlink:role="http://www.alnylam.com/role/NETLOSSPERCOMMONSHARETables" xlink:type="extended" id="ie46d4e9231114b738ec59f78dd46fdbb_NETLOSSPERCOMMONSHARETables"/>
  <link:roleRef roleURI="http://www.alnylam.com/role/NETLOSSPERCOMMONSHARECommonShareEquivalentsExcludedfromCalculationofNetLossPerCommonShareDetail" xlink:type="simple" xlink:href="alny-20210331.xsd#NETLOSSPERCOMMONSHARECommonShareEquivalentsExcludedfromCalculationofNetLossPerCommonShareDetail"/>
  <link:definitionLink xlink:role="http://www.alnylam.com/role/NETLOSSPERCOMMONSHARECommonShareEquivalentsExcludedfromCalculationofNetLossPerCommonShareDetail" xlink:type="extended" id="i194cd6fd5f9d4f5e9ec7b5442e0b0b6e_NETLOSSPERCOMMONSHARECommonShareEquivalentsExcludedfromCalculationofNetLossPerCommonShareDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0a60e30b-32e3-4494-9175-4d96b2847709" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_50f14f74-d7ff-4702-9401-62e31651be0a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0a60e30b-32e3-4494-9175-4d96b2847709" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_50f14f74-d7ff-4702-9401-62e31651be0a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_bfd341de-5146-4982-be21-9d93b5c1e7e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0a60e30b-32e3-4494-9175-4d96b2847709" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_bfd341de-5146-4982-be21-9d93b5c1e7e9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_d5f63e93-2db4-4067-9da9-9a131c55c778" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_bfd341de-5146-4982-be21-9d93b5c1e7e9" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_d5f63e93-2db4-4067-9da9-9a131c55c778" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_d5f63e93-2db4-4067-9da9-9a131c55c778_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_d5f63e93-2db4-4067-9da9-9a131c55c778" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_d5f63e93-2db4-4067-9da9-9a131c55c778_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f532d7b8-904d-4bfa-ba25-aba9b7dfdf3c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_d5f63e93-2db4-4067-9da9-9a131c55c778" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f532d7b8-904d-4bfa-ba25-aba9b7dfdf3c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_407033b2-20f3-405d-8b38-8dcfb53585b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f532d7b8-904d-4bfa-ba25-aba9b7dfdf3c" xlink:to="loc_us-gaap_EmployeeStockOptionMember_407033b2-20f3-405d-8b38-8dcfb53585b3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_e610165d-ba63-43ce-8175-0a201103ddcf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f532d7b8-904d-4bfa-ba25-aba9b7dfdf3c" xlink:to="loc_us-gaap_RestrictedStockMember_e610165d-ba63-43ce-8175-0a201103ddcf" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="simple" xlink:href="alny-20210331.xsd#COMMITMENTSANDCONTINGENCIES"/>
  <link:definitionLink xlink:role="http://www.alnylam.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="extended" id="ic6ff7e527c124fb6b24f4ffb9b85eb6c_COMMITMENTSANDCONTINGENCIES"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>alny-20210331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:45529fdd-2cb3-415e-a8b1-14659af4a28e,g:8b4a69cc-2403-45c9-b738-5835a1e5fb0d-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_DocumentType_89e6fa05-81bc-4da1-88e8-8e164757c066_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_676402db-c108-48a2-b1c7-9bc4a745ae9e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_5c54a0e4-348d-49cc-8fcb-a201365340ce_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statements of Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_71994a9c-20d2-49a3-9a32-8d5f87a107cf_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_NumberOfTargetedPrograms_f601181c-fe48-4cb2-8554-ca84b645bee9_terseLabel_en-US" xlink:label="lab_alny_NumberOfTargetedPrograms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of targeted programs</link:label>
    <link:label id="lab_alny_NumberOfTargetedPrograms_label_en-US" xlink:label="lab_alny_NumberOfTargetedPrograms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Targeted Programs</link:label>
    <link:label id="lab_alny_NumberOfTargetedPrograms_documentation_en-US" xlink:label="lab_alny_NumberOfTargetedPrograms" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of targeted programs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_NumberOfTargetedPrograms" xlink:href="alny-20210331.xsd#alny_NumberOfTargetedPrograms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_NumberOfTargetedPrograms" xlink:to="lab_alny_NumberOfTargetedPrograms" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_8c04ef2d-3972-4d3e-92a3-a39df77744e2_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable, accrued expenses and other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_34aa7ffd-2498-47bc-bd02-1f48f6899763_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash, beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_fc5ae6bf-0f3e-48c3-b54b-ac9545c687f1_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash, end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_b913d05d-e508-4863-8a0f-d40948eaef9f_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash, cash equivalents, and restricted cash shown in the condensed consolidated statements of cash flows</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_d3633d8d-fd62-4456-9ad9-fe44e0bbeac1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Changes in Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_fd93f742-157c-4076-8d0f-b80b0627a07c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Unobservable Inputs (Level 3)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_41d04b0e-a47e-427d-bcca-2e118f1b95ff_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales and maturities of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireRestrictedInvestments_d2d7a893-1556-4033-92f2-c15e3f074512_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireRestrictedInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of restricted investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireRestrictedInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireRestrictedInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Restricted Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireRestrictedInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireRestrictedInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireRestrictedInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireRestrictedInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_0cf4cb8a-780d-498e-9277-e56d641755c3_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_37bf87a2-2519-467a-a0fb-20ca19a63463_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditMember_12501a22-2dfa-45b8-ba05-a4ee49ce8f7e_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit</link:label>
    <link:label id="lab_us-gaap_LineOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditMember" xlink:to="lab_us-gaap_LineOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_422d5554-9198-425d-abeb-d175d6969add_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_ResearchCollaboratorAxis_2d0a2717-00b2-4487-8dc6-2263b28b0358_terseLabel_en-US" xlink:label="lab_alny_ResearchCollaboratorAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Collaborator [Axis]</link:label>
    <link:label id="lab_alny_ResearchCollaboratorAxis_label_en-US" xlink:label="lab_alny_ResearchCollaboratorAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Collaborator [Axis]</link:label>
    <link:label id="lab_alny_ResearchCollaboratorAxis_documentation_en-US" xlink:label="lab_alny_ResearchCollaboratorAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research collaborator.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_ResearchCollaboratorAxis" xlink:href="alny-20210331.xsd#alny_ResearchCollaboratorAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_ResearchCollaboratorAxis" xlink:to="lab_alny_ResearchCollaboratorAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_OtherMember_d8c250b8-9a24-43e2-9fa5-47041030d936_terseLabel_en-US" xlink:label="lab_alny_OtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_alny_OtherMember_label_en-US" xlink:label="lab_alny_OtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other [Member]</link:label>
    <link:label id="lab_alny_OtherMember_documentation_en-US" xlink:label="lab_alny_OtherMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_OtherMember" xlink:href="alny-20210331.xsd#alny_OtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_OtherMember" xlink:to="lab_alny_OtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_bc5547a9-966c-4b89-a0e6-37f440320004_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DEVELOPMENT DERIVATIVE LIABILITY</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_7b05e1fc-0ecc-4b34-9912-94d8c63d11e4_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_NumberOfPartneredProducts_ddfe7c34-7509-4c89-9465-ba799b104300_terseLabel_en-US" xlink:label="lab_alny_NumberOfPartneredProducts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of partnered products</link:label>
    <link:label id="lab_alny_NumberOfPartneredProducts_label_en-US" xlink:label="lab_alny_NumberOfPartneredProducts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Partnered Products</link:label>
    <link:label id="lab_alny_NumberOfPartneredProducts_documentation_en-US" xlink:label="lab_alny_NumberOfPartneredProducts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Partnered Products</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_NumberOfPartneredProducts" xlink:href="alny-20210331.xsd#alny_NumberOfPartneredProducts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_NumberOfPartneredProducts" xlink:to="lab_alny_NumberOfPartneredProducts" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_HELIOSBPhase3ClinicalTrialMember_f0db433d-dc22-4b5b-8f4f-cd8d7e0503df_terseLabel_en-US" xlink:label="lab_alny_HELIOSBPhase3ClinicalTrialMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HELIOS-B Phase 3 Clinical Trial</link:label>
    <link:label id="lab_alny_HELIOSBPhase3ClinicalTrialMember_label_en-US" xlink:label="lab_alny_HELIOSBPhase3ClinicalTrialMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HELIOS-B Phase 3 Clinical Trial [Member]</link:label>
    <link:label id="lab_alny_HELIOSBPhase3ClinicalTrialMember_documentation_en-US" xlink:label="lab_alny_HELIOSBPhase3ClinicalTrialMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HELIOS-B Phase 3 Clinical Trial</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_HELIOSBPhase3ClinicalTrialMember" xlink:href="alny-20210331.xsd#alny_HELIOSBPhase3ClinicalTrialMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_HELIOSBPhase3ClinicalTrialMember" xlink:to="lab_alny_HELIOSBPhase3ClinicalTrialMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_edbf6608-407f-4374-9b97-38d9239969d5_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_ScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTableTextBlock_3d95844d-b7bc-4376-a3d2-9e98d8d5bcd4_terseLabel_en-US" xlink:label="lab_alny_ScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Reconciliation of Cash, Cash Equivalents And Restricted Cash</link:label>
    <link:label id="lab_alny_ScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTableTextBlock_label_en-US" xlink:label="lab_alny_ScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Reconciliation Of Cash Cash Equivalents And Restricted Cash Table [Table Text Block]</link:label>
    <link:label id="lab_alny_ScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTableTextBlock_documentation_en-US" xlink:label="lab_alny_ScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of reconciliation of cash, cash equivalents and restricted cash.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_ScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTableTextBlock" xlink:href="alny-20210331.xsd#alny_ScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_ScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTableTextBlock" xlink:to="lab_alny_ScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_7b3c14c3-6815-4f32-9726-3770d54f6523_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_cbff1c89-9665-41a7-9ced-4f42d93512fb_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance and Change in Receivables and Contract Liabilities Related to Collaboration Agreements</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:to="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_382e3601-80e3-46ee-8fee-d8e3856ef81c_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateDomain_3a0519c3-e1b8-4a8d-9bd0-fdb13f27b8d7_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateAxis_74d63499-9001-48e4-a184-32f7ea22edf9_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_ONPATTROMember_c499fb4e-7e5a-4c67-8bca-63d9ccb04c8d_terseLabel_en-US" xlink:label="lab_alny_ONPATTROMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ONPATTRO</link:label>
    <link:label id="lab_alny_ONPATTROMember_label_en-US" xlink:label="lab_alny_ONPATTROMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ONPATTRO [Member]</link:label>
    <link:label id="lab_alny_ONPATTROMember_documentation_en-US" xlink:label="lab_alny_ONPATTROMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ONPATTRO</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_ONPATTROMember" xlink:href="alny-20210331.xsd#alny_ONPATTROMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_ONPATTROMember" xlink:to="lab_alny_ONPATTROMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_be23aee0-621f-46a6-b34a-b3fa944348c1_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_198cf8d9-48f5-4de9-ac71-430cc5cafea8_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_7b249f7a-eb3b-46df-a1f7-3982fc6f1677_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_RoyaltyLiabilityClosingCosts_e324bd07-8fd9-494a-80fc-a488149e4b61_negatedTerseLabel_en-US" xlink:label="lab_alny_RoyaltyLiabilityClosingCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Closing costs</link:label>
    <link:label id="lab_alny_RoyaltyLiabilityClosingCosts_label_en-US" xlink:label="lab_alny_RoyaltyLiabilityClosingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Liability, Closing Costs</link:label>
    <link:label id="lab_alny_RoyaltyLiabilityClosingCosts_documentation_en-US" xlink:label="lab_alny_RoyaltyLiabilityClosingCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Liability, Closing Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_RoyaltyLiabilityClosingCosts" xlink:href="alny-20210331.xsd#alny_RoyaltyLiabilityClosingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_RoyaltyLiabilityClosingCosts" xlink:to="lab_alny_RoyaltyLiabilityClosingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_0dea61ef-7d10-4e5e-a77c-27f58465954c_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_6ca20a6a-35dc-406f-b4dc-69c5263e479b_negatedLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_e407d776-7200-4244-96fa-e13bb57cf9fb_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_0b9928b9-2a03-424e-9e0e-688838b0456f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation gains</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_a4cf4e78-94b7-4aad-bbd2-84d04695109a_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_NovartisMember_93ff756c-f3fa-4010-8edd-16c87e627760_verboseLabel_en-US" xlink:label="lab_alny_NovartisMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Novartis AG</link:label>
    <link:label id="lab_alny_NovartisMember_40dc8d1c-8122-4300-ad23-460f6e601ef0_terseLabel_en-US" xlink:label="lab_alny_NovartisMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Novartis AG</link:label>
    <link:label id="lab_alny_NovartisMember_label_en-US" xlink:label="lab_alny_NovartisMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Novartis [Member]</link:label>
    <link:label id="lab_alny_NovartisMember_documentation_en-US" xlink:label="lab_alny_NovartisMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The Medicines Company.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_NovartisMember" xlink:href="alny-20210331.xsd#alny_NovartisMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_NovartisMember" xlink:to="lab_alny_NovartisMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_4c5e0677-f592-4134-a43d-563c864c9974_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_VutrisiranAndALNAGTMember_3acdb5ac-cbf5-4ce8-b780-23f184f5f337_terseLabel_en-US" xlink:label="lab_alny_VutrisiranAndALNAGTMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vutrisiran and ALN-AGT</link:label>
    <link:label id="lab_alny_VutrisiranAndALNAGTMember_label_en-US" xlink:label="lab_alny_VutrisiranAndALNAGTMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vutrisiran and ALN-AGT [Member]</link:label>
    <link:label id="lab_alny_VutrisiranAndALNAGTMember_documentation_en-US" xlink:label="lab_alny_VutrisiranAndALNAGTMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vutrisiran and ALN-AGT</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_VutrisiranAndALNAGTMember" xlink:href="alny-20210331.xsd#alny_VutrisiranAndALNAGTMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_VutrisiranAndALNAGTMember" xlink:to="lab_alny_VutrisiranAndALNAGTMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_RoyaltiesReceivableCurrent_ab33db20-9a10-4959-80c4-2f91bc8ffe40_terseLabel_en-US" xlink:label="lab_alny_RoyaltiesReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable related to the sale of future royalties</link:label>
    <link:label id="lab_alny_RoyaltiesReceivableCurrent_label_en-US" xlink:label="lab_alny_RoyaltiesReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalties Receivable, Current</link:label>
    <link:label id="lab_alny_RoyaltiesReceivableCurrent_documentation_en-US" xlink:label="lab_alny_RoyaltiesReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalties Receivable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_RoyaltiesReceivableCurrent" xlink:href="alny-20210331.xsd#alny_RoyaltiesReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_RoyaltiesReceivableCurrent" xlink:to="lab_alny_RoyaltiesReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_e905ab0b-4b75-480e-942c-2c5a17aada1a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value of Assets Measured on a Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_LineOfCreditFacilityPrepaymentAndTerminationFeePercentage_a3449606-86ad-49ff-b20c-5dd451ca6195_terseLabel_en-US" xlink:label="lab_alny_LineOfCreditFacilityPrepaymentAndTerminationFeePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepayment and termination fee percentage</link:label>
    <link:label id="lab_alny_LineOfCreditFacilityPrepaymentAndTerminationFeePercentage_label_en-US" xlink:label="lab_alny_LineOfCreditFacilityPrepaymentAndTerminationFeePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line Of Credit Facility, Prepayment And Termination Fee Percentage</link:label>
    <link:label id="lab_alny_LineOfCreditFacilityPrepaymentAndTerminationFeePercentage_documentation_en-US" xlink:label="lab_alny_LineOfCreditFacilityPrepaymentAndTerminationFeePercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line Of Credit Facility, Prepayment And Termination Fee Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_LineOfCreditFacilityPrepaymentAndTerminationFeePercentage" xlink:href="alny-20210331.xsd#alny_LineOfCreditFacilityPrepaymentAndTerminationFeePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_LineOfCreditFacilityPrepaymentAndTerminationFeePercentage" xlink:to="lab_alny_LineOfCreditFacilityPrepaymentAndTerminationFeePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_5732f0d2-1b49-48fd-a9a7-7bfbe76336b9_terseLabel_en-US" xlink:label="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent, Net of Tax [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_label_en-US" xlink:label="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent, Net of Tax [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AOCIAttributableToParentNetOfTaxRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:to="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_161d84c2-6266-4cd2-8f60-81d71d34e95a_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $0.01 par value per share, 5,000 shares authorized and no shares issued and outstanding as of March&#160;31, 2021 and December&#160;31, 2020</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_3fa44cdd-1ed3-419c-839c-a2f8a96e5335_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive (loss) income:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_78ed6b0c-e8f5-48f4-8c31-2886cdec6e1f_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_9dcc2fa2-0eb3-41ac-b62b-5a130570d173_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_6f39f509-1208-4909-9282-37088b939d11_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other investing activities</link:label>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for (Proceeds from) Other Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:to="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_91ffd43b-dd22-40d4-9846-3724e735b4cd_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense related to equity-classified awards</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7101cc07-df0a-4e27-87aa-33fdcdbe618f_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rate changes on cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_d284c8eb-069f-49c8-ae4e-3adc4c893439_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_69967c11-9f3b-49b9-a7d6-68f0f263e676_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_bbe21dbb-eb0b-4fd1-93e6-33fd3269995a_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue recognized under ASC 606</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeMember_5a9639df-c475-4130-96ec-c43c3b521ead_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative</link:label>
    <link:label id="lab_us-gaap_DerivativeMember_label_en-US" xlink:label="lab_us-gaap_DerivativeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeMember" xlink:to="lab_us-gaap_DerivativeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_59b74226-730e-40cc-8766-32762015bb12_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement Frequency</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryLineItems_db401af0-d081-4895-a440-5624a8e5d819_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Line Items]</link:label>
    <link:label id="lab_us-gaap_InventoryLineItems_label_en-US" xlink:label="lab_us-gaap_InventoryLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryLineItems" xlink:to="lab_us-gaap_InventoryLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_FundingAnAnnualDiscoveryMember_e24d7939-d6d3-4e0c-a4e1-e50337c093ca_terseLabel_en-US" xlink:label="lab_alny_FundingAnAnnualDiscoveryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funding At Steady State</link:label>
    <link:label id="lab_alny_FundingAnAnnualDiscoveryMember_label_en-US" xlink:label="lab_alny_FundingAnAnnualDiscoveryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funding An Annual Discovery [Member]</link:label>
    <link:label id="lab_alny_FundingAnAnnualDiscoveryMember_documentation_en-US" xlink:label="lab_alny_FundingAnAnnualDiscoveryMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funding an annual discovery.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_FundingAnAnnualDiscoveryMember" xlink:href="alny-20210331.xsd#alny_FundingAnAnnualDiscoveryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_FundingAnAnnualDiscoveryMember" xlink:to="lab_alny_FundingAnAnnualDiscoveryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities_931638d3-af5a-44cb-a20a-74dcc7864ef1_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from development derivative</link:label>
    <link:label id="lab_us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Derivative Instrument, Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities" xlink:to="lab_us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_428e7565-c93d-45da-a680-ae3a218a16c8_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_74ef8c84-474b-44af-b762-6527683bbf92_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_f941528b-2998-45da-86d9-f16e9f633bb3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Common Share Equivalents Excluded from the Calculation of Net Loss Per Common Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioForecastMember_50610479-2fc8-4da4-b660-b71c2fc11978_terseLabel_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast</link:label>
    <link:label id="lab_srt_ScenarioForecastMember_label_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioForecastMember" xlink:to="lab_srt_ScenarioForecastMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7ebdbdbd-b287-4560-926f-e2096cf1f632_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_da17aa99-865c-4a12-a384-67abde6fde7e_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_CollaborativeArrangementRoyaltiesPayablePercent_5f2bc8b3-7da5-4ae6-aa2c-ebd0c7732378_terseLabel_en-US" xlink:label="lab_alny_CollaborativeArrangementRoyaltiesPayablePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalties payable, percent</link:label>
    <link:label id="lab_alny_CollaborativeArrangementRoyaltiesPayablePercent_label_en-US" xlink:label="lab_alny_CollaborativeArrangementRoyaltiesPayablePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Royalties Payable, Percent</link:label>
    <link:label id="lab_alny_CollaborativeArrangementRoyaltiesPayablePercent_documentation_en-US" xlink:label="lab_alny_CollaborativeArrangementRoyaltiesPayablePercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Royalties Payable, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_CollaborativeArrangementRoyaltiesPayablePercent" xlink:href="alny-20210331.xsd#alny_CollaborativeArrangementRoyaltiesPayablePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_CollaborativeArrangementRoyaltiesPayablePercent" xlink:to="lab_alny_CollaborativeArrangementRoyaltiesPayablePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_41e7fb82-b8b6-4abc-9916-b2f891c7a288_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_ScheduleOfResearchAndDevelopmentExpensesIncurredForCollaborationAgreementsTableTableTextBlock_e6eca3d9-13d4-4220-a650-97b509ce98d9_terseLabel_en-US" xlink:label="lab_alny_ScheduleOfResearchAndDevelopmentExpensesIncurredForCollaborationAgreementsTableTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Research and Development Expenses Incurred by Type that are Directly Attributable to Collaboration Agreements</link:label>
    <link:label id="lab_alny_ScheduleOfResearchAndDevelopmentExpensesIncurredForCollaborationAgreementsTableTableTextBlock_label_en-US" xlink:label="lab_alny_ScheduleOfResearchAndDevelopmentExpensesIncurredForCollaborationAgreementsTableTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Research And Development Expenses Incurred For Collaboration Agreements Table [Table Text Block]</link:label>
    <link:label id="lab_alny_ScheduleOfResearchAndDevelopmentExpensesIncurredForCollaborationAgreementsTableTableTextBlock_documentation_en-US" xlink:label="lab_alny_ScheduleOfResearchAndDevelopmentExpensesIncurredForCollaborationAgreementsTableTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of research and development expenses incurred for collaboration agreements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_ScheduleOfResearchAndDevelopmentExpensesIncurredForCollaborationAgreementsTableTableTextBlock" xlink:href="alny-20210331.xsd#alny_ScheduleOfResearchAndDevelopmentExpensesIncurredForCollaborationAgreementsTableTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_ScheduleOfResearchAndDevelopmentExpensesIncurredForCollaborationAgreementsTableTableTextBlock" xlink:to="lab_alny_ScheduleOfResearchAndDevelopmentExpensesIncurredForCollaborationAgreementsTableTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_004157dd-b5ae-47a3-99b1-b74d2bed2254_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_c34dbe68-62f9-42e3-a60c-d0a4845f20a7_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_e46d6421-1528-4812-83e0-2560b9a208e7_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_66fac473-bd5f-4142-9275-372914f5ec4d_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_ed06007e-b798-4fa9-94d5-51f4abade2d9_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per common share - basic and diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic and Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_2701278f-564b-4f5c-925d-50047b7babd6_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_4c7a756a-9aaa-4cd8-9ce3-8d41ba0765a0_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation and Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4a42489e-c448-4abb-a0d1-a948c15e2768_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_RoyaltyRate_d33f9781-62ef-46cb-b041-4f12cf24b64a_terseLabel_en-US" xlink:label="lab_alny_RoyaltyRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty rate</link:label>
    <link:label id="lab_alny_RoyaltyRate_label_en-US" xlink:label="lab_alny_RoyaltyRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Rate</link:label>
    <link:label id="lab_alny_RoyaltyRate_documentation_en-US" xlink:label="lab_alny_RoyaltyRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential maximum royalty percentage that will received for sales completed by collaboration partner.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_RoyaltyRate" xlink:href="alny-20210331.xsd#alny_RoyaltyRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_RoyaltyRate" xlink:to="lab_alny_RoyaltyRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_7d205f8f-945c-4c88-bc41-6e252bfbbbd7_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CREDIT AGREEMENT</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b9e1167f-18e4-4fcd-80b9-b3e0abb5e787_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_c135f13e-d8e1-40d5-8b0e-f1530d050c38_verboseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net revenues from collaborations</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_c7e1c03e-1e17-4a0c-8444-f585f67210db_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementMember" xlink:to="lab_us-gaap_CollaborativeArrangementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_9d8dabb8-edbb-4848-8e5c-c9f88d139dc7_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_45f9c5d8-6344-4ad1-8a2d-c7e3c4627181_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_OtherCollaborationsMember_ecb79d89-ea27-405f-b6d8-80177e13187e_terseLabel_en-US" xlink:label="lab_alny_OtherCollaborationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_alny_OtherCollaborationsMember_label_en-US" xlink:label="lab_alny_OtherCollaborationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Collaborations [Member]</link:label>
    <link:label id="lab_alny_OtherCollaborationsMember_documentation_en-US" xlink:label="lab_alny_OtherCollaborationsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other collaboration.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_OtherCollaborationsMember" xlink:href="alny-20210331.xsd#alny_OtherCollaborationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_OtherCollaborationsMember" xlink:to="lab_alny_OtherCollaborationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_a47adeba-6ea3-4e41-b94c-2d8b55f26628_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development derivative liability, beginning balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_c2b31e40-b38e-47c7-afcd-1d1139992fef_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development derivative liability, ending balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_OXLUMOMember_5628e2f9-ba4c-4796-b079-ff42fbac927c_terseLabel_en-US" xlink:label="lab_alny_OXLUMOMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OXLUMO</link:label>
    <link:label id="lab_alny_OXLUMOMember_label_en-US" xlink:label="lab_alny_OXLUMOMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OXLUMO [Member]</link:label>
    <link:label id="lab_alny_OXLUMOMember_documentation_en-US" xlink:label="lab_alny_OXLUMOMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OXLUMO</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_OXLUMOMember" xlink:href="alny-20210331.xsd#alny_OXLUMOMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_OXLUMOMember" xlink:to="lab_alny_OXLUMOMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_2f54a527-b4f7-457a-b3f8-e9f1b82b59c8_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OTHER BALANCE SHEET DETAILS</link:label>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Balance Sheet Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_b00708e3-b1eb-454d-8857-3427ec20bbdf_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_e3be74f6-c2ca-4ca1-9ce3-fe7651ade61f_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_ce20e350-4ac7-4b38-b8e6-52c0b2419067_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_FundingAtProgramInitiationMember_302fde7e-529a-4266-a17d-0d1a47aba034_terseLabel_en-US" xlink:label="lab_alny_FundingAtProgramInitiationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funding At Program Initiation</link:label>
    <link:label id="lab_alny_FundingAtProgramInitiationMember_label_en-US" xlink:label="lab_alny_FundingAtProgramInitiationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funding At Program Initiation [Member]</link:label>
    <link:label id="lab_alny_FundingAtProgramInitiationMember_documentation_en-US" xlink:label="lab_alny_FundingAtProgramInitiationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funding at program initiation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_FundingAtProgramInitiationMember" xlink:href="alny-20210331.xsd#alny_FundingAtProgramInitiationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_FundingAtProgramInitiationMember" xlink:to="lab_alny_FundingAtProgramInitiationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_2f108ce7-df29-46d3-a753-d2e6c11c797e_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable debt securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_2e971ca5-6a9f-404f-bb83-c1d372b85380_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable debt securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_CollaborativeArrangementAdditionalDevelopmentCandidatesToBeDelivered_99ea10e7-a75a-4227-81d4-569b39de878c_terseLabel_en-US" xlink:label="lab_alny_CollaborativeArrangementAdditionalDevelopmentCandidatesToBeDelivered" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional development candidates to be delivered</link:label>
    <link:label id="lab_alny_CollaborativeArrangementAdditionalDevelopmentCandidatesToBeDelivered_label_en-US" xlink:label="lab_alny_CollaborativeArrangementAdditionalDevelopmentCandidatesToBeDelivered" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Additional Development Candidates To Be Delivered</link:label>
    <link:label id="lab_alny_CollaborativeArrangementAdditionalDevelopmentCandidatesToBeDelivered_documentation_en-US" xlink:label="lab_alny_CollaborativeArrangementAdditionalDevelopmentCandidatesToBeDelivered" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Additional Development Candidates To Be Delivered</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_CollaborativeArrangementAdditionalDevelopmentCandidatesToBeDelivered" xlink:href="alny-20210331.xsd#alny_CollaborativeArrangementAdditionalDevelopmentCandidatesToBeDelivered"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_CollaborativeArrangementAdditionalDevelopmentCandidatesToBeDelivered" xlink:to="lab_alny_CollaborativeArrangementAdditionalDevelopmentCandidatesToBeDelivered" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_76d310e5-ec27-4164-9efd-c27e8769f7ad_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock_ef3f55fd-fb82-40e2-880b-55efc14874d4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Fair Value of Marketable Debt Securities</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedInvestmentsNoncurrent_90247464-6e5e-4764-a7f1-2ffbc9d64be5_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedInvestmentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted investments</link:label>
    <link:label id="lab_us-gaap_RestrictedInvestmentsNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedInvestmentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Investments, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedInvestmentsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedInvestmentsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedInvestmentsNoncurrent" xlink:to="lab_us-gaap_RestrictedInvestmentsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_8f0985d5-b178-4757-9760-557ddcbb9cd3_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital expenditures included in accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_3fd56e6b-bc49-4516-bf81-f4dd842ff70f_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_RoyaltyLiabilityInterestExpenseIncludingAmortizationOfClosingCosts_6c186e74-bb79-492e-8b05-02e7027083bd_terseLabel_en-US" xlink:label="lab_alny_RoyaltyLiabilityInterestExpenseIncludingAmortizationOfClosingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense including amortization of closing costs</link:label>
    <link:label id="lab_alny_RoyaltyLiabilityInterestExpenseIncludingAmortizationOfClosingCosts_label_en-US" xlink:label="lab_alny_RoyaltyLiabilityInterestExpenseIncludingAmortizationOfClosingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Liability, Interest Expense Including Amortization Of Closing Costs</link:label>
    <link:label id="lab_alny_RoyaltyLiabilityInterestExpenseIncludingAmortizationOfClosingCosts_documentation_en-US" xlink:label="lab_alny_RoyaltyLiabilityInterestExpenseIncludingAmortizationOfClosingCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Liability, Interest Expense Including Amortization Of Closing Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_RoyaltyLiabilityInterestExpenseIncludingAmortizationOfClosingCosts" xlink:href="alny-20210331.xsd#alny_RoyaltyLiabilityInterestExpenseIncludingAmortizationOfClosingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_RoyaltyLiabilityInterestExpenseIncludingAmortizationOfClosingCosts" xlink:to="lab_alny_RoyaltyLiabilityInterestExpenseIncludingAmortizationOfClosingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_b1cce119-a190-4f94-911c-8f587209c0af_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_bd8204d7-28d6-4068-b09a-db998404115c_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_77d581ab-1b8c-4035-9255-086458c25b0b_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityAbstract_c170c58c-e1d7-4ff7-a7c6-5c174e48fdb5_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Abstract]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityAbstract_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityAbstract" xlink:to="lab_us-gaap_LineOfCreditFacilityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_38ed729c-4365-478a-8d1b-f43fbdb05c18_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_a779901f-264d-425d-82eb-cd16f721c79c_verboseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_d96ad38a-d142-4af9-8f50-b24f5fc9cb47_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_7df6a660-5018-46dc-ac30-d6cc42668cdf_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_f1a31181-d077-4711-9c18-ab6d0656fb4a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Marketable Debt Securities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_e4530509-684c-419b-8688-30e0b93e4926_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_ScheduleOfRevenueRecognizedBasedOnAccountingGuidanceTableTextBlock_bdb8cdfb-03b0-40db-82ad-68928849d864_terseLabel_en-US" xlink:label="lab_alny_ScheduleOfRevenueRecognizedBasedOnAccountingGuidanceTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue Recognized Based on Accounting Guidance</link:label>
    <link:label id="lab_alny_ScheduleOfRevenueRecognizedBasedOnAccountingGuidanceTableTextBlock_label_en-US" xlink:label="lab_alny_ScheduleOfRevenueRecognizedBasedOnAccountingGuidanceTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue Recognized Based on Accounting Guidance [Table Text Block]</link:label>
    <link:label id="lab_alny_ScheduleOfRevenueRecognizedBasedOnAccountingGuidanceTableTextBlock_documentation_en-US" xlink:label="lab_alny_ScheduleOfRevenueRecognizedBasedOnAccountingGuidanceTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue Recognized Based on Accounting Guidance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_ScheduleOfRevenueRecognizedBasedOnAccountingGuidanceTableTextBlock" xlink:href="alny-20210331.xsd#alny_ScheduleOfRevenueRecognizedBasedOnAccountingGuidanceTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_ScheduleOfRevenueRecognizedBasedOnAccountingGuidanceTableTextBlock" xlink:to="lab_alny_ScheduleOfRevenueRecognizedBasedOnAccountingGuidanceTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_ExtendedAdditionalDiscoveryPeriodOfProgramsDevelopment_3c50ca42-3abe-45ed-af1a-9a1c9fd0da6e_terseLabel_en-US" xlink:label="lab_alny_ExtendedAdditionalDiscoveryPeriodOfProgramsDevelopment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Extended additional discovery period of programs development</link:label>
    <link:label id="lab_alny_ExtendedAdditionalDiscoveryPeriodOfProgramsDevelopment_label_en-US" xlink:label="lab_alny_ExtendedAdditionalDiscoveryPeriodOfProgramsDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Extended Additional Discovery Period Of Programs Development</link:label>
    <link:label id="lab_alny_ExtendedAdditionalDiscoveryPeriodOfProgramsDevelopment_documentation_en-US" xlink:label="lab_alny_ExtendedAdditionalDiscoveryPeriodOfProgramsDevelopment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Extended additional discovery period of programs development.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_ExtendedAdditionalDiscoveryPeriodOfProgramsDevelopment" xlink:href="alny-20210331.xsd#alny_ExtendedAdditionalDiscoveryPeriodOfProgramsDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_ExtendedAdditionalDiscoveryPeriodOfProgramsDevelopment" xlink:to="lab_alny_ExtendedAdditionalDiscoveryPeriodOfProgramsDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_CollaborativeArrangementFixedPaymentMultiplier_5552a908-4b3a-4426-b5c2-3a25722239ac_terseLabel_en-US" xlink:label="lab_alny_CollaborativeArrangementFixedPaymentMultiplier" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed payment multiplier</link:label>
    <link:label id="lab_alny_CollaborativeArrangementFixedPaymentMultiplier_label_en-US" xlink:label="lab_alny_CollaborativeArrangementFixedPaymentMultiplier" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Fixed Payment Multiplier</link:label>
    <link:label id="lab_alny_CollaborativeArrangementFixedPaymentMultiplier_documentation_en-US" xlink:label="lab_alny_CollaborativeArrangementFixedPaymentMultiplier" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Fixed Payment Multiplier</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_CollaborativeArrangementFixedPaymentMultiplier" xlink:href="alny-20210331.xsd#alny_CollaborativeArrangementFixedPaymentMultiplier"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_CollaborativeArrangementFixedPaymentMultiplier" xlink:to="lab_alny_CollaborativeArrangementFixedPaymentMultiplier" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_FuturePaymentsOnAchievementOfSpecifiedCommercializationMilestones_7d6067f3-c44b-472c-9279-dab4ebfbb171_terseLabel_en-US" xlink:label="lab_alny_FuturePaymentsOnAchievementOfSpecifiedCommercializationMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future payments on achievement of specified commercialization milestones</link:label>
    <link:label id="lab_alny_FuturePaymentsOnAchievementOfSpecifiedCommercializationMilestones_label_en-US" xlink:label="lab_alny_FuturePaymentsOnAchievementOfSpecifiedCommercializationMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future Payments On Achievement Of Specified Commercialization Milestones</link:label>
    <link:label id="lab_alny_FuturePaymentsOnAchievementOfSpecifiedCommercializationMilestones_documentation_en-US" xlink:label="lab_alny_FuturePaymentsOnAchievementOfSpecifiedCommercializationMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future payments on achievement of specified commercialization milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_FuturePaymentsOnAchievementOfSpecifiedCommercializationMilestones" xlink:href="alny-20210331.xsd#alny_FuturePaymentsOnAchievementOfSpecifiedCommercializationMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_FuturePaymentsOnAchievementOfSpecifiedCommercializationMilestones" xlink:to="lab_alny_FuturePaymentsOnAchievementOfSpecifiedCommercializationMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_2176656d-db10-426d-a4fe-19b7d94656e9_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_6ede2b3e-6745-4d8c-9aa1-0879d5f0b6a8_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_53df0b4e-47d7-4207-b84a-c4b435787a76_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_CollaborativeArrangementConsiderationReceived_2372da8a-80fb-4687-96a1-a3620dd74af7_terseLabel_en-US" xlink:label="lab_alny_CollaborativeArrangementConsiderationReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration received</link:label>
    <link:label id="lab_alny_CollaborativeArrangementConsiderationReceived_label_en-US" xlink:label="lab_alny_CollaborativeArrangementConsiderationReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Consideration Received</link:label>
    <link:label id="lab_alny_CollaborativeArrangementConsiderationReceived_documentation_en-US" xlink:label="lab_alny_CollaborativeArrangementConsiderationReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Consideration Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_CollaborativeArrangementConsiderationReceived" xlink:href="alny-20210331.xsd#alny_CollaborativeArrangementConsiderationReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_CollaborativeArrangementConsiderationReceived" xlink:to="lab_alny_CollaborativeArrangementConsiderationReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_c14e8d6f-a241-4841-9e49-42c47b7fa34e_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementScenarioAxis_eaef62af-7542-4a38-915c-63077c560efd_terseLabel_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_srt_StatementScenarioAxis_label_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_40e52523-ceb2-450a-9bb2-1a605967476e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount received under the Funding Agreement</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LondonInterbankOfferedRateLiborSwapRateMember_6c491641-204c-46f0-bc4f-291c83992dbc_terseLabel_en-US" xlink:label="lab_us-gaap_LondonInterbankOfferedRateLiborSwapRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIBOR</link:label>
    <link:label id="lab_us-gaap_LondonInterbankOfferedRateLiborSwapRateMember_label_en-US" xlink:label="lab_us-gaap_LondonInterbankOfferedRateLiborSwapRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">London Interbank Offered Rate (LIBOR) Swap Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLiborSwapRateMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LondonInterbankOfferedRateLiborSwapRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LondonInterbankOfferedRateLiborSwapRateMember" xlink:to="lab_us-gaap_LondonInterbankOfferedRateLiborSwapRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_0d8ee5ac-f151-4e03-8214-e07446ae0a90_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiGainLoss_998034b5-cff3-47f5-9227-b77b4d3af190_negatedLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Realized and unrealized gain on marketable equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiGainLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_GlobalStrategicCollaborationMember_1960e2a6-75ae-4646-bb17-6eee09f7fd5b_terseLabel_en-US" xlink:label="lab_alny_GlobalStrategicCollaborationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global Strategic Collaboration</link:label>
    <link:label id="lab_alny_GlobalStrategicCollaborationMember_label_en-US" xlink:label="lab_alny_GlobalStrategicCollaborationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global Strategic Collaboration [Member]</link:label>
    <link:label id="lab_alny_GlobalStrategicCollaborationMember_documentation_en-US" xlink:label="lab_alny_GlobalStrategicCollaborationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global strategic collaboration.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_GlobalStrategicCollaborationMember" xlink:href="alny-20210331.xsd#alny_GlobalStrategicCollaborationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_GlobalStrategicCollaborationMember" xlink:to="lab_alny_GlobalStrategicCollaborationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_bd187e31-1aec-472f-865e-57d6e1db705f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized (loss) gain on marketable securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_c3007a25-9b92-4323-b4f5-182c37962f01_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_AccumulatedLossOnInvestmentInJointVentureMember_cd70bc56-cbfa-4977-9b26-431b9527d407_terseLabel_en-US" xlink:label="lab_alny_AccumulatedLossOnInvestmentInJointVentureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on Investment in Joint Venture</link:label>
    <link:label id="lab_alny_AccumulatedLossOnInvestmentInJointVentureMember_label_en-US" xlink:label="lab_alny_AccumulatedLossOnInvestmentInJointVentureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Loss On Investment In Joint Venture [Member]</link:label>
    <link:label id="lab_alny_AccumulatedLossOnInvestmentInJointVentureMember_documentation_en-US" xlink:label="lab_alny_AccumulatedLossOnInvestmentInJointVentureMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated loss on investment in joint venture.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_AccumulatedLossOnInvestmentInJointVentureMember" xlink:href="alny-20210331.xsd#alny_AccumulatedLossOnInvestmentInJointVentureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_AccumulatedLossOnInvestmentInJointVentureMember" xlink:to="lab_alny_AccumulatedLossOnInvestmentInJointVentureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_6fe118b0-fd97-4b51-9e2a-d4ca55e7fb27_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_9f893c9d-5a3b-4736-8997-cddabf9e6e6b_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BASIS OF PRESENTATION AND PRINCIPLES OF CONSOLIDATION</link:label>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Description and Basis of Presentation [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_36d7f8aa-ee39-423a-b24c-09883d5c8331_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_RoyaltyLiabilityCurrent_e1b90a66-7d17-4e21-bb6e-c04dc42fb6b0_terseLabel_en-US" xlink:label="lab_alny_RoyaltyLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability related to the sale of future royalties</link:label>
    <link:label id="lab_alny_RoyaltyLiabilityCurrent_label_en-US" xlink:label="lab_alny_RoyaltyLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Liability, Current</link:label>
    <link:label id="lab_alny_RoyaltyLiabilityCurrent_documentation_en-US" xlink:label="lab_alny_RoyaltyLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_RoyaltyLiabilityCurrent" xlink:href="alny-20210331.xsd#alny_RoyaltyLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_RoyaltyLiabilityCurrent" xlink:to="lab_alny_RoyaltyLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_dbd44459-13b8-4112-ae07-b1a23b232dbd_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_86ff574d-ec67-4aee-aad7-8892dfd5c04a_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_50b78ca2-872c-4c21-a7f7-9378b8edcde0_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with customer liability revenue recognized</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_f6fa8162-e7ff-4a4f-aea5-676404b07f71_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_765610f4-74a6-40f5-b270-cd17ba80832a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quoted Prices in Active Markets (Level 1)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_acdc01d5-ba0a-4876-b6ef-768cb8f7fda2_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_ExpectedRoyaltyInterestPayments_7e519ada-a1fb-4f51-9471-f566850f198e_terseLabel_en-US" xlink:label="lab_alny_ExpectedRoyaltyInterestPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected royalty interest payments</link:label>
    <link:label id="lab_alny_ExpectedRoyaltyInterestPayments_label_en-US" xlink:label="lab_alny_ExpectedRoyaltyInterestPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected Royalty Interest Payments</link:label>
    <link:label id="lab_alny_ExpectedRoyaltyInterestPayments_documentation_en-US" xlink:label="lab_alny_ExpectedRoyaltyInterestPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected Royalty Interest Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_ExpectedRoyaltyInterestPayments" xlink:href="alny-20210331.xsd#alny_ExpectedRoyaltyInterestPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_ExpectedRoyaltyInterestPayments" xlink:to="lab_alny_ExpectedRoyaltyInterestPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_VutrisiranMember_89a581e3-d954-4657-b4be-530b01c60383_terseLabel_en-US" xlink:label="lab_alny_VutrisiranMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vutrisiran</link:label>
    <link:label id="lab_alny_VutrisiranMember_label_en-US" xlink:label="lab_alny_VutrisiranMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vutrisiran [Member]</link:label>
    <link:label id="lab_alny_VutrisiranMember_documentation_en-US" xlink:label="lab_alny_VutrisiranMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vutrisiran</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_VutrisiranMember" xlink:href="alny-20210331.xsd#alny_VutrisiranMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_VutrisiranMember" xlink:to="lab_alny_VutrisiranMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b1ed6b00-6f3d-4916-8b7b-af5fa5385629_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_f2015d70-d784-473f-b682-53f12cab0cb1_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_65341c1b-4608-4b4e-b5e7-6bfbcef1acdd_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_ac8de9e9-c721-42a3-9258-8409caaa6330_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement_9d012e7a-6883-4451-b486-ce4bc62c8a33_terseLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement_label_en-US" xlink:label="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Operating Activities, Cash Flow Statement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:to="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_101ac461-ec32-42fe-a6c3-8d32d73f8b0d_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_ee268d3c-6dd5-4395-981c-1e332cdd2c94_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class</link:label>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByAssetClassAxis" xlink:to="lab_us-gaap_FairValueByAssetClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilities_00ce868b-a101-4234-a45a-bd3778aff994_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development derivative liability (Note 10)</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilities_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilities" xlink:to="lab_us-gaap_DerivativeLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_CollaborativeAgreementTerminationPeriod_2d0dfea6-5d66-46a5-b115-f984db5c05af_terseLabel_en-US" xlink:label="lab_alny_CollaborativeAgreementTerminationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreement termination period</link:label>
    <link:label id="lab_alny_CollaborativeAgreementTerminationPeriod_label_en-US" xlink:label="lab_alny_CollaborativeAgreementTerminationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement Termination Period</link:label>
    <link:label id="lab_alny_CollaborativeAgreementTerminationPeriod_documentation_en-US" xlink:label="lab_alny_CollaborativeAgreementTerminationPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative agreement termination period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_CollaborativeAgreementTerminationPeriod" xlink:href="alny-20210331.xsd#alny_CollaborativeAgreementTerminationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_CollaborativeAgreementTerminationPeriod" xlink:to="lab_alny_CollaborativeAgreementTerminationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3e98401d-76e7-46d6-94cc-48feb70759d2_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_CollaborativeArrangementFixedPaymentTerm_c041ac4c-8ebf-490d-9e1a-7a284a045215_terseLabel_en-US" xlink:label="lab_alny_CollaborativeArrangementFixedPaymentTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed payment, term</link:label>
    <link:label id="lab_alny_CollaborativeArrangementFixedPaymentTerm_label_en-US" xlink:label="lab_alny_CollaborativeArrangementFixedPaymentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Fixed Payment, Term</link:label>
    <link:label id="lab_alny_CollaborativeArrangementFixedPaymentTerm_documentation_en-US" xlink:label="lab_alny_CollaborativeArrangementFixedPaymentTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Fixed Payment, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_CollaborativeArrangementFixedPaymentTerm" xlink:href="alny-20210331.xsd#alny_CollaborativeArrangementFixedPaymentTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_CollaborativeArrangementFixedPaymentTerm" xlink:to="lab_alny_CollaborativeArrangementFixedPaymentTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_c7529220-9e6d-4a33-ba53-03cf6c511fcb_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_4196352a-5c30-402a-a07b-121d5f3031d8_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_299aa7df-3807-4d97-ba8c-b9ff87af1dff_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_dc0c3439-a351-400a-9b40-712f8e7878c7_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_108acc28-c655-4a20-8cae-8c0d5d3f8512_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_eb1acc95-8d8a-449e-aa14-8d0dd7df592e_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_b1eb0549-c766-4e0c-b320-16e683a04ae9_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total research and development expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_233b61f4-5bda-4c4c-a2b6-d4143ca50789_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_CostOfCollaborationManufacturingAndRoyalties_fc290187-6153-4ae3-ad8d-7ac82ca825a6_terseLabel_en-US" xlink:label="lab_alny_CostOfCollaborationManufacturingAndRoyalties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of collaborations</link:label>
    <link:label id="lab_alny_CostOfCollaborationManufacturingAndRoyalties_label_en-US" xlink:label="lab_alny_CostOfCollaborationManufacturingAndRoyalties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost Of Collaboration Manufacturing And Royalties</link:label>
    <link:label id="lab_alny_CostOfCollaborationManufacturingAndRoyalties_documentation_en-US" xlink:label="lab_alny_CostOfCollaborationManufacturingAndRoyalties" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost Of Collaboration Manufacturing And Royalties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_CostOfCollaborationManufacturingAndRoyalties" xlink:href="alny-20210331.xsd#alny_CostOfCollaborationManufacturingAndRoyalties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_CostOfCollaborationManufacturingAndRoyalties" xlink:to="lab_alny_CostOfCollaborationManufacturingAndRoyalties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cfa9dbc5-e68e-4b1b-9d67-36f0ffde893d_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_8b6fc60c-c0e2-4b53-9561-2bdaf3829d11_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_09a35d56-cd23-402c-97a7-339c7c164113_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_NumberOfClinicalProgramsInLateStages_e16a8a74-bdf2-40f3-9a24-2e44fe1b9305_terseLabel_en-US" xlink:label="lab_alny_NumberOfClinicalProgramsInLateStages" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of clinical programs in late stages</link:label>
    <link:label id="lab_alny_NumberOfClinicalProgramsInLateStages_label_en-US" xlink:label="lab_alny_NumberOfClinicalProgramsInLateStages" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Clinical Programs In Late Stages</link:label>
    <link:label id="lab_alny_NumberOfClinicalProgramsInLateStages_documentation_en-US" xlink:label="lab_alny_NumberOfClinicalProgramsInLateStages" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Clinical Programs In Late Stages</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_NumberOfClinicalProgramsInLateStages" xlink:href="alny-20210331.xsd#alny_NumberOfClinicalProgramsInLateStages"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_NumberOfClinicalProgramsInLateStages" xlink:to="lab_alny_NumberOfClinicalProgramsInLateStages" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_da7eb139-bcc4-4e9c-a112-589885f8cf90_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liability, net of current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_98cefbff-0319-4ac5-9e61-fc976e9437e0_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_b3d8f317-88e6-4ccf-9139-3bffe9830724_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_MilestonePaymentEarnedShares_1951d098-51e2-4d22-95eb-e97a71f2aeda_terseLabel_en-US" xlink:label="lab_alny_MilestonePaymentEarnedShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone shares earned (in shares)</link:label>
    <link:label id="lab_alny_MilestonePaymentEarnedShares_label_en-US" xlink:label="lab_alny_MilestonePaymentEarnedShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payment Earned, Shares</link:label>
    <link:label id="lab_alny_MilestonePaymentEarnedShares_documentation_en-US" xlink:label="lab_alny_MilestonePaymentEarnedShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payment Earned, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_MilestonePaymentEarnedShares" xlink:href="alny-20210331.xsd#alny_MilestonePaymentEarnedShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_MilestonePaymentEarnedShares" xlink:to="lab_alny_MilestonePaymentEarnedShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_7dd6aa9b-f213-4f0d-86fa-e908b0a11f4f_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_dafb43c3-42e9-49ef-a148-41bd6cd978ca_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_5f42b9d8-b7c4-4bfc-a51a-aa7fda999095_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_6dd10549-f660-4624-a698-46354fdfbb71_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_e66e1199-40a4-41a8-9bdc-68a439fb70d1_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. government-sponsored enterprise securities</link:label>
    <link:label id="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government-sponsored Enterprises Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_690be678-1403-4c0c-bb9a-c4e7dc8465b2_terseLabel_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_label_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_48a585c2-e263-4dff-bedc-2a493726cbf5_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_40b36ebe-6270-484f-8a2e-cd44e98ae530_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_c79b6a0b-a370-40c4-8635-7ed602f6a384_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_7f4c63e6-876a-4a6e-8f8c-57f0965c8274_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_f04fb032-787d-40d1-9668-d0cab2adec3a_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_ScheduleOfAllocatedTransactionPriceTableTextBlock_4c47989a-e5d0-43dc-ae84-297a151a6b3b_terseLabel_en-US" xlink:label="lab_alny_ScheduleOfAllocatedTransactionPriceTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Allocated Transaction Price Based on Accounting Guidance</link:label>
    <link:label id="lab_alny_ScheduleOfAllocatedTransactionPriceTableTextBlock_label_en-US" xlink:label="lab_alny_ScheduleOfAllocatedTransactionPriceTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Allocated Transaction Price [Table Text Block]</link:label>
    <link:label id="lab_alny_ScheduleOfAllocatedTransactionPriceTableTextBlock_documentation_en-US" xlink:label="lab_alny_ScheduleOfAllocatedTransactionPriceTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Allocated Transaction Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_ScheduleOfAllocatedTransactionPriceTableTextBlock" xlink:href="alny-20210331.xsd#alny_ScheduleOfAllocatedTransactionPriceTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_ScheduleOfAllocatedTransactionPriceTableTextBlock" xlink:to="lab_alny_ScheduleOfAllocatedTransactionPriceTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_UpfrontFeeReceived_e1b7181e-42bf-45ee-beb9-ff60767e6eaa_terseLabel_en-US" xlink:label="lab_alny_UpfrontFeeReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront fee received</link:label>
    <link:label id="lab_alny_UpfrontFeeReceived_label_en-US" xlink:label="lab_alny_UpfrontFeeReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront Fee Received</link:label>
    <link:label id="lab_alny_UpfrontFeeReceived_documentation_en-US" xlink:label="lab_alny_UpfrontFeeReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the amount of upfront fees received under the terms of collaborative and licensing agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_UpfrontFeeReceived" xlink:href="alny-20210331.xsd#alny_UpfrontFeeReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_UpfrontFeeReceived" xlink:to="lab_alny_UpfrontFeeReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_b5749da9-8e3d-4aaf-ace3-857bf43ddc8b_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Net Product Revenues</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_b9552a1b-8715-444c-9480-3e0b9e3f7d5a_negatedLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts reclassified from other comprehensive income</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:to="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_3118d9ec-cc27-4d1c-ad32-adf92b298b3f_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_e9657dec-f475-4691-9e46-93e3cc7f35b8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_ProductAlliancesMember_71a0d532-d809-4ece-957c-be9b919cb572_terseLabel_en-US" xlink:label="lab_alny_ProductAlliancesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Alliances</link:label>
    <link:label id="lab_alny_ProductAlliancesMember_label_en-US" xlink:label="lab_alny_ProductAlliancesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Alliances [Member]</link:label>
    <link:label id="lab_alny_ProductAlliancesMember_documentation_en-US" xlink:label="lab_alny_ProductAlliancesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product alliances.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_ProductAlliancesMember" xlink:href="alny-20210331.xsd#alny_ProductAlliancesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_ProductAlliancesMember" xlink:to="lab_alny_ProductAlliancesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_7ec4fbfc-8c53-47d3-bc3d-79d7d9270a49_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock Based Compensation</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Cost by Plan [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_faec8252-a572-4793-82ec-3c12602a8677_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_PercentageOfMaximumRoyaltyPayments_bc77f5e7-827e-42a5-85c4-b115beb9228d_terseLabel_en-US" xlink:label="lab_alny_PercentageOfMaximumRoyaltyPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum percentage of royalty payments</link:label>
    <link:label id="lab_alny_PercentageOfMaximumRoyaltyPayments_label_en-US" xlink:label="lab_alny_PercentageOfMaximumRoyaltyPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Maximum Royalty Payments</link:label>
    <link:label id="lab_alny_PercentageOfMaximumRoyaltyPayments_documentation_en-US" xlink:label="lab_alny_PercentageOfMaximumRoyaltyPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of maximum royalty payments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_PercentageOfMaximumRoyaltyPayments" xlink:href="alny-20210331.xsd#alny_PercentageOfMaximumRoyaltyPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_PercentageOfMaximumRoyaltyPayments" xlink:to="lab_alny_PercentageOfMaximumRoyaltyPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_04ec9e0a-21a6-462c-bc8c-989fd767b9ec_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_d96cf325-f16b-4095-a109-e23e28656136_verboseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_d32a50e4-0783-4e8a-a21e-d6d66fbac284_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNi" xlink:to="lab_us-gaap_EquitySecuritiesFvNi" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_8c192e77-d963-4b0e-9c47-8321feff20d5_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNoncurrent_e4f8815e-8edc-48cc-8515-42e0ff14fc42_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNoncurrent_label_en-US" xlink:label="lab_us-gaap_InventoryNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNoncurrent" xlink:to="lab_us-gaap_InventoryNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BaseRateMember_e125fdf8-cf77-4a53-8721-ffc05a8b159d_terseLabel_en-US" xlink:label="lab_us-gaap_BaseRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Base Rate</link:label>
    <link:label id="lab_us-gaap_BaseRateMember_label_en-US" xlink:label="lab_us-gaap_BaseRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Base Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BaseRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BaseRateMember" xlink:to="lab_us-gaap_BaseRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_3a4b836a-64b3-420a-8b4a-b0d60531aa76_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive (loss) income before reclassifications</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), before Reclassifications, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_2a8bd95e-5c9e-4acf-bd47-f52e5de77a69_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_2378532b-3aa9-49bd-a8d8-402964955f94_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_c086500c-d1a9-46c7-a26e-72e7dd911145_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalents_d1fd4472-921c-459a-87bf-7d4baa25d950_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash (money market funds)</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalents_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalents" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_48b131e1-58e1-434f-99c3-840272567397_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of goods sold</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_060eaf03-8c56-4f91-90eb-82e489145eb9_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable debt securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_868c31a4-4768-46e6-aa7d-646b3eced11e_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_f99a29e0-1bd1-42c7-9f00-28a1269cdf93_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_04b2f31f-4078-4af7-a0e0-5cb23008808b_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating costs and expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_0a1eaec3-fb2f-4847-82d7-8d4ee0f97ec6_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockMember_a8ddf75f-1d75-4517-838c-735732f97b45_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested restricted common stock</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9d1f7670-d0b5-45c7-b226-1a7345e715cb_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_2de7adcc-df7c-49af-80a4-19a356f53ac8_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_ed10cfe1-ad5e-4c34-b5f2-e08585ef5a9a_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_83cd0507-34ff-4cea-a4fd-67a124b608e2_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_e5920d03-1ea1-4d83-ad6d-becc811452d9_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EuropeMember_83945d1e-37b8-4ce9-a2aa-4c65848087ad_terseLabel_en-US" xlink:label="lab_srt_EuropeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Europe</link:label>
    <link:label id="lab_srt_EuropeMember_label_en-US" xlink:label="lab_srt_EuropeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Europe [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EuropeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EuropeMember" xlink:to="lab_srt_EuropeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_DebtInstrumentNumberOfTranches_b64f154f-37a8-4458-9218-e33f8eec41ca_terseLabel_en-US" xlink:label="lab_alny_DebtInstrumentNumberOfTranches" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of tranches</link:label>
    <link:label id="lab_alny_DebtInstrumentNumberOfTranches_label_en-US" xlink:label="lab_alny_DebtInstrumentNumberOfTranches" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Number Of Tranches</link:label>
    <link:label id="lab_alny_DebtInstrumentNumberOfTranches_documentation_en-US" xlink:label="lab_alny_DebtInstrumentNumberOfTranches" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Number Of Tranches</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_DebtInstrumentNumberOfTranches" xlink:href="alny-20210331.xsd#alny_DebtInstrumentNumberOfTranches"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_DebtInstrumentNumberOfTranches" xlink:to="lab_alny_DebtInstrumentNumberOfTranches" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_babef190-a222-4df9-978d-3903fa94168d_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_ScheduleOfRoyaltyLiabilityTableTextBlock_1eda3c6a-3c60-42dc-ac8a-8b24c846c1c3_terseLabel_en-US" xlink:label="lab_alny_ScheduleOfRoyaltyLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Royalty Liability</link:label>
    <link:label id="lab_alny_ScheduleOfRoyaltyLiabilityTableTextBlock_label_en-US" xlink:label="lab_alny_ScheduleOfRoyaltyLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Royalty Liability [Table Text Block]</link:label>
    <link:label id="lab_alny_ScheduleOfRoyaltyLiabilityTableTextBlock_documentation_en-US" xlink:label="lab_alny_ScheduleOfRoyaltyLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Royalty Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_ScheduleOfRoyaltyLiabilityTableTextBlock" xlink:href="alny-20210331.xsd#alny_ScheduleOfRoyaltyLiabilityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_ScheduleOfRoyaltyLiabilityTableTextBlock" xlink:to="lab_alny_ScheduleOfRoyaltyLiabilityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_RegeneronPharmaceuticalsIncorporationMember_73dbc452-68a1-48f9-a43a-9a3441dd610a_terseLabel_en-US" xlink:label="lab_alny_RegeneronPharmaceuticalsIncorporationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regeneron Pharmaceuticals</link:label>
    <link:label id="lab_alny_RegeneronPharmaceuticalsIncorporationMember_label_en-US" xlink:label="lab_alny_RegeneronPharmaceuticalsIncorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regeneron Pharmaceuticals Incorporation [Member]</link:label>
    <link:label id="lab_alny_RegeneronPharmaceuticalsIncorporationMember_documentation_en-US" xlink:label="lab_alny_RegeneronPharmaceuticalsIncorporationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regeneron Pharmaceuticals, Incorporation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_RegeneronPharmaceuticalsIncorporationMember" xlink:href="alny-20210331.xsd#alny_RegeneronPharmaceuticalsIncorporationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_RegeneronPharmaceuticalsIncorporationMember" xlink:to="lab_alny_RegeneronPharmaceuticalsIncorporationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_44d89a82-0931-4345-bdbd-0caf2ee0fe29_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_9b4476cf-0510-4adb-9df0-8a147a68307d_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_525fb865-8766-475c-9a5d-da613dd47dd4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FAIR VALUE MEASUREMENTS</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_21172e66-3287-4dca-ba5b-33b62beddd60_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_eb17c9e9-e171-41a1-afe2-30424d0c1482_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitment fee percentage</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Commitment Fee Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:to="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_Tranche2LoanAndTranche3LoanMember_7e3c5b43-fbbd-449a-b0df-540b7e6f106d_terseLabel_en-US" xlink:label="lab_alny_Tranche2LoanAndTranche3LoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tranche 2 Loan And Tranche 3 Loan</link:label>
    <link:label id="lab_alny_Tranche2LoanAndTranche3LoanMember_label_en-US" xlink:label="lab_alny_Tranche2LoanAndTranche3LoanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tranche 2 Loan And Tranche 3 Loan [Member]</link:label>
    <link:label id="lab_alny_Tranche2LoanAndTranche3LoanMember_documentation_en-US" xlink:label="lab_alny_Tranche2LoanAndTranche3LoanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tranche 2 Loan And Tranche 3 Loan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_Tranche2LoanAndTranche3LoanMember" xlink:href="alny-20210331.xsd#alny_Tranche2LoanAndTranche3LoanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_Tranche2LoanAndTranche3LoanMember" xlink:to="lab_alny_Tranche2LoanAndTranche3LoanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_6a5be179-986a-4807-ae95-c7411da57f34_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationAmortizationAndAccretionNet_2c92370c-bfc8-488b-a336-81f64e0923f7_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAmortizationAndAccretionNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationAmortizationAndAccretionNet_label_en-US" xlink:label="lab_us-gaap_DepreciationAmortizationAndAccretionNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Amortization and Accretion, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAmortizationAndAccretionNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationAmortizationAndAccretionNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAmortizationAndAccretionNet" xlink:to="lab_us-gaap_DepreciationAmortizationAndAccretionNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_291fc8ae-c7b5-4272-b223-008974eb8719_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeTable_8b960859-f90e-4f9f-9fdb-b4eebab8ba9c_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Table]</link:label>
    <link:label id="lab_us-gaap_DerivativeTable_label_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeTable" xlink:to="lab_us-gaap_DerivativeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_84d5b808-73d1-4126-b2bf-e4db72ee7353_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_4b225562-024f-450e-a794-35de06a0cdda_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial assets</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesLineItemsLineItems_2658b414-726a-4410-ab7e-acb9a692c03d_terseLabel_en-US" xlink:label="lab_alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesLineItemsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Related To The Sale Of Future Royalties Line Items [Line Items]</link:label>
    <link:label id="lab_alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesLineItemsLineItems_label_en-US" xlink:label="lab_alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesLineItemsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Related To The Sale Of Future Royalties Line Items [Line Items]</link:label>
    <link:label id="lab_alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesLineItemsLineItems_documentation_en-US" xlink:label="lab_alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesLineItemsLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Related To The Sale Of Future Royalties Line Items</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesLineItemsLineItems" xlink:href="alny-20210331.xsd#alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesLineItemsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesLineItemsLineItems" xlink:to="lab_alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesLineItemsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_FuturePaymentsOnAchievementOfOtherSpecifiedRegulatoryMilestones_db9c4908-201a-4268-898f-9b0cf4ca2bf5_terseLabel_en-US" xlink:label="lab_alny_FuturePaymentsOnAchievementOfOtherSpecifiedRegulatoryMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future payments on achievement of other specified regulatory milestones</link:label>
    <link:label id="lab_alny_FuturePaymentsOnAchievementOfOtherSpecifiedRegulatoryMilestones_label_en-US" xlink:label="lab_alny_FuturePaymentsOnAchievementOfOtherSpecifiedRegulatoryMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future Payments On Achievement Of Other Specified Regulatory Milestones</link:label>
    <link:label id="lab_alny_FuturePaymentsOnAchievementOfOtherSpecifiedRegulatoryMilestones_documentation_en-US" xlink:label="lab_alny_FuturePaymentsOnAchievementOfOtherSpecifiedRegulatoryMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future Payments On Achievement Of Other Specified Regulatory Milestones</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_FuturePaymentsOnAchievementOfOtherSpecifiedRegulatoryMilestones" xlink:href="alny-20210331.xsd#alny_FuturePaymentsOnAchievementOfOtherSpecifiedRegulatoryMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_FuturePaymentsOnAchievementOfOtherSpecifiedRegulatoryMilestones" xlink:to="lab_alny_FuturePaymentsOnAchievementOfOtherSpecifiedRegulatoryMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_1716055d-37de-4cd5-8bb0-2ec7d6fe2a46_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development Derivative Liability Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Derivative Liabilities at Fair Value [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_TrancheThreeLoanMember_4fcf5964-1232-4d71-bd45-571523011d2d_terseLabel_en-US" xlink:label="lab_alny_TrancheThreeLoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tranche 3 Loan</link:label>
    <link:label id="lab_alny_TrancheThreeLoanMember_label_en-US" xlink:label="lab_alny_TrancheThreeLoanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tranche Three Loan [Member]</link:label>
    <link:label id="lab_alny_TrancheThreeLoanMember_documentation_en-US" xlink:label="lab_alny_TrancheThreeLoanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tranche Loan Three Member</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_TrancheThreeLoanMember" xlink:href="alny-20210331.xsd#alny_TrancheThreeLoanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_TrancheThreeLoanMember" xlink:to="lab_alny_TrancheThreeLoanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_6cea86f6-15e0-42d3-bda9-657725229e0a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate floor</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_8828e2d2-7fa4-4459-a140-8f3648944745_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_MaximumNumberOfPotentialFutureMilestones_1a24adf9-38ed-43f1-af14-33ea1802c0df_terseLabel_en-US" xlink:label="lab_alny_MaximumNumberOfPotentialFutureMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum amount of potential future milestones</link:label>
    <link:label id="lab_alny_MaximumNumberOfPotentialFutureMilestones_label_en-US" xlink:label="lab_alny_MaximumNumberOfPotentialFutureMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Number Of Potential Future Milestones</link:label>
    <link:label id="lab_alny_MaximumNumberOfPotentialFutureMilestones_documentation_en-US" xlink:label="lab_alny_MaximumNumberOfPotentialFutureMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the maximum amount of pre-specified milestone payments that could potentially be received under the collaborative and licensing agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_MaximumNumberOfPotentialFutureMilestones" xlink:href="alny-20210331.xsd#alny_MaximumNumberOfPotentialFutureMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_MaximumNumberOfPotentialFutureMilestones" xlink:to="lab_alny_MaximumNumberOfPotentialFutureMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_AmortizationAndInterestAccretionRelatedToOperatingLeases_04d96e22-48a4-4040-9c10-0935ce239a2e_terseLabel_en-US" xlink:label="lab_alny_AmortizationAndInterestAccretionRelatedToOperatingLeases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization and interest accretion related to operating leases</link:label>
    <link:label id="lab_alny_AmortizationAndInterestAccretionRelatedToOperatingLeases_label_en-US" xlink:label="lab_alny_AmortizationAndInterestAccretionRelatedToOperatingLeases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization and Interest Accretion Related to Operating Leases</link:label>
    <link:label id="lab_alny_AmortizationAndInterestAccretionRelatedToOperatingLeases_documentation_en-US" xlink:label="lab_alny_AmortizationAndInterestAccretionRelatedToOperatingLeases" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization and Interest Accretion Related to Operating Leases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_AmortizationAndInterestAccretionRelatedToOperatingLeases" xlink:href="alny-20210331.xsd#alny_AmortizationAndInterestAccretionRelatedToOperatingLeases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_AmortizationAndInterestAccretionRelatedToOperatingLeases" xlink:to="lab_alny_AmortizationAndInterestAccretionRelatedToOperatingLeases" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_9d593acd-49ef-401d-9602-f4cb2de07c6f_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_54dda1e2-5df1-4f8e-aefd-2ae4950df73f_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_db4b2e53-5749-4c23-a885-01fab2fcbf99_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables included in &#8220;Accounts receivable, net&#8221;</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_4e69ba75-834b-4c20-83c6-62138ef77ec9_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoods" xlink:to="lab_us-gaap_InventoryFinishedGoods" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_NonCashInterestExpenseOnSaleOfFutureRoyalties_3f180034-4d25-4ddf-b4a1-fae18428bb4e_terseLabel_en-US" xlink:label="lab_alny_NonCashInterestExpenseOnSaleOfFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash interest expense on liability related to the sale of future royalties</link:label>
    <link:label id="lab_alny_NonCashInterestExpenseOnSaleOfFutureRoyalties_label_en-US" xlink:label="lab_alny_NonCashInterestExpenseOnSaleOfFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Cash Interest Expense On Sale Of Future Royalties</link:label>
    <link:label id="lab_alny_NonCashInterestExpenseOnSaleOfFutureRoyalties_documentation_en-US" xlink:label="lab_alny_NonCashInterestExpenseOnSaleOfFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Cash Interest Expense On Sale Of Future Royalties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_NonCashInterestExpenseOnSaleOfFutureRoyalties" xlink:href="alny-20210331.xsd#alny_NonCashInterestExpenseOnSaleOfFutureRoyalties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_NonCashInterestExpenseOnSaleOfFutureRoyalties" xlink:to="lab_alny_NonCashInterestExpenseOnSaleOfFutureRoyalties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_c56f9e5a-10a6-4699-a88a-c69084b49f65_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross_1ad26929-d752-4a25-9c0f-eef18bd09673_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under equity plans (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-based Payment Arrangement, before Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_3c6ce912-782c-4251-afa1-12fd62b51962_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_f5c98258-6456-4997-a128-543b57ab1d7c_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares used to compute basic and diluted net loss per common share (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_21031dad-3815-4f21-b683-90450d4add96_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancingReceivableImpairedLineItems_3d4b0051-8163-4acb-8bc4-c839b701fa83_terseLabel_en-US" xlink:label="lab_us-gaap_FinancingReceivableImpairedLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable, Impaired [Line Items]</link:label>
    <link:label id="lab_us-gaap_FinancingReceivableImpairedLineItems_label_en-US" xlink:label="lab_us-gaap_FinancingReceivableImpairedLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable, Impaired [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivableImpairedLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancingReceivableImpairedLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancingReceivableImpairedLineItems" xlink:to="lab_us-gaap_FinancingReceivableImpairedLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_ResearchCollaboratorDomain_e450254d-6cf2-42b3-936d-c60ccfbdcbd7_terseLabel_en-US" xlink:label="lab_alny_ResearchCollaboratorDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Collaborator [Domain]</link:label>
    <link:label id="lab_alny_ResearchCollaboratorDomain_label_en-US" xlink:label="lab_alny_ResearchCollaboratorDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Collaborator [Domain]</link:label>
    <link:label id="lab_alny_ResearchCollaboratorDomain_documentation_en-US" xlink:label="lab_alny_ResearchCollaboratorDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Collaborator</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_ResearchCollaboratorDomain" xlink:href="alny-20210331.xsd#alny_ResearchCollaboratorDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_ResearchCollaboratorDomain" xlink:to="lab_alny_ResearchCollaboratorDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_TrancheTwoLoanMember_4c5aeb5e-0250-4288-a09f-b0db1097ad08_terseLabel_en-US" xlink:label="lab_alny_TrancheTwoLoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tranche 2 Loan</link:label>
    <link:label id="lab_alny_TrancheTwoLoanMember_label_en-US" xlink:label="lab_alny_TrancheTwoLoanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tranche Two Loan [Member]</link:label>
    <link:label id="lab_alny_TrancheTwoLoanMember_documentation_en-US" xlink:label="lab_alny_TrancheTwoLoanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tranche Loan Two Member</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_TrancheTwoLoanMember" xlink:href="alny-20210331.xsd#alny_TrancheTwoLoanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_TrancheTwoLoanMember" xlink:to="lab_alny_TrancheTwoLoanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_acc0b98c-70dc-4735-984e-2f553bed2a4d_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_FundingAtLeadCandidateIdentificationMember_78bbeb6c-a91b-4fb8-b696-61f28383de17_terseLabel_en-US" xlink:label="lab_alny_FundingAtLeadCandidateIdentificationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funding At Lead Candidate Identification</link:label>
    <link:label id="lab_alny_FundingAtLeadCandidateIdentificationMember_label_en-US" xlink:label="lab_alny_FundingAtLeadCandidateIdentificationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funding At Lead Candidate Identification [Member]</link:label>
    <link:label id="lab_alny_FundingAtLeadCandidateIdentificationMember_documentation_en-US" xlink:label="lab_alny_FundingAtLeadCandidateIdentificationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funding at lead candidate identification.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_FundingAtLeadCandidateIdentificationMember" xlink:href="alny-20210331.xsd#alny_FundingAtLeadCandidateIdentificationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_FundingAtLeadCandidateIdentificationMember" xlink:to="lab_alny_FundingAtLeadCandidateIdentificationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b36cbea8-230e-42c2-b28d-f13baaa619e7_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arrangements and Non-arrangement Transactions</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_CollaborativeArrangementMaximumFunding_ebc3ff1a-e10e-443d-a597-61c1846d7934_terseLabel_en-US" xlink:label="lab_alny_CollaborativeArrangementMaximumFunding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum funding</link:label>
    <link:label id="lab_alny_CollaborativeArrangementMaximumFunding_label_en-US" xlink:label="lab_alny_CollaborativeArrangementMaximumFunding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Maximum Funding</link:label>
    <link:label id="lab_alny_CollaborativeArrangementMaximumFunding_documentation_en-US" xlink:label="lab_alny_CollaborativeArrangementMaximumFunding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Maximum Funding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_CollaborativeArrangementMaximumFunding" xlink:href="alny-20210331.xsd#alny_CollaborativeArrangementMaximumFunding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_CollaborativeArrangementMaximumFunding" xlink:to="lab_alny_CollaborativeArrangementMaximumFunding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_c840f5b1-ec35-423a-92aa-577832bad2d3_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (expense) income:</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_57d9e4dc-231e-4daf-91e4-8cbce388e73b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Principal Amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_07aade0a-7b32-420e-9729-fc09bade6e51_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Observable Inputs (Level 2)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_31e0d50a-1a43-480a-bc1c-49714e59fa01_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_925bfbdd-9f89-4396-8dde-cd1ff91d9813_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_MaximumRoyaltiesAndCommercialMilestonePaymentsUponPotentialProductSale_c3deffd4-fc67-4a11-aab1-655f28c027ba_terseLabel_en-US" xlink:label="lab_alny_MaximumRoyaltiesAndCommercialMilestonePaymentsUponPotentialProductSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum royalties and commercial milestone payments upon potential product sale</link:label>
    <link:label id="lab_alny_MaximumRoyaltiesAndCommercialMilestonePaymentsUponPotentialProductSale_label_en-US" xlink:label="lab_alny_MaximumRoyaltiesAndCommercialMilestonePaymentsUponPotentialProductSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Royalties And Commercial Milestone Payments Upon Potential Product Sale</link:label>
    <link:label id="lab_alny_MaximumRoyaltiesAndCommercialMilestonePaymentsUponPotentialProductSale_documentation_en-US" xlink:label="lab_alny_MaximumRoyaltiesAndCommercialMilestonePaymentsUponPotentialProductSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum royalties and commercial milestone payments upon potential product sale.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_MaximumRoyaltiesAndCommercialMilestonePaymentsUponPotentialProductSale" xlink:href="alny-20210331.xsd#alny_MaximumRoyaltiesAndCommercialMilestonePaymentsUponPotentialProductSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_MaximumRoyaltiesAndCommercialMilestonePaymentsUponPotentialProductSale" xlink:to="lab_alny_MaximumRoyaltiesAndCommercialMilestonePaymentsUponPotentialProductSale" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_d4e77a5a-deb9-4946-800c-d63912ee0e65_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_a191b00d-225f-4d80-a8ae-b246bec0dd82_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total financial assets</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_b8246ac6-3d11-4341-89d1-773fc5543dac_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_DebtInstrumentExitFeePercent_254104ad-f365-4133-b7b3-d70d338f418f_terseLabel_en-US" xlink:label="lab_alny_DebtInstrumentExitFeePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exit fee percent</link:label>
    <link:label id="lab_alny_DebtInstrumentExitFeePercent_label_en-US" xlink:label="lab_alny_DebtInstrumentExitFeePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Exit Fee Percent</link:label>
    <link:label id="lab_alny_DebtInstrumentExitFeePercent_documentation_en-US" xlink:label="lab_alny_DebtInstrumentExitFeePercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Exit Fee Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_DebtInstrumentExitFeePercent" xlink:href="alny-20210331.xsd#alny_DebtInstrumentExitFeePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_DebtInstrumentExitFeePercent" xlink:to="lab_alny_DebtInstrumentExitFeePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_680ba93e-d1a0-47a7-9478-8c3939275a22_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of noncash investing and financing activities:</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_31c96529-3eeb-4a1d-9ca0-13807dcaac17_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_ae913b46-7157-4c56-9b72-16209ec7a803_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_ResearchTermExtensionFee_c072b5f8-8958-449c-8c96-4aebd0e506e0_terseLabel_en-US" xlink:label="lab_alny_ResearchTermExtensionFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research term extension fee</link:label>
    <link:label id="lab_alny_ResearchTermExtensionFee_label_en-US" xlink:label="lab_alny_ResearchTermExtensionFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Term Extension Fee</link:label>
    <link:label id="lab_alny_ResearchTermExtensionFee_documentation_en-US" xlink:label="lab_alny_ResearchTermExtensionFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research term extension fee.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_ResearchTermExtensionFee" xlink:href="alny-20210331.xsd#alny_ResearchTermExtensionFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_ResearchTermExtensionFee" xlink:to="lab_alny_ResearchTermExtensionFee" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_MilestonePaymentEarned_9828c069-2ab3-4ec9-9146-6c73785efdcc_terseLabel_en-US" xlink:label="lab_alny_MilestonePaymentEarned" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payment earned</link:label>
    <link:label id="lab_alny_MilestonePaymentEarned_label_en-US" xlink:label="lab_alny_MilestonePaymentEarned" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payment Earned</link:label>
    <link:label id="lab_alny_MilestonePaymentEarned_documentation_en-US" xlink:label="lab_alny_MilestonePaymentEarned" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the amount earned upon achievement of milestone.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_MilestonePaymentEarned" xlink:href="alny-20210331.xsd#alny_MilestonePaymentEarned"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_MilestonePaymentEarned" xlink:to="lab_alny_MilestonePaymentEarned" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_0b8fed36-0533-46e8-9f2d-d58aa7b662bc_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryCurrentTable_97fbc48c-7aec-4e60-80b2-bf0b2315910a_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryCurrentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Current [Table]</link:label>
    <link:label id="lab_us-gaap_InventoryCurrentTable_label_en-US" xlink:label="lab_us-gaap_InventoryCurrentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Current [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCurrentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryCurrentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryCurrentTable" xlink:to="lab_us-gaap_InventoryCurrentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_ALNAGTPhase2ClinicalTrialMember_fc01bd04-a7c2-4cef-9d9c-faa5ccd01b0b_terseLabel_en-US" xlink:label="lab_alny_ALNAGTPhase2ClinicalTrialMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ALN-AGT Phase 2 Clinical Trial</link:label>
    <link:label id="lab_alny_ALNAGTPhase2ClinicalTrialMember_label_en-US" xlink:label="lab_alny_ALNAGTPhase2ClinicalTrialMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ALN-AGT Phase 2 Clinical Trial [Member]</link:label>
    <link:label id="lab_alny_ALNAGTPhase2ClinicalTrialMember_documentation_en-US" xlink:label="lab_alny_ALNAGTPhase2ClinicalTrialMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ALN-AGT Phase 2 Clinical Trial</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_ALNAGTPhase2ClinicalTrialMember" xlink:href="alny-20210331.xsd#alny_ALNAGTPhase2ClinicalTrialMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_ALNAGTPhase2ClinicalTrialMember" xlink:to="lab_alny_ALNAGTPhase2ClinicalTrialMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_9128b74c-516e-485e-be90-07e1a0053261_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue recognized under ASC 808</link:label>
    <link:label id="lab_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_label_en-US" xlink:label="lab_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:to="lab_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_7d4ce5c6-693f-4359-99a2-c6543caf40e8_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_ef70bfb3-0c62-434a-9540-6c5a8a2f6f58_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transactional price remaining performance obligation</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_e4abce66-40ca-489f-acf9-d9a9bc9db900_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_086f7330-d58b-490e-978e-2cfe73d00b44_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gains from Debt Securities</link:label>
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:to="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_9e9b31ee-5a8b-4ec8-b49b-ee3b6444c775_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_bf79c95f-a831-4df7-ae7a-fa6eb63b96d8_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_8b08b144-d6a0-4928-a260-1a311540c08c_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.01 par value per share, 250,000 shares authorized; 117,321 shares issued and outstanding as of March&#160;31, 2021; 116,427 shares issued and outstanding as of December&#160;31, 2020</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_a9eb0e70-0da7-4c8f-ba64-d073685c453c_verboseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_PotentialProceedsFromCollaborationArrangement_642e6367-5635-4d9b-bd3f-72c2a574ec5c_terseLabel_en-US" xlink:label="lab_alny_PotentialProceedsFromCollaborationArrangement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential proceeds from collaboration arrangement</link:label>
    <link:label id="lab_alny_PotentialProceedsFromCollaborationArrangement_label_en-US" xlink:label="lab_alny_PotentialProceedsFromCollaborationArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Proceeds From Collaboration Arrangement</link:label>
    <link:label id="lab_alny_PotentialProceedsFromCollaborationArrangement_documentation_en-US" xlink:label="lab_alny_PotentialProceedsFromCollaborationArrangement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential proceeds from collaboration arrangement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_PotentialProceedsFromCollaborationArrangement" xlink:href="alny-20210331.xsd#alny_PotentialProceedsFromCollaborationArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_PotentialProceedsFromCollaborationArrangement" xlink:to="lab_alny_PotentialProceedsFromCollaborationArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_44706567-69f6-4ffc-8fd2-f94c265881c2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Receivables Related to Net Product Revenues</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_59236231-4adc-4941-89b1-282168eea24c_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_d6e04267-71b2-4d20-bfe6-013400ff9c3f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss recorded from remeasurement of development derivative liability</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_BlackstoneLifeSciencesMember_3f93523b-35d4-47a0-a2d3-fbd66f3f1a59_terseLabel_en-US" xlink:label="lab_alny_BlackstoneLifeSciencesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Blackstone Life Sciences</link:label>
    <link:label id="lab_alny_BlackstoneLifeSciencesMember_label_en-US" xlink:label="lab_alny_BlackstoneLifeSciencesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Blackstone Life Sciences [Member]</link:label>
    <link:label id="lab_alny_BlackstoneLifeSciencesMember_documentation_en-US" xlink:label="lab_alny_BlackstoneLifeSciencesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Blackstone Life Sciences</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_BlackstoneLifeSciencesMember" xlink:href="alny-20210331.xsd#alny_BlackstoneLifeSciencesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_BlackstoneLifeSciencesMember" xlink:to="lab_alny_BlackstoneLifeSciencesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_006248f4-d09e-4733-9e45-481ee1658262_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_b07c4d33-9707-4592-ae78-0202614d05a4_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NET REVENUES FROM COLLABORATIONS</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_61927ff6-b00b-47f1-899a-8bd63ef37a85_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_92561797-2c4e-4a44-849c-5a7c1572b7b9_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_46b97c53-d487-49fe-a3df-bc630b4c7a5a_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfImpairedFinancingReceivableTable_93d938ab-08eb-4cea-962e-046fc9786d72_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfImpairedFinancingReceivableTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Impaired Financing Receivable [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfImpairedFinancingReceivableTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfImpairedFinancingReceivableTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Impaired Financing Receivable [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfImpairedFinancingReceivableTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfImpairedFinancingReceivableTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfImpairedFinancingReceivableTable" xlink:to="lab_us-gaap_ScheduleOfImpairedFinancingReceivableTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentOwnedBalanceShares_436d5ae5-4491-4c48-86fc-dfe9c524fee1_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentOwnedBalanceShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares of Vir common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_InvestmentOwnedBalanceShares_label_en-US" xlink:label="lab_us-gaap_InvestmentOwnedBalanceShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Owned, Balance, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedBalanceShares" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentOwnedBalanceShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentOwnedBalanceShares" xlink:to="lab_us-gaap_InvestmentOwnedBalanceShares" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_FuturePaymentsOnAchievementOfSpecifiedRegulatoryMilestones_3ebcaf89-5ad1-4c89-b7ff-1c8a085585dc_terseLabel_en-US" xlink:label="lab_alny_FuturePaymentsOnAchievementOfSpecifiedRegulatoryMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future payments on achievement of specified regulatory milestones</link:label>
    <link:label id="lab_alny_FuturePaymentsOnAchievementOfSpecifiedRegulatoryMilestones_label_en-US" xlink:label="lab_alny_FuturePaymentsOnAchievementOfSpecifiedRegulatoryMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future Payments On Achievement Of Specified Regulatory Milestones</link:label>
    <link:label id="lab_alny_FuturePaymentsOnAchievementOfSpecifiedRegulatoryMilestones_documentation_en-US" xlink:label="lab_alny_FuturePaymentsOnAchievementOfSpecifiedRegulatoryMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future payments on achievement of specified regulatory milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_FuturePaymentsOnAchievementOfSpecifiedRegulatoryMilestones" xlink:href="alny-20210331.xsd#alny_FuturePaymentsOnAchievementOfSpecifiedRegulatoryMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_FuturePaymentsOnAchievementOfSpecifiedRegulatoryMilestones" xlink:to="lab_alny_FuturePaymentsOnAchievementOfSpecifiedRegulatoryMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNet_687f5a5a-11f3-48ca-8ffb-9b1e0d6c0000_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables included in &#8220;Accounts receivable, net&#8221;</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNet_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNet" xlink:to="lab_us-gaap_AccountsReceivableNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_fa15b11b-c454-49ea-b21a-849add3390eb_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_b5183a02-dd45-41fe-822b-ef7f891051b8_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_832f97b6-b5a8-4eb4-a3cf-ee22213643f3_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_687455bf-3f75-496d-9bfe-f3d5fd11df61_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_InventoryCurrentAndNoncurrent_f69fe074-e9a4-4dd1-a2fc-964e4cc49209_totalLabel_en-US" xlink:label="lab_alny_InventoryCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_alny_InventoryCurrentAndNoncurrent_label_en-US" xlink:label="lab_alny_InventoryCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Current And Noncurrent</link:label>
    <link:label id="lab_alny_InventoryCurrentAndNoncurrent_documentation_en-US" xlink:label="lab_alny_InventoryCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Current And Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_InventoryCurrentAndNoncurrent" xlink:href="alny-20210331.xsd#alny_InventoryCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_InventoryCurrentAndNoncurrent" xlink:to="lab_alny_InventoryCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_MaximumAdditionalMilestonePaymentsToBeReceiveUponAchievementOfCertainCriteria_7ee7a15d-ba5f-4313-9d28-c7b9dfdd1e98_terseLabel_en-US" xlink:label="lab_alny_MaximumAdditionalMilestonePaymentsToBeReceiveUponAchievementOfCertainCriteria" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum additional milestone payments to be receive upon achievement of certain criteria</link:label>
    <link:label id="lab_alny_MaximumAdditionalMilestonePaymentsToBeReceiveUponAchievementOfCertainCriteria_label_en-US" xlink:label="lab_alny_MaximumAdditionalMilestonePaymentsToBeReceiveUponAchievementOfCertainCriteria" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Additional Milestone Payments To Be Receive Upon Achievement Of Certain Criteria</link:label>
    <link:label id="lab_alny_MaximumAdditionalMilestonePaymentsToBeReceiveUponAchievementOfCertainCriteria_documentation_en-US" xlink:label="lab_alny_MaximumAdditionalMilestonePaymentsToBeReceiveUponAchievementOfCertainCriteria" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum additional milestone payments to be receive upon achievement of certain criteria.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_MaximumAdditionalMilestonePaymentsToBeReceiveUponAchievementOfCertainCriteria" xlink:href="alny-20210331.xsd#alny_MaximumAdditionalMilestonePaymentsToBeReceiveUponAchievementOfCertainCriteria"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_MaximumAdditionalMilestonePaymentsToBeReceiveUponAchievementOfCertainCriteria" xlink:to="lab_alny_MaximumAdditionalMilestonePaymentsToBeReceiveUponAchievementOfCertainCriteria" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NatureOfOperations_c9bf1fd5-a600-4925-ae69-f4129d30096e_terseLabel_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NATURE OF BUSINESS</link:label>
    <link:label id="lab_us-gaap_NatureOfOperations_label_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nature of Operations [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NatureOfOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NatureOfOperations" xlink:to="lab_us-gaap_NatureOfOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_9d8f845f-7935-4388-bcd0-0ff0344dff1a_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityCommitmentFeeAmount_5b0cddce-1bd3-4aad-9bfc-096530aacc5f_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCommitmentFeeAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitment fee amount</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityCommitmentFeeAmount_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCommitmentFeeAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Commitment Fee Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeeAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityCommitmentFeeAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityCommitmentFeeAmount" xlink:to="lab_us-gaap_LineOfCreditFacilityCommitmentFeeAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_01ba4786-c7f5-4807-9b42-6c72ad5165e6_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterials_03397d42-a7f1-4ca7-a396-555829f8562c_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterials" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterials_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterials" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterials"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterials" xlink:to="lab_us-gaap_InventoryRawMaterials" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_f6ab13f6-4ebe-4754-bea0-41642d90d612_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_ExternalServicesMember_86089cdf-a2c2-4fe9-9673-cca07da9d668_terseLabel_en-US" xlink:label="lab_alny_ExternalServicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">External Services</link:label>
    <link:label id="lab_alny_ExternalServicesMember_label_en-US" xlink:label="lab_alny_ExternalServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">External Services [Member]</link:label>
    <link:label id="lab_alny_ExternalServicesMember_documentation_en-US" xlink:label="lab_alny_ExternalServicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">External services.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_ExternalServicesMember" xlink:href="alny-20210331.xsd#alny_ExternalServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_ExternalServicesMember" xlink:to="lab_alny_ExternalServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_e206c7ec-99e1-4573-b8c3-bba52c6d1621_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsMember_bb509221-7d0d-4c9a-9f8a-74d3add8140f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsMember" xlink:to="lab_us-gaap_OtherAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_ded6a53d-162b-40a4-8791-a97a986b0a65_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_CollaborativeArrangementRoyaltiesAndCommercialMilestonesAcquiredByCollaboratorPercent_acfa689c-ee10-4269-b323-abc7bcd1e4e7_terseLabel_en-US" xlink:label="lab_alny_CollaborativeArrangementRoyaltiesAndCommercialMilestonesAcquiredByCollaboratorPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangement, royalties and commercial milestones acquired by collaborator, percent</link:label>
    <link:label id="lab_alny_CollaborativeArrangementRoyaltiesAndCommercialMilestonesAcquiredByCollaboratorPercent_label_en-US" xlink:label="lab_alny_CollaborativeArrangementRoyaltiesAndCommercialMilestonesAcquiredByCollaboratorPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Royalties And Commercial Milestones Acquired By Collaborator, Percent</link:label>
    <link:label id="lab_alny_CollaborativeArrangementRoyaltiesAndCommercialMilestonesAcquiredByCollaboratorPercent_documentation_en-US" xlink:label="lab_alny_CollaborativeArrangementRoyaltiesAndCommercialMilestonesAcquiredByCollaboratorPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Royalties Acquired By Collaborator, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_CollaborativeArrangementRoyaltiesAndCommercialMilestonesAcquiredByCollaboratorPercent" xlink:href="alny-20210331.xsd#alny_CollaborativeArrangementRoyaltiesAndCommercialMilestonesAcquiredByCollaboratorPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_CollaborativeArrangementRoyaltiesAndCommercialMilestonesAcquiredByCollaboratorPercent" xlink:to="lab_alny_CollaborativeArrangementRoyaltiesAndCommercialMilestonesAcquiredByCollaboratorPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_6143fd4b-a63d-4d3a-a453-860a2a430eae_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anti-dilutive securities excluded from computation of earnings per share (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax_16ea3600-6bec-4cbb-b5c6-d1630d941dbb_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined benefit pension plans, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, before Reclassification Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_BlackstoneGroupIncMember_97fdab58-87d0-4eff-b395-e42eb117f7bf_terseLabel_en-US" xlink:label="lab_alny_BlackstoneGroupIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Blackstone Group Inc.</link:label>
    <link:label id="lab_alny_BlackstoneGroupIncMember_label_en-US" xlink:label="lab_alny_BlackstoneGroupIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Blackstone Group Inc. [Member]</link:label>
    <link:label id="lab_alny_BlackstoneGroupIncMember_documentation_en-US" xlink:label="lab_alny_BlackstoneGroupIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Blackstone Group Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_BlackstoneGroupIncMember" xlink:href="alny-20210331.xsd#alny_BlackstoneGroupIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_BlackstoneGroupIncMember" xlink:to="lab_alny_BlackstoneGroupIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductMember_64f62c4e-09a1-4101-b605-5a2f5d81b68f_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net product revenues</link:label>
    <link:label id="lab_us-gaap_ProductMember_label_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_ClinicalTrialAndManufacturingMember_da731a70-b8eb-4784-a13a-d4518a6ede3e_terseLabel_en-US" xlink:label="lab_alny_ClinicalTrialAndManufacturingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical Trial and Manufacturing</link:label>
    <link:label id="lab_alny_ClinicalTrialAndManufacturingMember_label_en-US" xlink:label="lab_alny_ClinicalTrialAndManufacturingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical Trial And Manufacturing [Member]</link:label>
    <link:label id="lab_alny_ClinicalTrialAndManufacturingMember_documentation_en-US" xlink:label="lab_alny_ClinicalTrialAndManufacturingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical trial and manufacturing.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_ClinicalTrialAndManufacturingMember" xlink:href="alny-20210331.xsd#alny_ClinicalTrialAndManufacturingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_ClinicalTrialAndManufacturingMember" xlink:to="lab_alny_ClinicalTrialAndManufacturingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_00780689-ba64-47c4-af30-43d4aa3d6d8d_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_9d6e0e8f-f49c-43d7-b85b-db6461560556_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_InvestmentsInMarketableDebtSecuritiesDisclosureTextBlock_cb3818fc-0ffd-4f46-918b-74e56f30b947_terseLabel_en-US" xlink:label="lab_alny_InvestmentsInMarketableDebtSecuritiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MARKETABLE DEBT SECURITIES</link:label>
    <link:label id="lab_alny_InvestmentsInMarketableDebtSecuritiesDisclosureTextBlock_label_en-US" xlink:label="lab_alny_InvestmentsInMarketableDebtSecuritiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments In Marketable Debt Securities Disclosure [Text Block]</link:label>
    <link:label id="lab_alny_InvestmentsInMarketableDebtSecuritiesDisclosureTextBlock_documentation_en-US" xlink:label="lab_alny_InvestmentsInMarketableDebtSecuritiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in marketable debt securities disclosure.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_InvestmentsInMarketableDebtSecuritiesDisclosureTextBlock" xlink:href="alny-20210331.xsd#alny_InvestmentsInMarketableDebtSecuritiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_InvestmentsInMarketableDebtSecuritiesDisclosureTextBlock" xlink:to="lab_alny_InvestmentsInMarketableDebtSecuritiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_450d0347-dad5-44d3-8ef9-85faf5fbac91_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_65b2edbd-6fab-4c3e-922a-c79fb4833f65_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_69ddfba4-c2b3-43e5-adfb-25177c135a5e_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">STOCK-BASED COMPENSATION</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_0f37ef54-6337-4bcc-be8d-b93cea7cbf28_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_ff6c9903-677f-495a-8153-4444e4b06f5a_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c7d20cd8-8600-4ec9-9699-3b87e26fa1d7_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_RoyaltyLiabilityNoncurrent_6b80b9ed-96a9-4879-b2de-394b4afb9dcb_terseLabel_en-US" xlink:label="lab_alny_RoyaltyLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability related to the sale of future royalties, net of current portion</link:label>
    <link:label id="lab_alny_RoyaltyLiabilityNoncurrent_label_en-US" xlink:label="lab_alny_RoyaltyLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Liability, Noncurrent</link:label>
    <link:label id="lab_alny_RoyaltyLiabilityNoncurrent_documentation_en-US" xlink:label="lab_alny_RoyaltyLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_RoyaltyLiabilityNoncurrent" xlink:href="alny-20210331.xsd#alny_RoyaltyLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_RoyaltyLiabilityNoncurrent" xlink:to="lab_alny_RoyaltyLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_StandaloneSellingPrice_0557ec88-ea41-4b92-80d8-9c365b47e051_terseLabel_en-US" xlink:label="lab_alny_StandaloneSellingPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Standalone Selling Price</link:label>
    <link:label id="lab_alny_StandaloneSellingPrice_label_en-US" xlink:label="lab_alny_StandaloneSellingPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Standalone Selling Price</link:label>
    <link:label id="lab_alny_StandaloneSellingPrice_documentation_en-US" xlink:label="lab_alny_StandaloneSellingPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Standalone Selling Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_StandaloneSellingPrice" xlink:href="alny-20210331.xsd#alny_StandaloneSellingPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_StandaloneSellingPrice" xlink:to="lab_alny_StandaloneSellingPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_1ca4935a-3f22-46c5-ad24-22b41e048625_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other comprehensive income</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_e9a6dea8-2084-417e-980c-9b26e8b95c1c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss), net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcess_477fce17-8fc9-440e-939e-9a06b0b7e2c5_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work in progress</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcess_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcess" xlink:to="lab_us-gaap_InventoryWorkInProcess" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_ONPATTROAndGIVLAARIMember_ba9e7bfb-b776-45e5-9f7f-c2990004cce3_terseLabel_en-US" xlink:label="lab_alny_ONPATTROAndGIVLAARIMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ONPATTRO And GIVLAARI</link:label>
    <link:label id="lab_alny_ONPATTROAndGIVLAARIMember_label_en-US" xlink:label="lab_alny_ONPATTROAndGIVLAARIMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ONPATTRO And GIVLAARI [Member]</link:label>
    <link:label id="lab_alny_ONPATTROAndGIVLAARIMember_documentation_en-US" xlink:label="lab_alny_ONPATTROAndGIVLAARIMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ONPATTRO And GIVLAARI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_ONPATTROAndGIVLAARIMember" xlink:href="alny-20210331.xsd#alny_ONPATTROAndGIVLAARIMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_ONPATTROAndGIVLAARIMember" xlink:to="lab_alny_ONPATTROAndGIVLAARIMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_NonUSOrEuropeMember_15875d0e-befb-47c3-8026-621ab9996c30_terseLabel_en-US" xlink:label="lab_alny_NonUSOrEuropeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rest of World</link:label>
    <link:label id="lab_alny_NonUSOrEuropeMember_label_en-US" xlink:label="lab_alny_NonUSOrEuropeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-US Or Europe [Member]</link:label>
    <link:label id="lab_alny_NonUSOrEuropeMember_documentation_en-US" xlink:label="lab_alny_NonUSOrEuropeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-US Or Europe</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_NonUSOrEuropeMember" xlink:href="alny-20210331.xsd#alny_NonUSOrEuropeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_NonUSOrEuropeMember" xlink:to="lab_alny_NonUSOrEuropeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_ALNAGTPhase3ClinicalTrialMember_544e4bef-9cb5-4e9e-9156-10e9348e99ac_terseLabel_en-US" xlink:label="lab_alny_ALNAGTPhase3ClinicalTrialMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ALN-AGT Phase 3 Clinical Trial</link:label>
    <link:label id="lab_alny_ALNAGTPhase3ClinicalTrialMember_label_en-US" xlink:label="lab_alny_ALNAGTPhase3ClinicalTrialMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ALN-AGT Phase 3 Clinical Trial [Member]</link:label>
    <link:label id="lab_alny_ALNAGTPhase3ClinicalTrialMember_documentation_en-US" xlink:label="lab_alny_ALNAGTPhase3ClinicalTrialMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ALN-AGT Phase 3 Clinical Trial</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_ALNAGTPhase3ClinicalTrialMember" xlink:href="alny-20210331.xsd#alny_ALNAGTPhase3ClinicalTrialMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_ALNAGTPhase3ClinicalTrialMember" xlink:to="lab_alny_ALNAGTPhase3ClinicalTrialMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_aed5e8c7-909f-48a8-be03-f9d50b43ec7f_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_2a53991f-4eb7-458e-ab5c-d7b039e6f69a_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_642d6f10-54de-4da1-8b96-fcd9a0ee788a_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_27a794ae-2ea5-4c9b-8ae2-90ddb13b3d7e_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_a2f8f30a-672c-4729-a5db-da1f2d52ad3f_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_517f2a52-b0c3-4fd9-bddb-f7d37c2e95dd_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Pension Plans</link:label>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:to="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_79b1b8d8-4e38-40df-88a5-5965565bdcbd_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_dc19e759-2d95-40b9-921e-a5ab7dc8da38_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_bc5cf88a-acb0-4abc-8375-182680918338_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_CollaborativeArrangementRoyaltiesPayableTerm_dcb5c18e-d156-429a-8b4a-01ead804bd57_terseLabel_en-US" xlink:label="lab_alny_CollaborativeArrangementRoyaltiesPayableTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalties payable, term</link:label>
    <link:label id="lab_alny_CollaborativeArrangementRoyaltiesPayableTerm_label_en-US" xlink:label="lab_alny_CollaborativeArrangementRoyaltiesPayableTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Royalties Payable, Term</link:label>
    <link:label id="lab_alny_CollaborativeArrangementRoyaltiesPayableTerm_documentation_en-US" xlink:label="lab_alny_CollaborativeArrangementRoyaltiesPayableTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Royalties Payable, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_CollaborativeArrangementRoyaltiesPayableTerm" xlink:href="alny-20210331.xsd#alny_CollaborativeArrangementRoyaltiesPayableTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_CollaborativeArrangementRoyaltiesPayableTerm" xlink:to="lab_alny_CollaborativeArrangementRoyaltiesPayableTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_TransactionPrice_9cffe49c-6874-4b7b-b024-fbff46eb01c9_verboseLabel_en-US" xlink:label="lab_alny_TransactionPrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction price</link:label>
    <link:label id="lab_alny_TransactionPrice_5a4ec49a-678a-4628-8d25-124166cb8519_terseLabel_en-US" xlink:label="lab_alny_TransactionPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction Price Allocated</link:label>
    <link:label id="lab_alny_TransactionPrice_label_en-US" xlink:label="lab_alny_TransactionPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction Price</link:label>
    <link:label id="lab_alny_TransactionPrice_documentation_en-US" xlink:label="lab_alny_TransactionPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The transaction price of a contract is the amount of consideration to which the Company expects to be entitled in exchange for transferring promised goods or services to the customer, excluding amounts that will be collected on behalf of third parties. This amount is expected to include both fixed and variable consideration, subject to certain restrictions.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_TransactionPrice" xlink:href="alny-20210331.xsd#alny_TransactionPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_TransactionPrice" xlink:to="lab_alny_TransactionPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_01f77036-d80b-48ab-a435-20264302ea48_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue, net of current portion</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_RoyaltyLiabilityInterestRate_4f038d71-0064-41df-bb29-93d29484cd4b_terseLabel_en-US" xlink:label="lab_alny_RoyaltyLiabilityInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate</link:label>
    <link:label id="lab_alny_RoyaltyLiabilityInterestRate_label_en-US" xlink:label="lab_alny_RoyaltyLiabilityInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Liability, Interest Rate</link:label>
    <link:label id="lab_alny_RoyaltyLiabilityInterestRate_documentation_en-US" xlink:label="lab_alny_RoyaltyLiabilityInterestRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Liability, Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_RoyaltyLiabilityInterestRate" xlink:href="alny-20210331.xsd#alny_RoyaltyLiabilityInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_RoyaltyLiabilityInterestRate" xlink:to="lab_alny_RoyaltyLiabilityInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_b372ca57-0eba-46b8-8629-2f2dbda6f0a9_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_4c907e75-ab45-4a38-8284-4d0cd4fc27d5_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_a70603ad-63f7-45f4-976c-6b7fa82876a3_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Translation Adjustment</link:label>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Foreign Currency Adjustment Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:to="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_95745797-6306-4c39-ae55-b168e7f7b486_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_8b94e5d9-bba2-47c5-8f42-d6a1839d2afd_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue from Collaborators</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SecuredDebtMember_3fd12a7b-8b49-4752-96b2-3ac3b3cbc151_terseLabel_en-US" xlink:label="lab_us-gaap_SecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Debt</link:label>
    <link:label id="lab_us-gaap_SecuredDebtMember_label_en-US" xlink:label="lab_us-gaap_SecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SecuredDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuredDebtMember" xlink:to="lab_us-gaap_SecuredDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_52ea0fbe-d802-4940-96f7-f6e9516e1a59_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. treasury securities</link:label>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasurySecuritiesMember" xlink:to="lab_us-gaap_USTreasurySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock_f2b3f8f8-bd34-4284-bc5f-b503584e88f2_terseLabel_en-US" xlink:label="lab_alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITY RELATED TO SALE OF FUTURE ROYALTIES</link:label>
    <link:label id="lab_alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock_label_en-US" xlink:label="lab_alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Related To The Sale Of Future Royalties [Text Block]</link:label>
    <link:label id="lab_alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock_documentation_en-US" xlink:label="lab_alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Related To The Sale Of Future Royalties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock" xlink:href="alny-20210331.xsd#alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock" xlink:to="lab_alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_74097bb0-8590-4a5b-875e-ff9f58174195_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of borrowing</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_2ade9ee8-891c-46aa-b923-c7af19b8ec48_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_LiquidityPolicyPolicyTextBlock_ae1ac596-bb33-47d1-b40e-c44f0a999927_terseLabel_en-US" xlink:label="lab_alny_LiquidityPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liquidity</link:label>
    <link:label id="lab_alny_LiquidityPolicyPolicyTextBlock_label_en-US" xlink:label="lab_alny_LiquidityPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liquidity Policy [Policy Text Block]</link:label>
    <link:label id="lab_alny_LiquidityPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_alny_LiquidityPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liquidity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_LiquidityPolicyPolicyTextBlock" xlink:href="alny-20210331.xsd#alny_LiquidityPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_LiquidityPolicyPolicyTextBlock" xlink:to="lab_alny_LiquidityPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_13c538fa-fcd9-4f23-9173-15d17c6293ce_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of common stock options, net of tax withholdings (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_NumberOfMarketedProducts_143d787d-4606-401a-8f57-1401da0f7f2c_terseLabel_en-US" xlink:label="lab_alny_NumberOfMarketedProducts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of marketed products</link:label>
    <link:label id="lab_alny_NumberOfMarketedProducts_label_en-US" xlink:label="lab_alny_NumberOfMarketedProducts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Marketed Products</link:label>
    <link:label id="lab_alny_NumberOfMarketedProducts_documentation_en-US" xlink:label="lab_alny_NumberOfMarketedProducts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Marketed Products</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_NumberOfMarketedProducts" xlink:href="alny-20210331.xsd#alny_NumberOfMarketedProducts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_NumberOfMarketedProducts" xlink:to="lab_alny_NumberOfMarketedProducts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_3ec930d4-e849-4385-9940-384d9cef68c0_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net decrease in cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_1f3ab0c8-0a37-49ed-9c66-3d778cadc8f7_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other (expense) income</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_e849ab7d-4054-4a38-b991-14cdc0316f41_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options to purchase common stock</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_ResearchServicesObligationMember_489daffb-9b88-4570-84bd-d4b4a1865a9a_terseLabel_en-US" xlink:label="lab_alny_ResearchServicesObligationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Services Obligation</link:label>
    <link:label id="lab_alny_ResearchServicesObligationMember_label_en-US" xlink:label="lab_alny_ResearchServicesObligationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Services Obligation [Member]</link:label>
    <link:label id="lab_alny_ResearchServicesObligationMember_documentation_en-US" xlink:label="lab_alny_ResearchServicesObligationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research services obligation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_ResearchServicesObligationMember" xlink:href="alny-20210331.xsd#alny_ResearchServicesObligationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_ResearchServicesObligationMember" xlink:to="lab_alny_ResearchServicesObligationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_80543318-81f2-4a74-ae8a-240839df1915_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, basis spread on variable rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_f87f3c0f-41b1-4b3e-ba4b-499820c1a093_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating costs and expenses:</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract" xlink:to="lab_us-gaap_CostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_dfadeced-a0f9-4495-ad86-dea04356b510_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NET PRODUCT REVENUES</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Revenues_fdb25ace-2413-48f4-b5c8-08dfc30134ee_totalLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_Revenues_label_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_86650da8-bcc1-4e6c-a9fd-ae84b4e1973e_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_CollaborativeArrangementMilestonePayments_d50b512d-e016-44ff-9ee0-9b833d93024f_terseLabel_en-US" xlink:label="lab_alny_CollaborativeArrangementMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangement milestone payments</link:label>
    <link:label id="lab_alny_CollaborativeArrangementMilestonePayments_label_en-US" xlink:label="lab_alny_CollaborativeArrangementMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Milestone Payments</link:label>
    <link:label id="lab_alny_CollaborativeArrangementMilestonePayments_documentation_en-US" xlink:label="lab_alny_CollaborativeArrangementMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangement milestone payments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_CollaborativeArrangementMilestonePayments" xlink:href="alny-20210331.xsd#alny_CollaborativeArrangementMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_CollaborativeArrangementMilestonePayments" xlink:to="lab_alny_CollaborativeArrangementMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_2f81da0f-357c-4eed-9056-5be426de7af5_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_593c98f1-1add-4c9b-8f7a-5bad83f792ff_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_CollaborativeArrangementCommercialMilestonesAcquiredByCollaboratorPercent_8b11b5e7-8237-418e-9cb7-98e481160ec2_terseLabel_en-US" xlink:label="lab_alny_CollaborativeArrangementCommercialMilestonesAcquiredByCollaboratorPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial milestones acquired by collaborator, percent</link:label>
    <link:label id="lab_alny_CollaborativeArrangementCommercialMilestonesAcquiredByCollaboratorPercent_label_en-US" xlink:label="lab_alny_CollaborativeArrangementCommercialMilestonesAcquiredByCollaboratorPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Commercial Milestones Acquired By Collaborator, Percent</link:label>
    <link:label id="lab_alny_CollaborativeArrangementCommercialMilestonesAcquiredByCollaboratorPercent_documentation_en-US" xlink:label="lab_alny_CollaborativeArrangementCommercialMilestonesAcquiredByCollaboratorPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Commercial Milestones Acquired By Collaborator, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_CollaborativeArrangementCommercialMilestonesAcquiredByCollaboratorPercent" xlink:href="alny-20210331.xsd#alny_CollaborativeArrangementCommercialMilestonesAcquiredByCollaboratorPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_CollaborativeArrangementCommercialMilestonesAcquiredByCollaboratorPercent" xlink:to="lab_alny_CollaborativeArrangementCommercialMilestonesAcquiredByCollaboratorPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_DebtInstrumentCovenantTermsMinimumConsolidatedLiquidity_ade8151b-34f8-4176-aa76-84e74af26fae_terseLabel_en-US" xlink:label="lab_alny_DebtInstrumentCovenantTermsMinimumConsolidatedLiquidity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum consolidated liquidity</link:label>
    <link:label id="lab_alny_DebtInstrumentCovenantTermsMinimumConsolidatedLiquidity_label_en-US" xlink:label="lab_alny_DebtInstrumentCovenantTermsMinimumConsolidatedLiquidity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant Terms, Minimum Consolidated Liquidity</link:label>
    <link:label id="lab_alny_DebtInstrumentCovenantTermsMinimumConsolidatedLiquidity_documentation_en-US" xlink:label="lab_alny_DebtInstrumentCovenantTermsMinimumConsolidatedLiquidity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant Terms, Minimum Consolidated Liquidity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_DebtInstrumentCovenantTermsMinimumConsolidatedLiquidity" xlink:href="alny-20210331.xsd#alny_DebtInstrumentCovenantTermsMinimumConsolidatedLiquidity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_DebtInstrumentCovenantTermsMinimumConsolidatedLiquidity" xlink:to="lab_alny_DebtInstrumentCovenantTermsMinimumConsolidatedLiquidity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_35aa872c-7947-482f-b61a-30f58d9036a8_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLineItems_1e65ce06-4cb5-40c9-83a9-eb5e7b840af0_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativeLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativeLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLineItems" xlink:to="lab_us-gaap_DerivativeLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfRestrictedInvestments_b4e20e05-c68d-497e-aa1d-a3560a3e134f_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfRestrictedInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from maturity of restricted investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfRestrictedInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfRestrictedInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Restricted Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfRestrictedInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfRestrictedInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfRestrictedInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleOfRestrictedInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_2c6dacbe-e1bf-4df8-add3-277c7092a3d7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_DiscoveryPeriodOfProgramsDevelopment_7ea14ea3-1af1-4954-8589-4d0388aaf24e_terseLabel_en-US" xlink:label="lab_alny_DiscoveryPeriodOfProgramsDevelopment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discovery period of programs development</link:label>
    <link:label id="lab_alny_DiscoveryPeriodOfProgramsDevelopment_label_en-US" xlink:label="lab_alny_DiscoveryPeriodOfProgramsDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discovery Period Of Programs Development</link:label>
    <link:label id="lab_alny_DiscoveryPeriodOfProgramsDevelopment_documentation_en-US" xlink:label="lab_alny_DiscoveryPeriodOfProgramsDevelopment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discovery period of programs development.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_DiscoveryPeriodOfProgramsDevelopment" xlink:href="alny-20210331.xsd#alny_DiscoveryPeriodOfProgramsDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_DiscoveryPeriodOfProgramsDevelopment" xlink:to="lab_alny_DiscoveryPeriodOfProgramsDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_74912278-beff-4ce3-b506-a55dc3e1ca24_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Term Loan</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_d4db0483-89c6-4d4e-89cf-2c8f72fc05b3_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_42ca69db-0c6e-4bfc-bbd3-fe815c14aed1_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross_e2636aa4-0c9d-4b32-aed9-efb77792c72e_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under equity plans</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-based Payment Arrangement, before Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_261276ce-5c2d-4081-a550-4f81160dd7dd_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract liabilities included in &#8220;Deferred revenue&#8221;</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_67f469b1-8aad-4a07-8f15-aa9500e07b6b_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_9b0185b9-18bd-4fed-bf16-c9167e737b0e_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of common stock options, net of tax withholdings</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_4a7f848b-2848-4a44-a481-c05e57e0cc1a_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan facility</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_C5CoCoObligationMember_3feb1d0b-ad8d-404c-a6c2-9f0b787bf0bf_terseLabel_en-US" xlink:label="lab_alny_C5CoCoObligationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">C5 Co-Co Obligation</link:label>
    <link:label id="lab_alny_C5CoCoObligationMember_label_en-US" xlink:label="lab_alny_C5CoCoObligationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">C5 Co Co Obligation [Member]</link:label>
    <link:label id="lab_alny_C5CoCoObligationMember_documentation_en-US" xlink:label="lab_alny_C5CoCoObligationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">C5 Co-Co obligation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_C5CoCoObligationMember" xlink:href="alny-20210331.xsd#alny_C5CoCoObligationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_C5CoCoObligationMember" xlink:to="lab_alny_C5CoCoObligationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_cf5180d6-f627-4b32-bf44-0ca5571d9726_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_4bfb966b-7126-4ce8-b3f8-6c5490599e12_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCash_3c3955b5-2dae-45b6-8ef5-44df042c4ee7_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total restricted cash included in prepaid expenses, other current assets and long-term other assets</link:label>
    <link:label id="lab_us-gaap_RestrictedCash_label_en-US" xlink:label="lab_us-gaap_RestrictedCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCash" xlink:to="lab_us-gaap_RestrictedCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_4a9fd8e4-4af6-4efa-9050-b453d747c1ee_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_GIVLAARIMember_657f9f5f-07f5-4e08-b51f-2760d8be4c3a_terseLabel_en-US" xlink:label="lab_alny_GIVLAARIMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GIVLAARI</link:label>
    <link:label id="lab_alny_GIVLAARIMember_label_en-US" xlink:label="lab_alny_GIVLAARIMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GIVLAARI [Member]</link:label>
    <link:label id="lab_alny_GIVLAARIMember_documentation_en-US" xlink:label="lab_alny_GIVLAARIMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GIVLAARI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_GIVLAARIMember" xlink:href="alny-20210331.xsd#alny_GIVLAARIMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_GIVLAARIMember" xlink:to="lab_alny_GIVLAARIMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_f7a8e0a2-30f2-47ce-874d-edd66caaa1ae_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_32cacca3-54c6-48d8-901f-33dc7c10c5e1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_43d1d009-4e02-4b59-bc8f-6c8c11468103_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_edac2ea6-9157-4b7f-9070-0f4069e92539_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_LineOfCreditFacilityMaximumBorrowingCapacityAccordionFeature_0f24db59-cd0d-4f55-91d7-8d06e0caf708_terseLabel_en-US" xlink:label="lab_alny_LineOfCreditFacilityMaximumBorrowingCapacityAccordionFeature" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum borrowing capacity, accordion feature</link:label>
    <link:label id="lab_alny_LineOfCreditFacilityMaximumBorrowingCapacityAccordionFeature_label_en-US" xlink:label="lab_alny_LineOfCreditFacilityMaximumBorrowingCapacityAccordionFeature" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line Of Credit Facility, Maximum Borrowing Capacity, Accordion Feature</link:label>
    <link:label id="lab_alny_LineOfCreditFacilityMaximumBorrowingCapacityAccordionFeature_documentation_en-US" xlink:label="lab_alny_LineOfCreditFacilityMaximumBorrowingCapacityAccordionFeature" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line Of Credit Facility, Maximum Borrowing Capacity, Accordion Feature</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_LineOfCreditFacilityMaximumBorrowingCapacityAccordionFeature" xlink:href="alny-20210331.xsd#alny_LineOfCreditFacilityMaximumBorrowingCapacityAccordionFeature"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_LineOfCreditFacilityMaximumBorrowingCapacityAccordionFeature" xlink:to="lab_alny_LineOfCreditFacilityMaximumBorrowingCapacityAccordionFeature" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_ImpairmentOfMarketableDebtSecurities_3981f79d-2678-44e7-8dfd-e5b9398a96d9_terseLabel_en-US" xlink:label="lab_alny_ImpairmentOfMarketableDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment charges of marketable debt securities</link:label>
    <link:label id="lab_alny_ImpairmentOfMarketableDebtSecurities_label_en-US" xlink:label="lab_alny_ImpairmentOfMarketableDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment Of Marketable Debt Securities</link:label>
    <link:label id="lab_alny_ImpairmentOfMarketableDebtSecurities_documentation_en-US" xlink:label="lab_alny_ImpairmentOfMarketableDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of marketable debt securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_ImpairmentOfMarketableDebtSecurities" xlink:href="alny-20210331.xsd#alny_ImpairmentOfMarketableDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_ImpairmentOfMarketableDebtSecurities" xlink:to="lab_alny_ImpairmentOfMarketableDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_SanofiGenzymeMember_3e5e2b97-daf9-4e8b-b7ed-5814326dc036_verboseLabel_en-US" xlink:label="lab_alny_SanofiGenzymeMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_alny_SanofiGenzymeMember_label_en-US" xlink:label="lab_alny_SanofiGenzymeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Genzyme [Member]</link:label>
    <link:label id="lab_alny_SanofiGenzymeMember_documentation_en-US" xlink:label="lab_alny_SanofiGenzymeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Genzyme.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_SanofiGenzymeMember" xlink:href="alny-20210331.xsd#alny_SanofiGenzymeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_SanofiGenzymeMember" xlink:to="lab_alny_SanofiGenzymeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_3daca4dd-1798-4ebb-b2fd-786c38516cde_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_65e277a8-3ba9-4a72-b20c-90f503cac855_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_97385fd7-c149-47f5-9ccb-fd0ac9048a57_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from exercise of stock options and other types of equity, net</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_DebtInstrumentCovenantTermsMinimumProductRevenue_4a091a4b-19d6-482c-814c-cae9076f8868_terseLabel_en-US" xlink:label="lab_alny_DebtInstrumentCovenantTermsMinimumProductRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum product revenue</link:label>
    <link:label id="lab_alny_DebtInstrumentCovenantTermsMinimumProductRevenue_label_en-US" xlink:label="lab_alny_DebtInstrumentCovenantTermsMinimumProductRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant Terms, Minimum Product Revenue</link:label>
    <link:label id="lab_alny_DebtInstrumentCovenantTermsMinimumProductRevenue_documentation_en-US" xlink:label="lab_alny_DebtInstrumentCovenantTermsMinimumProductRevenue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant Terms, Minimum Product Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_DebtInstrumentCovenantTermsMinimumProductRevenue" xlink:href="alny-20210331.xsd#alny_DebtInstrumentCovenantTermsMinimumProductRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_DebtInstrumentCovenantTermsMinimumProductRevenue" xlink:to="lab_alny_DebtInstrumentCovenantTermsMinimumProductRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_d24ce101-01a6-4606-b6ad-b194689c5e5d_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NET LOSS PER COMMON SHARE</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a92ab58a-3ef4-46f0-9c0c-2e9895d95914_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_e132e55f-8e10-4ddf-9f54-3b42893bc2e7_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_4a6d69af-385d-4159-ac59-35df92e2c85d_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_DebtInstrumentInterestInKindInterestRateIncrease_65a8bd81-5fc3-4540-ba73-00fbcd7d0a6a_terseLabel_en-US" xlink:label="lab_alny_DebtInstrumentInterestInKindInterestRateIncrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest in kind, interest rate increase</link:label>
    <link:label id="lab_alny_DebtInstrumentInterestInKindInterestRateIncrease_label_en-US" xlink:label="lab_alny_DebtInstrumentInterestInKindInterestRateIncrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest In Kind, Interest Rate Increase</link:label>
    <link:label id="lab_alny_DebtInstrumentInterestInKindInterestRateIncrease_documentation_en-US" xlink:label="lab_alny_DebtInstrumentInterestInKindInterestRateIncrease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest In Kind, Interest Rate Increase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_DebtInstrumentInterestInKindInterestRateIncrease" xlink:href="alny-20210331.xsd#alny_DebtInstrumentInterestInKindInterestRateIncrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_DebtInstrumentInterestInKindInterestRateIncrease" xlink:to="lab_alny_DebtInstrumentInterestInKindInterestRateIncrease" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_VirBiotechnologyIncMember_51774b70-c6de-435e-b1b4-e30386a5dad2_terseLabel_en-US" xlink:label="lab_alny_VirBiotechnologyIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vir Biotechnology</link:label>
    <link:label id="lab_alny_VirBiotechnologyIncMember_29de855e-1828-4b9f-8747-9f698fe4978d_verboseLabel_en-US" xlink:label="lab_alny_VirBiotechnologyIncMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vir Biotechnology</link:label>
    <link:label id="lab_alny_VirBiotechnologyIncMember_label_en-US" xlink:label="lab_alny_VirBiotechnologyIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vir Biotechnology Inc [Member]</link:label>
    <link:label id="lab_alny_VirBiotechnologyIncMember_documentation_en-US" xlink:label="lab_alny_VirBiotechnologyIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vir biotechnology Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_VirBiotechnologyIncMember" xlink:href="alny-20210331.xsd#alny_VirBiotechnologyIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_VirBiotechnologyIncMember" xlink:to="lab_alny_VirBiotechnologyIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_16ad388a-65b7-4715-a6af-1ae1b4c8f9ec_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromLinesOfCredit_2ff1c35f-50f8-484b-ba41-92ebc6611336_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from lines of credit</link:label>
    <link:label id="lab_us-gaap_ProceedsFromLinesOfCredit_label_en-US" xlink:label="lab_us-gaap_ProceedsFromLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Lines of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLinesOfCredit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromLinesOfCredit" xlink:to="lab_us-gaap_ProceedsFromLinesOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_C5LicenseObligationMember_9a4c77f6-c2b0-4f49-8e9e-6499eca0eb64_terseLabel_en-US" xlink:label="lab_alny_C5LicenseObligationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">C5 License Obligation</link:label>
    <link:label id="lab_alny_C5LicenseObligationMember_label_en-US" xlink:label="lab_alny_C5LicenseObligationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">C5 License Obligation [Member]</link:label>
    <link:label id="lab_alny_C5LicenseObligationMember_documentation_en-US" xlink:label="lab_alny_C5LicenseObligationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">C5 license obligation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_C5LicenseObligationMember" xlink:href="alny-20210331.xsd#alny_C5LicenseObligationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_C5LicenseObligationMember" xlink:to="lab_alny_C5LicenseObligationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_7bb37024-53cd-441c-b794-c93b3364f462_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesTable_0456142f-6499-4ead-9a0e-008acc00c1b7_terseLabel_en-US" xlink:label="lab_alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Related To The Sale Of Future Royalties [Table]</link:label>
    <link:label id="lab_alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesTable_label_en-US" xlink:label="lab_alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Related To The Sale Of Future Royalties [Table]</link:label>
    <link:label id="lab_alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesTable_documentation_en-US" xlink:label="lab_alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Related To The Sale Of Future Royalties Table</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesTable" xlink:href="alny-20210331.xsd#alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesTable" xlink:to="lab_alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesTable" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>alny-20210331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:45529fdd-2cb3-415e-a8b1-14659af4a28e,g:8b4a69cc-2403-45c9-b738-5835a1e5fb0d-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.alnylam.com/role/CoverPage" xlink:type="simple" xlink:href="alny-20210331.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.alnylam.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_019b3c02-bfc2-493f-805b-3e8e83b71739" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_87086642-2a88-4e9a-87db-63ed42583621" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019b3c02-bfc2-493f-805b-3e8e83b71739" xlink:to="loc_dei_DocumentType_87086642-2a88-4e9a-87db-63ed42583621" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_43aac61e-bded-4cd1-8e41-0c9ccaf29499" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019b3c02-bfc2-493f-805b-3e8e83b71739" xlink:to="loc_dei_DocumentQuarterlyReport_43aac61e-bded-4cd1-8e41-0c9ccaf29499" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_b573d51a-f1c6-4ce9-8a6a-bfdcebaae126" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019b3c02-bfc2-493f-805b-3e8e83b71739" xlink:to="loc_dei_DocumentPeriodEndDate_b573d51a-f1c6-4ce9-8a6a-bfdcebaae126" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_09d38af6-98f4-4bfd-bdfb-f47d117b8871" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019b3c02-bfc2-493f-805b-3e8e83b71739" xlink:to="loc_dei_DocumentTransitionReport_09d38af6-98f4-4bfd-bdfb-f47d117b8871" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_2310c8ab-f6d6-4634-a7c4-463596c4830d" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019b3c02-bfc2-493f-805b-3e8e83b71739" xlink:to="loc_dei_EntityFileNumber_2310c8ab-f6d6-4634-a7c4-463596c4830d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_816fbfa8-fc2e-483c-84b4-bb9a5a189f62" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019b3c02-bfc2-493f-805b-3e8e83b71739" xlink:to="loc_dei_EntityRegistrantName_816fbfa8-fc2e-483c-84b4-bb9a5a189f62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_3d62b9e3-2077-4f38-846e-1e8f73603a24" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019b3c02-bfc2-493f-805b-3e8e83b71739" xlink:to="loc_dei_EntityIncorporationStateCountryCode_3d62b9e3-2077-4f38-846e-1e8f73603a24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_e395620c-e7ce-421e-939d-5b933b79441d" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019b3c02-bfc2-493f-805b-3e8e83b71739" xlink:to="loc_dei_EntityTaxIdentificationNumber_e395620c-e7ce-421e-939d-5b933b79441d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_6eb367f4-684c-4487-9fb0-072cf37de2e4" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019b3c02-bfc2-493f-805b-3e8e83b71739" xlink:to="loc_dei_EntityAddressAddressLine1_6eb367f4-684c-4487-9fb0-072cf37de2e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_c3f8d738-a84c-434f-a1e1-b46387e626d4" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019b3c02-bfc2-493f-805b-3e8e83b71739" xlink:to="loc_dei_EntityAddressAddressLine2_c3f8d738-a84c-434f-a1e1-b46387e626d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_0cd40b01-c11c-4740-9eed-1e0d64532231" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019b3c02-bfc2-493f-805b-3e8e83b71739" xlink:to="loc_dei_EntityAddressCityOrTown_0cd40b01-c11c-4740-9eed-1e0d64532231" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_9cf3b5ce-4c1e-4868-8b50-fe544acc7d61" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019b3c02-bfc2-493f-805b-3e8e83b71739" xlink:to="loc_dei_EntityAddressStateOrProvince_9cf3b5ce-4c1e-4868-8b50-fe544acc7d61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_067ae701-26cd-4c47-b607-d01b4028b060" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019b3c02-bfc2-493f-805b-3e8e83b71739" xlink:to="loc_dei_EntityAddressPostalZipCode_067ae701-26cd-4c47-b607-d01b4028b060" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_9f73a547-033e-4820-9623-e9d67a475c65" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019b3c02-bfc2-493f-805b-3e8e83b71739" xlink:to="loc_dei_CityAreaCode_9f73a547-033e-4820-9623-e9d67a475c65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_65ae7303-640a-48c6-b464-91098fbed0c1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019b3c02-bfc2-493f-805b-3e8e83b71739" xlink:to="loc_dei_LocalPhoneNumber_65ae7303-640a-48c6-b464-91098fbed0c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_1cb2b565-3fcc-41a8-8b1c-32bd90b43eaa" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019b3c02-bfc2-493f-805b-3e8e83b71739" xlink:to="loc_dei_Security12bTitle_1cb2b565-3fcc-41a8-8b1c-32bd90b43eaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_986d0abb-a4ac-46a6-8b28-bade1272584d" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019b3c02-bfc2-493f-805b-3e8e83b71739" xlink:to="loc_dei_TradingSymbol_986d0abb-a4ac-46a6-8b28-bade1272584d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_bba6eaa7-0de3-45a6-941a-1448e292815a" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019b3c02-bfc2-493f-805b-3e8e83b71739" xlink:to="loc_dei_SecurityExchangeName_bba6eaa7-0de3-45a6-941a-1448e292815a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_8053f631-3afb-413a-a657-bb6664202bde" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019b3c02-bfc2-493f-805b-3e8e83b71739" xlink:to="loc_dei_EntityCurrentReportingStatus_8053f631-3afb-413a-a657-bb6664202bde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_2865c453-ed8b-4d78-b13f-185da22f2904" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019b3c02-bfc2-493f-805b-3e8e83b71739" xlink:to="loc_dei_EntityInteractiveDataCurrent_2865c453-ed8b-4d78-b13f-185da22f2904" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_3d737812-c769-420c-9c64-65dc48832d08" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019b3c02-bfc2-493f-805b-3e8e83b71739" xlink:to="loc_dei_EntityFilerCategory_3d737812-c769-420c-9c64-65dc48832d08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_ccadbc26-85d8-465b-bd1f-5a894939b8e2" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019b3c02-bfc2-493f-805b-3e8e83b71739" xlink:to="loc_dei_EntitySmallBusiness_ccadbc26-85d8-465b-bd1f-5a894939b8e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_29d36335-8d4b-4c90-89ea-f73dd3bbdcfc" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019b3c02-bfc2-493f-805b-3e8e83b71739" xlink:to="loc_dei_EntityEmergingGrowthCompany_29d36335-8d4b-4c90-89ea-f73dd3bbdcfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_a3361f8f-48c3-4aa8-8138-6783e157a790" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019b3c02-bfc2-493f-805b-3e8e83b71739" xlink:to="loc_dei_EntityShellCompany_a3361f8f-48c3-4aa8-8138-6783e157a790" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_2e5409f4-4236-489f-bc0e-12984be5f350" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019b3c02-bfc2-493f-805b-3e8e83b71739" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_2e5409f4-4236-489f-bc0e-12984be5f350" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_8ea45dcb-e4d8-4236-80df-8a70c0a99578" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019b3c02-bfc2-493f-805b-3e8e83b71739" xlink:to="loc_dei_AmendmentFlag_8ea45dcb-e4d8-4236-80df-8a70c0a99578" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_c1916df0-f5c4-4906-8f88-4d7dc0927aee" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019b3c02-bfc2-493f-805b-3e8e83b71739" xlink:to="loc_dei_DocumentFiscalYearFocus_c1916df0-f5c4-4906-8f88-4d7dc0927aee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_fe77fe3d-707b-4807-941c-15a9a61afc11" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019b3c02-bfc2-493f-805b-3e8e83b71739" xlink:to="loc_dei_CurrentFiscalYearEndDate_fe77fe3d-707b-4807-941c-15a9a61afc11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_e83b70b7-5bbb-434c-8f9e-86eae42e9c24" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019b3c02-bfc2-493f-805b-3e8e83b71739" xlink:to="loc_dei_DocumentFiscalPeriodFocus_e83b70b7-5bbb-434c-8f9e-86eae42e9c24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_630699d4-1b10-4a6a-b4bb-ab8f1c65c16e" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019b3c02-bfc2-493f-805b-3e8e83b71739" xlink:to="loc_dei_EntityCentralIndexKey_630699d4-1b10-4a6a-b4bb-ab8f1c65c16e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="alny-20210331.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_9cdac5af-f2ae-4583-9958-de600ada1e6a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_edd07c98-4636-4e30-ae99-20967003bee0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_9cdac5af-f2ae-4583-9958-de600ada1e6a" xlink:to="loc_us-gaap_AssetsAbstract_edd07c98-4636-4e30-ae99-20967003bee0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_2ea42696-f6eb-4c86-8efa-7d23822fd9cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_edd07c98-4636-4e30-ae99-20967003bee0" xlink:to="loc_us-gaap_AssetsCurrentAbstract_2ea42696-f6eb-4c86-8efa-7d23822fd9cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4e722770-d2fa-452b-b07e-e49b7e8bc334" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2ea42696-f6eb-4c86-8efa-7d23822fd9cb" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4e722770-d2fa-452b-b07e-e49b7e8bc334" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_651748e3-46ef-4979-a46e-4d6cb88fe4fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2ea42696-f6eb-4c86-8efa-7d23822fd9cb" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_651748e3-46ef-4979-a46e-4d6cb88fe4fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_086b308a-6dda-4101-9da7-a2d3329de0b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2ea42696-f6eb-4c86-8efa-7d23822fd9cb" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_086b308a-6dda-4101-9da7-a2d3329de0b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_b2e47349-2c54-4064-a0b9-bae7a83319b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2ea42696-f6eb-4c86-8efa-7d23822fd9cb" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_b2e47349-2c54-4064-a0b9-bae7a83319b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_34079a29-32dc-40c5-91f7-e7fe2d59e2ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2ea42696-f6eb-4c86-8efa-7d23822fd9cb" xlink:to="loc_us-gaap_InventoryNet_34079a29-32dc-40c5-91f7-e7fe2d59e2ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_5cd19ce5-d978-4f05-85d7-8cf55617c37c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2ea42696-f6eb-4c86-8efa-7d23822fd9cb" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_5cd19ce5-d978-4f05-85d7-8cf55617c37c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_RoyaltiesReceivableCurrent_45368f33-6c83-4662-b617-2f93b4eb4096" xlink:href="alny-20210331.xsd#alny_RoyaltiesReceivableCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2ea42696-f6eb-4c86-8efa-7d23822fd9cb" xlink:to="loc_alny_RoyaltiesReceivableCurrent_45368f33-6c83-4662-b617-2f93b4eb4096" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_6ed48160-a0ec-41b1-ae9e-3b950525036a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2ea42696-f6eb-4c86-8efa-7d23822fd9cb" xlink:to="loc_us-gaap_AssetsCurrent_6ed48160-a0ec-41b1-ae9e-3b950525036a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_3d9a9c9f-4782-4561-8dc8-447b657f4542" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_edd07c98-4636-4e30-ae99-20967003bee0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_3d9a9c9f-4782-4561-8dc8-447b657f4542" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_8f400316-87a3-42ad-aba9-3e8a5f08dca2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_edd07c98-4636-4e30-ae99-20967003bee0" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_8f400316-87a3-42ad-aba9-3e8a5f08dca2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedInvestmentsNoncurrent_07587b87-1364-4744-97c7-6cbb43874fea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedInvestmentsNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_edd07c98-4636-4e30-ae99-20967003bee0" xlink:to="loc_us-gaap_RestrictedInvestmentsNoncurrent_07587b87-1364-4744-97c7-6cbb43874fea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_fb6fcc5e-cfa5-428a-b093-b6af49830529" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_edd07c98-4636-4e30-ae99-20967003bee0" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_fb6fcc5e-cfa5-428a-b093-b6af49830529" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_4046e3b3-5296-42aa-bb0f-127cf2d07cfd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_edd07c98-4636-4e30-ae99-20967003bee0" xlink:to="loc_us-gaap_Assets_4046e3b3-5296-42aa-bb0f-127cf2d07cfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6210b2a4-703d-48c5-88a7-d43f507f0ffd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_9cdac5af-f2ae-4583-9958-de600ada1e6a" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6210b2a4-703d-48c5-88a7-d43f507f0ffd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_f3afa3ce-76f3-4b7c-b60f-eb0652a26707" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6210b2a4-703d-48c5-88a7-d43f507f0ffd" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_f3afa3ce-76f3-4b7c-b60f-eb0652a26707" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_bac39fd7-0af2-4ead-b678-294e343f8fb2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_f3afa3ce-76f3-4b7c-b60f-eb0652a26707" xlink:to="loc_us-gaap_AccountsPayableCurrent_bac39fd7-0af2-4ead-b678-294e343f8fb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_16c86b28-f137-4d2a-bda4-c279ca53315c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_f3afa3ce-76f3-4b7c-b60f-eb0652a26707" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_16c86b28-f137-4d2a-bda4-c279ca53315c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_cffaff11-126d-463c-8264-5d84b5df4bc0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_f3afa3ce-76f3-4b7c-b60f-eb0652a26707" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_cffaff11-126d-463c-8264-5d84b5df4bc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_fbd974a1-c8ee-46aa-b225-0d32bcc27429" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_f3afa3ce-76f3-4b7c-b60f-eb0652a26707" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_fbd974a1-c8ee-46aa-b225-0d32bcc27429" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_RoyaltyLiabilityCurrent_6e2cbe12-bd17-48d5-9fe5-fe75de5203bb" xlink:href="alny-20210331.xsd#alny_RoyaltyLiabilityCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_f3afa3ce-76f3-4b7c-b60f-eb0652a26707" xlink:to="loc_alny_RoyaltyLiabilityCurrent_6e2cbe12-bd17-48d5-9fe5-fe75de5203bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_6d987434-243b-42c2-a321-068379a85256" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_f3afa3ce-76f3-4b7c-b60f-eb0652a26707" xlink:to="loc_us-gaap_LiabilitiesCurrent_6d987434-243b-42c2-a321-068379a85256" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_7e7c4723-8146-4700-bd97-bfeef307066f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6210b2a4-703d-48c5-88a7-d43f507f0ffd" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_7e7c4723-8146-4700-bd97-bfeef307066f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_3d623189-d1d7-476e-8599-d5cc70f1ba5c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6210b2a4-703d-48c5-88a7-d43f507f0ffd" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_3d623189-d1d7-476e-8599-d5cc70f1ba5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_78a8b0a4-0167-4a6f-9cd1-fab209f41475" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6210b2a4-703d-48c5-88a7-d43f507f0ffd" xlink:to="loc_us-gaap_LongTermDebt_78a8b0a4-0167-4a6f-9cd1-fab209f41475" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_RoyaltyLiabilityNoncurrent_172f6482-7601-4dff-86a4-40081b284db7" xlink:href="alny-20210331.xsd#alny_RoyaltyLiabilityNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6210b2a4-703d-48c5-88a7-d43f507f0ffd" xlink:to="loc_alny_RoyaltyLiabilityNoncurrent_172f6482-7601-4dff-86a4-40081b284db7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_43b8d808-4e22-4603-81c3-364b8434efca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6210b2a4-703d-48c5-88a7-d43f507f0ffd" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_43b8d808-4e22-4603-81c3-364b8434efca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_a01d2d28-7d5e-41b9-aa7d-eb917763d228" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6210b2a4-703d-48c5-88a7-d43f507f0ffd" xlink:to="loc_us-gaap_Liabilities_a01d2d28-7d5e-41b9-aa7d-eb917763d228" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_3534c4a0-809c-4b1d-b0de-0dd40e484809" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6210b2a4-703d-48c5-88a7-d43f507f0ffd" xlink:to="loc_us-gaap_CommitmentsAndContingencies_3534c4a0-809c-4b1d-b0de-0dd40e484809" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_c27f0ebc-684a-4b50-b1a6-e5272622fb01" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6210b2a4-703d-48c5-88a7-d43f507f0ffd" xlink:to="loc_us-gaap_StockholdersEquityAbstract_c27f0ebc-684a-4b50-b1a6-e5272622fb01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_bda4c78e-3ebd-4fc6-84c5-c7ccfc3ed51c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_c27f0ebc-684a-4b50-b1a6-e5272622fb01" xlink:to="loc_us-gaap_PreferredStockValue_bda4c78e-3ebd-4fc6-84c5-c7ccfc3ed51c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_431b01bd-4e52-4674-8f1a-8fa3981d1f1f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_c27f0ebc-684a-4b50-b1a6-e5272622fb01" xlink:to="loc_us-gaap_CommonStockValue_431b01bd-4e52-4674-8f1a-8fa3981d1f1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_c2f9d072-4d49-4149-9c05-b7d602af2acb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_c27f0ebc-684a-4b50-b1a6-e5272622fb01" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_c2f9d072-4d49-4149-9c05-b7d602af2acb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_2217e45e-bff4-40e7-b57d-6d36f40fa84a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_c27f0ebc-684a-4b50-b1a6-e5272622fb01" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_2217e45e-bff4-40e7-b57d-6d36f40fa84a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_df956c21-8e86-4e5d-b0a0-89dd6f416bed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_c27f0ebc-684a-4b50-b1a6-e5272622fb01" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_df956c21-8e86-4e5d-b0a0-89dd6f416bed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_87c13a7d-ad99-4398-a15c-8d2c32e953a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_c27f0ebc-684a-4b50-b1a6-e5272622fb01" xlink:to="loc_us-gaap_StockholdersEquity_87c13a7d-ad99-4398-a15c-8d2c32e953a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_18999aba-8bc1-4938-9834-31c3d16ad09f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6210b2a4-703d-48c5-88a7-d43f507f0ffd" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_18999aba-8bc1-4938-9834-31c3d16ad09f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="alny-20210331.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:presentationLink xlink:role="http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_1f49113b-e1b5-4af2-a106-72e72d553a07" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_6936bccd-4e5b-40bc-8607-a6d468be764d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1f49113b-e1b5-4af2-a106-72e72d553a07" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_6936bccd-4e5b-40bc-8607-a6d468be764d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_dc6ad6de-76e6-41e0-aa62-26e5a5a441ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1f49113b-e1b5-4af2-a106-72e72d553a07" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_dc6ad6de-76e6-41e0-aa62-26e5a5a441ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_b70bef5b-c0a4-4add-8990-28f65843e5e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1f49113b-e1b5-4af2-a106-72e72d553a07" xlink:to="loc_us-gaap_PreferredStockSharesIssued_b70bef5b-c0a4-4add-8990-28f65843e5e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_4cc4c9dc-090f-4f54-97c3-aa93b46ed9d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1f49113b-e1b5-4af2-a106-72e72d553a07" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_4cc4c9dc-090f-4f54-97c3-aa93b46ed9d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_46269932-8cf7-421d-8012-807c63231583" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1f49113b-e1b5-4af2-a106-72e72d553a07" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_46269932-8cf7-421d-8012-807c63231583" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_dbfe3938-01b5-4f18-bbd1-3796351aac50" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1f49113b-e1b5-4af2-a106-72e72d553a07" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_dbfe3938-01b5-4f18-bbd1-3796351aac50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_5225d549-f4c9-4f5e-899c-9af53a757343" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1f49113b-e1b5-4af2-a106-72e72d553a07" xlink:to="loc_us-gaap_CommonStockSharesIssued_5225d549-f4c9-4f5e-899c-9af53a757343" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_42cd54c2-96b7-46fb-b83f-8b70c96b86bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1f49113b-e1b5-4af2-a106-72e72d553a07" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_42cd54c2-96b7-46fb-b83f-8b70c96b86bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="alny-20210331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"/>
  <link:presentationLink xlink:role="http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_32d94f37-0702-4229-8a97-e8bb98a1fa01" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_4c65e3a1-0408-4a45-827a-fd6ca0fd30e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_32d94f37-0702-4229-8a97-e8bb98a1fa01" xlink:to="loc_us-gaap_StatementTable_4c65e3a1-0408-4a45-827a-fd6ca0fd30e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_60358dff-4d63-4bbb-832c-e204b1067f26" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4c65e3a1-0408-4a45-827a-fd6ca0fd30e8" xlink:to="loc_srt_ProductOrServiceAxis_60358dff-4d63-4bbb-832c-e204b1067f26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_bf5352b2-955b-41c8-8fc4-418c995d68e7" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_60358dff-4d63-4bbb-832c-e204b1067f26" xlink:to="loc_srt_ProductsAndServicesDomain_bf5352b2-955b-41c8-8fc4-418c995d68e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_2e767576-73a0-409d-8b04-ce5299e3ee21" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_bf5352b2-955b-41c8-8fc4-418c995d68e7" xlink:to="loc_us-gaap_ProductMember_2e767576-73a0-409d-8b04-ce5299e3ee21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_af32f604-842c-4627-88ec-f4c1f0cb992f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4c65e3a1-0408-4a45-827a-fd6ca0fd30e8" xlink:to="loc_us-gaap_TypeOfArrangementAxis_af32f604-842c-4627-88ec-f4c1f0cb992f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f5479c24-0cae-4248-b919-c1dcda8ffee9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_af32f604-842c-4627-88ec-f4c1f0cb992f" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f5479c24-0cae-4248-b919-c1dcda8ffee9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_2d943a2f-2346-477a-abf6-5901378f694a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f5479c24-0cae-4248-b919-c1dcda8ffee9" xlink:to="loc_us-gaap_CollaborativeArrangementMember_2d943a2f-2346-477a-abf6-5901378f694a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_94347044-5d7b-4f32-aafe-cc8e91e9ce9f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4c65e3a1-0408-4a45-827a-fd6ca0fd30e8" xlink:to="loc_us-gaap_StatementLineItems_94347044-5d7b-4f32-aafe-cc8e91e9ce9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_9e8fc736-6f2a-4bcb-a464-8e72b6a1bd53" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_94347044-5d7b-4f32-aafe-cc8e91e9ce9f" xlink:to="loc_us-gaap_RevenuesAbstract_9e8fc736-6f2a-4bcb-a464-8e72b6a1bd53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9622e429-619b-474d-9943-e4d252c7e6d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_9e8fc736-6f2a-4bcb-a464-8e72b6a1bd53" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9622e429-619b-474d-9943-e4d252c7e6d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_fc26e793-b093-4bce-88b6-ef03175d4cd4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_94347044-5d7b-4f32-aafe-cc8e91e9ce9f" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_fc26e793-b093-4bce-88b6-ef03175d4cd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_87727662-9097-4fd5-ae0a-2b92aa5531e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_fc26e793-b093-4bce-88b6-ef03175d4cd4" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_87727662-9097-4fd5-ae0a-2b92aa5531e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_CostOfCollaborationManufacturingAndRoyalties_55d1afde-2c91-4f6b-96ab-174972231926" xlink:href="alny-20210331.xsd#alny_CostOfCollaborationManufacturingAndRoyalties"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_fc26e793-b093-4bce-88b6-ef03175d4cd4" xlink:to="loc_alny_CostOfCollaborationManufacturingAndRoyalties_55d1afde-2c91-4f6b-96ab-174972231926" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_9351dfda-8ab9-4ae0-ac93-5b3ddcb14ddb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_fc26e793-b093-4bce-88b6-ef03175d4cd4" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_9351dfda-8ab9-4ae0-ac93-5b3ddcb14ddb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_8a8ce690-a395-463b-af55-a9ebc9c5d82d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_fc26e793-b093-4bce-88b6-ef03175d4cd4" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_8a8ce690-a395-463b-af55-a9ebc9c5d82d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_82fa010f-d84e-4478-822c-9f6913115492" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_fc26e793-b093-4bce-88b6-ef03175d4cd4" xlink:to="loc_us-gaap_CostsAndExpenses_82fa010f-d84e-4478-822c-9f6913115492" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_6ea56993-d8d4-4acc-82f8-9892acd37738" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_94347044-5d7b-4f32-aafe-cc8e91e9ce9f" xlink:to="loc_us-gaap_OperatingIncomeLoss_6ea56993-d8d4-4acc-82f8-9892acd37738" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_ee8cf7ad-b493-4ade-9c94-cd14852e5f4f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_94347044-5d7b-4f32-aafe-cc8e91e9ce9f" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_ee8cf7ad-b493-4ade-9c94-cd14852e5f4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_d74eb795-6ba4-44db-85b2-2177a98ac60d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_ee8cf7ad-b493-4ade-9c94-cd14852e5f4f" xlink:to="loc_us-gaap_InterestExpense_d74eb795-6ba4-44db-85b2-2177a98ac60d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_09b93983-da42-4e35-954b-817b9065190a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_ee8cf7ad-b493-4ade-9c94-cd14852e5f4f" xlink:to="loc_us-gaap_InvestmentIncomeInterest_09b93983-da42-4e35-954b-817b9065190a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_f48ffde5-77ac-4aaf-9aeb-033032a85c37" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_ee8cf7ad-b493-4ade-9c94-cd14852e5f4f" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_f48ffde5-77ac-4aaf-9aeb-033032a85c37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_973c3f3b-8a65-4953-bb71-56f73a956932" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_ee8cf7ad-b493-4ade-9c94-cd14852e5f4f" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_973c3f3b-8a65-4953-bb71-56f73a956932" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_9c13beb6-591e-48e4-9320-821c5b475724" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_94347044-5d7b-4f32-aafe-cc8e91e9ce9f" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_9c13beb6-591e-48e4-9320-821c5b475724" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_54614ced-ee2b-4aea-903c-27dff3d6eecf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_94347044-5d7b-4f32-aafe-cc8e91e9ce9f" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_54614ced-ee2b-4aea-903c-27dff3d6eecf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_71247ab6-bc0d-4ff4-bb42-7a6e086f4ad5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_94347044-5d7b-4f32-aafe-cc8e91e9ce9f" xlink:to="loc_us-gaap_NetIncomeLoss_71247ab6-bc0d-4ff4-bb42-7a6e086f4ad5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_a9deed92-8e25-49a5-9407-603db881845f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_94347044-5d7b-4f32-aafe-cc8e91e9ce9f" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_a9deed92-8e25-49a5-9407-603db881845f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_ce6607c7-4dbf-41c6-ab55-7752de63107b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_94347044-5d7b-4f32-aafe-cc8e91e9ce9f" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_ce6607c7-4dbf-41c6-ab55-7752de63107b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_83e63880-c7a2-4707-b975-78ffcc048ab7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_94347044-5d7b-4f32-aafe-cc8e91e9ce9f" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_83e63880-c7a2-4707-b975-78ffcc048ab7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_ba8f4b78-4494-4c0d-916c-2a466e9a29c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_83e63880-c7a2-4707-b975-78ffcc048ab7" xlink:to="loc_us-gaap_NetIncomeLoss_ba8f4b78-4494-4c0d-916c-2a466e9a29c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_28ad1828-1a0d-4a2b-97b4-2306226b9823" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_83e63880-c7a2-4707-b975-78ffcc048ab7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_28ad1828-1a0d-4a2b-97b4-2306226b9823" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_1eeab120-c96e-4c9c-9ebf-ad464153a9d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_28ad1828-1a0d-4a2b-97b4-2306226b9823" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_1eeab120-c96e-4c9c-9ebf-ad464153a9d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_f14f6ad7-639a-495a-93cf-6cf0916f0436" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_28ad1828-1a0d-4a2b-97b4-2306226b9823" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_f14f6ad7-639a-495a-93cf-6cf0916f0436" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax_45394c75-4f07-4381-a2ae-f521742205b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_28ad1828-1a0d-4a2b-97b4-2306226b9823" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax_45394c75-4f07-4381-a2ae-f521742205b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_ed20a202-55cf-4f44-9847-cf378ca5dd46" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_28ad1828-1a0d-4a2b-97b4-2306226b9823" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_ed20a202-55cf-4f44-9847-cf378ca5dd46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_f51b7e7b-81fe-4cfa-bae9-1c138305c0cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_83e63880-c7a2-4707-b975-78ffcc048ab7" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_f51b7e7b-81fe-4cfa-bae9-1c138305c0cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="alny-20210331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_105acb2d-d3e3-4140-b767-b9e030b24185" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_7f86e23c-0d10-4386-9f22-6181dfa7488d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_105acb2d-d3e3-4140-b767-b9e030b24185" xlink:to="loc_us-gaap_StatementTable_7f86e23c-0d10-4386-9f22-6181dfa7488d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_73fdbb89-d5f6-4bbc-8031-ed6c3a209556" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_7f86e23c-0d10-4386-9f22-6181dfa7488d" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_73fdbb89-d5f6-4bbc-8031-ed6c3a209556" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_a6e6865d-ad26-4a10-b9c2-5b32f56e57db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_73fdbb89-d5f6-4bbc-8031-ed6c3a209556" xlink:to="loc_us-gaap_EquityComponentDomain_a6e6865d-ad26-4a10-b9c2-5b32f56e57db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_332ce1b4-b323-4025-ad0f-fa49955d251b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_a6e6865d-ad26-4a10-b9c2-5b32f56e57db" xlink:to="loc_us-gaap_CommonStockMember_332ce1b4-b323-4025-ad0f-fa49955d251b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_f559a356-5fed-45fc-bc83-033db4f5dbbd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_a6e6865d-ad26-4a10-b9c2-5b32f56e57db" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_f559a356-5fed-45fc-bc83-033db4f5dbbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_490d7e12-8464-4e57-ac51-69c17eb4e527" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_a6e6865d-ad26-4a10-b9c2-5b32f56e57db" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_490d7e12-8464-4e57-ac51-69c17eb4e527" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_611d2846-e4ba-4f97-8359-f6d02147c4bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_a6e6865d-ad26-4a10-b9c2-5b32f56e57db" xlink:to="loc_us-gaap_RetainedEarningsMember_611d2846-e4ba-4f97-8359-f6d02147c4bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_0c1fcf53-087b-4a6b-8339-416c6b88567f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_7f86e23c-0d10-4386-9f22-6181dfa7488d" xlink:to="loc_us-gaap_StatementLineItems_0c1fcf53-087b-4a6b-8339-416c6b88567f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c5149f2a-936f-44ed-8d7a-5ce0cea466cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0c1fcf53-087b-4a6b-8339-416c6b88567f" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c5149f2a-936f-44ed-8d7a-5ce0cea466cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_e593ca16-8358-4528-92f4-45a6590ced5e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c5149f2a-936f-44ed-8d7a-5ce0cea466cc" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_e593ca16-8358-4528-92f4-45a6590ced5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_1694080f-547b-421f-b8fe-e15221cc7d7a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c5149f2a-936f-44ed-8d7a-5ce0cea466cc" xlink:to="loc_us-gaap_StockholdersEquity_1694080f-547b-421f-b8fe-e15221cc7d7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3fb06e8b-653b-4eb4-971e-37d749e2bb52" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c5149f2a-936f-44ed-8d7a-5ce0cea466cc" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3fb06e8b-653b-4eb4-971e-37d749e2bb52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_b1447eab-921c-419d-be8f-5729d093f6ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c5149f2a-936f-44ed-8d7a-5ce0cea466cc" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_b1447eab-921c-419d-be8f-5729d093f6ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross_c12d547f-13fd-4d41-9118-360dd6a457c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c5149f2a-936f-44ed-8d7a-5ce0cea466cc" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross_c12d547f-13fd-4d41-9118-360dd6a457c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross_41c49284-70b5-422f-a310-8efcc17091c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c5149f2a-936f-44ed-8d7a-5ce0cea466cc" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross_41c49284-70b5-422f-a310-8efcc17091c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_5944136f-59e6-489c-b53a-e906259b20c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c5149f2a-936f-44ed-8d7a-5ce0cea466cc" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_5944136f-59e6-489c-b53a-e906259b20c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_298b4ce4-df91-4e59-9c87-da7a2c9f87bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c5149f2a-936f-44ed-8d7a-5ce0cea466cc" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_298b4ce4-df91-4e59-9c87-da7a2c9f87bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_9e16ad0a-8be5-4b40-ae9e-36dc36ce9646" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c5149f2a-936f-44ed-8d7a-5ce0cea466cc" xlink:to="loc_us-gaap_NetIncomeLoss_9e16ad0a-8be5-4b40-ae9e-36dc36ce9646" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_186e4a2d-41d8-4869-bf35-e077be8756d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c5149f2a-936f-44ed-8d7a-5ce0cea466cc" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_186e4a2d-41d8-4869-bf35-e077be8756d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_19023f4c-48d0-44d7-8eb0-d79ebfb5c03a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c5149f2a-936f-44ed-8d7a-5ce0cea466cc" xlink:to="loc_us-gaap_StockholdersEquity_19023f4c-48d0-44d7-8eb0-d79ebfb5c03a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="alny-20210331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_65cd7478-d4b6-4e42-8abd-542f0b53afce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_d24a96db-d67e-447f-8a0e-bb16f70ceb1a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_65cd7478-d4b6-4e42-8abd-542f0b53afce" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_d24a96db-d67e-447f-8a0e-bb16f70ceb1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_64ff806b-5b95-4a14-8d45-a7bc51c35c3d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_d24a96db-d67e-447f-8a0e-bb16f70ceb1a" xlink:to="loc_us-gaap_NetIncomeLoss_64ff806b-5b95-4a14-8d45-a7bc51c35c3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3b9eebc5-6799-44f4-9388-6197fc20397f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_d24a96db-d67e-447f-8a0e-bb16f70ceb1a" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3b9eebc5-6799-44f4-9388-6197fc20397f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAmortizationAndAccretionNet_d159c28c-a819-4447-b7c0-a7eff1c0725c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationAmortizationAndAccretionNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3b9eebc5-6799-44f4-9388-6197fc20397f" xlink:to="loc_us-gaap_DepreciationAmortizationAndAccretionNet_d159c28c-a819-4447-b7c0-a7eff1c0725c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_AmortizationAndInterestAccretionRelatedToOperatingLeases_e42c6c9c-5f7b-4289-b2f4-ff42f71bb5ea" xlink:href="alny-20210331.xsd#alny_AmortizationAndInterestAccretionRelatedToOperatingLeases"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3b9eebc5-6799-44f4-9388-6197fc20397f" xlink:to="loc_alny_AmortizationAndInterestAccretionRelatedToOperatingLeases_e42c6c9c-5f7b-4289-b2f4-ff42f71bb5ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_NonCashInterestExpenseOnSaleOfFutureRoyalties_e02e4d07-5ae5-4052-b479-87fad58846b4" xlink:href="alny-20210331.xsd#alny_NonCashInterestExpenseOnSaleOfFutureRoyalties"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3b9eebc5-6799-44f4-9388-6197fc20397f" xlink:to="loc_alny_NonCashInterestExpenseOnSaleOfFutureRoyalties_e02e4d07-5ae5-4052-b479-87fad58846b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_e151750a-3b9c-4833-957a-1e1158dfafb3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3b9eebc5-6799-44f4-9388-6197fc20397f" xlink:to="loc_us-gaap_ShareBasedCompensation_e151750a-3b9c-4833-957a-1e1158dfafb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_595d8f96-2fdb-45cb-a93e-76efa147040e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3b9eebc5-6799-44f4-9388-6197fc20397f" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLoss_595d8f96-2fdb-45cb-a93e-76efa147040e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_62463684-a310-4d4d-a0e0-93d0f231fbea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3b9eebc5-6799-44f4-9388-6197fc20397f" xlink:to="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_62463684-a310-4d4d-a0e0-93d0f231fbea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a0a3880d-7374-456f-8c46-825ad96543c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3b9eebc5-6799-44f4-9388-6197fc20397f" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a0a3880d-7374-456f-8c46-825ad96543c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_14225bba-6a5f-4148-a1c1-0b2b423ef1d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a0a3880d-7374-456f-8c46-825ad96543c1" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_14225bba-6a5f-4148-a1c1-0b2b423ef1d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_740a8dfc-5e22-4a3d-864e-534d89109eef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a0a3880d-7374-456f-8c46-825ad96543c1" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_740a8dfc-5e22-4a3d-864e-534d89109eef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_17f7a071-1efb-47b7-8a95-099bca9e862a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a0a3880d-7374-456f-8c46-825ad96543c1" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_17f7a071-1efb-47b7-8a95-099bca9e862a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_e8d8f379-652b-443e-bcfb-dc6151cca288" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a0a3880d-7374-456f-8c46-825ad96543c1" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_e8d8f379-652b-443e-bcfb-dc6151cca288" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_daa87fdb-bba4-4f22-a9bd-cf4a179f809c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a0a3880d-7374-456f-8c46-825ad96543c1" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_daa87fdb-bba4-4f22-a9bd-cf4a179f809c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_eca55252-673b-4641-bd70-8e896c6be68f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a0a3880d-7374-456f-8c46-825ad96543c1" xlink:to="loc_us-gaap_OperatingLeasePayments_eca55252-673b-4641-bd70-8e896c6be68f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_cc1be3b3-098b-4a7c-a1d3-8024d5cafd23" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_d24a96db-d67e-447f-8a0e-bb16f70ceb1a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_cc1be3b3-098b-4a7c-a1d3-8024d5cafd23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_2f696307-9351-4d65-80c3-4ab6b32440c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_65cd7478-d4b6-4e42-8abd-542f0b53afce" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_2f696307-9351-4d65-80c3-4ab6b32440c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_768af197-4c8f-402b-8596-ca784106a7b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_2f696307-9351-4d65-80c3-4ab6b32440c7" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_768af197-4c8f-402b-8596-ca784106a7b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_418b888b-787b-4199-a855-557c2a5926a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_2f696307-9351-4d65-80c3-4ab6b32440c7" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_418b888b-787b-4199-a855-557c2a5926a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_6aa06a0c-e5ea-444d-b516-4733deb3e4cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_2f696307-9351-4d65-80c3-4ab6b32440c7" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_6aa06a0c-e5ea-444d-b516-4733deb3e4cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireRestrictedInvestments_ec99c031-a26c-492f-8b63-724fee7ed3d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireRestrictedInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_2f696307-9351-4d65-80c3-4ab6b32440c7" xlink:to="loc_us-gaap_PaymentsToAcquireRestrictedInvestments_ec99c031-a26c-492f-8b63-724fee7ed3d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfRestrictedInvestments_9e638ecb-466b-4da0-8290-4fb96fc6849d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfRestrictedInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_2f696307-9351-4d65-80c3-4ab6b32440c7" xlink:to="loc_us-gaap_ProceedsFromSaleOfRestrictedInvestments_9e638ecb-466b-4da0-8290-4fb96fc6849d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_02ef38a7-cb36-40b9-a356-10c489a61d59" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_2f696307-9351-4d65-80c3-4ab6b32440c7" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_02ef38a7-cb36-40b9-a356-10c489a61d59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1de9dd75-2583-4c6b-8ef8-ba5c0b0fe2bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_2f696307-9351-4d65-80c3-4ab6b32440c7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1de9dd75-2583-4c6b-8ef8-ba5c0b0fe2bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_65fca319-a969-429e-9c8e-de2328c8f50b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_65cd7478-d4b6-4e42-8abd-542f0b53afce" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_65fca319-a969-429e-9c8e-de2328c8f50b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_f9fec650-61ac-4825-bfba-9d86f44d5fce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_65fca319-a969-429e-9c8e-de2328c8f50b" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_f9fec650-61ac-4825-bfba-9d86f44d5fce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities_df1435dc-1ba6-47bd-b987-ad72429db6c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_65fca319-a969-429e-9c8e-de2328c8f50b" xlink:to="loc_us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities_df1435dc-1ba6-47bd-b987-ad72429db6c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_341e490a-187f-4a95-ba29-8c19d9e9b1f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_65fca319-a969-429e-9c8e-de2328c8f50b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_341e490a-187f-4a95-ba29-8c19d9e9b1f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a79d03c2-2d0e-42b4-a170-58f35b9354bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_65cd7478-d4b6-4e42-8abd-542f0b53afce" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a79d03c2-2d0e-42b4-a170-58f35b9354bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_4e79b081-ef0f-4b70-9c2f-4e8e41e21893" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_65cd7478-d4b6-4e42-8abd-542f0b53afce" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_4e79b081-ef0f-4b70-9c2f-4e8e41e21893" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_210da3e4-904f-446b-8969-f5dd48c5f53e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_65cd7478-d4b6-4e42-8abd-542f0b53afce" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_210da3e4-904f-446b-8969-f5dd48c5f53e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_5dff9f68-0a96-40ab-8cc8-6d9c9abc7e84" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_65cd7478-d4b6-4e42-8abd-542f0b53afce" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_5dff9f68-0a96-40ab-8cc8-6d9c9abc7e84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_306d86b0-137b-4fcf-8146-bbc8f175d2fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_65cd7478-d4b6-4e42-8abd-542f0b53afce" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_306d86b0-137b-4fcf-8146-bbc8f175d2fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_7ed9620e-4d2d-49a8-bea6-701141c6dc33" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_306d86b0-137b-4fcf-8146-bbc8f175d2fd" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_7ed9620e-4d2d-49a8-bea6-701141c6dc33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/NATUREOFBUSINESS" xlink:type="simple" xlink:href="alny-20210331.xsd#NATUREOFBUSINESS"/>
  <link:presentationLink xlink:role="http://www.alnylam.com/role/NATUREOFBUSINESS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_29366f34-71ba-4fd3-9be7-699858ad8cf4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations_598573c7-d2ae-4a53-902c-1120e63733d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NatureOfOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_29366f34-71ba-4fd3-9be7-699858ad8cf4" xlink:to="loc_us-gaap_NatureOfOperations_598573c7-d2ae-4a53-902c-1120e63733d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/NATUREOFBUSINESSDetails" xlink:type="simple" xlink:href="alny-20210331.xsd#NATUREOFBUSINESSDetails"/>
  <link:presentationLink xlink:role="http://www.alnylam.com/role/NATUREOFBUSINESSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_74e02a6a-7df8-4f21-b837-5cdab38a49bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_NumberOfMarketedProducts_03aca199-e3ce-47a0-b778-aa24d1c642b7" xlink:href="alny-20210331.xsd#alny_NumberOfMarketedProducts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_74e02a6a-7df8-4f21-b837-5cdab38a49bd" xlink:to="loc_alny_NumberOfMarketedProducts_03aca199-e3ce-47a0-b778-aa24d1c642b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_NumberOfPartneredProducts_4b806f9e-1d9d-4646-878e-c88e80bbe06e" xlink:href="alny-20210331.xsd#alny_NumberOfPartneredProducts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_74e02a6a-7df8-4f21-b837-5cdab38a49bd" xlink:to="loc_alny_NumberOfPartneredProducts_4b806f9e-1d9d-4646-878e-c88e80bbe06e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_NumberOfClinicalProgramsInLateStages_27debd15-4f03-46c9-b61b-a8915800dfc4" xlink:href="alny-20210331.xsd#alny_NumberOfClinicalProgramsInLateStages"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_74e02a6a-7df8-4f21-b837-5cdab38a49bd" xlink:to="loc_alny_NumberOfClinicalProgramsInLateStages_27debd15-4f03-46c9-b61b-a8915800dfc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/BASISOFPRESENTATIONANDPRINCIPLESOFCONSOLIDATION" xlink:type="simple" xlink:href="alny-20210331.xsd#BASISOFPRESENTATIONANDPRINCIPLESOFCONSOLIDATION"/>
  <link:presentationLink xlink:role="http://www.alnylam.com/role/BASISOFPRESENTATIONANDPRINCIPLESOFCONSOLIDATION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_75261066-3573-4ac1-b99a-c211dd24af02" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_b0e46e81-6ec6-45e4-8c41-5282b73e8ff3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_75261066-3573-4ac1-b99a-c211dd24af02" xlink:to="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_b0e46e81-6ec6-45e4-8c41-5282b73e8ff3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/BASISOFPRESENTATIONANDPRINCIPLESOFCONSOLIDATIONPolicies" xlink:type="simple" xlink:href="alny-20210331.xsd#BASISOFPRESENTATIONANDPRINCIPLESOFCONSOLIDATIONPolicies"/>
  <link:presentationLink xlink:role="http://www.alnylam.com/role/BASISOFPRESENTATIONANDPRINCIPLESOFCONSOLIDATIONPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_43c616a9-6ceb-4065-b82a-ae97a26dd2a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_580ec03d-be93-480a-b9b8-b41d25632490" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_43c616a9-6ceb-4065-b82a-ae97a26dd2a8" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_580ec03d-be93-480a-b9b8-b41d25632490" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_3b50b713-0361-4aac-a622-75868a6e57bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_43c616a9-6ceb-4065-b82a-ae97a26dd2a8" xlink:to="loc_us-gaap_UseOfEstimates_3b50b713-0361-4aac-a622-75868a6e57bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_LiquidityPolicyPolicyTextBlock_5b5a657f-2e35-4e9c-a1a2-ce30ef3f7ef4" xlink:href="alny-20210331.xsd#alny_LiquidityPolicyPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_43c616a9-6ceb-4065-b82a-ae97a26dd2a8" xlink:to="loc_alny_LiquidityPolicyPolicyTextBlock_5b5a657f-2e35-4e9c-a1a2-ce30ef3f7ef4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/NETPRODUCTREVENUES" xlink:type="simple" xlink:href="alny-20210331.xsd#NETPRODUCTREVENUES"/>
  <link:presentationLink xlink:role="http://www.alnylam.com/role/NETPRODUCTREVENUES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_5998887c-2dde-497d-be9b-df986725cfed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_5d2ea564-7612-45a8-ae62-400311074918" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_5998887c-2dde-497d-be9b-df986725cfed" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_5d2ea564-7612-45a8-ae62-400311074918" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/NETPRODUCTREVENUESTables" xlink:type="simple" xlink:href="alny-20210331.xsd#NETPRODUCTREVENUESTables"/>
  <link:presentationLink xlink:role="http://www.alnylam.com/role/NETPRODUCTREVENUESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_3061ae7a-e672-49f3-807e-3243a7e3971b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_08c11ed9-bc71-43cc-b2c7-2fcb56b4e3ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_3061ae7a-e672-49f3-807e-3243a7e3971b" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_08c11ed9-bc71-43cc-b2c7-2fcb56b4e3ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_2a2a5496-332d-4b87-a433-3363849a35e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_3061ae7a-e672-49f3-807e-3243a7e3971b" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_2a2a5496-332d-4b87-a433-3363849a35e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/NETPRODUCTREVENUESSummaryofNetProductRevenuesDetail" xlink:type="simple" xlink:href="alny-20210331.xsd#NETPRODUCTREVENUESSummaryofNetProductRevenuesDetail"/>
  <link:presentationLink xlink:role="http://www.alnylam.com/role/NETPRODUCTREVENUESSummaryofNetProductRevenuesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_f53ab229-4dda-4e80-a7b6-87a7d3d6384c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_2005e44b-3ffe-499e-8333-e3f5e6c127a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_f53ab229-4dda-4e80-a7b6-87a7d3d6384c" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_2005e44b-3ffe-499e-8333-e3f5e6c127a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_4db6e1ce-4693-449e-8e14-0236ae98ecb2" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_2005e44b-3ffe-499e-8333-e3f5e6c127a9" xlink:to="loc_srt_StatementGeographicalAxis_4db6e1ce-4693-449e-8e14-0236ae98ecb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_297bdef5-77be-4e27-8b3e-2d8db51ea7a0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_4db6e1ce-4693-449e-8e14-0236ae98ecb2" xlink:to="loc_srt_SegmentGeographicalDomain_297bdef5-77be-4e27-8b3e-2d8db51ea7a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_f5d93604-5dde-43d8-bac1-4ce72c331dd4" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_297bdef5-77be-4e27-8b3e-2d8db51ea7a0" xlink:to="loc_country_US_f5d93604-5dde-43d8-bac1-4ce72c331dd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_3bbb9d1e-f2f0-4913-8894-87e4a5927fe0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EuropeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_297bdef5-77be-4e27-8b3e-2d8db51ea7a0" xlink:to="loc_srt_EuropeMember_3bbb9d1e-f2f0-4913-8894-87e4a5927fe0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_NonUSOrEuropeMember_9597241d-56ea-4014-82c5-0741ba270271" xlink:href="alny-20210331.xsd#alny_NonUSOrEuropeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_297bdef5-77be-4e27-8b3e-2d8db51ea7a0" xlink:to="loc_alny_NonUSOrEuropeMember_9597241d-56ea-4014-82c5-0741ba270271" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_4d3263b8-2167-4808-807e-132710713a3f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_2005e44b-3ffe-499e-8333-e3f5e6c127a9" xlink:to="loc_srt_ProductOrServiceAxis_4d3263b8-2167-4808-807e-132710713a3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_43ca69da-b250-4953-b98f-bfb6d0cd47fb" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_4d3263b8-2167-4808-807e-132710713a3f" xlink:to="loc_srt_ProductsAndServicesDomain_43ca69da-b250-4953-b98f-bfb6d0cd47fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_ecc6e9a2-2c0b-4488-a86b-4b949ddf3c67" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_43ca69da-b250-4953-b98f-bfb6d0cd47fb" xlink:to="loc_us-gaap_ProductMember_ecc6e9a2-2c0b-4488-a86b-4b949ddf3c67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_ONPATTROMember_4af147b3-293e-4371-a01b-54ba4bb18f11" xlink:href="alny-20210331.xsd#alny_ONPATTROMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_ecc6e9a2-2c0b-4488-a86b-4b949ddf3c67" xlink:to="loc_alny_ONPATTROMember_4af147b3-293e-4371-a01b-54ba4bb18f11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_GIVLAARIMember_58abbb06-2a97-4d0d-98f0-f6d260f1836c" xlink:href="alny-20210331.xsd#alny_GIVLAARIMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_ecc6e9a2-2c0b-4488-a86b-4b949ddf3c67" xlink:to="loc_alny_GIVLAARIMember_58abbb06-2a97-4d0d-98f0-f6d260f1836c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_OXLUMOMember_3704bab0-ceb5-4381-a313-5c10f2bd3719" xlink:href="alny-20210331.xsd#alny_OXLUMOMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_ecc6e9a2-2c0b-4488-a86b-4b949ddf3c67" xlink:to="loc_alny_OXLUMOMember_3704bab0-ceb5-4381-a313-5c10f2bd3719" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_e99ece99-62a1-4556-ab1c-48cc0af6672f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_2005e44b-3ffe-499e-8333-e3f5e6c127a9" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_e99ece99-62a1-4556-ab1c-48cc0af6672f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_11918797-9e45-4eca-9519-063810258e3e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_e99ece99-62a1-4556-ab1c-48cc0af6672f" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_11918797-9e45-4eca-9519-063810258e3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/NETPRODUCTREVENUESReceivablesDetail" xlink:type="simple" xlink:href="alny-20210331.xsd#NETPRODUCTREVENUESReceivablesDetail"/>
  <link:presentationLink xlink:role="http://www.alnylam.com/role/NETPRODUCTREVENUESReceivablesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_eabc3a85-6cb2-44cd-ab07-de536700bba0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_3a701e07-d79c-4820-97b4-3309034d5951" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_eabc3a85-6cb2-44cd-ab07-de536700bba0" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_3a701e07-d79c-4820-97b4-3309034d5951" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_f3d9cdc4-547f-4bf2-a829-bc01848f9525" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_3a701e07-d79c-4820-97b4-3309034d5951" xlink:to="loc_srt_ProductOrServiceAxis_f3d9cdc4-547f-4bf2-a829-bc01848f9525" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_5ec5fd10-58a4-4842-af4a-a920ecc99b43" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_f3d9cdc4-547f-4bf2-a829-bc01848f9525" xlink:to="loc_srt_ProductsAndServicesDomain_5ec5fd10-58a4-4842-af4a-a920ecc99b43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_f484b496-416d-4c38-a2c2-f9d94da953af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5ec5fd10-58a4-4842-af4a-a920ecc99b43" xlink:to="loc_us-gaap_ProductMember_f484b496-416d-4c38-a2c2-f9d94da953af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_73bfb0a0-ba1b-4657-bd63-f9ddfe8d23b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_3a701e07-d79c-4820-97b4-3309034d5951" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_73bfb0a0-ba1b-4657-bd63-f9ddfe8d23b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_4bc3549a-4438-41b8-ad43-c12452cb62fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_73bfb0a0-ba1b-4657-bd63-f9ddfe8d23b3" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_4bc3549a-4438-41b8-ad43-c12452cb62fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONS" xlink:type="simple" xlink:href="alny-20210331.xsd#NETREVENUESFROMCOLLABORATIONS"/>
  <link:presentationLink xlink:role="http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_86b6e54e-d641-4e96-8e06-1727f49e902c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_626fe8a4-d8c7-4aac-a17f-a1eaa2ae61f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_86b6e54e-d641-4e96-8e06-1727f49e902c" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_626fe8a4-d8c7-4aac-a17f-a1eaa2ae61f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSTables" xlink:type="simple" xlink:href="alny-20210331.xsd#NETREVENUESFROMCOLLABORATIONSTables"/>
  <link:presentationLink xlink:role="http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a5ac1c3b-4b50-45f3-8a73-0ce666378858" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_174a2d79-52cd-40ff-b3be-0dd015d981fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a5ac1c3b-4b50-45f3-8a73-0ce666378858" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_174a2d79-52cd-40ff-b3be-0dd015d981fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_1406dca1-d2c7-4132-b8b9-e2493bd3ff24" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a5ac1c3b-4b50-45f3-8a73-0ce666378858" xlink:to="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_1406dca1-d2c7-4132-b8b9-e2493bd3ff24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_ScheduleOfResearchAndDevelopmentExpensesIncurredForCollaborationAgreementsTableTableTextBlock_19da70bc-9e18-491c-9f7f-7f0855fa9314" xlink:href="alny-20210331.xsd#alny_ScheduleOfResearchAndDevelopmentExpensesIncurredForCollaborationAgreementsTableTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a5ac1c3b-4b50-45f3-8a73-0ce666378858" xlink:to="loc_alny_ScheduleOfResearchAndDevelopmentExpensesIncurredForCollaborationAgreementsTableTableTextBlock_19da70bc-9e18-491c-9f7f-7f0855fa9314" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_ScheduleOfAllocatedTransactionPriceTableTextBlock_fc7f13bf-a6f9-4329-bb80-587d3a7e629b" xlink:href="alny-20210331.xsd#alny_ScheduleOfAllocatedTransactionPriceTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a5ac1c3b-4b50-45f3-8a73-0ce666378858" xlink:to="loc_alny_ScheduleOfAllocatedTransactionPriceTableTextBlock_fc7f13bf-a6f9-4329-bb80-587d3a7e629b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_ScheduleOfRevenueRecognizedBasedOnAccountingGuidanceTableTextBlock_4d524dde-5242-4d80-9fa9-ad983ab9f445" xlink:href="alny-20210331.xsd#alny_ScheduleOfRevenueRecognizedBasedOnAccountingGuidanceTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a5ac1c3b-4b50-45f3-8a73-0ce666378858" xlink:to="loc_alny_ScheduleOfRevenueRecognizedBasedOnAccountingGuidanceTableTextBlock_4d524dde-5242-4d80-9fa9-ad983ab9f445" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSRevenuefromCollaboratorsDetail" xlink:type="simple" xlink:href="alny-20210331.xsd#NETREVENUESFROMCOLLABORATIONSRevenuefromCollaboratorsDetail"/>
  <link:presentationLink xlink:role="http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSRevenuefromCollaboratorsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_33ba379e-861a-4225-a74e-6b50489e0130" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_adc4fe25-b46e-4610-a28f-057cda504df4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_33ba379e-861a-4225-a74e-6b50489e0130" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_adc4fe25-b46e-4610-a28f-057cda504df4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_6a0dc35d-b22e-4c97-8d81-4ee429bbb760" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_adc4fe25-b46e-4610-a28f-057cda504df4" xlink:to="loc_us-gaap_TypeOfArrangementAxis_6a0dc35d-b22e-4c97-8d81-4ee429bbb760" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ed64d072-cebe-4fc5-95e6-10842906a997" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_6a0dc35d-b22e-4c97-8d81-4ee429bbb760" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ed64d072-cebe-4fc5-95e6-10842906a997" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_f5f984ae-5d39-43ff-a96e-564905b46331" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ed64d072-cebe-4fc5-95e6-10842906a997" xlink:to="loc_us-gaap_CollaborativeArrangementMember_f5f984ae-5d39-43ff-a96e-564905b46331" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_90f2ed39-0b0e-49bc-8b27-dcfc83b9790f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_adc4fe25-b46e-4610-a28f-057cda504df4" xlink:to="loc_srt_CounterpartyNameAxis_90f2ed39-0b0e-49bc-8b27-dcfc83b9790f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_08d71dfa-d8a2-4f76-bbd6-d9ae969f9b35" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_90f2ed39-0b0e-49bc-8b27-dcfc83b9790f" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_08d71dfa-d8a2-4f76-bbd6-d9ae969f9b35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_RegeneronPharmaceuticalsIncorporationMember_0c3ab737-8f7d-4fed-862b-328ebbf08d42" xlink:href="alny-20210331.xsd#alny_RegeneronPharmaceuticalsIncorporationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_08d71dfa-d8a2-4f76-bbd6-d9ae969f9b35" xlink:to="loc_alny_RegeneronPharmaceuticalsIncorporationMember_0c3ab737-8f7d-4fed-862b-328ebbf08d42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_NovartisMember_9a436ae0-2183-4ec7-9de0-200cac826d6f" xlink:href="alny-20210331.xsd#alny_NovartisMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_08d71dfa-d8a2-4f76-bbd6-d9ae969f9b35" xlink:to="loc_alny_NovartisMember_9a436ae0-2183-4ec7-9de0-200cac826d6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_VirBiotechnologyIncMember_c07c34c1-0dc2-4ba6-b856-3d90823a5de7" xlink:href="alny-20210331.xsd#alny_VirBiotechnologyIncMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_08d71dfa-d8a2-4f76-bbd6-d9ae969f9b35" xlink:to="loc_alny_VirBiotechnologyIncMember_c07c34c1-0dc2-4ba6-b856-3d90823a5de7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_OtherCollaborationsMember_e9d9297f-bb5a-4fea-a420-586756f0fb81" xlink:href="alny-20210331.xsd#alny_OtherCollaborationsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_08d71dfa-d8a2-4f76-bbd6-d9ae969f9b35" xlink:to="loc_alny_OtherCollaborationsMember_e9d9297f-bb5a-4fea-a420-586756f0fb81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7ca27bae-3a13-4be3-8d26-a575f863cb25" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_adc4fe25-b46e-4610-a28f-057cda504df4" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7ca27bae-3a13-4be3-8d26-a575f863cb25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2138d4f8-81e9-4910-9417-cc5ded69d51e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7ca27bae-3a13-4be3-8d26-a575f863cb25" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2138d4f8-81e9-4910-9417-cc5ded69d51e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSBalanceofReceivablesandContractLiabilitiesRelatedtoCollaborationAgreementsDetail" xlink:type="simple" xlink:href="alny-20210331.xsd#NETREVENUESFROMCOLLABORATIONSBalanceofReceivablesandContractLiabilitiesRelatedtoCollaborationAgreementsDetail"/>
  <link:presentationLink xlink:role="http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSBalanceofReceivablesandContractLiabilitiesRelatedtoCollaborationAgreementsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f0ab0f71-e6bf-40d1-9a5a-379f085e5c2f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNet_ac72a55e-fbfb-4bf9-bd0c-29e4bb020e6a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f0ab0f71-e6bf-40d1-9a5a-379f085e5c2f" xlink:to="loc_us-gaap_AccountsReceivableNet_ac72a55e-fbfb-4bf9-bd0c-29e4bb020e6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_df791e0b-9cfa-400d-a393-9cebd600484a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f0ab0f71-e6bf-40d1-9a5a-379f085e5c2f" xlink:to="loc_us-gaap_ContractWithCustomerLiability_df791e0b-9cfa-400d-a393-9cebd600484a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSAdditionalInformationDetail" xlink:type="simple" xlink:href="alny-20210331.xsd#NETREVENUESFROMCOLLABORATIONSAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d7e5a36d-cacd-4b4f-a6f1-6ceb938851d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3f5e925c-de67-40df-bc0f-f51863aa2a9a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d7e5a36d-cacd-4b4f-a6f1-6ceb938851d0" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3f5e925c-de67-40df-bc0f-f51863aa2a9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_7e78c9dd-2606-4a5d-866c-f154c8b5ab76" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3f5e925c-de67-40df-bc0f-f51863aa2a9a" xlink:to="loc_us-gaap_TypeOfArrangementAxis_7e78c9dd-2606-4a5d-866c-f154c8b5ab76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_22d7d464-3347-4f3c-8db8-98e32c5901e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_7e78c9dd-2606-4a5d-866c-f154c8b5ab76" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_22d7d464-3347-4f3c-8db8-98e32c5901e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_GlobalStrategicCollaborationMember_ff5d5fe2-a201-4deb-a281-a8db900e4506" xlink:href="alny-20210331.xsd#alny_GlobalStrategicCollaborationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_22d7d464-3347-4f3c-8db8-98e32c5901e5" xlink:to="loc_alny_GlobalStrategicCollaborationMember_ff5d5fe2-a201-4deb-a281-a8db900e4506" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_ProductAlliancesMember_d19b14f2-5b3c-4be3-b31b-619aff655490" xlink:href="alny-20210331.xsd#alny_ProductAlliancesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_22d7d464-3347-4f3c-8db8-98e32c5901e5" xlink:to="loc_alny_ProductAlliancesMember_d19b14f2-5b3c-4be3-b31b-619aff655490" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_deb5748b-f6a3-4cd0-b9cb-aec2c8626e4f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3f5e925c-de67-40df-bc0f-f51863aa2a9a" xlink:to="loc_srt_RangeAxis_deb5748b-f6a3-4cd0-b9cb-aec2c8626e4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0346bd0a-6946-4245-bf18-a4f374940c50" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_deb5748b-f6a3-4cd0-b9cb-aec2c8626e4f" xlink:to="loc_srt_RangeMember_0346bd0a-6946-4245-bf18-a4f374940c50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_5c263f42-b711-4a62-b9fe-0754d6010cb7" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_0346bd0a-6946-4245-bf18-a4f374940c50" xlink:to="loc_srt_MinimumMember_5c263f42-b711-4a62-b9fe-0754d6010cb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_1a74f6ac-d8b1-4838-a58a-12c822b0e35b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_0346bd0a-6946-4245-bf18-a4f374940c50" xlink:to="loc_srt_MaximumMember_1a74f6ac-d8b1-4838-a58a-12c822b0e35b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_a2b6c5a7-9b86-4de5-9696-ed9741e37507" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3f5e925c-de67-40df-bc0f-f51863aa2a9a" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_a2b6c5a7-9b86-4de5-9696-ed9741e37507" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_7814660a-b3b9-4307-a698-b406ffd21371" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_a2b6c5a7-9b86-4de5-9696-ed9741e37507" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_7814660a-b3b9-4307-a698-b406ffd21371" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_FundingAtProgramInitiationMember_2dc8ed6c-00ce-4165-b5ce-d9475d8a6412" xlink:href="alny-20210331.xsd#alny_FundingAtProgramInitiationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_7814660a-b3b9-4307-a698-b406ffd21371" xlink:to="loc_alny_FundingAtProgramInitiationMember_2dc8ed6c-00ce-4165-b5ce-d9475d8a6412" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_FundingAtLeadCandidateIdentificationMember_bc26ac54-dcdc-4e6d-98cc-4fb99c72c950" xlink:href="alny-20210331.xsd#alny_FundingAtLeadCandidateIdentificationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_7814660a-b3b9-4307-a698-b406ffd21371" xlink:to="loc_alny_FundingAtLeadCandidateIdentificationMember_bc26ac54-dcdc-4e6d-98cc-4fb99c72c950" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_FundingAnAnnualDiscoveryMember_401e883c-dba2-48fb-ab92-7808bbff2461" xlink:href="alny-20210331.xsd#alny_FundingAnAnnualDiscoveryMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_7814660a-b3b9-4307-a698-b406ffd21371" xlink:to="loc_alny_FundingAnAnnualDiscoveryMember_401e883c-dba2-48fb-ab92-7808bbff2461" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_ResearchCollaboratorAxis_de2debd0-4973-4a8a-b6d8-3a29d486d7c5" xlink:href="alny-20210331.xsd#alny_ResearchCollaboratorAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3f5e925c-de67-40df-bc0f-f51863aa2a9a" xlink:to="loc_alny_ResearchCollaboratorAxis_de2debd0-4973-4a8a-b6d8-3a29d486d7c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_ResearchCollaboratorDomain_7e22b74e-2f01-4f27-ab23-43685a91c1f4" xlink:href="alny-20210331.xsd#alny_ResearchCollaboratorDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alny_ResearchCollaboratorAxis_de2debd0-4973-4a8a-b6d8-3a29d486d7c5" xlink:to="loc_alny_ResearchCollaboratorDomain_7e22b74e-2f01-4f27-ab23-43685a91c1f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_NovartisMember_e839d4e5-63a8-4769-992d-1e21f7c00dc2" xlink:href="alny-20210331.xsd#alny_NovartisMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alny_ResearchCollaboratorDomain_7e22b74e-2f01-4f27-ab23-43685a91c1f4" xlink:to="loc_alny_NovartisMember_e839d4e5-63a8-4769-992d-1e21f7c00dc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_24d97e8d-d549-4185-a060-5c05aedb25e8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3f5e925c-de67-40df-bc0f-f51863aa2a9a" xlink:to="loc_srt_CounterpartyNameAxis_24d97e8d-d549-4185-a060-5c05aedb25e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7a9d543f-4f6a-4c51-9716-0baa662277a2" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_24d97e8d-d549-4185-a060-5c05aedb25e8" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7a9d543f-4f6a-4c51-9716-0baa662277a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_VirBiotechnologyIncMember_c1acf2bc-c867-450d-bba2-672d487a0b40" xlink:href="alny-20210331.xsd#alny_VirBiotechnologyIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7a9d543f-4f6a-4c51-9716-0baa662277a2" xlink:to="loc_alny_VirBiotechnologyIncMember_c1acf2bc-c867-450d-bba2-672d487a0b40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_RegeneronPharmaceuticalsIncorporationMember_82b9d0f9-f505-4cbd-8763-fd97bd15ac1c" xlink:href="alny-20210331.xsd#alny_RegeneronPharmaceuticalsIncorporationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7a9d543f-4f6a-4c51-9716-0baa662277a2" xlink:to="loc_alny_RegeneronPharmaceuticalsIncorporationMember_82b9d0f9-f505-4cbd-8763-fd97bd15ac1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2493336a-5014-4ac0-a321-32bad4392538" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3f5e925c-de67-40df-bc0f-f51863aa2a9a" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2493336a-5014-4ac0-a321-32bad4392538" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_4add214b-49bc-45d3-92a1-7d039943ffec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2493336a-5014-4ac0-a321-32bad4392538" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_4add214b-49bc-45d3-92a1-7d039943ffec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_DiscoveryPeriodOfProgramsDevelopment_2eb16cbc-969f-4200-9b7c-d66fef7ab910" xlink:href="alny-20210331.xsd#alny_DiscoveryPeriodOfProgramsDevelopment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2493336a-5014-4ac0-a321-32bad4392538" xlink:to="loc_alny_DiscoveryPeriodOfProgramsDevelopment_2eb16cbc-969f-4200-9b7c-d66fef7ab910" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_ExtendedAdditionalDiscoveryPeriodOfProgramsDevelopment_498c92de-67e8-4beb-87b5-ea666d833c6e" xlink:href="alny-20210331.xsd#alny_ExtendedAdditionalDiscoveryPeriodOfProgramsDevelopment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2493336a-5014-4ac0-a321-32bad4392538" xlink:to="loc_alny_ExtendedAdditionalDiscoveryPeriodOfProgramsDevelopment_498c92de-67e8-4beb-87b5-ea666d833c6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_ResearchTermExtensionFee_2e152418-bfa8-401b-9097-0f6ebb99a1de" xlink:href="alny-20210331.xsd#alny_ResearchTermExtensionFee"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2493336a-5014-4ac0-a321-32bad4392538" xlink:to="loc_alny_ResearchTermExtensionFee_2e152418-bfa8-401b-9097-0f6ebb99a1de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_MaximumRoyaltiesAndCommercialMilestonePaymentsUponPotentialProductSale_830c87e1-8e1f-4746-9bc5-331b4e49b7d5" xlink:href="alny-20210331.xsd#alny_MaximumRoyaltiesAndCommercialMilestonePaymentsUponPotentialProductSale"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2493336a-5014-4ac0-a321-32bad4392538" xlink:to="loc_alny_MaximumRoyaltiesAndCommercialMilestonePaymentsUponPotentialProductSale_830c87e1-8e1f-4746-9bc5-331b4e49b7d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_UpfrontFeeReceived_fd853c5e-4192-434e-ba8a-8b1469d09db8" xlink:href="alny-20210331.xsd#alny_UpfrontFeeReceived"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2493336a-5014-4ac0-a321-32bad4392538" xlink:to="loc_alny_UpfrontFeeReceived_fd853c5e-4192-434e-ba8a-8b1469d09db8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_MaximumAdditionalMilestonePaymentsToBeReceiveUponAchievementOfCertainCriteria_0bac42f7-0475-425c-a144-e0baabc24dc4" xlink:href="alny-20210331.xsd#alny_MaximumAdditionalMilestonePaymentsToBeReceiveUponAchievementOfCertainCriteria"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2493336a-5014-4ac0-a321-32bad4392538" xlink:to="loc_alny_MaximumAdditionalMilestonePaymentsToBeReceiveUponAchievementOfCertainCriteria_0bac42f7-0475-425c-a144-e0baabc24dc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_NumberOfTargetedPrograms_e81733f7-1e88-4339-992e-f4d7d306b36c" xlink:href="alny-20210331.xsd#alny_NumberOfTargetedPrograms"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2493336a-5014-4ac0-a321-32bad4392538" xlink:to="loc_alny_NumberOfTargetedPrograms_e81733f7-1e88-4339-992e-f4d7d306b36c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_PotentialProceedsFromCollaborationArrangement_21cc6ede-d416-4909-9578-9d38e5f7d602" xlink:href="alny-20210331.xsd#alny_PotentialProceedsFromCollaborationArrangement"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2493336a-5014-4ac0-a321-32bad4392538" xlink:to="loc_alny_PotentialProceedsFromCollaborationArrangement_21cc6ede-d416-4909-9578-9d38e5f7d602" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_CollaborativeAgreementTerminationPeriod_1bacb337-5a99-454a-9874-ca6e1e8297dc" xlink:href="alny-20210331.xsd#alny_CollaborativeAgreementTerminationPeriod"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2493336a-5014-4ac0-a321-32bad4392538" xlink:to="loc_alny_CollaborativeAgreementTerminationPeriod_1bacb337-5a99-454a-9874-ca6e1e8297dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_CollaborativeArrangementMilestonePayments_93136f46-999f-45db-92a7-f2fd503979d4" xlink:href="alny-20210331.xsd#alny_CollaborativeArrangementMilestonePayments"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2493336a-5014-4ac0-a321-32bad4392538" xlink:to="loc_alny_CollaborativeArrangementMilestonePayments_93136f46-999f-45db-92a7-f2fd503979d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_RoyaltyRate_baf5b2aa-9f8e-469d-b61e-3e9e98464f6b" xlink:href="alny-20210331.xsd#alny_RoyaltyRate"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2493336a-5014-4ac0-a321-32bad4392538" xlink:to="loc_alny_RoyaltyRate_baf5b2aa-9f8e-469d-b61e-3e9e98464f6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_PercentageOfMaximumRoyaltyPayments_42a95e4d-4269-4fff-9524-73e609676cfc" xlink:href="alny-20210331.xsd#alny_PercentageOfMaximumRoyaltyPayments"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2493336a-5014-4ac0-a321-32bad4392538" xlink:to="loc_alny_PercentageOfMaximumRoyaltyPayments_42a95e4d-4269-4fff-9524-73e609676cfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_TransactionPrice_166c5bae-c4d9-4ad5-a899-bed436d07ae5" xlink:href="alny-20210331.xsd#alny_TransactionPrice"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2493336a-5014-4ac0-a321-32bad4392538" xlink:to="loc_alny_TransactionPrice_166c5bae-c4d9-4ad5-a899-bed436d07ae5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_98fa76d1-bfbf-47a9-99b0-661bdb239f8f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2493336a-5014-4ac0-a321-32bad4392538" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_98fa76d1-bfbf-47a9-99b0-661bdb239f8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_MilestonePaymentEarned_0bec5a96-66b3-4f81-b994-cb1dcbef98f4" xlink:href="alny-20210331.xsd#alny_MilestonePaymentEarned"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2493336a-5014-4ac0-a321-32bad4392538" xlink:to="loc_alny_MilestonePaymentEarned_0bec5a96-66b3-4f81-b994-cb1dcbef98f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_MaximumNumberOfPotentialFutureMilestones_2315f615-5144-406f-970f-a8801c374fcb" xlink:href="alny-20210331.xsd#alny_MaximumNumberOfPotentialFutureMilestones"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2493336a-5014-4ac0-a321-32bad4392538" xlink:to="loc_alny_MaximumNumberOfPotentialFutureMilestones_2315f615-5144-406f-970f-a8801c374fcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_FuturePaymentsOnAchievementOfSpecifiedRegulatoryMilestones_87674758-5eb2-4517-814a-b8a6850eccd2" xlink:href="alny-20210331.xsd#alny_FuturePaymentsOnAchievementOfSpecifiedRegulatoryMilestones"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2493336a-5014-4ac0-a321-32bad4392538" xlink:to="loc_alny_FuturePaymentsOnAchievementOfSpecifiedRegulatoryMilestones_87674758-5eb2-4517-814a-b8a6850eccd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_FuturePaymentsOnAchievementOfOtherSpecifiedRegulatoryMilestones_a5336fee-a78b-4858-a801-99a707a21b5f" xlink:href="alny-20210331.xsd#alny_FuturePaymentsOnAchievementOfOtherSpecifiedRegulatoryMilestones"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2493336a-5014-4ac0-a321-32bad4392538" xlink:to="loc_alny_FuturePaymentsOnAchievementOfOtherSpecifiedRegulatoryMilestones_a5336fee-a78b-4858-a801-99a707a21b5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_FuturePaymentsOnAchievementOfSpecifiedCommercializationMilestones_bdc3c5fb-4e57-42ce-955e-513f7b28ec7c" xlink:href="alny-20210331.xsd#alny_FuturePaymentsOnAchievementOfSpecifiedCommercializationMilestones"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2493336a-5014-4ac0-a321-32bad4392538" xlink:to="loc_alny_FuturePaymentsOnAchievementOfSpecifiedCommercializationMilestones_bdc3c5fb-4e57-42ce-955e-513f7b28ec7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedBalanceShares_19313369-5391-4888-9b67-860d7bd1f6b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentOwnedBalanceShares"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2493336a-5014-4ac0-a321-32bad4392538" xlink:to="loc_us-gaap_InvestmentOwnedBalanceShares_19313369-5391-4888-9b67-860d7bd1f6b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_MilestonePaymentEarnedShares_8beae3cc-5b64-4729-8464-4a55481967c2" xlink:href="alny-20210331.xsd#alny_MilestonePaymentEarnedShares"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2493336a-5014-4ac0-a321-32bad4392538" xlink:to="loc_alny_MilestonePaymentEarnedShares_8beae3cc-5b64-4729-8464-4a55481967c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_CollaborativeArrangementAdditionalDevelopmentCandidatesToBeDelivered_fdc1d09d-c5e3-439a-8e3f-3f65562aaae6" xlink:href="alny-20210331.xsd#alny_CollaborativeArrangementAdditionalDevelopmentCandidatesToBeDelivered"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2493336a-5014-4ac0-a321-32bad4392538" xlink:to="loc_alny_CollaborativeArrangementAdditionalDevelopmentCandidatesToBeDelivered_fdc1d09d-c5e3-439a-8e3f-3f65562aaae6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofResearchandDevelopmentExpensesIncurredbyTypethatareDirectlyAttributabletoCollaborationAgreementsDetail" xlink:type="simple" xlink:href="alny-20210331.xsd#NETREVENUESFROMCOLLABORATIONSScheduleofResearchandDevelopmentExpensesIncurredbyTypethatareDirectlyAttributabletoCollaborationAgreementsDetail"/>
  <link:presentationLink xlink:role="http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofResearchandDevelopmentExpensesIncurredbyTypethatareDirectlyAttributabletoCollaborationAgreementsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_50ccc282-50b9-4f85-ba67-c2480652ea10" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_36288480-3455-422c-862a-fc536afd98f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_50ccc282-50b9-4f85-ba67-c2480652ea10" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_36288480-3455-422c-862a-fc536afd98f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_a2c89823-93ec-4562-bf2e-9380e62a4fec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_36288480-3455-422c-862a-fc536afd98f0" xlink:to="loc_us-gaap_TypeOfArrangementAxis_a2c89823-93ec-4562-bf2e-9380e62a4fec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_18be133d-ca3b-4f4d-8ef9-441a53a4be5f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_a2c89823-93ec-4562-bf2e-9380e62a4fec" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_18be133d-ca3b-4f4d-8ef9-441a53a4be5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_ClinicalTrialAndManufacturingMember_1cb8e5c8-a80b-4e3f-8799-45e9b7339277" xlink:href="alny-20210331.xsd#alny_ClinicalTrialAndManufacturingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_18be133d-ca3b-4f4d-8ef9-441a53a4be5f" xlink:to="loc_alny_ClinicalTrialAndManufacturingMember_1cb8e5c8-a80b-4e3f-8799-45e9b7339277" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_ExternalServicesMember_043dcd1c-313e-47f6-b202-ecb609439833" xlink:href="alny-20210331.xsd#alny_ExternalServicesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_18be133d-ca3b-4f4d-8ef9-441a53a4be5f" xlink:to="loc_alny_ExternalServicesMember_043dcd1c-313e-47f6-b202-ecb609439833" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_OtherMember_4f1f5a63-f758-45a7-b71b-052fa16ab612" xlink:href="alny-20210331.xsd#alny_OtherMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_18be133d-ca3b-4f4d-8ef9-441a53a4be5f" xlink:to="loc_alny_OtherMember_4f1f5a63-f758-45a7-b71b-052fa16ab612" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_f7497f56-3f40-4127-8209-9c2289b34bd2" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_36288480-3455-422c-862a-fc536afd98f0" xlink:to="loc_srt_CounterpartyNameAxis_f7497f56-3f40-4127-8209-9c2289b34bd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6196d434-9ab9-4a79-8916-0380601f9cfd" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_f7497f56-3f40-4127-8209-9c2289b34bd2" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6196d434-9ab9-4a79-8916-0380601f9cfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_RegeneronPharmaceuticalsIncorporationMember_bd38fb23-04a8-45db-a5ad-6e59afb57d2c" xlink:href="alny-20210331.xsd#alny_RegeneronPharmaceuticalsIncorporationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6196d434-9ab9-4a79-8916-0380601f9cfd" xlink:to="loc_alny_RegeneronPharmaceuticalsIncorporationMember_bd38fb23-04a8-45db-a5ad-6e59afb57d2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_VirBiotechnologyIncMember_18a3dd45-b3af-4e23-af8d-e413fc27f203" xlink:href="alny-20210331.xsd#alny_VirBiotechnologyIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6196d434-9ab9-4a79-8916-0380601f9cfd" xlink:to="loc_alny_VirBiotechnologyIncMember_18a3dd45-b3af-4e23-af8d-e413fc27f203" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_NovartisMember_1789f5c8-09e2-4e06-9163-fd972e6c5f5a" xlink:href="alny-20210331.xsd#alny_NovartisMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6196d434-9ab9-4a79-8916-0380601f9cfd" xlink:to="loc_alny_NovartisMember_1789f5c8-09e2-4e06-9163-fd972e6c5f5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_SanofiGenzymeMember_05b4f4b6-ebfd-4a0d-9320-0f9e9cb1a2ba" xlink:href="alny-20210331.xsd#alny_SanofiGenzymeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6196d434-9ab9-4a79-8916-0380601f9cfd" xlink:to="loc_alny_SanofiGenzymeMember_05b4f4b6-ebfd-4a0d-9320-0f9e9cb1a2ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7bc79223-fe1a-40a2-b03c-c944a8d30968" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_36288480-3455-422c-862a-fc536afd98f0" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7bc79223-fe1a-40a2-b03c-c944a8d30968" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_b2138bae-c8e6-476f-90be-e029b6ee6ca2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7bc79223-fe1a-40a2-b03c-c944a8d30968" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_b2138bae-c8e6-476f-90be-e029b6ee6ca2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofTransactionPriceAllocatedDetails" xlink:type="simple" xlink:href="alny-20210331.xsd#NETREVENUESFROMCOLLABORATIONSScheduleofTransactionPriceAllocatedDetails"/>
  <link:presentationLink xlink:role="http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofTransactionPriceAllocatedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_15caea1f-cc53-4bb5-9fab-1b04999a00b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_70943086-255b-451f-9735-d2e86fa797fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_15caea1f-cc53-4bb5-9fab-1b04999a00b1" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_70943086-255b-451f-9735-d2e86fa797fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_7874f9fc-0c2f-4d2b-8562-b07bbcff8e9b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_70943086-255b-451f-9735-d2e86fa797fb" xlink:to="loc_srt_ProductOrServiceAxis_7874f9fc-0c2f-4d2b-8562-b07bbcff8e9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_9925488c-fc86-44af-afea-23d42727e69e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_7874f9fc-0c2f-4d2b-8562-b07bbcff8e9b" xlink:to="loc_srt_ProductsAndServicesDomain_9925488c-fc86-44af-afea-23d42727e69e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_ResearchServicesObligationMember_8ba85646-3445-4cbc-86d9-d6819c521b7a" xlink:href="alny-20210331.xsd#alny_ResearchServicesObligationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_9925488c-fc86-44af-afea-23d42727e69e" xlink:to="loc_alny_ResearchServicesObligationMember_8ba85646-3445-4cbc-86d9-d6819c521b7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_C5LicenseObligationMember_6af82406-4c6f-44a7-82b2-29ae8f1dcfa9" xlink:href="alny-20210331.xsd#alny_C5LicenseObligationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_9925488c-fc86-44af-afea-23d42727e69e" xlink:to="loc_alny_C5LicenseObligationMember_6af82406-4c6f-44a7-82b2-29ae8f1dcfa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_C5CoCoObligationMember_93f715f4-dcf7-4cba-95c5-3db678354b66" xlink:href="alny-20210331.xsd#alny_C5CoCoObligationMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_9925488c-fc86-44af-afea-23d42727e69e" xlink:to="loc_alny_C5CoCoObligationMember_93f715f4-dcf7-4cba-95c5-3db678354b66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_4cc29350-561f-4b51-8a54-a1e0e408641f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_70943086-255b-451f-9735-d2e86fa797fb" xlink:to="loc_us-gaap_TypeOfArrangementAxis_4cc29350-561f-4b51-8a54-a1e0e408641f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8e562226-98e7-4eb2-af71-f51875d95b36" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_4cc29350-561f-4b51-8a54-a1e0e408641f" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8e562226-98e7-4eb2-af71-f51875d95b36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_GlobalStrategicCollaborationMember_115759dc-3c9e-4703-bb8d-fc219f4540dd" xlink:href="alny-20210331.xsd#alny_GlobalStrategicCollaborationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8e562226-98e7-4eb2-af71-f51875d95b36" xlink:to="loc_alny_GlobalStrategicCollaborationMember_115759dc-3c9e-4703-bb8d-fc219f4540dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_5473ef83-d602-4c04-bbbe-0ac91abdf0fd" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_70943086-255b-451f-9735-d2e86fa797fb" xlink:to="loc_srt_CounterpartyNameAxis_5473ef83-d602-4c04-bbbe-0ac91abdf0fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d4e5da26-94ce-4342-ba31-5847ed951325" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_5473ef83-d602-4c04-bbbe-0ac91abdf0fd" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d4e5da26-94ce-4342-ba31-5847ed951325" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_RegeneronPharmaceuticalsIncorporationMember_f7f8b332-82d9-4968-8431-546ed12bc774" xlink:href="alny-20210331.xsd#alny_RegeneronPharmaceuticalsIncorporationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d4e5da26-94ce-4342-ba31-5847ed951325" xlink:to="loc_alny_RegeneronPharmaceuticalsIncorporationMember_f7f8b332-82d9-4968-8431-546ed12bc774" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_26c37c2c-c429-488c-beb0-7668cb64bb2f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_70943086-255b-451f-9735-d2e86fa797fb" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_26c37c2c-c429-488c-beb0-7668cb64bb2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_StandaloneSellingPrice_c6815397-4013-4da1-a9ba-7a3a85c0bfff" xlink:href="alny-20210331.xsd#alny_StandaloneSellingPrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_26c37c2c-c429-488c-beb0-7668cb64bb2f" xlink:to="loc_alny_StandaloneSellingPrice_c6815397-4013-4da1-a9ba-7a3a85c0bfff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_TransactionPrice_aea8fbc0-4bb5-4101-88a0-642b515ae0d5" xlink:href="alny-20210331.xsd#alny_TransactionPrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_26c37c2c-c429-488c-beb0-7668cb64bb2f" xlink:to="loc_alny_TransactionPrice_aea8fbc0-4bb5-4101-88a0-642b515ae0d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofDeferredRevenueDetails" xlink:type="simple" xlink:href="alny-20210331.xsd#NETREVENUESFROMCOLLABORATIONSScheduleofDeferredRevenueDetails"/>
  <link:presentationLink xlink:role="http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofDeferredRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_24ff3e88-81cb-41b2-955d-d9dac80d5208" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_80569428-80e3-485c-b5e1-07457a8cdee4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_24ff3e88-81cb-41b2-955d-d9dac80d5208" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_80569428-80e3-485c-b5e1-07457a8cdee4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_1d83b2ff-ffaf-4519-ad44-84a590fe8496" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_80569428-80e3-485c-b5e1-07457a8cdee4" xlink:to="loc_srt_ProductOrServiceAxis_1d83b2ff-ffaf-4519-ad44-84a590fe8496" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_96cbab5b-a80c-4d6c-836c-99020f014bd0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_1d83b2ff-ffaf-4519-ad44-84a590fe8496" xlink:to="loc_srt_ProductsAndServicesDomain_96cbab5b-a80c-4d6c-836c-99020f014bd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_ResearchServicesObligationMember_01645191-41b5-435d-b816-6bbdfc5fd42f" xlink:href="alny-20210331.xsd#alny_ResearchServicesObligationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_96cbab5b-a80c-4d6c-836c-99020f014bd0" xlink:to="loc_alny_ResearchServicesObligationMember_01645191-41b5-435d-b816-6bbdfc5fd42f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_C5LicenseObligationMember_21b51b2c-329a-4310-8d58-dbc906b6d262" xlink:href="alny-20210331.xsd#alny_C5LicenseObligationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_96cbab5b-a80c-4d6c-836c-99020f014bd0" xlink:to="loc_alny_C5LicenseObligationMember_21b51b2c-329a-4310-8d58-dbc906b6d262" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_C5CoCoObligationMember_528b667f-f98e-4e60-a24e-ee1f231fcaac" xlink:href="alny-20210331.xsd#alny_C5CoCoObligationMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_96cbab5b-a80c-4d6c-836c-99020f014bd0" xlink:to="loc_alny_C5CoCoObligationMember_528b667f-f98e-4e60-a24e-ee1f231fcaac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_9f862c90-c977-46c0-9b25-47ef6a56b08d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_80569428-80e3-485c-b5e1-07457a8cdee4" xlink:to="loc_us-gaap_TypeOfArrangementAxis_9f862c90-c977-46c0-9b25-47ef6a56b08d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c9e4b349-0c70-4e0b-8b26-f53168e2c616" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_9f862c90-c977-46c0-9b25-47ef6a56b08d" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c9e4b349-0c70-4e0b-8b26-f53168e2c616" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_GlobalStrategicCollaborationMember_2806c656-b68f-45a2-bee4-50719fc899fe" xlink:href="alny-20210331.xsd#alny_GlobalStrategicCollaborationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c9e4b349-0c70-4e0b-8b26-f53168e2c616" xlink:to="loc_alny_GlobalStrategicCollaborationMember_2806c656-b68f-45a2-bee4-50719fc899fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_0e2e567d-b757-498e-92e0-2e439a9e7e9b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_80569428-80e3-485c-b5e1-07457a8cdee4" xlink:to="loc_srt_CounterpartyNameAxis_0e2e567d-b757-498e-92e0-2e439a9e7e9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_93b11caf-e8fc-469a-b963-9b3114f33114" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_0e2e567d-b757-498e-92e0-2e439a9e7e9b" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_93b11caf-e8fc-469a-b963-9b3114f33114" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_RegeneronPharmaceuticalsIncorporationMember_1e316100-541a-45ae-9efa-1da07aa00848" xlink:href="alny-20210331.xsd#alny_RegeneronPharmaceuticalsIncorporationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_93b11caf-e8fc-469a-b963-9b3114f33114" xlink:to="loc_alny_RegeneronPharmaceuticalsIncorporationMember_1e316100-541a-45ae-9efa-1da07aa00848" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7048eedc-d1c7-4f8c-bbd3-d358fe651ad1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_80569428-80e3-485c-b5e1-07457a8cdee4" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7048eedc-d1c7-4f8c-bbd3-d358fe651ad1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_TransactionPrice_3ffb8f55-a0ee-4662-b6e5-f60131180ca7" xlink:href="alny-20210331.xsd#alny_TransactionPrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7048eedc-d1c7-4f8c-bbd3-d358fe651ad1" xlink:to="loc_alny_TransactionPrice_3ffb8f55-a0ee-4662-b6e5-f60131180ca7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_f626abf5-dd44-4a36-b9f1-805d0fec8b6c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7048eedc-d1c7-4f8c-bbd3-d358fe651ad1" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_f626abf5-dd44-4a36-b9f1-805d0fec8b6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofRevenueRecognizedbyAccountingGuidanceDetails" xlink:type="simple" xlink:href="alny-20210331.xsd#NETREVENUESFROMCOLLABORATIONSScheduleofRevenueRecognizedbyAccountingGuidanceDetails"/>
  <link:presentationLink xlink:role="http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofRevenueRecognizedbyAccountingGuidanceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_46271f42-6ab5-47be-82b1-a4a18a29ed48" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e3991b38-b31d-47ee-81ed-8f461b24fbe0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_46271f42-6ab5-47be-82b1-a4a18a29ed48" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e3991b38-b31d-47ee-81ed-8f461b24fbe0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_4674162f-f822-43eb-92a9-a00b79601c7c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e3991b38-b31d-47ee-81ed-8f461b24fbe0" xlink:to="loc_srt_CounterpartyNameAxis_4674162f-f822-43eb-92a9-a00b79601c7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8e9fb0f1-51d8-4b52-a0a7-c82192870323" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_4674162f-f822-43eb-92a9-a00b79601c7c" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8e9fb0f1-51d8-4b52-a0a7-c82192870323" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_RegeneronPharmaceuticalsIncorporationMember_c019f6d6-45d8-46f8-8f73-7646e6ea6921" xlink:href="alny-20210331.xsd#alny_RegeneronPharmaceuticalsIncorporationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8e9fb0f1-51d8-4b52-a0a7-c82192870323" xlink:to="loc_alny_RegeneronPharmaceuticalsIncorporationMember_c019f6d6-45d8-46f8-8f73-7646e6ea6921" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_81edf8e9-9da7-48ff-895c-938d1182f83b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e3991b38-b31d-47ee-81ed-8f461b24fbe0" xlink:to="loc_srt_ProductOrServiceAxis_81edf8e9-9da7-48ff-895c-938d1182f83b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_def557d1-963e-4e6c-a8a6-d34abfa4fe3a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_81edf8e9-9da7-48ff-895c-938d1182f83b" xlink:to="loc_srt_ProductsAndServicesDomain_def557d1-963e-4e6c-a8a6-d34abfa4fe3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_ResearchServicesObligationMember_4350c062-9482-4cd1-ad19-a0fdd5e83dfd" xlink:href="alny-20210331.xsd#alny_ResearchServicesObligationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_def557d1-963e-4e6c-a8a6-d34abfa4fe3a" xlink:to="loc_alny_ResearchServicesObligationMember_4350c062-9482-4cd1-ad19-a0fdd5e83dfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_C5LicenseObligationMember_3a2c9001-6948-4f3b-b53e-f804c0ea215e" xlink:href="alny-20210331.xsd#alny_C5LicenseObligationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_def557d1-963e-4e6c-a8a6-d34abfa4fe3a" xlink:to="loc_alny_C5LicenseObligationMember_3a2c9001-6948-4f3b-b53e-f804c0ea215e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_C5CoCoObligationMember_44eaeae0-d7d4-4171-87d6-6baf5fd2686b" xlink:href="alny-20210331.xsd#alny_C5CoCoObligationMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_def557d1-963e-4e6c-a8a6-d34abfa4fe3a" xlink:to="loc_alny_C5CoCoObligationMember_44eaeae0-d7d4-4171-87d6-6baf5fd2686b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_be3bcc08-e671-4884-bbf8-83ef7177754a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e3991b38-b31d-47ee-81ed-8f461b24fbe0" xlink:to="loc_us-gaap_TypeOfArrangementAxis_be3bcc08-e671-4884-bbf8-83ef7177754a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_54f45078-5785-490c-959e-997ae42e4aac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_be3bcc08-e671-4884-bbf8-83ef7177754a" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_54f45078-5785-490c-959e-997ae42e4aac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_GlobalStrategicCollaborationMember_18bc879a-1aab-45a8-aac6-e38b3740ed12" xlink:href="alny-20210331.xsd#alny_GlobalStrategicCollaborationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_54f45078-5785-490c-959e-997ae42e4aac" xlink:to="loc_alny_GlobalStrategicCollaborationMember_18bc879a-1aab-45a8-aac6-e38b3740ed12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cdf662e5-129b-4c6c-be5d-d88cb5fd6863" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e3991b38-b31d-47ee-81ed-8f461b24fbe0" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cdf662e5-129b-4c6c-be5d-d88cb5fd6863" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_56df583b-a08e-4453-b5f3-4e5dbe379774" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cdf662e5-129b-4c6c-be5d-d88cb5fd6863" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_56df583b-a08e-4453-b5f3-4e5dbe379774" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_a80f15bc-f9e5-4aab-aa5b-1c894f3ed656" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cdf662e5-129b-4c6c-be5d-d88cb5fd6863" xlink:to="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_a80f15bc-f9e5-4aab-aa5b-1c894f3ed656" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_435db2a7-3280-439e-9bc1-abf8fa5b1185" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cdf662e5-129b-4c6c-be5d-d88cb5fd6863" xlink:to="loc_us-gaap_Revenues_435db2a7-3280-439e-9bc1-abf8fa5b1185" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/LIABILITYRELATEDTOTHESALEOFFUTUREROYALTIES" xlink:type="simple" xlink:href="alny-20210331.xsd#LIABILITYRELATEDTOTHESALEOFFUTUREROYALTIES"/>
  <link:presentationLink xlink:role="http://www.alnylam.com/role/LIABILITYRELATEDTOTHESALEOFFUTUREROYALTIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_c5d036b1-04e2-43ec-9891-cb59e2b9802d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock_9fd8170f-a6ce-4706-8b4a-0e663d84e9a2" xlink:href="alny-20210331.xsd#alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_c5d036b1-04e2-43ec-9891-cb59e2b9802d" xlink:to="loc_alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock_9fd8170f-a6ce-4706-8b4a-0e663d84e9a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/LIABILITYRELATEDTOTHESALEOFFUTUREROYALTIESTables" xlink:type="simple" xlink:href="alny-20210331.xsd#LIABILITYRELATEDTOTHESALEOFFUTUREROYALTIESTables"/>
  <link:presentationLink xlink:role="http://www.alnylam.com/role/LIABILITYRELATEDTOTHESALEOFFUTUREROYALTIESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_6527a62e-3713-4cf6-904e-1ad5ca4d1cc7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_ScheduleOfRoyaltyLiabilityTableTextBlock_7925088b-0873-4b81-ab7a-a81d1d638cd3" xlink:href="alny-20210331.xsd#alny_ScheduleOfRoyaltyLiabilityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_6527a62e-3713-4cf6-904e-1ad5ca4d1cc7" xlink:to="loc_alny_ScheduleOfRoyaltyLiabilityTableTextBlock_7925088b-0873-4b81-ab7a-a81d1d638cd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/LIABILITYRELATEDTOTHESALEOFFUTUREROYALTIESDetails" xlink:type="simple" xlink:href="alny-20210331.xsd#LIABILITYRELATEDTOTHESALEOFFUTUREROYALTIESDetails"/>
  <link:presentationLink xlink:role="http://www.alnylam.com/role/LIABILITYRELATEDTOTHESALEOFFUTUREROYALTIESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_21776288-a737-4666-8b8f-afa4c6bbdda1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesTable_a9b4b40e-4344-497e-abf8-b1738668c038" xlink:href="alny-20210331.xsd#alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_21776288-a737-4666-8b8f-afa4c6bbdda1" xlink:to="loc_alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesTable_a9b4b40e-4344-497e-abf8-b1738668c038" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_11ceadd1-157d-44e5-912f-8e1e6877db30" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesTable_a9b4b40e-4344-497e-abf8-b1738668c038" xlink:to="loc_srt_StatementScenarioAxis_11ceadd1-157d-44e5-912f-8e1e6877db30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_8dd7e7fd-56ab-43f5-b9d5-fbc468a87ccf" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_11ceadd1-157d-44e5-912f-8e1e6877db30" xlink:to="loc_srt_ScenarioUnspecifiedDomain_8dd7e7fd-56ab-43f5-b9d5-fbc468a87ccf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_4b9f0b97-ce65-403f-bdda-65b7cd9e9c80" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_8dd7e7fd-56ab-43f5-b9d5-fbc468a87ccf" xlink:to="loc_srt_ScenarioForecastMember_4b9f0b97-ce65-403f-bdda-65b7cd9e9c80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_f4cdb6fe-40d1-47e4-9ea4-ec3a2f92231c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesTable_a9b4b40e-4344-497e-abf8-b1738668c038" xlink:to="loc_srt_CounterpartyNameAxis_f4cdb6fe-40d1-47e4-9ea4-ec3a2f92231c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5a0552fa-8180-45dd-80b4-6a0802bd99af" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_f4cdb6fe-40d1-47e4-9ea4-ec3a2f92231c" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5a0552fa-8180-45dd-80b4-6a0802bd99af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_BlackstoneGroupIncMember_19ac8574-a172-42f1-b260-e291b23c8dca" xlink:href="alny-20210331.xsd#alny_BlackstoneGroupIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5a0552fa-8180-45dd-80b4-6a0802bd99af" xlink:to="loc_alny_BlackstoneGroupIncMember_19ac8574-a172-42f1-b260-e291b23c8dca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_a4ba3c41-52e4-4f34-806c-b625d6b5f79b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesTable_a9b4b40e-4344-497e-abf8-b1738668c038" xlink:to="loc_us-gaap_TypeOfArrangementAxis_a4ba3c41-52e4-4f34-806c-b625d6b5f79b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5b9f9693-dd72-4143-ae47-8ffda80c8e65" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_a4ba3c41-52e4-4f34-806c-b625d6b5f79b" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5b9f9693-dd72-4143-ae47-8ffda80c8e65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_f27aa328-62f9-4b52-b0cc-d5d7777865e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5b9f9693-dd72-4143-ae47-8ffda80c8e65" xlink:to="loc_us-gaap_CollaborativeArrangementMember_f27aa328-62f9-4b52-b0cc-d5d7777865e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesLineItemsLineItems_7c1200b1-8945-4f2d-bb3c-5c770fb941ef" xlink:href="alny-20210331.xsd#alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesLineItemsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesTable_a9b4b40e-4344-497e-abf8-b1738668c038" xlink:to="loc_alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesLineItemsLineItems_7c1200b1-8945-4f2d-bb3c-5c770fb941ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_CollaborativeArrangementRoyaltiesAndCommercialMilestonesAcquiredByCollaboratorPercent_35234c28-5ee8-4e59-b66c-b0b87c3712ed" xlink:href="alny-20210331.xsd#alny_CollaborativeArrangementRoyaltiesAndCommercialMilestonesAcquiredByCollaboratorPercent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesLineItemsLineItems_7c1200b1-8945-4f2d-bb3c-5c770fb941ef" xlink:to="loc_alny_CollaborativeArrangementRoyaltiesAndCommercialMilestonesAcquiredByCollaboratorPercent_35234c28-5ee8-4e59-b66c-b0b87c3712ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_CollaborativeArrangementCommercialMilestonesAcquiredByCollaboratorPercent_a4de1835-6a4e-4331-98f4-5a5f4ec324b4" xlink:href="alny-20210331.xsd#alny_CollaborativeArrangementCommercialMilestonesAcquiredByCollaboratorPercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesLineItemsLineItems_7c1200b1-8945-4f2d-bb3c-5c770fb941ef" xlink:to="loc_alny_CollaborativeArrangementCommercialMilestonesAcquiredByCollaboratorPercent_a4de1835-6a4e-4331-98f4-5a5f4ec324b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_ExpectedRoyaltyInterestPayments_89ee46c9-2572-4038-861f-c68d0a3db641" xlink:href="alny-20210331.xsd#alny_ExpectedRoyaltyInterestPayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesLineItemsLineItems_7c1200b1-8945-4f2d-bb3c-5c770fb941ef" xlink:to="loc_alny_ExpectedRoyaltyInterestPayments_89ee46c9-2572-4038-861f-c68d0a3db641" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_CollaborativeArrangementConsiderationReceived_a067c4d7-4d4e-4c32-a3e9-ae8616d79540" xlink:href="alny-20210331.xsd#alny_CollaborativeArrangementConsiderationReceived"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesLineItemsLineItems_7c1200b1-8945-4f2d-bb3c-5c770fb941ef" xlink:to="loc_alny_CollaborativeArrangementConsiderationReceived_a067c4d7-4d4e-4c32-a3e9-ae8616d79540" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_RoyaltiesReceivableCurrent_8265a8de-386f-4d72-8866-6e70b14c10a2" xlink:href="alny-20210331.xsd#alny_RoyaltiesReceivableCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesLineItemsLineItems_7c1200b1-8945-4f2d-bb3c-5c770fb941ef" xlink:to="loc_alny_RoyaltiesReceivableCurrent_8265a8de-386f-4d72-8866-6e70b14c10a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_RoyaltyLiabilityNoncurrent_ca0c6ef2-0208-4aa8-9608-7579560df349" xlink:href="alny-20210331.xsd#alny_RoyaltyLiabilityNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesLineItemsLineItems_7c1200b1-8945-4f2d-bb3c-5c770fb941ef" xlink:to="loc_alny_RoyaltyLiabilityNoncurrent_ca0c6ef2-0208-4aa8-9608-7579560df349" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_RoyaltyLiabilityInterestRate_2097e384-7508-4afd-a665-53d5e0c01ecd" xlink:href="alny-20210331.xsd#alny_RoyaltyLiabilityInterestRate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesLineItemsLineItems_7c1200b1-8945-4f2d-bb3c-5c770fb941ef" xlink:to="loc_alny_RoyaltyLiabilityInterestRate_2097e384-7508-4afd-a665-53d5e0c01ecd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_RoyaltyLiabilityClosingCosts_82f2af17-671e-40fa-95ef-94b432031bcf" xlink:href="alny-20210331.xsd#alny_RoyaltyLiabilityClosingCosts"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesLineItemsLineItems_7c1200b1-8945-4f2d-bb3c-5c770fb941ef" xlink:to="loc_alny_RoyaltyLiabilityClosingCosts_82f2af17-671e-40fa-95ef-94b432031bcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_RoyaltyLiabilityInterestExpenseIncludingAmortizationOfClosingCosts_1e4eaba4-19ab-4db7-9583-526289c67153" xlink:href="alny-20210331.xsd#alny_RoyaltyLiabilityInterestExpenseIncludingAmortizationOfClosingCosts"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesLineItemsLineItems_7c1200b1-8945-4f2d-bb3c-5c770fb941ef" xlink:to="loc_alny_RoyaltyLiabilityInterestExpenseIncludingAmortizationOfClosingCosts_1e4eaba4-19ab-4db7-9583-526289c67153" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/FAIRVALUEMEASUREMENTS" xlink:type="simple" xlink:href="alny-20210331.xsd#FAIRVALUEMEASUREMENTS"/>
  <link:presentationLink xlink:role="http://www.alnylam.com/role/FAIRVALUEMEASUREMENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_2c5ee0c0-7218-4451-bca0-48a92c7647e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_57113142-b348-4f59-a0de-2bca1fbc144f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_2c5ee0c0-7218-4451-bca0-48a92c7647e8" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_57113142-b348-4f59-a0de-2bca1fbc144f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/FAIRVALUEMEASUREMENTSTables" xlink:type="simple" xlink:href="alny-20210331.xsd#FAIRVALUEMEASUREMENTSTables"/>
  <link:presentationLink xlink:role="http://www.alnylam.com/role/FAIRVALUEMEASUREMENTSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_3b22384a-5982-41ca-b9f6-60276eaaf33e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_d1d3f556-244a-4e32-9301-935d151bfdfa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_3b22384a-5982-41ca-b9f6-60276eaaf33e" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_d1d3f556-244a-4e32-9301-935d151bfdfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/FAIRVALUEMEASUREMENTSFairValueofAssetsMeasuredonaRecurringBasisDetail" xlink:type="simple" xlink:href="alny-20210331.xsd#FAIRVALUEMEASUREMENTSFairValueofAssetsMeasuredonaRecurringBasisDetail"/>
  <link:presentationLink xlink:role="http://www.alnylam.com/role/FAIRVALUEMEASUREMENTSFairValueofAssetsMeasuredonaRecurringBasisDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_167f2b6e-8904-4a8c-9b82-d0ef54d6503f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7b319b21-0520-4149-b865-19a9a7775397" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_167f2b6e-8904-4a8c-9b82-d0ef54d6503f" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7b319b21-0520-4149-b865-19a9a7775397" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_00a1dabc-4a52-49f7-97dc-31b76db5d91f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7b319b21-0520-4149-b865-19a9a7775397" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_00a1dabc-4a52-49f7-97dc-31b76db5d91f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_1ca68652-a470-486f-bc39-5157612c4ba6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_00a1dabc-4a52-49f7-97dc-31b76db5d91f" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_1ca68652-a470-486f-bc39-5157612c4ba6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_a7e640c9-4473-4af5-99cc-2162ee5d4954" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_1ca68652-a470-486f-bc39-5157612c4ba6" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_a7e640c9-4473-4af5-99cc-2162ee5d4954" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_86650bd2-52d2-4f0c-92ae-902832d8aea9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7b319b21-0520-4149-b865-19a9a7775397" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_86650bd2-52d2-4f0c-92ae-902832d8aea9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_b5a398c5-0fe2-4673-b928-499f393eb8fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_86650bd2-52d2-4f0c-92ae-902832d8aea9" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_b5a398c5-0fe2-4673-b928-499f393eb8fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_c9a22073-9ddf-478d-939c-53d30a7b7225" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_b5a398c5-0fe2-4673-b928-499f393eb8fd" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_c9a22073-9ddf-478d-939c-53d30a7b7225" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_934fcd6b-8139-49e0-8c6f-891d74566812" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_b5a398c5-0fe2-4673-b928-499f393eb8fd" xlink:to="loc_us-gaap_MoneyMarketFundsMember_934fcd6b-8139-49e0-8c6f-891d74566812" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_638b80db-9c8b-4b6b-8939-279f86ea0a13" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_b5a398c5-0fe2-4673-b928-499f393eb8fd" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_638b80db-9c8b-4b6b-8939-279f86ea0a13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6bc75c70-c8da-4494-874b-b690a2b9640c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7b319b21-0520-4149-b865-19a9a7775397" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6bc75c70-c8da-4494-874b-b690a2b9640c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_182311d8-1320-472b-9cf8-8a2b70aee0b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6bc75c70-c8da-4494-874b-b690a2b9640c" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_182311d8-1320-472b-9cf8-8a2b70aee0b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_fa21ed84-ad9a-4c2f-b8da-0fe5be1ffcd3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_182311d8-1320-472b-9cf8-8a2b70aee0b0" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_fa21ed84-ad9a-4c2f-b8da-0fe5be1ffcd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_c673b796-b552-4666-b201-bb04ccfb5329" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_182311d8-1320-472b-9cf8-8a2b70aee0b0" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_c673b796-b552-4666-b201-bb04ccfb5329" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_cc936e9d-cc27-4f07-8cef-1a206e7fe7ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_182311d8-1320-472b-9cf8-8a2b70aee0b0" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_cc936e9d-cc27-4f07-8cef-1a206e7fe7ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0adcf9be-ea4f-4d67-8d48-176d03ba04d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7b319b21-0520-4149-b865-19a9a7775397" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0adcf9be-ea4f-4d67-8d48-176d03ba04d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_7496231d-bf9d-48f5-a3e2-2762306a2e19" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0adcf9be-ea4f-4d67-8d48-176d03ba04d7" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_7496231d-bf9d-48f5-a3e2-2762306a2e19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_301e60f3-fd83-4e31-9514-f2800d9ec788" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_7496231d-bf9d-48f5-a3e2-2762306a2e19" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_301e60f3-fd83-4e31-9514-f2800d9ec788" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_95778560-7b65-46bf-86bb-8a53e37aa6e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_7496231d-bf9d-48f5-a3e2-2762306a2e19" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_95778560-7b65-46bf-86bb-8a53e37aa6e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_75c8170f-9d87-425f-a17d-7a5ed1c62852" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_7496231d-bf9d-48f5-a3e2-2762306a2e19" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_75c8170f-9d87-425f-a17d-7a5ed1c62852" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_34fd3579-47f1-4e18-8a8e-e9b948f80e92" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_7496231d-bf9d-48f5-a3e2-2762306a2e19" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_34fd3579-47f1-4e18-8a8e-e9b948f80e92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_2af920d6-60f4-4952-91c7-92a11827b1a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_7496231d-bf9d-48f5-a3e2-2762306a2e19" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_2af920d6-60f4-4952-91c7-92a11827b1a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_b4c6157a-7b3d-4059-9b21-cc563ef96ef6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0adcf9be-ea4f-4d67-8d48-176d03ba04d7" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_b4c6157a-7b3d-4059-9b21-cc563ef96ef6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_6f8a2499-714e-42e3-ab70-557d6717f181" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_b4c6157a-7b3d-4059-9b21-cc563ef96ef6" xlink:to="loc_us-gaap_DerivativeLiabilities_6f8a2499-714e-42e3-ab70-557d6717f181" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/MARKETABLEDEBTSECURITIES" xlink:type="simple" xlink:href="alny-20210331.xsd#MARKETABLEDEBTSECURITIES"/>
  <link:presentationLink xlink:role="http://www.alnylam.com/role/MARKETABLEDEBTSECURITIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_077a9d72-bcb7-47c5-b0c7-2c2cb92d5a54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_InvestmentsInMarketableDebtSecuritiesDisclosureTextBlock_879e3795-e946-4cac-877b-e5d0e8482f7b" xlink:href="alny-20210331.xsd#alny_InvestmentsInMarketableDebtSecuritiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_077a9d72-bcb7-47c5-b0c7-2c2cb92d5a54" xlink:to="loc_alny_InvestmentsInMarketableDebtSecuritiesDisclosureTextBlock_879e3795-e946-4cac-877b-e5d0e8482f7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/MARKETABLEDEBTSECURITIESTables" xlink:type="simple" xlink:href="alny-20210331.xsd#MARKETABLEDEBTSECURITIESTables"/>
  <link:presentationLink xlink:role="http://www.alnylam.com/role/MARKETABLEDEBTSECURITIESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_be22f304-7918-4486-b500-47e416332f3f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_58634154-377d-4a0b-99e4-cc753f1d63fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_be22f304-7918-4486-b500-47e416332f3f" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_58634154-377d-4a0b-99e4-cc753f1d63fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock_046c916e-d04a-43ae-a308-d610bf59af8c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_be22f304-7918-4486-b500-47e416332f3f" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock_046c916e-d04a-43ae-a308-d610bf59af8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/MARKETABLEDEBTSECURITIESAdditionalInformationDetail" xlink:type="simple" xlink:href="alny-20210331.xsd#MARKETABLEDEBTSECURITIESAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.alnylam.com/role/MARKETABLEDEBTSECURITIESAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_9c1fbe5e-e248-4878-a0cf-b0396e475e5a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_ImpairmentOfMarketableDebtSecurities_ea29cbd3-18e7-467c-b501-83a25b76ffdd" xlink:href="alny-20210331.xsd#alny_ImpairmentOfMarketableDebtSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_9c1fbe5e-e248-4878-a0cf-b0396e475e5a" xlink:to="loc_alny_ImpairmentOfMarketableDebtSecurities_ea29cbd3-18e7-467c-b501-83a25b76ffdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/MARKETABLEDEBTSECURITIESSummaryofMarketableDebtSecuritiesDetail" xlink:type="simple" xlink:href="alny-20210331.xsd#MARKETABLEDEBTSECURITIESSummaryofMarketableDebtSecuritiesDetail"/>
  <link:presentationLink xlink:role="http://www.alnylam.com/role/MARKETABLEDEBTSECURITIESSummaryofMarketableDebtSecuritiesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_b64633a3-a2d4-46a2-b7c1-16261023c67b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_b723177e-526f-41e2-a4be-7d275156db05" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_b64633a3-a2d4-46a2-b7c1-16261023c67b" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_b723177e-526f-41e2-a4be-7d275156db05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_7ed263fc-36b4-4949-b415-29db32535b37" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_b723177e-526f-41e2-a4be-7d275156db05" xlink:to="loc_us-gaap_FinancialInstrumentAxis_7ed263fc-36b4-4949-b415-29db32535b37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_aa78d52c-27b0-4c9e-a5d0-23f657522d8a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_7ed263fc-36b4-4949-b415-29db32535b37" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_aa78d52c-27b0-4c9e-a5d0-23f657522d8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_14fdeb3a-d802-4b9a-b471-c3b101467ba2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_aa78d52c-27b0-4c9e-a5d0-23f657522d8a" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_14fdeb3a-d802-4b9a-b471-c3b101467ba2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_035b6dee-d146-4bd3-b1e0-583208de2856" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_aa78d52c-27b0-4c9e-a5d0-23f657522d8a" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_035b6dee-d146-4bd3-b1e0-583208de2856" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e5419dba-1919-4642-8338-60060d3732ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_b723177e-526f-41e2-a4be-7d275156db05" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e5419dba-1919-4642-8338-60060d3732ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_2a2eec87-c91e-4eee-b934-ab8a6cd1c0a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e5419dba-1919-4642-8338-60060d3732ac" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_2a2eec87-c91e-4eee-b934-ab8a6cd1c0a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_071d6819-c15e-46b8-ac0d-8e18242f639b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e5419dba-1919-4642-8338-60060d3732ac" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_071d6819-c15e-46b8-ac0d-8e18242f639b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_be2ebfd3-daa8-41c3-90ec-818130c16c72" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e5419dba-1919-4642-8338-60060d3732ac" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_be2ebfd3-daa8-41c3-90ec-818130c16c72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c1a09ed8-b893-46d9-a361-f4e0e612489c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e5419dba-1919-4642-8338-60060d3732ac" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c1a09ed8-b893-46d9-a361-f4e0e612489c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/MARKETABLEDEBTSECURITIESSummaryofFairValueofMarketableDebtSecuritiesDetail" xlink:type="simple" xlink:href="alny-20210331.xsd#MARKETABLEDEBTSECURITIESSummaryofFairValueofMarketableDebtSecuritiesDetail"/>
  <link:presentationLink xlink:role="http://www.alnylam.com/role/MARKETABLEDEBTSECURITIESSummaryofFairValueofMarketableDebtSecuritiesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_dd6539fc-9208-4295-9751-8c0c2661fa65" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_294986ce-4ab7-434e-a5f8-09c2146ce2c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_dd6539fc-9208-4295-9751-8c0c2661fa65" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_294986ce-4ab7-434e-a5f8-09c2146ce2c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_271e59ae-014d-4f30-b064-804b8f2b812f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_dd6539fc-9208-4295-9751-8c0c2661fa65" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_271e59ae-014d-4f30-b064-804b8f2b812f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_192b9c0a-befc-46f2-ae6f-086b29933556" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_dd6539fc-9208-4295-9751-8c0c2661fa65" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_192b9c0a-befc-46f2-ae6f-086b29933556" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/OTHERBALANCESHEETDETAILS" xlink:type="simple" xlink:href="alny-20210331.xsd#OTHERBALANCESHEETDETAILS"/>
  <link:presentationLink xlink:role="http://www.alnylam.com/role/OTHERBALANCESHEETDETAILS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5de51dce-7056-49aa-ba65-45737fe875b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_716a67a7-c3a2-4659-82f7-a6268a16501b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5de51dce-7056-49aa-ba65-45737fe875b4" xlink:to="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_716a67a7-c3a2-4659-82f7-a6268a16501b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/OTHERBALANCESHEETDETAILSTables" xlink:type="simple" xlink:href="alny-20210331.xsd#OTHERBALANCESHEETDETAILSTables"/>
  <link:presentationLink xlink:role="http://www.alnylam.com/role/OTHERBALANCESHEETDETAILSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_62c572be-644b-4cdd-9991-1aa1c21e01c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_bec8c9ea-4f6e-4e14-896a-15e53e5e8df0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_62c572be-644b-4cdd-9991-1aa1c21e01c5" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_bec8c9ea-4f6e-4e14-896a-15e53e5e8df0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_ScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTableTextBlock_5d4fc437-5a43-42e4-bb8b-81031ac753ed" xlink:href="alny-20210331.xsd#alny_ScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_62c572be-644b-4cdd-9991-1aa1c21e01c5" xlink:to="loc_alny_ScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTableTextBlock_5d4fc437-5a43-42e4-bb8b-81031ac753ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_0f71f3f5-012e-4359-ac63-0baa5206085b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_62c572be-644b-4cdd-9991-1aa1c21e01c5" xlink:to="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_0f71f3f5-012e-4359-ac63-0baa5206085b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/OTHERBALANCESHEETDETAILSScheduleofInventoryDetail" xlink:type="simple" xlink:href="alny-20210331.xsd#OTHERBALANCESHEETDETAILSScheduleofInventoryDetail"/>
  <link:presentationLink xlink:role="http://www.alnylam.com/role/OTHERBALANCESHEETDETAILSScheduleofInventoryDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_57102bf0-3b4f-4bf7-a15c-08e11e8aeba0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCurrentTable_5c45a65f-767a-4914-a2ea-58e04498f08c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryCurrentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_57102bf0-3b4f-4bf7-a15c-08e11e8aeba0" xlink:to="loc_us-gaap_InventoryCurrentTable_5c45a65f-767a-4914-a2ea-58e04498f08c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_f55e8d84-adbb-4bb8-bf60-afcdeef7a2e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_5c45a65f-767a-4914-a2ea-58e04498f08c" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_f55e8d84-adbb-4bb8-bf60-afcdeef7a2e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_2aa43839-58bb-4697-9526-d105fae1f5c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_f55e8d84-adbb-4bb8-bf60-afcdeef7a2e7" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_2aa43839-58bb-4697-9526-d105fae1f5c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsMember_b3978047-6b78-421c-a74f-7a38ffeae804" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_2aa43839-58bb-4697-9526-d105fae1f5c1" xlink:to="loc_us-gaap_OtherAssetsMember_b3978047-6b78-421c-a74f-7a38ffeae804" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems_fb2c0596-6b75-433e-a4b2-c4d0ee60343c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_5c45a65f-767a-4914-a2ea-58e04498f08c" xlink:to="loc_us-gaap_InventoryLineItems_fb2c0596-6b75-433e-a4b2-c4d0ee60343c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials_42f009e1-aecc-4500-9ee8-494c8f654dec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterials"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_fb2c0596-6b75-433e-a4b2-c4d0ee60343c" xlink:to="loc_us-gaap_InventoryRawMaterials_42f009e1-aecc-4500-9ee8-494c8f654dec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess_a139f555-1458-4320-87e7-0fbb3b71174e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_fb2c0596-6b75-433e-a4b2-c4d0ee60343c" xlink:to="loc_us-gaap_InventoryWorkInProcess_a139f555-1458-4320-87e7-0fbb3b71174e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_f321b663-d4e7-4aa9-af91-b5db1de9cdb8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_fb2c0596-6b75-433e-a4b2-c4d0ee60343c" xlink:to="loc_us-gaap_InventoryFinishedGoods_f321b663-d4e7-4aa9-af91-b5db1de9cdb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_InventoryCurrentAndNoncurrent_ce1ae97b-68a0-4ad2-a3ea-27fd0640e53c" xlink:href="alny-20210331.xsd#alny_InventoryCurrentAndNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_fb2c0596-6b75-433e-a4b2-c4d0ee60343c" xlink:to="loc_alny_InventoryCurrentAndNoncurrent_ce1ae97b-68a0-4ad2-a3ea-27fd0640e53c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_5b82bee6-cdc2-4701-884c-cb86961cbb23" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_fb2c0596-6b75-433e-a4b2-c4d0ee60343c" xlink:to="loc_us-gaap_InventoryNoncurrent_5b82bee6-cdc2-4701-884c-cb86961cbb23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/OTHERBALANCESHEETDETAILSScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetail" xlink:type="simple" xlink:href="alny-20210331.xsd#OTHERBALANCESHEETDETAILSScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetail"/>
  <link:presentationLink xlink:role="http://www.alnylam.com/role/OTHERBALANCESHEETDETAILSScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4a556b53-2e53-420c-8744-fff6101816a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_bacecfc0-ffaf-49cb-ab05-4f262bc3753f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4a556b53-2e53-420c-8744-fff6101816a7" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_bacecfc0-ffaf-49cb-ab05-4f262bc3753f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_21ec7f2f-515a-406f-b547-77eee8c50747" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCash"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4a556b53-2e53-420c-8744-fff6101816a7" xlink:to="loc_us-gaap_RestrictedCash_21ec7f2f-515a-406f-b547-77eee8c50747" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_ed703e68-96dd-4068-93d1-b39cdcd1c7dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4a556b53-2e53-420c-8744-fff6101816a7" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_ed703e68-96dd-4068-93d1-b39cdcd1c7dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/OTHERBALANCESHEETDETAILSSummaryofChangesinAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" xlink:href="alny-20210331.xsd#OTHERBALANCESHEETDETAILSSummaryofChangesinAccumulatedOtherComprehensiveIncomeLossDetails"/>
  <link:presentationLink xlink:role="http://www.alnylam.com/role/OTHERBALANCESHEETDETAILSSummaryofChangesinAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0a51d230-3f45-4153-b838-e91eec4bb597" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_de157ae7-f6a2-4907-8634-03a798d39e58" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0a51d230-3f45-4153-b838-e91eec4bb597" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_de157ae7-f6a2-4907-8634-03a798d39e58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_bb8cd6db-8bf7-47c6-b3a8-5eeb37862d84" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_de157ae7-f6a2-4907-8634-03a798d39e58" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_bb8cd6db-8bf7-47c6-b3a8-5eeb37862d84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_dbb7b27a-3043-4f25-84ee-c2245060fe8c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_bb8cd6db-8bf7-47c6-b3a8-5eeb37862d84" xlink:to="loc_us-gaap_EquityComponentDomain_dbb7b27a-3043-4f25-84ee-c2245060fe8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_AccumulatedLossOnInvestmentInJointVentureMember_14349ec9-ea5c-4156-b4a6-ae143b2ba997" xlink:href="alny-20210331.xsd#alny_AccumulatedLossOnInvestmentInJointVentureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_dbb7b27a-3043-4f25-84ee-c2245060fe8c" xlink:to="loc_alny_AccumulatedLossOnInvestmentInJointVentureMember_14349ec9-ea5c-4156-b4a6-ae143b2ba997" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_6d771043-0329-465d-af5e-6f1ad6d74167" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_dbb7b27a-3043-4f25-84ee-c2245060fe8c" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_6d771043-0329-465d-af5e-6f1ad6d74167" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_fcd76f17-38b7-4e59-892c-ea1890ce83b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_dbb7b27a-3043-4f25-84ee-c2245060fe8c" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_fcd76f17-38b7-4e59-892c-ea1890ce83b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_4798e607-6c8c-40d2-a243-068c8af1329c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_dbb7b27a-3043-4f25-84ee-c2245060fe8c" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_4798e607-6c8c-40d2-a243-068c8af1329c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_5303469b-d001-4fcf-9181-3ac43e65d1e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_dbb7b27a-3043-4f25-84ee-c2245060fe8c" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_5303469b-d001-4fcf-9181-3ac43e65d1e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_829131ff-8ba3-4f16-b910-f1f4df3f5334" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_de157ae7-f6a2-4907-8634-03a798d39e58" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_829131ff-8ba3-4f16-b910-f1f4df3f5334" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_71f20d54-e929-4e17-91c4-dc9a505b2217" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AOCIAttributableToParentNetOfTaxRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_829131ff-8ba3-4f16-b910-f1f4df3f5334" xlink:to="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_71f20d54-e929-4e17-91c4-dc9a505b2217" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_0c3c0b21-bd9a-42a0-97ae-f5705de6c3fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_71f20d54-e929-4e17-91c4-dc9a505b2217" xlink:to="loc_us-gaap_StockholdersEquity_0c3c0b21-bd9a-42a0-97ae-f5705de6c3fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_174263b5-d518-4095-97e1-585ffabf2d03" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_71f20d54-e929-4e17-91c4-dc9a505b2217" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_174263b5-d518-4095-97e1-585ffabf2d03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_7c83541b-25a3-4f30-b547-3f6d435228b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_71f20d54-e929-4e17-91c4-dc9a505b2217" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_7c83541b-25a3-4f30-b547-3f6d435228b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_bb005a54-c31f-4cc5-aa31-c5f1ebdbda17" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_71f20d54-e929-4e17-91c4-dc9a505b2217" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_bb005a54-c31f-4cc5-aa31-c5f1ebdbda17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_4824d276-2ffe-41de-853c-18176fcfb255" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_71f20d54-e929-4e17-91c4-dc9a505b2217" xlink:to="loc_us-gaap_StockholdersEquity_4824d276-2ffe-41de-853c-18176fcfb255" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/CREDITAGREEMENT" xlink:type="simple" xlink:href="alny-20210331.xsd#CREDITAGREEMENT"/>
  <link:presentationLink xlink:role="http://www.alnylam.com/role/CREDITAGREEMENT" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAbstract_46e26d71-c4b3-4b14-8686-669bd94f3cac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_3456fd2e-0b39-42d3-9ccc-70c634e2bf66" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityAbstract_46e26d71-c4b3-4b14-8686-669bd94f3cac" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_3456fd2e-0b39-42d3-9ccc-70c634e2bf66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/CREDITAGREEMENTTables" xlink:type="simple" xlink:href="alny-20210331.xsd#CREDITAGREEMENTTables"/>
  <link:presentationLink xlink:role="http://www.alnylam.com/role/CREDITAGREEMENTTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAbstract_69d215c2-0a23-4acf-b5ae-19965cd9beb7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_4de19e98-6e52-45ef-bd3f-edfda8bff5b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityAbstract_69d215c2-0a23-4acf-b5ae-19965cd9beb7" xlink:to="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_4de19e98-6e52-45ef-bd3f-edfda8bff5b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/CREDITAGREEMENTAdditionalInformationDetails" xlink:type="simple" xlink:href="alny-20210331.xsd#CREDITAGREEMENTAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.alnylam.com/role/CREDITAGREEMENTAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAbstract_54997133-d79e-4f2d-8a7c-fd8c1487eb92" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfImpairedFinancingReceivableTable_4d8b5a36-27c7-4bd1-bfda-eada4c9df8f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfImpairedFinancingReceivableTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityAbstract_54997133-d79e-4f2d-8a7c-fd8c1487eb92" xlink:to="loc_us-gaap_ScheduleOfImpairedFinancingReceivableTable_4d8b5a36-27c7-4bd1-bfda-eada4c9df8f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_26793578-68fc-41b6-b3cc-887e8be1f8db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfImpairedFinancingReceivableTable_4d8b5a36-27c7-4bd1-bfda-eada4c9df8f1" xlink:to="loc_us-gaap_CreditFacilityAxis_26793578-68fc-41b6-b3cc-887e8be1f8db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_debeb6ac-e925-492f-92ef-45755b34be97" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_26793578-68fc-41b6-b3cc-887e8be1f8db" xlink:to="loc_us-gaap_CreditFacilityDomain_debeb6ac-e925-492f-92ef-45755b34be97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_5d8571d2-237d-4499-8990-de41ac12abec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_debeb6ac-e925-492f-92ef-45755b34be97" xlink:to="loc_us-gaap_LineOfCreditMember_5d8571d2-237d-4499-8990-de41ac12abec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_94174b8d-002f-45f0-8e0c-9bd5c48fc9a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfImpairedFinancingReceivableTable_4d8b5a36-27c7-4bd1-bfda-eada4c9df8f1" xlink:to="loc_us-gaap_DebtInstrumentAxis_94174b8d-002f-45f0-8e0c-9bd5c48fc9a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_ec3da683-686a-4bf4-84d9-487b88643e37" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_94174b8d-002f-45f0-8e0c-9bd5c48fc9a1" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_ec3da683-686a-4bf4-84d9-487b88643e37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_TrancheTwoLoanMember_a767e3d4-b346-4f36-a9c2-221053ba3d5a" xlink:href="alny-20210331.xsd#alny_TrancheTwoLoanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_ec3da683-686a-4bf4-84d9-487b88643e37" xlink:to="loc_alny_TrancheTwoLoanMember_a767e3d4-b346-4f36-a9c2-221053ba3d5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_TrancheThreeLoanMember_6b081467-4421-40c9-9d68-4ad3c1c87c89" xlink:href="alny-20210331.xsd#alny_TrancheThreeLoanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_ec3da683-686a-4bf4-84d9-487b88643e37" xlink:to="loc_alny_TrancheThreeLoanMember_6b081467-4421-40c9-9d68-4ad3c1c87c89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_Tranche2LoanAndTranche3LoanMember_a3ab2281-9138-4238-97c7-f3a53273c5f6" xlink:href="alny-20210331.xsd#alny_Tranche2LoanAndTranche3LoanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_ec3da683-686a-4bf4-84d9-487b88643e37" xlink:to="loc_alny_Tranche2LoanAndTranche3LoanMember_a3ab2281-9138-4238-97c7-f3a53273c5f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_3c184ebf-90bc-43f0-8624-5a6621ac968d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfImpairedFinancingReceivableTable_4d8b5a36-27c7-4bd1-bfda-eada4c9df8f1" xlink:to="loc_srt_ProductOrServiceAxis_3c184ebf-90bc-43f0-8624-5a6621ac968d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_eedc375e-8cf8-415b-8279-826aa87042c8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_3c184ebf-90bc-43f0-8624-5a6621ac968d" xlink:to="loc_srt_ProductsAndServicesDomain_eedc375e-8cf8-415b-8279-826aa87042c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_ONPATTROAndGIVLAARIMember_395205a3-2370-4e7e-8316-7559b932048a" xlink:href="alny-20210331.xsd#alny_ONPATTROAndGIVLAARIMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_eedc375e-8cf8-415b-8279-826aa87042c8" xlink:to="loc_alny_ONPATTROAndGIVLAARIMember_395205a3-2370-4e7e-8316-7559b932048a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_98b32d9f-0357-48ce-aff7-b24f83309eb0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfImpairedFinancingReceivableTable_4d8b5a36-27c7-4bd1-bfda-eada4c9df8f1" xlink:to="loc_us-gaap_VariableRateAxis_98b32d9f-0357-48ce-aff7-b24f83309eb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_677848ab-ad69-4665-b7c0-06ad6d7193eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_98b32d9f-0357-48ce-aff7-b24f83309eb0" xlink:to="loc_us-gaap_VariableRateDomain_677848ab-ad69-4665-b7c0-06ad6d7193eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLiborSwapRateMember_319fe997-e7da-43d5-bc75-3570a27ae8f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LondonInterbankOfferedRateLiborSwapRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_677848ab-ad69-4665-b7c0-06ad6d7193eb" xlink:to="loc_us-gaap_LondonInterbankOfferedRateLiborSwapRateMember_319fe997-e7da-43d5-bc75-3570a27ae8f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember_57ac6df9-d4ee-457a-8d2c-ba926cf331e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BaseRateMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_677848ab-ad69-4665-b7c0-06ad6d7193eb" xlink:to="loc_us-gaap_BaseRateMember_57ac6df9-d4ee-457a-8d2c-ba926cf331e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_bd6520bd-c992-42d8-a0ac-ff221762a7ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfImpairedFinancingReceivableTable_4d8b5a36-27c7-4bd1-bfda-eada4c9df8f1" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_bd6520bd-c992-42d8-a0ac-ff221762a7ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_d89343cc-1536-466f-b246-68c3e6236eea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_bd6520bd-c992-42d8-a0ac-ff221762a7ec" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_d89343cc-1536-466f-b246-68c3e6236eea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_a1fcb2d5-e78e-4f79-bcb5-2e66462eb8eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_d89343cc-1536-466f-b246-68c3e6236eea" xlink:to="loc_us-gaap_SecuredDebtMember_a1fcb2d5-e78e-4f79-bcb5-2e66462eb8eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_1ddd73ef-2fb9-48c2-a80f-900d252957c7" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfImpairedFinancingReceivableTable_4d8b5a36-27c7-4bd1-bfda-eada4c9df8f1" xlink:to="loc_srt_RangeAxis_1ddd73ef-2fb9-48c2-a80f-900d252957c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6f41a552-d6ef-4144-bfd2-3fd26534775e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_1ddd73ef-2fb9-48c2-a80f-900d252957c7" xlink:to="loc_srt_RangeMember_6f41a552-d6ef-4144-bfd2-3fd26534775e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_de4023e9-9cf2-49d0-b743-50c0d75adaf9" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_6f41a552-d6ef-4144-bfd2-3fd26534775e" xlink:to="loc_srt_MinimumMember_de4023e9-9cf2-49d0-b743-50c0d75adaf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_1a14bf96-aa21-4803-8af7-3d2da216ee34" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_6f41a552-d6ef-4144-bfd2-3fd26534775e" xlink:to="loc_srt_MaximumMember_1a14bf96-aa21-4803-8af7-3d2da216ee34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivableImpairedLineItems_298895ab-6979-4527-8208-a2e5629f5eeb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancingReceivableImpairedLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfImpairedFinancingReceivableTable_4d8b5a36-27c7-4bd1-bfda-eada4c9df8f1" xlink:to="loc_us-gaap_FinancingReceivableImpairedLineItems_298895ab-6979-4527-8208-a2e5629f5eeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_DebtInstrumentNumberOfTranches_a205bb5e-7ced-4683-af13-a741c0af075a" xlink:href="alny-20210331.xsd#alny_DebtInstrumentNumberOfTranches"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancingReceivableImpairedLineItems_298895ab-6979-4527-8208-a2e5629f5eeb" xlink:to="loc_alny_DebtInstrumentNumberOfTranches_a205bb5e-7ced-4683-af13-a741c0af075a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_d5f69945-b1d2-4393-a1af-86bfb6643357" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancingReceivableImpairedLineItems_298895ab-6979-4527-8208-a2e5629f5eeb" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_d5f69945-b1d2-4393-a1af-86bfb6643357" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLinesOfCredit_87cd29e7-b58b-40c6-91c8-0340fd615054" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancingReceivableImpairedLineItems_298895ab-6979-4527-8208-a2e5629f5eeb" xlink:to="loc_us-gaap_ProceedsFromLinesOfCredit_87cd29e7-b58b-40c6-91c8-0340fd615054" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_b4956814-aff4-4f79-9c5d-ffcfa1229a9f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancingReceivableImpairedLineItems_298895ab-6979-4527-8208-a2e5629f5eeb" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_b4956814-aff4-4f79-9c5d-ffcfa1229a9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_LineOfCreditFacilityMaximumBorrowingCapacityAccordionFeature_4eeb51dc-dcc4-472e-aad1-4f75d268ccb6" xlink:href="alny-20210331.xsd#alny_LineOfCreditFacilityMaximumBorrowingCapacityAccordionFeature"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancingReceivableImpairedLineItems_298895ab-6979-4527-8208-a2e5629f5eeb" xlink:to="loc_alny_LineOfCreditFacilityMaximumBorrowingCapacityAccordionFeature_4eeb51dc-dcc4-472e-aad1-4f75d268ccb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_DebtInstrumentCovenantTermsMinimumProductRevenue_f0bf2074-67e5-4839-a4f2-b9aa6f13676c" xlink:href="alny-20210331.xsd#alny_DebtInstrumentCovenantTermsMinimumProductRevenue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancingReceivableImpairedLineItems_298895ab-6979-4527-8208-a2e5629f5eeb" xlink:to="loc_alny_DebtInstrumentCovenantTermsMinimumProductRevenue_f0bf2074-67e5-4839-a4f2-b9aa6f13676c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_b7c5bcfa-3c1b-42eb-a237-4e36b78bd1b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancingReceivableImpairedLineItems_298895ab-6979-4527-8208-a2e5629f5eeb" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_b7c5bcfa-3c1b-42eb-a237-4e36b78bd1b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_228485be-ed49-47a5-9b38-35e16596ba5b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancingReceivableImpairedLineItems_298895ab-6979-4527-8208-a2e5629f5eeb" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_228485be-ed49-47a5-9b38-35e16596ba5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_DebtInstrumentInterestInKindInterestRateIncrease_f51ef462-f3d8-4c45-8f19-abfd9e560787" xlink:href="alny-20210331.xsd#alny_DebtInstrumentInterestInKindInterestRateIncrease"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancingReceivableImpairedLineItems_298895ab-6979-4527-8208-a2e5629f5eeb" xlink:to="loc_alny_DebtInstrumentInterestInKindInterestRateIncrease_f51ef462-f3d8-4c45-8f19-abfd9e560787" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeeAmount_f699a8bb-b0fc-448d-9316-54a1f9da03be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityCommitmentFeeAmount"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancingReceivableImpairedLineItems_298895ab-6979-4527-8208-a2e5629f5eeb" xlink:to="loc_us-gaap_LineOfCreditFacilityCommitmentFeeAmount_f699a8bb-b0fc-448d-9316-54a1f9da03be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_bf25cf66-0f11-427e-a266-61ea9ff93442" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancingReceivableImpairedLineItems_298895ab-6979-4527-8208-a2e5629f5eeb" xlink:to="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_bf25cf66-0f11-427e-a266-61ea9ff93442" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_DebtInstrumentExitFeePercent_1bdd1699-9630-4dce-b82b-32e83456ca03" xlink:href="alny-20210331.xsd#alny_DebtInstrumentExitFeePercent"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancingReceivableImpairedLineItems_298895ab-6979-4527-8208-a2e5629f5eeb" xlink:to="loc_alny_DebtInstrumentExitFeePercent_1bdd1699-9630-4dce-b82b-32e83456ca03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_LineOfCreditFacilityPrepaymentAndTerminationFeePercentage_58daee22-33a3-43ec-b279-2b7fe44929df" xlink:href="alny-20210331.xsd#alny_LineOfCreditFacilityPrepaymentAndTerminationFeePercentage"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancingReceivableImpairedLineItems_298895ab-6979-4527-8208-a2e5629f5eeb" xlink:to="loc_alny_LineOfCreditFacilityPrepaymentAndTerminationFeePercentage_58daee22-33a3-43ec-b279-2b7fe44929df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_DebtInstrumentCovenantTermsMinimumConsolidatedLiquidity_db382871-29b2-4e6d-aa1d-93bf247e3007" xlink:href="alny-20210331.xsd#alny_DebtInstrumentCovenantTermsMinimumConsolidatedLiquidity"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancingReceivableImpairedLineItems_298895ab-6979-4527-8208-a2e5629f5eeb" xlink:to="loc_alny_DebtInstrumentCovenantTermsMinimumConsolidatedLiquidity_db382871-29b2-4e6d-aa1d-93bf247e3007" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/DEVELOPMENTDERIVATIVELIABILITY" xlink:type="simple" xlink:href="alny-20210331.xsd#DEVELOPMENTDERIVATIVELIABILITY"/>
  <link:presentationLink xlink:role="http://www.alnylam.com/role/DEVELOPMENTDERIVATIVELIABILITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_d67e4487-8add-4d96-909b-3eea886d947c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_4d755013-65c1-4f21-a701-d8e339714d3e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_d67e4487-8add-4d96-909b-3eea886d947c" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_4d755013-65c1-4f21-a701-d8e339714d3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/DEVELOPMENTDERIVATIVELIABILITYTables" xlink:type="simple" xlink:href="alny-20210331.xsd#DEVELOPMENTDERIVATIVELIABILITYTables"/>
  <link:presentationLink xlink:role="http://www.alnylam.com/role/DEVELOPMENTDERIVATIVELIABILITYTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_6ac0f1e2-5543-44ee-b7ed-37840255ff83" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_bb70996b-1c4f-49b5-842c-0be141566610" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_6ac0f1e2-5543-44ee-b7ed-37840255ff83" xlink:to="loc_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_bb70996b-1c4f-49b5-842c-0be141566610" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/DEVELOPMENTDERIVATIVELIABILITYNarrativeDetails" xlink:type="simple" xlink:href="alny-20210331.xsd#DEVELOPMENTDERIVATIVELIABILITYNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.alnylam.com/role/DEVELOPMENTDERIVATIVELIABILITYNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_b766edb3-10d6-4c70-b7af-154f41c2d865" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_e5b13714-f5ef-4d0d-8646-c5e8e97b754c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_b766edb3-10d6-4c70-b7af-154f41c2d865" xlink:to="loc_us-gaap_DerivativeTable_e5b13714-f5ef-4d0d-8646-c5e8e97b754c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_8df535c8-0520-429c-afdc-59699f8e15ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_e5b13714-f5ef-4d0d-8646-c5e8e97b754c" xlink:to="loc_us-gaap_TypeOfArrangementAxis_8df535c8-0520-429c-afdc-59699f8e15ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9080b4f0-8b77-47db-a78e-6d6aa946f47d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_8df535c8-0520-429c-afdc-59699f8e15ec" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9080b4f0-8b77-47db-a78e-6d6aa946f47d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_b4162d4c-5cbe-4a36-8aeb-2bd1f15f906d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9080b4f0-8b77-47db-a78e-6d6aa946f47d" xlink:to="loc_us-gaap_CollaborativeArrangementMember_b4162d4c-5cbe-4a36-8aeb-2bd1f15f906d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_8469f2e3-4a84-4953-9eb8-3bf2801f4bfd" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_e5b13714-f5ef-4d0d-8646-c5e8e97b754c" xlink:to="loc_srt_CounterpartyNameAxis_8469f2e3-4a84-4953-9eb8-3bf2801f4bfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e22a3056-d48e-4abb-9f77-70fd2c5a8beb" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_8469f2e3-4a84-4953-9eb8-3bf2801f4bfd" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e22a3056-d48e-4abb-9f77-70fd2c5a8beb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_BlackstoneLifeSciencesMember_685a9297-0331-4398-9102-c4b871d0f2fe" xlink:href="alny-20210331.xsd#alny_BlackstoneLifeSciencesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e22a3056-d48e-4abb-9f77-70fd2c5a8beb" xlink:to="loc_alny_BlackstoneLifeSciencesMember_685a9297-0331-4398-9102-c4b871d0f2fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_34d474bb-2557-49c6-b786-57792d6c25e7" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_e5b13714-f5ef-4d0d-8646-c5e8e97b754c" xlink:to="loc_srt_ProductOrServiceAxis_34d474bb-2557-49c6-b786-57792d6c25e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a583b926-53bd-4dc9-9c29-69018fe9fae8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_34d474bb-2557-49c6-b786-57792d6c25e7" xlink:to="loc_srt_ProductsAndServicesDomain_a583b926-53bd-4dc9-9c29-69018fe9fae8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_VutrisiranAndALNAGTMember_4d6ebbbd-4644-49e1-b026-6edf4cbe8c4d" xlink:href="alny-20210331.xsd#alny_VutrisiranAndALNAGTMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_a583b926-53bd-4dc9-9c29-69018fe9fae8" xlink:to="loc_alny_VutrisiranAndALNAGTMember_4d6ebbbd-4644-49e1-b026-6edf4cbe8c4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_HELIOSBPhase3ClinicalTrialMember_6eb46dfa-ba57-4d42-9b25-4b1bdc4a43f5" xlink:href="alny-20210331.xsd#alny_HELIOSBPhase3ClinicalTrialMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_a583b926-53bd-4dc9-9c29-69018fe9fae8" xlink:to="loc_alny_HELIOSBPhase3ClinicalTrialMember_6eb46dfa-ba57-4d42-9b25-4b1bdc4a43f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_ALNAGTPhase2ClinicalTrialMember_c0edcd12-9f9f-49f7-9763-723d1e89a155" xlink:href="alny-20210331.xsd#alny_ALNAGTPhase2ClinicalTrialMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_a583b926-53bd-4dc9-9c29-69018fe9fae8" xlink:to="loc_alny_ALNAGTPhase2ClinicalTrialMember_c0edcd12-9f9f-49f7-9763-723d1e89a155" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_ALNAGTPhase3ClinicalTrialMember_e82deb45-0bbb-4adc-ab07-2ab31ee8f7e9" xlink:href="alny-20210331.xsd#alny_ALNAGTPhase3ClinicalTrialMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_a583b926-53bd-4dc9-9c29-69018fe9fae8" xlink:to="loc_alny_ALNAGTPhase3ClinicalTrialMember_e82deb45-0bbb-4adc-ab07-2ab31ee8f7e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_VutrisiranMember_04a7dffd-3326-4802-b655-5b466ae3018e" xlink:href="alny-20210331.xsd#alny_VutrisiranMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_a583b926-53bd-4dc9-9c29-69018fe9fae8" xlink:to="loc_alny_VutrisiranMember_04a7dffd-3326-4802-b655-5b466ae3018e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_fcd37371-96d1-476f-825b-02dc53122052" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_e5b13714-f5ef-4d0d-8646-c5e8e97b754c" xlink:to="loc_dei_LegalEntityAxis_fcd37371-96d1-476f-825b-02dc53122052" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_4a700cd3-f5c4-4066-b528-28012e960b72" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_fcd37371-96d1-476f-825b-02dc53122052" xlink:to="loc_dei_EntityDomain_4a700cd3-f5c4-4066-b528-28012e960b72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_BlackstoneLifeSciencesMember_7c2f3fc0-ed22-462b-8e29-6ab82b2c11e4" xlink:href="alny-20210331.xsd#alny_BlackstoneLifeSciencesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_4a700cd3-f5c4-4066-b528-28012e960b72" xlink:to="loc_alny_BlackstoneLifeSciencesMember_7c2f3fc0-ed22-462b-8e29-6ab82b2c11e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_643ace9b-4762-4dcf-b104-bfcda8a75489" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_e5b13714-f5ef-4d0d-8646-c5e8e97b754c" xlink:to="loc_us-gaap_DerivativeLineItems_643ace9b-4762-4dcf-b104-bfcda8a75489" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_CollaborativeArrangementMaximumFunding_752ed2a1-24de-4eb8-9397-fe7152d36da0" xlink:href="alny-20210331.xsd#alny_CollaborativeArrangementMaximumFunding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_643ace9b-4762-4dcf-b104-bfcda8a75489" xlink:to="loc_alny_CollaborativeArrangementMaximumFunding_752ed2a1-24de-4eb8-9397-fe7152d36da0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_CollaborativeArrangementRoyaltiesPayablePercent_c4975e7d-a681-4537-bef0-0dc3afc9d179" xlink:href="alny-20210331.xsd#alny_CollaborativeArrangementRoyaltiesPayablePercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_643ace9b-4762-4dcf-b104-bfcda8a75489" xlink:to="loc_alny_CollaborativeArrangementRoyaltiesPayablePercent_c4975e7d-a681-4537-bef0-0dc3afc9d179" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_CollaborativeArrangementRoyaltiesPayableTerm_3d9d5ffb-96ba-46ef-922b-3872fc5fa037" xlink:href="alny-20210331.xsd#alny_CollaborativeArrangementRoyaltiesPayableTerm"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_643ace9b-4762-4dcf-b104-bfcda8a75489" xlink:to="loc_alny_CollaborativeArrangementRoyaltiesPayableTerm_3d9d5ffb-96ba-46ef-922b-3872fc5fa037" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_CollaborativeArrangementFixedPaymentMultiplier_9b7f27c3-e40b-4a29-a448-b07fc2ffa8da" xlink:href="alny-20210331.xsd#alny_CollaborativeArrangementFixedPaymentMultiplier"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_643ace9b-4762-4dcf-b104-bfcda8a75489" xlink:to="loc_alny_CollaborativeArrangementFixedPaymentMultiplier_9b7f27c3-e40b-4a29-a448-b07fc2ffa8da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_alny_CollaborativeArrangementFixedPaymentTerm_b84885e6-c57c-4ce6-a50f-4d07959a886f" xlink:href="alny-20210331.xsd#alny_CollaborativeArrangementFixedPaymentTerm"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_643ace9b-4762-4dcf-b104-bfcda8a75489" xlink:to="loc_alny_CollaborativeArrangementFixedPaymentTerm_b84885e6-c57c-4ce6-a50f-4d07959a886f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_9e7c282a-e479-41d1-a354-bf61336a3bc0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_643ace9b-4762-4dcf-b104-bfcda8a75489" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_9e7c282a-e479-41d1-a354-bf61336a3bc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/DEVELOPMENTDERIVATIVELIABILITYDevelopmentDerivativeLiabilityActivityDetails" xlink:type="simple" xlink:href="alny-20210331.xsd#DEVELOPMENTDERIVATIVELIABILITYDevelopmentDerivativeLiabilityActivityDetails"/>
  <link:presentationLink xlink:role="http://www.alnylam.com/role/DEVELOPMENTDERIVATIVELIABILITYDevelopmentDerivativeLiabilityActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_48d11edf-c6d2-4cc7-b31f-b89411181915" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_73616a11-8437-49fd-9530-883ef30b6f50" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_48d11edf-c6d2-4cc7-b31f-b89411181915" xlink:to="loc_us-gaap_DerivativeTable_73616a11-8437-49fd-9530-883ef30b6f50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_3f6f997b-0662-4184-b838-622cc0018271" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_73616a11-8437-49fd-9530-883ef30b6f50" xlink:to="loc_us-gaap_FinancialInstrumentAxis_3f6f997b-0662-4184-b838-622cc0018271" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1c836635-23d7-4dc5-9430-066714694ea2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_3f6f997b-0662-4184-b838-622cc0018271" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1c836635-23d7-4dc5-9430-066714694ea2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeMember_d9403e34-d617-451d-b856-1d6915d38089" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1c836635-23d7-4dc5-9430-066714694ea2" xlink:to="loc_us-gaap_DerivativeMember_d9403e34-d617-451d-b856-1d6915d38089" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_977ab1b3-dcfe-40c2-83f9-25ab5b010299" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_73616a11-8437-49fd-9530-883ef30b6f50" xlink:to="loc_us-gaap_DerivativeLineItems_977ab1b3-dcfe-40c2-83f9-25ab5b010299" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_7eedee15-6442-4cc5-be0f-75a374e4d06f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_977ab1b3-dcfe-40c2-83f9-25ab5b010299" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_7eedee15-6442-4cc5-be0f-75a374e4d06f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_451f951d-3e8b-49fd-b24e-9b6abc68f1b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_7eedee15-6442-4cc5-be0f-75a374e4d06f" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_451f951d-3e8b-49fd-b24e-9b6abc68f1b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_7021a0af-33d8-4536-9dc1-5f206f5b0934" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_7eedee15-6442-4cc5-be0f-75a374e4d06f" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_7021a0af-33d8-4536-9dc1-5f206f5b0934" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_b9911140-2454-480a-ab66-780c358e1675" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_7eedee15-6442-4cc5-be0f-75a374e4d06f" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_b9911140-2454-480a-ab66-780c358e1675" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_3973badd-5e94-4586-b068-fb5d5df3af0a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_7eedee15-6442-4cc5-be0f-75a374e4d06f" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_3973badd-5e94-4586-b068-fb5d5df3af0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/STOCKBASEDCOMPENSATION" xlink:type="simple" xlink:href="alny-20210331.xsd#STOCKBASEDCOMPENSATION"/>
  <link:presentationLink xlink:role="http://www.alnylam.com/role/STOCKBASEDCOMPENSATION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_db60b62e-8800-4d9a-8b32-7a6892051f2e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_db8c1e6a-5739-49d9-ada6-0b42ca3f6547" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_db60b62e-8800-4d9a-8b32-7a6892051f2e" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_db8c1e6a-5739-49d9-ada6-0b42ca3f6547" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/STOCKBASEDCOMPENSATIONTables" xlink:type="simple" xlink:href="alny-20210331.xsd#STOCKBASEDCOMPENSATIONTables"/>
  <link:presentationLink xlink:role="http://www.alnylam.com/role/STOCKBASEDCOMPENSATIONTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_82957654-4c59-4676-9b4c-c5a306b3d1e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_7ea13d74-ecdd-430d-8af1-7bee656e2c82" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_82957654-4c59-4676-9b4c-c5a306b3d1e5" xlink:to="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_7ea13d74-ecdd-430d-8af1-7bee656e2c82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/STOCKBASEDCOMPENSATIONSummaryofShareBasedCompensationExpensesIncludedOperatingCostsandExpenseDetail" xlink:type="simple" xlink:href="alny-20210331.xsd#STOCKBASEDCOMPENSATIONSummaryofShareBasedCompensationExpensesIncludedOperatingCostsandExpenseDetail"/>
  <link:presentationLink xlink:role="http://www.alnylam.com/role/STOCKBASEDCOMPENSATIONSummaryofShareBasedCompensationExpensesIncludedOperatingCostsandExpenseDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_712b1c73-e759-4dc5-bff9-e54014b525bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_68ec98ad-e01f-4206-96ff-3323fa4253f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_712b1c73-e759-4dc5-bff9-e54014b525bd" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_68ec98ad-e01f-4206-96ff-3323fa4253f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_fe507e7d-43a7-44d7-8374-c64b2757a49b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_68ec98ad-e01f-4206-96ff-3323fa4253f7" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_fe507e7d-43a7-44d7-8374-c64b2757a49b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_fe46ffb4-ae26-4ff6-91c7-cdb46747168a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_fe507e7d-43a7-44d7-8374-c64b2757a49b" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_fe46ffb4-ae26-4ff6-91c7-cdb46747168a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_304ceda5-476d-43cf-8429-a27734bfaf5b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_fe46ffb4-ae26-4ff6-91c7-cdb46747168a" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_304ceda5-476d-43cf-8429-a27734bfaf5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_6d39f54d-6655-4651-b1dd-3f98ae6c9d4d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_fe46ffb4-ae26-4ff6-91c7-cdb46747168a" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_6d39f54d-6655-4651-b1dd-3f98ae6c9d4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2658b752-e11b-47b8-8f60-4e0bb3e9bad7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_68ec98ad-e01f-4206-96ff-3323fa4253f7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2658b752-e11b-47b8-8f60-4e0bb3e9bad7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_2b25605c-43a1-4fe8-aabe-cb30887a14c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2658b752-e11b-47b8-8f60-4e0bb3e9bad7" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_2b25605c-43a1-4fe8-aabe-cb30887a14c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/NETLOSSPERCOMMONSHARE" xlink:type="simple" xlink:href="alny-20210331.xsd#NETLOSSPERCOMMONSHARE"/>
  <link:presentationLink xlink:role="http://www.alnylam.com/role/NETLOSSPERCOMMONSHARE" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_b72e9efc-75b7-4e00-a4ad-9bce87155380" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_576e8ce3-8e66-48b4-ae7a-a6b51ef2f6a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_b72e9efc-75b7-4e00-a4ad-9bce87155380" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_576e8ce3-8e66-48b4-ae7a-a6b51ef2f6a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/NETLOSSPERCOMMONSHARETables" xlink:type="simple" xlink:href="alny-20210331.xsd#NETLOSSPERCOMMONSHARETables"/>
  <link:presentationLink xlink:role="http://www.alnylam.com/role/NETLOSSPERCOMMONSHARETables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_271ad731-7337-4bf1-a0c8-72039cc49179" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_90958f79-f942-47ec-8686-d4c2860000a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_271ad731-7337-4bf1-a0c8-72039cc49179" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_90958f79-f942-47ec-8686-d4c2860000a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/NETLOSSPERCOMMONSHARECommonShareEquivalentsExcludedfromCalculationofNetLossPerCommonShareDetail" xlink:type="simple" xlink:href="alny-20210331.xsd#NETLOSSPERCOMMONSHARECommonShareEquivalentsExcludedfromCalculationofNetLossPerCommonShareDetail"/>
  <link:presentationLink xlink:role="http://www.alnylam.com/role/NETLOSSPERCOMMONSHARECommonShareEquivalentsExcludedfromCalculationofNetLossPerCommonShareDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_0e284958-9624-4659-94c2-b7a19b7cd43a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_bfd341de-5146-4982-be21-9d93b5c1e7e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0e284958-9624-4659-94c2-b7a19b7cd43a" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_bfd341de-5146-4982-be21-9d93b5c1e7e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_d5f63e93-2db4-4067-9da9-9a131c55c778" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_bfd341de-5146-4982-be21-9d93b5c1e7e9" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_d5f63e93-2db4-4067-9da9-9a131c55c778" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f532d7b8-904d-4bfa-ba25-aba9b7dfdf3c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_d5f63e93-2db4-4067-9da9-9a131c55c778" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f532d7b8-904d-4bfa-ba25-aba9b7dfdf3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_407033b2-20f3-405d-8b38-8dcfb53585b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f532d7b8-904d-4bfa-ba25-aba9b7dfdf3c" xlink:to="loc_us-gaap_EmployeeStockOptionMember_407033b2-20f3-405d-8b38-8dcfb53585b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_e610165d-ba63-43ce-8175-0a201103ddcf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f532d7b8-904d-4bfa-ba25-aba9b7dfdf3c" xlink:to="loc_us-gaap_RestrictedStockMember_e610165d-ba63-43ce-8175-0a201103ddcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0a60e30b-32e3-4494-9175-4d96b2847709" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_bfd341de-5146-4982-be21-9d93b5c1e7e9" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0a60e30b-32e3-4494-9175-4d96b2847709" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_50f14f74-d7ff-4702-9401-62e31651be0a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0a60e30b-32e3-4494-9175-4d96b2847709" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_50f14f74-d7ff-4702-9401-62e31651be0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alnylam.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="simple" xlink:href="alny-20210331.xsd#COMMITMENTSANDCONTINGENCIES"/>
  <link:presentationLink xlink:role="http://www.alnylam.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_f8416609-0df8-4c3e-9007-a5e4593cdb70" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_ca0d63a7-a687-4461-af2f-f456540aab82" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_f8416609-0df8-4c3e-9007-a5e4593cdb70" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_ca0d63a7-a687-4461-af2f-f456540aab82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>alny-20210331_g1.jpg
<TEXT>
begin 644 alny-20210331_g1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" +Z!4\# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH ***2@!:*** "BBB@ HHHH ****
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M91AD(I4@'!7@[?V?*_*I*]KI&7UZ-N9Q=KVN?L+17Y)_&ZX_:VT+X?V?QO\
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M=-O_ .Q/[(\WS/LAB.SS_/7&_P KKL.-W0XK2_;&_8E_X:TU7PQ>_P#"9_\
M"*_V+#/#L_LO[9YWF,ASGSH]N-GOG-:T\32C4HR;TBK/?L9SP]5PJI+=W7WG
M6_$Q%_X8@\5+M&!\.[K QZ::V*^6O^"./_(M_%#_ *^]/_\ 0)Z^W_$WPS_X
M2+X(ZK\//[2^S_;O#LN@?VEY&[9OMC!YOE[AG&=VW</3/>O)OV0_V3(/V.]!
M\7BY\9)XCMM4:&ZEN)-/^PK;+"LF2?WTF1AR<\8VUQQJP6'J4[ZMJQU2IS]O
M"=M$CXJ^(VH1_L1_\%%I/$KQ-%X4U=VU%XXD.&M+M668 #^Y.'( _P">:\=J
M[C_@EKX-O?B1\6/B/\:->43W;S26T,K#(-U<OYUPRGL578OTF-<]_P %5OBE
M\,_B0O@1/"GB+3?$WB*Q:X\^YT:ZCN8([9PF$>1"5W;U! !R!OSC(S]N_L3_
M  E/P9_9K\'Z)<0>1JEU;_VGJ (^;SY_WA5O=5*)_P  KNK5.7"*35I25ODC
MCHT[XEQ3O&.OS9\9?\%C?^1J^&/_ %Y7W_HR&O4OVS/VK?%'[.OP-^%>D>"Y
M8['7O$.E([:G) LIM888(00BN"I=FE')!P%/'(->G?MC?L2_\-::KX8O?^$S
M_P"$5_L6&>'9_9?VSSO,9#G/G1[<;/?.:Z;X\?L@>&/V@OA3X=\(Z]?7%K?^
M'X$CT[6K- )(F$:QOF,D@H^Q25SGY5PPQ6$*]'DHQGKRWN;2HUN>K*&E[6/B
M?XL_ >\O_P!EZ;XI_$[]H+5O%5YJ&EK>Z9HD-Z#9RW3J#' @=R)-K,-P1$(P
MW3&:[;_@E+_R0[XN?]?*_P#I,U=)\-O^"1G@WPSJDMYXL\8WWBY%1A;VD-BM
MC"K$8#2#S)&?:>< J"0,Y&0?6_V3_P!C&\_9@T7QGI'_  G8\3:?XBB0",Z1
M]E-M*JNN\'SWW9#C(X^Z.:UK8BDZ,J:G=W5M+&=*A456,W&VG>Y\E_\ !'G_
M )*7\0?^P1!_Z.K)_:A@CNO^"I?A6&5!)%)K_AM'1AD,I:V!!KZ^_8\_8:_X
M9.\3>(-7_P"$V_X2G^UK2.U\G^R?L?E;7W;L^?)NSTQ@56^)O[!W_"QOVJ=(
M^,W_  G']G_V?J.FW_\ 8G]D>;YGV0Q'9Y_GKC?Y778<;NAQ0\32^LSJ7T:M
MU\A+#U?J\*=M4[G(_P#!7?\ Y-M\-_\ 8VVW_I'>5Z[^P#_R9_\ #?\ Z])_
M_2J:M/\ :\_9G_X:J^&VF^$_^$D_X1?['JT>J?;/L/VO?LAFB\O9YD>,^=G=
MG^'&.<CKO@!\)_\ A1GP?\-^!?[5_MO^QX9(OM_V?[/YVZ5Y,^7O?;C?C[QZ
M5PRJP>%C3OK>YVQIR6)=2VECJ_&'AV+Q=X2UO0IVV0:I8SV4C#LLD;(3^35^
M3/\ P3U^(]M^S/\ M*^)O!GC^5/#O]I1/I,\]X_EQ6]Y#+F/>S8 1AY@#'NR
M]B:_7VOG']IK]A7P!^TQ>#6;XW'AWQ6J",ZUIH4M.H "K/&W$@4  '(;  W8
M %&&K0A&5*K\,OP#$49R<:E/>)Z+\<OCQX8^!OPTU3Q9J^IV@\JU:6PM3,I>
M_E*GRHXE!RVXXY' &22 ":\@_88_:R\6_M4:7XDN]?\ "=CHMII#0PKJ6GS2
M>5<3.&+1K&^2-JA23O.-Z\<UXEX=_P"".>AVNJI+KGQ-O]3TX."UM8Z0EI*R
MYY'F--*!QWVU]U_#'X7^&O@[X+L/"OA/3(]*T:S!V1*2S.Q.6=V/+.3U)_D
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M\.Q:!_:7D;=^RV$'F^7N.,XW;=Q],]ZXI58/#TX)ZINYUQI35><[:-'Y\?\
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M0>10!V]%4])UBP\0:;;ZCI=[;ZEI]RGF07=I*LL4JG^)74D,/<&KE !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?GS
M\/\ 3=3OOC!\;6L/@1HOQ=1?%MT&O-5OK&W:S/FR?NU%Q&Q(;K\N!Q7Z#5PO
MPX^#VC?##7/&.JZ5<WUQ<>*=3?5;U;R1&2.5BQ*QA44A?F/#%C[T >/?$KQU
MXQM?'WPW^#WP^&F_#*\U;2VU.[NDLX;M-.C16)MH(L"-L%'!. #P05YKB-3_
M &K/'?PK\%_%_1/$4VG^*/%W@BYL[>QUQ+0017B74A"O/$A"JZ*<[4X) 4YP
M6/T1\8/@#X;^,TVCWNI76JZ)KNCNSZ?KF@WGV6]MPV-RJ^",' Z@D<X(R<YG
MAO\ 9;\!^'_A]XC\)3VMYKUOXDD,VM:EK%T9[[4)=Y=9)90!\R-RNT#!&[[Q
M8D YKPOI/QN\#Z9JNK>)O'^D>,]$D\/S76]M,CL;NPO5B9U\E8X]DT>< F0@
MG PHP0WF6O?M#>/K']AOPC\0(O$ C\7ZAJ"P3ZC]CMSYB?:ITV^68_+'R(HX
M7/&?6O8OAY^R3X2\!>(8];NM9\2^,[^WL&TRS;Q3J0NULK=E*/'"H10JLK%<
M<@ G&,G/'2_\$^? ,VB_V*_B?QLVB1W/VNSTMM71K6RDW$EHHC$5!(8J2P8X
M)YR<T <=^TE\8/C#X+^*VO16NK:AX$\"6%K;MI^MQ>%QJ>ESNR@LUY<[7>#,
MC>7^[1C]WY.=S'QG_:C\:W%W\-_#_@NZN%N]=T%->OM6\%Z'_;DTN=R".WMK
M@QD1AD<L9 '7Y0=I5@WK_P 1?V1_"OQ \4:SKT&O^*O"%WKD @UB+PSJ@M8-
M24*5!GC9&#?*2I' .22"22;'BO\ 9,\$>(=*\)VNF3ZUX-O/"T36^EZMX:U!
MK:]A@96#Q&5@V5;>221NR3@@,P8 \0O/VEOBU9_!#0K/4-*N_#?Q"UGQ1%X:
MM-7UW1C9[X'4,MX;=@5WDD*54,@PQ'85=\(Z'XP\.?MX>'K#QIXGMO&&HQ^#
M)3!JT&GK8O+ ;B8@21(2@=7,@RO!4(3SFO89_P!D;X?W'P=7X<M!?C2UN_[2
M_M$7/^G_ &W&#=>85QYA!(^[MP<;<4GP[_93\.?#OXCP>.8_$GBKQ!XC2R>Q
MDNO$&I+=M.K$_,[&,-N5=JC!"@*.,Y) ,']ISQ%=:+\4O@3;6\5C)'?^)?)E
M:[T^WN75<Q<Q/(C-$W/WHRK=.>!7F<WQ"^-?C;6OCL^@_$.T\/:5X%OKE[.&
M31;:XEF2-9F%OO9<*F(Q\Y5VR1VSGZ:^(?P>T;XE^)/!FM:G<WT%UX5U#^TK
M)+21%223Y>)0R,2ORCA2IZ\UF:%^S_X>\/\ _"R!;WFIO_PGDLTNI^;+&?),
MB.K>1B,;1B1L;MW04 3?L]_$&_\ B9\$?"GBO6O)CU&_LO,NFB&R,LK,A;';
M.W..@S7P=\>OC%9?&;XH^$_&@\26%OX:TCQ3;:9I.D->Q><MLCA[C4)H]VZ-
M794"E@/E49Z9/Z'_  U^'.F?"WP#I/A#2Y;F[TO386@B>^97E=2S,=Y554\L
M>@%>?>//V/?A9XZ_L?\ XI?3_#W]FWJ7O_$AT^UMOM6W_EE/^Y.^(]UXSZT
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M_CE'_#3GQB_Z*QXX_P#"CO/_ (Y7H?V3/^9'!_:</Y6?T%T5_/I_PTY\8O\
MHK'CC_PH[S_XY1_PTY\8O^BL>./_  H[S_XY1_9,_P"9!_:</Y6?T%T5_/I_
MPTY\8O\ HK'CC_PH[S_XY1_PTY\8O^BL>./_  H[S_XY1_9,_P"9!_:</Y6?
MT%T5_/I_PTY\8O\ HK'CC_PH[S_XY1_PTY\8O^BL>./_  H[S_XY1_9,_P"9
M!_:</Y6?T%T5_/I_PTY\8O\ HK'CC_PH[S_XY1_PTY\8O^BL>./_  H[S_XY
M1_9,_P"9!_:</Y6?T%T5_/I_PTY\8O\ HK'CC_PH[S_XY1_PTY\8O^BL>./_
M  H[S_XY1_9,_P"9!_:</Y6?T%T5_/I_PTY\8O\ HK'CC_PH[S_XY1_PTY\8
MO^BL>./_  H[S_XY1_9,_P"9!_:</Y6?T%T5_/I_PTY\8O\ HK'CC_PH[S_X
MY1_PTY\8O^BL>./_  H[S_XY1_9,_P"9!_:</Y6?T%T5_/I_PTY\8O\ HK'C
MC_PH[S_XY1_PTY\8O^BL>./_  H[S_XY1_9,_P"9!_:</Y6?T%T5_/I_PTY\
M8O\ HK'CC_PH[S_XY1_PTY\8O^BL>./_  H[S_XY1_9,_P"9!_:</Y6?T%T5
M_/I_PTY\8O\ HK'CC_PH[S_XY1_PTY\8O^BL>./_  H[S_XY1_9,_P"9!_:<
M/Y6?T%T5_/I_PTY\8O\ HK'CC_PH[S_XY1_PTY\8O^BL>./_  H[S_XY1_9,
M_P"9!_:</Y6?T%T5_/I_PTY\8O\ HK'CC_PH[S_XY1_PTY\8O^BL>./_  H[
MS_XY1_9,_P"9!_:</Y6?T%T5_/I_PTY\8O\ HK'CC_PH[S_XY1_PTY\8O^BL
M>./_  H[S_XY1_9,_P"9!_:</Y6?T%T5_/I_PTY\8O\ HK'CC_PH[S_XY1_P
MTY\8O^BL>./_  H[S_XY1_9,_P"9!_:</Y6?T%T5_/I_PTY\8O\ HK'CC_PH
M[S_XY1_PTY\8O^BL>./_  H[S_XY1_9,_P"9!_:</Y6?T%T5_/I_PTY\8O\
MHK'CC_PH[S_XY1_PTY\8O^BL>./_  H[S_XY1_9,_P"9!_:</Y6?T%T5_/I_
MPTY\8O\ HK'CC_PH[S_XY1_PTY\8O^BL>./_  H[S_XY1_9,_P"9!_:</Y6?
MT%T5_/I_PTY\8O\ HK'CC_PH[S_XY1_PTY\8O^BL>./_  H[S_XY1_9,_P"9
M!_:</Y6?T%T5_/I_PTY\8O\ HK'CC_PH[S_XY1_PTY\8O^BL>./_  H[S_XY
M1_9,_P"9!_:</Y6?T%T5_/I_PTY\8O\ HK'CC_PH[S_XY1_PTY\8O^BL>./_
M  H[S_XY1_9,_P"9!_:</Y6?T%T5_/I_PTY\8O\ HK'CC_PH[S_XY1_PTY\8
MO^BL>./_  H[S_XY1_9,_P"9!_:</Y6?T%T5_/I_PTY\8O\ HK'CC_PH[S_X
MY1_PTY\8O^BL>./_  H[S_XY1_9,_P"9!_:</Y6?T%T5_/I_PTY\8O\ HK'C
MC_PH[S_XY1_PTY\8O^BL>./_  H[S_XY1_9,_P"9!_:</Y6?T%T5_/I_PTY\
M8O\ HK'CC_PH[S_XY1_PTY\8O^BL>./_  H[S_XY1_9,_P"9!_:</Y6?T%T5
M_/I_PTY\8O\ HK'CC_PH[S_XY1_PTY\8O^BL>./_  H[S_XY1_9,_P"9!_:<
M/Y6?T%T5_/I_PTY\8O\ HK'CC_PH[S_XY1_PTY\8O^BL>./_  H[S_XY1_9,
M_P"9!_:</Y6?T%T5_/I_PTY\8O\ HK'CC_PH[S_XY1_PTY\8O^BL>./_  H[
MS_XY1_9,_P"9!_:</Y6?T%T5_/I_PTY\8O\ HK'CC_PH[S_XY1_PTY\8O^BL
M>./_  H[S_XY1_9,_P"9!_:</Y6?T%T5_/I_PTY\8O\ HK'CC_PH[S_XY1_P
MTY\8O^BL>./_  H[S_XY1_9,_P"9!_:</Y6?T%T5_/I_PTY\8O\ HK'CC_PH
M[S_XY1_PTY\8O^BL>./_  H[S_XY1_9,_P"9!_:</Y6?T%T5_/I_PTY\8O\
MHK'CC_PH[S_XY1_PTY\8O^BL>./_  H[S_XY1_9,_P"9!_:</Y6?T%T5_/I_
MPTY\8O\ HK'CC_PH[S_XY1_PTY\8O^BL>./_  H[S_XY1_9,_P"9!_:</Y6?
MT%T5_/I_PTY\8O\ HK'CC_PH[S_XY1_PTY\8O^BL>./_  H[S_XY1_9,_P"9
M!_:</Y6?T%T5_/I_PTY\8O\ HK'CC_PH[S_XY1_PTY\8O^BL>./_  H[S_XY
M1_9,_P"9!_:</Y6?T%T5_/I_PTY\8O\ HK'CC_PH[S_XY1_PTY\8O^BL>./_
M  H[S_XY1_9,_P"9!_:</Y6?T%T5_/I_PTY\8O\ HK'CC_PH[S_XY1_PTY\8
MO^BL>./_  H[S_XY1_9,_P"9!_:</Y6?T%T5_/I_PTY\8O\ HK'CC_PH[S_X
MY1_PTY\8O^BL>./_  H[S_XY1_9,_P"9!_:</Y6?T%T5_/I_PTY\8O\ HK'C
MC_PH[S_XY1_PTY\8O^BL>./_  H[S_XY1_9,_P"9!_:</Y6?T%T5_/I_PTY\
M8O\ HK'CC_PH[S_XY1_PTY\8O^BL>./_  H[S_XY1_9,_P"9!_:</Y6?T%T5
M_/I_PTY\8O\ HK'CC_PH[S_XY1_PTY\8O^BL>./_  H[S_XY1_9,_P"9!_:<
M/Y6?T%T5_/I_PTY\8O\ HK'CC_PH[S_XY1_PTY\8O^BL>./_  H[S_XY1_9,
M_P"9!_:</Y6?T%T5_/I_PTY\8O\ HK'CC_PH[S_XY1_PTY\8O^BL>./_  H[
MS_XY1_9,_P"9!_:</Y6?T%T5_/I_PTY\8O\ HK'CC_PH[S_XY1_PTY\8O^BL
M>./_  H[S_XY1_9,_P"9!_:</Y6?T%T5_/I_PTY\8O\ HK'CC_PH[S_XY1_P
MTY\8O^BL>./_  H[S_XY1_9,_P"9!_:</Y6?T%T5_/I_PTY\8O\ HK'CC_PH
M[S_XY1_PTY\8O^BL>./_  H[S_XY1_9,_P"9!_:</Y6?T%T5_/I_PTY\8O\
MHK'CC_PH[S_XY1_PTY\8O^BL>./_  H[S_XY1_9,_P"9!_:</Y6?T%T5_/I_
MPTY\8O\ HK'CC_PH[S_XY1_PTY\8O^BL>./_  H[S_XY1_9,_P"9!_:</Y6?
MT%T5_/I_PTY\8O\ HK'CC_PH[S_XY1_PTY\8O^BL>./_  H[S_XY1_9,_P"9
M!_:</Y6?T%T5_/I_PTY\8O\ HK'CC_PH[S_XY1_PTY\8O^BL>./_  H[S_XY
M1_9,_P"9!_:</Y6?T%T5_/I_PTY\8O\ HK'CC_PH[S_XY1_PTY\8O^BL>./_
M  H[S_XY1_9,_P"9!_:</Y6?T%T5_/I_PTY\8O\ HK'CC_PH[S_XY1_PTY\8
MO^BL>./_  H[S_XY1_9,_P"9!_:</Y6?T%T5_/I_PTY\8O\ HK'CC_PH[S_X
MY1_PTY\8O^BL>./_  H[S_XY1_9,_P"9!_:</Y6?T%T5_/I_PTY\8O\ HK'C
MC_PH[S_XY1_PTY\8O^BL>./_  H[S_XY1_9,_P"9!_:</Y6?T%T5^?/_  2<
M^)WC'XC?\+3_ .$L\6:YXH^Q_P!E?9O[9U*:[\C?]LW[/,9MN[8N<==HST%?
MH-7DUZ+H5'3;O8]2C55:FJB6X4445@;!117B/[5?QBO_ (4^"[.'1G\C6=7D
M>*&YVY\B- #(XSQN^90,_P!XGM79A,+4QM>&'I?%+^OP//S#'4<MPL\77^&"
MN_T7S>A[=17Y,W/B'5+S4FU&XU*\GOV;<;J2=FE)]=Q.<U]F?L>?&_5_'0U'
MPMXANY=2O[& 7=K>S'=(\(94=7;JQ#,A#').XY/ KZK,N%ZV7X=XB-132WTM
M;\7?\#X3)>.,/FV,6#G2=-R^%WNGY/16_$^FJ*\O\=>)M;U;XG:3X$T75V\-
M0MI4VMZGK$,,4MPL*2I%'%")E>-2S,Q9G1L*N  3D8/A?XT6/AO0]7DN_'&F
M_%*%=4M[+2)/#TUK/J=PUQGR[>=(=D"R;EDVN-BE$);:58GXD_2SVZBO))/V
MC](\[3M/@\-^(+SQ%>:C<Z2V@0QVWVNVN88Q*Z2LTXA ,1$@=9"I4]<\5+:_
MM%:/JVDZ!<:+H&O:]J>L17<\>B6$5O\ ;+>.UE,-P\WF3+&H67$?$AW,P";N
M< 'JU%?,WC+]IZ[U"^U:/0?MFF^%_P#A'--UNS\1VMC;W,X:XO3"V899URA
M\K:R!U=92> A;US3?B]9ZSXJN-)T_0=<O["VU%](GUZVMXWLHKM$W/&P$GG
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M_L;=6_\ 2R6O=RGXY>AXN9_!'U/-****^F/G@HKN_@+_ ,ER^'7_ &,>G?\
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MG2Y^9;_UT]!.I4Y.5[?UU/<=6_:HLM>L?@/8ZCX-:>S^%Y8O&FJ!?[6_>0R
M$F ^2N8 "/GR&.".M;-]^W[\2[G]H ?$.'6M:M]!&II=_P#"&#6IC8?9E 4V
MVW&SYD!!?R_O'?MS7S)13^KTOY>_XZL/;U._](^G=#_;0LM-\1?$:RU+X<V/
MB#X8>.-2DU:^\&W^HOOMKIQEI8+M8P48OAL[,@*H7:1NJSJ7[;.FZ3I/A+PQ
M\/\ X7Z;X$\#:/XBL_$MYI<>IRWMWJ-S;S"3:UW*N55@L8Y1F'EKAMOR5\PV
M%A=:K?6UE96TUY>7,BPP6]NA>261B J*HY9B2  .236UXB^'/BSPC?7=EKOA
M?6=%O+.V6]N;?4=/F@D@@:18UE=74%4,CH@8\%F SDBI]A1OJOQ?Y?J5[:K;
M1_A_7W'TCXZ_:P^"'Q*\7:GXG\2?LU?VCKFI2^==W7_">7T7F/@#.U(E4< =
M *^3***UITXTU:/YM_F9SJ2J.\OR2_(****U,@HHHH **** "BBB@ KW7]F7
M]I+2_@'I_CS2];\$_P#";Z/XOT]--O+/^U7T_$(\P.-Z1NWS"0C@J1C@UX51
M6<X1J1Y9;%PFZ<N:.Y]7^!_VL/@Y\+_'.A^+O"'[.QT36])EDDBF_P"$VN[@
M-OADB(*RPLN,29Z9RHYK%^#_ .WE\1/ 7Q&OO$/BS5M:^(6B:A;W-O=^&]2U
MN9+1A-SF-6$BQ;3C&U.%RHP#7D6C? SXD>(I+J/2?A]XJU22U\L7"V>BW,QA
M\R-9(]X5#MW(RN,]58$<&N7U+P]JNCP^;?Z9>6,7VJ:RWW,#QK]HA"&:') ^
M=/,CW+U7>N0,BL/8T973UOYM_J;^VJQLUI;RL>J_LT_M"0?LX_$K5_%%KX<D
MURVO-,N=,BL9M0$+Q)*R%6:41$.5" '"+G.>.E=)\#?VH_#/PT^"OB3X9^+_
M (:?\)_H.N:HFIS+_;TNFX*+$$7]W$S<-$&R&&<XQZ_.U%:2HPG=M;V[]-C.
M-:<;)/O^.YZG\8OB%\,_&FGZ=#X#^$O_  KBZ@E9[JX_X22ZU3[2A "IMF4!
M,')R.N:ZOX-?M/:/X(^$^J?#3Q[\/+7XE^"[G45U>ULYM4ET^>RN@H4M',BL
MP4J.B[3\[Y)#D'PBQL;G4[RWL[.WEN[NXD6*&W@0O)(['"JJCDDD@ #DDUI^
M+/!/B+P#JBZ;XGT#5/#FHM&)A9ZM9R6LQC)(#[)%!VD@\XQP:'3@X\C_ #=_
MOW!5)I\Z_)6^[8[W]I7X_7?[1GQ#A\13:-;>';"QT^'2=-TJUD,JVMK$69$+
MD#>=TCG.U>H&.*]8N_VY+'4OVE/"'Q;O?A\T[^&M"32;;2!K6T/*HE47!E^S
M]-LS?)MZ@'=VKP&'X-?$"X\*GQ/%X&\22>&A UR=932+@V?DKG=)YVS9M&#E
MLX&#7,ZEI-]HTL,6H65Q8RS01W,:7,31EXI$#QR*"!E65@RL.""".#4^RI22
MBNFF_P!Y7M:L7S=]3Z+^$W[>OQ(\"_%*Y\4>)M8UCQUHEZMTEYX8OM9G2S99
M@2!$K>8L6QMN,(<*"HQG(@\#?M9:%8?#EOAWX_\ AE:_$?P+8WTMYH%G=:O+
M97NDAW+&(7<2;G3D_P *DDG)V[57YPHIO#TGK;]-A*O477]3ZULOV^GT?XG_
M  SUC2/AUINC>!_A['>1:-X5LK^3S2+FT,#F:[=&+L&)?=Y8)R0VXG?7*>.O
MCM\#_%FDZ_\ 8/V=O[&\0ZE%.8-8_P"$WOI_LUS(&VS^24"/M<[MAP#C'2O#
M/"_A#7O'&K)I7AS1-1\0:HZLZV6EVDES,RJ,L0B L0!U..*CU3PQK.AI,^I:
M3?:>D-W+I\C75L\02YBQYL#;@,2)N7<AY7<,@9J50I1>FC]7_GJ4ZU1K75>B
M_P C,HHHKJ.8**** "BBB@ HHHH **** "BBB@#VCX"_LVR?%[0_$7BW7O%-
MCX"^'GAL*-5\17\+W!61E)CB@@4@S2%M@*A@<.,;F(5M[XF_LD+HMCX#U3X;
M>.=-^*6D^-+MM-TI;:W;3[][I6*NIM96++&OR9D+ *7&X*"K-Z#^S380?&K]
MD/XB?!;0KZRB^(USKL6O:5I=]<I;G5(TBCWQ0LQ 9U6WD)!P!E22%W$-\'_!
MQ_V&_BA\(/'?Q*\0:99ZO+J<C:IX2M91<7^FV;*\27;>4762/_6$[?[H"^82
MP3S95I<\ES:K:-M]/O\ GMT/0C2CR1?+H]WVU^X0_L'>#SXP?X=I\>]!;XM+
M#M/ALZ-<"S-WL#?9Q?%MI/./N;_^F>>*S_AW_P $^=>\<?!7QSXRN]??1?$O
MA:[U"QD\*R::)7GGM(@[1B<3  MR!A&'&<D&O51^Q;XM'[6)^*SZUH0^$@\0
M'QE_PFJZI;FU^S?:/M03_6;MW\&_&S^+=CBO=OAW\?M'UW08O'&GEU\->(/C
M"^EKN0J)[>>P^RH[J0" S%)"#R._2N2>(JJ*]G+FVZ+?M_6ITPH4VWSQMOWV
M[_UH?$WA7]AFX\1?LE7_ ,;KCQ=_9_V>TN;R+03I>\RQQ2M$#YWG#;N*,1\A
MX]:T_P!HK_@GQJ?P+\3_  ZTJQ\6+XIA\7ZNNB_:_P"S?LHLKAWB6-67SI-V
MX2,PY'^K/J*^L_BC=:=X=^%?[17PST.>1]$\ > ]!TB..0?\MF6\E>0GNS(\
M.['&5[<UZYXD\2>'-0^*GQ%B\3!C%\-IK'QS;/(WRC=ID\+8YZ+Y;-CIEE/6
ML_KE92YKZ:Z>32M^9I]5I./+;737SUO^1\3>(/\ @F#:>&_B5;^&+SXJ[+)O
M#E_XBGU3_A'BWDI:SV\;1^4+DELBX+9!R-F-ISQXEX@^!GP;\FQM_"'Q\_X2
M[7KV_M;*'2_^$-O++<)9DC=_-D?:-BL6P?O;<9&:_1SX=:MJOBS7/A5JC6MO
MK&MZG\%[ZY-K=J##=7$DNEML<$@;69L$$@8)YKY@^(GP_P#C-9VOAV_\6_L\
M_#/X=:!9>(=+EN-=\*V-E!>1YNXXT0-'=2,59I%! 4]N@%:4<14D[3GK\EW\
MOR(JT*:5X0_-]O/\SD]3_80^&.E?%K_A5\_[0\4/CUIH[9-)F\'7*JTTD2R1
MIY_GF(%E9<?-U8#KQ7G/@/\ 8UO-0;X@:G\0/&.G?#OP?X)U.71-2UV6VDO3
M-?(VWRK>!2KR#E6SP2'4@-SC[HU3XW>%;C]MWQW\-M7\.>$O"WBR:""V\*?$
M&/18)-3AU&6QCV":64,)&_>A8Q\H.Q8R&WC'A*_#?Q/\:/@#X]^"%Y=6K?'/
MPSXZF\2W6EW5RD,FMK)&X>>)W"*V[SG?/ VB,DJ' IPKU;+GE:Z7;KU6FWK>
MQ,Z-*[Y8[7[].CUW]-SR>^_8CTZX\>?"RP\-?%'2?%'A#X@220V.O6UGY5U
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M?#FC6VBP7_\ PF=U9[HHEQGRX85 RVYN<D9QDXKYD\:ZMHVN>*]4O_#VA?\
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M'CCQ!J.JW_C#5UTOQ)%8I]JFG$*I=8MIGWE+;?A7B91.3U<$=QXC^-&A^)_
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MH_\ !'-7M%175U%9V\DTS[(HU+,WH!U-3*2BG*3LD!XY_P -W?#;_GS\4?\
M@CFH_P"&[OAM_P ^?BC_ ,$<U>EZ7XC34/$VI:6C+,EO;6]TDB$$;9=XV_\
MC@/_  *MVIIU(U(\T'=?Y: >+_\ #=WPV_Y\_%'_ ((YJ/\ AN[X;?\ /GXH
M_P#!'-7M%%: >+_\-W?#;_GS\4?^".:C_AN[X;?\^?BC_P $<U>T44 >+_\
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M^%?T!44?VI7\@_LZCYG\_O\ PJ/Q;_T!+S_OP_\ A1_PJ/Q;_P! 2\_[\/\
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MH"HH_M2OY!_9U'S/Y_?^%1^+?^@)>?\ ?A_\*/\ A4?BW_H"7G_?A_\ "OZ
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M2JLJ/(Z%69<KM/48J36O!'CGXE>(/'E]J.@Q^';;6_!<NAZ;#/=1RR12,\A
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MHB,9;S3)&\$GEA4VEI@Y926H ]Q3QWX:DUR]T1?$.E-K-E$9[K3EO8C<01@
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M&Y16!'J7B-O+WZ%9ID+N_P")D3M_U.?^67.-\_\ WY7_ )Z?(W^U/$WDEO[
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M,RKHMFT>\A7.HD$KN< D>5QE0AQ_M,/X06 -VBL&/4O$19-^AV:J2NXKJ))
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ML%,+^8\>T;I7+84 ]-HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MF_X1_P 5>+[36;1H=/TFQTF:TM;>+S+ZXNKQ[B,6P"N5=R\4:*%P,LQ+;>0
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MZRLD;-XBF=592R?9(@& :(D=.,A)%]O./=5(WJ* .>70=;6$*WB>X9P@7?\
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MX:V@ZVT+J/%$ZNR,HD^QP95BK@,!MQP65L'/W .A-=%10!@R:)K#22,OB.=
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M&[ AS_#QGRY?^_Y_NKAK:#K9AVCQ/<!]FW?]C@SNV$;ONX^\0V/]G'0UT-%
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M8GDD<< #W]IK\MX@Q%'%9A4J4-8Z:]VEN?N7">#Q.!RBE1Q2M+5V>Z3=TO\
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MFQ%V=I"<MRS.SG//]YV/XT ;M%8,?@308G1ETV,,A5E.YC@JT+#OZV\)_P"
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MC,3W[FYG_P"_A]L*O@;0HY%D73HPZN'#;FSN#JX/7LR*?P]S0!NT5ST?P_\
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M++&4!!!8$8J"X^,'A272]3N=%UK3_$]U8&.-]/T:^@N)S-)((HHB ^$9Y&"
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MWM<_9_T_2U\266D>&I9#:V6BZ+IMR;1V\VZ,Q\W4.009(DF4>=G,:HZ@@9%
M'T]#?1W%Y<VRK,)+?;O9X'1#N&1M<@*_OM)QT.*L5\L>.-+UNZN]0N+[PG_:
M=EJ.JZKJD4.J>&[O68IYX3%96L3VL4D:QEX( Z33?(%8<J<FO=_@[I=YHOPF
M\&V.H?:/[0@TBU6X6Z#"1)/*7>I#<C!R,'D8QVH ["BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M \6Y21@$Y%=C;W"W5O%,@=4D4.HD1D8 C/*L 5/L0".]?+OCWP79?#J75?\
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MP]K(R22)<^66X^U^6ML/E EP,* =PH ^H**^2K?3?%.DZ?X3L=5BU$:Q\2-
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M\O?QE9<E=Y]^#MV_CGM0!NT5@1CQ1F/>VD 9&_:LOK#G'/I]I_\ (7^U3?\
MBK/*'.C>9LYXEQNV_P MWZ>] '0T5@2+XHW/Y;Z0%RVS<DI/6;;GGT^S9_[:
M_P"S3E_X2;S5W'2?+WC( ESMWC/X[-WXX[4 ;M%<_&/%6Q/,;1R^%W[5EQG;
M%NQS_>^T8]O+Z_-39!XL\IMC:,)-AQN6; ;8^._3?Y?X;N^* .BHK"D_X2;S
M7V'21%O;9N$I.W=)MS[[?)S[[_:DC_X2?S$\PZ3Y>Y=VT2Y"[X]V/4[/.Q[[
M.V: -ZBN>C_X2SR4WG1O-VKN"B7:6V)G'MN\S'MM[YI9/^$JV-Y9T<OM;;N$
MH&[;-MSSTW?9\^WF?[- '045A-_PDWG-M.D^5O. 1+NV[FQ^.W;^.?:FQ_\
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M@K5OOBG\3-#FUA=2B\,?\2=-+DNH;>TN&9Y;N;RS9H?/QO'RGSL8^=1Y9Y(
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MT\565I:I]FT[7^84445X9].%%%% !1110 4444 %%%% !1110 4444 %%%%
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MPQ_:VWA]FWR).N\I_=_O#%-C\>:%,(RM\2)-NW]S(,Y$)'\/_3Q#_P!]^QP
M<YJWP!\"ZWIMKI]UI$XL[?3_ .RA#;ZE=0"2UR2(I=DH\U022/,W$$DC!.:T
MYOA+X4N/%$?B!]+/]HI)%/L6YF6V:6)-D4K6P?R6D10H60H67:N"-HQ=;X@:
M"L)E-\P0)YA/V>7A=I?)&W^Z#^7K4DGCK0XG=6O<,A96'DR'E6F4_P //-O-
M_P!\^XR 8"? KP2DEV?[(D:.X$J_9WO[EH(5EE66401&39 '=5+"(+G&#QQ6
MA9_"GPQ8>+G\2P:?)'JK3O=C%Y/]G2=X_+>9;??Y*R,A(:14#'<V2=QSH1^-
M]%DD6-;QB[.L>/)D'S%U0 _+Q\SJ.?7/2HX_'^@S1QR)?%ED567]Q)R&2)UX
MV_W9HS_P+V. #1;P_8-X@36S!G5$M6LEG+MQ"7#E0N=O+*I)QG@<\4?\(_8'
MQ -;,&=4%J;(3[VXA+ARNW.W[P!SC/'6LZ3X@:##"\KWQ$:(SL?(D. $D<_P
M_P!V*3CK\N.I ,DGC;1HIGB:[;S$=HRH@D)W*SJ<?+S\T3CCT]QD 7P;X*T7
MX?Z''H_A^Q&GZ;'(\JP+([@,[%FP6).,G@9P!@#  %;E8,?CC1)F14O&8NRJ
MN().2SQ(!]W^]/$/^!>QPQ?B!H+PK(+YBC*''[B3.THK@XVY^ZZG\?8T =#1
M7/R^/="A5V:]8*H+$B"0\!9F/1?2WF_[Y]UR\^-M&68Q&[82!_+*^1)G=N*_
MW?[P(H W:*P(O'FAS>64O6(D"E3Y$@!SY./X?^GF'_OOV;#&^(&@K"93?,(P
MN\G[/+P-F_)&W^Z": .BHK E\=:'"SA[Q@4+ CR)"?E,P/\ #SS;S?7;[C+E
M\;Z*TRPB\/F,XC \F3&XNJ 9VX'S.OYYZ4 ;M%<]%X_T&:.-TOBRR*KK^XDR
M0RQ,#C;_ '9XC_P+V."3X@:#%"\S7S"-%9V;R). J.Y_A_NQ/Q_LXZD"@#H:
M*PI/'&BPR/&UX=Z.R,!#(>5>1&'"]FBD'X>XR1^.-$DDCC6]W-(ZHN(9,%F>
M) ,[?[T\7_?6>@. #=HKGD^(&@R1+(MZQ1D$@/V>7[I57!QM_NNI_'V-+)X]
MT*%'9KU@J!B2()#T69C_  ^EO-_WQ[C(!T%%83>.-%60QF\(<.4(\F3@ARF#
M\O'S*1_^NFIXZT21D"WC,7*A<02<Y\G'\/\ T\P_]]^S8 -^BN=/Q T%83*;
MY@@3S"?L\O"[=_/R_P!WG%/D\=:)"T@>\8&,L&_<2=C,#_#SS;S?79[C(!OT
M5A+XXT5I5C%X2S.(Q^YDQN+J@&=O]YE'XTR/Q]H4RQLMZQ$BJR_N),X98F'&
MWCB>(^V[GH< '045SLGQ T"*)Y'OB$1&D9O(D^ZJ.Y_AZ[8WXZ\8ZXJ63QQH
ML4DD;7AWQNR,!#(<%7D0CA?[T,@_X#[C(!NT5A1^.-%DDC1;PEI'5$_<R88E
MXD !V_WIH_\ OK/0'$:?$#09(DD6^)1T60-Y$GW2J.#]WCY9$/X^QP =#17/
MR>/="B5RUZ0%#,?W$AX59F/\/86\O_?/N,O;QQHJR-&;MMROL(\B3AMY3!^7
M^\I'_P"L4 ;M%8$?CK1)#&%O&8R$!?W$G.3"!_#_ -/$/_??L<-_X6!H/E"3
M[<=FS?N\B3IMW_W?[O.* .AHK D\=:)$SJUV^4+!@+>4_=,P/\/K;3?]\>ZY
M<OCC16E6,7A+,XC'[F3&XN$ SM_O,!^- &[17/Q^/M"F1&6]8API7_1Y1D,L
M3#^'TGB/MNYZ'#9/B!H,<32-?-L5#(2+>4_*$=S_  \_+&YQ[?2@#HJ*PI/'
M&BQ2O&UX=Z.R,!#(<%6D4CA?[T,@_P" ^XRD?CG1)I$C2])=V5%'DR<EGC08
M^7^]-&/^!9Z X -ZBN>C^(&@R0I*M\3&RJX;R),;2B.#]WCY9$/X^QI9/'VA
M0HS/>LJJK.<P2=%69B?N^EO+_P!\^XR =!16$WC?15F:(WA#JYC(\F3 8,RX
MSM]58?\ ZQ38_'6AS,@2\9BVW:/(DYR80/X>YN(?^^O9L &_17/?\+ T'R?-
M^W-Y>W?N\B3&-F_^[_=.<4Z7QWHD.\/>,"F[=_H\IQM,P/\ #_T[S?\ ?'N,
M@&_16&OC;16G$(O,R,_EC]T^"VX)C.W'WB!^-1Q>/M"F5&2\<AU5A_H\HX98
M6'\/'%Q#]-WL< '045SK_$#08X6E:^;8J,Y/V>4\!&<D?+S\J.?PQUJ27QQH
MD,CH]XRLC,C?N)."K2(W\/\ >AD&?]GW&0#>HK"C\<:+),D2W;&1W5%7R).2
MSQH/X?[TL8_X%GH#B./X@:#+$LBWQ,;() WD28VE4<'[O'RRH?Q]C@ Z&BN>
MD\?Z#$CN]\55 S-F"3@*DKD_=_NP2G_@/J1F1O'&BQR-&;P[E<H?W,GW@[(1
MG;_>1A^'N* -VBL%/'6B2.B+>G<Y4 &&0?>,('\/<W$/_??LV&#X@:"8O,^W
M'9LW[C!)TVA_[O\ =(..M '0T5@2>/-#A\S=>,/+W;QY$AQCSL_P_P#3O-_W
MS[KEP\;Z*TPC%XV]G\L?N9,%MX3 .WGYB!^- &[17/Q^/="E"%;UB'"E3Y$@
M'S+"P_AXXN(?^^O8X1OB!H*0O(;YMBHTA/D2?=",Y(^7GY4;IZ8ZT =#16#)
MXXT6&21'NV#1LR-^XDP"K2H>=O\ >@E'_ ?<96/QQHLLR1+=L9'=45?(DY)>
M-!_#_>EC_P"^L] 30!NT5ST?Q T&6..1;YBDB*ZDP2#Y66-U_AXRLJ'\?8X)
M/'^A1K(S7K*L:L[?N). JRL3]WT@E_[YQU(R =#16$WCC14D:,WA#*Y0_N9/
MO!V0C.W^\C#\/<9;'XZT.9D5;TDN0 ##(.2T*C^'CFXA_P"^O8X -^BN>'Q
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M).0R1.O&W^[-&?\ @7L<$GQ T&&%Y7OB(T1G8^1(< )(Y_A_NQ2<=?EQU(!
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M8*@8DB"0]%F8_P /I;S?]\>XR]O'&BK(8S>$.'*$>3)P0Y3!^7CYE(__ %T
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M!LX&WK6/X7_:[T;QIX7N]?T7P%X_U/3X"B1M::&)C<NS%2L120ABFUBQ) &
M,Y(! /=Z*\(D_;&\'0>%K+6I=&\3127&MOX?DTE].47]O>*H;RY(?,SD@J %
M+')QC(('>?"/XQ:/\9-'U*]TNQU32I]-O7T^]T[6;86]U;S* 2KH&;'7USP0
M<$4 =W1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M53UC6+/P_I-YJ>H3K;6-G$T\\S D(BC).!R>!T'-<;X9^(.M^,O 7]M:;X?L
M[368[N>UN=)U?4WMUMC%*Z-OE2"0AMJJV-F/FQGC) .^HKRC1?B=XXUGX<Q>
M,!X0\/6MG-9IJ,4-QXDG#?9C&TA9C]@^5L!,#D$,<D8Y6U^*7C&XTOPRS^$=
M%AU?Q&ZM8V+:_,52'[,\\CSR?8LH5VQIM57RT@Y '(!ZM17&^ _'&H>)-7\1
M:-K&EV>F:OHDT*3KIU^U[;LLL0D3]XT43!\'E"G *$$[N(_^%G0-\5$\'1V3
M/']ED>34O,PBW2K')]F"[?F;R9%D)#<!D&#DX .VHKS=_P!HCP$MP\":O=7$
MRF=56VTJ\F,S0N%F6+9$?-9,AF5-Q5/G(V?-6\?BEX8_L^\O1J@>VM(K6:5X
MX)6)6YQ]GV +ES)N  4$Y.,9XH ZJBO-H_CUX:L[2:?5YI+$+<7PC6U@GO2+
M6UN&@>[E\J(^3"61CO?"8YW'FM/5OBWH&AZI>VUW>*\<)MH8DL8;B[NIYY4D
MD\M((HF+@1*K@QES@N6"!<L =M17E.B_M'^%-0T5]5NY)[:SFNKV.Q^R6MQ>
MR7-K;2>7)=F.*(M'$&!!9AM'&6R<5TNH?%[PEINM6NES:MNGN1;E)X+:::U7
MSSB 27"(8HS(?NAW!;*XSN&0#L:*\[D^.WA73U5M2U!8$DEG$<MI;75S''#'
M<-;^=<.(0+=?,5EW2$)\I(=@":]$H **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K+U#Q5HND7*
M6]_J]A97#G"Q7%RD;GZ G->:_M-?%&\^&O@6,:4_DZMJDIMX9QUA4#+N/?&
M/3=GM7P?=74U[<23W$LD\\C%GEE8LS,>I)/)-?:9-PW+,Z/UBI/ECLM+M_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 >#_M>> K[Q9X%LM4T^$W$VC2O++&HRWDN '('?!52?8$]J^)*
M_5.O/-:_9]^'NO:BU]>>&;8W+.9':"22%68]251@#SSTK[W(^)(9=0^K8B#<
M5LU;KTUMU/RKB?@VKG&*^NX2HHR:2DI7MIHFFD^G2Q\A_LV^ KWQI\3])N8H
M<V&DSI?7,S<*NQ@47W)8#CTR>U??]9OA[PWI?A/2X].T>P@TZRC)*PP)M&3U
M)]3[GFM*O"SK-7FV(551M%*R7^9]3PWD,<APCHN7-.3O)]+]EY(****^?/K
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ML/2NJK)U;_CX7_<_J: .3C\(^6R$:SJ[;2#AKO(.&A.#QSGR<?267^]31X-
MB"?VWK)P@0M]L.3A0N>G7C.?4GUILWQ#\/V_CR#P9+?^7XEGLCJ$5D\$@$D
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MRY21,@XZCS<CW1#_  U))X3621G_ +6U9=SLQ5;LXY=VP.. -^![*H[5NT4
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MPL2Y)QU/E9/J9)#_ !42>#1)"\?]MZRI967>MX0PRCID<=1YF0?5$/:NAHH
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M=DJ</&V",=#Y>".X=QWJ./P;Y<2I_;>LL50)O:\R3A47)XY)\O/U=_6NAHH
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MO+<+>$8R9CQQQ_KL#T$47]WER^% )5?^U]6)5P^TW1P<.K8(QT^7'T)%;M%
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MC@Y2OH*LC2/"FFZ'JFJ:E:QS&_U)E-S<7%S+.Q52Q2-3(S;(U,DA6-,(I=B
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M;M-5FAL[I-%74Y;.[NUU"Z,J7%EM=ENS"K+&UO-$\:K&1E!DM]=444 %%%%
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MXC)L#*.*TG-WMVTM]_<****^3/O0HHHH **** "BBB@ HHHH **** "BBB@
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M(4\-F1U5BJ_;HQN(64@ ^[)$.>GG9_A-2-K&M"9E'A]C'O*A_MD?(W,-V/\
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M9_A[]E'PEX9FTM[/4M===.\0-XEA2XNHY=UVT:QMO=HR[*0@)RV[.3NYKN?
M?PQTOX>ZEXIOM.N+R:7Q%J;ZM=K=.C*DK@ K'M487CH<GWH Z^BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#@OC%XUN/!.BZ)):O=
M1S7^M6EFS65D]Y-Y.XRSA(41V8F**0<*2 21TKA/%?[25GH6OZC>PFYCT?3[
M*VM19:U:2:.)M0NYV$.^2ZB1HXTC@D9G *A2QPS!17L&K>%[76=>T/5IY)A/
MH\DTMO&C#RR\D31%F!&20K,!@C[QZU@:]\)=+UZ]U._:^U"SU2\O;6_BO[=X
M_,LI;>/RX_*#HRXP9,JZN#YK^H  ./T3]H:7Q3I^GPZ#HNGZ[KMSK4^C/%IV
MM++IZF.V^T&=+L1?/$$>'<?+# NP"LR@/#H_[2$TFDVVJZUX8&EV%YHD^KV:
M6VH"YN)S%-;P>7L\M%42R7*"%]_SJ,L(^@[FS^%]K;7=G>S:YK=_J5K:WENE
M[=W2O)NN6C:24?(%1AY2A50+&H) 3FJ-U\#?#EYI"Z;(UZ+2/0[?0;=4E53;
M0POOCDC(7B3<L9R<C,2?+UR 85Y\;]=T2XN-&U;P;&GB[S-.^R:5I^JBXAN(
MKN21 QG:)-C1_9[@LI7'R##$-D4[SXP>)M6U#P_I.EZ'##XD77;RPU/3HM05
M[5H[>W+%A<M#N$1::U8L(@X^90I.,W-6^ ]U>>(-(U"'Q3JC7:7QU#4-;F>#
M[?))';206J1HL'D+&@FF)7RPI+$D,S$UTFB_![2=#VO!?ZG)=?8;RSDNY9D,
MLKW4B2SW#D(,RLT:<@!5"A54*   <'JWQNU#Q)IN@OH@N-'OM4T_3YD4/%+&
MDE[?1VZDAX27"K'<.K J"H)*$E=L6N?M+0^%-#?4Y?[)D65;_4%@UWQ#;V,K
MVT-Q)%%':QK"7F>182ZJR@ L%,K&N[TWX):%I5YIEQ;W6H*=/%DL,9D0KMM+
M>:"!3\F2H\]I,9^^ >F5.'??LTZ#<:*VD6VO:_IFF3Z7::5?6UI-!B_CM@PB
M>5GA9@_S'=Y90/GY@02" >L6L_VJUAF\N2'S$#^7*NUUR,X8=B*EHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MH!'LQ#?A7Z%U\;_LQ? O5[_Q18^*]:LYM/TJQ;SK59EVO<3#[I"GD*.N<<D
M#OC[(KY#BRO0K8V*HM-I6;7>^WR_X!^A< X7%8;+9/$)J,I7BGVLM?1_\'J%
M%%%?$GZ6%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M"?V59;0-H7[.F ,;<=/3CZ4K>&])?=NTNR;=G=FW3G._.>/^FLG_ '\;^\:
M'_V[INXK_:%KNW;<><N<YQCKUSQ0NO:9)M*ZC:,&QC$ZG.0A'?N)(_\ OM?4
M4@T'3%D$@TZT#@[@WD+D'(.<X]0#]13%\-Z0BA5TJR50, "W3 X0>GI'&/\
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M/J: )6US3HV*MJ%JK E2IF4'(+ CKU!1Q_P$^AH77-.=MJZA:LV0N!,N<DJ
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M3IEF2Y);,"?-DN3GCGF63_OXW]XTH\/Z6K*PTVS#*=RGR$X.0<CCKD _4"@
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MNFH_^$;TC:$_LJRV@;0OV=, 8VXZ>G'TIS>'=*=F+:99L6)+$VZ<D[\D\?\
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MA% 55%LF  %4 #'3"J/HH]*5O#>DR*ZMI=DRN"&!MT.X$,"#QSD2./H[>IH
M>=>TP,RG4;0,I((\]<@@D$'GU5A]0?2@:]IC%0-1M"6Q@>>O.2@'?UDC'_ U
M]12-H&F,VYM.M"VXMN,"YR26)Z=<DGZDTB^'=*3!73+-2"",6Z<$%"#T[&*/
M_OVO]T4 '_"0Z7L+_P!I6>T#<6\],8P&SU]"#]#3FU[3%W9U&T&WKF=>/O\
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MEV9!SG-NG<.#V])9/^_C?WC0 _\ MW3=P7^T+7=NVX\Y<YSC'7KGBD77],?
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MPP8,#Y"9R"I!Z=054_\  1Z4U?#>D1JH72K)0JA5 MT&  J@#CH B#Z(OH*
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M&]#3O[<T[<%_M"UR3M \Y>3G&.O7((^M1MX=TE@0VEV9!SG-NG<.#V])9/\
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M'UYE<)XB520VUC8(2"5E [\X+Q'W\G'\9P]M)UPR%AKZA=Y.S[$GW=Y..O\
M=(7/MF@#=HK CT?759-WB$.!MR#8H,X,.>A[A)A[>=_L#+?[%\0>45_X2-=^
MS;N-@G7;C=C=_>^;]* -RZM8;ZWEM[F&.XMY5*212J&5U/4$'@BO%-:_8_\
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M9]?5U#*646* , T18#GC(249[>;G^ 98NBZ^(@I\2 OLQO\ L$?+;5&<9_O
MMC_:QV% '0T5S\FC:\RN$\1!"=V#]A0[<B8#OV+PG_MC_MG#_P"R=<\S/]OK
MLWY"_8DZ;\X)S_=^7]: -VBL"/1]=7R]WB(-C&[_ $%!NQY.>_&=DW_?_P#V
M!EIT7Q!Y14>)%#["H8V"?>VD!B,\_-AL>V.] '0T5@2:/KK,Y7Q"$5BVT?84
M)7+3$=^P>$?]L<_QFG+I.N"16;7U*AP2GV)!E=ZDCK_=#+G_ &L]J .NT?\
MY;?A_6M*N>\'V=_9PW"W^HC47Q$!)Y"Q8(C"L< _Q.&;VW8Z"NAH *R=6_X^
M%_W/ZFM:LG5O^/A?]S^IH P?$'B32?">FOJ.MZI9:-I\9"O=ZA<)!$I)P 7<
M@ D\=:/#_B32?%FFIJ.B:I9:SI\A*I=Z?<)/$Q!P0'0D$@\=:^>/V@_^$?\
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M8^)?$)U>=M-MM3BCC@@-F\,[R^5/:2QI'(L9",K17",X* K(P!+>PT %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MLG5UW%<[K)QMR81S]//!/M'+_<--'C)#")/[&UGE-^W["V[[@;&/7G&/4$4
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M #<T2Y/H!YP)]!'(?X#4:^-$:$2'1M94E0^PV+;AE%;'U^;&/56% $<'PO\
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M:*PI/%B1R.G]E:LY5V7*V;$':\BY![@^7D>H=#WX$\6))*B#2M6&YU0,UDP
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M_:O\4^+HOA?JO@[09GGU75-2T[4/#,-U;2B\D@C4HB7;+M"?,&\Q=O&>H R
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MXHAOIK2&>.&TOI[ R3*%$KPN8Y&3!.5#JZY.#E#QT) ->BBB@ HHHH ****
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MFDW[_,_X^)<;MY?.-V/O$_GCI6[10!@1> ]$A\O9:RC8%"G[5+GCR<?Q<_\
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M"TD$801A?M,O"A508^;KM1!GKQ3I/ >AS*ZO:2$2;MW^DR\[EF4_Q>EQ*/\
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M,F[[3+]XLSG^+^\S''O3(O FB0[-EK(-FW;FYE.,&$CJW7-O#_WR?[S9WZ*
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M=)X#T282!K60^9NW?Z3*.HF!_B]+B;_OH?W5QOT4 87_  A.C>9YGV:3=O\
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M.2TAD;*Q1VWG2F%.K!&8,N_#*A!4>BT4 %%%% !1110 4444 %%%% !1110
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MFA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MR]_>27)7>?\ 9Z[,?B#VIL;>*<Q[X]( ^7?MDEX_U.['R_\ 7SCZ1>K8WZ*
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MG_:?,DDC4*OD>402/,^8?159_AW0;3POX?TS1;!#'8Z=:Q6=NK')$<:!%'Y
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M<>*?$=G;Z->ZW;Z='8Z]?1ZGJ&CVEU:-=V5E:K/(8O+NQ)$?,/DD"0[L[L@
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M:M $52Y)SPH1G)Z?W4<_133Y/'6@1NRMJ<(9693UZJTJL.G9H)A_P ^U;U%
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M ,"7QYH$+.'U2%60L&!SGY3,K=NQMYA_P ^U.3QQH,DRQ+JD!=G$8&3RQ9%
MSC^](@_X$/6MVB@#GHOB#X=FC21-6@9'19%(SRK)$X/3H5GB/_ Q[T2?$+P[
M#"\KZM L<:L[,<X 5)')Z=EAE/\ P ^E=#10!A2>.-!BD>-]3A$B.T;+SD,K
MNA'3LT4@_P" _2DC\=:!-)'&FJ0,\C*B $_,S-$J@<=S/"/^VBUO44 <\OQ"
M\.O")1JT'EE!)N.1\I17R>.!M=3^-+)X_P##T*NSZK"H3=NZ\;5F8]NPMY_^
M_;5T%% &$WCC05D\LZI 'WF/;DYW!RF.G]X8IL?CWP_*8PFJ0L9-NS&?FW>3
MC''?[3!_W\'O6_10!SO_  L+PYY)E.KVXC"&0L21A0I<D\?W03] ?2GR>/-
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M<+N[JBJ"<EF>-%'3NTL8_P"!BHH_B%X<EACE75H#'(JNK<X*E(W!Z=UEC/\
MP+ZUT5% '/2_$#P[#&[OJT"K&K.YY^5565F)X[""8_\ ;-O2I&\<:"D[0G4X
M?-5S&4YSN#LA'3D[D8?A6[10!@Q^//#\S($U2!BY4+@G^(PA>W<W$/\ W\6H
MU^(7AQH?-&K0&/8'W<_=*!\].FTY_P#U5T5% &!+X^\/0^9OU6W7RPQ?D_+C
MSLYX[?9I_P#OV:?_ ,)OH7G^2-2B,N_R]@R3NW!,=/[Q ^I%;E% '/Q>/_#L
MRHR:M;LKA2IR<'<(2.WI<P'_ +:#WI&^(7AV.%I6U: (JER3GA0C.3T_NHY^
MBFNAHH P9/'6@1NRMJ<(9693UZJTJL.G9H)A_P  /M2Q^.-!EF2)-3A:1W6-
M5&<[F9% Z=VEC'_ U]:W:* .>C^(7AR:%)4U:W,;HLBMDX*E(W!'']V:,_\
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MXT'SC#_:</FA_+V<YW;]F.G][BFQ^/O#TWEE-5MV$@4H03A@?)P1QW^TP?\
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MU9.K?\?"_P"Y_4T >7?'/XO)\&?!L.K1Z2^OZI>7D-A8:3%-Y+7,SGD;]K8
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M /3Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .?\
M&GBS_A$;'3I5M?MMQ?:E:Z=##YGEC=-*J,Q;!X1"[XQSLQQG-9^M_$JQ\/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M7VHJEFFCRV$B7)^3J?*W'WDD[' )?",TD3I_PD.LH61D#K-'E<K(N1^[ZCS
M1[QI[[@#H:*PW\+R/,\G]MZJH9R_EK,FT9=VP/DS@;]O7HB^F:;'X5EC9&.O
M:LY4J3NECPVUHFP1LZ'RB#[2R#NNT WJ*YY?",RPK&/$.L\*%WF:,MPBKG/E
M]?EW>F2?7%++X3EE5Q_;^L)N##*S(,9$PX^3MYP(]X8O0[@#H**PO^$7E\XR
M?V[JV-^_R_-3;]_=M^YG'\/7I^=-C\)RQ^7_ ,5!K#E0N2TL?S8\GD_)W\DY
MQ_SVE]1M -^BN=_X1"7R3&/$6L@[=HD\Z/</D*Y_U?)Y#<]U';(+Y?"LDC.1
MKVKH&+<+,G&3,>/D[>< /:*/T.0#?HK"3PO*DRR?V[JS%7#;6ECVG#(VTC9T
M.TCZ.WL1'%X1ECC1#XAUE]J*FYIH\G"1+N)V=3Y18^\DGJ  #H:*YZ3PC+)"
MZ#Q#K*%E9=ZS1[ERDBY'R8R/,!'O&A]=TDGA>621W_MW5E#.S[%E0!<N[8'R
M=!YFT>R)Z9(!NT5@Q^%I8Y(W.O:L^UE8JTL>&VM$V#\G0^40<=I9!W7:Q?",
MJPB/_A(=9)"!0YFC+<(J[ON<GY=WIEF]<4 =#17/R>$Y9%=?[?UA-^[E9D!&
M5F''R<8\X$>\,1[-N>WA>4R;_P"W=6 WE]HECQRY;;]SISM^GOS0!NT5@1^%
M)8S&3K^KOMVYW3)\V/)Z_)W\DYQ_SVE]1M9_PB,WDF,>(M9!V% _G1[A\I7/
M^KZ@D-]0.V00#HJ*P)/"LDC2$:]JZ!RW"S)\N3,>/D[>< /:&+T.7+X7E617
M_MW5FVN&*F6/!PZM@C9T^4K]';O@@ Z[1_\ EM^']:TJY[P?I+Z1#<1MJ%YJ
M&X1?/>.K,-L:IP0H^]MW'_:9CQG%=#0 5DZM_P ?"_[G]36M63JW_'PO^Y_4
MT 8>N:_IGA?2Y]3UG4;32=-@V^;>7TZPPQ[F"KN=B ,L0!D\D@4R\\3:/IUO
MI]Q=ZK8VMOJ$T=O9RS7"(MS+)_JXXR3AV;^$+DGM7@7[4VH:?XL\:?#_ .'>
MHQ:A=:/=7$FMZU#IEC/>2_98%*Q*8H(W<J\K 9VX&WFO,M'\63:]\%_@WH]\
MTO\ :WA?XF:7H5TMQ&\4H$,D@B+1N Z9B*<,,@@CM@ 'V9K/B+2O#J6CZMJ=
MGIBW=PEI;M>7"0B:=\[(DW$;G.#A1R<&EAU_3+G6+G28=1M)=5MHUEGL4G4S
MQ(WW69 =R@]B1@UX#^V]X7_X3;P=\/?#_P!I>S_M3QI8V8N(_O1&2&Y4,/IG
M/X5PO[./Q"U27XT?$._\965\FOZ+HMCI.JI9V<UY+-/#*T1ECCA5G=7^5\JN
M,,3]T9H ^N(M?TR?69](BU&TDU:WB6>:P6=3/'&QPKM'G<%)Z$C!K/D^(/A:
M'PROB.3Q+H\?AYFV+JS7\0M"P<I@2[MF=P*]>H(ZUX'HMUK?B;]K#Q7>^%=1
MM=',WABQ=CK^AW,CE/-8 >29K=XVS_>[=N]<5\-?!][XQ_96^$T>B^*],\-^
M+]/UN\U#18]5=1;WUPEY= Q[#EF(5V(*AB.>.<@ ^J;[XI>"]-T6QUB\\7:#
M::3?%A:7\^IPI!<%3AA'(6VOC!S@G&*U?#_B;1_%NFKJ.AZK8ZSI[,46ZT^X
M2>(L." Z$C(^M?(.D^,G\9:]\''NO"VG>$=5T_QMJ&G:E9Z2$^RRWD=N/.F3
M9P0S,>['(/S-UKV'X6H4_:2^,']F@#1#'IIN?)V^5]O\IO,Z?Q[-N['?&[G%
M 'M]%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %35-
M6L=#L7O-1O+?3[-"JM<74JQQJ68*H+,0 2S #U) I[:C:+J"6!NH1?/$TZVQ
MD'FF,$*7"YSM!903TR1ZUYO\<O#]CX^_X13P3J*M)8:YJ3M>1J!S;P6\LIZ_
M]-!".^,Y[5YAX8^(?B"1=>O#:-J7C_3;&W\&65JK)YEUJ4;SO=3@2,%*>6(9
MSN8 JGWOF% 'TC;:[IMY!>3V^H6L\-E(\-U)',K+!(GWT<@_*R]P>1WK*TCX
MD^$?$&F7^I:7XIT74M.L%W7EW9ZC#+%;#!.9'5B$& 3R1T->%:3_ &1H/AGX
MD>%?%&A:_P"'O#5X]@93>-;37%M#<6RVS7DTD<DL>SS+1W=V+#.XNN-U9VM:
MR_C\ZCIUKJFB^*=7NIM*T"U\<:3$YLYXGN/M$]M/"DOER2QI \C>6X&)P,1;
ML, ?4,^HVEK=6UK-=0PW-T6$$,D@5Y2HW,$!.6P.3CH*L5Y)X?M?$E]\<HXO
M$6J:5JXT+07FC;2],ELECDNYU4;P]Q-N;;:28P5P';(.17K= !1110 4444
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M1<KII:)VMK;\SI****XC\S"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M)<Z=#()YPI42N&4[G 8@,><$C/->6_\ "Y/C3_T;U??^%/:__$4?\+D^-/\
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M?^%/:_\ Q%'_  N3XT_]&]7W_A3VO_Q% 'N]%>$?\+D^-/\ T;U??^%/:_\
MQ%'_  N3XT_]&]7W_A3VO_Q% 'N]%>$?\+D^-/\ T;U??^%/:_\ Q%'_  N3
MXT_]&]7W_A3VO_Q% 'N]%>$?\+D^-/\ T;U??^%/:_\ Q%'_  N3XT_]&]7W
M_A3VO_Q% 'N]%>$?\+D^-/\ T;U??^%/:_\ Q%'_  N3XT_]&]7W_A3VO_Q%
M 'N]%>$?\+D^-/\ T;U??^%/:_\ Q%'_  N3XT_]&]7W_A3VO_Q% 'N]%>$?
M\+D^-/\ T;U??^%/:_\ Q%'_  N3XT_]&]7W_A3VO_Q% 'N]%>$?\+D^-/\
MT;U??^%/:_\ Q%'_  N3XT_]&]7W_A3VO_Q% 'N]%>$?\+D^-/\ T;U??^%/
M:_\ Q%'_  N3XT_]&]7W_A3VO_Q% 'N]%>$?\+D^-/\ T;U??^%/:_\ Q%'_
M  N3XT_]&]7W_A3VO_Q% 'N]%>$?\+D^-/\ T;U??^%/:_\ Q%'_  N3XT_]
M&]7W_A3VO_Q% 'N]%>$?\+D^-/\ T;U??^%/:_\ Q%'_  N3XT_]&]7W_A3V
MO_Q% 'N]%>$?\+D^-/\ T;U??^%/:_\ Q%'_  N3XT_]&]7W_A3VO_Q% 'N]
M%>$?\+D^-/\ T;U??^%/:_\ Q%'_  N3XT_]&]7W_A3VO_Q% 'N]%>$?\+D^
M-/\ T;U??^%/:_\ Q%'_  N3XT_]&]7W_A3VO_Q% 'N]%>$?\+D^-/\ T;U?
M?^%/:_\ Q%'_  N3XT_]&]7W_A3VO_Q% 'N]%>$?\+D^-/\ T;U??^%/:_\
MQ%'_  N3XT_]&]7W_A3VO_Q% 'N]%>$?\+D^-/\ T;U??^%/:_\ Q%'_  N3
MXT_]&]7W_A3VO_Q% 'N]%>$?\+D^-/\ T;U??^%/:_\ Q%'_  N3XT_]&]7W
M_A3VO_Q% 'N]%>$?\+D^-/\ T;U??^%/:_\ Q%'_  N3XT_]&]7W_A3VO_Q%
M 'N]%>$?\+D^-/\ T;U??^%/:_\ Q%'_  N3XT_]&]7W_A3VO_Q% 'N]%>$?
M\+D^-/\ T;U??^%/:_\ Q%'_  N3XT_]&]7W_A3VO_Q% 'N]%>$?\+D^-/\
MT;U??^%/:_\ Q%'_  N3XT_]&]7W_A3VO_Q% 'N]%>$?\+D^-/\ T;U??^%/
M:_\ Q%'_  N3XT_]&]7W_A3VO_Q% 'N]%>$?\+D^-/\ T;U??^%/:_\ Q%'_
M  N3XT_]&]7W_A3VO_Q% 'N]%>$?\+D^-/\ T;U??^%/:_\ Q%'_  N3XT_]
M&]7W_A3VO_Q% 'N]%>$?\+D^-/\ T;U??^%/:_\ Q%'_  N3XT_]&]7W_A3V
MO_Q% 'N]%>$?\+D^-/\ T;U??^%/:_\ Q%'_  N3XT_]&]7W_A3VO_Q% 'N]
M%>$?\+D^-/\ T;U??^%/:_\ Q%'_  N3XT_]&]7W_A3VO_Q% 'N]%>$?\+D^
M-/\ T;U??^%/:_\ Q%'_  N3XT_]&]7W_A3VO_Q% 'N]%>$?\+D^-/\ T;U?
M?^%/:_\ Q%'_  N3XT_]&]7W_A3VO_Q% 'N]?+/Q2_8)\.>,=:N-5\-:N_A:
M2<EY+(V_VBW+DY)4;E* ^F2!V Z5U_\ PN3XT_\ 1O5]_P"%/:__ !%'_"Y/
MC3_T;U??^%/:_P#Q%7&<H.\6>C@<QQ673=3"SY6]_/U3T,?X,_L2^&?ACKEO
MKFK:C)XHU:U=9;7S(?(@@D'(<(&;<P.,$G QG&<8^CZ\(_X7)\:?^C>K[_PI
M[7_XBC_A<GQI_P"C>K[_ ,*>U_\ B*4I2F[R9.,QV)S"I[7%3<G_ %LEHCW>
MBO"/^%R?&G_HWJ^_\*>U_P#B*/\ A<GQI_Z-ZOO_  I[7_XBI. ]WHKPC_A<
MGQI_Z-ZOO_"GM?\ XBC_ (7)\:?^C>K[_P *>U_^(H ]WHKPC_A<GQI_Z-ZO
MO_"GM?\ XBC_ (7)\:?^C>K[_P *>U_^(H ]WHKPC_A<GQI_Z-ZOO_"GM?\
MXBC_ (7)\:?^C>K[_P *>U_^(H ]WHKPC_A<GQI_Z-ZOO_"GM?\ XBC_ (7)
M\:?^C>K[_P *>U_^(H ]WHKPC_A<GQI_Z-ZOO_"GM?\ XBC_ (7)\:?^C>K[
M_P *>U_^(H ]WHKPC_A<GQI_Z-ZOO_"GM?\ XBC_ (7)\:?^C>K[_P *>U_^
M(H ]WHKPC_A<GQI_Z-ZOO_"GM?\ XBC_ (7)\:?^C>K[_P *>U_^(H ]WHKP
MC_A<GQI_Z-ZOO_"GM?\ XBC_ (7)\:?^C>K[_P *>U_^(H ]WHKPC_A<GQI_
MZ-ZOO_"GM?\ XBC_ (7)\:?^C>K[_P *>U_^(H ]WHKPC_A<GQI_Z-ZOO_"G
MM?\ XBC_ (7)\:?^C>K[_P *>U_^(H ]WHKPC_A<GQI_Z-ZOO_"GM?\ XBC_
M (7)\:?^C>K[_P *>U_^(H ]WHKPC_A<GQI_Z-ZOO_"GM?\ XBC_ (7)\:?^
MC>K[_P *>U_^(H ]WHKPC_A<GQI_Z-ZOO_"GM?\ XBC_ (7)\:?^C>K[_P *
M>U_^(H ]WHKPC_A<GQI_Z-ZOO_"GM?\ XBC_ (7)\:?^C>K[_P *>U_^(H ]
MWHKPC_A<GQI_Z-ZOO_"GM?\ XBC_ (7)\:?^C>K[_P *>U_^(H ]WHKPC_A<
MGQI_Z-ZOO_"GM?\ XBC_ (7)\:?^C>K[_P *>U_^(H ]WHKPC_A<GQI_Z-ZO
MO_"GM?\ XBC_ (7)\:?^C>K[_P *>U_^(H ]WHKPC_A<GQI_Z-ZOO_"GM?\
MXBC_ (7)\:?^C>K[_P *>U_^(H ]WHKPC_A<GQI_Z-ZOO_"GM?\ XBC_ (7)
M\:?^C>K[_P *>U_^(H ]WHKPC_A<GQI_Z-ZOO_"GM?\ XBC_ (7)\:?^C>K[
M_P *>U_^(H ]WHKPC_A<GQI_Z-ZOO_"GM?\ XBC_ (7)\:?^C>K[_P *>U_^
M(H ]WHKPC_A<GQI_Z-ZOO_"GM?\ XBC_ (7)\:?^C>K[_P *>U_^(H ]WHKP
MC_A<GQI_Z-ZOO_"GM?\ XBC_ (7)\:?^C>K[_P *>U_^(H ]WHKPC_A<GQI_
MZ-ZOO_"GM?\ XBC_ (7)\:?^C>K[_P *>U_^(H ]WHKPC_A<GQI_Z-ZOO_"G
MM?\ XBC_ (7)\:?^C>K[_P *>U_^(H ]WHKPC_A<GQI_Z-ZOO_"GM?\ XBC_
M (7)\:?^C>K[_P *>U_^(H ]WHKPC_A<GQI_Z-ZOO_"GM?\ XBC_ (7)\:?^
MC>K[_P *>U_^(H ]WHKPC_A<GQI_Z-ZOO_"GM?\ XBC_ (7)\:?^C>K[_P *
M>U_^(H ]WHKPC_A<GQI_Z-ZOO_"GM?\ XBC_ (7)\:?^C>K[_P *>U_^(H ]
MWHKPC_A<GQI_Z-ZOO_"GM?\ XBC_ (7)\:?^C>K[_P *>U_^(H ]WHKPC_A<
MGQI_Z-ZOO_"GM?\ XBC_ (7)\:?^C>K[_P *>U_^(H ]WHKPC_A<GQI_Z-ZO
MO_"GM?\ XBC_ (7)\:?^C>K[_P *>U_^(H ]WHKPC_A<GQI_Z-ZOO_"GM?\
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M!X(([BL+PS\/_"_@JQNK+P]X;TC0;*Z.ZXM],L(K:.8XQEU10&...>U>3_\
M"Y/C3_T;U??^%/:__$4?\+D^-/\ T;U??^%/:_\ Q%*[M8=E>YZYX4\#>&_
M=G-:>&O#^E^';6:3S98-)LHK5'? &YEC4 G  R?2MNO"/^%R?&G_ *-ZOO\
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MZM\&_#%_H?PM\:Z"VG:KI=M#KFNP:79V(%I<1VC7,I@%H9"JH"K QMD(,@Y
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M=:IX5D@^'FMQ?"6WO-3^V:'/H%S)$UY)%%Y%RFFA7E2$8N%'[E LCE]OSAR
M?45%?'6E:!XL\'Z39OKWA_Q#>W.J?#N\T2T6WLYM0FCN/M4CP6L[1AO*;R98
MEWRE4RK9?Y361J'P?U*^\"^.M2N/!M]<^);'PWX;70II=-D>Y@N8[9!-]ERN
M5D5D4/L^8;0&Z8H ^Q= \6:5XHGUB'3+K[3)I%\VFWJ^6Z>5<+&DA3Y@-WRR
MH<KD?-UR#1X=\1?\)$NI'^S-1TS[%?2V7_$QM_*\_80/.BY.Z)L_*W?!XKY8
MO/A#$WC'6=,?P2[P77Q2M-2NRFCO]FN=+?36VLT@3RY8A*TX=<D*TC!P/,^;
M/UGX<Z]:WD2/X>\OP;;^-==FN-/O?#%QK%F4>*-;.8Z?"R/-$ LJHZ[E1F4X
MXRH!]G5S?C[QU:?#W0XM1NK2[U&2XO+?3[6QL!&9[BXGE6*-%\QT0?,V2690
M "<U\F>(/AS?V_@OPK+?:3KOB+5K7P[<QZ?::]X0N;J%B;IY;:&(VMRT^E7*
MIY4?FR2<1F/=AXF5/;_VAO!C?$+PCX%2_P#"T>JW,?B?1YKNR:V%Z+:$W,?V
MD,=I'EA-P=L!2N<\4 >Q6DSW%K#+)!):R2(K-!,5+QDC)5BI*Y'0X)''!-35
M\IZ#X)U6U^(FELWAW4H_B!!XSN+O4/$BV,J6\NB$2>7']LV^6\7DF"-;<.65
MD^ZNTD>C?LO_  ZL_#GP(T6RU+PU%IVI:A9E-7M[RR$<]S\SJ%N%9=S_ "':
M ^<+@#CB@#K/#'QF\-^,_$&C:5HLMQ?+JVCS:W:7HA,<+6\4\<+ A\.&WRC
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MH4YCPOI/@?PUJLO['L.@:Q:>(H+]='N+)[6R3;J<<:NZ(L:3,N2(PN%8_,H
M&<@4 >R>(O%FE>$UTTZK=?91J-]%IUK^[=_,N)21&GR@XS@\G '<BM>OBS_A
M7IO-*MTE\!6]YX?TKQ;HU\;K3_!U[I@NHRA2[9=*F#LFT+#O>) DF[D9C-78
M] \2W?QVT;7;;PC+HNI1^++]+V\M_#UYYOV5X9XH99]2D=UGA<"(B.)1'$,
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MWK^E^(+:%_+EFTN\CN41\9VLR,0#@@X/K7'^)?BEX@\(^(M/75/",5OX7O\
M6H-$@U%=4#WIDF.R*8VJQ%!$9"%SYV\*=Q0<J.<^!_@?7M-\9ZIXBUS3/$&F
MRRZ1:Z8HUR]THEA&SL$2'3H5CV1[B%D=]Q#$;% HGC\5>)/BT+_Q1X!URZT+
M1;_9X?BM+K36LD/*'4IPUVLKR89MB>7^Z4D@-(WR@'J?B;QOX=\%0QS>(=?T
MO089 2DFIWD=LK %02"[#."Z#ZL/45!K'Q&\)^'].TW4-4\3Z-IMAJ04V-U>
M:A%%%=!@&4Q,S /D$$;2>"*\L^.5U/8?&WX.W=MX?E\2SV[:O(EA;O"DY_<1
M#?&9F2/<N<_,Z\ X.< \7H'P;\8^!+&*YD\+#Q,-2\,ZIH[Z-:75LJZ9)=7T
METL3&5XU:'9*L;F,L<P+M5EQ@ ]QT?XJ6.H_$SQ'X-N5M]/NM,-HEK)+=KOO
MWF@DF98XR <HD;$@%N 3P!5[5_BMX)\/JS:IXPT#35626(F\U."(!XG"2K\S
M#E'958=BP!P37SGJ7PJ\2_"WP9XM\07L<-W>^%].\.:CIM\TX*7]QIEJ4N5
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MN>'_ (C>$/$=[X4D\S7O'LVK6GA3S[9IX1'I;1EV;S# )W:$S8$F,E,N#G:
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M?: @(![QH'[0GA;Q'X]U/0[+5M'N-(M+&SN8M>@U6*2WGFN)Y85MUQ\N_=&
M,,22X&/6QX^^.&B^!=>T33WFLKR*ZOI[/4IUOT3^R_*LY+LM*,''R1@X8K@,
M&SCKXMXU^&/CGQQXQ\0>*[7P'+H8:'P_/;Z;<7UEY]W)97S2S1YCE9%;R\!2
MS;2 F2IRJW+'X3^-M>^+8\37GAJ;1M.NO%K:HRW%Y;2206IT8VH=Q'*P+>;A
M2JD\]"5^:@#V#PE^T%X!\6^%_#FMKXFTO2H_$"!K&SU2_MX;EWW!3%L\PY=6
M(4JI."<5W5UJUC8WEE9W%Y;V]W>LR6MO+*JR3LJEV"*3EB%!8XZ $U\DV7PA
M\=Z;\._#UA;>#=6L_$MKX570)IH;[2;NPNWBD9HX[^VN2RFW#DNLD!,NV60,
MJD*#[E\;O#?BG6O .F7_ (<MH;_QKH5];ZI9VT;K%'-,H:*9%:1@%!BEF W'
MT!ZT :_C;XL:3X;\%SZYI=]HVLS,DK6-M)K5O:17C1/ME59W.P;#G<><$8.*
MX[4OVK/"%O?F"TN;6:&T\4KX9U2YN;^&&.SS:RW'VK(+9B_<N@+;,LDG/R'/
MEFM?LS^*[7PKXYT"QL4O]/L='2P\+*+B,&XDN3;27S'>XV,)+8?,V-WF-COG
MK+GX3^*)/'DA;0FGTV/XFP>*UOVGM_)>S;2S"653)YF^.95!!0'YE*[ADJ ?
M06AZ]IOB;2[?4]'U&UU73;@%H;RQG6:&0 D$JZD@\@C@]0:SM!^('A?Q5J=[
MINB^)-(UC4;$D75I87\4\MOAMI\Q$8E<-QR!SQ7)?!WPAK7@W0_&=O<V<5C<
M7GB75=0T^.1U:-H9IB\+G83M!SDKPPR<@&O =-^!/Q.\31)::C:7FAR3^"-1
M\-R37$NFP6=G<RF!EC@AL0"MHQ1@"P:3@[E "[@#ZCT?XH>#/$5JMSI7B[0M
M3MVNDLEFL]2AE0W#_<A!5B-[=EZGL*R?$'QP\'>'?&7AWPQ<:S:2:IK=_+ID
M2PW4)%O<1Q[S',"X968E$"@$EY8QCYA7FGBSP[XI\76'A[4[+X5_V#>:!J6C
M7DL$E]8_;KZ.WE?S+>$I(T?EQ+(60RS)DEAM7J<_PO\ #?QG;^/-'\57GABX
MMHO^$]U#5I;#[9:O/!8W>F"V2=R)=AV/]]$9FX.P2#!(![YI/CGPWKVN7^C:
M9X@TO4=8T\D7FGVE['+<6V#M/F1JQ9,'CD#FN3U3XZ:!X=^*6H>#]?O=-T".
MWTZTO8-1U+48X!<R3R3((51\?,/)SPQ)W=!CGRCX%_!;Q;X/\0>![3Q#!KLL
M?A*/4$74)[[3%TUS-E,VZ0PFZE\W<)&%PR;67)+D 'H?BC\)]>\4>*?BY?6N
MCQWD6M^ AHNERO+$#+>#[4?*&Y@4^9X3N;"YP<_+P >E>*+OP/)XZ\.6NO:U
M80^)H&,^E:3=:MY3RLX9!(MJ9 LK##A7*,5.[:0<UI6OQ&\)WWB+^P+;Q/HU
MQKV9!_9<6H1-=9C+"0>4&W?*4<'C@JV>AKYLUCX$^-9M9\164]OKU_IGB0Z/
M,S:7J&F6]M"UO'"C)=2SQ2W*&)X3(AMPX.X8VDL:=X#\+ZOXPU;6M-T_PV;>
MWL_BM=Z[<>)/-MQ"([>Y8M&5W><9F \H80ILDSYG50 ?0>H?%[P5I[:]$?%6
MC3WNAVTMUJ-C!J,#7%M''@.9(]^4PQ5?FP 6 .,UA^ _CMHWCY'U.T>PM?"W
M]@6^N_VI<:M;>9"KF42QSP*Q,/E>40SLVW<'7.4:O&_"_P */B3J7C#PS+KF
ME75E:Z?;ZW9SL9-,@TZU-VC[&M(;4"5HF*Q[C-NDW$':,NU9NE_ OQ[>>'[%
MKCPX]G-IOA;PS9OI=Y>6Y&H3Z9=O)/:YCE90)%12C,0IWIN*G=M /JWP_P"+
M-$\6:3_:NB:SI^LZ9EE^VZ?=)/#E?O#>A*\=^>*I^'/B)X4\87DUIH'B;1]<
MNH8EGD@TV_BN'2-@"KLJ,2%((P3P<BLGP[->7VE>*+^[\&KX.:[=I DTUO)=
MWA$"J9K@0%T#?+L7]Y(2J*3M^Z/F#X:?"OQ+\6O@C\/K+2]''A"WT_PAJ-FF
MMRSP&.^DO80B"-8F:0(6S)(75"&' ?[U 'UAIOQ/\':QI-YJMAXLT.^TRRD6
M*ZO;;4H9(8'8@*KN&*J22  3SD55A^,G@"XDLHXO'/AN5[YUCM535[<FX9CA
M5C&_YB3P ,Y->!^,/A'XQ\?:+X@NH?!1\.R2>'-*T)-(N+NU9[R2"]2:1P8Y
M6C\J.,%4WL&(+#:. 5\>:!JGB[XK?''PWI/A-==N=?T#2])&IO-;QQZ898IU
M$LOF,',:D^9^Z#MF%<+G! ![)X1^.7A_Q#XL\1>&[^^TW1=:TW6I-(M+"XU&
M/[1J 2"&7S8XCM;_ ):E=H#?<)SS@=8?''AQ;"SOCX@TL65Y%)/;7/VV/RYX
MXT+R.C;L,JJ"Q(X !)XKP"X^"?BJ+0_$D::;]KU2X^(FF:W!>--"LL]E +(-
M<%M_RD>5.=I.[[V!\PS3TOX;ZWJ7B;XL^'H((KG2_#NF:E8>&X8W"YFU:,74
MD9)P%,9*(-QP%E&,"@#VO2_B[HNN>+;G3],U+1-1T2UTV6^N=8M=;MY?(DCE
M"/$\*L6554[C(?E'0\FNA\+^-?#WCBSEO/#FO:9X@M(I/*DN-+O([F-'P#M+
M(Q ."#CW%?/_ (D^$OC>.Q@;1]"LY[BW^&\.@I#=_99HOMBSQ,T/ER$QL0BM
MM+@Q[@N3BNP^ _A#Q7H?CKX@ZWXDM-6B@UH:>]I<:Y<6,EW+Y4<L;B5+/$2,
MN$X08*E#N+;\ '8O\5K&#_A-[^>'R?#OA-"EWJ9EYDG2+SIXTCQ@JB-$-^[E
MV=<#9D\E9?')-+^"=[XP?PF-)U*QU,66H^'/M 0VUU+>I')ND$8R6\\39V9;
M?S@DFN2C\'ZUXPT?Q)X!MC<6<<WCN[N=<U")H%DMK%W-]"R+(&W^86@C'R.N
M!(&X4BJ?Q.^!WC21?&VDZ?+?>.=)\66^F7=U<:L]C$Z7EK>P*ZE(TA0J]JJ\
M["?]'P3RHH ]<^)GQ:_X5UKFDZ=_97]H?;],U34?,^T>5L^QPI)LQL.=^_&<
MC;C.#6#H/QI\2S+X'N]>\):7IFE>,-D6G7.GZY+>/%<26KW,4<\;6D>U66-P
M70OM(&1@YKF_B/\ L]V=IXLTB^\!>"='TF :%KEE>R:3;6UD7EGMXTMD<#:6
MRP< \A<G.,UU_P )?@=H_A'0_!NHZC:ZE-XGTG3(H0-2UN[OH[*9H%CF$,<D
MSQ1G[R9C &TD#Y3B@#L_A_XRC\=>&8M2^S&PNTEEM+VQ9][6MU#(T<T6<#(#
MJ<-@;E*M@!JF\5>//#/@6&WE\2^(M)\/17#%87U6^BMEE(P2%,C#)&1T]:\X
M^#OB&*SOM8?[/<36OBSQ3JESITT>S8L4*+&9&4L'V.T#E6"D?.N2-ZYROV@O
M!OCCQ1X@,7AS3[F;2[WP]>:8]QI?]G13>?*ZXBNIKI3*MJ5&3]F^?()ZA30!
MZEJWQ0\&^']4ATW5/%NA:;J,Q18[.[U*&*9R^-@5&8$[LC&!SD5S_P 6/CEX
M?^%]A*C7VFZAXA2:SC70#J,<-V\<]S%!Y@3YGVJ)"_W<';C(ZCQ.Z^!OC.[^
M&_Q)LSX?QK6L>#M"TNP1[JW\Q[FWMW6>+?YF%VN5Y)"D@$$XS6G\0/A;XRN(
M/'&@V?A#^WO[>\66/B*U\0B\M42"&.6U+Q,LCB021I Z+M4J4?[P.5(![OXG
M\;+X8\2Z%87$=E'I]_%>375_=ZE%;FU2",/N$3G=*I!.XKP@&6X-6O#7Q \+
M^-+B\M_#_B32-=GLR!<Q:;?17#0$D@;PC$KDJW7T/I7FO[0/P\\0>-]:T*?1
M=/\ ML5KHVO6DK>=''MEN;,1P+\[#.Y^,C@=3@4[X<_#G6_#?Q"\*:A/IJVF
MF6'@*WT.9DECVQW231MY6U6R0%#88#;Z&@!WBG]J3PKX?\1:CHMO+!=WFE:Y
MI^CZDTU]%%' MSC=.""Q*Q9*N&"892,C&:[J[^('@>_\)+X@N?$GA^X\,+.A
M&J37\#60F20%/WI;9N615(YR& QR*\9\<?";Q/K7Q0URXBT!K[1]0\5^'=9%
MVT]OY/V>U1([@,C2;]R[2V-G(Z9/%9?B#X+^-H_$5_KUA:7\<=KX]N]<@M=)
MGL/M<UK-I\,"W$(N@UN'602?+*%;!<@@E20#Z*U'Q99P^#+SQ)ITT&KV$5C)
M?P26LZM%<(L9<%9%R"& X89Z]ZY+X<^./'/CC2?#VMW7A3P_INA:M:0WWF0^
M(IY[J**6,.O[HV**S?, 1Y@'7D]\KX??#[5= ^!>N:')8WMMJ>HKJ=Q'8ZA?
M6\\J27+2.%+01Q01[F<L4C&Q"Q 9AS7._ [P-8>"=/\ "%O-\"Y-!\26-A!:
M7?B6.VT4%9A"(YI3+%=&9@QW9(4L0W(Y- %S3?BAI6G_  EG^-EMX8\K5_$$
M6GP7EG_:#G<@NC;Q#>5VC9]H=N$&[.#V(Z[XS?&*T^$MGH"-_9<NJ:YJ*:?9
MV^JZH+"'D$O*\FQR$7"@D(>70?Q"O+[3X;^,G^%.D_"*3PO+;V5IJ4"S>)VO
M+=K%K&&\%R'1!+]H\UE18]AB #,<OM&ZO4/C!X3U7Q3>_#V32[7[4FE>*;;4
MKP^8B>5;I#.K/\Q&[!=1@9//3K0!TMCX_P##6H:IJ&E0^(M'GU?38S+?V$%_
M$\UHJXW-(@.Y "1RP'456_X6AX4E\+ZQXAL_$.EZGI&DH[7EU8WL4J0E$WE6
M8-M5L$<$CJ/6O!O#WP=\8PV/@W0;C0#;/X1CUTS:XUU 8M5-W%.D:PA9#(#(
MTR2R>:B -'U;@UZ_\.?!-_H_[/\ X;\)WEO'IVK0>&K?3KF'<K+%<?9E20$H
M2#A]V2"<\GF@#G/#O[5'@O7M<TR&74]-T;1-4\/V>N6FIZIJ<,.^2>:>(VA4
MG;YL9@8, [$,&7'RY/I6J>.?#>B:]8Z'J/B#2[#6KX VFFW5[''<W&20/+C9
M@SY((X!Y!KYOT#X,>+[KPC?P7_A9K2];X1VWA&*&ZN+5V;4(C<JT0*2LH5LP
MN&)"X9<X8,%IZU\!_&UQJ&OV4UKKUWIWB:TT-'72=0TNWM[=[:"**1;J6XBE
MN$\MXC,K6P<'>< -DD ^AOB!\6?#GPROO#%IKMXEM-XAU$:;: RQIARC,9'W
MNO[L$*I89PTD8Q\U3M\6O ZV>IW9\9^'Q:Z88UOYSJD&RT,A(C$K;\(7((7=
MC..*P?C1X9U?7[CX?WND:=+JAT3Q1;ZG=6\,D2/Y M[B)F'F.BG!F4D9S@'
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M%_B;QD?$T?A^7P_!?^,M.U1M.FN;<W%K;P6$T$EU)Y4K1EV=U^6-V;"J3SD
M ]YTWQ]X8UG5-3TW3_$>DWVHZ7N^WV=M?1236FTD-YJ!B4P00=P&"*@TOXF^
M#]<T._UK3O%>AZAHUAG[7J%KJ,,EO;X&3YDBL53@@\D<5\V^ /@'XKT_2]&T
M/Q%H>KZY%X?T;5M-\O4-7TZTTJ\%PGE-' UM;M=LLXP[-.49" 3O85<A^%?Q
M!OM-E=M'U"[T_3KC0[U-/\3OI?\ :NHM93LTEN;BS(BDC$>PQFX.[S,YV@EJ
M /H.;XI>"[?PS#XCE\7:#'X>FE\F+5GU.$6DDF2-BR[MA;*MP#GY3Z4FN?%3
MP5X7CMGUGQAH.DI=1)/ U]J<$(EC?.QT+,-RMM;!'!VG'2O&?&W@OQEXE\5>
M%O&6E>$=3\(?V;?:E]HL-#N=)?5Y_M$$*+>.)P]IO_<M&1YC/L<$-]Y!F^$O
M@/XAT&WN8QH<L<<GP\O-%A6[U"WN98[N>[FG^RF1$B7@.@RJ",;0H9@H) /8
MK3X[>"KCQ=XJ\/2:Y965SX:MX+J_N+N[@C@$<F?F#;\X0[0Y8 *9$'.X5U^@
M^(=*\5:3!JFB:G9ZQIEQN\F]L)TGADVL5;:Z$J<,I!P>"".U?,]K\&_%-K9Z
MM;:AX6U#4%O-$\,M'<Z9JUM;7-K>6 *R^2[L0;B-BLB;P(7V$-(,\^P? W1_
M$VD:'KA\2VSVLMUJTUS:+>064=])"RI^\NS9?N&E+A^4ZJ$W'.0 #JM'\?>&
M/$6N7^BZ5XCTG4]8L"RWFGV=]%+<6Q5MC"2-6+)AOE.0,'BN>C\1_#GXA:M9
MZO;>*-'UV?0!-=I]CUM98+;:H$DTD22>62@<?.ZDIOX*[N?G2W^$7Q&OX;:;
MQ'#)X;@M?"FO:3>:A=7&F6NF:;)<1*4DMX[0*RVP*%B\F9.Y"XR:'B#PCKGQ
M9UK5/#VF^&H?#>KI\.K*V2&2]M)1=".^AE50\+2QB&18I(XS)U&XL@7J ?6U
MC\2/"6I^&[GQ%9^*-%N_#]JQ6?58-0A>UB(QD/*&VJ1N7J>X]:QOAG\6K#XH
M:MXNM]+6VGT_0[Z*S@U*SO%N(KU7MXYO,4J, ?O-O!;.W.><5XS/\(_&&J?V
MQXF;2M?OM2_M[1M2?3?$VHZ6+G58K+>641V<:V\1_>C:7D8N8%W>6%!/H_P-
M\+ZYH_B;XE:SK'AYO#</B#6H]0L[22>"5S']EB1F?R790Y=6W#)YS@L/F(!;
M\*_':S\:^.O$_A_2-"U2XBT73(=0CNI8_LS:BSM*NR".;9E<Q%1([*K'./E
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M1SR*QOC-\<-&^%>A:XAN#)XDM='GU.VM!8W%S$N%<1-<-$I6*-I%VAG9 <,
M>#CF?AG\%?$WAG5O <&LW&D_V+X%L;NPTVXL99'N=1$JK&DDT;1JL!6-.55Y
M-S'.X <R_$[X2^+M4UKQW<^%)-%EM_&V@1Z/?_VS<31/921K.B2Q".-_,5DN
M&!1BF&4,&.2M '2:?\>/"\,&D6NL:E]FU:XL[&>\^SV=P]I9R70'E+-.J-'
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M[) R 003!JGQ^\'V?A'3M?M+Z?4H-6TVZU32X;>RN&DO(H$5I"%$99,;E^\
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MW2HH?[3UN]E$-Y<W4BI?6,<"#S)DWRNL@?<[MEP _5BJ@'IG@_\ :$\*^)O
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M%%% !1110 4444 %%%% '$?&SQKJ'PY^%'B?Q+I45M/J6FV;3P1WBLT+."
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M@/KUV/#.F>,WT=]"\+^&KKPS9G29I&EU*.=(86FF5XE$'[F!?W:-)\SD[L*
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M_3[J/6#_ ,)9K6J6^K:C,U]<:8VH6<6R*.'[3"&FA#V\,394$@LPQ@FE\*_
M#Q]X+U+1=7L#X<N[W3_$FI:TUG=ZG=NLD-W9I#Y9N'A>1I%;?F5@Q; <\L4
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M-]HB0@+, R*0&YXP1QD,RD,7^'?">A^#[6>UT'1M/T2VGF:YFATZU2W225@
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MD&K27<>JVLUW9);:?<SR&.([9))(TC+Q(C$*[2!0IX)!JOX%^,MK=? 7P_\
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M7\+Z0T_A\Z!X=UK5M2@O!=3_ &JYCO%NRJO%Y.V-D:Y .'8,.>",, >DZ?\
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MQDF@#5\$_M,Z/<:#$_BR9K76[B\U5+>RT?2KR[:2VM+QX#)LB25LA0A;ZDX
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MB?$/XG>+M<\7Z/I&MZ-JVC6FFV8FCWW=H\9G\UT8I^Z)$B89&SE><8%<S?\
MP!\87%IX&N)[G3]1U+PG%>:/'%9ZW>Z&E]IS[!!*9K2,/!,HAB#0JKQGYL,.
M, 'INK_'OP)HNGZ9?SZ[Y]EJ-D=2AGL+2>[1;0%0;B4PHWDQ L 7DVJ"",_*
M<%S\>? UI<6<4FM.5NK>UN_/CL;AX+:*Y.+=[F58REL)/X?.9,U\\^/M)C^
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M9Z1KUSIUS=ZI>:;IUWJ,-NNG7<<=^EN=LAMYC#LF0.5!DB+J V[[HS7.Z/\
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MTWX%>)9_B!H_C/4[C2;?4G\3RZ[J5A9SR20P0C3FLH8H9#$IE? 1V9EC&68
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MZXK0^)WQJC^'WC#0_#2:7<W=WJ^GW]Y'=B"=X8&MXPR*VR,JP8D[OG78 "V
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M0:E^S'9ZWI6DZ=J&NRO:V/@L^$6,%L(Y&;?;.MTI+D*5:V!"$,/F^]QR 7/
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MIZ7HTNEZ%KFJZQJ<][ N@6L=N+V#[([)<M)OF6(*CA5^61BQD7:&R<8GAO\
M9D_X1[QAI6N_\))]H^PZO%JOV?[!MW[-+%AY>[S#C./,W8/]W'\5<YXC^&]U
M\';S0]5TG4-8FU@7^MSC4]/\+S:O;QPWLHG:VEMH)A*'WB/RYA\F8F#@;E%
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M0=Q#*: (=+_:%M4\8>,;MKZ;7?#1M]!_X1ZRT^W3SKF:^28A(]VPDN50_O&
M4*<E0#6W+^TEHRG3;2+P[XAN?$%YJMQHC:!#!;F[M[N*(S,DA,PB"F/#B19&
M3:P)8 '&9+^S+#%<7EU8:^MG>K_8LVF2+ID2QVEQIR2*KO%$41TD$K!HT$0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
B**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>alny-20210331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:alny="http://www.alnylam.com/20210331"
  xmlns:country="http://xbrl.sec.gov/country/2020-01-31"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2020-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="alny-20210331.xsd" xlink:type="simple"/>
    <context id="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i34488122c9fd4fb68a5067e173effcb0_I20210423">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
        </entity>
        <period>
            <instant>2021-04-23</instant>
        </period>
    </context>
    <context id="idd7204dc87d24972a01f15b098c4f56b_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="id365c5f1d37444ac9e1da5b5891cd81a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia489a15348ae4ae390bc47557aaca423_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="iae589afb590a4f5984a5dd4001d656cb_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i6912a2c4b43f46838e7d9157c5b3a723_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i738b536de6724c23b1637b0913d14f26_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ide9f6e15665746279d0000be700fcc6a_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i781a6cf71b15431fb0056bd6a2d9ba9f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7c2ae885ee354f1c9e0aa3c387519965_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie217873afb06447795dc36a1e1606a74_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4ed3654498ae467fa00b86595fc2fd74_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie41b061be2004e5993962162ca83d40e_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i5919ecb151d7401699f63ec0b4537716_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i41a01c886cd440cd8cf8eb694fb78c84_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i8c5ae4ff57e341c7951e97ef4434647e_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i898030c659864177808288abf9a59aac_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ic292a95f9d27470da961a5af69a8168d_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ic1a5c9f95c104828afb8e8cfafe56963_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i228f04c4c7b54cc6b36a2842a9727865_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i529e7b1cdc924faf8a02fa556a4493bc_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i2e5f4eb4a821432ba3f5cd2a2ffe2754_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if6294416a69f4b6daebcdebf72f5c179_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i7d5f25d01b88417aa57a44792c225b17_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iebcb948108ce4342974f490750a7c986_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id329f7a0b2394ad5a1935867e133e7f0_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ib01acb7d931b4460a0e434d20db18c85_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i074c45cb3f5642eea30ad48202c86fc9_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i35858c4e152c41c983e25b7741dcfb36_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i1e51c390ee2b4b95b9d11592d9610350_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i4219d6246f0f4615b7f66a38c10fc9fe_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i0cd32b4827314c02b0aeae69087c66b0_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i1a2a3f2a9d1744519ed77d4a1400c065_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ic378e7f6183c40b4b7371ed7b7370867_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i4a2ac71261a84e87a3d5590a679c5507_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:ONPATTROMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i3093ec8b753b455ebe0533565a97caff_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:ONPATTROMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ie071fd2fff7141d790e9ce1f75e3ad69_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:ONPATTROMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="icf591ef643074bb59a23948ceb15ebb6_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:ONPATTROMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i0e00566ee692462ca9f65f7d6faa57e9_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:ONPATTROMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">alny:NonUSOrEuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i407b32b70e73469c9bb2867c7e8c53ab_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:ONPATTROMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">alny:NonUSOrEuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i938688f7d99a4e7b97c127dc1da4aa45_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:ONPATTROMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ic38400d6eea7497f8bb34244730955f4_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:ONPATTROMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i86f381c6519b4114a9f993ca05678e84_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:GIVLAARIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ifa94975325ea4c21bc761e8c37cace85_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:GIVLAARIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i6223cc9a7bb7452ebf43606a6436d328_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:GIVLAARIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i129948d8d7484c52bc400ee978922740_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:GIVLAARIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ied24bfeab08a4433b3f48a2b7f17c882_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:GIVLAARIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">alny:NonUSOrEuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i46dfc7f31a1c42149b4c59b183486728_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:GIVLAARIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">alny:NonUSOrEuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i5cd7ede64f374cf0a1a1c96376d99ca8_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:GIVLAARIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i9a8146b23bc64bb0989fb48fd0ed09c9_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:GIVLAARIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i6c6836ed9e254b72b169ede860583569_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:OXLUMOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ifbd043497e914bc1bee58c0daa2546c6_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:OXLUMOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="if62b86057a964bb0a0b767d745aa53b7_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:OXLUMOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ic52bf960eb1f4c9ba53b059468d7993e_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:OXLUMOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ic33a14cb7a1b47898a6aa7a5a5d657a4_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:OXLUMOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i416a8546a935440ba7736b9614aa8073_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:OXLUMOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="id1a37ec48832445999d722992c9485a5_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i27b6b4c7a00f4e4eb8bf4fb46f229034_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i95f1c1ed3c154524aceec386b964d3e5_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ic41d4a1b34194fdb92365734e524ff34_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ifafd9b348c4c4d3bb08ec5381577d767_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:NovartisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ia500fa9e2b224d0ea1d970ddb3c83d05_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:NovartisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i7b35d0a44ca0429b8b8202051f1b3678_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:VirBiotechnologyIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="iab7c02eb57194c1192e785ccd3886998_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:VirBiotechnologyIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i33cced07680d487d8f3ae8596484a8ca_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:OtherCollaborationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i1b9f37fb1a5c435aadb1d93990451d0a_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:OtherCollaborationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="id3753a1357334f66bd9801d06cb5303b_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:ClinicalTrialAndManufacturingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i2e5101b0b8bd410196b91d29fd823e81_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:ExternalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i503bb08b80284da78e7d56a82595e959_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:OtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i6f98765bfdbc4e44a1223eaa20633d22_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:ClinicalTrialAndManufacturingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i99846caa80964377a5573940a812180e_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:ExternalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ic2a36524f2b9464c9ddd8548541ad993_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:OtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i9b580b28bb314ef6839a51260f628026_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:VirBiotechnologyIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:ClinicalTrialAndManufacturingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i09f8081c6a5246a0a017275e36ee340d_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:VirBiotechnologyIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:ExternalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ie9502a31100149eaa773ddbb07c78892_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:VirBiotechnologyIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:OtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i7c2e51b9aa354777af021d48ff53f086_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:VirBiotechnologyIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:ClinicalTrialAndManufacturingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i7d4070f9748d4216be619760cb306306_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:VirBiotechnologyIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:ExternalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i17406128628f47da8dc12cab978ee990_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:VirBiotechnologyIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:OtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="iba8c6028e53a4d3cb52c96d04a38aa3e_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:NovartisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:ClinicalTrialAndManufacturingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i403e5c57487b45d7953d44822a0f4e08_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:NovartisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:ExternalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i040c336d87a74305b70be62dbab90158_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:NovartisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:OtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ib9fefc66152040119b7d0c2744ada9b9_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:NovartisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:ClinicalTrialAndManufacturingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i5a5cdc0ffb3e42fbb82f9bf7e926e815_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:NovartisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:ExternalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i3e2701f10753482bb31aaa795ebf9601_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:NovartisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:OtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i7032666edaaa4e429bcb5742671daf6b_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:SanofiGenzymeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:ClinicalTrialAndManufacturingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ib9d9e02e83704b5dace40b5fa634af46_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:SanofiGenzymeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:ExternalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="if7a5922b1df34274baf2cab389d93825_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:SanofiGenzymeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:OtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i089d57f59b26493db395f392a738a27c_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:SanofiGenzymeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:ClinicalTrialAndManufacturingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ifcf043d12a364c6d8f621f3ce9eb05b3_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:SanofiGenzymeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:ExternalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i0a0b334cef804098995f34a0b7102f9f_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:SanofiGenzymeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:OtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ic693d204e9e347ae897f48a7db4e8373_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:ClinicalTrialAndManufacturingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i11ab95266c9c458da1f4e2524c453219_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:ExternalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i87f5d930fa0e4dd885c325ce478459fc_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:OtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i864e263b7e9f4629b9b97b9cfc3bed2f_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:ClinicalTrialAndManufacturingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i6496ce2c62514d00a0ced101ce91a17f_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:ExternalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="iab9f59c06f804edca916d76b33ea3ca1_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:OtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ia5305aa8b123480a9f5873905426845c_D20190408-20190408">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalStrategicCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-08</startDate>
            <endDate>2019-04-08</endDate>
        </period>
    </context>
    <context id="i73f0e7523666480d9c1deb15ed7a387e_D20190408-20190408">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalStrategicCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-08</startDate>
            <endDate>2019-04-08</endDate>
        </period>
    </context>
    <context id="if2bf4b0c1f3049e3958e56012db213d3_I20190408">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">alny:FundingAtProgramInitiationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalStrategicCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-08</instant>
        </period>
    </context>
    <context id="i5e0a1eb0aca04059bb786c05e4dd32bc_I20190408">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">alny:FundingAtLeadCandidateIdentificationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalStrategicCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-08</instant>
        </period>
    </context>
    <context id="i0fe175fb793a4f5e9a26e0bd683c3620_I20190408">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">alny:FundingAnAnnualDiscoveryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalStrategicCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-08</instant>
        </period>
    </context>
    <context id="i971ffad5c679466dbaa1a956091dff5b_I20190408">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalStrategicCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-08</instant>
        </period>
    </context>
    <context id="ice333d52f3d1470e9ef529637248a8dc_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:ResearchServicesObligationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalStrategicCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i36f4850caa714d72a30d3755dee41330_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:ResearchServicesObligationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalStrategicCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ie1b05d9fbec1490d8547da979164246c_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:C5LicenseObligationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalStrategicCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i9afb38e70eac4aa0940613e1656a62b6_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:C5LicenseObligationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalStrategicCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i5ed9a55f1a8143bd9068e4f6bbafe8a1_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:C5CoCoObligationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalStrategicCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i034331457ce94629bdc278cc2f5e440c_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:C5CoCoObligationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalStrategicCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="id46811031a3d408bac58580e626f8e3b_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalStrategicCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ibb1a94652b264aa4980ac89d4f3e71e0_D20210331-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalStrategicCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-31</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="if0be8a0acd8c4f4a936e1a39b3321d4e_D20210331-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:ResearchServicesObligationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalStrategicCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-31</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i15dc0fb5b4cf413aa1bddc7de9dc8427_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:ResearchServicesObligationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalStrategicCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i658edd34d7bb479582be347d92985839_D20210331-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:C5LicenseObligationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalStrategicCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-31</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i861836d62a924d62ab2e4e1d6bb80274_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:C5LicenseObligationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalStrategicCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i80b049fd41474712a64d29d35fabd92b_D20210331-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:C5CoCoObligationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalStrategicCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-31</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ifccb7d9fff7c476987c83ac85c1953b1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:C5CoCoObligationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalStrategicCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8ee04dc4bddd49289fea1361ef9a5f63_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalStrategicCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i845dea082db84f4bad647918893f1a91_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalStrategicCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5fd8d80f765d41dcb65fffa60ec775cf_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:ResearchServicesObligationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalStrategicCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="id8599564d7e94d6db58cf776fcdfcc51_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:C5LicenseObligationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalStrategicCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i7f816a549c3b442c81980771e664236b_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:C5CoCoObligationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalStrategicCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="if12146e5cbeb4f978bb78a0f76137cb2_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:GlobalStrategicCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i5c760c86aa8249a6be17c482badca19e_D20130201-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:ProductAlliancesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="alny:ResearchCollaboratorAxis">alny:NovartisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2013-02-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i7d36bc345e7f4e4197c9a712cb73b817_D20130201-20130228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:ProductAlliancesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="alny:ResearchCollaboratorAxis">alny:NovartisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2013-02-01</startDate>
            <endDate>2013-02-28</endDate>
        </period>
    </context>
    <context id="id397f59fc9a04a808d2a7f2a7cabc579_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:ProductAlliancesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="alny:ResearchCollaboratorAxis">alny:NovartisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ifd789fbb2ade454a843734d22e2a2dee_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alny:ProductAlliancesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="alny:ResearchCollaboratorAxis">alny:NovartisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i3cbd53aa2a944f6a951e88ca5b785aad_D20171001-20171031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:VirBiotechnologyIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-10-01</startDate>
            <endDate>2017-10-31</endDate>
        </period>
    </context>
    <context id="i0390c083c3b0456c88744cf92cb6d82a_I20171031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:VirBiotechnologyIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-31</instant>
        </period>
    </context>
    <context id="i2775cf552c5d4a16bd403c04d07b23ba_D20200301-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:VirBiotechnologyIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i1ddcbd1cbf9d4242a0d2e7d1fd99d35f_D20200601-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:VirBiotechnologyIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i79b6733ec63b46b0b79d00ec324efa30_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:VirBiotechnologyIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i1cb0ba7808ab43b78c92dd6668914339_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:VirBiotechnologyIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ic79f02f0d0d84870a4ef4d488e636d1b_D20210331-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:VirBiotechnologyIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-31</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i730e5e5b0bcd4d5c81f5a71c66d172a2_I20200410">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:BlackstoneGroupIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-10</instant>
        </period>
    </context>
    <context id="i2a9037b7365649f2bb1a3ef6bcbe2849_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:BlackstoneGroupIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i4b7aa8adee8f42469579af529e81b38d_I20300101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:BlackstoneGroupIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2030-01-01</instant>
        </period>
    </context>
    <context id="i49fe9edf0f9044908d252f6eb19b5518_D20200401-20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:BlackstoneGroupIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="id7b8291a96fc46dd8b540dbcc7a6d813_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:BlackstoneGroupIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i399f66dd6ce741d28d06204e9a1dddfb_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:BlackstoneGroupIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i16892019541d48c892ff9d24e698ebd5_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ifa5bdd3013ac476381fc4350a3ee7cf4_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ic77e6331f376437fb260dd9f97ea58e8_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ie8a0bfabe2b94e05a37ef21b7586c1b8_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i14ad949ff20f4e34a5bff828ba895714_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i294e21898c6c4ba19308833eeeec70d9_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i8637deaa1c634995a355fa860ea50c94_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ibdb3bef5ea924074b966e38860b348a9_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ief62e6e6b5794e1e9aac7a9b35576e8e_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i9b9bb880bac0407b815f6fd57e76cd83_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ie3ebff18dd48442faf99a73c773d55fa_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i6e887f34bbab43fa8752d3d60f8d1b10_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="if05c960039774dd9b4ad2920b9816c04_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i6d138b2bd73a4ef49fdec7e2d7119c17_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i00ed30d5d69b424e81f823616e722813_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="if93a1d02ab2c44359e2b2873b0965791_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i65a4965cd593490dbf6466695a4a77e4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i839a27ef72924781a3487df7e5d7b395_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5590fd684f1a4aa090bf9b83c5673927_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9f72f19e489246dea7d90e3176d37999_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie1d58cc31b1e414591ea2ec01318868f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i522c65977b4e4cfaa993b2b5ff3d2f94_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i641ddedd23b34601ba66a76b01282b1b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib25e85f29b8c40708ecc002c16e6e683_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9eaaf5231e504c2f914f6c3a0ddd13ee_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3f0a2ea993f04064aadad295133972b4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia79c16400354457793c02c74c6ff001d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7bf1dac612484a0685308b19a503a754_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie44adffa3b2e429993b1d4c047f9453c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i515aff7391d84e1bae1add95d453fe61_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6c2621b1e8d440ffa4c9d403e127ab4d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4526151777954123a086b101de9b112e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i233d78b0ba3f4206a3bfc816b3ab7454_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i58cbbc0a79de4859b6344bf8949aeb85_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ib30b025bf153422e892ecc638911a8fc_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iab2144e8f1994353ab908cc9c23d059a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3ed44ddacf3f45e2bc4858376f339d6b_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i4ef95a791e56443b9b1182d6253d4e4c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ida1aa88277834c4aa06d4523f3777c2d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alny:AccumulatedLossOnInvestmentInJointVentureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8ed22d63570b49f888c7e1fdb4cba720_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iba4e611a80aa4214b1a15ed34d5a650a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if39d09cfa6ef470198658625bf6c69f0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i088faa415d1b4a52be51abef4f75bc5c_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alny:AccumulatedLossOnInvestmentInJointVentureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i41887b4841f2496cb04e4f1ed9bd84bf_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i700594dde5154e6abd7676e0bf8a2e3e_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i4e5a33a85da249f89d6d9b5939bed9ea_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i6a94dbeff4054c1a9f6ebaadd2bdf963_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alny:AccumulatedLossOnInvestmentInJointVentureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i867716826176427d9f8a787730df0336_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i1502b1c4289f4259906b093e10b187bc_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i67bb7cc00cd44487b367ee4e7e37c13a_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i05cc6e61b17647308bdf6e55c772bfb8_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alny:AccumulatedLossOnInvestmentInJointVentureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i44ce780df6884d729dccbf45747996b9_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i3242f9b2e5e34d0cbb1a6439a9c3f8bc_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iae0f5f6b01c54e3dab00225a8834ae5d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i45667cf06d374f0f8d2c6a08350e2740_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alny:AccumulatedLossOnInvestmentInJointVentureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="iace4f6c1fa9543cd8b55cb7840648649_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i8748a9e750264dbeb3452686c17d0b3f_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i5a4a416c9f8b4fac9455e693cd9e2710_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i8fda1a7ccba9498489e7ddfe1a07281b_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alny:AccumulatedLossOnInvestmentInJointVentureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="id869bd21f8364305aa97626bdb27c7db_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i11580be1480f41978578dd943839ecb5_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i01494f6ccbfc49d191f7454445e0fc32_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i7c3cf9f64e5c4dba8a27cbdc2664e3da_I20200410">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-10</instant>
        </period>
    </context>
    <context id="ibc345957dc834afab5787e085c2b24f5_D20201231-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-31</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ifeeb0e1889fe4d049042d329b80919f6_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alny:TrancheTwoLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="iead1e9b005df4a1f9a86fc4b31611ed7_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alny:TrancheThreeLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="id5babbf83da24b918e081dc61eef1961_I20200410">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:ONPATTROAndGIVLAARIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alny:Tranche2LoanAndTranche3LoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-10</instant>
        </period>
    </context>
    <context id="i01120d900c46459e8dcddb8d56d9478b_D20200410-20200410">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLiborSwapRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-10</startDate>
            <endDate>2020-04-10</endDate>
        </period>
    </context>
    <context id="i16e5cf96bf70403d9deb63cea2e51969_I20200410">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLiborSwapRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-10</instant>
        </period>
    </context>
    <context id="i08cf9801b78c48129c565578666b38ea_D20200410-20200410">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-10</startDate>
            <endDate>2020-04-10</endDate>
        </period>
    </context>
    <context id="i753fbbe92da442cfb258516ac25f2d2b_I20200410">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-10</instant>
        </period>
    </context>
    <context id="icbb72ec509854a04bfdedc3536c9cc08_D20200410-20200410">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-10</startDate>
            <endDate>2020-04-10</endDate>
        </period>
    </context>
    <context id="i5f0630732fe54bfca1f008c864bcaa8c_D20201201-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLiborSwapRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i93e4ff2210fb41fdaf2e202c8b0d204a_D20201201-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib9d80c24381a4a579abefd71b39a3841_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i00dcec45b31345649463ce0a808354bb_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if56939063a9e4f659db2a74fe02c611f_D20200801-20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:BlackstoneLifeSciencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:VutrisiranAndALNAGTMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="i30025a2dd91d4350946281176f871659_D20200801-20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:BlackstoneLifeSciencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:HELIOSBPhase3ClinicalTrialMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="i4349daaa321340fbb35c0fb62328e9d0_D20200801-20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:BlackstoneLifeSciencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:ALNAGTPhase2ClinicalTrialMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="i9f3237ef00524733ac2cd4cdc77591ed_D20200801-20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:BlackstoneLifeSciencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:ALNAGTPhase3ClinicalTrialMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="i2e274ae018274dad8cbd61b7b4043868_D20200801-20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alny:BlackstoneLifeSciencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alny:VutrisiranMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="i5d397d1b29de44e99ebf93138e25c1bc_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">alny:BlackstoneLifeSciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i021eb4ce0e054ceabf5ba8f817404e90_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DerivativeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i097088dd315b40bbb18334f3ebd18b0e_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DerivativeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i892bbea5207d47319b4fa4f08ab306e0_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DerivativeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ib854d6b980064faa8bfd9bdf17daffcb_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i2660c94c8bfb4720bf4ba79623dc2385_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i29e2b4a3041244bc8330c8eb0e1998c2_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i6dc64ac1298247ef958115623a6ea350_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i625afeb909e24226bf8911556e57dd36_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i113a05651fb044f49ef9180c67dcd7e3_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ib6505072e0e14228bee195251af31d4a_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="if503e1a8de82421e9fe69c7f00e791be_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="product">
        <measure>alny:product</measure>
    </unit>
    <unit id="program">
        <measure>alny:program</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="candidate">
        <measure>alny:candidate</measure>
    </unit>
    <unit id="tranche">
        <measure>alny:tranche</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80L2ZyYWc6MGRmMmRjMjc5OWUxNDBiOTlkYTI5YWM1MDE5YWM4NmEvdGFibGU6YmNkMWU1NWQxYWQ3NDQ4MDk2OTk1Njc0YzVjMmM1Y2QvdGFibGVyYW5nZTpiY2QxZTU1ZDFhZDc0NDgwOTY5OTU2NzRjNWMyYzVjZF8yLTEtMS0xLTA_08072fdd-0ca9-4a9f-8650-5e2ead148d2b">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80L2ZyYWc6MGRmMmRjMjc5OWUxNDBiOTlkYTI5YWM1MDE5YWM4NmEvdGFibGU6YmNkMWU1NWQxYWQ3NDQ4MDk2OTk1Njc0YzVjMmM1Y2QvdGFibGVyYW5nZTpiY2QxZTU1ZDFhZDc0NDgwOTY5OTU2NzRjNWMyYzVjZF8zLTEtMS0xLTA_133e5491-2047-422c-9ace-873b2c8ac1a9">2021</dei:DocumentFiscalYearFocus>
    <dei:CurrentFiscalYearEndDate
      contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80L2ZyYWc6MGRmMmRjMjc5OWUxNDBiOTlkYTI5YWM1MDE5YWM4NmEvdGFibGU6YmNkMWU1NWQxYWQ3NDQ4MDk2OTk1Njc0YzVjMmM1Y2QvdGFibGVyYW5nZTpiY2QxZTU1ZDFhZDc0NDgwOTY5OTU2NzRjNWMyYzVjZF8zLTEtMS0xLTgyMg_f067950e-d0d8-4229-9f05-525239840789">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80L2ZyYWc6MGRmMmRjMjc5OWUxNDBiOTlkYTI5YWM1MDE5YWM4NmEvdGFibGU6YmNkMWU1NWQxYWQ3NDQ4MDk2OTk1Njc0YzVjMmM1Y2QvdGFibGVyYW5nZTpiY2QxZTU1ZDFhZDc0NDgwOTY5OTU2NzRjNWMyYzVjZF80LTEtMS0xLTA_adefb36e-2a04-436e-8ea3-685b7cff1fc2">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80L2ZyYWc6MGRmMmRjMjc5OWUxNDBiOTlkYTI5YWM1MDE5YWM4NmEvdGFibGU6YmNkMWU1NWQxYWQ3NDQ4MDk2OTk1Njc0YzVjMmM1Y2QvdGFibGVyYW5nZTpiY2QxZTU1ZDFhZDc0NDgwOTY5OTU2NzRjNWMyYzVjZF81LTEtMS0xLTA_e9366142-384d-4d5f-a03b-e902fedcf1f5">0001178670</dei:EntityCentralIndexKey>
    <dei:DocumentType
      contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xL2ZyYWc6NTg4OGE0NTFjN2U0NDdhN2FjZjdhMzhiYWE0Yzk4YzcvdGV4dHJlZ2lvbjo1ODg4YTQ1MWM3ZTQ0N2E3YWNmN2EzOGJhYTRjOThjN18xMzE_f2096da3-891a-4c25-83f6-79c162e4849c">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xL2ZyYWc6NTg4OGE0NTFjN2U0NDdhN2FjZjdhMzhiYWE0Yzk4YzcvdGFibGU6MDNjZjhjYTk4MjMxNDFjOGEzOGI3YjI2NzA0OTZkNzMvdGFibGVyYW5nZTowM2NmOGNhOTgyMzE0MWM4YTM4YjdiMjY3MDQ5NmQ3M18wLTAtMS0xLTA_511c018e-1692-405d-ae73-19a8e6ccd232">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xL2ZyYWc6NTg4OGE0NTFjN2U0NDdhN2FjZjdhMzhiYWE0Yzk4YzcvdGV4dHJlZ2lvbjo1ODg4YTQ1MWM3ZTQ0N2E3YWNmN2EzOGJhYTRjOThjN18zODQ4MjkwNjk5NDAz_f61f4ded-8a5d-40f7-b310-dfbd0e0aeee8">2021-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xL2ZyYWc6NTg4OGE0NTFjN2U0NDdhN2FjZjdhMzhiYWE0Yzk4YzcvdGFibGU6ZDQ1OWNiNTVhYjJhNGNkNmI4MWE3MjU3NjZkZTRhYTIvdGFibGVyYW5nZTpkNDU5Y2I1NWFiMmE0Y2Q2YjgxYTcyNTc2NmRlNGFhMl8wLTAtMS0xLTA_65771209-bc36-466c-95ec-0654154fcb2f">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xL2ZyYWc6NTg4OGE0NTFjN2U0NDdhN2FjZjdhMzhiYWE0Yzk4YzcvdGV4dHJlZ2lvbjo1ODg4YTQ1MWM3ZTQ0N2E3YWNmN2EzOGJhYTRjOThjN18yMTY1_1c381fde-0795-4a67-8a76-f92d766c890b">001-36407</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xL2ZyYWc6NTg4OGE0NTFjN2U0NDdhN2FjZjdhMzhiYWE0Yzk4YzcvdGV4dHJlZ2lvbjo1ODg4YTQ1MWM3ZTQ0N2E3YWNmN2EzOGJhYTRjOThjN18yMTY2_364c065d-e284-493c-9dfd-69dd2b1edca6">ALNYLAM PHARMACEUTICALS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xL2ZyYWc6NTg4OGE0NTFjN2U0NDdhN2FjZjdhMzhiYWE0Yzk4YzcvdGFibGU6NzM5MGIwMzNhZGY0NGMxMmExZGJjMzI4N2I5OGZiZjUvdGFibGVyYW5nZTo3MzkwYjAzM2FkZjQ0YzEyYTFkYmMzMjg3Yjk4ZmJmNV8wLTAtMS0xLTAvdGV4dHJlZ2lvbjowOGFhYjBiZDBlZjI0YjE1YTU3ZDFjYTgwYWFkMjEzY181_64f84b67-a7dc-4c62-8b77-af28db0f2c02">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xL2ZyYWc6NTg4OGE0NTFjN2U0NDdhN2FjZjdhMzhiYWE0Yzk4YzcvdGFibGU6NzM5MGIwMzNhZGY0NGMxMmExZGJjMzI4N2I5OGZiZjUvdGFibGVyYW5nZTo3MzkwYjAzM2FkZjQ0YzEyYTFkYmMzMjg3Yjk4ZmJmNV8wLTEtMS0xLTAvdGV4dHJlZ2lvbjpjYjQ2YmFlZDhmMDM0M2I3ODc5OTU4NjUyNWE4OTIxN181_9b9a038f-a269-406e-a65a-b5d7b18c5270">77-0602661</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xL2ZyYWc6NTg4OGE0NTFjN2U0NDdhN2FjZjdhMzhiYWE0Yzk4YzcvdGFibGU6ZjMzMGY3ZmUwN2EwNDE3N2EyYjY4OTc4MDhlMzQyOWMvdGFibGVyYW5nZTpmMzMwZjdmZTA3YTA0MTc3YTJiNjg5NzgwOGUzNDI5Y18wLTAtMS0xLTAvdGV4dHJlZ2lvbjo0NjE2MmNkNGEzNjU0NTNlYTMzODhmNzlmNDE5NjlhMl81_02975d2f-14dd-48b8-8b05-709d03d6ab3c">675 West Kendall Street,</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xL2ZyYWc6NTg4OGE0NTFjN2U0NDdhN2FjZjdhMzhiYWE0Yzk4YzcvdGFibGU6ZjMzMGY3ZmUwN2EwNDE3N2EyYjY4OTc4MDhlMzQyOWMvdGFibGVyYW5nZTpmMzMwZjdmZTA3YTA0MTc3YTJiNjg5NzgwOGUzNDI5Y18wLTAtMS0xLTAvdGV4dHJlZ2lvbjo0NjE2MmNkNGEzNjU0NTNlYTMzODhmNzlmNDE5NjlhMl84_0e3b2568-282c-4c31-a0dd-342c5e4178c0">Henri A. Termeer Square</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xL2ZyYWc6NTg4OGE0NTFjN2U0NDdhN2FjZjdhMzhiYWE0Yzk4YzcvdGFibGU6ZjMzMGY3ZmUwN2EwNDE3N2EyYjY4OTc4MDhlMzQyOWMvdGFibGVyYW5nZTpmMzMwZjdmZTA3YTA0MTc3YTJiNjg5NzgwOGUzNDI5Y18wLTAtMS0xLTAvdGV4dHJlZ2lvbjo0NjE2MmNkNGEzNjU0NTNlYTMzODhmNzlmNDE5NjlhMl8xMQ_cbcf1c44-622d-43c3-aea2-c999eb855db5">Cambridge</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xL2ZyYWc6NTg4OGE0NTFjN2U0NDdhN2FjZjdhMzhiYWE0Yzk4YzcvdGFibGU6ZjMzMGY3ZmUwN2EwNDE3N2EyYjY4OTc4MDhlMzQyOWMvdGFibGVyYW5nZTpmMzMwZjdmZTA3YTA0MTc3YTJiNjg5NzgwOGUzNDI5Y18wLTAtMS0xLTAvdGV4dHJlZ2lvbjo0NjE2MmNkNGEzNjU0NTNlYTMzODhmNzlmNDE5NjlhMl8xNQ_cbc8ffa5-b736-4ebd-aa4d-cac052fed9d1">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xL2ZyYWc6NTg4OGE0NTFjN2U0NDdhN2FjZjdhMzhiYWE0Yzk4YzcvdGFibGU6ZjMzMGY3ZmUwN2EwNDE3N2EyYjY4OTc4MDhlMzQyOWMvdGFibGVyYW5nZTpmMzMwZjdmZTA3YTA0MTc3YTJiNjg5NzgwOGUzNDI5Y18wLTEtMS0xLTAvdGV4dHJlZ2lvbjo2OGI1NTRmYzZkMWY0YmVhOGExNDNlNTQ0MzVmNDlhN181_297f193e-7130-435e-993f-d740fba2dfed">02142</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xL2ZyYWc6NTg4OGE0NTFjN2U0NDdhN2FjZjdhMzhiYWE0Yzk4YzcvdGV4dHJlZ2lvbjo1ODg4YTQ1MWM3ZTQ0N2E3YWNmN2EzOGJhYTRjOThjN180ODk_b536be89-eb55-4c2a-814b-20fc8087e395">617</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xL2ZyYWc6NTg4OGE0NTFjN2U0NDdhN2FjZjdhMzhiYWE0Yzk4YzcvdGV4dHJlZ2lvbjo1ODg4YTQ1MWM3ZTQ0N2E3YWNmN2EzOGJhYTRjOThjN180OTM_7d826229-1df3-441e-86fd-9b1ad3b211ce">551-8200</dei:LocalPhoneNumber>
    <dei:LocalPhoneNumber
      contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xL2ZyYWc6NTg4OGE0NTFjN2U0NDdhN2FjZjdhMzhiYWE0Yzk4YzcvdGV4dHJlZ2lvbjo1ODg4YTQ1MWM3ZTQ0N2E3YWNmN2EzOGJhYTRjOThjN180OTM_ecee9bee-f4fe-4325-b411-7c8f578c9e2c">551-8200</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xL2ZyYWc6NTg4OGE0NTFjN2U0NDdhN2FjZjdhMzhiYWE0Yzk4YzcvdGFibGU6NjQ4OWI4YjQxOTU0NDExMGFjNDE2OTY0NzQ1ODVkODAvdGFibGVyYW5nZTo2NDg5YjhiNDE5NTQ0MTEwYWM0MTY5NjQ3NDU4NWQ4MF8xLTEtMS0xLTA_1c98e579-bd15-47d5-8289-da459ee4e9c8">Common Stock, $0.01&#160;par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xL2ZyYWc6NTg4OGE0NTFjN2U0NDdhN2FjZjdhMzhiYWE0Yzk4YzcvdGFibGU6NjQ4OWI4YjQxOTU0NDExMGFjNDE2OTY0NzQ1ODVkODAvdGFibGVyYW5nZTo2NDg5YjhiNDE5NTQ0MTEwYWM0MTY5NjQ3NDU4NWQ4MF8xLTMtMS0xLTA_a93458c5-dcce-4c8d-a59b-0f729642e8cb">ALNY</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xL2ZyYWc6NTg4OGE0NTFjN2U0NDdhN2FjZjdhMzhiYWE0Yzk4YzcvdGFibGU6NjQ4OWI4YjQxOTU0NDExMGFjNDE2OTY0NzQ1ODVkODAvdGFibGVyYW5nZTo2NDg5YjhiNDE5NTQ0MTEwYWM0MTY5NjQ3NDU4NWQ4MF8xLTUtMS0xLTA_fd88246c-4107-49c9-a462-91492554a38a">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xL2ZyYWc6NTg4OGE0NTFjN2U0NDdhN2FjZjdhMzhiYWE0Yzk4YzcvdGV4dHJlZ2lvbjo1ODg4YTQ1MWM3ZTQ0N2E3YWNmN2EzOGJhYTRjOThjN18xMDAx_13ce99b8-ed79-4cda-8d9c-687268fecbc5">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xL2ZyYWc6NTg4OGE0NTFjN2U0NDdhN2FjZjdhMzhiYWE0Yzk4YzcvdGV4dHJlZ2lvbjo1ODg4YTQ1MWM3ZTQ0N2E3YWNmN2EzOGJhYTRjOThjN18xMzI2_4912b0a0-d718-46c7-a2d9-156fd9498994">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xL2ZyYWc6NTg4OGE0NTFjN2U0NDdhN2FjZjdhMzhiYWE0Yzk4YzcvdGFibGU6NTA5NzExNzIxZDJkNDdjY2EzMGQxNmQ2NDQzOGRiNzEvdGFibGVyYW5nZTo1MDk3MTE3MjFkMmQ0N2NjYTMwZDE2ZDY0NDM4ZGI3MV8wLTAtMS0xLTA_9847ed2f-fea4-4284-a189-31139cabb0f6">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xL2ZyYWc6NTg4OGE0NTFjN2U0NDdhN2FjZjdhMzhiYWE0Yzk4YzcvdGFibGU6NTA5NzExNzIxZDJkNDdjY2EzMGQxNmQ2NDQzOGRiNzEvdGFibGVyYW5nZTo1MDk3MTE3MjFkMmQ0N2NjYTMwZDE2ZDY0NDM4ZGI3MV8xLTMtMS0xLTA_51441e98-64dc-4923-9096-da9ac30de2b4">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xL2ZyYWc6NTg4OGE0NTFjN2U0NDdhN2FjZjdhMzhiYWE0Yzk4YzcvdGFibGU6NTA5NzExNzIxZDJkNDdjY2EzMGQxNmQ2NDQzOGRiNzEvdGFibGVyYW5nZTo1MDk3MTE3MjFkMmQ0N2NjYTMwZDE2ZDY0NDM4ZGI3MV8yLTEtMS0xLTA_8e7fabe3-e0d4-4272-8125-d9cb0ca0f4da">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xL2ZyYWc6NTg4OGE0NTFjN2U0NDdhN2FjZjdhMzhiYWE0Yzk4YzcvdGV4dHJlZ2lvbjo1ODg4YTQ1MWM3ZTQ0N2E3YWNmN2EzOGJhYTRjOThjN18yMDYw_e506bd93-bdc4-459e-a037-c24d10b7dd8d">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i34488122c9fd4fb68a5067e173effcb0_I20210423"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xL2ZyYWc6NTg4OGE0NTFjN2U0NDdhN2FjZjdhMzhiYWE0Yzk4YzcvdGV4dHJlZ2lvbjo1ODg4YTQ1MWM3ZTQ0N2E3YWNmN2EzOGJhYTRjOThjN18yMDk3_ff4fe431-c57a-4a93-bafb-f1b47aaf4fe4"
      unitRef="shares">117545040</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="idd7204dc87d24972a01f15b098c4f56b_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xNi9mcmFnOmM4NzUzODM2OGZlMzQ5OWQ4OTA1NjI3ZTdmN2U4MWEzL3RhYmxlOjJjMmQxMWM4NDU4YzQ4ZTFiMDFkNmI5NTY3N2YzNmYwL3RhYmxlcmFuZ2U6MmMyZDExYzg0NThjNDhlMWIwMWQ2Yjk1Njc3ZjM2ZjBfMy0xLTEtMS0w_9e2242cd-ce35-430c-89a3-b13036d751b3"
      unitRef="usd">379543000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="id365c5f1d37444ac9e1da5b5891cd81a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xNi9mcmFnOmM4NzUzODM2OGZlMzQ5OWQ4OTA1NjI3ZTdmN2U4MWEzL3RhYmxlOjJjMmQxMWM4NDU4YzQ4ZTFiMDFkNmI5NTY3N2YzNmYwL3RhYmxlcmFuZ2U6MmMyZDExYzg0NThjNDhlMWIwMWQ2Yjk1Njc3ZjM2ZjBfMy0zLTEtMS0w_ac798048-5cf4-4140-b7ac-81bed39aade5"
      unitRef="usd">496580000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="idd7204dc87d24972a01f15b098c4f56b_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xNi9mcmFnOmM4NzUzODM2OGZlMzQ5OWQ4OTA1NjI3ZTdmN2U4MWEzL3RhYmxlOjJjMmQxMWM4NDU4YzQ4ZTFiMDFkNmI5NTY3N2YzNmYwL3RhYmxlcmFuZ2U6MmMyZDExYzg0NThjNDhlMWIwMWQ2Yjk1Njc3ZjM2ZjBfNC0xLTEtMS0w_521ade9a-b2a3-4a04-8c4b-f0177dd0c1c7"
      unitRef="usd">1273027000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="id365c5f1d37444ac9e1da5b5891cd81a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xNi9mcmFnOmM4NzUzODM2OGZlMzQ5OWQ4OTA1NjI3ZTdmN2U4MWEzL3RhYmxlOjJjMmQxMWM4NDU4YzQ4ZTFiMDFkNmI5NTY3N2YzNmYwL3RhYmxlcmFuZ2U6MmMyZDExYzg0NThjNDhlMWIwMWQ2Yjk1Njc3ZjM2ZjBfNC0zLTEtMS0w_e68c89ee-31b4-4b84-8768-c564322c3c1b"
      unitRef="usd">1333182000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="idd7204dc87d24972a01f15b098c4f56b_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xNi9mcmFnOmM4NzUzODM2OGZlMzQ5OWQ4OTA1NjI3ZTdmN2U4MWEzL3RhYmxlOjJjMmQxMWM4NDU4YzQ4ZTFiMDFkNmI5NTY3N2YzNmYwL3RhYmxlcmFuZ2U6MmMyZDExYzg0NThjNDhlMWIwMWQ2Yjk1Njc3ZjM2ZjBfNS0xLTEtMS0w_f8693738-0359-40ed-8afa-fa20c27a67f7"
      unitRef="usd">56967000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="id365c5f1d37444ac9e1da5b5891cd81a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xNi9mcmFnOmM4NzUzODM2OGZlMzQ5OWQ4OTA1NjI3ZTdmN2U4MWEzL3RhYmxlOjJjMmQxMWM4NDU4YzQ4ZTFiMDFkNmI5NTY3N2YzNmYwL3RhYmxlcmFuZ2U6MmMyZDExYzg0NThjNDhlMWIwMWQ2Yjk1Njc3ZjM2ZjBfNS0zLTEtMS0w_71eaa147-cb20-48b4-ab75-8d8f7068a97f"
      unitRef="usd">44633000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="idd7204dc87d24972a01f15b098c4f56b_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xNi9mcmFnOmM4NzUzODM2OGZlMzQ5OWQ4OTA1NjI3ZTdmN2U4MWEzL3RhYmxlOjJjMmQxMWM4NDU4YzQ4ZTFiMDFkNmI5NTY3N2YzNmYwL3RhYmxlcmFuZ2U6MmMyZDExYzg0NThjNDhlMWIwMWQ2Yjk1Njc3ZjM2ZjBfNi0xLTEtMS0w_01e663a2-28dc-4ae5-a95d-e8440aa26a45"
      unitRef="usd">110626000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="id365c5f1d37444ac9e1da5b5891cd81a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xNi9mcmFnOmM4NzUzODM2OGZlMzQ5OWQ4OTA1NjI3ZTdmN2U4MWEzL3RhYmxlOjJjMmQxMWM4NDU4YzQ4ZTFiMDFkNmI5NTY3N2YzNmYwL3RhYmxlcmFuZ2U6MmMyZDExYzg0NThjNDhlMWIwMWQ2Yjk1Njc3ZjM2ZjBfNi0zLTEtMS0w_2f1e178d-1df1-4994-b3cf-fb7dd63d7fce"
      unitRef="usd">102413000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="idd7204dc87d24972a01f15b098c4f56b_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xNi9mcmFnOmM4NzUzODM2OGZlMzQ5OWQ4OTA1NjI3ZTdmN2U4MWEzL3RhYmxlOjJjMmQxMWM4NDU4YzQ4ZTFiMDFkNmI5NTY3N2YzNmYwL3RhYmxlcmFuZ2U6MmMyZDExYzg0NThjNDhlMWIwMWQ2Yjk1Njc3ZjM2ZjBfNy0xLTEtMS0w_8c393b17-0a55-4333-9628-b74328448954"
      unitRef="usd">73940000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="id365c5f1d37444ac9e1da5b5891cd81a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xNi9mcmFnOmM4NzUzODM2OGZlMzQ5OWQ4OTA1NjI3ZTdmN2U4MWEzL3RhYmxlOjJjMmQxMWM4NDU4YzQ4ZTFiMDFkNmI5NTY3N2YzNmYwL3RhYmxlcmFuZ2U6MmMyZDExYzg0NThjNDhlMWIwMWQ2Yjk1Njc3ZjM2ZjBfNy0zLTEtMS0w_4f612a02-8b5d-4abb-83b0-aa87c92f8687"
      unitRef="usd">75202000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="idd7204dc87d24972a01f15b098c4f56b_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xNi9mcmFnOmM4NzUzODM2OGZlMzQ5OWQ4OTA1NjI3ZTdmN2U4MWEzL3RhYmxlOjJjMmQxMWM4NDU4YzQ4ZTFiMDFkNmI5NTY3N2YzNmYwL3RhYmxlcmFuZ2U6MmMyZDExYzg0NThjNDhlMWIwMWQ2Yjk1Njc3ZjM2ZjBfOC0xLTEtMS0w_5cc06d72-0153-4138-a5d9-5737517e043c"
      unitRef="usd">75980000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="id365c5f1d37444ac9e1da5b5891cd81a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xNi9mcmFnOmM4NzUzODM2OGZlMzQ5OWQ4OTA1NjI3ZTdmN2U4MWEzL3RhYmxlOjJjMmQxMWM4NDU4YzQ4ZTFiMDFkNmI5NTY3N2YzNmYwL3RhYmxlcmFuZ2U6MmMyZDExYzg0NThjNDhlMWIwMWQ2Yjk1Njc3ZjM2ZjBfOC0zLTEtMS0w_3312f36c-8d6d-49b6-9487-3b06c5422fd8"
      unitRef="usd">62767000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <alny:RoyaltiesReceivableCurrent
      contextRef="idd7204dc87d24972a01f15b098c4f56b_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xNi9mcmFnOmM4NzUzODM2OGZlMzQ5OWQ4OTA1NjI3ZTdmN2U4MWEzL3RhYmxlOjJjMmQxMWM4NDU4YzQ4ZTFiMDFkNmI5NTY3N2YzNmYwL3RhYmxlcmFuZ2U6MmMyZDExYzg0NThjNDhlMWIwMWQ2Yjk1Njc3ZjM2ZjBfOS0xLTEtMS0w_d17b730a-a8e1-4d9f-907f-e0de94684974"
      unitRef="usd">500000000</alny:RoyaltiesReceivableCurrent>
    <alny:RoyaltiesReceivableCurrent
      contextRef="id365c5f1d37444ac9e1da5b5891cd81a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xNi9mcmFnOmM4NzUzODM2OGZlMzQ5OWQ4OTA1NjI3ZTdmN2U4MWEzL3RhYmxlOjJjMmQxMWM4NDU4YzQ4ZTFiMDFkNmI5NTY3N2YzNmYwL3RhYmxlcmFuZ2U6MmMyZDExYzg0NThjNDhlMWIwMWQ2Yjk1Njc3ZjM2ZjBfOS0zLTEtMS0w_bfac6252-21b8-4f51-86d6-7831687d7289"
      unitRef="usd">500000000</alny:RoyaltiesReceivableCurrent>
    <us-gaap:AssetsCurrent
      contextRef="idd7204dc87d24972a01f15b098c4f56b_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xNi9mcmFnOmM4NzUzODM2OGZlMzQ5OWQ4OTA1NjI3ZTdmN2U4MWEzL3RhYmxlOjJjMmQxMWM4NDU4YzQ4ZTFiMDFkNmI5NTY3N2YzNmYwL3RhYmxlcmFuZ2U6MmMyZDExYzg0NThjNDhlMWIwMWQ2Yjk1Njc3ZjM2ZjBfMTAtMS0xLTEtMA_58491f29-a9de-4d9a-a9d0-de6cc819682b"
      unitRef="usd">2470083000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="id365c5f1d37444ac9e1da5b5891cd81a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xNi9mcmFnOmM4NzUzODM2OGZlMzQ5OWQ4OTA1NjI3ZTdmN2U4MWEzL3RhYmxlOjJjMmQxMWM4NDU4YzQ4ZTFiMDFkNmI5NTY3N2YzNmYwL3RhYmxlcmFuZ2U6MmMyZDExYzg0NThjNDhlMWIwMWQ2Yjk1Njc3ZjM2ZjBfMTAtMy0xLTEtMA_702bf945-7ab7-449a-aafa-ffb59217a15c"
      unitRef="usd">2614777000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="idd7204dc87d24972a01f15b098c4f56b_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xNi9mcmFnOmM4NzUzODM2OGZlMzQ5OWQ4OTA1NjI3ZTdmN2U4MWEzL3RhYmxlOjJjMmQxMWM4NDU4YzQ4ZTFiMDFkNmI5NTY3N2YzNmYwL3RhYmxlcmFuZ2U6MmMyZDExYzg0NThjNDhlMWIwMWQ2Yjk1Njc3ZjM2ZjBfMTEtMS0xLTEtMA_fd90f67d-623c-443a-8517-ac09f815ca79"
      unitRef="usd">464572000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="id365c5f1d37444ac9e1da5b5891cd81a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xNi9mcmFnOmM4NzUzODM2OGZlMzQ5OWQ4OTA1NjI3ZTdmN2U4MWEzL3RhYmxlOjJjMmQxMWM4NDU4YzQ4ZTFiMDFkNmI5NTY3N2YzNmYwL3RhYmxlcmFuZ2U6MmMyZDExYzg0NThjNDhlMWIwMWQ2Yjk1Njc3ZjM2ZjBfMTEtMy0xLTEtMA_be8c263a-853e-43e3-b434-47febd0db778"
      unitRef="usd">465029000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="idd7204dc87d24972a01f15b098c4f56b_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xNi9mcmFnOmM4NzUzODM2OGZlMzQ5OWQ4OTA1NjI3ZTdmN2U4MWEzL3RhYmxlOjJjMmQxMWM4NDU4YzQ4ZTFiMDFkNmI5NTY3N2YzNmYwL3RhYmxlcmFuZ2U6MmMyZDExYzg0NThjNDhlMWIwMWQ2Yjk1Njc3ZjM2ZjBfMTItMS0xLTEtMA_5bb29d4b-2032-461a-b7f0-75f8eec6ae69"
      unitRef="usd">237213000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="id365c5f1d37444ac9e1da5b5891cd81a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xNi9mcmFnOmM4NzUzODM2OGZlMzQ5OWQ4OTA1NjI3ZTdmN2U4MWEzL3RhYmxlOjJjMmQxMWM4NDU4YzQ4ZTFiMDFkNmI5NTY3N2YzNmYwL3RhYmxlcmFuZ2U6MmMyZDExYzg0NThjNDhlMWIwMWQ2Yjk1Njc3ZjM2ZjBfMTItMy0xLTEtMA_5d7365f9-fd2c-4695-83c9-404ecf81923c"
      unitRef="usd">241485000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:RestrictedInvestmentsNoncurrent
      contextRef="idd7204dc87d24972a01f15b098c4f56b_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xNi9mcmFnOmM4NzUzODM2OGZlMzQ5OWQ4OTA1NjI3ZTdmN2U4MWEzL3RhYmxlOjJjMmQxMWM4NDU4YzQ4ZTFiMDFkNmI5NTY3N2YzNmYwL3RhYmxlcmFuZ2U6MmMyZDExYzg0NThjNDhlMWIwMWQ2Yjk1Njc3ZjM2ZjBfMTMtMS0xLTEtMA_c3a23ed6-2c70-4ae0-b520-a67551c519c7"
      unitRef="usd">40725000</us-gaap:RestrictedInvestmentsNoncurrent>
    <us-gaap:RestrictedInvestmentsNoncurrent
      contextRef="id365c5f1d37444ac9e1da5b5891cd81a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xNi9mcmFnOmM4NzUzODM2OGZlMzQ5OWQ4OTA1NjI3ZTdmN2U4MWEzL3RhYmxlOjJjMmQxMWM4NDU4YzQ4ZTFiMDFkNmI5NTY3N2YzNmYwL3RhYmxlcmFuZ2U6MmMyZDExYzg0NThjNDhlMWIwMWQ2Yjk1Njc3ZjM2ZjBfMTMtMy0xLTEtMA_e7a010c6-c0f9-40b9-be58-319184532567"
      unitRef="usd">40725000</us-gaap:RestrictedInvestmentsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="idd7204dc87d24972a01f15b098c4f56b_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xNi9mcmFnOmM4NzUzODM2OGZlMzQ5OWQ4OTA1NjI3ZTdmN2U4MWEzL3RhYmxlOjJjMmQxMWM4NDU4YzQ4ZTFiMDFkNmI5NTY3N2YzNmYwL3RhYmxlcmFuZ2U6MmMyZDExYzg0NThjNDhlMWIwMWQ2Yjk1Njc3ZjM2ZjBfMTQtMS0xLTEtMA_b80edf0e-2efa-443a-95b5-4504218c63d7"
      unitRef="usd">42676000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="id365c5f1d37444ac9e1da5b5891cd81a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xNi9mcmFnOmM4NzUzODM2OGZlMzQ5OWQ4OTA1NjI3ZTdmN2U4MWEzL3RhYmxlOjJjMmQxMWM4NDU4YzQ4ZTFiMDFkNmI5NTY3N2YzNmYwL3RhYmxlcmFuZ2U6MmMyZDExYzg0NThjNDhlMWIwMWQ2Yjk1Njc3ZjM2ZjBfMTQtMy0xLTEtMA_b79a658b-4bf8-4052-8834-59b514dc4483"
      unitRef="usd">45045000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="idd7204dc87d24972a01f15b098c4f56b_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xNi9mcmFnOmM4NzUzODM2OGZlMzQ5OWQ4OTA1NjI3ZTdmN2U4MWEzL3RhYmxlOjJjMmQxMWM4NDU4YzQ4ZTFiMDFkNmI5NTY3N2YzNmYwL3RhYmxlcmFuZ2U6MmMyZDExYzg0NThjNDhlMWIwMWQ2Yjk1Njc3ZjM2ZjBfMTUtMS0xLTEtMA_1d7b9fa0-a459-4917-a0e9-789a33b1c7a9"
      unitRef="usd">3255269000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="id365c5f1d37444ac9e1da5b5891cd81a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xNi9mcmFnOmM4NzUzODM2OGZlMzQ5OWQ4OTA1NjI3ZTdmN2U4MWEzL3RhYmxlOjJjMmQxMWM4NDU4YzQ4ZTFiMDFkNmI5NTY3N2YzNmYwL3RhYmxlcmFuZ2U6MmMyZDExYzg0NThjNDhlMWIwMWQ2Yjk1Njc3ZjM2ZjBfMTUtMy0xLTEtMA_50cd6d7c-8f1c-4528-9405-4eda9fbce972"
      unitRef="usd">3407061000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="idd7204dc87d24972a01f15b098c4f56b_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xNi9mcmFnOmM4NzUzODM2OGZlMzQ5OWQ4OTA1NjI3ZTdmN2U4MWEzL3RhYmxlOjJjMmQxMWM4NDU4YzQ4ZTFiMDFkNmI5NTY3N2YzNmYwL3RhYmxlcmFuZ2U6MmMyZDExYzg0NThjNDhlMWIwMWQ2Yjk1Njc3ZjM2ZjBfMTgtMS0xLTEtMA_831ca1a5-73f4-4789-ace0-a607f2660dfe"
      unitRef="usd">45381000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="id365c5f1d37444ac9e1da5b5891cd81a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xNi9mcmFnOmM4NzUzODM2OGZlMzQ5OWQ4OTA1NjI3ZTdmN2U4MWEzL3RhYmxlOjJjMmQxMWM4NDU4YzQ4ZTFiMDFkNmI5NTY3N2YzNmYwL3RhYmxlcmFuZ2U6MmMyZDExYzg0NThjNDhlMWIwMWQ2Yjk1Njc3ZjM2ZjBfMTgtMy0xLTEtMA_2e6e1ea9-2818-45aa-8fdb-4b4f3c8c20eb"
      unitRef="usd">51966000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="idd7204dc87d24972a01f15b098c4f56b_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xNi9mcmFnOmM4NzUzODM2OGZlMzQ5OWQ4OTA1NjI3ZTdmN2U4MWEzL3RhYmxlOjJjMmQxMWM4NDU4YzQ4ZTFiMDFkNmI5NTY3N2YzNmYwL3RhYmxlcmFuZ2U6MmMyZDExYzg0NThjNDhlMWIwMWQ2Yjk1Njc3ZjM2ZjBfMTktMS0xLTEtMA_93180980-4a1c-4720-988d-e4944c03a2bf"
      unitRef="usd">280527000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="id365c5f1d37444ac9e1da5b5891cd81a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xNi9mcmFnOmM4NzUzODM2OGZlMzQ5OWQ4OTA1NjI3ZTdmN2U4MWEzL3RhYmxlOjJjMmQxMWM4NDU4YzQ4ZTFiMDFkNmI5NTY3N2YzNmYwL3RhYmxlcmFuZ2U6MmMyZDExYzg0NThjNDhlMWIwMWQ2Yjk1Njc3ZjM2ZjBfMTktMy0xLTEtMA_41ace118-3b2e-4668-b019-c42ca4b47912"
      unitRef="usd">355909000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="idd7204dc87d24972a01f15b098c4f56b_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xNi9mcmFnOmM4NzUzODM2OGZlMzQ5OWQ4OTA1NjI3ZTdmN2U4MWEzL3RhYmxlOjJjMmQxMWM4NDU4YzQ4ZTFiMDFkNmI5NTY3N2YzNmYwL3RhYmxlcmFuZ2U6MmMyZDExYzg0NThjNDhlMWIwMWQ2Yjk1Njc3ZjM2ZjBfMjAtMS0xLTEtMA_d807788e-339a-4ce5-b10d-3b843e32763e"
      unitRef="usd">38917000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="id365c5f1d37444ac9e1da5b5891cd81a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xNi9mcmFnOmM4NzUzODM2OGZlMzQ5OWQ4OTA1NjI3ZTdmN2U4MWEzL3RhYmxlOjJjMmQxMWM4NDU4YzQ4ZTFiMDFkNmI5NTY3N2YzNmYwL3RhYmxlcmFuZ2U6MmMyZDExYzg0NThjNDhlMWIwMWQ2Yjk1Njc3ZjM2ZjBfMjAtMy0xLTEtMA_f957006e-584c-4a3c-9609-3265d53ad06a"
      unitRef="usd">36872000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="idd7204dc87d24972a01f15b098c4f56b_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xNi9mcmFnOmM4NzUzODM2OGZlMzQ5OWQ4OTA1NjI3ZTdmN2U4MWEzL3RhYmxlOjJjMmQxMWM4NDU4YzQ4ZTFiMDFkNmI5NTY3N2YzNmYwL3RhYmxlcmFuZ2U6MmMyZDExYzg0NThjNDhlMWIwMWQ2Yjk1Njc3ZjM2ZjBfMjEtMS0xLTEtMA_76483954-c33f-403b-a35d-a3f5150370d5"
      unitRef="usd">116340000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="id365c5f1d37444ac9e1da5b5891cd81a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xNi9mcmFnOmM4NzUzODM2OGZlMzQ5OWQ4OTA1NjI3ZTdmN2U4MWEzL3RhYmxlOjJjMmQxMWM4NDU4YzQ4ZTFiMDFkNmI5NTY3N2YzNmYwL3RhYmxlcmFuZ2U6MmMyZDExYzg0NThjNDhlMWIwMWQ2Yjk1Njc3ZjM2ZjBfMjEtMy0xLTEtMA_8c0c58ec-360f-4a14-a555-0d6b1b28516f"
      unitRef="usd">127207000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <alny:RoyaltyLiabilityCurrent
      contextRef="idd7204dc87d24972a01f15b098c4f56b_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xNi9mcmFnOmM4NzUzODM2OGZlMzQ5OWQ4OTA1NjI3ZTdmN2U4MWEzL3RhYmxlOjJjMmQxMWM4NDU4YzQ4ZTFiMDFkNmI5NTY3N2YzNmYwL3RhYmxlcmFuZ2U6MmMyZDExYzg0NThjNDhlMWIwMWQ2Yjk1Njc3ZjM2ZjBfMjItMS0xLTEtMA_1a613327-a02f-470a-8e05-89c0f552f35a"
      unitRef="usd">13660000</alny:RoyaltyLiabilityCurrent>
    <alny:RoyaltyLiabilityCurrent
      contextRef="id365c5f1d37444ac9e1da5b5891cd81a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xNi9mcmFnOmM4NzUzODM2OGZlMzQ5OWQ4OTA1NjI3ZTdmN2U4MWEzL3RhYmxlOjJjMmQxMWM4NDU4YzQ4ZTFiMDFkNmI5NTY3N2YzNmYwL3RhYmxlcmFuZ2U6MmMyZDExYzg0NThjNDhlMWIwMWQ2Yjk1Njc3ZjM2ZjBfMjItMy0xLTEtMA_da5696f6-7155-4fa0-9978-f21e4b67a624"
      unitRef="usd">13316000</alny:RoyaltyLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="idd7204dc87d24972a01f15b098c4f56b_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xNi9mcmFnOmM4NzUzODM2OGZlMzQ5OWQ4OTA1NjI3ZTdmN2U4MWEzL3RhYmxlOjJjMmQxMWM4NDU4YzQ4ZTFiMDFkNmI5NTY3N2YzNmYwL3RhYmxlcmFuZ2U6MmMyZDExYzg0NThjNDhlMWIwMWQ2Yjk1Njc3ZjM2ZjBfMjMtMS0xLTEtMA_d252b9c3-e2ff-4d32-a1b3-2319ed302065"
      unitRef="usd">494825000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="id365c5f1d37444ac9e1da5b5891cd81a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xNi9mcmFnOmM4NzUzODM2OGZlMzQ5OWQ4OTA1NjI3ZTdmN2U4MWEzL3RhYmxlOjJjMmQxMWM4NDU4YzQ4ZTFiMDFkNmI5NTY3N2YzNmYwL3RhYmxlcmFuZ2U6MmMyZDExYzg0NThjNDhlMWIwMWQ2Yjk1Njc3ZjM2ZjBfMjMtMy0xLTEtMA_498b6dd1-4c35-4e74-8570-24247cd78c73"
      unitRef="usd">585270000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="idd7204dc87d24972a01f15b098c4f56b_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xNi9mcmFnOmM4NzUzODM2OGZlMzQ5OWQ4OTA1NjI3ZTdmN2U4MWEzL3RhYmxlOjJjMmQxMWM4NDU4YzQ4ZTFiMDFkNmI5NTY3N2YzNmYwL3RhYmxlcmFuZ2U6MmMyZDExYzg0NThjNDhlMWIwMWQ2Yjk1Njc3ZjM2ZjBfMjQtMS0xLTEtMA_5f0c48c0-84b1-49a5-9086-9bf949ea3d48"
      unitRef="usd">288015000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="id365c5f1d37444ac9e1da5b5891cd81a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xNi9mcmFnOmM4NzUzODM2OGZlMzQ5OWQ4OTA1NjI3ZTdmN2U4MWEzL3RhYmxlOjJjMmQxMWM4NDU4YzQ4ZTFiMDFkNmI5NTY3N2YzNmYwL3RhYmxlcmFuZ2U6MmMyZDExYzg0NThjNDhlMWIwMWQ2Yjk1Njc3ZjM2ZjBfMjQtMy0xLTEtMA_531d1092-2858-4d78-a720-7aea5efd0682"
      unitRef="usd">293039000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="idd7204dc87d24972a01f15b098c4f56b_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xNi9mcmFnOmM4NzUzODM2OGZlMzQ5OWQ4OTA1NjI3ZTdmN2U4MWEzL3RhYmxlOjJjMmQxMWM4NDU4YzQ4ZTFiMDFkNmI5NTY3N2YzNmYwL3RhYmxlcmFuZ2U6MmMyZDExYzg0NThjNDhlMWIwMWQ2Yjk1Njc3ZjM2ZjBfMjUtMS0xLTEtMA_cc279283-a1ba-4806-891e-11e08026589a"
      unitRef="usd">208123000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="id365c5f1d37444ac9e1da5b5891cd81a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xNi9mcmFnOmM4NzUzODM2OGZlMzQ5OWQ4OTA1NjI3ZTdmN2U4MWEzL3RhYmxlOjJjMmQxMWM4NDU4YzQ4ZTFiMDFkNmI5NTY3N2YzNmYwL3RhYmxlcmFuZ2U6MmMyZDExYzg0NThjNDhlMWIwMWQ2Yjk1Njc3ZjM2ZjBfMjUtMy0xLTEtMA_ef6572be-e876-4192-bce2-530f154a69b7"
      unitRef="usd">225094000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:LongTermDebt
      contextRef="idd7204dc87d24972a01f15b098c4f56b_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xNi9mcmFnOmM4NzUzODM2OGZlMzQ5OWQ4OTA1NjI3ZTdmN2U4MWEzL3RhYmxlOjJjMmQxMWM4NDU4YzQ4ZTFiMDFkNmI5NTY3N2YzNmYwL3RhYmxlcmFuZ2U6MmMyZDExYzg0NThjNDhlMWIwMWQ2Yjk1Njc3ZjM2ZjBfMjYtMS0xLTEtMTgx_842b9859-9d21-478d-9cde-11524cad204a"
      unitRef="usd">191590000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="id365c5f1d37444ac9e1da5b5891cd81a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xNi9mcmFnOmM4NzUzODM2OGZlMzQ5OWQ4OTA1NjI3ZTdmN2U4MWEzL3RhYmxlOjJjMmQxMWM4NDU4YzQ4ZTFiMDFkNmI5NTY3N2YzNmYwL3RhYmxlcmFuZ2U6MmMyZDExYzg0NThjNDhlMWIwMWQ2Yjk1Njc3ZjM2ZjBfMjYtMy0xLTEtMTgx_5637ddb0-b70a-4c58-9874-267d69468d72"
      unitRef="usd">191278000</us-gaap:LongTermDebt>
    <alny:RoyaltyLiabilityNoncurrent
      contextRef="idd7204dc87d24972a01f15b098c4f56b_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xNi9mcmFnOmM4NzUzODM2OGZlMzQ5OWQ4OTA1NjI3ZTdmN2U4MWEzL3RhYmxlOjJjMmQxMWM4NDU4YzQ4ZTFiMDFkNmI5NTY3N2YzNmYwL3RhYmxlcmFuZ2U6MmMyZDExYzg0NThjNDhlMWIwMWQ2Yjk1Njc3ZjM2ZjBfMjctMS0xLTEtMA_56ea8a09-8ffb-4e3b-b824-ab9fd315c5ce"
      unitRef="usd">1086065000</alny:RoyaltyLiabilityNoncurrent>
    <alny:RoyaltyLiabilityNoncurrent
      contextRef="id365c5f1d37444ac9e1da5b5891cd81a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xNi9mcmFnOmM4NzUzODM2OGZlMzQ5OWQ4OTA1NjI3ZTdmN2U4MWEzL3RhYmxlOjJjMmQxMWM4NDU4YzQ4ZTFiMDFkNmI5NTY3N2YzNmYwL3RhYmxlcmFuZ2U6MmMyZDExYzg0NThjNDhlMWIwMWQ2Yjk1Njc3ZjM2ZjBfMjctMy0xLTEtMA_054963d4-ba18-4bb7-98ab-743438bb0635"
      unitRef="usd">1058225000</alny:RoyaltyLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="idd7204dc87d24972a01f15b098c4f56b_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xNi9mcmFnOmM4NzUzODM2OGZlMzQ5OWQ4OTA1NjI3ZTdmN2U4MWEzL3RhYmxlOjJjMmQxMWM4NDU4YzQ4ZTFiMDFkNmI5NTY3N2YzNmYwL3RhYmxlcmFuZ2U6MmMyZDExYzg0NThjNDhlMWIwMWQ2Yjk1Njc3ZjM2ZjBfMjgtMS0xLTEtMA_26669a1e-5968-4723-8a74-c6242bb0811b"
      unitRef="usd">60461000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="id365c5f1d37444ac9e1da5b5891cd81a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xNi9mcmFnOmM4NzUzODM2OGZlMzQ5OWQ4OTA1NjI3ZTdmN2U4MWEzL3RhYmxlOjJjMmQxMWM4NDU4YzQ4ZTFiMDFkNmI5NTY3N2YzNmYwL3RhYmxlcmFuZ2U6MmMyZDExYzg0NThjNDhlMWIwMWQ2Yjk1Njc3ZjM2ZjBfMjgtMy0xLTEtMA_23af4eb6-8031-4974-8796-8bcf9fc8954a"
      unitRef="usd">37908000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="idd7204dc87d24972a01f15b098c4f56b_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xNi9mcmFnOmM4NzUzODM2OGZlMzQ5OWQ4OTA1NjI3ZTdmN2U4MWEzL3RhYmxlOjJjMmQxMWM4NDU4YzQ4ZTFiMDFkNmI5NTY3N2YzNmYwL3RhYmxlcmFuZ2U6MmMyZDExYzg0NThjNDhlMWIwMWQ2Yjk1Njc3ZjM2ZjBfMjktMS0xLTEtMA_a4de43d0-833c-4a51-b883-75883736059b"
      unitRef="usd">2329079000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="id365c5f1d37444ac9e1da5b5891cd81a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xNi9mcmFnOmM4NzUzODM2OGZlMzQ5OWQ4OTA1NjI3ZTdmN2U4MWEzL3RhYmxlOjJjMmQxMWM4NDU4YzQ4ZTFiMDFkNmI5NTY3N2YzNmYwL3RhYmxlcmFuZ2U6MmMyZDExYzg0NThjNDhlMWIwMWQ2Yjk1Njc3ZjM2ZjBfMjktMy0xLTEtMA_c5db52df-c9d5-4981-b45e-c48cb5a4ddc3"
      unitRef="usd">2390814000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="idd7204dc87d24972a01f15b098c4f56b_I20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xNi9mcmFnOmM4NzUzODM2OGZlMzQ5OWQ4OTA1NjI3ZTdmN2U4MWEzL3RhYmxlOjJjMmQxMWM4NDU4YzQ4ZTFiMDFkNmI5NTY3N2YzNmYwL3RhYmxlcmFuZ2U6MmMyZDExYzg0NThjNDhlMWIwMWQ2Yjk1Njc3ZjM2ZjBfMzAtMS0xLTEtMA_3e4e8d7c-e733-4a8b-a632-38d4e03a830a"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="id365c5f1d37444ac9e1da5b5891cd81a_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xNi9mcmFnOmM4NzUzODM2OGZlMzQ5OWQ4OTA1NjI3ZTdmN2U4MWEzL3RhYmxlOjJjMmQxMWM4NDU4YzQ4ZTFiMDFkNmI5NTY3N2YzNmYwL3RhYmxlcmFuZ2U6MmMyZDExYzg0NThjNDhlMWIwMWQ2Yjk1Njc3ZjM2ZjBfMzAtMy0xLTEtMA_ec38adad-7659-4f35-b137-8d20166fd471"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="id365c5f1d37444ac9e1da5b5891cd81a_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xNi9mcmFnOmM4NzUzODM2OGZlMzQ5OWQ4OTA1NjI3ZTdmN2U4MWEzL3RhYmxlOjJjMmQxMWM4NDU4YzQ4ZTFiMDFkNmI5NTY3N2YzNmYwL3RhYmxlcmFuZ2U6MmMyZDExYzg0NThjNDhlMWIwMWQ2Yjk1Njc3ZjM2ZjBfMzItMC0xLTEtMC90ZXh0cmVnaW9uOmMzODNhOGYzNTYzYTQyZDU4ZWNkODliNTE3YTllZmM1XzIy_701b265a-c89e-4f4b-b6f7-6c8d70829183"
      unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="idd7204dc87d24972a01f15b098c4f56b_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xNi9mcmFnOmM4NzUzODM2OGZlMzQ5OWQ4OTA1NjI3ZTdmN2U4MWEzL3RhYmxlOjJjMmQxMWM4NDU4YzQ4ZTFiMDFkNmI5NTY3N2YzNmYwL3RhYmxlcmFuZ2U6MmMyZDExYzg0NThjNDhlMWIwMWQ2Yjk1Njc3ZjM2ZjBfMzItMC0xLTEtMC90ZXh0cmVnaW9uOmMzODNhOGYzNTYzYTQyZDU4ZWNkODliNTE3YTllZmM1XzIy_e39bd595-ad75-4702-81b4-ff0cde40e8d6"
      unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="id365c5f1d37444ac9e1da5b5891cd81a_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xNi9mcmFnOmM4NzUzODM2OGZlMzQ5OWQ4OTA1NjI3ZTdmN2U4MWEzL3RhYmxlOjJjMmQxMWM4NDU4YzQ4ZTFiMDFkNmI5NTY3N2YzNmYwL3RhYmxlcmFuZ2U6MmMyZDExYzg0NThjNDhlMWIwMWQ2Yjk1Njc3ZjM2ZjBfMzItMC0xLTEtMC90ZXh0cmVnaW9uOmMzODNhOGYzNTYzYTQyZDU4ZWNkODliNTE3YTllZmM1XzQ2_13429f06-d230-4db6-ac0a-f4021916bde0"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="idd7204dc87d24972a01f15b098c4f56b_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xNi9mcmFnOmM4NzUzODM2OGZlMzQ5OWQ4OTA1NjI3ZTdmN2U4MWEzL3RhYmxlOjJjMmQxMWM4NDU4YzQ4ZTFiMDFkNmI5NTY3N2YzNmYwL3RhYmxlcmFuZ2U6MmMyZDExYzg0NThjNDhlMWIwMWQ2Yjk1Njc3ZjM2ZjBfMzItMC0xLTEtMC90ZXh0cmVnaW9uOmMzODNhOGYzNTYzYTQyZDU4ZWNkODliNTE3YTllZmM1XzQ2_fc70e64e-5917-4be6-92ef-c8ac428cbc95"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="id365c5f1d37444ac9e1da5b5891cd81a_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xNi9mcmFnOmM4NzUzODM2OGZlMzQ5OWQ4OTA1NjI3ZTdmN2U4MWEzL3RhYmxlOjJjMmQxMWM4NDU4YzQ4ZTFiMDFkNmI5NTY3N2YzNmYwL3RhYmxlcmFuZ2U6MmMyZDExYzg0NThjNDhlMWIwMWQ2Yjk1Njc3ZjM2ZjBfMzItMC0xLTEtMC90ZXh0cmVnaW9uOmMzODNhOGYzNTYzYTQyZDU4ZWNkODliNTE3YTllZmM1Xzcx_1e9f52c3-46ad-4e5a-9192-e232adb89665"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="id365c5f1d37444ac9e1da5b5891cd81a_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xNi9mcmFnOmM4NzUzODM2OGZlMzQ5OWQ4OTA1NjI3ZTdmN2U4MWEzL3RhYmxlOjJjMmQxMWM4NDU4YzQ4ZTFiMDFkNmI5NTY3N2YzNmYwL3RhYmxlcmFuZ2U6MmMyZDExYzg0NThjNDhlMWIwMWQ2Yjk1Njc3ZjM2ZjBfMzItMC0xLTEtMC90ZXh0cmVnaW9uOmMzODNhOGYzNTYzYTQyZDU4ZWNkODliNTE3YTllZmM1Xzcx_7a0cbbf6-197b-4a2e-9c7f-21d01a61b684"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="idd7204dc87d24972a01f15b098c4f56b_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xNi9mcmFnOmM4NzUzODM2OGZlMzQ5OWQ4OTA1NjI3ZTdmN2U4MWEzL3RhYmxlOjJjMmQxMWM4NDU4YzQ4ZTFiMDFkNmI5NTY3N2YzNmYwL3RhYmxlcmFuZ2U6MmMyZDExYzg0NThjNDhlMWIwMWQ2Yjk1Njc3ZjM2ZjBfMzItMC0xLTEtMC90ZXh0cmVnaW9uOmMzODNhOGYzNTYzYTQyZDU4ZWNkODliNTE3YTllZmM1Xzcx_b1d57adc-7668-48f1-b82c-153983bc57a9"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="idd7204dc87d24972a01f15b098c4f56b_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xNi9mcmFnOmM4NzUzODM2OGZlMzQ5OWQ4OTA1NjI3ZTdmN2U4MWEzL3RhYmxlOjJjMmQxMWM4NDU4YzQ4ZTFiMDFkNmI5NTY3N2YzNmYwL3RhYmxlcmFuZ2U6MmMyZDExYzg0NThjNDhlMWIwMWQ2Yjk1Njc3ZjM2ZjBfMzItMC0xLTEtMC90ZXh0cmVnaW9uOmMzODNhOGYzNTYzYTQyZDU4ZWNkODliNTE3YTllZmM1Xzcx_d6210fc7-f322-4a35-9024-d1abb063bb41"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="idd7204dc87d24972a01f15b098c4f56b_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xNi9mcmFnOmM4NzUzODM2OGZlMzQ5OWQ4OTA1NjI3ZTdmN2U4MWEzL3RhYmxlOjJjMmQxMWM4NDU4YzQ4ZTFiMDFkNmI5NTY3N2YzNmYwL3RhYmxlcmFuZ2U6MmMyZDExYzg0NThjNDhlMWIwMWQ2Yjk1Njc3ZjM2ZjBfMzItMS0xLTEtMA_51951c5e-8dc8-4ad7-b1e0-0e50af9e6ef4"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="id365c5f1d37444ac9e1da5b5891cd81a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xNi9mcmFnOmM4NzUzODM2OGZlMzQ5OWQ4OTA1NjI3ZTdmN2U4MWEzL3RhYmxlOjJjMmQxMWM4NDU4YzQ4ZTFiMDFkNmI5NTY3N2YzNmYwL3RhYmxlcmFuZ2U6MmMyZDExYzg0NThjNDhlMWIwMWQ2Yjk1Njc3ZjM2ZjBfMzItMy0xLTEtMA_1ee0ac5e-fa72-4556-9c92-082e99ddb826"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="idd7204dc87d24972a01f15b098c4f56b_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xNi9mcmFnOmM4NzUzODM2OGZlMzQ5OWQ4OTA1NjI3ZTdmN2U4MWEzL3RhYmxlOjJjMmQxMWM4NDU4YzQ4ZTFiMDFkNmI5NTY3N2YzNmYwL3RhYmxlcmFuZ2U6MmMyZDExYzg0NThjNDhlMWIwMWQ2Yjk1Njc3ZjM2ZjBfMzMtMC0xLTEtMC90ZXh0cmVnaW9uOjk4OTZkZjEzZDBkMjRkNzc4ODM4ZjljZDY3Njg1NzkxXzE4_57718799-5589-4767-888f-a9157a98b289"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="id365c5f1d37444ac9e1da5b5891cd81a_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xNi9mcmFnOmM4NzUzODM2OGZlMzQ5OWQ4OTA1NjI3ZTdmN2U4MWEzL3RhYmxlOjJjMmQxMWM4NDU4YzQ4ZTFiMDFkNmI5NTY3N2YzNmYwL3RhYmxlcmFuZ2U6MmMyZDExYzg0NThjNDhlMWIwMWQ2Yjk1Njc3ZjM2ZjBfMzMtMC0xLTEtMC90ZXh0cmVnaW9uOjk4OTZkZjEzZDBkMjRkNzc4ODM4ZjljZDY3Njg1NzkxXzE4_ed6a1954-ed41-49a7-ac69-6a6911101500"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="id365c5f1d37444ac9e1da5b5891cd81a_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xNi9mcmFnOmM4NzUzODM2OGZlMzQ5OWQ4OTA1NjI3ZTdmN2U4MWEzL3RhYmxlOjJjMmQxMWM4NDU4YzQ4ZTFiMDFkNmI5NTY3N2YzNmYwL3RhYmxlcmFuZ2U6MmMyZDExYzg0NThjNDhlMWIwMWQ2Yjk1Njc3ZjM2ZjBfMzMtMC0xLTEtMC90ZXh0cmVnaW9uOjk4OTZkZjEzZDBkMjRkNzc4ODM4ZjljZDY3Njg1NzkxXzQy_e5b2d55f-9376-42be-a6ba-5e509fe3976f"
      unitRef="shares">250000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="idd7204dc87d24972a01f15b098c4f56b_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xNi9mcmFnOmM4NzUzODM2OGZlMzQ5OWQ4OTA1NjI3ZTdmN2U4MWEzL3RhYmxlOjJjMmQxMWM4NDU4YzQ4ZTFiMDFkNmI5NTY3N2YzNmYwL3RhYmxlcmFuZ2U6MmMyZDExYzg0NThjNDhlMWIwMWQ2Yjk1Njc3ZjM2ZjBfMzMtMC0xLTEtMC90ZXh0cmVnaW9uOjk4OTZkZjEzZDBkMjRkNzc4ODM4ZjljZDY3Njg1NzkxXzQy_fcaf0eab-b31d-4d97-aff7-103154cd5426"
      unitRef="shares">250000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="idd7204dc87d24972a01f15b098c4f56b_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xNi9mcmFnOmM4NzUzODM2OGZlMzQ5OWQ4OTA1NjI3ZTdmN2U4MWEzL3RhYmxlOjJjMmQxMWM4NDU4YzQ4ZTFiMDFkNmI5NTY3N2YzNmYwL3RhYmxlcmFuZ2U6MmMyZDExYzg0NThjNDhlMWIwMWQ2Yjk1Njc3ZjM2ZjBfMzMtMC0xLTEtMC90ZXh0cmVnaW9uOjk4OTZkZjEzZDBkMjRkNzc4ODM4ZjljZDY3Njg1NzkxXzY0_1aa1182f-dca0-4570-8ed2-a91e5e15279c"
      unitRef="shares">117321000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="idd7204dc87d24972a01f15b098c4f56b_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xNi9mcmFnOmM4NzUzODM2OGZlMzQ5OWQ4OTA1NjI3ZTdmN2U4MWEzL3RhYmxlOjJjMmQxMWM4NDU4YzQ4ZTFiMDFkNmI5NTY3N2YzNmYwL3RhYmxlcmFuZ2U6MmMyZDExYzg0NThjNDhlMWIwMWQ2Yjk1Njc3ZjM2ZjBfMzMtMC0xLTEtMC90ZXh0cmVnaW9uOjk4OTZkZjEzZDBkMjRkNzc4ODM4ZjljZDY3Njg1NzkxXzY0_df6f7388-9c05-435f-8e18-7eefe14c5320"
      unitRef="shares">117321000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="id365c5f1d37444ac9e1da5b5891cd81a_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xNi9mcmFnOmM4NzUzODM2OGZlMzQ5OWQ4OTA1NjI3ZTdmN2U4MWEzL3RhYmxlOjJjMmQxMWM4NDU4YzQ4ZTFiMDFkNmI5NTY3N2YzNmYwL3RhYmxlcmFuZ2U6MmMyZDExYzg0NThjNDhlMWIwMWQ2Yjk1Njc3ZjM2ZjBfMzMtMC0xLTEtMC90ZXh0cmVnaW9uOjk4OTZkZjEzZDBkMjRkNzc4ODM4ZjljZDY3Njg1NzkxXzEwNw_12bf7017-92e0-4a8f-a2cb-30274c53f729"
      unitRef="shares">116427000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="id365c5f1d37444ac9e1da5b5891cd81a_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xNi9mcmFnOmM4NzUzODM2OGZlMzQ5OWQ4OTA1NjI3ZTdmN2U4MWEzL3RhYmxlOjJjMmQxMWM4NDU4YzQ4ZTFiMDFkNmI5NTY3N2YzNmYwL3RhYmxlcmFuZ2U6MmMyZDExYzg0NThjNDhlMWIwMWQ2Yjk1Njc3ZjM2ZjBfMzMtMC0xLTEtMC90ZXh0cmVnaW9uOjk4OTZkZjEzZDBkMjRkNzc4ODM4ZjljZDY3Njg1NzkxXzEwNw_b67af575-e4db-484d-b2eb-9a47f3be15f5"
      unitRef="shares">116427000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="idd7204dc87d24972a01f15b098c4f56b_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xNi9mcmFnOmM4NzUzODM2OGZlMzQ5OWQ4OTA1NjI3ZTdmN2U4MWEzL3RhYmxlOjJjMmQxMWM4NDU4YzQ4ZTFiMDFkNmI5NTY3N2YzNmYwL3RhYmxlcmFuZ2U6MmMyZDExYzg0NThjNDhlMWIwMWQ2Yjk1Njc3ZjM2ZjBfMzMtMS0xLTEtMA_50b7d8f9-4529-4ac3-bf7c-ede7d1862949"
      unitRef="usd">1173000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="id365c5f1d37444ac9e1da5b5891cd81a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xNi9mcmFnOmM4NzUzODM2OGZlMzQ5OWQ4OTA1NjI3ZTdmN2U4MWEzL3RhYmxlOjJjMmQxMWM4NDU4YzQ4ZTFiMDFkNmI5NTY3N2YzNmYwL3RhYmxlcmFuZ2U6MmMyZDExYzg0NThjNDhlMWIwMWQ2Yjk1Njc3ZjM2ZjBfMzMtMy0xLTEtMA_5a45f4d3-3c4e-4c33-be7d-203aa0f547b0"
      unitRef="usd">1164000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="idd7204dc87d24972a01f15b098c4f56b_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xNi9mcmFnOmM4NzUzODM2OGZlMzQ5OWQ4OTA1NjI3ZTdmN2U4MWEzL3RhYmxlOjJjMmQxMWM4NDU4YzQ4ZTFiMDFkNmI5NTY3N2YzNmYwL3RhYmxlcmFuZ2U6MmMyZDExYzg0NThjNDhlMWIwMWQ2Yjk1Njc3ZjM2ZjBfMzQtMS0xLTEtMA_660e989f-d8b7-4c9e-95f0-670e09d20088"
      unitRef="usd">5747394000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="id365c5f1d37444ac9e1da5b5891cd81a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xNi9mcmFnOmM4NzUzODM2OGZlMzQ5OWQ4OTA1NjI3ZTdmN2U4MWEzL3RhYmxlOjJjMmQxMWM4NDU4YzQ4ZTFiMDFkNmI5NTY3N2YzNmYwL3RhYmxlcmFuZ2U6MmMyZDExYzg0NThjNDhlMWIwMWQ2Yjk1Njc3ZjM2ZjBfMzQtMy0xLTEtMA_c4970306-2902-4b37-91ef-13a6ee1f0faf"
      unitRef="usd">5644074000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="idd7204dc87d24972a01f15b098c4f56b_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xNi9mcmFnOmM4NzUzODM2OGZlMzQ5OWQ4OTA1NjI3ZTdmN2U4MWEzL3RhYmxlOjJjMmQxMWM4NDU4YzQ4ZTFiMDFkNmI5NTY3N2YzNmYwL3RhYmxlcmFuZ2U6MmMyZDExYzg0NThjNDhlMWIwMWQ2Yjk1Njc3ZjM2ZjBfMzUtMS0xLTEtMA_59394d7e-2995-44f3-9646-9279245ef15d"
      unitRef="usd">-36717000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="id365c5f1d37444ac9e1da5b5891cd81a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xNi9mcmFnOmM4NzUzODM2OGZlMzQ5OWQ4OTA1NjI3ZTdmN2U4MWEzL3RhYmxlOjJjMmQxMWM4NDU4YzQ4ZTFiMDFkNmI5NTY3N2YzNmYwL3RhYmxlcmFuZ2U6MmMyZDExYzg0NThjNDhlMWIwMWQ2Yjk1Njc3ZjM2ZjBfMzUtMy0xLTEtMA_73147315-3a27-45cc-85da-3712aa2fbc87"
      unitRef="usd">-43622000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="idd7204dc87d24972a01f15b098c4f56b_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xNi9mcmFnOmM4NzUzODM2OGZlMzQ5OWQ4OTA1NjI3ZTdmN2U4MWEzL3RhYmxlOjJjMmQxMWM4NDU4YzQ4ZTFiMDFkNmI5NTY3N2YzNmYwL3RhYmxlcmFuZ2U6MmMyZDExYzg0NThjNDhlMWIwMWQ2Yjk1Njc3ZjM2ZjBfMzYtMS0xLTEtMA_16bf590e-ac28-4fb7-add6-e86c6af567f5"
      unitRef="usd">-4785660000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="id365c5f1d37444ac9e1da5b5891cd81a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xNi9mcmFnOmM4NzUzODM2OGZlMzQ5OWQ4OTA1NjI3ZTdmN2U4MWEzL3RhYmxlOjJjMmQxMWM4NDU4YzQ4ZTFiMDFkNmI5NTY3N2YzNmYwL3RhYmxlcmFuZ2U6MmMyZDExYzg0NThjNDhlMWIwMWQ2Yjk1Njc3ZjM2ZjBfMzYtMy0xLTEtMA_751df80d-3868-439b-bdc0-d77a5b5736cd"
      unitRef="usd">-4585369000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="idd7204dc87d24972a01f15b098c4f56b_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xNi9mcmFnOmM4NzUzODM2OGZlMzQ5OWQ4OTA1NjI3ZTdmN2U4MWEzL3RhYmxlOjJjMmQxMWM4NDU4YzQ4ZTFiMDFkNmI5NTY3N2YzNmYwL3RhYmxlcmFuZ2U6MmMyZDExYzg0NThjNDhlMWIwMWQ2Yjk1Njc3ZjM2ZjBfMzctMS0xLTEtMA_fd9535fa-cdcc-439b-8372-35154660a80b"
      unitRef="usd">926190000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id365c5f1d37444ac9e1da5b5891cd81a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xNi9mcmFnOmM4NzUzODM2OGZlMzQ5OWQ4OTA1NjI3ZTdmN2U4MWEzL3RhYmxlOjJjMmQxMWM4NDU4YzQ4ZTFiMDFkNmI5NTY3N2YzNmYwL3RhYmxlcmFuZ2U6MmMyZDExYzg0NThjNDhlMWIwMWQ2Yjk1Njc3ZjM2ZjBfMzctMy0xLTEtMA_b3d21b2f-21ea-41f3-8f88-3084025c5a28"
      unitRef="usd">1016247000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="idd7204dc87d24972a01f15b098c4f56b_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xNi9mcmFnOmM4NzUzODM2OGZlMzQ5OWQ4OTA1NjI3ZTdmN2U4MWEzL3RhYmxlOjJjMmQxMWM4NDU4YzQ4ZTFiMDFkNmI5NTY3N2YzNmYwL3RhYmxlcmFuZ2U6MmMyZDExYzg0NThjNDhlMWIwMWQ2Yjk1Njc3ZjM2ZjBfMzgtMS0xLTEtMA_e219c72e-0f5b-4644-92cf-4f3f29e9c91c"
      unitRef="usd">3255269000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="id365c5f1d37444ac9e1da5b5891cd81a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8xNi9mcmFnOmM4NzUzODM2OGZlMzQ5OWQ4OTA1NjI3ZTdmN2U4MWEzL3RhYmxlOjJjMmQxMWM4NDU4YzQ4ZTFiMDFkNmI5NTY3N2YzNmYwL3RhYmxlcmFuZ2U6MmMyZDExYzg0NThjNDhlMWIwMWQ2Yjk1Njc3ZjM2ZjBfMzgtMy0xLTEtMA_50f09ff1-e438-4817-8f8b-9e6b21bca7ab"
      unitRef="usd">3407061000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia489a15348ae4ae390bc47557aaca423_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yMi9mcmFnOjBmN2NkMTY0ZGEzMjQyNmQ4NWU3OWQ5MzcxMTNmNTBkL3RhYmxlOjRmMzYzODc2YmY5NzRiODliYjcyY2Q1MjczZjU4NGFmL3RhYmxlcmFuZ2U6NGYzNjM4NzZiZjk3NGI4OWJiNzJjZDUyNzNmNTg0YWZfNC0xLTEtMS0w_63ccd53f-437b-4811-b8e4-a71b6dc0adc6"
      unitRef="usd">135769000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iae589afb590a4f5984a5dd4001d656cb_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yMi9mcmFnOjBmN2NkMTY0ZGEzMjQyNmQ4NWU3OWQ5MzcxMTNmNTBkL3RhYmxlOjRmMzYzODc2YmY5NzRiODliYjcyY2Q1MjczZjU4NGFmL3RhYmxlcmFuZ2U6NGYzNjM4NzZiZjk3NGI4OWJiNzJjZDUyNzNmNTg0YWZfNC0zLTEtMS0w_4f96f8b2-796b-47ca-b989-20590a7ad8fb"
      unitRef="usd">71938000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6912a2c4b43f46838e7d9157c5b3a723_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yMi9mcmFnOjBmN2NkMTY0ZGEzMjQyNmQ4NWU3OWQ5MzcxMTNmNTBkL3RhYmxlOjRmMzYzODc2YmY5NzRiODliYjcyY2Q1MjczZjU4NGFmL3RhYmxlcmFuZ2U6NGYzNjM4NzZiZjk3NGI4OWJiNzJjZDUyNzNmNTg0YWZfNS0xLTEtMS0w_7ad4a1c1-7750-4ada-a1e1-457a8f6e9672"
      unitRef="usd">41797000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i738b536de6724c23b1637b0913d14f26_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yMi9mcmFnOjBmN2NkMTY0ZGEzMjQyNmQ4NWU3OWQ5MzcxMTNmNTBkL3RhYmxlOjRmMzYzODc2YmY5NzRiODliYjcyY2Q1MjczZjU4NGFmL3RhYmxlcmFuZ2U6NGYzNjM4NzZiZjk3NGI4OWJiNzJjZDUyNzNmNTg0YWZfNS0zLTEtMS0w_af04b2c9-4398-4e0f-a905-685154b9e3df"
      unitRef="usd">27538000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yMi9mcmFnOjBmN2NkMTY0ZGEzMjQyNmQ4NWU3OWQ5MzcxMTNmNTBkL3RhYmxlOjRmMzYzODc2YmY5NzRiODliYjcyY2Q1MjczZjU4NGFmL3RhYmxlcmFuZ2U6NGYzNjM4NzZiZjk3NGI4OWJiNzJjZDUyNzNmNTg0YWZfNi0xLTEtMS0w_d1d17b89-cb12-47f5-84fe-e455a87fb820"
      unitRef="usd">177566000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ide9f6e15665746279d0000be700fcc6a_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yMi9mcmFnOjBmN2NkMTY0ZGEzMjQyNmQ4NWU3OWQ5MzcxMTNmNTBkL3RhYmxlOjRmMzYzODc2YmY5NzRiODliYjcyY2Q1MjczZjU4NGFmL3RhYmxlcmFuZ2U6NGYzNjM4NzZiZjk3NGI4OWJiNzJjZDUyNzNmNTg0YWZfNi0zLTEtMS0w_50590d2f-0954-457c-8865-170c619c30d9"
      unitRef="usd">99476000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yMi9mcmFnOjBmN2NkMTY0ZGEzMjQyNmQ4NWU3OWQ5MzcxMTNmNTBkL3RhYmxlOjRmMzYzODc2YmY5NzRiODliYjcyY2Q1MjczZjU4NGFmL3RhYmxlcmFuZ2U6NGYzNjM4NzZiZjk3NGI4OWJiNzJjZDUyNzNmNTg0YWZfOC0xLTEtMS0w_a2378341-9f1b-4dd0-9604-bb2557719286"
      unitRef="usd">23023000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ide9f6e15665746279d0000be700fcc6a_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yMi9mcmFnOjBmN2NkMTY0ZGEzMjQyNmQ4NWU3OWQ5MzcxMTNmNTBkL3RhYmxlOjRmMzYzODc2YmY5NzRiODliYjcyY2Q1MjczZjU4NGFmL3RhYmxlcmFuZ2U6NGYzNjM4NzZiZjk3NGI4OWJiNzJjZDUyNzNmNTg0YWZfOC0zLTEtMS0w_d0d1f058-924d-4119-8bda-cb184e096fc0"
      unitRef="usd">13302000</us-gaap:CostOfGoodsAndServicesSold>
    <alny:CostOfCollaborationManufacturingAndRoyalties
      contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yMi9mcmFnOjBmN2NkMTY0ZGEzMjQyNmQ4NWU3OWQ5MzcxMTNmNTBkL3RhYmxlOjRmMzYzODc2YmY5NzRiODliYjcyY2Q1MjczZjU4NGFmL3RhYmxlcmFuZ2U6NGYzNjM4NzZiZjk3NGI4OWJiNzJjZDUyNzNmNTg0YWZfOS0xLTEtMS02ODU_c8cfe557-e4fb-4190-9297-8094425a06f5"
      unitRef="usd">8039000</alny:CostOfCollaborationManufacturingAndRoyalties>
    <alny:CostOfCollaborationManufacturingAndRoyalties
      contextRef="ide9f6e15665746279d0000be700fcc6a_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yMi9mcmFnOjBmN2NkMTY0ZGEzMjQyNmQ4NWU3OWQ5MzcxMTNmNTBkL3RhYmxlOjRmMzYzODc2YmY5NzRiODliYjcyY2Q1MjczZjU4NGFmL3RhYmxlcmFuZ2U6NGYzNjM4NzZiZjk3NGI4OWJiNzJjZDUyNzNmNTg0YWZfOS0zLTEtMS02ODU_86a8e56f-72be-411e-ab3f-d28e6a9b7068"
      unitRef="usd">0</alny:CostOfCollaborationManufacturingAndRoyalties>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yMi9mcmFnOjBmN2NkMTY0ZGEzMjQyNmQ4NWU3OWQ5MzcxMTNmNTBkL3RhYmxlOjRmMzYzODc2YmY5NzRiODliYjcyY2Q1MjczZjU4NGFmL3RhYmxlcmFuZ2U6NGYzNjM4NzZiZjk3NGI4OWJiNzJjZDUyNzNmNTg0YWZfOS0xLTEtMS0w_98062a4b-d51e-411d-b683-39dc63dd8441"
      unitRef="usd">185899000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ide9f6e15665746279d0000be700fcc6a_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yMi9mcmFnOjBmN2NkMTY0ZGEzMjQyNmQ4NWU3OWQ5MzcxMTNmNTBkL3RhYmxlOjRmMzYzODc2YmY5NzRiODliYjcyY2Q1MjczZjU4NGFmL3RhYmxlcmFuZ2U6NGYzNjM4NzZiZjk3NGI4OWJiNzJjZDUyNzNmNTg0YWZfOS0zLTEtMS0w_6c43da1d-b1cd-4b98-b85a-d8c2a734402a"
      unitRef="usd">169571000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yMi9mcmFnOjBmN2NkMTY0ZGEzMjQyNmQ4NWU3OWQ5MzcxMTNmNTBkL3RhYmxlOjRmMzYzODc2YmY5NzRiODliYjcyY2Q1MjczZjU4NGFmL3RhYmxlcmFuZ2U6NGYzNjM4NzZiZjk3NGI4OWJiNzJjZDUyNzNmNTg0YWZfMTAtMS0xLTEtMA_4c3b7db0-c126-4998-99f6-ffe29f907b6c"
      unitRef="usd">146859000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="ide9f6e15665746279d0000be700fcc6a_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yMi9mcmFnOjBmN2NkMTY0ZGEzMjQyNmQ4NWU3OWQ5MzcxMTNmNTBkL3RhYmxlOjRmMzYzODc2YmY5NzRiODliYjcyY2Q1MjczZjU4NGFmL3RhYmxlcmFuZ2U6NGYzNjM4NzZiZjk3NGI4OWJiNzJjZDUyNzNmNTg0YWZfMTAtMy0xLTEtMA_24ff3e7c-c09d-48a4-a082-f1fc733df8ec"
      unitRef="usd">126761000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:CostsAndExpenses
      contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yMi9mcmFnOjBmN2NkMTY0ZGEzMjQyNmQ4NWU3OWQ5MzcxMTNmNTBkL3RhYmxlOjRmMzYzODc2YmY5NzRiODliYjcyY2Q1MjczZjU4NGFmL3RhYmxlcmFuZ2U6NGYzNjM4NzZiZjk3NGI4OWJiNzJjZDUyNzNmNTg0YWZfMTEtMS0xLTEtMA_9dd10383-047e-4cd9-8756-ea8e2f28126e"
      unitRef="usd">363820000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="ide9f6e15665746279d0000be700fcc6a_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yMi9mcmFnOjBmN2NkMTY0ZGEzMjQyNmQ4NWU3OWQ5MzcxMTNmNTBkL3RhYmxlOjRmMzYzODc2YmY5NzRiODliYjcyY2Q1MjczZjU4NGFmL3RhYmxlcmFuZ2U6NGYzNjM4NzZiZjk3NGI4OWJiNzJjZDUyNzNmNTg0YWZfMTEtMy0xLTEtMA_e0b95f45-417e-48a5-b4da-26413b93c7a6"
      unitRef="usd">309634000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yMi9mcmFnOjBmN2NkMTY0ZGEzMjQyNmQ4NWU3OWQ5MzcxMTNmNTBkL3RhYmxlOjRmMzYzODc2YmY5NzRiODliYjcyY2Q1MjczZjU4NGFmL3RhYmxlcmFuZ2U6NGYzNjM4NzZiZjk3NGI4OWJiNzJjZDUyNzNmNTg0YWZfMTItMS0xLTEtMA_30c39a08-261d-4984-a2b7-4b22e0593cd0"
      unitRef="usd">-186254000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ide9f6e15665746279d0000be700fcc6a_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yMi9mcmFnOjBmN2NkMTY0ZGEzMjQyNmQ4NWU3OWQ5MzcxMTNmNTBkL3RhYmxlOjRmMzYzODc2YmY5NzRiODliYjcyY2Q1MjczZjU4NGFmL3RhYmxlcmFuZ2U6NGYzNjM4NzZiZjk3NGI4OWJiNzJjZDUyNzNmNTg0YWZfMTItMy0xLTEtMA_66d11d1a-17d7-48b9-a5f5-902bf270e161"
      unitRef="usd">-210158000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpense
      contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yMi9mcmFnOjBmN2NkMTY0ZGEzMjQyNmQ4NWU3OWQ5MzcxMTNmNTBkL3RhYmxlOjRmMzYzODc2YmY5NzRiODliYjcyY2Q1MjczZjU4NGFmL3RhYmxlcmFuZ2U6NGYzNjM4NzZiZjk3NGI4OWJiNzJjZDUyNzNmNTg0YWZfMTQtMS0xLTEtMA_23d4ef98-176a-4e66-b588-eb189a46ff78"
      unitRef="usd">32515000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="ide9f6e15665746279d0000be700fcc6a_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yMi9mcmFnOjBmN2NkMTY0ZGEzMjQyNmQ4NWU3OWQ5MzcxMTNmNTBkL3RhYmxlOjRmMzYzODc2YmY5NzRiODliYjcyY2Q1MjczZjU4NGFmL3RhYmxlcmFuZ2U6NGYzNjM4NzZiZjk3NGI4OWJiNzJjZDUyNzNmNTg0YWZfMTQtMy0xLTEtMA_887ccff4-8f22-4c02-a082-e4993ed07ab4"
      unitRef="usd">0</us-gaap:InterestExpense>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yMi9mcmFnOjBmN2NkMTY0ZGEzMjQyNmQ4NWU3OWQ5MzcxMTNmNTBkL3RhYmxlOjRmMzYzODc2YmY5NzRiODliYjcyY2Q1MjczZjU4NGFmL3RhYmxlcmFuZ2U6NGYzNjM4NzZiZjk3NGI4OWJiNzJjZDUyNzNmNTg0YWZfMTUtMS0xLTEtMA_3a070ce2-43f3-4314-8811-dee10a14ee80"
      unitRef="usd">450000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="ide9f6e15665746279d0000be700fcc6a_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yMi9mcmFnOjBmN2NkMTY0ZGEzMjQyNmQ4NWU3OWQ5MzcxMTNmNTBkL3RhYmxlOjRmMzYzODc2YmY5NzRiODliYjcyY2Q1MjczZjU4NGFmL3RhYmxlcmFuZ2U6NGYzNjM4NzZiZjk3NGI4OWJiNzJjZDUyNzNmNTg0YWZfMTUtMy0xLTEtMA_2b5e5eba-778f-4bac-8658-bf9b038c0bc9"
      unitRef="usd">5480000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yMi9mcmFnOjBmN2NkMTY0ZGEzMjQyNmQ4NWU3OWQ5MzcxMTNmNTBkL3RhYmxlOjRmMzYzODc2YmY5NzRiODliYjcyY2Q1MjczZjU4NGFmL3RhYmxlcmFuZ2U6NGYzNjM4NzZiZjk3NGI4OWJiNzJjZDUyNzNmNTg0YWZfMTYtMS0xLTEtMA_cc6a939a-ea2c-4e14-b6a3-3dbc767e902b"
      unitRef="usd">19044000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ide9f6e15665746279d0000be700fcc6a_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yMi9mcmFnOjBmN2NkMTY0ZGEzMjQyNmQ4NWU3OWQ5MzcxMTNmNTBkL3RhYmxlOjRmMzYzODc2YmY5NzRiODliYjcyY2Q1MjczZjU4NGFmL3RhYmxlcmFuZ2U6NGYzNjM4NzZiZjk3NGI4OWJiNzJjZDUyNzNmNTg0YWZfMTYtMy0xLTEtMA_962b0082-118b-4fa5-9f74-631d88225273"
      unitRef="usd">23032000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yMi9mcmFnOjBmN2NkMTY0ZGEzMjQyNmQ4NWU3OWQ5MzcxMTNmNTBkL3RhYmxlOjRmMzYzODc2YmY5NzRiODliYjcyY2Q1MjczZjU4NGFmL3RhYmxlcmFuZ2U6NGYzNjM4NzZiZjk3NGI4OWJiNzJjZDUyNzNmNTg0YWZfMTgtMS0xLTEtMA_65c1c772-62db-4763-a9e0-bbddf9cf8e4f"
      unitRef="usd">-13021000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="ide9f6e15665746279d0000be700fcc6a_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yMi9mcmFnOjBmN2NkMTY0ZGEzMjQyNmQ4NWU3OWQ5MzcxMTNmNTBkL3RhYmxlOjRmMzYzODc2YmY5NzRiODliYjcyY2Q1MjczZjU4NGFmL3RhYmxlcmFuZ2U6NGYzNjM4NzZiZjk3NGI4OWJiNzJjZDUyNzNmNTg0YWZfMTgtMy0xLTEtMA_ee3c0f07-47cc-485d-a69f-1e04c7ab4f7d"
      unitRef="usd">28512000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yMi9mcmFnOjBmN2NkMTY0ZGEzMjQyNmQ4NWU3OWQ5MzcxMTNmNTBkL3RhYmxlOjRmMzYzODc2YmY5NzRiODliYjcyY2Q1MjczZjU4NGFmL3RhYmxlcmFuZ2U6NGYzNjM4NzZiZjk3NGI4OWJiNzJjZDUyNzNmNTg0YWZfMTktMS0xLTEtMA_d42b0225-eaa4-4595-bc2b-98b04aef0faa"
      unitRef="usd">-199275000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ide9f6e15665746279d0000be700fcc6a_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yMi9mcmFnOjBmN2NkMTY0ZGEzMjQyNmQ4NWU3OWQ5MzcxMTNmNTBkL3RhYmxlOjRmMzYzODc2YmY5NzRiODliYjcyY2Q1MjczZjU4NGFmL3RhYmxlcmFuZ2U6NGYzNjM4NzZiZjk3NGI4OWJiNzJjZDUyNzNmNTg0YWZfMTktMy0xLTEtMA_ed65fe37-253b-4374-8d2d-cf9f829265f0"
      unitRef="usd">-181646000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yMi9mcmFnOjBmN2NkMTY0ZGEzMjQyNmQ4NWU3OWQ5MzcxMTNmNTBkL3RhYmxlOjRmMzYzODc2YmY5NzRiODliYjcyY2Q1MjczZjU4NGFmL3RhYmxlcmFuZ2U6NGYzNjM4NzZiZjk3NGI4OWJiNzJjZDUyNzNmNTg0YWZfMjAtMS0xLTEtMA_5ea94c6d-2e2d-4e75-a1dd-dfad110e1548"
      unitRef="usd">1016000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ide9f6e15665746279d0000be700fcc6a_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yMi9mcmFnOjBmN2NkMTY0ZGEzMjQyNmQ4NWU3OWQ5MzcxMTNmNTBkL3RhYmxlOjRmMzYzODc2YmY5NzRiODliYjcyY2Q1MjczZjU4NGFmL3RhYmxlcmFuZ2U6NGYzNjM4NzZiZjk3NGI4OWJiNzJjZDUyNzNmNTg0YWZfMjAtMy0xLTEtMA_f9abec99-95a8-4ddd-9660-08e353e45a9b"
      unitRef="usd">575000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yMi9mcmFnOjBmN2NkMTY0ZGEzMjQyNmQ4NWU3OWQ5MzcxMTNmNTBkL3RhYmxlOjRmMzYzODc2YmY5NzRiODliYjcyY2Q1MjczZjU4NGFmL3RhYmxlcmFuZ2U6NGYzNjM4NzZiZjk3NGI4OWJiNzJjZDUyNzNmNTg0YWZfMjEtMS0xLTEtMA_f8e541f9-8015-40e9-ba34-7da825deefed"
      unitRef="usd">-200291000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ide9f6e15665746279d0000be700fcc6a_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yMi9mcmFnOjBmN2NkMTY0ZGEzMjQyNmQ4NWU3OWQ5MzcxMTNmNTBkL3RhYmxlOjRmMzYzODc2YmY5NzRiODliYjcyY2Q1MjczZjU4NGFmL3RhYmxlcmFuZ2U6NGYzNjM4NzZiZjk3NGI4OWJiNzJjZDUyNzNmNTg0YWZfMjEtMy0xLTEtMA_d298190e-6dab-469f-b47c-98a472fd165f"
      unitRef="usd">-182221000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yMi9mcmFnOjBmN2NkMTY0ZGEzMjQyNmQ4NWU3OWQ5MzcxMTNmNTBkL3RhYmxlOjRmMzYzODc2YmY5NzRiODliYjcyY2Q1MjczZjU4NGFmL3RhYmxlcmFuZ2U6NGYzNjM4NzZiZjk3NGI4OWJiNzJjZDUyNzNmNTg0YWZfMjItMS0xLTEtMA_3ef2e0f1-f62b-44e4-a886-d7db0451a569"
      unitRef="usdPerShare">-1.71</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="ide9f6e15665746279d0000be700fcc6a_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yMi9mcmFnOjBmN2NkMTY0ZGEzMjQyNmQ4NWU3OWQ5MzcxMTNmNTBkL3RhYmxlOjRmMzYzODc2YmY5NzRiODliYjcyY2Q1MjczZjU4NGFmL3RhYmxlcmFuZ2U6NGYzNjM4NzZiZjk3NGI4OWJiNzJjZDUyNzNmNTg0YWZfMjItMy0xLTEtMA_df9f50bd-2a4b-4f2f-95a9-0490de4c5446"
      unitRef="usdPerShare">-1.62</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yMi9mcmFnOjBmN2NkMTY0ZGEzMjQyNmQ4NWU3OWQ5MzcxMTNmNTBkL3RhYmxlOjRmMzYzODc2YmY5NzRiODliYjcyY2Q1MjczZjU4NGFmL3RhYmxlcmFuZ2U6NGYzNjM4NzZiZjk3NGI4OWJiNzJjZDUyNzNmNTg0YWZfMjMtMS0xLTEtMA_0fe40dd5-05ff-4c6b-a376-40019f617ba4"
      unitRef="shares">117080000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="ide9f6e15665746279d0000be700fcc6a_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yMi9mcmFnOjBmN2NkMTY0ZGEzMjQyNmQ4NWU3OWQ5MzcxMTNmNTBkL3RhYmxlOjRmMzYzODc2YmY5NzRiODliYjcyY2Q1MjczZjU4NGFmL3RhYmxlcmFuZ2U6NGYzNjM4NzZiZjk3NGI4OWJiNzJjZDUyNzNmNTg0YWZfMjMtMy0xLTEtMA_eee079f0-090d-4e72-977b-60934de04fee"
      unitRef="shares">112748000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:NetIncomeLoss
      contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yMi9mcmFnOjBmN2NkMTY0ZGEzMjQyNmQ4NWU3OWQ5MzcxMTNmNTBkL3RhYmxlOjRmMzYzODc2YmY5NzRiODliYjcyY2Q1MjczZjU4NGFmL3RhYmxlcmFuZ2U6NGYzNjM4NzZiZjk3NGI4OWJiNzJjZDUyNzNmNTg0YWZfMjYtMS0xLTEtMA_6c5aa7ab-baa6-46f2-b114-8452003a1794"
      unitRef="usd">-200291000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ide9f6e15665746279d0000be700fcc6a_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yMi9mcmFnOjBmN2NkMTY0ZGEzMjQyNmQ4NWU3OWQ5MzcxMTNmNTBkL3RhYmxlOjRmMzYzODc2YmY5NzRiODliYjcyY2Q1MjczZjU4NGFmL3RhYmxlcmFuZ2U6NGYzNjM4NzZiZjk3NGI4OWJiNzJjZDUyNzNmNTg0YWZfMjYtMy0xLTEtMA_72d4e83c-0e91-467e-999f-2b584dd6c8a3"
      unitRef="usd">-182221000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yMi9mcmFnOjBmN2NkMTY0ZGEzMjQyNmQ4NWU3OWQ5MzcxMTNmNTBkL3RhYmxlOjRmMzYzODc2YmY5NzRiODliYjcyY2Q1MjczZjU4NGFmL3RhYmxlcmFuZ2U6NGYzNjM4NzZiZjk3NGI4OWJiNzJjZDUyNzNmNTg0YWZfMjgtMS0xLTEtMA_735d5c55-9cf3-4583-8db3-7d300eaa7278"
      unitRef="usd">-1000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ide9f6e15665746279d0000be700fcc6a_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yMi9mcmFnOjBmN2NkMTY0ZGEzMjQyNmQ4NWU3OWQ5MzcxMTNmNTBkL3RhYmxlOjRmMzYzODc2YmY5NzRiODliYjcyY2Q1MjczZjU4NGFmL3RhYmxlcmFuZ2U6NGYzNjM4NzZiZjk3NGI4OWJiNzJjZDUyNzNmNTg0YWZfMjgtMy0xLTEtMA_8d490a57-5bab-4b21-a8b5-e6ba96c8d498"
      unitRef="usd">4045000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yMi9mcmFnOjBmN2NkMTY0ZGEzMjQyNmQ4NWU3OWQ5MzcxMTNmNTBkL3RhYmxlOjRmMzYzODc2YmY5NzRiODliYjcyY2Q1MjczZjU4NGFmL3RhYmxlcmFuZ2U6NGYzNjM4NzZiZjk3NGI4OWJiNzJjZDUyNzNmNTg0YWZfMjktMS0xLTEtMA_ddfe1d67-55ac-4159-aa98-8e265b63aeb9"
      unitRef="usd">6848000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="ide9f6e15665746279d0000be700fcc6a_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yMi9mcmFnOjBmN2NkMTY0ZGEzMjQyNmQ4NWU3OWQ5MzcxMTNmNTBkL3RhYmxlOjRmMzYzODc2YmY5NzRiODliYjcyY2Q1MjczZjU4NGFmL3RhYmxlcmFuZ2U6NGYzNjM4NzZiZjk3NGI4OWJiNzJjZDUyNzNmNTg0YWZfMjktMy0xLTEtMA_f10e3ad1-0549-4d0b-9acc-2fab0c2aa0d9"
      unitRef="usd">340000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax
      contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yMi9mcmFnOjBmN2NkMTY0ZGEzMjQyNmQ4NWU3OWQ5MzcxMTNmNTBkL3RhYmxlOjRmMzYzODc2YmY5NzRiODliYjcyY2Q1MjczZjU4NGFmL3RhYmxlcmFuZ2U6NGYzNjM4NzZiZjk3NGI4OWJiNzJjZDUyNzNmNTg0YWZfMzAtMS0xLTEtMA_aafd16d4-ae06-4665-ab06-c7827cec122f"
      unitRef="usd">-58000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax
      contextRef="ide9f6e15665746279d0000be700fcc6a_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yMi9mcmFnOjBmN2NkMTY0ZGEzMjQyNmQ4NWU3OWQ5MzcxMTNmNTBkL3RhYmxlOjRmMzYzODc2YmY5NzRiODliYjcyY2Q1MjczZjU4NGFmL3RhYmxlcmFuZ2U6NGYzNjM4NzZiZjk3NGI4OWJiNzJjZDUyNzNmNTg0YWZfMzAtMy0xLTEtMA_f7612a14-b6e3-4289-9fb8-3718ab8fda81"
      unitRef="usd">-74000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yMi9mcmFnOjBmN2NkMTY0ZGEzMjQyNmQ4NWU3OWQ5MzcxMTNmNTBkL3RhYmxlOjRmMzYzODc2YmY5NzRiODliYjcyY2Q1MjczZjU4NGFmL3RhYmxlcmFuZ2U6NGYzNjM4NzZiZjk3NGI4OWJiNzJjZDUyNzNmNTg0YWZfMzEtMS0xLTEtMA_8c87ae09-bf25-42be-8807-f8135cc42ef7"
      unitRef="usd">6905000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ide9f6e15665746279d0000be700fcc6a_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yMi9mcmFnOjBmN2NkMTY0ZGEzMjQyNmQ4NWU3OWQ5MzcxMTNmNTBkL3RhYmxlOjRmMzYzODc2YmY5NzRiODliYjcyY2Q1MjczZjU4NGFmL3RhYmxlcmFuZ2U6NGYzNjM4NzZiZjk3NGI4OWJiNzJjZDUyNzNmNTg0YWZfMzEtMy0xLTEtMA_fa79e7be-7ec2-422f-9029-adec164f8b71"
      unitRef="usd">4459000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yMi9mcmFnOjBmN2NkMTY0ZGEzMjQyNmQ4NWU3OWQ5MzcxMTNmNTBkL3RhYmxlOjRmMzYzODc2YmY5NzRiODliYjcyY2Q1MjczZjU4NGFmL3RhYmxlcmFuZ2U6NGYzNjM4NzZiZjk3NGI4OWJiNzJjZDUyNzNmNTg0YWZfMzItMS0xLTEtMA_3a718066-c594-404a-a84f-ad36b74e8906"
      unitRef="usd">-193386000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ide9f6e15665746279d0000be700fcc6a_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yMi9mcmFnOjBmN2NkMTY0ZGEzMjQyNmQ4NWU3OWQ5MzcxMTNmNTBkL3RhYmxlOjRmMzYzODc2YmY5NzRiODliYjcyY2Q1MjczZjU4NGFmL3RhYmxlcmFuZ2U6NGYzNjM4NzZiZjk3NGI4OWJiNzJjZDUyNzNmNTg0YWZfMzItMy0xLTEtMA_04c886bc-60e7-4f7e-bc3e-48c328339065"
      unitRef="usd">-177762000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i781a6cf71b15431fb0056bd6a2d9ba9f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yNS9mcmFnOmZhNDE3YThiNWEyYjQwYmViMzBkYjcwYzZkYzVjMTljL3RhYmxlOmM1ZTdhZmI5NmQxYzQzODA5YmExOTFiMzkxMjY0YTM0L3RhYmxlcmFuZ2U6YzVlN2FmYjk2ZDFjNDM4MDliYTE5MWIzOTEyNjRhMzRfMi0xLTEtMS0w_bb1db569-0863-4466-a6ff-dd7f155a35c8"
      unitRef="shares">116427000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i781a6cf71b15431fb0056bd6a2d9ba9f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yNS9mcmFnOmZhNDE3YThiNWEyYjQwYmViMzBkYjcwYzZkYzVjMTljL3RhYmxlOmM1ZTdhZmI5NmQxYzQzODA5YmExOTFiMzkxMjY0YTM0L3RhYmxlcmFuZ2U6YzVlN2FmYjk2ZDFjNDM4MDliYTE5MWIzOTEyNjRhMzRfMi0zLTEtMS0w_56f22f65-cb37-40b2-a7fb-d7d60f82b544"
      unitRef="usd">1164000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7c2ae885ee354f1c9e0aa3c387519965_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yNS9mcmFnOmZhNDE3YThiNWEyYjQwYmViMzBkYjcwYzZkYzVjMTljL3RhYmxlOmM1ZTdhZmI5NmQxYzQzODA5YmExOTFiMzkxMjY0YTM0L3RhYmxlcmFuZ2U6YzVlN2FmYjk2ZDFjNDM4MDliYTE5MWIzOTEyNjRhMzRfMi01LTEtMS0w_6dff58c9-26ad-475e-b7f3-4213b538d988"
      unitRef="usd">5644074000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie217873afb06447795dc36a1e1606a74_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yNS9mcmFnOmZhNDE3YThiNWEyYjQwYmViMzBkYjcwYzZkYzVjMTljL3RhYmxlOmM1ZTdhZmI5NmQxYzQzODA5YmExOTFiMzkxMjY0YTM0L3RhYmxlcmFuZ2U6YzVlN2FmYjk2ZDFjNDM4MDliYTE5MWIzOTEyNjRhMzRfMi03LTEtMS0w_78cc7e0c-46d4-4b44-b5a2-e47cd20bf691"
      unitRef="usd">-43622000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4ed3654498ae467fa00b86595fc2fd74_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yNS9mcmFnOmZhNDE3YThiNWEyYjQwYmViMzBkYjcwYzZkYzVjMTljL3RhYmxlOmM1ZTdhZmI5NmQxYzQzODA5YmExOTFiMzkxMjY0YTM0L3RhYmxlcmFuZ2U6YzVlN2FmYjk2ZDFjNDM4MDliYTE5MWIzOTEyNjRhMzRfMi05LTEtMS0w_b9194760-da1e-41d0-bc42-fadb345ba018"
      unitRef="usd">-4585369000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id365c5f1d37444ac9e1da5b5891cd81a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yNS9mcmFnOmZhNDE3YThiNWEyYjQwYmViMzBkYjcwYzZkYzVjMTljL3RhYmxlOmM1ZTdhZmI5NmQxYzQzODA5YmExOTFiMzkxMjY0YTM0L3RhYmxlcmFuZ2U6YzVlN2FmYjk2ZDFjNDM4MDliYTE5MWIzOTEyNjRhMzRfMi0xMS0xLTEtMA_4d30b6f1-cf16-458d-8924-367797fa1d0d"
      unitRef="usd">1016247000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ie41b061be2004e5993962162ca83d40e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yNS9mcmFnOmZhNDE3YThiNWEyYjQwYmViMzBkYjcwYzZkYzVjMTljL3RhYmxlOmM1ZTdhZmI5NmQxYzQzODA5YmExOTFiMzkxMjY0YTM0L3RhYmxlcmFuZ2U6YzVlN2FmYjk2ZDFjNDM4MDliYTE5MWIzOTEyNjRhMzRfMy0xLTEtMS0w_88fdcf38-bf7b-4210-9667-aeecc99c7fb3"
      unitRef="shares">614000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ie41b061be2004e5993962162ca83d40e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yNS9mcmFnOmZhNDE3YThiNWEyYjQwYmViMzBkYjcwYzZkYzVjMTljL3RhYmxlOmM1ZTdhZmI5NmQxYzQzODA5YmExOTFiMzkxMjY0YTM0L3RhYmxlcmFuZ2U6YzVlN2FmYjk2ZDFjNDM4MDliYTE5MWIzOTEyNjRhMzRfMy0zLTEtMS0w_fdc4b75b-59cc-4c54-848a-ec64bddc1479"
      unitRef="usd">6000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i5919ecb151d7401699f63ec0b4537716_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yNS9mcmFnOmZhNDE3YThiNWEyYjQwYmViMzBkYjcwYzZkYzVjMTljL3RhYmxlOmM1ZTdhZmI5NmQxYzQzODA5YmExOTFiMzkxMjY0YTM0L3RhYmxlcmFuZ2U6YzVlN2FmYjk2ZDFjNDM4MDliYTE5MWIzOTEyNjRhMzRfMy01LTEtMS0w_fe76ea53-e810-412b-b89f-2e24d9c30b86"
      unitRef="usd">47028000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yNS9mcmFnOmZhNDE3YThiNWEyYjQwYmViMzBkYjcwYzZkYzVjMTljL3RhYmxlOmM1ZTdhZmI5NmQxYzQzODA5YmExOTFiMzkxMjY0YTM0L3RhYmxlcmFuZ2U6YzVlN2FmYjk2ZDFjNDM4MDliYTE5MWIzOTEyNjRhMzRfMy0xMS0xLTEtMA_a004a8fb-cc36-474b-a8f8-ff1d30307b21"
      unitRef="usd">47034000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross
      contextRef="ie41b061be2004e5993962162ca83d40e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yNS9mcmFnOmZhNDE3YThiNWEyYjQwYmViMzBkYjcwYzZkYzVjMTljL3RhYmxlOmM1ZTdhZmI5NmQxYzQzODA5YmExOTFiMzkxMjY0YTM0L3RhYmxlcmFuZ2U6YzVlN2FmYjk2ZDFjNDM4MDliYTE5MWIzOTEyNjRhMzRfNC0xLTEtMS0w_fc207848-33e2-45bd-8f8f-3951282b8f68"
      unitRef="shares">280000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="ie41b061be2004e5993962162ca83d40e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yNS9mcmFnOmZhNDE3YThiNWEyYjQwYmViMzBkYjcwYzZkYzVjMTljL3RhYmxlOmM1ZTdhZmI5NmQxYzQzODA5YmExOTFiMzkxMjY0YTM0L3RhYmxlcmFuZ2U6YzVlN2FmYjk2ZDFjNDM4MDliYTE5MWIzOTEyNjRhMzRfNC0zLTEtMS0w_945f9a70-1c1f-4e73-be3b-fb7f5df09bba"
      unitRef="usd">3000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="i5919ecb151d7401699f63ec0b4537716_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yNS9mcmFnOmZhNDE3YThiNWEyYjQwYmViMzBkYjcwYzZkYzVjMTljL3RhYmxlOmM1ZTdhZmI5NmQxYzQzODA5YmExOTFiMzkxMjY0YTM0L3RhYmxlcmFuZ2U6YzVlN2FmYjk2ZDFjNDM4MDliYTE5MWIzOTEyNjRhMzRfNC01LTEtMS0w_90d92fe2-ddba-4755-b572-250b1d8252aa"
      unitRef="usd">-3000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yNS9mcmFnOmZhNDE3YThiNWEyYjQwYmViMzBkYjcwYzZkYzVjMTljL3RhYmxlOmM1ZTdhZmI5NmQxYzQzODA5YmExOTFiMzkxMjY0YTM0L3RhYmxlcmFuZ2U6YzVlN2FmYjk2ZDFjNDM4MDliYTE5MWIzOTEyNjRhMzRfNC0xMS0xLTEtMA_cb2983ab-04bc-461b-8fe7-c0bc375b9ac6"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i5919ecb151d7401699f63ec0b4537716_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yNS9mcmFnOmZhNDE3YThiNWEyYjQwYmViMzBkYjcwYzZkYzVjMTljL3RhYmxlOmM1ZTdhZmI5NmQxYzQzODA5YmExOTFiMzkxMjY0YTM0L3RhYmxlcmFuZ2U6YzVlN2FmYjk2ZDFjNDM4MDliYTE5MWIzOTEyNjRhMzRfNS01LTEtMS0w_fe393b42-df8b-4cbc-98ec-5cbf9f85ef2b"
      unitRef="usd">56295000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yNS9mcmFnOmZhNDE3YThiNWEyYjQwYmViMzBkYjcwYzZkYzVjMTljL3RhYmxlOmM1ZTdhZmI5NmQxYzQzODA5YmExOTFiMzkxMjY0YTM0L3RhYmxlcmFuZ2U6YzVlN2FmYjk2ZDFjNDM4MDliYTE5MWIzOTEyNjRhMzRfNS0xMS0xLTEtMA_28e0c5ab-e51d-42d6-83af-28ae43863dc4"
      unitRef="usd">56295000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i41a01c886cd440cd8cf8eb694fb78c84_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yNS9mcmFnOmZhNDE3YThiNWEyYjQwYmViMzBkYjcwYzZkYzVjMTljL3RhYmxlOmM1ZTdhZmI5NmQxYzQzODA5YmExOTFiMzkxMjY0YTM0L3RhYmxlcmFuZ2U6YzVlN2FmYjk2ZDFjNDM4MDliYTE5MWIzOTEyNjRhMzRfNi03LTEtMS0w_4de0b5d6-0193-4b0e-b1da-3b8eabd5903b"
      unitRef="usd">6905000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yNS9mcmFnOmZhNDE3YThiNWEyYjQwYmViMzBkYjcwYzZkYzVjMTljL3RhYmxlOmM1ZTdhZmI5NmQxYzQzODA5YmExOTFiMzkxMjY0YTM0L3RhYmxlcmFuZ2U6YzVlN2FmYjk2ZDFjNDM4MDliYTE5MWIzOTEyNjRhMzRfNi0xMS0xLTEtMA_bc0cf00e-30b4-4094-9cc8-3f6bd2339f7a"
      unitRef="usd">6905000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="i8c5ae4ff57e341c7951e97ef4434647e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yNS9mcmFnOmZhNDE3YThiNWEyYjQwYmViMzBkYjcwYzZkYzVjMTljL3RhYmxlOmM1ZTdhZmI5NmQxYzQzODA5YmExOTFiMzkxMjY0YTM0L3RhYmxlcmFuZ2U6YzVlN2FmYjk2ZDFjNDM4MDliYTE5MWIzOTEyNjRhMzRfNy05LTEtMS0w_a9a30df6-11de-48e5-aa72-d5dd1a415f38"
      unitRef="usd">-200291000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yNS9mcmFnOmZhNDE3YThiNWEyYjQwYmViMzBkYjcwYzZkYzVjMTljL3RhYmxlOmM1ZTdhZmI5NmQxYzQzODA5YmExOTFiMzkxMjY0YTM0L3RhYmxlcmFuZ2U6YzVlN2FmYjk2ZDFjNDM4MDliYTE5MWIzOTEyNjRhMzRfNy0xMS0xLTEtMA_3de5233f-0b09-4b45-9d22-da0679974014"
      unitRef="usd">-200291000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i898030c659864177808288abf9a59aac_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yNS9mcmFnOmZhNDE3YThiNWEyYjQwYmViMzBkYjcwYzZkYzVjMTljL3RhYmxlOmM1ZTdhZmI5NmQxYzQzODA5YmExOTFiMzkxMjY0YTM0L3RhYmxlcmFuZ2U6YzVlN2FmYjk2ZDFjNDM4MDliYTE5MWIzOTEyNjRhMzRfOC0xLTEtMS0w_8659e44c-0b39-452c-8161-e76475f209e9"
      unitRef="shares">117321000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i898030c659864177808288abf9a59aac_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yNS9mcmFnOmZhNDE3YThiNWEyYjQwYmViMzBkYjcwYzZkYzVjMTljL3RhYmxlOmM1ZTdhZmI5NmQxYzQzODA5YmExOTFiMzkxMjY0YTM0L3RhYmxlcmFuZ2U6YzVlN2FmYjk2ZDFjNDM4MDliYTE5MWIzOTEyNjRhMzRfOC0zLTEtMS0w_df51c063-6b50-46a0-8964-fb666279a0e7"
      unitRef="usd">1173000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic292a95f9d27470da961a5af69a8168d_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yNS9mcmFnOmZhNDE3YThiNWEyYjQwYmViMzBkYjcwYzZkYzVjMTljL3RhYmxlOmM1ZTdhZmI5NmQxYzQzODA5YmExOTFiMzkxMjY0YTM0L3RhYmxlcmFuZ2U6YzVlN2FmYjk2ZDFjNDM4MDliYTE5MWIzOTEyNjRhMzRfOC01LTEtMS0w_f366a3ee-f644-4589-b9cf-51d46b4cd93f"
      unitRef="usd">5747394000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic1a5c9f95c104828afb8e8cfafe56963_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yNS9mcmFnOmZhNDE3YThiNWEyYjQwYmViMzBkYjcwYzZkYzVjMTljL3RhYmxlOmM1ZTdhZmI5NmQxYzQzODA5YmExOTFiMzkxMjY0YTM0L3RhYmxlcmFuZ2U6YzVlN2FmYjk2ZDFjNDM4MDliYTE5MWIzOTEyNjRhMzRfOC03LTEtMS0w_9dc24a9f-c6b3-462e-a99d-fc4f5ee32c70"
      unitRef="usd">-36717000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i228f04c4c7b54cc6b36a2842a9727865_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yNS9mcmFnOmZhNDE3YThiNWEyYjQwYmViMzBkYjcwYzZkYzVjMTljL3RhYmxlOmM1ZTdhZmI5NmQxYzQzODA5YmExOTFiMzkxMjY0YTM0L3RhYmxlcmFuZ2U6YzVlN2FmYjk2ZDFjNDM4MDliYTE5MWIzOTEyNjRhMzRfOC05LTEtMS0w_bb47771a-2a24-47da-ac2a-90767f730540"
      unitRef="usd">-4785660000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="idd7204dc87d24972a01f15b098c4f56b_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yNS9mcmFnOmZhNDE3YThiNWEyYjQwYmViMzBkYjcwYzZkYzVjMTljL3RhYmxlOmM1ZTdhZmI5NmQxYzQzODA5YmExOTFiMzkxMjY0YTM0L3RhYmxlcmFuZ2U6YzVlN2FmYjk2ZDFjNDM4MDliYTE5MWIzOTEyNjRhMzRfOC0xMS0xLTEtMA_6ec85e22-c245-48f3-ac82-fb4854ff23ab"
      unitRef="usd">926190000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i529e7b1cdc924faf8a02fa556a4493bc_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yNS9mcmFnOmZhNDE3YThiNWEyYjQwYmViMzBkYjcwYzZkYzVjMTljL3RhYmxlOjhlNjQ5MTEwZDM2ZjQ5ODc5MzRiMGY5NzIyYThiZjBkL3RhYmxlcmFuZ2U6OGU2NDkxMTBkMzZmNDk4NzkzNGIwZjk3MjJhOGJmMGRfMi0xLTEtMS0w_246d32e7-13f8-45ca-93bd-dac04f69a82c"
      unitRef="shares">112188000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i529e7b1cdc924faf8a02fa556a4493bc_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yNS9mcmFnOmZhNDE3YThiNWEyYjQwYmViMzBkYjcwYzZkYzVjMTljL3RhYmxlOjhlNjQ5MTEwZDM2ZjQ5ODc5MzRiMGY5NzIyYThiZjBkL3RhYmxlcmFuZ2U6OGU2NDkxMTBkMzZmNDk4NzkzNGIwZjk3MjJhOGJmMGRfMi0zLTEtMS0w_a7148ed7-5c8c-4a82-ad64-f41cfe2c03a8"
      unitRef="usd">1122000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2e5f4eb4a821432ba3f5cd2a2ffe2754_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yNS9mcmFnOmZhNDE3YThiNWEyYjQwYmViMzBkYjcwYzZkYzVjMTljL3RhYmxlOjhlNjQ5MTEwZDM2ZjQ5ODc5MzRiMGY5NzIyYThiZjBkL3RhYmxlcmFuZ2U6OGU2NDkxMTBkMzZmNDk4NzkzNGIwZjk3MjJhOGJmMGRfMi01LTEtMS0w_3b66eadd-2a34-4372-a37a-6e28cf5af4d6"
      unitRef="usd">5201176000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if6294416a69f4b6daebcdebf72f5c179_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yNS9mcmFnOmZhNDE3YThiNWEyYjQwYmViMzBkYjcwYzZkYzVjMTljL3RhYmxlOjhlNjQ5MTEwZDM2ZjQ5ODc5MzRiMGY5NzIyYThiZjBkL3RhYmxlcmFuZ2U6OGU2NDkxMTBkMzZmNDk4NzkzNGIwZjk3MjJhOGJmMGRfMi03LTEtMS0w_a0ef1436-141b-4183-a0a9-9956b18047af"
      unitRef="usd">-36518000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7d5f25d01b88417aa57a44792c225b17_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yNS9mcmFnOmZhNDE3YThiNWEyYjQwYmViMzBkYjcwYzZkYzVjMTljL3RhYmxlOjhlNjQ5MTEwZDM2ZjQ5ODc5MzRiMGY5NzIyYThiZjBkL3RhYmxlcmFuZ2U6OGU2NDkxMTBkMzZmNDk4NzkzNGIwZjk3MjJhOGJmMGRfMi05LTEtMS0w_2677c8a9-760e-47b9-a006-1978b1ed065b"
      unitRef="usd">-3727088000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iebcb948108ce4342974f490750a7c986_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yNS9mcmFnOmZhNDE3YThiNWEyYjQwYmViMzBkYjcwYzZkYzVjMTljL3RhYmxlOjhlNjQ5MTEwZDM2ZjQ5ODc5MzRiMGY5NzIyYThiZjBkL3RhYmxlcmFuZ2U6OGU2NDkxMTBkMzZmNDk4NzkzNGIwZjk3MjJhOGJmMGRfMi0xMS0xLTEtMA_a7f70021-8949-46e1-be26-c01de43c6f5b"
      unitRef="usd">1438692000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="id329f7a0b2394ad5a1935867e133e7f0_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yNS9mcmFnOmZhNDE3YThiNWEyYjQwYmViMzBkYjcwYzZkYzVjMTljL3RhYmxlOjhlNjQ5MTEwZDM2ZjQ5ODc5MzRiMGY5NzIyYThiZjBkL3RhYmxlcmFuZ2U6OGU2NDkxMTBkMzZmNDk4NzkzNGIwZjk3MjJhOGJmMGRfNC0xLTEtMS0w_bc50968d-2135-40b4-9491-b8c81f8cca5e"
      unitRef="shares">976000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="id329f7a0b2394ad5a1935867e133e7f0_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yNS9mcmFnOmZhNDE3YThiNWEyYjQwYmViMzBkYjcwYzZkYzVjMTljL3RhYmxlOjhlNjQ5MTEwZDM2ZjQ5ODc5MzRiMGY5NzIyYThiZjBkL3RhYmxlcmFuZ2U6OGU2NDkxMTBkMzZmNDk4NzkzNGIwZjk3MjJhOGJmMGRfNC0zLTEtMS0w_9ad3077c-4da1-4eca-9c88-c1f6140dd7a1"
      unitRef="usd">9000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ib01acb7d931b4460a0e434d20db18c85_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yNS9mcmFnOmZhNDE3YThiNWEyYjQwYmViMzBkYjcwYzZkYzVjMTljL3RhYmxlOjhlNjQ5MTEwZDM2ZjQ5ODc5MzRiMGY5NzIyYThiZjBkL3RhYmxlcmFuZ2U6OGU2NDkxMTBkMzZmNDk4NzkzNGIwZjk3MjJhOGJmMGRfNC01LTEtMS0w_1c623fdb-9a5b-4ad9-8c55-e75fe00f8f84"
      unitRef="usd">54212000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ide9f6e15665746279d0000be700fcc6a_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yNS9mcmFnOmZhNDE3YThiNWEyYjQwYmViMzBkYjcwYzZkYzVjMTljL3RhYmxlOjhlNjQ5MTEwZDM2ZjQ5ODc5MzRiMGY5NzIyYThiZjBkL3RhYmxlcmFuZ2U6OGU2NDkxMTBkMzZmNDk4NzkzNGIwZjk3MjJhOGJmMGRfNC0xMS0xLTEtMA_4feeaa01-d17c-43d1-8356-6a64a1943950"
      unitRef="usd">54221000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross
      contextRef="id329f7a0b2394ad5a1935867e133e7f0_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yNS9mcmFnOmZhNDE3YThiNWEyYjQwYmViMzBkYjcwYzZkYzVjMTljL3RhYmxlOjhlNjQ5MTEwZDM2ZjQ5ODc5MzRiMGY5NzIyYThiZjBkL3RhYmxlcmFuZ2U6OGU2NDkxMTBkMzZmNDk4NzkzNGIwZjk3MjJhOGJmMGRfNS0xLTEtMS0w_e689d6f5-3033-42c8-8a9f-38a59d06e4b1"
      unitRef="shares">4000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ib01acb7d931b4460a0e434d20db18c85_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yNS9mcmFnOmZhNDE3YThiNWEyYjQwYmViMzBkYjcwYzZkYzVjMTljL3RhYmxlOjhlNjQ5MTEwZDM2ZjQ5ODc5MzRiMGY5NzIyYThiZjBkL3RhYmxlcmFuZ2U6OGU2NDkxMTBkMzZmNDk4NzkzNGIwZjk3MjJhOGJmMGRfNy01LTEtMS0w_dda2e165-da24-41b0-b0dc-124269017852"
      unitRef="usd">34578000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ide9f6e15665746279d0000be700fcc6a_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yNS9mcmFnOmZhNDE3YThiNWEyYjQwYmViMzBkYjcwYzZkYzVjMTljL3RhYmxlOjhlNjQ5MTEwZDM2ZjQ5ODc5MzRiMGY5NzIyYThiZjBkL3RhYmxlcmFuZ2U6OGU2NDkxMTBkMzZmNDk4NzkzNGIwZjk3MjJhOGJmMGRfNy0xMS0xLTEtMA_3227b3e0-4f6d-4dfb-9b9f-7f9a709f8c2c"
      unitRef="usd">34578000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i074c45cb3f5642eea30ad48202c86fc9_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yNS9mcmFnOmZhNDE3YThiNWEyYjQwYmViMzBkYjcwYzZkYzVjMTljL3RhYmxlOjhlNjQ5MTEwZDM2ZjQ5ODc5MzRiMGY5NzIyYThiZjBkL3RhYmxlcmFuZ2U6OGU2NDkxMTBkMzZmNDk4NzkzNGIwZjk3MjJhOGJmMGRfOC03LTEtMS0w_d9154be4-cceb-4879-bbd2-d0d7eb9266ac"
      unitRef="usd">4459000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ide9f6e15665746279d0000be700fcc6a_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yNS9mcmFnOmZhNDE3YThiNWEyYjQwYmViMzBkYjcwYzZkYzVjMTljL3RhYmxlOjhlNjQ5MTEwZDM2ZjQ5ODc5MzRiMGY5NzIyYThiZjBkL3RhYmxlcmFuZ2U6OGU2NDkxMTBkMzZmNDk4NzkzNGIwZjk3MjJhOGJmMGRfOC0xMS0xLTEtMA_d63dcccc-5d8c-4713-a5fa-e563984fd3a7"
      unitRef="usd">4459000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="i35858c4e152c41c983e25b7741dcfb36_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yNS9mcmFnOmZhNDE3YThiNWEyYjQwYmViMzBkYjcwYzZkYzVjMTljL3RhYmxlOjhlNjQ5MTEwZDM2ZjQ5ODc5MzRiMGY5NzIyYThiZjBkL3RhYmxlcmFuZ2U6OGU2NDkxMTBkMzZmNDk4NzkzNGIwZjk3MjJhOGJmMGRfOS05LTEtMS0w_5cf5e905-5fe2-4f41-81dc-2466e17f4f82"
      unitRef="usd">-182221000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ide9f6e15665746279d0000be700fcc6a_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yNS9mcmFnOmZhNDE3YThiNWEyYjQwYmViMzBkYjcwYzZkYzVjMTljL3RhYmxlOjhlNjQ5MTEwZDM2ZjQ5ODc5MzRiMGY5NzIyYThiZjBkL3RhYmxlcmFuZ2U6OGU2NDkxMTBkMzZmNDk4NzkzNGIwZjk3MjJhOGJmMGRfOS0xMS0xLTEtMA_1483e831-88cb-48d5-aa73-0cd946c558cd"
      unitRef="usd">-182221000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i1e51c390ee2b4b95b9d11592d9610350_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yNS9mcmFnOmZhNDE3YThiNWEyYjQwYmViMzBkYjcwYzZkYzVjMTljL3RhYmxlOjhlNjQ5MTEwZDM2ZjQ5ODc5MzRiMGY5NzIyYThiZjBkL3RhYmxlcmFuZ2U6OGU2NDkxMTBkMzZmNDk4NzkzNGIwZjk3MjJhOGJmMGRfMTAtMS0xLTEtMA_75c410a9-db8a-4516-b7dc-3d29b6bede69"
      unitRef="shares">113168000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i1e51c390ee2b4b95b9d11592d9610350_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yNS9mcmFnOmZhNDE3YThiNWEyYjQwYmViMzBkYjcwYzZkYzVjMTljL3RhYmxlOjhlNjQ5MTEwZDM2ZjQ5ODc5MzRiMGY5NzIyYThiZjBkL3RhYmxlcmFuZ2U6OGU2NDkxMTBkMzZmNDk4NzkzNGIwZjk3MjJhOGJmMGRfMTAtMy0xLTEtMA_9e0598f6-5c3b-487b-adcb-18ba5873e0e4"
      unitRef="usd">1131000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4219d6246f0f4615b7f66a38c10fc9fe_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yNS9mcmFnOmZhNDE3YThiNWEyYjQwYmViMzBkYjcwYzZkYzVjMTljL3RhYmxlOjhlNjQ5MTEwZDM2ZjQ5ODc5MzRiMGY5NzIyYThiZjBkL3RhYmxlcmFuZ2U6OGU2NDkxMTBkMzZmNDk4NzkzNGIwZjk3MjJhOGJmMGRfMTAtNS0xLTEtMA_c63d4ed3-0b3f-4c6a-9303-440e11e66431"
      unitRef="usd">5289966000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0cd32b4827314c02b0aeae69087c66b0_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yNS9mcmFnOmZhNDE3YThiNWEyYjQwYmViMzBkYjcwYzZkYzVjMTljL3RhYmxlOjhlNjQ5MTEwZDM2ZjQ5ODc5MzRiMGY5NzIyYThiZjBkL3RhYmxlcmFuZ2U6OGU2NDkxMTBkMzZmNDk4NzkzNGIwZjk3MjJhOGJmMGRfMTAtNy0xLTEtMA_d1aaac73-72cd-4e85-b667-b816f16b1317"
      unitRef="usd">-32059000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i1a2a3f2a9d1744519ed77d4a1400c065_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yNS9mcmFnOmZhNDE3YThiNWEyYjQwYmViMzBkYjcwYzZkYzVjMTljL3RhYmxlOjhlNjQ5MTEwZDM2ZjQ5ODc5MzRiMGY5NzIyYThiZjBkL3RhYmxlcmFuZ2U6OGU2NDkxMTBkMzZmNDk4NzkzNGIwZjk3MjJhOGJmMGRfMTAtOS0xLTEtMA_56a0b9a3-c5c7-4b45-85b7-531f48eef57d"
      unitRef="usd">-3909309000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic378e7f6183c40b4b7371ed7b7370867_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yNS9mcmFnOmZhNDE3YThiNWEyYjQwYmViMzBkYjcwYzZkYzVjMTljL3RhYmxlOjhlNjQ5MTEwZDM2ZjQ5ODc5MzRiMGY5NzIyYThiZjBkL3RhYmxlcmFuZ2U6OGU2NDkxMTBkMzZmNDk4NzkzNGIwZjk3MjJhOGJmMGRfMTAtMTEtMS0xLTA_02297ada-a805-4d21-937b-d82a4c7165dd"
      unitRef="usd">1349729000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yOC9mcmFnOmUzZDg2ZjExMWM3ODQwYTVhN2EyOGE3OWViOGIxN2QwL3RhYmxlOjJhZGY5OWY2YTA0NjRkNTBiOTkxMTZjNDc0M2M4ZTdiL3RhYmxlcmFuZ2U6MmFkZjk5ZjZhMDQ2NGQ1MGI5OTExNmM0NzQzYzhlN2JfMy0xLTEtMS0w_a1ad6034-7124-4fe4-8264-27a2aa082829"
      unitRef="usd">-200291000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ide9f6e15665746279d0000be700fcc6a_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yOC9mcmFnOmUzZDg2ZjExMWM3ODQwYTVhN2EyOGE3OWViOGIxN2QwL3RhYmxlOjJhZGY5OWY2YTA0NjRkNTBiOTkxMTZjNDc0M2M4ZTdiL3RhYmxlcmFuZ2U6MmFkZjk5ZjZhMDQ2NGQ1MGI5OTExNmM0NzQzYzhlN2JfMy0zLTEtMS0w_c2ee1da2-515f-4860-a002-368554ebe7da"
      unitRef="usd">-182221000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationAmortizationAndAccretionNet
      contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yOC9mcmFnOmUzZDg2ZjExMWM3ODQwYTVhN2EyOGE3OWViOGIxN2QwL3RhYmxlOjJhZGY5OWY2YTA0NjRkNTBiOTkxMTZjNDc0M2M4ZTdiL3RhYmxlcmFuZ2U6MmFkZjk5ZjZhMDQ2NGQ1MGI5OTExNmM0NzQzYzhlN2JfNS0xLTEtMS0w_4c645db1-1463-4c1e-9581-ef4cd8047a57"
      unitRef="usd">12601000</us-gaap:DepreciationAmortizationAndAccretionNet>
    <us-gaap:DepreciationAmortizationAndAccretionNet
      contextRef="ide9f6e15665746279d0000be700fcc6a_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yOC9mcmFnOmUzZDg2ZjExMWM3ODQwYTVhN2EyOGE3OWViOGIxN2QwL3RhYmxlOjJhZGY5OWY2YTA0NjRkNTBiOTkxMTZjNDc0M2M4ZTdiL3RhYmxlcmFuZ2U6MmFkZjk5ZjZhMDQ2NGQ1MGI5OTExNmM0NzQzYzhlN2JfNS0zLTEtMS0w_efd7a116-6a50-4517-9502-297238c909d6"
      unitRef="usd">7613000</us-gaap:DepreciationAmortizationAndAccretionNet>
    <alny:AmortizationAndInterestAccretionRelatedToOperatingLeases
      contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yOC9mcmFnOmUzZDg2ZjExMWM3ODQwYTVhN2EyOGE3OWViOGIxN2QwL3RhYmxlOjJhZGY5OWY2YTA0NjRkNTBiOTkxMTZjNDc0M2M4ZTdiL3RhYmxlcmFuZ2U6MmFkZjk5ZjZhMDQ2NGQ1MGI5OTExNmM0NzQzYzhlN2JfNi0xLTEtMS0w_0d286142-2e1c-4911-991b-5f515f2c510a"
      unitRef="usd">10261000</alny:AmortizationAndInterestAccretionRelatedToOperatingLeases>
    <alny:AmortizationAndInterestAccretionRelatedToOperatingLeases
      contextRef="ide9f6e15665746279d0000be700fcc6a_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yOC9mcmFnOmUzZDg2ZjExMWM3ODQwYTVhN2EyOGE3OWViOGIxN2QwL3RhYmxlOjJhZGY5OWY2YTA0NjRkNTBiOTkxMTZjNDc0M2M4ZTdiL3RhYmxlcmFuZ2U6MmFkZjk5ZjZhMDQ2NGQ1MGI5OTExNmM0NzQzYzhlN2JfNi0zLTEtMS0w_86303acf-395f-46df-8493-c18b02103a7b"
      unitRef="usd">9393000</alny:AmortizationAndInterestAccretionRelatedToOperatingLeases>
    <alny:NonCashInterestExpenseOnSaleOfFutureRoyalties
      contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yOC9mcmFnOmUzZDg2ZjExMWM3ODQwYTVhN2EyOGE3OWViOGIxN2QwL3RhYmxlOjJhZGY5OWY2YTA0NjRkNTBiOTkxMTZjNDc0M2M4ZTdiL3RhYmxlcmFuZ2U6MmFkZjk5ZjZhMDQ2NGQ1MGI5OTExNmM0NzQzYzhlN2JfNy0xLTEtMS0w_c66fabd5-109f-42e5-b7d8-fc7f1a309233"
      unitRef="usd">28184000</alny:NonCashInterestExpenseOnSaleOfFutureRoyalties>
    <alny:NonCashInterestExpenseOnSaleOfFutureRoyalties
      contextRef="ide9f6e15665746279d0000be700fcc6a_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yOC9mcmFnOmUzZDg2ZjExMWM3ODQwYTVhN2EyOGE3OWViOGIxN2QwL3RhYmxlOjJhZGY5OWY2YTA0NjRkNTBiOTkxMTZjNDc0M2M4ZTdiL3RhYmxlcmFuZ2U6MmFkZjk5ZjZhMDQ2NGQ1MGI5OTExNmM0NzQzYzhlN2JfNy0zLTEtMS0w_a9ae7042-9fb5-47af-af7f-5addaa6827b9"
      unitRef="usd">0</alny:NonCashInterestExpenseOnSaleOfFutureRoyalties>
    <us-gaap:ShareBasedCompensation
      contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yOC9mcmFnOmUzZDg2ZjExMWM3ODQwYTVhN2EyOGE3OWViOGIxN2QwL3RhYmxlOjJhZGY5OWY2YTA0NjRkNTBiOTkxMTZjNDc0M2M4ZTdiL3RhYmxlcmFuZ2U6MmFkZjk5ZjZhMDQ2NGQ1MGI5OTExNmM0NzQzYzhlN2JfOC0xLTEtMS0w_3fd6c478-52bf-4fdf-a314-e5d8fece757a"
      unitRef="usd">55690000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ide9f6e15665746279d0000be700fcc6a_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yOC9mcmFnOmUzZDg2ZjExMWM3ODQwYTVhN2EyOGE3OWViOGIxN2QwL3RhYmxlOjJhZGY5OWY2YTA0NjRkNTBiOTkxMTZjNDc0M2M4ZTdiL3RhYmxlcmFuZ2U6MmFkZjk5ZjZhMDQ2NGQ1MGI5OTExNmM0NzQzYzhlN2JfOC0zLTEtMS0w_43821925-f4c3-403a-8d19-87c0c6d812d5"
      unitRef="usd">34578000</us-gaap:ShareBasedCompensation>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yOC9mcmFnOmUzZDg2ZjExMWM3ODQwYTVhN2EyOGE3OWViOGIxN2QwL3RhYmxlOjJhZGY5OWY2YTA0NjRkNTBiOTkxMTZjNDc0M2M4ZTdiL3RhYmxlcmFuZ2U6MmFkZjk5ZjZhMDQ2NGQ1MGI5OTExNmM0NzQzYzhlN2JfOS0xLTEtMS0w_dd16f25e-2083-423c-b929-5f11ec4b1ed1"
      unitRef="usd">47016000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="ide9f6e15665746279d0000be700fcc6a_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yOC9mcmFnOmUzZDg2ZjExMWM3ODQwYTVhN2EyOGE3OWViOGIxN2QwL3RhYmxlOjJhZGY5OWY2YTA0NjRkNTBiOTkxMTZjNDc0M2M4ZTdiL3RhYmxlcmFuZ2U6MmFkZjk5ZjZhMDQ2NGQ1MGI5OTExNmM0NzQzYzhlN2JfOS0zLTEtMS0w_472cbb2a-e3f8-44bd-9aaa-9bf0d51e6386"
      unitRef="usd">24111000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement
      contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yOC9mcmFnOmUzZDg2ZjExMWM3ODQwYTVhN2EyOGE3OWViOGIxN2QwL3RhYmxlOjJhZGY5OWY2YTA0NjRkNTBiOTkxMTZjNDc0M2M4ZTdiL3RhYmxlcmFuZ2U6MmFkZjk5ZjZhMDQ2NGQ1MGI5OTExNmM0NzQzYzhlN2JfMTEtMS0xLTEtMA_44f3a47d-2ae6-4662-8b2d-404ba173612e"
      unitRef="usd">30777000</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement
      contextRef="ide9f6e15665746279d0000be700fcc6a_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yOC9mcmFnOmUzZDg2ZjExMWM3ODQwYTVhN2EyOGE3OWViOGIxN2QwL3RhYmxlOjJhZGY5OWY2YTA0NjRkNTBiOTkxMTZjNDc0M2M4ZTdiL3RhYmxlcmFuZ2U6MmFkZjk5ZjZhMDQ2NGQ1MGI5OTExNmM0NzQzYzhlN2JfMTEtMy0xLTEtMA_da789f00-dc84-4a94-ad6a-8f9f803fc577"
      unitRef="usd">660000</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yOC9mcmFnOmUzZDg2ZjExMWM3ODQwYTVhN2EyOGE3OWViOGIxN2QwL3RhYmxlOjJhZGY5OWY2YTA0NjRkNTBiOTkxMTZjNDc0M2M4ZTdiL3RhYmxlcmFuZ2U6MmFkZjk5ZjZhMDQ2NGQ1MGI5OTExNmM0NzQzYzhlN2JfMTMtMS0xLTEtMA_71ea47a0-4168-41f7-8f43-36a6e49c62c5"
      unitRef="usd">10709000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="ide9f6e15665746279d0000be700fcc6a_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yOC9mcmFnOmUzZDg2ZjExMWM3ODQwYTVhN2EyOGE3OWViOGIxN2QwL3RhYmxlOjJhZGY5OWY2YTA0NjRkNTBiOTkxMTZjNDc0M2M4ZTdiL3RhYmxlcmFuZ2U6MmFkZjk5ZjZhMDQ2NGQ1MGI5OTExNmM0NzQzYzhlN2JfMTMtMy0xLTEtMA_6c03b729-7932-47d8-bb8e-9fc49545eeac"
      unitRef="usd">32882000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yOC9mcmFnOmUzZDg2ZjExMWM3ODQwYTVhN2EyOGE3OWViOGIxN2QwL3RhYmxlOjJhZGY5OWY2YTA0NjRkNTBiOTkxMTZjNDc0M2M4ZTdiL3RhYmxlcmFuZ2U6MmFkZjk5ZjZhMDQ2NGQ1MGI5OTExNmM0NzQzYzhlN2JfMTUtMS0xLTEtMA_9ed9de06-2596-4f4b-bff0-cd88ff2d0689"
      unitRef="usd">-1934000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="ide9f6e15665746279d0000be700fcc6a_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yOC9mcmFnOmUzZDg2ZjExMWM3ODQwYTVhN2EyOGE3OWViOGIxN2QwL3RhYmxlOjJhZGY5OWY2YTA0NjRkNTBiOTkxMTZjNDc0M2M4ZTdiL3RhYmxlcmFuZ2U6MmFkZjk5ZjZhMDQ2NGQ1MGI5OTExNmM0NzQzYzhlN2JfMTUtMy0xLTEtMA_7ab1a8c5-b9da-48a2-bcee-0204db7a0f92"
      unitRef="usd">11952000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yOC9mcmFnOmUzZDg2ZjExMWM3ODQwYTVhN2EyOGE3OWViOGIxN2QwL3RhYmxlOjJhZGY5OWY2YTA0NjRkNTBiOTkxMTZjNDc0M2M4ZTdiL3RhYmxlcmFuZ2U6MmFkZjk5ZjZhMDQ2NGQ1MGI5OTExNmM0NzQzYzhlN2JfMTYtMS0xLTEtMA_60e3c30b-4dfa-4662-b866-829091bf1f4f"
      unitRef="usd">13654000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="ide9f6e15665746279d0000be700fcc6a_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yOC9mcmFnOmUzZDg2ZjExMWM3ODQwYTVhN2EyOGE3OWViOGIxN2QwL3RhYmxlOjJhZGY5OWY2YTA0NjRkNTBiOTkxMTZjNDc0M2M4ZTdiL3RhYmxlcmFuZ2U6MmFkZjk5ZjZhMDQ2NGQ1MGI5OTExNmM0NzQzYzhlN2JfMTYtMy0xLTEtMA_f148d117-8ec7-420f-a92e-4a714f8583b3"
      unitRef="usd">19958000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yOC9mcmFnOmUzZDg2ZjExMWM3ODQwYTVhN2EyOGE3OWViOGIxN2QwL3RhYmxlOjJhZGY5OWY2YTA0NjRkNTBiOTkxMTZjNDc0M2M4ZTdiL3RhYmxlcmFuZ2U6MmFkZjk5ZjZhMDQ2NGQ1MGI5OTExNmM0NzQzYzhlN2JfMTctMS0xLTEtMA_41f86537-e898-40d2-a623-04abfa340e64"
      unitRef="usd">-66573000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="ide9f6e15665746279d0000be700fcc6a_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yOC9mcmFnOmUzZDg2ZjExMWM3ODQwYTVhN2EyOGE3OWViOGIxN2QwL3RhYmxlOjJhZGY5OWY2YTA0NjRkNTBiOTkxMTZjNDc0M2M4ZTdiL3RhYmxlcmFuZ2U6MmFkZjk5ZjZhMDQ2NGQ1MGI5OTExNmM0NzQzYzhlN2JfMTctMy0xLTEtMA_73788935-ef5d-4894-80ba-82b2dabdb11a"
      unitRef="usd">-14215000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yOC9mcmFnOmUzZDg2ZjExMWM3ODQwYTVhN2EyOGE3OWViOGIxN2QwL3RhYmxlOjJhZGY5OWY2YTA0NjRkNTBiOTkxMTZjNDc0M2M4ZTdiL3RhYmxlcmFuZ2U6MmFkZjk5ZjZhMDQ2NGQ1MGI5OTExNmM0NzQzYzhlN2JfMTgtMS0xLTEtMA_f93901c6-f99c-4ccd-aa83-32286166f99e"
      unitRef="usd">-27804000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="ide9f6e15665746279d0000be700fcc6a_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yOC9mcmFnOmUzZDg2ZjExMWM3ODQwYTVhN2EyOGE3OWViOGIxN2QwL3RhYmxlOjJhZGY5OWY2YTA0NjRkNTBiOTkxMTZjNDc0M2M4ZTdiL3RhYmxlcmFuZ2U6MmFkZjk5ZjZhMDQ2NGQ1MGI5OTExNmM0NzQzYzhlN2JfMTgtMy0xLTEtMA_a0908501-ae33-4d4a-8042-f20719ac291c"
      unitRef="usd">-4030000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:OperatingLeasePayments
      contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yOC9mcmFnOmUzZDg2ZjExMWM3ODQwYTVhN2EyOGE3OWViOGIxN2QwL3RhYmxlOjJhZGY5OWY2YTA0NjRkNTBiOTkxMTZjNDc0M2M4ZTdiL3RhYmxlcmFuZ2U6MmFkZjk5ZjZhMDQ2NGQ1MGI5OTExNmM0NzQzYzhlN2JfMTktMS0xLTEtMA_68b5b91d-976c-4f4b-b9d2-eecbdf265dbd"
      unitRef="usd">9060000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="ide9f6e15665746279d0000be700fcc6a_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yOC9mcmFnOmUzZDg2ZjExMWM3ODQwYTVhN2EyOGE3OWViOGIxN2QwL3RhYmxlOjJhZGY5OWY2YTA0NjRkNTBiOTkxMTZjNDc0M2M4ZTdiL3RhYmxlcmFuZ2U6MmFkZjk5ZjZhMDQ2NGQ1MGI5OTExNmM0NzQzYzhlN2JfMTktMy0xLTEtMA_0301d1aa-29bd-489e-a9ac-e7f7f854c9e3"
      unitRef="usd">9036000</us-gaap:OperatingLeasePayments>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yOC9mcmFnOmUzZDg2ZjExMWM3ODQwYTVhN2EyOGE3OWViOGIxN2QwL3RhYmxlOjJhZGY5OWY2YTA0NjRkNTBiOTkxMTZjNDc0M2M4ZTdiL3RhYmxlcmFuZ2U6MmFkZjk5ZjZhMDQ2NGQ1MGI5OTExNmM0NzQzYzhlN2JfMjAtMS0xLTEtMA_e6856502-eb8f-4362-b74d-8624f871ff66"
      unitRef="usd">-235660000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ide9f6e15665746279d0000be700fcc6a_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yOC9mcmFnOmUzZDg2ZjExMWM3ODQwYTVhN2EyOGE3OWViOGIxN2QwL3RhYmxlOjJhZGY5OWY2YTA0NjRkNTBiOTkxMTZjNDc0M2M4ZTdiL3RhYmxlcmFuZ2U6MmFkZjk5ZjZhMDQ2NGQ1MGI5OTExNmM0NzQzYzhlN2JfMjAtMy0xLTEtMA_f66baa00-7d4c-47ed-bcc0-f34ef0cff8fc"
      unitRef="usd">-246161000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yOC9mcmFnOmUzZDg2ZjExMWM3ODQwYTVhN2EyOGE3OWViOGIxN2QwL3RhYmxlOjJhZGY5OWY2YTA0NjRkNTBiOTkxMTZjNDc0M2M4ZTdiL3RhYmxlcmFuZ2U6MmFkZjk5ZjZhMDQ2NGQ1MGI5OTExNmM0NzQzYzhlN2JfMjItMS0xLTEtMA_8ad43a65-6771-4279-accb-66b3516da6a1"
      unitRef="usd">17178000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ide9f6e15665746279d0000be700fcc6a_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yOC9mcmFnOmUzZDg2ZjExMWM3ODQwYTVhN2EyOGE3OWViOGIxN2QwL3RhYmxlOjJhZGY5OWY2YTA0NjRkNTBiOTkxMTZjNDc0M2M4ZTdiL3RhYmxlcmFuZ2U6MmFkZjk5ZjZhMDQ2NGQ1MGI5OTExNmM0NzQzYzhlN2JfMjItMy0xLTEtMA_59909cdc-0bb5-4f2e-b872-74e0818a6fa4"
      unitRef="usd">19617000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yOC9mcmFnOmUzZDg2ZjExMWM3ODQwYTVhN2EyOGE3OWViOGIxN2QwL3RhYmxlOjJhZGY5OWY2YTA0NjRkNTBiOTkxMTZjNDc0M2M4ZTdiL3RhYmxlcmFuZ2U6MmFkZjk5ZjZhMDQ2NGQ1MGI5OTExNmM0NzQzYzhlN2JfMjMtMS0xLTEtMA_19cf3db3-ca56-415d-8fbb-b5b2aee892f5"
      unitRef="usd">345954000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="ide9f6e15665746279d0000be700fcc6a_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yOC9mcmFnOmUzZDg2ZjExMWM3ODQwYTVhN2EyOGE3OWViOGIxN2QwL3RhYmxlOjJhZGY5OWY2YTA0NjRkNTBiOTkxMTZjNDc0M2M4ZTdiL3RhYmxlcmFuZ2U6MmFkZjk5ZjZhMDQ2NGQ1MGI5OTExNmM0NzQzYzhlN2JfMjMtMy0xLTEtMA_9b80dbbe-b1d4-416e-a29e-c811a84cce09"
      unitRef="usd">396409000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yOC9mcmFnOmUzZDg2ZjExMWM3ODQwYTVhN2EyOGE3OWViOGIxN2QwL3RhYmxlOjJhZGY5OWY2YTA0NjRkNTBiOTkxMTZjNDc0M2M4ZTdiL3RhYmxlcmFuZ2U6MmFkZjk5ZjZhMDQ2NGQ1MGI5OTExNmM0NzQzYzhlN2JfMjQtMS0xLTEtODc2_f6af33d6-d380-4fae-bf85-2289ed9e6d7f"
      unitRef="usd">438682000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="ide9f6e15665746279d0000be700fcc6a_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yOC9mcmFnOmUzZDg2ZjExMWM3ODQwYTVhN2EyOGE3OWViOGIxN2QwL3RhYmxlOjJhZGY5OWY2YTA0NjRkNTBiOTkxMTZjNDc0M2M4ZTdiL3RhYmxlcmFuZ2U6MmFkZjk5ZjZhMDQ2NGQ1MGI5OTExNmM0NzQzYzhlN2JfMjQtMy0xLTEtODc2_239b9765-3c7d-4151-a8ee-dc48493e86e2"
      unitRef="usd">539614000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:PaymentsToAcquireRestrictedInvestments
      contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yOC9mcmFnOmUzZDg2ZjExMWM3ODQwYTVhN2EyOGE3OWViOGIxN2QwL3RhYmxlOjJhZGY5OWY2YTA0NjRkNTBiOTkxMTZjNDc0M2M4ZTdiL3RhYmxlcmFuZ2U6MmFkZjk5ZjZhMDQ2NGQ1MGI5OTExNmM0NzQzYzhlN2JfMjQtMS0xLTEtMA_f9c02699-a410-414e-bc27-16c0925c0287"
      unitRef="usd">10650000</us-gaap:PaymentsToAcquireRestrictedInvestments>
    <us-gaap:PaymentsToAcquireRestrictedInvestments
      contextRef="ide9f6e15665746279d0000be700fcc6a_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yOC9mcmFnOmUzZDg2ZjExMWM3ODQwYTVhN2EyOGE3OWViOGIxN2QwL3RhYmxlOjJhZGY5OWY2YTA0NjRkNTBiOTkxMTZjNDc0M2M4ZTdiL3RhYmxlcmFuZ2U6MmFkZjk5ZjZhMDQ2NGQ1MGI5OTExNmM0NzQzYzhlN2JfMjQtMy0xLTEtMA_00961663-104f-4ad5-af0e-f59a7a40f991"
      unitRef="usd">9900000</us-gaap:PaymentsToAcquireRestrictedInvestments>
    <us-gaap:ProceedsFromSaleOfRestrictedInvestments
      contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yOC9mcmFnOmUzZDg2ZjExMWM3ODQwYTVhN2EyOGE3OWViOGIxN2QwL3RhYmxlOjJhZGY5OWY2YTA0NjRkNTBiOTkxMTZjNDc0M2M4ZTdiL3RhYmxlcmFuZ2U6MmFkZjk5ZjZhMDQ2NGQ1MGI5OTExNmM0NzQzYzhlN2JfMjUtMS0xLTEtMA_8e5c092b-0967-4595-b312-56393214f4a9"
      unitRef="usd">10650000</us-gaap:ProceedsFromSaleOfRestrictedInvestments>
    <us-gaap:ProceedsFromSaleOfRestrictedInvestments
      contextRef="ide9f6e15665746279d0000be700fcc6a_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yOC9mcmFnOmUzZDg2ZjExMWM3ODQwYTVhN2EyOGE3OWViOGIxN2QwL3RhYmxlOjJhZGY5OWY2YTA0NjRkNTBiOTkxMTZjNDc0M2M4ZTdiL3RhYmxlcmFuZ2U6MmFkZjk5ZjZhMDQ2NGQ1MGI5OTExNmM0NzQzYzhlN2JfMjUtMy0xLTEtMA_85802541-0ca2-4ded-b204-ba29e659c87d"
      unitRef="usd">0</us-gaap:ProceedsFromSaleOfRestrictedInvestments>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yOC9mcmFnOmUzZDg2ZjExMWM3ODQwYTVhN2EyOGE3OWViOGIxN2QwL3RhYmxlOjJhZGY5OWY2YTA0NjRkNTBiOTkxMTZjNDc0M2M4ZTdiL3RhYmxlcmFuZ2U6MmFkZjk5ZjZhMDQ2NGQ1MGI5OTExNmM0NzQzYzhlN2JfMjctMS0xLTEtMA_ebf33add-4ad1-49d2-b9da-800077fad69c"
      unitRef="usd">4198000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="ide9f6e15665746279d0000be700fcc6a_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yOC9mcmFnOmUzZDg2ZjExMWM3ODQwYTVhN2EyOGE3OWViOGIxN2QwL3RhYmxlOjJhZGY5OWY2YTA0NjRkNTBiOTkxMTZjNDc0M2M4ZTdiL3RhYmxlcmFuZ2U6MmFkZjk5ZjZhMDQ2NGQ1MGI5OTExNmM0NzQzYzhlN2JfMjctMy0xLTEtMA_98461d66-ea44-42f2-b28b-72cdf840724c"
      unitRef="usd">0</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yOC9mcmFnOmUzZDg2ZjExMWM3ODQwYTVhN2EyOGE3OWViOGIxN2QwL3RhYmxlOjJhZGY5OWY2YTA0NjRkNTBiOTkxMTZjNDc0M2M4ZTdiL3RhYmxlcmFuZ2U6MmFkZjk5ZjZhMDQ2NGQ1MGI5OTExNmM0NzQzYzhlN2JfMjgtMS0xLTEtMA_31351f70-ce1c-422a-802b-37a09c4e1bd6"
      unitRef="usd">71352000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ide9f6e15665746279d0000be700fcc6a_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yOC9mcmFnOmUzZDg2ZjExMWM3ODQwYTVhN2EyOGE3OWViOGIxN2QwL3RhYmxlOjJhZGY5OWY2YTA0NjRkNTBiOTkxMTZjNDc0M2M4ZTdiL3RhYmxlcmFuZ2U6MmFkZjk5ZjZhMDQ2NGQ1MGI5OTExNmM0NzQzYzhlN2JfMjgtMy0xLTEtMA_82e3a27a-9da3-428b-9c2d-439c1eb9a6b5"
      unitRef="usd">113688000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yOC9mcmFnOmUzZDg2ZjExMWM3ODQwYTVhN2EyOGE3OWViOGIxN2QwL3RhYmxlOjJhZGY5OWY2YTA0NjRkNTBiOTkxMTZjNDc0M2M4ZTdiL3RhYmxlcmFuZ2U6MmFkZjk5ZjZhMDQ2NGQ1MGI5OTExNmM0NzQzYzhlN2JfMzAtMS0xLTEtMA_aa172176-4f37-4a43-add3-b6a599aee176"
      unitRef="usd">46977000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="ide9f6e15665746279d0000be700fcc6a_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yOC9mcmFnOmUzZDg2ZjExMWM3ODQwYTVhN2EyOGE3OWViOGIxN2QwL3RhYmxlOjJhZGY5OWY2YTA0NjRkNTBiOTkxMTZjNDc0M2M4ZTdiL3RhYmxlcmFuZ2U6MmFkZjk5ZjZhMDQ2NGQ1MGI5OTExNmM0NzQzYzhlN2JfMzAtMy0xLTEtMA_41cc4366-540b-4b54-8963-32d544bcf2a7"
      unitRef="usd">53869000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromDerivativeInstrumentFinancingActivities
      contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yOC9mcmFnOmUzZDg2ZjExMWM3ODQwYTVhN2EyOGE3OWViOGIxN2QwL3RhYmxlOjJhZGY5OWY2YTA0NjRkNTBiOTkxMTZjNDc0M2M4ZTdiL3RhYmxlcmFuZ2U6MmFkZjk5ZjZhMDQ2NGQ1MGI5OTExNmM0NzQzYzhlN2JfMzItMS0xLTEtMA_ca43f32d-d11a-45b3-84c3-1bb74b88949d"
      unitRef="usd">4200000</us-gaap:ProceedsFromDerivativeInstrumentFinancingActivities>
    <us-gaap:ProceedsFromDerivativeInstrumentFinancingActivities
      contextRef="ide9f6e15665746279d0000be700fcc6a_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yOC9mcmFnOmUzZDg2ZjExMWM3ODQwYTVhN2EyOGE3OWViOGIxN2QwL3RhYmxlOjJhZGY5OWY2YTA0NjRkNTBiOTkxMTZjNDc0M2M4ZTdiL3RhYmxlcmFuZ2U6MmFkZjk5ZjZhMDQ2NGQ1MGI5OTExNmM0NzQzYzhlN2JfMzItMy0xLTEtMA_446462ca-f114-4d6d-815e-c7d77f09ae55"
      unitRef="usd">0</us-gaap:ProceedsFromDerivativeInstrumentFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yOC9mcmFnOmUzZDg2ZjExMWM3ODQwYTVhN2EyOGE3OWViOGIxN2QwL3RhYmxlOjJhZGY5OWY2YTA0NjRkNTBiOTkxMTZjNDc0M2M4ZTdiL3RhYmxlcmFuZ2U6MmFkZjk5ZjZhMDQ2NGQ1MGI5OTExNmM0NzQzYzhlN2JfMzctMS0xLTEtMA_a311539d-afd8-480d-b12b-3f0ef5eacaa1"
      unitRef="usd">51177000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ide9f6e15665746279d0000be700fcc6a_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yOC9mcmFnOmUzZDg2ZjExMWM3ODQwYTVhN2EyOGE3OWViOGIxN2QwL3RhYmxlOjJhZGY5OWY2YTA0NjRkNTBiOTkxMTZjNDc0M2M4ZTdiL3RhYmxlcmFuZ2U6MmFkZjk5ZjZhMDQ2NGQ1MGI5OTExNmM0NzQzYzhlN2JfMzctMy0xLTEtMA_d593ab50-6880-4f68-a7cd-0066e2632eec"
      unitRef="usd">53869000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yOC9mcmFnOmUzZDg2ZjExMWM3ODQwYTVhN2EyOGE3OWViOGIxN2QwL3RhYmxlOjJhZGY5OWY2YTA0NjRkNTBiOTkxMTZjNDc0M2M4ZTdiL3RhYmxlcmFuZ2U6MmFkZjk5ZjZhMDQ2NGQ1MGI5OTExNmM0NzQzYzhlN2JfMzgtMS0xLTEtMA_ba4fa6c2-7d74-4153-9b81-47f574cb12e2"
      unitRef="usd">-3910000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ide9f6e15665746279d0000be700fcc6a_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yOC9mcmFnOmUzZDg2ZjExMWM3ODQwYTVhN2EyOGE3OWViOGIxN2QwL3RhYmxlOjJhZGY5OWY2YTA0NjRkNTBiOTkxMTZjNDc0M2M4ZTdiL3RhYmxlcmFuZ2U6MmFkZjk5ZjZhMDQ2NGQ1MGI5OTExNmM0NzQzYzhlN2JfMzgtMy0xLTEtMA_fbb13245-57f9-4cba-a4c6-cd5e7cfa1671"
      unitRef="usd">-631000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yOC9mcmFnOmUzZDg2ZjExMWM3ODQwYTVhN2EyOGE3OWViOGIxN2QwL3RhYmxlOjJhZGY5OWY2YTA0NjRkNTBiOTkxMTZjNDc0M2M4ZTdiL3RhYmxlcmFuZ2U6MmFkZjk5ZjZhMDQ2NGQ1MGI5OTExNmM0NzQzYzhlN2JfMzktMS0xLTEtMA_235dabbd-88b9-4670-a9f6-a20b7832f2af"
      unitRef="usd">-117041000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ide9f6e15665746279d0000be700fcc6a_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yOC9mcmFnOmUzZDg2ZjExMWM3ODQwYTVhN2EyOGE3OWViOGIxN2QwL3RhYmxlOjJhZGY5OWY2YTA0NjRkNTBiOTkxMTZjNDc0M2M4ZTdiL3RhYmxlcmFuZ2U6MmFkZjk5ZjZhMDQ2NGQ1MGI5OTExNmM0NzQzYzhlN2JfMzktMy0xLTEtMA_61babc63-30c8-4c73-8e1c-8d1a18fe8bb7"
      unitRef="usd">-79235000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="id365c5f1d37444ac9e1da5b5891cd81a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yOC9mcmFnOmUzZDg2ZjExMWM3ODQwYTVhN2EyOGE3OWViOGIxN2QwL3RhYmxlOjJhZGY5OWY2YTA0NjRkNTBiOTkxMTZjNDc0M2M4ZTdiL3RhYmxlcmFuZ2U6MmFkZjk5ZjZhMDQ2NGQ1MGI5OTExNmM0NzQzYzhlN2JfNDAtMS0xLTEtMA_23da9bb6-6d42-43f6-abe5-23512d3f777f"
      unitRef="usd">499046000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="iebcb948108ce4342974f490750a7c986_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yOC9mcmFnOmUzZDg2ZjExMWM3ODQwYTVhN2EyOGE3OWViOGIxN2QwL3RhYmxlOjJhZGY5OWY2YTA0NjRkNTBiOTkxMTZjNDc0M2M4ZTdiL3RhYmxlcmFuZ2U6MmFkZjk5ZjZhMDQ2NGQ1MGI5OTExNmM0NzQzYzhlN2JfNDAtMy0xLTEtMA_bc3d96d4-968b-4d5d-ba08-b5ee80bfcf0a"
      unitRef="usd">549628000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="idd7204dc87d24972a01f15b098c4f56b_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yOC9mcmFnOmUzZDg2ZjExMWM3ODQwYTVhN2EyOGE3OWViOGIxN2QwL3RhYmxlOjJhZGY5OWY2YTA0NjRkNTBiOTkxMTZjNDc0M2M4ZTdiL3RhYmxlcmFuZ2U6MmFkZjk5ZjZhMDQ2NGQ1MGI5OTExNmM0NzQzYzhlN2JfNDEtMS0xLTEtMA_90fd83ce-9736-4df3-b812-3a67ef9c8891"
      unitRef="usd">382005000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="ic378e7f6183c40b4b7371ed7b7370867_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yOC9mcmFnOmUzZDg2ZjExMWM3ODQwYTVhN2EyOGE3OWViOGIxN2QwL3RhYmxlOjJhZGY5OWY2YTA0NjRkNTBiOTkxMTZjNDc0M2M4ZTdiL3RhYmxlcmFuZ2U6MmFkZjk5ZjZhMDQ2NGQ1MGI5OTExNmM0NzQzYzhlN2JfNDEtMy0xLTEtMA_913f0330-ce2e-4619-843e-8e7ed84c6205"
      unitRef="usd">470393000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yOC9mcmFnOmUzZDg2ZjExMWM3ODQwYTVhN2EyOGE3OWViOGIxN2QwL3RhYmxlOjJhZGY5OWY2YTA0NjRkNTBiOTkxMTZjNDc0M2M4ZTdiL3RhYmxlcmFuZ2U6MmFkZjk5ZjZhMDQ2NGQ1MGI5OTExNmM0NzQzYzhlN2JfNDMtMS0xLTEtMA_134eddfd-c926-4252-8f12-23c21a10a09a"
      unitRef="usd">7289000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="ide9f6e15665746279d0000be700fcc6a_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8yOC9mcmFnOmUzZDg2ZjExMWM3ODQwYTVhN2EyOGE3OWViOGIxN2QwL3RhYmxlOjJhZGY5OWY2YTA0NjRkNTBiOTkxMTZjNDc0M2M4ZTdiL3RhYmxlcmFuZ2U6MmFkZjk5ZjZhMDQ2NGQ1MGI5OTExNmM0NzQzYzhlN2JfNDMtMy0xLTEtMA_44a14e23-cf16-4ccf-a95c-50f87ddb3962"
      unitRef="usd">6619000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:NatureOfOperations
      contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8zNC9mcmFnOjc0MDI0ZTZjMDNjNjRkNTI4YzJlNzBjNWI5YTU0ZTVhL3RleHRyZWdpb246NzQwMjRlNmMwM2M2NGQ1MjhjMmU3MGM1YjlhNTRlNWFfMjc4Ng_d9f6175d-d46b-4037-b10b-78332e16485b">NATURE OF BUSINESS&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Alnylam Pharmaceuticals, Inc. (also referred to as Alnylam, we, our or us) commenced operations on June&#160;14, 2002 as a biopharmaceutical company seeking to develop and commercialize novel therapeutics based on RNA interference, or RNAi. We are committed to the advancement of our company strategy of building a multi-product, global, commercial biopharmaceutical company with a deep and sustainable clinical pipeline of RNAi therapeutics for future growth and a robust, organic research engine for sustainable innovation and great potential for patient impact. Since inception, we have focused on discovering, developing and commercializing RNAi therapeutics by establishing and maintaining a strong intellectual property position in the RNAi field, establishing strategic alliances with leading pharmaceutical and life sciences companies, generating revenues through licensing agreements, and ultimately developing and commercializing RNAi therapeutics globally, either independently or with our strategic partners. We have devoted substantially all of our efforts to business planning, research, development, manufacturing and early commercial efforts, acquiring, filing and expanding intellectual property rights, recruiting management and technical staff, and raising capital. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In early 2021, we launched our &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Alnylam P&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;x25 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;strategy, which focuses on our planned transition to a top five biotech company, as measured by market capitalization, by the end of 2025. With &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Alnylam P&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;x25&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;, we aim to deliver transformative rare and prevalent disease medicines for patients around the world through sustainable innovation, delivering exceptional financial performance and driving profitability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As of March&#160;31, 2021, we have four products that have received marketing approval, including one partnered product, and six late-stage investigational programs advancing towards potential commercialization. We currently generate product revenues from ONPATTRO in the U.S., Europe, Japan and in several additional countries as well as from GIVLAARI and OXLUMO in the U.S. and several countries in Europe.&lt;/span&gt;&lt;/div&gt;</us-gaap:NatureOfOperations>
    <alny:NumberOfMarketedProducts
      contextRef="idd7204dc87d24972a01f15b098c4f56b_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8zNC9mcmFnOjc0MDI0ZTZjMDNjNjRkNTI4YzJlNzBjNWI5YTU0ZTVhL3RleHRyZWdpb246NzQwMjRlNmMwM2M2NGQ1MjhjMmU3MGM1YjlhNTRlNWFfODI0NjMzNzIxNDMwOQ_890dcaf1-f039-4a43-b339-676c52a439bd"
      unitRef="product">4</alny:NumberOfMarketedProducts>
    <alny:NumberOfPartneredProducts
      contextRef="idd7204dc87d24972a01f15b098c4f56b_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8zNC9mcmFnOjc0MDI0ZTZjMDNjNjRkNTI4YzJlNzBjNWI5YTU0ZTVhL3RleHRyZWdpb246NzQwMjRlNmMwM2M2NGQ1MjhjMmU3MGM1YjlhNTRlNWFfODI0NjMzNzIxNDMxNw_426c642a-a06e-4b17-bab4-c16cf9f78474"
      unitRef="product">1</alny:NumberOfPartneredProducts>
    <alny:NumberOfClinicalProgramsInLateStages
      contextRef="idd7204dc87d24972a01f15b098c4f56b_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8zNC9mcmFnOjc0MDI0ZTZjMDNjNjRkNTI4YzJlNzBjNWI5YTU0ZTVhL3RleHRyZWdpb246NzQwMjRlNmMwM2M2NGQ1MjhjMmU3MGM1YjlhNTRlNWFfODI0NjMzNzIxNDMyNQ_39f39d04-634b-464e-b037-444624a26542"
      unitRef="program">6</alny:NumberOfClinicalProgramsInLateStages>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock
      contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8zNy9mcmFnOjYwMTQxMmZlMWFjYjRkZjBhNmIwMWI1ZWY5ODM2Njg3L3RleHRyZWdpb246NjAxNDEyZmUxYWNiNGRmMGE2YjAxYjVlZjk4MzY2ODdfODA1Mw_457d56be-4ea4-419d-98c6-349d195936b9">BASIS OF PRESENTATION AND PRINCIPLES OF CONSOLIDATION&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The accompanying condensed consolidated financial statements of Alnylam are unaudited and have been prepared in accordance with accounting principles generally accepted in the United States of America, or GAAP, applicable to interim periods and, in the opinion of management, include all normal and recurring adjustments that are necessary to state fairly the results of operations for the reported periods. Our condensed consolidated financial statements have also been prepared on a basis substantially consistent with, and should be read in conjunction with, our audited consolidated financial statements for the year ended December&#160;31, 2020, which were included in our Annual Report on Form 10-K that was filed with the Securities and Exchange Commission on February 11, 2021. The year-end condensed consolidated balance sheet data was derived from our audited financial statements but does not include all disclosures required by GAAP. The results of our operations for any interim period are not necessarily indicative of the results of our operations for any other interim period or for a full fiscal year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The accompanying condensed consolidated financial statements reflect the operations of Alnylam and our wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Our significant accounting policies are described in Note 2 of the Notes to Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. In our condensed consolidated financial statements, we use estimates and assumptions related to our inventory valuation and related reserves, liability related to the sale of future royalties, development derivative liability, income taxes, revenue recognition, research and development expenses, and stock-based compensation. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable. Actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The full extent to which the COVID-19 pandemic will directly or indirectly impact our business, results of operations and financial condition, including sales, expenses, reserves and allowances, the supply of our products and product candidates, clinical trials and research and development costs, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and variants thereof, and the actions taken to contain or treat it or vaccinate against it, as well as the economic impact on local, regional, national and international customers and markets. We have made estimates of the impact of COVID-19 within our financial statements and there may be changes to those estimates in future periods. Actual results may differ from these estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Liquidity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Based on our current operating plan, we believe that our cash, cash equivalents and marketable securities as of March&#160;31, 2021, together with the cash we expect to generate from product sales and under our current alliances, in addition to our strategic financing collaboration with The Blackstone Group Inc. and certain of its affiliates, will be sufficient to enable us to advance our &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Alnylam P&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;x25 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;strategy for at least the next 12 months from the filing of this Quarterly Report on Form 10-Q.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8zNy9mcmFnOjYwMTQxMmZlMWFjYjRkZjBhNmIwMWI1ZWY5ODM2Njg3L3RleHRyZWdpb246NjAxNDEyZmUxYWNiNGRmMGE2YjAxYjVlZjk4MzY2ODdfODA1NA_bf3306dc-932e-4923-a7e0-90afe48df245">&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The accompanying condensed consolidated financial statements of Alnylam are unaudited and have been prepared in accordance with accounting principles generally accepted in the United States of America, or GAAP, applicable to interim periods and, in the opinion of management, include all normal and recurring adjustments that are necessary to state fairly the results of operations for the reported periods. Our condensed consolidated financial statements have also been prepared on a basis substantially consistent with, and should be read in conjunction with, our audited consolidated financial statements for the year ended December&#160;31, 2020, which were included in our Annual Report on Form 10-K that was filed with the Securities and Exchange Commission on February 11, 2021. The year-end condensed consolidated balance sheet data was derived from our audited financial statements but does not include all disclosures required by GAAP. The results of our operations for any interim period are not necessarily indicative of the results of our operations for any other interim period or for a full fiscal year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The accompanying condensed consolidated financial statements reflect the operations of Alnylam and our wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Our significant accounting policies are described in Note 2 of the Notes to Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8zNy9mcmFnOjYwMTQxMmZlMWFjYjRkZjBhNmIwMWI1ZWY5ODM2Njg3L3RleHRyZWdpb246NjAxNDEyZmUxYWNiNGRmMGE2YjAxYjVlZjk4MzY2ODdfODA2MA_661ccdc2-4764-425c-b819-af8d0964d68d">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. In our condensed consolidated financial statements, we use estimates and assumptions related to our inventory valuation and related reserves, liability related to the sale of future royalties, development derivative liability, income taxes, revenue recognition, research and development expenses, and stock-based compensation. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable. Actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The full extent to which the COVID-19 pandemic will directly or indirectly impact our business, results of operations and financial condition, including sales, expenses, reserves and allowances, the supply of our products and product candidates, clinical trials and research and development costs, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and variants thereof, and the actions taken to contain or treat it or vaccinate against it, as well as the economic impact on local, regional, national and international customers and markets. We have made estimates of the impact of COVID-19 within our financial statements and there may be changes to those estimates in future periods. Actual results may differ from these estimates.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <alny:LiquidityPolicyPolicyTextBlock
      contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF8zNy9mcmFnOjYwMTQxMmZlMWFjYjRkZjBhNmIwMWI1ZWY5ODM2Njg3L3RleHRyZWdpb246NjAxNDEyZmUxYWNiNGRmMGE2YjAxYjVlZjk4MzY2ODdfODA1NQ_93135ab1-881e-4e21-80e1-7e5e1aa287ff">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Liquidity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Based on our current operating plan, we believe that our cash, cash equivalents and marketable securities as of March&#160;31, 2021, together with the cash we expect to generate from product sales and under our current alliances, in addition to our strategic financing collaboration with The Blackstone Group Inc. and certain of its affiliates, will be sufficient to enable us to advance our &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Alnylam P&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;x25 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;strategy for at least the next 12 months from the filing of this Quarterly Report on Form 10-Q.&lt;/span&gt;&lt;/div&gt;</alny:LiquidityPolicyPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80MC9mcmFnOmViNzk5OGUzNTJhZDQ1ZTE4YTU5OTVmMWQ2YWJmNmMzL3RleHRyZWdpb246ZWI3OTk4ZTM1MmFkNDVlMThhNTk5NWYxZDZhYmY2YzNfMTc5_171ae792-438c-412c-ad63-e05f86fc45ea">NET PRODUCT REVENUES&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net product revenues consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt;padding-left:18pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:82.309%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.047%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.971%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.510%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.972%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;ONPATTRO&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,471&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rest of World (primarily Japan)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101,951&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;GIVLAARI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,762&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,873&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rest of World &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;OXLUMO&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total net product revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135,769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the balance of our receivables related to our net product revenues: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:82.456%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.942%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.686%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.937%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Receivables included in &#x201c;Accounts receivable, net&#x201d;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91,516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,871&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80MC9mcmFnOmViNzk5OGUzNTJhZDQ1ZTE4YTU5OTVmMWQ2YWJmNmMzL3RleHRyZWdpb246ZWI3OTk4ZTM1MmFkNDVlMThhNTk5NWYxZDZhYmY2YzNfMTgy_e04487e8-38f4-417b-97df-74eff533db57">&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net product revenues consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt;padding-left:18pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:82.309%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.047%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.971%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.510%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.972%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;ONPATTRO&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,471&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rest of World (primarily Japan)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101,951&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;GIVLAARI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,762&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,873&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rest of World &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;OXLUMO&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total net product revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135,769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4a2ac71261a84e87a3d5590a679c5507_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80MC9mcmFnOmViNzk5OGUzNTJhZDQ1ZTE4YTU5OTVmMWQ2YWJmNmMzL3RhYmxlOmJmZWJkMzA5MmE1YTQzMjNiM2Q2NWI0YTdjMzUzNGZiL3RhYmxlcmFuZ2U6YmZlYmQzMDkyYTVhNDMyM2IzZDY1YjRhN2MzNTM0ZmJfMy0xLTEtMS0w_7e19c57e-433b-4413-aac4-7f00758eb48a"
      unitRef="usd">49471000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3093ec8b753b455ebe0533565a97caff_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80MC9mcmFnOmViNzk5OGUzNTJhZDQ1ZTE4YTU5OTVmMWQ2YWJmNmMzL3RhYmxlOmJmZWJkMzA5MmE1YTQzMjNiM2Q2NWI0YTdjMzUzNGZiL3RhYmxlcmFuZ2U6YmZlYmQzMDkyYTVhNDMyM2IzZDY1YjRhN2MzNTM0ZmJfMy0zLTEtMS0w_5e79f756-d0a4-4c62-a536-d6b04e02d9e6"
      unitRef="usd">37196000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie071fd2fff7141d790e9ce1f75e3ad69_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80MC9mcmFnOmViNzk5OGUzNTJhZDQ1ZTE4YTU5OTVmMWQ2YWJmNmMzL3RhYmxlOmJmZWJkMzA5MmE1YTQzMjNiM2Q2NWI0YTdjMzUzNGZiL3RhYmxlcmFuZ2U6YmZlYmQzMDkyYTVhNDMyM2IzZDY1YjRhN2MzNTM0ZmJfNC0xLTEtMS0w_3549d691-4acd-4684-b02e-4b40cb7928cd"
      unitRef="usd">40653000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icf591ef643074bb59a23948ceb15ebb6_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80MC9mcmFnOmViNzk5OGUzNTJhZDQ1ZTE4YTU5OTVmMWQ2YWJmNmMzL3RhYmxlOmJmZWJkMzA5MmE1YTQzMjNiM2Q2NWI0YTdjMzUzNGZiL3RhYmxlcmFuZ2U6YmZlYmQzMDkyYTVhNDMyM2IzZDY1YjRhN2MzNTM0ZmJfNC0zLTEtMS0w_b018b104-3076-4de6-b03d-dcbb1082bfc1"
      unitRef="usd">21166000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0e00566ee692462ca9f65f7d6faa57e9_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80MC9mcmFnOmViNzk5OGUzNTJhZDQ1ZTE4YTU5OTVmMWQ2YWJmNmMzL3RhYmxlOmJmZWJkMzA5MmE1YTQzMjNiM2Q2NWI0YTdjMzUzNGZiL3RhYmxlcmFuZ2U6YmZlYmQzMDkyYTVhNDMyM2IzZDY1YjRhN2MzNTM0ZmJfNS0xLTEtMS0w_a0841052-9c75-4356-a562-a538d1f98f37"
      unitRef="usd">11827000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i407b32b70e73469c9bb2867c7e8c53ab_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80MC9mcmFnOmViNzk5OGUzNTJhZDQ1ZTE4YTU5OTVmMWQ2YWJmNmMzL3RhYmxlOmJmZWJkMzA5MmE1YTQzMjNiM2Q2NWI0YTdjMzUzNGZiL3RhYmxlcmFuZ2U6YmZlYmQzMDkyYTVhNDMyM2IzZDY1YjRhN2MzNTM0ZmJfNS0zLTEtMS0w_1fcbafc4-2ea1-450c-88bf-17a61f07d229"
      unitRef="usd">8302000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i938688f7d99a4e7b97c127dc1da4aa45_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80MC9mcmFnOmViNzk5OGUzNTJhZDQ1ZTE4YTU5OTVmMWQ2YWJmNmMzL3RhYmxlOmJmZWJkMzA5MmE1YTQzMjNiM2Q2NWI0YTdjMzUzNGZiL3RhYmxlcmFuZ2U6YmZlYmQzMDkyYTVhNDMyM2IzZDY1YjRhN2MzNTM0ZmJfNi0xLTEtMS0w_17e2f5dc-fe57-454f-827c-c46c5a70c220"
      unitRef="usd">101951000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic38400d6eea7497f8bb34244730955f4_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80MC9mcmFnOmViNzk5OGUzNTJhZDQ1ZTE4YTU5OTVmMWQ2YWJmNmMzL3RhYmxlOmJmZWJkMzA5MmE1YTQzMjNiM2Q2NWI0YTdjMzUzNGZiL3RhYmxlcmFuZ2U6YmZlYmQzMDkyYTVhNDMyM2IzZDY1YjRhN2MzNTM0ZmJfNi0zLTEtMS0w_09385378-c3c0-4953-9ad3-55d797f998cb"
      unitRef="usd">66664000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i86f381c6519b4114a9f993ca05678e84_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80MC9mcmFnOmViNzk5OGUzNTJhZDQ1ZTE4YTU5OTVmMWQ2YWJmNmMzL3RhYmxlOmJmZWJkMzA5MmE1YTQzMjNiM2Q2NWI0YTdjMzUzNGZiL3RhYmxlcmFuZ2U6YmZlYmQzMDkyYTVhNDMyM2IzZDY1YjRhN2MzNTM0ZmJfOS0xLTEtMS0w_405806b8-37db-46f5-84fc-2dca7f559d49"
      unitRef="usd">17762000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifa94975325ea4c21bc761e8c37cace85_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80MC9mcmFnOmViNzk5OGUzNTJhZDQ1ZTE4YTU5OTVmMWQ2YWJmNmMzL3RhYmxlOmJmZWJkMzA5MmE1YTQzMjNiM2Q2NWI0YTdjMzUzNGZiL3RhYmxlcmFuZ2U6YmZlYmQzMDkyYTVhNDMyM2IzZDY1YjRhN2MzNTM0ZmJfOS0zLTEtMS0w_47d3476b-0144-4731-a17d-1670314e9489"
      unitRef="usd">5274000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6223cc9a7bb7452ebf43606a6436d328_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80MC9mcmFnOmViNzk5OGUzNTJhZDQ1ZTE4YTU5OTVmMWQ2YWJmNmMzL3RhYmxlOmJmZWJkMzA5MmE1YTQzMjNiM2Q2NWI0YTdjMzUzNGZiL3RhYmxlcmFuZ2U6YmZlYmQzMDkyYTVhNDMyM2IzZDY1YjRhN2MzNTM0ZmJfMTAtMS0xLTEtMA_11415fea-6fa3-4929-8e5b-2f35924efe8f"
      unitRef="usd">6873000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i129948d8d7484c52bc400ee978922740_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80MC9mcmFnOmViNzk5OGUzNTJhZDQ1ZTE4YTU5OTVmMWQ2YWJmNmMzL3RhYmxlOmJmZWJkMzA5MmE1YTQzMjNiM2Q2NWI0YTdjMzUzNGZiL3RhYmxlcmFuZ2U6YmZlYmQzMDkyYTVhNDMyM2IzZDY1YjRhN2MzNTM0ZmJfMTAtMy0xLTEtMA_05ab7a44-9356-4b98-bcbe-37db36217a12"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ied24bfeab08a4433b3f48a2b7f17c882_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80MC9mcmFnOmViNzk5OGUzNTJhZDQ1ZTE4YTU5OTVmMWQ2YWJmNmMzL3RhYmxlOmJmZWJkMzA5MmE1YTQzMjNiM2Q2NWI0YTdjMzUzNGZiL3RhYmxlcmFuZ2U6YmZlYmQzMDkyYTVhNDMyM2IzZDY1YjRhN2MzNTM0ZmJfMTEtMS0xLTEtMA_3981a0d0-a4ad-4216-80e1-a77e27253b1c"
      unitRef="usd">38000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i46dfc7f31a1c42149b4c59b183486728_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80MC9mcmFnOmViNzk5OGUzNTJhZDQ1ZTE4YTU5OTVmMWQ2YWJmNmMzL3RhYmxlOmJmZWJkMzA5MmE1YTQzMjNiM2Q2NWI0YTdjMzUzNGZiL3RhYmxlcmFuZ2U6YmZlYmQzMDkyYTVhNDMyM2IzZDY1YjRhN2MzNTM0ZmJfMTEtMy0xLTEtMA_90309062-e13d-414c-b318-641449cbf358"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5cd7ede64f374cf0a1a1c96376d99ca8_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80MC9mcmFnOmViNzk5OGUzNTJhZDQ1ZTE4YTU5OTVmMWQ2YWJmNmMzL3RhYmxlOmJmZWJkMzA5MmE1YTQzMjNiM2Q2NWI0YTdjMzUzNGZiL3RhYmxlcmFuZ2U6YmZlYmQzMDkyYTVhNDMyM2IzZDY1YjRhN2MzNTM0ZmJfMTItMS0xLTEtMA_598777e2-b5b2-4414-a9eb-b5e486c0030c"
      unitRef="usd">24673000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9a8146b23bc64bb0989fb48fd0ed09c9_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80MC9mcmFnOmViNzk5OGUzNTJhZDQ1ZTE4YTU5OTVmMWQ2YWJmNmMzL3RhYmxlOmJmZWJkMzA5MmE1YTQzMjNiM2Q2NWI0YTdjMzUzNGZiL3RhYmxlcmFuZ2U6YmZlYmQzMDkyYTVhNDMyM2IzZDY1YjRhN2MzNTM0ZmJfMTItMy0xLTEtMA_079e91a0-f580-4542-b9f8-e58e572bff3a"
      unitRef="usd">5274000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6c6836ed9e254b72b169ede860583569_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80MC9mcmFnOmViNzk5OGUzNTJhZDQ1ZTE4YTU5OTVmMWQ2YWJmNmMzL3RhYmxlOmJmZWJkMzA5MmE1YTQzMjNiM2Q2NWI0YTdjMzUzNGZiL3RhYmxlcmFuZ2U6YmZlYmQzMDkyYTVhNDMyM2IzZDY1YjRhN2MzNTM0ZmJfMTUtMS0xLTEtMzQyOA_343c3a71-14df-4baa-a1c2-4b981b85ae70"
      unitRef="usd">1408000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifbd043497e914bc1bee58c0daa2546c6_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80MC9mcmFnOmViNzk5OGUzNTJhZDQ1ZTE4YTU5OTVmMWQ2YWJmNmMzL3RhYmxlOmJmZWJkMzA5MmE1YTQzMjNiM2Q2NWI0YTdjMzUzNGZiL3RhYmxlcmFuZ2U6YmZlYmQzMDkyYTVhNDMyM2IzZDY1YjRhN2MzNTM0ZmJfMTUtMy0xLTEtMzQyOA_c4027548-844e-4106-be43-e4ee7c5204e6"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if62b86057a964bb0a0b767d745aa53b7_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80MC9mcmFnOmViNzk5OGUzNTJhZDQ1ZTE4YTU5OTVmMWQ2YWJmNmMzL3RhYmxlOmJmZWJkMzA5MmE1YTQzMjNiM2Q2NWI0YTdjMzUzNGZiL3RhYmxlcmFuZ2U6YmZlYmQzMDkyYTVhNDMyM2IzZDY1YjRhN2MzNTM0ZmJfMTUtMS0xLTEtMjg0NQ_ef275819-44ab-46b2-8fdd-a1d97b0cf215"
      unitRef="usd">7737000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic52bf960eb1f4c9ba53b059468d7993e_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80MC9mcmFnOmViNzk5OGUzNTJhZDQ1ZTE4YTU5OTVmMWQ2YWJmNmMzL3RhYmxlOmJmZWJkMzA5MmE1YTQzMjNiM2Q2NWI0YTdjMzUzNGZiL3RhYmxlcmFuZ2U6YmZlYmQzMDkyYTVhNDMyM2IzZDY1YjRhN2MzNTM0ZmJfMTUtMy0xLTEtMjg0NQ_8a54e146-5ee1-41dd-8149-e15124b5c328"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic33a14cb7a1b47898a6aa7a5a5d657a4_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80MC9mcmFnOmViNzk5OGUzNTJhZDQ1ZTE4YTU5OTVmMWQ2YWJmNmMzL3RhYmxlOmJmZWJkMzA5MmE1YTQzMjNiM2Q2NWI0YTdjMzUzNGZiL3RhYmxlcmFuZ2U6YmZlYmQzMDkyYTVhNDMyM2IzZDY1YjRhN2MzNTM0ZmJfMTctMS0xLTEtMTg2Ng_ecc0981a-3b19-4b89-b563-58e25b02578e"
      unitRef="usd">9145000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i416a8546a935440ba7736b9614aa8073_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80MC9mcmFnOmViNzk5OGUzNTJhZDQ1ZTE4YTU5OTVmMWQ2YWJmNmMzL3RhYmxlOmJmZWJkMzA5MmE1YTQzMjNiM2Q2NWI0YTdjMzUzNGZiL3RhYmxlcmFuZ2U6YmZlYmQzMDkyYTVhNDMyM2IzZDY1YjRhN2MzNTM0ZmJfMTctMy0xLTEtMTg3NQ_4ca45d9d-e0f3-4cdb-bce3-24d2eadca3be"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia489a15348ae4ae390bc47557aaca423_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80MC9mcmFnOmViNzk5OGUzNTJhZDQ1ZTE4YTU5OTVmMWQ2YWJmNmMzL3RhYmxlOmJmZWJkMzA5MmE1YTQzMjNiM2Q2NWI0YTdjMzUzNGZiL3RhYmxlcmFuZ2U6YmZlYmQzMDkyYTVhNDMyM2IzZDY1YjRhN2MzNTM0ZmJfMTQtMS0xLTEtMA_9afd9f11-afef-4326-8077-d0debe0c1d88"
      unitRef="usd">135769000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iae589afb590a4f5984a5dd4001d656cb_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80MC9mcmFnOmViNzk5OGUzNTJhZDQ1ZTE4YTU5OTVmMWQ2YWJmNmMzL3RhYmxlOmJmZWJkMzA5MmE1YTQzMjNiM2Q2NWI0YTdjMzUzNGZiL3RhYmxlcmFuZ2U6YmZlYmQzMDkyYTVhNDMyM2IzZDY1YjRhN2MzNTM0ZmJfMTQtMy0xLTEtMA_59f5c29f-e4b1-4ca8-ab9a-f7db073ec4f6"
      unitRef="usd">71938000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock
      contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80MC9mcmFnOmViNzk5OGUzNTJhZDQ1ZTE4YTU5OTVmMWQ2YWJmNmMzL3RleHRyZWdpb246ZWI3OTk4ZTM1MmFkNDVlMThhNTk5NWYxZDZhYmY2YzNfMTg0_cc79e106-c859-45da-83f5-a216adbb36b0">&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the balance of our receivables related to our net product revenues: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:82.456%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.942%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.686%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.937%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Receivables included in &#x201c;Accounts receivable, net&#x201d;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91,516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,871&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="id1a37ec48832445999d722992c9485a5_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80MC9mcmFnOmViNzk5OGUzNTJhZDQ1ZTE4YTU5OTVmMWQ2YWJmNmMzL3RhYmxlOjZkMzYxODQ2NjNkYjRjZWE5YjUyOTcwNWYwZTFhMTU2L3RhYmxlcmFuZ2U6NmQzNjE4NDY2M2RiNGNlYTliNTI5NzA1ZjBlMWExNTZfMS0xLTEtMS0w_da645163-2b2d-41ab-8910-57ea1e1ebfc4"
      unitRef="usd">91516000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i27b6b4c7a00f4e4eb8bf4fb46f229034_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80MC9mcmFnOmViNzk5OGUzNTJhZDQ1ZTE4YTU5OTVmMWQ2YWJmNmMzL3RhYmxlOjZkMzYxODQ2NjNkYjRjZWE5YjUyOTcwNWYwZTFhMTU2L3RhYmxlcmFuZ2U6NmQzNjE4NDY2M2RiNGNlYTliNTI5NzA1ZjBlMWExNTZfMS0zLTEtMS0w_4d980a8c-a61d-4d65-8c06-74ac3a88f0ea"
      unitRef="usd">68871000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RleHRyZWdpb246MWE2ZWQwNzZlMTc2NDkyMzllYTFhMjgxNTMwYjdjYjRfMzExMDE_76c84d48-7d13-40c4-b03e-fc691b69ce31">NET REVENUES FROM COLLABORATIONS&lt;div style="margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Net revenues from collaborations consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:84.941%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.616%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.111%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.660%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.113%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Regeneron Pharmaceuticals&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Novartis AG&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vir Biotechnology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,822&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,797&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the balance of our receivables and contract liabilities related to our collaboration agreements:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:84.795%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.313%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.762%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.662%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Receivables included in &#x201c;Accounts receivable, net&#x201d;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract liabilities included in &#x201c;Deferred revenue&#x201d;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,759&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120,021&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognized revenue of $25.3 million and $14.7 million in the three months ended March&#160;31, 2021 and 2020, respectively, that was included in the contract liability balance at the beginning of the respective period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In order to determine revenue recognized in the period from contract liabilities, we first allocate revenue to the individual contract liability balance outstanding at the beginning of the period until the revenue exceeds that balance. If additional consideration is received on those contracts in subsequent periods, we assume all revenue recognized in the reporting period first applies to the beginning contract liability as opposed to a portion applying to the new consideration for the period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table provides research and development expenses incurred by type, for which we recognize net revenue, that are directly attributable to our collaboration agreements, by collaboration partner:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.083%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.759%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.759%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.759%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.759%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.759%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.762%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Clinical Trial and Manufacturing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;External Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Clinical Trial and Manufacturing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;External Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Regeneron Pharmaceuticals&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,799&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,612&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vir Biotechnology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,029&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Novartis AG&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,839&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,949&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The research and development expenses incurred for each agreement listed in the table above consist of costs incurred for (i) clinical expenses, including manufacturing of clinical product, (ii) external services including consulting services and lab supplies and services, and (iii) other expenses, including professional services, facilities and overhead allocations, and a reasonable estimate of compensation and related costs as billed to our counterparties, for which we recognize net revenue from collaborations. For the three months ended March&#160;31, 2021 and 2020, we did not incur material selling, general and administrative expenses related to our collaboration agreements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Product Alliances&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Regeneron Pharmaceuticals, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In April&#160;2019, we entered into a global, strategic collaboration with Regeneron Pharmaceuticals, Inc., or Regeneron, to discover, develop and commercialize RNAi therapeutics for a broad range of diseases by addressing therapeutic targets expressed in the eye and central nervous system, or CNS, in addition to a select number of targets expressed in the liver, which we refer to as the Regeneron Collaboration. The Regeneron Collaboration is governed by a Master Agreement, referred to as the Regeneron Master Agreement, which became effective on May 21, 2019, or the Effective Date. In connection with the Regeneron Master Agreement, we and Regeneron entered into (i) a binding co-co collaboration term sheet covering the continued development of cemdisiran, our C5 small interfering RNA, or siRNA, currently in Phase 2 development for C5 complement-mediated diseases, as a monotherapy and (ii) a binding license term sheet to evaluate anti-C5 antibody-siRNA combinations for C5 complement-mediated diseases including evaluating the combination of Regeneron&#x2019;s pozelimab (REGN3918), currently in Phase 2 development, and cemdisiran. The C5 co-co collaboration and license agreements were executed in August 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Under the terms of the Regeneron Collaboration, we are working exclusively with Regeneron to discover RNAi therapeutics for eye and CNS diseases for an initial five-year research period, which we refer to as the Initial Research Term. Regeneron has an option to extend the Initial Research Term (referred to as the Research Term Extension Period, and together with the Initial Research Term, the Research Term) for up to an additional five years, for a research term extension fee of up to $400.0 million. The Regeneron Collaboration also covers a select number of RNAi therapeutic programs designed to target genes expressed in the liver, including our previously announced collaboration with Regeneron to identify RNAi therapeutics for the chronic liver disease nonalcoholic steatohepatitis. We retain broad global rights to all of our other unpartnered liver-&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;directed clinical and pre-clinical pipeline programs. The Regeneron Collaboration is governed by a joint steering committee that is comprised of an equal number of representatives from each party.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Regeneron will lead development and commercialization for all programs targeting eye diseases (subject to limited exceptions), entitling us to certain potential milestone and royalty payments pursuant to the terms of a license agreement, the form of which has been agreed upon by the parties. We and Regeneron will alternate leadership on CNS and liver programs, with the lead party retaining global development and commercial responsibility. For CNS and liver programs, both we and Regeneron will have the option at lead candidate selection to enter into a&#160;co-co&#160;collaboration agreement, the form of which has been agreed upon by the parties, whereby both companies will share equally all costs of, and profits from, all development and commercialization activities under the program. If the&#160;non-lead&#160;party elects to not enter into a&#160;co-co&#160;collaboration agreement with respect to a given CNS or liver program, we and Regeneron will enter into a license agreement with respect to such program and the lead party will be the &#x201c;Licensee&#x201d; for the purposes of the license agreement. If the lead party for a CNS or liver program elects to not enter into the&#160;co-co&#160;collaboration agreement, then we and Regeneron will enter into a license agreement with respect to such program and leadership of the program will transfer to the other party and the former&#160;non-lead&#160;party will be the &#x201c;Licensee&#x201d; for the purposes of the license agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;With respect to the programs directed to C5 complement-mediated diseases, we retain control of cemdisiran monotherapy development, and Regeneron is leading combination product development. Under the C5 co-co collaboration agreement, we and Regeneron equally share costs and potential future profits on any monotherapy program. Under the C5 license agreement, for cemdisiran to be used as part of a combination product, Regeneron is solely responsible for all development and commercialization costs and we will receive low double-digit royalties and commercial milestones of up to $325.0 million on any potential combination product sales. The C5 co-co collaboration agreement, the C5 license agreement, and the Master Agreement have been combined for accounting purposes and treated as a single agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In connection with the Regeneron Master Agreement, Regeneron made an upfront payment of $400.0 million. We are also eligible to receive up to an additional $200.0 million in milestone payments upon achievement of certain criteria during early clinical development for eye and CNS programs. We and Regeneron plan to advance programs directed to up to 30 targets under the Regeneron Collaboration during the Initial Research Term. For each program, Regeneron will provide us with $2.5 million in funding at program initiation and an additional $2.5 million at lead candidate identification, with the potential for approximately $30.0 million in annual discovery funding to us as the Regeneron Collaboration reaches steady state.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Regeneron has the right to terminate the Regeneron Master Agreement for convenience upon ninety days&#x2019; notice. The termination of the Regeneron Master Agreement does not affect the term of any license agreement or&#160;co-co&#160;collaboration agreement then in effect. In addition, either party may terminate the Regeneron Master Agreement for a material breach by, or insolvency of, the other party. Unless earlier terminated pursuant to its terms, the Regeneron Master Agreement will remain in effect with respect to each program until (a)&#160;such program becomes a terminated program or (b)&#160;the parties enter into a license agreement or&#160;co-co&#160;collaboration agreement with respect to such program.&#160;The Regeneron Master Agreement includes various representations, warranties, covenants, dispute escalation and resolution mechanisms, indemnities and other provisions customary for transactions of this nature.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;For any license agreement subsequently entered into, the licensee will generally be responsible for its own costs and expenses incurred in connection with the development and commercialization of the collaboration products. The licensee will pay to the licensor certain development and/or commercialization milestone payments totaling up to $150.0 million for each collaboration product. In addition, following the first commercial sale of the applicable collaboration product under a license agreement, the licensee is required to make certain tiered royalty payments, ranging from low double-digits up to 20%, to the licensor based on the aggregate annual net sales of the collaboration product, subject to customary reductions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;For any co-co&#160;collaboration agreement subsequently entered into, we and Regeneron will share equally all costs of, and profits from, development and commercialization activities. Reimbursement of our share of costs will be recognized as a reduction to research and development expense in the condensed consolidated statements of operations and comprehensive loss. In the event that a party exercises its&#160;opt-out&#160;right, the lead party will be responsible for all costs and expenses incurred in connection with the development and commercialization of the collaboration products under the applicable&#160;co-co&#160;collaboration agreement, subject to continued sharing of costs through defined points. If a party exercises its&#160;opt-out&#160;right, following the first commercial sale of the applicable collaboration product under a&#160;co-co&#160;collaboration agreement, the lead party is required to make certain tiered royalty payments, ranging from low double-digits up to 20%, to the other party based on the aggregate annual net sales of the collaboration product and the timing of the exercise of the&#160;opt-out&#160;right, subject to customary reductions and a reduction for&#160;opt-out&#160;transition costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Due to the uncertainty of pharmaceutical development and the high historical failure rates generally associated with drug development, we may not receive any milestone or royalty payments from Regeneron under the Regeneron Master Agreement, the C5 license agreement, or any future license agreement, or under any co-co collaboration agreement in the event we exercise our opt-out right.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Our obligations under the Regeneron Collaboration include: (i) a research license and research services, collectively referred to as the Research Services Obligation; (ii) a worldwide license to cemdisiran for combination therapies, and manufacturing and supply, and development service obligations, collectively referred to as the C5 License Obligation; and (iii) development, manufacturing and commercialization activities for cemdisiran monotherapies, referred to as the C5 Co-Co Obligation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The research license is not distinct from the research services primarily as a result of Regeneron being unable to benefit on its own or with other resources reasonably available, as the license is providing access to specialized expertise, particularly as it relates to RNAi technology that is not available in the marketplace.&#160;Similarly, the worldwide license to cemdisiran for combination therapies is not distinct from the manufacturing and supply, and development service obligations, as Regeneron cannot benefit on its own from the value of the license without receipt of supply.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Separately, the cemdisiran monotherapy co-co collaboration agreement is under the scope of ASC 808 as we and Regeneron are both active participants in the development and manufacturing activities and are exposed to significant risks and rewards that are dependent on commercial success of the activities of the arrangement. The development and manufacturing activities are a combined unit of account under the scope of ASC 808 and are not deliverables under ASC 606.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The total transaction price is comprised of the&#160;$400.0 million&#160;upfront payment and&#160;additional variable consideration related to research, development, manufacturing and supply activities related to the Research Services Obligation and the C5 License Obligation. We utilized the expected value method to determine the amount of reimbursement for these activities. We determined that any variable consideration related to sales-based royalties and milestones related to the worldwide license to cemdisiran for combination therapies is deemed to be constrained and therefore has been excluded from the transaction price. In addition, we are eligible to receive future milestones upon the achievement of certain criteria during early clinical development for the eye and CNS programs.&#160;We are also eligible to receive royalties on future commercial sales for certain eye, CNS or liver targets, if any; however, these amounts are excluded from variable consideration under the Regeneron Collaboration as we are only eligible to receive such amounts if, after a drug candidate is identified, the form of license agreement is subsequently executed resulting in a license that is granted to Regeneron. Any such subsequently granted license would represent a separate transaction under ASC 606. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;We allocated the initial transaction price to each unit of account based on the applicable accounting guidance as follows, in thousands: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.467%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.806%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.412%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.736%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.412%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.736%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.331%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.567%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:83%"&gt;Performance Obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:83%"&gt;Standalone Selling Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:83%"&gt;Transaction Price Allocated&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:83%"&gt;Accounting Guidance&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%"&gt;Research Services Obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%"&gt;130,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%"&gt;183,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%"&gt;ASC 606&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%"&gt;C5 License Obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%"&gt;97,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%"&gt;92,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:95%"&gt;ASC 606&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%"&gt;C5 Co-Co Obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%"&gt;364,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%"&gt;246,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%"&gt;ASC 808&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%"&gt;521,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The transaction price was allocated to the obligations based on the relative estimated standalone selling prices of each obligation, over which management has applied significant judgment. We developed the estimated standalone selling price for the licenses included in the Research Services Obligation and the C5 License Obligation primarily based on the probability-weighted present value of expected future cash flows associated with each license related to each specific program. In developing such estimate, we applied judgment in the determination of the forecasted revenues, taking into consideration the applicable market conditions and relevant entity-specific factors, the expected number of targets or indications expected to be pursued under each license, the probability of success, the time needed to develop a product candidate pursuant to the associated license and the discount rate. We developed the estimated standalone selling price for the services and/or manufacturing and supply included in each of the obligations, as applicable, primarily based on the nature of the services to be performed and/or goods to be manufactured and estimates of the associated costs. The estimated standalone selling price of the C5 Co-Co Obligation was developed by estimating the present value of expected future cash flows that Regeneron is entitled to receive. In developing such estimate, we applied judgment in determining the indications that will be pursued, the forecasted revenues for such indications, the probability of success and the discount rate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;For the Research Services Obligation and the C5 License Obligation accounted for under ASC 606, we measure proportional performance over time using an input method based on cost incurred relative to the total estimated costs for each of the identified obligations, on a quarterly basis, by determining the proportion of effort incurred as a percentage of total effort we expect to expend.&#160;This ratio is applied to the transaction price allocated to each obligation. Management has applied significant judgment in the process of developing our estimates. Any changes to these estimates will be recognized in the period in which they change as a cumulative catch up. We re-evaluate the transaction price as of the end of each reporting period, as of March&#160;31, 2021, the total transaction price was $530.5&#160;million. As of March&#160;31, 2021, the transaction price is comprised of the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;upfront payment and variable consideration related to development, manufacture and supply activities. For the C5 Co-Co Obligation accounted for under ASC 808, the transaction price allocated to this obligation is recognized using a proportional performance method. Revenue recognized under this agreement, inclusive of the amount allocated to the C5 Co-Co Obligation, is accounted for as collaboration revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following tables provide a summary of the transaction price allocated to each unit of account based on the applicable accounting guidance, in addition to revenue activity during the period, in thousands:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:91.374%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.300%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.440%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.660%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.440%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.660%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.440%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.660%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.440%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.660%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Transaction Price Allocated&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Deferred Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Performance Obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Accounting Guidance&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Research Services Obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;200,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;45,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;54,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;ASC 606&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;C5 License Obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;83,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;45,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;58,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;ASC 606&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;C5 Co-Co Obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;246,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;228,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;231,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;ASC 808&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;530,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;319,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;345,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:66.959%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.926%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.673%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.699%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.673%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.699%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.673%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.657%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Revenue Recognized During&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Performance Obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Accounting Guidance&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Research Services Obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;9,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;12,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;ASC 606&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;C5 License Obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;13,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;ASC 606&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;C5 Co-Co Obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;4,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;ASC 808&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;25,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;16,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As of&#160;March&#160;31, 2021, the aggregate amount of the transaction price allocated to the remaining Research Services Obligation and C5 License Obligation that was unsatisfied was&#160;$188.3 million, which&#160;is expected to be recognized through the term of the Regeneron Collaboration as the services are performed. This amount excludes the transaction price allocated to the C5 Co-Co Obligation accounted for under ASC 808. Deferred revenue related to the Regeneron Collaboration is classified as either current or non-current in the condensed consolidated balance sheets based on the period the revenue is expected to be recognized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Novartis AG&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In February 2013, we and The Medicines Company, or MDCO, entered into a license and collaboration agreement pursuant to which we granted to MDCO an exclusive, worldwide license to develop, manufacture and commercialize RNAi therapeutics targeting proprotein convertase subtilisin/kexin type 9, or PCSK9, for the treatment of hypercholesterolemia and other human diseases, including inclisiran. We refer to this agreement, as amended through the date hereof, as the MDCO License Agreement. On January 6, 2020, Novartis completed its acquisition of MDCO, and assumed all rights and obligations under the MDCO License Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As of March&#160;31, 2021, we have earned $45.0&#160;million of milestones and upon achievement of certain events, we will be entitled to receive additional milestones, up to an aggregate of $135.0&#160;million, including $25.0&#160;million associated with the U.S. regulatory approval milestone, $10.0&#160;million in other specified regulatory milestones and $100.0&#160;million in specified commercialization milestones. In addition, we will be entitled to royalties ranging from 10% up to 20% based on annual worldwide net sales of licensed products by Novartis, its affiliates and sublicensees, subject to reduction under specified circumstances. Due to the uncertainty of pharmaceutical development and the high historical failure rates generally associated with drug development, we may not receive any additional milestone payments under the MDCO License Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Unless terminated earlier in accordance with the terms of the agreement, the MDCO License Agreement expires on a licensed product-by-licensed product and country-by-country basis upon expiration of the last royalty term for any licensed product in any country, where a royalty term is defined as the latest to occur of (1) the expiration of the last valid claim of patent rights covering a licensed product, (2) the expiration of the Regulatory Exclusivity, as defined in the MDCO License Agreement, and (3) the twelfth anniversary of the first commercial sale of the licensed product in such country. We estimate that our fundamental RNAi patents covering licensed products under the MDCO License Agreement will expire both in and outside of the U.S. generally between 2016 and 2028. We also estimate that our inclisiran product-specific patents covering licensed products under the MDCO License Agreement will expire in the U.S., Europe, China and Japan in 2036 and elsewhere at the end of 2033. These patent rights are subject to potential patent term extensions and/or supplemental protection certificates &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;extending such terms in countries where such extensions may become available due to regulatory delay. In addition, more patent filings relating to the collaboration may be made in the future.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Either party may terminate the MDCO License Agreement in the event the other party fails to cure a material breach or upon patent-related challenges by the other party. In addition, Novartis has the right to terminate the agreement without cause at any time upon four months&#x2019; prior written notice.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;During the term of the MDCO License Agreement, neither party will, alone or with an affiliate or third party, research, develop or commercialize, or grant a license to any third party to research, develop or commercialize, in any country, any siRNA product directed to the PCSK9 gene, other than a licensed product, without the prior written agreement of the other party, subject to the terms of the MDCO License Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;We evaluated the MDCO License Agreement and concluded that Novartis meets the definition of a customer and that the MDCO License Agreement is a contract. During 2018, we completed the performance obligations identified in the MDCO License Agreement. However, we continue to receive additional orders for supply of certain material. Given Novartis now has the ability to manufacture on its own through its own vendors, such orders will be treated as separate agreements and any associated revenue will be recognized upon transfer of control.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Vir Biotechnology, Inc. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In October 2017, we and Vir Biotechnology, Inc., or Vir, entered into a collaboration and license agreement, or the Vir Agreement, for the development and commercialization of RNAi therapeutics for infectious diseases, including chronic hepatitis B virus, or HBV, infection. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Pursuant to the Vir Agreement, we granted to Vir an exclusive license to develop, manufacture and commercialize ALN-HBV02 (VIR-2218), for all uses and purposes other than certain excluded fields, as set forth in the Vir Agreement. In addition, we granted Vir an exclusive option for up to four additional RNAi therapeutic programs for the treatment of infectious diseases. Under the terms of the Vir Agreement, for each product arising from the HBV program, including ALN-HBV02, we retained the right to opt into a profit-sharing arrangement prior to the start of a Phase 3 clinical trial. In addition, we have the right on a product-by-product basis with respect to each additional infectious disease program that Vir elects to pursue, to opt into a profit-sharing arrangement for each such product at any time during a specified period prior to the initiation of a Phase 3 clinical trial for each such product. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Pursuant to the Vir Agreement, Vir paid us an upfront fee of $10.0 million and issued to us 1,111,111 shares of its common stock. Under the Vir Agreement, we may also receive milestone payments upon the achievement of certain development, regulatory and commercial milestones, as well as royalties on the net sales of licensed products ranging from high-single-digit to sub-teen double-digit percentages. In March 2020, we achieved a development milestone relating to ALN-HBV02 and earned a $15.0 million cash milestone and 1,111,111 shares of Vir's common stock, which were received in the second quarter of 2020. In June 2020, we earned and received a $10.0&#160;million payment from Vir related to Vir's sublicense for ALN-HBV02 in China. Due to the uncertainty of pharmaceutical development and the high historical failure rates generally associated with drug development, we may not receive any additional milestone payments or any royalty payments under the Vir Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In March and April 2020, we entered into amendments to the Vir Agreement to expand our collaboration to include the development and commercialization of RNAi therapeutics targeting SARS-CoV-2, the virus that causes the disease COVID-19, along with three additional targets focused on human host factors for SARS-CoV-2, including angiotensin converting enzyme-2 and transmembrane protease, serine 2 and potentially a third mutually selected host factor target. Under the Vir amendments, we and Vir were each responsible for our own pre-clinical development costs incurred in performing our allocated responsibilities under an agreed-upon initial pre-clinical development plan. Under the original agreements, we and Vir agreed to equally share certain costs incurred in connection with the manufacture of non-GMP drug product required for pre-clinical development prior to filing an IND for the first product in the coronavirus program. We also agreed that Vir would lead all development and commercialization of any selected development candidates. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In December 2020, we signed a letter agreement to amend the Vir Agreement such that we are solely responsible for conducting pre-clinical research activities under the pre-clinical development plan, related to the COVID-19 activities in the March and April 2020 amendments, at our discretion and sole expense, and effective as of July 1, 2020, we are responsible for all pre-clinical development costs incurred under such plan for such COVID-19 related activities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Unless terminated earlier in accordance with the terms of the agreement, the Vir Agreement expires on a licensed product-by-product and country-by-country basis upon expiration of all royalty payment obligations under the agreement. If Vir does not exercise its option for an infectious disease program, the Vir Agreement will expire upon the expiration of the applicable option period with respect to such program. However, if we exercise our profit-sharing option for any product, the term of the agreement will continue until the expiration of the profit-sharing arrangement for such product. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Either party may terminate the agreement in the event the other party fails to cure a material breach, or upon patent-related challenges by the other party. In addition, Vir has the right to terminate the agreement on a program-by-program basis or in its entirety for any reason on 90 days&#x2019; written notice.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;We identified one performance obligation under the Vir Agreement, as amended, comprised of: i) the exclusive license to develop, manufacture and commercialize RNAi therapeutics (including ALN-HBV02); ii) the obligation to deliver four additional development candidates and supply product for each such RNAi therapeutic program; and iii) the obligation to deliver up to four development candidates and supply product for RNAi therapeutic programs targeting SARS-CoV-2. The license is not distinct from the services, including the obligation to deliver development candidates and supply product, as Vir cannot benefit on its own from the value of the license without receipt of such services and supply.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;We measure proportional performance over time using an input method based on cost incurred relative to the total estimated costs for the identified performance obligation, on a quarterly basis, by determining the proportion of effort incurred as a percentage of total effort we expect to expend. This ratio is applied to the total transaction price. Management has applied significant judgment in the process of developing our estimates. Any changes to these estimates will be recognized in the period in which they change as a cumulative catch up. As of March&#160;31, 2021, the total transaction price was determined to be $110.1&#160;million, and is comprised of the upfront payment, fair value of non-cash equity consideration at contract inception, milestones achieved and variable consideration related to development, manufacture and supply activities. We utilized the expected value method to determine the amount of reimbursement for these activities. The total transaction price is allocated entirely to the single performance obligation. We determined any variable consideration related to sales-based royalties and milestones related to the exclusive license to be constrained and therefore excluded such consideration from the transaction price.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As of March&#160;31, 2021, the aggregate amount of the transaction price allocated to the performance obligation that was unsatisfied was $48.8&#160;million, which is expected to be recognized through the term of the Vir Agreement as the services are performed.&lt;/span&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock
      contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RleHRyZWdpb246MWE2ZWQwNzZlMTc2NDkyMzllYTFhMjgxNTMwYjdjYjRfMzExMjA_d211761f-df36-4afb-81e1-9fa6ba55c9f4">&lt;div style="margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Net revenues from collaborations consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:84.941%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.616%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.111%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.660%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.113%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Regeneron Pharmaceuticals&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Novartis AG&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vir Biotechnology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,822&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,797&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i95f1c1ed3c154524aceec386b964d3e5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RhYmxlOjBmNmRhZjU0ZTkyYTQ0OTE5YjNkMzM0ZWEwZDg2YzIxL3RhYmxlcmFuZ2U6MGY2ZGFmNTRlOTJhNDQ5MTliM2QzMzRlYTBkODZjMjFfMi0xLTEtMS0w_f7ac0f78-dbd9-4661-a0d5-9f1d1915ce34"
      unitRef="usd">30343000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic41d4a1b34194fdb92365734e524ff34_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RhYmxlOjBmNmRhZjU0ZTkyYTQ0OTE5YjNkMzM0ZWEwZDg2YzIxL3RhYmxlcmFuZ2U6MGY2ZGFmNTRlOTJhNDQ5MTliM2QzMzRlYTBkODZjMjFfMi0zLTEtMS0w_65949215-484a-416d-9f7f-d988f3fa6a6d"
      unitRef="usd">19503000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifafd9b348c4c4d3bb08ec5381577d767_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RhYmxlOjBmNmRhZjU0ZTkyYTQ0OTE5YjNkMzM0ZWEwZDg2YzIxL3RhYmxlcmFuZ2U6MGY2ZGFmNTRlOTJhNDQ5MTliM2QzMzRlYTBkODZjMjFfMy0xLTEtMS0yNDEy_5d139707-947a-4ee5-9e4e-beca1c29bf0e"
      unitRef="usd">8111000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia500fa9e2b224d0ea1d970ddb3c83d05_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RhYmxlOjBmNmRhZjU0ZTkyYTQ0OTE5YjNkMzM0ZWEwZDg2YzIxL3RhYmxlcmFuZ2U6MGY2ZGFmNTRlOTJhNDQ5MTliM2QzMzRlYTBkODZjMjFfMy0zLTEtMS0yNDEy_cc56bf44-3874-4247-a722-4c2f45a1370a"
      unitRef="usd">1060000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7b35d0a44ca0429b8b8202051f1b3678_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RhYmxlOjBmNmRhZjU0ZTkyYTQ0OTE5YjNkMzM0ZWEwZDg2YzIxL3RhYmxlcmFuZ2U6MGY2ZGFmNTRlOTJhNDQ5MTliM2QzMzRlYTBkODZjMjFfMy0xLTEtMS0w_516f3bbc-cb27-4e35-85af-cfd9a11ff814"
      unitRef="usd">2822000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iab7c02eb57194c1192e785ccd3886998_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RhYmxlOjBmNmRhZjU0ZTkyYTQ0OTE5YjNkMzM0ZWEwZDg2YzIxL3RhYmxlcmFuZ2U6MGY2ZGFmNTRlOTJhNDQ5MTliM2QzMzRlYTBkODZjMjFfMy0zLTEtMS0w_323bf31a-c688-4528-b7c6-4a40bee46b10"
      unitRef="usd">6516000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i33cced07680d487d8f3ae8596484a8ca_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RhYmxlOjBmNmRhZjU0ZTkyYTQ0OTE5YjNkMzM0ZWEwZDg2YzIxL3RhYmxlcmFuZ2U6MGY2ZGFmNTRlOTJhNDQ5MTliM2QzMzRlYTBkODZjMjFfNi0xLTEtMS0w_3d1a56b9-ba85-4a8b-abf8-5ed1db460f16"
      unitRef="usd">521000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1b9f37fb1a5c435aadb1d93990451d0a_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RhYmxlOjBmNmRhZjU0ZTkyYTQ0OTE5YjNkMzM0ZWEwZDg2YzIxL3RhYmxlcmFuZ2U6MGY2ZGFmNTRlOTJhNDQ5MTliM2QzMzRlYTBkODZjMjFfNi0zLTEtMS0w_37bda0cf-6641-4bb1-86f0-285467141c1a"
      unitRef="usd">459000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6912a2c4b43f46838e7d9157c5b3a723_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RhYmxlOjBmNmRhZjU0ZTkyYTQ0OTE5YjNkMzM0ZWEwZDg2YzIxL3RhYmxlcmFuZ2U6MGY2ZGFmNTRlOTJhNDQ5MTliM2QzMzRlYTBkODZjMjFfNy0xLTEtMS0w_e31923c2-b75c-400c-8957-7583fd32eb12"
      unitRef="usd">41797000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i738b536de6724c23b1637b0913d14f26_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RhYmxlOjBmNmRhZjU0ZTkyYTQ0OTE5YjNkMzM0ZWEwZDg2YzIxL3RhYmxlcmFuZ2U6MGY2ZGFmNTRlOTJhNDQ5MTliM2QzMzRlYTBkODZjMjFfNy0zLTEtMS0w_9e979a34-b800-456b-8f99-968765903f54"
      unitRef="usd">27538000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock
      contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RleHRyZWdpb246MWE2ZWQwNzZlMTc2NDkyMzllYTFhMjgxNTMwYjdjYjRfMzExMjM_5ec13fd7-475f-47c5-a803-f725d87a543c">&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the balance of our receivables and contract liabilities related to our collaboration agreements:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:84.795%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.313%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.762%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.662%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Receivables included in &#x201c;Accounts receivable, net&#x201d;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract liabilities included in &#x201c;Deferred revenue&#x201d;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,759&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120,021&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
    <us-gaap:AccountsReceivableNet
      contextRef="idd7204dc87d24972a01f15b098c4f56b_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RhYmxlOjNjYjgxNWE0ODNkMDQwMjFhM2NiYjhmOWVjNzI5YTI2L3RhYmxlcmFuZ2U6M2NiODE1YTQ4M2QwNDAyMWEzY2JiOGY5ZWM3MjlhMjZfMS0xLTEtMS0w_0fb88fa7-abcf-4f72-af59-2febde262746"
      unitRef="usd">19111000</us-gaap:AccountsReceivableNet>
    <us-gaap:AccountsReceivableNet
      contextRef="id365c5f1d37444ac9e1da5b5891cd81a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RhYmxlOjNjYjgxNWE0ODNkMDQwMjFhM2NiYjhmOWVjNzI5YTI2L3RhYmxlcmFuZ2U6M2NiODE1YTQ4M2QwNDAyMWEzY2JiOGY5ZWM3MjlhMjZfMS0zLTEtMS0w_c4ffe9f9-cc88-4dca-9fe7-806ea7c7249e"
      unitRef="usd">33542000</us-gaap:AccountsReceivableNet>
    <us-gaap:ContractWithCustomerLiability
      contextRef="idd7204dc87d24972a01f15b098c4f56b_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RhYmxlOjNjYjgxNWE0ODNkMDQwMjFhM2NiYjhmOWVjNzI5YTI2L3RhYmxlcmFuZ2U6M2NiODE1YTQ4M2QwNDAyMWEzY2JiOGY5ZWM3MjlhMjZfMi0xLTEtMS0w_53cb85e7-b4df-4a8b-84b2-d3e5c0aeb672"
      unitRef="usd">94759000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="id365c5f1d37444ac9e1da5b5891cd81a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RhYmxlOjNjYjgxNWE0ODNkMDQwMjFhM2NiYjhmOWVjNzI5YTI2L3RhYmxlcmFuZ2U6M2NiODE1YTQ4M2QwNDAyMWEzY2JiOGY5ZWM3MjlhMjZfMi0zLTEtMS0w_7aca9adf-90db-4212-829d-6b0558f6126c"
      unitRef="usd">120021000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RleHRyZWdpb246MWE2ZWQwNzZlMTc2NDkyMzllYTFhMjgxNTMwYjdjYjRfNDk0NzgwMjQwNTc4OQ_6172159f-302c-4d13-a0b8-80068eedfd57"
      unitRef="usd">25300000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="ide9f6e15665746279d0000be700fcc6a_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RleHRyZWdpb246MWE2ZWQwNzZlMTc2NDkyMzllYTFhMjgxNTMwYjdjYjRfNDk0NzgwMjQwNTc3MA_23a4c4ea-3659-44ed-bd9c-5b8465e8b6cc"
      unitRef="usd">14700000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <alny:ScheduleOfResearchAndDevelopmentExpensesIncurredForCollaborationAgreementsTableTableTextBlock
      contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RleHRyZWdpb246MWE2ZWQwNzZlMTc2NDkyMzllYTFhMjgxNTMwYjdjYjRfMzExMTA_33733aa3-fc91-4806-b64a-b9912d1c5b81">&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table provides research and development expenses incurred by type, for which we recognize net revenue, that are directly attributable to our collaboration agreements, by collaboration partner:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.083%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.759%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.759%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.759%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.759%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.759%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.762%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Clinical Trial and Manufacturing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;External Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Clinical Trial and Manufacturing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;External Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Regeneron Pharmaceuticals&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,799&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,612&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vir Biotechnology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,029&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Novartis AG&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,839&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,949&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</alny:ScheduleOfResearchAndDevelopmentExpensesIncurredForCollaborationAgreementsTableTableTextBlock>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="id3753a1357334f66bd9801d06cb5303b_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RhYmxlOmFhNTJiZTViM2I1NDQwNDI4NTZmNDY1ODFiMGZiNTA0L3RhYmxlcmFuZ2U6YWE1MmJlNWIzYjU0NDA0Mjg1NmY0NjU4MWIwZmI1MDRfMy0xLTEtMS0w_cb854651-3210-4201-9dd9-b6ea3cbc08d8"
      unitRef="usd">4799000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i2e5101b0b8bd410196b91d29fd823e81_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RhYmxlOmFhNTJiZTViM2I1NDQwNDI4NTZmNDY1ODFiMGZiNTA0L3RhYmxlcmFuZ2U6YWE1MmJlNWIzYjU0NDA0Mjg1NmY0NjU4MWIwZmI1MDRfMy0zLTEtMS0w_8744c439-0720-4a90-b91e-2ba923a33754"
      unitRef="usd">94000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i503bb08b80284da78e7d56a82595e959_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RhYmxlOmFhNTJiZTViM2I1NDQwNDI4NTZmNDY1ODFiMGZiNTA0L3RhYmxlcmFuZ2U6YWE1MmJlNWIzYjU0NDA0Mjg1NmY0NjU4MWIwZmI1MDRfMy01LTEtMS0w_c383d71f-c966-435f-9742-156de1db797f"
      unitRef="usd">12235000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i6f98765bfdbc4e44a1223eaa20633d22_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RhYmxlOmFhNTJiZTViM2I1NDQwNDI4NTZmNDY1ODFiMGZiNTA0L3RhYmxlcmFuZ2U6YWE1MmJlNWIzYjU0NDA0Mjg1NmY0NjU4MWIwZmI1MDRfMy03LTEtMS0w_d073e073-5adc-46e0-be5a-56961794b7c3"
      unitRef="usd">4612000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i99846caa80964377a5573940a812180e_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RhYmxlOmFhNTJiZTViM2I1NDQwNDI4NTZmNDY1ODFiMGZiNTA0L3RhYmxlcmFuZ2U6YWE1MmJlNWIzYjU0NDA0Mjg1NmY0NjU4MWIwZmI1MDRfMy05LTEtMS0w_3018f510-4c4a-40d9-b572-01514390b938"
      unitRef="usd">0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ic2a36524f2b9464c9ddd8548541ad993_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RhYmxlOmFhNTJiZTViM2I1NDQwNDI4NTZmNDY1ODFiMGZiNTA0L3RhYmxlcmFuZ2U6YWE1MmJlNWIzYjU0NDA0Mjg1NmY0NjU4MWIwZmI1MDRfMy0xMS0xLTEtMA_cb6d34de-d176-4d07-8932-da98171e66a7"
      unitRef="usd">11491000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i9b580b28bb314ef6839a51260f628026_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RhYmxlOmFhNTJiZTViM2I1NDQwNDI4NTZmNDY1ODFiMGZiNTA0L3RhYmxlcmFuZ2U6YWE1MmJlNWIzYjU0NDA0Mjg1NmY0NjU4MWIwZmI1MDRfNC0xLTEtMS0w_92fd46e4-f512-4f38-ba6f-ee448967ca22"
      unitRef="usd">1029000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i09f8081c6a5246a0a017275e36ee340d_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RhYmxlOmFhNTJiZTViM2I1NDQwNDI4NTZmNDY1ODFiMGZiNTA0L3RhYmxlcmFuZ2U6YWE1MmJlNWIzYjU0NDA0Mjg1NmY0NjU4MWIwZmI1MDRfNC0zLTEtMS0w_ca3ce9ac-c244-4809-9256-6dc53e870176"
      unitRef="usd">159000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ie9502a31100149eaa773ddbb07c78892_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RhYmxlOmFhNTJiZTViM2I1NDQwNDI4NTZmNDY1ODFiMGZiNTA0L3RhYmxlcmFuZ2U6YWE1MmJlNWIzYjU0NDA0Mjg1NmY0NjU4MWIwZmI1MDRfNC01LTEtMS0w_154e27cc-ebbb-4c56-bd77-28ecc86a460e"
      unitRef="usd">1355000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i7c2e51b9aa354777af021d48ff53f086_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RhYmxlOmFhNTJiZTViM2I1NDQwNDI4NTZmNDY1ODFiMGZiNTA0L3RhYmxlcmFuZ2U6YWE1MmJlNWIzYjU0NDA0Mjg1NmY0NjU4MWIwZmI1MDRfNC03LTEtMS0w_0ec23569-de18-4467-937e-d2c7aa8c0473"
      unitRef="usd">339000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i7d4070f9748d4216be619760cb306306_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RhYmxlOmFhNTJiZTViM2I1NDQwNDI4NTZmNDY1ODFiMGZiNTA0L3RhYmxlcmFuZ2U6YWE1MmJlNWIzYjU0NDA0Mjg1NmY0NjU4MWIwZmI1MDRfNC05LTEtMS0w_45d3c048-3cb5-4197-bdd1-2b26e8e60c89"
      unitRef="usd">52000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i17406128628f47da8dc12cab978ee990_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RhYmxlOmFhNTJiZTViM2I1NDQwNDI4NTZmNDY1ODFiMGZiNTA0L3RhYmxlcmFuZ2U6YWE1MmJlNWIzYjU0NDA0Mjg1NmY0NjU4MWIwZmI1MDRfNC0xMS0xLTEtMA_c09d75d5-7f75-4533-bcfe-17725dba98f6"
      unitRef="usd">1693000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="iba8c6028e53a4d3cb52c96d04a38aa3e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RhYmxlOmFhNTJiZTViM2I1NDQwNDI4NTZmNDY1ODFiMGZiNTA0L3RhYmxlcmFuZ2U6YWE1MmJlNWIzYjU0NDA0Mjg1NmY0NjU4MWIwZmI1MDRfNS0xLTEtMS0w_b0e5f66c-5c41-42b9-a343-c6136fe57d7a"
      unitRef="usd">0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i403e5c57487b45d7953d44822a0f4e08_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RhYmxlOmFhNTJiZTViM2I1NDQwNDI4NTZmNDY1ODFiMGZiNTA0L3RhYmxlcmFuZ2U6YWE1MmJlNWIzYjU0NDA0Mjg1NmY0NjU4MWIwZmI1MDRfNS0zLTEtMS0w_1502b466-6909-47f4-b02a-38b67e1b770b"
      unitRef="usd">0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i040c336d87a74305b70be62dbab90158_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RhYmxlOmFhNTJiZTViM2I1NDQwNDI4NTZmNDY1ODFiMGZiNTA0L3RhYmxlcmFuZ2U6YWE1MmJlNWIzYjU0NDA0Mjg1NmY0NjU4MWIwZmI1MDRfNS01LTEtMS0w_f0bd53aa-6686-4fb4-ab4b-92698f1c8aff"
      unitRef="usd">3000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ib9fefc66152040119b7d0c2744ada9b9_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RhYmxlOmFhNTJiZTViM2I1NDQwNDI4NTZmNDY1ODFiMGZiNTA0L3RhYmxlcmFuZ2U6YWE1MmJlNWIzYjU0NDA0Mjg1NmY0NjU4MWIwZmI1MDRfNS03LTEtMS0w_c2b128ce-8695-49e4-94b0-42b11870ed05"
      unitRef="usd">998000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i5a5cdc0ffb3e42fbb82f9bf7e926e815_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RhYmxlOmFhNTJiZTViM2I1NDQwNDI4NTZmNDY1ODFiMGZiNTA0L3RhYmxlcmFuZ2U6YWE1MmJlNWIzYjU0NDA0Mjg1NmY0NjU4MWIwZmI1MDRfNS05LTEtMS0w_9ffcbbfe-c9ae-42cd-a659-567c62772c86"
      unitRef="usd">0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i3e2701f10753482bb31aaa795ebf9601_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RhYmxlOmFhNTJiZTViM2I1NDQwNDI4NTZmNDY1ODFiMGZiNTA0L3RhYmxlcmFuZ2U6YWE1MmJlNWIzYjU0NDA0Mjg1NmY0NjU4MWIwZmI1MDRfNS0xMS0xLTEtMA_95fb5cbb-c103-433f-9d08-df4af7bd13a4"
      unitRef="usd">266000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i7032666edaaa4e429bcb5742671daf6b_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RhYmxlOmFhNTJiZTViM2I1NDQwNDI4NTZmNDY1ODFiMGZiNTA0L3RhYmxlcmFuZ2U6YWE1MmJlNWIzYjU0NDA0Mjg1NmY0NjU4MWIwZmI1MDRfNi0xLTEtMS0w_f67ff0b9-ee02-4cae-9e3c-4d5494852d81"
      unitRef="usd">11000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ib9d9e02e83704b5dace40b5fa634af46_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RhYmxlOmFhNTJiZTViM2I1NDQwNDI4NTZmNDY1ODFiMGZiNTA0L3RhYmxlcmFuZ2U6YWE1MmJlNWIzYjU0NDA0Mjg1NmY0NjU4MWIwZmI1MDRfNi0zLTEtMS0w_45b691ef-4603-40b1-9245-75253049a05b"
      unitRef="usd">52000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="if7a5922b1df34274baf2cab389d93825_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RhYmxlOmFhNTJiZTViM2I1NDQwNDI4NTZmNDY1ODFiMGZiNTA0L3RhYmxlcmFuZ2U6YWE1MmJlNWIzYjU0NDA0Mjg1NmY0NjU4MWIwZmI1MDRfNi01LTEtMS0w_dbd96554-3412-4b43-ac7d-4326d378ae07"
      unitRef="usd">859000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i089d57f59b26493db395f392a738a27c_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RhYmxlOmFhNTJiZTViM2I1NDQwNDI4NTZmNDY1ODFiMGZiNTA0L3RhYmxlcmFuZ2U6YWE1MmJlNWIzYjU0NDA0Mjg1NmY0NjU4MWIwZmI1MDRfNi03LTEtMS0w_d3315138-fc9e-486f-b783-ce69ce9e9374"
      unitRef="usd">0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ifcf043d12a364c6d8f621f3ce9eb05b3_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RhYmxlOmFhNTJiZTViM2I1NDQwNDI4NTZmNDY1ODFiMGZiNTA0L3RhYmxlcmFuZ2U6YWE1MmJlNWIzYjU0NDA0Mjg1NmY0NjU4MWIwZmI1MDRfNi05LTEtMS0w_1f3220bc-60f8-492d-bf17-766f78a770ad"
      unitRef="usd">17000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i0a0b334cef804098995f34a0b7102f9f_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RhYmxlOmFhNTJiZTViM2I1NDQwNDI4NTZmNDY1ODFiMGZiNTA0L3RhYmxlcmFuZ2U6YWE1MmJlNWIzYjU0NDA0Mjg1NmY0NjU4MWIwZmI1MDRfNi0xMS0xLTEtMA_85353672-ed78-416a-90f9-b4ae2ec37f89"
      unitRef="usd">231000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ic693d204e9e347ae897f48a7db4e8373_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RhYmxlOmFhNTJiZTViM2I1NDQwNDI4NTZmNDY1ODFiMGZiNTA0L3RhYmxlcmFuZ2U6YWE1MmJlNWIzYjU0NDA0Mjg1NmY0NjU4MWIwZmI1MDRfNy0xLTEtMS0w_84b1391b-81b4-4061-b949-782810731d4f"
      unitRef="usd">5839000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i11ab95266c9c458da1f4e2524c453219_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RhYmxlOmFhNTJiZTViM2I1NDQwNDI4NTZmNDY1ODFiMGZiNTA0L3RhYmxlcmFuZ2U6YWE1MmJlNWIzYjU0NDA0Mjg1NmY0NjU4MWIwZmI1MDRfNy0zLTEtMS0w_fb31f892-39a1-4b0d-a8ee-402b0ea9c4cb"
      unitRef="usd">305000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i87f5d930fa0e4dd885c325ce478459fc_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RhYmxlOmFhNTJiZTViM2I1NDQwNDI4NTZmNDY1ODFiMGZiNTA0L3RhYmxlcmFuZ2U6YWE1MmJlNWIzYjU0NDA0Mjg1NmY0NjU4MWIwZmI1MDRfNy01LTEtMS0w_3a4c19ef-c685-4955-990c-6c7409c719ec"
      unitRef="usd">14452000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i864e263b7e9f4629b9b97b9cfc3bed2f_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RhYmxlOmFhNTJiZTViM2I1NDQwNDI4NTZmNDY1ODFiMGZiNTA0L3RhYmxlcmFuZ2U6YWE1MmJlNWIzYjU0NDA0Mjg1NmY0NjU4MWIwZmI1MDRfNy03LTEtMS0w_82c65267-a7ff-43a5-8f5f-428cca8cc82b"
      unitRef="usd">5949000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i6496ce2c62514d00a0ced101ce91a17f_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RhYmxlOmFhNTJiZTViM2I1NDQwNDI4NTZmNDY1ODFiMGZiNTA0L3RhYmxlcmFuZ2U6YWE1MmJlNWIzYjU0NDA0Mjg1NmY0NjU4MWIwZmI1MDRfNy05LTEtMS0w_b9e94a07-4d36-450a-859d-e1f4baf74b88"
      unitRef="usd">69000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="iab9f59c06f804edca916d76b33ea3ca1_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RhYmxlOmFhNTJiZTViM2I1NDQwNDI4NTZmNDY1ODFiMGZiNTA0L3RhYmxlcmFuZ2U6YWE1MmJlNWIzYjU0NDA0Mjg1NmY0NjU4MWIwZmI1MDRfNy0xMS0xLTEtMA_7f22cf47-a038-4b7d-85b4-5a2718a46c5e"
      unitRef="usd">13681000</us-gaap:ResearchAndDevelopmentExpense>
    <alny:DiscoveryPeriodOfProgramsDevelopment
      contextRef="ia5305aa8b123480a9f5873905426845c_D20190408-20190408"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RleHRyZWdpb246MWE2ZWQwNzZlMTc2NDkyMzllYTFhMjgxNTMwYjdjYjRfMzExMDY_983dcd27-6c0f-41a5-9406-8ad560051d1e">P5Y</alny:DiscoveryPeriodOfProgramsDevelopment>
    <alny:ExtendedAdditionalDiscoveryPeriodOfProgramsDevelopment
      contextRef="ia5305aa8b123480a9f5873905426845c_D20190408-20190408"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RleHRyZWdpb246MWE2ZWQwNzZlMTc2NDkyMzllYTFhMjgxNTMwYjdjYjRfMTAyMTE_87e234dc-be9d-4f7b-9cd7-7adc1e8220f6">P5Y</alny:ExtendedAdditionalDiscoveryPeriodOfProgramsDevelopment>
    <alny:ResearchTermExtensionFee
      contextRef="i73f0e7523666480d9c1deb15ed7a387e_D20190408-20190408"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RleHRyZWdpb246MWE2ZWQwNzZlMTc2NDkyMzllYTFhMjgxNTMwYjdjYjRfMTAyNTg_4bcfeecc-0d80-43a1-a88a-7fe4c7424cbb"
      unitRef="usd">400000000.0</alny:ResearchTermExtensionFee>
    <alny:MaximumRoyaltiesAndCommercialMilestonePaymentsUponPotentialProductSale
      contextRef="ia5305aa8b123480a9f5873905426845c_D20190408-20190408"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RleHRyZWdpb246MWE2ZWQwNzZlMTc2NDkyMzllYTFhMjgxNTMwYjdjYjRfMTI4MjU_8b4921de-cdab-4df0-97eb-effdf8d92a01"
      unitRef="usd">325000000.0</alny:MaximumRoyaltiesAndCommercialMilestonePaymentsUponPotentialProductSale>
    <alny:UpfrontFeeReceived
      contextRef="ia5305aa8b123480a9f5873905426845c_D20190408-20190408"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RleHRyZWdpb246MWE2ZWQwNzZlMTc2NDkyMzllYTFhMjgxNTMwYjdjYjRfMTMxMjc_8f7b475a-093f-423a-b58a-059a98d3920d"
      unitRef="usd">400000000.0</alny:UpfrontFeeReceived>
    <alny:MaximumAdditionalMilestonePaymentsToBeReceiveUponAchievementOfCertainCriteria
      contextRef="ia5305aa8b123480a9f5873905426845c_D20190408-20190408"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RleHRyZWdpb246MWE2ZWQwNzZlMTc2NDkyMzllYTFhMjgxNTMwYjdjYjRfMTMxODM_ce79c5a4-d242-454d-bd46-4cb1c00ec3a2"
      unitRef="usd">200000000.0</alny:MaximumAdditionalMilestonePaymentsToBeReceiveUponAchievementOfCertainCriteria>
    <alny:NumberOfTargetedPrograms
      contextRef="ia5305aa8b123480a9f5873905426845c_D20190408-20190408"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RleHRyZWdpb246MWE2ZWQwNzZlMTc2NDkyMzllYTFhMjgxNTMwYjdjYjRfMTMzNjU_381da3a7-b286-4243-ad09-7999a29f5f44"
      unitRef="program">30</alny:NumberOfTargetedPrograms>
    <alny:PotentialProceedsFromCollaborationArrangement
      contextRef="if2bf4b0c1f3049e3958e56012db213d3_I20190408"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RleHRyZWdpb246MWE2ZWQwNzZlMTc2NDkyMzllYTFhMjgxNTMwYjdjYjRfMTM0OTM_f862afb4-b8a7-441a-aec4-390559c2076b"
      unitRef="usd">2500000</alny:PotentialProceedsFromCollaborationArrangement>
    <alny:PotentialProceedsFromCollaborationArrangement
      contextRef="i5e0a1eb0aca04059bb786c05e4dd32bc_I20190408"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RleHRyZWdpb246MWE2ZWQwNzZlMTc2NDkyMzllYTFhMjgxNTMwYjdjYjRfMTM1NDc_2328617a-4611-4087-b304-2133eead982a"
      unitRef="usd">2500000</alny:PotentialProceedsFromCollaborationArrangement>
    <alny:PotentialProceedsFromCollaborationArrangement
      contextRef="i0fe175fb793a4f5e9a26e0bd683c3620_I20190408"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RleHRyZWdpb246MWE2ZWQwNzZlMTc2NDkyMzllYTFhMjgxNTMwYjdjYjRfMTM2MjE_c7f01ed3-975e-4d70-8cd9-490bd10ce7e8"
      unitRef="usd">30000000.0</alny:PotentialProceedsFromCollaborationArrangement>
    <alny:CollaborativeAgreementTerminationPeriod
      contextRef="ia5305aa8b123480a9f5873905426845c_D20190408-20190408"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RleHRyZWdpb246MWE2ZWQwNzZlMTc2NDkyMzllYTFhMjgxNTMwYjdjYjRfMTM4MDA_9c7cf93a-cb1b-4010-bf9b-1da8658dfce2">P90D</alny:CollaborativeAgreementTerminationPeriod>
    <alny:CollaborativeArrangementMilestonePayments
      contextRef="i73f0e7523666480d9c1deb15ed7a387e_D20190408-20190408"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RleHRyZWdpb246MWE2ZWQwNzZlMTc2NDkyMzllYTFhMjgxNTMwYjdjYjRfMTQ5NDA_c6b65793-d0cd-4010-a6c5-f4052c43550d"
      unitRef="usd">150000000.0</alny:CollaborativeArrangementMilestonePayments>
    <alny:RoyaltyRate
      contextRef="i971ffad5c679466dbaa1a956091dff5b_I20190408"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RleHRyZWdpb246MWE2ZWQwNzZlMTc2NDkyMzllYTFhMjgxNTMwYjdjYjRfMTUxOTQ_29ab8926-de65-41c1-b12e-1116de1676a0"
      unitRef="number">0.20</alny:RoyaltyRate>
    <alny:PercentageOfMaximumRoyaltyPayments
      contextRef="ia5305aa8b123480a9f5873905426845c_D20190408-20190408"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RleHRyZWdpb246MWE2ZWQwNzZlMTc2NDkyMzllYTFhMjgxNTMwYjdjYjRfMTYyNzA_d330a9ce-f11d-4e3f-adf7-8bd0017d001c"
      unitRef="number">0.20</alny:PercentageOfMaximumRoyaltyPayments>
    <alny:UpfrontFeeReceived
      contextRef="ia5305aa8b123480a9f5873905426845c_D20190408-20190408"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RleHRyZWdpb246MWE2ZWQwNzZlMTc2NDkyMzllYTFhMjgxNTMwYjdjYjRfMTg0Nzg_f5465d88-31b0-4169-b7a6-265fdf379dcb"
      unitRef="usd">400000000.0</alny:UpfrontFeeReceived>
    <alny:ScheduleOfAllocatedTransactionPriceTableTextBlock
      contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RleHRyZWdpb246MWE2ZWQwNzZlMTc2NDkyMzllYTFhMjgxNTMwYjdjYjRfMzExMDA_0bb18214-28f2-440d-a3db-944a4c0b5203">&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;We allocated the initial transaction price to each unit of account based on the applicable accounting guidance as follows, in thousands: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.467%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.806%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.412%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.736%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.412%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.736%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.331%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.567%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:83%"&gt;Performance Obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:83%"&gt;Standalone Selling Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:83%"&gt;Transaction Price Allocated&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:83%"&gt;Accounting Guidance&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%"&gt;Research Services Obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%"&gt;130,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%"&gt;183,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%"&gt;ASC 606&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%"&gt;C5 License Obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%"&gt;97,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%"&gt;92,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:95%"&gt;ASC 606&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%"&gt;C5 Co-Co Obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%"&gt;364,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%"&gt;246,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%"&gt;ASC 808&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%"&gt;521,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following tables provide a summary of the transaction price allocated to each unit of account based on the applicable accounting guidance, in addition to revenue activity during the period, in thousands:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:91.374%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.300%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.440%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.660%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.440%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.660%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.440%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.660%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.440%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.660%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Transaction Price Allocated&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Deferred Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Performance Obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Accounting Guidance&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Research Services Obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;200,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;45,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;54,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;ASC 606&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;C5 License Obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;83,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;45,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;58,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;ASC 606&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;C5 Co-Co Obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;246,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;228,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;231,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;ASC 808&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;530,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;319,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;345,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</alny:ScheduleOfAllocatedTransactionPriceTableTextBlock>
    <alny:StandaloneSellingPrice
      contextRef="ice333d52f3d1470e9ef529637248a8dc_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RhYmxlOmU4YTUzOTQzNzI3MjRkZGU4ZDZjNmZjNTlhYTVhMzY1L3RhYmxlcmFuZ2U6ZThhNTM5NDM3MjcyNGRkZThkNmM2ZmM1OWFhNWEzNjVfMS0yLTEtMS0w_fa403f3a-64b7-474d-807b-da1893746044"
      unitRef="usd">130700000</alny:StandaloneSellingPrice>
    <alny:TransactionPrice
      contextRef="i36f4850caa714d72a30d3755dee41330_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RhYmxlOmU4YTUzOTQzNzI3MjRkZGU4ZDZjNmZjNTlhYTVhMzY1L3RhYmxlcmFuZ2U6ZThhNTM5NDM3MjcyNGRkZThkNmM2ZmM1OWFhNWEzNjVfMS00LTEtMS0w_82a0577e-5497-4d39-ab73-17217e3566ea"
      unitRef="usd">183100000</alny:TransactionPrice>
    <alny:StandaloneSellingPrice
      contextRef="ie1b05d9fbec1490d8547da979164246c_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RhYmxlOmU4YTUzOTQzNzI3MjRkZGU4ZDZjNmZjNTlhYTVhMzY1L3RhYmxlcmFuZ2U6ZThhNTM5NDM3MjcyNGRkZThkNmM2ZmM1OWFhNWEzNjVfMi0yLTEtMS0w_8ed98849-98b9-4885-8bcc-dd164fdf1f23"
      unitRef="usd">97600000</alny:StandaloneSellingPrice>
    <alny:TransactionPrice
      contextRef="i9afb38e70eac4aa0940613e1656a62b6_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RhYmxlOmU4YTUzOTQzNzI3MjRkZGU4ZDZjNmZjNTlhYTVhMzY1L3RhYmxlcmFuZ2U6ZThhNTM5NDM3MjcyNGRkZThkNmM2ZmM1OWFhNWEzNjVfMi00LTEtMS0w_9a730ded-ab17-4c52-9fa0-36e7a39e0d8b"
      unitRef="usd">92500000</alny:TransactionPrice>
    <alny:StandaloneSellingPrice
      contextRef="i5ed9a55f1a8143bd9068e4f6bbafe8a1_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RhYmxlOmU4YTUzOTQzNzI3MjRkZGU4ZDZjNmZjNTlhYTVhMzY1L3RhYmxlcmFuZ2U6ZThhNTM5NDM3MjcyNGRkZThkNmM2ZmM1OWFhNWEzNjVfMy0yLTEtMS0w_fa87105d-e8d2-4406-b96d-edf9b4ac8cbd"
      unitRef="usd">364600000</alny:StandaloneSellingPrice>
    <alny:TransactionPrice
      contextRef="i034331457ce94629bdc278cc2f5e440c_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RhYmxlOmU4YTUzOTQzNzI3MjRkZGU4ZDZjNmZjNTlhYTVhMzY1L3RhYmxlcmFuZ2U6ZThhNTM5NDM3MjcyNGRkZThkNmM2ZmM1OWFhNWEzNjVfMy00LTEtMS0w_83c25a8d-afd0-4728-b8de-c15352af9ea7"
      unitRef="usd">246000000</alny:TransactionPrice>
    <alny:TransactionPrice
      contextRef="id46811031a3d408bac58580e626f8e3b_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RhYmxlOmU4YTUzOTQzNzI3MjRkZGU4ZDZjNmZjNTlhYTVhMzY1L3RhYmxlcmFuZ2U6ZThhNTM5NDM3MjcyNGRkZThkNmM2ZmM1OWFhNWEzNjVfNC00LTEtMS0w_ad6758c1-a45e-4743-a09a-a31f3bc5f63a"
      unitRef="usd">521600000</alny:TransactionPrice>
    <alny:TransactionPrice
      contextRef="ibb1a94652b264aa4980ac89d4f3e71e0_D20210331-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RleHRyZWdpb246MWE2ZWQwNzZlMTc2NDkyMzllYTFhMjgxNTMwYjdjYjRfODI0NjMzNzMwMjIzNQ_97d14e5a-6a37-43dc-b8be-6bb8a0fcfea3"
      unitRef="usd">530500000</alny:TransactionPrice>
    <alny:TransactionPrice
      contextRef="if0be8a0acd8c4f4a936e1a39b3321d4e_D20210331-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RhYmxlOjZjZTM1MWQ4ZDFkNjQ5MGRhZWUyYmNkYTMwODI0NDhhL3RhYmxlcmFuZ2U6NmNlMzUxZDhkMWQ2NDkwZGFlZTJiY2RhMzA4MjQ0OGFfMi0yLTEtMS0w_16061644-b459-415b-8c38-4b92926455c2"
      unitRef="usd">200600000</alny:TransactionPrice>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="ice333d52f3d1470e9ef529637248a8dc_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RhYmxlOjZjZTM1MWQ4ZDFkNjQ5MGRhZWUyYmNkYTMwODI0NDhhL3RhYmxlcmFuZ2U6NmNlMzUxZDhkMWQ2NDkwZGFlZTJiY2RhMzA4MjQ0OGFfMi00LTEtMS0w_59d4a0d6-c8d7-4e49-be82-d04e9b2744ec"
      unitRef="usd">45100000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i15dc0fb5b4cf413aa1bddc7de9dc8427_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RhYmxlOjZjZTM1MWQ4ZDFkNjQ5MGRhZWUyYmNkYTMwODI0NDhhL3RhYmxlcmFuZ2U6NmNlMzUxZDhkMWQ2NDkwZGFlZTJiY2RhMzA4MjQ0OGFfMi02LTEtMS0w_4fa15f42-c396-4d73-8b15-2285f3d09c7a"
      unitRef="usd">54900000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <alny:TransactionPrice
      contextRef="i658edd34d7bb479582be347d92985839_D20210331-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RhYmxlOjZjZTM1MWQ4ZDFkNjQ5MGRhZWUyYmNkYTMwODI0NDhhL3RhYmxlcmFuZ2U6NmNlMzUxZDhkMWQ2NDkwZGFlZTJiY2RhMzA4MjQ0OGFfMy0yLTEtMS0w_fb52b0a4-7eaf-4f94-ac53-3fc6e89ba690"
      unitRef="usd">83900000</alny:TransactionPrice>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="ie1b05d9fbec1490d8547da979164246c_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RhYmxlOjZjZTM1MWQ4ZDFkNjQ5MGRhZWUyYmNkYTMwODI0NDhhL3RhYmxlcmFuZ2U6NmNlMzUxZDhkMWQ2NDkwZGFlZTJiY2RhMzA4MjQ0OGFfMy00LTEtMS0w_5f8b26f9-e150-498e-96c6-183c20739541"
      unitRef="usd">45200000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i861836d62a924d62ab2e4e1d6bb80274_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RhYmxlOjZjZTM1MWQ4ZDFkNjQ5MGRhZWUyYmNkYTMwODI0NDhhL3RhYmxlcmFuZ2U6NmNlMzUxZDhkMWQ2NDkwZGFlZTJiY2RhMzA4MjQ0OGFfMy02LTEtMS0w_ffa4de3e-0613-4bf1-a1ca-db180ac0dd56"
      unitRef="usd">58700000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <alny:TransactionPrice
      contextRef="i80b049fd41474712a64d29d35fabd92b_D20210331-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RhYmxlOjZjZTM1MWQ4ZDFkNjQ5MGRhZWUyYmNkYTMwODI0NDhhL3RhYmxlcmFuZ2U6NmNlMzUxZDhkMWQ2NDkwZGFlZTJiY2RhMzA4MjQ0OGFfNC0yLTEtMS0w_d88d5d67-b12b-4203-89a5-7cb37191515c"
      unitRef="usd">246000000</alny:TransactionPrice>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i5ed9a55f1a8143bd9068e4f6bbafe8a1_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RhYmxlOjZjZTM1MWQ4ZDFkNjQ5MGRhZWUyYmNkYTMwODI0NDhhL3RhYmxlcmFuZ2U6NmNlMzUxZDhkMWQ2NDkwZGFlZTJiY2RhMzA4MjQ0OGFfNC00LTEtMS0w_8fe5dcb9-4317-4d83-9fd2-7d73d36dddee"
      unitRef="usd">228900000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="ifccb7d9fff7c476987c83ac85c1953b1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RhYmxlOjZjZTM1MWQ4ZDFkNjQ5MGRhZWUyYmNkYTMwODI0NDhhL3RhYmxlcmFuZ2U6NmNlMzUxZDhkMWQ2NDkwZGFlZTJiY2RhMzA4MjQ0OGFfNC02LTEtMS0w_92832837-fe98-4975-89c5-2c4015945db9"
      unitRef="usd">231400000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <alny:TransactionPrice
      contextRef="ibb1a94652b264aa4980ac89d4f3e71e0_D20210331-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RhYmxlOjZjZTM1MWQ4ZDFkNjQ5MGRhZWUyYmNkYTMwODI0NDhhL3RhYmxlcmFuZ2U6NmNlMzUxZDhkMWQ2NDkwZGFlZTJiY2RhMzA4MjQ0OGFfNS0yLTEtMS0w_81d473f3-fd4c-4442-85ea-5c91a637c7a9"
      unitRef="usd">530500000</alny:TransactionPrice>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i8ee04dc4bddd49289fea1361ef9a5f63_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RhYmxlOjZjZTM1MWQ4ZDFkNjQ5MGRhZWUyYmNkYTMwODI0NDhhL3RhYmxlcmFuZ2U6NmNlMzUxZDhkMWQ2NDkwZGFlZTJiY2RhMzA4MjQ0OGFfNS00LTEtMS0w_d90903b5-d3e4-4c1e-a420-af308379466b"
      unitRef="usd">319200000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i845dea082db84f4bad647918893f1a91_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RhYmxlOjZjZTM1MWQ4ZDFkNjQ5MGRhZWUyYmNkYTMwODI0NDhhL3RhYmxlcmFuZ2U6NmNlMzUxZDhkMWQ2NDkwZGFlZTJiY2RhMzA4MjQ0OGFfNS02LTEtMS0w_81b5740a-5714-45ac-9fad-9883e1e3e76e"
      unitRef="usd">345000000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <alny:ScheduleOfRevenueRecognizedBasedOnAccountingGuidanceTableTextBlock
      contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RleHRyZWdpb246MWE2ZWQwNzZlMTc2NDkyMzllYTFhMjgxNTMwYjdjYjRfMzExMTI_9f94e98e-2429-4cf7-8f9c-17cb286368d4">&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:66.959%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.926%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.673%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.699%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.673%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.699%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.673%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.657%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Revenue Recognized During&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Performance Obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Accounting Guidance&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Research Services Obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;9,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;12,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;ASC 606&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;C5 License Obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;13,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;ASC 606&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;C5 Co-Co Obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;4,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;ASC 808&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;25,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;16,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;</alny:ScheduleOfRevenueRecognizedBasedOnAccountingGuidanceTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i36f4850caa714d72a30d3755dee41330_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RhYmxlOmFlMzZmMTBhNDIyZTQ3N2ZhOWVlOWI4MzQ2MDA0OTdjL3RhYmxlcmFuZ2U6YWUzNmYxMGE0MjJlNDc3ZmE5ZWU5YjgzNDYwMDQ5N2NfMy0yLTEtMS0w_59b0aaea-2dbd-4f94-a3b6-00a9adec882e"
      unitRef="usd">9800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5fd8d80f765d41dcb65fffa60ec775cf_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RhYmxlOmFlMzZmMTBhNDIyZTQ3N2ZhOWVlOWI4MzQ2MDA0OTdjL3RhYmxlcmFuZ2U6YWUzNmYxMGE0MjJlNDc3ZmE5ZWU5YjgzNDYwMDQ5N2NfMy00LTEtMS0w_80b8e1df-a516-4f79-af38-5b99b5066fd2"
      unitRef="usd">12300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9afb38e70eac4aa0940613e1656a62b6_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RhYmxlOmFlMzZmMTBhNDIyZTQ3N2ZhOWVlOWI4MzQ2MDA0OTdjL3RhYmxlcmFuZ2U6YWUzNmYxMGE0MjJlNDc3ZmE5ZWU5YjgzNDYwMDQ5N2NfNC0yLTEtMS0w_e463d4c4-86f9-487a-a4f0-3425be430ab4"
      unitRef="usd">13500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id8599564d7e94d6db58cf776fcdfcc51_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RhYmxlOmFlMzZmMTBhNDIyZTQ3N2ZhOWVlOWI4MzQ2MDA0OTdjL3RhYmxlcmFuZ2U6YWUzNmYxMGE0MjJlNDc3ZmE5ZWU5YjgzNDYwMDQ5N2NfNC00LTEtMS0w_bb6b760b-20b5-4502-98ee-0cc5dd283195"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="i034331457ce94629bdc278cc2f5e440c_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RhYmxlOmFlMzZmMTBhNDIyZTQ3N2ZhOWVlOWI4MzQ2MDA0OTdjL3RhYmxlcmFuZ2U6YWUzNmYxMGE0MjJlNDc3ZmE5ZWU5YjgzNDYwMDQ5N2NfNS0yLTEtMS0w_d2f720f4-9f7f-4857-8de2-8bba85ea25f4"
      unitRef="usd">2500000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="i7f816a549c3b442c81980771e664236b_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RhYmxlOmFlMzZmMTBhNDIyZTQ3N2ZhOWVlOWI4MzQ2MDA0OTdjL3RhYmxlcmFuZ2U6YWUzNmYxMGE0MjJlNDc3ZmE5ZWU5YjgzNDYwMDQ5N2NfNS00LTEtMS0w_7c46a92b-67a1-4fb1-9fe8-16410e5d3f60"
      unitRef="usd">4200000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:Revenues
      contextRef="id46811031a3d408bac58580e626f8e3b_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RhYmxlOmFlMzZmMTBhNDIyZTQ3N2ZhOWVlOWI4MzQ2MDA0OTdjL3RhYmxlcmFuZ2U6YWUzNmYxMGE0MjJlNDc3ZmE5ZWU5YjgzNDYwMDQ5N2NfNi0yLTEtMS0w_0a161872-6e02-4d0c-a025-393e307dcfa6"
      unitRef="usd">25800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if12146e5cbeb4f978bb78a0f76137cb2_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RhYmxlOmFlMzZmMTBhNDIyZTQ3N2ZhOWVlOWI4MzQ2MDA0OTdjL3RhYmxlcmFuZ2U6YWUzNmYxMGE0MjJlNDc3ZmE5ZWU5YjgzNDYwMDQ5N2NfNi00LTEtMS0w_453c8b9e-c12c-475c-839c-d5a53e4b278a"
      unitRef="usd">16500000</us-gaap:Revenues>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="i8ee04dc4bddd49289fea1361ef9a5f63_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RleHRyZWdpb246MWE2ZWQwNzZlMTc2NDkyMzllYTFhMjgxNTMwYjdjYjRfMjI5NjM_f910b87e-0f6c-4659-a852-9a1eaec6bc49"
      unitRef="usd">188300000</us-gaap:RevenueRemainingPerformanceObligation>
    <alny:MilestonePaymentEarned
      contextRef="i5c760c86aa8249a6be17c482badca19e_D20130201-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RleHRyZWdpb246MWE2ZWQwNzZlMTc2NDkyMzllYTFhMjgxNTMwYjdjYjRfNDk0NzgwMjQwNjUzNg_8ea2aeca-8973-4c0e-b246-8056dc5832b3"
      unitRef="usd">45000000.0</alny:MilestonePaymentEarned>
    <alny:MaximumNumberOfPotentialFutureMilestones
      contextRef="i7d36bc345e7f4e4197c9a712cb73b817_D20130201-20130228"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RleHRyZWdpb246MWE2ZWQwNzZlMTc2NDkyMzllYTFhMjgxNTMwYjdjYjRfNDk0NzgwMjQwNjU1NA_1b18e5e8-35c1-4b6c-980a-07e20da3935a"
      unitRef="usd">135000000.0</alny:MaximumNumberOfPotentialFutureMilestones>
    <alny:FuturePaymentsOnAchievementOfSpecifiedRegulatoryMilestones
      contextRef="i7d36bc345e7f4e4197c9a712cb73b817_D20130201-20130228"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RleHRyZWdpb246MWE2ZWQwNzZlMTc2NDkyMzllYTFhMjgxNTMwYjdjYjRfNDk0NzgwMjQwNjU3Ng_e1321de9-c7ee-4577-acae-19a665850c96"
      unitRef="usd">25000000.0</alny:FuturePaymentsOnAchievementOfSpecifiedRegulatoryMilestones>
    <alny:FuturePaymentsOnAchievementOfOtherSpecifiedRegulatoryMilestones
      contextRef="i7d36bc345e7f4e4197c9a712cb73b817_D20130201-20130228"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RleHRyZWdpb246MWE2ZWQwNzZlMTc2NDkyMzllYTFhMjgxNTMwYjdjYjRfNDk0NzgwMjQwNjc0MQ_747b4bf5-09c3-4338-aad5-3d1dc7f1fd88"
      unitRef="usd">10000000.0</alny:FuturePaymentsOnAchievementOfOtherSpecifiedRegulatoryMilestones>
    <alny:FuturePaymentsOnAchievementOfSpecifiedCommercializationMilestones
      contextRef="i7d36bc345e7f4e4197c9a712cb73b817_D20130201-20130228"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RleHRyZWdpb246MWE2ZWQwNzZlMTc2NDkyMzllYTFhMjgxNTMwYjdjYjRfNDk0NzgwMjQwNjc0Nw_ef54bdc8-ea79-44d7-9317-1d86794b504b"
      unitRef="usd">100000000.0</alny:FuturePaymentsOnAchievementOfSpecifiedCommercializationMilestones>
    <alny:RoyaltyRate
      contextRef="id397f59fc9a04a808d2a7f2a7cabc579_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RleHRyZWdpb246MWE2ZWQwNzZlMTc2NDkyMzllYTFhMjgxNTMwYjdjYjRfMjQzMTk_b156a4bf-82ce-40d0-8aa7-fa9e583a37bc"
      unitRef="number">0.10</alny:RoyaltyRate>
    <alny:RoyaltyRate
      contextRef="ifd789fbb2ade454a843734d22e2a2dee_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RleHRyZWdpb246MWE2ZWQwNzZlMTc2NDkyMzllYTFhMjgxNTMwYjdjYjRfMjQzMjg_e6f8b86f-cfc0-4284-adda-f49a78bca200"
      unitRef="number">0.20</alny:RoyaltyRate>
    <alny:UpfrontFeeReceived
      contextRef="i3cbd53aa2a944f6a951e88ca5b785aad_D20171001-20171031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RleHRyZWdpb246MWE2ZWQwNzZlMTc2NDkyMzllYTFhMjgxNTMwYjdjYjRfMTA5OTUxMTY5OTk3Ng_280ca69e-db70-422c-985c-210e47bbda8a"
      unitRef="usd">10000000.0</alny:UpfrontFeeReceived>
    <us-gaap:InvestmentOwnedBalanceShares
      contextRef="i0390c083c3b0456c88744cf92cb6d82a_I20171031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RleHRyZWdpb246MWE2ZWQwNzZlMTc2NDkyMzllYTFhMjgxNTMwYjdjYjRfMTA5OTUxMTY5OTk5Nw_f88b27da-de3a-4389-b7fe-d6cb184888c2"
      unitRef="shares">1111111</us-gaap:InvestmentOwnedBalanceShares>
    <alny:MilestonePaymentEarned
      contextRef="i2775cf552c5d4a16bd403c04d07b23ba_D20200301-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RleHRyZWdpb246MWE2ZWQwNzZlMTc2NDkyMzllYTFhMjgxNTMwYjdjYjRfMTA5OTUxMTcwMDM5OQ_6d487f26-5c57-4fe9-a19e-f92b1e42d4f4"
      unitRef="usd">15000000.0</alny:MilestonePaymentEarned>
    <alny:MilestonePaymentEarnedShares
      contextRef="i2775cf552c5d4a16bd403c04d07b23ba_D20200301-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RleHRyZWdpb246MWE2ZWQwNzZlMTc2NDkyMzllYTFhMjgxNTMwYjdjYjRfMTA5OTUxMTcwMDQyMg_e91c5676-b105-41c0-8eb8-def3e05f4865"
      unitRef="shares">1111111</alny:MilestonePaymentEarnedShares>
    <alny:MilestonePaymentEarned
      contextRef="i1ddcbd1cbf9d4242a0d2e7d1fd99d35f_D20200601-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RleHRyZWdpb246MWE2ZWQwNzZlMTc2NDkyMzllYTFhMjgxNTMwYjdjYjRfMTA5OTUxMTcwMDU0Ng_ca2c7d71-643c-4dfd-8aa6-ef2b889af6eb"
      unitRef="usd">10000000.0</alny:MilestonePaymentEarned>
    <alny:CollaborativeAgreementTerminationPeriod
      contextRef="i79b6733ec63b46b0b79d00ec324efa30_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RleHRyZWdpb246MWE2ZWQwNzZlMTc2NDkyMzllYTFhMjgxNTMwYjdjYjRfMTA5OTUxMTcwMzE0NQ_3bec4715-0674-477c-a9f2-926e7c66a30d">P90D</alny:CollaborativeAgreementTerminationPeriod>
    <alny:CollaborativeArrangementAdditionalDevelopmentCandidatesToBeDelivered
      contextRef="i1cb0ba7808ab43b78c92dd6668914339_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RleHRyZWdpb246MWE2ZWQwNzZlMTc2NDkyMzllYTFhMjgxNTMwYjdjYjRfMTA5OTUxMTcwMzQyNg_fbb449aa-a8f1-4173-af6b-de78d3445b35"
      unitRef="candidate">4</alny:CollaborativeArrangementAdditionalDevelopmentCandidatesToBeDelivered>
    <alny:CollaborativeArrangementAdditionalDevelopmentCandidatesToBeDelivered
      contextRef="i1cb0ba7808ab43b78c92dd6668914339_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RleHRyZWdpb246MWE2ZWQwNzZlMTc2NDkyMzllYTFhMjgxNTMwYjdjYjRfMTA5OTUxMTcwMzYwOA_f68de996-6d77-48c1-beae-5570d9fe1320"
      unitRef="candidate">4</alny:CollaborativeArrangementAdditionalDevelopmentCandidatesToBeDelivered>
    <alny:TransactionPrice
      contextRef="ic79f02f0d0d84870a4ef4d488e636d1b_D20210331-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RleHRyZWdpb246MWE2ZWQwNzZlMTc2NDkyMzllYTFhMjgxNTMwYjdjYjRfMTA5OTUxMTcwNDYyOQ_fdde66d8-94a0-4c29-ace1-3e726e34b36c"
      unitRef="usd">110100000</alny:TransactionPrice>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="i1cb0ba7808ab43b78c92dd6668914339_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80My9mcmFnOjFhNmVkMDc2ZTE3NjQ5MjM5ZWExYTI4MTUzMGI3Y2I0L3RleHRyZWdpb246MWE2ZWQwNzZlMTc2NDkyMzllYTFhMjgxNTMwYjdjYjRfMTA5OTUxMTcwNTQzNw_07f4d24c-47ca-47db-ac0d-43b2664dad05"
      unitRef="usd">48800000</us-gaap:RevenueRemainingPerformanceObligation>
    <alny:LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock
      contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80Ni9mcmFnOjJkMDZmOTdlYzQxMzQ2MjE4NzVjYjg2OGU3YjIyZGY4L3RleHRyZWdpb246MmQwNmY5N2VjNDEzNDYyMTg3NWNiODY4ZTdiMjJkZjhfMzgxNQ_e276b195-7711-468b-964e-ebef4aafae74">LIABILITY RELATED TO THE SALE OF FUTURE ROYALTIES&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In April 2020, we entered into a purchase and sale agreement, or Purchase Agreement, with BX Bodyguard Royalties L.P. (an affiliate of The Blackstone Group Inc.), or Blackstone Royalties, under which Blackstone Royalties acquired 50% of royalties payable, or Royalty Interest, with respect to net sales by MDCO, its affiliates or sublicensees of inclisiran and any other licensed products under the MDCO License Agreement, and 75% of the commercial milestone payments payable under the MDCO License Agreement, together with the Royalty Interest, the Purchased Interest. If Blackstone Royalties does not receive payments in respect of the Royalty Interest by December 31, 2029, equaling at least $1.00&#160;billion, Blackstone Royalties will receive 55% of the Royalty Interest beginning on January 1, 2030. In consideration for the sale of the Purchased Interest, Blackstone Royalties paid us $500.0&#160;million in April 2020 and has an unconditional obligation to pay us an additional $500.0&#160;million on September 30, 2021, which was recorded as a receivable upon execution of the Purchase Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;We continue to own or control all inclisiran intellectual property rights and are responsible for certain ongoing manufacturing and supply obligations related to the generation of the Purchased Interest. Due to our continuing involvement, we will continue to account for any royalties and commercial milestones due to us under the MDCO License Agreement as revenue on our condensed consolidated statement of operations and comprehensive loss and record the proceeds from this transaction as a liability, net of closing costs, on our condensed consolidated balance sheet. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In order to determine the amortization of the liability related to the sale of future royalties, we are required to estimate the total amount of future payments to Blackstone Royalties over the life of the Purchase Agreement. The $1.00&#160;billion liability, recorded at execution of the agreement, will be accreted to the total of these royalty and commercial milestone payments as interest expense over the life of the Purchase Agreement. At execution, our estimate of this total interest expense resulted in an effective annual interest rate of 11%. This estimate contains assumptions that impact both the amount recorded at execution and the interest expense that will be recognized in future periods. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As payments are made to Blackstone Royalties, the balance of the liability will be effectively repaid over the life of the Purchase Agreement. The exact timing and amount of repayment is likely to change each reporting period. A significant increase or decrease in net sales of inclisiran will materially impact the liability related to the sale of future royalties, interest expense and the time period for repayment. We will periodically assess the expected payments to Blackstone Royalties and to the extent the amount or timing of such payments is materially different than our initial estimates, we will prospectively adjust the amortization of the liability related to the sale of future royalties and the related interest expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As of March&#160;31, 2021, the carrying value of the liability related to the sale of future royalties was $1.10&#160;billion, net of closing costs of $13.0&#160;million. The carrying value of the liability related to the sale of future royalties approximates fair value as &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;of March&#160;31, 2021 and is based on our current estimates of future royalties and commercial milestones expected to be paid to Blackstone Royalties over the life of the arrangement, which are considered Level 3 inputs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table shows the activity with respect to the liability related to the sale of future royalties, in thousands:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:87.134%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:81.282%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.638%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.680%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying value of liability related to sale of future royalties as of December&#160;31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,071,541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense recognized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying value of liability related to sale of future royalties as of March&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,099,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</alny:LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock>
    <alny:CollaborativeArrangementRoyaltiesAndCommercialMilestonesAcquiredByCollaboratorPercent
      contextRef="i730e5e5b0bcd4d5c81f5a71c66d172a2_I20200410"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80Ni9mcmFnOjJkMDZmOTdlYzQxMzQ2MjE4NzVjYjg2OGU3YjIyZGY4L3RleHRyZWdpb246MmQwNmY5N2VjNDEzNDYyMTg3NWNiODY4ZTdiMjJkZjhfMjkz_cd9189d0-8142-4ddd-95da-a8991f0c2b9a"
      unitRef="number">0.50</alny:CollaborativeArrangementRoyaltiesAndCommercialMilestonesAcquiredByCollaboratorPercent>
    <alny:CollaborativeArrangementCommercialMilestonesAcquiredByCollaboratorPercent
      contextRef="i730e5e5b0bcd4d5c81f5a71c66d172a2_I20200410"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80Ni9mcmFnOjJkMDZmOTdlYzQxMzQ2MjE4NzVjYjg2OGU3YjIyZGY4L3RleHRyZWdpb246MmQwNmY5N2VjNDEzNDYyMTg3NWNiODY4ZTdiMjJkZjhfNDg5_c5af23e2-cbe8-4200-a77c-c34a1e19ebac"
      unitRef="number">0.75</alny:CollaborativeArrangementCommercialMilestonesAcquiredByCollaboratorPercent>
    <alny:ExpectedRoyaltyInterestPayments
      contextRef="i2a9037b7365649f2bb1a3ef6bcbe2849_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80Ni9mcmFnOjJkMDZmOTdlYzQxMzQ2MjE4NzVjYjg2OGU3YjIyZGY4L3RleHRyZWdpb246MmQwNmY5N2VjNDEzNDYyMTg3NWNiODY4ZTdiMjJkZjhfNzU2_00e161cc-478a-4ee1-a696-b21980cdd29d"
      unitRef="usd">1000000000.00</alny:ExpectedRoyaltyInterestPayments>
    <alny:CollaborativeArrangementRoyaltiesAndCommercialMilestonesAcquiredByCollaboratorPercent
      contextRef="i4b7aa8adee8f42469579af529e81b38d_I20300101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80Ni9mcmFnOjJkMDZmOTdlYzQxMzQ2MjE4NzVjYjg2OGU3YjIyZGY4L3RleHRyZWdpb246MmQwNmY5N2VjNDEzNDYyMTg3NWNiODY4ZTdiMjJkZjhfNzk0_8e564a2b-4391-4136-a3b1-0770be926ea2"
      unitRef="number">0.55</alny:CollaborativeArrangementRoyaltiesAndCommercialMilestonesAcquiredByCollaboratorPercent>
    <alny:CollaborativeArrangementConsiderationReceived
      contextRef="i49fe9edf0f9044908d252f6eb19b5518_D20200401-20200430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80Ni9mcmFnOjJkMDZmOTdlYzQxMzQ2MjE4NzVjYjg2OGU3YjIyZGY4L3RleHRyZWdpb246MmQwNmY5N2VjNDEzNDYyMTg3NWNiODY4ZTdiMjJkZjhfOTM3_b1dbf7a6-65b0-45e2-b95e-f400f3009b59"
      unitRef="usd">500000000.0</alny:CollaborativeArrangementConsiderationReceived>
    <alny:RoyaltiesReceivableCurrent
      contextRef="id7b8291a96fc46dd8b540dbcc7a6d813_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80Ni9mcmFnOjJkMDZmOTdlYzQxMzQ2MjE4NzVjYjg2OGU3YjIyZGY4L3RleHRyZWdpb246MmQwNmY5N2VjNDEzNDYyMTg3NWNiODY4ZTdiMjJkZjhfMTAxNA_362f0f22-21fd-43e5-af01-b42290af1f08"
      unitRef="usd">500000000.0</alny:RoyaltiesReceivableCurrent>
    <alny:RoyaltyLiabilityNoncurrent
      contextRef="i730e5e5b0bcd4d5c81f5a71c66d172a2_I20200410"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80Ni9mcmFnOjJkMDZmOTdlYzQxMzQ2MjE4NzVjYjg2OGU3YjIyZGY4L3RleHRyZWdpb246MmQwNmY5N2VjNDEzNDYyMTg3NWNiODY4ZTdiMjJkZjhfMTkxOQ_cf6f5482-0f4c-44b6-ad64-fd3323c4feb6"
      unitRef="usd">1000000000.00</alny:RoyaltyLiabilityNoncurrent>
    <alny:RoyaltyLiabilityInterestRate
      contextRef="i730e5e5b0bcd4d5c81f5a71c66d172a2_I20200410"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80Ni9mcmFnOjJkMDZmOTdlYzQxMzQ2MjE4NzVjYjg2OGU3YjIyZGY4L3RleHRyZWdpb246MmQwNmY5N2VjNDEzNDYyMTg3NWNiODY4ZTdiMjJkZjhfMjIyMg_3b557da4-d843-483d-a2c3-07cb31940937"
      unitRef="number">0.11</alny:RoyaltyLiabilityInterestRate>
    <alny:RoyaltyLiabilityNoncurrent
      contextRef="id7b8291a96fc46dd8b540dbcc7a6d813_I20210331"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80Ni9mcmFnOjJkMDZmOTdlYzQxMzQ2MjE4NzVjYjg2OGU3YjIyZGY4L3RleHRyZWdpb246MmQwNmY5N2VjNDEzNDYyMTg3NWNiODY4ZTdiMjJkZjhfMTA5OTUxMTYzMTk1OQ_f9a10ec7-a0b1-4ccd-a5c0-dad728149e5d"
      unitRef="usd">1100000000</alny:RoyaltyLiabilityNoncurrent>
    <alny:RoyaltyLiabilityClosingCosts
      contextRef="id7b8291a96fc46dd8b540dbcc7a6d813_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80Ni9mcmFnOjJkMDZmOTdlYzQxMzQ2MjE4NzVjYjg2OGU3YjIyZGY4L3RleHRyZWdpb246MmQwNmY5N2VjNDEzNDYyMTg3NWNiODY4ZTdiMjJkZjhfMzI4MA_292a82d4-8771-4552-ab75-9f1e03c046e3"
      unitRef="usd">13000000.0</alny:RoyaltyLiabilityClosingCosts>
    <alny:ScheduleOfRoyaltyLiabilityTableTextBlock
      contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80Ni9mcmFnOjJkMDZmOTdlYzQxMzQ2MjE4NzVjYjg2OGU3YjIyZGY4L3RleHRyZWdpb246MmQwNmY5N2VjNDEzNDYyMTg3NWNiODY4ZTdiMjJkZjhfMzgxNg_6bb24457-360a-4f1a-abda-e171b14e4bee">&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table shows the activity with respect to the liability related to the sale of future royalties, in thousands:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:87.134%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:81.282%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.638%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.680%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying value of liability related to sale of future royalties as of December&#160;31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,071,541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense recognized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying value of liability related to sale of future royalties as of March&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,099,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</alny:ScheduleOfRoyaltyLiabilityTableTextBlock>
    <alny:RoyaltyLiabilityNoncurrent
      contextRef="i399f66dd6ce741d28d06204e9a1dddfb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80Ni9mcmFnOjJkMDZmOTdlYzQxMzQ2MjE4NzVjYjg2OGU3YjIyZGY4L3RhYmxlOmY4NDg3ZjI5MmVhZDQ1ZWJhMTdiOGJiYTI5NTY2YTJlL3RhYmxlcmFuZ2U6Zjg0ODdmMjkyZWFkNDVlYmExN2I4YmJhMjk1NjZhMmVfMy0yLTEtMS0w_7f71cde7-97ab-4d31-b73f-a75ce5780e22"
      unitRef="usd">1071541000</alny:RoyaltyLiabilityNoncurrent>
    <alny:RoyaltyLiabilityInterestExpenseIncludingAmortizationOfClosingCosts
      contextRef="i2a9037b7365649f2bb1a3ef6bcbe2849_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80Ni9mcmFnOjJkMDZmOTdlYzQxMzQ2MjE4NzVjYjg2OGU3YjIyZGY4L3RhYmxlOmY4NDg3ZjI5MmVhZDQ1ZWJhMTdiOGJiYTI5NTY2YTJlL3RhYmxlcmFuZ2U6Zjg0ODdmMjkyZWFkNDVlYmExN2I4YmJhMjk1NjZhMmVfNC0yLTEtMS0yNzQ_86c64d4c-8a8d-4f32-a2de-71e232e46a44"
      unitRef="usd">28184000</alny:RoyaltyLiabilityInterestExpenseIncludingAmortizationOfClosingCosts>
    <alny:RoyaltyLiabilityNoncurrent
      contextRef="id7b8291a96fc46dd8b540dbcc7a6d813_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80Ni9mcmFnOjJkMDZmOTdlYzQxMzQ2MjE4NzVjYjg2OGU3YjIyZGY4L3RhYmxlOmY4NDg3ZjI5MmVhZDQ1ZWJhMTdiOGJiYTI5NTY2YTJlL3RhYmxlcmFuZ2U6Zjg0ODdmMjkyZWFkNDVlYmExN2I4YmJhMjk1NjZhMmVfNS0yLTEtMS0yNzQ_98f505fb-3158-4e95-8ff5-49b7c3bf1d2b"
      unitRef="usd">1099725000</alny:RoyaltyLiabilityNoncurrent>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80OS9mcmFnOmYxYWI0YTVmNjYzMjQzM2FiMTJiYzczOTBlM2VkOWFlL3RleHRyZWdpb246ZjFhYjRhNWY2NjMyNDMzYWIxMmJjNzM5MGUzZWQ5YWVfMTY0OQ_5969be45-5e5b-4f7d-94d3-d226d5ddf79b">FAIR VALUE MEASUREMENTS&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following tables present information about our financial assets and liabilities that are measured at fair value on a recurring basis and indicate the fair value hierarchy of the valuation techniques we utilized to determine such fair value:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.973%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.650%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted&lt;br/&gt;Prices in&lt;br/&gt;Active&lt;br/&gt;Markets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Observable&lt;br/&gt;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financial assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177,470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177,470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government-sponsored enterprise securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;215,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;215,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,057,827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,057,827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,967&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,967&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash (money market funds)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total financial assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,508,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;235,920&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,273,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financial liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Development derivative liability (Note 10)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,038&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,038&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.973%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.650%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted&lt;br/&gt;Prices in&lt;br/&gt;Active&lt;br/&gt;Markets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Observable&lt;br/&gt;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financial assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government-sponsored enterprise securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;245,214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;245,214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,087,968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,087,968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,633&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,633&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash (money market funds)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total financial assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,475,024&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121,842&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,353,182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financial liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Development derivative liability (Note 10)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The carrying amounts reflected on our condensed consolidated balance sheets for cash, accounts receivable, net, other current assets, accounts payable and accrued expenses approximate fair value due to their short-term maturities. The carrying &lt;/span&gt;&lt;/div&gt;amount of our debt as of March&#160;31, 2021 approximates fair value as the debt was drawn on December 31, 2020 and has variable interest.</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80OS9mcmFnOmYxYWI0YTVmNjYzMjQzM2FiMTJiYzczOTBlM2VkOWFlL3RleHRyZWdpb246ZjFhYjRhNWY2NjMyNDMzYWIxMmJjNzM5MGUzZWQ5YWVfMTY0NA_655376d3-475b-4898-b85f-99a48a6050bc">&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following tables present information about our financial assets and liabilities that are measured at fair value on a recurring basis and indicate the fair value hierarchy of the valuation techniques we utilized to determine such fair value:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.973%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.650%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted&lt;br/&gt;Prices in&lt;br/&gt;Active&lt;br/&gt;Markets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Observable&lt;br/&gt;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financial assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177,470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177,470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government-sponsored enterprise securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;215,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;215,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,057,827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,057,827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,967&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,967&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash (money market funds)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total financial assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,508,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;235,920&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,273,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financial liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Development derivative liability (Note 10)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,038&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,038&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.973%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.650%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted&lt;br/&gt;Prices in&lt;br/&gt;Active&lt;br/&gt;Markets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Observable&lt;br/&gt;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financial assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government-sponsored enterprise securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;245,214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;245,214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,087,968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,087,968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,633&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,633&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash (money market funds)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total financial assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,475,024&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121,842&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,353,182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financial liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Development derivative liability (Note 10)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i16892019541d48c892ff9d24e698ebd5_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80OS9mcmFnOmYxYWI0YTVmNjYzMjQzM2FiMTJiYzczOTBlM2VkOWFlL3RhYmxlOjdhYWQ0NzdkZjhhZDQ1OTZiM2ZmNTBiZGI0N2YxNGE2L3RhYmxlcmFuZ2U6N2FhZDQ3N2RmOGFkNDU5NmIzZmY1MGJkYjQ3ZjE0YTZfNC0yLTEtMS0w_a9ce0fc7-08d1-42bc-81e9-d5e697250ce7"
      unitRef="usd">177470000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ifa5bdd3013ac476381fc4350a3ee7cf4_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80OS9mcmFnOmYxYWI0YTVmNjYzMjQzM2FiMTJiYzczOTBlM2VkOWFlL3RhYmxlOjdhYWQ0NzdkZjhhZDQ1OTZiM2ZmNTBiZGI0N2YxNGE2L3RhYmxlcmFuZ2U6N2FhZDQ3N2RmOGFkNDU5NmIzZmY1MGJkYjQ3ZjE0YTZfNC00LTEtMS0w_7c43dc0d-87f2-4423-8a41-917d9401270b"
      unitRef="usd">177470000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ic77e6331f376437fb260dd9f97ea58e8_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80OS9mcmFnOmYxYWI0YTVmNjYzMjQzM2FiMTJiYzczOTBlM2VkOWFlL3RhYmxlOjdhYWQ0NzdkZjhhZDQ1OTZiM2ZmNTBiZGI0N2YxNGE2L3RhYmxlcmFuZ2U6N2FhZDQ3N2RmOGFkNDU5NmIzZmY1MGJkYjQ3ZjE0YTZfNC02LTEtMS0w_817ac897-7870-4308-896f-774478a3f85e"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ie8a0bfabe2b94e05a37ef21b7586c1b8_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80OS9mcmFnOmYxYWI0YTVmNjYzMjQzM2FiMTJiYzczOTBlM2VkOWFlL3RhYmxlOjdhYWQ0NzdkZjhhZDQ1OTZiM2ZmNTBiZGI0N2YxNGE2L3RhYmxlcmFuZ2U6N2FhZDQ3N2RmOGFkNDU5NmIzZmY1MGJkYjQ3ZjE0YTZfNC04LTEtMS0w_3153f079-eccf-48d8-86e1-15663b79cece"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i14ad949ff20f4e34a5bff828ba895714_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80OS9mcmFnOmYxYWI0YTVmNjYzMjQzM2FiMTJiYzczOTBlM2VkOWFlL3RhYmxlOjdhYWQ0NzdkZjhhZDQ1OTZiM2ZmNTBiZGI0N2YxNGE2L3RhYmxlcmFuZ2U6N2FhZDQ3N2RmOGFkNDU5NmIzZmY1MGJkYjQ3ZjE0YTZfNy0yLTEtMS0w_1ae3cfa9-692a-45de-ba6a-95681e3d9e18"
      unitRef="usd">215200000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i294e21898c6c4ba19308833eeeec70d9_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80OS9mcmFnOmYxYWI0YTVmNjYzMjQzM2FiMTJiYzczOTBlM2VkOWFlL3RhYmxlOjdhYWQ0NzdkZjhhZDQ1OTZiM2ZmNTBiZGI0N2YxNGE2L3RhYmxlcmFuZ2U6N2FhZDQ3N2RmOGFkNDU5NmIzZmY1MGJkYjQ3ZjE0YTZfNy00LTEtMS0w_9871668d-639f-4ff0-8db0-b95800137b4b"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8637deaa1c634995a355fa860ea50c94_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80OS9mcmFnOmYxYWI0YTVmNjYzMjQzM2FiMTJiYzczOTBlM2VkOWFlL3RhYmxlOjdhYWQ0NzdkZjhhZDQ1OTZiM2ZmNTBiZGI0N2YxNGE2L3RhYmxlcmFuZ2U6N2FhZDQ3N2RmOGFkNDU5NmIzZmY1MGJkYjQ3ZjE0YTZfNy02LTEtMS0w_b04474c4-a85c-4fe6-99d4-316f6b6d0289"
      unitRef="usd">215200000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ibdb3bef5ea924074b966e38860b348a9_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80OS9mcmFnOmYxYWI0YTVmNjYzMjQzM2FiMTJiYzczOTBlM2VkOWFlL3RhYmxlOjdhYWQ0NzdkZjhhZDQ1OTZiM2ZmNTBiZGI0N2YxNGE2L3RhYmxlcmFuZ2U6N2FhZDQ3N2RmOGFkNDU5NmIzZmY1MGJkYjQ3ZjE0YTZfNy04LTEtMS0w_99e54b5e-9728-4517-9ef8-b3adeba0fb96"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ief62e6e6b5794e1e9aac7a9b35576e8e_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80OS9mcmFnOmYxYWI0YTVmNjYzMjQzM2FiMTJiYzczOTBlM2VkOWFlL3RhYmxlOjdhYWQ0NzdkZjhhZDQ1OTZiM2ZmNTBiZGI0N2YxNGE2L3RhYmxlcmFuZ2U6N2FhZDQ3N2RmOGFkNDU5NmIzZmY1MGJkYjQ3ZjE0YTZfOC0yLTEtMS0w_734a7b0c-ffdf-4aa4-bc03-e7cca136bec1"
      unitRef="usd">1057827000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9b9bb880bac0407b815f6fd57e76cd83_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80OS9mcmFnOmYxYWI0YTVmNjYzMjQzM2FiMTJiYzczOTBlM2VkOWFlL3RhYmxlOjdhYWQ0NzdkZjhhZDQ1OTZiM2ZmNTBiZGI0N2YxNGE2L3RhYmxlcmFuZ2U6N2FhZDQ3N2RmOGFkNDU5NmIzZmY1MGJkYjQ3ZjE0YTZfOC00LTEtMS0w_40b4bc33-156c-42fb-a436-df021b489db2"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie3ebff18dd48442faf99a73c773d55fa_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80OS9mcmFnOmYxYWI0YTVmNjYzMjQzM2FiMTJiYzczOTBlM2VkOWFlL3RhYmxlOjdhYWQ0NzdkZjhhZDQ1OTZiM2ZmNTBiZGI0N2YxNGE2L3RhYmxlcmFuZ2U6N2FhZDQ3N2RmOGFkNDU5NmIzZmY1MGJkYjQ3ZjE0YTZfOC02LTEtMS0w_35354bd9-1c2e-4816-879a-472164572cd8"
      unitRef="usd">1057827000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6e887f34bbab43fa8752d3d60f8d1b10_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80OS9mcmFnOmYxYWI0YTVmNjYzMjQzM2FiMTJiYzczOTBlM2VkOWFlL3RhYmxlOjdhYWQ0NzdkZjhhZDQ1OTZiM2ZmNTBiZGI0N2YxNGE2L3RhYmxlcmFuZ2U6N2FhZDQ3N2RmOGFkNDU5NmIzZmY1MGJkYjQ3ZjE0YTZfOC04LTEtMS0w_0f2ffe07-ab92-416d-a380-f1b3effdfab6"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="if05c960039774dd9b4ad2920b9816c04_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80OS9mcmFnOmYxYWI0YTVmNjYzMjQzM2FiMTJiYzczOTBlM2VkOWFlL3RhYmxlOjdhYWQ0NzdkZjhhZDQ1OTZiM2ZmNTBiZGI0N2YxNGE2L3RhYmxlcmFuZ2U6N2FhZDQ3N2RmOGFkNDU5NmIzZmY1MGJkYjQ3ZjE0YTZfOS0yLTEtMS0w_87e2f7ec-6ee9-4963-a8f7-616ca1a58d47"
      unitRef="usd">56967000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i6d138b2bd73a4ef49fdec7e2d7119c17_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80OS9mcmFnOmYxYWI0YTVmNjYzMjQzM2FiMTJiYzczOTBlM2VkOWFlL3RhYmxlOjdhYWQ0NzdkZjhhZDQ1OTZiM2ZmNTBiZGI0N2YxNGE2L3RhYmxlcmFuZ2U6N2FhZDQ3N2RmOGFkNDU5NmIzZmY1MGJkYjQ3ZjE0YTZfOS00LTEtMS0w_96e32d38-d222-40a1-ad91-4aa4b6b2494f"
      unitRef="usd">56967000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i00ed30d5d69b424e81f823616e722813_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80OS9mcmFnOmYxYWI0YTVmNjYzMjQzM2FiMTJiYzczOTBlM2VkOWFlL3RhYmxlOjdhYWQ0NzdkZjhhZDQ1OTZiM2ZmNTBiZGI0N2YxNGE2L3RhYmxlcmFuZ2U6N2FhZDQ3N2RmOGFkNDU5NmIzZmY1MGJkYjQ3ZjE0YTZfOS02LTEtMS0w_0b5777ca-f323-4a65-89a8-5f1003619ab3"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="if93a1d02ab2c44359e2b2873b0965791_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80OS9mcmFnOmYxYWI0YTVmNjYzMjQzM2FiMTJiYzczOTBlM2VkOWFlL3RhYmxlOjdhYWQ0NzdkZjhhZDQ1OTZiM2ZmNTBiZGI0N2YxNGE2L3RhYmxlcmFuZ2U6N2FhZDQ3N2RmOGFkNDU5NmIzZmY1MGJkYjQ3ZjE0YTZfOS04LTEtMS0w_cbba9ce8-ecf3-4f2f-9bcd-c085900a5548"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="i16892019541d48c892ff9d24e698ebd5_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80OS9mcmFnOmYxYWI0YTVmNjYzMjQzM2FiMTJiYzczOTBlM2VkOWFlL3RhYmxlOjdhYWQ0NzdkZjhhZDQ1OTZiM2ZmNTBiZGI0N2YxNGE2L3RhYmxlcmFuZ2U6N2FhZDQ3N2RmOGFkNDU5NmIzZmY1MGJkYjQ3ZjE0YTZfMTAtMi0xLTEtMA_8b306038-00a7-4328-864c-8270cadbdeb6"
      unitRef="usd">1483000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="ifa5bdd3013ac476381fc4350a3ee7cf4_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80OS9mcmFnOmYxYWI0YTVmNjYzMjQzM2FiMTJiYzczOTBlM2VkOWFlL3RhYmxlOjdhYWQ0NzdkZjhhZDQ1OTZiM2ZmNTBiZGI0N2YxNGE2L3RhYmxlcmFuZ2U6N2FhZDQ3N2RmOGFkNDU5NmIzZmY1MGJkYjQ3ZjE0YTZfMTAtNC0xLTEtMA_7aeeeb2f-c60b-4cac-974e-d81990c60784"
      unitRef="usd">1483000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="ic77e6331f376437fb260dd9f97ea58e8_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80OS9mcmFnOmYxYWI0YTVmNjYzMjQzM2FiMTJiYzczOTBlM2VkOWFlL3RhYmxlOjdhYWQ0NzdkZjhhZDQ1OTZiM2ZmNTBiZGI0N2YxNGE2L3RhYmxlcmFuZ2U6N2FhZDQ3N2RmOGFkNDU5NmIzZmY1MGJkYjQ3ZjE0YTZfMTAtNi0xLTEtMA_2d2251a0-7ddf-47fa-9f3a-c2dfc91cc080"
      unitRef="usd">0</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="ie8a0bfabe2b94e05a37ef21b7586c1b8_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80OS9mcmFnOmYxYWI0YTVmNjYzMjQzM2FiMTJiYzczOTBlM2VkOWFlL3RhYmxlOjdhYWQ0NzdkZjhhZDQ1OTZiM2ZmNTBiZGI0N2YxNGE2L3RhYmxlcmFuZ2U6N2FhZDQ3N2RmOGFkNDU5NmIzZmY1MGJkYjQ3ZjE0YTZfMTAtOC0xLTEtMA_659607bb-2ce9-467f-95af-c9bbaa10212d"
      unitRef="usd">0</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="if05c960039774dd9b4ad2920b9816c04_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80OS9mcmFnOmYxYWI0YTVmNjYzMjQzM2FiMTJiYzczOTBlM2VkOWFlL3RhYmxlOjdhYWQ0NzdkZjhhZDQ1OTZiM2ZmNTBiZGI0N2YxNGE2L3RhYmxlcmFuZ2U6N2FhZDQ3N2RmOGFkNDU5NmIzZmY1MGJkYjQ3ZjE0YTZfMTEtMi0xLTEtMA_36523f44-b931-4e48-99a8-86c4025826df"
      unitRef="usd">1508947000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i6d138b2bd73a4ef49fdec7e2d7119c17_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80OS9mcmFnOmYxYWI0YTVmNjYzMjQzM2FiMTJiYzczOTBlM2VkOWFlL3RhYmxlOjdhYWQ0NzdkZjhhZDQ1OTZiM2ZmNTBiZGI0N2YxNGE2L3RhYmxlcmFuZ2U6N2FhZDQ3N2RmOGFkNDU5NmIzZmY1MGJkYjQ3ZjE0YTZfMTEtNC0xLTEtMA_4fe8980e-7614-48bb-b972-e5fec9b5a338"
      unitRef="usd">235920000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i00ed30d5d69b424e81f823616e722813_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80OS9mcmFnOmYxYWI0YTVmNjYzMjQzM2FiMTJiYzczOTBlM2VkOWFlL3RhYmxlOjdhYWQ0NzdkZjhhZDQ1OTZiM2ZmNTBiZGI0N2YxNGE2L3RhYmxlcmFuZ2U6N2FhZDQ3N2RmOGFkNDU5NmIzZmY1MGJkYjQ3ZjE0YTZfMTEtNi0xLTEtMA_300023ed-26cb-49d6-806b-8f07f961d113"
      unitRef="usd">1273027000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="if93a1d02ab2c44359e2b2873b0965791_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80OS9mcmFnOmYxYWI0YTVmNjYzMjQzM2FiMTJiYzczOTBlM2VkOWFlL3RhYmxlOjdhYWQ0NzdkZjhhZDQ1OTZiM2ZmNTBiZGI0N2YxNGE2L3RhYmxlcmFuZ2U6N2FhZDQ3N2RmOGFkNDU5NmIzZmY1MGJkYjQ3ZjE0YTZfMTEtOC0xLTEtMA_79eab5fa-db28-4c9b-b8d8-58d9e82a208a"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:DerivativeLiabilities
      contextRef="if05c960039774dd9b4ad2920b9816c04_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80OS9mcmFnOmYxYWI0YTVmNjYzMjQzM2FiMTJiYzczOTBlM2VkOWFlL3RhYmxlOjdhYWQ0NzdkZjhhZDQ1OTZiM2ZmNTBiZGI0N2YxNGE2L3RhYmxlcmFuZ2U6N2FhZDQ3N2RmOGFkNDU5NmIzZmY1MGJkYjQ3ZjE0YTZfMTMtMi0xLTEtMA_723cc2c6-a216-45b1-8abe-d7b05903fc8d"
      unitRef="usd">48038000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i6d138b2bd73a4ef49fdec7e2d7119c17_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80OS9mcmFnOmYxYWI0YTVmNjYzMjQzM2FiMTJiYzczOTBlM2VkOWFlL3RhYmxlOjdhYWQ0NzdkZjhhZDQ1OTZiM2ZmNTBiZGI0N2YxNGE2L3RhYmxlcmFuZ2U6N2FhZDQ3N2RmOGFkNDU5NmIzZmY1MGJkYjQ3ZjE0YTZfMTMtNC0xLTEtMA_b387e85c-5ff3-4a48-942a-a84bc7ab2e95"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i00ed30d5d69b424e81f823616e722813_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80OS9mcmFnOmYxYWI0YTVmNjYzMjQzM2FiMTJiYzczOTBlM2VkOWFlL3RhYmxlOjdhYWQ0NzdkZjhhZDQ1OTZiM2ZmNTBiZGI0N2YxNGE2L3RhYmxlcmFuZ2U6N2FhZDQ3N2RmOGFkNDU5NmIzZmY1MGJkYjQ3ZjE0YTZfMTMtNi0xLTEtMA_b26ada18-5d81-4ade-845c-721d3c4e6af3"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="if93a1d02ab2c44359e2b2873b0965791_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80OS9mcmFnOmYxYWI0YTVmNjYzMjQzM2FiMTJiYzczOTBlM2VkOWFlL3RhYmxlOjdhYWQ0NzdkZjhhZDQ1OTZiM2ZmNTBiZGI0N2YxNGE2L3RhYmxlcmFuZ2U6N2FhZDQ3N2RmOGFkNDU5NmIzZmY1MGJkYjQ3ZjE0YTZfMTMtOC0xLTEtMA_347efdad-4e81-4152-8aad-2735c62b61a8"
      unitRef="usd">48038000</us-gaap:DerivativeLiabilities>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i65a4965cd593490dbf6466695a4a77e4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80OS9mcmFnOmYxYWI0YTVmNjYzMjQzM2FiMTJiYzczOTBlM2VkOWFlL3RhYmxlOmQ3YTdlNjQzZTUwMDQ1YWY4NTVkZmE2NGI5ZjM2YTk3L3RhYmxlcmFuZ2U6ZDdhN2U2NDNlNTAwNDVhZjg1NWRmYTY0YjlmMzZhOTdfNC0yLTEtMS0w_d296c9c3-e311-4167-b5d9-5eb8988c7f29"
      unitRef="usd">20000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i839a27ef72924781a3487df7e5d7b395_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80OS9mcmFnOmYxYWI0YTVmNjYzMjQzM2FiMTJiYzczOTBlM2VkOWFlL3RhYmxlOmQ3YTdlNjQzZTUwMDQ1YWY4NTVkZmE2NGI5ZjM2YTk3L3RhYmxlcmFuZ2U6ZDdhN2U2NDNlNTAwNDVhZjg1NWRmYTY0YjlmMzZhOTdfNC00LTEtMS0w_36b20c96-3007-4ce0-826a-782ac946e466"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i5590fd684f1a4aa090bf9b83c5673927_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80OS9mcmFnOmYxYWI0YTVmNjYzMjQzM2FiMTJiYzczOTBlM2VkOWFlL3RhYmxlOmQ3YTdlNjQzZTUwMDQ1YWY4NTVkZmE2NGI5ZjM2YTk3L3RhYmxlcmFuZ2U6ZDdhN2U2NDNlNTAwNDVhZjg1NWRmYTY0YjlmMzZhOTdfNC02LTEtMS0w_a2e1371c-7c3a-46e4-8e60-f9a4177b11f0"
      unitRef="usd">20000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i9f72f19e489246dea7d90e3176d37999_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80OS9mcmFnOmYxYWI0YTVmNjYzMjQzM2FiMTJiYzczOTBlM2VkOWFlL3RhYmxlOmQ3YTdlNjQzZTUwMDQ1YWY4NTVkZmE2NGI5ZjM2YTk3L3RhYmxlcmFuZ2U6ZDdhN2U2NDNlNTAwNDVhZjg1NWRmYTY0YjlmMzZhOTdfNC04LTEtMS0w_f16a241e-83ba-4159-8811-31aa7cfffe85"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ie1d58cc31b1e414591ea2ec01318868f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80OS9mcmFnOmYxYWI0YTVmNjYzMjQzM2FiMTJiYzczOTBlM2VkOWFlL3RhYmxlOmQ3YTdlNjQzZTUwMDQ1YWY4NTVkZmE2NGI5ZjM2YTk3L3RhYmxlcmFuZ2U6ZDdhN2U2NDNlNTAwNDVhZjg1NWRmYTY0YjlmMzZhOTdfNS0yLTEtMS0w_90ec336b-bd79-45ed-a5fd-bbfae0f7a86f"
      unitRef="usd">75726000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i522c65977b4e4cfaa993b2b5ff3d2f94_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80OS9mcmFnOmYxYWI0YTVmNjYzMjQzM2FiMTJiYzczOTBlM2VkOWFlL3RhYmxlOmQ3YTdlNjQzZTUwMDQ1YWY4NTVkZmE2NGI5ZjM2YTk3L3RhYmxlcmFuZ2U6ZDdhN2U2NDNlNTAwNDVhZjg1NWRmYTY0YjlmMzZhOTdfNS00LTEtMS0w_f85fb4a5-fe3e-4af2-9ea5-493b22a49430"
      unitRef="usd">75726000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i641ddedd23b34601ba66a76b01282b1b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80OS9mcmFnOmYxYWI0YTVmNjYzMjQzM2FiMTJiYzczOTBlM2VkOWFlL3RhYmxlOmQ3YTdlNjQzZTUwMDQ1YWY4NTVkZmE2NGI5ZjM2YTk3L3RhYmxlcmFuZ2U6ZDdhN2U2NDNlNTAwNDVhZjg1NWRmYTY0YjlmMzZhOTdfNS02LTEtMS0w_69aa462a-469f-44b5-a5d8-518d2fa70711"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ib25e85f29b8c40708ecc002c16e6e683_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80OS9mcmFnOmYxYWI0YTVmNjYzMjQzM2FiMTJiYzczOTBlM2VkOWFlL3RhYmxlOmQ3YTdlNjQzZTUwMDQ1YWY4NTVkZmE2NGI5ZjM2YTk3L3RhYmxlcmFuZ2U6ZDdhN2U2NDNlNTAwNDVhZjg1NWRmYTY0YjlmMzZhOTdfNS04LTEtMS0w_ac6f4760-77be-467b-a159-beb610cc1238"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9eaaf5231e504c2f914f6c3a0ddd13ee_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80OS9mcmFnOmYxYWI0YTVmNjYzMjQzM2FiMTJiYzczOTBlM2VkOWFlL3RhYmxlOmQ3YTdlNjQzZTUwMDQ1YWY4NTVkZmE2NGI5ZjM2YTk3L3RhYmxlcmFuZ2U6ZDdhN2U2NDNlNTAwNDVhZjg1NWRmYTY0YjlmMzZhOTdfMTAtMi0xLTEtMA_c0cbefdb-dccd-4ebe-a622-071555183cc4"
      unitRef="usd">245214000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3f0a2ea993f04064aadad295133972b4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80OS9mcmFnOmYxYWI0YTVmNjYzMjQzM2FiMTJiYzczOTBlM2VkOWFlL3RhYmxlOmQ3YTdlNjQzZTUwMDQ1YWY4NTVkZmE2NGI5ZjM2YTk3L3RhYmxlcmFuZ2U6ZDdhN2U2NDNlNTAwNDVhZjg1NWRmYTY0YjlmMzZhOTdfMTAtNC0xLTEtMA_47d2567c-9fef-4f9b-9e3b-1e22b4828d8e"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia79c16400354457793c02c74c6ff001d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80OS9mcmFnOmYxYWI0YTVmNjYzMjQzM2FiMTJiYzczOTBlM2VkOWFlL3RhYmxlOmQ3YTdlNjQzZTUwMDQ1YWY4NTVkZmE2NGI5ZjM2YTk3L3RhYmxlcmFuZ2U6ZDdhN2U2NDNlNTAwNDVhZjg1NWRmYTY0YjlmMzZhOTdfMTAtNi0xLTEtMA_83e625a1-1055-4c3b-9982-b175358050bf"
      unitRef="usd">245214000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7bf1dac612484a0685308b19a503a754_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80OS9mcmFnOmYxYWI0YTVmNjYzMjQzM2FiMTJiYzczOTBlM2VkOWFlL3RhYmxlOmQ3YTdlNjQzZTUwMDQ1YWY4NTVkZmE2NGI5ZjM2YTk3L3RhYmxlcmFuZ2U6ZDdhN2U2NDNlNTAwNDVhZjg1NWRmYTY0YjlmMzZhOTdfMTAtOC0xLTEtMA_1300f962-19a0-4453-8756-e496dbb503a1"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i65a4965cd593490dbf6466695a4a77e4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80OS9mcmFnOmYxYWI0YTVmNjYzMjQzM2FiMTJiYzczOTBlM2VkOWFlL3RhYmxlOmQ3YTdlNjQzZTUwMDQ1YWY4NTVkZmE2NGI5ZjM2YTk3L3RhYmxlcmFuZ2U6ZDdhN2U2NDNlNTAwNDVhZjg1NWRmYTY0YjlmMzZhOTdfMTEtMi0xLTEtMA_77e52fd4-1a18-498f-80e8-5168f3120fd5"
      unitRef="usd">1087968000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i839a27ef72924781a3487df7e5d7b395_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80OS9mcmFnOmYxYWI0YTVmNjYzMjQzM2FiMTJiYzczOTBlM2VkOWFlL3RhYmxlOmQ3YTdlNjQzZTUwMDQ1YWY4NTVkZmE2NGI5ZjM2YTk3L3RhYmxlcmFuZ2U6ZDdhN2U2NDNlNTAwNDVhZjg1NWRmYTY0YjlmMzZhOTdfMTEtNC0xLTEtMA_dae1f24e-4206-414b-99b2-955e3cfa57de"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5590fd684f1a4aa090bf9b83c5673927_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80OS9mcmFnOmYxYWI0YTVmNjYzMjQzM2FiMTJiYzczOTBlM2VkOWFlL3RhYmxlOmQ3YTdlNjQzZTUwMDQ1YWY4NTVkZmE2NGI5ZjM2YTk3L3RhYmxlcmFuZ2U6ZDdhN2U2NDNlNTAwNDVhZjg1NWRmYTY0YjlmMzZhOTdfMTEtNi0xLTEtMA_c533ebb1-c169-4843-ba6f-fbff1d10192f"
      unitRef="usd">1087968000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9f72f19e489246dea7d90e3176d37999_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80OS9mcmFnOmYxYWI0YTVmNjYzMjQzM2FiMTJiYzczOTBlM2VkOWFlL3RhYmxlOmQ3YTdlNjQzZTUwMDQ1YWY4NTVkZmE2NGI5ZjM2YTk3L3RhYmxlcmFuZ2U6ZDdhN2U2NDNlNTAwNDVhZjg1NWRmYTY0YjlmMzZhOTdfMTEtOC0xLTEtMA_b34b00bb-cf6e-44d8-b1eb-f90b918bb5b5"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ie44adffa3b2e429993b1d4c047f9453c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80OS9mcmFnOmYxYWI0YTVmNjYzMjQzM2FiMTJiYzczOTBlM2VkOWFlL3RhYmxlOmQ3YTdlNjQzZTUwMDQ1YWY4NTVkZmE2NGI5ZjM2YTk3L3RhYmxlcmFuZ2U6ZDdhN2U2NDNlNTAwNDVhZjg1NWRmYTY0YjlmMzZhOTdfMTItMi0xLTEtMA_cb33a238-594c-4584-854d-6852b10ebe96"
      unitRef="usd">44633000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i515aff7391d84e1bae1add95d453fe61_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80OS9mcmFnOmYxYWI0YTVmNjYzMjQzM2FiMTJiYzczOTBlM2VkOWFlL3RhYmxlOmQ3YTdlNjQzZTUwMDQ1YWY4NTVkZmE2NGI5ZjM2YTk3L3RhYmxlcmFuZ2U6ZDdhN2U2NDNlNTAwNDVhZjg1NWRmYTY0YjlmMzZhOTdfMTItNC0xLTEtMA_b61fa129-5633-4a99-a3cf-1955fd900bfb"
      unitRef="usd">44633000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i6c2621b1e8d440ffa4c9d403e127ab4d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80OS9mcmFnOmYxYWI0YTVmNjYzMjQzM2FiMTJiYzczOTBlM2VkOWFlL3RhYmxlOmQ3YTdlNjQzZTUwMDQ1YWY4NTVkZmE2NGI5ZjM2YTk3L3RhYmxlcmFuZ2U6ZDdhN2U2NDNlNTAwNDVhZjg1NWRmYTY0YjlmMzZhOTdfMTItNi0xLTEtMA_1e8597d5-98ec-40ee-a6e4-87ca81445949"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i4526151777954123a086b101de9b112e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80OS9mcmFnOmYxYWI0YTVmNjYzMjQzM2FiMTJiYzczOTBlM2VkOWFlL3RhYmxlOmQ3YTdlNjQzZTUwMDQ1YWY4NTVkZmE2NGI5ZjM2YTk3L3RhYmxlcmFuZ2U6ZDdhN2U2NDNlNTAwNDVhZjg1NWRmYTY0YjlmMzZhOTdfMTItOC0xLTEtMA_3c5f3134-ac64-4ded-b47c-1ea01f4ab1ce"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="ie1d58cc31b1e414591ea2ec01318868f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80OS9mcmFnOmYxYWI0YTVmNjYzMjQzM2FiMTJiYzczOTBlM2VkOWFlL3RhYmxlOmQ3YTdlNjQzZTUwMDQ1YWY4NTVkZmE2NGI5ZjM2YTk3L3RhYmxlcmFuZ2U6ZDdhN2U2NDNlNTAwNDVhZjg1NWRmYTY0YjlmMzZhOTdfMTMtMi0xLTEtMA_db0783ec-b0bb-49cf-92a2-073021bf4f69"
      unitRef="usd">1483000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="i522c65977b4e4cfaa993b2b5ff3d2f94_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80OS9mcmFnOmYxYWI0YTVmNjYzMjQzM2FiMTJiYzczOTBlM2VkOWFlL3RhYmxlOmQ3YTdlNjQzZTUwMDQ1YWY4NTVkZmE2NGI5ZjM2YTk3L3RhYmxlcmFuZ2U6ZDdhN2U2NDNlNTAwNDVhZjg1NWRmYTY0YjlmMzZhOTdfMTMtNC0xLTEtMA_6e141b96-d4aa-4dd5-8a07-7ac0f0cee6cb"
      unitRef="usd">1483000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="i641ddedd23b34601ba66a76b01282b1b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80OS9mcmFnOmYxYWI0YTVmNjYzMjQzM2FiMTJiYzczOTBlM2VkOWFlL3RhYmxlOmQ3YTdlNjQzZTUwMDQ1YWY4NTVkZmE2NGI5ZjM2YTk3L3RhYmxlcmFuZ2U6ZDdhN2U2NDNlNTAwNDVhZjg1NWRmYTY0YjlmMzZhOTdfMTMtNi0xLTEtMA_5a07769a-483e-4c4c-a0c9-90595c038d36"
      unitRef="usd">0</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="ib25e85f29b8c40708ecc002c16e6e683_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80OS9mcmFnOmYxYWI0YTVmNjYzMjQzM2FiMTJiYzczOTBlM2VkOWFlL3RhYmxlOmQ3YTdlNjQzZTUwMDQ1YWY4NTVkZmE2NGI5ZjM2YTk3L3RhYmxlcmFuZ2U6ZDdhN2U2NDNlNTAwNDVhZjg1NWRmYTY0YjlmMzZhOTdfMTMtOC0xLTEtMA_c6d8cb55-0496-49be-9fdb-62aa078dfff1"
      unitRef="usd">0</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ie44adffa3b2e429993b1d4c047f9453c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80OS9mcmFnOmYxYWI0YTVmNjYzMjQzM2FiMTJiYzczOTBlM2VkOWFlL3RhYmxlOmQ3YTdlNjQzZTUwMDQ1YWY4NTVkZmE2NGI5ZjM2YTk3L3RhYmxlcmFuZ2U6ZDdhN2U2NDNlNTAwNDVhZjg1NWRmYTY0YjlmMzZhOTdfMTQtMi0xLTEtMA_d41915b2-6959-4a95-a995-5fa1ef68fd45"
      unitRef="usd">1475024000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i515aff7391d84e1bae1add95d453fe61_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80OS9mcmFnOmYxYWI0YTVmNjYzMjQzM2FiMTJiYzczOTBlM2VkOWFlL3RhYmxlOmQ3YTdlNjQzZTUwMDQ1YWY4NTVkZmE2NGI5ZjM2YTk3L3RhYmxlcmFuZ2U6ZDdhN2U2NDNlNTAwNDVhZjg1NWRmYTY0YjlmMzZhOTdfMTQtNC0xLTEtMA_45c1575a-1cd0-4dca-a263-63391a58c52f"
      unitRef="usd">121842000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i6c2621b1e8d440ffa4c9d403e127ab4d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80OS9mcmFnOmYxYWI0YTVmNjYzMjQzM2FiMTJiYzczOTBlM2VkOWFlL3RhYmxlOmQ3YTdlNjQzZTUwMDQ1YWY4NTVkZmE2NGI5ZjM2YTk3L3RhYmxlcmFuZ2U6ZDdhN2U2NDNlNTAwNDVhZjg1NWRmYTY0YjlmMzZhOTdfMTQtNi0xLTEtMA_2b009db5-1bf5-4556-872f-47db6b7d1e70"
      unitRef="usd">1353182000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i4526151777954123a086b101de9b112e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80OS9mcmFnOmYxYWI0YTVmNjYzMjQzM2FiMTJiYzczOTBlM2VkOWFlL3RhYmxlOmQ3YTdlNjQzZTUwMDQ1YWY4NTVkZmE2NGI5ZjM2YTk3L3RhYmxlcmFuZ2U6ZDdhN2U2NDNlNTAwNDVhZjg1NWRmYTY0YjlmMzZhOTdfMTQtOC0xLTEtMA_aa1c26ed-48da-4d9d-80a2-11ea665e4eae"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:DerivativeLiabilities
      contextRef="ie44adffa3b2e429993b1d4c047f9453c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80OS9mcmFnOmYxYWI0YTVmNjYzMjQzM2FiMTJiYzczOTBlM2VkOWFlL3RhYmxlOmQ3YTdlNjQzZTUwMDQ1YWY4NTVkZmE2NGI5ZjM2YTk3L3RhYmxlcmFuZ2U6ZDdhN2U2NDNlNTAwNDVhZjg1NWRmYTY0YjlmMzZhOTdfMTYtMi0xLTEtNDEy_828d0ae7-f278-4251-ae11-fc1bed7b30bc"
      unitRef="usd">25585000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i515aff7391d84e1bae1add95d453fe61_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80OS9mcmFnOmYxYWI0YTVmNjYzMjQzM2FiMTJiYzczOTBlM2VkOWFlL3RhYmxlOmQ3YTdlNjQzZTUwMDQ1YWY4NTVkZmE2NGI5ZjM2YTk3L3RhYmxlcmFuZ2U6ZDdhN2U2NDNlNTAwNDVhZjg1NWRmYTY0YjlmMzZhOTdfMTYtNC0xLTEtNDEy_47d546fd-6425-478f-8017-586d519ce623"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i6c2621b1e8d440ffa4c9d403e127ab4d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80OS9mcmFnOmYxYWI0YTVmNjYzMjQzM2FiMTJiYzczOTBlM2VkOWFlL3RhYmxlOmQ3YTdlNjQzZTUwMDQ1YWY4NTVkZmE2NGI5ZjM2YTk3L3RhYmxlcmFuZ2U6ZDdhN2U2NDNlNTAwNDVhZjg1NWRmYTY0YjlmMzZhOTdfMTYtNi0xLTEtNDEy_e3329d48-2616-4fd0-b9e7-07b3bedcef1e"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i4526151777954123a086b101de9b112e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF80OS9mcmFnOmYxYWI0YTVmNjYzMjQzM2FiMTJiYzczOTBlM2VkOWFlL3RhYmxlOmQ3YTdlNjQzZTUwMDQ1YWY4NTVkZmE2NGI5ZjM2YTk3L3RhYmxlcmFuZ2U6ZDdhN2U2NDNlNTAwNDVhZjg1NWRmYTY0YjlmMzZhOTdfMTYtOC0xLTEtNDEy_5b9c2755-7351-4b0b-b8ce-3c3061765a24"
      unitRef="usd">25585000</us-gaap:DerivativeLiabilities>
    <alny:InvestmentsInMarketableDebtSecuritiesDisclosureTextBlock
      contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81Mi9mcmFnOmI5NWYyNjQxYWE2ZTQwMTU5MzFjODRlY2VmNTYxYWM4L3RleHRyZWdpb246Yjk1ZjI2NDFhYTZlNDAxNTkzMWM4NGVjZWY1NjFhYzhfNjM3_039d38b4-2419-4258-a6bd-12000fb06dc7">MARKETABLE DEBT SECURITIES&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;We invest our excess cash balances in marketable debt securities and at each balance sheet date presented, we classify all of our investments in debt securities as available-for-sale and as current assets as they represent the investment of funds available for current operations. We did not record any impairment charges related to our marketable debt securities during the three months ended March&#160;31, 2021 or 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following tables summarize our marketable debt securities:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.779%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government-sponsored enterprise securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;215,171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(58)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;215,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,057,509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,057,827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,272,680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(75)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,273,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.779%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government-sponsored enterprise securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;245,113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(34)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;245,214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,107,721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(81)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,107,968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,352,834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(115)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,353,182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The fair values of our marketable debt securities by classification in the condensed consolidated balance sheets were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.128%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.422%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,273,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,333,182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,273,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,353,182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</alny:InvestmentsInMarketableDebtSecuritiesDisclosureTextBlock>
    <alny:ImpairmentOfMarketableDebtSecurities
      contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81Mi9mcmFnOmI5NWYyNjQxYWE2ZTQwMTU5MzFjODRlY2VmNTYxYWM4L3RleHRyZWdpb246Yjk1ZjI2NDFhYTZlNDAxNTkzMWM4NGVjZWY1NjFhYzhfMzI0_3c32bd4a-5982-44de-9ba1-e1f22ad56e99"
      unitRef="usd">0</alny:ImpairmentOfMarketableDebtSecurities>
    <alny:ImpairmentOfMarketableDebtSecurities
      contextRef="ide9f6e15665746279d0000be700fcc6a_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81Mi9mcmFnOmI5NWYyNjQxYWE2ZTQwMTU5MzFjODRlY2VmNTYxYWM4L3RleHRyZWdpb246Yjk1ZjI2NDFhYTZlNDAxNTkzMWM4NGVjZWY1NjFhYzhfMzI0_7f4e9928-64ec-451f-ba76-8f42a8854e60"
      unitRef="usd">0</alny:ImpairmentOfMarketableDebtSecurities>
    <alny:ImpairmentOfMarketableDebtSecurities
      contextRef="ide9f6e15665746279d0000be700fcc6a_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81Mi9mcmFnOmI5NWYyNjQxYWE2ZTQwMTU5MzFjODRlY2VmNTYxYWM4L3RleHRyZWdpb246Yjk1ZjI2NDFhYTZlNDAxNTkzMWM4NGVjZWY1NjFhYzhfMzI0_adb73d4a-c146-483e-ade8-45173e82ac97"
      unitRef="usd">0</alny:ImpairmentOfMarketableDebtSecurities>
    <alny:ImpairmentOfMarketableDebtSecurities
      contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81Mi9mcmFnOmI5NWYyNjQxYWE2ZTQwMTU5MzFjODRlY2VmNTYxYWM4L3RleHRyZWdpb246Yjk1ZjI2NDFhYTZlNDAxNTkzMWM4NGVjZWY1NjFhYzhfMzI0_b141ae81-8ee7-4093-be47-ded5abd9c181"
      unitRef="usd">0</alny:ImpairmentOfMarketableDebtSecurities>
    <us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock
      contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81Mi9mcmFnOmI5NWYyNjQxYWE2ZTQwMTU5MzFjODRlY2VmNTYxYWM4L3RleHRyZWdpb246Yjk1ZjI2NDFhYTZlNDAxNTkzMWM4NGVjZWY1NjFhYzhfNjM4_944cf832-00ad-420b-b160-d2eb8bfce08d">&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following tables summarize our marketable debt securities:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.779%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government-sponsored enterprise securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;215,171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(58)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;215,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,057,509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,057,827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,272,680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(75)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,273,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.779%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government-sponsored enterprise securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;245,113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(34)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;245,214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,107,721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(81)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,107,968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,352,834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(115)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,353,182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i233d78b0ba3f4206a3bfc816b3ab7454_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81Mi9mcmFnOmI5NWYyNjQxYWE2ZTQwMTU5MzFjODRlY2VmNTYxYWM4L3RhYmxlOjJlNzliODk4OWMxMzRmZGI5YWZiYmUwNDdkMTk3OTEyL3RhYmxlcmFuZ2U6MmU3OWI4OTg5YzEzNGZkYjlhZmJiZTA0N2QxOTc5MTJfMy0xLTEtMS0w_7feb310f-0aba-4075-bea8-53f11a1899ad"
      unitRef="usd">215171000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i233d78b0ba3f4206a3bfc816b3ab7454_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81Mi9mcmFnOmI5NWYyNjQxYWE2ZTQwMTU5MzFjODRlY2VmNTYxYWM4L3RhYmxlOjJlNzliODk4OWMxMzRmZGI5YWZiYmUwNDdkMTk3OTEyL3RhYmxlcmFuZ2U6MmU3OWI4OTg5YzEzNGZkYjlhZmJiZTA0N2QxOTc5MTJfMy0zLTEtMS0w_68350d5e-c6d5-424e-b75c-f64102c783c0"
      unitRef="usd">87000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i233d78b0ba3f4206a3bfc816b3ab7454_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81Mi9mcmFnOmI5NWYyNjQxYWE2ZTQwMTU5MzFjODRlY2VmNTYxYWM4L3RhYmxlOjJlNzliODk4OWMxMzRmZGI5YWZiYmUwNDdkMTk3OTEyL3RhYmxlcmFuZ2U6MmU3OWI4OTg5YzEzNGZkYjlhZmJiZTA0N2QxOTc5MTJfMy01LTEtMS0w_0f0c6082-e3a9-498b-ac37-f5e04fda8a0b"
      unitRef="usd">58000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i233d78b0ba3f4206a3bfc816b3ab7454_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81Mi9mcmFnOmI5NWYyNjQxYWE2ZTQwMTU5MzFjODRlY2VmNTYxYWM4L3RhYmxlOjJlNzliODk4OWMxMzRmZGI5YWZiYmUwNDdkMTk3OTEyL3RhYmxlcmFuZ2U6MmU3OWI4OTg5YzEzNGZkYjlhZmJiZTA0N2QxOTc5MTJfMy03LTEtMS0w_ba7930b2-16a2-4a80-a426-3f2dd3511731"
      unitRef="usd">215200000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i58cbbc0a79de4859b6344bf8949aeb85_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81Mi9mcmFnOmI5NWYyNjQxYWE2ZTQwMTU5MzFjODRlY2VmNTYxYWM4L3RhYmxlOjJlNzliODk4OWMxMzRmZGI5YWZiYmUwNDdkMTk3OTEyL3RhYmxlcmFuZ2U6MmU3OWI4OTg5YzEzNGZkYjlhZmJiZTA0N2QxOTc5MTJfNC0xLTEtMS0w_629a7a37-a300-4cf1-81e3-e539a3107d0c"
      unitRef="usd">1057509000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i58cbbc0a79de4859b6344bf8949aeb85_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81Mi9mcmFnOmI5NWYyNjQxYWE2ZTQwMTU5MzFjODRlY2VmNTYxYWM4L3RhYmxlOjJlNzliODk4OWMxMzRmZGI5YWZiYmUwNDdkMTk3OTEyL3RhYmxlcmFuZ2U6MmU3OWI4OTg5YzEzNGZkYjlhZmJiZTA0N2QxOTc5MTJfNC0zLTEtMS0w_8662c04d-b68b-4350-ba22-4f69d57394d1"
      unitRef="usd">335000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i58cbbc0a79de4859b6344bf8949aeb85_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81Mi9mcmFnOmI5NWYyNjQxYWE2ZTQwMTU5MzFjODRlY2VmNTYxYWM4L3RhYmxlOjJlNzliODk4OWMxMzRmZGI5YWZiYmUwNDdkMTk3OTEyL3RhYmxlcmFuZ2U6MmU3OWI4OTg5YzEzNGZkYjlhZmJiZTA0N2QxOTc5MTJfNC01LTEtMS0w_95dae7c1-9b37-4035-934a-4366c8c953aa"
      unitRef="usd">17000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i58cbbc0a79de4859b6344bf8949aeb85_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81Mi9mcmFnOmI5NWYyNjQxYWE2ZTQwMTU5MzFjODRlY2VmNTYxYWM4L3RhYmxlOjJlNzliODk4OWMxMzRmZGI5YWZiYmUwNDdkMTk3OTEyL3RhYmxlcmFuZ2U6MmU3OWI4OTg5YzEzNGZkYjlhZmJiZTA0N2QxOTc5MTJfNC03LTEtMS0w_3f3a79ee-5367-41ac-a8ab-c4889a6c26b4"
      unitRef="usd">1057827000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="idd7204dc87d24972a01f15b098c4f56b_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81Mi9mcmFnOmI5NWYyNjQxYWE2ZTQwMTU5MzFjODRlY2VmNTYxYWM4L3RhYmxlOjJlNzliODk4OWMxMzRmZGI5YWZiYmUwNDdkMTk3OTEyL3RhYmxlcmFuZ2U6MmU3OWI4OTg5YzEzNGZkYjlhZmJiZTA0N2QxOTc5MTJfNS0xLTEtMS0w_fb1069f0-4d18-48d0-8e8f-2e3ec7ffd1aa"
      unitRef="usd">1272680000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="idd7204dc87d24972a01f15b098c4f56b_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81Mi9mcmFnOmI5NWYyNjQxYWE2ZTQwMTU5MzFjODRlY2VmNTYxYWM4L3RhYmxlOjJlNzliODk4OWMxMzRmZGI5YWZiYmUwNDdkMTk3OTEyL3RhYmxlcmFuZ2U6MmU3OWI4OTg5YzEzNGZkYjlhZmJiZTA0N2QxOTc5MTJfNS0zLTEtMS0w_0e5ad25b-d391-46e4-94db-b318ae6283d7"
      unitRef="usd">422000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="idd7204dc87d24972a01f15b098c4f56b_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81Mi9mcmFnOmI5NWYyNjQxYWE2ZTQwMTU5MzFjODRlY2VmNTYxYWM4L3RhYmxlOjJlNzliODk4OWMxMzRmZGI5YWZiYmUwNDdkMTk3OTEyL3RhYmxlcmFuZ2U6MmU3OWI4OTg5YzEzNGZkYjlhZmJiZTA0N2QxOTc5MTJfNS01LTEtMS0w_afdc5694-0736-4703-979c-ac720ef89b09"
      unitRef="usd">75000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="idd7204dc87d24972a01f15b098c4f56b_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81Mi9mcmFnOmI5NWYyNjQxYWE2ZTQwMTU5MzFjODRlY2VmNTYxYWM4L3RhYmxlOjJlNzliODk4OWMxMzRmZGI5YWZiYmUwNDdkMTk3OTEyL3RhYmxlcmFuZ2U6MmU3OWI4OTg5YzEzNGZkYjlhZmJiZTA0N2QxOTc5MTJfNS03LTEtMS0w_99ac8b54-7093-46c9-9daa-6f97ea8c822e"
      unitRef="usd">1273027000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ib30b025bf153422e892ecc638911a8fc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81Mi9mcmFnOmI5NWYyNjQxYWE2ZTQwMTU5MzFjODRlY2VmNTYxYWM4L3RhYmxlOjBlOGYyZjg0YmE4ODQzNjc4NWY1NjM0YzkzZDAxODlkL3RhYmxlcmFuZ2U6MGU4ZjJmODRiYTg4NDM2Nzg1ZjU2MzRjOTNkMDE4OWRfNS0xLTEtMS0w_6de9bf83-462b-4f2a-af5e-afc13d7cc1ab"
      unitRef="usd">245113000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ib30b025bf153422e892ecc638911a8fc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81Mi9mcmFnOmI5NWYyNjQxYWE2ZTQwMTU5MzFjODRlY2VmNTYxYWM4L3RhYmxlOjBlOGYyZjg0YmE4ODQzNjc4NWY1NjM0YzkzZDAxODlkL3RhYmxlcmFuZ2U6MGU4ZjJmODRiYTg4NDM2Nzg1ZjU2MzRjOTNkMDE4OWRfNS0zLTEtMS0w_e901387d-8679-4d61-b159-8929a8be28d1"
      unitRef="usd">135000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ib30b025bf153422e892ecc638911a8fc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81Mi9mcmFnOmI5NWYyNjQxYWE2ZTQwMTU5MzFjODRlY2VmNTYxYWM4L3RhYmxlOjBlOGYyZjg0YmE4ODQzNjc4NWY1NjM0YzkzZDAxODlkL3RhYmxlcmFuZ2U6MGU4ZjJmODRiYTg4NDM2Nzg1ZjU2MzRjOTNkMDE4OWRfNS01LTEtMS0w_e716df80-b1ca-4358-8242-1cb91800fbc3"
      unitRef="usd">34000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib30b025bf153422e892ecc638911a8fc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81Mi9mcmFnOmI5NWYyNjQxYWE2ZTQwMTU5MzFjODRlY2VmNTYxYWM4L3RhYmxlOjBlOGYyZjg0YmE4ODQzNjc4NWY1NjM0YzkzZDAxODlkL3RhYmxlcmFuZ2U6MGU4ZjJmODRiYTg4NDM2Nzg1ZjU2MzRjOTNkMDE4OWRfNS03LTEtMS0w_c77d8dee-081c-4e96-a3fe-c0ac073817d8"
      unitRef="usd">245214000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="iab2144e8f1994353ab908cc9c23d059a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81Mi9mcmFnOmI5NWYyNjQxYWE2ZTQwMTU5MzFjODRlY2VmNTYxYWM4L3RhYmxlOjBlOGYyZjg0YmE4ODQzNjc4NWY1NjM0YzkzZDAxODlkL3RhYmxlcmFuZ2U6MGU4ZjJmODRiYTg4NDM2Nzg1ZjU2MzRjOTNkMDE4OWRfNi0xLTEtMS0w_3c25c536-d87e-4682-966a-a5e9ad7ae4a7"
      unitRef="usd">1107721000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="iab2144e8f1994353ab908cc9c23d059a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81Mi9mcmFnOmI5NWYyNjQxYWE2ZTQwMTU5MzFjODRlY2VmNTYxYWM4L3RhYmxlOjBlOGYyZjg0YmE4ODQzNjc4NWY1NjM0YzkzZDAxODlkL3RhYmxlcmFuZ2U6MGU4ZjJmODRiYTg4NDM2Nzg1ZjU2MzRjOTNkMDE4OWRfNi0zLTEtMS0w_7367407d-3a17-416e-8e08-1129b69d1c3e"
      unitRef="usd">328000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="iab2144e8f1994353ab908cc9c23d059a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81Mi9mcmFnOmI5NWYyNjQxYWE2ZTQwMTU5MzFjODRlY2VmNTYxYWM4L3RhYmxlOjBlOGYyZjg0YmE4ODQzNjc4NWY1NjM0YzkzZDAxODlkL3RhYmxlcmFuZ2U6MGU4ZjJmODRiYTg4NDM2Nzg1ZjU2MzRjOTNkMDE4OWRfNi01LTEtMS0w_db5c4b23-154e-4e6e-b715-9245349d391b"
      unitRef="usd">81000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iab2144e8f1994353ab908cc9c23d059a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81Mi9mcmFnOmI5NWYyNjQxYWE2ZTQwMTU5MzFjODRlY2VmNTYxYWM4L3RhYmxlOjBlOGYyZjg0YmE4ODQzNjc4NWY1NjM0YzkzZDAxODlkL3RhYmxlcmFuZ2U6MGU4ZjJmODRiYTg4NDM2Nzg1ZjU2MzRjOTNkMDE4OWRfNi03LTEtMS0w_eeb124dc-9e0b-4171-a4f0-5e61cf6bb790"
      unitRef="usd">1107968000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="id365c5f1d37444ac9e1da5b5891cd81a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81Mi9mcmFnOmI5NWYyNjQxYWE2ZTQwMTU5MzFjODRlY2VmNTYxYWM4L3RhYmxlOjBlOGYyZjg0YmE4ODQzNjc4NWY1NjM0YzkzZDAxODlkL3RhYmxlcmFuZ2U6MGU4ZjJmODRiYTg4NDM2Nzg1ZjU2MzRjOTNkMDE4OWRfNy0xLTEtMS0w_c1913f0e-6025-4bd4-ac4c-8653bd278888"
      unitRef="usd">1352834000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="id365c5f1d37444ac9e1da5b5891cd81a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81Mi9mcmFnOmI5NWYyNjQxYWE2ZTQwMTU5MzFjODRlY2VmNTYxYWM4L3RhYmxlOjBlOGYyZjg0YmE4ODQzNjc4NWY1NjM0YzkzZDAxODlkL3RhYmxlcmFuZ2U6MGU4ZjJmODRiYTg4NDM2Nzg1ZjU2MzRjOTNkMDE4OWRfNy0zLTEtMS0w_c2ea4b2c-9978-4799-95f6-932a6dbc1599"
      unitRef="usd">463000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="id365c5f1d37444ac9e1da5b5891cd81a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81Mi9mcmFnOmI5NWYyNjQxYWE2ZTQwMTU5MzFjODRlY2VmNTYxYWM4L3RhYmxlOjBlOGYyZjg0YmE4ODQzNjc4NWY1NjM0YzkzZDAxODlkL3RhYmxlcmFuZ2U6MGU4ZjJmODRiYTg4NDM2Nzg1ZjU2MzRjOTNkMDE4OWRfNy01LTEtMS0w_8d1278f7-dee2-4dfd-9beb-081b08c2fd74"
      unitRef="usd">115000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id365c5f1d37444ac9e1da5b5891cd81a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81Mi9mcmFnOmI5NWYyNjQxYWE2ZTQwMTU5MzFjODRlY2VmNTYxYWM4L3RhYmxlOjBlOGYyZjg0YmE4ODQzNjc4NWY1NjM0YzkzZDAxODlkL3RhYmxlcmFuZ2U6MGU4ZjJmODRiYTg4NDM2Nzg1ZjU2MzRjOTNkMDE4OWRfNy03LTEtMS0w_3105bd47-4e87-4f8a-9d76-ccd43679e27e"
      unitRef="usd">1353182000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:FairValueByBalanceSheetGroupingTextBlock
      contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81Mi9mcmFnOmI5NWYyNjQxYWE2ZTQwMTU5MzFjODRlY2VmNTYxYWM4L3RleHRyZWdpb246Yjk1ZjI2NDFhYTZlNDAxNTkzMWM4NGVjZWY1NjFhYzhfNjQw_42722d7a-4e51-4518-bcdd-a6a5e019c918">&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The fair values of our marketable debt securities by classification in the condensed consolidated balance sheets were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.128%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.422%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,273,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,333,182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,273,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,353,182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueByBalanceSheetGroupingTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="idd7204dc87d24972a01f15b098c4f56b_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81Mi9mcmFnOmI5NWYyNjQxYWE2ZTQwMTU5MzFjODRlY2VmNTYxYWM4L3RhYmxlOmQ2OWQ0ZWE1ZWMwMjQzNjA5ODg5NTFjZjk4OGU3ODY3L3RhYmxlcmFuZ2U6ZDY5ZDRlYTVlYzAyNDM2MDk4ODk1MWNmOTg4ZTc4NjdfMS0xLTEtMS0w_6dd88d5b-1a04-4937-a821-44b1c8529699"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="id365c5f1d37444ac9e1da5b5891cd81a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81Mi9mcmFnOmI5NWYyNjQxYWE2ZTQwMTU5MzFjODRlY2VmNTYxYWM4L3RhYmxlOmQ2OWQ0ZWE1ZWMwMjQzNjA5ODg5NTFjZjk4OGU3ODY3L3RhYmxlcmFuZ2U6ZDY5ZDRlYTVlYzAyNDM2MDk4ODk1MWNmOTg4ZTc4NjdfMS0zLTEtMS0w_2503c607-8fcf-4660-8ea3-8a5c192c6f50"
      unitRef="usd">20000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="idd7204dc87d24972a01f15b098c4f56b_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81Mi9mcmFnOmI5NWYyNjQxYWE2ZTQwMTU5MzFjODRlY2VmNTYxYWM4L3RhYmxlOmQ2OWQ0ZWE1ZWMwMjQzNjA5ODg5NTFjZjk4OGU3ODY3L3RhYmxlcmFuZ2U6ZDY5ZDRlYTVlYzAyNDM2MDk4ODk1MWNmOTg4ZTc4NjdfMi0xLTEtMS0w_694da0b8-8f41-451e-9b49-39fec6d524c9"
      unitRef="usd">1273027000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="id365c5f1d37444ac9e1da5b5891cd81a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81Mi9mcmFnOmI5NWYyNjQxYWE2ZTQwMTU5MzFjODRlY2VmNTYxYWM4L3RhYmxlOmQ2OWQ0ZWE1ZWMwMjQzNjA5ODg5NTFjZjk4OGU3ODY3L3RhYmxlcmFuZ2U6ZDY5ZDRlYTVlYzAyNDM2MDk4ODk1MWNmOTg4ZTc4NjdfMi0zLTEtMS0w_7440f729-87e5-4e28-911f-9df9884a5076"
      unitRef="usd">1333182000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="idd7204dc87d24972a01f15b098c4f56b_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81Mi9mcmFnOmI5NWYyNjQxYWE2ZTQwMTU5MzFjODRlY2VmNTYxYWM4L3RhYmxlOmQ2OWQ0ZWE1ZWMwMjQzNjA5ODg5NTFjZjk4OGU3ODY3L3RhYmxlcmFuZ2U6ZDY5ZDRlYTVlYzAyNDM2MDk4ODk1MWNmOTg4ZTc4NjdfMy0xLTEtMS0w_e7795ae2-af0c-4b4d-8237-68b6cf1b2faf"
      unitRef="usd">1273027000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id365c5f1d37444ac9e1da5b5891cd81a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81Mi9mcmFnOmI5NWYyNjQxYWE2ZTQwMTU5MzFjODRlY2VmNTYxYWM4L3RhYmxlOmQ2OWQ0ZWE1ZWMwMjQzNjA5ODg5NTFjZjk4OGU3ODY3L3RhYmxlcmFuZ2U6ZDY5ZDRlYTVlYzAyNDM2MDk4ODk1MWNmOTg4ZTc4NjdfMy0zLTEtMS0w_886c84b4-957b-4a20-8fa2-89302ac71871"
      unitRef="usd">1353182000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock
      contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81NS9mcmFnOmJmMzFlNjM2ZGVmMTQxNGFhNDUwZmFiOTM5YWM3MDIwL3RleHRyZWdpb246YmYzMWU2MzZkZWYxNDE0YWE0NTBmYWI5MzlhYzcwMjBfMTE2Mg_e3ef3b47-ab4d-46e8-90c3-7136e5e057d7">OTHER BALANCE SHEET DETAILS&lt;div style="margin-top:6pt;text-align:justify;text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Inventory&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The components of inventory are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.128%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.422%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,694&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,753&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92,302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As of March&#160;31, 2021 and December&#160;31, 2020, we held $17.1 million of long- term inventory included within other assets in our condensed consolidated balance sheet as we anticipate it being consumed beyond our normal operating cycle.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Cash, Cash Equivalents and Restricted Cash&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within our condensed consolidated balance sheets that sum to the total of these amounts shown in the condensed consolidated statements of cash flows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.128%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.422%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;379,543&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;467,779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total restricted cash included in prepaid expenses, other current assets and long-term other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents, and restricted cash shown in the condensed consolidated statements of cash flows&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;382,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;470,393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Accumulated Other Comprehensive (Loss) Income&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following tables summarize the changes in accumulated other comprehensive loss, by component:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.256%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.157%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.234%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Loss on Investment in Joint Venture&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Defined Benefit Pension&lt;br/&gt;Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains (Losses) from Debt&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Foreign Currency Translation&lt;br/&gt;Adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total Accumulated Other&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Comprehensive Loss&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32,792)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,754)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,424)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(43,622)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive (loss) income before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amounts reclassified from other comprehensive income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32,792)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,696)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(576)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(36,717)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.256%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.157%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.234%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Loss on Investment in Joint Venture&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Defined Benefit Pension&lt;br/&gt;Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains from Debt&lt;br/&gt;Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Foreign Currency Translation&lt;br/&gt;Adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total Accumulated Other&lt;br/&gt;Comprehensive Loss&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32,792)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,520)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(343)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(36,518)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amounts reclassified from other comprehensive income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,802&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net other comprehensive income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,045&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32,792)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,446)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32,059)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts reclassified out of accumulated other comprehensive loss relate to settlements of marketable debt securities and amortization of our pension obligation which are recorded as interest income and other income, respectively, in the condensed consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81NS9mcmFnOmJmMzFlNjM2ZGVmMTQxNGFhNDUwZmFiOTM5YWM3MDIwL3RleHRyZWdpb246YmYzMWU2MzZkZWYxNDE0YWE0NTBmYWI5MzlhYzcwMjBfMTE2Mw_4fe346ce-5d9b-4323-b3e9-2941fed6fa76">&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The components of inventory are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.128%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.422%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,694&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,753&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92,302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterials
      contextRef="idd7204dc87d24972a01f15b098c4f56b_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81NS9mcmFnOmJmMzFlNjM2ZGVmMTQxNGFhNDUwZmFiOTM5YWM3MDIwL3RhYmxlOmU2NGE3MmFmZjdkMzRiNjRhYTkwZTQxOGFjM2Y1NzFmL3RhYmxlcmFuZ2U6ZTY0YTcyYWZmN2QzNGI2NGFhOTBlNDE4YWMzZjU3MWZfMS0xLTEtMS0w_baa57563-4e69-44af-b441-f06674694803"
      unitRef="usd">53694000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryRawMaterials
      contextRef="id365c5f1d37444ac9e1da5b5891cd81a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81NS9mcmFnOmJmMzFlNjM2ZGVmMTQxNGFhNDUwZmFiOTM5YWM3MDIwL3RhYmxlOmU2NGE3MmFmZjdkMzRiNjRhYTkwZTQxOGFjM2Y1NzFmL3RhYmxlcmFuZ2U6ZTY0YTcyYWZmN2QzNGI2NGFhOTBlNDE4YWMzZjU3MWZfMS0zLTEtMS0w_1016f75a-227f-49e4-9d61-5a85c5c91d2b"
      unitRef="usd">63460000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryWorkInProcess
      contextRef="idd7204dc87d24972a01f15b098c4f56b_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81NS9mcmFnOmJmMzFlNjM2ZGVmMTQxNGFhNDUwZmFiOTM5YWM3MDIwL3RhYmxlOmU2NGE3MmFmZjdkMzRiNjRhYTkwZTQxOGFjM2Y1NzFmL3RhYmxlcmFuZ2U6ZTY0YTcyYWZmN2QzNGI2NGFhOTBlNDE4YWMzZjU3MWZfMi0xLTEtMS0w_b1a7cd8f-41d9-4783-ad4c-95d75c92519e"
      unitRef="usd">23593000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryWorkInProcess
      contextRef="id365c5f1d37444ac9e1da5b5891cd81a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81NS9mcmFnOmJmMzFlNjM2ZGVmMTQxNGFhNDUwZmFiOTM5YWM3MDIwL3RhYmxlOmU2NGE3MmFmZjdkMzRiNjRhYTkwZTQxOGFjM2Y1NzFmL3RhYmxlcmFuZ2U6ZTY0YTcyYWZmN2QzNGI2NGFhOTBlNDE4YWMzZjU3MWZfMi0zLTEtMS0w_562e294c-99e7-4e1b-91fd-86913dcca4d8"
      unitRef="usd">16149000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryFinishedGoods
      contextRef="idd7204dc87d24972a01f15b098c4f56b_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81NS9mcmFnOmJmMzFlNjM2ZGVmMTQxNGFhNDUwZmFiOTM5YWM3MDIwL3RhYmxlOmU2NGE3MmFmZjdkMzRiNjRhYTkwZTQxOGFjM2Y1NzFmL3RhYmxlcmFuZ2U6ZTY0YTcyYWZmN2QzNGI2NGFhOTBlNDE4YWMzZjU3MWZfMy0xLTEtMS0w_6a89cac5-0798-4207-b80e-a30f154c308f"
      unitRef="usd">13753000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods
      contextRef="id365c5f1d37444ac9e1da5b5891cd81a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81NS9mcmFnOmJmMzFlNjM2ZGVmMTQxNGFhNDUwZmFiOTM5YWM3MDIwL3RhYmxlOmU2NGE3MmFmZjdkMzRiNjRhYTkwZTQxOGFjM2Y1NzFmL3RhYmxlcmFuZ2U6ZTY0YTcyYWZmN2QzNGI2NGFhOTBlNDE4YWMzZjU3MWZfMy0zLTEtMS0w_48e61539-9dc6-4e87-a827-729656d71101"
      unitRef="usd">12693000</us-gaap:InventoryFinishedGoods>
    <alny:InventoryCurrentAndNoncurrent
      contextRef="idd7204dc87d24972a01f15b098c4f56b_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81NS9mcmFnOmJmMzFlNjM2ZGVmMTQxNGFhNDUwZmFiOTM5YWM3MDIwL3RhYmxlOmU2NGE3MmFmZjdkMzRiNjRhYTkwZTQxOGFjM2Y1NzFmL3RhYmxlcmFuZ2U6ZTY0YTcyYWZmN2QzNGI2NGFhOTBlNDE4YWMzZjU3MWZfNC0xLTEtMS0w_7c8c6e70-df39-4809-9171-c10c82d1e36b"
      unitRef="usd">91040000</alny:InventoryCurrentAndNoncurrent>
    <alny:InventoryCurrentAndNoncurrent
      contextRef="id365c5f1d37444ac9e1da5b5891cd81a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81NS9mcmFnOmJmMzFlNjM2ZGVmMTQxNGFhNDUwZmFiOTM5YWM3MDIwL3RhYmxlOmU2NGE3MmFmZjdkMzRiNjRhYTkwZTQxOGFjM2Y1NzFmL3RhYmxlcmFuZ2U6ZTY0YTcyYWZmN2QzNGI2NGFhOTBlNDE4YWMzZjU3MWZfNC0zLTEtMS0w_cd0fcbaa-1563-46d0-b550-8ea93e5b88c8"
      unitRef="usd">92302000</alny:InventoryCurrentAndNoncurrent>
    <us-gaap:InventoryNoncurrent
      contextRef="i3ed44ddacf3f45e2bc4858376f339d6b_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81NS9mcmFnOmJmMzFlNjM2ZGVmMTQxNGFhNDUwZmFiOTM5YWM3MDIwL3RleHRyZWdpb246YmYzMWU2MzZkZWYxNDE0YWE0NTBmYWI5MzlhYzcwMjBfMTA5OTUxMTYyOTg4Mg_ddeaf93c-29fb-4933-8e87-157d82d5b909"
      unitRef="usd">17100000</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNoncurrent
      contextRef="i4ef95a791e56443b9b1182d6253d4e4c_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81NS9mcmFnOmJmMzFlNjM2ZGVmMTQxNGFhNDUwZmFiOTM5YWM3MDIwL3RleHRyZWdpb246YmYzMWU2MzZkZWYxNDE0YWE0NTBmYWI5MzlhYzcwMjBfMTA5OTUxMTYyOTg4Mg_ef1c4727-a30f-457e-9f3c-242509f999be"
      unitRef="usd">17100000</us-gaap:InventoryNoncurrent>
    <alny:ScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTableTextBlock
      contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81NS9mcmFnOmJmMzFlNjM2ZGVmMTQxNGFhNDUwZmFiOTM5YWM3MDIwL3RleHRyZWdpb246YmYzMWU2MzZkZWYxNDE0YWE0NTBmYWI5MzlhYzcwMjBfMTE2NA_4b3d37b6-6b46-4583-98a7-6d6f9bab7ee3">&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within our condensed consolidated balance sheets that sum to the total of these amounts shown in the condensed consolidated statements of cash flows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.128%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.422%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;379,543&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;467,779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total restricted cash included in prepaid expenses, other current assets and long-term other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents, and restricted cash shown in the condensed consolidated statements of cash flows&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;382,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;470,393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</alny:ScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTableTextBlock>
    <alny:ScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTableTextBlock
      contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81NS9mcmFnOmJmMzFlNjM2ZGVmMTQxNGFhNDUwZmFiOTM5YWM3MDIwL3RleHRyZWdpb246YmYzMWU2MzZkZWYxNDE0YWE0NTBmYWI5MzlhYzcwMjBfMTE2NQ_16d41105-867e-40c8-8faf-074f80526c3a">&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within our condensed consolidated balance sheets that sum to the total of these amounts shown in the condensed consolidated statements of cash flows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.128%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.422%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;379,543&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;467,779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total restricted cash included in prepaid expenses, other current assets and long-term other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents, and restricted cash shown in the condensed consolidated statements of cash flows&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;382,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;470,393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</alny:ScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="idd7204dc87d24972a01f15b098c4f56b_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81NS9mcmFnOmJmMzFlNjM2ZGVmMTQxNGFhNDUwZmFiOTM5YWM3MDIwL3RhYmxlOjJiZjEzYzA5OTAzODQzMjBhNTlkY2ExNDUwYWY5Njk3L3RhYmxlcmFuZ2U6MmJmMTNjMDk5MDM4NDMyMGE1OWRjYTE0NTBhZjk2OTdfMi0xLTEtMS0w_48c5533c-26d1-4b30-a094-046b917cff87"
      unitRef="usd">379543000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ic378e7f6183c40b4b7371ed7b7370867_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81NS9mcmFnOmJmMzFlNjM2ZGVmMTQxNGFhNDUwZmFiOTM5YWM3MDIwL3RhYmxlOjJiZjEzYzA5OTAzODQzMjBhNTlkY2ExNDUwYWY5Njk3L3RhYmxlcmFuZ2U6MmJmMTNjMDk5MDM4NDMyMGE1OWRjYTE0NTBhZjk2OTdfMi0zLTEtMS0w_8a23d715-fd56-424b-b436-a9f09d12f887"
      unitRef="usd">467779000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCash
      contextRef="idd7204dc87d24972a01f15b098c4f56b_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81NS9mcmFnOmJmMzFlNjM2ZGVmMTQxNGFhNDUwZmFiOTM5YWM3MDIwL3RhYmxlOjJiZjEzYzA5OTAzODQzMjBhNTlkY2ExNDUwYWY5Njk3L3RhYmxlcmFuZ2U6MmJmMTNjMDk5MDM4NDMyMGE1OWRjYTE0NTBhZjk2OTdfMy0xLTEtMS0w_14624978-c0e6-4c1b-b23f-f6d034bb1bde"
      unitRef="usd">2462000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="ic378e7f6183c40b4b7371ed7b7370867_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81NS9mcmFnOmJmMzFlNjM2ZGVmMTQxNGFhNDUwZmFiOTM5YWM3MDIwL3RhYmxlOjJiZjEzYzA5OTAzODQzMjBhNTlkY2ExNDUwYWY5Njk3L3RhYmxlcmFuZ2U6MmJmMTNjMDk5MDM4NDMyMGE1OWRjYTE0NTBhZjk2OTdfMy0zLTEtMS0w_200374a6-8e0d-415b-aaa5-d4cf7a815cfb"
      unitRef="usd">2614000</us-gaap:RestrictedCash>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="idd7204dc87d24972a01f15b098c4f56b_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81NS9mcmFnOmJmMzFlNjM2ZGVmMTQxNGFhNDUwZmFiOTM5YWM3MDIwL3RhYmxlOjJiZjEzYzA5OTAzODQzMjBhNTlkY2ExNDUwYWY5Njk3L3RhYmxlcmFuZ2U6MmJmMTNjMDk5MDM4NDMyMGE1OWRjYTE0NTBhZjk2OTdfNS0xLTEtMS0w_b931ce9e-9fc3-4c78-be1a-c51c57fd0671"
      unitRef="usd">382005000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="ic378e7f6183c40b4b7371ed7b7370867_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81NS9mcmFnOmJmMzFlNjM2ZGVmMTQxNGFhNDUwZmFiOTM5YWM3MDIwL3RhYmxlOjJiZjEzYzA5OTAzODQzMjBhNTlkY2ExNDUwYWY5Njk3L3RhYmxlcmFuZ2U6MmJmMTNjMDk5MDM4NDMyMGE1OWRjYTE0NTBhZjk2OTdfNS0zLTEtMS0w_7709aa08-61bc-4780-afe0-4cf716c109ee"
      unitRef="usd">470393000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock
      contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81NS9mcmFnOmJmMzFlNjM2ZGVmMTQxNGFhNDUwZmFiOTM5YWM3MDIwL3RleHRyZWdpb246YmYzMWU2MzZkZWYxNDE0YWE0NTBmYWI5MzlhYzcwMjBfMTE2Ng_1ab168e9-2b3c-4f91-9622-c45fd5597e27">&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following tables summarize the changes in accumulated other comprehensive loss, by component:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.256%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.157%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.234%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Loss on Investment in Joint Venture&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Defined Benefit Pension&lt;br/&gt;Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains (Losses) from Debt&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Foreign Currency Translation&lt;br/&gt;Adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total Accumulated Other&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Comprehensive Loss&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32,792)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,754)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,424)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(43,622)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive (loss) income before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amounts reclassified from other comprehensive income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32,792)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,696)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(576)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(36,717)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.256%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.157%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.234%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Loss on Investment in Joint Venture&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Defined Benefit Pension&lt;br/&gt;Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains from Debt&lt;br/&gt;Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Foreign Currency Translation&lt;br/&gt;Adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total Accumulated Other&lt;br/&gt;Comprehensive Loss&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32,792)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,520)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(343)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(36,518)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amounts reclassified from other comprehensive income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,802&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net other comprehensive income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,045&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32,792)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,446)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32,059)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:StockholdersEquity
      contextRef="ida1aa88277834c4aa06d4523f3777c2d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81NS9mcmFnOmJmMzFlNjM2ZGVmMTQxNGFhNDUwZmFiOTM5YWM3MDIwL3RhYmxlOjBmYTZiZWYxMWQ3NDQ1MWVhZDQ5ZGUyZWM1ZWIyMWY2L3RhYmxlcmFuZ2U6MGZhNmJlZjExZDc0NDUxZWFkNDlkZTJlYzVlYjIxZjZfMS0xLTEtMS0w_66f8181a-a4aa-4e45-bc46-a527a3818107"
      unitRef="usd">-32792000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8ed22d63570b49f888c7e1fdb4cba720_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81NS9mcmFnOmJmMzFlNjM2ZGVmMTQxNGFhNDUwZmFiOTM5YWM3MDIwL3RhYmxlOjBmYTZiZWYxMWQ3NDQ1MWVhZDQ5ZGUyZWM1ZWIyMWY2L3RhYmxlcmFuZ2U6MGZhNmJlZjExZDc0NDUxZWFkNDlkZTJlYzVlYjIxZjZfMS0zLTEtMS0w_acbcffae-51bc-429a-bec5-19ef7bb66932"
      unitRef="usd">-3754000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iba4e611a80aa4214b1a15ed34d5a650a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81NS9mcmFnOmJmMzFlNjM2ZGVmMTQxNGFhNDUwZmFiOTM5YWM3MDIwL3RhYmxlOjBmYTZiZWYxMWQ3NDQ1MWVhZDQ5ZGUyZWM1ZWIyMWY2L3RhYmxlcmFuZ2U6MGZhNmJlZjExZDc0NDUxZWFkNDlkZTJlYzVlYjIxZjZfMS01LTEtMS0w_33ded154-bbf2-4c07-87a7-71a8afbf8c93"
      unitRef="usd">348000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if39d09cfa6ef470198658625bf6c69f0_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81NS9mcmFnOmJmMzFlNjM2ZGVmMTQxNGFhNDUwZmFiOTM5YWM3MDIwL3RhYmxlOjBmYTZiZWYxMWQ3NDQ1MWVhZDQ5ZGUyZWM1ZWIyMWY2L3RhYmxlcmFuZ2U6MGZhNmJlZjExZDc0NDUxZWFkNDlkZTJlYzVlYjIxZjZfMS03LTEtMS0w_bb6adb0a-ffe5-4126-a715-1bb28423ac5f"
      unitRef="usd">-7424000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie217873afb06447795dc36a1e1606a74_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81NS9mcmFnOmJmMzFlNjM2ZGVmMTQxNGFhNDUwZmFiOTM5YWM3MDIwL3RhYmxlOjBmYTZiZWYxMWQ3NDQ1MWVhZDQ5ZGUyZWM1ZWIyMWY2L3RhYmxlcmFuZ2U6MGZhNmJlZjExZDc0NDUxZWFkNDlkZTJlYzVlYjIxZjZfMS05LTEtMS0w_265bbf0d-ebe2-4d8f-bb1c-67e1d65ec441"
      unitRef="usd">-43622000</us-gaap:StockholdersEquity>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i088faa415d1b4a52be51abef4f75bc5c_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81NS9mcmFnOmJmMzFlNjM2ZGVmMTQxNGFhNDUwZmFiOTM5YWM3MDIwL3RhYmxlOjBmYTZiZWYxMWQ3NDQ1MWVhZDQ5ZGUyZWM1ZWIyMWY2L3RhYmxlcmFuZ2U6MGZhNmJlZjExZDc0NDUxZWFkNDlkZTJlYzVlYjIxZjZfMi0xLTEtMS0w_3a8b2439-45c4-48ac-aa46-ee75c24fd557"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i41887b4841f2496cb04e4f1ed9bd84bf_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81NS9mcmFnOmJmMzFlNjM2ZGVmMTQxNGFhNDUwZmFiOTM5YWM3MDIwL3RhYmxlOjBmYTZiZWYxMWQ3NDQ1MWVhZDQ5ZGUyZWM1ZWIyMWY2L3RhYmxlcmFuZ2U6MGZhNmJlZjExZDc0NDUxZWFkNDlkZTJlYzVlYjIxZjZfMi0zLTEtMS0w_b83b5546-9bce-4069-a34c-44a3b7d8afbe"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i700594dde5154e6abd7676e0bf8a2e3e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81NS9mcmFnOmJmMzFlNjM2ZGVmMTQxNGFhNDUwZmFiOTM5YWM3MDIwL3RhYmxlOjBmYTZiZWYxMWQ3NDQ1MWVhZDQ5ZGUyZWM1ZWIyMWY2L3RhYmxlcmFuZ2U6MGZhNmJlZjExZDc0NDUxZWFkNDlkZTJlYzVlYjIxZjZfMi01LTEtMS0w_e2fa8c4c-dd90-43e7-b316-7d6e5d8c1223"
      unitRef="usd">-1000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i4e5a33a85da249f89d6d9b5939bed9ea_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81NS9mcmFnOmJmMzFlNjM2ZGVmMTQxNGFhNDUwZmFiOTM5YWM3MDIwL3RhYmxlOjBmYTZiZWYxMWQ3NDQ1MWVhZDQ5ZGUyZWM1ZWIyMWY2L3RhYmxlcmFuZ2U6MGZhNmJlZjExZDc0NDUxZWFkNDlkZTJlYzVlYjIxZjZfMi03LTEtMS0w_17c323fe-2a44-4dd5-b5da-a2f01650196b"
      unitRef="usd">6848000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81NS9mcmFnOmJmMzFlNjM2ZGVmMTQxNGFhNDUwZmFiOTM5YWM3MDIwL3RhYmxlOjBmYTZiZWYxMWQ3NDQ1MWVhZDQ5ZGUyZWM1ZWIyMWY2L3RhYmxlcmFuZ2U6MGZhNmJlZjExZDc0NDUxZWFkNDlkZTJlYzVlYjIxZjZfMi05LTEtMS0w_917f39ee-569e-487a-a13b-3c2a92d879a3"
      unitRef="usd">6847000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i088faa415d1b4a52be51abef4f75bc5c_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81NS9mcmFnOmJmMzFlNjM2ZGVmMTQxNGFhNDUwZmFiOTM5YWM3MDIwL3RhYmxlOjBmYTZiZWYxMWQ3NDQ1MWVhZDQ5ZGUyZWM1ZWIyMWY2L3RhYmxlcmFuZ2U6MGZhNmJlZjExZDc0NDUxZWFkNDlkZTJlYzVlYjIxZjZfMy0xLTEtMS0w_a54bbe9f-7f5e-4877-9c28-e00cc680c7be"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i41887b4841f2496cb04e4f1ed9bd84bf_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81NS9mcmFnOmJmMzFlNjM2ZGVmMTQxNGFhNDUwZmFiOTM5YWM3MDIwL3RhYmxlOjBmYTZiZWYxMWQ3NDQ1MWVhZDQ5ZGUyZWM1ZWIyMWY2L3RhYmxlcmFuZ2U6MGZhNmJlZjExZDc0NDUxZWFkNDlkZTJlYzVlYjIxZjZfMy0zLTEtMS0w_b7c79310-3d2d-47d6-a8c7-48f50b9c627f"
      unitRef="usd">-58000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i700594dde5154e6abd7676e0bf8a2e3e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81NS9mcmFnOmJmMzFlNjM2ZGVmMTQxNGFhNDUwZmFiOTM5YWM3MDIwL3RhYmxlOjBmYTZiZWYxMWQ3NDQ1MWVhZDQ5ZGUyZWM1ZWIyMWY2L3RhYmxlcmFuZ2U6MGZhNmJlZjExZDc0NDUxZWFkNDlkZTJlYzVlYjIxZjZfMy01LTEtMS0w_6ab9349e-5818-475a-9a87-a160557d5d97"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i4e5a33a85da249f89d6d9b5939bed9ea_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81NS9mcmFnOmJmMzFlNjM2ZGVmMTQxNGFhNDUwZmFiOTM5YWM3MDIwL3RhYmxlOjBmYTZiZWYxMWQ3NDQ1MWVhZDQ5ZGUyZWM1ZWIyMWY2L3RhYmxlcmFuZ2U6MGZhNmJlZjExZDc0NDUxZWFkNDlkZTJlYzVlYjIxZjZfMy03LTEtMS0w_ae60c6d8-ea00-40f6-9633-e31d173d6682"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81NS9mcmFnOmJmMzFlNjM2ZGVmMTQxNGFhNDUwZmFiOTM5YWM3MDIwL3RhYmxlOjBmYTZiZWYxMWQ3NDQ1MWVhZDQ5ZGUyZWM1ZWIyMWY2L3RhYmxlcmFuZ2U6MGZhNmJlZjExZDc0NDUxZWFkNDlkZTJlYzVlYjIxZjZfMy05LTEtMS0w_64276716-d48c-47b7-89d5-6eaef41aa890"
      unitRef="usd">-58000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i088faa415d1b4a52be51abef4f75bc5c_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81NS9mcmFnOmJmMzFlNjM2ZGVmMTQxNGFhNDUwZmFiOTM5YWM3MDIwL3RhYmxlOjBmYTZiZWYxMWQ3NDQ1MWVhZDQ5ZGUyZWM1ZWIyMWY2L3RhYmxlcmFuZ2U6MGZhNmJlZjExZDc0NDUxZWFkNDlkZTJlYzVlYjIxZjZfNC0xLTEtMS0w_013dd7f2-9947-486d-9be1-9d4ea7c933ca"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i41887b4841f2496cb04e4f1ed9bd84bf_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81NS9mcmFnOmJmMzFlNjM2ZGVmMTQxNGFhNDUwZmFiOTM5YWM3MDIwL3RhYmxlOjBmYTZiZWYxMWQ3NDQ1MWVhZDQ5ZGUyZWM1ZWIyMWY2L3RhYmxlcmFuZ2U6MGZhNmJlZjExZDc0NDUxZWFkNDlkZTJlYzVlYjIxZjZfNC0zLTEtMS0w_aafe4a54-c5bf-44bd-a665-cf3c3ee9f67f"
      unitRef="usd">58000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i700594dde5154e6abd7676e0bf8a2e3e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81NS9mcmFnOmJmMzFlNjM2ZGVmMTQxNGFhNDUwZmFiOTM5YWM3MDIwL3RhYmxlOjBmYTZiZWYxMWQ3NDQ1MWVhZDQ5ZGUyZWM1ZWIyMWY2L3RhYmxlcmFuZ2U6MGZhNmJlZjExZDc0NDUxZWFkNDlkZTJlYzVlYjIxZjZfNC01LTEtMS0w_6d7d72cd-d7fa-401f-8a27-6da2d99d6e9e"
      unitRef="usd">-1000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i4e5a33a85da249f89d6d9b5939bed9ea_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81NS9mcmFnOmJmMzFlNjM2ZGVmMTQxNGFhNDUwZmFiOTM5YWM3MDIwL3RhYmxlOjBmYTZiZWYxMWQ3NDQ1MWVhZDQ5ZGUyZWM1ZWIyMWY2L3RhYmxlcmFuZ2U6MGZhNmJlZjExZDc0NDUxZWFkNDlkZTJlYzVlYjIxZjZfNC03LTEtMS0w_6cbdc3ca-9eca-405a-b91c-f8a0ffb23f49"
      unitRef="usd">6848000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81NS9mcmFnOmJmMzFlNjM2ZGVmMTQxNGFhNDUwZmFiOTM5YWM3MDIwL3RhYmxlOjBmYTZiZWYxMWQ3NDQ1MWVhZDQ5ZGUyZWM1ZWIyMWY2L3RhYmxlcmFuZ2U6MGZhNmJlZjExZDc0NDUxZWFkNDlkZTJlYzVlYjIxZjZfNC05LTEtMS0w_9ec8dd97-5103-4985-a3a5-274ffdc0962a"
      unitRef="usd">6905000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="i6a94dbeff4054c1a9f6ebaadd2bdf963_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81NS9mcmFnOmJmMzFlNjM2ZGVmMTQxNGFhNDUwZmFiOTM5YWM3MDIwL3RhYmxlOjBmYTZiZWYxMWQ3NDQ1MWVhZDQ5ZGUyZWM1ZWIyMWY2L3RhYmxlcmFuZ2U6MGZhNmJlZjExZDc0NDUxZWFkNDlkZTJlYzVlYjIxZjZfNS0xLTEtMS0w_68029368-11cc-4943-83a7-c65c4b4c6db2"
      unitRef="usd">-32792000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i867716826176427d9f8a787730df0336_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81NS9mcmFnOmJmMzFlNjM2ZGVmMTQxNGFhNDUwZmFiOTM5YWM3MDIwL3RhYmxlOjBmYTZiZWYxMWQ3NDQ1MWVhZDQ5ZGUyZWM1ZWIyMWY2L3RhYmxlcmFuZ2U6MGZhNmJlZjExZDc0NDUxZWFkNDlkZTJlYzVlYjIxZjZfNS0zLTEtMS0w_7e9e9ee8-7618-45b4-9993-5e7a53e4c9c4"
      unitRef="usd">-3696000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i1502b1c4289f4259906b093e10b187bc_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81NS9mcmFnOmJmMzFlNjM2ZGVmMTQxNGFhNDUwZmFiOTM5YWM3MDIwL3RhYmxlOjBmYTZiZWYxMWQ3NDQ1MWVhZDQ5ZGUyZWM1ZWIyMWY2L3RhYmxlcmFuZ2U6MGZhNmJlZjExZDc0NDUxZWFkNDlkZTJlYzVlYjIxZjZfNS01LTEtMS0w_ffa082d8-0dd4-4ea1-870a-4b050ae82870"
      unitRef="usd">347000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i67bb7cc00cd44487b367ee4e7e37c13a_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81NS9mcmFnOmJmMzFlNjM2ZGVmMTQxNGFhNDUwZmFiOTM5YWM3MDIwL3RhYmxlOjBmYTZiZWYxMWQ3NDQ1MWVhZDQ5ZGUyZWM1ZWIyMWY2L3RhYmxlcmFuZ2U6MGZhNmJlZjExZDc0NDUxZWFkNDlkZTJlYzVlYjIxZjZfNS03LTEtMS0w_5cd061f3-1d1c-46f4-87a1-1cb167c50529"
      unitRef="usd">-576000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic1a5c9f95c104828afb8e8cfafe56963_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81NS9mcmFnOmJmMzFlNjM2ZGVmMTQxNGFhNDUwZmFiOTM5YWM3MDIwL3RhYmxlOjBmYTZiZWYxMWQ3NDQ1MWVhZDQ5ZGUyZWM1ZWIyMWY2L3RhYmxlcmFuZ2U6MGZhNmJlZjExZDc0NDUxZWFkNDlkZTJlYzVlYjIxZjZfNS05LTEtMS0w_796264bd-2bc8-44b8-8446-34130538ec4f"
      unitRef="usd">-36717000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i05cc6e61b17647308bdf6e55c772bfb8_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81NS9mcmFnOmJmMzFlNjM2ZGVmMTQxNGFhNDUwZmFiOTM5YWM3MDIwL3RhYmxlOmUxMmEzOTY2NWMwYzQzNTU4OWIxODkxNmZiZTk2ZTkyL3RhYmxlcmFuZ2U6ZTEyYTM5NjY1YzBjNDM1NTg5YjE4OTE2ZmJlOTZlOTJfMS0xLTEtMS0w_d8b8df21-92e7-46d9-a1bb-72a3db02c50d"
      unitRef="usd">-32792000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i44ce780df6884d729dccbf45747996b9_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81NS9mcmFnOmJmMzFlNjM2ZGVmMTQxNGFhNDUwZmFiOTM5YWM3MDIwL3RhYmxlOmUxMmEzOTY2NWMwYzQzNTU4OWIxODkxNmZiZTk2ZTkyL3RhYmxlcmFuZ2U6ZTEyYTM5NjY1YzBjNDM1NTg5YjE4OTE2ZmJlOTZlOTJfMS0zLTEtMS0w_0fb4b2dd-e0f0-4a3c-9eee-e2a794511b7a"
      unitRef="usd">-3520000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3242f9b2e5e34d0cbb1a6439a9c3f8bc_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81NS9mcmFnOmJmMzFlNjM2ZGVmMTQxNGFhNDUwZmFiOTM5YWM3MDIwL3RhYmxlOmUxMmEzOTY2NWMwYzQzNTU4OWIxODkxNmZiZTk2ZTkyL3RhYmxlcmFuZ2U6ZTEyYTM5NjY1YzBjNDM1NTg5YjE4OTE2ZmJlOTZlOTJfMS01LTEtMS0w_e57c6fb9-201e-4bc8-a772-91d7937a61c2"
      unitRef="usd">137000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iae0f5f6b01c54e3dab00225a8834ae5d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81NS9mcmFnOmJmMzFlNjM2ZGVmMTQxNGFhNDUwZmFiOTM5YWM3MDIwL3RhYmxlOmUxMmEzOTY2NWMwYzQzNTU4OWIxODkxNmZiZTk2ZTkyL3RhYmxlcmFuZ2U6ZTEyYTM5NjY1YzBjNDM1NTg5YjE4OTE2ZmJlOTZlOTJfMS03LTEtMS0w_069a1a4a-df9c-46d7-b8a2-f2f693856b37"
      unitRef="usd">-343000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if6294416a69f4b6daebcdebf72f5c179_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81NS9mcmFnOmJmMzFlNjM2ZGVmMTQxNGFhNDUwZmFiOTM5YWM3MDIwL3RhYmxlOmUxMmEzOTY2NWMwYzQzNTU4OWIxODkxNmZiZTk2ZTkyL3RhYmxlcmFuZ2U6ZTEyYTM5NjY1YzBjNDM1NTg5YjE4OTE2ZmJlOTZlOTJfMS05LTEtMS0w_78188b93-2c31-4140-9d46-2fa7d85b2cf9"
      unitRef="usd">-36518000</us-gaap:StockholdersEquity>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i45667cf06d374f0f8d2c6a08350e2740_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81NS9mcmFnOmJmMzFlNjM2ZGVmMTQxNGFhNDUwZmFiOTM5YWM3MDIwL3RhYmxlOmUxMmEzOTY2NWMwYzQzNTU4OWIxODkxNmZiZTk2ZTkyL3RhYmxlcmFuZ2U6ZTEyYTM5NjY1YzBjNDM1NTg5YjE4OTE2ZmJlOTZlOTJfMi0xLTEtMS0w_f8a20f55-c5fd-4682-95a7-0f1f6afe80c4"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="iace4f6c1fa9543cd8b55cb7840648649_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81NS9mcmFnOmJmMzFlNjM2ZGVmMTQxNGFhNDUwZmFiOTM5YWM3MDIwL3RhYmxlOmUxMmEzOTY2NWMwYzQzNTU4OWIxODkxNmZiZTk2ZTkyL3RhYmxlcmFuZ2U6ZTEyYTM5NjY1YzBjNDM1NTg5YjE4OTE2ZmJlOTZlOTJfMi0zLTEtMS0w_f7ac69ba-82fc-4d18-98cf-6286b57781d8"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i8748a9e750264dbeb3452686c17d0b3f_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81NS9mcmFnOmJmMzFlNjM2ZGVmMTQxNGFhNDUwZmFiOTM5YWM3MDIwL3RhYmxlOmUxMmEzOTY2NWMwYzQzNTU4OWIxODkxNmZiZTk2ZTkyL3RhYmxlcmFuZ2U6ZTEyYTM5NjY1YzBjNDM1NTg5YjE4OTE2ZmJlOTZlOTJfMi01LTEtMS0w_8667ac4d-8821-43b3-a1ae-5122ecdb98f2"
      unitRef="usd">1317000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i5a4a416c9f8b4fac9455e693cd9e2710_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81NS9mcmFnOmJmMzFlNjM2ZGVmMTQxNGFhNDUwZmFiOTM5YWM3MDIwL3RhYmxlOmUxMmEzOTY2NWMwYzQzNTU4OWIxODkxNmZiZTk2ZTkyL3RhYmxlcmFuZ2U6ZTEyYTM5NjY1YzBjNDM1NTg5YjE4OTE2ZmJlOTZlOTJfMi03LTEtMS0w_33bd18b4-b184-4079-af79-b3388b567fa2"
      unitRef="usd">340000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="ide9f6e15665746279d0000be700fcc6a_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81NS9mcmFnOmJmMzFlNjM2ZGVmMTQxNGFhNDUwZmFiOTM5YWM3MDIwL3RhYmxlOmUxMmEzOTY2NWMwYzQzNTU4OWIxODkxNmZiZTk2ZTkyL3RhYmxlcmFuZ2U6ZTEyYTM5NjY1YzBjNDM1NTg5YjE4OTE2ZmJlOTZlOTJfMi05LTEtMS0w_0653d85b-3815-44ad-957d-e8d30cea38f7"
      unitRef="usd">1657000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i45667cf06d374f0f8d2c6a08350e2740_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81NS9mcmFnOmJmMzFlNjM2ZGVmMTQxNGFhNDUwZmFiOTM5YWM3MDIwL3RhYmxlOmUxMmEzOTY2NWMwYzQzNTU4OWIxODkxNmZiZTk2ZTkyL3RhYmxlcmFuZ2U6ZTEyYTM5NjY1YzBjNDM1NTg5YjE4OTE2ZmJlOTZlOTJfMy0xLTEtMS0w_13fba60a-edf0-48ff-9417-f483e90a1c27"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="iace4f6c1fa9543cd8b55cb7840648649_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81NS9mcmFnOmJmMzFlNjM2ZGVmMTQxNGFhNDUwZmFiOTM5YWM3MDIwL3RhYmxlOmUxMmEzOTY2NWMwYzQzNTU4OWIxODkxNmZiZTk2ZTkyL3RhYmxlcmFuZ2U6ZTEyYTM5NjY1YzBjNDM1NTg5YjE4OTE2ZmJlOTZlOTJfMy0zLTEtMS0w_853911ed-a7e6-4f64-9c09-212765e0a3c1"
      unitRef="usd">-74000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i8748a9e750264dbeb3452686c17d0b3f_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81NS9mcmFnOmJmMzFlNjM2ZGVmMTQxNGFhNDUwZmFiOTM5YWM3MDIwL3RhYmxlOmUxMmEzOTY2NWMwYzQzNTU4OWIxODkxNmZiZTk2ZTkyL3RhYmxlcmFuZ2U6ZTEyYTM5NjY1YzBjNDM1NTg5YjE4OTE2ZmJlOTZlOTJfMy01LTEtMS0w_016e6ebd-95e6-41af-99b5-a7bc98ec3c41"
      unitRef="usd">-2728000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i5a4a416c9f8b4fac9455e693cd9e2710_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81NS9mcmFnOmJmMzFlNjM2ZGVmMTQxNGFhNDUwZmFiOTM5YWM3MDIwL3RhYmxlOmUxMmEzOTY2NWMwYzQzNTU4OWIxODkxNmZiZTk2ZTkyL3RhYmxlcmFuZ2U6ZTEyYTM5NjY1YzBjNDM1NTg5YjE4OTE2ZmJlOTZlOTJfMy03LTEtMS0w_75996db9-aff1-4da6-a464-3386feb64318"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="ide9f6e15665746279d0000be700fcc6a_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81NS9mcmFnOmJmMzFlNjM2ZGVmMTQxNGFhNDUwZmFiOTM5YWM3MDIwL3RhYmxlOmUxMmEzOTY2NWMwYzQzNTU4OWIxODkxNmZiZTk2ZTkyL3RhYmxlcmFuZ2U6ZTEyYTM5NjY1YzBjNDM1NTg5YjE4OTE2ZmJlOTZlOTJfMy05LTEtMS0w_f7ff9d67-fe9b-4f7e-ae25-b5b915c9fa83"
      unitRef="usd">-2802000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i45667cf06d374f0f8d2c6a08350e2740_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81NS9mcmFnOmJmMzFlNjM2ZGVmMTQxNGFhNDUwZmFiOTM5YWM3MDIwL3RhYmxlOmUxMmEzOTY2NWMwYzQzNTU4OWIxODkxNmZiZTk2ZTkyL3RhYmxlcmFuZ2U6ZTEyYTM5NjY1YzBjNDM1NTg5YjE4OTE2ZmJlOTZlOTJfNC0xLTEtMS0w_7be5a85d-fd03-4314-8902-ebbad0d59a3c"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="iace4f6c1fa9543cd8b55cb7840648649_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81NS9mcmFnOmJmMzFlNjM2ZGVmMTQxNGFhNDUwZmFiOTM5YWM3MDIwL3RhYmxlOmUxMmEzOTY2NWMwYzQzNTU4OWIxODkxNmZiZTk2ZTkyL3RhYmxlcmFuZ2U6ZTEyYTM5NjY1YzBjNDM1NTg5YjE4OTE2ZmJlOTZlOTJfNC0zLTEtMS0w_fa8b9cfc-ff7e-451a-8f4d-1040837f16a2"
      unitRef="usd">74000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i8748a9e750264dbeb3452686c17d0b3f_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81NS9mcmFnOmJmMzFlNjM2ZGVmMTQxNGFhNDUwZmFiOTM5YWM3MDIwL3RhYmxlOmUxMmEzOTY2NWMwYzQzNTU4OWIxODkxNmZiZTk2ZTkyL3RhYmxlcmFuZ2U6ZTEyYTM5NjY1YzBjNDM1NTg5YjE4OTE2ZmJlOTZlOTJfNC01LTEtMS0w_478da387-8433-4471-a0c0-f0c319947642"
      unitRef="usd">4045000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i5a4a416c9f8b4fac9455e693cd9e2710_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81NS9mcmFnOmJmMzFlNjM2ZGVmMTQxNGFhNDUwZmFiOTM5YWM3MDIwL3RhYmxlOmUxMmEzOTY2NWMwYzQzNTU4OWIxODkxNmZiZTk2ZTkyL3RhYmxlcmFuZ2U6ZTEyYTM5NjY1YzBjNDM1NTg5YjE4OTE2ZmJlOTZlOTJfNC03LTEtMS0w_a82c244a-eaf8-4eab-b9c7-3876713b0d65"
      unitRef="usd">340000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ide9f6e15665746279d0000be700fcc6a_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81NS9mcmFnOmJmMzFlNjM2ZGVmMTQxNGFhNDUwZmFiOTM5YWM3MDIwL3RhYmxlOmUxMmEzOTY2NWMwYzQzNTU4OWIxODkxNmZiZTk2ZTkyL3RhYmxlcmFuZ2U6ZTEyYTM5NjY1YzBjNDM1NTg5YjE4OTE2ZmJlOTZlOTJfNC05LTEtMS0w_47964abc-a326-4ab1-85d1-056f7722a0aa"
      unitRef="usd">4459000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="i8fda1a7ccba9498489e7ddfe1a07281b_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81NS9mcmFnOmJmMzFlNjM2ZGVmMTQxNGFhNDUwZmFiOTM5YWM3MDIwL3RhYmxlOmUxMmEzOTY2NWMwYzQzNTU4OWIxODkxNmZiZTk2ZTkyL3RhYmxlcmFuZ2U6ZTEyYTM5NjY1YzBjNDM1NTg5YjE4OTE2ZmJlOTZlOTJfNS0xLTEtMS0w_dcb5f4b1-be1c-444b-8f0a-742122d56366"
      unitRef="usd">-32792000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id869bd21f8364305aa97626bdb27c7db_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81NS9mcmFnOmJmMzFlNjM2ZGVmMTQxNGFhNDUwZmFiOTM5YWM3MDIwL3RhYmxlOmUxMmEzOTY2NWMwYzQzNTU4OWIxODkxNmZiZTk2ZTkyL3RhYmxlcmFuZ2U6ZTEyYTM5NjY1YzBjNDM1NTg5YjE4OTE2ZmJlOTZlOTJfNS0zLTEtMS0w_83c13c54-e22d-4f8a-86be-8effe01bfc51"
      unitRef="usd">-3446000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i11580be1480f41978578dd943839ecb5_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81NS9mcmFnOmJmMzFlNjM2ZGVmMTQxNGFhNDUwZmFiOTM5YWM3MDIwL3RhYmxlOmUxMmEzOTY2NWMwYzQzNTU4OWIxODkxNmZiZTk2ZTkyL3RhYmxlcmFuZ2U6ZTEyYTM5NjY1YzBjNDM1NTg5YjE4OTE2ZmJlOTZlOTJfNS01LTEtMS0w_91d126f8-b3d0-4b55-bd4e-04c210dbb989"
      unitRef="usd">4182000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i01494f6ccbfc49d191f7454445e0fc32_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81NS9mcmFnOmJmMzFlNjM2ZGVmMTQxNGFhNDUwZmFiOTM5YWM3MDIwL3RhYmxlOmUxMmEzOTY2NWMwYzQzNTU4OWIxODkxNmZiZTk2ZTkyL3RhYmxlcmFuZ2U6ZTEyYTM5NjY1YzBjNDM1NTg5YjE4OTE2ZmJlOTZlOTJfNS03LTEtMS0w_b5df8368-2b27-4049-85e0-194bdb6c7f88"
      unitRef="usd">-3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0cd32b4827314c02b0aeae69087c66b0_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81NS9mcmFnOmJmMzFlNjM2ZGVmMTQxNGFhNDUwZmFiOTM5YWM3MDIwL3RhYmxlOmUxMmEzOTY2NWMwYzQzNTU4OWIxODkxNmZiZTk2ZTkyL3RhYmxlcmFuZ2U6ZTEyYTM5NjY1YzBjNDM1NTg5YjE4OTE2ZmJlOTZlOTJfNS05LTEtMS0w_4393cbd6-5345-469b-b0d8-0bb4c3e5c51c"
      unitRef="usd">-32059000</us-gaap:StockholdersEquity>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81OC9mcmFnOjk4M2Q1YzdiZDBlYjQ2YWE4M2JjM2RlNDJmMGM0ZTUyL3RleHRyZWdpb246OTgzZDVjN2JkMGViNDZhYTgzYmMzZGU0MmYwYzRlNTJfNTQ3OA_a78c976c-2316-4b16-a479-287b5201cdd1">CREDIT AGREEMENT&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In April 2020, we entered into a credit agreement, or Credit Agreement, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;among us, certain of our subsidiaries (such subsidiaries, together with us, the Loan Parties), funds or accounts managed or advised by GSO Capital Partners LP (now Blackstone Alternative Credit Advisors LP) and certain other affiliates of T&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;he Blackstone Group Inc.&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;, and the other lenders from time to time parties thereto, collectively, the Lenders, and Wilmington Trust, National Association, as the administrative agent for the Lenders. The Credit Agreement provides for a senior secured delayed draw term loan facility, referred to as the Term Loans, which consists of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;three&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; tranches providing funding up to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$700.0&#160;million&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;. The Tranche 1 Loan of $200.0&#160;million &lt;/span&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;was drawn as of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;December&#160;31, 2020&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; and is included in long-term debt in the condensed consolidated balance sheets. The remaining two tranches will provide funds as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:61.111%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.435%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.996%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.435%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.996%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.438%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Tranche&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Requested No Later Than&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate Principal Amount, up to (in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tranche 2 Loan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tranche 3 Loan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In addition, we may request an increase in respect of the unfunded commitments in an amount not to exceed $50.0&#160;million on terms to be agreed and subject to the consent of the Lenders providing such increase. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Tranche 2 Loan will be requested no later than June 30, 2021 and the Tranche 3 Loan will be requested no later than December 31, 2021, in each case, subject to customary terms and conditions, including, in the case of the Tranche 2 Loan and Tranche 3 Loan, either (a) the first sale of inclisiran in the U.S. for end use or consumption after FDA regulatory approval thereof or (b) revenue attributable to ONPATTRO and GIVLAARI equal to or greater than $300.0&#160;million as of the last day of the most recently ended twelve month period, referred to as the Subsequent Borrowing Conditions. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In the event the Subsequent Borrowing Conditions are not satisfied as of the dates set forth in the table above, the Tranche 2 Loan and Tranche 3 Loan will be funded if such Subsequent Borrowing Conditions are satisfied on or prior to December 31, 2022. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Term Loans mature in December 2027. We can elect an interest rate of either LIBOR plus 7% subject to a floor of 1%, referred to as the LIBOR Rate, or a base rate plus 6%, subject to a floor of 2%. We may, at our option, pay interest in kind on interest due through 2023 at &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;a rate that is 1% higher than the interest rate otherwise applicable to such Term Loan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;. In December 2020, we drew the Tranche 1 Loan, elected a LIBOR Rate plus 7%, and paid a $5.0&#160;million funding fee. On the date the Tranche 2 Loan or Tranche 3 Loan is funded, we will pay a funding fee equal to 2.5% of the principal amount of the Term Loans funded on such date. In addition, we will pay an exit fee equal to 1% of the commitments in respect of the Term Loans, payable upon any repayment of the Term Loans or termination of the unfunded Term Loan commitments. Our interest rate was 8% as of March 31, 2021 and December 31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;We are obligated to pay interest due on the Term Loans from 2021 through 2022 which will be calculated without regard to the Term Loans being prepaid or an unfunded tranche being terminated during this period (in whole or in part). Any prepayments of Term Loans or terminations of unfunded tranches that occur between 2023 and 2025 are subject to a fee of up to 5% of the loan principal that is prepaid or the amount of the unfunded tranche that is terminated.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;All obligations under the Credit Agreement are secured, subject to certain exceptions, by security interests in the following assets: (i) intellectual property owned by us relating to ONPATTRO, GIVLAARI and vutrisiran, (ii) the equity interests held by the Loan Parties in their subsidiaries, (iii) all of our ownership of the inclisiran royalty remaining after the royalty purchase under the Purchase Agreement, and (iv) material real property, and certain personal property, including, without limitation, cash held in certain deposit accounts of the Loan Parties and equipment. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Credit Agreement contains negative covenants that, among other things and subject to certain exceptions, could restrict our ability to, incur additional liens, incur additional indebtedness, make investments, including acquisitions, engage in fundamental changes, sell or dispose of assets that constitute collateral, including certain intellectual property, pay dividends or make any distribution or payment on or redeem, retire or purchase any equity interests, amend, modify or waive certain material agreements or organizational documents and make payments of certain subordinated indebtedness. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Additionally, the Credit Agreement contains certain customary representations and warranties, affirmative covenants and provisions relating to events of default, including nonpayment of principal, interest and other amounts; failure to comply with covenants; the rendering of judgments or orders or default by us in respect of other material indebtedness; and certain insolvency and ERISA events.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; The Credit Agreement also requires us to have consolidated liquidity of at least $100.0&#160;million as of the last day of each fiscal quarter. As of March&#160;31, 2021, we were in compliance with the applicable terms and conditions of the covenants under the Credit Agreement.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <alny:DebtInstrumentNumberOfTranches
      contextRef="i7c3cf9f64e5c4dba8a27cbdc2664e3da_I20200410"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81OC9mcmFnOjk4M2Q1YzdiZDBlYjQ2YWE4M2JjM2RlNDJmMGM0ZTUyL3RleHRyZWdpb246OTgzZDVjN2JkMGViNDZhYTgzYmMzZGU0MmYwYzRlNTJfMTA5OTUxMTYzNDk5Ng_7f70bb35-693f-4c9a-94b2-6557c997e076"
      unitRef="tranche">3</alny:DebtInstrumentNumberOfTranches>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i7c3cf9f64e5c4dba8a27cbdc2664e3da_I20200410"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81OC9mcmFnOjk4M2Q1YzdiZDBlYjQ2YWE4M2JjM2RlNDJmMGM0ZTUyL3RleHRyZWdpb246OTgzZDVjN2JkMGViNDZhYTgzYmMzZGU0MmYwYzRlNTJfMTA5OTUxMTYzNDk4Nw_55ea7a98-1811-4f68-b38c-1df2c28801e0"
      unitRef="usd">700000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="ibc345957dc834afab5787e085c2b24f5_D20201231-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81OC9mcmFnOjk4M2Q1YzdiZDBlYjQ2YWE4M2JjM2RlNDJmMGM0ZTUyL3RleHRyZWdpb246OTgzZDVjN2JkMGViNDZhYTgzYmMzZGU0MmYwYzRlNTJfODI0NjMzNzIxNjQxMA_93b44941-b9f9-4863-985a-ece3a0b23d3d"
      unitRef="usd">200000000.0</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:ScheduleOfDebtInstrumentsTextBlock
      contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81OC9mcmFnOjk4M2Q1YzdiZDBlYjQ2YWE4M2JjM2RlNDJmMGM0ZTUyL3RleHRyZWdpb246OTgzZDVjN2JkMGViNDZhYTgzYmMzZGU0MmYwYzRlNTJfNTQ3Nw_67d743b1-f4d5-4f3e-ada4-1789f59362d1">&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:61.111%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.435%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.996%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.435%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.996%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.438%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Tranche&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Requested No Later Than&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate Principal Amount, up to (in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tranche 2 Loan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tranche 3 Loan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ifeeb0e1889fe4d049042d329b80919f6_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81OC9mcmFnOjk4M2Q1YzdiZDBlYjQ2YWE4M2JjM2RlNDJmMGM0ZTUyL3RhYmxlOmFhYjcyNTE4NmZiZDQ5ZDFiZTdmMjZmZjEyODNmOTUxL3RhYmxlcmFuZ2U6YWFiNzI1MTg2ZmJkNDlkMWJlN2YyNmZmMTI4M2Y5NTFfMi00LTEtMS0w_066b0ae5-9821-457f-a6f9-4be34577a702"
      unitRef="usd">250000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="iead1e9b005df4a1f9a86fc4b31611ed7_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81OC9mcmFnOjk4M2Q1YzdiZDBlYjQ2YWE4M2JjM2RlNDJmMGM0ZTUyL3RhYmxlOmFhYjcyNTE4NmZiZDQ5ZDFiZTdmMjZmZjEyODNmOTUxL3RhYmxlcmFuZ2U6YWFiNzI1MTg2ZmJkNDlkMWJlN2YyNmZmMTI4M2Y5NTFfMy00LTEtMS0w_e0df19ba-f8a5-44b2-b1a0-3387e04f8822"
      unitRef="usd">250000000</us-gaap:DebtInstrumentFaceAmount>
    <alny:LineOfCreditFacilityMaximumBorrowingCapacityAccordionFeature
      contextRef="i7c3cf9f64e5c4dba8a27cbdc2664e3da_I20200410"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81OC9mcmFnOjk4M2Q1YzdiZDBlYjQ2YWE4M2JjM2RlNDJmMGM0ZTUyL3RleHRyZWdpb246OTgzZDVjN2JkMGViNDZhYTgzYmMzZGU0MmYwYzRlNTJfODI1_df52a532-e3e5-43dc-9681-907b9828efac"
      unitRef="usd">50000000.0</alny:LineOfCreditFacilityMaximumBorrowingCapacityAccordionFeature>
    <alny:DebtInstrumentCovenantTermsMinimumProductRevenue
      contextRef="id5babbf83da24b918e081dc61eef1961_I20200410"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81OC9mcmFnOjk4M2Q1YzdiZDBlYjQ2YWE4M2JjM2RlNDJmMGM0ZTUyL3RleHRyZWdpb246OTgzZDVjN2JkMGViNDZhYTgzYmMzZGU0MmYwYzRlNTJfMTc1Mw_19779b44-c5fe-4e3d-91fd-8c876a66a5d1"
      unitRef="usd">300000000.0</alny:DebtInstrumentCovenantTermsMinimumProductRevenue>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i01120d900c46459e8dcddb8d56d9478b_D20200410-20200410"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81OC9mcmFnOjk4M2Q1YzdiZDBlYjQ2YWE4M2JjM2RlNDJmMGM0ZTUyL3RleHRyZWdpb246OTgzZDVjN2JkMGViNDZhYTgzYmMzZGU0MmYwYzRlNTJfNDk0NzgwMjMzMTc0NA_a9cdb0db-170a-47bd-a597-ff65bd3af524"
      unitRef="number">0.07</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i16e5cf96bf70403d9deb63cea2e51969_I20200410"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81OC9mcmFnOjk4M2Q1YzdiZDBlYjQ2YWE4M2JjM2RlNDJmMGM0ZTUyL3RleHRyZWdpb246OTgzZDVjN2JkMGViNDZhYTgzYmMzZGU0MmYwYzRlNTJfNDk0NzgwMjMzMTc0Nw_c3898421-4e78-44af-a3cd-690b1de151e5"
      unitRef="number">0.01</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i08cf9801b78c48129c565578666b38ea_D20200410-20200410"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81OC9mcmFnOjk4M2Q1YzdiZDBlYjQ2YWE4M2JjM2RlNDJmMGM0ZTUyL3RleHRyZWdpb246OTgzZDVjN2JkMGViNDZhYTgzYmMzZGU0MmYwYzRlNTJfMjM0Mg_e3ebb39d-335c-400f-ad31-7a0e1fdb99bc"
      unitRef="number">0.06</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i753fbbe92da442cfb258516ac25f2d2b_I20200410"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81OC9mcmFnOjk4M2Q1YzdiZDBlYjQ2YWE4M2JjM2RlNDJmMGM0ZTUyL3RleHRyZWdpb246OTgzZDVjN2JkMGViNDZhYTgzYmMzZGU0MmYwYzRlNTJfMjM2OA_3753f450-1b1f-4ad5-9280-79e864a4e7aa"
      unitRef="number">0.02</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <alny:DebtInstrumentInterestInKindInterestRateIncrease
      contextRef="icbb72ec509854a04bfdedc3536c9cc08_D20200410-20200410"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81OC9mcmFnOjk4M2Q1YzdiZDBlYjQ2YWE4M2JjM2RlNDJmMGM0ZTUyL3RleHRyZWdpb246OTgzZDVjN2JkMGViNDZhYTgzYmMzZGU0MmYwYzRlNTJfMjUxNA_ec8e1791-1550-4e93-8933-a3f10acae2f4"
      unitRef="number">0.01</alny:DebtInstrumentInterestInKindInterestRateIncrease>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i5f0630732fe54bfca1f008c864bcaa8c_D20201201-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81OC9mcmFnOjk4M2Q1YzdiZDBlYjQ2YWE4M2JjM2RlNDJmMGM0ZTUyL3RleHRyZWdpb246OTgzZDVjN2JkMGViNDZhYTgzYmMzZGU0MmYwYzRlNTJfODI0NjMzNzIxNjQ0Mw_fccfc963-1bbe-420f-b310-3822cef09a02"
      unitRef="number">0.07</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:LineOfCreditFacilityCommitmentFeeAmount
      contextRef="i93e4ff2210fb41fdaf2e202c8b0d204a_D20201201-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81OC9mcmFnOjk4M2Q1YzdiZDBlYjQ2YWE4M2JjM2RlNDJmMGM0ZTUyL3RleHRyZWdpb246OTgzZDVjN2JkMGViNDZhYTgzYmMzZGU0MmYwYzRlNTJfODI0NjMzNzIxNjQyNg_fb27a09f-b57a-4156-91f7-eaf0e7559f7a"
      unitRef="usd">5000000.0</us-gaap:LineOfCreditFacilityCommitmentFeeAmount>
    <us-gaap:LineOfCreditFacilityCommitmentFeePercentage
      contextRef="icbb72ec509854a04bfdedc3536c9cc08_D20200410-20200410"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81OC9mcmFnOjk4M2Q1YzdiZDBlYjQ2YWE4M2JjM2RlNDJmMGM0ZTUyL3RleHRyZWdpb246OTgzZDVjN2JkMGViNDZhYTgzYmMzZGU0MmYwYzRlNTJfMjY5OA_4e299346-fa5c-4473-8400-c19c75ec9cdf"
      unitRef="number">0.025</us-gaap:LineOfCreditFacilityCommitmentFeePercentage>
    <alny:DebtInstrumentExitFeePercent
      contextRef="icbb72ec509854a04bfdedc3536c9cc08_D20200410-20200410"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81OC9mcmFnOjk4M2Q1YzdiZDBlYjQ2YWE4M2JjM2RlNDJmMGM0ZTUyL3RleHRyZWdpb246OTgzZDVjN2JkMGViNDZhYTgzYmMzZGU0MmYwYzRlNTJfMjgxMA_fec3a5a2-8b57-48fc-a405-1ca3f4eca878"
      unitRef="number">0.01</alny:DebtInstrumentExitFeePercent>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="ib9d80c24381a4a579abefd71b39a3841_I20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81OC9mcmFnOjk4M2Q1YzdiZDBlYjQ2YWE4M2JjM2RlNDJmMGM0ZTUyL3RleHRyZWdpb246OTgzZDVjN2JkMGViNDZhYTgzYmMzZGU0MmYwYzRlNTJfMTA5OTUxMTYzNTc5Ng_4f363871-d383-4c45-a49e-204348c30b8a"
      unitRef="number">0.08</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i00dcec45b31345649463ce0a808354bb_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81OC9mcmFnOjk4M2Q1YzdiZDBlYjQ2YWE4M2JjM2RlNDJmMGM0ZTUyL3RleHRyZWdpb246OTgzZDVjN2JkMGViNDZhYTgzYmMzZGU0MmYwYzRlNTJfMTA5OTUxMTYzNTc5Ng_e0e6c73e-1ebb-43ad-b0b6-3475b579f581"
      unitRef="number">0.08</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <alny:LineOfCreditFacilityPrepaymentAndTerminationFeePercentage
      contextRef="icbb72ec509854a04bfdedc3536c9cc08_D20200410-20200410"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81OC9mcmFnOjk4M2Q1YzdiZDBlYjQ2YWE4M2JjM2RlNDJmMGM0ZTUyL3RleHRyZWdpb246OTgzZDVjN2JkMGViNDZhYTgzYmMzZGU0MmYwYzRlNTJfMzM4OA_c5cd9559-33d4-4270-9d9f-89269dadf2e6"
      unitRef="number">0.05</alny:LineOfCreditFacilityPrepaymentAndTerminationFeePercentage>
    <alny:DebtInstrumentCovenantTermsMinimumConsolidatedLiquidity
      contextRef="icbb72ec509854a04bfdedc3536c9cc08_D20200410-20200410"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF81OC9mcmFnOjk4M2Q1YzdiZDBlYjQ2YWE4M2JjM2RlNDJmMGM0ZTUyL3RleHRyZWdpb246OTgzZDVjN2JkMGViNDZhYTgzYmMzZGU0MmYwYzRlNTJfNTE0OA_25a5f7ed-8047-4081-a893-97d58e9e2d04"
      unitRef="usd">100000000.0</alny:DebtInstrumentCovenantTermsMinimumConsolidatedLiquidity>
    <us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock
      contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF82MS9mcmFnOjI4OGMwZmM3OWViYTRlNTc5NzY5NmVlYzhlYmQ3OTk3L3RleHRyZWdpb246Mjg4YzBmYzc5ZWJhNGU1Nzk3Njk2ZWVjOGViZDc5OTdfNTc3Mg_c4990ff9-73b8-460d-bcc6-6f60b6c475e0">DEVELOPMENT DERIVATIVE LIABILITYIn August 2020, we entered into a co-development agreement, referred to as the Funding Agreement, with BXLS V Bodyguard &#x2013; PCP L.P. and BXLS Family Investment Partnership V &#x2013; ESC L.P., collectively referred to as Blackstone Life Sciences, pursuant to which Blackstone Life Sciences will provide up to $150.0&#160;million in funding for the clinical development of vutrisiran and ALN-AGT, two of our cardiometabolic programs. With respect to vutrisiran, Blackstone Life Sciences has committed to provide up to $70.0&#160;million to fund development costs related to the HELIOS-B Phase 3 clinical trial. In addition, Blackstone Life Sciences has the right, but is not obligated, to fund up to $26.0&#160;million for development costs related to a Phase 2 clinical trial of ALN-AGT and up to $54.0&#160;million for development costs related to a Phase 3 clinical trial of ALN-AGT. The amount of funding ultimately provided by Blackstone Life Sciences is dependent on us achieving specified development &lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;milestones with respect to each clinical trial. We retain sole responsibility for the development and commercialization of both vutrisiran and ALN-AGT.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As consideration for Blackstone Life Sciences&#x2019; funding for vutrisiran clinical development costs, we have agreed to pay Blackstone Life Sciences a 1% royalty on net sales of vutrisiran for a 10-year term beginning upon the first commercial sale following regulatory approval of vutrisiran for ATTR-cardiomyopathy, as well as fixed payments of up to 2.5 times their investment over a two-year period upon regulatory approval of vutrisiran for ATTR-cardiomyopathy in specified countries, unless it is later withdrawn from the market following a mandatory recall. As consideration for Blackstone Life Sciences&#x2019; funding for Phase 2 clinical development costs of ALN-AGT, we have agreed to pay Blackstone Life Sciences fixed payments of up to 3.25 times their Phase 2 investment over a four-year period upon the successful completion of the ALN-AGT Phase 2 clinical trial, unless certain regulatory events affecting the continued development of ALN-AGT occur. As consideration for Blackstone Life Sciences&#x2019; funding for Phase 3 clinical development costs of ALN-AGT, we have agreed to pay Blackstone Life Sciences fixed payments of up to 4.5 times their Phase 3 investment over a four-year period upon regulatory approval of ALN-AGT in specified countries, unless it is later withdrawn from the market following a mandatory recall.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Our payment obligations under the Funding Agreement will be secured, subject to certain exceptions, by security interests in intellectual property owned by us relating to vutrisiran and ALN-AGT, as well as in our bank account in which the funding deposits will be made.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;We and Blackstone Life Sciences each have the right to terminate the Funding Agreement in its entirety in the event of the other party&#x2019;s bankruptcy or similar proceedings. We and Blackstone Life Sciences may each terminate the Funding Agreement in its entirety or with respect to either product in the event of an uncured material breach by the other party, or with respect to a product for certain patient health and safety reasons, or if regulatory approval in specified major market countries is not obtained for the product following the completion of clinical trials for the product. In addition, Blackstone Life Sciences has the right to terminate the Funding Agreement in its entirety upon the occurrence of certain events affecting our ability to make payments under the agreement or to develop or commercialize the products, or upon a change of control of us. Blackstone Life Sciences may also terminate the Funding Agreement with respect to a product if the joint steering committee elects to terminate the development program for that product in its entirety, if certain clinical endpoints are not achieved for that product or, with respect to vutrisiran only, if our right to develop or commercialize vutrisiran is enjoined in a specified major market as a result of an alleged patent infringement. In certain termination circumstances, we will be obligated to pay Blackstone Life Sciences an amount that is equal to, or a multiplier of, the development funding received from Blackstone Life Sciences, and we may remain obligated under certain circumstances to make the payments to Blackstone Life Sciences described above, or the royalty described above in the case of vutrisiran, should we obtain regulatory approval for vutrisiran or ALN-AGT following termination.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;We account for the Funding Agreement under ASC 815 as a derivative liability, measured at fair value, within other liabilities on our condensed consolidated balance sheets. The change in fair value due to the remeasurement of the development derivative liability is recorded as other expense on our condensed consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As of March&#160;31, 2021, the derivative liability is classified as a Level 3 financial liability in the fair value hierarchy. The valuation method incorporates certain unobservable Level 3 key inputs including (i) the probability and timing of achieving stated development milestones to receive payments from Blackstone Life Sciences, (ii) the probability and timing of achieving regulatory approval and payments to Blackstone Life Sciences, (iii) an estimate of the amount and timing of the royalty payable on net sales of vutrisiran, assuming regulatory approval, (iv) our cost of borrowing (15%), and (v) Blackstone Life Sciences' cost of borrowing (4%).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table presents the activity with respect to the development derivative liability, in thousands:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:86.549%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:81.163%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.644%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.793%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Development derivative liability as of December&#160;31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amount received under the Funding Agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss recorded from remeasurement of development derivative liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Development derivative liability as of March&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,038&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock>
    <alny:CollaborativeArrangementMaximumFunding
      contextRef="if56939063a9e4f659db2a74fe02c611f_D20200801-20200831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF82MS9mcmFnOjI4OGMwZmM3OWViYTRlNTc5NzY5NmVlYzhlYmQ3OTk3L3RleHRyZWdpb246Mjg4YzBmYzc5ZWJhNGU1Nzk3Njk2ZWVjOGViZDc5OTdfMzQy_1f6935fb-5f8f-4056-a355-66875a637f72"
      unitRef="usd">150000000.0</alny:CollaborativeArrangementMaximumFunding>
    <alny:CollaborativeArrangementMaximumFunding
      contextRef="i30025a2dd91d4350946281176f871659_D20200801-20200831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF82MS9mcmFnOjI4OGMwZmM3OWViYTRlNTc5NzY5NmVlYzhlYmQ3OTk3L3RleHRyZWdpb246Mjg4YzBmYzc5ZWJhNGU1Nzk3Njk2ZWVjOGViZDc5OTdfNTMz_030fad78-117b-42e3-b78b-30448666a610"
      unitRef="usd">70000000.0</alny:CollaborativeArrangementMaximumFunding>
    <alny:CollaborativeArrangementMaximumFunding
      contextRef="i4349daaa321340fbb35c0fb62328e9d0_D20200801-20200831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF82MS9mcmFnOjI4OGMwZmM3OWViYTRlNTc5NzY5NmVlYzhlYmQ3OTk3L3RleHRyZWdpb246Mjg4YzBmYzc5ZWJhNGU1Nzk3Njk2ZWVjOGViZDc5OTdfNjk5_fabb4451-62fb-4556-b3d8-f35da1019317"
      unitRef="usd">26000000.0</alny:CollaborativeArrangementMaximumFunding>
    <alny:CollaborativeArrangementMaximumFunding
      contextRef="i9f3237ef00524733ac2cd4cdc77591ed_D20200801-20200831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF82MS9mcmFnOjI4OGMwZmM3OWViYTRlNTc5NzY5NmVlYzhlYmQ3OTk3L3RleHRyZWdpb246Mjg4YzBmYzc5ZWJhNGU1Nzk3Njk2ZWVjOGViZDc5OTdfNzgx_31c562d8-2e9e-41e3-a62d-78a736abdae5"
      unitRef="usd">54000000.0</alny:CollaborativeArrangementMaximumFunding>
    <alny:CollaborativeArrangementRoyaltiesPayablePercent
      contextRef="i2e274ae018274dad8cbd61b7b4043868_D20200801-20200831"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF82MS9mcmFnOjI4OGMwZmM3OWViYTRlNTc5NzY5NmVlYzhlYmQ3OTk3L3RleHRyZWdpb246Mjg4YzBmYzc5ZWJhNGU1Nzk3Njk2ZWVjOGViZDc5OTdfMTI3NQ_f18aedae-9d3f-466a-9a26-a4cba678ec9d"
      unitRef="number">0.01</alny:CollaborativeArrangementRoyaltiesPayablePercent>
    <alny:CollaborativeArrangementRoyaltiesPayableTerm
      contextRef="i2e274ae018274dad8cbd61b7b4043868_D20200801-20200831"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF82MS9mcmFnOjI4OGMwZmM3OWViYTRlNTc5NzY5NmVlYzhlYmQ3OTk3L3RleHRyZWdpb246Mjg4YzBmYzc5ZWJhNGU1Nzk3Njk2ZWVjOGViZDc5OTdfMTMxOQ_96e32437-f74e-4214-a5e8-57d65e3f8659">P10Y</alny:CollaborativeArrangementRoyaltiesPayableTerm>
    <alny:CollaborativeArrangementFixedPaymentMultiplier
      contextRef="i2e274ae018274dad8cbd61b7b4043868_D20200801-20200831"
      decimals="1"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF82MS9mcmFnOjI4OGMwZmM3OWViYTRlNTc5NzY5NmVlYzhlYmQ3OTk3L3RleHRyZWdpb246Mjg4YzBmYzc5ZWJhNGU1Nzk3Njk2ZWVjOGViZDc5OTdfMTQ3Nw_0d5e9e3f-6680-4e12-90a1-cb40f91205b5"
      unitRef="number">2.5</alny:CollaborativeArrangementFixedPaymentMultiplier>
    <alny:CollaborativeArrangementFixedPaymentTerm
      contextRef="i2e274ae018274dad8cbd61b7b4043868_D20200801-20200831"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF82MS9mcmFnOjI4OGMwZmM3OWViYTRlNTc5NzY5NmVlYzhlYmQ3OTk3L3RleHRyZWdpb246Mjg4YzBmYzc5ZWJhNGU1Nzk3Njk2ZWVjOGViZDc5OTdfNTc3Mw_a6859f2d-7310-4da6-a727-226b5cbaa8fa">P2Y</alny:CollaborativeArrangementFixedPaymentTerm>
    <alny:CollaborativeArrangementFixedPaymentMultiplier
      contextRef="i4349daaa321340fbb35c0fb62328e9d0_D20200801-20200831"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF82MS9mcmFnOjI4OGMwZmM3OWViYTRlNTc5NzY5NmVlYzhlYmQ3OTk3L3RleHRyZWdpb246Mjg4YzBmYzc5ZWJhNGU1Nzk3Njk2ZWVjOGViZDc5OTdfMTg2NQ_f8130a22-aeec-4b49-9e61-e3e976128b8a"
      unitRef="number">3.25</alny:CollaborativeArrangementFixedPaymentMultiplier>
    <alny:CollaborativeArrangementFixedPaymentTerm
      contextRef="i4349daaa321340fbb35c0fb62328e9d0_D20200801-20200831"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF82MS9mcmFnOjI4OGMwZmM3OWViYTRlNTc5NzY5NmVlYzhlYmQ3OTk3L3RleHRyZWdpb246Mjg4YzBmYzc5ZWJhNGU1Nzk3Njk2ZWVjOGViZDc5OTdfNTc3NA_e2e03d21-a7ad-4ae3-aac7-f6995216e806">P4Y</alny:CollaborativeArrangementFixedPaymentTerm>
    <alny:CollaborativeArrangementFixedPaymentMultiplier
      contextRef="i9f3237ef00524733ac2cd4cdc77591ed_D20200801-20200831"
      decimals="1"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF82MS9mcmFnOjI4OGMwZmM3OWViYTRlNTc5NzY5NmVlYzhlYmQ3OTk3L3RleHRyZWdpb246Mjg4YzBmYzc5ZWJhNGU1Nzk3Njk2ZWVjOGViZDc5OTdfMjI1Ng_faac4bca-2bc7-4f3d-8f41-e3f26eaf8d74"
      unitRef="number">4.5</alny:CollaborativeArrangementFixedPaymentMultiplier>
    <alny:CollaborativeArrangementFixedPaymentTerm
      contextRef="i9f3237ef00524733ac2cd4cdc77591ed_D20200801-20200831"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF82MS9mcmFnOjI4OGMwZmM3OWViYTRlNTc5NzY5NmVlYzhlYmQ3OTk3L3RleHRyZWdpb246Mjg4YzBmYzc5ZWJhNGU1Nzk3Njk2ZWVjOGViZDc5OTdfNTc3NQ_906f5cf1-ddbf-45b8-a2ce-1e06c1a3de8a">P4Y</alny:CollaborativeArrangementFixedPaymentTerm>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="idd7204dc87d24972a01f15b098c4f56b_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF82MS9mcmFnOjI4OGMwZmM3OWViYTRlNTc5NzY5NmVlYzhlYmQ3OTk3L3RleHRyZWdpb246Mjg4YzBmYzc5ZWJhNGU1Nzk3Njk2ZWVjOGViZDc5OTdfNTU5Ng_ec1ab204-ffa1-46ef-88f0-4da3a0b3c96c"
      unitRef="number">0.15</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i5d397d1b29de44e99ebf93138e25c1bc_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF82MS9mcmFnOjI4OGMwZmM3OWViYTRlNTc5NzY5NmVlYzhlYmQ3OTk3L3RleHRyZWdpb246Mjg4YzBmYzc5ZWJhNGU1Nzk3Njk2ZWVjOGViZDc5OTdfNTY1NQ_c6f9d38b-ec61-488d-ba77-ee965e4e2946"
      unitRef="number">0.04</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock
      contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF82MS9mcmFnOjI4OGMwZmM3OWViYTRlNTc5NzY5NmVlYzhlYmQ3OTk3L3RleHRyZWdpb246Mjg4YzBmYzc5ZWJhNGU1Nzk3Njk2ZWVjOGViZDc5OTdfNTc3Ng_d8211fa8-5017-444a-9e86-baf9643ded50">&lt;div style="margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table presents the activity with respect to the development derivative liability, in thousands:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:86.549%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:81.163%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.644%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.793%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Development derivative liability as of December&#160;31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amount received under the Funding Agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss recorded from remeasurement of development derivative liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Development derivative liability as of March&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,038&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i021eb4ce0e054ceabf5ba8f817404e90_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF82MS9mcmFnOjI4OGMwZmM3OWViYTRlNTc5NzY5NmVlYzhlYmQ3OTk3L3RhYmxlOjQ5ODQ4MmRmNTFlZTQzOTc5MTc3ODgxMWZjYjFhMmE1L3RhYmxlcmFuZ2U6NDk4NDgyZGY1MWVlNDM5NzkxNzc4ODExZmNiMWEyYTVfMy0yLTEtMS0w_96d8b175-1fbf-4777-ba3b-0857b16fab8e"
      unitRef="usd">25585000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
      contextRef="i097088dd315b40bbb18334f3ebd18b0e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF82MS9mcmFnOjI4OGMwZmM3OWViYTRlNTc5NzY5NmVlYzhlYmQ3OTk3L3RhYmxlOjQ5ODQ4MmRmNTFlZTQzOTc5MTc3ODgxMWZjYjFhMmE1L3RhYmxlcmFuZ2U6NDk4NDgyZGY1MWVlNDM5NzkxNzc4ODExZmNiMWEyYTVfNC0yLTEtMS00MDI_1052ba37-3375-477d-a4ec-5daa855aa69e"
      unitRef="usd">4200000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="i097088dd315b40bbb18334f3ebd18b0e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF82MS9mcmFnOjI4OGMwZmM3OWViYTRlNTc5NzY5NmVlYzhlYmQ3OTk3L3RhYmxlOjQ5ODQ4MmRmNTFlZTQzOTc5MTc3ODgxMWZjYjFhMmE1L3RhYmxlcmFuZ2U6NDk4NDgyZGY1MWVlNDM5NzkxNzc4ODExZmNiMWEyYTVfNC0yLTEtMS0zNDI_975ecb33-7c09-48bd-9ced-56b5ba0a8ecd"
      unitRef="usd">-18253000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i892bbea5207d47319b4fa4f08ab306e0_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF82MS9mcmFnOjI4OGMwZmM3OWViYTRlNTc5NzY5NmVlYzhlYmQ3OTk3L3RhYmxlOjQ5ODQ4MmRmNTFlZTQzOTc5MTc3ODgxMWZjYjFhMmE1L3RhYmxlcmFuZ2U6NDk4NDgyZGY1MWVlNDM5NzkxNzc4ODExZmNiMWEyYTVfNS0yLTEtMS0zNDI_cbd74fc6-a938-4642-8370-cbbe39333aec"
      unitRef="usd">48038000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF82Ny9mcmFnOjY2OTNmOTgzOGJhNDQxODZhZWViMjE4NjljNTgzODk0L3RleHRyZWdpb246NjY5M2Y5ODM4YmE0NDE4NmFlZWIyMTg2OWM1ODM4OTRfMTQz_89fad183-235a-4635-b30c-b7c56869d899">STOCK-BASED COMPENSATION&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table summarizes stock-based compensation expenses included in operating costs and expenses:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:71.929%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.891%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.816%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.398%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,578&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock
      contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF82Ny9mcmFnOjY2OTNmOTgzOGJhNDQxODZhZWViMjE4NjljNTgzODk0L3RleHRyZWdpb246NjY5M2Y5ODM4YmE0NDE4NmFlZWIyMTg2OWM1ODM4OTRfMTQ0_ed7ea93f-520b-4ca9-9f48-4bd69b9c01d2">&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table summarizes stock-based compensation expenses included in operating costs and expenses:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:71.929%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.891%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.816%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.398%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,578&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ib854d6b980064faa8bfd9bdf17daffcb_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF82Ny9mcmFnOjY2OTNmOTgzOGJhNDQxODZhZWViMjE4NjljNTgzODk0L3RhYmxlOmNmYjk4Yzk0MTdjNjQ4YmQ4YTk5NzJiN2U0M2VlMTFjL3RhYmxlcmFuZ2U6Y2ZiOThjOTQxN2M2NDhiZDhhOTk3MmI3ZTQzZWUxMWNfMi0xLTEtMS0w_b05644e7-2a64-4b09-bb63-50382566bcc2"
      unitRef="usd">24375000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i2660c94c8bfb4720bf4ba79623dc2385_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF82Ny9mcmFnOjY2OTNmOTgzOGJhNDQxODZhZWViMjE4NjljNTgzODk0L3RhYmxlOmNmYjk4Yzk0MTdjNjQ4YmQ4YTk5NzJiN2U0M2VlMTFjL3RhYmxlcmFuZ2U6Y2ZiOThjOTQxN2M2NDhiZDhhOTk3MmI3ZTQzZWUxMWNfMi0zLTEtMS0w_e7a42730-8de0-4590-9fd2-573c723474a4"
      unitRef="usd">16049000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i29e2b4a3041244bc8330c8eb0e1998c2_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF82Ny9mcmFnOjY2OTNmOTgzOGJhNDQxODZhZWViMjE4NjljNTgzODk0L3RhYmxlOmNmYjk4Yzk0MTdjNjQ4YmQ4YTk5NzJiN2U0M2VlMTFjL3RhYmxlcmFuZ2U6Y2ZiOThjOTQxN2M2NDhiZDhhOTk3MmI3ZTQzZWUxMWNfMy0xLTEtMS0w_b00d8985-6e3e-48a9-8421-42c51b1a5770"
      unitRef="usd">31315000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i6dc64ac1298247ef958115623a6ea350_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF82Ny9mcmFnOjY2OTNmOTgzOGJhNDQxODZhZWViMjE4NjljNTgzODk0L3RhYmxlOmNmYjk4Yzk0MTdjNjQ4YmQ4YTk5NzJiN2U0M2VlMTFjL3RhYmxlcmFuZ2U6Y2ZiOThjOTQxN2M2NDhiZDhhOTk3MmI3ZTQzZWUxMWNfMy0zLTEtMS0w_adc82e7a-f093-4a99-a356-09e30c33ae24"
      unitRef="usd">18529000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF82Ny9mcmFnOjY2OTNmOTgzOGJhNDQxODZhZWViMjE4NjljNTgzODk0L3RhYmxlOmNmYjk4Yzk0MTdjNjQ4YmQ4YTk5NzJiN2U0M2VlMTFjL3RhYmxlcmFuZ2U6Y2ZiOThjOTQxN2M2NDhiZDhhOTk3MmI3ZTQzZWUxMWNfNC0xLTEtMS0w_45cdcee9-29b7-479c-86bd-49446033726b"
      unitRef="usd">55690000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ide9f6e15665746279d0000be700fcc6a_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF82Ny9mcmFnOjY2OTNmOTgzOGJhNDQxODZhZWViMjE4NjljNTgzODk0L3RhYmxlOmNmYjk4Yzk0MTdjNjQ4YmQ4YTk5NzJiN2U0M2VlMTFjL3RhYmxlcmFuZ2U6Y2ZiOThjOTQxN2M2NDhiZDhhOTk3MmI3ZTQzZWUxMWNfNC0zLTEtMS0w_7bd0185d-2ce9-4e93-8ba8-11adfb90edd8"
      unitRef="usd">34578000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF83MC9mcmFnOjdiN2UzMzI4MDBmNzQ3Zjc4Y2I5NWZlZWY1MTYzOGM0L3RleHRyZWdpb246N2I3ZTMzMjgwMGY3NDdmNzhjYjk1ZmVlZjUxNjM4YzRfOTE2_fd9a4302-a1b8-4893-9a79-fc1fef95957d">NET LOSS PER COMMON SHARE&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;We compute basic net loss per common share by dividing net loss by the weighted-average number of common shares outstanding during the period. We compute diluted net loss per common share by dividing net loss by the weighted-average number of common shares and dilutive potential common share equivalents outstanding during the period. Potential common shares consist of shares issuable upon the exercise of stock options (the proceeds of which are then assumed to have been used to repurchase outstanding shares using the treasury stock method). Because the inclusion of potential common shares would be anti-dilutive for all periods presented, diluted net loss per common share is the same as basic net loss per common share.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following common share equivalents were excluded from the calculation of net loss per common share because their inclusion would be anti-dilutive:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.128%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.422%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested restricted common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,411&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,020&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF83MC9mcmFnOjdiN2UzMzI4MDBmNzQ3Zjc4Y2I5NWZlZWY1MTYzOGM0L3RleHRyZWdpb246N2I3ZTMzMjgwMGY3NDdmNzhjYjk1ZmVlZjUxNjM4YzRfOTE3_5d5b20d6-f46b-4756-b6d9-844f38d452f5">&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following common share equivalents were excluded from the calculation of net loss per common share because their inclusion would be anti-dilutive:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.128%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.422%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested restricted common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,411&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,020&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i625afeb909e24226bf8911556e57dd36_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF83MC9mcmFnOjdiN2UzMzI4MDBmNzQ3Zjc4Y2I5NWZlZWY1MTYzOGM0L3RhYmxlOmIzMjZiNzAwMWUxNTQxYzliOWQ3NmJhYTVjNjZiNGMyL3RhYmxlcmFuZ2U6YjMyNmI3MDAxZTE1NDFjOWI5ZDc2YmFhNWM2NmI0YzJfMi0xLTEtMS0w_b1017301-1ef3-46a1-8915-f41072e1c60a"
      unitRef="shares">13859000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i113a05651fb044f49ef9180c67dcd7e3_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF83MC9mcmFnOjdiN2UzMzI4MDBmNzQ3Zjc4Y2I5NWZlZWY1MTYzOGM0L3RhYmxlOmIzMjZiNzAwMWUxNTQxYzliOWQ3NmJhYTVjNjZiNGMyL3RhYmxlcmFuZ2U6YjMyNmI3MDAxZTE1NDFjOWI5ZDc2YmFhNWM2NmI0YzJfMi0zLTEtMS0w_cc5223a5-698b-4e00-a82a-77cf35702eab"
      unitRef="shares">13609000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ib6505072e0e14228bee195251af31d4a_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF83MC9mcmFnOjdiN2UzMzI4MDBmNzQ3Zjc4Y2I5NWZlZWY1MTYzOGM0L3RhYmxlOmIzMjZiNzAwMWUxNTQxYzliOWQ3NmJhYTVjNjZiNGMyL3RhYmxlcmFuZ2U6YjMyNmI3MDAxZTE1NDFjOWI5ZDc2YmFhNWM2NmI0YzJfMy0xLTEtMS0w_8a6939a8-a3d4-40fa-893a-a3fa58e3087a"
      unitRef="shares">1538000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="if503e1a8de82421e9fe69c7f00e791be_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF83MC9mcmFnOjdiN2UzMzI4MDBmNzQ3Zjc4Y2I5NWZlZWY1MTYzOGM0L3RhYmxlOmIzMjZiNzAwMWUxNTQxYzliOWQ3NmJhYTVjNjZiNGMyL3RhYmxlcmFuZ2U6YjMyNmI3MDAxZTE1NDFjOWI5ZDc2YmFhNWM2NmI0YzJfMy0zLTEtMS0w_2a7f2411-bdb3-498f-9e7c-2c2c04c6af35"
      unitRef="shares">1411000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF83MC9mcmFnOjdiN2UzMzI4MDBmNzQ3Zjc4Y2I5NWZlZWY1MTYzOGM0L3RhYmxlOmIzMjZiNzAwMWUxNTQxYzliOWQ3NmJhYTVjNjZiNGMyL3RhYmxlcmFuZ2U6YjMyNmI3MDAxZTE1NDFjOWI5ZDc2YmFhNWM2NmI0YzJfNC0xLTEtMS0w_966a5335-ef35-430d-985c-37979a730495"
      unitRef="shares">15397000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ide9f6e15665746279d0000be700fcc6a_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF83MC9mcmFnOjdiN2UzMzI4MDBmNzQ3Zjc4Y2I5NWZlZWY1MTYzOGM0L3RhYmxlOmIzMjZiNzAwMWUxNTQxYzliOWQ3NmJhYTVjNjZiNGMyL3RhYmxlcmFuZ2U6YjMyNmI3MDAxZTE1NDFjOWI5ZDc2YmFhNWM2NmI0YzJfNC0zLTEtMS0w_d39f9549-ec8d-4ee0-8d44-cd4afa7c6abf"
      unitRef="shares">15020000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjlmODZiNmQzNjg2NTQ2NjE4YWRlM2M3NmU2YjIzZmM4L3NlYzo5Zjg2YjZkMzY4NjU0NjYxOGFkZTNjNzZlNmIyM2ZjOF83My9mcmFnOjY2NGIzYjBhMjgyZjRjYTI4NWZjYTQxY2NmZjI1OTJlL3RleHRyZWdpb246NjY0YjNiMGEyODJmNGNhMjg1ZmNhNDFjY2ZmMjU5MmVfNjI1Mw_a39e46f1-3316-4df5-8fbc-be0b06b5aebf">COMMITMENTS AND CONTINGENCIES&lt;div style="margin-top:6pt;text-align:justify;text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Legal Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;From time to time, we may be a party to litigation, arbitration or other legal proceedings in the course of our business, including the matters described below. The claims and legal proceedings in which we could be involved include challenges to the scope, validity or enforceability of patents relating to our products or product candidates, and challenges by us to the scope, validity or enforceability of the patents held by others. These include claims by third parties that we infringe their patents or breach our license or other agreements with such third parties. The outcome of any such legal proceedings, regardless of the merits, is inherently uncertain. In addition, litigation and related matters are costly and may divert the attention of our management and other resources that would otherwise be engaged in other activities. If we were unable to prevail in any such legal proceedings, our business, results of operations, liquidity and financial condition could be adversely affected. Our accounting policy for accrual of legal costs is to recognize such expenses as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Securities Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On September 26, 2018, Caryl Hull Leavitt, individually and on behalf of all others similarly situated, filed a class action complaint for violation of federal securities laws against us, our Chief Executive Officer and our former Chief Financial Officer in the United States District Court for the Southern District of New York. By stipulation of the parties and Order of the Court dated November 20, 2018, the action was transferred to the United States District Court for the District of Massachusetts. On May 8, 2019, the Court entered an order appointing a lead plaintiff, and on July 3, 2019, lead plaintiff filed a consolidated class action complaint, or the Complaint. In addition to the originally named defendants, the Complaint also named as defendants certain of our other executive officers, and purported to be brought on behalf of a class of persons who acquired our securities between September 20, 2017 and September 12, 2018 and sought to recover damages caused by defendants&#x2019; alleged violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended, and Rule 10b-5 promulgated thereunder. The Complaint alleged, among other things, that the defendants made materially false and misleading statements related to the efficacy and safety of our product, ONPATTRO. The plaintiff sought, among other things, the designation of this action as a class action, an award of unspecified compensatory damages, interest, costs and expenses, including counsel fees and expert fees, and other relief as the court deems appropriate. All defendants filed &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;a motion to dismiss the Complaint in its entirety on July 31, 2019. On March 23, 2020, the Court granted our motion and dismissed the Complaint without prejudice. Pursuant to a prior Order of the Court, on June 1, 2020, plaintiff filed a motion seeking leave to file a further amended complaint. That motion was fully briefed on June 22, 2020. By Memorandum &amp;amp; Order dated March 12, 2021, the Court denied plaintiffs&#x2019; motion.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On September 12, 2019, the Chester County Employees Retirement Fund, individually and on behalf of all others similarly situated, filed a purported securities class action complaint for violation of federal securities laws against us, certain of our current and former directors and officers, and the underwriters of our November 14, 2017 public stock offering, in the Supreme Court of the State of New York, New York County. On November 7, 2019, plaintiff filed an amended complaint, or the New York Complaint. The New York Complaint is brought on behalf of an alleged class of those who purchased our securities pursuant and/or traceable to our November 14, 2017 public stock offering. The New York Complaint purports to allege claims arising under Sections 11, 12(a)(2) and 15 of the Securities Act of 1933, as amended, and generally alleges that the defendants violated the federal securities laws by, among other things, making material misstatements or omissions concerning the results of our APOLLO Phase 3 clinical trial of patisiran. The plaintiff seeks, among other things, the designation of the action as a class action, an award of unspecified compensatory damages, rescissory damages, interest, costs and expenses, including counsel fees and expert fees, and other relief as the court deems appropriate. All defendants filed a joint motion to dismiss the New York Complaint in its entirety on December 20, 2019. On November 2, 2020, the Court entered a Decision and Order denying defendants&#x2019; motion to dismiss. In November 2020, defendants filed a notice of appeal of the Court&#x2019;s decision to the Appellate Division of the Supreme Court of the State of New York for the First Department. Defendants&#x2019; appeal was fully briefed in March 2021, and the Appellate Division heard oral argument on April 7, 2021. Defendants&#x2019; appeal remains pending. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;We believe that the allegations contained in the New York Complaint are without merit and intend to defend the case vigorously. We cannot predict at this point the length of time that this action will be ongoing or the liabilities, if any, which may arise therefrom.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Government Investigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On or about April 9, 2021, we received a subpoena from the U.S. Department of Justice, U.S. Attorney&#x2019;s Office for the District of Massachusetts, requiring production of documents pertaining to our marketing and promotion of ONPATTRO (patisiran) in the United States. We are preparing a response to the subpoena and cooperating with the government. Experienced outside legal counsel has been retained to assist with this matter.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Since learning of this federal government investigation, and consistent with its charter, our nominating and corporate governance committee is directing our review of and response to the matter. Given the early stage and ongoing nature of the investigation, no determination has been made that a loss, if any, arising from this matter is probable or that the amount of any such loss, or range of loss, is reasonably estimable.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140603038633496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Apr. 23, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36407<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ALNYLAM PHARMACEUTICALS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">77-0602661<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">675 West Kendall Street,<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Henri A. Termeer Square<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Cambridge<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">551-8200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.01&#160;par value per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ALNY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">117,545,040<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001178670<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140603034379192">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 379,543<span></span>
</td>
<td class="nump">$ 496,580<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Marketable debt securities</a></td>
<td class="nump">1,273,027<span></span>
</td>
<td class="nump">1,333,182<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="nump">56,967<span></span>
</td>
<td class="nump">44,633<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">110,626<span></span>
</td>
<td class="nump">102,413<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">73,940<span></span>
</td>
<td class="nump">75,202<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">75,980<span></span>
</td>
<td class="nump">62,767<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_RoyaltiesReceivableCurrent', window );">Receivable related to the sale of future royalties</a></td>
<td class="nump">500,000<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">2,470,083<span></span>
</td>
<td class="nump">2,614,777<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">464,572<span></span>
</td>
<td class="nump">465,029<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">237,213<span></span>
</td>
<td class="nump">241,485<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedInvestmentsNoncurrent', window );">Restricted investments</a></td>
<td class="nump">40,725<span></span>
</td>
<td class="nump">40,725<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">42,676<span></span>
</td>
<td class="nump">45,045<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">3,255,269<span></span>
</td>
<td class="nump">3,407,061<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">45,381<span></span>
</td>
<td class="nump">51,966<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">280,527<span></span>
</td>
<td class="nump">355,909<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability</a></td>
<td class="nump">38,917<span></span>
</td>
<td class="nump">36,872<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">116,340<span></span>
</td>
<td class="nump">127,207<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_RoyaltyLiabilityCurrent', window );">Liability related to the sale of future royalties</a></td>
<td class="nump">13,660<span></span>
</td>
<td class="nump">13,316<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">494,825<span></span>
</td>
<td class="nump">585,270<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, net of current portion</a></td>
<td class="nump">288,015<span></span>
</td>
<td class="nump">293,039<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="nump">208,123<span></span>
</td>
<td class="nump">225,094<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">191,590<span></span>
</td>
<td class="nump">191,278<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_RoyaltyLiabilityNoncurrent', window );">Liability related to the sale of future royalties, net of current portion</a></td>
<td class="nump">1,086,065<span></span>
</td>
<td class="nump">1,058,225<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities</a></td>
<td class="nump">60,461<span></span>
</td>
<td class="nump">37,908<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">2,329,079<span></span>
</td>
<td class="nump">2,390,814<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.01 par value per share, 5,000 shares authorized and no shares issued and outstanding as of March&#160;31, 2021 and December&#160;31, 2020</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.01 par value per share, 250,000 shares authorized; 117,321 shares issued and outstanding as of March&#160;31, 2021; 116,427 shares issued and outstanding as of December&#160;31, 2020</a></td>
<td class="nump">1,173<span></span>
</td>
<td class="nump">1,164<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">5,747,394<span></span>
</td>
<td class="nump">5,644,074<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(36,717)<span></span>
</td>
<td class="num">(43,622)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(4,785,660)<span></span>
</td>
<td class="num">(4,585,369)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">926,190<span></span>
</td>
<td class="nump">1,016,247<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 3,255,269<span></span>
</td>
<td class="nump">$ 3,407,061<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_RoyaltiesReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalties Receivable, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_RoyaltiesReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_RoyaltyLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty Liability, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_RoyaltyLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_RoyaltyLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty Liability, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_RoyaltyLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=99377092&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedInvestmentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the noncurrent portion of investments which are not defined as or included in marketable (debt, equity, or other) securities that are pledged or subject to withdrawal restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedInvestmentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140603038664552">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">250,000,000<span></span>
</td>
<td class="nump">250,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">117,321,000<span></span>
</td>
<td class="nump">116,427,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">117,321,000<span></span>
</td>
<td class="nump">116,427,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140603038074552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 177,566<span></span>
</td>
<td class="nump">$ 99,476<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Operating costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods sold</a></td>
<td class="nump">23,023<span></span>
</td>
<td class="nump">13,302<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_CostOfCollaborationManufacturingAndRoyalties', window );">Cost of collaborations</a></td>
<td class="nump">8,039<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">185,899<span></span>
</td>
<td class="nump">169,571<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">146,859<span></span>
</td>
<td class="nump">126,761<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating costs and expenses</a></td>
<td class="nump">363,820<span></span>
</td>
<td class="nump">309,634<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(186,254)<span></span>
</td>
<td class="num">(210,158)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other (expense) income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(32,515)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">450<span></span>
</td>
<td class="nump">5,480<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="nump">19,044<span></span>
</td>
<td class="nump">23,032<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other (expense) income</a></td>
<td class="num">(13,021)<span></span>
</td>
<td class="nump">28,512<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">(199,275)<span></span>
</td>
<td class="num">(181,646)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="num">(1,016)<span></span>
</td>
<td class="num">(575)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (200,291)<span></span>
</td>
<td class="num">$ (182,221)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per common share - basic and diluted (in dollars per share)</a></td>
<td class="num">$ (1.71)<span></span>
</td>
<td class="num">$ (1.62)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted-average common shares used to compute basic and diluted net loss per common share (in shares)</a></td>
<td class="nump">117,080<span></span>
</td>
<td class="nump">112,748<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract', window );"><strong>Statements of Comprehensive Loss</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (200,291)<span></span>
</td>
<td class="num">$ (182,221)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive (loss) income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized (loss) gain on marketable securities</a></td>
<td class="num">(1)<span></span>
</td>
<td class="nump">4,045<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax', window );">Foreign currency translation gains</a></td>
<td class="nump">6,848<span></span>
</td>
<td class="nump">340<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax', window );">Defined benefit pension plans, net of tax</a></td>
<td class="nump">58<span></span>
</td>
<td class="nump">74<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Total other comprehensive income</a></td>
<td class="nump">6,905<span></span>
</td>
<td class="nump">4,459<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">(193,386)<span></span>
</td>
<td class="num">(177,762)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Net revenues from collaborations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">41,797<span></span>
</td>
<td class="nump">27,538<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Net product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 135,769<span></span>
</td>
<td class="nump">$ 71,938<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_CostOfCollaborationManufacturingAndRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cost Of Collaboration Manufacturing And Royalties</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_CostOfCollaborationManufacturingAndRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121605123&amp;loc=d3e30304-110892<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=120253306&amp;loc=d3e28129-110885<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32022-110900<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a-c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121640130&amp;loc=d3e1436-108581<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, before reclassification adjustment, of (increase) decrease in accumulated other comprehensive income of defined benefit plan, that has not been recognized in net periodic benefit cost (credit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i-k)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140603034403192">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Loss</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">112,188,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2019</a></td>
<td class="nump">$ 1,438,692<span></span>
</td>
<td class="nump">$ 1,122<span></span>
</td>
<td class="nump">$ 5,201,176<span></span>
</td>
<td class="num">$ (36,518)<span></span>
</td>
<td class="num">$ (3,727,088)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of common stock options, net of tax withholdings (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">976,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of common stock options, net of tax withholdings</a></td>
<td class="nump">54,221<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">54,212<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross', window );">Issuance of common stock under equity plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense related to equity-classified awards</a></td>
<td class="nump">34,578<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,578<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="nump">4,459<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,459<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(182,221)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(182,221)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in shares) at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">113,168,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2020</a></td>
<td class="nump">$ 1,349,729<span></span>
</td>
<td class="nump">$ 1,131<span></span>
</td>
<td class="nump">5,289,966<span></span>
</td>
<td class="num">(32,059)<span></span>
</td>
<td class="num">(3,909,309)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in shares) at Dec. 31, 2020</a></td>
<td class="nump">116,427,000<span></span>
</td>
<td class="nump">116,427,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="nump">$ 1,016,247<span></span>
</td>
<td class="nump">$ 1,164<span></span>
</td>
<td class="nump">5,644,074<span></span>
</td>
<td class="num">(43,622)<span></span>
</td>
<td class="num">(4,585,369)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of common stock options, net of tax withholdings (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">614,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of common stock options, net of tax withholdings</a></td>
<td class="nump">47,034<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">47,028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross', window );">Issuance of common stock under equity plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">280,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross', window );">Issuance of common stock under equity plans</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense related to equity-classified awards</a></td>
<td class="nump">56,295<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,295<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="nump">6,905<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,905<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (200,291)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(200,291)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in shares) at Mar. 31, 2021</a></td>
<td class="nump">117,321,000<span></span>
</td>
<td class="nump">117,321,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2021</a></td>
<td class="nump">$ 926,190<span></span>
</td>
<td class="nump">$ 1,173<span></span>
</td>
<td class="nump">$ 5,747,394<span></span>
</td>
<td class="num">$ (36,717)<span></span>
</td>
<td class="num">$ (4,785,660)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326096&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121640130&amp;loc=d3e1436-108581<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140603038087512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (200,291)<span></span>
</td>
<td class="num">$ (182,221)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Non-cash adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAmortizationAndAccretionNet', window );">Depreciation and amortization</a></td>
<td class="nump">12,601<span></span>
</td>
<td class="nump">7,613<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_AmortizationAndInterestAccretionRelatedToOperatingLeases', window );">Amortization and interest accretion related to operating leases</a></td>
<td class="nump">10,261<span></span>
</td>
<td class="nump">9,393<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_NonCashInterestExpenseOnSaleOfFutureRoyalties', window );">Non-cash interest expense on liability related to the sale of future royalties</a></td>
<td class="nump">28,184<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">55,690<span></span>
</td>
<td class="nump">34,578<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiGainLoss', window );">Realized and unrealized gain on marketable equity securities</a></td>
<td class="num">(47,016)<span></span>
</td>
<td class="num">(24,111)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherOperatingActivitiesCashFlowStatement', window );">Other</a></td>
<td class="nump">30,777<span></span>
</td>
<td class="nump">660<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable, net</a></td>
<td class="num">(10,709)<span></span>
</td>
<td class="num">(32,882)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="nump">1,934<span></span>
</td>
<td class="num">(11,952)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="num">(13,654)<span></span>
</td>
<td class="num">(19,958)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable, accrued expenses and other liabilities</a></td>
<td class="num">(66,573)<span></span>
</td>
<td class="num">(14,215)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="num">(27,804)<span></span>
</td>
<td class="num">(4,030)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating lease liability</a></td>
<td class="num">(9,060)<span></span>
</td>
<td class="num">(9,036)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(235,660)<span></span>
</td>
<td class="num">(246,161)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property, plant and equipment</a></td>
<td class="num">(17,178)<span></span>
</td>
<td class="num">(19,617)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of marketable securities</a></td>
<td class="num">(345,954)<span></span>
</td>
<td class="num">(396,409)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Sales and maturities of marketable securities</a></td>
<td class="nump">438,682<span></span>
</td>
<td class="nump">539,614<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireRestrictedInvestments', window );">Purchases of restricted investments</a></td>
<td class="num">(10,650)<span></span>
</td>
<td class="num">(9,900)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfRestrictedInvestments', window );">Proceeds from maturity of restricted investments</a></td>
<td class="nump">10,650<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities', window );">Other investing activities</a></td>
<td class="num">(4,198)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by investing activities</a></td>
<td class="nump">71,352<span></span>
</td>
<td class="nump">113,688<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions', window );">Proceeds from exercise of stock options and other types of equity, net</a></td>
<td class="nump">46,977<span></span>
</td>
<td class="nump">53,869<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities', window );">Proceeds from development derivative</a></td>
<td class="nump">4,200<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">51,177<span></span>
</td>
<td class="nump">53,869<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash, cash equivalents and restricted cash</a></td>
<td class="num">(3,910)<span></span>
</td>
<td class="num">(631)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net decrease in cash, cash equivalents and restricted cash</a></td>
<td class="num">(117,041)<span></span>
</td>
<td class="num">(79,235)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash, cash equivalents and restricted cash, beginning of period</a></td>
<td class="nump">499,046<span></span>
</td>
<td class="nump">549,628<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash, cash equivalents and restricted cash, end of period</a></td>
<td class="nump">382,005<span></span>
</td>
<td class="nump">470,393<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of noncash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Capital expenditures included in accounts payable and accrued expenses</a></td>
<td class="nump">$ 7,289<span></span>
</td>
<td class="nump">$ 6,619<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_AmortizationAndInterestAccretionRelatedToOperatingLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortization and Interest Accretion Related to Operating Leases</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_AmortizationAndInterestAccretionRelatedToOperatingLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_NonCashInterestExpenseOnSaleOfFutureRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non-Cash Interest Expense On Sale Of Future Royalties</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_NonCashInterestExpenseOnSaleOfFutureRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAmortizationAndAccretionNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate net amount of depreciation, amortization, and accretion recognized during an accounting period. As a noncash item, the net amount is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAmortizationAndAccretionNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120269885&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingActivitiesCashFlowStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example,  cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingActivitiesCashFlowStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash (inflow) outflow from investing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromOtherInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireRestrictedInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire investments (not to include restricted cash) that are pledged or subject to withdrawal restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireRestrictedInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow provided by derivative instruments during the period, which are classified as financing activities, excluding those designated as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3505-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfRestrictedInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale of investments that are pledged or subject to withdrawal restrictions during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfRestrictedInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140603033132200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NATURE OF BUSINESS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">NATURE OF BUSINESS</a></td>
<td class="text">NATURE OF BUSINESS<div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Alnylam Pharmaceuticals, Inc. (also referred to as Alnylam, we, our or us) commenced operations on June&#160;14, 2002 as a biopharmaceutical company seeking to develop and commercialize novel therapeutics based on RNA interference, or RNAi. We are committed to the advancement of our company strategy of building a multi-product, global, commercial biopharmaceutical company with a deep and sustainable clinical pipeline of RNAi therapeutics for future growth and a robust, organic research engine for sustainable innovation and great potential for patient impact. Since inception, we have focused on discovering, developing and commercializing RNAi therapeutics by establishing and maintaining a strong intellectual property position in the RNAi field, establishing strategic alliances with leading pharmaceutical and life sciences companies, generating revenues through licensing agreements, and ultimately developing and commercializing RNAi therapeutics globally, either independently or with our strategic partners. We have devoted substantially all of our efforts to business planning, research, development, manufacturing and early commercial efforts, acquiring, filing and expanding intellectual property rights, recruiting management and technical staff, and raising capital. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In early 2021, we launched our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Alnylam P</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">x25 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">strategy, which focuses on our planned transition to a top five biotech company, as measured by market capitalization, by the end of 2025. With </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Alnylam P</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">x25</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, we aim to deliver transformative rare and prevalent disease medicines for patients around the world through sustainable innovation, delivering exceptional financial performance and driving profitability.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of March&#160;31, 2021, we have four products that have received marketing approval, including one partnered product, and six late-stage investigational programs advancing towards potential commercialization. We currently generate product revenues from ONPATTRO in the U.S., Europe, Japan and in several additional countries as well as from GIVLAARI and OXLUMO in the U.S. and several countries in Europe.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140603031688312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIS OF PRESENTATION AND PRINCIPLES OF CONSOLIDATION<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">BASIS OF PRESENTATION AND PRINCIPLES OF CONSOLIDATION</a></td>
<td class="text">BASIS OF PRESENTATION AND PRINCIPLES OF CONSOLIDATION<div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The accompanying condensed consolidated financial statements of Alnylam are unaudited and have been prepared in accordance with accounting principles generally accepted in the United States of America, or GAAP, applicable to interim periods and, in the opinion of management, include all normal and recurring adjustments that are necessary to state fairly the results of operations for the reported periods. Our condensed consolidated financial statements have also been prepared on a basis substantially consistent with, and should be read in conjunction with, our audited consolidated financial statements for the year ended December&#160;31, 2020, which were included in our Annual Report on Form 10-K that was filed with the Securities and Exchange Commission on February 11, 2021. The year-end condensed consolidated balance sheet data was derived from our audited financial statements but does not include all disclosures required by GAAP. The results of our operations for any interim period are not necessarily indicative of the results of our operations for any other interim period or for a full fiscal year.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The accompanying condensed consolidated financial statements reflect the operations of Alnylam and our wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our significant accounting policies are described in Note 2 of the Notes to Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December&#160;31, 2020.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Use of Estimates</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. In our condensed consolidated financial statements, we use estimates and assumptions related to our inventory valuation and related reserves, liability related to the sale of future royalties, development derivative liability, income taxes, revenue recognition, research and development expenses, and stock-based compensation. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable. Actual results could differ from those estimates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The full extent to which the COVID-19 pandemic will directly or indirectly impact our business, results of operations and financial condition, including sales, expenses, reserves and allowances, the supply of our products and product candidates, clinical trials and research and development costs, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and variants thereof, and the actions taken to contain or treat it or vaccinate against it, as well as the economic impact on local, regional, national and international customers and markets. We have made estimates of the impact of COVID-19 within our financial statements and there may be changes to those estimates in future periods. Actual results may differ from these estimates.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Liquidity</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Based on our current operating plan, we believe that our cash, cash equivalents and marketable securities as of March&#160;31, 2021, together with the cash we expect to generate from product sales and under our current alliances, in addition to our strategic financing collaboration with The Blackstone Group Inc. and certain of its affiliates, will be sufficient to enable us to advance our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Alnylam P</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">x25 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">strategy for at least the next 12 months from the filing of this Quarterly Report on Form 10-Q.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140603033132200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET PRODUCT REVENUES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">NET PRODUCT REVENUES</a></td>
<td class="text">NET PRODUCT REVENUES<div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net product revenues consist of the following:</span></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:18pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:82.309%"><tr><td style="width:1.0%"/><td style="width:58.047%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.971%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.510%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.972%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ONPATTRO</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,471&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,196&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,653&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,166&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rest of World (primarily Japan)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,827&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,302&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,951&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,664&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">GIVLAARI</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,762&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,274&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,873&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rest of World </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,673&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,274&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OXLUMO</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,408&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,737&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,145&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:11pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net product revenues</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135,769&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,938&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the balance of our receivables related to our net product revenues: </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:82.456%"><tr><td style="width:1.0%"/><td style="width:57.942%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.686%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.937%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables included in &#8220;Accounts receivable, net&#8221;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,516&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,871&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130551-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130556-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130550-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130558-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140603033131480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET REVENUES FROM COLLABORATIONS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">NET REVENUES FROM COLLABORATIONS</a></td>
<td class="text">NET REVENUES FROM COLLABORATIONS<div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Net revenues from collaborations consist of the following:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:84.941%"><tr><td style="width:1.0%"/><td style="width:63.616%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.111%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.660%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.113%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron Pharmaceuticals</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,343&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,503&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Novartis AG</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,111&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,060&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vir Biotechnology</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,822&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,516&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">521&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">459&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,797&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,538&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the balance of our receivables and contract liabilities related to our collaboration agreements:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:84.795%"><tr><td style="width:1.0%"/><td style="width:56.313%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.762%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.662%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.763%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables included in &#8220;Accounts receivable, net&#8221;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,111&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,542&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liabilities included in &#8220;Deferred revenue&#8221;</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,759&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,021&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized revenue of $25.3 million and $14.7 million in the three months ended March&#160;31, 2021 and 2020, respectively, that was included in the contract liability balance at the beginning of the respective period.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In order to determine revenue recognized in the period from contract liabilities, we first allocate revenue to the individual contract liability balance outstanding at the beginning of the period until the revenue exceeds that balance. If additional consideration is received on those contracts in subsequent periods, we assume all revenue recognized in the reporting period first applies to the beginning contract liability as opposed to a portion applying to the new consideration for the period.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table provides research and development expenses incurred by type, for which we recognize net revenue, that are directly attributable to our collaboration agreements, by collaboration partner:</span></div><div><span><br/></span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:24.083%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.759%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.759%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.759%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.759%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.759%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.762%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Clinical Trial and Manufacturing</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">External Services</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Clinical Trial and Manufacturing</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">External Services</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron Pharmaceuticals</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,799&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,235&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,612&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,491&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vir Biotechnology</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,029&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,355&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">339&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,693&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Novartis AG</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">998&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">859&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,839&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,452&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,949&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,681&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The research and development expenses incurred for each agreement listed in the table above consist of costs incurred for (i) clinical expenses, including manufacturing of clinical product, (ii) external services including consulting services and lab supplies and services, and (iii) other expenses, including professional services, facilities and overhead allocations, and a reasonable estimate of compensation and related costs as billed to our counterparties, for which we recognize net revenue from collaborations. For the three months ended March&#160;31, 2021 and 2020, we did not incur material selling, general and administrative expenses related to our collaboration agreements.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Product Alliances</span></div><div style="margin-top:6pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Regeneron Pharmaceuticals, Inc.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In April&#160;2019, we entered into a global, strategic collaboration with Regeneron Pharmaceuticals, Inc., or Regeneron, to discover, develop and commercialize RNAi therapeutics for a broad range of diseases by addressing therapeutic targets expressed in the eye and central nervous system, or CNS, in addition to a select number of targets expressed in the liver, which we refer to as the Regeneron Collaboration. The Regeneron Collaboration is governed by a Master Agreement, referred to as the Regeneron Master Agreement, which became effective on May 21, 2019, or the Effective Date. In connection with the Regeneron Master Agreement, we and Regeneron entered into (i) a binding co-co collaboration term sheet covering the continued development of cemdisiran, our C5 small interfering RNA, or siRNA, currently in Phase 2 development for C5 complement-mediated diseases, as a monotherapy and (ii) a binding license term sheet to evaluate anti-C5 antibody-siRNA combinations for C5 complement-mediated diseases including evaluating the combination of Regeneron&#8217;s pozelimab (REGN3918), currently in Phase 2 development, and cemdisiran. The C5 co-co collaboration and license agreements were executed in August 2019.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Under the terms of the Regeneron Collaboration, we are working exclusively with Regeneron to discover RNAi therapeutics for eye and CNS diseases for an initial five-year research period, which we refer to as the Initial Research Term. Regeneron has an option to extend the Initial Research Term (referred to as the Research Term Extension Period, and together with the Initial Research Term, the Research Term) for up to an additional five years, for a research term extension fee of up to $400.0 million. The Regeneron Collaboration also covers a select number of RNAi therapeutic programs designed to target genes expressed in the liver, including our previously announced collaboration with Regeneron to identify RNAi therapeutics for the chronic liver disease nonalcoholic steatohepatitis. We retain broad global rights to all of our other unpartnered liver-</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">directed clinical and pre-clinical pipeline programs. The Regeneron Collaboration is governed by a joint steering committee that is comprised of an equal number of representatives from each party.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Regeneron will lead development and commercialization for all programs targeting eye diseases (subject to limited exceptions), entitling us to certain potential milestone and royalty payments pursuant to the terms of a license agreement, the form of which has been agreed upon by the parties. We and Regeneron will alternate leadership on CNS and liver programs, with the lead party retaining global development and commercial responsibility. For CNS and liver programs, both we and Regeneron will have the option at lead candidate selection to enter into a&#160;co-co&#160;collaboration agreement, the form of which has been agreed upon by the parties, whereby both companies will share equally all costs of, and profits from, all development and commercialization activities under the program. If the&#160;non-lead&#160;party elects to not enter into a&#160;co-co&#160;collaboration agreement with respect to a given CNS or liver program, we and Regeneron will enter into a license agreement with respect to such program and the lead party will be the &#8220;Licensee&#8221; for the purposes of the license agreement. If the lead party for a CNS or liver program elects to not enter into the&#160;co-co&#160;collaboration agreement, then we and Regeneron will enter into a license agreement with respect to such program and leadership of the program will transfer to the other party and the former&#160;non-lead&#160;party will be the &#8220;Licensee&#8221; for the purposes of the license agreement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">With respect to the programs directed to C5 complement-mediated diseases, we retain control of cemdisiran monotherapy development, and Regeneron is leading combination product development. Under the C5 co-co collaboration agreement, we and Regeneron equally share costs and potential future profits on any monotherapy program. Under the C5 license agreement, for cemdisiran to be used as part of a combination product, Regeneron is solely responsible for all development and commercialization costs and we will receive low double-digit royalties and commercial milestones of up to $325.0 million on any potential combination product sales. The C5 co-co collaboration agreement, the C5 license agreement, and the Master Agreement have been combined for accounting purposes and treated as a single agreement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In connection with the Regeneron Master Agreement, Regeneron made an upfront payment of $400.0 million. We are also eligible to receive up to an additional $200.0 million in milestone payments upon achievement of certain criteria during early clinical development for eye and CNS programs. We and Regeneron plan to advance programs directed to up to 30 targets under the Regeneron Collaboration during the Initial Research Term. For each program, Regeneron will provide us with $2.5 million in funding at program initiation and an additional $2.5 million at lead candidate identification, with the potential for approximately $30.0 million in annual discovery funding to us as the Regeneron Collaboration reaches steady state.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Regeneron has the right to terminate the Regeneron Master Agreement for convenience upon ninety days&#8217; notice. The termination of the Regeneron Master Agreement does not affect the term of any license agreement or&#160;co-co&#160;collaboration agreement then in effect. In addition, either party may terminate the Regeneron Master Agreement for a material breach by, or insolvency of, the other party. Unless earlier terminated pursuant to its terms, the Regeneron Master Agreement will remain in effect with respect to each program until (a)&#160;such program becomes a terminated program or (b)&#160;the parties enter into a license agreement or&#160;co-co&#160;collaboration agreement with respect to such program.&#160;The Regeneron Master Agreement includes various representations, warranties, covenants, dispute escalation and resolution mechanisms, indemnities and other provisions customary for transactions of this nature.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For any license agreement subsequently entered into, the licensee will generally be responsible for its own costs and expenses incurred in connection with the development and commercialization of the collaboration products. The licensee will pay to the licensor certain development and/or commercialization milestone payments totaling up to $150.0 million for each collaboration product. In addition, following the first commercial sale of the applicable collaboration product under a license agreement, the licensee is required to make certain tiered royalty payments, ranging from low double-digits up to 20%, to the licensor based on the aggregate annual net sales of the collaboration product, subject to customary reductions.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For any co-co&#160;collaboration agreement subsequently entered into, we and Regeneron will share equally all costs of, and profits from, development and commercialization activities. Reimbursement of our share of costs will be recognized as a reduction to research and development expense in the condensed consolidated statements of operations and comprehensive loss. In the event that a party exercises its&#160;opt-out&#160;right, the lead party will be responsible for all costs and expenses incurred in connection with the development and commercialization of the collaboration products under the applicable&#160;co-co&#160;collaboration agreement, subject to continued sharing of costs through defined points. If a party exercises its&#160;opt-out&#160;right, following the first commercial sale of the applicable collaboration product under a&#160;co-co&#160;collaboration agreement, the lead party is required to make certain tiered royalty payments, ranging from low double-digits up to 20%, to the other party based on the aggregate annual net sales of the collaboration product and the timing of the exercise of the&#160;opt-out&#160;right, subject to customary reductions and a reduction for&#160;opt-out&#160;transition costs.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Due to the uncertainty of pharmaceutical development and the high historical failure rates generally associated with drug development, we may not receive any milestone or royalty payments from Regeneron under the Regeneron Master Agreement, the C5 license agreement, or any future license agreement, or under any co-co collaboration agreement in the event we exercise our opt-out right.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our obligations under the Regeneron Collaboration include: (i) a research license and research services, collectively referred to as the Research Services Obligation; (ii) a worldwide license to cemdisiran for combination therapies, and manufacturing and supply, and development service obligations, collectively referred to as the C5 License Obligation; and (iii) development, manufacturing and commercialization activities for cemdisiran monotherapies, referred to as the C5 Co-Co Obligation.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The research license is not distinct from the research services primarily as a result of Regeneron being unable to benefit on its own or with other resources reasonably available, as the license is providing access to specialized expertise, particularly as it relates to RNAi technology that is not available in the marketplace.&#160;Similarly, the worldwide license to cemdisiran for combination therapies is not distinct from the manufacturing and supply, and development service obligations, as Regeneron cannot benefit on its own from the value of the license without receipt of supply.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Separately, the cemdisiran monotherapy co-co collaboration agreement is under the scope of ASC 808 as we and Regeneron are both active participants in the development and manufacturing activities and are exposed to significant risks and rewards that are dependent on commercial success of the activities of the arrangement. The development and manufacturing activities are a combined unit of account under the scope of ASC 808 and are not deliverables under ASC 606.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The total transaction price is comprised of the&#160;$400.0 million&#160;upfront payment and&#160;additional variable consideration related to research, development, manufacturing and supply activities related to the Research Services Obligation and the C5 License Obligation. We utilized the expected value method to determine the amount of reimbursement for these activities. We determined that any variable consideration related to sales-based royalties and milestones related to the worldwide license to cemdisiran for combination therapies is deemed to be constrained and therefore has been excluded from the transaction price. In addition, we are eligible to receive future milestones upon the achievement of certain criteria during early clinical development for the eye and CNS programs.&#160;We are also eligible to receive royalties on future commercial sales for certain eye, CNS or liver targets, if any; however, these amounts are excluded from variable consideration under the Regeneron Collaboration as we are only eligible to receive such amounts if, after a drug candidate is identified, the form of license agreement is subsequently executed resulting in a license that is granted to Regeneron. Any such subsequently granted license would represent a separate transaction under ASC 606. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We allocated the initial transaction price to each unit of account based on the applicable accounting guidance as follows, in thousands: </span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.467%"><tr><td style="width:1.0%"/><td style="width:35.806%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.412%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.736%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.412%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.736%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.331%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.567%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:83%">Performance Obligations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:83%">Standalone Selling Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:83%">Transaction Price Allocated</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:83%">Accounting Guidance</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">Research Services Obligation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">130,700&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">183,100&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">ASC 606</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">C5 License Obligation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">97,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">92,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:95%">ASC 606</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">C5 Co-Co Obligation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">364,600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">246,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">ASC 808</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">521,600&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The transaction price was allocated to the obligations based on the relative estimated standalone selling prices of each obligation, over which management has applied significant judgment. We developed the estimated standalone selling price for the licenses included in the Research Services Obligation and the C5 License Obligation primarily based on the probability-weighted present value of expected future cash flows associated with each license related to each specific program. In developing such estimate, we applied judgment in the determination of the forecasted revenues, taking into consideration the applicable market conditions and relevant entity-specific factors, the expected number of targets or indications expected to be pursued under each license, the probability of success, the time needed to develop a product candidate pursuant to the associated license and the discount rate. We developed the estimated standalone selling price for the services and/or manufacturing and supply included in each of the obligations, as applicable, primarily based on the nature of the services to be performed and/or goods to be manufactured and estimates of the associated costs. The estimated standalone selling price of the C5 Co-Co Obligation was developed by estimating the present value of expected future cash flows that Regeneron is entitled to receive. In developing such estimate, we applied judgment in determining the indications that will be pursued, the forecasted revenues for such indications, the probability of success and the discount rate.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For the Research Services Obligation and the C5 License Obligation accounted for under ASC 606, we measure proportional performance over time using an input method based on cost incurred relative to the total estimated costs for each of the identified obligations, on a quarterly basis, by determining the proportion of effort incurred as a percentage of total effort we expect to expend.&#160;This ratio is applied to the transaction price allocated to each obligation. Management has applied significant judgment in the process of developing our estimates. Any changes to these estimates will be recognized in the period in which they change as a cumulative catch up. We re-evaluate the transaction price as of the end of each reporting period, as of March&#160;31, 2021, the total transaction price was $530.5&#160;million. As of March&#160;31, 2021, the transaction price is comprised of the </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">upfront payment and variable consideration related to development, manufacture and supply activities. For the C5 Co-Co Obligation accounted for under ASC 808, the transaction price allocated to this obligation is recognized using a proportional performance method. Revenue recognized under this agreement, inclusive of the amount allocated to the C5 Co-Co Obligation, is accounted for as collaboration revenue.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following tables provide a summary of the transaction price allocated to each unit of account based on the applicable accounting guidance, in addition to revenue activity during the period, in thousands:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:91.374%"><tr><td style="width:1.0%"/><td style="width:25.300%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.440%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.660%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.440%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.660%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.440%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.660%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.440%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.660%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Transaction Price Allocated</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Deferred Revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Performance Obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31,<br/>2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31,<br/>2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,<br/>2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Accounting Guidance</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Research Services Obligation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">200,600&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">45,100&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">54,900&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ASC 606</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">C5 License Obligation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">83,900&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">45,200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">58,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ASC 606</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">C5 Co-Co Obligation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">246,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">228,900&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">231,400&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ASC 808</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">530,500&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">319,200&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">345,000&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:66.959%"><tr><td style="width:1.0%"/><td style="width:34.926%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.673%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.699%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.673%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.699%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.673%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:12.657%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Revenue Recognized During</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Performance Obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31, 2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31, 2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Accounting Guidance</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Research Services Obligation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">9,800&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">12,300&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ASC 606</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">C5 License Obligation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">13,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ASC 606</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">C5 Co-Co Obligation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4,200&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ASC 808</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">25,800&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">16,500&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of&#160;March&#160;31, 2021, the aggregate amount of the transaction price allocated to the remaining Research Services Obligation and C5 License Obligation that was unsatisfied was&#160;$188.3 million, which&#160;is expected to be recognized through the term of the Regeneron Collaboration as the services are performed. This amount excludes the transaction price allocated to the C5 Co-Co Obligation accounted for under ASC 808. Deferred revenue related to the Regeneron Collaboration is classified as either current or non-current in the condensed consolidated balance sheets based on the period the revenue is expected to be recognized.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Novartis AG</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In February 2013, we and The Medicines Company, or MDCO, entered into a license and collaboration agreement pursuant to which we granted to MDCO an exclusive, worldwide license to develop, manufacture and commercialize RNAi therapeutics targeting proprotein convertase subtilisin/kexin type 9, or PCSK9, for the treatment of hypercholesterolemia and other human diseases, including inclisiran. We refer to this agreement, as amended through the date hereof, as the MDCO License Agreement. On January 6, 2020, Novartis completed its acquisition of MDCO, and assumed all rights and obligations under the MDCO License Agreement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of March&#160;31, 2021, we have earned $45.0&#160;million of milestones and upon achievement of certain events, we will be entitled to receive additional milestones, up to an aggregate of $135.0&#160;million, including $25.0&#160;million associated with the U.S. regulatory approval milestone, $10.0&#160;million in other specified regulatory milestones and $100.0&#160;million in specified commercialization milestones. In addition, we will be entitled to royalties ranging from 10% up to 20% based on annual worldwide net sales of licensed products by Novartis, its affiliates and sublicensees, subject to reduction under specified circumstances. Due to the uncertainty of pharmaceutical development and the high historical failure rates generally associated with drug development, we may not receive any additional milestone payments under the MDCO License Agreement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Unless terminated earlier in accordance with the terms of the agreement, the MDCO License Agreement expires on a licensed product-by-licensed product and country-by-country basis upon expiration of the last royalty term for any licensed product in any country, where a royalty term is defined as the latest to occur of (1) the expiration of the last valid claim of patent rights covering a licensed product, (2) the expiration of the Regulatory Exclusivity, as defined in the MDCO License Agreement, and (3) the twelfth anniversary of the first commercial sale of the licensed product in such country. We estimate that our fundamental RNAi patents covering licensed products under the MDCO License Agreement will expire both in and outside of the U.S. generally between 2016 and 2028. We also estimate that our inclisiran product-specific patents covering licensed products under the MDCO License Agreement will expire in the U.S., Europe, China and Japan in 2036 and elsewhere at the end of 2033. These patent rights are subject to potential patent term extensions and/or supplemental protection certificates </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">extending such terms in countries where such extensions may become available due to regulatory delay. In addition, more patent filings relating to the collaboration may be made in the future.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Either party may terminate the MDCO License Agreement in the event the other party fails to cure a material breach or upon patent-related challenges by the other party. In addition, Novartis has the right to terminate the agreement without cause at any time upon four months&#8217; prior written notice.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the term of the MDCO License Agreement, neither party will, alone or with an affiliate or third party, research, develop or commercialize, or grant a license to any third party to research, develop or commercialize, in any country, any siRNA product directed to the PCSK9 gene, other than a licensed product, without the prior written agreement of the other party, subject to the terms of the MDCO License Agreement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We evaluated the MDCO License Agreement and concluded that Novartis meets the definition of a customer and that the MDCO License Agreement is a contract. During 2018, we completed the performance obligations identified in the MDCO License Agreement. However, we continue to receive additional orders for supply of certain material. Given Novartis now has the ability to manufacture on its own through its own vendors, such orders will be treated as separate agreements and any associated revenue will be recognized upon transfer of control.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Vir Biotechnology, Inc. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In October 2017, we and Vir Biotechnology, Inc., or Vir, entered into a collaboration and license agreement, or the Vir Agreement, for the development and commercialization of RNAi therapeutics for infectious diseases, including chronic hepatitis B virus, or HBV, infection. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Pursuant to the Vir Agreement, we granted to Vir an exclusive license to develop, manufacture and commercialize ALN-HBV02 (VIR-2218), for all uses and purposes other than certain excluded fields, as set forth in the Vir Agreement. In addition, we granted Vir an exclusive option for up to four additional RNAi therapeutic programs for the treatment of infectious diseases. Under the terms of the Vir Agreement, for each product arising from the HBV program, including ALN-HBV02, we retained the right to opt into a profit-sharing arrangement prior to the start of a Phase 3 clinical trial. In addition, we have the right on a product-by-product basis with respect to each additional infectious disease program that Vir elects to pursue, to opt into a profit-sharing arrangement for each such product at any time during a specified period prior to the initiation of a Phase 3 clinical trial for each such product. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Pursuant to the Vir Agreement, Vir paid us an upfront fee of $10.0 million and issued to us 1,111,111 shares of its common stock. Under the Vir Agreement, we may also receive milestone payments upon the achievement of certain development, regulatory and commercial milestones, as well as royalties on the net sales of licensed products ranging from high-single-digit to sub-teen double-digit percentages. In March 2020, we achieved a development milestone relating to ALN-HBV02 and earned a $15.0 million cash milestone and 1,111,111 shares of Vir's common stock, which were received in the second quarter of 2020. In June 2020, we earned and received a $10.0&#160;million payment from Vir related to Vir's sublicense for ALN-HBV02 in China. Due to the uncertainty of pharmaceutical development and the high historical failure rates generally associated with drug development, we may not receive any additional milestone payments or any royalty payments under the Vir Agreement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In March and April 2020, we entered into amendments to the Vir Agreement to expand our collaboration to include the development and commercialization of RNAi therapeutics targeting SARS-CoV-2, the virus that causes the disease COVID-19, along with three additional targets focused on human host factors for SARS-CoV-2, including angiotensin converting enzyme-2 and transmembrane protease, serine 2 and potentially a third mutually selected host factor target. Under the Vir amendments, we and Vir were each responsible for our own pre-clinical development costs incurred in performing our allocated responsibilities under an agreed-upon initial pre-clinical development plan. Under the original agreements, we and Vir agreed to equally share certain costs incurred in connection with the manufacture of non-GMP drug product required for pre-clinical development prior to filing an IND for the first product in the coronavirus program. We also agreed that Vir would lead all development and commercialization of any selected development candidates. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In December 2020, we signed a letter agreement to amend the Vir Agreement such that we are solely responsible for conducting pre-clinical research activities under the pre-clinical development plan, related to the COVID-19 activities in the March and April 2020 amendments, at our discretion and sole expense, and effective as of July 1, 2020, we are responsible for all pre-clinical development costs incurred under such plan for such COVID-19 related activities.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Unless terminated earlier in accordance with the terms of the agreement, the Vir Agreement expires on a licensed product-by-product and country-by-country basis upon expiration of all royalty payment obligations under the agreement. If Vir does not exercise its option for an infectious disease program, the Vir Agreement will expire upon the expiration of the applicable option period with respect to such program. However, if we exercise our profit-sharing option for any product, the term of the agreement will continue until the expiration of the profit-sharing arrangement for such product. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Either party may terminate the agreement in the event the other party fails to cure a material breach, or upon patent-related challenges by the other party. In addition, Vir has the right to terminate the agreement on a program-by-program basis or in its entirety for any reason on 90 days&#8217; written notice.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We identified one performance obligation under the Vir Agreement, as amended, comprised of: i) the exclusive license to develop, manufacture and commercialize RNAi therapeutics (including ALN-HBV02); ii) the obligation to deliver four additional development candidates and supply product for each such RNAi therapeutic program; and iii) the obligation to deliver up to four development candidates and supply product for RNAi therapeutic programs targeting SARS-CoV-2. The license is not distinct from the services, including the obligation to deliver development candidates and supply product, as Vir cannot benefit on its own from the value of the license without receipt of such services and supply.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We measure proportional performance over time using an input method based on cost incurred relative to the total estimated costs for the identified performance obligation, on a quarterly basis, by determining the proportion of effort incurred as a percentage of total effort we expect to expend. This ratio is applied to the total transaction price. Management has applied significant judgment in the process of developing our estimates. Any changes to these estimates will be recognized in the period in which they change as a cumulative catch up. As of March&#160;31, 2021, the total transaction price was determined to be $110.1&#160;million, and is comprised of the upfront payment, fair value of non-cash equity consideration at contract inception, milestones achieved and variable consideration related to development, manufacture and supply activities. We utilized the expected value method to determine the amount of reimbursement for these activities. The total transaction price is allocated entirely to the single performance obligation. We determined any variable consideration related to sales-based royalties and milestones related to the exclusive license to be constrained and therefore excluded such consideration from the transaction price.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of March&#160;31, 2021, the aggregate amount of the transaction price allocated to the performance obligation that was unsatisfied was $48.8&#160;million, which is expected to be recognized through the term of the Vir Agreement as the services are performed.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140603031745480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LIABILITY RELATED TO THE SALE OF FUTURE ROYALTIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock', window );">LIABILITY RELATED TO SALE OF FUTURE ROYALTIES</a></td>
<td class="text">LIABILITY RELATED TO THE SALE OF FUTURE ROYALTIES<div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In April 2020, we entered into a purchase and sale agreement, or Purchase Agreement, with BX Bodyguard Royalties L.P. (an affiliate of The Blackstone Group Inc.), or Blackstone Royalties, under which Blackstone Royalties acquired 50% of royalties payable, or Royalty Interest, with respect to net sales by MDCO, its affiliates or sublicensees of inclisiran and any other licensed products under the MDCO License Agreement, and 75% of the commercial milestone payments payable under the MDCO License Agreement, together with the Royalty Interest, the Purchased Interest. If Blackstone Royalties does not receive payments in respect of the Royalty Interest by December 31, 2029, equaling at least $1.00&#160;billion, Blackstone Royalties will receive 55% of the Royalty Interest beginning on January 1, 2030. In consideration for the sale of the Purchased Interest, Blackstone Royalties paid us $500.0&#160;million in April 2020 and has an unconditional obligation to pay us an additional $500.0&#160;million on September 30, 2021, which was recorded as a receivable upon execution of the Purchase Agreement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We continue to own or control all inclisiran intellectual property rights and are responsible for certain ongoing manufacturing and supply obligations related to the generation of the Purchased Interest. Due to our continuing involvement, we will continue to account for any royalties and commercial milestones due to us under the MDCO License Agreement as revenue on our condensed consolidated statement of operations and comprehensive loss and record the proceeds from this transaction as a liability, net of closing costs, on our condensed consolidated balance sheet. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In order to determine the amortization of the liability related to the sale of future royalties, we are required to estimate the total amount of future payments to Blackstone Royalties over the life of the Purchase Agreement. The $1.00&#160;billion liability, recorded at execution of the agreement, will be accreted to the total of these royalty and commercial milestone payments as interest expense over the life of the Purchase Agreement. At execution, our estimate of this total interest expense resulted in an effective annual interest rate of 11%. This estimate contains assumptions that impact both the amount recorded at execution and the interest expense that will be recognized in future periods. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As payments are made to Blackstone Royalties, the balance of the liability will be effectively repaid over the life of the Purchase Agreement. The exact timing and amount of repayment is likely to change each reporting period. A significant increase or decrease in net sales of inclisiran will materially impact the liability related to the sale of future royalties, interest expense and the time period for repayment. We will periodically assess the expected payments to Blackstone Royalties and to the extent the amount or timing of such payments is materially different than our initial estimates, we will prospectively adjust the amortization of the liability related to the sale of future royalties and the related interest expense.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of March&#160;31, 2021, the carrying value of the liability related to the sale of future royalties was $1.10&#160;billion, net of closing costs of $13.0&#160;million. The carrying value of the liability related to the sale of future royalties approximates fair value as </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">of March&#160;31, 2021 and is based on our current estimates of future royalties and commercial milestones expected to be paid to Blackstone Royalties over the life of the arrangement, which are considered Level 3 inputs.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table shows the activity with respect to the liability related to the sale of future royalties, in thousands:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:87.134%"><tr><td style="width:1.0%"/><td style="width:81.282%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.638%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.680%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying value of liability related to sale of future royalties as of December&#160;31, 2020</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,071,541&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense recognized</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,184&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying value of liability related to sale of future royalties as of March&#160;31, 2021</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,099,725&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liability Related To The Sale Of Future Royalties</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140603031604952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE MEASUREMENTS</a></td>
<td class="text">FAIR VALUE MEASUREMENTS<div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following tables present information about our financial assets and liabilities that are measured at fair value on a recurring basis and indicate the fair value hierarchy of the valuation techniques we utilized to determine such fair value:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"/><td style="width:48.973%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.650%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted<br/>Prices in<br/>Active<br/>Markets<br/>(Level 1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Observable<br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177,470&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177,470&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable debt securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government-sponsored enterprise securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215,200&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215,200&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,057,827&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,057,827&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable equity securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,967&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,967&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash (money market funds)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,483&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,483&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total financial assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,508,947&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">235,920&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,273,027&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Development derivative liability (Note 10)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,038&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,038&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"/><td style="width:48.973%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.650%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted<br/>Prices in<br/>Active<br/>Markets<br/>(Level 1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Observable<br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,726&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,726&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable debt securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government-sponsored enterprise securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245,214&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245,214&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,087,968&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,087,968&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable equity securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,633&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,633&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash (money market funds)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,483&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,483&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total financial assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,475,024&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121,842&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,353,182&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Development derivative liability (Note 10)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,585&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,585&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The carrying amounts reflected on our condensed consolidated balance sheets for cash, accounts receivable, net, other current assets, accounts payable and accrued expenses approximate fair value due to their short-term maturities. The carrying </span></div>amount of our debt as of March&#160;31, 2021 approximates fair value as the debt was drawn on December 31, 2020 and has variable interest.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140603030753752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>MARKETABLE DEBT SECURITIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_InvestmentsInMarketableDebtSecuritiesDisclosureTextBlock', window );">MARKETABLE DEBT SECURITIES</a></td>
<td class="text">MARKETABLE DEBT SECURITIES<div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We invest our excess cash balances in marketable debt securities and at each balance sheet date presented, we classify all of our investments in debt securities as available-for-sale and as current assets as they represent the investment of funds available for current operations. We did not record any impairment charges related to our marketable debt securities during the three months ended March&#160;31, 2021 or 2020.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following tables summarize our marketable debt securities:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:49.779%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.632%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government-sponsored enterprise securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215,171&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(58)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215,200&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,057,509&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">335&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,057,827&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,272,680&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">422&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(75)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,273,027&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:49.779%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.632%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government-sponsored enterprise securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245,113&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245,214&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,107,721&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">328&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(81)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,107,968&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,352,834&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">463&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(115)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,353,182&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The fair values of our marketable debt securities by classification in the condensed consolidated balance sheets were as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.128%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.422%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,000&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable debt securities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,273,027&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,333,182&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,273,027&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,353,182&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_InvestmentsInMarketableDebtSecuritiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investments in marketable debt securities disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_InvestmentsInMarketableDebtSecuritiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140603033036488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER BALANCE SHEET DETAILS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">OTHER BALANCE SHEET DETAILS</a></td>
<td class="text">OTHER BALANCE SHEET DETAILS<div style="margin-top:6pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Inventory</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The components of inventory are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.128%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.422%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,694&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,460&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in progress</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,593&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,149&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,753&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,693&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,040&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,302&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-indent:18pt"><span><br/></span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of March&#160;31, 2021 and December&#160;31, 2020, we held $17.1 million of long- term inventory included within other assets in our condensed consolidated balance sheet as we anticipate it being consumed beyond our normal operating cycle.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Cash, Cash Equivalents and Restricted Cash</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within our condensed consolidated balance sheets that sum to the total of these amounts shown in the condensed consolidated statements of cash flows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.128%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.422%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">379,543&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">467,779&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total restricted cash included in prepaid expenses, other current assets and long-term other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,462&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,614&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents, and restricted cash shown in the condensed consolidated statements of cash flows</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">382,005&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">470,393&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Accumulated Other Comprehensive (Loss) Income</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following tables summarize the changes in accumulated other comprehensive loss, by component:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:33.256%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Loss on Investment in Joint Venture</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Defined Benefit Pension<br/>Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) from Debt</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Securities</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Foreign Currency Translation<br/>Adjustment</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Accumulated Other</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Comprehensive Loss</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32,792)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,754)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">348&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,424)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43,622)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive (loss) income before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,848&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,847&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from other comprehensive income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,848&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,905&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of March 31, 2021</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32,792)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,696)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(576)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36,717)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:33.256%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Loss on Investment in Joint Venture</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Defined Benefit Pension<br/>Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains from Debt<br/>Securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Foreign Currency Translation<br/>Adjustment</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Accumulated Other<br/>Comprehensive Loss</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2019</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32,792)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,520)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(343)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36,518)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,317&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">340&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,657&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from other comprehensive income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,728&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,802&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net other comprehensive income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,045&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">340&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,459&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of March 31, 2020</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32,792)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,446)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,182&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32,059)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts reclassified out of accumulated other comprehensive loss relate to settlements of marketable debt securities and amortization of our pension obligation which are recorded as interest income and other income, respectively, in the condensed consolidated statements of operations and comprehensive loss.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -URI http://asc.fasb.org/topic&amp;trid=2122208<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140603132977528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CREDIT AGREEMENT<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAbstract', window );"><strong>Line of Credit Facility [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">CREDIT AGREEMENT</a></td>
<td class="text">CREDIT AGREEMENT<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In April 2020, we entered into a credit agreement, or Credit Agreement, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">among us, certain of our subsidiaries (such subsidiaries, together with us, the Loan Parties), funds or accounts managed or advised by GSO Capital Partners LP (now Blackstone Alternative Credit Advisors LP) and certain other affiliates of T</span><span style="background-color:#ffffff;color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">he Blackstone Group Inc.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, and the other lenders from time to time parties thereto, collectively, the Lenders, and Wilmington Trust, National Association, as the administrative agent for the Lenders. The Credit Agreement provides for a senior secured delayed draw term loan facility, referred to as the Term Loans, which consists of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">three</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> tranches providing funding up to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$700.0&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. The Tranche 1 Loan of $200.0&#160;million </span><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">was drawn as of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">December&#160;31, 2020</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> and is included in long-term debt in the condensed consolidated balance sheets. The remaining two tranches will provide funds as follows:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:61.111%"><tr><td style="width:1.0%"/><td style="width:31.435%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.996%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.435%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.996%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.438%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Tranche</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Requested No Later Than</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate Principal Amount, up to (in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tranche 2 Loan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tranche 3 Loan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, we may request an increase in respect of the unfunded commitments in an amount not to exceed $50.0&#160;million on terms to be agreed and subject to the consent of the Lenders providing such increase. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Tranche 2 Loan will be requested no later than June 30, 2021 and the Tranche 3 Loan will be requested no later than December 31, 2021, in each case, subject to customary terms and conditions, including, in the case of the Tranche 2 Loan and Tranche 3 Loan, either (a) the first sale of inclisiran in the U.S. for end use or consumption after FDA regulatory approval thereof or (b) revenue attributable to ONPATTRO and GIVLAARI equal to or greater than $300.0&#160;million as of the last day of the most recently ended twelve month period, referred to as the Subsequent Borrowing Conditions. </span><span style="background-color:#ffffff;color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the event the Subsequent Borrowing Conditions are not satisfied as of the dates set forth in the table above, the Tranche 2 Loan and Tranche 3 Loan will be funded if such Subsequent Borrowing Conditions are satisfied on or prior to December 31, 2022. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Term Loans mature in December 2027. We can elect an interest rate of either LIBOR plus 7% subject to a floor of 1%, referred to as the LIBOR Rate, or a base rate plus 6%, subject to a floor of 2%. We may, at our option, pay interest in kind on interest due through 2023 at </span><span style="background-color:#ffffff;color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">a rate that is 1% higher than the interest rate otherwise applicable to such Term Loan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. In December 2020, we drew the Tranche 1 Loan, elected a LIBOR Rate plus 7%, and paid a $5.0&#160;million funding fee. On the date the Tranche 2 Loan or Tranche 3 Loan is funded, we will pay a funding fee equal to 2.5% of the principal amount of the Term Loans funded on such date. In addition, we will pay an exit fee equal to 1% of the commitments in respect of the Term Loans, payable upon any repayment of the Term Loans or termination of the unfunded Term Loan commitments. Our interest rate was 8% as of March 31, 2021 and December 31, 2020.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are obligated to pay interest due on the Term Loans from 2021 through 2022 which will be calculated without regard to the Term Loans being prepaid or an unfunded tranche being terminated during this period (in whole or in part). Any prepayments of Term Loans or terminations of unfunded tranches that occur between 2023 and 2025 are subject to a fee of up to 5% of the loan principal that is prepaid or the amount of the unfunded tranche that is terminated.  </span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">All obligations under the Credit Agreement are secured, subject to certain exceptions, by security interests in the following assets: (i) intellectual property owned by us relating to ONPATTRO, GIVLAARI and vutrisiran, (ii) the equity interests held by the Loan Parties in their subsidiaries, (iii) all of our ownership of the inclisiran royalty remaining after the royalty purchase under the Purchase Agreement, and (iv) material real property, and certain personal property, including, without limitation, cash held in certain deposit accounts of the Loan Parties and equipment. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Credit Agreement contains negative covenants that, among other things and subject to certain exceptions, could restrict our ability to, incur additional liens, incur additional indebtedness, make investments, including acquisitions, engage in fundamental changes, sell or dispose of assets that constitute collateral, including certain intellectual property, pay dividends or make any distribution or payment on or redeem, retire or purchase any equity interests, amend, modify or waive certain material agreements or organizational documents and make payments of certain subordinated indebtedness. </span><span style="background-color:#ffffff;color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Additionally, the Credit Agreement contains certain customary representations and warranties, affirmative covenants and provisions relating to events of default, including nonpayment of principal, interest and other amounts; failure to comply with covenants; the rendering of judgments or orders or default by us in respect of other material indebtedness; and certain insolvency and ERISA events.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> The Credit Agreement also requires us to have consolidated liquidity of at least $100.0&#160;million as of the last day of each fiscal quarter. As of March&#160;31, 2021, we were in compliance with the applicable terms and conditions of the covenants under the Credit Agreement.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140603033268744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEVELOPMENT DERIVATIVE LIABILITY<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock', window );">DEVELOPMENT DERIVATIVE LIABILITY</a></td>
<td class="text">DEVELOPMENT DERIVATIVE LIABILITYIn August 2020, we entered into a co-development agreement, referred to as the Funding Agreement, with BXLS V Bodyguard &#8211; PCP L.P. and BXLS Family Investment Partnership V &#8211; ESC L.P., collectively referred to as Blackstone Life Sciences, pursuant to which Blackstone Life Sciences will provide up to $150.0&#160;million in funding for the clinical development of vutrisiran and ALN-AGT, two of our cardiometabolic programs. With respect to vutrisiran, Blackstone Life Sciences has committed to provide up to $70.0&#160;million to fund development costs related to the HELIOS-B Phase 3 clinical trial. In addition, Blackstone Life Sciences has the right, but is not obligated, to fund up to $26.0&#160;million for development costs related to a Phase 2 clinical trial of ALN-AGT and up to $54.0&#160;million for development costs related to a Phase 3 clinical trial of ALN-AGT. The amount of funding ultimately provided by Blackstone Life Sciences is dependent on us achieving specified development <div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">milestones with respect to each clinical trial. We retain sole responsibility for the development and commercialization of both vutrisiran and ALN-AGT.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As consideration for Blackstone Life Sciences&#8217; funding for vutrisiran clinical development costs, we have agreed to pay Blackstone Life Sciences a 1% royalty on net sales of vutrisiran for a 10-year term beginning upon the first commercial sale following regulatory approval of vutrisiran for ATTR-cardiomyopathy, as well as fixed payments of up to 2.5 times their investment over a two-year period upon regulatory approval of vutrisiran for ATTR-cardiomyopathy in specified countries, unless it is later withdrawn from the market following a mandatory recall. As consideration for Blackstone Life Sciences&#8217; funding for Phase 2 clinical development costs of ALN-AGT, we have agreed to pay Blackstone Life Sciences fixed payments of up to 3.25 times their Phase 2 investment over a four-year period upon the successful completion of the ALN-AGT Phase 2 clinical trial, unless certain regulatory events affecting the continued development of ALN-AGT occur. As consideration for Blackstone Life Sciences&#8217; funding for Phase 3 clinical development costs of ALN-AGT, we have agreed to pay Blackstone Life Sciences fixed payments of up to 4.5 times their Phase 3 investment over a four-year period upon regulatory approval of ALN-AGT in specified countries, unless it is later withdrawn from the market following a mandatory recall.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our payment obligations under the Funding Agreement will be secured, subject to certain exceptions, by security interests in intellectual property owned by us relating to vutrisiran and ALN-AGT, as well as in our bank account in which the funding deposits will be made.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We and Blackstone Life Sciences each have the right to terminate the Funding Agreement in its entirety in the event of the other party&#8217;s bankruptcy or similar proceedings. We and Blackstone Life Sciences may each terminate the Funding Agreement in its entirety or with respect to either product in the event of an uncured material breach by the other party, or with respect to a product for certain patient health and safety reasons, or if regulatory approval in specified major market countries is not obtained for the product following the completion of clinical trials for the product. In addition, Blackstone Life Sciences has the right to terminate the Funding Agreement in its entirety upon the occurrence of certain events affecting our ability to make payments under the agreement or to develop or commercialize the products, or upon a change of control of us. Blackstone Life Sciences may also terminate the Funding Agreement with respect to a product if the joint steering committee elects to terminate the development program for that product in its entirety, if certain clinical endpoints are not achieved for that product or, with respect to vutrisiran only, if our right to develop or commercialize vutrisiran is enjoined in a specified major market as a result of an alleged patent infringement. In certain termination circumstances, we will be obligated to pay Blackstone Life Sciences an amount that is equal to, or a multiplier of, the development funding received from Blackstone Life Sciences, and we may remain obligated under certain circumstances to make the payments to Blackstone Life Sciences described above, or the royalty described above in the case of vutrisiran, should we obtain regulatory approval for vutrisiran or ALN-AGT following termination.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We account for the Funding Agreement under ASC 815 as a derivative liability, measured at fair value, within other liabilities on our condensed consolidated balance sheets. The change in fair value due to the remeasurement of the development derivative liability is recorded as other expense on our condensed consolidated statements of operations and comprehensive loss.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of March&#160;31, 2021, the derivative liability is classified as a Level 3 financial liability in the fair value hierarchy. The valuation method incorporates certain unobservable Level 3 key inputs including (i) the probability and timing of achieving stated development milestones to receive payments from Blackstone Life Sciences, (ii) the probability and timing of achieving regulatory approval and payments to Blackstone Life Sciences, (iii) an estimate of the amount and timing of the royalty payable on net sales of vutrisiran, assuming regulatory approval, (iv) our cost of borrowing (15%), and (v) Blackstone Life Sciences' cost of borrowing (4%).</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table presents the activity with respect to the development derivative liability, in thousands:</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:86.549%"><tr><td style="width:1.0%"/><td style="width:81.163%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.644%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.793%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Development derivative liability as of December&#160;31, 2020</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,585&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amount received under the Funding Agreement</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss recorded from remeasurement of development derivative liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,253&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Development derivative liability as of March&#160;31, 2021</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,038&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -URI http://asc.fasb.org/topic&amp;trid=2229140<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140603031822792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">STOCK-BASED COMPENSATION</a></td>
<td class="text">STOCK-BASED COMPENSATION<div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table summarizes stock-based compensation expenses included in operating costs and expenses:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:71.929%"><tr><td style="width:1.0%"/><td style="width:60.891%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.395%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.816%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.398%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,375&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,049&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,315&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,529&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,690&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,578&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140603120081752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET LOSS PER COMMON SHARE<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">NET LOSS PER COMMON SHARE</a></td>
<td class="text">NET LOSS PER COMMON SHARE<div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We compute basic net loss per common share by dividing net loss by the weighted-average number of common shares outstanding during the period. We compute diluted net loss per common share by dividing net loss by the weighted-average number of common shares and dilutive potential common share equivalents outstanding during the period. Potential common shares consist of shares issuable upon the exercise of stock options (the proceeds of which are then assumed to have been used to repurchase outstanding shares using the treasury stock method). Because the inclusion of potential common shares would be anti-dilutive for all periods presented, diluted net loss per common share is the same as basic net loss per common share.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following common share equivalents were excluded from the calculation of net loss per common share because their inclusion would be anti-dilutive:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.128%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.422%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,859&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,609&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested restricted common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,538&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,411&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,397&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,020&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140603031821656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text">COMMITMENTS AND CONTINGENCIES<div style="margin-top:6pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Legal Matters</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">From time to time, we may be a party to litigation, arbitration or other legal proceedings in the course of our business, including the matters described below. The claims and legal proceedings in which we could be involved include challenges to the scope, validity or enforceability of patents relating to our products or product candidates, and challenges by us to the scope, validity or enforceability of the patents held by others. These include claims by third parties that we infringe their patents or breach our license or other agreements with such third parties. The outcome of any such legal proceedings, regardless of the merits, is inherently uncertain. In addition, litigation and related matters are costly and may divert the attention of our management and other resources that would otherwise be engaged in other activities. If we were unable to prevail in any such legal proceedings, our business, results of operations, liquidity and financial condition could be adversely affected. Our accounting policy for accrual of legal costs is to recognize such expenses as incurred.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Securities Litigation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On September 26, 2018, Caryl Hull Leavitt, individually and on behalf of all others similarly situated, filed a class action complaint for violation of federal securities laws against us, our Chief Executive Officer and our former Chief Financial Officer in the United States District Court for the Southern District of New York. By stipulation of the parties and Order of the Court dated November 20, 2018, the action was transferred to the United States District Court for the District of Massachusetts. On May 8, 2019, the Court entered an order appointing a lead plaintiff, and on July 3, 2019, lead plaintiff filed a consolidated class action complaint, or the Complaint. In addition to the originally named defendants, the Complaint also named as defendants certain of our other executive officers, and purported to be brought on behalf of a class of persons who acquired our securities between September 20, 2017 and September 12, 2018 and sought to recover damages caused by defendants&#8217; alleged violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended, and Rule 10b-5 promulgated thereunder. The Complaint alleged, among other things, that the defendants made materially false and misleading statements related to the efficacy and safety of our product, ONPATTRO. The plaintiff sought, among other things, the designation of this action as a class action, an award of unspecified compensatory damages, interest, costs and expenses, including counsel fees and expert fees, and other relief as the court deems appropriate. All defendants filed </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">a motion to dismiss the Complaint in its entirety on July 31, 2019. On March 23, 2020, the Court granted our motion and dismissed the Complaint without prejudice. Pursuant to a prior Order of the Court, on June 1, 2020, plaintiff filed a motion seeking leave to file a further amended complaint. That motion was fully briefed on June 22, 2020. By Memorandum &amp; Order dated March 12, 2021, the Court denied plaintiffs&#8217; motion.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On September 12, 2019, the Chester County Employees Retirement Fund, individually and on behalf of all others similarly situated, filed a purported securities class action complaint for violation of federal securities laws against us, certain of our current and former directors and officers, and the underwriters of our November 14, 2017 public stock offering, in the Supreme Court of the State of New York, New York County. On November 7, 2019, plaintiff filed an amended complaint, or the New York Complaint. The New York Complaint is brought on behalf of an alleged class of those who purchased our securities pursuant and/or traceable to our November 14, 2017 public stock offering. The New York Complaint purports to allege claims arising under Sections 11, 12(a)(2) and 15 of the Securities Act of 1933, as amended, and generally alleges that the defendants violated the federal securities laws by, among other things, making material misstatements or omissions concerning the results of our APOLLO Phase 3 clinical trial of patisiran. The plaintiff seeks, among other things, the designation of the action as a class action, an award of unspecified compensatory damages, rescissory damages, interest, costs and expenses, including counsel fees and expert fees, and other relief as the court deems appropriate. All defendants filed a joint motion to dismiss the New York Complaint in its entirety on December 20, 2019. On November 2, 2020, the Court entered a Decision and Order denying defendants&#8217; motion to dismiss. In November 2020, defendants filed a notice of appeal of the Court&#8217;s decision to the Appellate Division of the Supreme Court of the State of New York for the First Department. Defendants&#8217; appeal was fully briefed in March 2021, and the Appellate Division heard oral argument on April 7, 2021. Defendants&#8217; appeal remains pending. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We believe that the allegations contained in the New York Complaint are without merit and intend to defend the case vigorously. We cannot predict at this point the length of time that this action will be ongoing or the liabilities, if any, which may arise therefrom.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Government Investigation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On or about April 9, 2021, we received a subpoena from the U.S. Department of Justice, U.S. Attorney&#8217;s Office for the District of Massachusetts, requiring production of documents pertaining to our marketing and promotion of ONPATTRO (patisiran) in the United States. We are preparing a response to the subpoena and cooperating with the government. Experienced outside legal counsel has been retained to assist with this matter.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Since learning of this federal government investigation, and consistent with its charter, our nominating and corporate governance committee is directing our review of and response to the matter. Given the early stage and ongoing nature of the investigation, no determination has been made that a loss, if any, arising from this matter is probable or that the amount of any such loss, or range of loss, is reasonably estimable.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140603038437240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIS OF PRESENTATION AND PRINCIPLES OF CONSOLIDATION (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Basis of Presentation and Principles of Consolidation</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The accompanying condensed consolidated financial statements of Alnylam are unaudited and have been prepared in accordance with accounting principles generally accepted in the United States of America, or GAAP, applicable to interim periods and, in the opinion of management, include all normal and recurring adjustments that are necessary to state fairly the results of operations for the reported periods. Our condensed consolidated financial statements have also been prepared on a basis substantially consistent with, and should be read in conjunction with, our audited consolidated financial statements for the year ended December&#160;31, 2020, which were included in our Annual Report on Form 10-K that was filed with the Securities and Exchange Commission on February 11, 2021. The year-end condensed consolidated balance sheet data was derived from our audited financial statements but does not include all disclosures required by GAAP. The results of our operations for any interim period are not necessarily indicative of the results of our operations for any other interim period or for a full fiscal year.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The accompanying condensed consolidated financial statements reflect the operations of Alnylam and our wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our significant accounting policies are described in Note 2 of the Notes to Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December&#160;31, 2020.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Use of Estimates</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. In our condensed consolidated financial statements, we use estimates and assumptions related to our inventory valuation and related reserves, liability related to the sale of future royalties, development derivative liability, income taxes, revenue recognition, research and development expenses, and stock-based compensation. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable. Actual results could differ from those estimates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The full extent to which the COVID-19 pandemic will directly or indirectly impact our business, results of operations and financial condition, including sales, expenses, reserves and allowances, the supply of our products and product candidates, clinical trials and research and development costs, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and variants thereof, and the actions taken to contain or treat it or vaccinate against it, as well as the economic impact on local, regional, national and international customers and markets. We have made estimates of the impact of COVID-19 within our financial statements and there may be changes to those estimates in future periods. Actual results may differ from these estimates.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_LiquidityPolicyPolicyTextBlock', window );">Liquidity</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Liquidity</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Based on our current operating plan, we believe that our cash, cash equivalents and marketable securities as of March&#160;31, 2021, together with the cash we expect to generate from product sales and under our current alliances, in addition to our strategic financing collaboration with The Blackstone Group Inc. and certain of its affiliates, will be sufficient to enable us to advance our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Alnylam P</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">x25 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">strategy for at least the next 12 months from the filing of this Quarterly Report on Form 10-Q.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_LiquidityPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liquidity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_LiquidityPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140603031650632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET PRODUCT REVENUES (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Summary of Net Product Revenues</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net product revenues consist of the following:</span></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:18pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:82.309%"><tr><td style="width:1.0%"/><td style="width:58.047%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.971%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.510%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.972%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ONPATTRO</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,471&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,196&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,653&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,166&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rest of World (primarily Japan)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,827&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,302&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,951&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,664&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">GIVLAARI</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,762&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,274&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,873&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rest of World </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,673&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,274&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OXLUMO</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,408&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,737&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,145&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:11pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net product revenues</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135,769&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,938&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock', window );">Schedule of Receivables Related to Net Product Revenues</a></td>
<td class="text"><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the balance of our receivables related to our net product revenues: </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:82.456%"><tr><td style="width:1.0%"/><td style="width:57.942%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.686%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.937%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables included in &#8220;Accounts receivable, net&#8221;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,516&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,871&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3,4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140603033288536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET REVENUES FROM COLLABORATIONS (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock', window );">Schedule of Revenue from Collaborators</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Net revenues from collaborations consist of the following:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:84.941%"><tr><td style="width:1.0%"/><td style="width:63.616%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.111%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.660%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.113%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron Pharmaceuticals</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,343&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,503&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Novartis AG</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,111&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,060&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vir Biotechnology</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,822&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,516&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">521&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">459&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,797&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,538&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Balance and Change in Receivables and Contract Liabilities Related to Collaboration Agreements</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the balance of our receivables and contract liabilities related to our collaboration agreements:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:84.795%"><tr><td style="width:1.0%"/><td style="width:56.313%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.762%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.662%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.763%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables included in &#8220;Accounts receivable, net&#8221;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,111&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,542&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liabilities included in &#8220;Deferred revenue&#8221;</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,759&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,021&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_ScheduleOfResearchAndDevelopmentExpensesIncurredForCollaborationAgreementsTableTableTextBlock', window );">Schedule of Research and Development Expenses Incurred by Type that are Directly Attributable to Collaboration Agreements</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table provides research and development expenses incurred by type, for which we recognize net revenue, that are directly attributable to our collaboration agreements, by collaboration partner:</span></div><div><span><br/></span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:24.083%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.759%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.759%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.759%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.759%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.759%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.762%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Clinical Trial and Manufacturing</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">External Services</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Clinical Trial and Manufacturing</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">External Services</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron Pharmaceuticals</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,799&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,235&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,612&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,491&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vir Biotechnology</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,029&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,355&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">339&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,693&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Novartis AG</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">998&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">859&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,839&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,452&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,949&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,681&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_ScheduleOfAllocatedTransactionPriceTableTextBlock', window );">Schedule of Allocated Transaction Price Based on Accounting Guidance</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We allocated the initial transaction price to each unit of account based on the applicable accounting guidance as follows, in thousands: </span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.467%"><tr><td style="width:1.0%"/><td style="width:35.806%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.412%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.736%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.412%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.736%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.331%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.567%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:83%">Performance Obligations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:83%">Standalone Selling Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:83%">Transaction Price Allocated</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:83%">Accounting Guidance</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">Research Services Obligation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">130,700&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">183,100&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">ASC 606</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">C5 License Obligation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">97,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">92,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:95%">ASC 606</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">C5 Co-Co Obligation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">364,600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">246,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">ASC 808</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">521,600&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following tables provide a summary of the transaction price allocated to each unit of account based on the applicable accounting guidance, in addition to revenue activity during the period, in thousands:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:91.374%"><tr><td style="width:1.0%"/><td style="width:25.300%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.440%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.660%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.440%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.660%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.440%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.660%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.440%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.660%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Transaction Price Allocated</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Deferred Revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Performance Obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31,<br/>2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31,<br/>2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,<br/>2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Accounting Guidance</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Research Services Obligation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">200,600&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">45,100&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">54,900&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ASC 606</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">C5 License Obligation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">83,900&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">45,200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">58,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ASC 606</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">C5 Co-Co Obligation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">246,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">228,900&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">231,400&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ASC 808</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">530,500&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">319,200&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">345,000&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_ScheduleOfRevenueRecognizedBasedOnAccountingGuidanceTableTextBlock', window );">Schedule of Revenue Recognized Based on Accounting Guidance</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:66.959%"><tr><td style="width:1.0%"/><td style="width:34.926%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.673%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.699%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.673%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.699%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.673%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:12.657%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Revenue Recognized During</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Performance Obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31, 2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31, 2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Accounting Guidance</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Research Services Obligation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">9,800&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">12,300&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ASC 606</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">C5 License Obligation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">13,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ASC 606</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">C5 Co-Co Obligation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4,200&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ASC 808</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">25,800&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">16,500&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_ScheduleOfAllocatedTransactionPriceTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of Allocated Transaction Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_ScheduleOfAllocatedTransactionPriceTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_ScheduleOfResearchAndDevelopmentExpensesIncurredForCollaborationAgreementsTableTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of research and development expenses incurred for collaboration agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_ScheduleOfResearchAndDevelopmentExpensesIncurredForCollaborationAgreementsTableTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_ScheduleOfRevenueRecognizedBasedOnAccountingGuidanceTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of Revenue Recognized Based on Accounting Guidance</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_ScheduleOfRevenueRecognizedBasedOnAccountingGuidanceTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140603121606648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LIABILITY RELATED TO THE SALE OF FUTURE ROYALTIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_ScheduleOfRoyaltyLiabilityTableTextBlock', window );">Schedule of Royalty Liability</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table shows the activity with respect to the liability related to the sale of future royalties, in thousands:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:87.134%"><tr><td style="width:1.0%"/><td style="width:81.282%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.638%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.680%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying value of liability related to sale of future royalties as of December&#160;31, 2020</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,071,541&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense recognized</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,184&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying value of liability related to sale of future royalties as of March&#160;31, 2021</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,099,725&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_ScheduleOfRoyaltyLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Royalty Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_ScheduleOfRoyaltyLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140603033858616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Fair Value of Assets Measured on a Recurring Basis</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following tables present information about our financial assets and liabilities that are measured at fair value on a recurring basis and indicate the fair value hierarchy of the valuation techniques we utilized to determine such fair value:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"/><td style="width:48.973%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.650%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted<br/>Prices in<br/>Active<br/>Markets<br/>(Level 1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Observable<br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177,470&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177,470&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable debt securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government-sponsored enterprise securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215,200&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215,200&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,057,827&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,057,827&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable equity securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,967&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,967&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash (money market funds)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,483&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,483&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total financial assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,508,947&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">235,920&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,273,027&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Development derivative liability (Note 10)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,038&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,038&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"/><td style="width:48.973%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.650%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted<br/>Prices in<br/>Active<br/>Markets<br/>(Level 1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Observable<br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,726&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,726&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable debt securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government-sponsored enterprise securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245,214&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245,214&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,087,968&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,087,968&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable equity securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,633&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,633&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash (money market funds)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,483&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,483&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total financial assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,475,024&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121,842&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,353,182&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Development derivative liability (Note 10)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,585&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,585&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140603033862808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>MARKETABLE DEBT SECURITIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock', window );">Summary of Marketable Debt Securities</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following tables summarize our marketable debt securities:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:49.779%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.632%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government-sponsored enterprise securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215,171&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(58)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215,200&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,057,509&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">335&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,057,827&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,272,680&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">422&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(75)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,273,027&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:49.779%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.632%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government-sponsored enterprise securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245,113&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245,214&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,107,721&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">328&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(81)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,107,968&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,352,834&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">463&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(115)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,353,182&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByBalanceSheetGroupingTextBlock', window );">Summary of Fair Value of Marketable Debt Securities</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The fair values of our marketable debt securities by classification in the condensed consolidated balance sheets were as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.128%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.422%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,000&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable debt securities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,273,027&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,333,182&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,273,027&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,353,182&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByBalanceSheetGroupingTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13467-108611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByBalanceSheetGroupingTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140603038444616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER BALANCE SHEET DETAILS (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The components of inventory are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.128%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.422%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,694&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,460&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in progress</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,593&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,149&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,753&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,693&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,040&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,302&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_ScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTableTextBlock', window );">Schedule of Reconciliation of Cash, Cash Equivalents And Restricted Cash</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within our condensed consolidated balance sheets that sum to the total of these amounts shown in the condensed consolidated statements of cash flows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.128%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.422%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">379,543&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">467,779&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total restricted cash included in prepaid expenses, other current assets and long-term other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,462&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,614&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents, and restricted cash shown in the condensed consolidated statements of cash flows</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">382,005&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">470,393&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Summary of Changes in Accumulated Other Comprehensive Income (Loss)</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following tables summarize the changes in accumulated other comprehensive loss, by component:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:33.256%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Loss on Investment in Joint Venture</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Defined Benefit Pension<br/>Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) from Debt</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Securities</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Foreign Currency Translation<br/>Adjustment</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Accumulated Other</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Comprehensive Loss</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32,792)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,754)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">348&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,424)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43,622)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive (loss) income before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,848&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,847&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from other comprehensive income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,848&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,905&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of March 31, 2021</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32,792)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,696)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(576)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36,717)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:33.256%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Loss on Investment in Joint Venture</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Defined Benefit Pension<br/>Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains from Debt<br/>Securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Foreign Currency Translation<br/>Adjustment</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Accumulated Other<br/>Comprehensive Loss</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2019</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32,792)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,520)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(343)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36,518)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,317&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">340&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,657&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from other comprehensive income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,728&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,802&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net other comprehensive income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,045&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">340&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,459&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of March 31, 2020</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32,792)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,446)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,182&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32,059)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_ScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Statement of reconciliation of cash, cash equivalents and restricted cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_ScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140603033923848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CREDIT AGREEMENT (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAbstract', window );"><strong>Line of Credit Facility [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Schedule of Term Loan</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:61.111%"><tr><td style="width:1.0%"/><td style="width:31.435%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.996%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.435%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.996%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.438%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Tranche</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Requested No Later Than</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate Principal Amount, up to (in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tranche 2 Loan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tranche 3 Loan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28541-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21506-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(e),(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21521-112644<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21538-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=75038535&amp;loc=d3e64711-112823<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140603033151800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEVELOPMENT DERIVATIVE LIABILITY (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock', window );">Development Derivative Liability Activity</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table presents the activity with respect to the development derivative liability, in thousands:</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:86.549%"><tr><td style="width:1.0%"/><td style="width:81.163%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.644%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.793%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Development derivative liability as of December&#160;31, 2020</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,585&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amount received under the Funding Agreement</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss recorded from remeasurement of development derivative liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,253&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Development derivative liability as of March&#160;31, 2021</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,038&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of derivative liabilities at fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140603032166808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Schedule of Stock Based Compensation</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table summarizes stock-based compensation expenses included in operating costs and expenses:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:71.929%"><tr><td style="width:1.0%"/><td style="width:60.891%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.395%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.816%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.398%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,375&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,049&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,315&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,529&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,690&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,578&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140603033151800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET LOSS PER COMMON SHARE (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Common Share Equivalents Excluded from the Calculation of Net Loss Per Common Share</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following common share equivalents were excluded from the calculation of net loss per common share because their inclusion would be anti-dilutive:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.128%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.422%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,859&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,609&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested restricted common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,538&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,411&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,397&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,020&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140603033215336">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>NATURE OF BUSINESS (Details)<br></strong></div></th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>product </div>
<div>program</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_NumberOfMarketedProducts', window );">Number of marketed products</a></td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_NumberOfPartneredProducts', window );">Number of partnered products</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_NumberOfClinicalProgramsInLateStages', window );">Number of clinical programs in late stages | program</a></td>
<td class="nump">6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_NumberOfClinicalProgramsInLateStages">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Clinical Programs In Late Stages</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_NumberOfClinicalProgramsInLateStages</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_NumberOfMarketedProducts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Marketed Products</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_NumberOfMarketedProducts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_NumberOfPartneredProducts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Partnered Products</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_NumberOfPartneredProducts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140603033965080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET PRODUCT REVENUES - Summary of Net Product Revenues (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 177,566<span></span>
</td>
<td class="nump">$ 99,476<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Net product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">135,769<span></span>
</td>
<td class="nump">71,938<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=alny_ONPATTROMember', window );">ONPATTRO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">101,951<span></span>
</td>
<td class="nump">66,664<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=alny_GIVLAARIMember', window );">GIVLAARI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">24,673<span></span>
</td>
<td class="nump">5,274<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=alny_OXLUMOMember', window );">OXLUMO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">9,145<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | ONPATTRO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">49,471<span></span>
</td>
<td class="nump">37,196<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | GIVLAARI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">17,762<span></span>
</td>
<td class="nump">5,274<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | OXLUMO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">1,408<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_EuropeMember', window );">Europe | ONPATTRO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">40,653<span></span>
</td>
<td class="nump">21,166<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_EuropeMember', window );">Europe | GIVLAARI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">6,873<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_EuropeMember', window );">Europe | OXLUMO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">7,737<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=alny_NonUSOrEuropeMember', window );">Rest of World | ONPATTRO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">11,827<span></span>
</td>
<td class="nump">8,302<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=alny_NonUSOrEuropeMember', window );">Rest of World | GIVLAARI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 38<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=alny_ONPATTROMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=alny_ONPATTROMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=alny_GIVLAARIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=alny_GIVLAARIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=alny_OXLUMOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=alny_OXLUMOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=alny_NonUSOrEuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=alny_NonUSOrEuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140603033278760">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>NET PRODUCT REVENUES - Receivables (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Receivables included in &#8220;Accounts receivable, net&#8221;</a></td>
<td class="nump">$ 110,626<span></span>
</td>
<td class="nump">$ 102,413<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Net product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Receivables included in &#8220;Accounts receivable, net&#8221;</a></td>
<td class="nump">$ 91,516<span></span>
</td>
<td class="nump">$ 68,871<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140603038155448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET REVENUES FROM COLLABORATIONS - Revenue from Collaborators (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 177,566<span></span>
</td>
<td class="nump">$ 99,476<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Net revenues from collaborations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">41,797<span></span>
</td>
<td class="nump">27,538<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Net revenues from collaborations | Regeneron Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">30,343<span></span>
</td>
<td class="nump">19,503<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Net revenues from collaborations | Novartis AG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">8,111<span></span>
</td>
<td class="nump">1,060<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Net revenues from collaborations | Vir Biotechnology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">2,822<span></span>
</td>
<td class="nump">6,516<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Net revenues from collaborations | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 521<span></span>
</td>
<td class="nump">$ 459<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=alny_RegeneronPharmaceuticalsIncorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=alny_RegeneronPharmaceuticalsIncorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=alny_NovartisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=alny_NovartisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=alny_VirBiotechnologyIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=alny_VirBiotechnologyIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=alny_OtherCollaborationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=alny_OtherCollaborationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140603033180120">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>NET REVENUES FROM COLLABORATIONS - Balance of Receivables and Contract Liabilities Related to Collaboration Agreements (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNet', window );">Receivables included in &#8220;Accounts receivable, net&#8221;</a></td>
<td class="nump">$ 19,111<span></span>
</td>
<td class="nump">$ 33,542<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract liabilities included in &#8220;Deferred revenue&#8221;</a></td>
<td class="nump">$ 94,759<span></span>
</td>
<td class="nump">$ 120,021<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140603037894536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET REVENUES FROM COLLABORATIONS - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">98 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($) </div>
<div>candidate</div>
</th>
<th class="th">
<div>Apr. 08, 2019 </div>
<div>USD ($) </div>
<div>program</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 31, 2017 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 28, 2013 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($) </div>
<div>candidate</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($) </div>
<div>candidate</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Contract with customer liability revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,300,000<span></span>
</td>
<td class="nump">$ 14,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=alny_VirBiotechnologyIncMember', window );">Vir Biotechnology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_UpfrontFeeReceived', window );">Upfront fee received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_CollaborativeAgreementTerminationPeriod', window );">Agreement termination period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_TransactionPrice', window );">Transaction price</a></td>
<td class="nump">$ 110,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Transactional price remaining performance obligation</a></td>
<td class="nump">$ 48,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 48,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 48,800,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_MilestonePaymentEarned', window );">Milestone payment earned</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
<td class="nump">$ 15,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentOwnedBalanceShares', window );">Shares of Vir common stock (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,111,111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_MilestonePaymentEarnedShares', window );">Milestone shares earned (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,111,111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_CollaborativeArrangementAdditionalDevelopmentCandidatesToBeDelivered', window );">Additional development candidates to be delivered | candidate</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=alny_GlobalStrategicCollaborationMember', window );">Global Strategic Collaboration | Regeneron Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_DiscoveryPeriodOfProgramsDevelopment', window );">Discovery period of programs development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_ExtendedAdditionalDiscoveryPeriodOfProgramsDevelopment', window );">Extended additional discovery period of programs development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_MaximumRoyaltiesAndCommercialMilestonePaymentsUponPotentialProductSale', window );">Maximum royalties and commercial milestone payments upon potential product sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 325,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_UpfrontFeeReceived', window );">Upfront fee received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_MaximumAdditionalMilestonePaymentsToBeReceiveUponAchievementOfCertainCriteria', window );">Maximum additional milestone payments to be receive upon achievement of certain criteria</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_NumberOfTargetedPrograms', window );">Number of targeted programs | program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_CollaborativeAgreementTerminationPeriod', window );">Agreement termination period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_PercentageOfMaximumRoyaltyPayments', window );">Maximum percentage of royalty payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_TransactionPrice', window );">Transaction price</a></td>
<td class="nump">$ 530,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 521,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Transactional price remaining performance obligation</a></td>
<td class="nump">$ 188,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 188,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 188,300,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=alny_GlobalStrategicCollaborationMember', window );">Global Strategic Collaboration | Funding At Program Initiation | Regeneron Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_PotentialProceedsFromCollaborationArrangement', window );">Potential proceeds from collaboration arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=alny_GlobalStrategicCollaborationMember', window );">Global Strategic Collaboration | Funding At Lead Candidate Identification | Regeneron Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_PotentialProceedsFromCollaborationArrangement', window );">Potential proceeds from collaboration arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=alny_GlobalStrategicCollaborationMember', window );">Global Strategic Collaboration | Funding At Steady State | Regeneron Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_PotentialProceedsFromCollaborationArrangement', window );">Potential proceeds from collaboration arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=alny_GlobalStrategicCollaborationMember', window );">Global Strategic Collaboration | Maximum | Regeneron Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_ResearchTermExtensionFee', window );">Research term extension fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_CollaborativeArrangementMilestonePayments', window );">Collaborative arrangement milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_RoyaltyRate', window );">Royalty rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=alny_ProductAlliancesMember', window );">Product Alliances | Novartis AG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_MilestonePaymentEarned', window );">Milestone payment earned</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45,000,000.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_MaximumNumberOfPotentialFutureMilestones', window );">Maximum amount of potential future milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 135,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_FuturePaymentsOnAchievementOfSpecifiedRegulatoryMilestones', window );">Future payments on achievement of specified regulatory milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_FuturePaymentsOnAchievementOfOtherSpecifiedRegulatoryMilestones', window );">Future payments on achievement of other specified regulatory milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_FuturePaymentsOnAchievementOfSpecifiedCommercializationMilestones', window );">Future payments on achievement of specified commercialization milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=alny_ProductAlliancesMember', window );">Product Alliances | Minimum | Novartis AG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_RoyaltyRate', window );">Royalty rate</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=alny_ProductAlliancesMember', window );">Product Alliances | Maximum | Novartis AG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_RoyaltyRate', window );">Royalty rate</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_CollaborativeAgreementTerminationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative agreement termination period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_CollaborativeAgreementTerminationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_CollaborativeArrangementAdditionalDevelopmentCandidatesToBeDelivered">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Additional Development Candidates To Be Delivered</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_CollaborativeArrangementAdditionalDevelopmentCandidatesToBeDelivered</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_CollaborativeArrangementMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative arrangement milestone payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_CollaborativeArrangementMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_DiscoveryPeriodOfProgramsDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Discovery period of programs development.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_DiscoveryPeriodOfProgramsDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_ExtendedAdditionalDiscoveryPeriodOfProgramsDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Extended additional discovery period of programs development.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_ExtendedAdditionalDiscoveryPeriodOfProgramsDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_FuturePaymentsOnAchievementOfOtherSpecifiedRegulatoryMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future Payments On Achievement Of Other Specified Regulatory Milestones</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_FuturePaymentsOnAchievementOfOtherSpecifiedRegulatoryMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_FuturePaymentsOnAchievementOfSpecifiedCommercializationMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future payments on achievement of specified commercialization milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_FuturePaymentsOnAchievementOfSpecifiedCommercializationMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_FuturePaymentsOnAchievementOfSpecifiedRegulatoryMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future payments on achievement of specified regulatory milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_FuturePaymentsOnAchievementOfSpecifiedRegulatoryMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_MaximumAdditionalMilestonePaymentsToBeReceiveUponAchievementOfCertainCriteria">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum additional milestone payments to be receive upon achievement of certain criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_MaximumAdditionalMilestonePaymentsToBeReceiveUponAchievementOfCertainCriteria</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_MaximumNumberOfPotentialFutureMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the maximum amount of pre-specified milestone payments that could potentially be received under the collaborative and licensing agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_MaximumNumberOfPotentialFutureMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_MaximumRoyaltiesAndCommercialMilestonePaymentsUponPotentialProductSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum royalties and commercial milestone payments upon potential product sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_MaximumRoyaltiesAndCommercialMilestonePaymentsUponPotentialProductSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_MilestonePaymentEarned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount earned upon achievement of milestone.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_MilestonePaymentEarned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_MilestonePaymentEarnedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone Payment Earned, Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_MilestonePaymentEarnedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_NumberOfTargetedPrograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of targeted programs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_NumberOfTargetedPrograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_PercentageOfMaximumRoyaltyPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of maximum royalty payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_PercentageOfMaximumRoyaltyPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_PotentialProceedsFromCollaborationArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential proceeds from collaboration arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_PotentialProceedsFromCollaborationArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_ResearchTermExtensionFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research term extension fee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_ResearchTermExtensionFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_RoyaltyRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential maximum royalty percentage that will received for sales completed by collaboration partner.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_RoyaltyRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_TransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The transaction price of a contract is the amount of consideration to which the Company expects to be entitled in exchange for transferring promised goods or services to the customer, excluding amounts that will be collected on behalf of third parties. This amount is expected to include both fixed and variable consideration, subject to certain restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_TransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_UpfrontFeeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of upfront fees received under the terms of collaborative and licensing agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_UpfrontFeeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentOwnedBalanceShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Balance held at close of period in number of shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99383244&amp;loc=d3e12121-115841<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column B))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401592&amp;loc=d3e611197-123010<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentOwnedBalanceShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=alny_VirBiotechnologyIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=alny_VirBiotechnologyIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=alny_GlobalStrategicCollaborationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=alny_GlobalStrategicCollaborationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=alny_RegeneronPharmaceuticalsIncorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=alny_RegeneronPharmaceuticalsIncorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=alny_FundingAtProgramInitiationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=alny_FundingAtProgramInitiationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=alny_FundingAtLeadCandidateIdentificationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=alny_FundingAtLeadCandidateIdentificationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=alny_FundingAnAnnualDiscoveryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=alny_FundingAnAnnualDiscoveryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=alny_ProductAlliancesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=alny_ProductAlliancesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_ResearchCollaboratorAxis=alny_NovartisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_ResearchCollaboratorAxis=alny_NovartisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140603038970888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET REVENUES FROM COLLABORATIONS - Schedule of Research and Development Expenses Incurred by Type that are Directly Attributable to Collaboration Agreements (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total research and development expenses</a></td>
<td class="nump">$ 185,899<span></span>
</td>
<td class="nump">$ 169,571<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=alny_ClinicalTrialAndManufacturingMember', window );">Clinical Trial and Manufacturing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total research and development expenses</a></td>
<td class="nump">5,839<span></span>
</td>
<td class="nump">5,949<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=alny_ClinicalTrialAndManufacturingMember', window );">Clinical Trial and Manufacturing | Regeneron Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total research and development expenses</a></td>
<td class="nump">4,799<span></span>
</td>
<td class="nump">4,612<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=alny_ClinicalTrialAndManufacturingMember', window );">Clinical Trial and Manufacturing | Vir Biotechnology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total research and development expenses</a></td>
<td class="nump">1,029<span></span>
</td>
<td class="nump">339<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=alny_ClinicalTrialAndManufacturingMember', window );">Clinical Trial and Manufacturing | Novartis AG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total research and development expenses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">998<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=alny_ClinicalTrialAndManufacturingMember', window );">Clinical Trial and Manufacturing | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total research and development expenses</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=alny_ExternalServicesMember', window );">External Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total research and development expenses</a></td>
<td class="nump">305<span></span>
</td>
<td class="nump">69<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=alny_ExternalServicesMember', window );">External Services | Regeneron Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total research and development expenses</a></td>
<td class="nump">94<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=alny_ExternalServicesMember', window );">External Services | Vir Biotechnology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total research and development expenses</a></td>
<td class="nump">159<span></span>
</td>
<td class="nump">52<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=alny_ExternalServicesMember', window );">External Services | Novartis AG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total research and development expenses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=alny_ExternalServicesMember', window );">External Services | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total research and development expenses</a></td>
<td class="nump">52<span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=alny_OtherMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total research and development expenses</a></td>
<td class="nump">14,452<span></span>
</td>
<td class="nump">13,681<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=alny_OtherMember', window );">Other | Regeneron Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total research and development expenses</a></td>
<td class="nump">12,235<span></span>
</td>
<td class="nump">11,491<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=alny_OtherMember', window );">Other | Vir Biotechnology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total research and development expenses</a></td>
<td class="nump">1,355<span></span>
</td>
<td class="nump">1,693<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=alny_OtherMember', window );">Other | Novartis AG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total research and development expenses</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">266<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=alny_OtherMember', window );">Other | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total research and development expenses</a></td>
<td class="nump">$ 859<span></span>
</td>
<td class="nump">$ 231<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=alny_ClinicalTrialAndManufacturingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=alny_ClinicalTrialAndManufacturingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=alny_RegeneronPharmaceuticalsIncorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=alny_RegeneronPharmaceuticalsIncorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=alny_VirBiotechnologyIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=alny_VirBiotechnologyIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=alny_NovartisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=alny_NovartisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=alny_SanofiGenzymeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=alny_SanofiGenzymeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=alny_ExternalServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=alny_ExternalServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=alny_OtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=alny_OtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140603034093848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET REVENUES FROM COLLABORATIONS - Schedule of Transaction Price Allocated (Details) - Global Strategic Collaboration - Regeneron Pharmaceuticals<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_TransactionPrice', window );">Transaction Price Allocated</a></td>
<td class="nump">$ 530,500<span></span>
</td>
<td class="nump">$ 521,600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=alny_ResearchServicesObligationMember', window );">Research Services Obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_StandaloneSellingPrice', window );">Standalone Selling Price</a></td>
<td class="nump">130,700<span></span>
</td>
<td class="nump">130,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_TransactionPrice', window );">Transaction Price Allocated</a></td>
<td class="nump">200,600<span></span>
</td>
<td class="nump">183,100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=alny_C5LicenseObligationMember', window );">C5 License Obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_StandaloneSellingPrice', window );">Standalone Selling Price</a></td>
<td class="nump">97,600<span></span>
</td>
<td class="nump">97,600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_TransactionPrice', window );">Transaction Price Allocated</a></td>
<td class="nump">83,900<span></span>
</td>
<td class="nump">92,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=alny_C5CoCoObligationMember', window );">C5 Co-Co Obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_StandaloneSellingPrice', window );">Standalone Selling Price</a></td>
<td class="nump">364,600<span></span>
</td>
<td class="nump">364,600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_TransactionPrice', window );">Transaction Price Allocated</a></td>
<td class="nump">$ 246,000<span></span>
</td>
<td class="nump">$ 246,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_StandaloneSellingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Standalone Selling Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_StandaloneSellingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_TransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The transaction price of a contract is the amount of consideration to which the Company expects to be entitled in exchange for transferring promised goods or services to the customer, excluding amounts that will be collected on behalf of third parties. This amount is expected to include both fixed and variable consideration, subject to certain restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_TransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=alny_GlobalStrategicCollaborationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=alny_GlobalStrategicCollaborationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=alny_RegeneronPharmaceuticalsIncorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=alny_RegeneronPharmaceuticalsIncorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=alny_ResearchServicesObligationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=alny_ResearchServicesObligationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=alny_C5LicenseObligationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=alny_C5LicenseObligationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=alny_C5CoCoObligationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=alny_C5CoCoObligationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140603038122984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET REVENUES FROM COLLABORATIONS - Schedule of Deferred Revenue (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">$ 116,340<span></span>
</td>
<td class="nump">$ 116,340<span></span>
</td>
<td class="nump">$ 127,207<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=alny_GlobalStrategicCollaborationMember', window );">Global Strategic Collaboration | Regeneron Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_TransactionPrice', window );">Transaction Price Allocated</a></td>
<td class="nump">530,500<span></span>
</td>
<td class="nump">521,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">319,200<span></span>
</td>
<td class="nump">319,200<span></span>
</td>
<td class="nump">345,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=alny_ResearchServicesObligationMember', window );">Research Services Obligation | Global Strategic Collaboration | Regeneron Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_TransactionPrice', window );">Transaction Price Allocated</a></td>
<td class="nump">200,600<span></span>
</td>
<td class="nump">183,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">45,100<span></span>
</td>
<td class="nump">45,100<span></span>
</td>
<td class="nump">54,900<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=alny_C5LicenseObligationMember', window );">C5 License Obligation | Global Strategic Collaboration | Regeneron Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_TransactionPrice', window );">Transaction Price Allocated</a></td>
<td class="nump">83,900<span></span>
</td>
<td class="nump">92,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">45,200<span></span>
</td>
<td class="nump">45,200<span></span>
</td>
<td class="nump">58,700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=alny_C5CoCoObligationMember', window );">C5 Co-Co Obligation | Global Strategic Collaboration | Regeneron Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_TransactionPrice', window );">Transaction Price Allocated</a></td>
<td class="nump">246,000<span></span>
</td>
<td class="nump">246,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">$ 228,900<span></span>
</td>
<td class="nump">$ 228,900<span></span>
</td>
<td class="nump">$ 231,400<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_TransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The transaction price of a contract is the amount of consideration to which the Company expects to be entitled in exchange for transferring promised goods or services to the customer, excluding amounts that will be collected on behalf of third parties. This amount is expected to include both fixed and variable consideration, subject to certain restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_TransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=alny_GlobalStrategicCollaborationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=alny_GlobalStrategicCollaborationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=alny_RegeneronPharmaceuticalsIncorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=alny_RegeneronPharmaceuticalsIncorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=alny_ResearchServicesObligationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=alny_ResearchServicesObligationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=alny_C5LicenseObligationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=alny_C5LicenseObligationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=alny_C5CoCoObligationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=alny_C5CoCoObligationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140603034395384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET REVENUES FROM COLLABORATIONS - Schedule of Revenue Recognized by Accounting Guidance (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue recognized under ASC 606</a></td>
<td class="nump">$ 177,566<span></span>
</td>
<td class="nump">$ 99,476<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=alny_RegeneronPharmaceuticalsIncorporationMember', window );">Regeneron Pharmaceuticals | Global Strategic Collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">25,800<span></span>
</td>
<td class="nump">16,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=alny_RegeneronPharmaceuticalsIncorporationMember', window );">Regeneron Pharmaceuticals | Research Services Obligation | Global Strategic Collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue recognized under ASC 606</a></td>
<td class="nump">9,800<span></span>
</td>
<td class="nump">12,300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=alny_RegeneronPharmaceuticalsIncorporationMember', window );">Regeneron Pharmaceuticals | C5 License Obligation | Global Strategic Collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue recognized under ASC 606</a></td>
<td class="nump">13,500<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=alny_RegeneronPharmaceuticalsIncorporationMember', window );">Regeneron Pharmaceuticals | C5 Co-Co Obligation | Global Strategic Collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Revenue recognized under ASC 808</a></td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="nump">$ 4,200<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=118644919&amp;loc=SL5834089-161433<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=alny_RegeneronPharmaceuticalsIncorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=alny_RegeneronPharmaceuticalsIncorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=alny_GlobalStrategicCollaborationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=alny_GlobalStrategicCollaborationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=alny_ResearchServicesObligationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=alny_ResearchServicesObligationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=alny_C5LicenseObligationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=alny_C5LicenseObligationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=alny_C5CoCoObligationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=alny_C5CoCoObligationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140603038693592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LIABILITY RELATED TO THE SALE OF FUTURE ROYALTIES (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Jan. 01, 2030</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Apr. 10, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesLineItemsLineItems', window );"><strong>Liability Related To The Sale Of Future Royalties Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_RoyaltiesReceivableCurrent', window );">Receivable related to the sale of future royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_RoyaltyLiabilityNoncurrent', window );">Liability related to the sale of future royalties, net of current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,086,065,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,058,225,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=alny_BlackstoneGroupIncMember', window );">Blackstone Group Inc. | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesLineItemsLineItems', window );"><strong>Liability Related To The Sale Of Future Royalties Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_CollaborativeArrangementRoyaltiesAndCommercialMilestonesAcquiredByCollaboratorPercent', window );">Collaborative arrangement, royalties and commercial milestones acquired by collaborator, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_CollaborativeArrangementCommercialMilestonesAcquiredByCollaboratorPercent', window );">Commercial milestones acquired by collaborator, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_ExpectedRoyaltyInterestPayments', window );">Expected royalty interest payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000,000.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_CollaborativeArrangementConsiderationReceived', window );">Consideration received</a></td>
<td class="nump">$ 500,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_RoyaltiesReceivableCurrent', window );">Receivable related to the sale of future royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_RoyaltyLiabilityNoncurrent', window );">Liability related to the sale of future royalties, net of current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,099,725,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,071,541,000<span></span>
</td>
<td class="nump">$ 1,000,000,000.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_RoyaltyLiabilityInterestRate', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_RoyaltyLiabilityClosingCosts', window );">Closing costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13,000,000.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_RoyaltyLiabilityInterestExpenseIncludingAmortizationOfClosingCosts', window );">Interest expense including amortization of closing costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,184,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Forecast | Blackstone Group Inc. | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesLineItemsLineItems', window );"><strong>Liability Related To The Sale Of Future Royalties Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_CollaborativeArrangementRoyaltiesAndCommercialMilestonesAcquiredByCollaboratorPercent', window );">Collaborative arrangement, royalties and commercial milestones acquired by collaborator, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_CollaborativeArrangementCommercialMilestonesAcquiredByCollaboratorPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Commercial Milestones Acquired By Collaborator, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_CollaborativeArrangementCommercialMilestonesAcquiredByCollaboratorPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_CollaborativeArrangementConsiderationReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Consideration Received</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_CollaborativeArrangementConsiderationReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_CollaborativeArrangementRoyaltiesAndCommercialMilestonesAcquiredByCollaboratorPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Royalties Acquired By Collaborator, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_CollaborativeArrangementRoyaltiesAndCommercialMilestonesAcquiredByCollaboratorPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_ExpectedRoyaltyInterestPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected Royalty Interest Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_ExpectedRoyaltyInterestPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesLineItemsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liability Related To The Sale Of Future Royalties Line Items</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesLineItemsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_RoyaltiesReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalties Receivable, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_RoyaltiesReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_RoyaltyLiabilityClosingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty Liability, Closing Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_RoyaltyLiabilityClosingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_RoyaltyLiabilityInterestExpenseIncludingAmortizationOfClosingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty Liability, Interest Expense Including Amortization Of Closing Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_RoyaltyLiabilityInterestExpenseIncludingAmortizationOfClosingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_RoyaltyLiabilityInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty Liability, Interest Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_RoyaltyLiabilityInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_RoyaltyLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty Liability, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_RoyaltyLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=alny_BlackstoneGroupIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=alny_BlackstoneGroupIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140603038708104">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS - Fair Value of Assets Measured on a Recurring Basis (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">1,273,027<span></span>
</td>
<td class="nump">1,353,182<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="nump">56,967<span></span>
</td>
<td class="nump">44,633<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="nump">56,967<span></span>
</td>
<td class="nump">44,633<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">1,508,947<span></span>
</td>
<td class="nump">1,475,024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Financial liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Development derivative liability (Note 10)</a></td>
<td class="nump">48,038<span></span>
</td>
<td class="nump">25,585<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Quoted Prices in Active Markets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="nump">56,967<span></span>
</td>
<td class="nump">44,633<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">235,920<span></span>
</td>
<td class="nump">121,842<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Financial liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Development derivative liability (Note 10)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Significant Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">1,273,027<span></span>
</td>
<td class="nump">1,353,182<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Financial liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Development derivative liability (Note 10)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Significant Unobservable Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Financial liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Development derivative liability (Note 10)</a></td>
<td class="nump">48,038<span></span>
</td>
<td class="nump">25,585<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">1,057,827<span></span>
</td>
<td class="nump">1,087,968<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | U.S. treasury securities | Quoted Prices in Active Markets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | U.S. treasury securities | Significant Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">1,057,827<span></span>
</td>
<td class="nump">1,087,968<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | U.S. treasury securities | Significant Unobservable Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">177,470<span></span>
</td>
<td class="nump">75,726<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted cash (money market funds)</a></td>
<td class="nump">1,483<span></span>
</td>
<td class="nump">1,483<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Money market funds | Quoted Prices in Active Markets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">177,470<span></span>
</td>
<td class="nump">75,726<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted cash (money market funds)</a></td>
<td class="nump">1,483<span></span>
</td>
<td class="nump">1,483<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Money market funds | Significant Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted cash (money market funds)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Money market funds | Significant Unobservable Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted cash (money market funds)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | U.S. government-sponsored enterprise securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">215,200<span></span>
</td>
<td class="nump">245,214<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | U.S. government-sponsored enterprise securities | Quoted Prices in Active Markets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | U.S. government-sponsored enterprise securities | Significant Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">215,200<span></span>
</td>
<td class="nump">245,214<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | U.S. government-sponsored enterprise securities | Significant Unobservable Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13433-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=99377092&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140603031682584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>MARKETABLE DEBT SECURITIES - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_ImpairmentOfMarketableDebtSecurities', window );">Impairment charges of marketable debt securities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_ImpairmentOfMarketableDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Impairment of marketable debt securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_ImpairmentOfMarketableDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140603034416536">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>MARKETABLE DEBT SECURITIES - Summary of Marketable Debt Securities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 1,272,680<span></span>
</td>
<td class="nump">$ 1,352,834<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">422<span></span>
</td>
<td class="nump">463<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(75)<span></span>
</td>
<td class="num">(115)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">1,273,027<span></span>
</td>
<td class="nump">1,353,182<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember', window );">U.S. government-sponsored enterprise securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">215,171<span></span>
</td>
<td class="nump">245,113<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">87<span></span>
</td>
<td class="nump">135<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(58)<span></span>
</td>
<td class="num">(34)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">215,200<span></span>
</td>
<td class="nump">245,214<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">1,057,509<span></span>
</td>
<td class="nump">1,107,721<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">335<span></span>
</td>
<td class="nump">328<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(17)<span></span>
</td>
<td class="num">(81)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">$ 1,057,827<span></span>
</td>
<td class="nump">$ 1,107,968<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140603029773432">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>MARKETABLE DEBT SECURITIES - Summary of Fair Value of Marketable Debt Securities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Marketable debt securities</a></td>
<td class="nump">1,273,027<span></span>
</td>
<td class="nump">1,333,182<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total</a></td>
<td class="nump">$ 1,273,027<span></span>
</td>
<td class="nump">$ 1,353,182<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140603033110232">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>OTHER BALANCE SHEET DETAILS - Schedule of Inventory (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Raw materials</a></td>
<td class="nump">$ 53,694<span></span>
</td>
<td class="nump">$ 63,460<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcess', window );">Work in progress</a></td>
<td class="nump">23,593<span></span>
</td>
<td class="nump">16,149<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods</a></td>
<td class="nump">13,753<span></span>
</td>
<td class="nump">12,693<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_InventoryCurrentAndNoncurrent', window );">Total</a></td>
<td class="nump">91,040<span></span>
</td>
<td class="nump">92,302<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherAssetsMember', window );">Other Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Long-term inventory</a></td>
<td class="nump">$ 17,100<span></span>
</td>
<td class="nump">$ 17,100<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_InventoryCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inventory, Current And Noncurrent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_InventoryCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140603029906328">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>OTHER BALANCE SHEET DETAILS - Schedule of Reconciliation of Cash, Cash Equivalents and Restricted Cash (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 379,543<span></span>
</td>
<td class="nump">$ 496,580<span></span>
</td>
<td class="nump">$ 467,779<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Total restricted cash included in prepaid expenses, other current assets and long-term other assets</a></td>
<td class="nump">2,462<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,614<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Total cash, cash equivalents, and restricted cash shown in the condensed consolidated statements of cash flows</a></td>
<td class="nump">$ 382,005<span></span>
</td>
<td class="nump">$ 499,046<span></span>
</td>
<td class="nump">$ 470,393<span></span>
</td>
<td class="nump">$ 549,628<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140603034037832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER BALANCE SHEET DETAILS - Summary of Changes in Accumulated Other Comprehensive Income (Loss) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>AOCI Attributable to Parent, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance</a></td>
<td class="nump">$ 1,016,247<span></span>
</td>
<td class="nump">$ 1,438,692<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive (loss) income before reclassifications</a></td>
<td class="nump">6,847<span></span>
</td>
<td class="nump">1,657<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from other comprehensive income</a></td>
<td class="nump">58<span></span>
</td>
<td class="nump">2,802<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Total other comprehensive income</a></td>
<td class="nump">6,905<span></span>
</td>
<td class="nump">4,459<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance</a></td>
<td class="nump">926,190<span></span>
</td>
<td class="nump">1,349,729<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=alny_AccumulatedLossOnInvestmentInJointVentureMember', window );">Loss on Investment in Joint Venture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>AOCI Attributable to Parent, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance</a></td>
<td class="num">(32,792)<span></span>
</td>
<td class="num">(32,792)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive (loss) income before reclassifications</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from other comprehensive income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Total other comprehensive income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance</a></td>
<td class="num">(32,792)<span></span>
</td>
<td class="num">(32,792)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember', window );">Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>AOCI Attributable to Parent, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance</a></td>
<td class="num">(3,754)<span></span>
</td>
<td class="num">(3,520)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive (loss) income before reclassifications</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from other comprehensive income</a></td>
<td class="nump">58<span></span>
</td>
<td class="nump">74<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Total other comprehensive income</a></td>
<td class="nump">58<span></span>
</td>
<td class="nump">74<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance</a></td>
<td class="num">(3,696)<span></span>
</td>
<td class="num">(3,446)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember', window );">Unrealized Gains from Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>AOCI Attributable to Parent, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance</a></td>
<td class="nump">348<span></span>
</td>
<td class="nump">137<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive (loss) income before reclassifications</a></td>
<td class="num">(1)<span></span>
</td>
<td class="nump">1,317<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from other comprehensive income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,728<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Total other comprehensive income</a></td>
<td class="num">(1)<span></span>
</td>
<td class="nump">4,045<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance</a></td>
<td class="nump">347<span></span>
</td>
<td class="nump">4,182<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember', window );">Foreign Currency Translation Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>AOCI Attributable to Parent, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance</a></td>
<td class="num">(7,424)<span></span>
</td>
<td class="num">(343)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive (loss) income before reclassifications</a></td>
<td class="nump">6,848<span></span>
</td>
<td class="nump">340<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from other comprehensive income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Total other comprehensive income</a></td>
<td class="nump">6,848<span></span>
</td>
<td class="nump">340<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance</a></td>
<td class="num">(576)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember', window );">Accumulated Other Comprehensive Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>AOCI Attributable to Parent, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance</a></td>
<td class="num">(43,622)<span></span>
</td>
<td class="num">(36,518)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Total other comprehensive income</a></td>
<td class="nump">6,905<span></span>
</td>
<td class="nump">4,459<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance</a></td>
<td class="num">$ (36,717)<span></span>
</td>
<td class="num">$ (32,059)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AOCIAttributableToParentNetOfTaxRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121640130&amp;loc=d3e1436-108581<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121640130&amp;loc=d3e1436-108581<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17B<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL34724394-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121640130&amp;loc=d3e1436-108581<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=alny_AccumulatedLossOnInvestmentInJointVentureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=alny_AccumulatedLossOnInvestmentInJointVentureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140603038502408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CREDIT AGREEMENT - Additional Information (Details) - Line of Credit - Secured Debt<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 10, 2020 </div>
<div>USD ($) </div>
<div>tranche</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancingReceivableImpairedLineItems', window );"><strong>Financing Receivable, Impaired [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_DebtInstrumentNumberOfTranches', window );">Number Of tranches | tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Loan facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLinesOfCredit', window );">Proceeds from lines of credit</a></td>
<td class="nump">$ 200,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_LineOfCreditFacilityMaximumBorrowingCapacityAccordionFeature', window );">Maximum borrowing capacity, accordion feature</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Interest rate floor</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_DebtInstrumentInterestInKindInterestRateIncrease', window );">Interest in kind, interest rate increase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeeAmount', window );">Commitment fee amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage', window );">Commitment fee percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_DebtInstrumentExitFeePercent', window );">Exit fee percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_LineOfCreditFacilityPrepaymentAndTerminationFeePercentage', window );">Prepayment and termination fee percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_DebtInstrumentCovenantTermsMinimumConsolidatedLiquidity', window );">Minimum consolidated liquidity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember', window );">LIBOR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancingReceivableImpairedLineItems', window );"><strong>Financing Receivable, Impaired [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt instrument, basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember', window );">LIBOR | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancingReceivableImpairedLineItems', window );"><strong>Financing Receivable, Impaired [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Interest rate floor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember', window );">Base Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancingReceivableImpairedLineItems', window );"><strong>Financing Receivable, Impaired [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt instrument, basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember', window );">Base Rate | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancingReceivableImpairedLineItems', window );"><strong>Financing Receivable, Impaired [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Interest rate floor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember', window );">Tranche 2 Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancingReceivableImpairedLineItems', window );"><strong>Financing Receivable, Impaired [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate Principal Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember', window );">Tranche 3 Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancingReceivableImpairedLineItems', window );"><strong>Financing Receivable, Impaired [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate Principal Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember', window );">Tranche 2 Loan And Tranche 3 Loan | ONPATTRO And GIVLAARI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancingReceivableImpairedLineItems', window );"><strong>Financing Receivable, Impaired [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_DebtInstrumentCovenantTermsMinimumProductRevenue', window );">Minimum product revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_DebtInstrumentCovenantTermsMinimumConsolidatedLiquidity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant Terms, Minimum Consolidated Liquidity</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_DebtInstrumentCovenantTermsMinimumConsolidatedLiquidity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_DebtInstrumentCovenantTermsMinimumProductRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant Terms, Minimum Product Revenue</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_DebtInstrumentCovenantTermsMinimumProductRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_DebtInstrumentExitFeePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Exit Fee Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_DebtInstrumentExitFeePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_DebtInstrumentInterestInKindInterestRateIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Interest In Kind, Interest Rate Increase</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_DebtInstrumentInterestInKindInterestRateIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_DebtInstrumentNumberOfTranches">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Number Of Tranches</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_DebtInstrumentNumberOfTranches</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_LineOfCreditFacilityMaximumBorrowingCapacityAccordionFeature">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line Of Credit Facility, Maximum Borrowing Capacity, Accordion Feature</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_LineOfCreditFacilityMaximumBorrowingCapacityAccordionFeature</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_LineOfCreditFacilityPrepaymentAndTerminationFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line Of Credit Facility, Prepayment And Termination Fee Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_LineOfCreditFacilityPrepaymentAndTerminationFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancingReceivableImpairedLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancingReceivableImpairedLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityCommitmentFeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the fee for available but unused credit capacity under the credit facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityCommitmentFeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityCommitmentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLiborSwapRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLiborSwapRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_BaseRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_BaseRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=alny_TrancheTwoLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=alny_TrancheTwoLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=alny_TrancheThreeLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=alny_TrancheThreeLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=alny_Tranche2LoanAndTranche3LoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=alny_Tranche2LoanAndTranche3LoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=alny_ONPATTROAndGIVLAARIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=alny_ONPATTROAndGIVLAARIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140603034247160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEVELOPMENT DERIVATIVE LIABILITY - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Cost of borrowing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=alny_BlackstoneLifeSciencesMember', window );">Blackstone Life Sciences</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Cost of borrowing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement | Blackstone Life Sciences | Vutrisiran and ALN-AGT</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_CollaborativeArrangementMaximumFunding', window );">Maximum funding</a></td>
<td class="nump">$ 150,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement | Blackstone Life Sciences | HELIOS-B Phase 3 Clinical Trial</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_CollaborativeArrangementMaximumFunding', window );">Maximum funding</a></td>
<td class="nump">70,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement | Blackstone Life Sciences | ALN-AGT Phase 2 Clinical Trial</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_CollaborativeArrangementMaximumFunding', window );">Maximum funding</a></td>
<td class="nump">$ 26,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_CollaborativeArrangementFixedPaymentMultiplier', window );">Fixed payment multiplier</a></td>
<td class="nump">3.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_CollaborativeArrangementFixedPaymentTerm', window );">Fixed payment, term</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement | Blackstone Life Sciences | ALN-AGT Phase 3 Clinical Trial</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_CollaborativeArrangementMaximumFunding', window );">Maximum funding</a></td>
<td class="nump">$ 54,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_CollaborativeArrangementFixedPaymentMultiplier', window );">Fixed payment multiplier</a></td>
<td class="nump">4.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_CollaborativeArrangementFixedPaymentTerm', window );">Fixed payment, term</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement | Blackstone Life Sciences | Vutrisiran</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_CollaborativeArrangementRoyaltiesPayablePercent', window );">Royalties payable, percent</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_CollaborativeArrangementRoyaltiesPayableTerm', window );">Royalties payable, term</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_CollaborativeArrangementFixedPaymentMultiplier', window );">Fixed payment multiplier</a></td>
<td class="nump">2.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_CollaborativeArrangementFixedPaymentTerm', window );">Fixed payment, term</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_CollaborativeArrangementFixedPaymentMultiplier">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Fixed Payment Multiplier</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_CollaborativeArrangementFixedPaymentMultiplier</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_CollaborativeArrangementFixedPaymentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Fixed Payment, Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_CollaborativeArrangementFixedPaymentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_CollaborativeArrangementMaximumFunding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Maximum Funding</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_CollaborativeArrangementMaximumFunding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_CollaborativeArrangementRoyaltiesPayablePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Royalties Payable, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_CollaborativeArrangementRoyaltiesPayablePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_CollaborativeArrangementRoyaltiesPayableTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Royalties Payable, Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alny_CollaborativeArrangementRoyaltiesPayableTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=alny_BlackstoneLifeSciencesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=alny_BlackstoneLifeSciencesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=alny_BlackstoneLifeSciencesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=alny_BlackstoneLifeSciencesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=alny_VutrisiranAndALNAGTMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=alny_VutrisiranAndALNAGTMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=alny_HELIOSBPhase3ClinicalTrialMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=alny_HELIOSBPhase3ClinicalTrialMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=alny_ALNAGTPhase2ClinicalTrialMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=alny_ALNAGTPhase2ClinicalTrialMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=alny_ALNAGTPhase3ClinicalTrialMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=alny_ALNAGTPhase3ClinicalTrialMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=alny_VutrisiranMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=alny_VutrisiranMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140603031886936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEVELOPMENT DERIVATIVE LIABILITY - Development Derivative Liability Activity (Details) - Derivative<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Development derivative liability, beginning balance</a></td>
<td class="nump">$ 25,585<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues', window );">Amount received under the Funding Agreement</a></td>
<td class="nump">4,200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Loss recorded from remeasurement of development derivative liability</a></td>
<td class="nump">18,253<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Development derivative liability, ending balance</a></td>
<td class="nump">$ 48,038<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_DerivativeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_DerivativeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140603031937032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION - Summary of Share-Based Compensation Expenses Included Operating Costs and Expense (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 55,690<span></span>
</td>
<td class="nump">$ 34,578<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">24,375<span></span>
</td>
<td class="nump">16,049<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 31,315<span></span>
</td>
<td class="nump">$ 18,529<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140603033093592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET LOSS PER COMMON SHARE - Common Share Equivalents Excluded from Calculation of Net Loss Per Common Share (Detail) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">15,397<span></span>
</td>
<td class="nump">15,020<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Options to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">13,859<span></span>
</td>
<td class="nump">13,609<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember', window );">Unvested restricted common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">1,538<span></span>
</td>
<td class="nump">1,411<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>66
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MQ5KY"<,5'XJ"($Q69/8:+V14Q[@!P%@>QJ0R#88K_#YK9/SBKWD"I?TQ#VX
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MC[^);4"I]5?)1@__H\<M%L]0U6LCVZTQ,&CK;O.W_+E-Q($!20(&=&M 7VK
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M__1\\QW4;G_>H+O'V0R-T8_9-3KZ\A7)52R81&F!7E9\(^,BD<?H2^?];*(
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M /Q_P;G:O90+[.?X%_\#4$L#!!0    ( (2!G5(E:'DY=04  /T6   8
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ML4L.&2\3K,DC98[83BHM?M4?7&YLNHL&[L$D#L9.M*V2&%.W!Y,.:N*%>C%
M5D,5I>:*5QI<DBFNFV1:, T> Q?V'BLXY#9G3"0VF8#$8S*V54K3"3++CLS2
M'ZG/X="1X$\@1Q5'P*(0[$X40A^'?/26HXI!G,@-VAST07&DY)$5)A)<W)86
M:K+$RW#$S;8*W,32CECJ);;6,OLQ-VJ2HTSN#*?)6$JMP:,H3H,11-N*AE&R
M=,/$09_L R_0;YP5XA>@-*%T*-7SZSTSRZT$85$_N&9WX''^\V FH^+908DI
M?[?##7'.PR3 \8B.RXZ$&$_D%SQ0+^PE= ,1HIS(L.W!($F2,3#;+(XGH@&3
M'A7QI_XM*^]Y-<IA5<4A_1G//\?Z?^0SW$L-IOXTD67R8)(KY#4N'LP$GIA\
MZO0,M><"!TF0CEWCL*-DN203WNGU"OL%ZW/Y $(@U=&)+K334TK'*]AA-<<X
MC::P]8*%(R^V6\7W3.3/B:F9+FF"K)T_)^;(@8;&D87:99>FT=2R[O4,^P6M
MF_X].S9S;]3AP)T\!L'G)&/+V#R.HX2.R3CL<$AP-$&F5SSLE[Q+ON%* 7;%
M(4X.W G2EJ<Y29:!Y7&'71C0J07>"QGV*]G-2YWMQ<L)UM:;>1K$XY3O-J/Q
M!-9>F[!?G*Y?LZURXK9%:$YH%-O(789AC..)]$YZO2+!F_;0 E)']88=(>F%
MA/B%Y/:@LJW9,IFMQEX9'^GC"=H7K-3UXC%ZN#<[6)>KB"TC<YS@@6"W%8C+
M+HUQ,N&H7G$(>3W\@8K[Y;OM]&6*#Z/4REQ.PS0.!Z+Q$GBO7,2O7&O8W379
M"4KR%NK;.-@R%=)E/)"IEH)M%P$%'$XPZ.6,^.7LA>O-KE:)3-<KS<1J7?,X
M<;LD+(BC\>)RV:5I,)'"2*]TY+^43F:<Y^W":IU_?",'6]"<%&RS*?B]Y!&_
MY-4;/V<^< )UB%6(4VMYVF930'LY(WXYZ](O))4'D8-3[XZOQVWK5X)I9,6V
MHZ:##<AR8F-!>ITCRS?EWXTH&13NK\^_O4H1OTJ]#$?^Q%4FJKKNJTQQ!:)E
M"JKA/D8?]\V::RJ5R?TNL=4IC%.K$G"819!')A(<[26,^DNNE\1RV-,4LM81
M>%:P53>GF"[8U"Z90A*,EY;#:B)B:2^%U"^%SHAUS;P3MJUP$<:6MUUF'F_W
M.DC].GBUV?!,UU'QE-55&(*]#D=96Y%!C6NHG30$3>0\@ "5;5TVR'SF=R<_
MIQ)B:UX<9C&=V _1P9&B7RW-U.0\4_6F4_QO+JY*$"=!.#X,<ADF*>P%)_CT
MVDG]VKEZ-?X3=,?O15F:"#0[-%@[,G>2LO4R!+T,QT<2#KLH3&,RD3-I+ZS4
M+ZQOX<1--O.RL:63+B$-1&,VMEV8!),G=K3761I[%6!]V.\+;O(5*U NJJR0
ME3F& ]2E+-O3O$[,@,Y;)8+V2DK]2KIB>V%0U#5M+LQIH#EBR8I#WA0V;%0&
M-V>[HTK8Z>7$.O].R')\(.*PBF,\3EF+P5W,CJO[^HJJ0C6RYBZC^]I=@UW4
MES^C[Q_P^U5SF=5WT]RM?64*ED(%M><&N@S>)3#MJKFN:EZTW-<W/G=2:[FK
M'[><@=X8 _A](Z5^?C$#=)>&Y_\"4$L#!!0    ( (2!G5(E]E=(P 4  +<,
M   8    >&PO=V]R:W-H965T<R]S:&5E=#<N>&ULI5==;]LV%/TK%W[: -5V
MG&0;BB2 TZ5;AN8#<=,.&/9 2Y1$A")5DK+C_OJ=2TJ*T[7!BKW($LE[>.[7
M(7VRM>[!UU(&>FRT\:>3.H3V]6SF\UHVPD]M*PUF2NL:$?#IJIEOG11%-&KT
M;#&?_S1KA#*3LY,X=NO.3FP7M#+RUI'OFD:XW;G4=GLZ.9@, W>JJ@,/S,Y.
M6E')E0SW[:W#UVQ$*50CC5?6D)/EZ61Y\/K\B-?'!1^4W/J]=V)/UM8^\,=E
M<3J9,R&I91X80>!G(]](K1D(-#[UF)-Q2S;<?Q_0WT;?X<M:>/G&ZH^J"/7I
MY)<)%;(4G0YW=ON[[/TY9KS<:A^?M.W7SB>4=S[8IC<&@T:9]"L>^SC\%X-%
M;["(O--&D>6O(HBS$V>WY'@UT/@ENAJM04X93LHJ.,PJV(6SZ^7[^[L+NGE+
MY_>KR^N+U>ID%H#+L[.\QSA/&(MO8!S2E36A]G1A"ED\MY^!STAJ,9 Z7[P(
M>"7<E X/,EK,%P<OX!V.3AY&O,-OX-VX2ACU67 =9/3&&F^U*D0J"U/0K9->
MFI &;$EOE1$F5T+3"H,2-1@\_;5<^^!017^_P.AH9'04&1W]K[!_+P8MM=EI
MT=!M+5"QN>R"RH7V&5V:?$H_X-5R)TGG9$'!DO"#249;F9'M'%E'G?^1<MO
M[QSK(  NAL83PO-'9R0=''%NY@L&$+16MGVV(1NWPNS(2_F@3,5;%7(#!6AC
MO".VXP"KSY*,Q0R%&KNT$<#'/BMXM[OK)2D3I -G9I,Q/0RJ*7V4))R,6"J$
MY ] 2!0;)"\FC7/)+HUTD+\@JQV/KSNE"^8FJ$$'JU>MLT67AXPJ;=="9WLL
M7_!PJT(-B$+*Y)I'RT(*Q5J#&C(6%[>JE9P]WI?)/W<6RDIE%SHX4Z&,& ]
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M:^EX >9+BPST'[S!^%_E[!]02P,$%     @ A(&=4H'&?D#3!P  0!,  !@
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M2\$6"G13551]OV)<'L8>\4X3RW)?&#L13$8UW;,'9M;U0N$HZ%"V9<6$+J4
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M1N*#>5]4\H\&^%WOR[C&%=A]B<@>H%HIMP4(/D!NZ,<4VFXSY$U-&(=?#UV
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M'RT@@[R+LP8U7PQ(C6 C_']1I/L1 8C[P@(Z.+P'+)Z&UDL[LMF5D%CV6,B
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M_;;&;^0TBB(,/8<R&CP/KPX#X25)/F__X3Q*GR,:W(DT/(GM+C%P!!V&_=X
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MNX4T2#%M@F-;)G"!_3DL%]RV9);)L*?CHJCZ K96-IW^P!!"8VN"RPZ]@&/
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MB5)J>T9VG,:=M/'83OK0Z0-$KD1,0$ !("O.K^\N2!VQ%3>]7DA<^V&/;Q?
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M(XOO(#L\-3,PTDH*UMX8DN)X^;Z0MEP;PMK)Q0(>E1%6P+)[ 1T'\CY[US8
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MU"B4FJ:\?''!BE.U*&DDIS97YW:JJQW\!._ +]301.TYT?4<I,W;(4+.P0G
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MG4D5+S?HOU.=:K]JF+U1#@ <<4O9"!+T_R3W6G@Y-="WG^L],2%"0G"L;-A
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MHJ_T(VN".4S@;PL],WWFB.6R@Z!D*1-'#J"</J6&M*I=&-5&'D!Z] [Q9!<
ME86,08++3!0-3WS[M[DB$8N\G+3YEC#IX&.L#HXO.[>*+6U8W/2^[R''HR]0
MX).E?&<+ H68/D8-3X=/>6?I"]9N>?H."%9=,M_55&'KR?3IDR/ET[>U]$=T
MK7S/6C@48B,_0;& "2_ ^\JYF/]@!<,'SE?_ 5!+ P04    " "$@9U2]E\
M\ L(   6%   &0   'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6R=6%U3(S<6
M_2LJ/V6KC UF8+,IH,I\3$)E!L@PDSRD\B!WRVX%M=21U#;^]WONE;IMB/&&
M?0%W2[J?YYY[U6<KYY]"I504S[6QX7Q0Q=C\,!Z'HE*U#"/7*(N5N?.UC'CT
MBW%HO)(E'ZK->')X>#JNI;:#BS-^]^ OSEP;C;;JP8O0UK7TZTMEW.I\<#3H
M7GS1BRK2B_'%62,7ZE'%;\V#Q].XEU+J6MF@G15>S<\'TZ,?+D]I/V_X5:M5
MV/HMR).9<T_T<%N>#P[)(&54$4F"Q+^ENE+&D""8\5>6.>A5TL'MWYWTC^P[
M?)G)H*Z<^4V7L3H??#\0I9K+UL0O;O63ROZ<D+S"F<!_Q2KM/3T9B*(-T=7Y
M,"RHM4W_Y7..P]:![P_?.##)!R9L=U+$5E[+*"_.O%L)3[LAC7ZPJWP:QFE+
M27F,'JL:Y^+%Y?3Q]E'<?Q0/7VX>;^Z^3K_>WM^)Z=TU7MS>7=T^?+KAY:O[
MN\?[3[?7:?V[!V=TH57XU]DXP@J2-2ZRQLND<?*&QF/QV=E8!7%C2U6^/#^&
M];T+D\Z%R\E>@9^E'XGCHZ&8'$Z.]L@[[D-RS/*.WY W+0K7VJCM0G1NBM^G
MLQ ](/3''@4?>@4?6,&'MV(N@P["S<6#5T'9*!,^;8D7VA:Z,8J7KYP-,*#D
M]5V!WJ_F:Z4 ^L+5C;1K\J9PB+@-JJ1?63(>YMI*:)5&!)BB4'&1U4^-71M9
M"^F5:*UL2TV[R<Q*+I68*64%B*#!>BFT95V^A"@%#,>*GW,<FXU?"V65E\:L
M:5TU,9V-L/6;906/9$0RH%9>%W(HG!<_3J</0R&;!@F1,Z-$=#@7L:$6#?ZZ
M,I!IPTZ8:[2EJ$),+2WHA=RBU<*T)>)BC+!4U88=\JIHO2=+9?DGBB[%(%8R
MLO=6%2H$<!9IY2")N=0>/I J)!$4P!:#*SUG*PCP95YMG">_LI4C<=_Z=Z6"
MHRU-<*]"3I@A1@*60@MX2L2: TLB=8@XS(D8LHNA<JTI(4(0=U.8L.W/UB9R
M3/L<+.OR_+_MZCQ<*^F%HF(6UPA4/5.^*\?#H5A5NJC$2B&,.?BLG%1-K6TA
M\@M'B-PAGA5'AP<_I]"O))1H@P.,)]+U2(G2D4J2G+IY+BII%PJE4M<Z<*<@
M.6KF6TK746:%D?B:#3V H6]%?R8-HS=U0[R3;$*)Q"TI"-[5+T*T,RJS%D<=
M[+,NOH!;J4-A7&@!%Z3@KU93#F=K1G:R;QM(4/,*3"CB5XA/V(2:#I_:T)82
M%4*MCN2\QN=NL0[;_&OA6.-U,6]A_1S6PU$*83+V_V86=%UJR;E*>UNV"0<I
M(DM7E0.<#]S*0A9!7)<:3BK4T!0FL;W9B(YL$BS U#;((@G>D)4R&AV4+$M%
M&/3"ZCFBA4+9)JN.]"F\I0J%U[,$VCN'RI]T<:6G0(QPM>WSQ][GQXW/[T#^
M/ZFJT9XF=-(WH9.]W>%;8(#<A*AK(MQ=_>5]$A@6B9U21\/B3@0D[J&!4L=U
MJFTJ@JXJPA9C4WAK^:2$ZK50@F7 $-FD_":6GL\[3/6$*^N$")B!_2ICPV@Y
MTV9#(71D4YJT&;81#DC[6^>2)DIX!X;W5$"G=I>E7BV5;;-MZKDAF:"@EIO3
MYA#CE.MT)&X3IMYA 5@9+3WLBZI7AH\C_B1<6Y@5'2AU*4V[&5BZ;33(^*6"
MY"Y.ZVT19'B0AJ,U;R,%VKNU-!3-(6ILB<M!P_EFLDWTU4OBMNUJ]'SY3/MS
MC*AK.U0P&3-D"Z1'JR&SMB5V0<QM,+KBZ8#F>(I334OLS4C\IGB\9W<W<8&?
M%7JIHT'$L"P0$#4))BF+<" );<@4^C=<KHAZC(8Y%(;4?(.S-,& Q(I(+-#Q
M<\$-NM2 LD_-)E9N.TF)>)F.U7/,U9'Z*P7XZO[7V^N#H_\($&*I:EV@M+CO
M($X1G<%Y;@[Y28,W43'D[:P-*.W D=TURI"K&Q@1SG+,$ZT1%BFY.+^)=0>(
M!"R#NQ^U5BPP%%K,<>NN(37>E6V1ZR(_")!RR0C&D0+,P^&/'@:$#+PWTEVX
MP !GUU6C4IHRZ+8V;HUW%6YN, >SD/(1]]AMQ]#_90X+V6MQS=0VW86I!EA&
M+=<"A>473 ,08NEDGPZRD& BDU),0FX^[$F@:U,1+&<IH40_DOH$^@#0@B$B
MTN\E.A0W+R$76 [T?DCFK7"CI?\D# 5A'66^RZX5QB%RE(\%U- ORY;GP9=[
M:/\FW3>53R'&)?T)[,>5P4VTEN4V963FZU3--QX3I>=.MX\ O>+0H2K2%!<2
M5;S /#6+G+Q^@'Y5-R3C9=6H%U6SIUF>]LWR=&^K^Z31F8#Z]:XN^0^/BDLF
M'9?9&O<-@FLN,Z)S#)_#%X1!V.*],F XI[^".B08N(]BRA%?B,+6:,S)^<SU
MT5V,47ENH9BE^FF:14(CE6W!;))N9W2_H4AVQ<C5S?I:,(M_X0!J6^?2ICM@
MF;BAZQMT:8Z 7M$!@8=%8^3,Y2&!C2%>NS2R> +^K!(_>M<VZ&O%B)7FLB2?
M-/D]QZ5 )VK@,I\1H^ EAK;$B8H)%AV.'F2YY*F>YZX\83Z($_$\.>G,6Z=)
M-PH#=DZ]W8)AQ=%$U.E;10<LNH^0#XQ]7+Q^P34#%03V^/LL]\M.Y(VWOM4P
M9] 7*29_&]-GF_YM_]%KFK[U;+:G+V9(\ ), *OG.'HX^C?F-9^^0J6'Z!K^
M\C-S$77-/RM<_I2G#5B?.XRP^8$4])\"+_X+4$L#!!0    ( (2!G5(CB*N=
MC ,  /,'   9    >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;(U5;6_;-A#^
M*X16# T@1*)>;<<VX#C>EJ%)#+^D X9]H"7:$DJ1*DG%[;_?D9(=MW&,?I&.
MY-USSQWOCL.]D%]40:E&WRK&U<@IM*X'GJ>R@E9$78N:<CC9"ED1#4NY\U0M
M*<FM4<6\P/<3KR(E=\9#NS>7XZ%H-"LYG4NDFJHB\OLM96(_<K!SV%B4NT*;
M#6\\K,F.+JE>UW,)*^^(DI<5Y:H4'$FZ'3D3/+B-C;Y5>"[I7IW(R$2R$>*+
M6=SG(\<WA"BCF38(!'XO=$H9,T! XVN'Z1Q=&L-3^8#^AXT=8MD01:>"?2YS
M78R<GH-RNB4-TPNQ_XMV\5B"F6#*?M&^U8T3!V6-TJ+JC(%!5?+V3[YU>3@Q
MZ/GO& 2=06!YMXXLRSNBR7@HQ1Y)HPUH1K"A6FL@5W)S*4LMX;0$.SU^G*W0
M?/%TMYZNT&+V/'M<SY;HXXIL&%570T^#"Z/H91W<;0L7O ,7H@?!=:'0C.<T
M_]'> VI'?L&!WVUP$?"!R&L48A<%?H OX(7'>$.+%[Z#MZ OE#<4;:6HT!2X
M2J@+R+DNT-1FFTKT[V2C[/Y_%QQ&1X>1=1B]XW#95CL26_0(/3:7(F_ 8\=#
MG4OQ14#3I0-5DXR.'&A#1>4+=<8&NNZ@90>-,@&]H[1QK0L(63!HP9+O!FA5
M2$I_N"KT\9Z#EF@4X;FZLNDV'Q\]/<XGJ]7B":UYJ4%QJ8D&\ \HZKM1BD$(
M4Q?W$S1K),P*%/EN$H<HP"Y.$HBS)?!92 9.:EE"-DKV'?U-:L*O$,9N+TA1
MSPW] *V$)@P L8_=?FR@D\1-D@C]>?_\:3)9W+_A@%,W30(08C=(HP.%Q.VE
M(?K]MUZ @YN?*(2]X\'!71"Y">@?0)[^^;1^>!LN=B._!_^#=><+"(3I&\B^
MBZ/X1+G=Y^=N"9##&*+H@Y1"W$#P0MG%Q[*++Y<=3.^\8=0$OJ 9+5]L2X/,
MB E+BU\NQXN.SI?CZK3<D#:ND3WE6ME:W!!&>&;9B49",EX9RE>&YNA<S@8_
M5^M$&228%5EAAT6[O@/4:@,-;;9.DU#RC#6FZ$MN;RCP;R99)AK#[I6*:WS;
M8WQCKA2[,4Y,3?:@O/#92_).!C%,DIU];DPC G0[DX^[QQ=MT@[R5_7V.81@
M=B57B-$MF/K7*5R#;)^8=J%%;<?Z1F@86U8LX%6FTBC ^58(?5@8!\=W?OP_
M4$L#!!0    ( (2!G5(@F4Z85@8  *H1   9    >&PO=V]R:W-H965T<R]S
M:&5E=#(R+GAM;*586V_;-A3^*P=>,;0 5^MN*4T"V$[:!6B3P'';AV$/M$3;
M1&51(ZDXV:_?(76QG3IJT[W8XN5<O^\<4CK="OE-K1G3\+#)"W4V6&M=G@R'
M*EVS#55O1<D*7%D*N:$:AW(U5*5D-+-"FWSH.4XTW%!>#,Y/[=RM/#\5E<YY
MP6XEJ&JSH?)QPG*Q/1NX@W9BQE=K;2:&YZ<E7;$[IC^7MQ)'PTY+QC>L4%P4
M(-GR;#!V3R:QV6\W?.%LJ_:>P42R$.*;&5QE9P/'.,1REFJC@>+?/9NR/#>*
MT(U_&IV#SJ01W']NM;^WL6,L"ZK85.1?>:;79X-X !E;TBK7,[']DS7QA$9?
M*G)E?V';['4&D%9*BTTCC!YL>%'_TX<F#S\CX#4"GO6[-F2]O*":GI]*L05I
M=J,V\V!#M=+H'"\,*'=:XBI'.7U^?3F'V>67R^O/EW?P?G;S":8W'S^.)S>S
M\?SJYOH.7L_I(F?JS>E0HSDC-$P;U9-:M?>,:A\^B4*O%5P6&<L.Y8?H9N>K
MU_HZ\7H5?J+R+?@N <_QW!Y]?A>[;_7YS^B[D2M:\'^IH0>!J2B4R'E&:[84
M&=Q*IEBAZPFQA/>\H$7*:0YW.,F0FEK!7^.%TA+)]7>/1T'G46 ]"I[QZ YK
M+JMR9JS-V#TK*@9+*3;H7)[3A9!4"ZF.0=&KUU3VB2IIRLX&I0E*WK/!^366
MO*R-J-I*VEG!B!4.L?:4-L[H-3J"JV++B]4)S->2L0-X <%)UQ:=UU<%[A>5
MPARJ-Q8L\^-@1"M6,(G)O%U3K*B459JG-%?P"GR'^(&/#VY"0L>':W%/I>8*
MQA\@)J[K@DN<R($O7,*$"\W2=2%RL7H$C\2>!Q$)W0ANT$\)(1H,P@3F0B-6
MKR!PR2@9X8,W(J$?0P]080=4V O4A.9(!69I,EW38L6 %QA@ROB]K9=Z!1-D
MJ $?.5WPG&N."S.6(WDRT&(/5<.P\0J3:DEU#.!>?XX#/-\'#;3Q"\J:T\HB
MNFBB0(!%)9$,A^ZGK?OYGOMRY[Z1.: ,T"Z$DZ<T&"MC9L<22XMZ\@+M;A8(
M7#/O'"22%VE>&89A@G__#;%VWHW35%0FB)W'! JF[;+[KF:1X0SRRB=AX.V0
MV _EB.8+MF12XE13&#N-24!&R"E4[3G$^-[#HJAC4?2"<E?,)L=D_@*MYZ(T
MF83+!SR %;I[5:25]6WQ"//'DF%VJ08J&5QP3(3.'V&LM>2+JH;ZA03K=?4E
M!!/W/+-$V0LHVPN(M0'QO8 T!D10F83MFJ/0EAEPQ0K[,S/0MH"07=19&S5]
M$G4?+XDQ=KA88J/!MO2#KK9K8T^(/<54F2X&<VF.!A/M)UI42V1;)4U>+A\T
MDX4Y-3!K/,7 ZS;URX)]?119FB26KI:JQ/-#.QNY'OX;.KN>+1"7!(E[I)UB
MF_42<)'J+O'#$ LHP8:*@R@Y[,JMKO;?AR2)NY$7M=T8RQ#E8U38KKDC\'RW
M:\\AB?W$'@'&53<@0>C9Z20PTY$M.I]$<6_-C;J:&_UTS8V1NJGM9G-)"T7K
MB^*MQ%S#!*]Z&9BJJ9N- >1#A=<#;)C'RJ?7ZO'R^8KG1^>!Z<?(!VVHH/>\
M*:TWR&I&D8D5[C">T]HI>R&U7AIQ6I8Y\L!4 =TYO6J<!JJ:8L4BX'L4/H%;
M)NWUWNRZ6>1\U5P \)I39#07!4,*YKG15B?G^W3M4GDD7[OFMF-R9\:BZY"1
MXYBGV"<N/HWOIA Y$4Q#/#M3TR[V)9(1B7!3XN%5X6#O5/PQ%?L[_2BP6[T@
M(DZS-W9B0R_/M2M'>IAJFQC0]F6EO0-]C\P>@O\?(PL,S3)N#:#"INO5+R]<
M/T)6MP:CJF22B^PIEGW0=*=;>[=\#OBGA_7Q\<&Y_0NPXXNCA0#[4VA11U0"
MDOP0?N2(V81"J '"V'*GCP4M^IX76TGL/B0X9 ,R,+0>^'AU\.HG-&"D>II.
MW#6=^,7W^EE[O&4O[C6]QH[WFB-6+VHJ/<>!(Z?AD:E?@#TA<5WK'O%_B#4V
M?H-+>W3THFQW!A:]';)>V)J+[/HQ-(=[[\\;)E?V*X%Y_\'(ZE?I;K;[$#&N
MW[]WV^NO&%@C*X[9R]D219VW([RWR_K+0#W0HK1OXPNA\=W>/JX9S9@T&W!]
M*? T;@;&0/=YYOP_4$L#!!0    ( (2!G5(5@[R3Q0(  /8%   9    >&PO
M=V]R:W-H965T<R]S:&5E=#(S+GAM;*U446_:,!#^*Z=H#YN$FA!@I0B0H*4J
M$E41I)NJ:0\F.8A5QV:V4\I^_<X.9$PJ/.TE\?GNON^S?7?]G=*O)D>T\%X(
M:09!;NVV%X8FS;%@YDIM49)GK73!+)EZ$YJM1I;YI$*$<11]#0O&93#L^[VY
M'O95:067.-=@RJ)@>C]&H7:#H!D<-Q9\DUNW$0[[6[;!)=KG[5R3%=8H&2]0
M&JXD:%P/@E&S-VZ[>!_PC>/.G*S!G62EU*LSIMD@B)P@%)A:A\#H]X:W*(0#
M(AF_#IA!3>D23]=']'M_=CK+BAF\5>([SVP^"+H!9+AFI; +M7O PWDZ#B]5
MPO@O[*K8SDT :6FL*@[)I*#@LOJS]\,]G"1THS,)\2$A]KHK(J_RCEDV[&NU
M ^VB"<TM_%%]-HGCTCW*TFKR<LJSP]ET-)[.ILD++":S43*Y@^0)DH<)+$>S
M"3S=P_US\KR8P.+I931+II,E?$[82J#YT@\M\3N4,#UPC2NN^ Q7"QZ5M+F!
MB<PP^S<_)-VU^/@H?AQ?!'QD^@I:S0;$4=R\@->J+Z/E\5IG\!8HF,4,YDS;
M/22:2<-\\1CX,5H9J\GZ>8&G7?.T/4_[#,^26BLK!8):PT+MF2"V&6<K+KC=
M?W2O%^%<W_;,EJ4X"*@Q#>HW#(9)CK!6@IJ.RPU8]V9@<K4S8,GCFX'(J-IL
M3LUEMM0E8)5WBJ,4<E07<G 85FE>E[;4"-I+YV@:P"4%J-(PF9D>W#*M]X[V
MC8G29WP(>0X.F'';=YABL4)]?.$(/D&S$5TW&YUV$Z;2(NFV@.\TH RE8ZHV
MDO\F[+C;:';;_TD&%5F:UU56:;BY:5S''?BH%,*37BQ0;_S$,9"J4MJJ+>O=
M>JB-JE[^&UY-1&+><*H]@6M*C:ZN.P'H:LI4AE5;W]DK96E.^&5.@QFU"R#_
M6BE[-!Q!/>J'?P!02P,$%     @ A(&=4E6]RZ$?!   H@H  !D   !X;"]W
M;W)K<VAE971S+W-H965T,C0N>&ULO59;;^I&$/XK([>J$LD-OF*'$B1R4R.5
MHQ22]*'JPV(&O(KMY>RNPTE_?6?7X#@D\!3UA;W.-S/??F-FN!'R6>6(&GZ4
M1:4NG%SK]:#74UF.)5-G8HT5G2R%+)FFI5SUU%HB6UBCLN@%GM?OE8Q7SFAH
M]^[E:"AJ7? *[R6HNBR9?+W$0FPN'-_9;4SY*M=FHS<:KMD*9Z@?U_>25KT6
M9<%+K!07%4A<7CAC?W 9F?OVPA/'C>K,P60R%^+9+.X6%XYG L(",VT0& TO
M>(5%88 HC.];3*=U:0R[\QWZK<V=<IDSA5>B^(LO='[AI XL<,GJ0D_%YG?<
MYA,;O$P4RO["IKG;#QW(:J5%N36F"$I>-2/[L>6A8Y!Z!PR"K4%@XVX<V2BO
MF6:CH10;D.8VH9F)3=5:4W"\,H\RTY)..=GIT>WX;@I/XS\>;V!R,YX]3F\F
M-]\>9G#RP.8%JM-A3Y,7<[>7;1$O&\3@ &(($U'I7,%-M<#%>_L>1=>&&.Q"
MO R. DZ8/(/0=R'P O\(7MBF'%J\\%#*C$MX8D6-<,U55@A52U3P]WBNM"25
M_'/$1]3ZB*R/Z("/&17/HBX0Q!(Z_F@U5@JU@@DRXW8!1IDPQ:R6DE<KN&2*
MJ\](/^K/E.Y K5F&%P[5ID+Y@L[H(4=8BH+JSB!K^Z!@CRL-O&HJVI;&G,H5
M1"UAR2M699P5P)HX6;6 @K,Y+[CF9*YSIH%)A'*7 *V7)L.7)D.3CFS3F9MT
M+ BO%CQC&@D!NP8Y1\EDEK\:<LR9V6["TICE%?]>D]L-0JTIAG_)H194=AHE
M50/2QR3+.W #.+DCPUS4BIRJ4Z+;X$Z,AU9#\&<M- '-^*KB2XJ*Z.C.;_=)
MN&(J!_Q><_)!W*F!D3B^4AW*9_IN+FMR!3^#GR1NE'CO9K_\E 9^\%MG-K%&
MYC$HC;D&9<BRY [@\6QV!BOQ@K*B#Y_^5:U%I81AF58HUY(K[!A X,<N?7Y;
M[/VUQ=/2/M5KU]!WO3AQTR!IKW[<Z01J<M?O .*^>]Y/=L/.9#=.D4J)9X;D
MS'!W4G[@ZY0\1FFX_=T'>!":Z/^@1F+6C;W4/8\2F@=A[)X'EF\W2$+7"Y(.
MSV^OV-7O-;[0']':L$OT2WI1\Z_07GF%DV^D#?"]4X**4M<+TT]?L3W\5&_7
MF&$Y1[F3G/<%DCOXED2$YWK>>[5]V/I$L4GL)D%_-^P_P9?J-")=^M&;3O?6
MQW2:)B2QM*O3O9VC.HTBMQ^&N^'_U&E$O'I!9.:![Z918'?#.'3]-/A:G0:Q
M&Z?Q 9UN#S_[4^MU^H82Y<IV1PHR45>Z:2':W;8!&S=]Q]OUIGNC1UCQ2D&!
M2S+USI+8 =ET1,U"B[7M0N9"4T]CISDUD2C-!3I?"LIGNS .VK9T]!]02P,$
M%     @ A(&=4EJ@8[NC P  M0@  !D   !X;"]W;W)K<VAE971S+W-H965T
M,C4N>&ULO59=;^I&$/TK([>J0')C>XUCWQ20(.&VJ(T4!7+[4/5AL0>\BNWE
M[J[AIK^^L[9Q:'6A[4M?S'[-F7-F9G<8'Z5ZU3FB@2]E4>F)DQNSO_,\G>98
M<GTC]UC1SE:JDAN:JIVG]PIYUAB5A<=\_]8KN:B<Z;A9>U+3L:Q-(2I\4J#K
MLN3J;8Z%/$Z<P#DM/(M=;NR"-QWO^0Y7:%[V3XIF7H^2B1(K+60%"K<39Q;<
MS2-[OCGP2>!1GXW!*ME(^6HGRVSB^)80%I@:B\#IYX#W6!06B&A\[C"=WJ4U
M/!^?T#\VVDG+AFN\E\6O(C/YQ$D<R'#+Z\(\R^-/V.EI"*:RT,T7CNW9B#F0
MUMK(LC,F!J6HVE_^I8O#F4'B7S!@G0%K>+>.&I8/W/#I6,DC*'N:T.R@D=I8
M$SE1V:2LC*)=079F^CA[_GFQGLU_6<##8KZ&U>+^Y7FY7BY6,%CS38%Z./8,
M.;+'O;0#G;>@[ )H"(^R,KF&195A]E=[CPCV+-F)Y9Q=!7SDZ@;"P 7FL^ *
M7MBK#AN\\ +>LCJ@-E1;1KOP@!L#O,I@\;D6Y@U6F-9*&($:?IMMM%%4.;]?
M<3KJG8X:IZ,+3E=MW8/< NEY16/#VWI_=_FU8%^%M;?V3N]YBA.'KJ5&=4!G
MNLX1MK*@*R>J'32>='?QQ!\(LE941#V'S'+0/8<[F.F.99KW88?!L@*3RUI3
MK/009J54AL R^%%)K;OO1RX4?.)%C?!RL[J!G3R@JFRDO]=[66FIR(!FJ/9*
M:#SS"M\""R(WB ,:)3%]!E$R[%;IC6GQ#+T\NJ8HGAD&KA_%;N1_@#",8!#$
MPVXI83&LI>$%H00NBYE[F_@T'C%FX>-HV&V$KD]'6]4/F&*Y0742[O\?PD<D
M/ @M&U) U,+1L%MFP>B:\L"/W9B2$[($!DDP[)8^W"9GRL.(N4DXLLIOK9-!
M$'32PRAT@X3!E?*.^O*._FUYG\7B/Q?[52=7BMVZ/%B731*O%SALWB MN-9B
M*U+>= =A4XR02GJQ*DVI2FW."I%Q0Y,-+WB54M+L.ZOAB J!Z^Z&T7WY>X5\
M[?I<JJY[KO/F^4GM .D-(AGV9:($??=-P@+V@RT%W_7I#CQ>UO1>QY36L$WK
M>?&W>_^4=.^LE92H=DW#U!2-NC)M5^E7^YX\:UO1^_&VH1/7G:@T%+@E4_\F
MIM2JMDFV$R/W36/:2$-MKAGF]+\"E3U ^ULIS6EB'?3_5*9_ E!+ P04
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MAC.NP%6ZL4P5]ASVA&E0"=\;*E"6M 6'3Y!>)1=)DG2PK(7=8HYR34'W_^8
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M=#L?V-G6+5A/R%2A[!>&N(G"<,VO%EIOP/M+8V@_\9W4OH/9;U!+ P04
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MJHMMU_$JZM;-7.CA?K.Z_3*[OC:[E^?9>+F<OV@*]<I07K>*0E,QR+Q2TR+
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MCB(3;P,>"6SDSA@9)4O.G\SD+ALZGBD(**3*9,#ZM8814&H2Z3)^M3F=CM(
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M3#94J 5P?\P!T_2)^MQG]=W<T7]02P,$%     @ A(&=4@<?I@]-!0  ?!\
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M(_9;O?L3R=?9;NF<2\FC[-!G=,%$:J!^7W*EL/E)>H-BPWWX/U!+ P04
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MP[,B@IV.(\952Q*#8O/@;56W4SC6:<U*R3:9RCC"G3D7$:9H65?HH[&@5)K
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M3':[7/MHW8.H>B@3<S54@UEMNT&W4(GL@55#&JNE,:LTY?P?:D9?8JDRXZ5
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MKO.<BI<A9'S;LUQKMW"?QHG2"W:_NZ(QS$$]KF8"9W:%$J4Y,)ER1@0L>];
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MAX#0!KB_Y%SM)OJ ZF;3_P=02P,$%     @ A8&=4N'8%QL$ P  F0D  !D
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M"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @ A8&=4J:-UX=Y!   L2,   \
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M'BA,3Q>0/;^#B!E%5ZV4B+I>3)S[B+9W5^;")*(KMH@+J]@/%PT2A"SR5K"
M5Y2<5HZ,B6E$5^P1%H?3KU>0M5O=S1<@OG>9!M.)KM@G34+T0\;( B8B ,[!
M)NS!B:@,B*E$5^R2ALF+V[S2:@Z>&6(ON*?!],TZQJRB*]8*:N7.<Y>!:<50
MK)6/O$P^01F5\NH?&1*3BJ%8*JBBN[%$:Q;%<D$5W<7$#&,H-LP919_NNHR)
M6<90;)GSJFY)94Q,.H9BZ2"^;CAE3$PZAF+IO'7VAVL<LXZAV#JHO+N+!W./
MH=@]Y^3].YXR)F8?XP)%S8<./W+*_1/,/J9J^[PKJ<DGE]>)2#L3T\3D8UY
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M1 7CZR1=+TK2;(Y_:UEVTW#>'M)T"F-A[A?)YO3&R>EMF2^_ %!+ P04
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MS5!DS5!DS5!DS?Y3UG=CEG_]N[B]I[4NFT,^Z_[)3SX!4$L! A0#%     @
MA(&=4@=!36*!    L0   !               ( !     &1O8U!R;W!S+V%P
M<"YX;6Q02P$"% ,4    " "$@9U2AE-B?>\    K @  $0
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M965T-"YX;6Q02P$"% ,4    " "$@9U2)6AY.74%  #]%@  &
M    @(%+'@  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @
MA(&=4HWW>KXG!P  0!P  !@              ("!]B,  'AL+W=O<FMS:&5E
M=',O<VAE970V+GAM;%!+ 0(4 Q0    ( (2!G5(E]E=(P 4  +<,   8
M          " @5,K  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4
M    " "$@9U2@<9^0-,'  ! $P  &               @(%),0  >&PO=V]R
M:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @ A(&=4@?]=+9? P  ,P<
M !@              ("!4CD  'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+
M 0(4 Q0    ( (2!G5)L<\^&-B$  /5W   9              " @><\  !X
M;"]W;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @ A(&=4NCUF Y8
M!P  *A0  !D              ("!5%X  'AL+W=O<FMS:&5E=',O<VAE970Q
M,2YX;6Q02P$"% ,4    " "$@9U2+H1I^X($  !^"P  &0
M@('C90  >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( (2!
MG5)^L"]P*@0  *$)   9              " @9QJ  !X;"]W;W)K<VAE971S
M+W-H965T,3,N>&UL4$L! A0#%     @ A(&=4B>UC)_,!0  $@\  !D
M         ("!_6X  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4
M    " "$@9U2@KJ5-2X*   U&0  &0              @($ =0  >&PO=V]R
M:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    ( (2!G5+W"'VT?0D  .8;
M   9              " @65_  !X;"]W;W)K<VAE971S+W-H965T,38N>&UL
M4$L! A0#%     @ A(&=4H"3XS2J @  GP4  !D              ("!&8D
M 'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4    " "$@9U2C&(@
M-8P#  "'"   &0              @('ZBP  >&PO=V]R:W-H965T<R]S:&5E
M=#$X+GAM;%!+ 0(4 Q0    ( (2!G5+#;XY',@L  .P<   9
M  " @;V/  !X;"]W;W)K<VAE971S+W-H965T,3DN>&UL4$L! A0#%     @
MA(&=4O9? / +"   %A0  !D              ("!)IL  'AL+W=O<FMS:&5E
M=',O<VAE970R,"YX;6Q02P$"% ,4    " "$@9U2(XBKG8P#  #S!P  &0
M            @(%HHP  >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4
M Q0    ( (2!G5(@F4Z85@8  *H1   9              " @2NG  !X;"]W
M;W)K<VAE971S+W-H965T,C(N>&UL4$L! A0#%     @ A(&=4A6#O)/% @
M]@4  !D              ("!N*T  'AL+W=O<FMS:&5E=',O<VAE970R,RYX
M;6Q02P$"% ,4    " "$@9U25;W+H1\$  "B"@  &0              @(&T
ML   >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    ( (2!G5):
MH&.[HP,  +4(   9              " @0JU  !X;"]W;W)K<VAE971S+W-H
M965T,C4N>&UL4$L! A0#%     @ A(&=4L97_$AD!0  %PX  !D
M     ("!Y+@  'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( (2!G5+H!#H.0@(  !,%   9              "
M@1O*  !X;"]W;W)K<VAE971S+W-H965T,S$N>&UL4$L! A0#%     @ A(&=
M4CG-FMYE!   IA4  !D              ("!E,P  'AL+W=O<FMS:&5E=',O
M<VAE970S,BYX;6Q02P$"% ,4    " "$@9U2&'>B9W "   V!@  &0
M        @($PT0  >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0
M   ( (2!G5(P47?=?P,  +\-   9              " @=?3  !X;"]W;W)K
M<VAE971S+W-H965T,S0N>&UL4$L! A0#%     @ A(&=4NF6PGNN @  \P4
M !D              ("!C=<  'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q0
M2P$"% ,4    " "$@9U2>\^S4'D'  !#)P  &0              @(%RV@
M>&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    ( (2!G5(''Z8/
M304  'P?   9              " @2+B  !X;"]W;W)K<VAE971S+W-H965T
M,S<N>&UL4$L! A0#%     @ A(&=4NL>,2=# P  " P  !D
M ("!IN<  'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q02P$"% ,4    " "$
M@9U28"2AUK4#  #Q#P  &0              @($@ZP  >&PO=V]R:W-H965T
M<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0    ( (2!G5(:RE2:?0,  .P,   9
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M970T-"YX;6Q02P$"% ,4    " "%@9U2)K_H$'D"  #]!0  &0
M    @(&?! $ >&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+ 0(4 Q0    (
M (6!G5(6@B.UNP(  )$'   9              " @4\' 0!X;"]W;W)K<VAE
M971S+W-H965T-#8N>&UL4$L! A0#%     @ A8&=4MX2B HE P  -0@  !D
M             ("!00H! 'AL+W=O<FMS:&5E=',O<VAE970T-RYX;6Q02P$"
M% ,4    " "%@9U28_ E_;P%  "/'   &0              @(&=#0$ >&PO
M=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+ 0(4 Q0    ( (6!G5($84.2T@0
M $45   9              " @9 3 0!X;"]W;W)K<VAE971S+W-H965T-#DN
M>&UL4$L! A0#%     @ A8&=4G PE'#V P  ,Q$  !D              ("!
MF1@! 'AL+W=O<FMS:&5E=',O<VAE970U,"YX;6Q02P$"% ,4    " "%@9U2
MW_T7=_$"  #L!@  &0              @('&' $ >&PO=V]R:W-H965T<R]S
M:&5E=#4Q+GAM;%!+ 0(4 Q0    ( (6!G5)"+_*[! ,  .4(   9
M      " @>X? 0!X;"]W;W)K<VAE971S+W-H965T-3(N>&UL4$L! A0#%
M  @ A8&=4N'8%QL$ P  F0D  !D              ("!*2,! 'AL+W=O<FMS
M:&5E=',O<VAE970U,RYX;6Q02P$"% ,4    " "%@9U2POUHMA,#   ,$0
M#0              @ %D)@$ >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( (6!
MG5*7BKL<P    !,"   +              "  :(I 0!?<F5L<R\N<F5L<U!+
M 0(4 Q0    ( (6!G5*FC=>'>00  +$C   /              "  8LJ 0!X
M;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " "%@9U2?'[I&]0!  #&'P  &@
M            @ $Q+P$ >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"
M% ,4    " "%@9U2*F32ILH!  ";'P  $P              @ $],0$ 6T-O
F;G1E;G1?5'EP97-=+GAM;%!+!08     /0 ] *(0   X,P$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>233</ContextCount>
  <ElementCount>304</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>67</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>8</UnitCount>
  <MyReports>
    <Report instance="alny-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="alny-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="alny-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="alny-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="alny-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="alny-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="alny-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - NATURE OF BUSINESS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/role/NATUREOFBUSINESS</Role>
      <ShortName>NATURE OF BUSINESS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="alny-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2103102 - Disclosure - BASIS OF PRESENTATION AND PRINCIPLES OF CONSOLIDATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/role/BASISOFPRESENTATIONANDPRINCIPLESOFCONSOLIDATION</Role>
      <ShortName>BASIS OF PRESENTATION AND PRINCIPLES OF CONSOLIDATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="alny-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2105103 - Disclosure - NET PRODUCT REVENUES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/role/NETPRODUCTREVENUES</Role>
      <ShortName>NET PRODUCT REVENUES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="alny-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2109104 - Disclosure - NET REVENUES FROM COLLABORATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONS</Role>
      <ShortName>NET REVENUES FROM COLLABORATIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="alny-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2118105 - Disclosure - LIABILITY RELATED TO THE SALE OF FUTURE ROYALTIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/role/LIABILITYRELATEDTOTHESALEOFFUTUREROYALTIES</Role>
      <ShortName>LIABILITY RELATED TO THE SALE OF FUTURE ROYALTIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="alny-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2121106 - Disclosure - FAIR VALUE MEASUREMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/role/FAIRVALUEMEASUREMENTS</Role>
      <ShortName>FAIR VALUE MEASUREMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="alny-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2124107 - Disclosure - MARKETABLE DEBT SECURITIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/role/MARKETABLEDEBTSECURITIES</Role>
      <ShortName>MARKETABLE DEBT SECURITIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="alny-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2129108 - Disclosure - OTHER BALANCE SHEET DETAILS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/role/OTHERBALANCESHEETDETAILS</Role>
      <ShortName>OTHER BALANCE SHEET DETAILS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="alny-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2134109 - Disclosure - CREDIT AGREEMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/role/CREDITAGREEMENT</Role>
      <ShortName>CREDIT AGREEMENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="alny-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2137110 - Disclosure - DEVELOPMENT DERIVATIVE LIABILITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/role/DEVELOPMENTDERIVATIVELIABILITY</Role>
      <ShortName>DEVELOPMENT DERIVATIVE LIABILITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="alny-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2141111 - Disclosure - STOCK-BASED COMPENSATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/role/STOCKBASEDCOMPENSATION</Role>
      <ShortName>STOCK-BASED COMPENSATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="alny-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2144112 - Disclosure - NET LOSS PER COMMON SHARE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/role/NETLOSSPERCOMMONSHARE</Role>
      <ShortName>NET LOSS PER COMMON SHARE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="alny-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2147113 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/role/COMMITMENTSANDCONTINGENCIES</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="alny-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2204201 - Disclosure - BASIS OF PRESENTATION AND PRINCIPLES OF CONSOLIDATION (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/role/BASISOFPRESENTATIONANDPRINCIPLESOFCONSOLIDATIONPolicies</Role>
      <ShortName>BASIS OF PRESENTATION AND PRINCIPLES OF CONSOLIDATION (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="alny-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2306301 - Disclosure - NET PRODUCT REVENUES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/role/NETPRODUCTREVENUESTables</Role>
      <ShortName>NET PRODUCT REVENUES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.alnylam.com/role/NETPRODUCTREVENUES</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="alny-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2310302 - Disclosure - NET REVENUES FROM COLLABORATIONS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSTables</Role>
      <ShortName>NET REVENUES FROM COLLABORATIONS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONS</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="alny-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2319303 - Disclosure - LIABILITY RELATED TO THE SALE OF FUTURE ROYALTIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/role/LIABILITYRELATEDTOTHESALEOFFUTUREROYALTIESTables</Role>
      <ShortName>LIABILITY RELATED TO THE SALE OF FUTURE ROYALTIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.alnylam.com/role/LIABILITYRELATEDTOTHESALEOFFUTUREROYALTIES</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="alny-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2322304 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/role/FAIRVALUEMEASUREMENTSTables</Role>
      <ShortName>FAIR VALUE MEASUREMENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.alnylam.com/role/FAIRVALUEMEASUREMENTS</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="alny-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2325305 - Disclosure - MARKETABLE DEBT SECURITIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/role/MARKETABLEDEBTSECURITIESTables</Role>
      <ShortName>MARKETABLE DEBT SECURITIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.alnylam.com/role/MARKETABLEDEBTSECURITIES</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="alny-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2330306 - Disclosure - OTHER BALANCE SHEET DETAILS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/role/OTHERBALANCESHEETDETAILSTables</Role>
      <ShortName>OTHER BALANCE SHEET DETAILS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.alnylam.com/role/OTHERBALANCESHEETDETAILS</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="alny-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2335307 - Disclosure - CREDIT AGREEMENT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/role/CREDITAGREEMENTTables</Role>
      <ShortName>CREDIT AGREEMENT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.alnylam.com/role/CREDITAGREEMENT</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="alny-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2338308 - Disclosure - DEVELOPMENT DERIVATIVE LIABILITY (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/role/DEVELOPMENTDERIVATIVELIABILITYTables</Role>
      <ShortName>DEVELOPMENT DERIVATIVE LIABILITY (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.alnylam.com/role/DEVELOPMENTDERIVATIVELIABILITY</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="alny-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2342309 - Disclosure - STOCK-BASED COMPENSATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/role/STOCKBASEDCOMPENSATIONTables</Role>
      <ShortName>STOCK-BASED COMPENSATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.alnylam.com/role/STOCKBASEDCOMPENSATION</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="alny-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2345310 - Disclosure - NET LOSS PER COMMON SHARE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/role/NETLOSSPERCOMMONSHARETables</Role>
      <ShortName>NET LOSS PER COMMON SHARE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.alnylam.com/role/NETLOSSPERCOMMONSHARE</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="alny-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2402401 - Disclosure - NATURE OF BUSINESS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/role/NATUREOFBUSINESSDetails</Role>
      <ShortName>NATURE OF BUSINESS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.alnylam.com/role/NATUREOFBUSINESS</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="alny-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2407402 - Disclosure - NET PRODUCT REVENUES - Summary of Net Product Revenues (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/role/NETPRODUCTREVENUESSummaryofNetProductRevenuesDetail</Role>
      <ShortName>NET PRODUCT REVENUES - Summary of Net Product Revenues (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="alny-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2408403 - Disclosure - NET PRODUCT REVENUES - Receivables (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/role/NETPRODUCTREVENUESReceivablesDetail</Role>
      <ShortName>NET PRODUCT REVENUES - Receivables (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="alny-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2411404 - Disclosure - NET REVENUES FROM COLLABORATIONS - Revenue from Collaborators (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSRevenuefromCollaboratorsDetail</Role>
      <ShortName>NET REVENUES FROM COLLABORATIONS - Revenue from Collaborators (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="alny-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2412405 - Disclosure - NET REVENUES FROM COLLABORATIONS - Balance of Receivables and Contract Liabilities Related to Collaboration Agreements (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSBalanceofReceivablesandContractLiabilitiesRelatedtoCollaborationAgreementsDetail</Role>
      <ShortName>NET REVENUES FROM COLLABORATIONS - Balance of Receivables and Contract Liabilities Related to Collaboration Agreements (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="alny-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2413406 - Disclosure - NET REVENUES FROM COLLABORATIONS - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSAdditionalInformationDetail</Role>
      <ShortName>NET REVENUES FROM COLLABORATIONS - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="alny-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2414407 - Disclosure - NET REVENUES FROM COLLABORATIONS - Schedule of Research and Development Expenses Incurred by Type that are Directly Attributable to Collaboration Agreements (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofResearchandDevelopmentExpensesIncurredbyTypethatareDirectlyAttributabletoCollaborationAgreementsDetail</Role>
      <ShortName>NET REVENUES FROM COLLABORATIONS - Schedule of Research and Development Expenses Incurred by Type that are Directly Attributable to Collaboration Agreements (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="alny-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2415408 - Disclosure - NET REVENUES FROM COLLABORATIONS - Schedule of Transaction Price Allocated (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofTransactionPriceAllocatedDetails</Role>
      <ShortName>NET REVENUES FROM COLLABORATIONS - Schedule of Transaction Price Allocated (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="alny-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2416409 - Disclosure - NET REVENUES FROM COLLABORATIONS - Schedule of Deferred Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofDeferredRevenueDetails</Role>
      <ShortName>NET REVENUES FROM COLLABORATIONS - Schedule of Deferred Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="alny-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2417410 - Disclosure - NET REVENUES FROM COLLABORATIONS - Schedule of Revenue Recognized by Accounting Guidance (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofRevenueRecognizedbyAccountingGuidanceDetails</Role>
      <ShortName>NET REVENUES FROM COLLABORATIONS - Schedule of Revenue Recognized by Accounting Guidance (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="alny-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2420411 - Disclosure - LIABILITY RELATED TO THE SALE OF FUTURE ROYALTIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/role/LIABILITYRELATEDTOTHESALEOFFUTUREROYALTIESDetails</Role>
      <ShortName>LIABILITY RELATED TO THE SALE OF FUTURE ROYALTIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.alnylam.com/role/LIABILITYRELATEDTOTHESALEOFFUTUREROYALTIESTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="alny-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2423412 - Disclosure - FAIR VALUE MEASUREMENTS - Fair Value of Assets Measured on a Recurring Basis (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/role/FAIRVALUEMEASUREMENTSFairValueofAssetsMeasuredonaRecurringBasisDetail</Role>
      <ShortName>FAIR VALUE MEASUREMENTS - Fair Value of Assets Measured on a Recurring Basis (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="alny-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2426413 - Disclosure - MARKETABLE DEBT SECURITIES - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/role/MARKETABLEDEBTSECURITIESAdditionalInformationDetail</Role>
      <ShortName>MARKETABLE DEBT SECURITIES - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="alny-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2427414 - Disclosure - MARKETABLE DEBT SECURITIES - Summary of Marketable Debt Securities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/role/MARKETABLEDEBTSECURITIESSummaryofMarketableDebtSecuritiesDetail</Role>
      <ShortName>MARKETABLE DEBT SECURITIES - Summary of Marketable Debt Securities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="alny-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2428415 - Disclosure - MARKETABLE DEBT SECURITIES - Summary of Fair Value of Marketable Debt Securities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/role/MARKETABLEDEBTSECURITIESSummaryofFairValueofMarketableDebtSecuritiesDetail</Role>
      <ShortName>MARKETABLE DEBT SECURITIES - Summary of Fair Value of Marketable Debt Securities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="alny-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2431416 - Disclosure - OTHER BALANCE SHEET DETAILS - Schedule of Inventory (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/role/OTHERBALANCESHEETDETAILSScheduleofInventoryDetail</Role>
      <ShortName>OTHER BALANCE SHEET DETAILS - Schedule of Inventory (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="alny-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2432417 - Disclosure - OTHER BALANCE SHEET DETAILS - Schedule of Reconciliation of Cash, Cash Equivalents and Restricted Cash (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/role/OTHERBALANCESHEETDETAILSScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetail</Role>
      <ShortName>OTHER BALANCE SHEET DETAILS - Schedule of Reconciliation of Cash, Cash Equivalents and Restricted Cash (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="alny-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2433418 - Disclosure - OTHER BALANCE SHEET DETAILS - Summary of Changes in Accumulated Other Comprehensive Income (Loss) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/role/OTHERBALANCESHEETDETAILSSummaryofChangesinAccumulatedOtherComprehensiveIncomeLossDetails</Role>
      <ShortName>OTHER BALANCE SHEET DETAILS - Summary of Changes in Accumulated Other Comprehensive Income (Loss) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="alny-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2436419 - Disclosure - CREDIT AGREEMENT - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/role/CREDITAGREEMENTAdditionalInformationDetails</Role>
      <ShortName>CREDIT AGREEMENT - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="alny-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2439420 - Disclosure - DEVELOPMENT DERIVATIVE LIABILITY - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/role/DEVELOPMENTDERIVATIVELIABILITYNarrativeDetails</Role>
      <ShortName>DEVELOPMENT DERIVATIVE LIABILITY - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="alny-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2440421 - Disclosure - DEVELOPMENT DERIVATIVE LIABILITY - Development Derivative Liability Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/role/DEVELOPMENTDERIVATIVELIABILITYDevelopmentDerivativeLiabilityActivityDetails</Role>
      <ShortName>DEVELOPMENT DERIVATIVE LIABILITY - Development Derivative Liability Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="alny-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2443422 - Disclosure - STOCK-BASED COMPENSATION - Summary of Share-Based Compensation Expenses Included Operating Costs and Expense (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/role/STOCKBASEDCOMPENSATIONSummaryofShareBasedCompensationExpensesIncludedOperatingCostsandExpenseDetail</Role>
      <ShortName>STOCK-BASED COMPENSATION - Summary of Share-Based Compensation Expenses Included Operating Costs and Expense (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="alny-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2446423 - Disclosure - NET LOSS PER COMMON SHARE - Common Share Equivalents Excluded from Calculation of Net Loss Per Common Share (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alnylam.com/role/NETLOSSPERCOMMONSHARECommonShareEquivalentsExcludedfromCalculationofNetLossPerCommonShareDetail</Role>
      <ShortName>NET LOSS PER COMMON SHARE - Common Share Equivalents Excluded from Calculation of Net Loss Per Common Share (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="alny-20210331.htm">alny-20210331.htm</File>
    <File>alny-20210331.xsd</File>
    <File>alny-20210331_cal.xml</File>
    <File>alny-20210331_def.xml</File>
    <File>alny-20210331_lab.xml</File>
    <File>alny-20210331_pre.xml</File>
    <File>alny2021q110-qex311.htm</File>
    <File>alny2021q110-qex312.htm</File>
    <File>alny2021q110-qex321.htm</File>
    <File>alny2021q110-qex322.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>alny-20210331_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/country/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>71
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "alny-20210331.htm": {
   "axisCustom": 1,
   "axisStandard": 20,
   "contextCount": 233,
   "dts": {
    "calculationLink": {
     "local": [
      "alny-20210331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "alny-20210331_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "alny-20210331.htm"
     ]
    },
    "labelLink": {
     "local": [
      "alny-20210331_lab.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml",
      "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "alny-20210331_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml",
      "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "alny-20210331.xsd"
     ],
     "remote": [
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 404,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2020-01-31": 5,
    "total": 5
   },
   "keyCustom": 59,
   "keyStandard": 245,
   "memberCustom": 32,
   "memberStandard": 31,
   "nsprefix": "alny",
   "nsuri": "http://www.alnylam.com/20210331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alny-20210331.htm",
      "contextRef": "i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover Page",
     "role": "http://www.alnylam.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alny-20210331.htm",
      "contextRef": "i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alny-20210331.htm",
      "contextRef": "i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2109104 - Disclosure - NET REVENUES FROM COLLABORATIONS",
     "role": "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONS",
     "shortName": "NET REVENUES FROM COLLABORATIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alny-20210331.htm",
      "contextRef": "i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alny-20210331.htm",
      "contextRef": "i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "alny:LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2118105 - Disclosure - LIABILITY RELATED TO THE SALE OF FUTURE ROYALTIES",
     "role": "http://www.alnylam.com/role/LIABILITYRELATEDTOTHESALEOFFUTUREROYALTIES",
     "shortName": "LIABILITY RELATED TO THE SALE OF FUTURE ROYALTIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alny-20210331.htm",
      "contextRef": "i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "alny:LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alny-20210331.htm",
      "contextRef": "i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2121106 - Disclosure - FAIR VALUE MEASUREMENTS",
     "role": "http://www.alnylam.com/role/FAIRVALUEMEASUREMENTS",
     "shortName": "FAIR VALUE MEASUREMENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alny-20210331.htm",
      "contextRef": "i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alny-20210331.htm",
      "contextRef": "i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "alny:InvestmentsInMarketableDebtSecuritiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2124107 - Disclosure - MARKETABLE DEBT SECURITIES",
     "role": "http://www.alnylam.com/role/MARKETABLEDEBTSECURITIES",
     "shortName": "MARKETABLE DEBT SECURITIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alny-20210331.htm",
      "contextRef": "i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "alny:InvestmentsInMarketableDebtSecuritiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alny-20210331.htm",
      "contextRef": "i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2129108 - Disclosure - OTHER BALANCE SHEET DETAILS",
     "role": "http://www.alnylam.com/role/OTHERBALANCESHEETDETAILS",
     "shortName": "OTHER BALANCE SHEET DETAILS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alny-20210331.htm",
      "contextRef": "i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alny-20210331.htm",
      "contextRef": "i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2134109 - Disclosure - CREDIT AGREEMENT",
     "role": "http://www.alnylam.com/role/CREDITAGREEMENT",
     "shortName": "CREDIT AGREEMENT",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alny-20210331.htm",
      "contextRef": "i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alny-20210331.htm",
      "contextRef": "i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2137110 - Disclosure - DEVELOPMENT DERIVATIVE LIABILITY",
     "role": "http://www.alnylam.com/role/DEVELOPMENTDERIVATIVELIABILITY",
     "shortName": "DEVELOPMENT DERIVATIVE LIABILITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alny-20210331.htm",
      "contextRef": "i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alny-20210331.htm",
      "contextRef": "i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2141111 - Disclosure - STOCK-BASED COMPENSATION",
     "role": "http://www.alnylam.com/role/STOCKBASEDCOMPENSATION",
     "shortName": "STOCK-BASED COMPENSATION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alny-20210331.htm",
      "contextRef": "i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alny-20210331.htm",
      "contextRef": "i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2144112 - Disclosure - NET LOSS PER COMMON SHARE",
     "role": "http://www.alnylam.com/role/NETLOSSPERCOMMONSHARE",
     "shortName": "NET LOSS PER COMMON SHARE",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alny-20210331.htm",
      "contextRef": "i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alny-20210331.htm",
      "contextRef": "i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2147113 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "role": "http://www.alnylam.com/role/COMMITMENTSANDCONTINGENCIES",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alny-20210331.htm",
      "contextRef": "i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "alny:ScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTableTextBlock",
       "alny:ScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20210331.htm",
      "contextRef": "idd7204dc87d24972a01f15b098c4f56b_I20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS",
     "role": "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alny-20210331.htm",
      "contextRef": "idd7204dc87d24972a01f15b098c4f56b_I20210331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:InventoryNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20210331.htm",
      "contextRef": "i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2204201 - Disclosure - BASIS OF PRESENTATION AND PRINCIPLES OF CONSOLIDATION (Policies)",
     "role": "http://www.alnylam.com/role/BASISOFPRESENTATIONANDPRINCIPLESOFCONSOLIDATIONPolicies",
     "shortName": "BASIS OF PRESENTATION AND PRINCIPLES OF CONSOLIDATION (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20210331.htm",
      "contextRef": "i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20210331.htm",
      "contextRef": "i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2306301 - Disclosure - NET PRODUCT REVENUES (Tables)",
     "role": "http://www.alnylam.com/role/NETPRODUCTREVENUESTables",
     "shortName": "NET PRODUCT REVENUES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20210331.htm",
      "contextRef": "i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20210331.htm",
      "contextRef": "i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2310302 - Disclosure - NET REVENUES FROM COLLABORATIONS (Tables)",
     "role": "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSTables",
     "shortName": "NET REVENUES FROM COLLABORATIONS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20210331.htm",
      "contextRef": "i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20210331.htm",
      "contextRef": "i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "alny:ScheduleOfRoyaltyLiabilityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2319303 - Disclosure - LIABILITY RELATED TO THE SALE OF FUTURE ROYALTIES (Tables)",
     "role": "http://www.alnylam.com/role/LIABILITYRELATEDTOTHESALEOFFUTUREROYALTIESTables",
     "shortName": "LIABILITY RELATED TO THE SALE OF FUTURE ROYALTIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20210331.htm",
      "contextRef": "i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "alny:ScheduleOfRoyaltyLiabilityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20210331.htm",
      "contextRef": "i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2322304 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)",
     "role": "http://www.alnylam.com/role/FAIRVALUEMEASUREMENTSTables",
     "shortName": "FAIR VALUE MEASUREMENTS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20210331.htm",
      "contextRef": "i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20210331.htm",
      "contextRef": "i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2325305 - Disclosure - MARKETABLE DEBT SECURITIES (Tables)",
     "role": "http://www.alnylam.com/role/MARKETABLEDEBTSECURITIESTables",
     "shortName": "MARKETABLE DEBT SECURITIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20210331.htm",
      "contextRef": "i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20210331.htm",
      "contextRef": "i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2330306 - Disclosure - OTHER BALANCE SHEET DETAILS (Tables)",
     "role": "http://www.alnylam.com/role/OTHERBALANCESHEETDETAILSTables",
     "shortName": "OTHER BALANCE SHEET DETAILS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20210331.htm",
      "contextRef": "i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20210331.htm",
      "contextRef": "i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2335307 - Disclosure - CREDIT AGREEMENT (Tables)",
     "role": "http://www.alnylam.com/role/CREDITAGREEMENTTables",
     "shortName": "CREDIT AGREEMENT (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20210331.htm",
      "contextRef": "i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20210331.htm",
      "contextRef": "i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2338308 - Disclosure - DEVELOPMENT DERIVATIVE LIABILITY (Tables)",
     "role": "http://www.alnylam.com/role/DEVELOPMENTDERIVATIVELIABILITYTables",
     "shortName": "DEVELOPMENT DERIVATIVE LIABILITY (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20210331.htm",
      "contextRef": "i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20210331.htm",
      "contextRef": "i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2342309 - Disclosure - STOCK-BASED COMPENSATION (Tables)",
     "role": "http://www.alnylam.com/role/STOCKBASEDCOMPENSATIONTables",
     "shortName": "STOCK-BASED COMPENSATION (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20210331.htm",
      "contextRef": "i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alny-20210331.htm",
      "contextRef": "idd7204dc87d24972a01f15b098c4f56b_I20210331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "role": "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alny-20210331.htm",
      "contextRef": "idd7204dc87d24972a01f15b098c4f56b_I20210331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20210331.htm",
      "contextRef": "i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2345310 - Disclosure - NET LOSS PER COMMON SHARE (Tables)",
     "role": "http://www.alnylam.com/role/NETLOSSPERCOMMONSHARETables",
     "shortName": "NET LOSS PER COMMON SHARE (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20210331.htm",
      "contextRef": "i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20210331.htm",
      "contextRef": "idd7204dc87d24972a01f15b098c4f56b_I20210331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "alny:NumberOfMarketedProducts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "product",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402401 - Disclosure - NATURE OF BUSINESS (Details)",
     "role": "http://www.alnylam.com/role/NATUREOFBUSINESSDetails",
     "shortName": "NATURE OF BUSINESS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20210331.htm",
      "contextRef": "idd7204dc87d24972a01f15b098c4f56b_I20210331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "alny:NumberOfMarketedProducts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "product",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alny-20210331.htm",
      "contextRef": "i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407402 - Disclosure - NET PRODUCT REVENUES - Summary of Net Product Revenues (Detail)",
     "role": "http://www.alnylam.com/role/NETPRODUCTREVENUESSummaryofNetProductRevenuesDetail",
     "shortName": "NET PRODUCT REVENUES - Summary of Net Product Revenues (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20210331.htm",
      "contextRef": "i938688f7d99a4e7b97c127dc1da4aa45_D20210101-20210331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alny-20210331.htm",
      "contextRef": "idd7204dc87d24972a01f15b098c4f56b_I20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408403 - Disclosure - NET PRODUCT REVENUES - Receivables (Detail)",
     "role": "http://www.alnylam.com/role/NETPRODUCTREVENUESReceivablesDetail",
     "shortName": "NET PRODUCT REVENUES - Receivables (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20210331.htm",
      "contextRef": "id1a37ec48832445999d722992c9485a5_I20210331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alny-20210331.htm",
      "contextRef": "i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411404 - Disclosure - NET REVENUES FROM COLLABORATIONS - Revenue from Collaborators (Detail)",
     "role": "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSRevenuefromCollaboratorsDetail",
     "shortName": "NET REVENUES FROM COLLABORATIONS - Revenue from Collaborators (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20210331.htm",
      "contextRef": "i95f1c1ed3c154524aceec386b964d3e5_D20210101-20210331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20210331.htm",
      "contextRef": "idd7204dc87d24972a01f15b098c4f56b_I20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412405 - Disclosure - NET REVENUES FROM COLLABORATIONS - Balance of Receivables and Contract Liabilities Related to Collaboration Agreements (Detail)",
     "role": "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSBalanceofReceivablesandContractLiabilitiesRelatedtoCollaborationAgreementsDetail",
     "shortName": "NET REVENUES FROM COLLABORATIONS - Balance of Receivables and Contract Liabilities Related to Collaboration Agreements (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20210331.htm",
      "contextRef": "idd7204dc87d24972a01f15b098c4f56b_I20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20210331.htm",
      "contextRef": "i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerLiabilityRevenueRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413406 - Disclosure - NET REVENUES FROM COLLABORATIONS - Additional Information (Detail)",
     "role": "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSAdditionalInformationDetail",
     "shortName": "NET REVENUES FROM COLLABORATIONS - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20210331.htm",
      "contextRef": "i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerLiabilityRevenueRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alny-20210331.htm",
      "contextRef": "i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414407 - Disclosure - NET REVENUES FROM COLLABORATIONS - Schedule of Research and Development Expenses Incurred by Type that are Directly Attributable to Collaboration Agreements (Detail)",
     "role": "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofResearchandDevelopmentExpensesIncurredbyTypethatareDirectlyAttributabletoCollaborationAgreementsDetail",
     "shortName": "NET REVENUES FROM COLLABORATIONS - Schedule of Research and Development Expenses Incurred by Type that are Directly Attributable to Collaboration Agreements (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "alny:ScheduleOfResearchAndDevelopmentExpensesIncurredForCollaborationAgreementsTableTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20210331.htm",
      "contextRef": "ic693d204e9e347ae897f48a7db4e8373_D20210101-20210331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20210331.htm",
      "contextRef": "ibb1a94652b264aa4980ac89d4f3e71e0_D20210331-20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "alny:TransactionPrice",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2415408 - Disclosure - NET REVENUES FROM COLLABORATIONS - Schedule of Transaction Price Allocated (Details)",
     "role": "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofTransactionPriceAllocatedDetails",
     "shortName": "NET REVENUES FROM COLLABORATIONS - Schedule of Transaction Price Allocated (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alny-20210331.htm",
      "contextRef": "idd7204dc87d24972a01f15b098c4f56b_I20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerLiabilityCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416409 - Disclosure - NET REVENUES FROM COLLABORATIONS - Schedule of Deferred Revenue (Details)",
     "role": "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofDeferredRevenueDetails",
     "shortName": "NET REVENUES FROM COLLABORATIONS - Schedule of Deferred Revenue (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20210331.htm",
      "contextRef": "i845dea082db84f4bad647918893f1a91_I20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerLiabilityCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alny-20210331.htm",
      "contextRef": "i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "role": "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alny-20210331.htm",
      "contextRef": "i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alny-20210331.htm",
      "contextRef": "i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417410 - Disclosure - NET REVENUES FROM COLLABORATIONS - Schedule of Revenue Recognized by Accounting Guidance (Details)",
     "role": "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofRevenueRecognizedbyAccountingGuidanceDetails",
     "shortName": "NET REVENUES FROM COLLABORATIONS - Schedule of Revenue Recognized by Accounting Guidance (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "alny:ScheduleOfRevenueRecognizedBasedOnAccountingGuidanceTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20210331.htm",
      "contextRef": "id46811031a3d408bac58580e626f8e3b_D20210101-20210331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alny-20210331.htm",
      "contextRef": "idd7204dc87d24972a01f15b098c4f56b_I20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "alny:RoyaltiesReceivableCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420411 - Disclosure - LIABILITY RELATED TO THE SALE OF FUTURE ROYALTIES (Details)",
     "role": "http://www.alnylam.com/role/LIABILITYRELATEDTOTHESALEOFFUTUREROYALTIESDetails",
     "shortName": "LIABILITY RELATED TO THE SALE OF FUTURE ROYALTIES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20210331.htm",
      "contextRef": "i730e5e5b0bcd4d5c81f5a71c66d172a2_I20200410",
      "decimals": "INF",
      "lang": "en-US",
      "name": "alny:CollaborativeArrangementRoyaltiesAndCommercialMilestonesAcquiredByCollaboratorPercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20210331.htm",
      "contextRef": "idd7204dc87d24972a01f15b098c4f56b_I20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423412 - Disclosure - FAIR VALUE MEASUREMENTS - Fair Value of Assets Measured on a Recurring Basis (Detail)",
     "role": "http://www.alnylam.com/role/FAIRVALUEMEASUREMENTSFairValueofAssetsMeasuredonaRecurringBasisDetail",
     "shortName": "FAIR VALUE MEASUREMENTS - Fair Value of Assets Measured on a Recurring Basis (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20210331.htm",
      "contextRef": "if05c960039774dd9b4ad2920b9816c04_I20210331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:EquitySecuritiesFvNi",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20210331.htm",
      "contextRef": "i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "alny:ImpairmentOfMarketableDebtSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2426413 - Disclosure - MARKETABLE DEBT SECURITIES - Additional Information (Detail)",
     "role": "http://www.alnylam.com/role/MARKETABLEDEBTSECURITIESAdditionalInformationDetail",
     "shortName": "MARKETABLE DEBT SECURITIES - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20210331.htm",
      "contextRef": "i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "alny:ImpairmentOfMarketableDebtSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20210331.htm",
      "contextRef": "idd7204dc87d24972a01f15b098c4f56b_I20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2427414 - Disclosure - MARKETABLE DEBT SECURITIES - Summary of Marketable Debt Securities (Detail)",
     "role": "http://www.alnylam.com/role/MARKETABLEDEBTSECURITIESSummaryofMarketableDebtSecuritiesDetail",
     "shortName": "MARKETABLE DEBT SECURITIES - Summary of Marketable Debt Securities (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20210331.htm",
      "contextRef": "idd7204dc87d24972a01f15b098c4f56b_I20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20210331.htm",
      "contextRef": "idd7204dc87d24972a01f15b098c4f56b_I20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2428415 - Disclosure - MARKETABLE DEBT SECURITIES - Summary of Fair Value of Marketable Debt Securities (Detail)",
     "role": "http://www.alnylam.com/role/MARKETABLEDEBTSECURITIESSummaryofFairValueofMarketableDebtSecuritiesDetail",
     "shortName": "MARKETABLE DEBT SECURITIES - Summary of Fair Value of Marketable Debt Securities (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20210331.htm",
      "contextRef": "idd7204dc87d24972a01f15b098c4f56b_I20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterials",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2431416 - Disclosure - OTHER BALANCE SHEET DETAILS - Schedule of Inventory (Detail)",
     "role": "http://www.alnylam.com/role/OTHERBALANCESHEETDETAILSScheduleofInventoryDetail",
     "shortName": "OTHER BALANCE SHEET DETAILS - Schedule of Inventory (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20210331.htm",
      "contextRef": "idd7204dc87d24972a01f15b098c4f56b_I20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterials",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "alny:ScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTableTextBlock",
       "alny:ScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20210331.htm",
      "contextRef": "idd7204dc87d24972a01f15b098c4f56b_I20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2432417 - Disclosure - OTHER BALANCE SHEET DETAILS - Schedule of Reconciliation of Cash, Cash Equivalents and Restricted Cash (Detail)",
     "role": "http://www.alnylam.com/role/OTHERBALANCESHEETDETAILSScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetail",
     "shortName": "OTHER BALANCE SHEET DETAILS - Schedule of Reconciliation of Cash, Cash Equivalents and Restricted Cash (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "alny:ScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTableTextBlock",
       "alny:ScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20210331.htm",
      "contextRef": "ic378e7f6183c40b4b7371ed7b7370867_I20200331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alny-20210331.htm",
      "contextRef": "id365c5f1d37444ac9e1da5b5891cd81a_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2433418 - Disclosure - OTHER BALANCE SHEET DETAILS - Summary of Changes in Accumulated Other Comprehensive Income (Loss) (Details)",
     "role": "http://www.alnylam.com/role/OTHERBALANCESHEETDETAILSSummaryofChangesinAccumulatedOtherComprehensiveIncomeLossDetails",
     "shortName": "OTHER BALANCE SHEET DETAILS - Summary of Changes in Accumulated Other Comprehensive Income (Loss) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20210331.htm",
      "contextRef": "i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alny-20210331.htm",
      "contextRef": "i7c3cf9f64e5c4dba8a27cbdc2664e3da_I20200410",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "alny:DebtInstrumentNumberOfTranches",
      "reportCount": 1,
      "unique": true,
      "unitRef": "tranche",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2436419 - Disclosure - CREDIT AGREEMENT - Additional Information (Details)",
     "role": "http://www.alnylam.com/role/CREDITAGREEMENTAdditionalInformationDetails",
     "shortName": "CREDIT AGREEMENT - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alny-20210331.htm",
      "contextRef": "i7c3cf9f64e5c4dba8a27cbdc2664e3da_I20200410",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "alny:DebtInstrumentNumberOfTranches",
      "reportCount": 1,
      "unique": true,
      "unitRef": "tranche",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alny-20210331.htm",
      "contextRef": "i529e7b1cdc924faf8a02fa556a4493bc_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "role": "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alny-20210331.htm",
      "contextRef": "i529e7b1cdc924faf8a02fa556a4493bc_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20210331.htm",
      "contextRef": "idd7204dc87d24972a01f15b098c4f56b_I20210331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2439420 - Disclosure - DEVELOPMENT DERIVATIVE LIABILITY - Narrative (Details)",
     "role": "http://www.alnylam.com/role/DEVELOPMENTDERIVATIVELIABILITYNarrativeDetails",
     "shortName": "DEVELOPMENT DERIVATIVE LIABILITY - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20210331.htm",
      "contextRef": "idd7204dc87d24972a01f15b098c4f56b_I20210331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20210331.htm",
      "contextRef": "i021eb4ce0e054ceabf5ba8f817404e90_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2440421 - Disclosure - DEVELOPMENT DERIVATIVE LIABILITY - Development Derivative Liability Activity (Details)",
     "role": "http://www.alnylam.com/role/DEVELOPMENTDERIVATIVELIABILITYDevelopmentDerivativeLiabilityActivityDetails",
     "shortName": "DEVELOPMENT DERIVATIVE LIABILITY - Development Derivative Liability Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20210331.htm",
      "contextRef": "i021eb4ce0e054ceabf5ba8f817404e90_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20210331.htm",
      "contextRef": "i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2443422 - Disclosure - STOCK-BASED COMPENSATION - Summary of Share-Based Compensation Expenses Included Operating Costs and Expense (Detail)",
     "role": "http://www.alnylam.com/role/STOCKBASEDCOMPENSATIONSummaryofShareBasedCompensationExpensesIncludedOperatingCostsandExpenseDetail",
     "shortName": "STOCK-BASED COMPENSATION - Summary of Share-Based Compensation Expenses Included Operating Costs and Expense (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20210331.htm",
      "contextRef": "i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20210331.htm",
      "contextRef": "i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2446423 - Disclosure - NET LOSS PER COMMON SHARE - Common Share Equivalents Excluded from Calculation of Net Loss Per Common Share (Detail)",
     "role": "http://www.alnylam.com/role/NETLOSSPERCOMMONSHARECommonShareEquivalentsExcludedfromCalculationofNetLossPerCommonShareDetail",
     "shortName": "NET LOSS PER COMMON SHARE - Common Share Equivalents Excluded from Calculation of Net Loss Per Common Share (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "alny-20210331.htm",
      "contextRef": "i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alny-20210331.htm",
      "contextRef": "i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "role": "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alny-20210331.htm",
      "contextRef": "i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DepreciationAmortizationAndAccretionNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alny-20210331.htm",
      "contextRef": "i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - NATURE OF BUSINESS",
     "role": "http://www.alnylam.com/role/NATUREOFBUSINESS",
     "shortName": "NATURE OF BUSINESS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alny-20210331.htm",
      "contextRef": "i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alny-20210331.htm",
      "contextRef": "i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103102 - Disclosure - BASIS OF PRESENTATION AND PRINCIPLES OF CONSOLIDATION",
     "role": "http://www.alnylam.com/role/BASISOFPRESENTATIONANDPRINCIPLESOFCONSOLIDATION",
     "shortName": "BASIS OF PRESENTATION AND PRINCIPLES OF CONSOLIDATION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alny-20210331.htm",
      "contextRef": "i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alny-20210331.htm",
      "contextRef": "i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2105103 - Disclosure - NET PRODUCT REVENUES",
     "role": "http://www.alnylam.com/role/NETPRODUCTREVENUES",
     "shortName": "NET PRODUCT REVENUES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alny-20210331.htm",
      "contextRef": "i830216d97d534f5a8150c2a02c5c670d_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 67,
   "tag": {
    "alny_ALNAGTPhase2ClinicalTrialMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ALN-AGT Phase 2 Clinical Trial",
        "label": "ALN-AGT Phase 2 Clinical Trial [Member]",
        "terseLabel": "ALN-AGT Phase 2 Clinical Trial"
       }
      }
     },
     "localname": "ALNAGTPhase2ClinicalTrialMember",
     "nsuri": "http://www.alnylam.com/20210331",
     "presentation": [
      "http://www.alnylam.com/role/DEVELOPMENTDERIVATIVELIABILITYNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "alny_ALNAGTPhase3ClinicalTrialMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ALN-AGT Phase 3 Clinical Trial",
        "label": "ALN-AGT Phase 3 Clinical Trial [Member]",
        "terseLabel": "ALN-AGT Phase 3 Clinical Trial"
       }
      }
     },
     "localname": "ALNAGTPhase3ClinicalTrialMember",
     "nsuri": "http://www.alnylam.com/20210331",
     "presentation": [
      "http://www.alnylam.com/role/DEVELOPMENTDERIVATIVELIABILITYNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "alny_AccumulatedLossOnInvestmentInJointVentureMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated loss on investment in joint venture.",
        "label": "Accumulated Loss On Investment In Joint Venture [Member]",
        "terseLabel": "Loss on Investment in Joint Venture"
       }
      }
     },
     "localname": "AccumulatedLossOnInvestmentInJointVentureMember",
     "nsuri": "http://www.alnylam.com/20210331",
     "presentation": [
      "http://www.alnylam.com/role/OTHERBALANCESHEETDETAILSSummaryofChangesinAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "alny_AmortizationAndInterestAccretionRelatedToOperatingLeases": {
     "auth_ref": [],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortization and Interest Accretion Related to Operating Leases",
        "label": "Amortization and Interest Accretion Related to Operating Leases",
        "terseLabel": "Amortization and interest accretion related to operating leases"
       }
      }
     },
     "localname": "AmortizationAndInterestAccretionRelatedToOperatingLeases",
     "nsuri": "http://www.alnylam.com/20210331",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "alny_BlackstoneGroupIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Blackstone Group Inc.",
        "label": "Blackstone Group Inc. [Member]",
        "terseLabel": "Blackstone Group Inc."
       }
      }
     },
     "localname": "BlackstoneGroupIncMember",
     "nsuri": "http://www.alnylam.com/20210331",
     "presentation": [
      "http://www.alnylam.com/role/LIABILITYRELATEDTOTHESALEOFFUTUREROYALTIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "alny_BlackstoneLifeSciencesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Blackstone Life Sciences",
        "label": "Blackstone Life Sciences [Member]",
        "terseLabel": "Blackstone Life Sciences"
       }
      }
     },
     "localname": "BlackstoneLifeSciencesMember",
     "nsuri": "http://www.alnylam.com/20210331",
     "presentation": [
      "http://www.alnylam.com/role/DEVELOPMENTDERIVATIVELIABILITYNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "alny_C5CoCoObligationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "C5 Co-Co obligation.",
        "label": "C5 Co Co Obligation [Member]",
        "terseLabel": "C5 Co-Co Obligation"
       }
      }
     },
     "localname": "C5CoCoObligationMember",
     "nsuri": "http://www.alnylam.com/20210331",
     "presentation": [
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofDeferredRevenueDetails",
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofRevenueRecognizedbyAccountingGuidanceDetails",
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofTransactionPriceAllocatedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "alny_C5LicenseObligationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "C5 license obligation.",
        "label": "C5 License Obligation [Member]",
        "terseLabel": "C5 License Obligation"
       }
      }
     },
     "localname": "C5LicenseObligationMember",
     "nsuri": "http://www.alnylam.com/20210331",
     "presentation": [
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofDeferredRevenueDetails",
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofRevenueRecognizedbyAccountingGuidanceDetails",
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofTransactionPriceAllocatedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "alny_ClinicalTrialAndManufacturingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Clinical trial and manufacturing.",
        "label": "Clinical Trial And Manufacturing [Member]",
        "terseLabel": "Clinical Trial and Manufacturing"
       }
      }
     },
     "localname": "ClinicalTrialAndManufacturingMember",
     "nsuri": "http://www.alnylam.com/20210331",
     "presentation": [
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofResearchandDevelopmentExpensesIncurredbyTypethatareDirectlyAttributabletoCollaborationAgreementsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "alny_CollaborativeAgreementTerminationPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative agreement termination period.",
        "label": "Collaborative Agreement Termination Period",
        "terseLabel": "Agreement termination period"
       }
      }
     },
     "localname": "CollaborativeAgreementTerminationPeriod",
     "nsuri": "http://www.alnylam.com/20210331",
     "presentation": [
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "alny_CollaborativeArrangementAdditionalDevelopmentCandidatesToBeDelivered": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Additional Development Candidates To Be Delivered",
        "label": "Collaborative Arrangement, Additional Development Candidates To Be Delivered",
        "terseLabel": "Additional development candidates to be delivered"
       }
      }
     },
     "localname": "CollaborativeArrangementAdditionalDevelopmentCandidatesToBeDelivered",
     "nsuri": "http://www.alnylam.com/20210331",
     "presentation": [
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "alny_CollaborativeArrangementCommercialMilestonesAcquiredByCollaboratorPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Commercial Milestones Acquired By Collaborator, Percent",
        "label": "Collaborative Arrangement, Commercial Milestones Acquired By Collaborator, Percent",
        "terseLabel": "Commercial milestones acquired by collaborator, percent"
       }
      }
     },
     "localname": "CollaborativeArrangementCommercialMilestonesAcquiredByCollaboratorPercent",
     "nsuri": "http://www.alnylam.com/20210331",
     "presentation": [
      "http://www.alnylam.com/role/LIABILITYRELATEDTOTHESALEOFFUTUREROYALTIESDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "alny_CollaborativeArrangementConsiderationReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Consideration Received",
        "label": "Collaborative Arrangement, Consideration Received",
        "terseLabel": "Consideration received"
       }
      }
     },
     "localname": "CollaborativeArrangementConsiderationReceived",
     "nsuri": "http://www.alnylam.com/20210331",
     "presentation": [
      "http://www.alnylam.com/role/LIABILITYRELATEDTOTHESALEOFFUTUREROYALTIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "alny_CollaborativeArrangementFixedPaymentMultiplier": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Fixed Payment Multiplier",
        "label": "Collaborative Arrangement, Fixed Payment Multiplier",
        "terseLabel": "Fixed payment multiplier"
       }
      }
     },
     "localname": "CollaborativeArrangementFixedPaymentMultiplier",
     "nsuri": "http://www.alnylam.com/20210331",
     "presentation": [
      "http://www.alnylam.com/role/DEVELOPMENTDERIVATIVELIABILITYNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "alny_CollaborativeArrangementFixedPaymentTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Fixed Payment, Term",
        "label": "Collaborative Arrangement, Fixed Payment, Term",
        "terseLabel": "Fixed payment, term"
       }
      }
     },
     "localname": "CollaborativeArrangementFixedPaymentTerm",
     "nsuri": "http://www.alnylam.com/20210331",
     "presentation": [
      "http://www.alnylam.com/role/DEVELOPMENTDERIVATIVELIABILITYNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "alny_CollaborativeArrangementMaximumFunding": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Maximum Funding",
        "label": "Collaborative Arrangement, Maximum Funding",
        "terseLabel": "Maximum funding"
       }
      }
     },
     "localname": "CollaborativeArrangementMaximumFunding",
     "nsuri": "http://www.alnylam.com/20210331",
     "presentation": [
      "http://www.alnylam.com/role/DEVELOPMENTDERIVATIVELIABILITYNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "alny_CollaborativeArrangementMilestonePayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement milestone payments.",
        "label": "Collaborative Arrangement Milestone Payments",
        "terseLabel": "Collaborative arrangement milestone payments"
       }
      }
     },
     "localname": "CollaborativeArrangementMilestonePayments",
     "nsuri": "http://www.alnylam.com/20210331",
     "presentation": [
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "alny_CollaborativeArrangementRoyaltiesAndCommercialMilestonesAcquiredByCollaboratorPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Royalties Acquired By Collaborator, Percent",
        "label": "Collaborative Arrangement, Royalties And Commercial Milestones Acquired By Collaborator, Percent",
        "terseLabel": "Collaborative arrangement, royalties and commercial milestones acquired by collaborator, percent"
       }
      }
     },
     "localname": "CollaborativeArrangementRoyaltiesAndCommercialMilestonesAcquiredByCollaboratorPercent",
     "nsuri": "http://www.alnylam.com/20210331",
     "presentation": [
      "http://www.alnylam.com/role/LIABILITYRELATEDTOTHESALEOFFUTUREROYALTIESDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "alny_CollaborativeArrangementRoyaltiesPayablePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Royalties Payable, Percent",
        "label": "Collaborative Arrangement, Royalties Payable, Percent",
        "terseLabel": "Royalties payable, percent"
       }
      }
     },
     "localname": "CollaborativeArrangementRoyaltiesPayablePercent",
     "nsuri": "http://www.alnylam.com/20210331",
     "presentation": [
      "http://www.alnylam.com/role/DEVELOPMENTDERIVATIVELIABILITYNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "alny_CollaborativeArrangementRoyaltiesPayableTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Royalties Payable, Term",
        "label": "Collaborative Arrangement, Royalties Payable, Term",
        "terseLabel": "Royalties payable, term"
       }
      }
     },
     "localname": "CollaborativeArrangementRoyaltiesPayableTerm",
     "nsuri": "http://www.alnylam.com/20210331",
     "presentation": [
      "http://www.alnylam.com/role/DEVELOPMENTDERIVATIVELIABILITYNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "alny_CostOfCollaborationManufacturingAndRoyalties": {
     "auth_ref": [],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost Of Collaboration Manufacturing And Royalties",
        "label": "Cost Of Collaboration Manufacturing And Royalties",
        "terseLabel": "Cost of collaborations"
       }
      }
     },
     "localname": "CostOfCollaborationManufacturingAndRoyalties",
     "nsuri": "http://www.alnylam.com/20210331",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "alny_DebtInstrumentCovenantTermsMinimumConsolidatedLiquidity": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant Terms, Minimum Consolidated Liquidity",
        "label": "Debt Instrument, Covenant Terms, Minimum Consolidated Liquidity",
        "terseLabel": "Minimum consolidated liquidity"
       }
      }
     },
     "localname": "DebtInstrumentCovenantTermsMinimumConsolidatedLiquidity",
     "nsuri": "http://www.alnylam.com/20210331",
     "presentation": [
      "http://www.alnylam.com/role/CREDITAGREEMENTAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "alny_DebtInstrumentCovenantTermsMinimumProductRevenue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant Terms, Minimum Product Revenue",
        "label": "Debt Instrument, Covenant Terms, Minimum Product Revenue",
        "terseLabel": "Minimum product revenue"
       }
      }
     },
     "localname": "DebtInstrumentCovenantTermsMinimumProductRevenue",
     "nsuri": "http://www.alnylam.com/20210331",
     "presentation": [
      "http://www.alnylam.com/role/CREDITAGREEMENTAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "alny_DebtInstrumentExitFeePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Exit Fee Percent",
        "label": "Debt Instrument, Exit Fee Percent",
        "terseLabel": "Exit fee percent"
       }
      }
     },
     "localname": "DebtInstrumentExitFeePercent",
     "nsuri": "http://www.alnylam.com/20210331",
     "presentation": [
      "http://www.alnylam.com/role/CREDITAGREEMENTAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "alny_DebtInstrumentInterestInKindInterestRateIncrease": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Interest In Kind, Interest Rate Increase",
        "label": "Debt Instrument, Interest In Kind, Interest Rate Increase",
        "terseLabel": "Interest in kind, interest rate increase"
       }
      }
     },
     "localname": "DebtInstrumentInterestInKindInterestRateIncrease",
     "nsuri": "http://www.alnylam.com/20210331",
     "presentation": [
      "http://www.alnylam.com/role/CREDITAGREEMENTAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "alny_DebtInstrumentNumberOfTranches": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Number Of Tranches",
        "label": "Debt Instrument, Number Of Tranches",
        "terseLabel": "Number Of tranches"
       }
      }
     },
     "localname": "DebtInstrumentNumberOfTranches",
     "nsuri": "http://www.alnylam.com/20210331",
     "presentation": [
      "http://www.alnylam.com/role/CREDITAGREEMENTAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "alny_DiscoveryPeriodOfProgramsDevelopment": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discovery period of programs development.",
        "label": "Discovery Period Of Programs Development",
        "terseLabel": "Discovery period of programs development"
       }
      }
     },
     "localname": "DiscoveryPeriodOfProgramsDevelopment",
     "nsuri": "http://www.alnylam.com/20210331",
     "presentation": [
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "alny_ExpectedRoyaltyInterestPayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected Royalty Interest Payments",
        "label": "Expected Royalty Interest Payments",
        "terseLabel": "Expected royalty interest payments"
       }
      }
     },
     "localname": "ExpectedRoyaltyInterestPayments",
     "nsuri": "http://www.alnylam.com/20210331",
     "presentation": [
      "http://www.alnylam.com/role/LIABILITYRELATEDTOTHESALEOFFUTUREROYALTIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "alny_ExtendedAdditionalDiscoveryPeriodOfProgramsDevelopment": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extended additional discovery period of programs development.",
        "label": "Extended Additional Discovery Period Of Programs Development",
        "terseLabel": "Extended additional discovery period of programs development"
       }
      }
     },
     "localname": "ExtendedAdditionalDiscoveryPeriodOfProgramsDevelopment",
     "nsuri": "http://www.alnylam.com/20210331",
     "presentation": [
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "alny_ExternalServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "External services.",
        "label": "External Services [Member]",
        "terseLabel": "External Services"
       }
      }
     },
     "localname": "ExternalServicesMember",
     "nsuri": "http://www.alnylam.com/20210331",
     "presentation": [
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofResearchandDevelopmentExpensesIncurredbyTypethatareDirectlyAttributabletoCollaborationAgreementsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "alny_FundingAnAnnualDiscoveryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Funding an annual discovery.",
        "label": "Funding An Annual Discovery [Member]",
        "terseLabel": "Funding At Steady State"
       }
      }
     },
     "localname": "FundingAnAnnualDiscoveryMember",
     "nsuri": "http://www.alnylam.com/20210331",
     "presentation": [
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "alny_FundingAtLeadCandidateIdentificationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Funding at lead candidate identification.",
        "label": "Funding At Lead Candidate Identification [Member]",
        "terseLabel": "Funding At Lead Candidate Identification"
       }
      }
     },
     "localname": "FundingAtLeadCandidateIdentificationMember",
     "nsuri": "http://www.alnylam.com/20210331",
     "presentation": [
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "alny_FundingAtProgramInitiationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Funding at program initiation.",
        "label": "Funding At Program Initiation [Member]",
        "terseLabel": "Funding At Program Initiation"
       }
      }
     },
     "localname": "FundingAtProgramInitiationMember",
     "nsuri": "http://www.alnylam.com/20210331",
     "presentation": [
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "alny_FuturePaymentsOnAchievementOfOtherSpecifiedRegulatoryMilestones": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future Payments On Achievement Of Other Specified Regulatory Milestones",
        "label": "Future Payments On Achievement Of Other Specified Regulatory Milestones",
        "terseLabel": "Future payments on achievement of other specified regulatory milestones"
       }
      }
     },
     "localname": "FuturePaymentsOnAchievementOfOtherSpecifiedRegulatoryMilestones",
     "nsuri": "http://www.alnylam.com/20210331",
     "presentation": [
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "alny_FuturePaymentsOnAchievementOfSpecifiedCommercializationMilestones": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future payments on achievement of specified commercialization milestones.",
        "label": "Future Payments On Achievement Of Specified Commercialization Milestones",
        "terseLabel": "Future payments on achievement of specified commercialization milestones"
       }
      }
     },
     "localname": "FuturePaymentsOnAchievementOfSpecifiedCommercializationMilestones",
     "nsuri": "http://www.alnylam.com/20210331",
     "presentation": [
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "alny_FuturePaymentsOnAchievementOfSpecifiedRegulatoryMilestones": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future payments on achievement of specified regulatory milestones.",
        "label": "Future Payments On Achievement Of Specified Regulatory Milestones",
        "terseLabel": "Future payments on achievement of specified regulatory milestones"
       }
      }
     },
     "localname": "FuturePaymentsOnAchievementOfSpecifiedRegulatoryMilestones",
     "nsuri": "http://www.alnylam.com/20210331",
     "presentation": [
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "alny_GIVLAARIMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "GIVLAARI",
        "label": "GIVLAARI [Member]",
        "terseLabel": "GIVLAARI"
       }
      }
     },
     "localname": "GIVLAARIMember",
     "nsuri": "http://www.alnylam.com/20210331",
     "presentation": [
      "http://www.alnylam.com/role/NETPRODUCTREVENUESSummaryofNetProductRevenuesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "alny_GlobalStrategicCollaborationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Global strategic collaboration.",
        "label": "Global Strategic Collaboration [Member]",
        "terseLabel": "Global Strategic Collaboration"
       }
      }
     },
     "localname": "GlobalStrategicCollaborationMember",
     "nsuri": "http://www.alnylam.com/20210331",
     "presentation": [
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSAdditionalInformationDetail",
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofDeferredRevenueDetails",
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofRevenueRecognizedbyAccountingGuidanceDetails",
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofTransactionPriceAllocatedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "alny_HELIOSBPhase3ClinicalTrialMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "HELIOS-B Phase 3 Clinical Trial",
        "label": "HELIOS-B Phase 3 Clinical Trial [Member]",
        "terseLabel": "HELIOS-B Phase 3 Clinical Trial"
       }
      }
     },
     "localname": "HELIOSBPhase3ClinicalTrialMember",
     "nsuri": "http://www.alnylam.com/20210331",
     "presentation": [
      "http://www.alnylam.com/role/DEVELOPMENTDERIVATIVELIABILITYNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "alny_ImpairmentOfMarketableDebtSecurities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Impairment of marketable debt securities.",
        "label": "Impairment Of Marketable Debt Securities",
        "terseLabel": "Impairment charges of marketable debt securities"
       }
      }
     },
     "localname": "ImpairmentOfMarketableDebtSecurities",
     "nsuri": "http://www.alnylam.com/20210331",
     "presentation": [
      "http://www.alnylam.com/role/MARKETABLEDEBTSECURITIESAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "alny_InventoryCurrentAndNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.alnylam.com/role/OTHERBALANCESHEETDETAILSScheduleofInventoryDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inventory, Current And Noncurrent",
        "label": "Inventory, Current And Noncurrent",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "InventoryCurrentAndNoncurrent",
     "nsuri": "http://www.alnylam.com/20210331",
     "presentation": [
      "http://www.alnylam.com/role/OTHERBALANCESHEETDETAILSScheduleofInventoryDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "alny_InvestmentsInMarketableDebtSecuritiesDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments in marketable debt securities disclosure.",
        "label": "Investments In Marketable Debt Securities Disclosure [Text Block]",
        "terseLabel": "MARKETABLE DEBT SECURITIES"
       }
      }
     },
     "localname": "InvestmentsInMarketableDebtSecuritiesDisclosureTextBlock",
     "nsuri": "http://www.alnylam.com/20210331",
     "presentation": [
      "http://www.alnylam.com/role/MARKETABLEDEBTSECURITIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesLineItemsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liability Related To The Sale Of Future Royalties Line Items",
        "label": "Liability Related To The Sale Of Future Royalties Line Items [Line Items]",
        "terseLabel": "Liability Related To The Sale Of Future Royalties Line Items [Line Items]"
       }
      }
     },
     "localname": "LiabilityRelatedToTheSaleOfFutureRoyaltiesLineItemsLineItems",
     "nsuri": "http://www.alnylam.com/20210331",
     "presentation": [
      "http://www.alnylam.com/role/LIABILITYRELATEDTOTHESALEOFFUTUREROYALTIESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liability Related To The Sale Of Future Royalties Table",
        "label": "Liability Related To The Sale Of Future Royalties [Table]",
        "terseLabel": "Liability Related To The Sale Of Future Royalties [Table]"
       }
      }
     },
     "localname": "LiabilityRelatedToTheSaleOfFutureRoyaltiesTable",
     "nsuri": "http://www.alnylam.com/20210331",
     "presentation": [
      "http://www.alnylam.com/role/LIABILITYRELATEDTOTHESALEOFFUTUREROYALTIESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "alny_LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liability Related To The Sale Of Future Royalties",
        "label": "Liability Related To The Sale Of Future Royalties [Text Block]",
        "terseLabel": "LIABILITY RELATED TO SALE OF FUTURE ROYALTIES"
       }
      }
     },
     "localname": "LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock",
     "nsuri": "http://www.alnylam.com/20210331",
     "presentation": [
      "http://www.alnylam.com/role/LIABILITYRELATEDTOTHESALEOFFUTUREROYALTIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "alny_LineOfCreditFacilityMaximumBorrowingCapacityAccordionFeature": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line Of Credit Facility, Maximum Borrowing Capacity, Accordion Feature",
        "label": "Line Of Credit Facility, Maximum Borrowing Capacity, Accordion Feature",
        "terseLabel": "Maximum borrowing capacity, accordion feature"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacityAccordionFeature",
     "nsuri": "http://www.alnylam.com/20210331",
     "presentation": [
      "http://www.alnylam.com/role/CREDITAGREEMENTAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "alny_LineOfCreditFacilityPrepaymentAndTerminationFeePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line Of Credit Facility, Prepayment And Termination Fee Percentage",
        "label": "Line Of Credit Facility, Prepayment And Termination Fee Percentage",
        "terseLabel": "Prepayment and termination fee percentage"
       }
      }
     },
     "localname": "LineOfCreditFacilityPrepaymentAndTerminationFeePercentage",
     "nsuri": "http://www.alnylam.com/20210331",
     "presentation": [
      "http://www.alnylam.com/role/CREDITAGREEMENTAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "alny_LiquidityPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liquidity.",
        "label": "Liquidity Policy [Policy Text Block]",
        "terseLabel": "Liquidity"
       }
      }
     },
     "localname": "LiquidityPolicyPolicyTextBlock",
     "nsuri": "http://www.alnylam.com/20210331",
     "presentation": [
      "http://www.alnylam.com/role/BASISOFPRESENTATIONANDPRINCIPLESOFCONSOLIDATIONPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "alny_MaximumAdditionalMilestonePaymentsToBeReceiveUponAchievementOfCertainCriteria": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum additional milestone payments to be receive upon achievement of certain criteria.",
        "label": "Maximum Additional Milestone Payments To Be Receive Upon Achievement Of Certain Criteria",
        "terseLabel": "Maximum additional milestone payments to be receive upon achievement of certain criteria"
       }
      }
     },
     "localname": "MaximumAdditionalMilestonePaymentsToBeReceiveUponAchievementOfCertainCriteria",
     "nsuri": "http://www.alnylam.com/20210331",
     "presentation": [
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "alny_MaximumNumberOfPotentialFutureMilestones": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the maximum amount of pre-specified milestone payments that could potentially be received under the collaborative and licensing agreement.",
        "label": "Maximum Number Of Potential Future Milestones",
        "terseLabel": "Maximum amount of potential future milestones"
       }
      }
     },
     "localname": "MaximumNumberOfPotentialFutureMilestones",
     "nsuri": "http://www.alnylam.com/20210331",
     "presentation": [
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "alny_MaximumRoyaltiesAndCommercialMilestonePaymentsUponPotentialProductSale": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum royalties and commercial milestone payments upon potential product sale.",
        "label": "Maximum Royalties And Commercial Milestone Payments Upon Potential Product Sale",
        "terseLabel": "Maximum royalties and commercial milestone payments upon potential product sale"
       }
      }
     },
     "localname": "MaximumRoyaltiesAndCommercialMilestonePaymentsUponPotentialProductSale",
     "nsuri": "http://www.alnylam.com/20210331",
     "presentation": [
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "alny_MilestonePaymentEarned": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount earned upon achievement of milestone.",
        "label": "Milestone Payment Earned",
        "terseLabel": "Milestone payment earned"
       }
      }
     },
     "localname": "MilestonePaymentEarned",
     "nsuri": "http://www.alnylam.com/20210331",
     "presentation": [
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "alny_MilestonePaymentEarnedShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Payment Earned, Shares",
        "label": "Milestone Payment Earned, Shares",
        "terseLabel": "Milestone shares earned (in shares)"
       }
      }
     },
     "localname": "MilestonePaymentEarnedShares",
     "nsuri": "http://www.alnylam.com/20210331",
     "presentation": [
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "alny_NonCashInterestExpenseOnSaleOfFutureRoyalties": {
     "auth_ref": [],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-Cash Interest Expense On Sale Of Future Royalties",
        "label": "Non-Cash Interest Expense On Sale Of Future Royalties",
        "terseLabel": "Non-cash interest expense on liability related to the sale of future royalties"
       }
      }
     },
     "localname": "NonCashInterestExpenseOnSaleOfFutureRoyalties",
     "nsuri": "http://www.alnylam.com/20210331",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "alny_NonUSOrEuropeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-US Or Europe",
        "label": "Non-US Or Europe [Member]",
        "terseLabel": "Rest of World"
       }
      }
     },
     "localname": "NonUSOrEuropeMember",
     "nsuri": "http://www.alnylam.com/20210331",
     "presentation": [
      "http://www.alnylam.com/role/NETPRODUCTREVENUESSummaryofNetProductRevenuesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "alny_NovartisMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Medicines Company.",
        "label": "Novartis [Member]",
        "terseLabel": "Novartis AG",
        "verboseLabel": "Novartis AG"
       }
      }
     },
     "localname": "NovartisMember",
     "nsuri": "http://www.alnylam.com/20210331",
     "presentation": [
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSAdditionalInformationDetail",
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSRevenuefromCollaboratorsDetail",
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofResearchandDevelopmentExpensesIncurredbyTypethatareDirectlyAttributabletoCollaborationAgreementsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "alny_NumberOfClinicalProgramsInLateStages": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Clinical Programs In Late Stages",
        "label": "Number Of Clinical Programs In Late Stages",
        "terseLabel": "Number of clinical programs in late stages"
       }
      }
     },
     "localname": "NumberOfClinicalProgramsInLateStages",
     "nsuri": "http://www.alnylam.com/20210331",
     "presentation": [
      "http://www.alnylam.com/role/NATUREOFBUSINESSDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "alny_NumberOfMarketedProducts": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Marketed Products",
        "label": "Number Of Marketed Products",
        "terseLabel": "Number of marketed products"
       }
      }
     },
     "localname": "NumberOfMarketedProducts",
     "nsuri": "http://www.alnylam.com/20210331",
     "presentation": [
      "http://www.alnylam.com/role/NATUREOFBUSINESSDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "alny_NumberOfPartneredProducts": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Partnered Products",
        "label": "Number Of Partnered Products",
        "terseLabel": "Number of partnered products"
       }
      }
     },
     "localname": "NumberOfPartneredProducts",
     "nsuri": "http://www.alnylam.com/20210331",
     "presentation": [
      "http://www.alnylam.com/role/NATUREOFBUSINESSDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "alny_NumberOfTargetedPrograms": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of targeted programs.",
        "label": "Number Of Targeted Programs",
        "terseLabel": "Number of targeted programs"
       }
      }
     },
     "localname": "NumberOfTargetedPrograms",
     "nsuri": "http://www.alnylam.com/20210331",
     "presentation": [
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "alny_ONPATTROAndGIVLAARIMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ONPATTRO And GIVLAARI",
        "label": "ONPATTRO And GIVLAARI [Member]",
        "terseLabel": "ONPATTRO And GIVLAARI"
       }
      }
     },
     "localname": "ONPATTROAndGIVLAARIMember",
     "nsuri": "http://www.alnylam.com/20210331",
     "presentation": [
      "http://www.alnylam.com/role/CREDITAGREEMENTAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "alny_ONPATTROMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ONPATTRO",
        "label": "ONPATTRO [Member]",
        "terseLabel": "ONPATTRO"
       }
      }
     },
     "localname": "ONPATTROMember",
     "nsuri": "http://www.alnylam.com/20210331",
     "presentation": [
      "http://www.alnylam.com/role/NETPRODUCTREVENUESSummaryofNetProductRevenuesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "alny_OXLUMOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "OXLUMO",
        "label": "OXLUMO [Member]",
        "terseLabel": "OXLUMO"
       }
      }
     },
     "localname": "OXLUMOMember",
     "nsuri": "http://www.alnylam.com/20210331",
     "presentation": [
      "http://www.alnylam.com/role/NETPRODUCTREVENUESSummaryofNetProductRevenuesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "alny_OtherCollaborationsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other collaboration.",
        "label": "Other Collaborations [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherCollaborationsMember",
     "nsuri": "http://www.alnylam.com/20210331",
     "presentation": [
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSRevenuefromCollaboratorsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "alny_OtherMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other.",
        "label": "Other [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherMember",
     "nsuri": "http://www.alnylam.com/20210331",
     "presentation": [
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofResearchandDevelopmentExpensesIncurredbyTypethatareDirectlyAttributabletoCollaborationAgreementsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "alny_PercentageOfMaximumRoyaltyPayments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of maximum royalty payments.",
        "label": "Percentage Of Maximum Royalty Payments",
        "terseLabel": "Maximum percentage of royalty payments"
       }
      }
     },
     "localname": "PercentageOfMaximumRoyaltyPayments",
     "nsuri": "http://www.alnylam.com/20210331",
     "presentation": [
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "alny_PotentialProceedsFromCollaborationArrangement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential proceeds from collaboration arrangement.",
        "label": "Potential Proceeds From Collaboration Arrangement",
        "terseLabel": "Potential proceeds from collaboration arrangement"
       }
      }
     },
     "localname": "PotentialProceedsFromCollaborationArrangement",
     "nsuri": "http://www.alnylam.com/20210331",
     "presentation": [
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "alny_ProductAlliancesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product alliances.",
        "label": "Product Alliances [Member]",
        "terseLabel": "Product Alliances"
       }
      }
     },
     "localname": "ProductAlliancesMember",
     "nsuri": "http://www.alnylam.com/20210331",
     "presentation": [
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "alny_RegeneronPharmaceuticalsIncorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Regeneron Pharmaceuticals, Incorporation.",
        "label": "Regeneron Pharmaceuticals Incorporation [Member]",
        "terseLabel": "Regeneron Pharmaceuticals"
       }
      }
     },
     "localname": "RegeneronPharmaceuticalsIncorporationMember",
     "nsuri": "http://www.alnylam.com/20210331",
     "presentation": [
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSAdditionalInformationDetail",
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSRevenuefromCollaboratorsDetail",
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofDeferredRevenueDetails",
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofResearchandDevelopmentExpensesIncurredbyTypethatareDirectlyAttributabletoCollaborationAgreementsDetail",
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofRevenueRecognizedbyAccountingGuidanceDetails",
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofTransactionPriceAllocatedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "alny_ResearchCollaboratorAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research collaborator.",
        "label": "Research Collaborator [Axis]",
        "terseLabel": "Research Collaborator [Axis]"
       }
      }
     },
     "localname": "ResearchCollaboratorAxis",
     "nsuri": "http://www.alnylam.com/20210331",
     "presentation": [
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "alny_ResearchCollaboratorDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research Collaborator",
        "label": "Research Collaborator [Domain]",
        "terseLabel": "Research Collaborator [Domain]"
       }
      }
     },
     "localname": "ResearchCollaboratorDomain",
     "nsuri": "http://www.alnylam.com/20210331",
     "presentation": [
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "alny_ResearchServicesObligationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research services obligation.",
        "label": "Research Services Obligation [Member]",
        "terseLabel": "Research Services Obligation"
       }
      }
     },
     "localname": "ResearchServicesObligationMember",
     "nsuri": "http://www.alnylam.com/20210331",
     "presentation": [
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofDeferredRevenueDetails",
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofRevenueRecognizedbyAccountingGuidanceDetails",
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofTransactionPriceAllocatedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "alny_ResearchTermExtensionFee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research term extension fee.",
        "label": "Research Term Extension Fee",
        "terseLabel": "Research term extension fee"
       }
      }
     },
     "localname": "ResearchTermExtensionFee",
     "nsuri": "http://www.alnylam.com/20210331",
     "presentation": [
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "alny_RoyaltiesReceivableCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 7.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalties Receivable, Current",
        "label": "Royalties Receivable, Current",
        "terseLabel": "Receivable related to the sale of future royalties"
       }
      }
     },
     "localname": "RoyaltiesReceivableCurrent",
     "nsuri": "http://www.alnylam.com/20210331",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.alnylam.com/role/LIABILITYRELATEDTOTHESALEOFFUTUREROYALTIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "alny_RoyaltyLiabilityClosingCosts": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty Liability, Closing Costs",
        "label": "Royalty Liability, Closing Costs",
        "negatedTerseLabel": "Closing costs"
       }
      }
     },
     "localname": "RoyaltyLiabilityClosingCosts",
     "nsuri": "http://www.alnylam.com/20210331",
     "presentation": [
      "http://www.alnylam.com/role/LIABILITYRELATEDTOTHESALEOFFUTUREROYALTIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "alny_RoyaltyLiabilityCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty Liability, Current",
        "label": "Royalty Liability, Current",
        "terseLabel": "Liability related to the sale of future royalties"
       }
      }
     },
     "localname": "RoyaltyLiabilityCurrent",
     "nsuri": "http://www.alnylam.com/20210331",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "alny_RoyaltyLiabilityInterestExpenseIncludingAmortizationOfClosingCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty Liability, Interest Expense Including Amortization Of Closing Costs",
        "label": "Royalty Liability, Interest Expense Including Amortization Of Closing Costs",
        "terseLabel": "Interest expense including amortization of closing costs"
       }
      }
     },
     "localname": "RoyaltyLiabilityInterestExpenseIncludingAmortizationOfClosingCosts",
     "nsuri": "http://www.alnylam.com/20210331",
     "presentation": [
      "http://www.alnylam.com/role/LIABILITYRELATEDTOTHESALEOFFUTUREROYALTIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "alny_RoyaltyLiabilityInterestRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty Liability, Interest Rate",
        "label": "Royalty Liability, Interest Rate",
        "terseLabel": "Interest rate"
       }
      }
     },
     "localname": "RoyaltyLiabilityInterestRate",
     "nsuri": "http://www.alnylam.com/20210331",
     "presentation": [
      "http://www.alnylam.com/role/LIABILITYRELATEDTOTHESALEOFFUTUREROYALTIESDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "alny_RoyaltyLiabilityNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty Liability, Noncurrent",
        "label": "Royalty Liability, Noncurrent",
        "terseLabel": "Liability related to the sale of future royalties, net of current portion"
       }
      }
     },
     "localname": "RoyaltyLiabilityNoncurrent",
     "nsuri": "http://www.alnylam.com/20210331",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.alnylam.com/role/LIABILITYRELATEDTOTHESALEOFFUTUREROYALTIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "alny_RoyaltyRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential maximum royalty percentage that will received for sales completed by collaboration partner.",
        "label": "Royalty Rate",
        "terseLabel": "Royalty rate"
       }
      }
     },
     "localname": "RoyaltyRate",
     "nsuri": "http://www.alnylam.com/20210331",
     "presentation": [
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "alny_SanofiGenzymeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sanofi Genzyme.",
        "label": "Sanofi Genzyme [Member]",
        "verboseLabel": "Other"
       }
      }
     },
     "localname": "SanofiGenzymeMember",
     "nsuri": "http://www.alnylam.com/20210331",
     "presentation": [
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofResearchandDevelopmentExpensesIncurredbyTypethatareDirectlyAttributabletoCollaborationAgreementsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "alny_ScheduleOfAllocatedTransactionPriceTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Allocated Transaction Price",
        "label": "Schedule of Allocated Transaction Price [Table Text Block]",
        "terseLabel": "Schedule of Allocated Transaction Price Based on Accounting Guidance"
       }
      }
     },
     "localname": "ScheduleOfAllocatedTransactionPriceTableTextBlock",
     "nsuri": "http://www.alnylam.com/20210331",
     "presentation": [
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "alny_ScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Statement of reconciliation of cash, cash equivalents and restricted cash.",
        "label": "Schedule Of Reconciliation Of Cash Cash Equivalents And Restricted Cash Table [Table Text Block]",
        "terseLabel": "Schedule of Reconciliation of Cash, Cash Equivalents And Restricted Cash"
       }
      }
     },
     "localname": "ScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTableTextBlock",
     "nsuri": "http://www.alnylam.com/20210331",
     "presentation": [
      "http://www.alnylam.com/role/OTHERBALANCESHEETDETAILSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "alny_ScheduleOfResearchAndDevelopmentExpensesIncurredForCollaborationAgreementsTableTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of research and development expenses incurred for collaboration agreements.",
        "label": "Schedule Of Research And Development Expenses Incurred For Collaboration Agreements Table [Table Text Block]",
        "terseLabel": "Schedule of Research and Development Expenses Incurred by Type that are Directly Attributable to Collaboration Agreements"
       }
      }
     },
     "localname": "ScheduleOfResearchAndDevelopmentExpensesIncurredForCollaborationAgreementsTableTableTextBlock",
     "nsuri": "http://www.alnylam.com/20210331",
     "presentation": [
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "alny_ScheduleOfRevenueRecognizedBasedOnAccountingGuidanceTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Revenue Recognized Based on Accounting Guidance",
        "label": "Schedule of Revenue Recognized Based on Accounting Guidance [Table Text Block]",
        "terseLabel": "Schedule of Revenue Recognized Based on Accounting Guidance"
       }
      }
     },
     "localname": "ScheduleOfRevenueRecognizedBasedOnAccountingGuidanceTableTextBlock",
     "nsuri": "http://www.alnylam.com/20210331",
     "presentation": [
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "alny_ScheduleOfRoyaltyLiabilityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Royalty Liability",
        "label": "Schedule Of Royalty Liability [Table Text Block]",
        "terseLabel": "Schedule of Royalty Liability"
       }
      }
     },
     "localname": "ScheduleOfRoyaltyLiabilityTableTextBlock",
     "nsuri": "http://www.alnylam.com/20210331",
     "presentation": [
      "http://www.alnylam.com/role/LIABILITYRELATEDTOTHESALEOFFUTUREROYALTIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "alny_StandaloneSellingPrice": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Standalone Selling Price",
        "label": "Standalone Selling Price",
        "terseLabel": "Standalone Selling Price"
       }
      }
     },
     "localname": "StandaloneSellingPrice",
     "nsuri": "http://www.alnylam.com/20210331",
     "presentation": [
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofTransactionPriceAllocatedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "alny_Tranche2LoanAndTranche3LoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tranche 2 Loan And Tranche 3 Loan",
        "label": "Tranche 2 Loan And Tranche 3 Loan [Member]",
        "terseLabel": "Tranche 2 Loan And Tranche 3 Loan"
       }
      }
     },
     "localname": "Tranche2LoanAndTranche3LoanMember",
     "nsuri": "http://www.alnylam.com/20210331",
     "presentation": [
      "http://www.alnylam.com/role/CREDITAGREEMENTAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "alny_TrancheThreeLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tranche Loan Three Member",
        "label": "Tranche Three Loan [Member]",
        "terseLabel": "Tranche 3 Loan"
       }
      }
     },
     "localname": "TrancheThreeLoanMember",
     "nsuri": "http://www.alnylam.com/20210331",
     "presentation": [
      "http://www.alnylam.com/role/CREDITAGREEMENTAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "alny_TrancheTwoLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tranche Loan Two Member",
        "label": "Tranche Two Loan [Member]",
        "terseLabel": "Tranche 2 Loan"
       }
      }
     },
     "localname": "TrancheTwoLoanMember",
     "nsuri": "http://www.alnylam.com/20210331",
     "presentation": [
      "http://www.alnylam.com/role/CREDITAGREEMENTAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "alny_TransactionPrice": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The transaction price of a contract is the amount of consideration to which the Company expects to be entitled in exchange for transferring promised goods or services to the customer, excluding amounts that will be collected on behalf of third parties. This amount is expected to include both fixed and variable consideration, subject to certain restrictions.",
        "label": "Transaction Price",
        "terseLabel": "Transaction Price Allocated",
        "verboseLabel": "Transaction price"
       }
      }
     },
     "localname": "TransactionPrice",
     "nsuri": "http://www.alnylam.com/20210331",
     "presentation": [
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSAdditionalInformationDetail",
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofDeferredRevenueDetails",
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofTransactionPriceAllocatedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "alny_UpfrontFeeReceived": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount of upfront fees received under the terms of collaborative and licensing agreement.",
        "label": "Upfront Fee Received",
        "terseLabel": "Upfront fee received"
       }
      }
     },
     "localname": "UpfrontFeeReceived",
     "nsuri": "http://www.alnylam.com/20210331",
     "presentation": [
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "alny_VirBiotechnologyIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vir biotechnology Inc.",
        "label": "Vir Biotechnology Inc [Member]",
        "terseLabel": "Vir Biotechnology",
        "verboseLabel": "Vir Biotechnology"
       }
      }
     },
     "localname": "VirBiotechnologyIncMember",
     "nsuri": "http://www.alnylam.com/20210331",
     "presentation": [
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSAdditionalInformationDetail",
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSRevenuefromCollaboratorsDetail",
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofResearchandDevelopmentExpensesIncurredbyTypethatareDirectlyAttributabletoCollaborationAgreementsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "alny_VutrisiranAndALNAGTMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vutrisiran and ALN-AGT",
        "label": "Vutrisiran and ALN-AGT [Member]",
        "terseLabel": "Vutrisiran and ALN-AGT"
       }
      }
     },
     "localname": "VutrisiranAndALNAGTMember",
     "nsuri": "http://www.alnylam.com/20210331",
     "presentation": [
      "http://www.alnylam.com/role/DEVELOPMENTDERIVATIVELIABILITYNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "alny_VutrisiranMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vutrisiran",
        "label": "Vutrisiran [Member]",
        "terseLabel": "Vutrisiran"
       }
      }
     },
     "localname": "VutrisiranMember",
     "nsuri": "http://www.alnylam.com/20210331",
     "presentation": [
      "http://www.alnylam.com/role/DEVELOPMENTDERIVATIVELIABILITYNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "United States"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/NETPRODUCTREVENUESSummaryofNetProductRevenuesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "verboseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "verboseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/DEVELOPMENTDERIVATIVELIABILITYNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/DEVELOPMENTDERIVATIVELIABILITYNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r49",
      "r104"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/DEVELOPMENTDERIVATIVELIABILITYNarrativeDetails",
      "http://www.alnylam.com/role/LIABILITYRELATEDTOTHESALEOFFUTUREROYALTIESDetails",
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSAdditionalInformationDetail",
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSRevenuefromCollaboratorsDetail",
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofDeferredRevenueDetails",
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofResearchandDevelopmentExpensesIncurredbyTypethatareDirectlyAttributabletoCollaborationAgreementsDetail",
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofRevenueRecognizedbyAccountingGuidanceDetails",
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofTransactionPriceAllocatedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_EuropeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Europe [Member]",
        "terseLabel": "Europe"
       }
      }
     },
     "localname": "EuropeMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/NETPRODUCTREVENUESSummaryofNetProductRevenuesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r240",
      "r242",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r362",
      "r398",
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CREDITAGREEMENTAdditionalInformationDetails",
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r240",
      "r242",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r362",
      "r398",
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CREDITAGREEMENTAdditionalInformationDetails",
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r153",
      "r219",
      "r223",
      "r363",
      "r397",
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.alnylam.com/role/CREDITAGREEMENTAdditionalInformationDetails",
      "http://www.alnylam.com/role/DEVELOPMENTDERIVATIVELIABILITYNarrativeDetails",
      "http://www.alnylam.com/role/NETPRODUCTREVENUESReceivablesDetail",
      "http://www.alnylam.com/role/NETPRODUCTREVENUESSummaryofNetProductRevenuesDetail",
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofDeferredRevenueDetails",
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofRevenueRecognizedbyAccountingGuidanceDetails",
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofTransactionPriceAllocatedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r153",
      "r219",
      "r223",
      "r363",
      "r397",
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.alnylam.com/role/CREDITAGREEMENTAdditionalInformationDetails",
      "http://www.alnylam.com/role/DEVELOPMENTDERIVATIVELIABILITYNarrativeDetails",
      "http://www.alnylam.com/role/NETPRODUCTREVENUESReceivablesDetail",
      "http://www.alnylam.com/role/NETPRODUCTREVENUESSummaryofNetProductRevenuesDetail",
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofDeferredRevenueDetails",
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofRevenueRecognizedbyAccountingGuidanceDetails",
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofTransactionPriceAllocatedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r231",
      "r240",
      "r242",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r362",
      "r398",
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Range"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CREDITAGREEMENTAdditionalInformationDetails",
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r231",
      "r240",
      "r242",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r362",
      "r398",
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Range"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CREDITAGREEMENTAdditionalInformationDetails",
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/DEVELOPMENTDERIVATIVELIABILITYNarrativeDetails",
      "http://www.alnylam.com/role/LIABILITYRELATEDTOTHESALEOFFUTUREROYALTIESDetails",
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSAdditionalInformationDetail",
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSRevenuefromCollaboratorsDetail",
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofDeferredRevenueDetails",
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofResearchandDevelopmentExpensesIncurredbyTypethatareDirectlyAttributabletoCollaborationAgreementsDetail",
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofRevenueRecognizedbyAccountingGuidanceDetails",
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofTransactionPriceAllocatedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioForecastMember": {
     "auth_ref": [
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forecast [Member]",
        "terseLabel": "Forecast"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/LIABILITYRELATEDTOTHESALEOFFUTUREROYALTIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]",
        "terseLabel": "Scenario [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/LIABILITYRELATEDTOTHESALEOFFUTUREROYALTIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r154",
      "r155",
      "r219",
      "r224",
      "r400",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/NETPRODUCTREVENUESSummaryofNetProductRevenuesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r154",
      "r155",
      "r219",
      "r224",
      "r400",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/NETPRODUCTREVENUESSummaryofNetProductRevenuesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r195",
      "r241",
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]",
        "terseLabel": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/LIABILITYRELATEDTOTHESALEOFFUTUREROYALTIESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AOCIAttributableToParentNetOfTaxRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "AOCI Attributable to Parent, Net of Tax [Roll Forward]",
        "terseLabel": "AOCI Attributable to Parent, Net of Tax [Roll Forward]"
       }
      }
     },
     "localname": "AOCIAttributableToParentNetOfTaxRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/OTHERBALANCESHEETDETAILSSummaryofChangesinAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r30"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNet": {
     "auth_ref": [
      "r16",
      "r383"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.",
        "label": "Accounts Receivable, after Allowance for Credit Loss",
        "verboseLabel": "Receivables included in \u201cAccounts receivable, net\u201d"
       }
      }
     },
     "localname": "AccountsReceivableNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSBalanceofReceivablesandContractLiabilitiesRelatedtoCollaborationAgreementsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r4",
      "r16",
      "r157",
      "r158"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable, net",
        "verboseLabel": "Receivables included in \u201cAccounts receivable, net\u201d"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.alnylam.com/role/NETPRODUCTREVENUESReceivablesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember": {
     "auth_ref": [
      "r56",
      "r61",
      "r62",
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive (income) loss related to defined benefit plans attributable to the parent.",
        "label": "Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]",
        "terseLabel": "Defined Benefit Pension Plans"
       }
      }
     },
     "localname": "AccumulatedDefinedBenefitPlansAdjustmentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/OTHERBALANCESHEETDETAILSSummaryofChangesinAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember": {
     "auth_ref": [
      "r53",
      "r54",
      "r55",
      "r61",
      "r62"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.",
        "label": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member]",
        "terseLabel": "Unrealized Gains from Debt Securities"
       }
      }
     },
     "localname": "AccumulatedNetUnrealizedInvestmentGainLossMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/OTHERBALANCESHEETDETAILSSummaryofChangesinAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/OTHERBALANCESHEETDETAILSSummaryofChangesinAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r19",
      "r59",
      "r60",
      "r61",
      "r387",
      "r406",
      "r407"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "auth_ref": [
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).",
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/OTHERBALANCESHEETDETAILSSummaryofChangesinAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r58",
      "r61",
      "r62",
      "r109",
      "r110",
      "r111",
      "r277",
      "r402",
      "r403"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.alnylam.com/role/OTHERBALANCESHEETDETAILSSummaryofChangesinAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedTranslationAdjustmentMember": {
     "auth_ref": [
      "r51",
      "r61",
      "r62",
      "r277",
      "r316",
      "r317",
      "r318",
      "r319",
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent.",
        "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]",
        "terseLabel": "Foreign Currency Translation Adjustment"
       }
      }
     },
     "localname": "AccumulatedTranslationAdjustmentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/OTHERBALANCESHEETDETAILSSummaryofChangesinAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r17"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r109",
      "r110",
      "r111",
      "r252",
      "r253",
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r243",
      "r244",
      "r257",
      "r258"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation expense related to equity-classified awards"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Non-cash adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r244",
      "r249",
      "r256"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/STOCKBASEDCOMPENSATIONSummaryofShareBasedCompensationExpensesIncludedOperatingCostsandExpenseDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r123"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Anti-dilutive securities excluded from computation of earnings per share (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/NETLOSSPERCOMMONSHARECommonShareEquivalentsExcludedfromCalculationofNetLossPerCommonShareDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r123"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/NETLOSSPERCOMMONSHARECommonShareEquivalentsExcludedfromCalculationofNetLossPerCommonShareDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/NETLOSSPERCOMMONSHARECommonShareEquivalentsExcludedfromCalculationofNetLossPerCommonShareDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r123"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/NETLOSSPERCOMMONSHARECommonShareEquivalentsExcludedfromCalculationofNetLossPerCommonShareDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Arrangements and Non-arrangement Transactions"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.alnylam.com/role/DEVELOPMENTDERIVATIVELIABILITYNarrativeDetails",
      "http://www.alnylam.com/role/LIABILITYRELATEDTOTHESALEOFFUTUREROYALTIESDetails",
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSAdditionalInformationDetail",
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSRevenuefromCollaboratorsDetail",
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofDeferredRevenueDetails",
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofResearchandDevelopmentExpensesIncurredbyTypethatareDirectlyAttributabletoCollaborationAgreementsDetail",
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofRevenueRecognizedbyAccountingGuidanceDetails",
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofTransactionPriceAllocatedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r102",
      "r142",
      "r145",
      "r151",
      "r177",
      "r274",
      "r278",
      "r310",
      "r366",
      "r384"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r5",
      "r6",
      "r46",
      "r102",
      "r177",
      "r274",
      "r278",
      "r310"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r296"
     ],
     "calculation": {
      "http://www.alnylam.com/role/FAIRVALUEMEASUREMENTSFairValueofAssetsMeasuredonaRecurringBasisDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total financial assets"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/FAIRVALUEMEASUREMENTSFairValueofAssetsMeasuredonaRecurringBasisDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "terseLabel": "Financial assets"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/FAIRVALUEMEASUREMENTSFairValueofAssetsMeasuredonaRecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r166"
     ],
     "calculation": {
      "http://www.alnylam.com/role/MARKETABLEDEBTSECURITIESSummaryofMarketableDebtSecuritiesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/MARKETABLEDEBTSECURITIESSummaryofMarketableDebtSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r167"
     ],
     "calculation": {
      "http://www.alnylam.com/role/MARKETABLEDEBTSECURITIESSummaryofMarketableDebtSecuritiesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/MARKETABLEDEBTSECURITIESSummaryofMarketableDebtSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r164",
      "r184"
     ],
     "calculation": {
      "http://www.alnylam.com/role/MARKETABLEDEBTSECURITIESSummaryofMarketableDebtSecuritiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/MARKETABLEDEBTSECURITIESSummaryofMarketableDebtSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r161",
      "r165",
      "r184",
      "r370"
     ],
     "calculation": {
      "http://www.alnylam.com/role/FAIRVALUEMEASUREMENTSFairValueofAssetsMeasuredonaRecurringBasisDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      },
      "http://www.alnylam.com/role/MARKETABLEDEBTSECURITIESSummaryofFairValueofMarketableDebtSecuritiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.alnylam.com/role/MARKETABLEDEBTSECURITIESSummaryofMarketableDebtSecuritiesDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Marketable debt securities",
        "totalLabel": "Total",
        "verboseLabel": "Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/FAIRVALUEMEASUREMENTSFairValueofAssetsMeasuredonaRecurringBasisDetail",
      "http://www.alnylam.com/role/MARKETABLEDEBTSECURITIESSummaryofFairValueofMarketableDebtSecuritiesDetail",
      "http://www.alnylam.com/role/MARKETABLEDEBTSECURITIESSummaryofMarketableDebtSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r163",
      "r184"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.alnylam.com/role/MARKETABLEDEBTSECURITIESSummaryofFairValueofMarketableDebtSecuritiesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-sale, Current",
        "terseLabel": "Marketable debt securities",
        "verboseLabel": "Marketable debt securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.alnylam.com/role/MARKETABLEDEBTSECURITIESSummaryofFairValueofMarketableDebtSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/OTHERBALANCESHEETDETAILSScheduleofInventoryDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r286",
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/OTHERBALANCESHEETDETAILSScheduleofInventoryDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BaseRateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum rate investor will accept.",
        "label": "Base Rate [Member]",
        "terseLabel": "Base Rate"
       }
      }
     },
     "localname": "BaseRateMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CREDITAGREEMENTAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "auth_ref": [
      "r1",
      "r108",
      "r136"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Business Description and Basis of Presentation [Text Block]",
        "terseLabel": "BASIS OF PRESENTATION AND PRINCIPLES OF CONSOLIDATION"
       }
      }
     },
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/BASISOFPRESENTATIONANDPRINCIPLESOFCONSOLIDATION"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r97",
      "r98",
      "r99"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Capital expenditures included in accounts payable and accrued expenses"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r2",
      "r28",
      "r96"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.alnylam.com/role/OTHERBALANCESHEETDETAILSScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.alnylam.com/role/OTHERBALANCESHEETDETAILSScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.alnylam.com/role/FAIRVALUEMEASUREMENTSFairValueofAssetsMeasuredonaRecurringBasisDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      },
      "http://www.alnylam.com/role/MARKETABLEDEBTSECURITIESSummaryofFairValueofMarketableDebtSecuritiesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash equivalents",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/FAIRVALUEMEASUREMENTSFairValueofAssetsMeasuredonaRecurringBasisDetail",
      "http://www.alnylam.com/role/MARKETABLEDEBTSECURITIESSummaryofFairValueofMarketableDebtSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "auth_ref": [
      "r91",
      "r96",
      "r100"
     ],
     "calculation": {
      "http://www.alnylam.com/role/OTHERBALANCESHEETDETAILSScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "periodEndLabel": "Cash, cash equivalents and restricted cash, end of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash, beginning of period",
        "totalLabel": "Total cash, cash equivalents, and restricted cash shown in the condensed consolidated statements of cash flows"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.alnylam.com/role/OTHERBALANCESHEETDETAILSScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r91",
      "r313"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net decrease in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Supplemental disclosure of noncash investing and financing activities:"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r269",
      "r270",
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "NET REVENUES FROM COLLABORATIONS"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementMember": {
     "auth_ref": [
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity.",
        "label": "Collaborative Arrangement [Member]",
        "terseLabel": "Collaborative Arrangement",
        "verboseLabel": "Net revenues from collaborations"
       }
      }
     },
     "localname": "CollaborativeArrangementMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.alnylam.com/role/DEVELOPMENTDERIVATIVELIABILITYNarrativeDetails",
      "http://www.alnylam.com/role/LIABILITYRELATEDTOTHESALEOFFUTUREROYALTIESDetails",
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSRevenuefromCollaboratorsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSAdditionalInformationDetail",
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSRevenuefromCollaboratorsDetail",
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofDeferredRevenueDetails",
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofResearchandDevelopmentExpensesIncurredbyTypethatareDirectlyAttributabletoCollaborationAgreementsDetail",
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofRevenueRecognizedbyAccountingGuidanceDetails",
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofTransactionPriceAllocatedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r38",
      "r194",
      "r371",
      "r391"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r191",
      "r192",
      "r193",
      "r196"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "COMMITMENTS AND CONTINGENCIES"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/COMMITMENTSANDCONTINGENCIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r109",
      "r110"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r15",
      "r201"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Balance (in shares)",
        "periodStartLabel": "Balance (in shares)",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r15"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.01 par value per share, 250,000 shares authorized; 117,321 shares issued and outstanding as of March\u00a031, 2021; 116,427 shares issued and outstanding as of December\u00a031, 2020"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r65",
      "r67",
      "r68",
      "r75",
      "r375",
      "r394"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]",
        "terseLabel": "Statements of Comprehensive Loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r101",
      "r276"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation and Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/BASISOFPRESENTATIONANDPRINCIPLESOFCONSOLIDATIONPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": {
     "auth_ref": [
      "r209"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.",
        "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]",
        "terseLabel": "Balance and Change in Receivables and Contract Liabilities Related to Collaboration Agreements"
       }
      }
     },
     "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r207",
      "r208",
      "r220"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "verboseLabel": "Contract liabilities included in \u201cDeferred revenue\u201d"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSBalanceofReceivablesandContractLiabilitiesRelatedtoCollaborationAgreementsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r207",
      "r208",
      "r220"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofDeferredRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r207",
      "r208",
      "r220"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "terseLabel": "Deferred revenue, net of current portion"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "auth_ref": [
      "r221"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "terseLabel": "Contract with customer liability revenue recognized"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r77",
      "r363"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 4.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of goods sold"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total operating costs and expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Costs and Expenses [Abstract]",
        "terseLabel": "Operating costs and expenses:"
       }
      }
     },
     "localname": "CostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CREDITAGREEMENTAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CREDITAGREEMENTAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r200"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "CREDIT AGREEMENT"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CREDITAGREEMENT"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r11",
      "r12",
      "r13",
      "r367",
      "r368",
      "r382"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CREDITAGREEMENTAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "Debt instrument, basis spread on variable rate"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CREDITAGREEMENTAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r324",
      "r326"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Aggregate Principal Amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CREDITAGREEMENTAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "auth_ref": [
      "r35",
      "r199",
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.",
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "terseLabel": "Interest rate floor"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CREDITAGREEMENTAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r35"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Cost of borrowing"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/DEVELOPMENTDERIVATIVELIABILITYNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r36"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CREDITAGREEMENTAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DepreciationAmortizationAndAccretionNet": {
     "auth_ref": [
      "r94"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate net amount of depreciation, amortization, and accretion recognized during an accounting period. As a noncash item, the net amount is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Depreciation, Amortization and Accretion, Net",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationAmortizationAndAccretionNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": {
     "auth_ref": [
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.",
        "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]",
        "terseLabel": "DEVELOPMENT DERIVATIVE LIABILITY"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/DEVELOPMENTDERIVATIVELIABILITY"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DerivativeLiabilities": {
     "auth_ref": [
      "r47",
      "r48",
      "r308"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Liability",
        "terseLabel": "Development derivative liability (Note 10)"
       }
      }
     },
     "localname": "DerivativeLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/FAIRVALUEMEASUREMENTSFairValueofAssetsMeasuredonaRecurringBasisDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivative [Line Items]",
        "terseLabel": "Derivative [Line Items]"
       }
      }
     },
     "localname": "DerivativeLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/DEVELOPMENTDERIVATIVELIABILITYDevelopmentDerivativeLiabilityActivityDetails",
      "http://www.alnylam.com/role/DEVELOPMENTDERIVATIVELIABILITYNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeMember": {
     "auth_ref": [
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents types of derivative financial instruments which are financial instruments or other contractual arrangements with all three of the following characteristics: (a) it has (1) one or more underlyings and (2) one or more notional amounts or payment provisions or both. Those terms determine the amount of the settlement or settlements, and, in some cases, whether or not a settlement is required; (b) it requires no initial net investment or an initial net investment that is smaller than would be required for other types of contracts that would be expected to have a similar response to changes in market factors; and (c) its terms require or permit net settlement, it can readily be settled net by a means outside the contract, or it provides for delivery of an asset that puts the recipient in a position not substantially different from net settlement. Notwithstanding the above characteristics, loan commitments that relate to the origination of mortgage loans that will be held for sale are accounted for as derivative instruments by the issuer of the loan commitment (that is, the potential lender).",
        "label": "Derivative [Member]",
        "terseLabel": "Derivative"
       }
      }
     },
     "localname": "DerivativeMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/DEVELOPMENTDERIVATIVELIABILITYDevelopmentDerivativeLiabilityActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeTable": {
     "auth_ref": [
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r288",
      "r289",
      "r290",
      "r291",
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.",
        "label": "Derivative [Table]",
        "terseLabel": "Derivative [Table]"
       }
      }
     },
     "localname": "DerivativeTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/DEVELOPMENTDERIVATIVELIABILITYDevelopmentDerivativeLiabilityActivityDetails",
      "http://www.alnylam.com/role/DEVELOPMENTDERIVATIVELIABILITYNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/NETPRODUCTREVENUESReceivablesDetail",
      "http://www.alnylam.com/role/NETPRODUCTREVENUESSummaryofNetProductRevenuesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r219",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/NETPRODUCTREVENUESReceivablesDetail",
      "http://www.alnylam.com/role/NETPRODUCTREVENUESSummaryofNetProductRevenuesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Summary of Net Product Revenues"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/NETPRODUCTREVENUESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "STOCK-BASED COMPENSATION"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/STOCKBASEDCOMPENSATION"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]",
        "terseLabel": "Disclosure of Compensation Related Costs, Share-based Payments [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r122"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic and Diluted",
        "terseLabel": "Net loss per common share - basic and diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r123",
      "r124",
      "r125",
      "r126"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "NET LOSS PER COMMON SHARE"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/NETLOSSPERCOMMONSHARE"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r313"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "terseLabel": "Effect of exchange rate changes on cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r247"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Options to purchase common stock"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/NETLOSSPERCOMMONSHARECommonShareEquivalentsExcludedfromCalculationofNetLossPerCommonShareDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r109",
      "r110",
      "r111",
      "r113",
      "r118",
      "r120",
      "r127",
      "r178",
      "r201",
      "r206",
      "r252",
      "r253",
      "r254",
      "r264",
      "r265",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r321",
      "r402",
      "r403",
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.alnylam.com/role/OTHERBALANCESHEETDETAILSSummaryofChangesinAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquitySecuritiesFvNi": {
     "auth_ref": [
      "r307"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.alnylam.com/role/FAIRVALUEMEASUREMENTSFairValueofAssetsMeasuredonaRecurringBasisDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI",
        "terseLabel": "Marketable equity securities",
        "verboseLabel": "Marketable equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNi",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.alnylam.com/role/FAIRVALUEMEASUREMENTSFairValueofAssetsMeasuredonaRecurringBasisDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiGainLoss": {
     "auth_ref": [
      "r176"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Gain (Loss)",
        "negatedLabel": "Realized and unrealized gain on marketable equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/FAIRVALUEMEASUREMENTSFairValueofAssetsMeasuredonaRecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r296",
      "r297",
      "r298",
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/FAIRVALUEMEASUREMENTSFairValueofAssetsMeasuredonaRecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "auth_ref": [
      "r301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of asset.",
        "label": "Asset Class [Domain]",
        "terseLabel": "Asset Class"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/FAIRVALUEMEASUREMENTSFairValueofAssetsMeasuredonaRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "auth_ref": [
      "r296",
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of asset.",
        "label": "Asset Class [Axis]",
        "terseLabel": "Asset Class"
       }
      }
     },
     "localname": "FairValueByAssetClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/FAIRVALUEMEASUREMENTSFairValueofAssetsMeasuredonaRecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByBalanceSheetGroupingTextBlock": {
     "auth_ref": [
      "r296",
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.",
        "label": "Fair Value, by Balance Sheet Grouping [Table Text Block]",
        "terseLabel": "Summary of Fair Value of Marketable Debt Securities"
       }
      }
     },
     "localname": "FairValueByBalanceSheetGroupingTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/MARKETABLEDEBTSECURITIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r297",
      "r335",
      "r336",
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/FAIRVALUEMEASUREMENTSFairValueofAssetsMeasuredonaRecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r296",
      "r297",
      "r299",
      "r300",
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/FAIRVALUEMEASUREMENTSFairValueofAssetsMeasuredonaRecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "FAIR VALUE MEASUREMENTS"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/FAIRVALUEMEASUREMENTS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r232",
      "r233",
      "r238",
      "r239",
      "r297",
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Quoted Prices in Active Markets (Level 1)"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/FAIRVALUEMEASUREMENTSFairValueofAssetsMeasuredonaRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r232",
      "r233",
      "r238",
      "r239",
      "r297",
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Significant Observable Inputs (Level 2)"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/FAIRVALUEMEASUREMENTSFairValueofAssetsMeasuredonaRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r297",
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Significant Unobservable Inputs (Level 3)"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/FAIRVALUEMEASUREMENTSFairValueofAssetsMeasuredonaRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/DEVELOPMENTDERIVATIVELIABILITYDevelopmentDerivativeLiabilityActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Fair Value, Measurement Frequency"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/FAIRVALUEMEASUREMENTSFairValueofAssetsMeasuredonaRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "auth_ref": [
      "r302"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings",
        "negatedTerseLabel": "Loss recorded from remeasurement of development derivative liability"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/DEVELOPMENTDERIVATIVELIABILITYDevelopmentDerivativeLiabilityActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues": {
     "auth_ref": [
      "r303"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances",
        "terseLabel": "Amount received under the Funding Agreement"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/DEVELOPMENTDERIVATIVELIABILITYDevelopmentDerivativeLiabilityActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "auth_ref": [
      "r301"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "periodEndLabel": "Development derivative liability, ending balance",
        "periodStartLabel": "Development derivative liability, beginning balance"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/DEVELOPMENTDERIVATIVELIABILITYDevelopmentDerivativeLiabilityActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r335",
      "r336",
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/FAIRVALUEMEASUREMENTSFairValueofAssetsMeasuredonaRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r304",
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/FAIRVALUEMEASUREMENTSFairValueofAssetsMeasuredonaRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r170",
      "r171",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r185",
      "r186",
      "r187",
      "r188",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/DEVELOPMENTDERIVATIVELIABILITYDevelopmentDerivativeLiabilityActivityDetails",
      "http://www.alnylam.com/role/MARKETABLEDEBTSECURITIESSummaryofMarketableDebtSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancingReceivableImpairedLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Financing Receivable, Impaired [Line Items]",
        "terseLabel": "Financing Receivable, Impaired [Line Items]"
       }
      }
     },
     "localname": "FinancingReceivableImpairedLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CREDITAGREEMENTAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r72",
      "r142",
      "r144",
      "r147",
      "r150",
      "r152",
      "r364",
      "r372",
      "r377",
      "r395"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r190"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/STOCKBASEDCOMPENSATIONSummaryofShareBasedCompensationExpensesIncludedOperatingCostsandExpenseDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/STOCKBASEDCOMPENSATIONSummaryofShareBasedCompensationExpensesIncludedOperatingCostsandExpenseDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r103",
      "r119",
      "r120",
      "r141",
      "r263",
      "r266",
      "r267",
      "r396"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedLabel": "Provision for income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r93"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accounts payable, accrued expenses and other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r93"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r93"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r93"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventory"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r93"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r70",
      "r140",
      "r322",
      "r325",
      "r376"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedTerseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryCurrentTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about inventory expected to be sold or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Current [Table]",
        "terseLabel": "Inventory, Current [Table]"
       }
      }
     },
     "localname": "InventoryCurrentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/OTHERBALANCESHEETDETAILSScheduleofInventoryDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryFinishedGoods": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://www.alnylam.com/role/OTHERBALANCESHEETDETAILSScheduleofInventoryDetail": {
       "order": 3.0,
       "parentTag": "alny_InventoryCurrentAndNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.",
        "label": "Inventory, Finished Goods, Gross",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoods",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/OTHERBALANCESHEETDETAILSScheduleofInventoryDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Inventory [Line Items]",
        "terseLabel": "Inventory [Line Items]"
       }
      }
     },
     "localname": "InventoryLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/OTHERBALANCESHEETDETAILSScheduleofInventoryDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r3",
      "r44"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNoncurrent": {
     "auth_ref": [
      "r45"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.",
        "label": "Inventory, Noncurrent",
        "terseLabel": "Long-term inventory"
       }
      }
     },
     "localname": "InventoryNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/OTHERBALANCESHEETDETAILSScheduleofInventoryDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryRawMaterials": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://www.alnylam.com/role/OTHERBALANCESHEETDETAILSScheduleofInventoryDetail": {
       "order": 1.0,
       "parentTag": "alny_InventoryCurrentAndNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Raw Materials, Gross",
        "terseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterials",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/OTHERBALANCESHEETDETAILSScheduleofInventoryDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcess": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://www.alnylam.com/role/OTHERBALANCESHEETDETAILSScheduleofInventoryDetail": {
       "order": 2.0,
       "parentTag": "alny_InventoryCurrentAndNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.",
        "label": "Inventory, Work in Process, Gross",
        "terseLabel": "Work in progress"
       }
      }
     },
     "localname": "InventoryWorkInProcess",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/OTHERBALANCESHEETDETAILSScheduleofInventoryDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r79",
      "r139"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentOwnedBalanceShares": {
     "auth_ref": [
      "r408",
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Balance held at close of period in number of shares.",
        "label": "Investment Owned, Balance, Shares",
        "terseLabel": "Shares of Vir common stock (in shares)"
       }
      }
     },
     "localname": "InvestmentOwnedBalanceShares",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]",
        "terseLabel": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r32",
      "r102",
      "r146",
      "r177",
      "r275",
      "r278",
      "r279",
      "r310"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r22",
      "r102",
      "r177",
      "r310",
      "r369",
      "r389"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r34",
      "r102",
      "r177",
      "r275",
      "r278",
      "r279",
      "r310"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Fair Value Disclosure [Abstract]",
        "terseLabel": "Financial liabilities"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/FAIRVALUEMEASUREMENTSFairValueofAssetsMeasuredonaRecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Line of Credit Facility [Abstract]",
        "terseLabel": "Line of Credit Facility [Abstract]"
       }
      }
     },
     "localname": "LineOfCreditFacilityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityCommitmentFeeAmount": {
     "auth_ref": [
      "r31"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the fee for available but unused credit capacity under the credit facility.",
        "label": "Line of Credit Facility, Commitment Fee Amount",
        "terseLabel": "Commitment fee amount"
       }
      }
     },
     "localname": "LineOfCreditFacilityCommitmentFeeAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CREDITAGREEMENTAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityCommitmentFeePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used.",
        "label": "Line of Credit Facility, Commitment Fee Percentage",
        "terseLabel": "Commitment fee percentage"
       }
      }
     },
     "localname": "LineOfCreditFacilityCommitmentFeePercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CREDITAGREEMENTAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r31"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Loan facility"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CREDITAGREEMENTAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.",
        "label": "Line of Credit [Member]",
        "terseLabel": "Line of Credit"
       }
      }
     },
     "localname": "LineOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CREDITAGREEMENTAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LondonInterbankOfferedRateLiborSwapRateMember": {
     "auth_ref": [
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fixed rate on single-currency, constant-notional interest rate swap that has its variable-rate leg referenced to London Interbank Offered Rate (LIBOR) with no additional spread on variable-rate leg.",
        "label": "London Interbank Offered Rate (LIBOR) Swap Rate [Member]",
        "terseLabel": "LIBOR"
       }
      }
     },
     "localname": "LondonInterbankOfferedRateLiborSwapRateMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CREDITAGREEMENTAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r13",
      "r198",
      "r368",
      "r385"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt",
        "terseLabel": "Long-term debt"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r36"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CREDITAGREEMENTAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r36",
      "r197"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CREDITAGREEMENTAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r232"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/FAIRVALUEMEASUREMENTSFairValueofAssetsMeasuredonaRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NatureOfOperations": {
     "auth_ref": [
      "r128",
      "r136"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.",
        "label": "Nature of Operations [Text Block]",
        "terseLabel": "NATURE OF BUSINESS"
       }
      }
     },
     "localname": "NatureOfOperations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/NATUREOFBUSINESS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r91"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r91"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r91",
      "r92",
      "r95"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r0",
      "r63",
      "r66",
      "r73",
      "r95",
      "r102",
      "r112",
      "r114",
      "r115",
      "r116",
      "r117",
      "r119",
      "r120",
      "r121",
      "r142",
      "r144",
      "r147",
      "r150",
      "r152",
      "r177",
      "r310",
      "r373",
      "r392"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other (expense) income"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other (expense) income:"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r142",
      "r144",
      "r147",
      "r150",
      "r152"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r328"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r328"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liability, net of current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r329",
      "r330"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "negatedLabel": "Operating lease liability"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r327"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAssetsMember": {
     "auth_ref": [
      "r286",
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other assets.",
        "label": "Other Assets [Member]",
        "terseLabel": "Other Assets"
       }
      }
     },
     "localname": "OtherAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/OTHERBALANCESHEETDETAILSScheduleofInventoryDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r52",
      "r59",
      "r311",
      "r312",
      "r314"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax",
        "terseLabel": "Foreign currency translation gains"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax": {
     "auth_ref": [
      "r61",
      "r69",
      "r315",
      "r317",
      "r321"
     ],
     "calculation": {
      "http://www.alnylam.com/role/OTHERBALANCESHEETDETAILSSummaryofChangesinAccumulatedOtherComprehensiveIncomeLossDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax, before reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), before Reclassifications, Net of Tax",
        "terseLabel": "Other comprehensive (loss) income before reclassifications"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/OTHERBALANCESHEETDETAILSSummaryofChangesinAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r64",
      "r67",
      "r69",
      "r74",
      "r201",
      "r315",
      "r320",
      "r321",
      "r374",
      "r393"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://www.alnylam.com/role/OTHERBALANCESHEETDETAILSSummaryofChangesinAccumulatedOtherComprehensiveIncomeLossDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Other comprehensive income (loss), net of tax",
        "totalLabel": "Total other comprehensive income"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.alnylam.com/role/OTHERBALANCESHEETDETAILSSummaryofChangesinAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "terseLabel": "Other comprehensive (loss) income:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax": {
     "auth_ref": [
      "r57",
      "r59"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax, before reclassification adjustment, of (increase) decrease in accumulated other comprehensive income of defined benefit plan, that has not been recognized in net periodic benefit cost (credit).",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, before Reclassification Adjustment, after Tax",
        "negatedLabel": "Defined benefit pension plans, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r53",
      "r59"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Unrealized (loss) gain on marketable securities"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other income, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherOperatingActivitiesCashFlowStatement": {
     "auth_ref": [],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example,  cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).",
        "label": "Other Operating Activities, Cash Flow Statement",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherOperatingActivitiesCashFlowStatement",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": {
     "auth_ref": [
      "r83",
      "r86",
      "r107"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash (inflow) outflow from investing activities classified as other.",
        "label": "Payments for (Proceeds from) Other Investing Activities",
        "negatedTerseLabel": "Other investing activities"
       }
      }
     },
     "localname": "PaymentsForProceedsFromOtherInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r82",
      "r84",
      "r162"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Payments to Acquire Debt Securities, Available-for-sale",
        "negatedLabel": "Purchases of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r85"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property, plant and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireRestrictedInvestments": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to acquire investments (not to include restricted cash) that are pledged or subject to withdrawal restrictions.",
        "label": "Payments to Acquire Restricted Investments",
        "negatedLabel": "Purchases of restricted investments"
       }
      }
     },
     "localname": "PaymentsToAcquireRestrictedInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r14"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.01 par value per share, 5,000 shares authorized and no shares issued and outstanding as of March\u00a031, 2021 and December\u00a031, 2020"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r5",
      "r26",
      "r27"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities": {
     "auth_ref": [
      "r89",
      "r90"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow provided by derivative instruments during the period, which are classified as financing activities, excluding those designated as hedging instruments.",
        "label": "Proceeds from Derivative Instrument, Financing Activities",
        "terseLabel": "Proceeds from development derivative"
       }
      }
     },
     "localname": "ProceedsFromDerivativeInstrumentFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": {
     "auth_ref": [
      "r87",
      "r251"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.",
        "label": "Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised",
        "terseLabel": "Proceeds from exercise of stock options and other types of equity, net"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromLinesOfCredit": {
     "auth_ref": [
      "r88",
      "r106"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.",
        "label": "Proceeds from Lines of Credit",
        "terseLabel": "Proceeds from lines of credit"
       }
      }
     },
     "localname": "ProceedsFromLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CREDITAGREEMENTAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.",
        "label": "Proceeds from Sale and Maturity of Marketable Securities",
        "terseLabel": "Sales and maturities of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfRestrictedInvestments": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the sale of investments that are pledged or subject to withdrawal restrictions during the period.",
        "label": "Proceeds from Sale of Restricted Investments",
        "terseLabel": "Proceeds from maturity of restricted investments"
       }
      }
     },
     "localname": "ProceedsFromSaleOfRestrictedInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]",
        "terseLabel": "Net product revenues"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.alnylam.com/role/NETPRODUCTREVENUESReceivablesDetail",
      "http://www.alnylam.com/role/NETPRODUCTREVENUESSummaryofNetProductRevenuesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r9",
      "r10",
      "r189",
      "r390"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property, plant and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax": {
     "auth_ref": [
      "r61",
      "r62",
      "r69",
      "r315",
      "r319",
      "r321"
     ],
     "calculation": {
      "http://www.alnylam.com/role/OTHERBALANCESHEETDETAILSSummaryofChangesinAccumulatedOtherComprehensiveIncomeLossDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss).",
        "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax",
        "negatedLabel": "Amounts reclassified from other comprehensive income"
       }
      }
     },
     "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/OTHERBALANCESHEETDETAILSSummaryofChangesinAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": {
     "auth_ref": [
      "r261",
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by form of arrangement related to research and development.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": {
     "auth_ref": [
      "r261",
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r260",
      "r420"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development",
        "verboseLabel": "Total research and development expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofResearchandDevelopmentExpensesIncurredbyTypethatareDirectlyAttributabletoCollaborationAgreementsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/STOCKBASEDCOMPENSATIONSummaryofShareBasedCompensationExpensesIncludedOperatingCostsandExpenseDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCash": {
     "auth_ref": [
      "r100",
      "r365",
      "r386"
     ],
     "calculation": {
      "http://www.alnylam.com/role/OTHERBALANCESHEETDETAILSScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash",
        "terseLabel": "Total restricted cash included in prepaid expenses, other current assets and long-term other assets"
       }
      }
     },
     "localname": "RestrictedCash",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/OTHERBALANCESHEETDETAILSScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalents": {
     "auth_ref": [
      "r8",
      "r96",
      "r100",
      "r365",
      "r386"
     ],
     "calculation": {
      "http://www.alnylam.com/role/FAIRVALUEMEASUREMENTSFairValueofAssetsMeasuredonaRecurringBasisDetail": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents",
        "terseLabel": "Restricted cash (money market funds)"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/FAIRVALUEMEASUREMENTSFairValueofAssetsMeasuredonaRecurringBasisDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedInvestmentsNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the noncurrent portion of investments which are not defined as or included in marketable (debt, equity, or other) securities that are pledged or subject to withdrawal restrictions.",
        "label": "Restricted Investments, Noncurrent",
        "terseLabel": "Restricted investments"
       }
      }
     },
     "localname": "RestrictedInvestmentsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r123"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "terseLabel": "Unvested restricted common stock"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/NETLOSSPERCOMMONSHARECommonShareEquivalentsExcludedfromCalculationofNetLossPerCommonShareDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r18",
      "r206",
      "r255",
      "r388",
      "r405",
      "r407"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r109",
      "r110",
      "r111",
      "r113",
      "r118",
      "r120",
      "r178",
      "r252",
      "r253",
      "r254",
      "r264",
      "r265",
      "r402",
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer": {
     "auth_ref": [
      "r268",
      "r271"
     ],
     "calculation": {
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofRevenueRecognizedbyAccountingGuidanceDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606.",
        "label": "Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer",
        "terseLabel": "Revenue recognized under ASC 808"
       }
      }
     },
     "localname": "RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofRevenueRecognizedbyAccountingGuidanceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]",
        "terseLabel": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r137",
      "r138",
      "r143",
      "r148",
      "r149",
      "r153",
      "r154",
      "r156",
      "r218",
      "r219",
      "r363"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      },
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofRevenueRecognizedbyAccountingGuidanceDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Total revenues",
        "verboseLabel": "Revenue recognized under ASC 606"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.alnylam.com/role/NETPRODUCTREVENUESSummaryofNetProductRevenuesDetail",
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSRevenuefromCollaboratorsDetail",
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofRevenueRecognizedbyAccountingGuidanceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r216",
      "r217",
      "r222",
      "r230"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "NET PRODUCT REVENUES"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/NETPRODUCTREVENUES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "auth_ref": [
      "r215"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.",
        "label": "Revenue, Remaining Performance Obligation, Amount",
        "terseLabel": "Transactional price remaining performance obligation"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r71",
      "r102",
      "r137",
      "r138",
      "r143",
      "r148",
      "r149",
      "r153",
      "r154",
      "r156",
      "r177",
      "r310",
      "r377"
     ],
     "calculation": {
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofRevenueRecognizedbyAccountingGuidanceDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "totalLabel": "Revenues"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofRevenueRecognizedbyAccountingGuidanceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenues:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": {
     "auth_ref": [
      "r40"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.",
        "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]",
        "terseLabel": "Schedule of Receivables Related to Net Product Revenues"
       }
      }
     },
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/NETPRODUCTREVENUESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r61",
      "r320",
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).",
        "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "terseLabel": "Summary of Changes in Accumulated Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/OTHERBALANCESHEETDETAILSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r123"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/NETLOSSPERCOMMONSHARECommonShareEquivalentsExcludedfromCalculationofNetLossPerCommonShareDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r123"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Common Share Equivalents Excluded from the Calculation of Net Loss Per Common Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/NETLOSSPERCOMMONSHARETables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-sale [Line Items]",
        "terseLabel": "Schedule of Available-for-sale Securities [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/MARKETABLEDEBTSECURITIESSummaryofMarketableDebtSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.",
        "label": "Schedule of Available-for-sale Securities Reconciliation [Table Text Block]",
        "terseLabel": "Summary of Marketable Debt Securities"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/MARKETABLEDEBTSECURITIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesTable": {
     "auth_ref": [
      "r168",
      "r169",
      "r172",
      "r173",
      "r174",
      "r175",
      "r379",
      "r380"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.",
        "label": "Schedule of Available-for-sale Securities [Table]",
        "terseLabel": "Schedule of Available-for-sale Securities [Table]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/MARKETABLEDEBTSECURITIESSummaryofMarketableDebtSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSAdditionalInformationDetail",
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSRevenuefromCollaboratorsDetail",
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofDeferredRevenueDetails",
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofResearchandDevelopmentExpensesIncurredbyTypethatareDirectlyAttributabletoCollaborationAgreementsDetail",
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofRevenueRecognizedbyAccountingGuidanceDetails",
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofTransactionPriceAllocatedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock": {
     "auth_ref": [
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block]",
        "terseLabel": "Schedule of Revenue from Collaborators"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {
     "auth_ref": [
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.",
        "label": "Share-based Payment Arrangement, Cost by Plan [Table Text Block]",
        "terseLabel": "Schedule of Stock Based Compensation"
       }
      }
     },
     "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/STOCKBASEDCOMPENSATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDebtInstrumentsTextBlock": {
     "auth_ref": [
      "r36",
      "r105",
      "r202",
      "r203",
      "r204",
      "r205",
      "r323",
      "r324",
      "r326",
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table Text Block]",
        "terseLabel": "Schedule of Term Loan"
       }
      }
     },
     "localname": "ScheduleOfDebtInstrumentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CREDITAGREEMENTTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of derivative liabilities at fair value.",
        "label": "Schedule of Derivative Liabilities at Fair Value [Table Text Block]",
        "terseLabel": "Development Derivative Liability Activity"
       }
      }
     },
     "localname": "ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/DEVELOPMENTDERIVATIVELIABILITYTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r296",
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of Fair Value of Assets Measured on a Recurring Basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/FAIRVALUEMEASUREMENTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfImpairedFinancingReceivableTable": {
     "auth_ref": [
      "r159"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of the recorded investment, unpaid principal balance, associated allowance, average recorded investment, accounting policies, and interest income recognized on the accrual and cash basis for impaired financing receivables by class of financing receivable.",
        "label": "Schedule of Impaired Financing Receivable [Table]",
        "terseLabel": "Schedule of Impaired Financing Receivable [Table]"
       }
      }
     },
     "localname": "ScheduleOfImpairedFinancingReceivableTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CREDITAGREEMENTAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r7",
      "r23",
      "r24",
      "r25"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Schedule of Inventory"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/OTHERBALANCESHEETDETAILSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r245",
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/STOCKBASEDCOMPENSATIONSummaryofShareBasedCompensationExpensesIncludedOperatingCostsandExpenseDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SecuredDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collateralized debt obligation backed by, for example, but not limited to, pledge, mortgage or other lien on the entity's assets.",
        "label": "Secured Debt [Member]",
        "terseLabel": "Secured Debt"
       }
      }
     },
     "localname": "SecuredDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CREDITAGREEMENTAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, General and Administrative Expenses [Member]",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/STOCKBASEDCOMPENSATIONSummaryofShareBasedCompensationExpensesIncludedOperatingCostsandExpenseDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r93"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/STOCKBASEDCOMPENSATIONSummaryofShareBasedCompensationExpensesIncludedOperatingCostsandExpenseDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r39",
      "r109",
      "r110",
      "r111",
      "r113",
      "r118",
      "r120",
      "r127",
      "r178",
      "r201",
      "r206",
      "r252",
      "r253",
      "r254",
      "r264",
      "r265",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r321",
      "r402",
      "r403",
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.alnylam.com/role/OTHERBALANCESHEETDETAILSSummaryofChangesinAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r109",
      "r110",
      "r111",
      "r127",
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-based Payment Arrangement, before Forfeiture",
        "terseLabel": "Issuance of common stock under equity plans (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensationGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r14",
      "r15",
      "r201",
      "r206",
      "r246"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "terseLabel": "Exercise of common stock options, net of tax withholdings (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-based Payment Arrangement, before Forfeiture",
        "terseLabel": "Issuance of common stock under equity plans"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensationGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r39",
      "r201",
      "r206"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Exercise of common stock options, net of tax withholdings"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r15",
      "r20",
      "r21",
      "r102",
      "r160",
      "r177",
      "r310"
     ],
     "calculation": {
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.alnylam.com/role/OTHERBALANCESHEETDETAILSSummaryofChangesinAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "auth_ref": [
      "r50"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.",
        "label": "Supplemental Balance Sheet Disclosures [Text Block]",
        "terseLabel": "OTHER BALANCE SHEET DETAILS"
       }
      }
     },
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/OTHERBALANCESHEETDETAILS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r170",
      "r171",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/DEVELOPMENTDERIVATIVELIABILITYDevelopmentDerivativeLiabilityActivityDetails",
      "http://www.alnylam.com/role/MARKETABLEDEBTSECURITIESSummaryofMarketableDebtSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Type of Arrangement and Non-arrangement Transactions"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.alnylam.com/role/DEVELOPMENTDERIVATIVELIABILITYNarrativeDetails",
      "http://www.alnylam.com/role/LIABILITYRELATEDTOTHESALEOFFUTUREROYALTIESDetails",
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSAdditionalInformationDetail",
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSRevenuefromCollaboratorsDetail",
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofDeferredRevenueDetails",
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofResearchandDevelopmentExpensesIncurredbyTypethatareDirectlyAttributabletoCollaborationAgreementsDetail",
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofRevenueRecognizedbyAccountingGuidanceDetails",
      "http://www.alnylam.com/role/NETREVENUESFROMCOLLABORATIONSScheduleofTransactionPriceAllocatedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember": {
     "auth_ref": [
      "r232",
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debentures, bonds and other debt securities issued by US government sponsored entities (GSEs), for example, but not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB). Excludes debt issued by the Government National Mortgage Association (GNMA or Ginnie Mae).",
        "label": "US Government-sponsored Enterprises Debt Securities [Member]",
        "terseLabel": "U.S. government-sponsored enterprise securities"
       }
      }
     },
     "localname": "USGovernmentSponsoredEnterprisesDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/FAIRVALUEMEASUREMENTSFairValueofAssetsMeasuredonaRecurringBasisDetail",
      "http://www.alnylam.com/role/MARKETABLEDEBTSECURITIESSummaryofMarketableDebtSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "auth_ref": [
      "r232",
      "r239",
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).",
        "label": "US Treasury Securities [Member]",
        "terseLabel": "U.S. treasury securities"
       }
      }
     },
     "localname": "USTreasurySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/FAIRVALUEMEASUREMENTSFairValueofAssetsMeasuredonaRecurringBasisDetail",
      "http://www.alnylam.com/role/MARKETABLEDEBTSECURITIESSummaryofMarketableDebtSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r129",
      "r130",
      "r131",
      "r132",
      "r133",
      "r134",
      "r135"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/BASISOFPRESENTATIONANDPRINCIPLESOFCONSOLIDATIONPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]",
        "terseLabel": "Variable Rate"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CREDITAGREEMENTAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]",
        "terseLabel": "Variable Rate"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CREDITAGREEMENTAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted",
        "terseLabel": "Weighted-average common shares used to compute basic and diluted net loss per common share (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.alnylam.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 8
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(e),(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4428-111522"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4531-111522"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5212-111524"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26610-111562"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26853-111562"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26626-111562"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27198-111563"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27232-111563"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=SL120269820-111563"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27290-111563"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27337-111563"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27340-111563"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27357-111563"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=120269885&loc=SL75117546-209714"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919244-210447"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919253-210447"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919258-210447"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919230-210447"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121558606&loc=SL82898722-210454"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922888-210455"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922895-210455"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922900-210455"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6036836-161870"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130531-203044"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130532-203044"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130551-203045"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130558-203045"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130550-203045"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11149-113907"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11178-113907"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=118644919&loc=SL5834089-161433"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "http://asc.fasb.org/topic&trid=5833765"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "83",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121636179&loc=d3e34841-113949"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5579240-113959"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5579245-113959"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5580258-113959"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41620-113959"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41638-113959"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624171-113959"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41641-113959"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41678-113959"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "182",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121582272&loc=SL5629052-113961"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121607252&loc=SL5864739-113975"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "25",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "815",
   "URI": "http://asc.fasb.org/topic&trid=2229140"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=99377092&loc=SL75136599-209740"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13433-108611"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13467-108611"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=120253306&loc=d3e28129-110885"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=121605123&loc=d3e30304-110892"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32022-110900"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28541-108399"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28555-108399"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62557-112803"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62557-112803"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62586-112803"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(5))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3,4)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(c)",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=99383244&loc=d3e12121-115841"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r421": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r422": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r423": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r424": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r425": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r426": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(d))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "210",
   "URI": "http://asc.fasb.org/topic&trid=2122208"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a),(b),(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a-c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(i),(j),(k)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(i-k)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e681-108580"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669686-108580"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724394-108580"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e557-108580"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121640130&loc=d3e1436-108581"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3151-108585"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3505-108585"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4304-108586"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4313-108586"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4332-108586"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>72
<FILENAME>0001178670-21-000017-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001178670-21-000017-xbrl.zip
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M?75NO9>&*AE6T+H3M/;2.Z\*OS?->=X;]5:@?1C01F(CL\CA2!$#SUYS%;A
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MT*WK5-\%T=J.]1WWM0UNM^@?#D/92SLY.A>GX?H;J]T#2:K;!X<4:V!T#R+
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MV_S\]J+]_F8FPFD2XI^@[=Z'S@8]Z&R@9L?!WW_E,$;>^GP(AN2[SZVM'7Z
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MLC^L?*NDW-^M[Z]_S2 :%LG'J6,>ICP)PR<'R#G%W97.K^F2I7<EH;9V*;#
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MY;II%\1YQ9@.O,4J+Z$H+R/Z$__@4MQ.[5ZZMBEA6MS7 8^IBS=W:PU&]K0
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M%L038"BA@(K@C8/.""&3#K,FQ*I&.KQ"7>QN5[^#LGU^YW/CS.N^+X<'@FX
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ML-*#J]UQ4=E? E4\Y',0@[>]425(/^V(9N._?@9\;WWO\$3W_%Q(_%[KU8\
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MRA#P+! P(5R<.X0<T@ )%Q5?&@4T"PPHB$W  GK$T<9FQ.\F8C>[<"P+!*P
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M^[Q0Q4)9>WE^>98LS&)UBI!ZN4Y5OUOQFWLV5US'94M% +8]R*LSR;,KUJ7
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M2D<;;&)5D\D7CT3->_=-RFBTU&B4)_$L&QI=C]'(8N^1TQ@PQ *@DD.@(<2
M<,D8]5&(3N<Y/(LE<]T.L(GH:W=ZV1\4$8?&H-OH^:AUMGWF&YTAW4N_3=\7
M5U^FT$6[,W^;H"ZT_RF9?7G:X!>8U7AC[/B+N ?:A1._H3NNH<^[\<FNBU^L
MUP#BQ7+E>Q]*50EM582SU7%;UO9\^CX>7/FX>L!Q-6Z-GXXK:CEESB" *">
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M3RR!!E 7=!G0,Y)S(+&""IF  @T1MDB3LYL<)#MD5D'!GY=^9 5_"@6?\)*
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M0CS ,.N#(U)-AYL./_0./_[<ALM\_DUNPUK;"E>$,QL:<5L:L9* :1DA@IF
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M'-O^G[!$)_ -^#T/I#>8QE#?;MLD4M\, +L[VZL<*5CCG$0R<(HXR_3(18$
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M"CM-98&*]9K;+U3<]VI_\_VSO1)D\*@'FTZU(Q0>D 6Q@$;>=$?PC@JB,ZF
M?TY \0&*8,O,.CO;*-N9*AQ'F]-!2AE(T,A/I3QD4=W>5UMM0/!)QODZW1J4
M0 "Z9>A;K]5I)/]>)?]7"GX!7=L[KDAK'R9Q5$EY%8W+LCVJO*8!-K!8909F
MEE2*4AS'T/-Y7UWF6]G-FN,[1;1/AZ-^F-.)RPE<>_;FO+O%+S4]RR1N[GF%
MC;-T*!.XW)4PZGTN/&<T3##5#C;?R=G5OIP'LR%NE_N].IF65+8'(^W%YEA8
MSY5!V9K2WTER_E[W^4I %L;C<U 6EC.,XV#F%K  #+^!->KB:#]U"L;%\++J
MQR(?%#\Q'\$^O*/[L?.U^W7O2W>G<[K_UP=M</ V$90P,]5%5([!3U))+RC\
M:ES8V$JPUUR(IK;J=<VD'$R<(@/ '",H3*CWE4(\3W+9X6S)]69IN^LK*B\K
M+M_(RGE9^=(]_<"I]))3BRR6$7%'%'+6<>2)],DDI;GB&UO#0;Q$5&;SVIK;
M]QDMOR4'AR-[_,ODX%GM,WA9]6.\-W@!-.SU!&RA1B1JD3CK_O6!F<1,P!Q)
MQAWBDD?DLL^1<RXIMU0*3H'$]KY<% E@1A$X"<SH+!GYT-;;:[WZX]J)5+FN
M3BTLUY(C9=F:+U\L]G?)MBG&>NT]B#.)6_@0RIU(^]V7VP<'K_9G+HTWFZ\W
MVZW=:;:%VZW_VKS'9A&%C\?PQ1R4S7D@=0]+#NRHER.W8]@ P;*W=;M_[OW]
M8GO[U5[Y\O[_>_&FL_**RCM5-[AH!9ZH7GV.*OSKG._T1C$!=5E,8#DP+BZE
M'+\H\D+O/4;P1^UJV8EC/^H5+K<]"'_8<6\,R)^]+H-)F>4#>.L?_:'_]*L5
M_&RFX.]..P=_?>D<O^]WWC[_^ X4_/W'/X[@V=/.VSWR_NT[L;\#ROOQD%U0
M\(_;H*R[9^^/WWQY][;;Z_[YZKCSYR[T8?O+NX]_]]]__,2A+W1_)X"";Y,.
MX+R 298.(#[:7++3! 0(*Q'C)A C#)/.G(\A")ZD,1X'31P7B>M(69")A&!H
M=,2=CR'\L?UZ[W4.(;Q\M?MZMWNP?;"WWVUM=W?@#WO=9WLO7^R6CQ<11?C\
M!\(,W^_7N5A(C,9I&05AFDNF-:&:\AB5H$D1RN:YA_<EI,_F&1[YPD7XR9\]
M97'L;G]PB3$L@T>&Y2-(AC)D5<3(8)LBUR%1+LZ+UX.TL2[D!MT@[R=;9S-O
M2#:+I[,P=MEP"C=W,0ZRJ0Q<;'&48Q2*Z5K%3ZJC'97Y"F2]=]*'P57[:'%@
M^VP!5]\M^]F@O.!U[D35@:(2MD2'_MS>?MG.Y!\DN)C58,>7$!*8]-7Q_7+$
MOSUK++OIL]9",PN?\\QFB,5Y/L@<KE\7!L@;?3$O0E[%:@Z*'9)'/P S9#RV
MH[/\UC))K61[V9^;7P5(/^U74[846<N.@NK3D^$HCZONY69KO\2NKK\49;9+
MI&]URG-$*,?4>N-SD8'<9&^<B4U9B(H;CX^&TWZ )J!'MLPY//9Q.JB8<O5<
M=@'.UOG[_9J-\"S:47;MP7,[,%&9\:[8]'CF;#P%QKYR^">_;WLPR$&#5V6:
M\IB>P[*T"$;_MYK_T\R$>GWX0A&J_,+7>;7*H;(RLEG9M]:S'#0<C\NR0SO1
MC:9YS4CM6MAL'=2]1;&$;RY= F?[183'1S&7);436[I0[KG,,Y%)V?(\73HU
M;IJ/?T'_!L/)BLPM3L^-81UR4*7RFV;QKOJW+$TY>+LJ43DXN2KVE8#":V9"
M"D"2XTR@)L6K567]7:/981VA6FD\!S'SYZTT[6<_5395RA0^ A_4K?!Q%%..
M=]58LXBG+\'FH KNG!X-02G1\'10A_!ZH6<S2]^$1_O5A,_BSO/3<"4XEMV3
ME7DS7H+<V.\=0X^@9X]@#3(6YB*2O03RFH."2WM&)BN].IDU%([M*MCH@M'6
MHC/)[I:,5P#F9\N+]GR^:*\7BW8#[+DVN%UB82U3ROME=V_&<3_MCJL(]2]/
M4?KY?([F.I62>!\\15Q)GD^9^5R*PR";=,!&\B!UN!6?NS_5N#*$<GG:&ZQV
M%OKY>C]\]<\07/&9RL:"T5V*MA5;R4ZWWJ3.SLD[YFP+'2_G%0 2'-M/,2>2
M5--4)=Z,Q]/CZG+YFM=5M[FL4#1[7*$O= .>CS4.]WM5W&7&-_)75D_!5S;?
M8<EJN.)[U9LR-LUPZR:[S>RUE_5T[H>J4S+*B>E6J-(Z%E\JD%HV]<W6WJ!.
MH+IV#TI89CK^UJR6X&25L)4;STZXP60(_.NS[4\7"4RSQ[)_9/0YY^7,YNEL
MN8G<\;&MDK#K-*K1\,SV)R65Y_(;R!<M%:(_/ 8KP7Z))0.ES%'F^4/8;*I@
MW#SSJ@3:EEJ<36)-G"=@*J,J=RWOT_#1PC^8_UREX,SG!<9Y!.Q[."IY+;FM
M4<E%J@C! *8#%F$ZKOG6!;D\S=M\OP?=*>D\A:Z/AR64"(2ARK"9D3E?*'WH
M@2B/*F8Z.1HN+](C8 @9(@KYA.[4ZEU9$UE"GNW_O;>#B&GE1*1X##OL::^P
M;%CH.L,J4^'ZMRH_KBS7+$VJ?87UME3%HCA6!Z$6FD70*4LG?'\A+#.)KC2C
MWQ^>EH2U=B7+N8;&V8Q^ST-=5;BY<BC[G$R551"^,D\RG(R@ _/J=9?+JQ^.
MBX:6H9?\LBQGM=8L/;ADT1[!#$-WP/R+HQRI7AY8R?ZLIJ64^(!U[ WJ,'E.
M",EM'-NS%B##Z+#@&#12TO[FRY%[F.7<5B\%NV]8)W>57,Z:TTX IDN"2<9/
MFSE9CLGG_,;>)/_\&=A@8;HM>P@?C_/?V\L>\I)3 E\>YI6?K>Z@U1_Z'!\<
MQ</B76\#::K][)4''@CW_"\>I!V 8C2N<QASF'$I]>[8AF7,JZ%[]JJT&''>
MDVI6^2T$'\4R=6YQ:UC!NA6ES;M=O7ASG\$YQ<]MK*I]_(;:7W!S7AH%>,KG
MNLC5Y[J:(UK-$:WFB-93/*+UK=,FORJL4[(*7O3 ZH$>GU7QG":JT_WK@V&$
M">L(@K7(D48*/^%(D(HB$FNI5BD]#B_ ?/4?/K?_8W8@J%BC5:K%C(5G<[5O
MJ\,K<X,H4\_R[-4UGBL*5S:'\5*<X.I\P\GP,!93;!Y?*.W":S.U]\7BF"=_
M%+8U(^S% J@.B>0];&44\_,J)2(U2_68&<>+TQZ+4GDPZ7WKZEVQZDRV??[H
M6_\)..H@MDI9RNKD5SE_4E'W/+!>'GS*1S,J\Z&8 BY;'?!'WZOMIE@EI$X+
MZ:P/5#7G#YY:%O9:G#^HHDJ3?(YK7+G&!@!)+4);Q]#&T7ANULS.&Q7+JS=N
M_36U(^ *8+M>]-K_]4-VS_6RGSC^7O:37J?L)W;OV4^O*I?:<UBGS,!S'EX^
MT?&LMJ?7A([@SKPDU=^][M=/8O_/-U^[!_\]>K_S%WE_ .\Y>"/V#_X^[KS]
MB[Y[^]_C[G'GZWDZ\O[M'ML_^,3?'W1(+C75W?F[WSDX.NH>?!+=M^^^O-]Y
M?_3N^!U]][6;.@=>?""*V*A,OC1&>\0)]<@&R5#$ N0L>2ZB/9\II 4QU&@F
M711<V.@$%LS!?Z7Q+(4+Y*6[>]!Z^6I_Y\VS@]:KW;]WNV]V?^3<]'=?>]\A
MK)W>V!X>CF*5K;F?:KDJYMW3%:+#LP\1<ZY5U(CIE-/FE$,PSPDI'E,2C 4G
MU$//4Z*SZU\O)-76.2PSCUL:9G]J+IOV/=9;NZ'RD)?1.;MBZLIK*%=6O(#7
M<QNTYHXSIU8IZ5NXV<DX_C;[X?=9S;#>H RH?.F2JKNU^T?3389-]@#5-=#J
MYFOGT&9Q#ITK(%=])O0FYNK*C_$FN?*S;S5+]*915W_U6\U^^S-!KG[IK3I+
MK]OLPRDO=W4]O.]6HS87'KVD@F@ETC^GT*:^5B7Q@Z-1C*U.1?%V<U9%*5-3
M[+(6F&37J!'^4^;]EY9CO=Y4_F,OAV*&4V@BC"]<MWE9!=OKWE>^WB*4><2=
MC/8ZE=X?S93A>]>L7Z"M=U4=_W[6YON66EF<V<&A'[H>X7LW7-SN6H/KWJ3]
MLWKX" 3T&W?ZJ;41U,N+9*^DY]_F$L-?7.W\FL.]?KGSRX;XB\J=7W-L-ZAW
MSBVU7A$JB=4\:F59$,)@*Y7Q0F!UEW<R?,>EM/NESE#9'H\C_"\<V"_K4OK\
M1UT$5>GSX_\>OW_[7WC/MN@<[Y)W!W]][7SL]CH4^OAV#[\["!\[7Z&]/]]?
M*'W^[OA]_QV,J;/SZ:R46-_I0)]@'#OOR+N/KXZZM /]Z.#WQ_]-\[+GK_'I
M!Q4)K*"*B#/F$.>$(6L]1RIAK(2.CFN;;S=N<T76Z";3.[K6I\&K1XI7#!L6
MO79*,,>%B"YBP9B0PAKE;4IW>3]#@U?WCE=?YW@EHC))"8D"SJ>(O:3("@:_
M2H=YQ#28*#>VF&H3L_Z7L3\")ON-VRS6G<E6I1&N-+B^==_]=2_O>= 8&K$B
M*5!0 44X"<K@:'PDH'V1V2!-P_D>#H9VGRUQ/B:X@?4CB%L?$)>:(X?S(7C'
ML7?*4.T#<#[<EN*N+M]<HQNY&@6?7\B;A"$Q2<ZPXLX)8RDS7/OH"# F)QN2
M]* 4?$&2'";:$<P1+&R^ECS*7#\IH. =_%E3ESS9V**D3>2M2=*]*_@C($D/
MV-V7;\O.T?>WI;#E/TY&H-REMD"I975UP.E;X'I=X_I!@RN.& LI8Y2&<DF]
M-4F*I(),U@H5&_;TD,#U]1)[LEAS@@5%QBN!. -;U(K*#-6!)*-3+I%&2%M3
MM?86Z(]?A/WD%9QCY1AU"D?%N#3>.$>U5%Y%[06SKF%/#TK!%^R)).]L\AS1
M:,%&$M@CK5U"1%E)$E:!4K.QI=L,T[77[T= GKY!, E;<_9T,)S8_DVI]/72
M31Y;..)F@W\TNXAA6FH-O- 8RZ-R1GE"5? D6&XM%PU-?$"[2&^))A(5:1+!
MHQ2%@EV$)P2$T"//I1=684\ISE>)DK81MXZLWDAY?K'_K8&_!OX6+DBFH8T
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MDIO75\MS/G,R$D='$O?&9=7&PG"I@S*&Q88K/1P%/UM1<&T%CX1+)&(DP)5
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M",=V=-@;5'VAJV#V<3J>]-)9]:?>(( T_D9T =J?K+9$Y*#_46R-:AUIV4$
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MTT/ TB*1CP"(WT /:NH":S\N:'*U[E>* Q-R.AQ]*NOX!59T#*H(:W .C9>
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M>F=5F.RJ=P%].KKHERW=/K*?8^E&;>B#)I0.>7BV%_)P*F8\<P)D,*UC"%6
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M@I/I))]>A?UU^;QJ21G,OQY'?V0'O?%Q.3H;XO%@Z6ALM<;9LAF7XS<>D!T
M>50%*TM4K]J%ZE!;#\3>YMC+(]@VGI<C(I<IZWCJQO%_I]69H.4C7>WE:&,=
MJ*G/U<*3+EZ(_I3HU.ER?.?B8>[>Y=[>[P>-:IQ:E<K:95][ZU>[>I+Q8K@T
MAA+[JKPSYU[WK[(?GG_C)1Z?22Y77])8?G;J^?6IZNI^NF"E%[R(3YBF_B6Z
ML+=ZZ:0 BP$%[$.UMUKI!4I@A5+/F1#9\4S$-WGJO#K!I9)Y;D-+\,SP=.:<
M2;W1>+(<U,R1IYF@VUPHP)=\U4M;KOU 5^8_S96AE_'U?Z>]^OS.L?T4YWH
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M=?4T[](1WG.S<2LR$/+.$NJSS;E;@ 2ET_4T E\= A3."U64<JRYZ/Q\)[\
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MX^2$XSYQPJPE+@2O0C3!:TY503E,:(MR*X5R=()R/%DB$J?(,R,1#XHA[8A
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M>7BE>#AY[U0PH) JSY4T6GG-K-?"$R.8(ZVUM9(\/+6V#-4,_E,H1:,1-TJ
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M7V<!:>T>TM9N5M9: KN8P#S>?OU1<>6X2P)AXT%(,J:1M4$@%DCP*I$4M 9
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MOE]<6GBGS/<FCL;#KA]'6&J^S."WPS-MBBYS.TWKW5SE/D730UY<4-V"W)5
M;GO6&1 <5IJ!6N*R?Y,;,"8,M;D8@6'0,!-/TN0X!=<W-BC:&,7J<O$OZ$_4
M<O&2N7C&+R CX<09B0*W%E05L#6TQ0HIZW'"0,#2NY:+'SP7WVY?HI:!E\W
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M"DU.BZ+#<3DJ_$GU5=&WK@_(EP=A^<AP2P4Z[0]<Y#$%^ >20BCQ,!@/(YC
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M311"@;Q[M[''@H(75M"VI8;F8%+-EMYKIZ&F$,<]K<YR _]-C+Y4@<FG86U
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M;%C98B5R1\$$%QE/DTQ:')MV61Q[ V9X([*?))>+N5,4P="=2%A.!>%<6;#
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MX"H,<P/E03LC0>P8Z^WC(RD5P!R;_6CM:%ATP^'_2G3LHM"4&/ %T&H0J<C
MYV(4J?VA"VBS$@V&T=OJR[79EY,5GY_#A2$<CS4Y0.O^?C0N5R(#4E(54\@N
MQ[HL;*&&B.M_E&, Z_FO5D P[+N S,?%Z" \ 9'XPP F]U$-41S\N1)YF%F)
MRP$BIY)',&*UCW('OK,_"L1L?1*]W]Z*WJJC GLKX]U]4..B#Q^C/_J#X^A-
M%U:I' WZ+EKKPLKW%<+_=(7Q*8-P^9\5L$\F$D:GO"^Z!<B!( ,ZM]F$A"8B
MD0^X";!N<W-\#T,YBC;[9G4I*68E+#+N=;7 7=='I;LJ3C:"-Z'*$/X]JL@
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M"2MPKHA?8*ZJ9-_IH*6Z_B.&)![5@4KZ9%*F> 9DY226H$JE1]A09>E&Y5\
M&7^&RT*Y0K0HCH98/1AN'ASWJXJ5X[I"<D";6=#0RBQB"%'@QW@TK$*85N"A
M117EY$)]\KEQ'+AN>.;9 IKU (OAF=*;\"1XE,*EJHIUXJB&Y4%Q-"&7N="I
MX>!$=4<G<]4%JB@IO&SRV]$81!N>Y<V6^^/DJ[D*ICBC/XH??V)@ 6POK,O0
MS2W.RJGRF_!5&6HWSGZ>"Q>;P'^W %VZKNMH5'E0K07</GF,=:'(T*R Z"1"
M<'Z=\+VXJD<XSN<2''B.X%$<P)*441^38+'FI:DCO"I1M!)5U5RKNIP@ OO[
MY=E8RT7, 0L+:XZD."Q,=<"C=! ($5;MA%W#;VK;&S:T6[@Z^._T][AL&H"H
M[TKXN:>^(QW^@,<& 3NW_;"9L%GE)(K0]?=!KN"F(\8IO!J>!M37WT=J+QT2
M^C#"4@:#*KJPXM,* S'^;U2,QB,7ZHLB9:KN_,LF4U[(T-49%I!( 5M>E:H-
M T=KT6)Q48P,+.JHGXGM&/Z"W8%]P7/R43$,NL64B_#FLTR.FP-O@'496" T
MO/Y8A3VLAS?EJ6D=X3":P7!?]>MRZO"C'9BJ9$;8V##4>0UF\C#8<0QGKG2B
M^7U9TI"QM2D532K#7DS]DSG.@E-!<,(:(]G,RKL?JR&@WRC@)=8 1I_S:98)
M'G",+R[#3?-H'D+7PH):Y]6X.YJG)Y#I<UZ$J1Q?F6G(LZKUE1 O_XZ\*KH8
MBX4L..@==4^JLLG3T?Q=X7$(>\:7P),/QW9_C@Q"/#2R036B6@:==H!4+YU2
MTOS&_WT*G LL10.O-B?AZXW/F]MK]:P75AU^M+HZ"X$/%-A!B&<&1BMQUK"*
M!^J'.UU2IUO !1:9#A$"1(O#2,R;'&[<4<6^SSC=MW,S^S"9V(L]Z6AW-F+0
MO!.AA,^<)7G,L9]33HG*)2-8DRAWTB4VQG/>6X?KAB!X7^ B1_\9@V[AAF G
MSHS_4X6I:.6%=E6 96#J(I1T"HP=-/BY0^,%X?,S?^8$D2Y6=N^Q-45*K]&:
MXC<5:*/Q(S2B&!8_@BB8JS\%YNZ_G84%V%]#EUIH9K)TW2J2UJ21T.$FWWK?
M.H;GL*V=K\5N![G$B/:O7='N?87G'G1W>Y_85N<[.\MUK<-]OOOK36_WEQ%[
M._\<M-]_H>U?WUG[\'NRM_/U< LX<6_=B*V.!:XSK+7_S7 I8^\ER9C."4]C
M2[0Q*4E]&NO4\$RX^&PKAY@FG.J<QCXSW'&=I]()JK1/A<PHB\]6LUK?^+KQ
M8>LCEA&,UD$:?5WK;'[=B#YLKKW9_+#9V7W8[A6_JRS[^6J#5Z_;Z74&Q<T[
M2UW"F>7 !(J)7 F9IS:VU#A9=:\8[\/<+VY?,2 61']W<%0)VYF]MR $]%U]
M@CMG%0:\>_/_/FQ'7Z,W WNR/T:'WO_\5YY0^G?T\>W'Z,/JQ]4 ?N&J=V$Y
MH\VI:3#M^( &[-?IG1O;;\.=I_L&G!W47..$#X5WT;8!Z\2@U@?J>#E6_6#V
M5&[(BZX]76*O<L[=1&_P(I5,QBE3TG'<*JL3E7'O )A22GVM-^1U4$2<WR9=
M.2@.;]'"T8.JY<$::KC[81?JM,9Z=Y9%3WATQ&K]^G3RC7K8#>$U$3[WH"6(
ME !;")*F>294RC*?)2!JKI&]6,P%0M1>.0.<C/G#T3S+@""?.7H"H:]]:).U
M]YV54,FQ=M(8A0FF/6R=!9J=07K;'ZH>F&0[R$$3-1YH;]YK="'-@J59'T5.
MG/2WIE\6QZ!:)=9*:CD#]9>G24YIEOH\HT#.#?T^FL1M_?H6L]@KF^4$=D 3
MGCA&=)9KPF+.,3A>I324K[^2?($*D'Q/D:H9E*-);[?IJ<N_-SYL;FV3-]''
MX+Y@,RH?H1UY)O;B4HH,5BR*N95(CX.#&A.[IH=)*]-!W9Q*.>/2*J580AF/
M/3;&,/!/FK $E'\;-U3Z6%1Z^%U\\TIKS@4E:0)0RP6@K&8V)YX)JT !EXQF
MKUXGZ=6A9L&G<0F%JIHLDS-DB;A:XVS W)M3E/0L89GS<2P2GC&F3&) C;(F
MRX2DSC84]5@4]6O_YS=&C4@3(*$$3'G"*>">@K])EJN,I4I;A;E*@M\?19T%
MNCF*JBHRS\[@IEUJNJ,"_6O=DXF\#2<W%V(B *!U1RZ8&^@X'I>1,@>%^Q%J
M&H# KQISS@]W4>N&"ZR=%]G!(6DZ."S!6)H.#DL^^G;3P:$2HE?[2.[2P>&Q
M_$7P2!<$3%DY7.;,Q:IVRQF5?0=/DZJS0 Q]PLNQ(6%]KCLQ9T\Y?JJFR#TW
M-/"$N0[.("P.+C!PGT&\VUI9M6JT=7?HL#87R?/@F\K^/N46F%N9A=Z!H'X$
MQULXLZIK(-51=1<J#NJ&X6&)2S*N7$QS^-<JFV,'=ZHSS6/.\C2_0I=-KJ6N
M?@[Q(H4K/U:1U<L6T_[X#J?.)FM_^N9!ZCG03XFTV*@1;'0B58)=G8U6:98[
M(^WBF/9)! [L;]]5I8_*,_ZDJD?I9<<BM]K[L]TZ[7AXXM3P5G2 )Y<O;N=;
M/[<^?9.I8R!8,N(SCAEXE!,E7$Y$9E/A&.A&0N*YUMD##()K7367U0Z LE^U
MP*SC:JLZ6#,PKDIBS>+4%E6W.D\T&)!&:J_CR>!(C0Y.0O/<8PRHP18RQ4]G
M3X6/W"8N]8[ 0Z]%<.]PJ!^KD;;0!COJ%CB2Y>@5^QN(+_2-B:T 4QD0)TUS
MS'NF"9&QHL3 VGL)&I/08G$V5FC07-;!A;,@K6CPPST6V"QJ#7R=[7^!6!,.
M8H^_J307TJ-'!'-\8>U!P&1)1I(DU0($C<J]>O5Z=#P(X'(6<2;A\ %D;@T@
M>"8R<UN$D,PJ)G7<!\E51D7P^5;E!E%/K7J+5;W!L1B:&GX/I;RF$;?8$-Y6
M(QDZX.9NB+BXFT9VSE]XWALT\_3<6#.[']B\HS?[>OI: YMG8!/F -I:3EFL
MDH0HYPSAFDLB74JQV*G,4IKD(=V+K297X.:$S&Z&G[?:^ 8_[XJ?6"8D<3&S
M"0745): #&-$*0.J6RJE2&CJ\CA]]=H/QL.K 13!K!P;P(/2C[M5^)>;3QR=
MG$PL/KN8XN4D(',.D.O@4U7E]X5D)C<+^SA[\#QY3TA#NC?L9$N-G7<\MVE4
MSMM@Y^$FQ0(3P#%8XX4D&CB'>V9)[CEBIT]2IWQN,_[J-;]*Y9Q0V<V@\U;[
MWD#GG:$3S-PX]<)X2JS5GG"A<Z(2@[FU<6JH8M:AR+P>=%Z@>TZ [.$5S*?O
ML\2J ],<A(79<N?B]*8YN'=.F;M98MQ%@5%S?@AX)L9':=7_/DGSBD+.+L;L
M!7=(/9DZ%ZR<SJ6GK'L&VXDIUQ@=>9'4# [^(&:GX34A=&>2^GG!CN->P6+!
MQV+HPB[.U66NU90J8P13HD]J;: ,&S$<'XU,R%(J"YBQPIK' VSQ@$EEX73A
MTA%CAXDPZIN.<3 \?[Q1U2(^JBJ7GYM%2 L/)#U+?,&#7WAYG5(Y-\>512]0
MTV>C C3-7P02QE<<.-6%ZT,>G?(N9%*J,K (YI/[A7AV"L1ZZC"DE05DFB+:
M+#8*7P>73<YD9H.98%A=]61.PSRM399G[[U5Q-9M2&JJ"P?U<XA/G4]#.Z?*
MGLXM/)._-D.O:0QR5)79KG70JMS_[(3*S<^YVH^JU$N=/!B& MPW' 0),P;"
MO91B0Y[154MP,?44%4L=#@ A 4)<E<DUB=%T5?&]\OPRSVO8=5!HO:%J-$_V
M\RN_@F^;9L)-J,'U[1&^?592O0HVF5+7W ,'PY5S<YD#ZT&_6[T$MVQ*'Q=N
MQ-R=!8X2%Z%JBZXNX@2%AUSP<DQFJ_@8A+/;#_;!J"(VCRM8)< @14_F.U^G
MQQ1#,^Z5(U4%?4\*0^D%%2PN/FN;=K.99-5/ZDC5=8Y[4_T?1KIR;M,F\@FK
M_!=AL5$=N3@R/>0G3MKP8%;VW%@K)ICN[/SLIAP3J'["-?#EA1.SKC3#0F/!
MQZI2_N!TWO>9W\\V\9B/0RX/0I;PL:L!:R'LG3D.11=BK=7-@=EL\YZ)Z*Y5
ME@D&GX>,:D_7MM]&.145W=MI&E+4+6I$7(EZ(%F") ,J] KL)%C4L:OX%*DD
M"++)]2A#!I7JA$EEKE\&A7DN(U*K;LA(*P^<PV)5&-)6(R.&MD]?4)7I'=0I
MJ/4@YLMDS1/[HI$CRPPQ2LC6O1O"0-W/(QS4%8,$XAZYJ3L M<FY+%Z4>D-W
M +>%]PW*\AG0S"49A=5B+UY@TU5E64S:8ZCH VX*V- >N*D?3@GG+J_/$6=;
M#&)@B&\\J<@ OZP M.=&!P-$:MB^([1_W<PK->X/-$SR1PC?FKSON\/G'XV#
M-3!)BOZCKFT!0* G@P@-BD![K-*9Y\(>1U6IGCFBFHMN&0TF.#K#N"OP=%I9
MXSIO7X1;53'4JP%U6GH#5)NR"@2=L$@M0$Z_]52-C;H8W<4G_6@4E>/>!8-<
MJ4IO5)Q4CJK G$F_DC]NYD"S-DMB;DV>V83++%$Q]53H6.:&>Y'J2]HJ7K<\
MV7;8Y"4L&_0;7"A?0CTR0Y6&52?>*TIXZCS)<Q_.\9B*-3,R-9B6=#Y(Y,^Z
M\@KL_D6$^?_=G2:$93*S5"?2.LZ=E$Y[R2C+72(,U::AB7NEB5W:_O3-I%Y:
MEFOB3 HTD>>6:)5EQ#F9"H?%5GGZZC5?0!)GQ.##YDQOFP-GQUVWY6?9TQ]F
M6LC:Z!W(F:\H9CI5--#+S9<&1K>8ONI53D1,,\(Y5P0;+,#.>IER!BJ2.)?_
M?)4>\_N5ELZI0EE5^ZVZZDKE0U!5YOS).:/R.@IDW3]P,(8AVO*OR^.0SR_&
MZ__5PW]=F11>)SV<40ZG\<S5G*8)$J%M>J@H=%2ZOR8?_L8J1%UU\E?1#VL4
M;CK;51:VKDXER--5P25F$]0=TNO'UXD&JR'1X$R+V_I.NDI3=N'/\2J]Y6\I
MY[>Z\[+!4K&:R>L-]HIV\9/E!31SE[='O]N5S3!N,(SSY:&,<>[R3O27=E2_
M++7F@;O17V'(5H5A)G5=3YEG\9F,@YOTKS^S7M?N7[]@G9];__I%4WPV_>M!
MH7*:&Q>[6, _2GNA5>YSFO$8=.QX<15HPF[0)6.J>[5F?ALL*/!ESG;?#.;Z
M9P=CPTJOE8/E,Y[NH8,U-%N9Z',GX5E3S9P]31TN]+'?.OPDMM8_\5;O<Z_=
M>=?=ZWSZM07WM$!/VUK?_]G:V3O</7QWT.IMT,D]\*[Q7O(E;:]_Y^WU_9.]
M][NTM?.UVUYOP;N^_VS_,GQK?>/G7J]=M'8V3G8[7WWK)#[YT-D8M;;CXV\R
MM;FFF2#4XTEY!MJ\5DR3.!>9IJE7.@?83<2*R,^;>A7>W(5U !>B&[+0[21
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M1BU7C3+TI,%M/A$@5ZED4N5$,<L)C[T"98@I^-,KD3L6YQDJ0ROBWNK<-GD
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M6$&%N8*E,#CM@]M7W:BE1B,W+&]1[WS)8NW>A; Y>"(>]N._*]&QBWKJ) 3
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MS- EC=^$"8%0!&+M3TX-YEVEL+YK'[<^?-B*/H:$109K4_3Q%!DVHJC\FT?
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MH1W0-#$F5)\>#*<Z$HBE R#._D3^!0$,<JV+X?<J:A/0Y&!)]E57F=&@A#4
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M3^L&&^U+#,\W8\N7Q*KT$6F8B1G+,Y_?P-1A\,\7=ZN"9\,7MY^$-27I^R]
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M)@M!4URD G<[(RS<! -SSB+)84*A1HY]>(S8UJ #W\K(>T8*7F'D)KXBFGE
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M9V&L+8RU'?D<1QX]A 1ZI?!L7B5)D*&$"2Q^]6.MO]U)#?V!V^U;S%_+RT?
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MV[!\_#SX& /-O?[K]O47L<QLF=D*Y;M5](=8TU/I[AN2]>-W%U9I;Y/2?F@
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MJQ.Q8I)RM8GTNDJ7W%PERI#5+%U6*ZHL.\LX_Y>N9VGZX9:O8A<P_,!MA&N
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M:]9T;SE9? WW@//YXT6H$G\I&**<3I@>%L*WNBT%_%)<8^903G%?^5+@F97
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M2DB,7/LR2YNY^2D!Q9EA6TD5.G7CH:;#K6>T1IO2A/OE[9O+4@\EW=X@<Y#
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MR9B5X]]U1#[AO/QC?XTB+AU(2+TPXR_=-O0-NGYH .QQ3R6'LW?QPV<S3-0
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M=ZWI"V[=(6XYX4$:=LR[>5O-":HLLK]$03=W_<24."NW]5(R+'SANNB!S)S
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M!M]NOYQ05.%.BT$:,A5/'URHJF_+E"?2^NK/J_Y>BY9*!1/NOZI50?&P_J6
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MP*N4EH7HRO;]HAKRA\SW=;.4&O\(L1'^KITH]E:X>*^;;BZ5!2MJK?J2\15
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MQ^IB"20QA,C<M,F=-+'UFWR,,&$LV.)UY/0H9XTPUI@CC4]2)OM7_(NXC<?
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MM4>#F7]"(331=)4,DLI$)#N6UM@1;RK&'@P;/L+,+1BT3CE\;F=)=4+""W8
M#QUOA[M['QP7IK@3Z?WUQ/UJW6U9>YWCJ\TX$7]Y&YS#2<&Y"X\*/\",>MFN
M#&_% 5NI&-QOFWT57BM<KX[Z@X I10:#TB9!;<=N50)^Q/EF.G5TC.QS[&9%
M:304(#U!STD,)[D#P?V[H<[<$:*+B7WAB)MRG!S.VDMF\53;&W5[[GKL%H1
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MZ,6H25O+,?[J8%(";CV=3 ^7VU&; [<:!C>4:,Z2F3*.6(H4VH$%4;DH3AS
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M( LN>CCN0EF\P2P 34]Z#*AUD]W2G T[C-QXFZHY>D8*=Q/'NCC,%6 _["&
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M&\@M;E?O _D'K0G3,XN>J0UK,GN[,O>X,A;%%N6_"-FTG?Q[G/RR_GDM^GB
M>6SG_O[F?D0KRU6:&6[%3:M6<QXI&4NU4IIY@=_*^F7<C=59J\J)8J/5IQ]
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M]M8@9(BF-)IU8W,NTS<)6]6LF')EE@XX\9&+/1Q]"+?=KG%&A:@&]4GPI--
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MI[3*F1'?;>B4='1_;V :JQBWA" _''@,%:8"^;KU*EC^(ALNCSFY<87";0.
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MHX+5:5C.8G)"!3H*-Q^(ZZX!5J_F RLAG:5+3$=?81VR6Y2)"@<8F;=Q,)S
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MY"'RQQM]AA1'P)*7M_A:D =][X[61^.(_E1(OGU<XH-+EE5.6A[, !!95!^
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MOJBJ-BLZ[_F,)("T!"!7@,(,9I*$B(0\49PI"K@BG^T9K-@<3S"#X3T1EX+
M1T,NR54.([< ^\"(?D[T\H]3AW6FP7\?U)$V&]^/)^I4T0;PJS*"1@^3J?H%
M" 9?U>%X=M "+=&+'/9VL]DI!GO4)1K?HZA3!+VB1+>(]WO6@PBAF3;N_?9E
M/.RKTYGZ?X\#[<]C8;^#LQSO#FQP]L$[WM'_(K^K,\01$#UE]N5^./[]:*LZ
M8B@']+K9?+\/H)P_$AV<$(PC17N<JN/[[N-L,%(+F^ 4F002B+Q;+3]$I8YN
MVH['"'SP6?")#YF<\+3WB8NIZ>PY^R&U#(1.$_XI  +Z.>!V2G%+5YD-P,*
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M-,4ZW<=>P+3I=.$Y]]CG5"(D)@E <IY4<8&,"0 )O#W%*+&.5CGA\ #%+JG
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M>Z>'^.G>>_RE=Q^.#_Z._^#PCX.W1R?=O3PMFJS$Y*:=7F(V*>U\])*"!&F
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M\LH+'H^FKR"/)W#Y>Z?^&TP/OJ$]L/WAR$^^SQTL[%TLNS+C>;Q\/2*ZR$0
M#+,4.EE$6I $.T/1=691!6F4X54V.BKVZ<F[LX^%[VI21LA7K]8K&"$_LX&2
MFLD(B0#P4%;T/'%41,)-REDD#1"KQ$9K\#P3"6UGYPKK(N]A=B-B-XQ+XU&+
M(=*$'<P2AU7TRXS70*W..'RK*C/:311/GNK-;7J78+TMP0=^,L+A9OH!)B>?
M_01>^>DPED7\X=G%#-+ NP20'"<6>)E)/3K@DAJBJ4C!6F:EJO*>/X#KR8N@
M2[O?E8795A;_@'*0 ]+>5YS!/L'[BV*<HSR'>G0Q*X<<2F;(,NH(6E,3#<'(
M/1/)HB8^J.*:*YY "T9-E1VVS> ^>1'UP-)=;=GM]U;.OTS@<TGY_WKE$N&0
M>)1Q\KL."ZQ '-92$HW'N-^@\H,S"!%CO1BIM#Y4B:P;8'ORJNG:_G<EXKIU
M.X*W609CB908&<HR3SJFT0?R4FMPGJ./W+/;L>%2T@K3EV<OS(^3P7"<\.<3
M\%-X#9?_O2:%6Y^8Y98P7UP%CPZA,T$2+JCF7 =G>97\INVA[V+7LF.1KUJ4
MZH_.6FN;*WKP<80PSX;_@O3W\5F9/GY'>Y=N'8U.(%Y,AB719V\RG.)'K^<9
M0)?]7/1ZP !\8*BDZ#1&K-%%X@ G&I^DEDP)=&VJK'O5ZE#_XNU;7 VUW:LR
M*FSOK.O7F_$$':G1_L5D J/X_73B1U.T8:%XE.;?G<U7<1;=O:^+F<FL?4)'
M73A?5AXQ7A<Q$QTSQ4DK4RETG^+OL&\_WX,=ZZ7'2:# _G!Y*!?[-/^M#V,T
M*<R&D[DK>K4^]>$,>[N7_N_%Y>[=Y3+G,<0S/YT.\_#R-/N/SZ]9&T@EG(PX
MV<J,TZX4EA'//9"L.#.2<ZI"KY-$[0[_?'D>H[(J[ <V,?L $J<>%4J4PG==
M9@SDG)6&Q"R,C5XEG!!WY<G_5.JVC%7)1UT;S@RR8L& *4D1N7A5V9/@P1$6
MF;""JDACE46W>S ]OWBO*P)J9+<OEH=.?3B#@8Q:@?",4$DMO@I2$<N-)SGI
MZ&E.@D*5M-7;,#I4P(V*,]77QK:PY:J Y9?+^B%_C6?C*:2__3J;7,"/'XY'
M,_@V.SB;-_BW7Z?PJ7RQJ1RFD]G@PV2<+N+L:')U1FOOVW ZT%0HFS*.6DF7
M/.V 0A4\$N!4!D:UR<LGGU8* I]_0PSXW;(0U@'H4 KW%/JY1QH;<#GNT*8=
M1K(W\-P\B?=Z/D8V C58JC;4$>%WT70Y!:PKE?2#\VZ(NLMZ1U;N30(A*Z%X
MX,0I%<K6CB4V1XE?V>B<2MI"DWV3QTC]K:I3.V&^C7$K+%]= 7LW]X0&'(PV
MRFABA*=$4I>(#522"(H[!P* 5]D4N86B/S^O0V;&79FU0L&,4_R]H[PWF?C1
MI_G<-9>R1Q\F:T1A)0I8:FZ(M1!)EI%E="Z=XU62,%:B><+3>7=6KK 4=P-.
M4?C[\<C_^,F--<;IE5*;P&TQV[<61TN\_?H#'3(][I^F"I-'6]A92>,BEX1&
MCS$MEQ9C9>9(9"FF4A,-P#U;5:UQ-1Z/J-JP4Z4&RW4QB*]P _MB#DT8@GN>
M"1=2$VEP5/8AEPQFRH2Q63M9Y;34_;#Z7Y.JRNJ=]:G.*%GKUOS[;TNF>XO?
MUBIH>')ZM/^??S]Z^_K@^.3@__MX>/K?M_%U5,1P13,]%"Y\J'-+Q0I%,-S$
MR$H>E$0I>*T",,?Q1Y':=35"'VBP\P*%%,>YB(XXH;:LNWE= B[AT G740=K
M%89<51<>WW95H'!YF^%P=#(;QW]^'I_AZS ]^)^+X>S[,;YP;\:3/_TD#:)B
MTI7Z:TYHC#<E8-"0\!53$6B$DJ468Z7#$&UP/HK,Q38J67%(HAHO%8*Y_?'Y
M^?@2XCPE=WHC)W< RHGHF<;>*XQ?%+<$'00,616^W0[A);6Z2/7VNS9K0?4O
MD*J,WMW"Z8:."A[5W5X/&,[)U-),T"O %X6S3(+-0( ISEF,!OM=9SA=AO*\
M9;&EZ2NL!,P1'4ZG%Y!NY@Q=BG;^X=&7N=]X\ TF<3B%-! Y4 TV$*T$(H8@
MB3,,B$"HT@$/055)IVD/]06(J1YU57:/5R+^PY]=P&K @4EIP <<(!D&NLPE
M$L#BRV*X2]2)K&.5F:LUTA<IM8Z(JY##<O^[<74(#E+)M  ,C><9E)-R_B,R
MGG DSH2)G(A,DA''F"5"TY2TE\K4.?^Q*> 7J;MN::QPE/G>]^4>V))%Z;B5
MQ-"@T!G@F7C!*+%0K@PPU+%8Y2C:AGA?I/@Z);'"*>L;>:JGX[V4YHSXLP]^
MF Y'^_[+<.;/YO##,OQC0/M-AS.XVO&\[.\QQ/&G2U[G71\H)R4KYE0.-)'6
M11*4\ 0<U5RYP&F=(;)VQYZWFA^5+"J<(F^46<N=#3*")"F7DM$8B!,7K2')
M&\^CR]:$*NFKCS,7ND_Y=4Y/A</BMT\".V#:)^J)#8##>)"4>' 8*^D4!7JO
M3M?)F]]Q 9(^1;&YP2N< []WR8Y9#=)S="59LCBX:4="%HH -0;C&J-THKM=
M0>UF'=!1+K+$@,TF6FIB&O1: B7)E+.3044J=K(.N'6BNLE((!>1T(2>F!16
M$Q0M)YI9EK(WTMHZY=8?2Z+Z-ELA6]ARUXGJ=[IPJ:XR$8U'\[WRDDYA,$@,
MP3J25-8E?3,22P4CD'04GE.G5)6A_EY4CR3WK17;ZX2SM=4K;(,L8;K*[FP"
MJF:FVTI4N\EGZY"]Y8)4G9F^-UUX#=IJE8A/',%Y?!>"B[S<*L*STJ!,G?M<
M>M3# YEH?<NAC<6KY)U=>UY7>4U"\ @L2(( !)&4*X1&,\E>.NQ>XHK5.OMX
M&TG_04$'#*W?(-_ O!42*-8LB5RGRRGGA=)$90QPI,J1A&A%*?R<@LP*M5_%
M?[P7U7/007=FKY'('./%^<49CGMIW?K%%5#I:#+ .+'E0DR)728>(V.B760&
M OZ 5UFX;XSP66BE"AU5KH:;85\A+0IO7J'2C"6.B C(X(G,SI0,($>R3I0S
M::*L,XBLAO,<%-&!H=>F.?2:@;R_=_+W-V^/_E'G]O0?3^\AWWA-5Y;2C&6Y
M$QUHM"P("3COV^"-$*4 .6<87SZ<9KRR4ZU8>;]W^O'XX.C-JX\GA^\/-KNY
M_LXSMK?P_;"6[(BSH-$:8W1G$[X[VD>G''/4>BXAL32X#^!6UGI=WKVS:1=&
M6SRJ>]NM!+ED0F:UT2"RX DDURA(9Z43AF9F7-#^C@E7P&UER5=[)X<HX _'
M!R<HY;W3PZ/W>^]??S@^?+]_^.'M0='VM>;QLTTLW+:)[2V_5:>6&''1Z:2,
MLDQG"3D$EG!P<$Y38-$Z,=BB>S69^C ^&\9R%6]]QJZ;ZIVYU9U<8A!LTC8Z
ML-1HZ0SUC#D3'!.2^V!,;,O@JNZV&[T.3C\<'[W^N']Z?/#'P?N/!YN-]G>?
MTL&8]0"TY9DSE"K$P4-&1U9&YJ+07D>.7R:'(?3@?I!;6FV^*+S9H+_N634L
MN KFDAV3CL93EA@+1EHAO?8RV\A43%28F%;8\2[@+:UY<G%^[B??Q_D]S*YJ
M QS#5QA=P/1RDNG&T \W4X.#EIU;HL=;9ZWTZ/P++I6U7JFL,*9SKJ0M>[^"
MGH<;W"ZL>SV<^D^?)O!IGA9SE*\>_F.3#9R#B'\1S3TC4JE2[+ZDO]H8J<]:
MFSJU$QX"MGT\.W_>XL*A4N#L'\/9Y_V+Z0QC[LG!MWAV47:D]Z93P#]I7G^7
M.68-1EX.I,(0/'KB%'.$:F$9Y<J"J)*YO0'6_B/A3I5T-RBNRU:%Q=<U]KC<
M@>24*I R$)%+R3NT3-FZ%@1==@4Z,FY\E?( ]X'J:R>_JE ZL_JN=_E+P9[K
M[:G?8?QIXK]\'D9_-M^:DBEHC!NP$[I<^R=+3X!)0CDZ3N LQ$;E?QO5J5J+
M8E>[^=UQ/.[:UAT7*CNYU-!-2%<KC$U =5VK;BV:_FO5=<36N):I>],!QQ 4
MVRZ7#^'+(Z%430D""$\V!<7 8SSP1/F_IV!=G_2WL7"'M,?Q!?HYWP<?3P99
M)2=*91R5$B(0R9+@(\Z,$0R/&"*EM.+*TNG"S%.(?_DT_OK;U1,O>;[Z9IGF
M'ZWV6YJN(_./M[)=ATY@Z=/!Q63\9;%[)T((+C$@F6>*TQ(3Q%HGB34@O7+<
M9.CL/;W9\%.F<2LC=O@JEG6!<EGRQY.CR2T\3CG#)4M$:?!$4AQG+(^*4"-9
M\-Q0;I9.#=U=V5CW\*=,7"<&ZW />VV-4YD$UR)8PIDV&%]02RPU0)A (-0P
MX463Q8TG5]JYB@>]M87K,+ZBW&D34"^MT',KHAJ5^]W$RKT5>I8B>NV2)X$K
M>G7#O;.9A!QTHC%)DYLD/CY&ZML6>J[ ? OC5B_T##'.+[DD/-* $8&UQ%N-
M7P4G74I91%TEC>U1%GINQ<R]A9[;F+5#QWKN6AR]_[!W>GI\M,B,\YE)$P3A
M3A0?WS#B*0M$R>!E",QFULP-N_W<_I?0M[#PN!OS=.TU_W[XQ]N]O>/#*RC*
M>G3AJ2;<NW)]<KF)UJ(KGW7BFF9FA8Z-F+K]W"?+U!;FZ=!9NA3-?[W]^&XA
M&6$HBB-0$J&4>YC? 28PVE*1T<Q#0@VY9F_4C:<^698V-DTO>9AW]XR/(<+P
MZWQ?O\L=][N/K;'#_@#X.SOJ5KMH. 4E9,X*0]/ E DA1B$D=RMVU.\V4'D'
MW0B<7:FG)'@<=:56AH1RI48NH@.;N A5KIVNO8.^%^?K;-,?!GT/L\M+/6<#
M&:)0LES)B:\(P>C>EEMJ!<'P42H>@^:Y2DG7^T ]PCWQ-MI8<72@&_OWO?DM
MO*$,J"E'\,NN+A(YOVQ0".JHD$DY5:78SI/8_-Y&$9U9_3%L?J^,5;-(+J8H
MR;P0F@R9XQS.'0F1,BMM=HJK%[=@UXK9AQ;LVEBXM]6:)J!>VH)=*Z(:+=ML
M8N7>)* @JES*-6"0)%'D$L%EZ8EWZ/S%Z%R03;RHQTA]VP6[[IEO8]SJ"W89
MVP_2Z5+')1$9T7_Q//(R SJ9O%/"5\DX?90+=JV8N7?!KHU9>[G"!$.S14SV
MYOCHW?[1V[=[KXZ.YV<C-CW)<,\#.PE6FP)>"E.M$4Y;"UGQ)#4$QRT(YJD5
MG-JDY* Q].XLO-6IAP<?6]G:3<Y">,4#^L^)&U_NJG8<WQ;'O0=P' *]W^;;
M'XM8_^PKYRW/DYD7UPZ-)]LMUFS<7&6FVG1V^=H>G7+44E.>L\Q<.<VQQS1(
MI7'ZBP^\-0\T7.<&KZM[JN*:CV]>6G4CY(N>F^"!",_*3:L@B"WGQKTR*ELM
M8F@4U&Q0A*6[3NSB. 9GPB:9+;$,7$D'PKA',D-B5"@B[9)B+_<XQLX4VL71
MC3;,5EB].HF?(5V<P5'NP(J7,;I'?ST#5P2GI)*<BCWRW&9"E8DX4U&9\HH<
MS@[*\77>E;Y6RAZ-@'>LAEVOQ2W,L/K63NUIBD(E$CC'GL12EB394N@8)'<A
M!*.K%)%]7%<K[U@AC:YG;L/4([A MPG<G]<S;\_TEC?I;D+3(U 7.A$R4</+
M+C["SE$1IT 31BW"IMH[5Z>VV6-0U4;7,_<IJC;L]'\]<U;968F^A$JEV+3(
MF7B'@[32TE&%XS5&Y7V&:T_E>N96K+:[GKD-)1V?\MDO>_ P^>(GL^_O_?GE
M"KVCF4.!0@,M*?2E<FS@AJ28HQ7!&?R%KC8K5@%XX8Y0)[QT?!KA&+Y<3.)G
M/X6]3Q.8=W89XM62?Q.076]V-D;7_^;G]D2.^V*AX\W0YF"I3:94KB?)>DY*
M^3P20M(D.0].N^R"Z"PM8L=2N6>S=$=*:6/\KO.KC^$3C& R'GWX["?G/L+%
MK)S=FY;*L9,O\_%U/+J:)&D4/AB!?ELV"7&66VTT#T1P"R%D[(9<JAFQ)JFW
M1:/];J-6XFS<@\&[/B+Q?OP5NSQ<^%[.RW+^G1+.K"BU< QQJ7Q+:?31<IUT
M;L3][><^.WJW,%O7K_8?P\FKX7@&\?-H?#;^]!T5=H4J4A.%C(Q@1(:]"QY[
M9Y4F(CEJN? J@6E$YMHFGAVOW1BS\S,7EQ6_KUWA&[&22XX[D[%[JE1[!D^\
MY"4+1!NE,\W!-CS2M*Z)9T=Q-\;LZ\C&^GWK5_[,CR*,\XV#"GZ4%GMG;X<^
M#,\0 4R/85XW?C:^U>MK ]?*)^@<8.4,A+H&7<I9B)IJT HXRU32E .G/F;I
MO+8!G%?WYRS4-&UW"OUQO\7A*(_1"RK?5!+;?6U5UDWC;BY)@ KFLX@A*2W+
MI=P6.\IQF#%9L:3 WB^!^UI]1#DK7#HAT#<BJA3QD#Y2X@7'0)&'<L[$<27L
M<\]9697.L'A%OU^E/5Q=*?PO2 /I4^),ALL@5*HDB"L%#DVBPKFR: E5CD2U
M@_G$,U7:Z/+N(G,U/KL.[UX/IW'\%2;?+R^N/LH?)J5RSSF.^U_A;/RE&&C
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MA;*EE>^2KKH8A7Y,GW>T>CI^M8!:9+L7/P]Q(BT?'>5]F)3+]_8GPQE.MGY
M@X^29QQ I5'HMZE(/).2 '[@0^0R1=EF,.H&UDN5VNZXO:M2O=WNW$6Q]U$^
M]9-/,(.T<.D&8)D1 D$QL#B!"^&(<QQ(ELDD075H6B!K70LO53N=6/RN#,Q6
M,K@Y94: -'USZ[#:G)9K@PPX*P6LT,=/DFDBT;$C3AE+7!(65#9)TV;[]ZV:
M?:F"J<?-7179K51TVUZ+'8 2&PQ'<Z"7@>. X8 7A#!$>>>(5-(39XTDT6M
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M$HRK<^V]#%Y$R8CBJ&B9A23EO@,2-%=)!Y5-H]L$GN:AJMX<B>XX> 3'I9K
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M2M;S(Q!8\YCS<>BK#54U=35W)*9S"[#%053/&20KB4\.C1!YQN$;S8%.A K
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MW<CMG[\U^^/S+Q/X7,;NKW XPB="2?*_Q-/IWM766"JJJE,S+2G*E@N5E$_
MJ)8)5 C1F"RSBXE3X>AZ16V+:LOC%<T:^Q$MEDUOP7(F%E\B(C/3)#A&2699
MIBRR$J+*O-86Z-;G3H[V#_=F^/*&B_G._.GX@R]ASWN8'>53_^UX?';V9CSY
MTT_2P+#,:5*2@..N7,]HRE5\DJ3HO*(J<,ZJA(@M,.[@7L2:RKIS *426Q7V
ME$YFX_C/S^,S?-KT\E;8 8TBTE(H,,S+&W%/B3,>2,8922704>0JN:]WH>Q
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M.(!==E$EDC$P\(QSYUVNH8IU@)ZA*#JQ?8<A_'Q6;#.F87");9;<*_!E$7V
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M<LC-]+4/#=H*:0#A[- I!8Q@=^=>(+._^BG@W)PV5[]B#J)4P&CCK/Z7/];
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M""(-?]@P-,H3I\]&J:#$4:K8 R/0.Z< G_W0@73OP85W-36BT) O=YQ+QMF
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M.S&>-_I]FQEB8O\K)('SO&_]27+.<TBY[Y',NE&8K^P@SR=$G+L%NT%[12;
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MMNLT-8;87W"?=;8S^LW5OL7A0;-M_/JZH%YX@**4N5@<>[JE!)/#;567C.^
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MG2+5?=]PV_P/OI!W[TOH1VO;+([/T_R^17%9F_AIZ.ZYC&RK1_QORV*E=LX
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M+_DR#2/]%(6$H%7_J =??C!H>90+?7O^M@*'HK<*.@A)J%@B-72$)*M@AO=
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M9J8Y1\QMNB[#98G1^3@D-RRFARH_X1=%%$+3O9A2II-[U>3R?/]]D7];G&E
M[TV>07MJQ7GNMU)'OFTQ\+KPGOS68XX&]Y:I,%S=^]E??7]_Y#7_VW</ BO3
M\+9Q0/>; _)BIZF[LGZU(FV_N!ZG6)O8+_5H7V/>O5KC(9,GMSN3&RUBFOO!
MD.\G_4KB\U-F/0#\M"QL2,'>BNP&Q-^AU;#N5)PWPH 1N_N>ULP?O5R2X]AK
M8KN,^(<6<M';3+HDTY8I+0;,'OT(UD2,-&PTD?$P?N\Q8<K7;IY#:\%J5,RR
M\7WT0J9B]>94%'_DH1[[A17\B=06@?QOP[ZQ=5RDH6U::+H4:MIK\7?^\_M[
M?PR1C@ZU:J\8??D4T]'61I>@,-,5K7G:/C+%(:AB*XOK<14VZ)]GC&!N:!G=
MG"'7P:#8<.X;?05VA+S%MGQH\/^N+?]#7XX/3TNU5U<[I1&_T16(K5<-IY=G
M#[9.'B%^_(!;G0%JFBS. !,_W!>'PM2#!66="093!P\D"CL_'.-"NL(DS@!O
MA0=! D3@7"?Z-*T<[ 9T.M!"J0V]?S771NL9@+M]>TP7\I!R][2*2@]_2HPN
MP>:SAXWDSP>3"H?^6B((N4N]ZQQZ=P,,6,N.S0T ?LATB4KG!RI I>4?#<=\
M^I6?6RR6XJC.X_;*IW5P';5>[8MD(*8O&-4S(MSKO4!W_O\:CINV68<PPVU"
M UU7%*^7Y)PZVU\.I J>&YIXX](=0<99?R^:D6IRE@ZA:C#JSY'KT83HU(0N
MG?6JC.=/@8>/'EDG\%AEY*'$7:G79H^@,@U2 LQF[9-98XM!7J[GKDR4TVA_
MQ>&OR^;(V%!E\0J+&03&U==J7YSMOQ?3 +ZCLXM^ C;:+3&RF7[I:O,ZRG<M
M=GRA4S7*;*Y+K!86+&-][C<()AS!/Q9!RP1F&[+NR1.C%;G(3F6R'1;!W)2D
MQ86]^A=LHT)NR'C0,@HG\_??&%U)JD_TO!O2N'>7*(Z/(S1A96,P?! !RH7S
MV2Y]0EA/@A9V(\X =+G3>9N%ML[#T1PT,BTM/W@&'DEM@/?>=JI/4,2!\5YP
M'BR#*:,1O\^7!E"6AK6B^@7NAT]?,%H!?$?U-:9 _&0'')#[-.6$IL=FO874
MK01&.&W5V09AA2+,<MC__'Z5$@#Z<S2J*.'G\J.%:H+\$5%A(95U:'IPQW(%
M@E<H@E\\_>S/'!LF2! <8;62E<%KJ9Q^V]BM^=%$@Y?CJ\.CIZH?N<>3O8E1
M5'ZX%CD%@S:1&YF"OW" ?DFR>L12637AI>A']VV/-;PLS+&+9R/1V15QJ5-H
M)WBTHMAUZ0+Q#K6JA-WN7L^L?DMZB.+*.S;],IL[7:QJ%S[QF_/M15$5)R@Z
MW@7V9&.[NAE\538I5#54]55+_&4SO)2^I<_GQU8UW !G%7A]#D*VHU$XN]!X
M8[)S8Q+!? 98*9@%79@&<2SJK+SQYHIH5_'&M,4^JFHZ>:!^Z9(A<RJ\\DZK
MZ@(H^)5_6;OF&>#RE>;QW78I@>6(RZ<S";CS(]S&KU6\I.WN_&I;O+)\8[>[
M33P,K G:' .*N_R[<P:(53&V4S*N:9EJD&KAY O1O)UM_24MF8.%G?6GZ=TK
M[F4SG?047<+"UC7DBC:;ZU,M5COIP-8[?=(O$LO2[_+0?B^9]/7CR[JC]XIP
M*.>$ D(.G!)8;&9-"8=G )'0*ZC&P8AVO14!W1Z0!EGIG ;)[[VQ(7ML/?F$
M=V,.JR/>TM5<\CT\C=*C+>),LRXX?MI^Y#RNSUX91:A"1<A\(9MC$'0V#5\B
MB\D(LP\F'@)W/ZZV7+:W!GZJH8GP3;?+Z5.14=W3G_*L/[TWX\YW8FW#D #^
M\-.G5RB],KGX8N75&Y'?A8H;QE7X\*HG3QJ_M39/[FJA&A;U&)0M3M!N0<E7
MV+RY>83%W]CH1TETOD)Q01$716V*W^=0F%^3-4_LW#LO3[4_SU/_EH.M?H-C
MN'J(]QFTFQ;C4F,9X+]GMKGG=VM=]=JU"SC7"U' >692>B.Y'X.BA1GTVC,U
M$&C?P*78"WOO-W6$S!PX0B<,#S3*/?*??*I+_PE.T2(@>DSY*??J\@YZ.AF(
MS'%5-S*&,G$&$Z5MR6I=FM9%]RYTT])^XNV;:M?\NDDB+D"VLC+EC;1FRF5&
MV@:JE,'PW]TW+FYUJ,F9+[0,Z-'GRH8YHHXF?STJ>?3(LNEHZJ\ F%16.UL9
M1O-[&\3DNDOERI3C=7N#:$ %,8:S/@<]6 =</=[G7DENJ L]":,8MYQ^INV[
M[5_EMJS#FVUW!NCA5BE/BIE[=UD5[5VW?E<'(;<G<.(+47QBNGV(RD+A*IB]
MGJ(.4TK]M-'WADV(7'WN,L:8D918$#<,9Y9AT4F 4@M/\-6?'$LB\ Z7N3OY
M-!4OEMD5>U9H9.'KOFQIF+YM5R"< 3!A.2NF-"Y4H3JBS'J68*D,?JG(UTL^
MP]UNJ,7\>4WRDP]![M'H?<N?JIQ<-E5'#>_?U\]F92E*RX/1!4&B:;'T\469
M+PT!UXQ4&K!R,2!I0M+18F8;)M19K[VN$8S."34PS::[\:;8:L;2\K$Y8W(L
M-\$Z?-2PG,3N]94"6?OW'O\5;4!&0+P/4Y)1[LP10-9VNW)R?E]^G24IN:7<
M>,-N$=$3%,KU@4RC:2;ZI$L @,R0*&PH?:0\773<=/QQM/BKYO"^\3[]^4'%
M_^T[WG\A<UFD] GJA2VJUL01ZM+YE'H5D5&F)JK[8R?FAY1[6EVX8'W\ =W5
ME7+NE=FH)]:C+.6"UAZV8EO#V9KYEF0@Z1M9G8 :U  FM-\\T11@ T\XIAN>
MV^*W\W]65,FO8B-J>X83C?(^#B6[<ZV< ?!K1+8N" NR71<[ K8A1Q6Z<?Y5
M_1O&-]70DC[^=F%=Y850?SV.[VG44"*-O5X1G)&<AKTE6S01!H15/$N?'>9B
M<"Y<^/GB0-A:>(GCVN+W(=P=\S?\O&M'<LQNK5H@*/5CD /7_)?:95^: 93+
MVYO9_*D@OP/AA0[+X%7&^-[?X^\G9ZA0ZA?J?*7'3.9^S3:JSA1/1[N+(TI9
M$O60,2*S,DCEX5Q%*9Z&"PQ]Z;4<3N_NZ[Z_>J%'UC=/P]*(H$8J(HSUFD9T
MBI"=L6> Z'Q"_J;&>EGVI^'3#MF<B(3K>J<+#Q>4=6JYG6\/(D>G+-*+Z!8;
M.MH.?X^JE/*)G% U\TJ)"5BN7FU>UW]^(!JR\1F 'KM-9_VG6ALCTCH-FG@+
M*&]TO"#OXZ.QWHJ*A-234E92WOXK[345I&@UD+-6VG+U_$/ Z@U&?L>[U1%1
M,OS?*[L?)"?44_;2=5/A0@,#&T_;F^KJFC+__,'JQ?/!KK>G:_)+?DTV$@D'
MK&;8A$D33&/;:;[*YF!#:9X1U@O'XZ+RJIQ%*P<4#9EK]6A=;QPDOG;Q6\%]
M/P.H(5"OS<7R-2CO._')?TGOR:>!)_IPW9B^IRXS2P+?:B8Q$WZ+DC.ZDO/S
M?=9I#*EJN1/JH]/;5VXCK=I.6Z3]Y>:?]@ Y]\* RGN8*CKE'.@-=[#N4*$Y
MUQ5(W2%:"9X3'!X8@+P0LS+;QY!"G\_6O^+%:H0IH+'-=51.B'1>K0XTVO"8
MJW^^5O<FTG:TI'C99:*7L\#1VT'ZEX$OKVW?>%;\?6;^^*L\%A:,E;=O1-Q6
M 0V]2X_?.J=?D/U,)40MU+20RA:VA&+58B ^V.@7%)M121%PR:KPR\KC[IQQ
M-E:U?G/C?M6Z-)C/4SZ&GC[168B9)FS&AB.F-Y,<B#L/KP6*A<+@$"JS_L;9
MOV+8,:0XQF?@9B"KI]_J>=C2C7Z@&RPWZ&^UWQ&O0IF\K9BR0SS= <NAMPX1
M<6< QJ,D8<Q,3A$,B-D-3'-9XJA%98P(K?_J6G=OTI?MC@M=LA(74<4&SM["
M(9.7:2C6Q3MG@.>GN:B:=MUR/?7(<Z_X=ND?HL[V.Y\'U>AN2L,H/@: $Y#J
MU9+#,(4,\M:ZVO./JP"ONR57[CB6S!OY*DDFUEP-KP'XW\8636LI5&ZZ*FW;
MF)#R4A>'2[_/6HQ=-_Y0L]Z%#N^+:PF\N1;(^";[_;UW]MG:EM3@=SO/W.TL
M"\\ PHKQ$M5%'_Y/4_N?04H)1]5YY'/5:[/ FNR))BGAG8(P#XEIN!Z"88$C
M[=T';,3E&R,WH>%ESU_C^#Y$0??B4+7W-AM!--,@/MB&";FDF#R!KU^\!:U"
MFZ)"2EY6?YFQD*Y!_OC( "@96/E<H?:9.J)Z'>YVFDH5@G/^0E86DI-\J_N1
MKC9V1T/@7#/E^#O$>S_O.ILWI::^OO(LG<N;B8#H'CR-IDK ;Q"7^Y#773.#
MVUL_)7V%/9AYXHWX,E?;;A2P],0_7?OH+9ZZR;#.VJTU9Y&EE:5:X8(.!9T!
M\A:9[RD7_> :+EHDS?ZY3NU>8@;)(V)<B7LZ7@G&UR8Q=46V#$J!W]3F^HG0
MXH.4%A3UXT;\&#GP#'#I>+;=FV Y"%)LFUW6(\I%51\Q\&A)B66+!FW4QVKJ
MB[,!&'RNL,3P_+C2\2RLOU,&V!!'KOPW\Q;$RGP=R(/H<6LM:6DX49L'3;&=
M.N&7NU%\V@D!MY$!Y$#BB<&L'W>[=VD6A D6B6/8<F^AC\-O?#N1U"P'A/\T
MN\<LC'JPFB?T-9[DLXXN7&XZ*I^D9T?#B8VGI+U3%[@)!O+;"=<'J34_ PSL
MI' AG$_S)M;W92YMA?RLZ9>ZSYR[P=06KP"\B9NI/P.X(,GB Z4$N;XSP+7Z
M"B"G7/P+8EAUJ]S\&: N;$BZ6@!K-9TUFA& $99?152 "COKR$7^I;! # 3/
M01C3S3,8U[JP<H?6,%F=EM+HV/Y^5;Q-44NS9L"R264G3X0H'J/"')_/\I(H
M[\#5ZUH)]_785QM2<\WH^;U1>.SQ>ROSZ4S=OS5'6?>MZCP3J3"G?/-BW##4
M;W8,3#7H6[KQGVT9YV%>6'-4M!Q(<K?6ZQJ$'!_ZE,J"77I@,^;%9[#&D X6
M6FG4^3Z75*H%RXH%78'S[7M *3>)!U16?#").C,D($>]CAZ6Z;%.5T.H&LRK
M2G%VGZ"]T[)/^<G^%6Z=TK,@#K<D=Z]*]^#\[I"=#/> S[W^WB*M8(_7AGS6
M.9=8K]"M=SXGQYT; 9Q*+C+&BP(^T:(HD?T_6\-BC#-Q=H2JI'=<:>M_;H_3
M&/@+<SBEZ5PP]0RW>.?-(8)7W]FWHZ"$)']]>8]A'B$=4$9-GYZ^!7%O03A1
M&,NQ$]U^YA0;%WR&44[WK&25<IIT6FG^QH<WCHZ#(]/A._U!8^%G  ?PB$[G
M#3?$=2V'4K@F 1'AK^YG8FR7.6\\J;*ONBRY=%ER_YIY7??-J? %W)^DI[C
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MLG'KIM'#%[_KH(G\K]:^*?W J?R+<? J@%N<%B"<M),%6:$/-@RG"U&$(_Q
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MWK+$]\>$4L<OX$$,T,R:$U5@HS5K/J!08XGF\1K< ?,LC=:Y/]<&'FGGPWO
M+_T,J+ZA&-@D3(_6%)Y3VV)RK,?&KYM$4BSSP>7"JKG,YA2"9:HG<@RB]!R<
M:VQ:EVA[3OK0(BM#R/=9I$2+/#QQL!CB" LYOB7V:1/=R(1UY%.##U^Z%0FZ
MI]M=2BB^BR=C\SA<^$;CV,L_9@=3BJ+%[;H3A\E%-#.OTA/MM!)-UJ2WU966
MAQUE*Y_:CA /87RC&'V#1V24C(X>Z^^D7R^)B]#IN9(+/2ZGZ!#M&1F[86QE
M";>]>&QH4*7$77^2]S;G^74:\V^TF*Y&<-Q-^SCF@M:@KQPBS!8V][9JFKMZ
M_U"K7!#7D0\ZID+D53DF'B3RA=+B#: "]6D 97F".<*KV%AF@U9HJK,.M>LJ
MMF4MJI#K3QOVXDXM_YLZSI389">]#9Q"M)!^%GP$5K]JFZ\W[,KF#AWF1D47
M]G+*#41J,^=HFKT[)CQ_:-HD%Y^ ];AV1HL-IZ6>%*6VC9HQ[-II%NG@Z%BG
M:@[Y545S;+B<T7NVSNH=(:7-$7FQTM0X.L />I\ 'U1SNM@R\#XYV%P4.I;Q
M=C%GT]6<]/7MTVIN"):'GZD2(EP-A:B$@\_$GA@?RS54-[0U-P%?X*DI4RFN
M$3_R1.^U !"[ANDA5$[E$%NF17K 3]>:T]NSJUZ0F>97+F0]D(;JD\UD?#-*
M\42'HO[JK\3RSZJ%H("KG$A$VQI]D*_YVJUTY\G^NU8)WJD_AZ8U-56PF9'@
MO:K*UIG&F>5MR]G+YKJ([]J6!\R #;%.?_09;D=?TT<(>]UQ 4>=#MX.MTP*
MV)<KX_W";?2)[XWQ:2<6"A8$1G6J='_>FF>TTW^<,'FRYT\(IYW[[#]0 -2>
MG>L@7^:L:VH-G>O4CQ9*^XQOAW$^;I$^^N*MRQ:Y_"^..)9?"S1?W7E"/R'1
M0]I4FUUH+<02=Y]^_LJ_=)4C?8E=AC.B\LD!4X-/,>M@<I VNP;?H/3F,\"U
M1F0GC.8J9B[(5U*H_ -4N_CI9WQWLPO\C[,G7^?<')F)1]]ODK,DR&G.UMG\
M3Y'__X:79]F_$Y:[;TTBV[_7^$E8#Y5_B+/S&H@0*//6=C.6C->DI73F;$V;
MF0%<+1XM\F@C0:0LMP]$WLP#IY9!Q*R+^=G+5,-ETV^+5C/HH.N73/9+W!=J
MG_7??8[#D7&Z&!SF>_2%)<!^W4A.NV5F,U+I>BAJGC%4S&9Y73LN3[U0?@,M
MD^P].HX( / <XG)K9+,P U(]%KUMFGEZ"VJ7&(%C9)@6W)C [W(R>6 Q*6'N
MRD3-1&M#0'%54[<4WG2+JB"]YE23@UEX'U:]58HINM9[_HR:441P3R.H^S@X
M;250'+W4UENY++44"C70MZ>J*8N&QL:@$7M]JEH45^\W/LQO2&#J^9R")<6(
M8I+$GH_D\H^50.[:*R>?>T"@>SHAYHW!7(TP_$:"&=PI0=H<)C=3EI%MD!YO
MX;A65T=,>Q0_])(H,,C\,^][DR0?T+Q.3^LC!+OX2^Z6]8)*.'U4^:K!%&1!
M?V4!NM.3QN_H*68H=RZ;H+DM(=[[ONYS9722),N$UO/G"OD7I/8BU9.OHLX]
M9_[< T)!)()C)'8ZC>:+0!WY::<2Q^WZ)8QL;W.A\3?1L:4,/+R)%P[4#@[M
M 7QB]X#Y#6.$2QDB84-O3L $&T%9>D9+!5U>YF@8]%+PF)O3P7%V8G4'/>\[
MN)X(N <HO&?F6VLUSOGAUG!T7$QJ]VG>X(U?QH8DV0W_;.N3+I\?MOX4<<"@
MR5&E6_TYW4H_/7>EU.ZYJ:CW%0E7K"$W\%JED#J;(/3%4=(.>)@6S#@>-O0>
M5K-<L^9'(3?=;'073-^UX"CYOL6(:G)9J]H^D11^V;.LY7A!?#F_;"#IYNOR
MUNKGKH'&DL<5O9SJ1GFH">$=[<W+"9-WLS>67)#;XXCY$D&$P/0I2\/C#MK-
M9V1#G%G6E8'#MGQ?NS<QALC+MKM7G@A(DB (KE7AI*V/IS-!6'94-Z=^F<L&
M(7,URIK 2$Q6!29>.;X*^9^(B.:1CO=L?:2:;DQG#HK5R<D2OQ&!>3<O'MK8
M*@FS"SG[X7[1'G?^-7E1?DK*-36I$*^MFIC?01P-9*11 P669I!HJ6^EX!L.
M"-RXJI4P[*HM7%.YPH#_Z>_ O+>.>'4Z^!^?@ECW%1OJ0]!_'$>2>4;*,FJ_
MY3#!4U<_<^0:-ID5; $[P*IGE[EO"Y].BQ.5V;3A_CDM&O&T_:%4R*+M\8+=
M; 1W\6F]XX:$H4.\M7<148#BU=/S^DSJR1M7)ZZ#PV;<M7+TH;4,AM<EO_:F
M#,= 0,NHD<QEG>CA$]SB8&(:.=HF #;URN95_57/3=H[4<T5P]H4O&-WVD3%
M7M+4&:W-]Z/C!Q6]N"@)1*]W./0TFO1WK*EJWQ6\)=5Y/?H_O<^W>P^HX@D3
M&"/S=8-E9I7H]_@57)X8#EB+.L>N=N$ELJBT=9=-_(A??$'VF\Q:>;KLCZ/L
MG-K447Y%6TV2=5UC;5P?)]\SO+)HK.?M :]I@IZS?,N9?,Z3K%"U8W <28==
MB3!9C0*1Z]G3B< Q<G^L(+ITC'BZXW4+H/G?I(O<HVRSO)0<$3H17U14== \
MZ9@1$]F(K/:Z<W\6":)I;A[QIR6(S-U9Z++7/:#._=6;RX]28ZWR+"$LD=(5
M2;[,E'P5,5DT$[KBXGJ-I2Q^?1N';&LAK2EK,<SOPM;V!\S7E_B69VW/,CC?
M%NXBS1@E)%-)/M,'6):G.WU;:3N8@OZ9*:\J?6UXF7LFTX<'L *,=XO2^5E'
MD8:1@OY#R4\XBZ;JTE-?:Z2;*.HCK:D"2ZBV8Q03F4DH>^%5:_)OGGVJY;Y:
MH/_OL9Z5FA>M,(F:G!N>GXX:2L6O] W.8@=[U(@GNT_[ %V'YC2.-(:-K+_Z
ME"3)?L.Z#'41FEHSY0*.J)U7/C)KA7]DIYK?7)CIY2?K\7 ['FN+&&TY7+H<
M$Q6AH@6SM)*]=3PX4[E^<JU,5;L]G474R@T4[KH'$!5,^=(7+.Y!SQ.S^U9C
M>'HHEAE"JL-SKMDK,W^+$,_S41IOAMF'@?E2>77L8N\!W<M\"&>X9*]-6B',
M3L_V3MCGE0BGA[J"9]YNHUL0H^"0N&5.4YQ!;[[M&T4I'.ELU+5!#LGB/J57
MZ@5UWDLV?DW^RZCIZ[(QK_+380@3N;5'C9]YBG>(62A<308S'>0.QFUU=,AA
MX0,AL\Q,_1Y-#L2?P]XCE'(1UMV> SD($B/"HGW;DFK]C.0,ZL_.W#,.I58U
M3<WR6]*5LK-\3+F#:QD:@L_@M&22V@8F5W>U]+/B8%4$V=K^B+E.:_*"-FQ8
M*'>@9MI-E00146TC**9 [QH:IT2 V #F>+QFO;ET*+PVH$N\ED8T$C[VE81+
M%-P62Q1;KX_1*Q<B_.W334D3;6L_*CAN;^!(UZ7CF3_/2_?L1]<E3-T[+RJS
MT]_0KX44&MGAVSO30AH:4R&\G<'8Q$YL=NRK[*L>I1#5-#L=/BTN HT84G6#
MKR'_:GOJX2#_T\)Z;=A\S9IAZ8+TPI^4-O6[)R7Z)_+B:PO9<"*'53_D9:([
MU'6I4I0'Z_1L=S;^@J73X -WI_P^9_$/M6<YC9T%%)@TOYAM @?[Z]QPT,?0
M6YR"UACN 9_]%_I//)VOZ<]CRJ%P\+EOR\J?L>$[VIEC$F#7ZWM R)@KW )1
M]0844HF057XI+B2HJWT](.I2;?1D-[MYIJ>7</'D$5A 4L:PJIB]-F'A#B-+
M[ [SW;,BEH6[ME5Z.CLZFIGJE*G):Z7F2C]IM,8J@RC/Z,7.S<\)XN",)T&H
M>,'!D;N^RC#)=<F@:J\:Y\<(U!XJ@B1LK81KS8DRQ^_2W<]#/:5R60+XO%A;
MHM;/(S,YI_P)'S[PWI??-7\G$W_RX QK+,(-<;2:]@QBRRQ4*O*U,DPS(*R\
MHJSX/!2V' 5GWO"H<Z'-ZN+BZ?+NB]0<AF>F;MA8M]GK.4G7="W40IC8H0L+
MY/O5CSY^I\IR_G&9=.!F/28JV2X9L<Q49Q_#L386Y2[F#L6K]::=_B$L6\G#
M04F3%[XQ8Z0JS9'0/.[^2E)IZDRL5/1H07E:?*QB61F515C"P#%QZ!/OM6Z
M1V)P1WFYK^6U#)!:&U8>=F-0K+L"C%*O003_L*>RBH?L_[2MTH/FS..^%J7V
M^M:WU1E?1$UXE/Z;+1YR#\ -[J)_?$>P&P_,,<%4*MQ+HX@5M!^R_WJ8Z4.K
MJ&?L\S00PL75)!#M6Z.-\2[ \]!0L51=;U!R%N)#Y;2K=#6."(V\SE+^B3#(
M]WT"6[>C !&Z'YHM@W"7NUBF;)/]/]C&F1@,U\)?[;R1PQ5;K([>'G8+)!?7
MVH_P)Q:.25=+F.K@6E>X8>.L%<7SU,=O@92N+# OD5X,T$ -J[Q,;$Z,2L<O
M3=_\8'GV5++D'N!Y==>ZYF=RW=>AU=B*!N=,2TXM* ^KT6Z;X4H^[YS64[1L
MJF,,3WZZD")-%&Z)9JHJ3O4'3&-T(P(^SYSF=N<2>N)/UU?$L;Q[A]]T[<9-
MAI(L9JOGF)1K*X/W_0U.W^!3:9+C%6H)-@2__@PS(B8?6#FG-<=Y1UF6;FL7
MA/O,M+4YS> C4Q!'A(>XFJ%AE33VB717T$*@09)5@R-M?PS+T<(OQ(4&PG.]
MA6*8*BS4/8J$=M&#\#P=VWS!E<DKOM.3O3LZBZ] HSDP,J6G#<_7?)4ZB@-$
M@E UA&U>S%]SZM>F"Q8;?@CPK6 *^L79PC_M/0=M(Y-XMG."2-=HAI7'^G+8
M%Y=W+Q%J3AV7'VO;"\I7FX7:HKW^U?ZTVV$/2^.CXAD-I!'!H=P,TRY??V6N
M )LYREA7*G]LYT\&.X[.G753.JNI\P'7,GF=?N5F<PN:&_)*W1Q@_R%"*4?$
MP3IW9BXG+6S+OQ&CI-PT44-=*JE6D]9[-ZL=M#[[FY_F9W]>,7,1H/@1%L,)
MUH^9\XNP&R_8J3%<^'.B<0W,N CDODIY%L&6P,4]<]2LRC+E9# TL)K $M=)
M\[E!\[%'3*03N[U]QY5SU_%C7ZF6J1O^/-^'CVV.O>Z!HK="\E>,=Z^2\M(,
MVLD/!2Z2EY^DR7W->N&PL=00$,;\ 7_=T#,\F?95GB^'5[:=OD=ZP1Z%M_M,
M:6A.V;F.IM0 V6#N%U?J^#"<]B*H"A;#Z;MTA=:Z*4=W2H<RIJFCO 0.G[J(
MSYKBIN\B8V6?%,;SH6QX;Q>6M]X@LP9.HMPL)R=DTI]>(H=M]D/+M7MO"MJY
M>ED+:^]).;/09#P@PK?!^)EO]"7!RQ^/$0OMYZVH4Z4L;0CW,MM62F>:EJ2,
M'DAX1)G'\125F&WJ[Q>#6K6/QIJ(BOGY(#PE;5MW-?0S<Z<@?7K</2A!P?=;
M\+6J2M-4Z[Q#2G*;?6#.Z:KO09(P2@,U)IZ(B(B@=.L=++0(%GG2)=L6]0X!
M*@1V;DC##NIFZRX:N>,_"-=,M+&-5:>1?7D9/!+#K/#9QS='*,D)0PD<*IIR
ML+_^BZOD!C^[IG[:<NHHI*<U%^2F?)IN_[$2T@HA_9%E333::H&/'3=&7+OZ
MI8+0FD@4UYUYL]1 H77<G:-43+.R?JH&5P]/$VK4/:&$&QQ4%HVB06CV'.*#
M><BU"7) $(I)UDJNX4[< VI<[JK&3B0]?WNNG(.JML7_E-.7%2JE/?LV">9,
MPV'/*?DW?]>+/% 7[@%FH,>[QJ2W1?[T>]#E NO<7>VZ!($+Z.==-")4M  *
M3\;W%H$#1P__S83P;F[BQJT9,07S[+T'$)O"2B@NYOHZ_47JFD)[E]F9TR\\
MR@5\M'+<7I\2OPL_*?+]4CY"Q1%;1B4(&;W8W2H=_0&,T  _7SB5?"U!>>,+
MJVM?"4*:1:/>[)+=M-C<-1#)/C;R*Z=L_)F1$I*:3?P7\O.5V5;+>1\WJ!7P
M\)U]G\'&.GE"6P7@/!&"8]0W^/"ZSE*S(R-' Z.::\^(M<@WB\EPZ$\N2KQV
MOD-K,85?>4DF(U".EZ8D+1#[XXO%";.TFHVZ2]U;=+C<H0.2:R"+6Y0[0D2?
MXKB[3SFEW:A;NDW)5D/=E$5#4\+CV4J.KXD8G+ZYE  :JM.5!= &)SUE*_;=
MF'[,2J3 "A&B]I6D>J*ATLM5?H/A>X!%7P:I+A'YKU_H.F(JF!BMXCEE3W2E
M%>W=%J[[DUD_147-Y[5N[*E"<WNI",/;K'GFR]]-UK0(:TY79Y!?<<F.CAZ]
MM*KR$%K0MM!X9W'H@($JI@KQ4X)9KV,&WY#D[AJK]I43(,+.O1.[IO#E.NC$
M&H*V34*-8LL=:1Z1QN5\42L:K$S&IL:0*Q^R>Z:$ T''O;@!E6+2*$4O'B[
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MR=!?N39\%&P //?VDA'[=W!PE 2NK786+'3)MO$\T =B6);B[N.D?#QO%:J
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M,;[H,'<\]XCE:FH^?BD>&D/*VM'F?Z<81ZA7CXA?&Q$T.E,V5YW(N7;='5<
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MZC[:8461E23 <D[#%K((4PTH>ERB#2<R"*)6*"#CR4W/G @-N[@3H_8_S5^
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MT7VG+_]2>80X:"BT]Z.L_? =B\S:<2C^#SG,&'^VG:O:+*KAM)KV&4$C(9*
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MJT0P65"R'%$,;/7D8SA)I(M>O!W'Q9!'"H;,IU/F'"--9B2K/-*UHW[?YSY
M_K$,&%9$)(DA5[Y=/C]7AA_\&LO:9T'!%'^DHZ>>V>?>RL;&2PEP+@6OCJ@/
M8 3PA4]NY5$;@ N$:[6KB@[]J55>"/X?')W;N^D103+" 0[]6^[!R_A'?3-Y
MIA"#0Y>LPHI<VK:Y;X_\K^D\K$<@LC]&8WO[-%$Y=9GGS;J,#KWN%D^+=!":
M"K0!]2:?=\ R9-#W7H&H2D9?YLRT-_O=HCP+@ )'=]][P36>$W\T]<T4_*.I
MA=<?3<^/IELI_O)69S[GZ"<JD*9[4+ZTU\[X'V6Y;DZ!-FE#M D*T"8\1C<Q
M0)L0+^,BV@1S9^5/F^QL3#868K3US;2HY1XW1&[W]& @ HK$LB]\?ZTR]\ 1
MJP3Z8O\P-E^UMCO%'%&I5"3:W1.+*'D""/SA_9,=N*)VI$;[=0YK$G,;"O':
MQE$&.N *XGIUM;L9K8J40E$['CK:5H(U<5UBEE72B/:?UO K842\N\6D0&,X
M<;NZRW%)V;C#ZG64;K>#X[Y2FQ\>=WRP)N _G_60?3+6L-A0)2V#CQY;@>X
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MG,8N5GQZLL+8-%;DWUA4U415JMGW2ZY(4=/56_.MX?Y-X7*I1)--&BQR#3G
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M@Z+!Q &*:]\ZF-]DTX1*33I-W_&OX!;V+1LR+]E1//\5WX[;%^N>=,[A0D,
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M0515C?*$+5L_TRL.^WCY)?N%%@;36H1T<[_+4_S!_>2G<;L)/DCM6#Z<@ "
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MF)7.X,$B,X)!0-X?Z,:1*87QQ6Z&/%"-!9#;*)3-G%^KEL*4,J^%)0*HE6F
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MQ#R/QFO6_)3J4,,W63$GH.S>F"Q*4EP^.RW@_Z%^-"<=RZC-]JM<O:QX?G:
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M(F0L^/V@;W_8+U;M6%J=A@/UZ1 M(X6YH/U'>/L-'IY+-O&.!,)^H_@O'E+
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MY3=SQ=33I(^ZCO<;L..RE!\8$GTQ^XBU,=J\W+1M0=!RHRHK)#)C_5>T*?=
M^4PIPYMW<4W&"QD6C9_YW9\KLT1?E!4QNUJTS\=0<7&:$#DSVN%E1O&="U:@
MGBOR*P,_%)[2F9TR^];1C0),YBO\/VX,6ZYA""F!].BV;-$5V9(MK@H*$2$$
M"\+4,%V,K;]7NO2R6GEI:>L^\,VAG/5ZCG7!G D)CD CFXMV7X%T8 0@8(&<
M& P!U)A0S#;[]Y+Y3#FNN#?JC./LI2DR.K%'H:JH=I2$=N^?T8!)^1]U@41:
MD=V\A$^JWF:VKZ7_PFZ(J8I-M1)Q-?Q0HHQ]L8EQZ5V@D?U-!M%G:U0GG+Y
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M$1V4;&QBH58GWS:;6^J%".?YVI]^A&G"I"70\%;[8)IR.GM,%>N%G)GE@N%
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MV7\N!A7^ATZG]%,4\R"]L07!GK^?GW&,]!_B4P%(*UA='4@OM4>42T7(W40
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M!..[KG9-9D#U-=5+B(*$PBC>4</2K>,!Q'Z!"==O!/:P3G[6\F)XTJXA.>7
M#D(&&_ZB*EQ8%O7%)[__[WY*^8[372J>*$_/FC5RNYZ)/'^30+[-T.PT8\X!
MTZ4 WNRS;.);J0H6D"B&2"YT>FSJZ+@_G1O617DN'=FS*9WP\QLM([*DZ7(S
M76$=).Z3OE7Z53JS0.J%#IJ>XHYRVJ2-T#A/:GYY1BL,7#(M" :)+M,#%Q)A
M,.%#L'N/%S[7K_\4G!STCB #ORGD@O-+?4<2M>;F.Y=G]8T':-@5\>!$8JSZ
M2/7G7]8?0(3[*8N7]U6?5M^_E3+=0%M17^3!#\Z_TCI^UA%,V=F6-L<?^=[>
M1PWNI[*(8)DF9&A#D+O'<E-'3WM.;S+JKB-S3EMP1 .GH$XV#F.,P@+51&7Y
M!Z:]IWI#3I\PZKX^6<O<D8!"_HJ%>E_Y=0$W6+#\M3%5(4:#]#)?]M9LASLD
M+6_5?5H9[!9F+4!5;N#^_NR@-U:A2*YH%&.L_.I7CUR:SRA]61!VK43+=U&<
M;-=*J[=]\58IV;3@D$@OX8VP!U"MG2V'G'.&YNE1WSDM($-ZDOR(*/9'R/$(
M*GBL+^.2HOT$?7:VD()\:ZTY!=G5&L'X03\K[#Y5]$<XX4]).;"7%KMJ=,%Y
M)HR)4*[_;)/]S2!].AYJ=_NFTN!+2EB#22O8+MCNR=M9#@=+P1F6V/@1X^@7
M/=36.X[!:J@&Q/!W5O_OW\6IVQ1VR,F0)<O+Q/G&'"O9K\<F63YV1&:(]P>V
M8(W(DS>:.+O7^XDKFPCVS>/7J!C+/4H^&\\IKI;N_),?0$8']\H&$!E"G]'"
M^ZZ<#[;<QL*KOVL@RDCB$H8R^0?E)DN;V+D)37<(*,KR\R=CW+V/JT)X'/?X
M=E)1YF:*3F7OPOCLX/V<[B8T!"['WX-6/K5 +KP]C$7NJ35<EI)O8$'SFOY;
M@L.ROD>-PGXJ0A%5J6D:??ZZ>3#WW<2]-H:8['>;43%7K*M^?$\9$"ZB' KC
M4OI02_7"\VK%\.6D55UV4"<KH?_]F4:./*&B/-3  -/_>YI/WT=[+&+3,??A
M\HBCG^80"9#MI.ZAYZM0 CQU,&6\<CCQ:* A*[)?IGED;9MQXZTK7NUNZXT4
M]>?0'E9UU#5#\8;P81B!\P P%_]OS7L:Z!O->VSH=-C9,;Q?FPZA7-%NN+'"
M\=[OJ8W?\!Y;U@ #3%K;Q'G.M7.'@&C_CJ[3/@'+CO_./Q;CFB'[_NO<;5;G
M:3SS7?.K*_B#.F(X8(2=N"^G+*[//3($Q$HRCQY HN)-=Z["$9EV(?>W#Z!&
M>YA.B7<8=#KG'\F\/#[\PB.0R6KS7\I\ +DQY'A-TTQ>7K[&VGSF"N/HT_61
M1U/TGGG[N?#5$D77"[C<3RT_)UW.T>@A<6K#L12'R-(VD3#]#KWXUKYUT1>_
M.:(<TL+=_2@9^U[-Q_JA#:NZ'%;AWD#')T(RHX[GJ=A81\/50<[I8I1C)*(E
M3L60^4LMUKPI+6>#.)R)L \%E<$]SB26NHRW6C09U:\19HNQ<OX!5)1ZCR-"
MAH\_+O/IX(@T/)L&^:LFC;<_YI2*<D'D>;![!G1AS=.X^BCKP:]>H@UH"4V'
MTO9M\WZ8'UX^3M "SC6\2X%"3UULE0H=1C>F.G<0 ^7=7+-,2%/6?=<WR8A-
M+ 9+,'7*0M0#R%#I2SWZEO J0LU).&C7HAR%P]LC$!ACL0Z_[X0R,$J]Z-LM
M+^%?.W=U(;XF!SZ&PDM;9G=???JRN#\V\=X?:X!'H>][!T!_76H+1F4E<?/-
MI42"Q?:-B$Q,?5SY@\!9K^?5-RP@C7^%776%#+$IA^GW^&N ,%E@M"Y6+[&.
MT^^5A>:?]X7(:SH^+!TP0&Z_-U.O:FX:,):HPVRONKE)?/6HK+CARN GLU(\
M/2I*>E? '<KD)?%Y07M9KJB-+T^K8M7*&0L7\>Z';<9P0A.,JD:53,%!Y)B&
M@2I":O$-*EEN>P'FEZ1-@QO3G$WJ)(XL!Q.QQ>M:A@"-0VENC%UI.L'O>N[W
M][XAL5@OIH4P(9]["!<U0IU)O'&W]*/U).7:R.0T.]-QYUY:AU&UI2HPUDHV
MQE'QTZ"7S^-<<'EIG'8."%'.-A0O'HCD*,X93U6X8(AF6Q3I6+DQ.:"K+Y&)
M.-$>%A;QG'/%^MQYJGHR=]3T5VRRC.&H+1TB<[-(]W*Q]VN96+N>L]Y2AW'H
M>>?'TD%/CJI=-=6B["!^C,!&^O-?9S6W4B!2F\\]'\[M"@JGYP$Z"6S<Z6N-
MDS1;;?ML92*?NSR4(2(S</U)TAU_7,L+8<9&P,7#FUI[=4_%ZLP]C)F9\TB:
M,+8I@U2RF]AF,EXA5UX^A]&8%=?'0 ,XC&RL>E[PS-(&-514;C4@T@>0<^G.
M7>0OCOD+;Q=9 C"R-?XR0CA&%\?KZ'83VE[HXBU4T-FHW+IMI\-Z%IU,4_NT
MQ'W.AK=DMYFYB^3W5_@$,A#QT(&34!ZFFS'1'<&Y2 $T[HAVI *(S6']P0=V
M0?\9:WVI=*PZ<49'&5C<CR,8V[]]V8I-C6/YU)LG7<#8 $W">/L1<N&<+8F,
ML=^MZY!#/@,4.=II%QI@TKAV@<>S:>UVU$%1E7"_T(64",FXLJ@Q Q?F!-7?
M$8I,"<@4Z?2?+HE>F44?HXC35R7ZE;/EHD*L2_2&"^K4<K!N<6<VOS-QDNR6
M5Y#K:8^=77'--F#HV]4M2K'KY#:W\3I=A8FOTXJJQIW'8GCZ7BDV_30Y '"_
MY-.7UG][-.;;=G9?#TS&0XW;/4@O>&7@\ 6<H7C.YM8S*''<^8N0ORV[)0&'
MI#9Q$<[6?EFY*O/P-B=O\2ZB2W/@([%\/5M*FS(<S!G9]U4MC!8GB*8 \O*T
M2@7B9(-U57^5PLUJX6D;7ZLC?88[45YE_Z.V:BW= ],SME1) +.[7L]WF+Z#
M5OF&A72>ZG=C]1#Q/5A]X(;G1"E!9HYXOK*CN# UZ :5%'8JB>P#0Y_@+4!S
M.+E8/."!7F%"R-CVX?&[TZ/NX-ME2Q\62Y,0]:E<R^2WI&]HB1A+.]0W^)"4
M"WN]NO-J(09;9%AO:N:L<R?L.,N8#+1:;CB_WDZ*NB <^D^IQ^K41&OV#)!W
M1:(&_SZSFLZ?<FF(TVHXW:TLJ)J/M56&'J@9OA_.:]G+ ^015>5ORMRC]'J*
MS6]@,?IHWT5#T6YGQT[1\P)NY&(M@.\^ZI.5?7>)Y?E^"CEYZ_01\[S ^Z:F
M%/;EE6$1=!5A-FG78D;[0%)[*^Y[XD8=7X(U*5QQIPVK@S;^,)/F.1>B FF;
M]6 J6^M<B_7$^PW7X9.S8&(I9#C/B]97H4^Y438YHX;9R@ "1=$"6=ONH$\V
MY9V!;Z5PAPH.%/AK#VZHS<UP[J)0U!A_,#LM:&D('YJWY&(B=0ECW*KE0BX;
MHA3UGA-YE16?V'&TZ%'HF"=IHU0RO99!5^G_:!FG+66]9:_/,%L&*TBAIU)X
M*T:"X(8%)5P<FBK[^!@[;N$NMN^37B)4J%[2A5=^!H<H\4N@<5WO=1V*(R.H
M".>D2,YE"HWC( ^-"4\H;X75K-6X*SWNZ)P&;))+)[_;%>3LU_'"%>W8RL*C
M9FV/;XF0U&L(D\=4O4KI[)/] =-V!P,R#G5:BSS,N'\ ^5:S17V"?!RB%Y#.
MNXHEG:?3"X25]&T7=]T#"'=B4I/-XGJ+W1H,DGA6<Q\8&%E?X'9(3G6R;0Z)
MHK?DVQPI7SRK18(?N*(%5?Z@-1?L<AF_\3B"?J @]$Y:5&URNB*7CE[!DZ32
M&C;ILWVC,6[*B-G @VH5GK^ = D55/'%\!)CX0"MLEA:^S8 )@4Y<ZCCI2LV
M3O,_[\!E.U03Z@L,8GZ<-J'@E7E+08S,'('TPN6E"WIAHF8N.MQK34SW01E)
MZ$Y+F%B,?89L/4(#' 0A6H0K8]]YFNW&XD=&H#@RKBY,D)Q+TZ4+#7C2AG3X
MPO6'/)+/UPWHEJXZ/\R \)[[H3F!D0>07>7H;[0KVKU.'CKAE=^^VM:>0JT=
M^B<XB/W<OKFY*S%T@I"Q(>@3QALX2I(+#0%G VP/":DP/*&>O*@ [Z,"1!J!
MVWGK#\9?^ !9-7/LH$(NU[&X0<5ML0P]F1>@N9_?@8R"["8UY0H. B3,YF:*
M[66]PQ U/./Y !YEV[DKORJ2RK?:CPL&$QF5YF4<(J-AUP1X@I-E,/D]FJ%B
MCP 5>X@_E/B_D\4EZ1PBN\;7(OQ7L )R9L,1V0J1_E:C2B M6^)&Y91M7QX!
M7=(U@7B$_Y$\KI(QK@[BKR?^TN4&%P00M?\XL6K2AZW1\=/(&N""D&<H<,IX
M1-"\_7EM2E'ZCP^):^YG^5%!NU;^$/]3BBY?/-N.N4T#3!V#U4.<NPJMC0R+
M7;3^845^<\Z.:Z'VI2M(*//Z_*.W8F#1OXOH\;[-N1HCNTNH^!W4V=2_ AWP
M3=M0-^_]R;<<ZVF%BC<-3R_MSZ\23;:8]Q;N$34 ,_NQ QVB7>?;\RI7QU)%
M/H\V34Z&H?C0Q%$'B-/#U8 1^W[VRSV4:]D6^!C1MCO%#^"L!-^UDRM$;>@=
MT?'=H%&^X3J^@759E#RTO;\B.?V*T52&K]W ,#I31O=2J&(E"P/?_WE,)7N+
M ?:ABL[[NW V#296TIUJ=ZF[FG%P.F"D-P?+ >$_@?\\'VOJ5D)3Y8+>\@"R
M$FR1E#S"'Y?Z=+ ?2M+W;AX!H:/K(RVM2/:7A6=V=MP 4R5(@.%>#W?0JCH&
MB0-4,KNXSL6^D$9"<6@,B?HWO)G_@G<(JM:@[DXF ^7CWN"GTA=0PW%]W1JL
M\NT*CQ@FGQ%)P%1=[22&6[B'#>:+A-,WX.:_4[/#*9/&@UTS%$&S5E;D=C,<
MC;FJF5<9RK<:J7S2)RJ##L/UPEYV!.9@OIUN;6@ G ERQE/'F7(9YZF>2S&[
M#;WO2UUJSC07"F3VKE.(D)K3,'L 88> T!] N;E#=V,??BUP/RX--H'S"=_I
MK'%Y -%1G,9CL=MR>_NS9J4"9^J0>T\Q06I.*\<\M!&N#4 XJ<F(E(\].0Y
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MY^9PRM_JKEE6CS*&%N"KFZE((VB +KHN2DZ$R"$:*DTS1\>WG/DK.OOQY;_
M"N^>5"R'BVHDXO=%(A,QQ;.^]F&1P2>YH=%47O*YC(!MT52BJ2)W$P++"@>G
MK[)+A&7N+@[UV"TR:B:<L1L?G.'$J.0WYR+40=PV%(3&%>L:3OMC;"R+EKTK
MAY&MJ:6/S,:\YA.9<7X+LZV?*P$6%JD72;1U8CR$(^=0K@2]Z:G=O-$-QY@F
MJWF,[>PS/^NX_T/;6T7%M6W=PH5L"*[!H;  08.[!(*%D )"< GN[@0+!'<(
MD* )[NX0' KWX&[!H?"@_RKV.>?[V[UMGW;OPWVH1]I:LX_1^^A]KKD6J7[F
M\=T%%'$TXRZ&>-_<V.)Q7:N+8G=Q$F+@+_5W=T#7NN)4(RRT*A-=%(=,VS";
MK>*\4;^BG:'_OE($J4$"[[&B^"(!%%BM;68*=\K]WJ"K(47^-$+^?+\M0%+R
M413IS<2YHM2[FHD2MAHVV8$;FXT7S(I.FZ4SMU DCAIY) <!5,0J(UB</*:C
MKY$5$^7[\BE6$A,Z:[Q)O*T/UX0.\W$04GH'P(P;6;'5D/:7A./;5]:B%H@I
M@[!SUN^/X8F_T^YIYO"8KXEE'O8[]RJ;/,R]U&NO;R-9SX_>A'?WL5#?]_V:
M<%!2T'PQ'__D]\YO1&]D1U_[4?B>($=$[(]3\8J:V!.[.6MMMP6L",_3"$]_
M4:X=KP^Q?S)@3%/@#]8'%4ZI'@LX.G]0P>=3'$=A\'WQ!] J\SO^1)X2=>$+
ME!OROVYNG#+>/H#>6@HT&U$4!@/5E&B'#!FND^*FR]9EC#2K1*\^;@FF],B5
M5V?,S/71*%@3L6I_-H-.;_:(RE%VBT&(Z:W7;QC5/N0DL1AW498PP_:]4J.5
MZ<VN\I$\PSJBN\/I!X@OU(IS4AFVJCYDL8?'>8N[8WL_'3E.CN(@A=++/8!F
MKOM1I>W)NMM)->:17>D&VR\CH;820F0LZ?$]\A3 [<W,#5BK&189=J45L'S
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M2./_VR_9_-_\RMBN<F"6#Z#5HRX[T/:.A958>"GYC_P1]E6VQNS$"EE:7-=
M+*>D!9Q^[H1V'H1=5?6D73!1F2PTDJYM2BWQ(*>F^L#7@V&=NEXC437TA81N
M_O90VBQ^*=]Z*@[F_1B:$V5Z3B')< #CYX/SBW1RU*@M^9QZ\U=63Q)U;#O\
M/GT]M&LV1YK?+N-IN3K*V79MA%Y<!)>X^ZI,? _:L' KLCU=E.7I>!(!(1S!
M6V1A]>4)KX[1MHRQXH""R6M*D.0F;%F;L4K:?1E:3;(79G:5M8L\G+B\QN38
M7ZD0X=1H&INH(\O7H?B)^H2=6I5%S4FGYW#)9UN!9VKGDK>G?6A.?A#QU1D7
M>MB^:;$=HRLVE8[H(5EIQ7R%YS-*]J9QOU9\ANQD1JKT =0AR%XYVL:&?]6W
M6>A;>OK$E FIV$3F'#D@!B0J&7;:)\9GH;S+Z)I0A(,3J7!#TZRXV7V7SMX\
MPFAV/2)LEW:3P3UP<@EK(N4=<1]8RPO-@J%--(O-2?]L;F&H.=Y03[IP7+!Q
MK8I;<V.JDFU"[7\91$+[YG<$Z..SIYO)OEV*5ATM8I->HNMLLC(M50&=)^Y^
MNYZZ$5.&XTPY)QN:61ZYO1_F$P)PSAVQFI'>Q%\$C^^?W83_E.T4HQN?OF%0
MM.UG*7(7&9*9>I$K\YD5BAVV?4"80H\^.]_>AEJDK!-XV77 MZ1P5ETY61-O
MD=-9&)LS]VVP@%NHDXQ)D'V3Y 31CVLP*WFM6?-&0C'7O(4A# ='W]R'<4RE
MPW7B?"-P7([=5@V/MJ;Z,-L;=MF.C,V$-,M41G4<#0U/.<*W;#0+$1'VSIDO
M"R/OK"7N+:^FN1]^)IUB?=@>BFR+47<9BXV][ZD>=*MHLQ9BEUL=Y+Y:W9+>
MUL<5B-_,;A0;C[PI553Z%EL)-AJ#Y?F_]"^/L^\?FRM?K?'B1?"]M@]XJOJ?
M/DQ*?]5PK&<7HE4;NL:&VE4GA@6+"M^2-2O6GL_I_YH-_498WH!!FVJ/MI)Z
M.EZOL#R+U2RU4N(#[4H7;(7AA/%ZO\72/2]J8AIJ=L-EH=>HI(=6&1$:#Y.
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M QT?0"ZL?/'8%N_K"K:U\D(8)K]/.G$$OQS?-#]80OH]R_-[R%73F '"0SF
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M-K_1D4Q&+"7:H(,[DE00?22;R?M7&M!KU=FY(C*_M_?N06*MBY>"VX"O\X2
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MKKN!83#^NS/QQGK@3U\DM0L)#3/<B.0JK2GV;+T[1<49&1H9_'YO](.GMQG
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MVX<W9KZ7$N! 9QXE%.1TY#&&4_XYP5-^6[!Y$L6?6>@0]-9+\>_0AH-LWF'
M,9O-#O91',QC=/?*2,GXBC12OZUH"[]?'Z0QVB=$4R_+F=Y=%#@^)JP=H'Y
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MN\_GT[,W_GN.4CY>[O;%NBK24&0>7KN85HDC<'A:6I2S:'$"(1$P"[6EA;S
MC/@RS,4=$;:W#:0%Y.WQP9.:HB0W"_([VC< H1G)*Z8TQ8_*<NA]4,9^&!O7
MQG ]_> S\5Q0+33IZN>'D'O4FZ&TW:#K$TJ^X;7#U=LF=SH+8R^"&E7C5&P(
M4@W(X)_3F',+TNB6.HX%'2HF.3![7Q(@BEWF &".WN^N#8>NE0AWV<] \D0N
MB:8O.'?YIL$F"8;N.HC!'YF4NG!=\<$4ZT_+)$ADVX4X4X9N>%(N_V3 8.S\
M=AQP.6,\A;ZVAFO9R856/]]?Z#Z_V-U/'&YU@ A=+>K;^"^?M+Z"]:3#\(;>
M7[3I!7L."3GZ!\H%K^PHT6@E+"%]Q.TJ[B0@];-J>.<J8:__.V5<D,!MTC1@
MD]Y4AGL@AZU)+/]_S+UE6%3MWS8ZBHHHTB ]"BC2W6E0<E,B72+=W24BTB @
M(#DH(-+2,70WTC$PQ! 2 S/DT'L-WO?S_I^]G_L]]OMA'\?^X"<.9UCG=?[.
M6.M:%]@9O"H9:7X^I%^^_3V"W<3D:G(S.>*L[5F8XZ7;33MI!\Q"KF!2J\;'
M>JNC]OXC54)Q4_K^R'A3=)JH;[,%;DVW1)2+=W6G [[ER6I!MKQ;*A3)$<NE
MI82Z^.I#BX\NS*>6?^/:(Z>Y"7\GL(RZ%<S/17HUQE+KKX(JLD-E/2RV>Q'
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ML&BM"X@\( QOHK@$_:P<N/\<]]5/TD?;L9R9K<]S9G:CJ[DC"6"?UJ@.2SR
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M5H\&YW;MNF&3#@D0O_/29P"88_,4<0QP:%4/H.8R@+0R.T!BG, %V(T":QK
M5$9AI[(E34%P!*;%N(T2<C@3/!H0E45K3@(L._*%"2EP2F[!7'9/SB&2G48R
MV,=9QGR>J0-+',Q]\W %9RTO0!Z+^_T?''[OA+/T^R!&0,<>R#A#J3% 4R]!
M1L(G,AM3V-N<(X"N1#,,1Z822'EQWZQR.A._ASE8.(DV8O3,<GTOO!]I5D7A
MY6<.BXU1*5^;[;L8<  FZ"4P0?=YUADD+D&"3 "E2QC_@<W4;JFH]#CV]VE5
M\7F98B0RPEW2,+7^S,<K *F%?>0V(@7 MKLT''E%LKM-)D@LR1+^BV0]@.9
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M@&#5=2J>GKR_3-"%77!(5+W&ASV&X;U@.(6"-_)/&#"!]5Z"+-5UZG56)*>
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MNUS&@5EAQ*I_%I,"MP'L/N/V_GP3"C;/OZ[7H6?4%R,W]Q$@M/?250D<@)@
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M,0Y<1&R-A%AA*01S?R+1*)2>[J.0QWBF1I3.[-YN?F%A.WKJ*<\EJ,IN'?L
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MA'^]C47X*1,SB,GV#3YGJR,>+9<!UOG=.0LC>B*0/[83D+5=WF\@E?[^8=;
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MW ;P=(0GK1A']^1/5XO1)2:>>=--USSN6>%N'#8E;GXBZ,#WPD6EYXOI/7Z
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M&#P8L9)4[=J6LN4S-I<3QAF +/Y7[P#Z/W4\J1R,D3]2W*&SQ!.H:%<7B_/
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M4C'ID>0>KUY0Z!+X9/%JLJWJ0T,%4&,WRRIEY1W7A#[7MSTJE0F[BHK!*@!
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M\!98L:"TK+9QWM,=3) 2K("5CPMCXXQ=O&"TRJ,S!0(6<QJFX0%%Q*AV:Q&
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MN2G]7/>>:^#H]\_E.^R+^$]K8H.-C,7=9H4^B@0_V2B8/ [JF]^TTX[J/N_
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M"R#'+$_U1ZO5Z9W_FS]]?D<8!3O> F"4\:/'A'4_8MM\DGZS+36C#/KMOG?
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M@I^29;1KSK_0,_,$%C;+L/])ZW_:#?3_/R_;C/S[C;S#WGB(H=X,[IM?MX"
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ML:T/'M.Z'.UG1$]#!*U05;-M;VF;8Y@JW+57'7/@G)$84^^?SGW!%F?G+3G
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M,YH'&U<!LZUKGN03_^V;$)JO)3W%KU2#=J^S,$5"3L6FZ1LN,?WQ\5@3=@W
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M%M"NWP$%LLBM$9BV+EI+"'V85]?G4;8:Y3]9/R\>K8^>N#-E:,CF/EU+_:'
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M')*3Z5-Z/N"H&X@/'WH #J-LQ4O&G!V*3 PWJ5U IC+K=,/VI <N(MEG>^J
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M<]]&[IGY0XP.AFV.J < 5]H,8[MBPBM&P;R(NBH7P!I_VDEK6W].>8HYIQ[
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M1>\I5H8XWI^+J\1EIX;\%\MZ++" JM&0&E+3P\=WV]W'DYTIE)4;4F/;4+Y
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M#5)]+"[&13_6"XNV>O,=Q*+9XOSJ8[/V9F&LJA*6JN.;C9MV+Y+F<+A,Y?=
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MC&<]>%,UIGXGBQOGSJT.7SD)2+MI<JTB^?*7PUEG\?Q8-2NL>+STC9X=<J;
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M^LHH1$20KK3/^/NT^DCPRV_@21FOR#!QG':<V#6X0C71&5/Q6U3@;$8'T5$
M9$SI,WB@JQ!M*5WHGK=+4RCN :,^=RFKP7IAB.8S*I;^J+*C&G"J7:JM&'V^
M@TO&2CX7^;<Q(TK1S0&PA.]EYI)?0QH=A!]%O'OX#] L%U'S*UG85+&_+\LZ
M,\J]7EG1=B4IZZ6ZG.F3/FM2W_#YE[0Z]_< "\*"@[;/KTUG_:GA/\W_RB"Z
M0&6](C]6=&5646U&*"_1XI4"E_.T<;CLXT>(IZE;D^]5'^.\XCG[/EJ").W<
MK:DO1$^2.1-DE-B4'!^E,]LZP1-DVY)*JEE9Z)0='VSQS0I?/3W,"I.-,FYJ
MG^:=KOF=Q_;SJT6.);"[Z":BPISJV;F$NMBZH+EH-^!$--Q=+>;R!W <4KV^
MPC]>MPSYH,A^!1\#.)=$/V?)-,W?(5B*:O>D=#]4XT21?>EU5IF'\R[;6CVK
M%!TOC1Z_"YEC/A0SN@\]ZGG/8SY5R*O&/N)\'P; Q_;2XBD]ZZ2'J:(V1B>I
M5OY(#06NO/R1Z3_F*)GZN-& FG='I@^6> '$1U>'R,1V[UG/U-98]" 4E1_\
MW;F!UT3/D@OF_@,X)ZB)'3L+B"@ONEU$,B"BN3B^;JZC>5_] WRX&K![A!/M
M>P>:D5ELKB+;;&B1R$PGM59K-B!\P89*5ZS=U5\$W -/H6RW:MB^8ZV&JPP5
M.[8'UN;1(Q/@T;SX>T\S4YB-MT-XGK)_\WZ8\=[NZ;<0>MQ$3?!6\A-M["]5
M%IQ7G"@T.+&D_?,:^@7=LE<R_3 YKR020'= SU^_A%8Z32J@Q*DE+O26]RZT
MP!L[@N"4XE>>IUI7'BYDM"3H8^-2VY2190!Z<?NZ*$)DZ3H :UXL%[O1."<F
M7K[P58XU1#;7>7:2[ZVAZ.H<CP!7ZEE#AN<DIM\:6SB@1@I;MU*T2_X&GYO2
M=7I?TES [#DM>+8=#')ZD;+)4$_^? (5]9D&/!9&?3OQ]S3B-R4%F*G-X\*<
M@V/NER[0,%W]9,$Z867@9VVA$&TDJ4B?++%ER&P7T3^ :X?CYF['9MD<8\_)
M3*]Y-F/ NX\+4*6E$X;(03;^DEK1HR;6ZX,"-T&"@.AQP#O7)%4IF.;W=VW[
MN6O?+I!O&5K_>^&JC$/W3#8XMZ1+.R.3$%I_7M913I*0U88X8U-C0XPZ.;MF
MRQ*-SX^/;=-[,'HPE\_O*4Q6^%R$\L]:+*!\4I_?Q(3,8)!'-S7XJD$[OGGI
MN@9W1@Z^&8?Z#OBLS+&>?@HAL[_(E%4]L 6M0"JI,QQ)2D7XV3E$_2;_V@N3
M[[OC,"?BZ>\&I10[?P7L<+\5.MJ$G\DMUZ17:69)MI/EY-]ZT$YL$.S;2>!Q
MFS54ZWV, =:Q>37[.-L79+DC6T<F=B\\ST/SCKGOBPJ9\?4U>K%9.M#XB/=P
M)EN+]U,*ZD6+62F_$/@(J5RU@B?W-TH-?9%.8S$C*Z+S-,(UU1GF?2PP7]]T
M36GFI,97]; J%[![4;E?OLM'NV?/&'C)VL8[23#322286_GL!=6<B?\M,B">
M?!]&?W#+C"O_  VNRGLLVIQ*)!@K:&D["A]*)Q:+^$*L_'PE_4X0OP#[\-/$
MM8?8R;BN!AGVESIUG[XW-0?XC1)5YB TQ 2?2ZK;MA@+B_E*SIIRXX<W_ORZ
M8?TC$SK?UK\ZEYQ4Z))WV00,ZGRWY6+A]5%<-"( :Z 5=($U3%9^BJ/O?]<5
M0Q7E\P:3F"=<E9=L;94%)(YYB$SCDRP3(]2FRQQK>!,_\<);5JWICI>.[7O^
M:AINGG^!!5K/P87$B6;_ =Q;4W">(U7]V\?)'VO5Y0,H%#:2)$A*]N]LS^*]
MS)NB/.&;EX=7;CIHAT2-+D=80]PH2G/HS]3S(3WJ3R$KUS6)Z/!!\?L'V0NR
MB+^]#3%*E>8!C2UZP=$(/IO0 I<D;6]'KA/:IQ^C?H+3L9S=$*^>2T[B[;:V
MF6T.2NSOW8R*("F%<^<LI=?FB4)R0A*J>A#E.I+//F'4-UF_NZ@TG<L,;_(#
M0<5H=V\0NF;B+L'K\MJ\$)&$-+@PSO^7XD(UNKO'^:3VJ(($C$E%-W6WV;^'
MGM*X)0?73I:#7"TBAYL/1Y\%$V,C=;9A$E.>SL0O**H^-]RKP5-O]2,35/G
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M\75Z<]4AP%".9"^,?O" XGWS-MN.V::E/L2H1.I8BZ36D>UVR$?.$=D-607
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M-JKY9"'RH)Z7*V$<;XJSA.5MV$5O_0,\''<L$1WX3X;\C^,J.XK+J8$M)PY
MM9U[WG)+"#LXQ,3$8D0M7C?-UOPJI%LYJ(+ZU:R_/+,::1+Q'G0;W@8V@WFH
M,Y0NSD93\XJG.XD.'"^ C7C'T KK9]6:I8/N7ER4HBTYCQ0_2Y@[K505$ RX
M$7Z+W4)&[DR=P.DKUC00"Q)+'9D#F8&4YWH2Q QZVG&& KCT4IJ8!]NA WT6
MG'<U1?37#0?6_9))N"JT_,C(:C\[D$E*IM78.X84 V+86I'C%7(FB&<VYRW
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MC<A]O7VN^9!Z9Y+O1XF6SFO.'9>/9H3=M>VVN+#DS2Z*20R[ME$,)2/S\^.
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M L>>[5U$HM_0B2F3/,MO):D!F.$-KY[#_ 8+**?KH"I:*G+6_P ? MB#35/
M2HEZ;EMGLRMZ#S.$K'B2%RN= \F_"S07WQ0IWT.S[]8(-/B 0&[S55)KH,"
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M;S[)K[;"!^SV=H<]:>?@R763CIM6XEI(IFMZJ0[^V&#AN%.R2"4E12I3_@]
M2?#&;R-?K0_M&AVB5VVUTANHC$4O?Z]YBZB=FA!,UTVG&3GX_F1H;%G7Z#N=
M,%YM@_.:)^L?@ )SNWIE<<WM:Z];V'!TY8IVS)2\K?\3'')78AD#+L9]L\,;
M7]J"VB@_YUX4AG/D<]20B]5\K=EV$Z\+FW5%:/TGPB1YT__I3T3*RX O5(<8
MN;XX1SQ'"*C8?<'Z=>E.1_).[5<O1_;9T8=GO<A+*:G*E4:'G18*G6' ZTF*
M:\=&G&NBES1$37V!KQG>U3:];D/S?%[C8/W&0Q]A*F(32:C+*NP $?0]F9Q5
M?=!9BB5YA0<)(+[-FS,R$IH!51\!I9_+9>YZ6SXGEL-]OC)_=WV_(#PA*TRJ
M8]Y_R:6Y*WB[K?G'5O-<N2;Y<P22J6'H_H\G]02OGL6E2%AN9 %<DU4EU'I/
M$]\=6?=O=V$30;</$;/1F1UMJ$;;X5"^!_2$?DJ%8C(FR[[:!OI>5M=N2!1R
M_HW] WP<+%&W!8EHP6*Z[R,C)@BB+P>?JO.^:?F3+/1ZL3N.E^$CSO0BN E?
M4PV^S/Y;B8PR^U'S"XIDK.)*T!&G7/&3W>VMO8D8L+C_F&4O)6#KPB+EL.>R
M+1"-$G94&:AQK633?]I#@]Z7XF]+JS=T;_R34<44H.JT1^+YXPO-=W;]PF/J
MXH, 15C]#WC5:MBY6<?40F]]HG$0>W_9:3-)P&=UAGM1+2^?K44XIPB/=++?
MSLAE(>3>_0,DPFVM3R8F]>=.2Z??3D.F4"U0'P@]$T4UWW-G0W%/TE%&$8E@
M<8JP,60G>91^VY2RL3.H=C^W8[?857(*T*#C^35%H4;_VZO"=F*9QPT+;F:<
MLF0>SC>I3JJ<L[_V42ZNN5=Z73-V^\WU5(<U+[Q>E3[_$E(: &$F4=@Z^4'B
M_[\]>?.4(!EQ:O!?@X8R?4>2"_Y9\^- */^6%+J:1V&5+,"<V=6VW>#XBTN;
M86SX0Y%;'EM8S#2[H-E473-;?T,G?,XQWM;9+=WF<8JV.4">[7WW 1FSX&2G
M6,ACB0,[?MRGP-R2A6RDXJ/YRI)]EPM;12!+J;"2!A^E'^WY!/Z'%[JF67)
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M?'9V(9U [DD.VW[9'I0*.W541+)<M7$9JUDP%32]D@/DU82+U#3H_*V03GK
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M<EX^L=^_7*L&=MA*X&;3U%0A>A) M+WT4G_!7SDD\#&;*(<73[%]5F)+>+M
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M]+'-\#'"L!N:/.<UF$/;3V7,^X:ZF[E(+D SU(WFH*5Z>8S=4AYH[>LW08T
MJ"  %0870*&@;WHK'!S::.,-FE.#;P2QQ[4>QQN''5-TQ*[[+6W?Q$+U(?@U
MR6>J[4*MG\OG97GE\:.0&<L6$X*81"+!,$4T@8@0#BGE <2(>RA.(]]+B<W*
M=+S+<UM86A("7HEHMY(8H&RV$+C%;N@SA5I8T$@+?F@C60OL,+.4.3HN"=.@
MUU'YSAR%;;JR>+-/$N3Y*\D765%'OJ:AE$D4,RA#72O5\SV(!>?0CQE.1!RH
M7;4W>14YG9OE/MYHW686M/L8;C(T\H'+7VPR]VYBACS.,/<9Q+Y.AQIZ'B0\
MT+=//1F+V/.%M,@6W1NQ45)$N\#+X'RV/PH#L^<*@!Y!YELPV&1Y[@W'2,>L
M#T\"?!%<D=%,%.4F@<S>7.5=VJ]]=R;GS5=&3-^\5];-G,W['W%Q%O(M>WQ2
M!NBOA2C#WB:(1<*+DP3**%7,Y(<($A1R&,4APS%B:9I85?/I[.W<N&K[5"37
MXL*YA$M]B[O'#?ANK/L<DYR X-BG)=\:])2PU<WWH<Y-#H RW/')=H?O>(IR
M0/?NPY1#+_6P!G];+O2F5NUUU9;W\O/7RU\>ZM4J)(S3B##(J Y+9P)#FF /
M!J'T,9*1#$.C^-;N;LZ-0]:"EOXK)2I4LEJL^8<!-;""G, T,%'L1ZB/>708
M*@M+R0ED(QE-EA^7G=%T%(A.^^GPV^.94D<UV+"JCC_=.X0W$\4ZC55S,$IH
M&'*J5I>4Z""T-$HA]AB"@4Q]RK"4 IEO^@[W<VZ$V,KGE:]SL"V4^5^0*K6R
M7"YT[;V\4<DZ1G4OW 9LZ0;$H;UOC9"MS&C'#Z.MH+(.YCT5LE%#>6VAZQ/'
MVP6(013OWM?'CN'MTF%/!&_GX_VVINNTO)](EO]&IDM17\9:)XA3W7Y1)JPB
M#'X[^Z;KN^FSE ^DR(JM9(LB]2)"/0H1393]B3T!4Q0P&+"(^ DAG/A6YQU.
MI3LWEFZGNM?J@5(__:_ZMF&C%M 'LV"E&BAUL]L5NQUFLUWTNPW>P*O#_G&[
M:$9-6XGM+*CM4=P:PT&S;0X"O\O]O5L!1_4'#(+MMO]@F$YZ&-B?LYD2XDKU
MD2T^$58&+9>I^\KP4'WL+O+G;%9:%I^$N!-JHBE#XU%,2(A0&GLQQ#'AROZ6
M$BIKG,&(<Q3YC,1^&AG;W[W%.#?B7PM=DL5B+3:00H"7E> 6IF;_,3(PVD=!
M?F#6UCJ4Y4=*+4"CQ@5HC88N0M)2!2A=P-VXHV&Q+QAE5$;:-@PX.G9[BY-!
M[=QZ]&]]O)W)R0AL;%Q.;ZWGI8/;JYO+Q2+/Z')1+H3S.Z*W2TWLU[?Y=/II
MGO])<CZ)DC"0'@^@3U&9T85#DI($)E12D<1A&%.KY)$6?9_;TJ1%!VW9M>.H
MDKX=Z0E^USJ 6@G;]!$60V.VTQ@(\(%7),=8V]^%L$?-Z04)B^['O35AC\O.
M58H>3?1.MR]%KNCU?J&L_'*3,/%CGV/$ A@'<0P1TP&G,O8@]GGB\Q")-++R
MPNSIX]QX:R4B*+2,%^#_]'[R?/!"<O!:>E6440V*)S4(%R"Z\#RO^H?:K2\7
M3_,\^]_J36V+S^;-+[*B6-8_G"\7Q4+]1>_;2:&GY1<U3D__]5_\V/MOH7\!
M]$)?/OE1L/(X8^-7GG4*_YT1-:/!$\=I8+I;#]%]-42UV^2F!-II7OY#*#C.
MP[_3S=AY]P_IN2?/_L%'W5[KTA'W#<E5P?;JY[F.?U!3H_SO*E54* E2W,2A
M+W@(D9\RB$/U!PDD)FDLHC T\@VX$^G<2*VZS,,V+O/\,"WOXF2E:G]U<RG+
M8M#,B&C<H1B8MPRN5+6-M0$RA+F#<XS+3A92G<5=)GL43:\J]6BY?TKC^:PD
M=V5GWN9E)@]>\KSJ]UX;-),$"QY3CT%19BS%$D',0A\&&,>,"Q8+W^J2K$&?
MY\:GE<B-A;BV#7_(9H#K G5YL;83#]^MZ3T$9N3I&-B!V;'&M#;IE, Z<T\E
M<GV>J80&I=1N,R(;0N0Z,_*Q;D?/D&R(P[Y,R::OGF BMLZIOBJ=ZN"7E#,6
M2!) 3U!M^A$&:1Q0&!$_]*+$XWX26IM^>[LZ-PJJC(G>A78[,+6PS$Y&:A2+
M:Z/\[EI.QV95)Q;.S:7]O8UO!G5JO=>\Z7ZCI^^JSB_T::Z3CC$A>/%)R5OV
M=S-[%84.GK]DB^RU['<2RS"5D9="/_ P1*GZ6QK@ (:)AS%-PY3[-NE8>XIA
M-%'&3]):39JLD1>0E<"6[B?+03%T30V \4ANJUIR()5A\T,C/- 3Z\>ZQ.1*
M 7!Y''1[?U8_Z)SZNBQ%&-</U@^?'1]9SV9Z'D_R_UP65:&*A_DEYYD^_R33
M.Y*I/>(5><D69%H:853M$KG>6ZJ-97E(^DW\8YD5V4+<B_PU8Z+:6'X3;/XX
M*UNI/,:I+R5'(86<Z^O.'D<PQ2A67!D@D8011<RHH-98 I^;H59:QK!4IO3
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M 2#"?@!Q*#P81+%'4Q)X6%AQ]^&NSHV0=TJS;Q98U\4WJY]85MSL -N,1=U
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M/PT!G\NMB5/Y1MVW#('L]J9FD#Y./C9MQX[]DL^7+TJH=72DD*&,(L7!DN(
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MD'HI@9RJKQIYR/<CHR!7IU*=V^:@E!6LA05:VA-#_?L-EQ.N=#\(9T&@:[7
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M3_5PF7W)IJ)8S&>BSE%R3?*9X%7TX<1/(Y][*8:1KX_^>!# -!(4"NW<]V5
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M!()>@D.(!":0!+Z /.9Q+"EA ;:JN7@JJ.-8NX-":D:XIP(U,-U6XK42U%Z
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M->>2XESE,,YDF48XU0Q("<RSHDBR)"'2+O^D5^]CX\9&7+#4\IH$"HO3'W0
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MBN,,(I7$D.4XA21"6200%8)X9FFRZ'UL/-O.$'1XPM4Z //(]^HW/)8;V+Y
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MU7XQK3*COH5%/<;%CN;Z1;MGMCN3AVE;2+15.K2/>J'^( Z0FJE+BC&D:+)
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M(+ ->).PN2%HUTVHY.[!7^0L.B&YXW1G@W+'69WWN>/\"S[Y4N5*ZC>>FKP
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MPF]"U3:LS26%;*.R?:==&]?&T$1R.I /]MWG3]T1^^*T SY_^A]02P,$%
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M>%1,N,@,:QLFMRAH!I(!YTU;$F[/$*D6\&B.846WIV@K:**625FA3>KT1DA
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MK;0HV)+X/7L7G"_@4PA?1ZORNVHE3LJ;\31,TYA,Q>SB/>(5TGS*(>E0H(B
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M\?>O.%T@^8$GR\\XOR6CD4Z9^X0:LK<4NA2F:\&/!9>*UH;;).V&^IC],=.
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MO0<+>TAY."AY0W+:U,OJ^'N:G-?<>AT/0?_+]96/-T*@$AX,][$.ELG@28:
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MU(^]T.S(*.2D"I(4HS*U20)G$(0KP+1-.9!,<S<3 =MGY27D0K9!=_>YD*W
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MR(KE@"864"QS\(%<(6E]+7=$G;IIV3:(&HF-;UA'(5D1M$8HL=3ZJ>(A9I9
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ML],>P7L;4 E4]UZT_%$ZO@LR]BP=WT9-?1^ 33IJNIB<]0%X"+5E4W! #!A
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M5L6RJQ_41UE&!Q)[*KWXX$?3/_W5+;P?S2(J&J&WD%H?%91=C!C.;.E$P4A
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M[LH#9P^BO&1&<BV"(DDQB^[MO#<H,**LRMF'S!.MDB2\ \T#[\I[ N>^E-J
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MM!M S**A?LA?2E89ECCAPB0BT5@3ZQPE"23SD7%\2/6SCA8J!G97[Z1763>
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M4!L"R$JP@^4)\:X(1;-8!J=%X@,UA/L@&(#-!KH-HOO)BX;I.E$?(#L+=6B
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M[E547GT#=_]!^:<40_WO__'_ 5!+ P04    " "%@9U2J!_)/=H'  !%)
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M 'G^W?7'J\%_;F_8V&6*W?[KW8_]*U:K-YN?#J^:S>O!-?MA\,\?6:?1BMG
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M9I?/?.Q2_89/;_Q'0!?_ U!+ P04    " "%@9U2'JQ6)!L%   =$   %P
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MPJ4H,RUX$S?#S36[H?"2110N)57,G%X3)BFC"9PS3GC$2 :+)$$-V;3[K[:
M[WCDZ'03BE*JDN Q:V' &-*K'4T*&5XG*2F0E>KC:=M\"DWMQ:QKPC5GIIHO
M-8)3"#JF!@"QUE*FX"T7&^1K30\/3GK#KPW.@L0QM@<GHPGFQ:E[L@O8.CJ=
MCF^^/5" '@7'%1G[3W-V=7@F98:Q&F&H928X;@-&TG<ED]0T,66XK#G'BG5$
MC@$C,3@YBH^-Y%YXW8;6.-)&'/3;'62U/S2!]S]AMO5%9AG'3,V)I0M+A"9H
M(,:O<)=VPDR-*# 7#,--(R99!K@,?<)40$&!E*LJT9+;%$&#L9UU;!ZC%B:9
M/2!14&GW5+M#J>N'^T]ZB28K3*%:?R4DYKN#-&>D4'2P>QG&3!49V0X8MV39
M1<,;D[Q8VFJ3N$L]IO3[;M?OFDE%XWBBXYWY>HAQ[1#CZ7A?UNFY??_S8M\-
M/BO[3F8]ZW+E-L)72/#C1KNQ6U#'[:!5O(?@8TI-*-_G9"6T%OG=D>T_#&6+
M>&JF7%OT8%Q(EE51W.I7C>3>[%B3\QUQ/P3DPX-.=ZCL$_;;U2WD;SAMWV!N
M?)&@.G5,JJ$N*)&Q&'98?R3V/L$87C*^N<7OT^S9JO&-K>$!Y[\Q5(,/]D*&
M_B$T6W9QF-A@)]24HT.87/8V63?3&'"F^6AX,;-RBM/:BJ)^(<4-,R,=#B5W
MZK<M]!N&S6%EVG+=3M#2?9VDE)RI](.!KQGZ)##L'^AJDD!9X!?C*U7Z\UWC
MWM6S$-7=>R!I1DP([%U&/^2 B=N!_V$)66$BE'I_R5_<7^MG=9NV]_JS/P%0
M2P$"% ,4    " "%@9U2?OG-C;[> @"-NAH $0              @ $
M86QN>2TR,#(Q,#,S,2YH=&U02P$"% ,4    " "%@9U29!7Q-L 3  #>Q@
M$0              @ 'MW@( 86QN>2TR,#(Q,#,S,2YX<V102P$"% ,4
M" "%@9U2UX0EUPT?   V,P$ %0              @ '<\@( 86QN>2TR,#(Q
M,#,S,5]C86PN>&UL4$L! A0#%     @ A8&=4OTY%"X96   E:\# !4
M         ( !'!(# &%L;GDM,C R,3 S,S%?9&5F+GAM;%!+ 0(4 Q0    (
M (6!G5+S8Z=?YW0# '+* P 4              "  6AJ P!A;&YY+3(P,C$P
M,S,Q7V<Q+FIP9U!+ 0(4 Q0    ( (6!G5*;HZ;Y4L   -3*!P 5
M      "  8'?!@!A;&YY+3(P,C$P,S,Q7VQA8BYX;6Q02P$"% ,4    " "%
M@9U2YBNBRC%Y  !?8 4 %0              @ $&H < 86QN>2TR,#(Q,#,S
M,5]P<F4N>&UL4$L! A0#%     @ A8&=4J@?R3W:!P  120  !<
M     ( !:AD( &%L;GDR,#(Q<3$Q,"UQ97@S,3$N:'1M4$L! A0#%     @
MA8&=4FO>61KE!P  7R0  !<              ( !>2$( &%L;GDR,#(Q<3$Q
M,"UQ97@S,3(N:'1M4$L! A0#%     @ A8&=4AZL5B0;!0  '1   !<
M         ( !DRD( &%L;GDR,#(Q<3$Q,"UQ97@S,C$N:'1M4$L! A0#%
M  @ A8&=4AD&1BHC!0  ,A   !<              ( !XRX( &%L;GDR,#(Q
E<3$Q,"UQ97@S,C(N:'1M4$L%!@     +  L X (  #LT"     $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
